Program - Society of Toxicology

50 th Anniversary 

Annual Meeting 

& ToxExpo TM 

March 6–10, 2011 

Program 

Washington, D.C. 

www.toxicology.org


2011 

Awards Ceremony 

Sunday, March 6 

5:15 PM–6:30 PM 

Room 207 

25-Year (or More) 

Member Reception 


6:30 PM–7:30 PM 

Room 103 

50th Anniversary 

Member 

Celebration 

Meeting 

(SOT Members Only; 

Full, Associate, 

Postdoctoral, and 

Student Members Invited) 

Tuesday, March 8 

4:30 PM–6:00 PM 

Room 207 

Celebration Event 

(Ticket Required) 


6:30 PM–9:30 PM 

Grand Ballroom 

The above events take 

place in the Walter E. 

Washington Convention 

Center. 

Dear Colleagues: 

I cordially invite you to attend SOT’s 50th Annual Meeting, March 6–10, 2011, at 

the Walter E. Washington Convention Center in Washington, D.C. Visit the 50th 

Anniversary Web site for special hosting opportunities, events, and activities. 

The SOT Annual Meeting is the forum to showcase toxicology’s novel discoveries. 

For the science of toxicology, this 5-day event is the culmination of a year’s worth 

of achievements in research and education. 

The Annual Meeting also affords attendees the opportunity to learn about the latest 

scientific achievements from a myriad of experts in the field of toxicology. The SOT 

thematic program provides participants with a unique opportunity to deepen their 

knowledge in topical areas and interact with leaders in their respective disciplines. 

Opportunities abound for members to meet other scientists they have never met and 

to network with friends and colleagues. The Annual Meeting also offers a chance to 

pause and pay tribute to those scientists who have distinguished themselves in their 

field of expertise and are the recipients of the Society’s most prestigious awards. 

Finally, SOT attendees can take advantage of the ToxExpo, which is the world’s 

largest exposition of its kind, offering a comprehensive marketplace for product 

information and cutting-edge technology in one place. 

The SOT Annual Meeting is the premier event that the Society hosts every year 

to meet the needs of the entire toxicology community. More importantly, the 

Annual Meeting goes a long way toward fulfilling the SOT strategy of building for 

the future of toxicology, highlighting the significant scientific achievements, and 

broadening the awareness of these accomplishments and their potential impact. 

I urge you to join us for this event. Help us to make the 50th SOT Annual Meeting 

an event to remember. 

Sincerely, 

Michael P. Holsapple, Ph.D., ATS 

2010–2011 SOT President 

50 th Anniversary Annual Meeting and ToxExpo

Scientific Program 

Overview 

A page reference follows the session information. 


CE TARGET AREAS 

Course titles related to each theme are color coded in the listing below. 

Cardiovascular Toxicology 

This topic provides an overview of cardiovascular function at 

the gross and cellular level. It includes descriptions of cellular 

biochemistry and the impact of toxicants on system components 

or functions and presents methods and techniques to measure 

toxicity. 

Epigenetic Mechanisms 

This topic describes the field of epigenetic mechanisms and 

reviews fundamental cellular biochemistry. Roles of epigenetic 

mechanisms in cellular differentiation, aging, disease, therapeutic 

gene regulation, and toxicity may be presented. 

Systems Biology 

This topic describes and demonstrates the systems biology 

approach to the study of chemical mode of action and toxicity. 

It describes the interdisciplinary nature of the field and provides 

examples of how a multi-faceted systems biology approach 

can yield powerful results that both predict and describe the 

relationship between chemical exposure and cellular/systemic 

response. 

7:00 AM–7:45 AM 

SunriSE Continuing eduCATion CouRSE 

1. Biodegradable Materials for Tissue Engineering: Applications and 

Safety Assessment (p89) 

8:15 Am–12:00 NOON 

Morning Continuing eduCATion CouRSES 

2. Best Practices for Developing, Characterizing, and Applying 

Physiologically Based Pharmacokinetic Models in Risk Assessment 

(p89) 

3. Current Nonclinical Strategies and Methods for Evaluating Drug- 

Induced Cardiovascular Toxicity (p90) 

4. Dealing with the Data Deluge: A Live Data Discovery and Analysis 

Course (Note: Participants are asked to bring their own computer 

with Internet access) (p90) 

5. Epigenetics in Toxicology: Introduction, Mechanistic 

Understanding, and Applications in Safety Assessment (p91) 

6. Protecting Human Health: Use of Toxicological and 

Epidemiological Data in Determining Safe Levels for Human 

Exposure (p91) 

7. Drug Hypersensitivity Reactions: Risk Assessment and 

Management (p92) 

8. Toxicology and Risk Assessment of Chemical Mixtures (p92) 

1:15 PM–5:00 PM 

AfTERnoon Continuing eduCATion CouRSES 

9. Applications of Computational Systems Biology for Toxicology 

(p93) 

10. Evaluating Toxicity of Engineered Nanomaterials: Issues with 

Conventional Toxicology Approaches (p93) 

11. New Technologies and Approaches in Genetic Toxicology and 

Their Expanding Role in General Toxicology and Safety Assessment 

(p94) 

12. Practical How-To and Pitfalls Associated with Current Epigenetic 

Studies (p94) 

13. Quantitative In Vitro to In Vivo Extrapolation: The Essential Element 

of In Vitro Assay-Based Risk Assessment (p95) 

14. Stem Cell Utility in Toxicology Screening (p95) 

15. The Biology and Toxicology of the Peri- and Post-Natal 

Development (p96) 

THEMATIC APPROACH 

Monday–Thursday session titles related to each theme are color coded in the Program 

overview. 

Emerging Global Public Health Issues 

The global economy raises challenges to protecting human health 

within the United States for our regulatory agencies. Ultimately, 

public health issues are no longer just local issues affecting a 

single country or specific geographic region of the world, but have 

international health implications. The global public health issues 

theme has been selected to highlight recent advances in these 

areas, as well as how this knowledge is impacting regulation and 

policy. 

Environment and Disease 

Growing evidence suggest that the environment is a 

significant factor in the susceptibility and progression of 

cardiovascular and neurodegenerative diseases and cancer. 

The environmental influence on disease theme has been selected 

to highlight recent advances in these areas as well as contrast how 

this knowledge is impacting regulation and policy. 

Global Air Quality and Human Health 

It is becoming increasingly apparent that air pollution is not just a 

local issue, but has international health implications. The goal of 

this theme is to integrate information on individual susceptibility, 

disease mechanisms and levels of exposure and to demonstrate 

how this information can have a significant impact on the 

development of global air quality policies and regulations. 

Integration of Toxicological and Epidemiological Evidence to 

Understand Human Risk 

As novel technologies expand the range of biomarker assessments 

and the NAS vision for toxicity testing begins to be implemented, 

the integration of mechanistic laboratory animal testing and in 

vitro systems with human epidemiological data will require new 

strategies to fully utilize and integrate these data for extending the 

range of observations and to characterize the exposure-response 

of human risk. The goal of this theme is to initiate discussion on 

how new technologies can improve assessment of the doseresponse 

curve and thereby improve human risk assessment from 

environmental exposures. 

Novel Approaches to Preclinical Safety Assessment: 

Bridging the Gap between Discovery and the Clinic through 

Translational Toxicology 

Toxicology can play a key role in identifying and implementing 

advances in toxicological mechanisms, safety assessment, and 

biomarkers when cross-disciplinary efforts are coordinated 

during the drug development process. The goal of this theme is 

to highlight advances in toxicology that improve translation from 

animal models to humans. 

Toxicity Testing: State of Science and Strategies 

to Improve Public Health 

In order for Federal regulations to best reflect the current state 

of the science, toxicity testing paradigms need to adapt to the 

advances of science. The main challenge inherent in bringing this 

vision to fruition is to have testing strategies that provide sufficient 

context for evaluating potential risk. The goal of the toxicity 

testing theme is to initiate discussion on how toxicity testing could 

integrate state of the science methodologies and thereby reduce 

the uncertainties in the interpretation of toxicity-pathway data to 

humans.

Monday, March 7 

8:00 AM–9:00 AM 

PlenARy Opening LectuRE 

NIH Vision, Lecturer: Francis S. Collins, National 

Institute of Health (p116) 

9:15 AM–12:00 NOON 

SYMPOSIum SESSionS 

• Emerging Issues at the Intersection of 

Reproductive and Mixtures Toxicology (p116) 

• Environmental Oxidative Pollutant-Induced 

Pulmonary Toxicity (p117) 

• High Content Imaging: Applications in 

Toxicology and Toxicity Testing (p118) 

• Ribotoxic Stress: Mechanisms and Models for 

Human Disease (p118) 

WORKSHOP SESSionS 

• Disease Prevention: The Next 50 Years (p119) 

• New Approaches for Integrating Toxicological 

and Epidemiological Data to Better Inform 

Risk Assessment (p120) 

PLATfoRM SESSionS 

• Nanotoxicology—Carbon Nanotubes and 

Carbon Nanoparticles (p120) 

• New Insights into Male Reproductive 

Toxicology (p121) 

• Use of Embryonic Stem Cells in Toxicology 

(p122) 

9:30 AM–12:30 PM 

POSTER SESSionS 

• Bioinformatic Profiling and Computational 

Pathway Prediction (p126) 

• Carcinogenesis I (p133) 

• Cardiovascular Toxicology (p131) 

• Cell Signaling and Gene Regulation (p147) 

• DNA Replication and Repair (p125) 

• Epigenetic Mechanisms (p124) 

• Genotoxicity (p142) 

• Hypersensitivity: Methods and Mechanisms 

(p123) 

• Inflammatory Mediators in Disease 

Pathogenesis (p136) 

• Metals I (p137) 

• Metals II (p139) 

• Neurodegenerative Diseases (p129) 

• Receptor and Receptor-Mediated Toxicity 

(p144) 

12:10 PM–1:30 PM 

RoundTABLE SESSion 

• Reforming the Toxic Substances Control Act 

(TSCA): Challenges, Opportunities, and Timing 

(p151) 

INFORMATionAL SESSion 

• The International Cooperation on Alternative 

Test Methods (ICATM): Translating Science 

to Provide Improved Public Health Safety 

Assessment Tools (p152) 

EduCATion-CAREER DEVEloPMENT 

SESSion 

• Social Media and Informatics Essentials for 

Toxicologists (p152) 

12:15 PM–1:05 PM 

MERit AWARd LectuRE 

Neurotoxicology Goes Global: 

Scientific Collaboration and Mentorship, 

Lecturer: Michael Aschner (p153) 

1:00 PM–2:00 PM 

ToxExpo TiME! (NEW) 

1:00 PM–4:30 PM 


• Acetaminophen Hepatotoxicity (p155) 

• Animal Models in Toxicological Research 

(p160) 

• Animal Models in Toxicology (p162) 

• Biological Modeling: Computational 

Approaches, Mixtures, Multiroute and 

Lifestage Applications (p175) 

• Children’s Health/Juvenile Toxicology (p168) 

• Drug Induced Liver Injury (p153) 

• Immunotoxicity: Methods and Evaluation 

(p171) 

• Inhalation and Cardiopulmonary Toxicology 

(p164) 

• Kidney (p178) 

• Mechanisms of Immunotoxicity (p172) 

• Pharmaceutical Safety Assessment: 

Therapeutic Agents (p181) 

• Risk Assessment: Computational Approaches, 

Analyses, and Applications (p157) 

• Skin (p169) 

2:00 PM–4:45 PM 


• Epigenetics, Metals, and Cancer (p184) 

• Human Variability in Susceptibility to 

Environmental Toxicants (p185) 

• Toxicological Considerations in the Gulf of 

Mexico Oil Spill (p185) 

• Translational Toxicology: Molecules to Global 

Health (p186) 

• Vascular Developmental Toxicity: 

Identification, Prioritization, and Application 

(p186) 


• Protein Aggregation As a Common 

Mechanism of Toxicity in Neurodegenerative 

Diseases (p187) 

• Technical Characterization and Dosimetry 

Challenges Associated with Conducting or 

Interpreting Nanotoxicity (p187) 

• Understanding Structural and Physical 

Chemical Drivers of Drug Toxicity: Utility and 

Translatable Value (p188) 


• Advancing Assessment Approaches: 

Pesticides and Other Key Contaminants (p189) 

• Alternative Methods in Developmental 

Neurotoxicology: Validation and Application 

(p189) 

• Biomarkers of Carcinogenesis (p190) 

4:35 PM–5:55 PM 

SOT/EUROTox DEBATE 

Biomarkers from Blood and Urine Will Replace 

Traditional Histopathological Evaluation to 

Determine Adverse Responses (p191) 


6:30 AM–7:50 AM 

RoundTABLE SESSionS 

• Current Uses and Understanding of the Tissue 

Cross Reactivity Assay (p193) 

• Risk and Risk Management of Potentially Toxic 

Compounds Formed by Cooking Food (p193) 


• Emerging Science for Environmental Health 

Decisions: Tools, Strategies, and Evidence 

(p194) 

7:00 AM–7:50 AM 

lEAding EdGE in BASic ScienCE 

AWARd LectuRE 

Roles of Keap1-Nrf2 in Environmental 

Response, Lecturer: Masayuki Yamamoto (p194) 

8:00 AM–9:00 AM 

KeynoTE PlenARy LectuRE 

Increasing the Prestige of Regulatory Sciences, 

Lecturer: Margaret Hamburg, U.S. FDA (p195) 

9:00 AM–11:45 AM 


• Metabolic Basis of Respiratory Tract Chemical 

Toxicity (p195) 

• Stem Cell Biology and Cell Therapy 

Approaches to Understanding Cellular Injury 

and Wound Healing in Dermal, Ocular, and 

Pulmonary Injury (p196) 

• Uncovering the Role of Non-Coding RNAs in 



• Identification of Chemical Respiratory 

Allergens: Principles and New Developments 

(p197) 

• Safer Products for a Sustainable World: 

Linking Chemical Design and Toxicology 

(p197) 

• Using Mode of Action Data to Guide 

Quantitative Cancer Risk Assessment: A Case 

Study of Hexavalent Chromium in Drinking 

Water (p198) 

HISTORICAL HIGHliGHTS SESSion 

• 1961 to 2011 and Beyond: The Evolution of 


REGionAL INTEREST SESSion 

• Bombs in Our Backyards? Historical Military 

Activities and Current Public Health Issues in 

the U.S. Capital Region (p199) 


• Computational Approaches to Address DILI 

and Hepatoxicity (p200) 

• Epigenetic Mechanisms in Development and 

Disease 

(p200) 

• Gene Regulatory Mechanisms of 

Carcinogenesis (p201)

9:00 AM–12:30 PM 


• Ah Receptor in Immune Regulation and 


• Alternative Approaches to Animal Testing for 

Toxicological Research (p204) 

• Alternatives to Mammalian Models for Testing 

(p202) 

• Cholestasis, Lipid Homeostasis, and Liver 


• Epidemiology and Exposure Evaluations 

(p220) 

• Exposure Assessments and Biomonitoring 

Applications (p223) 

• Hepatotoxicity (p211) 

• ImmunoSafety Methods in Non-Rodents 

(p213) 

• Nanotoxicology: Carbon Nanotubes, Carbon 

Nanoparticles, and Quantum Dots (p218) 

• Oxidative Stress and Redox Biology (p225) 

• Reproductive Toxicology I (p207) 

• Reproductive Toxicology II (p209) 

• Stem Cell Toxicology (p216) 

12:00 NOON–1:20 PM 


• Integrating Alternative Test Methods into the 

Federal Regulatory Framework (p230) 

INFORMATionAL SESSionS 

• Coordinating Global Chemical Safety: The Big 

Four (p231) 

• Livers on a Plate: Next Generation Hepatocyte 

Models for High-Throughput Screening and 

Mode of Action Prediction (p231) 

12:15 PM–1:05 PM 

DiSTinguiSHEd Toxicology SCHolAR 

AWARd LectuRE 

Cloning and Functional Analysis of the Aryl 

Hydrocarbon Nuclear Translocator (ARNT), 

Lecturer: Oliver Hankinson (p232) 

1:00 PM–4:30 PM 


• Apoptosis/Cell Death (p258) 

• Biomarkers of Environmental Exposures (p260) 

• Developmental Toxicology (p255) 

• Drug Allergy, Pseudoallergy, IDRH, and 

Autoimmunity (p247) 

• Genetic Polymorphisms (p236) 

• Medical Devices (p232) 

• Metal Neurotoxicity: Methylmercury and 

General (p237) 

• Methods in Biomarker Discovery and 

Validation (p241) 

• Mutagenecity (p240) 

• Nanotoxicology (p244) 

• Neurotoxicity of Pesticides (p232) 

• ‘Omics in Toxicology Research (p253) 

• Risk Assessment and Regulatory Policy 

Applications (p249) 

• Safety and Risk Assessment: Critical 

Characterizations for Chemicals and New 

Concerns (p250) 

1:30 PM–4:15 PM 


• Developmental Origins of Adult Disease: The 

Effects of Low Dose Lead (p263) 

• Does the Clock Make the Poison? Influence 

of the Circadian Clock on Toxicological 

Mechanisms and Outcomes (p263) 

• Macrophages: Regulators of Toxicity and 

Disease Pathogenesis (p264) 

• When Is Exposure Not Exposure? Defining 

the Dose-Response Region between ”Effect” 

and “Adverse Effect” Implications for Human 

Health Risk Assessment (p265) 


• Nonclinical to Clinical Abuse Liability 

Assessment of Drugs: Current Practices, 

Challenges, and Impact of Recent Regulatory 

Guidance (p265) 

• Risk Assessment for Proteins Introduced into 

Genetically Modified Crops (p266) 

• The Spectrum of Systems Biology (p267) 


• Application of Zebrafish Models in Toxicology 

(p267) 

• Chemical and Biological Weapons—Sulfur 

Mustard Effects (p268) 

• Nanotoxicology—Nanosilver Particulates 

(p268) 

4:30 PM–6:00 PM 

50TH AnniVERSARy MEMBER 

CelEBRATion MEETing 

Wednesday, March 9 

6:30 AM–7:50 AM 

HISTORICAL HIGHliGHTS SESSion 

• 50 Years of “the Pill”: Risk Reduction and 

Discovery of Benefits Beyond Contraception 

(p271) 


• Precision-Cut Tissue Slices Revisited: A 

Classical Method Meets New Challenges 

(p271) 

• The Application of the Threshold of 

Toxicological Concern Concept to the 

Preclinical Safety Assessment of Non- 

Pharmaceutical Medical Products, Including 

Medical Devices and Combination Drug- 

Device Products (p272) 


SESSion 

• From Pilot Grants to High-End Journals: The 

Science of Writing (p272) 

8:00 AM–9:00 AM 

KeynoTE MediCAl RESEARCH Council 

(MRC) LectuRE 

Cellular Responses to DNA Damage: New 

Molecular Insights and New Approaches for 

Cancer Therapy, Lecturer: Stephen P. Jackson, 

University of Cambridge (p273) 

9:00 AM–11:45 AM 


• Autism: Genetic, Epigenetic, and 

Environmental Factors Influencing Neural 

Networks (p273) 

• Gene-Environment Disease Interactions in 

Fish Models of Human Disease (p274) 

• Mechanisms of Inflammation in Skin 

Carcinogenesis(p275) 

• New Insights into the Nrf2-Keap1 Pathway and 

Its Impact on Human Disease (p275) 


• Approaches for Incorporating Non-Chemical 

Stressors into Cumulative Risk Assessments 

(p276) 

• Extending Pulmonary Toxicity Findings for 

Nanomaterials (p276) 

• Understanding the Implications of Preclinical 

Seizures for Clinical Drug Development (p277) 

PLATfoRM SESSion 

• QSAR Approaches and Predictive Pathways 

(p278) 

9:00 AM–12:30 PM 


• Arsenic (p289) 

• Chemical and Biological Weapons (p293) 

• Metal Neurotoxicity: Manganese and Lead 

(p302) 

• Nanotoxicology: Metal Oxides, Silver, Gold, 

and Silica Nanoparticle Toxicity (p296) 

• Pesticides: General (p299) 

• Pharmaceutical Safety Assessment: Novel 

Methods (p284) 

• Phase I and II Biotransformation Enzymes 

(p280) 

• Risk Assessment: Conceptual Constructs and 

Current Controversies (p287) 

• Safety Testing of Pharmaceuticals (p283) 

• Toxicology Education: K–12 and Beyond (p282) 

• Xenobiotic Biotransformation (p278) 

9:30 AM–10:30 AM 

MEET the DiRECTor 

NIEHS Director, Lecturer: Linda Birnbaum, 

NIEHS (p305) 

Name: 

If found, please return to: 

Contact Telephone:

10:45 AM–11:45 AM 


CDC/NIOSH Director, Lecturer: John Howard, 

CDC/NIOSH (p306) 

12:00 NOON–1:00 PM 


Eunice Kennedy Shriver National Institute of 

Child Health & Human Development Director, 

Lecturer: Yvonne Maddox, NICHD (p307) 

12:00 NOON–1:20 PM 


• ‘Omics in Toxic Tort (p307) 


• Current and Changing Perspectives on 

Mycotoxins and Their Potential Health Risks 

Worldwide (p307) 

12:15 PM–1:05 PM 

TRAnslATional Impact AWARd 

lECTuRE 

Integration of Bioinformatics into Regulatory 

Decision Making, Lecturer: Weida Tong (p308) 

1:00 PM–4:30 PM 


• Aquatic and Ecotoxicology (p325) 

• Cellular Effects of Natural Product Extracts 

(p312) 

• Developmental Basis of Adult Disease (p310) 

• Endocrine Toxicology (p323) 

• Food Safety and Nutrition (p328) 

• Mechanisms of Aspiration Injury and Airway 

Disease 

(p321) 

• Mechanistic Assessments of Chemical 

Mixtures (p319) 

• Nanotoxicology: In Vitro and Ex Vivo Studies 

(p308) 

• Persistent Organic Compounds (POPs) (p314) 

• Pharmacokinetics and Disposition (p316) 

• Risk Assessment: Models and Approaches for 

Inhaled Agents (p318) 

• Toxicology of the Gulf Oil Spill (p322) 

1:15 PM–2:15 PM 


Center for Scientific Review Director, Lecturer: 

Sy Garte, Center for Scientific Review (p330) 

1:30 PM–4:15 PM 


• Autophagy in Toxicology: Essential Process, 

Adaptive Process, and Disease Process (p331) 

• Human Pluripotent Stem Cells and Neural 

Progenitors As Models of Gene-Environment 

Interactions in Neurological Disease (p331) 

• The Use of Epidemiological Data and PBPK 

Modeling in a Risk Assessment: Manganese As 

a Case Study (p332) 


• Advancing Predictive Ecotoxicology Testing 

and Environmental Risk Assessment in the 

21st Century (p333) 

• De-Risking the Potential for Cardiovascular 

Toxicity of Type-2 Diabetic Drugs: Preclinical 

and Clinical Strategies (p333) 

• Meeting the Challenges of Respiratory 

Toxicology Testing—In Search of Best 

Practices (p334) 

• Polishing Today’s Job Candidate in a Tough 

Economy 

(p335) 


• Airborne Particulates and Health Effects (p335) 

• Nrf2 and Antioxidant Response Networks 

(p336) 

2:30 PM–3:30 PM 


U.S. FDA Director, Lecturer: Jesse Goodman, U.S. 

FDA (p337) 

3:45 PM–4:45 PM 


U.S. EPA Director, Lecturer: Paul Anastas, U.S. 

EPA (invited) (p337) 

4:30 PM–5:50 PM 


• Assessment of Nanoparticle Exposure in 

Occupational Settings and in Inhalation 

Toxicology Studies: Is There a Best Dosemetric 

to Use? (p337) 


• Progress of the Tox21 Consortium in High- 

Throughput Bioactivity Profiling of Chemicals 

(p338) 

• Toxicological Considerations of 

Pharmacotherapy during Pregnancy (p338) 

Thursday, March 10 

6:30 AM–7:50 AM 

ISSUES SESSion 

• What It Means to Be Global (p340) 


• Beyond Science and Decisions: From Problem 

Formulation to Dose-Response (p340) 


SESSion 

• Bringing Toxicology to the Decision-Makers 

Table: Opportunities for Science Policy 

Positions in Washington, D.C. (p341) 

8:00 AM–9:00 AM 

KeynoTE PlenARy LectuRE 

U.S. EPA Vision, Lecturer: Lisa Jackson, U.S. EPA 

(invited) (p341) 

8:30 AM–12:00 NOON 


• Alternatives to Animal Models in Toxicology 

(p341) 

• Alternatives to Mammalian Models (p344) 

• Carcinogenesis II (p351) 

• Developmental Neurotoxicity: General (p348) 

• Disease Prevention (p346) 

9:00 AM–11:45 AM 


• Developmental Exposure to Environmental 

Toxicants: From Persistent Toxicities to 

Diseases (p354) 

• Vascular Injury: A Figment of Your 

Inflammation? (p354) 


• Are We There Yet? Attrition in the 

Pharmaceutical Industry and Impactful 

Strategies for Reducing Failure (p355) 

• Autoimmunity versus Systemic 

Hypersensitivity: Commonalities Useful for 

Immunotoxicity Testing (p355) 

• PBPK Model Use in Risk Assessment: Why 

Being Published Is Not Enough (p356) 

• Role of Biomarkers in Assessing Tobacco Harm 

Reduction: A Toxicological Perspective (p357) 

12:00 NOON–3:00 PM 

SATElliTE MEETinG 

Johns Hopkins Center for Alternatives to 

Animal Testing—Evidence-Based Toxicology 

(EBT) Collaboration Kick-Off Meeting (p87)

March 6–10, 2011 

Walter E. Washington Convention Center 


Visit www.toxicology.org for complete information 

Scan this code for quick and easy access to 

up-to-date Annual Meeting information. 

This is a QR (Quick Response) code. The code can be decoded by 

most camera-equipped mobile phones with a free downloadable 

application, thereby offering a direct link from this printed 

material to the latest and greatest 50th Anniversary and Annual 

Meeting information on the SOT Web site. Download a QR reader 

application and try it!

50 th Anniversary 

In honor of the Society’s 50th Anniversary, a number of celebration activities, events, and programs have been developed 

by the various Committees, Regional Chapters, Special Interest Groups, Specialty Sections, and Task Forces. Please take 

a moment to visit the 50th Anniversary Web site to view full descriptions of all the 50th Anniversary events and activities. 

All events will be held at the Walter E. Washington Convention Center unless otherwise noted. 

50th Anniversary Member 

Celebration Meeting 

Tuesday, March 8, 4:30 PM–6:00 PM 

All members are invited to celebrate the 

Society’s first 50 years of accomplishments. 

This fun event will highlight the history and 

growth of the Society over the past 50 years 

recognizing the members who are responsible 

for the Society’s success. Come see what is 

going in the Time Capsule that will be opened 

in 2036 by current and future SOT members. 

Receive your copy of The Society of Toxicology: 

The First Fifty Years. 

50th Anniversary Book 

SOT is publishing a deluxe publication, The 

Society of Toxicology: The First Fifty Years, 

which features the many significant events and 

people who have helped move the toxicology 

field to where it is today. The historical articles 

and photographs that make up the book are 

priceless. Please visit the SOT 50th Anniversary 

Web site to view the table of contents and to 

get an idea of materials collected so far. Society 

members who attend the 50th Anniversary 

Members Celebration on Tuesday, March 8, 

will receive a complimentary copy of the book 

(see previous listing). In addition, the book can 

be picked up at the SOT Registration Area on 

Wednesday, March 9. All members will be able 

to download the book from the SOT Web site 

after the Annual Meeting. 


Sunday, March 6, 5:15 PM–6:30 PM 

SOT will recognize our prestigious award 

recipients at the SOT Awards Ceremony 

(pages 63–71). Please refer to the Awards and 

Fellowships section of the SOT Web site for 

complete details about the award recipients 

and criteria. In commemoration of the 50th 

Anniversary, two individuals who have significantly 

and positively influenced the fields 

of toxicology will be inducted as Honorary 

Members: William C. Hays, Esq. and Dr. 

Frances Kathleen Oldham Kelsey. 

Benchmarks in Toxicology Banner 

SOT and the National Institute of 

Environmental Health Sciences (NIEHS) will 

showcase the winning benchmarks on a huge 

banner that will be displayed prominently at 

the Walter E. Washington Convention Center. 

In addition, a Benchmarks poster will be 

distributed to attendees and will also appear 

on the SOT Web site. 




Come celebrate the 50th Anniversary in style. 

Dance the night away with tunes from the 

Beatles as performed by BeatleMania Live. 

Dress in your favorite decade’s attire (60’s to 

the future)! Additional entertainment plans 

include festive decorations, games, delicious 

food stations, and beverages. This is truly an 

event you will not want to miss! Purchase your 

ticket now by signing up on the 2011 Annual 

Meeting registration form. A limited number 

of discounted tickets have been set aside for 

trainees (undergraduate students, graduate 

students, and postdocs). All tickets will be sold 

on a first-come, first-served basis and are nonrefundable 

after February 11, 2011. 

Committee on Diversity 

Initiatives Reunion 

Saturday, March 5, 8:00 PM–9:00 PM 

The Committee on Diversity Initiatives 

(CDI) will host the CDI Reunion from 

8:00 PM–9:00 PM on Saturday, March 5. 

Whether as a student, peer mentor, host 

mentor, speaker, or organizer, anyone who has 

ever been involved in the SOT Undergraduate 

Program is invited to attend. Visit with 

colleagues who have been involved in the 

program over the last 22 years, meet with 

program alums, and greet the undergraduate 

students who are attending the program this 

year. The 2011 Endowment Gehring Diversity 

Student Travel Award will be presented. Enjoy 

dessert, coffee, and tea. Start off your 50th 

Anniversary meeting celebration by joining 

with the special people who have contributed 

to the diversity in SOT through this important 

activity. 

Commemorative Posters 

A picture says it all! SOT has created a 

series of posters highlighting important 

aspects of the Society and the science. Please 

visit the SOT Web site to view the latest 

posters. The posters will also be on display 

from Sunday, March 6, to Wednesday, 

March 9, in the pre-function space outside 

the Exhibit Hall at the Walter E. Washington 

Convention Center. 

Decades Keepsake Brochure— 

Fifty Years of Impact 

Get a snapshot of the past 50 years. This 

colorful brochure features short summaries by 

decade of global history, along with brief writeups 

about major toxicological innovations. 

Each attendee to the 2011 Annual Meeting will 

want to get their copy to enjoy and save until 

the next major SOT anniversary. The brochure 

will also be posted on the SOT Web site after 

the Annual Meeting. 

SOT 50th Anniversary 

Endowment Fund Matching 

In honor of SOT’s 50th Anniversary, SOT 

Council has committed to match $750,000 of 

contributions to the Endowment Fund. Almost 

$600,000 in contributions have already been 

matched. Help us meet the match with your 

contribution. All contributions to the General 

Purpose Fund are currently being matched. 

Visit www.toxicology.org/ai/csot/contribute. 

asp. 

Endowment Fund 

50th Anniversary Undergraduate 

Educator Award 

The new Endowment Fund Undergraduate 

Educator Award is being sponsored by 

the Endowment Education Fund and the 

Endowment SOT Priorities Fund in honor 

of the 50th Anniversary and outstanding 

undergraduate education. The awardee, 

Joan B. Tarloff, will be recognized at the 

Sunday, March 6, Awards Ceremony. To learn 

more about the award criteria, please visit 

www.toxicology.org/ai/af/awards.aspx.

Celebration Activities 

Historical Highlights 

In recognition of the SOT 50th Anniversary, 

the Scientific Program Committee has selected 

two special Historical Highlight sessions: 

1961–2011 History of Toxicology 

Tuesday, March 8 , 9:00 AM–11:45 AM 

50 Years of “the Pill” 

Wednesday, March 9, 6:30 AM–7:30 AM 

Historical Photo Gallery 

SOT Historical Photo Gallery is comprised 

of pictures from the SOT archives; most are 

from the various Annual Meetings. Take a 

few moments to view the slide show and share 

these images with colleagues and friends. Help 

contribute to the photo gallery by posting 

your pictures from SOT events. Please come 

back and visit again as pictures will be added 

regularly, and let us know if any of the captions 

need to be corrected. 

Landmarks Program Presentation 

to the National Academy of 

Science 

Monday, March 7, 7:45 AM–8:00 AM 

Michael P. Holsapple, SOT President, will 

present a landmark plaque to leaders of the 

Committee on Toxicology, National Academy 

of Sciences (NAS), where the Society of 

Toxicology was founded March 4, 1961, 

and subsequently re-defined, fostered, and 

supported. The plaque represents the gratitude 

and appreciation of the leadership and 

membership of the Society of Toxicology. 

Regional Chapter, Special Interest 

Group, and Specialty Section 

Posters 

The Regional Chapters, Special Interest 

Groups, and Specialty Sections are important 

components of the Society and have 

contributed to the Society’s overall diversity. 

From Sunday, March 6 to Wednesday, 

March 9, posters highlighting these component 

groups’ roles in the Society will be displayed 

in the pre-function space outside the Exhibit 

Hall at the Walter E. Washington Convention 

Center. The posters will also be available on 

the SOT Web site after the Annual Meeting. 

Past Presidents 5K Fun Run 

Sunday, March 6, 6:00 AM 

In celebration of 50 years of moving the 

Society of Toxicology forward, the SOT 

Past Presidents have organized a 5K Fun 

Run at the 2011 SOT Annual Meeting. 

Can you keep up? SOT Past Presidents 

Jay Goodman (1999–2000) and Bill Greenlee 

(2002–2003) will be the pace presidents for an 

extremely fun, competitive, and entertaining 

5K race at scenic Hains Point in East Potomac 

Park. Past Presidents will cheer and greet you 

as you cross the finish line. 

Sign up on the SOT Annual Meeting Web site. 

Those who pre-register before February 15, 

2011, will receive a free 2011 Fun Run T-Shirt! 

Transportation to the Fun Run will depart 

at 6:00 AM from the L Street entrance of the 


and return to the same location. Results will 

be announced on ToXchange, at the 50th 

Anniversary Member Celebration Meeting, 

as well as on the SOT Web site and in the 

Communiqué. 

Protecting You and Your 

Pet through the Science of 

Toxicology: Paracelsus Goes to 

Washington 

Saturday, March 5, 10:00 AM–5:00 PM 

Marian Koshland Science Museum 

of the National Academy of Sciences 

SOT is sponsoring a free Family Day at the 

Marion Koshland Science Museum of the 

National Academy of Sciences. In addition 

to the activities that are on display, SOT 

will supplement the topic areas of Wonders 

of Science, Safe Drinking Water, Global 

Warming, and Infectious Disease with 

toxicology-related activities. Toxicologists 

from a variety of employment sectors will 

be available to engage with visitors. Renate 

Reimschuessel, V.M.D., Ph.D., Veterinary 

Laboratory Response Network Program 

Director, U.S. FDA Center for Veterinary 

Medicine, will speak at 12:00 NOON 

on “Poisoned Pet Food—Unraveling the 

Melamine Mystery.” Bring your family or 

volunteer to assist. 

50th Anniversary Silent Auction 

Live on SOT Web site on February 1 

(Access on-site in the E-mail Center or via your 

Internet connection) 

In honor of the 50th Anniversary of SOT, the 

Postdoctoral Assembly is organizing the 50th 

Anniversary Silent Auction. Bid on vacation 

get-a-ways or purchase items of historical 

significance to SOT and toxicology (such 

as books, laboratory items, memorabilia, 

photographs) as well as other items of general 

interest. Bids for some items will close in 

the E-mail Center Monday, March 7, from 

4:45 PM–5:45 PM. Join the excitement! Cash 

bar available. Bring your laptop or smart 

phone to join in the bidding. 

Bids for remaining items will close beginning 

at 10:00 AM Wednesday and conclude at 

1:00 PM. All proceeds from the Silent Auction 

will go to the Endowment Priorities Fund. 

Smithsonian Seminar: Poisons: 

When Good Chemicals Turn Bad 


S. Dillon Ripley Center 

To commemorate SOT’s 50th Anniversary, 

the Smithsonian Institution is holding an 

all-day seminar for the public featuring the 

latest research in the science of toxicology, and 

information about the positive and adverse 

effects that chemical, biological, and physical 

substances can have on people, animals, and 

the environment. We are surrounded by 

chemicals that may be beneficial, harmful, 

or neither depending on the dose. This daylong 

session, which features several SOT 

members, is open to the public and requires 

separate registration. SOT members receive 

the Smithsonian member discount. To learn 

more please visit www.toxicology.org/ai/ 

meet/am2011. 

ToxExpo 50th Anniversary Raffle 

While visiting the Exhibit Hall, be sure to 

stop by the Diamond Level Sponsor booths to 

drop off your business card and have a chance 

at winning $500. Drawings will take place 

on Monday, Tuesday, and Wednesday in the 

Exhibit Hall. The Diamond Level Sponsors are 

acknowledged on the back cover.

The Founding 

Society of Toxicology Founders 

Top Row (from left): Paul Larson, Medical College of Virginia; 

C. Boyd Shaffer, American Cynamid; Victor A. Drill, G.D. Searle & 

Company; Frederick Coulston, Sterling Winthrop Institute; 

Kenneth DuBois, University of Chicago. Seated (from left): 

Harry W. Hays, National Academy of Sciences-National Research 

Council; Harold C. Hodge, University of Rochester School of Medicine; 

Arnold J. Lehman, Food and Drug Administration; and 

William B. Deichmann, University of Miami School of Medicine. 

Ref. Hays, H.W. Society of Toxicology History 1961–1986 

The First Annual Meeting of the Society of Toxicology was held in Atlantic City, New Jersey, 

on April 15, 1962. There were 180 Charter members and 3 Honorary members by that time. 

This meeting followed organizational meetings in Atlantic City, New Jersey (FASEB), Detroit, Michigan (AIHA), Meriden, New 

Hampshire (Gordon Conference), and Rochester, New York (ASPET). 

The Founding of the Society 

On Saturday, March 4, 1961, a small group met in Washington, D.C., to talk about the need for providing a forum where 

toxicologists could meet and share their research findings. By the end of their day-long meeting the Founders had concluded that 

the advantages of forming a society outweighed the disadvantages. They had even suggested a name, “The Society of 

Toxicology” and it was to be an international learned society drawing together persons trained in the various disciplines related to 

toxicology. 

The follow-up work from this organizational meeting required preparation of a draft constitution, by-laws, scheduling 

presentations at upcoming scientific meetings, and notifying key people in the field of their plans. To finance all this, each 

attendee at the first meeting contributed $5 to the treasury. Accordingly, the Society of Toxicology was launched with assets of $35. 

1821 Michael Faraday Drive, Suite 300, Reston, VA 20190 

E-mail: sothq@toxicology.org | Phone:703.438.3115 | Fax: 703.438.3113 

Web site: www.toxicology.org

of the Society 

Regional Chapter Year Founded 

1981 Michigan 

Specialty Section Year Founded 

1981 Mechanisms 

1981 Mid-Atlantic 

1981 

Metals 

1981 Midwest 

1981 

Reproductive and 

Developmental Toxicology 

1981 North Carolina 

1982 

Inhalation and Respiratory 

1982 National Capital Area 

1982 

Neurotoxicology 

1982 South Central 

1985 

Immunotoxicology 

THE SOCIETY OF TOXICOLOGY SEAL 

SALUS—Latin for “Safety” 

The Ribband—A Token of Pre-Eminence or Superiority 

The Arrow—Toxicum (Latin for poison arrow) 

The Shield—Protection 

The Wreath—Symbol of Success 

Radiating Lines—Force Manifesting Itself: Victory Over 

Ignorance 

COLORS 

White for the Shield 

Red Background, Suggesting Warning or Danger 

Black Arrow—Meaning Ignorance 

White Ribband—Meaning Wisdom 

Olive Green for the Wreath Indicating Vigor 

1984 Gulf Coast 

1984 Mountain West 

1984 Ohio Valley 

1984 Pacific Northwest 

1984 Southeastern 

1986 Central States 

1986 Northeast 

1986 Northern California 

1988 Allegheny-Erie 

1986 

1989 

1989 

1993 

1993 

1994 

1997 

1998 

Carcinogenesis 

Molecular Biology 

Risk Assessment 

Food Safety 

Regulatory and 

Safety Evaluation 

In Vitro and 

Alternative Methods 

Occupational and 

Public Health 

Comparative and Veterinary 

Designed by Louise Shaffer, wife of C. Boyd Shaffer, 

a Founder of the Society 

1988 Southern California 

1989 Northland 

2000 

2000 

Biological Modeling 

Toxicologic and 

Exploratory Pathology 

1997 Lake Ontario 

2000 

Dermal Toxicology 

2004 

Ethical, Legal, and 

Social Issues 

2005 

Drug Discovery Toxicology 

2006 

Mixtures 

2007 

Nanotoxicology 

2008 

Ocular Toxicology 

2009 

Biotechnology Toxicology 

2009 


Allegheny-Erie ........................ AE 

Central States.......................... CS 

Gulf Coast.................................GC 

Lake Ontario............................ LO 

Michigan................................... MI 

Mid-Atlantic............................MA 

Midwest ..................................MW 

Mountain West ................MtnW 

National Capital Area .....NCAC 

North Carolina ........................NC 

Northeast .................................NE 

Northern California............ NCa 

Northland................................. NL 

Ohio Valley.............................. OV 

Pacific Northwest.............. PNW 

South Central.......................... SC 

Southeastern............................SE 

Southern California.............SCa 

REGIONAL CHAPTERS 

2009 

2010 

Medical Device 

Stem Cells 

Special Interest Group Year Founded 

2001 

Women in Toxicology 

(founded as a Specialty Section) 

2006 

American Association of 

Chinese in Toxicology 

2006 

Association of Scientists of 

Indian Origin 

2006 

Hispanic Organization of 

Toxicologists 

2006 

Korean Toxicologists 

Association of America 

2008 Toxicologists of African Origin

Fifty Years of Outstanding Leadership 

1961 1962 1962 1963 1963 1964 1964 1965 1965 1966 

Harold C. Hodge C. Boyd Shaffer Paul S. Larson Harry W. Hays Frederick Coulston 

1971 1972 1972 1973 1973 1974 1974 1975 1975 1976 

Wayland J. Hayes, Jr. Victor A. Drill Joseph F. Borzelleca Sheldon D. Murphy Seymour L. Friess 

1981 1982 1982 1983 1983 1984 1984 1985 1985 1986 

Robert B. Forney Robert L. Dixon Gabriel L. Plaa Frederick W. Oehme Emil A. Pfitzer 

1991 1992 1992 1993 1993 1994 1994 1995 1995 1996 

Donald J. Reed John L. Emmerson I. Glenn Sipes Meryl H. Karol Jack H. Dean 

2001 2002 2002 2003 2003 2004 2004 2005 2005 2006 

David L. Eaton William F. Greenlee Marion F. Ehrich Linda S. Birnbaum Kendall B. Wallace 

Celebrating Fifty Years of Service to the

SOT Presidents 1961–2011 

1966 1967 1967 1968 1968 1969 1969 1970 1970 1971 

Verald K. Rowe John A. Zapp, Jr. Carrol S. Weil Ted A. Loomis Robert L. Roudabush 

1976 1977 1977 1978 1978 1979 1979 1980 1980 1981 

Robert A. Scala Harold M. Peck Leon Golberg Tom S. Miya Perry J. Gehring 

1986 1987 1987 1988 1988 1989 1989 1990 1990 1991 

John Doull Jerry B. Hook James E. Gibson Roger O. McClellan Curtis D. Klaassen 

1996 1997 1997 1998 1998 1999 1999 2000 2000 2001 

James S. Bus R. Michael McClain Steven D. Cohen Jay I. Goodman Daniel Acosta, Jr. 

2006 2007 2007 2008 2008 2009 2009 2010 2010 2011 

James A. Popp George B. Corcoran Kenneth S. Ramos Cheryl Lyn Walker Michael P. Holsapple 

Science and Profession of Toxicology

Building on the Foundation 

of Our Membership 

The Founders of the Society of Toxicology 

The Founders of the Society of Toxicology, March 4, 1961: 

(top row from left) Paul S. Larson, C. Boyd Shaffer, 

Victor A. Drill, Fredrick Coulston, Kenneth P. DuBois; 

(bottom row from left) Harry W. Hays, Harold C. Hodge, 

Arnold J. Lehman, William B. Deichmann. 

Honorary Members 

1962 ...... Eugene M. K. Geiling* 

1962 ...... W. F. Von Oettingen* 

1962 ...... Torald H. Sollman* 

1963 ....... Ethel Browning* 

1966 ...... R. Tecwyn Williams* 

1976 ....... Norton Nelson* 

1982 ...... George H. Hitchings* 

1986 ....... Bernard B. Brodie* 

1986 ....... Herbert Remmer* 

1991 ........ Hyman J. Zimmerman* 

1994 ...... Ronald W. Estabrook 

1994 ...... Wendell W. Weber 

1995 ....... Gertrude B. Elion* 

1995 ....... Charles S. Lieber* 

1996 ...... Sten G. Orrenius 

1996 ...... Dennis Parke* 

1997 ....... John E. Casida 

1997 ....... Roger W. Russell* 

1998 ....... Jud Coon 

1998 ....... Michel Mercier 

1999 ...... William O. Robertson 

1999 ...... Takashi Sugimura 

2000 .... Findlay Russell 

2001 ...... Herbert Needleman 

2007 ...... Mario Molina 

2008 ...... Lee Hartwell 

2008 ...... H. Robert Horvitz 

2009 ...... Gilbert S. Omenn 

2009 ...... Sir John E. Walker 

2010 ....... Sir Philip Cohen 

2010 ....... Ferid Murad 

2011 ....... William C. Hays, Esq. 

2011 ....... Frances Kathleen Oldham Kelsey 

The Society of Toxicology recognizes nonmembers who embody outstanding and sustained achievements 

in the field of toxicology with Honorary Membership. Candidates are nominated by two Full or Associate 

members of the Society. Seconding letters and information regarding career achievements in toxicology 

accompany the nomination. A two-thirds vote of Council determines recipients, with not more than two 

Honorary Members elected during any one term of Council.

The SOT Council Thanks and Recognizes Some of the Many 

Members Who Have Contributed to the Success of the Society: 

84 Charter Members 

Edgar M. Adams, Ph.D. 

Anthony M. Ambrose, Ph.D. 

Kenneth C. Back, Ph.D. 

Robert E. Bagdon, Ph.D., DABT 

Tibor Balazs, D.V.M. 

Bernard A. Becker, M.S. 

Karl Friedrich Benitz, M.D. 

Karl H. Beyer, Jr., M.D., Ph.D. 

Frank R. Blood, Ph.D. 

Albert N. Booth, Ph.D. 

Carl E. Boyd, M.D. 

Eldon M. Boyd, M.D. 

Herbert A. Braun, Ph.D. 

Theodore M. Brody, Ph.D. 

Charles P. Carpenter, Ph.D. 

Louis J. Casarett, Ph.D. 

Maynard B. Chenoweth, M.D. 

Herbert E. Christensen, D.Sc. 

Gerald R. Clements, Ph.D. 

Julius M. Coon, M.D., Ph.D. 

Herbert H. Cornish, Ph.D., DABT 

Frederick Coulston, Ph.D. 

Bernard Davidow, Ph.D. 

Kent J. Davis, D.V.M. 

Earl H. Dearborn, M.D., Ph.D. 

William B. Deichmann, Ph.D. 

Charles S. Delahunt, D.V.M. 

Harold F. Diermeier, Ph.D. 

Abel M. Dominguez, Ph.D. 

John Doull, M.D., Ph.D., ATS 

William L. Downs, M.S. 

Victor A. Drill, M.D., Ph.D. 

Hans P. Drobeck, Ph.D. 

Kenneth P. DuBois, Ph.D. 

Charles G. Durbin, V.M.D. 

William F. Durham, Ph.D., DABT 

Edward Eagle, Ph.D. 

Alfred E. Earl, D.V.M. 

Otho D. Easterday, Ph.D. 

John R. Elsea, Ph.D. 

George A. Emerson, Ph.D. 

David W. Fassett, M.D. 

O. Garth Fitzhugh, Ph.D. 

John P. Frawley, Ph.D. 

Alastair C. Frazer, M.D., Ph.D. 

Seymour L. Friess, Ph.D. 

William H. Funderburk, Ph.D. 

Karl L. Gabriel, Ph.D., V.M.D., 

DABT 

Eugene Maxmillian Karl Geiling, 

M.D., Ph.D. 

Horace W. Gerarde, M.D., Ph.D. 

Jerome M. Glassman, Ph.D. 

Morton E. Goldberg, D.Sc. 

Richard C. Graham, Ph.D. 

Edward LeB Gray, Ph.D. 

Zareh Hadidian, Ph.D. 

Thomas J. Haley, Ph.D. 

Duane W. Hallesy, Ph.D. 

Walter E. Hambourger, M.D., 

Ph.D. 

Philip L. Harris, Ph.D. 

Joseph W. E. Harrisson, D.Sc. 

Wayland J. Hayes, Jr., M.D., Ph.D. 

Harry W. Hays, Ph.D. 

Lloyd W. Hazleton, Ph.D. 

Gordon Ross Hennigar, M.D. 

Bernard E. Hietbrink, Ph.D. 

Charles H. Hine, M.D., Ph.D. 

Harold C. Hodge, Ph.D. 

James O. Hoppe, Ph.D. 

William H. Hunt, Ph.D. 

Colin H. Hunter, M.D. 

John W. Hylin, Ph.D. 

Don D. Irish, Ph.D. 

Margaret Ives, Ph.D. 

Benjamin A. Jackson, M.B.A., Ph.D. 

Keith H. Jacobson, Ph.D. 

Daniel C. Jessup, Ph.D. 

L. Meyer Jones, D.V.M., Ph.D. 

Ralph Jones, Jr., M.D. 

Joseph A. Kaiser, Ph.D. 

John H. Kay, Ph.D. 

Sidney Kaye, Ph.D. 

Charles J. Kensler, Ph.D. 

Moreno L. Keplinger, Ph.D. 

Kathel B. Kerr, D.Sc. 

Jiro K. Kodama, Ph.D. 

Harry A. Kornberg, Ph.D. 

Herman F. Kraybill, Ph.D. 

Stephen Krop, Ph.D. 

Souheil Laham, Ph.D., CIH 

Kenneth F. Lampe, Ph.D. 

Paul S. Larson, Ph.D. 

Leonard J. Leach, B.S. 

Arnold J. Lehman, M.D., Ph.D. 

Margaret I. Leonard, Ph.D. 

George J. Levinskas, Ph.D., DABT 

Amos E. Light, M.A. 

Charles R. Linegar, Ph.D. 

Ted A. Loomis, M.D., Ph.D., ATS 

Frank C. Lu, M.D. 

Lehman M. Lusky, B.A. 

William E. MacDonald, Ph.D. 

Harold N. MacFarland, Ph.D., 

FRCP 

Willard Machle, M.D. 

William A. Mannell, Ph.D. 

Gilbert J. Mannering, Ph.D. 

Hiromu Matsumoto, Ph.D. 

Paul A. Mattis, D.Sc. 

Elliot A. Maynard, Ph.D. 

John D. McColl, Ph.D. 

Donald D. McCollister, B.S. 

Francis P. McGrath, M.S. 

Herbert McKennis, Jr., Ph.D. 

Bernard P. McNamara, Ph.D. 

James C. Munch, Ph.D. 

John I. Munn, Ph.D. 

Sheldon D. Murphy, Ph.D. 

John H. Nair, M.S. 

Joe B. Nash, Ph.D. 

James W. Newberne, D.V.M., Ph.D., 

ATS 

Gordon W. Newell, Ph.D., ATS 

Fred W. Oberst, Ph.D. 

Yvo T. Oester, M.D., Ph.D. 

Donald L. Opdyke, Ph.D. 

Bernard L. Oser, Ph.D. 

Elias W. Packman, Sc.D. 

Arthur J. Pallotta, Ph.D. 

Edward D. Palmes, Ph.D. 

Orville E. Paynter, Ph.D. 

Harold M. Peck, M.D. 

Rafael A. Penalver, M.D. 

Gabriel L. Plaa, Ph.D., DABT, ATS 

Albert J. Plummer, M.D., Ph.D. 

Urbano C. Pozzani, M.S. 

Charles D. Proctor, Ph.D., D.Sc. 

Charles L. Punte, B.S. 

Jack L. Radomski, Ph.D., ATS 

Virgil B. Robinson, Ph.D. 

Harry Rosen, Ph.D. 

Robert L. Roudabush, Ph.D. 

Verald K. Rowe, D.Sc. 

Jack P. Saunders, Ph.D. 

Jean Scholler, Ph.D. 

Joseph Seifter, M.D. 

C. Boyd Shaffer, Ph.D. 

Martin Sherman, Ph.D. 

Gary J. Sibert, D.V.M., Ph.D. 

Jacob Siegel, Ph.D 

Frank A. Smith, Ph.D. 

R. Blackwell Smith, Jr., Ph.D. 

Fred H. Snyder, Ph.D. 

Torald H. Sollmann, M.D. 

Frederick Sperling, Ph.D. 

William B. Stavinoha, Ph.D. 

James H. Sterner, M.D. 

Herbert E. Stokinger, Ph.D. 

Joseph L. Svirbely, Ph.D. 

Maurice L. Tainter, M.D. 

Anton A. Tamas, M.D. 

Jean M. Taylor, Ph.D. 

Clinton H. Thienes, M.D., Ph.D. 

Richard F. Tislow, D.Sc., M.D. 

Joseph F. Treon, Ph.D. 

Thomas W. Tusing, M.D. 

Clarence G. Van Arman, Ph.D. 

Leonard J. Vinson, Ph.D. 

Wolfgang Felix Von Oettingen, 

M.D., Ph.D. 

John W. Ward, Ph.D. 

Francis X. Wazeter, Ph.D. 

Lawrence C. Weaver, Ph.D. 

Stewart H. Webster, Ph.D. 

Maurice H. Weeks, M.S. 

John H. Weikel, Jr., Ph.D. 

Carrol S. Weil, M.A. 

John H. Weisburger, Ph.D., M.D. 

(hon) 

Bob West, Ph.D. 

Norman G. White, Ph.D. 

Martin W. Williams, Ph.D. 

Geoffrey Woodard, Ph.D. 

Alastair N. Worden, M.A. 

Frederick F. Yonkman, M.D., Ph.D. 

John Zapp, Jr., Ph.D. 

Virginia Zaratzian, Ph.D. 

Benjamin R. Zeitlin, M.S. 

Robert E. Zwickey, D.V.M.

Celebrating Achievements 

Honorary Membership 

The Society of Toxicology 

recognizes non-members 

who embody outstanding 

and sustained achievements 

in the field of toxicology 

with Honorary Membership. 

Candidates are nominated 

by two Full or Associate 

members of the Society. A 

two-thirds vote of Council 

determines recipients, with 

not more than two Honorary 

Members elected during any 

one term of Council. 

Inductees 

1962 Eugene M.K. Geiling 

W. F. Von Oettingen 

Torald H. Sollman 

1963 Ethel Browning 

1966 R. Tecwyn Williams 

1976 Norton Nelson 

1982 George H. Hitchings 

1986 Bernard B. Brodie 

Herbert Remmer 

1991 Hyman J. Zimmerman 

1994 Ronald W. Estabrook 

Wendell W. Weber 

1995 Gertrude B. Elion 

Charles S. Lieber 

1996 Sten G. Orrenius 

Dennis Parke 

1997 John E. Casida 

Roger W. Russell 

1998 Jud Coon 

Michel Mercier 

1999 William O. Robertson 

Takashi Sugimura 

2000 Findlay Russell 

2001 Herbert Needleman 

2007 Mario Molina 

2008 Lee Hartwell 

H. Robert Horvitz 

2009 Gilbert Omenn 

John E. Walker 

2010 Philip Cohen 

Ferid Murad 

2011 William C. Hays 

Frances Oldham Kelsey 

Achievement Award 

The Achievement Award is 

presented to a member of the 

Society of Toxicology who 

has less than 15 years experience 

since obtaining his/her 

highest earned degree (in the 

year of the Annual Meeting 

of the Society of Toxicology) 

and who has made significant 

contributions to toxicology. 

Award Recipients 

1967 Gabriel L. Plaa 

1968 Allan H. Conney 

1969 Samuel S. Epstein 

1970 Sheldon D. Murphy 

1971 Yves Alarie 

1972 Robert L. Dixon 

1973 (No Award) 

1974 Morris F. Cranmer 

1975 Ian C. Munro 

1976 Curtis D. Klaassen 

1977 James E. Gibson 

1978 Raymond D. Harbison 

1979 Michael R. Boyd 

1980 Philip G. Watanabe 


1982 Frederick P. Guengerich 


1984 Melvin E. Andersen 

1985 Alan R. Buckpitt 

1986 Sam Kacew 

1987 James S. Bus 

1988 Jeanne M. Manson 

1989 James P. Kehrer 

1990 Michael P. Waalkes 

1991 Debra Lynn Laskin 

1992 Michael P. Holsapple 

1993 David L. Eaton 

1994 James L. Stevens 

1995 Lucio G. Costa 

1996 Kenneth S. Ramos 

1997 Kevin E. Driscoll 

1998 Rick G. Schnellmann 

1999 Michel Charbonneau 

2000 Christopher Bradfield 

2001 Martin A. Philbert 

2002 Ruth A. Roberts 

2003 Lois D. Lehman- 

McKeeman 

2004 David C. Dorman 


2006 Jose E. Manautou 

2007 Jeffrey M. Peters 

2008 Ivan Rusyn 

2009 Russell S. Thomas 

2010 Gary W. Miller 

2011 Nathan Cherrington 

Arnold J. Lehman 

Award 

The Arnold J. Lehman Award 

is presented to recognize an 

individual who has made 

a major contribution to 

risk assessment and/or the 

regulation of chemical agents, 

including pharmaceuticals. 

The contribution may have 

resulted from the application 

of sound scientific 

principles to regulation and/ 

or from research activities that 

have significantly influenced 

the regulatory process. 


1980 Allan H. Conney 


1982 Gary M. Williams 

1983 David P. Rall 

1984 Tibor Balasz 

1985 Frederick Coulston 

1986 Gerrit Johannes Van 

Esch 

1987 John P. Frawley 

1988 Kundan S. Khera 

1989 Richard H. Adamson 

1990 Harold C. Grice 

1991 Bernard A. Schwetz 

1992 Roger O. McClellan 

1993 Thomas W. Clarkson 

1994 Bruce Ames 

1995 Emil A. Pfitzer 

1996 John F. Rosen 


1998 Helmut Alfred Greim 


2000 Carole A. Kimmel, 

Janardan K. Reddy 

2001 Samuel M. Cohen 

2002 Dennis Paustenbach 

2003 Michael L. Dourson 

2004 Melvin E. Andersen 

2005 Rory B. Conolly 

2006 Kathryn R. Mahaffey 

2007 Harvey J. Clewell 

2008 Vicki Dellarco 

2009 Michael Bolger 

2010 Edward V. Ohanian 

2011 Bette Meek 

Best Postdoctoral 

Publication Awards 

The Best Postdoctoral 

Publication Awards were 

created by the Postdoctoral 

Assembly to recognize talented 

postdoctoral researchers 

who have recently published 

exceptional papers in the field 

of toxicology. 


2007 Nadine Dragin, 

Kristen Mitchell, 

Drobna Zuzana 

2008 Joshua P. Gray, 

Christie M. Sayes, 

Khristy J. Thompson 

2009 Jeffrey W. Card, 

Kembra Howdeshell 

Lewis Zhichang Shi 

2010 Bret F. Bessac, 

Manabu Nukaya, 

Nicolas Radio 

2011 Dieldrich S. Bermudez 

Joshua A. Harrill 

Jordan Ned Smith 

Board of Publications 

Best Paper in 

Toxicological Sciences 

Award 

The Board of Publications 

Award for the Best Paper in 

Toxicological Sciences is 

presented to the author(s) of 

the best paper published in 

this official SOT publication 

during a 12-month period, terminating 

with the June issue 

of the calendar year preceding 

the Annual Meeting at which 

the award is presented. (This 

award was formerly known as 

the Frank R. Blood Award.) 

Best Paper in 


(formerly published as 

Fundamental and Applied 

Toxicology) 


1995 J. L. Larson, 

D. C. Wolf, 

B. E. Butterworth 

1995 M. I. Luster, C. Portier, 

D. G. Pait, 

G. J. Rosenthal, 

D. R. Germolec, 

E. Corsini, 

B. L. Blaylock, 

P. Pollock, 

Y. Kouchi, W. Craig, 

K. L. White, 

A. E. Munson, 

C. E. Comment 

1996 B. C. Allen, 

R. J. Kavlock, 

C. A. Kimmel, 

E. M. Faustman 

1997 F. L. Fort, H. Ando, 

T. Suzuki, 

M. Yamamoto, 

T. Hamashima, 

S. Sato, T. Kitazaki, 

M. C. Matony, 

G. D. Hodgen 

1998 D. D. Parrish, 

M. J. Schlosser, 

J. C. Kapeghian, 

V. M. Traina 

1999 C. A. Franklin, 

M. J. Inskip, 

C. L. Baccanale, 

C. M. Edwards, 

W. I. Manton, 

E. Edwards, 

E. J. O’Flaherty 

2000 H.A Boulares, 

C. Giardina, 

C.L. Navarro, 

E.A. Khairallah, 

S.D. Cohen 

2001 Jinqiang Chen, 

Yunbo Li, 

Jackie A. Lavigne, 

Michael A. Trush, 

James D. Yager 

2002 M. J. Bajt, 

J. A. Lawson, 

S. L. Vonderfecht, 

J. S. Gujral, 

H. Jaeschke 

2003 S. Haddad, M. Beliveau, 

R. Tardif, K. Krishnan 

2004 Abraham Nyska, 

Carolyn Moyer, 

Allen Ledbetter, 

David Christiani, 

Mette Schlasweiler, 

Daniel Costa, 

Russ Hauser, 

Urmila Kodavanti, 

2005 Nicole V. Soucy, 

Michael A. Ihnat, 

Linda Hess, 

Chandrashekhar D. 

Kamat, 

Aaron Barchowsky, 

Mark J. Post, 

Linda R. Klei, 

Callie Clark 

2006 Hiroshi Sawada, 

Kenji Takami, 

Satoru Ashai 

2007 Trevor Green, 

Robert Lee, Sara Lloyd, 

James Noakes, 

Timothy Pastoor, 

Richard Peffer, 

Mervyn Robinson, 

Patrick Rose, 

Alison Toghill, 

Felix Waechter, 

Edgar Weber 

2008 Sarah Snykers, 

Tamara Vanhaecke, 

Peggy Papelue, 

Aernout Luttun, 

Yuehua Jiang, 

Yvan Vander Heyden, 

Catherine Verfaillie, 

Vera Rogiers 

2009 Qian Yang, 

Tomokazu Nagano, 

Yatrik Shah, 

Connie Cheung, 

Shinji Ito, 

Frank J. Gonzalez 

2010 Roy L.M. Dobson, 

Safa Motlagh, 

Mike Quijano, 

R. Thomas Cambron, 

Timothy R. Baker, 

Aletha M. Pullen, 

Brian T. Regg, 

Adrienne S. Bigalow- 

Kern, Thomas Vennard, 

Andrew Fix, 

Ranate Reimschuessel, 

Gary Overmann, 

Yuching Shan, 

George P. Daston 

2011 Kun Lu, 

Leonard B. Collins, 

Hongyu Ru, 

Edilberto Bermudez, 

James A. Swenberg 

Best Paper in Toxicology 

and Applied Pharmacology 


1995 M. F. Denny, 

M. F. Ware, 

W. D. Atchison 

1996 T. A. Slotkin, C. Lau, 

E. C. McCook, 

S. E. Lappi, 

F. J. Seidler 

1997 P. R. S. Kodavanti, 

T. R. Ward, 

J. D. McKinney, 

C. L. Waller, 

H. A. Tilson 

1998 J. S. Landin, 

S. D. Cohen, 

E. A. Khairallah 

1999 S. K. Ramaiah, 

M G. Soni, 

T. J. Bucci, 

H. M. Mehendale, 

1999 C. L. Zuch, 

D. J. O’Mara, 

D. A. Cory-Slechta 

2000 J.E. Staples, 

N.C. Fiore, 

D.E. Frazier, Jr., 

T.A. Gasiewicz, 

A.E. Silverstone 

2001 Barbara J. Mounho, 

Brian D. Thrall 

2002 G.S. Ratra, 

S.G. Kamita, 

J.E. Casida 

2003 J. Doorn, M. Schall, 

D. Gage, T. Talley, 

C. Thompson, 

R. Richardson 

Frank R. Blood 



1975 Donald J. Ecobichon, 

G. J. Johnstone, 

O. Hutzinger 

1976 Richard D. Brown 

1977 J. Dedinas, 

George D. DiVincenzo, 

C. J. Kaplan 

1978 Perry J. Gehring, 

E. O. Madrid, 

G. R. McGowan, 

Philip G. Watanabe 

1979 R. Fradkin, 

E. J. Ritter, 

W. J. Scott, 

James G. Wilson 

1980 Jerold A. Last, 

Peter F. Moore, 

Otto G. Raabe, 

Brian K. Tarkington 

1981 Yves Alarie, 

Martin Brady, 

Christine Dixon, Meryl 

Karol 

1982 Melvin E. Andersen, 

Michael L. Gargas, 

Lawrence J. Jenkins, Jr., 

Robert A. Jones 

1983 Henry D. Heck 

1984 Erik Dybing, 

Sidney Nelson, 

Erik Soderlund, 

Christer Von Bahr 

1985 Nobumasa Imura, 

Masae Inokawa, Kyoko 

Miura 

1986 Calvin C. Wilhite, 

M. I. Dawson, 

K. J. Williams 

1987 John Kao, 

Frances K. Patterson, 

Jerry Hall 

1988 Debra L. Laskin, 

Sungchul Ji, 

Anne M. Pilaro 

1989 R. G. Cuddihy, 

W. C. Griffith, 

Rogene F. Henderson, 

Joe L. Mauderly, 

Roger O. McClellan, 

M. D. Snipes, 

Ronald K. Wolff 

1990 William P. Beierschmitt, 

Joseph T. Brady, 

John B. Bartolone, 

D. Stuart Wyand, 

Edward A. Khairallah, 

Steven D. Cohen 

1991 Jay Babcock Silkworth, 

Daryl Cutler, 

LuAnn Antrim, 

Don Houston, 

Casimir Tumasonis, 

Laurence S. Kaminsky 

1992 Donald A. Fox, 

Steve D. Rubinstein, 

Pauline Hsu 

1993 Thomas Mably, 

Robert W. Moore, 

Robert W. Goy, 

Richard E. Peterson 

1994 Susan J. Borghoff, 

William H. Lagarde 

Congressional Science 

Leadership Award 

Congressional Science 

Leadership Award provides 

recognition of a Congressional 

leader who demonstrates reliance 

upon sound scientific 

principles in either 1) public 

policy or decision-making 

relating to health and safety or 

2) dedicated advancement of 

legislation for the protection 

of human, animal, and environmental 

health. The award 

consists of a plaque. 

Award Recipient 

2009 Congressman 

David Wu (D-OR) 

2010 Congressman 

David Price (D-NC) 

Senator Johnny Isakson 

(R-GA) 

Contributions to Public 

Awareness of the 

Importance of Animals 

in Toxicology Research 

Award 

The Contributions to Public 

Awareness of the Importance 

of Animals in Toxicology 

Research Award is presented 

annually to an individual (or 

organization) in recognition 

of the contributions made to 

the public understanding of 

the role and importance of 

experimental animals in toxicological 

science. 


2000 Allegheny-Erie Chapter 

2001 Massachusetts Society 

for Medical Research 

2002 George Nethercutt 

Full description of each award and application procedure may be found on the SOT Web site 

at www.toxicology.org. The annual deadline for award nominations is October 9.

of the Past 50 Years 

2003 Michael Derelanko 

2004 North Carolina 

Association for 

Biomedical Research 

(NCABR), Americans 

for Medical Progress 

(AMP) 

2005 Orrin G. Hatch, 

Foundation for 

Biomedical Research 

(FBR) 

2006 Jayne Mackta 

Distinguished 

Toxicology Scholar 

Award 

The Distinguished Toxicology 

Scholar Award is presented 

to a member of SOT who 

has made substantial and 

seminal scientific contributions 

to our understanding 

of the science of toxicology. 

Nominees should be active 

scientists involved in toxicological 

research. The prime 

consideration for this award 

is scientific accomplishments. 

(This award was presented 

in 2001 as the Scientific 

Achievement Award.) 


2001 James E. Troska 


2003 Henry C. Pitot 

2004 Gerald N. Wogan 

2005 Daniel Nebert 

2006 Sten G. Orrenius 

2007 Stephen H. Safe 

2008 Toshio Narahashi 

2009 Lance R. Pohl 

2010 Harihara M. Mehendale 

2011 Oliver Hankinson 

Education Award 

The Education Award is presented 

to an individual who is 

distinguished by the teaching 

and training of toxicologists 

and who has made significant 

contributions to education in 

the broad field of toxicology. 


1975 Harold C. Hodge 

1976 Ted A. Loomis 

1977 Robert B. Forney 


1980 Herbert H. Cornish 

1981 Frederick Sperling 

1982 Lloyd W. Hazleton 

1983 Julius M. Coon 

1984 Frank Guthrie, 

Ernest Hodgson 

1985 William B. Buck 

1986 Robert I. Krieger 


1988 John Autian 

1989 Tom S. Miya 

1990 Charles H. Hine 

1991 Hanspeter R. Witschi 

1992 Dean E. Carter 

1993 Curtis D. Klaassen 

1994 Robert A. Neal 

1995 William Carlton 

1996 Robert Snyder 

1997 Albert E. Munson 

1998 David J. Holbrook 

1999 Jules Brodeur 

2000 Gary Carlson 

2001 Harihara Mehendale 

2002 Joseph Borzelleca 

2003 Frederick W. Oehme 

2004 A. Jay Gandolfi 

2005 Nobuyuki Ito 

2006 Robert A. Schatz 

2007 Torbjörn Malmfors 

2008 Steven Cohen 

2009 Janice E. Chambers, 

Serrine S. Lau 

2010 Tetsuo Satoh 

2011 Michael Gallo 

Enhancement of 

Animal Welfare Award 

The Enhancement of Animal 

Welfare Award is presented 

annually to a member of 

the Society in recognition 

of the contribution made to 

the advancement of toxicological 

science through the 

development and application 

of methods that replace, 

refine, or reduce the need for 

experimental animals. This 

award recognizes outstanding/ 

significant contributions made 

by members of the Society of 

Toxicology to the sound and 

responsible use of animals in 

scientific research. 



2001 Alan Goldberg 

2002 Gary Williams 

2003 G. Frank Gerberick, 

Ian Kimber 


2005 Daniel Acosta 

2006 William S. Stokes 

2007 Thomas Hartung 


2009 Sally Robinson 

2010 Leonard M. Schechtman 



Undergraduate 


The SOT Endowment 50th 

Anniversary Undergraduate 

Educator Award is presented 

to an SOT member who is 

distinguished by outstanding 

contributions to the teaching 

of undergraduate students in 

toxicology and toxicologyrelated 

areas, and whose 

efforts support SOT's strategic 

efforts to “Build for the Future 

of Toxicology.” 

Award Recipient 

2011 Joan B. Tarloff 

Founders Award 

The SOT Founders Award is 

presented to a Full or Retired 

Full member of the Society of 

Toxicology who has demonstrated 

outstanding leadership 

in fostering the role of toxicological 

sciences in safety 

decision-making through 

the development and/or 

application of state-of-the-art 

approaches that elucidate, with 

a high degree of confidence, 

the distinctions for humans 

between safe and unsafe levels 

of exposures to chemical and 

physical agents. 


2008 John Doull 


2010 James S. Bus 

2011 Joseph Borzelleca 

Leading Edge in 

Basic Science Award 

The Leading Edge in Basic 

Science Award is presented 

to a scientist who, based on 

his/her research, has made 

a recent (within the last 5 

years), seminal basic scientific 

contribution to understanding 

fundamental mechanisms of 

toxicity. 


2009 John Katzenellenbogen 

2010 Richard S. Paules 

2011 Masayuki Yamamoto 

Merit Award 

The Merit Award is presented 

to a member of the Society of 

Toxicology in recognition of 

distinguished contributions 

to toxicology throughout an 

entire career in areas such as 

research, teaching, regulatory 

activities, consulting, and 

service to the Society. The 

recipient delivers the Merit 

Awardee Lecture at the SOT 

Annual Meeting. 


1966 Henry F. Smyth, Jr. 

1967 Arnold J. Lehman 

1968 R. T. Williams 

1969 Harold C. Hodge 

1970 Don D. Irish 

1971 Kenneth P. DuBois 

1972 O. Garth Fitzhugh 

1973 Herbert E. Stokinger 

1974 William B. Deichmann 

1975 Frederick Coulston 

1976 Verald K. Rowe 

1977 Harry W. Hays 

1978 Julius M. Coon 

1979 David W. Fassett 

1980 Bernard L. Oser 

1981 John H. Weisburger 

1982 Harold M. Peck 

1983 Perry J. Gehring 

1984 Tom S. Miya 

1985 Carrol S. Weil 

1986 Ted A. Loomis 

1987 Bo Holmstedt 

1988 Seymour L. Friess 

1989 Wayland J. Hayes, Jr. 


1991 Toshio Narahashi 

1992 W. Norman Aldridge 

1993 John Doull 

1994 Ernest Hodgson 

1995 Robert A. Scala 


1997 Mary O. Amdur 

1998 John A. Thomas 

1999 Thomas Clarkson 

2000 Philippe Shubik 

2001 Donald Reed 

2002 Bernard Schwetz 

2003 M.W. Anders 

2004 Robert Goyer 


2006 A. Wallace Hayes 

2007 James A. Swenberg 

2008 Hanspeter Witschi 

2009 Gary M. Williams 

2010 Marion F. Ehrich 

2011 Michael Aschner 

Perry J. Gehring 

Diversity Student 

Travel Award 

The Perry J. Gehring Diversity 

Student Award recognizes a 

student who was selected to 

participate in a previous SOT 

Undergraduate Program, is 

from an ethnic group underrepresented 

in toxicology 

(African American, Hispanic, 

Native American or Pacific 

Islander), and is presenting a 

paper at the upcoming SOT 

meeting. 


2009 Vanessa De La Rosa 

2010 Nygerma L. Dangleben 

2011 Eva A. Amouzougan 

Public 

Communications 

Award 

The Public Communications 

Award is presented by the 

Society of Toxicology to 

recognize an individual who 

has made a major contribution 

to broadening the awareness 

of the general public on toxicological 

issues through any 

aspect of public communications. 

The award should reflect 

accomplishments made over a 

significant period of time. 


1994 Michael A. Kamrin 

1995 Philip Abelson 

1996 Bruce N. Ames 

1997 Audrey Gotsch 


1999 Ann de Peyster 


2001 Anna Shvedova 

2002 Sam Kacew 

2003 Charlene A. McQueen 

2004 Kenneth Olden 

2005 Robert Kreiger 


2007 Linda S. Birnbaum 



2010 Philip Wexler 

SOT/AstraZeneca/ 

IUTOX Travel 

Fellowship 

AstraZeneca and SOT sponsor 

travel fellowship awards 

annually, which are administered 

by IUTOX. Awards are 

available to junior and senior 

scientists from a country 

where toxicology is underrepresented 

to assist with 

travel to attend the Society of 

Toxicology Annual Meeting. 


2002 Christophor Dishovsky 

(Bulgaria), 

Zoltan Gregus 

(Hungary), 

Maritza Rojas Martini 

(Venezuela), 

Choon-Nam Ong 

(Singapore), 

W. Wasowicz (Poland), 

Ping-kun Zhou (China) 

2003 Jian-Hui Liang (China), 

Eman A. Seif (Egypt), 

Marjan G. Vracko 

(Slovenia) 

2004 Cristina Bolaton 

(Phillipines), 

P.K. Gupta (India), 

Salmaan Inayat-Hussain 

(Malaysia), 

Xianping Ying (China) 

2005 Diana B. Apostolova 

(Bulgaria), 

Marite Arija Bake 

(Latvia), 

Teresa I. Fortuoul 

(Mexico), 

Mary Gulumian 

(South Africa), 

He Jiliang (China), 

Khalidya Khamidulina 

(Russia), 

L. Orish Orisakwe 

(Nigeria), 

Songsak Srianujata 

(Thailand), 

Sinan Suzen (Turkey) 

2006 Olanike Adeyemo 

(Nigeria), 

Deepak Argwal (India), 

Carlos Colangelo 

(Argentina), 

Sandra Demichelis 

(Argentina), 

Mumtaz Iscan (Turkey), 

Karolina Lyubomirova 

(Bulgaria), 

Osman Aly Osman 

(Egypt), 

Shuang-Qing Peng 

(China), 

Julia Radenkova-Saeva 

(Bulgaria) 

2007 Hatem Ahmed (Egypt), 

Jiri Bajgar (Czech 

Republic), 

Ismet Çok (Turkey), 

Carlos Garcia (Peru), 

Wenceslao Kiat 

(Philippines), 

Calivarathan 

Latchoumycandane 

(Singapore), 

Fateheya Metwally 

(Egypt), 

Hilmi Orhan (Turkey), 

Nwoha Umunna 

(Nigeria) 

2008 Gafer Rageh Ahmed 

(Egypt), 

Sayed Bakry (Egypt), 

Phillip Burcham 

(Australia), 

Kemal Buyukguzel 

(Turkey), 

Jin-Ho Chung (Korea), 

Hande Gurer-Orhan 

(Turkey), 

Lyndy McGaw 

(South Africa), 

Zdravko Paskalev 

(Bulgaria) 

2009 Sema Burgaz (Turkey) 

Estefania G. Moreira 

(Brazil) 

Kolawole V. 

Olorunshola (Nigeria) 

Kelly P.K. Olympio 

(Brazil) 

Betzabet Quintanilla- 

Vega (Mexico) 

Jalila Ben Salah-Abbes 

(Tunisia) 

Suleeporn Sangrajang 

(Thailand) 

2010 Asongalem Emmanuel 

Acha (Cameroon) 

Ayse Basak Engin 

(Turkey) 

Ronnie A. D. Frazer- 

Williams (Sierra Leone) 

Yan Li (China) 

Jesus Olivero-Verbel 

(Colombia) 

Suresh V.S. Rana 

(India) 

Ganna Shayakhmetova 

(Ukraine) 

Vanessa Steenkamp 

(South Africa) 

Marcelo Wolansky 

(Argentina) 

Motao Zhu (China) 

2011 Sonali Das (India) 

David K. Essumang 

(Ghana) 

Rawiwan 

Maniratanachote   

(Thailand) 

Anoka A. Njan 

(Nigeria) 

Osman S. Shaik (India) 

Songsak Srianujata 

(Thailand) 

Dexter Tagwireyi 

(Zimbabwe) 

Qinli Zhang (China) 

Bin Zhao (China) 

SOT Endowment 

Fund/IUTOX Travel 

Fellowship 

In 2011 the SOT Endowment 

Fund sponsored two travel 

fellowship awards in 2011. The 

two awards are administered 

by IUTOX and are available 

to junior and senior scientists 

from a country where toxicology 

is underrepresented. 

The 2011 awards were to 

assist with travel to attend the 

Society of Toxicology Annual 

Meeting. 


2011 Daam Settachan 

(Thailand) 

Omoniyi Kayode 

Yemitan (Nigeria) 

Translational Impact 

Award 

The Translational Impact 

Award is presented to a 

scientist whose recent (in the 

last 10 years) outstanding 

clinical, environmental health, 

or translational research has 

improved human and/or public 

health in an area of toxicological 

concern. Scientists 

who are leaders in multidisciplinary 

team efforts who 

have contributed to alleviating 

toxicity-related health problems 

are particularly attractive 

candidates. 


2009 Thomas W. Kensler 

2010 Kenneth E. McMartin 

2011 Weida Tong

Smithsonian and SOT Collaborate to 

Host Seminar on Toxicology 

When Good 

Chemicals Turn Bad 

Saturday, March 5, 2011 9:30 AM–4:30 PM 

Ripley Center, Smithsonian 

The Smithsonian 

Associates 

This seminar features an overview of, and the latest research in, the science of toxicology. 

Many of the sessions feature SOT members. A sampling of the program follows: 

9:30 AM–10:30 AM Poisoning through 

the Ages 

Presenters talk about early experimentation 

with botanicals and intentional and unintentional 

poisoning and then on to natural and synthetic 

chemicals, highlighting some of the accidents 

that sometimes resulted. 

Michael Gallo, Robert Wood Medical School 

Philip Wexler, National Library of Medicine 

10:30 AM–11:30 AM The Dose Makes the 

Poison—What’s Safe? 

Guest speaker talks about how poisons interact 

with an organism and provides an overview of cell 

damage and repair, cancer-causing chemicals, 

and chemicals that disrupt reproduction and 

development. 

Marion Ehrich, Virginia Tech 

11:45 AM–12:45 PM The Nature of 

Poisoning 

2:00 PM–3:00 PM Water and Land 

Researchers offer the latest information about 

the effects of chemical, physical, and biological 

substances on the ecosystem. 

Gerhardt Riedel, Smithsonian 

Environmental Research Center 

Kathy Boomer, Smithsonian 

Environmental Research Center 

3:15 PM–4:30 PM Cutting-Edge Research 

Presenters explore the potential danger of 

miniscule particles, the promise of epigenetics 

studies, implementation of animal testing 

alternatives, and the future of toxicology. 

Martin Philbert, University of Michigan 

Cheryl Lyn Walker, University of Texas, 

MD Anderson Cancer Center 

Thomas Hartung, Johns Hopkins 

Bloomberg School of Public Health 

Session focuses on human poisoning and its 

treatment. Speaker talks about emergency and 

disaster responses, forensic toxicology, and legal 

issues. 

Cathleen Clancy, Capital Poison Center 

SOT members can purchase tickets by calling 202.633.3030 and telling 

the Smithsonian Associate office (program or staff) that he/she is a member of SOT.

Thank You to the following individuals who contributed to the Benchmarks in Toxicology project: 

Please pick up a FREE copy of the Benchmarks poster located throughout the center. 

Rebecca Adams 

Yves Alarie 

William Allaben 

Njwen Anyangwe 

Wimolnut Auttachoat 

Ned Ballatori 

Stelvio Bandiera 

Thomas Barfknecht 

David Basketter 

Ilona Bebenek 

Sudheer Beedanagari 

Robert Beliles 

John Benitez 

Robert Biles 

Edwin Bisinger, Jr. 

Bas Blaauboer 

Ann Blacker 

Amanda Burns 

Byron Butterworth 

Daniel Casciano 

Michel Charbonneau 

Guosheng Chen 

John Christopher 

Larry Claxton 

Harvey Clewell, III 

Samuel Cohen 

Margaret Collins 

Joseph Contrera 

Dallas Cowan 

Edmond Creppy 

Edward Croom 

Michael J. Davis 

Myrtle Davis 

Walter Decker 

Michael Derelanko 

Stephen Dertinger 

John Doherty 

James Doyle 

Marion Ehrich 

Alison Elder 

Joanne English 

Andrew Ewens 

Jeffrey Fisher 

Paul Donald Forbes 

Sue Ford 

Donald Fox 

Steven Gilbert 

Anne Gilson 

Terry Gordon 

Cnythia Graham 

John Groopman 

Mark Hahn 

Lois Haighton 

Helen Hakansson 

Pertti Hakkinen 

Stephen Harris 

Ronald Hines 

Seishiro Hirano 

Alan Hoberman 

Ernest Hodgson 

Robert Howd 

Dennis Hsieh 

Benjamin Jackson 

Ijaz Jamall 

Erik Janus 

Michael Kamrin 

James Keenan 

Kevin J. Kerzee 

John Kille 

James Kim 

Tracy Kimmel 

Weixi Kong 

Charles Lapin 

Paige B. Lawrence 

Joseph LeBeau 

Doreen Lehner 

Uford Madden 

Brinda Mahadevan 

Frank Mastrocco 

Roger McClellan 

Donald McCollister 

Daniel Mclain 

Harihara Mehendale 

Sharon Meyer 

Charles Miller, III 

Lesley Mills 

Isaac Mohar 

John Morris 

Ron Myers 

Rachel Novick 

Günter Oberdörster 

Gilbert Omenn 

Robert Osterberg 

Michael Ottlinger 

Angela Perez 

Isaac Pessah 

Jean Pfau 

Sidhartha Ray 

Lynnda Reid 

Ciara Remillard 

John Richburg 

Cynthia Rider 

Ruth Roberts 

Sally Robinson 

James Romano 

Mohamed Salama 

Regina Santella 

Edward Sargent 

Robert Scala 

James Sherman 

Robert Snyder 

John Stegeman 

Marc Stifelman 

Richard Storer 

Steave Su 

Jack Thrasher 

Kerry Thuett 

James Trosko 

Rochelle Tyl 

Phil Wexler 

Calvin Willhite 

Hanspeter Witschi 

Marcelo Wolansky

Space is limited so remember to purchase your ticket when you register for the Annual Meeting 

50TH ANNIVERSARY | SOCIETY OF TOXICOLOGY 

3.8.2011 | 6:30 PM–9:30 PM | Walter E. Washington Convention Center 

BeatleMania Live 

Wii Stations 

Golf Putting Station 

Additional Sponsorship Opportunities Remain—Contact SOT Headquarters to inquire! 

Entertainment by BeatleMania Live 

Food Stations by the Decades 

Wii Stations, Photo Book Center, Golf Putting Station, and more 

Dress in Your Favorite Decade Attire or Come As You Are!!! 

To become a host or reserve a table (10 tickets per table), 

please contact SOT Headquarters 703.438.3115 

Please note that due to the numerous 50th Anniversary activities scheduled, 

there will not be a Sunday evening Welcoming Reception.

SOT Celebration Event Floor Plan 

Balcony 

Seating 

201 

202 

203 

204 

205 

206 

207 

208 

301 

302 303 

304 

Green 

Screen 

Wii 

Bar 

305 

306 

308 

309 

307 

311 

310 312 

Bar 

Bar 

101 107 

102 108 

103 109 

104 110 

105 111 

106 112 

313 

314 315 

316 

317 

318 319 

113 

138 

114 116 

139 140 

115 117 

141 149 

118 123 

142 

119 124 126 

132 

150 

143 151 157 

120 125 127 133 144 152 

158 163 

121 

134 145 153 

128 

159 

164 

122 

135 146 154 

165 

129 

160 

136 147 155 

130 

161 

137 148 156 

131 

STAGE 

300 

100 100 

400 

200 500 

TECH 

ENTRANCE 

162 

Oxygen 

Bar 

166 171 

167 172 

168 173 

169 174 

170 175 

Bar 

413 

414 

415 416 

417 

405 

406 

408 

409 

407 

411 

410 412 

418 419 

Bar 

Golf 

Bar 

402 

403 

FlipBook 

401 

404 

E 

501 

502 

503 

504 

505 

506 

Bar 

Balcony 

Seating 

Escalator 

Escalator 

Stairs 

E 

E 

601 

Message 

Board 

603 

602 

Dessert Stations 

604 

605 

E 

E 

606 

ENTRANCE 

Host ........................................................... Table 

Anti Lytics ....................................................................................................... 113 

AstraZeneca .........................................................................114, 115, 117, 118 

Birnbaum Bash .............................................................................................. 150 

Boehringer Ingelheim ................................................................................. 143 

Calvert Labs ................................................................................................... 144 

Celsis In Vitro Technologies ......................................................................... 116 

Charles River ......................................................................................... 501–506 

Dean’s Lab @ CIIT .......................................................................................... 145 

Doull & Rozman LL ....................................................................................... 122 

Dow Chemical Company, Toxicology 

and Environmental Research and Consulting, The .............................. 167 

Dupont .................................................................................................. 127, 133 

ExxonMobil .................................................................................................... 132 

Friends of SOT ............................................................................................... 149 

Genzyme ........................................................................................................ 123 

Host ........................................................... Table 

Hamner Institute, The .................................................................................. 134 

Harlan ............................................................................................................. 166 

HESI ........................................................................................................ 139, 141 

MatTek Corporation ..................................................................................... 168 

Oregon State University. ............................................................................. 158 

Pfizer ...................................................................................................... 101–112 

ProDev Consulting Services, Ltd. ............................................................... 142 

Renal Failure .................................................................................................. 140 

sanofi-aventis ................................................................................................ 126 

SNBL ................................................................................................................ 138 

ToxServices, LLC ............................................................................................ 152 

University of Pittsburgh .............................................................................. 157 

University of Connecticut ........................................................................... 153 

University of Michigan ....................................................................... 119–124 

University of Washington............................................................................ 151 

Additional Hosting Opportunities are available—Contact SOT Headquarters to inquire. 

(Table assignments as of January 5, 2011)

50 th Anniversary Silent Auction 

Bid on fabulous items 

Historic toxicology materials • Fantastic vacation opportunities 

• Hand crafted art pieces 

Special Event in the E-mail Center 

Monday, March 7 4:45 PM–5:45 PM 

Sponsored by the Postdoctoral Assembly 

Proceeds to SOT Endowment Priority Fund 

All bidding on-line—linked from 50th Anniversary Web site 

See donated items on display in the SOT Pavilion in ToxExpo TM 

Participate in the excitement as bids close 

Get a close look at these items and hear why you should bid 

Cash bar available 

Bring your computer, smart phone, or use an E-mail Center computer to place last-minute bids on these items 

• Timeshare at Marriott Grande Vista in Orlando, FL 

• 40th Anniversary Edition of The Double Helix Signed 

by Dr. James Watson 

• Used "Hot Science and all that Jazz" T-shirt from 

the SOT New Orleans 2005 Annual Meeting 

Final bids close on these items 

Wednesday, March 9 10:00 AM–1:00 PM 

• House on Block Island, RI 

• Casarett and Doull’s Toxicology textbook, 

2nd Edition, Autographed 

• Needlepoint of Toxicants 

• Handmade Pottery Vase 

• 1st Edition of Encyclopedia of Toxicology, 

Wexler, ed. (1998), Autographed 

• Photo & Plaque of CIIT Founders 

• Framed Underwater Photographs 

• White House Athletic Center Gym Bag 

• Information Resources in Toxicology, 

Wexler, ed., 4th Edition (2009), Autographed 

• Antique Clay Bottle 

• SOT Anniversary Desk Art Piece 

• Framed Photograph of SOT Founders 

• 2nd Edition of Encyclopedia of Toxicology, 

Wexler, ed., (2005) Autographed 

• Smoked Salmon and Fruit Candy 

• Dinner with John and Vera Doull during SOT 

Annual Meeting 2012 

• Dr. Doull Antismoking Photo 

• SOT Fun Run Sunglasses from 1993 Annual Meeting 

• Ski Vermont! Condo in Okemo, VT 

• Handmade Ceramic Wall Hanging 

• Vintage Copies (1970’s) of The Toxicologist 

• Compendium of CIIT Activities (1981–2004), 

Signed by CIIT Presidents 

• 3rd Edition of the Handbook of Pesticide Toxicology, 

2 Volume Set (2010), Autographed 

• Antique Pharmaceutical Bottle—Stoddard's 

Dyspepsia Tonic 

• A Handcrafted Wooden 4-Legged Stool 

• Wine Cork Trivet, SOT 50th Anniversary 

Commemorative Edition 

• 3 Handcrafted Washington State ja lanea Red 

Wines by Chaos Vintners 

• Framed Photograph of John Doull 

• Handcrafted Beaded Necklace and Earrings 

• House on the Chesapeake Bay, VA

50 th Anniversary Annual Meeting and ToxExpo Society of Toxicology 2011 

March 6–10, 2011 

Program Contents 

President’s Letter.......................................................... Inside Front Cover 

Scientific Program Overview...........................................Front Fold-Out 

How to Use this Program...............................................................................2 

Sponsorship 

Sponsorship Opportunities....................................................................432 

2011 Annual Meeting Sponsors.............................................................432 

2011 Annual Meeting Diamond Sponsors..........................Back Cover 

Events and Maps 

Daily Pocket Calendar....................................................................................3 

Schedule by Event Name........................................................................... 13 

Walter E. Washington Convention Center Maps............................... 24 

Washington, D.C. Hotel Accommodations.......................................... 26 

Map of Washington, D.C. Hotel Locations...........................................28 

Renaissance Hotel Map..............................................................................30 

Washington, D.C. Restaurant Listings................................................... 32 

Metro Map.........................................................................Inside Back Cover 

2011 ToxExpo 

ToxExpo Information................................................................................ 35 

ToxExpo Floor Plan....................................................................................36 

ToxExpo 2011 Exhibitors.........................................................................38 

Exhibitor Hosted Session Index.............................................................. 41 

Registration 

Registration Information...........................................................................44 

General Information 

Accessibility for Persons with Disabilities............................................ 45 

Attire.................................................................................................................. 45 

Badges.............................................................................................................. 45 

Business Center ............................................................................................. 45 

Career Resources and Development Services................................... 45 

Climate.............................................................................................................. 45 

Coat/Luggage Check................................................................................... 45 

Exhibitor Information..................................................................................46 

Exhibit Hall (Hours/Location)...................................................................46 

First Aid and Emergency Services 

at the Convention Center.................................................................46 

Food Services.................................................................................................46 

Green in Washington, D.C......................................................................... 47 

Guest/Spouse Hospitality Room............................................................ 47 

Housing Desk................................................................................................. 47 

Internet Access at the Convention Center........................................... 47 

Letter of Attendance...................................................................................48 

Lost and Found..............................................................................................48 

Lunch with an Expert Information Board............................................48 

Media Support Services.............................................................................48 

Memorabilia...................................................................................................48 

Parking Information.....................................................................................48 

Photography Policy and Session Etiquette for Attendees............48 

Poster Printing Service (NEW).................................................................. 49 

Registration Desk Hours............................................................................ 49 

Safety and Security...................................................................................... 49 

SOT Headquarters Office...........................................................................50 

SOT Pavilion....................................................................................................50 

Speaker Ready Room..................................................................................50 

Sponsorship....................................................................................................50 

Tour Information...........................................................................................50 

The Toxicologist (Print and CD-ROM)/Itinerary Planner 

and the Program.................................................................................. 51 

Transportation............................................................................................... 51 

Washington, D.C. Area Activities.............................................................54 

Washington, D.C. Information Desks.....................................................58 

Career Resources and Development 

Career Resources and Development Services...................................60 

Special Events 

2011 Award Recipients................................................................................ 63 

2011 Honorary Memberships...................................................................72 

SOT Endowment Fund 2010 Award Recipients................................. 75 

Recognition and Special Events..............................................................77 

RC, SIG, and SS Receptions........................................................................80 

Student and Postdoctoral Scholar Events........................................... 83 

Outreach Activities and Events............................................................... 85 

Satellite Meetings......................................................................................... 87 

Continuing Education 

Continuing Education Courses................................................................88 

Sessions Index 

Scientific Session Index.............................................................................. 97 

Posters 

Poster Session Board Surface Maps.....................................................104 

Poster Session Schedule..........................................................................108 

Historical Posters Floor Plan................................................................... 112 


Program Description................................................................................. 113 

Author Index.................................................................................................359 

Abstract Key Word Index.........................................................................387 

SOT Leadership 

2010–2011 Council......................................................................................402 

Elected and Appointed Committees................................................. 404 

Officers—Regional Chapters................................................................. 409 

Officers—Specialty Sections.................................................................. 411 

Officers—Special Interest Groups........................................................ 414 

SOT References 

Endowment Fund (Donor Contribution Form)................................ 415 

SOT Affiliates.................................................................................................425 

Headquarters Staff ....................................................................................431 

The Toxicologist on CD-ROM.......................................Inside Back Cover 

up-to-date information at www.toxicology.org 

1 

All text and graphics are ©2011 by the Society of Toxicology unless noted. Some 

Washington, D.C., photos are courtesy of the Destination D.C. unless otherwise noted.

How to Use this Program 

The Society of Toxicology’s (SOT) Annual Meeting is always an exciting opportunity to highlight advancements in the science of toxicology. 

In order to maximize the value of your Annual Meeting attendance, we offer this Program Publication Layout Overview, the Scientific 

Session Reference, and Scientific Session Type Legend to assist you. We hope that you find this information useful and welcome your 

comments. 

Program Publication Layout Overview 

Section 

Front Fold-Out Cover — 

Scientific Program 

Overview 

Daily Pocket Calendar 

(pages 3–11) 

Schedule by Event Name 

(pages 13–22) 

Scientific Session Index 

(pages 97–103) 

Poster Session Board 

Surface Maps, Schedule, 

and Historical Poster 

Floor Plan 

(pages 104–112) 

Author Index 

(pages 359–386) 

Abstract Key Word 

Index 

(pages 387–401) 

Description 

This quick reference guide lists the Annual Meeting scientific sessions with corresponding page numbers in the Program Description 

section. Color-coded presentation titles assist you in identifying sessions within each theme. A brief description for each theme is 

available as well. 

This at-a-glance calendar is your guide to the daily activities of the Annual Meeting including special sessions; Specialty Section, 

Regional Chapter, Special Interest Group, and ancillary functions; and SOT committee meetings. We encourage you to tear out the 

daily guide for easy reference. Please note that the scientific session details are included at the end of each day’s guide. 

This is an alphabetical listing of all the functions held during the Annual Meeting. You may use this easy-to-read schedule to quickly 

locate an event. Please note that for the scientific sessions detail, you must refer to the Scientific Program Overview on the front 

fold-out cover or Daily Pocket Calendar on pages 3–11. 

This index lists the scientific sessions by type, date, and time. In addition, this information includes the session titles with abstract 

numbers, poster boards, session locations, and corresponding page numbers in the Program Description section. 

The Poster Session Schedule and Poster Board Surface Maps are displayed with a mock layout of the ToxExpo Exhibit Hall to 

assist you in finding poster sessions. Each poster schedule and surface map shows the poster session abstract numbers and the poster 

surface locations for each poster session time. Posters are displayed in the Exhibit Hall Monday–Wednesday and Registration Area 

and Room 202 on Thursday. 

The numerals following the author’s names refer to the abstract numbers referenced in this Program and The Toxicologist. 

The asterisk after the abstract number indicates the author is the first presenter. 

This index provides a listing of key words by subject or chemical and the relevant abstract(s) referenced in this Program and 

The Toxicologist. 

Program Description Scientific Session Reference (pages 113–357) 

The Program Description layout is ordered by date and start time. Please refer to the description below. Each scientific session listing includes a session abstract and 

list of speakers or the featured presenters. 

Listing 

Session Type and Title 

Sponsors or Endorsers 

Abstract Number or 

Presentation Time 

Poster Sessions 

50th Celebration Events 

& Activities 

Description 

Session type and title display in bold type. A brief description for each scientific session type is listed below. 

This section lists the sponsors and endorsers from SOT Special Interest Groups, Specialty Sections, Regional Chapters, or 

SOT Committees. For each scientific session, the sponsor, the group that developed the session, is listed first and followed 

by the endorsers. The list of endorsers, groups that support the session, is sorted alphabetically. 

The first number listed is the abstract number, or the SOT final identifying number. For scientific sessions (but not Continuing 

Education Courses or Poster Presentations), the second number is the presentation time. Individual abstracts can be found on 

The Toxicologist CD-ROM (free to all attendees), The Toxicologist publication (available for purchase on-site for $20), and on 

the SOT Web site. 

The poster board surface number is listed above the title of each individual poster presentation for easy reference. 

SOT 50th Anniversary Events and Activities display in the Program Description section with a grey background and 

50th Anniversary icon. 

Scientific Session Type Legend 

CE Target Areas (45 or 225 minutes)—Continuing Education courses 

highlighting specialized areas of interest 

Education-Career Development Sessions (80 minutes)—Sessions that provide 

the tools and resources to toxicologists that will enhance their professional 

and scientific development 

Exhibitor Hosted Sessions (60 minutes)—Informative sessions developed by 

an exhibiting company 

Featured Sessions (50–60 minutes)—Keynote and other special lectures 

Historical Highlights (80 minutes)—Review of a historical body of science 

that has impacted toxicology 

Informational Sessions (80 minutes)—Scientific planning or membership 

development 

Platform Sessions (165 minutes)—Oral presentations that cover new areas, 

concepts, or data 

Poster Sessions (180–210 minutes)—Topic specific presentations that cover 

new areas, concepts, or data 

Regional Interest Session (165 minutes)—Central topics of relevance that 

describe public health and/or ecological problems of a particular region 

Roundtable Sessions (80 minutes)—Controversial subjects 

Symposium Sessions (80 or 165 minutes)—Cutting-edge science; new areas, 


Thematic Sessions (80–210 minutes)—Timely topics of relevance to 

toxicology 

Workshop Sessions (165 minutes)—State-of-the-art knowledge in toxicology 

2 SOT 50th Anniversary Annual Meeting

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page for a convenient daily calendar _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 


Events are listed alphabetically by the 

event start time. 

Events at the Walter E. Washington 

Convention Center are noted as CC. 

8:00 AM to 11:30 AM 

Council Orientation Meeting 

Renaissance Meeting Room 14 

8:00 AM to 5:00 PM 

IUTOX Meetings 

CC Rooms 305, 306 

8:00 AM to 5:00 PM 

ToxExpo Set Up 

CC Exhibit Hall 

9:30 AM to 4:30 PM 

Smithsonian Seminar: Poisons: 

When Good Chemicals Turn Bad 

Smithsonian S. Dillon Ripley Center 

10:00 AM to 5:00 PM 

K–12 Outreach: Protecting 

You and Your Pet through 

the Science of Toxicology: 

Paracelsus Goes to Washington 

Koshland Science Museum of the National 

Academy of Sciences 





6:00 AM to 8:00 AM 

Past Presidents 

5K Fun Run 

Hains Point Buses Depart L Street 

6:30 AM to 8:00 PM 

Registration 

CC East Salon 

7:00 AM to 8:00 PM 

Coat/Luggage Check 

CC Salon F 

7:00 AM to 7:45 AM 

Continuing Education Sunrise Mini-Course 


CC (See Signage for Room Location) 

7:00 AM to 6:00 PM 

E-mail Center 

CC East Salon 

7:00 AM to 5:30 PM 

SOT Office 

CC Room 101 

7:00 AM to 5:30 PM 

Speaker Ready Room 

CC Room 208 

7:30 AM to 9:30 AM 

Career Resource and Development 

Committee Meeting 

CC Room 301 

7:30 AM to 2:30 PM 

Concession Stands 

CC First and Second Levels 

8:00 AM to 5:00 PM 

Guest/Spouse Hospitality Room 

Renaissance Penn Quarter 

8:00 AM to 5:00 PM 

Housing Desk 

CC East Salon 

8:00 AM to 5:00 PM 


CC 305, 306 

8:00 AM to 1:30 PM 

Scientific Liaison Coalition Meeting 

Renaissance Ballroom West B 

10:00 AM to 12:00 NOON 

Minority Health Cooperative Agreement: 

An Overview with FAMU and Texas A&M 


11:30 AM to 1:00 PM 

Council Orientation Luncheon 


11:30 AM to 6:00 PM 

Johnson & Johnson Toxicology Interest 

Group Meeting 

Grand Hyatt Burnham Room 

12:00 NOON to 5:00 PM 

Board of Publications ToxSci Editor 

Interviews 

CC Room 303 

12:00 NOON to 1:00 PM 

K–12 Outreach: 

Poisoned Pet Food– 

Unraveling the 

Melamine Mystery, 

Lecturer: Renate Reimschuessel 



8:00 AM to 1:00 PM 

Tour Desk 

CC East Salon 

8:00 AM to 5:00 PM 

ToxExpo Set Up 


8:00 AM to 12:00 NOON 

Toxicology Education Foundation Board 

of Trustees Meeting 


8:00 AM to 11:30 AM 

Undergraduate Education Program: 

Toxicology Lectures 

CC Room 156 

8:15 AM to 12:00 NOON 

Continuing Education Morning Courses 


CC (See Signage for Room Locations) 

11:30 AM to 12:45 PM 

Undergraduate Education Program: Lunch 

and Networking (Ticket Required) 

CC Room 103 

11:45 AM to 1:15 PM 

Continuing Education Luncheon for 

Speakers, Committee, and Student 

Volunteers (By Invitation Only) 

CC Room 146A 

12:00 NOON to 1:30 PM 

Food Safety Specialty Section 

Officers Meeting 

CC Room 140A 

12:00 NOON to 3:00 PM 

Toxicological Sciences Associate 

Editors Meeting 


12:15 PM to 1:15 PM 

Alliance for Risk Assessment (ARA) 

Open Meeting/Lunch 


12:45 PM to 1:45 PM 

Undergraduate Education Program— 

Students: Planning for Graduate School 

CC Rooms 301, 302, 303 

1:00 PM to 4:30 PM 

Job Bank Center 

CC Room 157 


3 

1:00 PM to 6:00 PM 

American Board of Toxicology 

Board of Directors Meeting 


1:00 PM to 5:30 PM 

Council Meeting 


4:00 PM to 7:00 PM 

E-mail Center 

CC East Salon 

4:00 PM to 7:00 PM 

Housing Desk 

CC East Salon 

4:00 PM to 7:00 PM 

Registration 

CC East Salon 

4:00 PM to 7:00 PM 

SOT Office 

CC Room 101 

4:00 PM to 7:00 PM 


CC Room 208 

4:00 PM to 7:00 PM 

Tour Desk 

CC East Salon 

1:15 PM to 5:00 PM 

Continuing Education Afternoon Courses 


CC (See Signage for Room Locations) 

1:30 PM to 3:30 PM 

SOT Committee/Task Force 

Chair Orientation 

Renaissance Congressional A 

2:00 PM to 5:00 PM 

Tox-21c Implementation Meeting 

Renaissance Ballroom West A 

2:30 PM to 6:30 PM 

Safety Pharmacology Society Meeting 


3:00 PM to 5:00 PM 

Congressional Task Force Meeting 

CC Room 302 

3:00 PM to 5:00 PM 


Academic Toxicology Programs and 

Internships 

CC Room 102 

3:00 PM to 3:30 PM 

Undergraduate Education Program: Host 

Mentor and Peer Mentor Meeting 

CC Room 303 

4:00 PM to 5:15 PM 

Awards Recipients Photographed 

CC Room 206 

4:00 PM to 6:00 PM 

Dermal Toxicology Specialty Section 


CC Room 203 

4:45 PM to 5:15 PM 

Awards Ceremony Music—Performed by 

Gail Shanta, Harpist 

CC Room 207 

5:15 PM to 6:30 PM 


(All Attendees Welcome) 

CC Room 207 

6:00 PM to 8:00 PM 

Metals Specialty Section 

Meeting/Reception 

District Chophouse Restaurant 

Society of Toxicology 2011 

For your convenience, please tear out and carry 

with you. Easily folds to nest within your badge holder. 

(Calendar as of January 7; private events are not listed.) 

Saturday March 5 

4:15 PM to 5:45 PM 


Orientation for SOT Hosts, Peer Mentors, 

and Advisors 

CC Room 302 

5:00 PM to 5:45 PM 

Continuing Education Committee 

Walk-Through 

CC Room 201 

5:45 PM to 9:00 PM 


Opening Event (By Invitation Only) 

CC Room 103 

7:30 PM to 9:30 PM 

Graduate Fellowship Interviews 

by Awards Committee 

CC Room 301 

8:00 PM to 9:00 PM 

CDI Reunion 

(Networking and Dessert—Invited: Anyone 

involved with the SOT Undergraduate 

Education Program through the years) 

CC Room 103 

Sunday March 6 

6:30 PM to 7:30 PM 

25-Year (or More) Member Reception 

(By Invitation Only) 

CC Room 103 

6:30 PM to 8:00 PM 

Carcinogenesis Specialty Section 


CC Room 146A 

6:30 PM to 8:00 PM 



CC Room 203 

6:30 PM to 8:00 PM 



CC Room 140A 

6:30 PM to 8:30 PM 

Hispanic Organization of Toxicologists 

Special Interest Group Meeting/Reception 

RFD Restaurant 

6:30 PM to 8:00 PM 

Medical Device Specialty Section 


CC Room 156 

6:30 PM to 8:00 PM 

Nanotoxicology Specialty Section 


CC Room 143 

6:30 PM to 8:00 PM 

Occupational and Public Health Specialty 

Section Meeting/Reception 

CC Room 144 

6:30 PM to 8:00 PM 

Ocular Toxicology Specialty Section 


CC Room 142 

7:30 PM to 10:00 PM 

Arizona Night 

Renaissance Ballroom West B 

7:30 PM to 10:30 PM 

Lovelace Respiratory Research 

Institute Reception 


8:00 PM to 9:30 PM 

Student/Postdoctoral Scholar Mixer 

(Ticket and Meeting Badge Required) 

CC Salon G 

Event Calendar

Event Calendar 

Daily Pocket Calendar. 

7:00 AM–7:45 AM 

Continuing eduCAtion Sunrise 

Mini-Course 

1. Biodegradable Materials for Tissue Engineering: 

Applications and Safety Assessment 

CE courses held on the First and Second Levels. 

(Pick up a course location flyer upon entering the 

Convention Center or see signage at the CE booths 

for room assignments.) 

50 th Anniversary Annual Meeting and ToxExpo 

Scientific Program Overview by Day & Time 

Sunday March 6 

Home Members Member CVs Blogs Communities 

8:15 AM–12:00 NOON 

Continuing eduCAtion Morning Courses 

2. Best Practices for Developing, Characterizing, 

and Applying Physiologically Based 

Pharmacokinetic Models in Risk Assessment 

3. Current Nonclinical Strategies and Methods 

for Evaluating Drug-Induced Cardiovascular 

Toxicity 

4. Dealing with the Data Deluge: A Live Data 

Discovery and Analysis Course 

(Note: Participants are asked to bring 

their own computer with Internet access) 

5. Epigenetics in Toxicology: Introduction, 

Mechanistic Understanding, and Applications in 

Safety Assessment 

6. Protecting Human Health: Use of Toxicological 

and Epidemiological Data in Determining Safe 

Levels for Human Exposure 

7. Drug Hypersensitivity Reactions: Risk 

Assessment and Management 

8. Toxicology and Risk Assessment of Chemical 

Mixtures 

1:15 PM–5:00 PM 

Continuing eduCAtion Afternoon 

Courses 

9. Applications of Computational Systems Biology 

for Toxicology 

10. Evaluating Toxicity of Engineered 

Nanomaterials: Issues with Conventional 

Toxicology Approaches 

11. New Technologies and Approaches in Genetic 

Toxicology and Their Expanding Role in General 

Toxicology and Safety Assessment 

12. Practical How-To and Pitfalls Associated with 

Current Epigenetic Studies 

13. Quantitative In Vitro to In Vivo Extrapolation: 

The Essential Element of In Vitro Assay-Based 

Risk Assessment 

14. Stem Cell Utility in Toxicology Screening 

15. The Biology and Toxicology of the Peri- and 

Post-Natal Development 

at the heart of toXchange is an enhanced SOt membership directory 

that allows you to: 

• Create a customized SOT member My Page that you can update on-line 24/7 

• Search for and find other SOT members based on their profile information 

• Be found by other SOT members based on YOUR profile information 

• Communicate with your SOT peers with easy-to-use, secure networking tools 

• Participate in blogs, community discussions, and more! 

Plus, you can pull in content from other social networking systems, making ToXchange 

your one-stop professional on-line resource. 

Hosted on a safe and secure network platform, ToXchange is specifically designed for SOT members. 

Be sure to visit the Sot Pavilion in the Exhibit Hall for on-site information. 

It’s YOUR Network. Be a part of it. 

For on-line information, go to www.toXchange.org. 




4 SOT 50th Anniversary Annual Meeting 

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page for a convenient daily calendar _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _







6:15 AM to 7:45 AM 

Past Presidents Breakfast 

CC Room 203 

6:30 AM to 8:00 AM 



CC Salon G 

6:30 AM to 7:45 AM 

In Vitro and Alternative Methods Specialty 

Section Officers Meeting 

CC Salon G 

6:30 AM to 7:45 AM 

Mechanisms Specialty Section 


CC Salon G 

6:30 AM to 7:45 AM 



CC Salon G 

6:30 AM to 7:45 AM 

Mixtures Specialty Section 


CC Salon G 

6:30 AM to 7:45 AM 



CC Salon G 

6:30 AM to 7:45 AM 

Neurotoxicology Specialty Section 


CC Salon G 

6:30 AM to 7:45 AM 

Reproductive and Developmental 

Toxicology Specialty Section 


CC Salon G 

6:30 AM to 7:45 AM 

Risk Assessment Specialty Section 


CC Salon G 

6:30 AM to 7:45 AM 

Toxicologic and Exploratory Pathology 

Specialty Section Officers Meeting 

CC Room 302 

6:45 AM to 7:45 AM 

Postdoctoral Assembly Board Meeting 

CC Room 303 

6:45 AM to 7:45 AM 

Regional Chapter/Special Interest Group 

Graduate Committee Meeting 

CC Room 103 

7:00 AM to 8:00 PM 


CC Salon F 

7:00 AM to 4:45 PM 

E-mail Center 

CC East Salon 

7:00 AM to 5:00 PM 

Housing Desk 

CC East Salon 

7:00 AM to 8:00 AM 

Journal of Cutaneous and Ocular 

Toxicology Editorial Board Meeting 


7:00 AM to 5:00 PM 

Registration 

CC East Salon 

7:00 AM to 7:45 AM 

Scientific Program Committee 

Walk-Through 

CC Room 201 

7:00 AM to 5:00 PM 

SOT Office 

CC Room 101 

7:00 AM to 5:00 PM 


CC Room 208 

7:20 AM to 7:30 AM 

Undergraduate Education Program: Meeting 

for Student, Advisor, Peer 

Mentors and SOT Hosts 

CC Room 102 

7:30 AM to 9:30 AM 



7:30 AM to 9:30 AM 

Poster Set Up (See Poster Board Surface 

Maps on Pages 104–107) 


7:45 AM to 8:00 AM 

Landmarks Program 

Presentation to the 

National Academy of Science 

CC Grand Ballroom 

8:00 AM to 5:00 PM 



8:00 AM to 5:00 PM 


CC Rooms 305, 306 

8:00 AM to 9:00 AM 

Plenary Opening Lecture: NIH Vision, 

Lecturer: Francis S. Collins, National 

Institute of Health 


8:00 AM to 1:00 PM 

Tour Desk 

CC East Salon 

9:00 AM to 10:00 AM 

Complimentary Coffee 


9:00 AM to 4:30 PM 



9:00 AM to 4:30 PM 


CC Room 157 

9:00 AM to 4:30 PM 

SOT Pavilion 

CC Exhibit Hall, Booth 464 

9:00 AM to 4:30 PM 

ToxExpo Exhibits Open 


9:00 AM to 4:30 PM 

Wi-Fi Lounges (Wireless Internet Access) 


9:15 AM to 10:15 AM 

Exhibitor Hosted Session: Charles River 

CC Room 140A 

9:15 AM to 10:15 AM 

Exhibitor Hosted Session: MPI Research 

CC Room 156 

9:15 AM to 12:00 NOON 

Scientific Sessions 

CC (See Session Index on Pages 97–103 for 

Room Location) 

9:30 AM to 10:30 AM 

Conversation with Dr. Collins 

CC Room 304 (Ticket Required; 

Postdoctoral Scholars only, limited seating) 

9:30 AM to 12:30 PM 



9:30 AM to 10:50 AM 


Poster Session for Visiting Students 



5 

10:30 AM to 11:30 AM 

Exhibitor Hosted Session: 

Harlan Laboratories, Inc. 

CC Room 140B 

10:30 AM to 11:30 AM 


Huntingdon Life Sciences 

CC Room 156 

11:00 AM to 11:45 AM 

Undergraduate Education 

Program Wrap Up 

CC Room 102 

11:30 AM to 2:30 PM 

Communications Committee Meeting 

CC Room 303 

11:45 AM to 12:45 PM 

Exhibitor Hosted Session: Porsolt & 

Partners Pharmacology 

CC Room 140A 

11:45 AM to 12:45 PM 

Exhibitor Hosted Session: Rules-Based 

Medicine 

CC Room 156 

11:45 AM to 12:45 PM 


Sigma Life Science 

CC Room 140B 

12:00 NOON to 2:00 PM 

Central States Regional Chapter 

Meeting/Luncheon 

Embassy Suites, Capital Ballroom B 

12:00 NOON to 1:30 PM 

Continuing Education Committee Meeting 

CC Room 301 

12:00 NOON to 1:30 PM 

Disease Prevention Task Force Meeting 

CC Room 302 

12:00 NOON to 2:00 PM 

HESI Seminar: Putting Health Risks into 

Perspective by Dr. Bruce Ames 

Renaissance Congressional Ballroom 

12:00 NOON to 1:20 PM 

In Vitro Toxicology Lecture and Luncheon 

for Students, Lecturer: Robert E. Chapin 


CC Salon G 

12:00 NOON to 1:30 PM 

Journal of Toxicology Mechanisms and 

Methods Editorial Board Meeting 


12:00 NOON to 1:30 PM 

Scientific Liaison Task Force Meeting 

CC Room 304 

12:00 NOON to 1:00 PM 

Special Interest Group Presidents and 


CC Room 103 

12:00 NOON to 1:30 PM 

Toxicologic and Exploratory Pathology 

Specialty Section Meeting/Luncheon 

CC Room 149 

12:00 NOON to 2:00 PM 

Toxicology and Applied Pharmacology 

Associate Editors Meeting 


12:10 PM to 1:30 PM 




12:15 PM to 1:05 PM 

Merit Award Lecture: Neurotoxicology 

Goes Global: Scientific Collaboration and 

Mentorship, Lecturer: Michael Aschner 

CC Room 201 





Monday March 7 

12:30 PM to 1:00 PM 




1:00 PM to 4:30 PM 



1:00 PM to 1:30 PM 

Special Interest Group Collaboration 

Group Meeting 

CC Room 103 

1:00 PM to 2:00 PM 

ToxExpo Time! (NEW) 


2:00 PM to 4:45 PM 




2:00 PM to 3:00 PM 

ToxExpo Exhibit Hall 

VIP Walk-Through 


2:15 PM to 3:15 PM 

Exhibitor Hosted Session: SNBL USA, Ltd. 

CC Room 140B 

2:15 PM to 3:15 PM 

Exhibitor Hosted Session: STEMCELL 

Technologies, Inc. 

CC Room 156 

2:15 PM to 3:15 PM 

Exhibitor Hosted Session: WIL Research 

Laboratories 

CC Room 140A 

3:00 PM to 4:00 PM 

Specialty Section Governance 

Group Meeting 

CC Room 103 

3:30 PM to 4:30 PM 

Exhibitor Hosted Session: In Vitro ADMET 

Laboratories, LLC (IVAL) 

CC Room 140A 

3:30 PM to 4:30 PM 

Exhibitor Hosted Session: U.S. 

Environmental Protection Agency 

CC Room 140B 

4:30 PM to 6:00 PM 

American Board of Toxicology 

Open Mixer Meeting 


4:30 PM to 7:00 PM 

Roundtable of Toxicology Consultants 


Renaissance Ballroom East 

4:30 PM to 6:00 PM 

Specialty Section Presidents and 


CC Room 103 

4:35 PM to 5:55 PM 

SOT/EUROTOX Debate: Biomarkers from 

Blood and Urine Will Replace Traditional 

Histopathological Evaluation to Determine 

Adverse Responses, 

SOT Debater: Kim Boekelheide 

EUROTOX Debater: Ina Schuppe Koistinen 

CC Room 150 

4:45 PM to 5:45 PM 


Silent Auction 

CC East Salon 

5:00 PM to 6:00 PM 

AACT Distinguished Chinese Toxicologist 

Lectureship: Oxidative Stress and Metal 

Carcinogenesis; Lecturer: Xianglin Shi, 

Renaissance Grand Ballroom South 

Continued on next page 

Event Calendar



5:00 PM to 7:00 PM 

Elsevier Reception 


5:00 PM to 7:00 PM 

Gulf Coast/South Central Regional 

Chapters Joint Reception 

Fado Irish Pub 

5:00 PM to 6:30 PM 

Regulatory and Safety Evaluation Specialty 

Section Meeting/Reception on Capitol 

Hill—The Great Debate 

Sen. Johnny Isakson, Honorary Host 

(Limited Seating) 

Russell Senate Building SR-325 

(Buses Depart CC from L Street beginning 

at 4:00 PM) 

5:00 PM to 6:00 PM 

International Neurotoxicology Association 

Business Meeting 

Renaissance Congressional B 

5:00 PM to 8:00 PM 

University of Iowa Toxicology Center 

Alumni 50th Anniversary Gathering 

Hamilton Crown Plaza Hotel 

Lobby Lounge 

8:00 AM–9:00 AM 

PLEnARy OPEning LECTuRE 

NIH Vision, Lecturer: Francis S. Collins, 

National Institute of Health 

(Grand Ballroom) 

9:15 AM–12:00 NOON 

SYMPOSIum SESSIONS 

• Emerging Issues at the Intersection of 

Reproductive and Mixtures Toxicology 

(Room 143) 

• Environmental Oxidative Pollutant-Induced 

Pulmonary Toxicity (Room 151) 

• High Content Imaging: Applications in 

Toxicology and Toxicity Testing (Room 150) 

• Ribotoxic Stress: Mechanisms and Models for 

Human Disease (Room 207) 

WORKSHOP SESSIONS 

• Disease Prevention: The Next 50 Years 

(Room 144) 

• New Approaches for Integrating Toxicological 

and Epidemiological Data to Better Inform Risk 

Assessment (Room 145) 

PLATFORM SESSIONS 

• Nanotoxicology—Carbon Nanotubes and Carbon 

Nanoparticles (Room 206) 

• New Insights into Male Reproductive Toxicology 

(Room 202A) 

• Use of Embryonic Stem Cells in Toxicology 

(Room 204) 

9:30 AM–12:30 PM 

POSTER SESSIONS 

(Exhibit Hall—See Poster Board Surface Map on 

Pages 104–107) 

• Bioinformatic Profiling and Computational 

Pathway Prediction 

• Carcinogenesis I 

• Cardiovascular Toxicology 

• Cell Signaling and Gene Regulation 

• DNA Replication and Repair 

• Epigenetic Mechanisms 

5:15 PM to 6:30 PM 

Toxicologist without Borders, Inc. 

Information Meeting 


5:30 PM to 7:30 PM 

National Capital Area Regional 

Chapter/NRC Committee on 

Toxicology Joint Reception 

Embassy Suites Capital Ballroom A 

6:00 PM to 8:00 PM 

American Association of Chinese 

in Toxicology Special Interest Group 



6:00 PM to 7:30 PM 

Association of Scientists of Indian Origin 


CC Salon H 

6:00 PM to 7:30 PM 

Biotechnology Specialty Section 


CC 140B 

6:00 PM to 7:30 PM 

Cardiovascular Toxicology Specialty 


CC Room 102 


6:00 PM to 7:30 PM 

Molecular Biology Specialty Section 


CC Room 159 

6:00 PM to 7:30 PM 

Mountain West/Southern California 

Regional Chapters Joint Reception 


6:00 PM to 7:30 PM 



CC Salon G 

6:00 PM to 7:30 PM 



CC Salon I 

6:00 PM to 7:30 PM 

Stem Cells Specialty Section Inaugural 


CC Room 149 

6:00 PM to 9:00 PM 

Toxicological Sciences/Oxford 

University Press Appreciation Dinner 


Clydes of Gallery Place Piedmont Room 

• Genotoxicity 

• Hypersensitivity: Methods and Mechanisms 

• Inflammatory Mediators in Disease Pathogenesis 

• Metals I 

• Metals II 

• Neurodegenerative Diseases 

• Receptor and Receptor-Mediated Toxicity 

12:10 PM–1:30 PM 

ROunDTABLE SESSION 

• Reforming the Toxic Substances Control Act 

(TSCA): Challenges, Opportunities, and Timing 

(Room 144) 

InfORMATIONAL SESSION 

• The International Cooperation on Alternative 

Test Methods (ICATM): Translating Science 

to Provide Improved Public Health Safety 

Assessment Tools (Room 143) 

EDUCATION-CAREER DEVELOPMENT SESSION 


Toxicologists (Room 147) 

12:15 PM–1:05 PM 

MERIT AWARD LECTuRE 

Neurotoxicology Goes Global: Scientific 

Collaboration and Mentorship, 

Lecturer: Michael Aschner (Room 201) 

1:00 PM–4:30 PM 


(Exhibit Hall—SSee Poster Board Surface Map on 

Pages 104–107) 

• Acetaminophen Hepatotoxicity 

• Animal Models in Toxicological Research 

• Animal Models in Toxicology 

• Biological Modeling: Computational Approaches, 

Mixtures, Multiroute and Lifestage Applications 

• Children’s Health/Juvenile Toxicology 

• Drug Induced Liver Injury 

• Immunotoxicity: Methods and Evaluation 

• Inhalation and Cardiopulmonary Toxicology 

• Kidney 




Monday (Continued) March 7 

6:00 PM to 8:00 PM 

Toxicologists of African Origin Special 

Interest Group Meeting/Reception 

Embassy Suites Capital Ballroom B 

6:30 PM to 8:30 PM 

Korean Toxicologists Association 

in America Special Interest Group 



6:30 PM to 10:00 PM 

MPI Research Event: Got Science? 

Grand Hyatt Constitution A 

6:30 PM to 8:30 PM 

Northern California Regional 

Chapter Reception 


7:30 PM to 9:30 PM 

North Carolina State University 

Alumni Reception 


9:00 PM to 11:00 PM 

Michigan State University Environmental 

Toxicology Reception 

Renaissance Ballroom West A 


Monday March 7 

• Mechanisms of Immunotoxicity 

• Pharmaceutical Safety Assessment: Therapeutic 

Agents 

• Risk Assessment: Computational Approaches, 

Analyses, and Applications 

• Skin 

2:00 PM–4:45 PM 


• Epigenetics, Metals, and Cancer (Room 151) 

• Human Variability in Susceptibility to 

Environmental Toxicants (Room 207) 

• Toxicological Considerations in the Gulf of 

Mexico Oil Spill (Room 204) 

• Translational Toxicology: Molecules to Global 

Health (Room 147) 

• Vascular Developmental Toxicity: Identification, 

Prioritization, and Application (Room 206) 


• Protein Aggregation As a Common Mechanism 

of Toxicity in Neurodegenerative Diseases 

(Room 143) 

• Technical Characterization and Dosimetry 

Challenges Associated with Conducting or 

Interpreting Nanotoxicity (Room 145) 

• Understanding Structural and Physical Chemical 

Drivers of Drug Toxicity: Utility and Translatable 

Value (Room 144) 


• Advancing Assessment Approaches: Pesticides 

and Other Key Contaminants (Room 202B) 

• Alternative Methods in Developmental 


(Room 201) 

• Biomarkers of Carcinogenesis (Room 202A) 

4:35 PM–5:55 PM 

SOT/EUROTOX DEBATE 

Biomarkers from Blood and Urine Will Replace 

Traditional Histopathological Evaluation to 

Determine Adverse Responses (Room 150) 






7 


Tuesday March 8 





6:00 AM to 10:00 PM 


CC Salon F 

6:00 AM to 4:30 PM 

Registration 

CC East Salon 

6:00 AM to 4:30 PM 


CC Room 208 

6:15 AM to 6:30 AM 


(For Sunrise Session Attendees) 

CC (Outside Sunrise Session Meeting 

Rooms) 

6:30 AM to 7:50 AM 

Scientific Sessions (Sunrise) 



6:45 AM to 7:45 AM 

American Board of Veterinary 

Toxicology Meeting 


7:00 AM to 8:00 AM 

Awards Committee Meeting 

CC Room 303 

7:00 AM to 8:30 AM 

Education Committee Meeting 

CC Room 305 

7:00 AM to 7:50 AM 

Leading Edge in Basic Science Award 

Lecture: Roles of Keap1-Nrf2 in 

Environmental Response, 

Lecturer: Masayuki Yamamoto 

CC Room 201 

7:00 AM to 8:30 AM 

Regional Chapter Presidents and 


CC Room 103 

7:00 AM to 4:30 PM 

SOT Office 

CC Room 101 

7:00 AM to 8:30 AM 

Specialty Section Graduate 


CC Room 142 

7:30 AM to 8:30 AM 

50th Year Anniversary SOT Task 

Force Meeting 

CC Room 304 

7:30 AM to 9:30 AM 



7:30 AM to 9:00 AM 




8:00 AM to 6:00 PM 

E-mail Center 

CC East Salon 

8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Housing Desk 

CC East Salon 

8:00 AM to 9:00 AM 

Keynote Plenary Lecture: Increasing 

the Prestige of Regulatory Sciences, 

Lecturer: Margaret Hamburg, U.S. FDA 


8:00 AM to 1:00 PM 

Tour Desk 

CC East Salon 

8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 


CC Room 157 

8:30 AM to 4:30 PM 

SOT Pavilion 


8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 



9:00 AM to 10:30 AM 

Audit Committee Meeting 

CC Room 302 

9:00 AM to 10:00 AM 



9:00 AM to 12:30 PM 



9:00 AM to 4:30 PM 

Research Funding Resource Room 

CC Room 203 

9:00 AM to 11:45 AM 




9:15 AM to 10:15 AM 


Celsis In Vitro Technologies 

CC Room 140B 

9:15 AM to 10:15 AM 


CC Room 140A 

9:15 AM to 10:15 AM 


CC Room 156 

10:30 AM to 11:30 AM 

Exhibitor Hosted Session: Harlan 

Laboratories, Inc. 

CC Room 140B 

10:30 AM to 11:30 AM 

Exhibitor Hosted Session: Huntingdon 

Life Sciences 

CC Room 156 

10:30 AM to 11:30 AM 

Exhibitor Hosted Session: National 

Toxicology Program 

CC Room 140A 

10:30 AM to 11:30 AM 

ToxLearn Work Group 

CC Room 303 

11:45 AM to 12:45 PM 

Exhibitor Hosted Session: Data 

Sciences International 

CC Room 140B 

11:45 AM to 12:45 PM 


Ingenuity Systems, Inc. 

CC Room 156 




11:45 AM to 12:45 PM 

Exhibitor Hosted Session: LAB Research 

CC Room 140A 

11:45 AM to 1:30 PM 

Toxicology Letters Editorial Board Meeting 


12:00 NOON to 1:30 PM 

ASIO Lunch and Learn Program 

CC Room 141 

12:00 NOON to 1:30 PM 

Comparative and Veterinary Specialty 

Section Meeting/Luncheon 

CC Room 149 

12:00 NOON to 1:30 PM 

Endowment Fund Board Meeting 

CC Room 305 

12:00 NOON to 1:30 PM 

Global Strategy Task Force Meeting 

CC Room 306 

12:00 NOON to 1:00 PM 

Human Toxicology Project Consortium: 

Recommendations for Accelerating 

Implementation of the 2007 National 

Academy Report on 21st Century 

Toxicology: Outcome of an 

HTPC Workshop 

Grand Hyatt Constitution D 

12:00 NOON to 1:30 PM 

Journal of Inhalation Toxicology 

Editorial Board Meeting 


12:00 NOON to 1:15 PM 

New Investigator Lunch 

CC Salon I 

12:00 NOON to 1:15 PM 

Postdoctoral Assembly Luncheon 


CC Salon G 

12:00 NOON to 1:20 PM 




12:15 PM to 1:05 PM 

Distinguished Toxicology Scholar 

Award Lecture: Cloning and Functional 

Analysis of the Aryl Hydrocarbon Nuclear 

Translocator (ARNT), 

Lecturer: Oliver Hankinson 

CC Room 201 

12:30 PM to 2:00 PM 

Northeast Regional Chapter 

Student Luncheon 


12:30 PM to 1:00 PM 




1:00 PM to 2:00 PM 


emka TECHNOLOGIES 

CC Room 156 

1:00 PM to 2:00 PM 

Exhibitor Hosted Session: RTC Research 

Toxicology Centre 

CC Room 140B 

1:00 PM to 2:00 PM 

Exhibitor Hosted Session: WIL Research 

Laboratories 

CC Room 140A 

1:00 PM to 4:30 PM 



1:30 PM to 4:15 PM 




2:15 PM to 3:15 PM 

Exhibitor Hosted Session: Cyprotex 

Discovery 

CC Room 140A 

2:15 PM to 3:15 PM 


Instech Solomon 

CC Room 140B 

2:15 PM to 3:15 PM 


Promega Corporation 

CC Room 156 

3:00 PM to 4:15 PM 

Undergraduate Toxicology Faculty Meeting 

CC Room 103 

3:30 PM to 4:30 PM 

Exhibitor Hosted Session: Biopredic Inc 

CC Room 156 

3:30 PM to 4:30 PM 


Ellegaard Göttingen Minipigs A/S 

CC Room 140A 

3:30 PM to 4:30 PM 


Life Technologies 

CC Room 140B 

4:30 PM to 6:00 PM 


Member Celebration Meeting 

(SOT Members Only; Full, Associate, 

Postdoctoral, and Student Members 

Invited) 

CC Room 207 

4:45 PM to 6:00 PM 

ToxExpo 2012 Exhibit Space 

Selection Meeting 

CC Room 156 

6:30 PM to 9:30 PM 






Event Calendar



6:30 AM–7:50 AM 

Complimentary coffee service is available at 

6:15 AM for attendees participating in sunrise 

sessions. 

ROunDTABLE SESSIONS 

• Current Uses and Understanding of the Tissue 

Cross Reactivity Assay (Room 144) 

• Risk and Risk Management of Potentially Toxic 

Compounds Formed by Cooking Food 

(Room 143) 


• Emerging Science for Environmental Health 

Decisions: Tools, Strategies, and Evidence (Room 

147) 

7:00 AM–7:50 AM 

LEADIng EDGE in BASIC SCIEnCE 

AWARD LECTuRE 

Roles of Keap1-Nrf2 in Environmental Response, 

Lecturer: Masayuki Yamamoto (Room 201) 

8:00 AM–9:00 AM 

KeynOTE PLEnARy LECTuRE 

Increasing the Prestige of Regulatory Sciences, 

Lecturer: Margaret Hamburg, U.S. FDA 

(Grand Ballroom) 

9:00 AM–11:45 AM 


• Metabolic Basis of Respiratory Tract Chemical 

Toxicity (Room 206) 

• Stem Cell Biology and Cell Therapy Approaches 

to Understanding Cellular Injury and Wound 

Healing in Dermal, Ocular, and Pulmonary 

Injury (Room 202A) 

• Uncovering the Role of Non-Coding RNAs in 

Toxicology (Room 147) 


• Identification of Chemical Respiratory Allergens: 

Principles and New Developments (Room 207) 

• Safer Products for a Sustainable World: Linking 

Chemical Design and Toxicology (Room 144) 

• Using Mode of Action Data to Guide Quantitative 

Cancer Risk Assessment: A Case Study of 

Hexavalent Chromium in Drinking Water (Room 

143) 

HISTORICAL HIGHLIGHTS 

SESSION 

• 1961 to 2011 and Beyond: The Evolution of 

Toxicology (Room 151) 

REGIONAL INTEREST SESSION 

• Bombs in Our Backyards? Historical Military 

Activities and Current Public Health Issues in the 

U.S. Capital Region (Room 150) 


• Computational Approaches to Address DILI and 

Hepatoxicity (Room 204) 

• Epigenetic Mechanisms in Development and 

Disease (Room 201) 

• Gene Regulatory Mechanisms of Carcinogenesis 

(Room 202B) 


9:00 AM–12:30 PM 



Pages 104–107) 

• Ah Receptor in Immune Regulation and Toxicity 

• Alternative Approaches to Animal Testing for 

Toxicological Research 

• Alternatives to Mammalian Models for Testing 

• Cholestasis, Lipid Homeostasis, and Liver 

Toxicity 

• Epidemiology and Exposure Evaluations 

• Exposure Assessments and Biomonitoring 

Applications 

• Hepatotoxicity 

• ImmunoSafety Methods in Non-Rodents 

• Nanotoxicology: Carbon Nanotubes, Carbon 

Nanoparticles, and Quantum Dots 

• Oxidative Stress and Redox Biology 

• Reproductive Toxicology I 

• Reproductive Toxicology II 

• Stem Cell Toxicology 

12:00 NOON–1:20 PM 


• Integrating Alternative Test Methods into the 

Federal Regulatory Framework (Room 143) 

InfORMATIONAL SESSIONS 

• Coordinating Global Chemical Safety: The Big 

Four (Room 144) 

• Livers on a Plate: Next Generation Hepatocyte 

Models for High-Throughput Screening and 

Mode of Action Prediction (Room 147) 

12:15 PM–1:05 PM 

DISTInguISHED TOXICOLOGy SCHOLAR AWARD 

LECTuRE 



Lecturer: Oliver Hankinson (Room 201) 

1:00 PM–4:30 PM 



Pages 104–107) 

• Apoptosis/Cell Death 

• Biomarkers of Environmental Exposures 

• Developmental Toxicology 

• Drug Allergy, Pseudoallergy, IDRH, and 

Autoimmunity 

• Genetic Polymorphisms 

• Medical Devices 

• Metal Neurotoxicity: Methylmercury and 

General 

• Methods in Biomarker Discovery and Validation 

• Mutagenecity 

• Nanotoxicology 

• Neurotoxicity of Pesticides 

• ‘Omics in Toxicology Research 

• Risk Assessment and Regulatory Policy 

Applications 

• Safety and Risk Assessment: Critical 

Characterizations for Chemicals and New 

Concerns 





Tuesday March 8 

1:30 PM–4:15 PM 


• Developmental Origins of Adult Disease: 

The Effects of Low Dose Lead (Room 144) 

• Does the Clock Make the Poison? Influence 

of the Circadian Clock on Toxicological 

Mechanisms and Outcomes (Room 204) 

• Macrophages: Regulators of Toxicity and Disease 

Pathogenesis (Room 143) 

• When Is Exposure Not Exposure? Defining the 

Dose-Response Region between ”Effect” and 

“Adverse Effect” Implications for Human Health 

Risk Assessment (Room 147) 


• Nonclinical to Clinical Abuse Liability 

Assessment of Drugs: Current Practices, 

Challenges, and Impact of Recent Regulatory 

Guidance (Room 150) 

• Risk Assessment for Proteins Introduced into 

Genetically Modified Crops (Room 207) 

• The Spectrum of Systems Biology (Room 151) 


• Application of Zebrafish Models in Toxicology 

(Room 202B) 

• Chemical and Biological Weapons—Sulfur 

Mustard Effects (Room 145) 

• Nanotoxicology—Nanosilver Particulates 

(Room 202A) 

4:30 PM–6:00 PM 

50th Anniversary Member Celebration Meeting 

(Room 207) 









6:00 AM to 8:00 PM 


CC Salon F 

6:00 AM to 4:00 PM 

Registration 

CC East Salon 

6:00 AM to 4:30 PM 


CC Room 208 

6:15 AM to 6:30 AM 




Rooms) 

6:30 AM to 7:30 AM 

Academy of Toxicological Sciences Board 

of Directors Meeting 


6:30 AM to 7:50 AM 




7:00 AM to 8:30 AM 

Committee on Diversity Initiatives Meeting 

CC Room 302 

7:00 AM to 8:00 AM 

Contemporary Concepts in Toxicology 

Conference Committee Meeting 

CC Room 304 

7:00 AM to 4:30 PM 

SOT Office 

CC Room 101 

7:00 AM to 8:30 AM 

Student Advisory Council 

Business Meeting 

CC Room 103 

7:00 AM to 8:00 AM 

Toxicology In Vitro Editorial 

Board Meeting 


7:30 AM to 9:30 AM 



7:30 AM to 9:00 AM 




8:00 AM to 6:00 PM 

E-mail Center 

CC East Salon 

8:00 AM to 5:00 PM 



8:00 AM to 2:00 PM 

Housing Desk 

CC East Salon 

8:00 AM to 9:00 AM 

Keynote Medical Research Council (MRC) 

Lecture: Cellular Responses to DNA 

Damage: New Molecular Insights and 

New Approaches for Cancer Therapy, 

Lecturer: Stephen P. Jackson, University of 

Cambridge 


8:00 AM to 9:30 AM 

Tour Desk 

CC East Salon 

8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 


CC Room 157 

8:30 AM to 4:30 PM 

SOT Pavilion 


8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 



9:00 AM to 10:00 AM 



9:00 AM to 12:30 PM 



9:00 AM to 4:30 PM 


CC Room 203 

9:00 AM to 11:45 AM 




9:15 AM to 10:15 AM 


CC Room 140A 

9:15 AM to 10:15 AM 


Harlan Laboratories, Inc. 

CC Room 140B 

9:15 AM to 10:15 AM 



CC Room 156 

9:30 AM to 10:30 AM 

Meet the Director, 

Lecturer: Linda Birnbaum, NIEHS 

CC Room 201 

10:30 AM to 11:30 AM 


BioReliance ® Corporation 

CC Room 140B 

10:30 AM to 11:30 AM 


InSphero AG 

CC Room 140A 

10:30 AM to 11:30 AM 


CC Room 156 

10:45 AM to 11:45 AM 


Lecturer: John Howard, CDC/NIOSH 

CC Room 201 

11:30 AM to 1:30 PM 

Finance Committee Meeting 

CC Room 301 

11:30 AM to 1:00 PM 

Membership Committee Meeting 

CC Room 303 

11:45 AM to 12:45 PM 

Exhibitor Hosted Session: GeneGo, Inc., 

a Thomson Reuters Business 

CC Room 140A 

11:45 AM to 12:45 PM 

Exhibitor Hosted Session: Taconic 

CC Room 140B 

11:45 AM to 1:30 PM 

Toxicology Editorial Board Meeting 



9 

12:00 NOON to 1:30 PM 

In Vitro and Alternative Methods Specialty 

Section Meeting/Luncheon 

CC Salon G 

12:00 NOON to 1:30 PM 

Journal of Immunotoxicology Editorial 

Board Meeting 


12:00 NOON to 1:00 PM 


Lecturer: Yvonne Maddox, NICHD 

CC Room 201 

12:00 NOON to 1:30 PM 

Professional Needs Assessment 

Task Force Meeting 

CC Room 305 

12:00 NOON to 1:30 PM 

Regional Chapter Governance 


CC Room 304 

12:00 NOON to 1:20 PM 




12:15 PM to 1:05 PM 

Translational Impact Award Lecture: 

Integration of Bioinformatics into 

Regulatory Decision Making, 

Lecturer: Weida Tong 

CC Room 151 

12:30 PM to 1:00 PM 




1:00 PM to 2:00 PM 


Applied BioPhysics, Inc. 

CC Room 140A 

1:00 PM to 4:30 PM 



1:15 PM to 2:15 PM 

Meet the Director, Lecturer: Sy Garte, 

Center for Scientific Review 

CC Room 201 

1:30 PM to 4:15 PM 




2:00 PM to 4:00 PM 

Exhibitor Liaison Working Group 

CC Room 141 

2:30 PM to 3:30 PM 


Lecturer: Jesse Goodman, U.S. FDA 

CC Room 201 

3:45 PM to 4:45 PM 


Lecturer: Paul Anastas, U.S. EPA (invited) 

CC Room 201 

4:30 PM to 6:00 PM 

Board of Publications Meeting 

CC Room 305 

4:30 PM to 6:30 PM 

Women in Toxicology Special Interest 

Group Meeting/Reception 

Renaissance Ballroom West A and B 

4:30 PM to 5:50 PM 

Scientific Sessions (Sunset) 



5:00 PM to 6:30 PM 

Michigan Regional Chapter Reception 

(Happy Hour/Social Gathering) 

TBD 





Wednesday March 9 

6:00 PM to 7:30 PM 

Biological Modeling Specialty Section 


CC Room 149 

6:00 PM to 7:30 PM 

Drug Discovery Toxicology 

Specialty Section Meeting/Reception 

CC Room 103 

6:00 PM to 7:30 PM 

Ethical, Legal, and Social Issues Specialty 


CC Room 156 

6:00 PM to 7:30 PM 

Immunotoxicology Specialty Section 


CC Salon H 

6:00 PM to 7:30 PM 

Inhalation and Respiratory Specialty 


CC Room 102 

6:00 PM to 7:30 PM 



CC Salon I 

6:00 PM to 7:30 PM 



CC Room 140A 

6:00 PM to 7:30 PM 


Toxicology Specialty Section 


CC Salon G 

6:30 PM to 8:30 PM 

Kettering Laboratory Reception— 

University of Cincinnati 


7:00 PM to 8:30 PM 

President’s Reception (By Invitation Only) 

Renaissance Grand Ballroom Central 

8:00 PM to 10:00 PM 

Academy of Toxicological 

Sciences Reception 

Renaissance Congressional Ballroom 


Event Calendar








Wednesday March 9 

6:30 AM–7:50 AM 



sessions. 

HISTORICAL HIGHLIGHTS 

SESSION 

• 50 Years of “the Pill”: Risk Reduction and 

Discovery of Benefits Beyond Contraception 

(Room 147) 


• Precision-Cut Tissue Slices Revisited: A 

Classical Method Meets New Challenges 

(Room 145) 

• The Application of the Threshold of 

Toxicological Concern Concept to the Preclinical 

Safety Assessment of Non-Pharmaceutical 

Medical Products, Including Medical Devices 

and Combination Drug-Device Products 

(Room 150) 


• From Pilot Grants to High-End Journals: 

The Science of Writing (Room 144) 

8:00 AM–9:00 AM 

KeynOTE MEDICAL RESEARCH CounCIL 

(MRC) LECTuRE 

Cellular Responses to DNA Damage: New 

Molecular Insights and New Approaches for 

Cancer Therapy, Lecturer: Stephen P. Jackson, 

University of Cambridge (Grand Ballroom) 

9:00 AM–11:45 AM 


• Autism: Genetic, Epigenetic, and Environmental 

Factors Influencing Neural Networks 

(Room 202A) 

• Gene-Environment Disease Interactions in Fish 

Models of Human Disease (Room 144) 

• Mechanisms of Inflammation in Skin 

Carcinogenesis (Room 150) 

• New Insights into the Nrf2-Keap1 Pathway and 

Its Impact on Human Disease (Room 143) 


• Approaches for Incorporating Non-Chemical 

Stressors into Cumulative Risk Assessments 

(Room 204) 

• Extending Pulmonary Toxicity Findings for 

Nanomaterials (Room 206) 

• Understanding the Implications of Preclinical 

Seizures for Clinical Drug Development 

(Room 145) 

PLATFORM SESSION 

• QSAR Approaches and Predictive Pathways 

(Room 147) 

9:00 AM–12:30 PM 



Pages 104–107) 

• Arsenic 

• Chemical and Biological Weapons 

• Metal Neurotoxicity: Manganese and Lead 

• Nanotoxicology: Metal Oxides, Silver, Gold, and 

Silica Nanoparticle Toxicity 

• Pesticides: General 

• Pharmaceutical Safety Assessment: Novel 

Methods 

• Phase I and II Biotransformation Enzymes 

• Risk Assessment: Conceptual Constructs and 

Current Controversies 

• Safety Testing of Pharmaceuticals 

• Toxicology Education: K–12 and Beyond 

• Xenobiotic Biotransformation 

9:30 AM–10:30 AM 

MEET the DIRECTOR 

NIEHS Director, Lecturer: Linda Birnbaum, 

NIEHS (Room 201) 

10:45 AM–11:45 AM 


CDC/NIOSH Director, Lecturer: John Howard, 

CDC/NIOSH (Room 201) 

12:00 NOON–1:20 PM 


• ‘Omics in Toxic Tort (Room 144) 


• Current and Changing Perspectives on 

Mycotoxins and Their Potential Health Risks 

Worldwide (Room 145) 

12:00 NOON–1:00 PM 


Eunice Kennedy Shriver National Institute of 

Child Health & Human Development Director, 

Lecturer: Yvonne Maddox, NICHD (Room 201) 

12:15 PM–1:05 PM 

TRAnSLATIOnAL IMPACT AWARD LECTuRE 


Decision Making, Lecturer: Weida Tong 

(Room 151) 

1:00 PM–4:30 PM 



Pages 104–107) 

• Aquatic and Ecotoxicology 

• Cellular Effects of Natural Product Extracts 

• Developmental Basis of Adult Disease 

• Endocrine Toxicology 

• Food Safety and Nutrition 

• Mechanisms of Aspiration Injury and Airway 

Disease 

• Mechanistic Assessments of Chemical Mixtures 

• Nanotoxicology: In Vitro and Ex Vivo Studies 

• Persistent Organic Compounds (POPs) 

• Pharmacokinetics and Disposition 

• Risk Assessment: Models and Approaches for 

Inhaled Agents 

• Toxicology of the Gulf Oil Spill 

1:15 PM–2:15 PM 


Center for Scientific Review Director, 

Lecturer: Sy Garte, Center for Scientific Review 

(Room 201) 

1:30 PM–4:15 PM 


• Autophagy in Toxicology: Essential Process, 

Adaptive Process, and Disease Process 

(Room 147) 

• Human Pluripotent Stem Cells and Neural 

Progenitors As Models of Gene-Environment 

Interactions in Neurological Disease (Room 150) 

• The Use of Epidemiological Data and PBPK 

Modeling in a Risk Assessment: Manganese As a 

Case Study (Room 145) 


• Advancing Predictive Ecotoxicology Testing 

and Environmental Risk Assessment in the 21st 

Century (Room 144) 

• De-Risking the Potential for Cardiovascular 

Toxicity of Type-2 Diabetic Drugs: Preclinical 

and Clinical Strategies (Room 204) 

• Meeting the Challenges of Respiratory 

Toxicology Testing—In Search of Best Practices 

(Room 206) 

• Polishing Today’s Job Candidate in a Tough 

Economy (Room 202A) 


• Airborne Particulates and Health Effects 

(Room 143) 

• Nrf2 and Antioxidant Response Networks 

(Room 202B) 

2:30 PM–3:30 PM 


U.S. FDA Director, Lecturer: Jesse Goodman, 

U.S. FDA (Room 201) 

3:45 PM–4:45 PM 


U.S. EPA Director, Lecturer: Paul Anastas, 

U.S. EPA (invited) (Room 201) 

4:30 PM–5:50 PM 


• Assessment of Nanoparticle Exposure in 

Occupational Settings and in Inhalation 

Toxicology Studies: Is There a Best Dosemetric 

to Use? (Room 144) 


• Progress of the Tox21 Consortium in High- 

Throughput Bioactivity Profiling of Chemicals 

(Room 143) 

• Toxicological Considerations of 

Pharmacotherapy during Pregnancy (Room 145) 









6:00 AM to 1:00 PM 


CC Salon F 

6:00 AM to 11:30 AM 

Registration 

CC East Salon 

6:00 AM to 11:30 AM 


CC Room 208 

6:15 AM to 6:30 AM 




Rooms) 

6:30 AM–7:50 AM 



sessions. 

INFORMATIONAL SESSION 

• Beyond Science and Decisions: From Problem 

Formulation to Dose-Response (Room 143) 


• Bringing Toxicology to the Decision-Makers 

Table: Opportunities for Science Policy Positions 

in Washington, D.C. (Room 145) 

ISSUES SESSION 

• What It Means to Be Global (Room 147) 

8:00 AM–9:00 AM 

KeyNOTE PLENARy LECTURE 

U.S. EPA Vision, Lecturer: Lisa Jackson, 

U.S. EPA (invited) (Ballroom C) 

6:30 AM to 7:50 AM 




7:00 AM to 8:00 AM 



CC East Salon & Room 202 

7:00 AM to 11:30 AM 

SOT Office 

CC Room 101 

7:30 AM to 12:00 NOON 



8:00 AM to 11:30 AM 

E-mail Center 

CC East Salon 

8:00 AM to 11:30 AM 




8:30 AM–12:00 NOON 


(East Salon and Room 202*—See Poster Board Surface 


• Alternatives to Animal Models in Toxicology 

• Alternatives to Mammalian Models 

• Carcinogenesis II ) 

• Developmental Neurotoxicity: General 

• Disease Prevention 

9:00 AM–11:45 AM 

SYMPOSIUM SESSIONS 

• Developmental Exposure to Environmental 

Toxicants: From Persistent Toxicities to Diseases 

(Room 143) 

• Vascular Injury: A Figment of Your 

Inflammation? (Room 150) 

11 

8:00 AM to 9:00 AM 

Keynote Plenary Lecture: U.S. EPA Vision, 

Lecturer: Lisa Jackson, U.S. EPA (invited) 

CC Ballroom C 

8:00 AM to 12:00 NOON 

ToxExpo Tear Down 


8:30 AM to 12:00 NOON 


CC East Salon & Room 202 

9:00 AM to 11:45 AM 




11:00 AM to 1:00 PM 

Research Funding Committee Meeting 

CC Room 302 

12:00 NOON to 1:30 PM 

Scientific Program Committee Meeting 

CC Room 303 


Thursday March 10 


12:00 NOON to 3:00 PM 

Satellite Meeting: Johns Hopkins Center for 

Alternatives to Animal Testing—Evidence- 

Based Toxicology (EBT) Collaboration 

Kick-Off Meeting 

CC Room 206 

Thursday March 10 

*Late Breaking and Grace Period Abstracts accepted for presentation were not available for this publication. 

These abstracts will be available on-line through the Itinerary Planner and as separate printed supplement. 






Go to the SOt Pavilion for on-site information. 



• Are We There Yet? Attrition in the 

Pharmaceutical Industry and Impactful 

Strategies for Reducing Failure (Room 151) 

• Autoimmunity versus Systemic Hypersensitivity: 

Commonalities Useful for Immunotoxicity 

Testing (Room 201) 

• PBPK Model Use in Risk Assessment: Why 

Being Published Is Not Enough (Room 145) 

• Role of Biomarkers in Assessing Tobacco Harm 

Reduction: A Toxicological Perspective 

(Room 144) 

Event Calendar

SOT Pavilion 

Make the SOT Pavilion your meeting place on the exhibit floor. 

Stop by to see special presentations and to… 

• Obtain Information about SOT Membership 

• Support the SOT Endowment 

• Connect with SOT Volunteers 

• Learn More about SOT Regional Chapter, 

Specialty Section, and Special Interest Group Activities 

• Share and Discuss Communication Tips 

• Visit High School Research Posters 

• Learn about Outreach Materials for 

Animals in Research 

Public Outreach 

Regulatory and Legislative Initiatives 

The SOT Pavilion is your connection to key resources 

and people in toxicology. 


Visit the SOT Pavilion in the Exhibit Hall… 

Learn all about ToXchange exciting new SOT member resource and how you can— 

• Create a customized SOT member My Page you can update on-line 24/7 

• Search for and find other SOT members based on their profile information 

• Be found by other SOT members based on YOUR profile information 

• Communicate with YOUR SOT peers with easy-to-use, secure networking tools 





Schedule by Event Name 


13 


Event: Date: Time: Location: Room: 

25-Year (or More) Member Reception (By Invitation Only) Sunday, Mar 6 6:30 PM to 7:30 PM Convention Center Room 103 

50th Anniversary Celebration Event (Ticket Required) Tuesday, Mar 8 6:30 PM to 9:30 PM Convention Center Grand Ballroom 

50th Anniversary Member Celebration Meeting (SOT Members Only; 

Full, Associate, Postdoctoral, and Student Members Invited) 

Tuesday, Mar 8 4:30 PM to 6:00 PM Convention Center Room 207 

50th Anniversary Silent Auction Monday, Mar 7 4:45 PM to 5:45 PM Convention Center East Salon 

50th Year Anniversary SOT Task Force Meeting Tuesday, Mar 8 7:30 AM to 8:30 AM Convention Center Room 304 

A 

AACT Distinguished Chinese Toxicologist Lectureship: Oxidative 

Stress and Metal Carcinogenesis, Lecturer: Xianglin Shi 

Monday, Mar 7 5:00 PM to 6:00 PM Renaissance Grand Ballroom 

South 

Academy of Toxicological Sciences Board of Directors Meeting Wednesday, Mar 9 6:30 AM to 7:30 AM Renaissance Meeting Room 7 

Academy of Toxicological Sciences Reception Wednesday, Mar 9 8:00 PM to 10:00 PM Renaissance Congressional 

Ballroom 

Alliance for Risk Assessment (ARA) Open Meeting/Lunch Sunday, Mar 6 12:15 PM to 1:15 PM Renaissance Meeting Room 14 

American Association of Chinese in Toxicology Special Interest 


Monday, Mar 7 6:00 PM to 8:00 PM Renaissance Grand Ballroom 

South 

American Board of Toxicology Board of Directors Meeting Saturday, Mar 5 1:00 PM to 6:00 PM Renaissance Meeting Room 7 

American Board of Toxicology Open Mixer Meeting Monday, Mar 7 4:30 PM to 6:00 PM Renaissance Congressional A 

American Board of Veterinary Toxicology Meeting Tuesday, Mar 8 6:45 AM to 7:45 AM Renaissance Meeting Room 14 

Arizona Night Sunday, Mar 6 7:30 PM to 10:00 PM Renaissance Ballroom West B 

ASIO Lunch and Learn Program Tuesday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 141 

Association of Scientists of Indian Origin Special Interest Group 


(Schedule as of January 7; private events are not listed.) 

Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Salon H 

Audit Committee Meeting Tuesday, Mar 8 9:00 AM to 10:30 AM Convention Center Room 302 

Awards Ceremony (All Attendees Welcome) Sunday, Mar 6 5:15 PM to 6:30 PM Convention Center Room 207 

Awards Ceremony Music—Performed by Gail Shanta, Harpist Sunday, Mar 6 4:45 PM to 5:15 PM Convention Center Room 207 

Awards Committee Meeting Tuesday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 303 

Awards Recipients Photographed Sunday, Mar 6 4:00 PM to 5:15 PM Convention Center Room 206 

B 

Biological Modeling Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 149 

Biotechnology Specialty Section Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Room 140B 

Board of Publications Meeting Wednesday, Mar 9 4:30 PM to 6:00 PM Convention Center Room 305 

Board of Publications ToxSci Editor Interviews Monday, Mar 7 12:00 NOON to 5:00 PM Convention Center Room 303 

C 

Carcinogenesis Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 146A 

Carcinogenesis Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 8:00 AM Convention Center Salon G 

Cardiovascular Toxicology Specialty Section Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Room 102 

Career Resource and Development Committee Meeting Sunday, Mar 6 7:30 AM to 9:30 AM Convention Center Room 301 

CDI Reunion (Networking and Dessert—Invited: Anyone involved 

with the SOT Undergraduate Education Program through the years) 

Saturday, Mar 5 8:00 PM to 9:00 PM Convention Center Room 103 

Central States Regional Chapter Meeting/Luncheon Monday, Mar 7 12:00 NOON to 2:00 PM Embassy Suites Capital 

Ballroom B 

Coat/Luggage Check Sunday, Mar 6 7:00 AM to 8:00 PM Convention Center Salon F 

Coat/Luggage Check Monday, Mar 7 7:00 AM to 8:00 PM Convention Center Salon F 

Coat/Luggage Check Tuesday, Mar 8 6:00 AM to 10:00 PM Convention Center Salon F 

Coat/Luggage Check Wednesday, Mar 9 6:00 AM to 8:00 PM Convention Center Salon F 

Coat/Luggage Check Thursday, Mar 10 6:00 AM to 1:00 PM Convention Center Salon F 

Event Calendar


Schedule by Event Name (Continued) 


Committee on Diversity Initiatives Meeting Wednesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 302 

Communications Committee Meeting Monday, Mar 7 11:30 AM to 2:30 PM Convention Center Room 303 

Comparative and Veterinary Specialty Section Meeting/Luncheon Tuesday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 149 

Complimentary Coffee Monday, Mar 7 9:00 AM to 10:00 AM Convention Center Exhibit Hall 

Complimentary Coffee (For Sunrise Session Attendees) Tuesday, Mar 8 6:15 AM to 6:30 AM Convention Center (Outside Sunrise 

Session Meeting 

Rooms) 

Complimentary Coffee Tuesday, Mar 8 9:00 AM to 10:00 AM Convention Center Exhibit Hall 

Complimentary Coffee (For Sunrise Session Attendees) Wednesday, Mar 9 6:15 AM to 6:30 AM Convention Center (Outside Sunrise 


Rooms) 

Complimentary Coffee Wednesday, Mar 9 9:00 AM to 10:00 AM Convention Center Exhibit Hall 

Complimentary Coffee (For Sunrise Session Attendees) Thursday, Mar 10 6:15 AM to 6:30 AM Convention Center (Outside Sunrise 


Rooms) 

Concession Stands Sunday, Mar 6 7:30 AM to 2:30 PM Convention Center First and Second 

Levels 

Concession Stands Monday, Mar 7 7:30 AM to 9:30 AM Convention Center First and Second 

Levels 

Concession Stands Monday, Mar 7 9:00 AM to 4:30 PM Convention Center Exhibit Hall 

Concession Stands Tuesday, Mar 8 7:30 AM to 9:30 AM Convention Center First and Second 

Levels 

Concession Stands Tuesday, Mar 8 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Concession Stands Wednesday, Mar 9 7:30 AM to 9:30 AM Convention Center First and Second 

Levels 

Concession Stands Wednesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Concession Stands Thursday, Mar 10 7:30 AM to 12:00 NOON Convention Center First and Second 

Levels 

Congressional Task Force Meeting Sunday, Mar 6 3:00 PM to 5:00 PM Convention Center Room 302 

Contemporary Concepts in Toxicology Conference 


Wednesday, Mar 9 7:00 AM to 8:00 AM Convention Center 304 

Continuing Education Sunrise Mini-Course (Ticket Required) Sunday, Mar 6 7:00 AM to 7:45 AM Convention Center (See Signage for 


Continuing Education Morning Courses (Ticket Required) Sunday, Mar 6 8:15 AM to 12:00 NOON Convention Center (See Signage for 

Room Locations) 

Continuing Education Afternoon Courses (Ticket Required) Sunday, Mar 6 1:15 PM to 5:00 PM Convention Center (See Signage for 

Room Locations) 

Continuing Education Committee Meeting Monday, Mar 7 12:00 NOON to 1:30 PM Convention Center Room 301 

Continuing Education Committee Walk-Through Saturday, Mar 5 5:00 PM to 5:45 PM Convention Center Room 201 

Continuing Education Luncheon for Speakers, Committee, and 

Student Volunteers (By Invitation Only) 

Conversation with Dr. Collins (Ticket Required; Postdoctoral 

Scholars only, limited seating) 



Sunday, Mar 6 11:45 AM to 1:15 PM Convention Center Room 146A 

Monday, Mar 7 9:30 AM to 10:30 AM Convention Center Room 304 

Council Meeting Saturday, Mar 5 1:00 PM to 5:30 PM Renaissance Meeting Room 13 

Council Orientation Luncheon Saturday, Mar 5 11:30 AM to 1:00 PM Renaissance Meeting Room 14 

Council Orientation Meeting Saturday, Mar 5 8:00 AM to 11:30 AM Renaissance Meeting Room 14 

D 

Dermal Toxicology Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 203 

Dermal Toxicology Specialty Section Officers Meeting Sunday, Mar 6 4:00 PM to 6:00 PM Convention Center Room 203 

Disease Prevention Task Force Meeting Monday, Mar 7 12:00 NOON to 1:30 PM Convention Center Room 302 





Distinguished Toxicology Scholar Award Lecture: Cloning and 

Functional Analysis of the Aryl Hydrocarbon Nuclear Translocator 

(ARNT), Lecturer: Oliver Hankinson 


15 


Tuesday, Mar 8 12:15 PM to 1:05 PM Convention Center Room 201 

Drug Discovery Toxicology Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 103 

E 

E-mail Center Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center East Salon 

E-mail Center Sunday, Mar 6 7:00 AM to 6:00 PM Convention Center East Salon 

E-mail Center Monday, Mar 7 7:00 AM to 4:45 PM Convention Center East Salon 

E-mail Center Tuesday, Mar 8 8:00 AM to 6:00 PM Convention Center East Salon 

E-mail Center Wednesday, Mar 9 8:00 AM to 6:00 PM Convention Center East Salon 

E-mail Center Thursday, Mar 10 8:00 AM to 11:30 AM Convention Center East Salon 

Education Committee Meeting Tuesday, Mar 8 7:00 AM to 8:30 AM Convention Center Room 305 

Elsevier Reception Monday, Mar 7 5:00 PM to 7:00 PM Renaissance Meeting Room 12 

Endowment Fund Board Meeting Tuesday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 305 

Ethical, Legal, and Social Issues Specialty Section 




Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 156 

Exhibitor Hosted Session: Applied BioPhysics, Inc. Wednesday, Mar 9 1:00 PM to 2:00 PM Convention Center Room 140A 

Exhibitor Hosted Session: Biopredic Inc Tuesday, Mar 8 3:30 PM to 4:30 PM Convention Center Room 156 

Exhibitor Hosted Session: BioReliance ® Corporation Wednesday, Mar 9 10:30 AM to 11:30 AM Convention Center Room 140B 

Exhibitor Hosted Session: Celsis In Vitro Technologies Tuesday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 140B 

Exhibitor Hosted Session: Charles River Monday, Mar 7 9:15 AM to 10:15 AM Convention Center Room 140A 

Exhibitor Hosted Session: Charles River Tuesday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 140A 

Exhibitor Hosted Session: Charles River Wednesday, Mar 9 9:15 AM to 10:15 AM Convention Center Room 140A 

Exhibitor Hosted Session: Cyprotex Discovery Tuesday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 140A 

Exhibitor Hosted Session: Data Sciences International Tuesday, Mar 8 11:45 AM to 12:45 PM Convention Center Room 140B 

Exhibitor Hosted Session: Ellegaard Göttingen Minipigs A/S Tuesday, Mar 8 3:30 PM to 4:30 PM Convention Center Room 140A 

Exhibitor Hosted Session: emka TECHNOLOGIES Tuesday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 156 

Exhibitor Hosted Session: GeneGo, Inc., a Thomson Reuters Business Wednesday, Mar 9 11:45 AM to 12:45 PM Convention Center Room 140A 

Exhibitor Hosted Session: Harlan Laboratories, Inc. Monday, Mar 7 10:30 AM to 11:30 AM Convention Center Room 140B 

Exhibitor Hosted Session: Harlan Laboratories, Inc. Tuesday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 140B 

Exhibitor Hosted Session: Harlan Laboratories, Inc. Wednesday, Mar 9 9:15 AM to 10:15 AM Convention Center Room 140B 

Exhibitor Hosted Session: Huntingdon Life Sciences Monday, Mar 7 10:30 AM to 11:30 AM Convention Center Room 156 

Exhibitor Hosted Session: Huntingdon Life Sciences Tuesday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 156 

Exhibitor Hosted Session: Huntingdon Life Sciences Wednesday, Mar 9 9:15 AM to 10:15 AM Convention Center Room 156 

Exhibitor Hosted Session: In Vitro ADMET Laboratories, 

LLC (IVAL) 

Monday, Mar 7 3:30 PM to 4:30 PM Convention Center Room 140A 

Exhibitor Hosted Session: Ingenuity Systems, Inc. Tuesday, Mar 8 11:45 AM to 12:45 PM Convention Center Room 156 

Exhibitor Hosted Session: InSphero AG Wednesday, Mar 9 10:30 AM to 11:30 AM Convention Center Room 140A 

Exhibitor Hosted Session: Instech Solomon Tuesday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 140B 

Exhibitor Hosted Session: LAB Research Tuesday, Mar 8 11:45 AM to 12:45 PM Convention Center Room 140A 

Exhibitor Hosted Session: Life Technologies Tuesday, Mar 8 3:30 PM to 4:30 PM Convention Center Room 140B 

Exhibitor Hosted Session: MPI Research Monday, Mar 7 9:15 AM to 10:15 AM Convention Center Room 156 

Exhibitor Hosted Session: MPI Research Tuesday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 156 

Exhibitor Hosted Session: MPI Research Wednesday, Mar 9 10:30 AM to 11:30 AM Convention Center Room 156 

Event Calendar




Exhibitor Hosted Session: National Toxicology Program Tuesday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 140A 

Exhibitor Hosted Session: Porsolt & Partners Pharmacology Monday, Mar 7 11:45 AM to 12:45 PM Convention Center Room 140A 

Exhibitor Hosted Session: Promega Corporation Tuesday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 156 

Exhibitor Hosted Session: RTC Research Toxicology Centre Tuesday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 140B 

Exhibitor Hosted Session: Rules-Based Medicine Monday, Mar 7 11:45 AM to 12:45 PM Convention Center Room 156 

Exhibitor Hosted Session: Sigma Life Science Monday, Mar 7 11:45 AM to 12:45 PM Convention Center Room 140B 

Exhibitor Hosted Session: SNBL USA, Ltd. Monday, Mar 7 2:15 PM to 3:15 PM Convention Center Room 140B 

Exhibitor Hosted Session: STEMCELL Technologies, Inc. Monday, Mar 7 2:15 PM to 3:15 PM Convention Center Room 156 

Exhibitor Hosted Session: Taconic Wednesday, Mar 9 11:45 AM to 12:45 PM Convention Center Room 140B 

Exhibitor Hosted Session: U.S. Environmental Protection Agency Monday, Mar 7 3:30 PM to 4:30 PM Convention Center Room 140B 

Exhibitor Hosted Session: WIL Research Laboratories Monday, Mar 7 2:15 PM to 3:15 PM Convention Center Room 140A 

Exhibitor Hosted Session: WIL Research Laboratories Tuesday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 140A 

Exhibitor Liaison Working Group Wednesday, Mar 9 2:00 PM to 4:00 PM Convention Center Room 141 

F 

Finance Committee Meeting Wednesday, Mar 9 11:30 AM to 1:30 PM Convention Center Room 301 

Food Safety Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 140A 

Food Safety Specialty Section Officers Meeting Sunday, Mar 6 12:00 NOON to 1:30 PM Convention Center Room 140A 

G 

Global Strategy Task Force Meeting Tuesday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 306 

Graduate Fellowship Interviews by Awards Committee Saturday, Mar 5 7:30 PM to 9:30 PM Convention Center Room 301 

Guest/Spouse Hospitality Room Sunday, Mar 6 8:00 AM to 5:00 PM Renaissance Penn Quarter 

Guest/Spouse Hospitality Room Monday, Mar 7 8:00 AM to 5:00 PM Renaissance Penn Quarter 

Guest/Spouse Hospitality Room Tuesday, Mar 8 8:00 AM to 5:00 PM Renaissance Penn Quarter 

Guest/Spouse Hospitality Room Wednesday, Mar 9 8:00 AM to 5:00 PM Renaissance Penn Quarter 

Guest/Spouse Hospitality Room Thursday, Mar 10 8:00 AM to 11:30 AM Renaissance Penn Quarter 

Gulf Coast/South Central Regional Chapters Joint Reception Monday, Mar 7 5:00 PM to 7:00 PM Fado Irish Pub 

H 

HESI Seminar: Putting Health Risks into Perspective 

by Dr. Bruce Ames 

Hispanic Organization of Toxicologists Special Interest Group 


Monday, Mar 7 12:00 NOON to 2:00 PM Renaissance Congressional 

Ballroom 

Sunday, Mar 6 6:30 PM to 8:30 PM RFD Restaurant 

Housing Desk Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center East Salon 

Housing Desk Sunday, Mar 6 8:00 AM to 5:00 PM Convention Center East Salon 

Housing Desk Monday, Mar 7 7:00 AM to 5:00 PM Convention Center East Salon 

Housing Desk Tuesday, Mar 8 8:00 AM to 4:00 PM Convention Center East Salon 

Housing Desk Wednesday, Mar 9 8:00 AM to 2:00 PM Convention Center East Salon 

Human Toxicology Project Consortium: Recommendations for 

Accelerating Implementation of the 2007 National Academy Report 

on 21st Century Toxicology: Outcome of an HTPC Workshop 

I 

Tuesday, Mar 8 12:00 NOON to 1:00 PM Grand Hyatt Constitution D 

Immunotoxicology Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Salon H 

In Vitro and Alternative Methods Specialty Section 




Wednesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Salon G 

In Vitro and Alternative Methods Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

In Vitro Toxicology Lecture and Luncheon for Students, 

Monday, Mar 7 12:00 NOON to 1:20 PM Convention Center Salon G 

Lecturer: Robert E. Chapin (Ticket Required) 






17 


Inhalation and Respiratory Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 102 

International Neurotoxicology Association Business Meeting Monday, Mar 7 5:00 PM to 6:00 PM Renaissance Congressional B 

IUTOX Meetings Saturday, Mar 5 8:00 AM to 5:00 PM Convention Center Rooms 305, 306 

IUTOX Meetings Sunday, Mar 6 8:00 AM to 5:00 PM Convention Center Rooms 305, 306 

IUTOX Meetings Monday, Mar 7 8:00 AM to 5:00 PM Convention Center Rooms 305, 306 

J 

Job Bank Center Sunday, Mar 6 1:00 PM to 4:30 PM Convention Center Room 157 

Job Bank Center Monday, Mar 7 9:00 AM to 4:30 PM Convention Center Room 157 

Job Bank Center Tuesday, Mar 8 8:30 AM to 4:30 PM Convention Center Room 157 

Job Bank Center Wednesday, Mar 9 8:30 AM to 4:30 PM Convention Center Room 157 

Johnson & Johnson Toxicology Interest Group Meeting Saturday, Mar 5 11:30 AM to 6:00 PM Grand Hyatt Burnham Room 

Journal of Cutaneous and Ocular Toxicology Editorial 

Board Meeting 

Monday, Mar 7 7:00 AM to 8:00 AM Renaissance Meeting Room 5 

Journal of Immunotoxicology Editorial Board Meeting Wednesday, Mar 9 12:00 NOON to 1.30 PM Renaissance Meeting Room 10 

Journal of Inhalation Toxicology Editorial Board Meeting Tuesday, Mar 8 12:00 NOON to 1:30 PM Renaissance Meeting Room 5 

Journal of Toxicology Mechanisms and Methods Editorial 

Board Meeting 

K 

K–12 Outreach: Poisoned Pet Food—Unraveling the Melamine 

Mystery, Lecturer: Renate Reimschuessel 

K–12 Outreach: Protecting You and Your Pet through the Science 

of Toxicology: Paracelsus Goes to Washington 

Monday, Mar 7 12:00 NOON to 1.30 PM Renaissance Meeting Room 5 

Saturday, Mar 5 12:00 NOON to 1:00 PM Koshland Science Museum of the National 


Saturday, Mar 5 10:00 AM to 5:00 PM Koshland Science Museum of the National 


Kettering Laboratory Reception—University of Cincinnati Wednesday, Mar 9 6:30 PM to 8:30 PM Renaissance Meeting Room 2 

Keynote Medical Research Council (MRC) Lecture: Cellular 

Responses to DNA Damage: New Molecular Insights and New 

Approaches for Cancer Therapy, Lecturer: Stephen P. Jackson, 

University of Cambridge 

Keynote Plenary Lecture: Increasing the Prestige of Regulatory 

Sciences, Lecturer: Margaret Hamburg, U.S. FDA 

Keynote Plenary Lecture: U.S. EPA Vision, 

Lecturer: Lisa Jackson, U.S. EPA (invited) 

Korean Toxicologists Association in America Special Interest 


L 

Landmarks Program Presentation to the National 

Academy of Science 

Leading Edge in Basic Science Award Lecture: Roles of Keap1-Nrf2 

in Environmental Response, Lecturer: Masayuki Yamamoto 



Wednesday, Mar 9 8:00 AM to 9:00 AM Convention Center Grand Ballroom 

Tuesday, Mar 8 8:00 AM to 9:00 AM Convention Center Grand Ballroom 

Thursday, Mar 10 8:00 AM to 9:00 AM Convention Center Ballroom C 

Monday, Mar 7 6:30 PM to 8:30 PM Renaissance Meeting Room 10 

Monday, Mar 7 7:45 AM to 8:00 AM Convention Center Grand Ballroom 

Tuesday, Mar 8 7:00 AM to 7:50 AM Convention Center Room 201 

Lovelace Respiratory Research Institute Reception Sunday, Mar 6 7:30 PM to 10:30 PM Renaissance Meeting Room 16 

M 

Mechanisms Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Salon I 

Mechanisms Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

Medical Device Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 156 

Medical Device Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

Meet the Director, Lecturer: Linda Birnbaum, NIEHS Wednesday, Mar 9 9:30 AM to 10:30 AM Convention Center Room 201 

Meet the Director, Lecturer: John Howard, CDC/NIOSH Wednesday, Mar 9 10:45 AM to 11:45 AM Convention Center Room 201 

Meet the Director, Lecturer: Yvonne Maddox, NICHD Wednesday, Mar 9 12:00 NOON to 1:00 PM Convention Center Room 201 

Meet the Director, Lecturer: Sy Garte, Center for Scientific Review Wednesday, Mar 9 1:15 PM to 2:15 PM Convention Center Room 201 

Event Calendar




Meet the Director, Lecturer: Jesse Goodman, U.S. FDA Wednesday, Mar 9 2:30 PM to 3:30 PM Convention Center Room 201 

Meet the Director, Lecturer: Paul Anastas, U.S. EPA (invited) Wednesday, Mar 9 3:45 PM to 4:45 PM Convention Center Room 201 

Membership Committee Meeting Wednesday, Mar 9 11:30 AM to 1:00 PM Convention Center Room 303 

Merit Award Lecture: Neurotoxicology Goes Global: Scientific 

Collaboration and Mentorship, Lecturer: Michael Aschner 

Monday, Mar 7 12:15 PM to 1:05 PM Convention Center Room 201 

Metals Specialty Section Meeting/Reception Sunday, Mar 6 6:00 PM to 8:00 PM District Chophouse 

Restaurant 

Michigan Regional Chapter Reception 

(Happy Hour/Social Gathering) 

Wednesday, Mar 9 5:00 PM to 6:30 PM TBD 

Michigan State University Environmental Toxicology Reception Monday, Mar 7 9:00 PM to 11:00 PM Renaissance Ballroom West A 

Minority Health Cooperative Agreement: An Overview with FAMU 

and Texas A&M 

Saturday, Mar 5 10:00 AM to 12:00 NOON Renaissance Meeting Room 6 

Mixtures Specialty Section Meeting/Reception Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 140A 

Mixtures Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

Molecular Biology Specialty Section Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Room 159 

Mountain West/Southern California Regional Chapters Joint 

Reception 

Monday, Mar 7 6:00 PM to 7:30 PM RFD Restaurant 

MPI Research Event: Got Science? Monday, Mar 7 6:30 PM to 10:00 PM Grand Hyatt Constitution A 

N 

Nanotoxicology Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 143 

Nanotoxicology Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

National Capital Area Regional Chapter/NRC Committee on 




Monday, Mar 7 5:30 PM to 7:30 PM Embassy Suites Capital Ballroom 

A 

Neurotoxicology Specialty Section Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Salon G 

Neurotoxicology Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

New Investigator Lunch Tuesday, Mar 8 12:00 NOON to 1:15 PM Convention Center Salon I 

North Carolina State University Alumni Reception Monday, Mar 7 7:30 PM to 9:30 PM Renaissance Meeting Room 15 

Northeast Regional Chapter Student Luncheon Tuesday, Mar 8 12:30 PM to 2:00 PM Renaissance Congressional A 

Northern California Regional Chapter Reception Monday, Mar 7 6:30 PM to 8:30 PM District Chophouse 

Restaurant 

O 

Occupational and Public Health Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 144 

Ocular Toxicology Specialty Section Meeting/Reception Sunday, Mar 6 6:30 PM to 8:00 PM Convention Center Room 142 

P 

Past Presidents 5K Fun Run Sunday, Mar 6 6:00 AM to 8:00 AM Hains Point 

Buses Depart L Street, Convention Center 

Past Presidents Breakfast Monday, Mar 7 6:15 AM to 7:45 AM Convention Center Room 203 

Plenary Opening Lecture: NIH Vision, Lecturer: Francis S. Collins, 

National Institute of Health 

Monday, Mar 7 8:00 AM to 9:00 AM Convention Center Grand Ballroom 

Postdoctoral Assembly Board Meeting Monday, Mar 7 6:45 AM to 7:45 AM Convention Center Room 303 

Postdoctoral Assembly Luncheon (Ticket Required) Tuesday, Mar 8 12:00 NOON to 1:15 PM Convention Center Salon G 

Poster Sessions Monday, Mar 7 9:30 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Monday, Mar 7 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 8 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 8 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 9 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 9 1:00 PM to 4:30 PM Convention Center Exhibit Hall 






19 


Poster Sessions Thursday, Mar 10 8:30 AM to 12:00 NOON Convention Center East Salon & 

Room 202 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Monday, Mar 7 7:30 AM to 9:30 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Monday, Mar 7 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Tuesday, Mar 8 7:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Tuesday, Mar 8 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Wednesday, Mar 9 7:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Wednesday, Mar 9 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 104–107) Thursday, Mar 10 7:00 AM to 8:00 AM Convention Center East Salon & 

Room 202 

President’s Reception (By Invitation Only) Wednesday, Mar 9 7:00 PM to 8:30 PM Renaissance Grand Ballroom 

Central 

Professional Needs Assessment Task Force Meeting Wednesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 305 

R 

Regional Chapter Governance Committee Meeting Wednesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 304 

Regional Chapter Presidents and Officers Meeting Tuesday, Mar 8 7:00 AM to 8:30 AM Convention Center Room 103 

Regional Chapter/Special Interest Group Graduate 



Registration Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center East Salon 

Registration Sunday, Mar 6 6:30 AM to 8:00 PM Convention Center East Salon 

Registration Monday, Mar 7 7:00 AM to 5:00 PM Convention Center East Salon 

Registration Tuesday, Mar 8 6:00 AM to 4:30 PM Convention Center East Salon 

Registration Wednesday, Mar 9 6:00 AM to 4:00 PM Convention Center East Salon 

Registration Thursday, Mar 10 6:00 AM to 11:30 AM Convention Center East Salon 

Regulatory and Safety Evaluation Specialty Section Meeting/ 

Reception on Capitol Hill—The Great Debate, Sen. Johnny Isakson, 

Honorary Host (Limited Seating) 

Reproductive and Developmental Toxicology Specialty Section 




Monday, Mar 7 5:00 PM to 6:30 PM Russell Senate Building SR-325 

(Buses Depart CC from L Street beginning 

at 4:00 PM) 

Wednesday, Mar 9 6:00 PM to 7:30 PM Convention Center Salon G 

Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

Research Funding Committee Meeting Thursday, Mar 10 11:00 AM to 1:00 PM Convention Center Room 302 

Research Funding Resource Room Tuesday, Mar 8 9:00 AM to 4:30 PM Convention Center Room 203 

Research Funding Resource Room Wednesday, Mar 9 9:00 AM to 4:30 PM Convention Center Room 203 

Risk Assessment Specialty Section Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Salon I 

Risk Assessment Specialty Section Officers Meeting Monday, Mar 7 6:30 AM to 7:45 AM Convention Center Salon G 

Roundtable of Toxicology Consultants Meeting/Reception Monday, Mar 7 4:30 PM to 7:00 PM Renaissance Ballroom East 

S 

Safety Pharmacology Society Meeting Sunday, Mar 6 2:30 PM to 6:30 PM Renaissance Meeting Room 3 

Satellite Meeting: Johns Hopkins Center for Alternatives to Animal 

Testing—Evidence-Based Toxicology (EBT) Collaboration Kick-Off 

Meeting 



Thursday, Mar 10 12:00 NOON to 3:00 PM Convention Center Room 206 

Scientific Liaison Coalition Meeting Sunday, Mar 6 8:00 AM to 1:30 PM Renaissance Ballroom West B 

Scientific Liaison Task Force Meeting Monday, Mar 7 12:00 NOON to 1:30 PM Convention Center Room 304 

Scientific Program Committee Meeting Thursday, Mar 10 12:00 NOON to 1:30 PM Convention Center Room 303 

Scientific Program Committee Walk-Through Monday, Mar 7 7:00 AM to 7:45 AM Convention Center Room 201 

Event Calendar






Scientific Sessions Monday, Mar 7 9:15 AM to 12:00 NOON Convention Center (See Session 

Index on Pages 

97–103 for Room 

Location) 

Scientific Sessions Monday, Mar 7 12:10 PM to 1:30 PM Convention Center (See Session 



Location) 

Scientific Sessions Monday, Mar 7 2:00 PM to 4:45 PM Convention Center (See Session 



Location) 

Scientific Sessions (Sunrise) Tuesday, Mar 8 6:30 AM to 7:50 AM Convention Center (See Session 



Location) 

Scientific Sessions Tuesday, Mar 8 9:00 AM to 11:45 AM Convention Center (See Session 



Location) 

Scientific Sessions Tuesday, Mar 8 12:00 NOON to 1:20 PM Convention Center (See Session 



Location) 

Scientific Sessions Tuesday, Mar 8 1:30 PM to 4:15 PM Convention Center (See Session 



Location) 

Scientific Sessions (Sunrise) Wednesday, Mar 9 6:30 AM to 7:50 AM Convention Center (See Session 



Location) 

Scientific Sessions Wednesday, Mar 9 9:00 AM to 11:45 AM Convention Center (See Session 



Location) 

Scientific Sessions Wednesday, Mar 9 12:00 NOON to 1:20 PM Convention Center (See Session 



Location) 

Scientific Sessions Wednesday, Mar 9 1:30 PM to 4:15 PM Convention Center (See Session 



Location) 

Scientific Sessions (Sunset) Wednesday, Mar 9 4:30 PM to 5:50 PM Convention Center (See Session 



Location) 

Scientific Sessions (Sunrise) Thursday, Mar 10 6:30 AM to 7:50 AM Convention Center (See Session 



Location) 

Scientific Sessions Thursday, Mar 10 9:00 AM to 11:45 AM Convention Center (See Session 



Location) 

Smithsonian Seminar: Poisons: When Good Chemicals Turn Bad Saturday, Mar 5 9:30 AM to 4:30 PM Smithsonian S. Dillon Ripley 

Center 

SOT Committee/Task Force Chair Orientation Sunday, Mar 6 1:30 PM to 3:30 PM Renaissance Congressional A 






21 


SOT Office Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center Room 101 

SOT Office Sunday, Mar 6 7:00 AM to 5:30 PM Convention Center Room 101 

SOT Office Monday, Mar 7 7:00 AM to 5:00 PM Convention Center Room 101 

SOT Office Tuesday, Mar 8 7:00 AM to 4:30 PM Convention Center Room 101 

SOT Office Wednesday, Mar 9 7:00 AM to 4:30 PM Convention Center Room 101 

SOT Office Thursday, Mar 10 7:00 AM to 11:30 AM Convention Center Room 101 

SOT Pavilion Monday, Mar 7 9:00 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 464 

SOT Pavilion Tuesday, Mar 8 8:30 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 464 

SOT Pavilion Wednesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 464 

SOT/EUROTOX Debate: Biomarkers from Blood and Urine 

Will Replace Traditional Histopathological Evaluation to 

Determine Adverse Responses, SOT Debater: Kim Boekelheide 

and EUROTOX Debater: Ina Schuppe Koistinen 

Monday, Mar 7 4:35 PM to 5:55 PM Convention Center Room 150 

Speaker Ready Room Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center Room 208 

Speaker Ready Room Sunday, Mar 6 7:00 AM to 5:30 PM Convention Center Room 208 

Speaker Ready Room Monday, Mar 7 7:00 AM to 5:00 PM Convention Center Room 208 

Speaker Ready Room Tuesday, Mar 8 6:00 AM to 4:30 PM Convention Center Room 208 

Speaker Ready Room Wednesday, Mar 9 6:00 AM to 4:30 PM Convention Center Room 208 

Speaker Ready Room Thursday, Mar 10 6:00 AM to 11:30 AM Convention Center Room 208 

Special Interest Group Collaboration Group Meeting Monday, Mar 7 1:00 PM to 1:30 PM Convention Center Room 103 

Special Interest Group Presidents and Officers Meeting Monday, Mar 7 12:00 NOON to 1:00 PM Convention Center Room 103 

Specialty Section Governance Group Meeting Monday, Mar 7 3:00 PM to 4:00 PM Convention Center Room 103 

Specialty Section Graduate Committee Meeting Tuesday, Mar 8 7:00 AM to 8:30 AM Convention Center Room 142 

Specialty Section Presidents and Officers Meeting Monday, Mar 7 4:30 PM to 6:00 PM Convention Center Room 103 

Stem Cells Specialty Section Inaugural Meeting/Reception Monday, Mar 7 6:00 PM to 7:30 PM Convention Center Room 149 

Student Advisory Council Business Meeting Wednesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 103 



T 



Sunday, Mar 6 8:00 PM to 9:30 PM Convention Center Salon G 

Tour Desk Saturday, Mar 5 4:00 PM to 7:00 PM Convention Center East Salon 

Tour Desk Sunday, Mar 6 8:00 AM to 1:00 PM Convention Center East Salon 

Tour Desk Monday, Mar 7 8:00 AM to 1:00 PM Convention Center East Salon 

Tour Desk Tuesday, Mar 8 8:00 AM to 1:00 PM Convention Center East Salon 

Tour Desk Wednesday, Mar 9 8:00 AM to 9:30 AM Convention Center East Salon 

Tox-21c Implementation Meeting Sunday, Mar 6 2:00 PM to 5:00 PM Renaissance Ballroom West A 

ToxExpo 2012 Exhibit Space Selection Meeting Tuesday, Mar 8 4:45 PM to 6:00 PM Convention Center Room 156 

ToxExpo Exhibit Hall VIP Walk-Through Monday, Mar 7 2:00 PM to 3:00 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Monday, Mar 7 9:00 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Tuesday, Mar 8 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Wednesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Set Up Saturday, Mar 5 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

ToxExpo Set Up Sunday, Mar 6 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

Event Calendar




ToxExpo Tear Down Thursday, Mar 10 8:00 AM to 12:00 NOON Convention Center Exhibit Hall 

ToxExpo Time! (NEW) Monday, Mar 7 1:00 PM to 2:00 PM Convention Center Exhibit Hall 

Toxicologic and Exploratory Pathology Specialty Section 




Monday, Mar 7 12:00 NOON to 1:30 PM Convention Center Room 149 


Toxicological Sciences Associate Editors Meeting Sunday, Mar 6 12:00 NOON to 3:00 PM Renaissance Meeting Room 5 

Toxicological Sciences/Oxford University Press Appreciation Dinner 


Toxicologists of African Origin Special Interest Group 


Monday, Mar 7 6:00 PM to 9:00 PM Clydes of Gallery 

Place 

Piedmont Room 

Monday, Mar 7 6:00 PM to 8:00 PM Embassy Suites Capital 

Ballroom B 

Toxicologists without Borders, Inc. Information Meeting Monday, Mar 7 5:15 PM to 6:30 PM Renaissance Meeting Room 4 

Toxicology and Applied Pharmacology Associate Editors Meeting Monday, Mar 7 12:00 NOON to 2:00 PM Renaissance Meeting Room 4 

Toxicology Editorial Board Meeting Wednesday, Mar 9 11:45 AM to 1:30 PM Renaissance Meeting Room 3 

Toxicology Education Foundation Board of Trustees Meeting Sunday, Mar 6 8:00 AM to 12:00 NOON Renaissance Meeting Room 2 

Toxicology In Vitro Editorial Board Meeting Wednesday, Mar 9 7:00 AM to 8:00 AM Renaissance Meeting Room 3 

Toxicology Letters Editorial Board Meeting Tuesday, Mar 8 11:45 AM to 1:30 PM Renaissance Meeting Room 3 

ToxLearn Work Group Tuesday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 303 

Translational Impact Award Lecture: Integration of Bioinformatics 

into Regulatory Decision Making, Lecturer: Weida Tong 

U 

Undergraduate Education Program: Orientation for SOT Hosts, Peer 

Mentors, and Advisors 

Undergraduate Education Program: Opening Event 


Wednesday, Mar 9 12:15 PM to 1:05 PM Convention Center Room 151 



Undergraduate Education Program: Toxicology Lectures Sunday, Mar 6 8:00 AM to 11:30 AM Convention Center Room 156 

Undergraduate Education Program: Lunch and Networking 

(Ticket Required)) 

Undergraduate Education Program—Students: Planning for 

Graduate School 

Undergraduate Education Program: Host Mentor and Peer 

Mentor Meeting 

Undergraduate Education Program: Academic Toxicology 

Programs and Internships 

Undergraduate Education Program: Meeting for Student, Advisor, 

Peer Mentors and SOT Hosts 

Undergraduate Education Program: Poster Session for 

Visiting Students 

Sunday, Mar 6 11:30 AM to 12:45 PM Convention Center Room 103 

Sunday, Mar 6 12:45 PM to 1:45 PM Convention Center Rooms 301, 302, 

303 

Sunday, Mar 6 3:00 PM to 3:30 PM Convention Center Room 303 

Sunday, Mar 6 3:00 PM to 5:00 PM Convention Center Room 102 


Monday, Mar 7 9:30 AM to 10:50 AM Convention Center Exhibit Hall 

Undergraduate Education Program Wrap Up Monday, Mar 7 11:00 AM to 11:45 AM Convention Center Room 102 

Undergraduate Toxicology Faculty Meeting Tuesday, Mar 8 3:00 PM to 4:15 PM Convention Center Room 103 

University of Iowa Toxicology Center Alumni 

50th Anniversary Gathering 

W 



Monday, Mar 7 5:00 PM to 8:00 PM Hamilton Crown 

Plaza Hotel 

Lobby Lounge 

Wi-Fi Lounges (Wireless Internet Access) Monday, Mar 7 9:00 AM to 4:30 PM Convention Center Exhibit Hall 

Wi-Fi Lounges (Wireless Internet Access) Tuesday, Mar 8 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Wi-Fi Lounges (Wireless Internet Access) Wednesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Women in Toxicology Special Interest Group Meeting/Reception Wednesday, Mar 9 4:30 PM to 6:30 PM Renaissance Ballroom 

West A and B 




The Official Journal 

of the Society of 

Toxicology 

• New Impact Factor of 

4.814* 

• Ranked in the top 4 

most-cited journals in Toxicology! 

Congratulations to the Society of 

Toxicology on their 50th Anniversary! 

www.toxsci.oxfordjournals.org 

Visit our booth at TOXEXPO 2011 for a 

copy of the 50th Anniversary Supplement 

*ISI Journal Citation Reports 2009 Edition, published in 2010 


23


Walter E. Washington Convention Center Maps 

First Level (Street) 

CE Course Rooms, 

Registration, and 


M Street 

Mt. Vernon Sq/ 

7th St-Convention 

Center Metro 

Station 

MaPS 

9th Street 

CE Course Rooms and 


Job Bank 

Center 

CE Information Booth 

(Sunday Only) 

Exhibitor Hosted 

Sessions 

Escalators up to 

CE Courses, 

Scientific Sessions, 

and ToxExpo 

L Street 

Tour Departures 

L Street 

7th Street 

25-Year (or More) 

Member Reception 

SOT 

Office 

Student/Postdoctoral Scholar Mixer, 

In Vitro Toxicology Lecture and 

Luncheon, and Postdoctoral Lunch 

WEST SALON 

EAST SALON 

Business Center 

(under escalator) 

Registration 

Memorabilia 

Lunch with an Expert 

Information Board 

E-mail Center 

Coat/Luggage 

Check 

Starbucks 

Main Entrance 

Renaissance 

Hotel 

Mount Vernon Place 



Walter E. Washington Convention Center Maps (Continued) 

Second Level 

CE Course Rooms, 

Scientific Sessions, 

and ToxExpo 

ToxExpo Exhibition Entrance 

(see pages 36–37 for ToxExpo Floor Plan) 

Escalators down to 

CE Courses and 



Registration and 

E-mail Center 

maPS 

CE Information Booth 




CE Course Rooms 

and 


Research Funding 

Resource Room 


Third Level 

Plenary Lectures 

and 


(Tuesday) 

Plenary Lectures 

and 


Seating Available 



25


Washington, D.C. Hotel Accommodations 

1) Courtyard by Marriott 

Convention Center 

4) Embassy Suites D.C. 


7) Hampton Inn Convention Center 

MaPS 

$299 Single/Double 

900 F Street NW 

Washington, D.C. 20004 

Tel: 202.638.4600 

Fax: 202.638.4601 

Web site: www.marriott.com/wascn 

Club: Marriott Rewards 

Check in: 3:00 PM 

Check out: 12:00 NOON 

5 blocks from Convention Center 

$32/day valet parking 

Complimentary wireless Internet in guest 

rooms, public spaces 

2) Donovan House 

$284 Single/$314 Double 

900 Tenth Street NW 


Tel: 202.739.2001 

Fax: 202.739.2099 

Web site: washingtonconventioncenter. 

embassysuites.com 

Club: Hilton HHonors 



1.5 blocks from Convention Center 


Wired Internet in guest rooms, 

public spaces ($9.95/day) 

Complimentary Breakfast 


901 Sixth Street NW 


Tel: 202.842.2500 

Fax: 202.842.4100 

Web site: www.hamptoninn.com 




1.5 blocks from Convention Center 




Complimentary breakfast 

8) Henley Park** 

5) Grand Hyatt* 


1155 14th Street NW 


Tel: 202.737.1200 

Fax: 202.521.1410 

Web site: www.thompsonhotels.com/hotels/ 

dc/donovan-house 

Club: None 





Wireless Internet in guest rooms ($11.00/day), 

complimentary wireless in public spaces 

3) Eldon Suites** 


1000 H Street NW 


Tel: 202.582.1234 

Fax: 202.637.4781 

Web site: www.grandwashington.hyatt.com 

Club: Hyatt Gold Passport 




$30/day self parking and $35/day valet parking 

Wireless Internet in guest rooms and public 

space ($9.95/day) 

6) Hamilton Crowne Plaza 


926 Massachusetts Avenue NW 


Tel: 202.638.5200 

Fax: 202.638.6740 

Web site: www.henleypark.com 

Club: None 



1 block from Convention Center 




9) Hilton Garden Inn 


933 L Street NW 


Tel: 202.540.5000 

Fax: 202.290.1460 

Web site: www.eldonsuites.com 

Club: None 



0.5 block from Convention Center 




Complimentary breakfast 

(no room service available) 




Tel: 202.682.0111 

Fax: 202.682.3801 

Web site: www.hamiltonhoteldc.com 

Club: None 




$33/day overnight parking and $16 for daily 

parking 

Wireless Internet in guest rooms ($12.95/day) 


815 14th Street 


Tel: 202.783-7800 

Fax: 202.783-7801 

Web site: www.washingtondcdowntown. 

stayhgi.com 




4 block from Convention Center 



rooms, public space 

All hotel accommodations, rates, Internet access, and parking pricing are subject to change. Early departures are subject to penalty fees set by the hotels. 

Although we understand that making your reservations outside of the SOT hotel block can sometimes be more economical, it decreases the money available to 

the Society to carry out its strategic goals and may cause the Society to have to pay attrition fees for unutilized hotel rooms. In addition, the Society is unable to 

assist you if you have any difficulties with your room reservation, such as the hotel over-booking or misplacing your reservation. 

SOT depends on the Annual Meeting revenue (hotel room commissions and rebates) to fund other programs throughout the year and to keep future 

registration fees low. Please assist the Society by making your hotel room reservation through Destination D.C. 

* SOT Co-Headquarters Hotel | ** No ADA Accessibility 



Washington, D.C. Hotel Accommodations (Continued) 

10) Hotel Monaco D.C. 

13) Renaissance* 

15) Washington Plaza Hotel 




Tel: 202.628.7177 

Fax: 202.628.7277 

Web site: www.monaco-dc.com 

Club: Kimpton InTouch 





Wireless Internet in guest rooms and public 

space ($10/day) 

11) Madison Hotel 


999 Ninth Street NW 


Tel: 202.898.9000 

Fax: 202.289.0947 

Web site: www.marriott.com/wasrb 





$28/day self parking; $44.80 valet parking 

Complimentary wireless Internet in lobby, 

wired in guest rooms ($12.95/day) 

14) Sheraton Four Points 


10 Thomas Circle NW 


Tel: 202.842.1300 

Fax: 202.371.9602 

Web site: www.washingtonplazahotel.com 

Club: None 




$23/day self parking, $28/day valet parking 

(overnight) 


complimentary wireless and wired Internet in 

guest rooms 

maPS 

16) Westin City Center 




Tel: 202.862.1600 

Fax: 202.785.1255 

Web site: www.loewshotels.com 

Club: None 







12) Marriott Metro Center 


1201 K Street NW 


Tel: 202.289.7600 

Fax: 202.349.2215 

Web site: www.fourpointsdc.com 

Club: Starpoints 






complimentary wired in guest rooms 


1400 M Street NW 


Tel: 202.429.1700 

Fax: 202.785.0786 

Web site: www.westinwashington 

dccitycenter.com 

Club: Starpoints 





Wireless Internet in guest rooms is $12.95, 

an additional charge of $12.95 per usage in 

public areas 




Tel: 202.737.2200 

Fax: 202.347.5886 

Web site: www.marriott.com/wasmc 








Housing Bureau Information until February 3, 2011 

You may make your housing reservations through the on-line reservation system, 

Destination D.C., found on the SOT Annual Meeting Web site. 

You may also make a reservation by the following method(s): 

• Fax: 506.433.3033 

(International and Domestic) 

• Mail: Destination D.C./SOT 

901 7th Street NW, Suite 400 


United States 

• Toll-Free (USA and Canada): 866.805.4508 

Phone (International): 506.637.0320 

Hours of Operation: 9:00 AM–7:00 PM (EST) 

Monday–Friday 

Legend: Fitness Center In-Room Wireless Complimentary Breakfast 

Valet Parking Swimming Pool In-Room Safe Restaurant 

Self Parking Business Center Gift Shop 

All hotels have Internet access. 

Hotel sales tax is currently 14.5% 


27 

* SOT Co-Headquarters Hotel | ** No ADA Accessibility


Map of Washington, D.C. Hotel Locations 

MaPS 

10 

16 

2 

15 

6 

9 

14 

12 

8 

3 

4 

5 

1 

Courtyard by Marriott 


2 Donovan House 

3 Eldon Suites** 

4 

Embassy Suites D.C. 


5 Grand Hyatt* 

6 Hamilton Crowne Plaza 

7 

Hampton Inn 


8 Henley Park** 

9 Hilton Garden Inn 

10 Hotel Monaco D.C. 

11 Madison Hotel 

12 Marriott Metro Center 

13 Renaissance* 

14 Sheraton Four Points 

15 Washington Plaza Hotel 

16 Westin City Center 

Walter E. Washington 


Walter E. Washington 


13 7 

1 

10 

* SOT Co-Headquarters Hotel | ** No ADA Accessibility 



Map of Washington, D.C. Hotel Locations (Continued) 

2 

6 

9 

3 

8 

14 

4 13 7 

12 

5 

1 

10 

S. Dillon Ripley Center (International Gallery) 

1100 Jefferson Drive SW, Washington, D.C. 

Smithsonian Seminar: Poisons: When Good 


Marian Koshland Science Museum of 

the National Academy of Sciences 

525 E Street NW, Washington, D.C. 

Protecting You and Your Pet through 

the Science of Toxicology: Paracelsus 

Goes to Washington 

maPS 


29 

* SOT Co-Headquarters Hotel | ** No ADA Accessibility


Renaissance Hotel Map 

Meeting Room Level 

(One Level below Lobby) 

Ancillary Meetings 

(Sunday–Wednesday) 

17 

MaPS 


(Monday–Wednesday) 

(Bring your meal) 

11 

10 

12 

13 

14 

15 

16 

9 

8 

7 

6 

5 

4 

3 

2 

1 

Auditorium 

Ballroom Level 

(One Level below Breakout Rooms) 

Grand 

Ballroom 

Renaissance 

Ballroom 

South 

Central 

East 

West B 

West A 

C 

A 

B 

North 

18 

19 

B 

A 

Second Level 

Guest/Spouse Hospitality Room—Penn Quarter Room 


2011 SOT 50 th Anniversary Featured Articles 

and Special March 2011 Supplement 

review articles 

by distinguished International Experts 

Will Focus on Major Milestones and Impactful 

areas of toxicology 

The March 2011 Special Anniversary Supplement 

represents areas that are, or have been, a major 

focus and impactful areas in toxicology, along 

with forward-looking topics, including 

reviews on carcinogenesis, toxicogenomics, 

nanotoxicology, and synthetic biology. The 

articles provide historical perspective on 

the subject matter, major advances in 

the field, and thoughts on the future 

direction of research. 

Important contributions to toxicology 

will be celebrated in each issue of 

Toxicological Sciences in 2011. Topics in 

the regular monthly issue to include 

mechanisms of cell death, genetic 

polymorphism, epigenetics, flame 

retardants, and the toxicology of 

climate change. 


31


Washington, D.C. Restaurant Listings 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

MaPS 

1400 North 1400 M Street NW 202.429.1700 BLD $$$$ 

14K Restaurant and Lounge 1001 14th Street NW 202.218.7524 BLD $$$ 

15 Ria 1515 Rhode Island Avenue NW 202.742.0015 BLD $$$ 

15 Squares 999 9th Street NW 202.898.9000 BL $$$ 

Acadiana Restaurant 901 New York Avenue NW 202.408.8848 BLD $$$ 

Adour 923 16th & K Sts. NW 202.509.8000 BD $$$$ 

AGAINN D.C. 1099 New York Avenue NW 202.639.9830 LD $$$ 

Aria Trattoria 1300 Pennsylvania Avenue NW 202.312.1250 LD $$$ 

Asia Nine Bar & Lounge 915 E Street NW 202.629.4355 LD $$ 

Asian Spice Restaurant 717 H Street NW 202.589.0700 LD $$ 

Avenue Cafe & Lounge 1501 Rhode Island Avenue NW 202.483.2000 BLD $$$ 

Avenue Grill 1331 Pennsylvania Avenue NW 202.393.2000 BLD $$$$ 

Azi’s Café 1336 Ninth Street NW 202.232.0001 BL $ 

Bar Louie 701 7th Street NW 202.638.2460 LD $$ 

Ben & Jerry’s Ice Cream 1100 Pennsylvania Avenue NW 202.842.5882 Sweets $ 

Bobby Van’s Grill 1201 New York Avenue NW 202.589.1504 LD $$$$ 

Bobby Van’s Steakhouse 809 15th Street NW 202.589.0060 LD $$$$ 

Brasserie Beck 1101 K Street NW 202.408.1717 LD $$$ 

Buddha-Bar D.C. 455 Massachusetts Avenue NW 202.377.5555 LD $$$ 

Burger King 501 G Street NW 202.682.0497 BLD $ 

Café Atlantico 405 8th Street NW 202.393.0812 LD $$$ 

Cafe Mozart/German Deli 1331 H Street NW 202.347.5732 BLD $$$$ 

California Tortilla 728 7th Street NW 202.638.2233 LD $ 

Camille’s Sidewalk Café 650 F Street NW 202.639.9727 BLD $ 

Capitol City Brewing Company—Downtown 1100 New York Avenue NW 202.628.2222 LD $$$ 

Capitol Q BBQ 707 H Street NW 202.347.8396 LD $$ 

Carmine’s 425 7th Street NW 202.737.7770 LD $$$ 

The Caucus Room 401 9th Street NW 202.393.1300 LD $$$$ 

Chipotle 601 F Street NW 202.347.4701 LD $ 

Clyde’s of Gallery Place 707 7th Street NW 202.349.3700 BLD $$$ 

Co Co. Sala 929 F Street NW 202.347.4265 D $$$$ 

Cuba Libre Restaurant & Rum Bar 801 9th Street NW 202.408.1600 BLD $$$$ 

Cure Bar & Bistro 1000 H Street NW 202.637.4906 D $$$$ 

D.C. Coast 1401 K Street NW 202.216.5988 BLD $$$ 

District ChopHouse & Brewery 509 7th Street NW 202.347.3434 LD $$$$ 

Eat First 609 H Street NW 202.289.1703 LD $$ 

Ella’s Woodfired Pizza 901 F Street NW 202.638.3434 LD $$ 

B=Breakfast, L=Lunch, D=Dinner 



Washington, D.C. Restaurant Listings (Continued) 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically (continued) 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

Fado Irish Pub & Restaurant 808 7th Street NW 202.789.0066 BLD $$ 

The Federalist 1177 15th Street NW 202.862.1600 BLD $$$$ 

Finemondo Italian Country Kitchen 1319 F Street NW 202.737.3100 LD $$$$ 

Finn & Porter Restaurant 900 10th Street NW 202.719.1600 LD $$$ 

Firehook Bakery - National Building Museum 441 4th Street NW 202.347.1760 BL $ 

Five Guys 808 H Street NW 202.393.2900 LD $ 

The Fourth Estate at the National Press Club 529 14th Street NW, 13th Floor 202.662.7638 BLD $$$$ 

Fuddruckers 737 7th Street NW 202.628.3380 LD $ 

Gordon Biersch Brewery 900 F Street NW 202.783.5454 LD $$ 

Grand Cafe 1000 H Street NW 202.637.4903 BL $$$ 

Grand Slam 1000 H Street NW 202.637.4789 LD $$$ 

Greene Turtle 601 F Street NW 202.637.8889 LD $$ 

Hard Rock Cafe 999 E Street NW 202.737.7625 LD $$$ 

Harriet’s Family Restaurant 432 11th Street NW 202.628.8024 BLD $$$ 

Jackey Cafe 611 H Street NW 202.408.1288 LD $$$ 

Jaleo 480 7th Street NW 202.628.7949 LD $$$ 

Kanlaya Thai 740 6th Street NW 202.393.0070 LD $$ 

Kushi 465 K Street NW 202.682.3123 LD $$$ 

La Tasca 722 7th Street NW 202.347.9190 LD $$$ 

Market to Market 740 5th Street NW 202.589.0141 BLD $$ 

Marrakesh Restaurant 617 New York Avenue NW 202.393.9393 LD $$$$ 

Matchbox 713 H Street NW 202.289.4441 LD $$$ 

McCormick & Schmick’s Seafood 901 F Street NW 202.639.9330 LD $$$ 

McCormick & Schmick’s Seafood 1652 K Street NW 202.861.2233 LD $$$$ 

McDonald’s 601 F Street NW 202.737.2090 BLD $ 

Mehak Indian Restaurant 817 7th Street NW 202.408.9292 LD $$$ 

miXX Lounge 999 9th Street NW 202.898.9000 D $$$ 

Morrison-Clark Inn Restaurant 1015 L Street NW 202.898.1200 BLD $$$ 

Occidental 1475 Pennsylvania Avenue NW 202.783.1475 BLD $$$$ 

Old Ebbitt Grill 675 15th Street NW 202.347.4801 BLD $$$ 

OYA Restaurant & Lounge 777 9th Street NW 202.393.1400 LD $$$ 

Oyamel 401 7th Street NW 202.628.1005 LD $$ 

P.O.V. Rooftop Lounge and Terrace 515 15th Street NW 202.661.2478 LD $$$ 

Ping Pong Dim Sum 900 7th Street NW 202.506.3740 BLD $$$ 

Poste 555 8th Street NW 202.783.6060 BLD $$$ 

Potbelly 726 7th Street NW 202.478.0070 LD $ 

Potenza Trattoria 1430 H Street NW 202.638.4444 LD $$$ 

maPS 



33


Washington, D.C. Restaurant Listings (Continued) 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

MaPS 

President’s Sports Bar 999 9th Street NW 202.898.9000 BLD $$$ 

PS 7’s 777 I Street NW 202.742.8550 LD $$$ 

Quiznos 750 I Street NW 202.393.5800 LD $ 

Rasika 633 D Street NW 202.637.1222 LD $$$ 

RFD Restaurant 810 7th Street NW 202.289.2030 LD $$ 

Rosa Mexicano 575 7th Street NW 202.783.5522 LD $$$ 

Ruby Tuesday 712 7th Street NW 202.347.0276 LD $$ 

Ruth’s Chris Steakhouse 724 9th Street NW 202.393.4488 D $$$$ 

Spy City Cafe and Zola Kitchen Catering 800 F Street NW 202.654.0995 BLD $$$ 

Subway 709 H Street NW 202.842.2273 BLD $ 

Sushi Go-Round 705 7th Street NW 202.393.2825 LD $$$ 

Ten Penh 1001 Pennsylvania Avenue NW 202.393.4500 LD $$$ 

Thai Chili 701 7th Street NW 202.393.2905 LD $$$ 

Tony Cheng’s Mongolian and Seafood 

619 H Street NW 202.371.8669 LD $$ 

Restaurants 

Tuscana West 1350 I (Street NW 202.289.7300 LD $$$ 

Wok n’ Roll 604 H Street NW 202.347.4656 LD $$ 

Zaytinya 701 9th Street NW 202.638.0800 LD $$$ 

ZENGO Restaurant 781 7th Street NW 202.393.2929 LD $$$ 

Zentan Restaurant 1155 14th Street NW 202.379.4366 BLD $$$ 

Zephyr Deli 1000 H Street NW 202.637.4655 BL $$$ 

Zola 800 F Street NW 202.654.0999 LD $$$ 




ToxExpo Hours: 


9:00 AM–4:30 PM 


8:30 AM–4:30 PM 


8:30 AM–4:30 PM 

toxExpo Prize 

drawing $500! 

drawings to take place 

on Monday, tuesday, and 

Wednesday 

in the Exhibit Hall 

$500 american Express Gift 

card awarded each day 

New This Year: ToxExpo Time! 

In addition to the standard Exhibit Hall hours and poster presentation times, one hour of 

dedicated ToxExpo Time has been allotted in the scientific program for attendees to visit 

with exhibitors. ToxExpo Time will take place on Monday, March 7 from 1:00 PM–2:00 PM. 

drop your business cards 

in the toxExpo 

prize drawing boxes 

found in all 

diamond level 

Sponsor booths 

Toxexpo 

You probably know ToxExpo as the exhibition associated with the Society of 

Toxicology’s Annual Meeting—it’s that—but it’s also a great deal more. 

ToxExpo.com is: 

• A 24/7 comprehensive on-line resource, searchable by company 

name or by product or service. 

• A comprehensive approach to organizing the wealth of ideas and 

insights in cross-disciplinary areas of toxicology. 

• The toxicology market place—your source for product 

information and resources to keep your lab competitive. 

• The place where professionals will learn how to explore 

a rapidly changing science. 

• A chance to think outside the box—find out how your 

work relates to research in other disciplines. 

• Up-to-date information on state-of-the-art research equipment, 

technology, and the latest publications. 

• A unique environment to research products and 

services of exhibiting companies and keep you informed 

of new cutting-edge science and technology. 

Looking for a particular product or service? 

Check the category listing in the toxExpo directory 

or on www.ToxExpo.com to see which companies offer 

the best product or service for your needs. 

ToxExpo Directories are available at Registration and just inside the entrance of the Exhibit Hall. 

ToxExpo—24/7 up-to-date www.toxexpo.com information throughout at www.toxicology.org 

the year 

35 

at www.toxexpo.com


ToxExpo Floor Plan 

Exhibit Hall Second Level 

ToxExpo Hours: 

Monday 

9:00 AM–4:30 PM 

Tuesday 

8:30 AM–4:30 PM 

Wednesday 

8:30 AM–4:30 PM 

Concession Stand Hours: 

Monday....................................................... 9:00 AM–4:30 PM Wednesday.................................................. 8:30 AM–4:30 PM 

Tuesday....................................................... 8:30 AM–4:30 PM 

Exhibitors please note: The Coffee & Snack Cart in the 700 aisle will open one hour before show opening for your convenience. 

Toxexpo 

1677 

1679 

1681 

1683 

1685 

1687 

1689 

POPCOrn Stand 

FOOD 

COUrt 

POSTER Poster 

BOARD Board 

700s 

POSTERS (18) 

1572 1570 

1473 

1469 

1372 1370 1368 

1273 1271 1269 

POSTERS (30) 

1072 1070 1068 

1566 1558 

1552 

1546 1544 1542 1540 

678 

1409 

1403 

Wi-Fi 

Lounge 

POSTER Poster 

BOARD Board 

300s 

Poster Reclamation Tables 

POSTER Poster 

BOARD Board 

800s 

POSTERS (24) 

1459 

1455 1453 

POSTER Poster 

BOARD Board 

500s 

POSTERS (24) 

1258 1256 1254 

1250 

1159 1157 1155 1153 1151 

1154 1152 1150 

1053 1051 

1649 1647 

1449 1447 1445 1443 1441 

1444 

1346 1344 

1249 1247 

POSTERS (20) 

U.S. 

EPA 

1341 

1340 

1243 1241 

POSTER Poster 

BOARD Board 

400s 

POSTERS (24) 

POSTER Poster 

BOARD Board 

900s 

1038 

POSTER Poster 

BOARD Board 

600s 

POSTERS (24) 

1232 1230 1228 

1135 1133 

Meso Scale 

Discovery 

1032 

1031 

1631 1629 1627 

1626 1624 

1527 1525 

1224 

1129 1127 1125 

1416 1414 

1126 1124 

1027 1025 

1625 

AISLE 1600 

1522 

1323 

1026 1024 1022 

1620 1618 

1521 1519 

1218 

1121 1119 

1120 1118 1116 

1021 1019 

1412 1410 

1319 1317 

1320 1318 

1617 

1515 

1314 

1223 1221 1219 1217 1215 

1214 

1512 

1406 1404 1402 

1313 1311 

1115 1113 

AISLE 1000 

787 785 783 

AISLE 1400 

Coffee & Snack Cart 

1211 1209 

1210 

782 

683 

1308 

AISLE 1100 

1307 

180 

181 

Wi-Fi Lounge 

Thermo Fisher 

Scientific 

AISLE 1500 

AISLE 1300 

1306 

AISLE 1200 

279 

675 

676 674 

575 

374 

277 275 

276 274 

177 175 

176 174 

771 

770 

671 

670 668 666 

571 

767 765 

567 

SOT 

PAVILION 

SNBL 

464 

368 362 

265 263 

262 

165 163 

7 

Huntingt 

Life 

Science 

5 

162 1 

973 971 969 

POSTER Poster 

BOARD Board 

100s 

POSTERS (24) 

Poster 

POSTER 

BOARD 

Board 

200s 

POSTERS (26) 

Coffee & Snack Cart 

945 943 941 939 

935 933 

942 940 938 936 934 932 930 928 

841 839 837 835 833 831 

CONCESSION 

SEATING 

AISLE 800 

927 925 

ELECTRICAL 

INTERNET/ 

TELEPHONE 

PHOTOGRAPHY 

AISLE 900 

Exhibitor Service Center 

FLORAL 

SES LOGISTICS 

SES 

SES POSTER 

PICK UP 

909 907 

903 901 

908 906 904 902 900 

Poster 

Pick Up 

Desk 

EXIT OnlY DOORS 

SOT Show 

Management Office 


36 ToxExpo—24/7 SOT 50th Anniversary throughout Annual the Meeting year


ToxExpo Floor Plan (Continued) 

Exhibit Hall Second Level 

ToxExpo 2012 Exhibit Space Meeting 

Exhibiting companies should plan on attending 

the ToxExpo 2012 Space Selection Meeting 

on Tuesday, March 8 at 4:45 PM in Room 156 

on First Level. 

ToxExpo Prize Drawing Win $500! 

Drawings to take place on Monday, Tuesday, 

and Wednesday in the Exhibit Hall 

$500 American Express Gift card 

awarded each day 

Drop your business cards in the 

ToxExpo prize drawing boxes 

found in all Diamond Level 

Sponsor booths 

678 

575 571 567 

561 557 

2 551 549 547 545 542 

8 

9 

1307 

180 

1306 

374 

464 

652 

446 

121 119 

313 311 309 307 

368 362 

346 344 342 338 

324 322 320 318 314 312 310 

300 

279 277 275 

265 263 

257 

245 241 239 

233 

227 223 221 217 213 

181 

Thermo Fisher 

Scientific 

LE 1500 

SLE 1300 

LE 1200 

0 

675 

676 674 

276 274 

177 175 

176 174 

771 

770 

671 

670 668 666 

767 765 

SOT 

PAVILION 

Wi-Fi Lounge 

SNBL 

Huntington 

Life 

Sciences 

262 

165 163 

761 759 757 755 

657 

656 

BATTELLE 

256 254 

162 160 158 156 154 

653 

250 

157 155 153 151 149 

152 

749 747 745 743 741 

756 754 752 740 

451 449 447 445 

Harlan 

WIL 

Research 

543 

242 

641 

441 

638 636 634 632 

539 537 535 533 

238 

139 

737 

LAB 

Research 

635 

538 536 534 

Covance 

144 142 140 138 136 134 

433 

432 

Toxikon 

WuXi 

Apptec 

133 

729 728 727 

128 

726 724 

625 

327 325 323 321 

125 

723 721 

Charles River 

Southern 

Research 

720 

621 619 617 

422 420 418 416 

220 218 

120 

419 

716 

317 

116 

715 713 711 

515 513 

514 512 

415 413 

214 

707 

706 

507 

407 

406 

704 702 

205 

402 

703 

AISLE 700 

MPI 

Research 

603 

AISLE 600 

AISLE 500 

110 108 106 104 102 

501 

500 

403 401 

AISLE 400 

AISLE 300 

203 201 

AISLE 200 

101 

AISLE 100 

100 

Food 

Court 

ToxExpo 

Entrance 

To L Street 

Bridge 

Toxexpo 

907 

903 

901 

8 

906 

904 

902 

900 


CONCOURSE 



up-to-date www.toxexpo.com information at www.toxicology.org 

37


ToxExpo 2011 Exhibitors 

ToxExpo Directories are available at Registration and 

just inside the entrance of the Exhibit Hall. 

Toxexpo 

(As of January 10, 2011) 

Please visit www.ToxExpo.com or the ToxExpo Directory 

for product/service descriptions, a map of booth locations, and 

other information. 

✯ 2011 Annual Meeting Sponsors are indicated by the star. 

See listing of complete sponsors on page 432 and Back Cover. 

Companies that have been ToxExpo Exhibitors 

for 25 years or more are in bold. 

Company Name 

Booth Number 

A. Daigger & Co. ............................................................................ 223 

Absorption Systems...................................................................... 1125 

Accelera S.r.l. .................................................................................. 120 

Access Technologies....................................................................... 545 

ACGIH............................................................................................ 902 

ACS Publications............................................................................ 906 

Advanced Chemistry Development, Inc. (ACD/Labs)................... 221 

Advinus Therapeutics, Limited.................................................... 1228 

Advion BioServices, Inc. ................................................................ 729 

AEgis Technologies Group............................................................. 704 

AIT Bioscience............................................................................... 935 

Alabama Research & Development............................................. 1318 

Allentown, Inc. ............................................................................... 121 

Almac.............................................................................................. 841 

Alpha Genesis, Inc. ......................................................................... 907 

Alturas Analytics, Inc. .................................................................... 322 

American Association for Laboratory 

Animal Science (AALAS)........................................................ 1157 

American Board of Toxicology (ABT).......................................... 657 

American College of Toxicology.................................................... 943 

Americans for Medical Progress.................................................. 1129 

Analytical Bio-Chemistry Labs, Inc. ........................................... 1319 

✯ Ani Lytics, Inc. .............................................................................. 539 

ANILAB, LLC............................................................................... 110 

Animal Identification and Marking System (AIMS)................ 416 

Antech Diagnostics......................................................................... 668 

Aperio........................................................................................... 1218 

Applied BioPhysics, Inc................................................................ 1368 

Apredica........................................................................................ 1626 

Aptuit, Inc. ..................................................................................... 621 

Argutus Medical............................................................................. 927 

Arraystar Inc................................................................................. 1127 

Art’s Way Scientific........................................................................ 932 

AstraZeneca, LP........................................................................... 1649 

Aurigon Life Science GmbH........................................................ 1522 

Aushon BioSystems, Inc. .............................................................. 1022 

AVA Biomedical, Inc. ..................................................................... 205 

AVANZA Laboratories, LLC......................................................... 346 

Avogadro, Inc.................................................................................. 765 

✯ BASF SE....................................................................................... 1611 

BASi (Bioanalytical Systems, Inc)................................................. 441 

✯ Battelle........................................................................................... 257 

Bio Medic Data Systems, Inc. ........................................................ 406 

Bioagri Pharma............................................................................... 310 

BioChemed Services....................................................................... 743 

✯ Bioculture (Mauritius) Ltd.......................................................... 275 

Biological Test Center.................................................................. 279 

Biologics Consulting Group, Inc. ................................................... 175 

Company Name 

Booth Number 

Biopredic International................................................................. 1527 

Biopta Ltd..................................................................................... 1217 

✯ BioReliance ® Corporation............................................................ 603 

✯ Biosafety Research Center, Foods, Drugs and Pesticides............ 1627 

BioScience Laboratories................................................................. 309 

Bio-Serv, Inc. .................................................................................. 619 

BioStat Consultants, Inc. .............................................................. 1215 

BioStorage Technologies.............................................................. 1250 

BioTek Instruments, Inc. ................................................................. 155 

BioTox Sciences.............................................................................. 100 

Biotoxtech Co. Ltd. ......................................................................... 156 

BioVendor, LLC............................................................................ 1133 

Boston BioProducts........................................................................ 676 

✯ Bristol-Myers Squibb Company.................................................. 227 

Bruker Daltonics Inc. ..................................................................... 158 

Burdock Group............................................................................... 445 

Buxco Research Systems............................................................ 1241 

Calibrate, Inc. ................................................................................. 140 

Caliper Life Sciences, Inc. ........................................................... 1540 

Calvert Laboratories, Inc. ............................................................... 300 

Cayman Chemical........................................................................... 674 

CBSET, Inc. .................................................................................... 941 

Cedarlane........................................................................................ 939 

CeeTox, Inc. .................................................................................... 307 

Cellular Dynamics International, Inc. ............................................ 507 

Celsis In Vitro Technologies........................................................... 362 

Cerep Inc. ........................................................................................ 321 

CH Technologies (USA), Inc. ......................................................... 413 

ChanTest Corp. ............................................................................. 1340 

✯ Charles River................................................................................. 419 

Chemical Solutions Ltd. ................................................................. 755 

ChemRisk, Inc. ............................................................................... 683 

CIRION Clinical Trial Services Inc. ............................................ 1152 

CIT.................................................................................................. 139 

Class Biologically Clean, Ltd. ........................................................ 767 

Clever Sys Inc............................................................................... 1271 

Colonial Medical Supply................................................................ 128 

Colorado Histo-Prep....................................................................... 557 

Comparative Biosciences................................................................ 312 

Comparative Toxicogenomics Database (CTD)........................... 1681 

CompuCyte Corporation................................................................ 153 

Congressionally Directed Medical Research Program................ 1683 

Contract Pharma........................................................................... 1232 

CorDynamics................................................................................ 1019 

✯ Covance Inc. .................................................................................. 432 

✯ Covance Research Products, Inc. ................................................ 536 

CRC Press—Taylor & Francis Group LLC.................................... 724 

CTEH.............................................................................................. 741 

Cultex Laboratories GmbH............................................................ 761 

CXR Biosciences Limited............................................................ 1609 

Cyprotex Discovery Ltd................................................................. 771 

✯ Data Sciences International (DSI)............................................ 1320 

Data Unlimited International, Inc. ................................................. 754 

✯ Definiens Inc. ................................................................................ 1552 

Dermal Technology Laboratory Ltd............................................ 1412 

Detroit R & D, Inc. ......................................................................... 756 

DMt-USA Inc. ............................................................................... 1247 

Dojindo Molecular Technologies, Inc. ........................................... 142 

DTRA/SCC-WMD(RD-CB)........................................................ 1243 




ToxExpo 2011 Exhibitors (Continued) 



Company Name Booth Number Company Name Booth Number 

Ellegaard Göttingen Minipigs A/S................................................. 702 

Elm Hill Breeding Labs, Inc. ......................................................... 116 

✯ Elsevier........................................................................................... 422 

EMD Chemicals............................................................................. 241 

EMD Millipore............................................................................. 1544 

emka TECHNOLOGIES, INC. .................................................... 1210 

Environ International Corp. ......................................................... 1256 

Environmental Health Perspectives (EHP)................................... 1416 

Epithelix.......................................................................................... 945 

EPL Archives, Inc. .......................................................................... 571 

EPL, Inc. (Experimental Pathology Laboratories)................... 567 

Eurofins | Product Safety Labs (EPSL)...................................... 418 

EUROTOX.................................................................................... 1570 

Evotec (UK) Limited.................................................................... 1515 

Experimur....................................................................................... 749 

Expert Publishing, LLC................................................................. 1119 

Exponent, Inc. ................................................................................. 254 

FASEB........................................................................................... 1118 

Fraunhofer ITEM............................................................................ 324 

Frontier BioSciences, Inc. ............................................................... 250 

GE Healthcare............................................................................... 1308 

GeneGo, Inc., a Thomson Reuters Business................................ 1230 

Genentech, Inc. ............................................................................. 1402 

Gentronix, Limited......................................................................... 652 

Gyros............................................................................................. 1159 

H&T Corporation.......................................................................... 1410 

Hamilton Thorne............................................................................ 671 

Harlan Laboratories, Inc. ............................................................ 446 

Hepregen Corporation.................................................................. 1620 

Hilltop Lab Animals, Inc. ............................................................... 933 

Histo-Scientific Research Laboratories (HSRL)............................ 201 

✯ HistoTox Labs, Inc. ....................................................................... 1209 

✯ Huntingdon Life Sciences............................................................. 561 

ICF International.......................................................................... 1051 

IDEXX Laboratories, Inc. .............................................................. 151 

IIBAT............................................................................................ 1151 

IIT Research Institute................................................................... 1403 

In Vitro ADMET Laboratories, LLC (IVAL)................................ 239 

Ina Research, Inc. .......................................................................... 342 

INDIGO BioSciences................................................................... 1631 

Informa Healthcare.................................................................... 1311 

Ingenuity Systems, Inc. ................................................................ 327 

Innovive Inc.................................................................................... 534 

InSphero AG................................................................................. 1120 

Instech Solomon............................................................................ 433 

Instem............................................................................................. 407 

Institute for In Vitro Sciences, Inc. ............................................... 1313 

Institute of Industrial Organic Chemistry Branch Pszczyna......... 938 

Institute of Neurotoxicology & Neurological Disorders................ 934 

Integrated Laboratory Systems, Inc. .............................................. 311 

IntelliCyt Corporation.................................................................. 1153 

INTOX Pvt. Ltd. ........................................................................... 1219 

IPS Therapeutique, Inc. .................................................................. 752 

ITR Laboratories Canada, Inc. ..................................................... 1409 

IUTOX.......................................................................................... 1370 

Jackson Laboratory, The................................................................. 138 

Jai Research Foundation (JRF—America)..................................... 770 

Japanese Society of Immunotoxicology, The............................... 1443 

Japanese Society of Toxicology, The............................................ 1445 

JCL Bioassay USA......................................................................... 1116 

JOINN Laboratories....................................................................... 742 

KCAS, LLC..................................................................................... 277 

Kinder Scientific Company............................................................ 344 

Konigsberg Instruments, Inc........................................................ 1349 

Korea Institute of Toxicology......................................................... 256 

✯ Kubtec X-Ray................................................................................ 745 

L’Oréal Research............................................................................ 551 

Lab Products, Inc. ........................................................................ 500 

LAB Research, Inc. ........................................................................ 635 

Lablogic Systems, Ltd. ................................................................... 721 

Lampire Biological Laboratories, Inc. ......................................... 1525 

Leadscope, Inc. ............................................................................... 711 

Leyden Group, The......................................................................... 731 

Lhasa Limited................................................................................. 904 

Life Technologies......................................................................... 1459 

Litron Laboratories......................................................................... 513 

Living Systems Instrumentation................................................... 1234 

Lomir Biomedical, Inc. .................................................................. 317 

Lonza Bioscience.......................................................................... 1317 

Lovelace Respiratory Research Institute........................................ 374 

Luminex Corporation................................................................... 1647 

Luxcel Biosciences, Ltd. ............................................................... 1211 

Maccine Pte Ltd.............................................................................. 245 

Marshall BioResources................................................................ 703 

MatTek Corporation..................................................................... 1038 

Maxxam Analytics Inc. ................................................................ 1135 

MB Research Laboratories............................................................. 515 

Medicilon Preclinical Research (Shanghi), LLC........................... 174 

Merck & Co. Inc. (Publishing Group)............................................ 162 

Meso Scale Discovery.................................................................. 1031 

Metabolon, Inc. ............................................................................. 1154 

MetaSystems Group, Inc. ............................................................. 1629 

MIDWEST RESEARCH INSTITUTE....................................... 1249 

Millar Instruments, Inc. ................................................................ 1406 

Mitologics...................................................................................... 1617 

✯ MPI Research................................................................................ 101 

MultiCase........................................................................................ 666 

NAMSA.......................................................................................... 144 

Nanosight........................................................................................ 942 

National Biosafety & Biocontainment Training Program........... 1685 

National Center for Toxicological Research................................ 1687 

✯ National Institute of Environmental Health Sciences 

(NIEHS).................................................................................... 1414 

National Library of Medicine....................................................... 1212 

National Research Center for New Drug Safety 

Evaluation (Shenyang)................................................................. 265 

National Shanghai Center for New Drug Safety 

Evaluation and Research............................................................. 720 

✯ National Toxicology Program (NTP)........................................ 1323 

Naval Medical Research Unit—Dayton....................................... 1070 

NCEH/ATSDR.............................................................................. 1024 

NeuroScience Associates (NSA).................................................... 338 

Neuroservice................................................................................... 220 

Nexelom Bioscience...................................................................... 1126 

NIH Countermeasures Against Chemical Threats 

(CounterACT) Research Program............................................... 940 

NOTOCORD, Inc. .......................................................................... 632 

✯ NSF International............................................................................ 263 

Toxexpo 



39


ToxExpo 2011 Exhibitors (Continued) 



Toxexpo 

Company Name 

Booth Number 

Nucro-Technics Incorporated..................................................... 403 

Numira Biosciences...................................................................... 1032 

O’Mara Scientific, Inc. .................................................................. 1254 

Oak Ridge Institute for Science and Education (ORISE).............. 839 

Oxford University Press................................................................. 928 

Pacific BioLabs............................................................................... 715 

PDS Preclinical Data Systems, Inc. ............................................ 625 

Perceptive Instruments Ltd. ........................................................... 165 

✯ Pfizer Global Research and Development.................................. 575 

Pharmaceutical Outsourcing.......................................................... 160 

Pharmaron (formerly Bridge Laboratories).................................... 213 

Pharmatek Laboratories, Inc. ......................................................... 320 

PhoenixBio................................................................................... 1344 

Phylonix Pharmaceuticals Inc........................................................ 656 

Pinnacle Technology Inc. ............................................................... 747 

Poly Scientific R&D Corp. ............................................................. 542 

Porsolt & Partners Pharmacology................................................ 1512 

Pre-Clinical Research Services, Inc. .............................................. 636 

PreLabs........................................................................................... 516 

Premier Laboratory, LLC............................................................... 214 

Primate Products, Inc. .................................................................... 402 

Promega Corp............................................................................... 1223 

Purina LabDiet ........................................................................... 501 

PWG Genetics................................................................................. 157 

Qiagen (Acquired SA Bioscience)................................................ 1542 

QPS—Taiwan.................................................................................. 149 

Quansys Biosciences.................................................................... 1155 

Quertle, LLC................................................................................. 1226 

Quotient Bioresearch...................................................................... 727 

ReachBio....................................................................................... 1115 

Redshift Technologies, Inc. ............................................................ 449 

Regulatory Science Associates..................................................... 1121 

Research Diets, Inc. ...................................................................... 1453 

Research Essential Services LLC................................................... 831 

Ricerca Biosciences, LLC............................................................ 181 

Ridglan Farms, Inc......................................................................... 782 

✯ Roche Pharma............................................................................... 325 

RTC—Research Toxicology Centre S.p.A. .................................... 262 

RTI International............................................................................ 716 

Rules-Based Medicine, Inc............................................................. 218 

Sable Systems International........................................................... 925 

San Diego Instruments Inc. ......................................................... 533 

Sarstedt, Inc. ................................................................................... 203 

Science/AAAS................................................................................ 634 

Scientists Center for Animal Welfare (SCAW)............................ 1679 

SCIREQ, Inc. (Scientific Respiratory Equipment)....................... 1444 

Seahorse Bioscience..................................................................... 1269 

Sequani Limited............................................................................ 451 

Seventh Wave.................................................................................. 242 

Siemens Medical Solutions USA.................................................. 1455 

Sigma Life Science....................................................................... 1306 

Simulations Plus, Inc. ................................................................... 1258 

SimuGen....................................................................................... 1026 

Sinclair Research Center LLC...................................................... 1346 

SkinEthic Laboratories................................................................... 549 

Smithers (formerly Springborn)................................................. 447 

SNBL USA, Ltd. ............................................................................. 368 

SoBran Inc. ................................................................................... 1519 

Society of Quality Assurance (SQA)............................................ 1131 

Company Name 

Booth Number 

SOLVO Biotechnology.................................................................. 1618 

SOT Pavilion................................................................................. 464 

• Toxicological Sciences 

• Endowment Opportunities 

• Outreach Information 

• Member Services, RC, SIG, and SS Activities 

Southern Research.......................................................................... 224 

Spring Valley Laboratories, Inc. .................................................. 1449 

SRC Inc. .......................................................................................... 757 

SRI International........................................................................ 1307 

STEMCELL Technologies Inc....................................................... 670 

Stemina Biomarker Discovery, Inc. ............................................... 514 

Stillmeadow Inc............................................................................. 313 

Stratatech Corporation................................................................. 1404 

Stratedigm Inc................................................................................ 723 

Strategic Applications, Inc. (SAI).................................................. 180 

Studylog Systems, Inc. .................................................................. 1521 

SUBURBAN SURGICAL COMPANY...................................... 401 

Sysmex America, Inc. ..................................................................... 759 

Taconic........................................................................................... 653 

Tandem Labs................................................................................... 707 

Thermo Fisher Scientific................................................................ 675 

TNO................................................................................................ 535 

toXcel, LLC.................................................................................... 163 

Toxicology Education Foundation (TEF)...................................... 154 

✯ Toxicology Excellence for Risk Assessment (TERA)................... 930 

Toxicology Regulatory Services..................................................... 420 

Toxicology Research Laboratory................................................. 1441 

Toxikon Corporation.................................................................... 233 

✯ ToxServices LLC........................................................................... 547 

Transformational Medical Technologies (TMT)......................... 1221 

Transparent Inc. .............................................................................. 318 

Trevigen Inc. ................................................................................. 1150 

TSE Systems................................................................................. 1314 

U.S. EPA/Office of Research and Development.......................... 1341 

Vanta Bioscience LC...................................................................... 641 

Veritox, Inc. .................................................................................... 274 

Vet Path Services............................................................................ 217 

Vimta Labs Limited...................................................................... 1447 

VisualSonics................................................................................. 1003 

Vitrocell Systems GmbH................................................................ 415 

Vitron, Inc. ...................................................................................... 936 

Vivo Bio Tech Ltd. .......................................................................... 136 

VRL Laboratories........................................................................... 276 

✯ WIL Research Laboratories, LLC............................................. 543 

Wildlife International Ltd. .......................................................... 617 

Wiley............................................................................................... 737 

World Precision Instruments.......................................................... 678 

Worldwide Primates, Inc. ............................................................... 706 

WuXi AppTec................................................................................. 133 

XenoBiotic Laboratories, Inc. ...................................................... 1224 

Xenometrics.................................................................................... 577 

XenoTech, LLC............................................................................... 638 

XpressBio...................................................................................... 1347 

Xybion Medical Systems................................................................ 238 

Zenas Technologies...................................................................... 1021 

Zoologix, Inc. .................................................................................. 134 

Zyoxel Limited................................................................................ 119 




Exhibitor Hosted Session Index 

EXHIBITOR HOSTED SESSIONS 

(Listed by date and time, then alphabetically by presenter) 

Exhibitor Hosted Sessions are informative sessions developed by 

an exhibiting company. 

Monday 

Time: 9:15 AM–10:15 AM 

Presented by Topic Room Page 

Charles River 

Phototoxicology: Current Practices 

and Regulatory Status 

140A 122 

MPI Research Logistic and Technical Challenges 156 122 

of Conducting Developmental 

Toxicity Studies in Nonhuman 

Primates 

Time: 10:30 AM–11:30 AM 


Harlan 

Laboratories, 

Inc. 

Huntingdon Life 

Sciences 

From Guidelines to Protocol: 

Lessons from EDSP Validation 

First in Human Monoclonal 

Antibody Development Strategies 

for the Treatment of Cancer 

Patients 

140B 150 

156 149 

Time: 11:45 AM–12:45 PM 


Porsolt & 

Partners 

Pharmacology 

Rules-Based 

Medicine, Inc. 

Sigma Life 

Science 

Nonclinical Evaluation of 

Drug-Abuse Liability 

Urine and Blood Based Biomarkers 

for Detecting Nephrotoxicity 

Knockout Rats As More Effective 

Preclinical Models 

140A 150 

156 150 

140B 150 

Time: 2:15 PM–3:15 PM 


SNBL USA, Ltd 

STEMCELL 

Technologies 

Inc. 

Nonhuman Primate (NHP) Infant 

Age and Relevance of Postnatal 

and Juvenile Assessments: 

Principles for Understanding 

Specific Endpoints in Study 

Designs Supporting Biologics 

Regulatory Submissions 

Utility of Hematopoietic Colony 

Forming Cell (CFC) Assays in Drug 

Development 

140B 191 

156 191 

Time: 3:30 PM–4:30 PM 


In Vitro ADMET 

Laboratories, 

LLC (IVAL) 

U.S. 

Environmental 

Protection 

Agency 

Screening of Drug Candidates with 

Idiosyncratic Hepatoxic Potential: 

Concepts and Approaches 

Announcing EPA’s Clean Air 

Research Centers: Science to 

Protect Health in a Multipollutant 

Atmosphere 

Tuesday 

140A 191 

140B 191 

Time: 9:15 AM–10:15 AM 


Celsis In Vitro 

Technologies 

Charles River 

LiverPool: Pooled Human 

Cryopreserved Hepatocytes and 

Their Advantages Across Diverse 

ADME-Tox Applications 

Preclinical Cellular Therapeutic 

Safety Testing 

140B 229 

140A 229 

MPI Research Predicting the Human Clinical 156 229 

Dose 

Time: 10:30 AM–11:30 AM 


Harlan 

Laboratories, 

Inc. 


Sciences 

National 



Diets for GLP Studies, Including 

Those for REACH 

Developing a Noval Vaccine/ 

Adjuvant Combination for the 

Prophylaxis and Treatment of 

Infectious Disease 

National Toxicology Program 

Chemical Effects in Biological 

Systems 

140B 229 

156 229 

140A 229 

Time: 11:45 AM–12:45 PM 


Data Sciences 

International 

Ingenuity 

Systems, Inc. 

LAB Research, 

Inc. 

New Applications of Latest 

Telemetry Technology in 

Toxicology and Safety 

Pharmacology 

A Systems Toxicology Approach to 

Understanding Drug Toxicity and 

Compound Prioritization 

A Battery of Toxicity Screening 

Assays for Selection of Dermal 

Drug Candidates 

140B 230 

156 230 

140A 229 

Toxexpo 

WIL Research 

Laboratories 

How to Comply with the EPA’s 

Endocrine Disruption Screening 


140A 190 



41


Exhibitor Hosted Session Index (Continued) 

Toxexpo 

Time: 1:00 PM–2:00 PM 


emka 

TECHNOLOGIES, 

INC. 

RTC—Research 


Centre 

WIL Research 

Laboratories, 

LLC 

Latest Advances in Arrhythmia 

Detection and in Non-Invasive 

Blood Pressure Monitoring from 

Ambulatory Animals 

The Marmoset As an Experimental 

Model for the Development of 

Biopharmaceuticals 

Uses for Stereology in Toxicologic 

Pathology 

156 262 

140B 262 

140A 263 

Time: 2:15 PM–3:15 PM 


Cyprotex 

Discovery Ltd 

Instech 

Solomon 

Machine Learning and Exposure 

to Modeling in the Prediction of 

In Vivo Toxicity from High Content 

Screening (HCS) Data 

Automated GLP Infusion Studies: 

Improved Process Quality and 

Labor Utilization 

140A 269 

140B 269 

Promega Predictive Analysis of Cell Viability, 156 269 

Apoptosis and ADME/Tox 

Properties Using 

Time: 3:30 PM–4:30 PM 


Biopredic 

International 

Ellegaard 

Göttingen 

Minipigs A/S 

Life 

Technologies 

HepaRG, Novel Human Hepatic 

Cells for In Vitro Tox 

The Use of Minipigs in the 

Development of New Medicines 

Cryopreserved HepaRG: An 

Alternative In Vitro Screening Tool 

for Human Hepatic Drug 

156 270 

140A 270 

140B 269 

ToxExpo Prize Drawing $500! 

Wednesday 

Time: 9:15 AM–10:15 AM 


Charles River 

Harlan 

Laboratories, 

Inc. 


Sciences 


Toxicity Testing of Vaccines and 

Biologics 

Key Six Sigma Methods Applied to 

Surgical Services for Operational 

Excellence 

Developing Local and Systemic 

Biologics to Treat Inflammation of 

the Lung 

140A 305 

140B 305 

156 305 

Time: 10:30 AM–11:30 AM 


BioReliance® 

Corporation 

InSphero AG 

Overview, Design, and Review of 

Transgenic Carcinogenicity Studies 

Drug Testing Using 3D 

Microtissues 

140B 305 

140A 305 

MPI Research Challenges of Assessing Biologics 156 305 

for Efficacy and Safety 

Time: 11:45 AM–12:45 PM 


GeneGo, Inc., 

a Thomson 

Reuters 

Business 

Toxicity Knowledge Bases and 

Pathway Analysis Tools for Systems 


140A 306 

Taconic 

Humanized Mouse Models for PK 140B 306 

and Safety Profiling of Compounds 

Time: 1:00 PM–2:00 PM 


Applied 

BioPhysics, Inc. 

Electric Cell-Substrate 

Impedance Sensing: A Label Free, 

Non-Invasive Method of Cell 

Measurement 

140A 330 

Additional sessions may be scheduled after print deadline. Please see 

ToxExpo Directory for the most current schedule. 





Drop your business cards 

in the ToxExpo prize 

drawing boxes found in all 

Diamond Level Sponsor booths 

Your 24/7 source for the latest 

developments in equipment, 

technology, toxicology services, 

and publications 



Creating a Safer and Healthier World 

by Advancing the Science of Toxicology 

Founded in 1961, the Society of Toxicology (SOT) includes 

more than 6,700 members from nearly 60 countries worldwide. 

SOT members are drawn from academic institutions, industry, 

and government service, among others, and are active in a 

myriad of related fields and professions. All members partner 

with SOT in advancing science to enhance human, animal, and 

environmental health. You may apply to join the SOT at the 

following membership levels: 

Student—you must be enrolled in a graduate degree 

program related to toxicology. 

Postdoctoral fellow—you must hold a Ph.D. or other 

doctoral degree (e.g., M.D., D.V.M.) with an interest in 

toxicology and be under the direction of a research mentor. 

Associate—you must be engaged in continuing 

professional scientific activities in toxicology. 

full—you must demonstrate a continuing professional 

interest in toxicology and have conducted and published 

original research and/or are generally recognized as expert 

in some phase of toxicology. 

Apply for the level of membership that’s right for you! 

Please see the “Join SOT” section of the SOT Web site at 

www.toxicology.org/ms/join.asp for further information. 

Undergraduate students may become SOT Undergraduate 

Student Affiliates. 

As an SOT member you can … 

Communicate, Connect, and Collaborate with colleagues via 

ToXchange, the professional, secure SOT member network, 

and keep current at www.toxicology.org with member-only 

information 

Qualify for reduced SOT member rates for the SOT Annual 

Meeting , Continuing Education Courses, and Current Concepts 

in Toxicology topical meetings 

Receive SOT publications including the official journal of the 

SOT, Toxicological Sciences; the Toxicologist; the SOT newsletter, 

Communiqué, and the SOT Membership Directory 

utilize Career Resources such as the SOT Job Bank and 

register for Mentor Match as a mentor or mentee 

Qualify for exclusive SOT member awards—from Graduate 

Student Travel Support and Research Training to Postdoctoral 

Fellowships, Traveling Lectureships, SOT Awards, and more! 

Membership 

www.toxicology.org 

*For complete information about membership in 

the Society of Toxicology, visit the SOT Web site 

at www.toxicology.org and select Member Information. 

JOIN SOT 

Plus… 

Choose to join one or more of 26 Specialty Sections, 

18 Regional Chapters, or six Special Interest Groups that 

provide a variety of networks for exchanging information 

and collaborating with peers. Note: Graduate Student and 

Postdoctoral members may join one Specialty Section and one 

Special Interest Group at no additional cost. 

Membership Fees: 

Full Membership ................................................... $136 

associate Membership ........................................ $136 

Postdoctoral Membership ................................... $35 

Student Membership ........................................... $20 

Members from Developing Countries are eligible for reduced dues.* 

Full Membership ................................................... $50 

associate Membership ........................................ $50 

Postdoctoral Membership ................................... $10 

Student Membership ........................................... $10 

Easy on-line membership application takes approximately 

15 minutes to complete. 

50 th Anniversary Annual Meeting 

and ToxExpo 

2011 

Celebrating 50 Years of Service in Science 


March 6–10, 2011 



43


Registration 

REGIStratION 

Annual Meeting Registration Fees 

On-Site 

SOT Member........................................................$395 

Non-Member........................................................$690 

SOT Retired/Emeritus Member............................$145 

Postdoctoral SOT Member...................................$160 

Postdoctoral Non-Member...................................$240 

Graduate Student SOT Member...........................$140 

Graduate Student Non-Member...........................$200 

Undergraduate Student.............................................$0 

SOT Affiliate............................................................$0 

Press..........................................................................$0 

Guest (Non-Scientist)...........................................$100 

(Guests do not have access to the Scientific Sessions or 

the Exhibit Hall.) 

Continuing Education Sunrise 

Mini-Course Fees 

(includes continental breakfast) 

(Only Annual Meeting Registrants may enroll in 

CE Courses.) 

On-Site 

SOT Member/SOT Affiliate.................................$105 

SOT Retired/Emeritus Member............................$105 

Non-Member........................................................$125 

Postdoctoral (SOT Member or Non-Member)......$105 

Graduate or Undergraduate Student 

(SOT Member or Non-Member).............................$75 

Press..........................................................................$0 

Continuing Education Course Fees 

(per morning or afternoon course) 

(Only Annual Meeting Registrants may enroll in 

CE Courses.) 

On-Site 

SOT Member/SOT Affiliate.................................$200 

Retired..................................................................$160 

Non-Member........................................................$350 

Postdoctoral (SOT Member or Non-Member)...........$140 

Graduate or Undergraduate Student 

(SOT Member or Non-Member)..................................$95 

Press..........................................................................$0 

Annual Meeting Registration Includes: 

• Awards Ceremony, Sunday, March 6 from 

5:15 PM–6:30 PM. 

• Plenary Opening Lecture, Monday, March 7 from 

8:00 AM–9:00 AM. 

• All Scientific Sessions (see Program Description 

beginning on page 113) 9:15 AM, Monday, March 7 

through 12:00 NOON, Thursday, March 10 for additional 

start times. 

• ToxExpo Exhibit Hall, 9:00 AM–4:30 PM Monday, 

March 7; 8:30 AM–4:30 PM Tuesday, March 8 and 

Wednesday, March 9. 

Participants are also encouraged to register for the 

Continuing Education Courses. These are available during 

three time intervals on Sunday, March 6: the Sunrise Mini- 

Course is from 7:00 AM–7:45 AM, morning courses are 

8:15 AM–12:00 NOON, and afternoon courses are from 

1:15 PM–5:00 PM. 

Registration Desk 

The Registration Desk is located in the East Salon of the 

Grand Lobby in the Walter E. Washington Convention Center. 

Registration Desk hours: 

Saturday....................................................... 4:00 PM–7:00 PM 

Sunday........................................................ 6:30 AM–8:00 PM 

Monday........................................................7:00 AM–5:00 PM 

Tuesday....................................................... 6:00 AM–4:30 PM 

Wednesday.................................................. 6:00 AM–4:00 PM 

Thursday................................................... 6:00 AM–11:30 AM 

Registration Materials 

For those of you who registered before January 21, 2011, 

your badge, Program, and The Toxicologist on CD-ROM 

will be sent to you prior to the Annual Meeting. If you have 

registered and have NOT received your badge by mail, or 

need a replacement badge, go to the “Badge Pick Up Only” 

registration counter located in the East Salon. Your 2011 

Annual Meeting Registration badge must be presented to 

obtain access to SOT functions. 

When you arrive at the Walter E. Washington Convention 

Center, you will need to pick up your ToxExpo Directory 

and badge holder. If you have not already registered, please 

go to the registration counter in the East Salon in the Grand 

Lobby to obtain these materials. If you already have your 

registration badge and event/CE course tickets, simply stop 

by a handout table and present your badge to obtain the other 

registration materials (i.e., The Toxicologist on CD-ROM, the 

ToxExpo Directory, and other supplementary materials). 

The printed version of The Toxicologist will be available to 

purchase in the East Salon next to the registration desk. 



General Information 

Registration Confirmation 

You should receive a registration confirmation/receipt via 

e-mail regardless of whether you registered on-line, by mail, or 

by fax. If you don’t receive your confirmation within 2 weeks, 

please contact SOT Headquarters at sothq@toxicology.org or 

call 703.438.3115. 

Accessibility for Persons with Disabilities 

The Walter E. Washington Convention Center and most of the 

SOT hotels (with the exception of the Eldon Suites and Henley 

Park Hotel) are accessible to persons with disabilities. If you 

require special services, please mark the appropriate box on 

the Annual Meeting Registration Form. 

Scooters can also be rented from Scoot Around. For more 

information, please go to www.scootaround.com or call 

888.441.7575. They will deliver to your hotel. If you require 

a sign language interpreter, please contact the Sign Language 

Associates via e-mail: info@signlanguage.com or call 

301.946.9710. 

If you require more information about accessibility, please 

contact Heidi Prange at SOT Headquarters: 703.438.3115 ext. 

1424. 

Attire 

The official attire for the Annual Meeting is business casual. 

No coat or tie is required! We encourage you to bring 

comfortable clothing and shoes. Because meeting rooms may 

seem cold, please bring a sweater or jacket and/or dress in 

layers. 

Business Center 

Telephone: 202.289.5233 

Fax: 202.289.0299 

E-mail: info@capitalbusinesscenter.com 

The Walter E. Washington Convention Center’s Capital 

Business Center is conveniently located on First Level 

and offers services such as UPS, FedEx, USPS shipping 

and receiving, common office supplies, Internet access, 

high-quality copying and printing for brochures, fliers, and 

posters, binding and various finishing options, enlargements 

and reduction prints, and uploading documents from a disk, 

memory stick, or CD. You may also e-mail your files before 

arrival and have your documents ready for you at the start of 

the meeting. 

Business Center hours: 

Monday–Sunday......................................... 9:00 AM–5:00 PM 

Career Resources and Development Services 

As part of the Career Resources and Development (CRAD) 

services, the on-site Job Bank Center is located in the Walter 

E. Washington Convention Center in Rooms 157 and 158 on 

the First Level. 

The Job Bank Center hours: 

Sunday......................................................... 1:00 PM–4:30 PM 

Monday....................................................... 9:00 AM–4:30 PM 

Tuesday....................................................... 8:30 AM–4:30 PM 


Full CRAD details may be found on page 60. 

Badges 

Annual Meeting attendees who register by January 21, 2011, 

will receive badges and registration materials in the mail. 

Attendees who already have their 2011 Annual Meeting 

badges do not need to wait in the registration line. If you have 

registered and have NOT received your badge by mail, or 

need a replacement badge, go to the “Badge Pick Up Only” 

registration counter to pick up your badge. You will be asked 

to show a photo ID. 

All on-site badges will be issued on gold badge paper to assist 

with the registration auditing process. 

If you have not registered for the meeting before you arrive 

in D.C., please complete the on-site Registration Form found 

at the kiosks in the registration area and proceed to the 

appropriate registration line. 

For security reasons badges may not be altered. Please go to 

SOT Registration to update information on your badge. 


45 

Climate 

In March, D.C.’s typical temperature range is an average 

low of 37.4°F/3°C and an average high of 55.7°F/13.2°C. For 

an up-to-date and more detailed weather forecast, visit the 

National Weather Service Forecast Office at www.erh.noaa. 

gov/er/lwx. 


For your convenience, a coat/luggage check will be available 

in Salon F in the Grand Lobby near Registration on the First 

Level. The coat/luggage check will be open Sunday, March 

6 through Thursday, March 10. There will be a fee of $3 per 

item checked. Laptops, cameras, and other electronics will 

not be accepted. 

Hours of operation: 

Sunday........................................................ 7:00 AM–8:00 PM 

Monday....................................................... 7:00 AM–8:00 PM 

Tuesday......................................................6:00 AM–10:00 PM 


Thursday......................................................6:00 AM–1:00 PM 

Coat/Luggage check hours are subject to change. 

General Info


General Information (Continued) 

General Info 

Exhibitor Information 

Full exhibit information details may be found on 

pages 35–42. 

Exhibit Hall (Hours/Location) 

Exhibit hours at the Convention Center: 

Monday...............................................9:00 AM–4:30 PM 

Tuesday............................................... 8:30 AM–4:30 PM 

Wednesday.......................................... 8:30 AM–4:30 PM 

The ToxExpo Exhibition is located on the Second 

Level of the Convention Center. A map of the Exhibit 

Hall is located on pages 36–37. Exhibitor personnel may 

enter the hall one hour before the Exhibit Hall opens 

with appropriate identification. Poster presenters may 

enter the hall at the poster set-up times specified in the 

Event Calendar. ToxExpo Directories are available at 

Registration and just inside each entrance of the Exhibit 

Hall. 

New This Year: ToxExpo Time! 

In addition to the standard Exhibit Hall hours and poster 

presentation times, one hour of dedicated ToxExpo 

Time has been allotted in the scientific program for 

attendees to visit with exhibitors. ToxExpo Time will 

take place on Monday, March 7 from 1:00 PM–2:00 PM. 

2012 Exhibit Space Selection Meeting 

Exhibiting companies should plan on attending the 

2012 Space Selection Meeting on Tuesday, March 8, at 

4:45 PM in Room 156 on the First Level of the Convention 

Center. 






Drop your business cards 

in the ToxExpo prize 



First Aid and Emergency Services at the 


If an emergency should occur while at the Walter E. 

Washington Convention Center, proceed directly to the 

nearest house phone, located throughout the facility and in 

most meeting rooms, and dial 3333 for security. You will be 

connected directly to the 24-hour manned security department 

at the Convention Center. Dialing 202.249.3333 from your cell 

phone will also connect you directly to security. 

A First Aid room will be located in Exhibit Hall D and 

accessible from inside the hall and from the loading dock. 

The First Aid Administrator will be on duty: 

Sunday........................................................ 7:00 AM–8:00 PM 

Monday....................................................... 7:00 AM–8:00 PM 

Tuesday......................................................6:30 AM–10:00 PM 

Wednesday ................................................. 6:30 AM–8:00 PM 

Thursday..............................................6:30 AM–12:00 NOON 

Please note that in accordance with District of Columbia 

regulations, the First Aid Administrator is not permitted to 

dispense any medication. 

Food Services 

Coffee Breaks 

The exhibiting companies are pleased to sponsor 

complimentary coffee in the Exhibit Hall between 

9:00 AM–10:00 AM Monday—Wednesday. See Exhibit Hall 

signage for locations. 

Concessions 

Concession stands are available in the Exhibit Hall Monday 

9:00 AM–4:30 PM and Tuesday and Wednesday from 

8:30 AM–4:30 PM. Breakfast and lunch items will be 

available for purchase, as well as coffee, soda, bottled water, 

and snacks. Seating is available in the Concession areas in the 

Exhibit Hall. Please see the map on pages 36–37 for location. 

A full restaurant list may be found on page 32. 

Take a Break! 

Grab a bite! Check e-mail! Plenty of seating is available 

in the Wi-Fi Lounges in the Exhibit Hall where wireless 

Internet access is available. See map on pages 36–37 for 

location. 




Green in Washington, D.C. 

Seventy percent of land in Washington, D.C., is controlled 

by the National Park Service. There are 250,000 acres of 

parkland in the Greater Washington Metropolitan area. In 

2007, D.C. was named the most walkable city in the U.S. in a 

study by the Brookings Institute. In late 2006, the D.C. City 

Council passed an initiative making the nation’s capital the 

first major city to require developers to adhere to guidelines 

established by the U.S. Green Building Council. 

The Walter E. Washington Convention Center is a green 

meeting facility, with earth-friendly features like low 

emission glass that controls heat gain and loss and maximizes 

natural lighting; energy-conserving heating, ventilation and 

air conditioning systems that operate in zones; high-efficiency 

lighting; automatic controls on restroom fixtures; plus 

recycling programs and easy public transportation access. 

The following lists some of the ways the Center is going 

green: 

• The Center’s infrastructure supports storm water 

management. The extensive roof system feeds rain 

water into nine (9) large underground collection tanks 

around the property. The tanks collect, filter, then release 

rainwater into the District of Columbia’s storm system at a 

slower rate. 

• The Center recycles cardboard/mixed paper, glass, 

aluminum, plastic bottles and cans, fluorescent bulbs, 

toner cartridges, and batteries. 

• In addition to a food composting program, Centerplate 

(caterer for the Convention Center) offers organic and 

locally grown food and donates excess to the D.C. Central 

Kitchen, a nationally recognized, nonprofit organization. 

• Lighting in restrooms is controlled by a light sensor 

system. The restrooms also have infrared flush commodes, 

low flow urinals, and faucet sensors. 

• The lighting system in over a mile of the service corridors 

is sensored. 

• There are carbon dioxide sensors throughout the Center 

to ensure that appropriate levels of fresh air are being 

circulated. 

• Bike racks are available for guests and staff. 

• “Metrochecks” are provided as a transit benefit to all 

employees for daily commute on Metrorail and Metrobus. 


The SOT Guest/Spouse Hospitality Room provides guest 

participants (non-scientists) with a place to meet and socialize 

with other guests. To visit the Hospitality Room, guests must 

register for the Annual Meeting with the person they are 

accompanying. Guests will not have access to the scientific 

sessions or the Exhibit Hall. Please remember to wear your 

badge to all SOT events. The Guest Hospitality Room will be 

located in the Renaissance Hotel. 

Guest/Spouse Hospitality Room hours: 

Sunday........................................................ 8:00 AM–5:00 PM 

Monday....................................................... 8:00 AM–5:00 PM 

Tuesday....................................................... 8:00 AM–5:00 PM 


Thursday................................................... 8:00 AM–11:30 AM 

Housing Desk 

Destination D.C. 

The deadline date for new housing reservations is February 

3, 2011. Continue to make any requests through Destination 

D.C., through February 3. Beginning February 8, you may call 

the hotels directly for any housing requests. For information 

regarding your hotel room reservation on-site, please visit 

the SOT Housing Desk located in the registration area of the 

Walter E. Washington Convention Center. 

Housing Desk hours: 

Saturday....................................................... 4:00 PM–7:00 PM 

Sunday........................................................ 8:00 AM–5:00 PM 

Monday........................................................7:00 AM–5:00 PM 

Tuesday....................................................... 8:00 AM–4:00 PM 


Housing desk hours are subject to change. 

Internet Access at the Convention Center 

SOT knows the importance of staying connected to your daily 

activities while attending the Annual Meeting, and provides 

several ways for you to access the Internet while at the Walter 

E. Washington Convention Center. 

Computers with Internet Access/E-mail Center 

SOT will provide computers you can use to access the Internet. 

These computers are available to attendees in the E-mail 

Center located in the registration area. 

General Info 

The Cost of Big Gatherings 

Meetings can have a tremendous impact on the environment 

in ways you can’t imagine. For example, during a five-day 

conference, 7,000 attendees will use 175,000 plates, 245,000 

napkins, 75,000 cups/glasses, and 252,000 cans/bottles! 

Free Wireless Internet Access 

Free wireless Internet access is available through open “Wi-Fi 

Lounges” in designated areas in the Exhibit Hall. See map on 

pages 36–37 for locations. 


47



Free wireless Internet access is also available in the 

complimentary Convention Center Connect Lounges located 

in the Grand Lobby, Concourse A, Concourse B, Metro 

Entrance, L Street Entrance near rooms 156 and 140, across 

from 143C, Uptown Cafe and Downtown Cafe, and 2nd and 

3rd floor Wing seating areas. 

Secure Wireless Internet Access 

The Walter E. Washington Convention Center Wi-Fi is a selfservice 

wireless network that is available to all event attendees. 

The cost is $24.95 per day based on a 24-hour time frame, and 

can be purchased directly from any wireless capable computer. 

This service allows Internet access in the public space and 

meeting rooms only, but not in the Exhibit Hall. 

To access Internet in areas that are not designated for Wi-Fi in 

the Exhibit Hall, meeting rooms, and public space, the cost is 

$16.95 per hour or $99 per day. 

Letter of Attendance 

Please stop by the SOT Annual Meeting Registration Desk 

after Tuesday morning if you would like a letter of attendance 

for your participation in the 2011 SOT Annual Meeting and/or 

the Continuing Education Course(s). 

a media kit, by contacting Martha Lindauer, Media Contact 

at SOT Headquarters: 703.438.3115 or e-mail martha@ 

toxicology.org. Speaker interviews can be arranged on-site and 

media kits can be picked up at the SOT Headquarters Office, 

Room 101, in the Walter E. Washington Convention Center. 

Memorabilia 

Shirts, hats, coffee mugs, and other items customized for SOT 

are available for sale at the Annual Meeting in the Memorabilia 

Booth located in Registration area. Commemorative 50th 

Annual Meeting items will also be available for purchase. 

Parking Information 

Parking is at a premium throughout the entire city. There 

are over 3000 parking spaces in a three block radius of the 

Convention Center. There are also approximately 100 metered 

parking spaces within close proximity to the Convention 

Center. These spaces are available on a first-come, first-served 

basis. 

For those driving into Washington, D.C., and staying 

overnight, please check with the hotel or use the map 

with the locations of parking and price list found on 

www.toxicology.org/ai/meet/am2011. 

General Info 

Lost and Found 

Lost and found articles may be taken to the SOT Headquarters 

Office, Room 101, of the Walter E. Washington Convention 

Center. Any items left in the SOT Headquarters Office after 

11:30 AM, Thursday, March 10 will be taken back to SOT 

Headquarters Office. If you do not remove your poster at the 

end of your session, you will find it on the “Poster Reclamation 

Tables” at the end of the 1600 aisle in the Exhibit Hall (back 

right corner of hall). 

Lunch with an Expert Information Board 

The Lunch with an Expert (LWAE) events are informal 

gatherings of small groups of students and a Toxicology Expert 

over a meal or social hour. The Student Advisory Council 

sponsors these events to provide students an opportunity to 

network with well-established toxicologists while obtaining 

career advice and meeting new colleagues. The groups 

are matched by research interests and the Expert for each 

group identifies a time and place to assemble. The LWAE 

Information Bulletin Board provides all the details for the 

group meetings and is located in the registration area. Groups 

meet at the Board before proceeding to their meal. 

Media Support Services 

The Society of Toxicology welcomes accredited 

representatives of media organizations. Journalists may receive 

complimentary credentials for all meeting sessions, as well as 

Photography Policy and Session Etiquette 

for Attendees 

Out of courtesy for the scientific presenters, we appreciate 

your compliance with the following policies: 

15 and UNDER 

• Cell phones and other electronic devices should 

be set on mute. 

• Electronic capture of scientific sessions by any 

method is prohibited. 

• Children under the age of 15 are not allowed in 

scientific sessions unless the session chair gives 

consent. 

Session chairs are asked to enforce these policies and 

individuals who do not comply will be asked to leave the 

session. 

15 and UNDER 

• Photography of poster presentations is prohibited 

without the specific consent of the presenter(s)/ 

author(s). 

• Photography of exhibitor booths is prohibited. 

• Children under the age of 15 are prohibited from 

entering the Exhibit Hall at any time. 

If you have any questions regarding these polices, please 

contact the SOT Headquarter staff at the Registration Desk. 




Poster Printing Service (NEW) 

SOT is pleased to offer our poster presenters a convenient 

poster printing service through Shepard Exposition Services, 

the official general service contractor for the Annual Meeting. 

No need to worry about traveling with your poster or having 

your poster lost in shipping. Simply fill out the on-line form, 

e-mail or upload your poster using the link provided, review 

and approve the final layout of your poster, and then pick up 

your poster on-site at the “Poster Pick Up Desk” near the 

Exhibitor Service Center (900 Aisle). Shepard will produce 

the materials for a reasonable price, which will include 

production, transportation, and storage for the show. It’s as 

simple as that! Please call 410.737.9270 or send an e-mail to 

rstaub@shepardes.com for more information. More information 

and the order form can also be found on the SOT Web site at 

www.toxicology.org/ai/meet/am2011/present.asp. 




$500 American Express Gift card awarded each day 

Drop your business cards in the ToxExpo prize 



Registration Desk Hours 

The Annual Meeting Registration Desk is located in the 

Walter E. Washington Convention Center, East Salon in the 

Grand Lobby. 

Registration Desk hours: 

Saturday....................................................... 4:00 PM–7:00 PM 

Sunday........................................................ 6:30 AM–8:00 PM 

Monday........................................................7:00 AM–5:00 PM 

Tuesday....................................................... 6:00 AM–4:30 PM 


Thursday................................................... 6:00 AM–11:30 AM 

Full registration details may be found on page 44. 

Safety and Security 

The possibility of demonstrators is very real given the nature 

of our conference. Events of this nature range from verbal 

confrontations, protests, strikes, to riots. We recommend the 

following procedures in the event of demonstrations: 

• Have your name badge available upon entering the 

Convention Center. Wear your name badge in the 

Convention Center. When leaving the facility, remove it so 

as to blend with other people. 

• If you see a demonstration or protest beginning, please 

contact any member of the SOT Annual Meeting staff and 

they will initiate an SOT response. If you see actions that 

appear threatening, notify the nearest security officer. 

• Do not engage, defend either side, or subdue person(s) in 

any type of disturbance. Demonstrators are usually trying 

to attract media attention. Don’t help them! 

• SOT representatives will respond to media inquiries. Do 

not participate in interviews or other media responses. 

• In the unlikely event that outsiders disrupt a scientific 

session or other event, SOT security officials have 

developed a contingency plan. Please follow directions 

from the chairperson and avoid becoming involved in the 

situation. 

Safety Tips 

Walk “smart” when you leave the Convention Center: 

• Know your destination and the best way to reach it. 

• Travel along sidewalks in lighted areas at night, and don’t 

walk alone. 

• Establish a “buddy” system with another attendee to walk 

to and from the Convention Center. 

• Share schedules and check up on each other periodically. 

• Build your awareness of unknown surroundings by 

reviewing local information. 

• Laptop computers are attractive, easy targets for thieves. 

Be sure your laptop is in a secure place. 

• Jackets with pockets provide a convenient alternative to 

reduce the chance for lost or stolen handbags. 

Our first priority is safety. The best way to stay safe is to be 

aware of your surroundings and to avoid situations where you 

feel uncomfortable. 

General Info 


49



General Info 

SOT Headquarters Office 

The SOT Headquarters Office is located in the Walter E. 

Washington Convention Center Room 101 on First Level. 

SOT Headquarters Office hours: 

Saturday....................................................... 4:00 PM–7:00 PM 

Sunday.........................................................7:00 AM–5:30 PM 

Monday........................................................7:00 AM–5:00 PM 

Tuesday....................................................... 7:00 AM–4:30 PM 


Thursday................................................... 7:00 AM–11:30 AM 

SOT Pavilion 

Do you know all the resources available through SOT 

and where to find them? Stop by the SOT Pavilion, Booth 

#464, centrally located in the Exhibit Hall and learn about 

SOT services and membership benefits, and SOT Regional 

Chapters, Specialty Sections, and Special Interest Groups. 

Find out about the SOT Endowment Fund, Toxicological 

Sciences, awards and fellowships, educational resources, and 

more. Special presentations will be given on SOT activities 

and member benefits, including ToXchange, so be sure to 

stop by for the schedule of SOT Pavilion events. The SOT 

Pavilion is the one-stop shop for all of your SOT questions 

and membership needs. Make the SOT Pavilion your meeting 

place on the exhibit floor. 

Pavilion hours: 

Monday....................................................... 9:00 AM–4:30 PM 

Tuesday....................................................... 8:30 AM–4:30 PM 



The Speaker Ready Room will be located in Room 208 

and is available during the SOT Headquarters Office hours 

listed above. SOT will provide all confirmed presenters in 

scientific sessions log-in credentials to access the submission 

site to preload your presentations. All presentations should 

be preloaded in advance of the meeting, but not less than 

30 minutes prior to the start of the sessions in the Speaker 

Ready Room only. Presenters will not be able to upload a 

presentation in the session room. 

Sponsorship 

The SOT Annual Meeting is the largest scientific gathering of 

toxicologists in the world, and our Annual Meeting Sponsors 

play an integral role in the success of this important event. 

Becoming an Annual Meeting Sponsor demonstrates your 

organization’s commitment to SOT’s vision of “creating a safer 

and healthier world by advancing the science of toxicology.” 

Sponsorship also provides an opportunity for better name 

recognition of your company among SOT members and the 

Annual Meeting attendees. In addition, your support allows 

the Society to keep registration fees low, thereby enabling us 

to attract nearly 7,000 attendees to the Annual Meeting. 

There are four levels of sponsorship available: 

Diamond ($10,000 or more), Platinum ($5,000–$9,999), 

Gold ($2,500–$4,999), and Silver ($1,000–$2,499). 

You will find a complete menu of sponsorships designed 

to assist your organization in establishing a leadership 

position at the SOT 2011 Annual Meeting on the Web site at 

www.toxicology.org. 

Sponsor names are prominently displayed on the Annual 

Meeting Web site, as well as in print materials that are 

distributed before and during the Annual Meeting. Sponsorship 

is also recognized through signage displayed around the 

Convention Center during the Annual Meeting. 

Annual Meeting sponsorship contributions are tax deductible 

per IRS regulations. For detailed information about 

SOT sponsorship opportunities, please contact Liz Kasabian 

at SOT Headquarters: 703.438.3115 or e-mail: liz@toxicology. 

org. 

For a complete list of our 2011 Annual Meeting Sponsors (as 

of press time), please see page 480 and the back cover. 

Tour Information 

For tour information, visit the Tour Desk located in the 

Registration area, Grand Lobby on the First Level. 

Tour Desk hours: 

Saturday, March 6........................................ 4:00 PM–7:00 PM 

Sunday, March 7......................................... 8:00 AM–1:00 PM 

Monday, March 8........................................ 8:00 AM–1:00 PM 

Tuesday, March 9.........................................8:00 AM–1:00 PM 

Wednesday, March 10.................................8:00 AM–9:30 AM 

Tour desk hours are subject to change. 

Tour Tickets 

Pre-purchased ticket holders will receive an e-mail 

confirmation up until February 25. Your e-mail confirmation 

will serve as the ticket for admission. Tickets are also sold 

on-site on a first-come, first-served basis at the tour desk. 

After February 25, call ETS Tours for availability of tickets 

at 888.447.4387 ext. 340 or e-mail: sue@eventtrans.com. No 

refunds will be made after February 25, 2011. 

Tour Departures 

Tour departure information will be available at the Tour 

Desk located in the Grand Lobby. All tours will leave from 

the L Street entrance of the Walter E. Washington Convention 

Center. Please arrive at least 15 minutes prior to your 

scheduled tour departure time. 




The Toxicologist (Print and CD-ROM)/ 

Itinerary Planner and the Program 

All Annual Meeting registrants receive a copy of this 

Program and The Toxicologist on CD-ROM, a special issue of 

Toxicological Sciences that includes all meeting abstracts and 

SOT Annual Meeting events. Special software on the CD, the 

Itinerary Planner, allows the meeting attendee to search the 

meeting abstracts, events, and create a personalized schedule 

for the meeting. 

1. SOT Members in the U.S. and Canada will receive the 

printed Program and The Toxicologist on CD-ROM (with 

Itinerary Planner) prior to the Annual Meeting. 

SOT Members outside of the U.S. and Canada may pick 

up the printed Program and The Toxicologist on CD-ROM 

at the meeting or may request that these be mailed 

following the Annual Meeting. Send e-mail requests to 

jimd@toxicology.org. 

2. Non-SOT Members in the U.S. and Canada, who register 

on or before January 21 will receive the printed Program 

and The Toxicologist on CD-ROM (with Itinerary 

Planner) prior to the Annual Meeting. 

All Non-SOT Members who register after January 21 

(and non-SOT Members from outside of the U.S. or 

Canada) will receive the Program and The Toxicologist on 

CD-ROM (with Itinerary Planner) at the meeting. 

3. Registrants will receive the Annual Meeting abstracts 

in The Toxicologist on CD-ROM as part of the Annual 

Meeting registration fee. Annual Meeting attendees may 

purchase a printed version of The Toxicologist for $20 per 

copy. You may preorder using the Registration Form and 

pick up a copy on-site or wait to purchase a copy on-site 

(while supplies last). The Toxicologist will be available for 

download (beginning February 2011) free-of-charge on 

the SOT Web site. 

4. The Annual Meeting Itinerary Planner is available on the 

SOT Web site January–April. 

NOTE: Please bring your copy of the Program with you to the 

Annual Meeting. 

On-Line Itinerary Planning 

Tool Enhancements 

SOT is excited about the improved 

functionality of the on-line 

customizable Itinerary Planner. 

We invite you to use this tool to plan 

your Annual Meeting experience. 

Choose the presentations, featured lectures, 

meetings, or special event functions you wish 

to add to your personal itinerary. After you’ve 

selected your schedule of sessions, you’ll be able 

to export this information to your default calendar 

program for reference using iCal, a calendar 

software application that functions with Windows 

on the PC (www.brownbearsw.com), the Mac 

(www.apple.com), and most mobile devices. The 

downloaded information will contain specific 

details for these sessions or events such as 

date, time, and the location. Additionally, each 

presentation downloaded provides you with 

access to detailed abstract information including 

authors, institutions, and the full abstract. 

More information available 

on the SOT Web site. 

Transportation 

MAR 

6 

SOT Annual Meeting Begins 

Washington, D.C., is served by three major airports, Amtrak, 

and a world-class subway system (Metro). Ronald Reagan 

Washington National Airport (DCA) is approximately 6 miles 

from the Convention Center, Washington Dulles International 

Airport (IAD) is approximately 27 miles away, and the 

Baltimore-Washington International Thurgood Marshall 

Airport (BWI) is approximately 30 miles from the Convention 

Center. Amtrak’s Union Square station is approximately 

2 miles from the Convention Center. 

General Info 


51



General Info 

Special Airfare Discounts 

SOT has established discounted rates through American and 

Delta Airlines for flights originating in the United States and 

Canada. Be sure to use the reference numbers when making 

your reservations to receive the discount. You may purchase 

your ticket on-line, call the airline directly using the toll free 

numbers, or provide your travel agent with the reference/ 

discount numbers listed below. 

American Airlines 

800.433.1790 

www.aa.com 

Discount Code: 2931AX 

American Airlines is offering a 10% discount off the lowest 

applicable fare. The discount is valid March 3–14, 2011, for 

travel to Washington, D.C., and surrounding airports. You 

may make reservations by calling the Meeting Services 

Desk at 800.433.1790 from anywhere in the United States or 

Canada and referring to the Star File discount code 2931AX. 

A reservation service fee per ticket will apply for each ticket 

booked over the phone. You may also book your ticket on-line 

at www.aa.com (no service fee applies). Under the promotion 

code, type 2931AX to receive the SOT discount. 

Delta Airlines 

800.328.1111 

www.delta.com 

Discount Code: NM5UY 

Delta Airlines is offering up to a 5–7% discount off full/ 

non-restricted fares to Washington, D.C. The discount is 

valid March 3–13, 2011, for travel to Washington, D.C., and 

surrounding airports. You may make reservations by calling 

the Meeting Services Desk at 800.328.1111 from anywhere 

in the United States or Canada and refer to discount code 

NM5UY. Delta does not charge a reservation service fee. 

No discount applies if you book your ticket on-line at 

www.delta.com. 

SOT Travel Agent—Carlson Wagonlit 

Carlson Wagonlit is the official travel management firm 

for SOT’s 50th Annual Meeting. To take advantage of their 

services and savings, call toll-free 800.535.9117 Monday 

through Friday, 9:00 AM–5:30 PM (Eastern Standard Time) 

and ask to speak to anyone on our SOT dedicated team, or 

e-mail: washington.remote@carlsonwagonlit.com. To obtain 

the maximum discounted fares, call at least 60 days prior to 

departure. Lower fares are still obtainable up to 14 days in 

advance. Please note that Carlson Wagonlit charges a $42 

service fee per ticket. 

Before calling Carlson Wagonlit, please gather the 

following information: 

• The desired dates of arrival to and departure from 


• Your home city or originating airport 

• Your approximate time of departure from the originating 

airport 

• The number of persons traveling (adults/children) 

• Your method of payment, either credit card or check 

• Your airline frequent flyer number(s) 

• Your name as it appears on your ID and your date of birth 

Identify yourself as a Society of Toxicology attendee. Carlson 

Wagonlit will find the best fare for you and e-mail an itinerary 

to you. 

Ronald Reagan Washington National 

Airport (DCA) 

Ronald Reagan Washington National Airport (DCA) is 

located in Arlington, Virginia, just across the Potomac 

River from the Nation’s Capital. Reagan National is directly 

linked to the region’s Metrorail system which is adjacent to 

Terminal B/C. For more information, call 703.417.8000 or visit 

www.metwashairports.com/reagan. 

Metrorail: The Washington Metrorail system has an elevated 

Metrorail station connected to the concourse level of terminals 

B and C at Reagan National Airport. Metrorail fare cards 

may be purchased at machines located at all entrances to the 

Airport Metrorail station. The station is also fully accessible 

via elevators. Terminal B and C: Use either of two enclosed 

pedestrian bridges on the concourse level which connect 

directly to the station. Terminal A: Exit the terminal to the 

streetside curb and board any “Airport Shuttle” bus. At the 

stops for Parking Garages B and C (bus shelter #3 and bus 

shelter #5) you may access an enclosed bridge which connects 

to the Metrorail station. 




Taxicabs: Taxicab stands are conveniently located near the 

Arrivals (baggage claim) exits of each terminal. Dispatchers 

at each stand will help you select a taxicab based on your 

destination. Taxis to the SOT Hotels average around $14. 

Washington Dulles International Airport (IAD) 

Washington Dulles International Airport (IAD) is located in 

Chantilly, Virginia, 27 miles from downtown Washington, 

D.C. The airport is connected to the region’s highway system 

via an Authority-operated, 16-mile Airport Access Highway 

dedicated to airport users. For more information, call 

703.572.2700 or visit www.metwashairports.com/dulles. 

Metrorail: Purchase a ticket (one-way or round-trip) at the 

Washington Flyer Coach ticket counter located at Arrivals 

Door #4 in the Main Terminal. Travelers will also board the 

Coach from this location. The buses depart approximately 

every 30 minutes, but please listen for announcements for 

exact bus departure times. The Washington Flyer bus takes 

you to West Falls Church—VT/UVA station on the Orange 

Line. You may purchase a Metrorail fare card inside the 

train station at the West Falls Church Metro stop where you 

will board the train. Trains bound for “New Carrollton” 

will take you towards Downtown Washington, D.C. For 

more information, go to the Washington Flyer Web site at 

www.washfly.com. 

Taxicabs: Washington Flyer Taxicabs serve Dulles 

International Airport exclusively with 24-hour service 

from the airport. Taxicabs accept American Express, 

Diners Club, MasterCard, Discover Card, and Visa, and 

provide transportation at metered rates to any destination 

in metropolitan Washington. Approximate one way fares 

to Washington, D.C., range from $51 to $58. No reservation 

is required. Simply go to the “Taxi Passengers” area on the 

lower level of the Main Terminal, where a Taxicab Dispatcher 

is on duty 24 hours a day. Wheelchair-accessible minibuses 

can accommodate one person in his/her wheelchair plus three 

additional passengers. If paying by credit card, please confirm 

with the driver that credit is accepted before entering the taxi. 

Baltimore Washington International Airport (BWI) 

Baltimore Washington International Airport (BWI) is located 

in Baltimore, Maryland, 30 miles from downtown Washington, 

D.C. For more information call 410.859.7992 or 1.800.I FLY 

BWI (435.9294) or visit www.bwiairport.com. 

Metrorail: BWI Express Metro bus service provides a direct 

connection between BWI and the Greenbelt Metro Station. 

The BWI Express/B30 service runs every 40 minutes, 7 days 

a week to the Greenbelt Metro Station, which is located on 

the Green Line of the Washington Metro System. There are 

two Express Bus Stops. One is located on the lower level of 

the International Concourse and the other stop is located on 

the lower level of Concourse A/B. The B30 will pick you up 

outside at the bus shelter. 

Taxicabs: BWI Airport Taxi is the exclusive supplier of 

taxi transportation services from Baltimore-Washington 

International Airport. No reservations are needed and cabs are 

on-site waiting for you at the curb just outside of the baggage 

claim areas. Many of the vehicles are equipped to transport 

wheelchairs. There are manned service desks located at the 

baggage claim areas at A-Pier and D-Pier. Most cabs accept 

major credit cards. Ask your driver before departure to verify 

that the vehicle is credit card capable. Approximate one-way 

fare to Washington, D.C., is $90. 

Ground Transportation 

Washington, D.C., has one of the safest, cleanest, and most 

efficient transportation systems in the world. Metrorail 

and Metro Bus are the most convenient ways to get around 

Washington, D.C., with its logically laid-out streets and easyto-use 

public transportation system. Washington, D.C., has one 

of the highest ratios of taxis per citizen in the country. Details 

about public transportation in Washington, D.C., are available 

at www.wmata.com. 

SuperShuttle 

SuperShuttle provides ground transportation service between 

all major hotels in Washington, D.C., and Baltimore (BWI), 

Dulles (IAD), and Reagan (DCA) Airports. In order to 

receive an SOT discount of $3 one-way or $7 round trip, go 

to www.supershuttle.com/default.aspx?gc=dgbk2 and 

enter the group discount code DGBK2. You may also call 

in reservations at 800.258.3826 and mention DGBK2. Fares 

are subject to change without notice. Depending on the 

current price of fuel, there may be a fuel surcharge in place. 

Discount is valid for reservations made on the Web site or by 

phone, prepaid by credit card, for travel March 1–20, 2011. 

Note: You do not have to have an advance reservation to ride 

SuperShuttle, but without a reservation, you will pay the full 

fare at the ticket counter. 

Train 

800.872.7245 

Discount Code: X42C-988 

Amtrak offers 10% discount off the lowest available rail fare to 

Washington, D.C., from March 4–15, 2011. Includes travel up 

to three days prior to the convention start date and three days 

following the last day of the meeting. To book your reservation 

call Amtrak at 800.872.7245 or contact your local travel agent. 

Please refer to Convention Fare Code X42C-988 when 

making your reservation. Discount does not apply 

when booking on the Internet. This offer is not valid 

on the Auto Train and Acela service. Offer valid 

with sleepers, business class, or first class seats with 

payment of the full applicable accommodation charges. 

General Info 


53



General Info 

Union Station, 50 Massachusetts Avenue NE, Washington, 

D.C., is home to Amtrak and multiple commuter rail services; 

3.8 million Amtrak passengers travel through D.C., each year. 

For more information, go to www.amtrak.com. 

Metrorail and Metrobus 

The Metro system is the nation’s third-largest (with 5 rail 

lines, 106 miles of track and 86 stations) and the second-most 

utilized transport system (carrying 206 million riders each 

year). For hours, fares, and station information, visit www. 

wmata.com. The Walter E. Washington Convention Center 

even has a dedicated Metro station serviced by the Yellow 

and Green lines and many hotels are conveniently located 

near Metro stations or bus routes. Metro bus runs a total of 

338 routes throughout the city and the greater Washington, 

D.C., area, with more than 485 buses using compressed natural 

gas or a hybrid electric drive system helping to maintain D.C. 

as an eco-friendly city. Metro operates from 5:30 AM to 

MIDNIGHT on weekdays and to 3:00 AM on weekends. 

D.C. Circulator 

D.C. Circulator provides bus routes servicing 2.2 million riders 

each year, connecting Union Station with Adams Morgan, 

Georgetown, Capitol Riverfront, the Washington Convention 

Center and Southwest Waterfront, as well as seasonal service 

around the National Mall. 

Fares range from $1 for passengers, 50 cents for Senior 

Citizens and Disabled persons, and free for children 

under 5 years old. Exact change is required unless 

you are using a SmartTrip Card (rechargeable) or an 

unlimited, multiday, or weekly pass which are available at 

www.commuterdirect.com. 

Five different color route options can get you around 

Washington D.C., and the on-line circulator map can 

suggest restaurants, shopping, attractions and entertainment 

near each bus stop. For hours and route maps, visit 

www.dccirculator.com. 

• Orange line: Georgetown to Union Station 

• Green line: Woodley Park–Adams Morgan–McPherson Sq 

Metro 

• Red line: Convention Center–SW Waterfront 

• Dark blue line: Union Station–Navy Yard via Capitol Hill 

• Light blue line: Rosslyn–Georgetown–Dupont 

Taxis 

Taxicabs are abundant throughout the District of Columbia. 

With more than 6,000 servicing the city, D.C. has one of the 

highest ratios of taxis per person. Taxi cabs are equipped with 

meters. If paying by credit card, please confirm with the driver 

that credit is accepted before entering the taxi. 

SOT Ride Share 

SOT is offering a Ride Sharing Program in conjunction with 

the Annual Meeting. For those that live close enough to the 

Washington, D.C., area or those that do not wish to fly, you 

may want to consider the Ride Share Program. Avoid airport 

hassles by driving and make it easier for other scientists to 

attend by sharing rides. Students especially appreciate ways to 

make the meeting even more economical. 

Once you have registered for the Annual Meeting, you can 

access the Ride Sharing Program on-line at the Annual 

Meeting Web site. You can indicate whether you want to drive 

or be a passenger, and then see a list of others who have signed 

up. You will be responsible for matching your plans with 

another registrant, and removing your names when you have 

travel plans in place. 

Washington, D.C. Area Activities 

Here are just a few of the many popular attractions in 


International Spy Museum 


202.EYE SPY U (393.7798) 

www.spymuseum.org 

The International Spy Museum is the first and only public 

museum in the United States solely dedicated to espionage, 

and the only one in the world to provide a global perspective 

on this all-but-invisible profession. It features the largest 

collection of international spy-related artifacts ever placed on 

public display. The stories of individual spies, told through 

film, interactive, and state-of-the-art exhibits, provide a 

dynamic context to foster an understanding of espionage 

and its impact on current and historic events. In addition to 

the Museum, the Complex includes a Museum Store, private 

dining and event facilities, and two restaurants: Zola and Spy 

City Cafe. 




John F. Kennedy Center for the Performing Arts 


202.467.4600 

www.kennedy-center.org 

National Air and Space Museum 

6th Street and Independence Avenue SW 

202.633.1000 

www.nasm.si.edu/museum/flagship.cfm 

The Kennedy Center, located on 17 acres overlooking the 

Potomac River, is America’s living memorial to President 

Kennedy as well as the nation’s busiest arts facility. Touring 

Kennedy Center productions and its television, radio, and 

Internet broadcasts reach millions around the world. As 

part of the Kennedy Center’s Performing Arts for Everyone 

program, more than 400 free performances are offered each 

year featuring international, national, and local artists. These 

include daily 6:00 PM concerts on the Millennium Stage. 

During March, the Kennedy Center will be featuring Madama 

Butterfly, Shear Madness, and the National Symphony 

Orchestra. 

Library of Congress 

1st Street SE between Independence Avenue and 

East Capitol Street 

202.707.8000 

www.loc.gov 

The Library of Congress is the nation’s oldest federal cultural 

institution and serves as the research arm of Congress. It is 

also the largest library in the world, with millions of books, 

recordings, photographs, maps and manuscripts in its 

collections. 

Mount Vernon Estate and Gardens 

3200 Mount Vernon Memorial Highway, 

Mount Vernon, Virginia 

703.780.2000 

www.mountvernon.org 

The estate, gardens, and farm of George Washington’s Mount 

Vernon totaled some 8,000 acres in the 18th century. Today, 

roughly 500 acres of this historic estate have been preserved 

16 miles south of Washington, D.C., on the banks of the 

Potomac River. Visitors can see 20 structures and 50 acres of 

gardens as they existed in 1799. 

The estate also includes a museum, the tombs of George and 

Martha Washington, Washington’s greenhouse, an outdoor 

exhibit devoted to American agriculture as practiced by 

Washington, the nation’s most important memorial to the 

accomplishments of 18th century slaves, and a collection 

which features numerous decorative and domestic artifacts. 

The National Air and Space Museum on the National Mall in 

Washington, D.C., has hundreds of original historic artifacts 

on display, including the Wright 1903 Flyer, the Spirit of St. 

Louis, the Apollo 11 command module Columbia, and a Lunar 

rock sample that visitors can touch. 

The Museum offers 22 exhibition galleries, the Lockheed 

Martin IMAX Theater, flight simulators, a three-level Museum 

shop, and a food-court-style restaurant. 

National Gallery of Art 

Constitution Avenue NW between 3rd and 9th Streets 

202.737.4215 

www.nga.gov 

The National Gallery of Art, one of the world’s preeminent 

museums, was created for the people of the United States of 

America by a joint resolution of Congress accepting the gift of 

financier, public servant, and art collector Andrew W. Mellon 

in 1937, the year of his death. The Gallery’s collection of some 

116,000 paintings, drawings, prints, photographs, sculpture, 

and decorative arts traces the development of Western art from 

the Middle Ages to the present. 

National Mall and Memorial Parks 

202.426.6841 

www.nps.gov/nama 

The National Mall stretches west from the foot of Capitol Hill 

at the Ulysses S. Grant Memorial to encompass the original 

Mall area, the Washington Monument Grounds, the Tidal 

Basin area, and West Potomac Park before terminating at the 

Watergate Steps behind the Lincoln Memorial. 

National Mall and Memorial Parks includes the 

following icons: 

• National Mall 

• Washington Monument 

• Thomas Jefferson Memorial 

• Lincoln Memorial 

• Franklin Delano Roosevelt Memorial 

• World War II Memorial 

• Korean War Veterans Memorial 

• Vietnam Veterans Memorial 

General Info 


55



General Info 

National Museum of American History 

14th Street and Constitution Avenue NW 

202.633.1000 

www.americanhistory.si.edu 

The Smithsonian’s National Museum of American History 

dedicates its collections and scholarship to inspiring a broader 

understanding of our nation and its many peoples. It creates 

opportunities for learning, stimulates imaginations, and 

presents challenging ideas about our country’s past. 

The Museum collects and preserves more than 3 million 

artifacts—all true national treasures. It takes care of 

everything from the original Star-Spangled Banner and 

Abraham Lincoln’s top hat to Dizzy Gillespie’s angled trumpet 

and Dorothy’s ruby slippers from “The Wizard of Oz.” 

National Museum of the American Indian 

4th Street and Independence Avenue SW 

202.633.1000 

www.nmai.si.edu 

The National Museum of the American Indian is the sixteenth 

museum of the Smithsonian Institution. It is the first national 

museum dedicated to the preservation, study, and exhibition 

of the life, languages, literature, history, and arts of Native 

Americans. Established by an act of Congress in 1989 

(amendment in 1996), the museum works in collaboration 

with the Native peoples of the Western Hemisphere to 

protect and foster their cultures by reaffirming traditions and 

beliefs, encouraging contemporary artistic expression, and 

empowering the Indian voice. 

National Museum of Natural History 

10th Street and Constitution Avenue NW 

www.mnh.si.edu 

The National Museum of Natural History is part of the 

Smithsonian Institution, the world’s preeminent museum and 

research complex. The Museum is dedicated to inspiring 

curiosity, discovery, and learning about the natural world 

through its unparalleled research, collections, exhibitions, and 

education outreach programs. 

National Zoological Park 

3001 Connecticut Avenue NW 

202.633.4800 

www.nationalzoo.si.edu 

The National Zoo is a 163 acre zoological park set amid Rock 

Creek Park in the heart of Washington, D.C. Open to the 

public 364 days a year, it is home to 2,000 individual animals 

of nearly 400 different species. The best known residents are 

the giant pandas, Tian Tian and Mei Xiang. 

U.S. Capitol 

100 Constitution Ave NE 

202.226.8000 

www.visitthecapitol.gov 

The U.S. Capitol is among the most architecturally impressive 

and symbolically important buildings in the world. The Senate 

and the House of Representatives have met here for more than 

two centuries. 

The U.S. Capitol is open to the public for tours Monday 

through Saturday. Tickets are required to tour the U.S. Capitol. 

To guarantee availability, you should reserve your tour in 

advance on-line at www.visitthecapitol.gov or through your 

congressional representative or senator. 

A limited number of same-day tour tickets may also be 

available at the U.S. Capitol Visitor Center. Tickets are not 

required to tour the Capitol Visitor Center, which is open 8:30 

AM–4:30 PM, Monday through Saturday. Visit www.aoc.gov 

for more information. 

White House 

1600 Pennsylvania Avenue NW 

202.456.7041 

www.whitehouse.gov 

Tours of the White House are available by advance 

arrangement through your member of congress or senator. 

Tours are arranged for groups of ten or more, but smaller 

groups and families should not be discouraged from 

requesting to join a tour. You should submit a request 

through your congressperson’s office at least one month 

and up to six months in advance. Visitors who are not U.S. 

citizens should contact their embassy in D.C. about tours 

for international visitors, which are arranged through the 

Protocol Desk at the State Department. The tours are selfguided 

and will run from 7:30 AM until 12:30 PM Tuesday 

through Saturday. You can locate your congressperson’s office 

by visiting www.house.gov. For your senator’s office, visit 

www.senate.gov. 

Washington, D.C. 100 Free 

(and Almost Free) Things 

Take a look at some of the fun, free, and almost free 

experiences that await you in Washington, D.C. Visit 

www.washington.org for more information. 

Dining and Nightlife 

There’s a reason that D.C. is considered one of the most 

exciting restaurant towns in the country. Just footsteps from 

the Walter E. Washington Convention Center, the Penn 

Quarter section of downtown draws lively crowds to some of 




the city’s hottest restaurants, including Oyamel and Brasserie 

Beck, voted two of 2007’s best new restaurants in the country 

by Esquire food critic John Mariani. 

As local chefs and home-grown talent make names for 

themselves, some of the world’s leading chefs have also set up 

shop in the District. Celebrity chefs like Eric Ripert, Wolfgang 

Puck, and Laurent Tourondel have joined local culinary talents 

like Jose Andres, Michel Richard, and Robert Wiedmaier, 

opening new restaurants in the nation’s capital. 

While sleek and stylish hotspots add a new twist to the D.C. 

dining scene, you can’t go wrong by feasting on a steak 

and martini at a classic power dining spot. Rub elbows 

with a Representative or spot a Senator at award-winning 

restaurants like The Palm, Sam & Harry’s, or Capital Grille. 

When celebrities come to town, their destination is often 

Georgetown’s Café Milano. 

If you’re in the mood for more than just a great meal, you’re in 

luck. When the sun goes down, D.C. sizzles with great options 

for nightlife and entertainment. The D.C. music scene is best 

experienced live, and there are plenty of top-notch venues to 

check out. The 9:30 Club packs in crowds nightly and earns 

its reputation as the best live-music venue in the country, 

according to Esquire. In Georgetown, Blues Alley has hosted 

its share of musical greats as the nation’s oldest jazz supper 

club. For a distinctly D.C. live music experience, look for 

go-go, a fusion of African percussion with hints of Latin, jazz, 

funk, hip-hop, and soul that got its start in the District. 

North of the Convention Center, the U Street/Shaw 

neighborhood was once known as “Black Broadway,” a 

popular touring stop for jazz legends like Miles Davis, Cab 

Calloway, and D.C. native Duke Ellington, who was born on V 

Street. Today the neighborhood is a must-see for music history 

buffs and jazz fans who gather for live sets and jam sessions at 

Polly’s, HR-57, Bohemian Caverns, and other venues. 

You can experience D.C.’s international side and travel through 

a global village of casual, affordable restaurants and lively 

bars in Adams Morgan, a neighborhood that’s synonymous 

with late-night entertainment. After dinner, show off your 

salsa moves or sing along to 80s hits at the bars and clubs that 

line 18th Street and Columbia Road. 

Downtown pulses with its own nightlife scene, drawing 

fashionable crowds to restaurants and lounges like the Park at 

Fourteenth, Lima Restaurant and Lounge for chic cocktails, 

mellow music, dancing, and conversation. 

There’s more to D.C. after dark than dinner, drinks and 

dancing. Theatre lovers will discover that there’s almost 

always something playing at the John F. Kennedy Center 

for the Arts, Arena Stage, and downtown venues like the 

Shakespeare Theatre Company, the Woolly Mammoth Theatre 

Company, the Warner Theatre, and the National Theatre. If 

you’re a sports fan, check the calendar at the Verizon Center to 

see who’s playing. Or watch the Washington Nationals take the 

field at the new Nationals Park in Southeast D.C. Group ticket 

rates are frequently available for theatre and sporting events. 

Shopping 

Capitol Hill/Barracks Row 

Metro: Union Station, Capitol South, Eastern Market 

Circulator: East-West route 

The historic neighborhood that sits in the shadows of the 

Capitol dome offers shoppers a mix of nationally-known retail 

outlets and neighborhood specialty boutiques. Take Metro to 

the Eastern Market station and join locals at one of the city’s 

liveliest open-air weekend arts and crafts markets. On 8th 

Street SE, also known as Barracks Row, you’ll discover pet 

shops, antique shops and more. Union Station, D.C.’s glorious 

Beaux-Arts train station, houses dozens of familiar shops like 

Victoria’s Secret, The Body Shop, Ann Taylor, and Nine West. 

Chevy Chase and Friendship Heights 

Metro: Friendship Heights 

One of the most elite addresses in metropolitan Washington, 

Chevy Chase straddles the border of D.C. and Montgomery 

County, Maryland. Take Metro’s Red Line to the Friendship 

Heights station to shop for high-end designer fashions at 

Neiman Marcus, Saks Fifth Avenue and Bloomingdales. A 

new shopping development, the Collection at Chevy Chase, 

attracts discerning shoppers to exclusive boutiques like Jimmy 

Choo, Max Mara, Gucci, and Tiffany. Near the Friendship 

Heights Metro, you’ll also find budget-friendly favorites like 

TJ Maxx and Loehmann’s, along with shopping mainstays like 

J Crew, Pottery Barn, and World Market. 

Downtown 

Metro: Metro Center, Gallery Place-Chinatown 

Circulator: North-South and East-West routes 

D.C.’s downtown has welcomed a wave of development 

in recent years, including the arrival of new shopping 

destinations. Chinatown’s Gallery Place development includes 

popular shops like Urban Outfitters, Aveda, and City Sports. 

Take a walk down F Street to sample gourmet cheeses at 

Cowgirl Creamery or shop for hip fashions at H&M or Zara. 

Stock up on stylish home furnishings at West Elm or browse 

7th Street’s galleries for showpieces by emerging artists. 

Downtown is also home to Macy’s, Filene’s Basement and 

dozens of nationally-known retail outlets. 

General Info 


57



General Info 

Dupont Circle 

Metro: Dupont Circle 

This eclectic, cosmopolitan neighborhood is home to trendy 

galleries, used bookshops and national retail outlets. Pick 

up funky accessories at the Proper Topper, one-of-a-kind 

gift items at the Tiny Jewel Box, or browse gay and lesbian 

literature at Lambda Rising. Get a taste of D.C. after dark at 

Kramerbooks, a late-night bookstore and bar. Travel along 

Connecticut Avenue towards the White House and you’ll pass 

Brooks Brothers, Thomas Pink, and other leading names in 

retail. On Sundays, the neighborhood’s farmers market turns 

the Circle into a veritable feast for the senses. 

Georgetown 

Circulator: East-West route 

Serious shoppers won’t want to miss a trip to Georgetown, 

one of D.C.’s most celebrated shopping destinations. At once 

hip and historic, the neighborhood’s cobblestone streets 

are lined with locally-owned boutiques, antique shops and 

national retail outlets. Well-known chains like Banana 

Republic, Coach, and Restoration Hardware are located in the 

heart of the neighborhood, near the intersection of M Street 

and Wisconsin Avenue. Stroll up Wisconsin Avenue to shop 

independently-owned boutiques like Sassanova, Urban Chic, 

and Piccolo Piggies. On M Street, you’ll find a mix of retailers 

like Intermix and Anthropologie, along with D.C. exclusives 

like Hu’s Shoes and Dawn Price Baby. 

Logan Circle/U Street/Shaw 

Metro: U Street/Afr-Am Civil War Mem’l/Cardozo 

Locally-owned retail rules the shopping scene on 14th and U 

Streets, near Logan Circle. Fun and funky home furnishing 

shops like Go Mama Go! and Home Rule stock playful kitchen 

accessories, tableware, and wearable art. Locals gather at the 

bohemian bookstore and restaurant, Busboys & Poets, to surf 

the Internet, chat about politics, or participate in open mic 

nights. 

For apparel, check out Pink November, Nana, Destination U, 

Lettie Gooch, and other uniquely D.C. shopping destinations. 

Sports and Recreation 

Washington, D.C., is home to six professional sports teams. 

The Washington Nationals (MLB Baseball), The Washington 

Redskins (NFL Football), The Washington Capitals (NHL 

Hockey), The Washington Wizards (NBA Basketball), The 

Washington Mystics (WNBA Basketball), and D.C. United 

(MLS Soccer) offer fans a professional sports experience any 

time of year. 

You can combine your exercise regimen with your sightseeing 

adventures in D.C. by taking part in a walking or bicycle 

tour, designed with active travelers in mind. D.C.’s wide 

sidewalks and flat roads make it perfect for exploring on foot 

or on bicycle; in fact, the District was recently named the most 

pedestrian-friendly city in the U.S. in a study by the Brookings 

Institute. 

With more than 230,000 acres of parkland within the metro 

area, D.C. is a nature-lover’s paradise. If you’re looking for a 

place to picnic or an urban retreat, escape to a beautiful park 

or garden. 

Visitors and locals converge on the capital’s excellent jogging 

trails and beautiful biking routes—more than 800 miles of 

them in the region. Put on your sneakers and check out D.C.’s 

best paths. 

Washington, D.C. Information Desks 

An information desk is located in the Grand Lobby of the 

Convention Center and is staffed from 9:00 AM–5:00 PM 

daily. They can provide information about the Convention 

Center, general information about the city, and suggestions for 

dining. Brochures are also available. They cannot make dining 

reservations. A full listing of restaurants begins on page 32. 

Additionally, guest services staff are strategically located 

throughout the Convention Center. They can assist you 

in navigating the building, verifying and directing you to 

meeting locations, and providing information on things to do 

and places to go while visiting the city. As a part of the Public 

Safety Team, they also report safety hazards and suspicious 

activities. 

March 11–15, 2012 

51 st Annual Meeting 

and ToxExpo 

California 

San Francisco 

California 

San Francisco is the host city for SOT’s 2012 Annual Meeting, March 11–15. 

Be sure to visit the San Francisco Travel Association Booth located in the 

Registration Area for more information. 


SOT Job Bank 

YOUR RECRUITMENT AND EMPLOYMENT RESOURCE 

Job Seekers—Jobs await You in the SOt Job Bank!!! 

Employers are looking for Candidates through this Service 

and You don’t Want to Be left Out 

• all SOt Members can utilize the SOt Job Bank as 

a job seeker free-of-charge. 

• register and enter your candidate profile; 

it only takes 15 minutes to complete. 

• Post your resume. 

• review the positions posted by major 

corporations, academic institutions, 

government agencies, and private research 

organizations; positions range from junior to 

senior level. 

• Search by geographic location, employer name, 

salary, and other criteria. 

• Find potential matches to your skills and 

training at any stage of your career. 

• apply for positions. 

• Gain access to information that will help you 

plan your near-term and long-term goals and 

objectives. 

• See which sectors are hiring. 

• Stay abreast of new and emerging areas. 

Employers—recruit Highly Qualified Candidates 

through the SOt Job Bank!!! 

the SOt Job Bank is the Ideal Place to Streamline Your recruitment Process and 

Provides Your Organization with a valuable tool 

• Search from a pool of distinguished candidates. 

• Join the many employers who rely on this costeffective 

and efficient database to assist with 

their employment needs. 

• Find the right candidate from among scientists 

trained in toxicology and the biological sciences 

with the expertise and right work experience for 

your position. 

• Schedule interviews to hold during the SOt 

annual Meeting at the on-site Job Bank Center. 

• reserve interview rooms in advance or on-site. 

• SOt affiliates receive a reduced registration rate 

in appreciation for supporting the Society in 

achieving its objectives. 

The On-Line SOT Job Bank is available any time, from any place 

at www.toxicology.org/jobbank 


59


Career Resources and Development Services 

The Society of Toxicology’s Career Resource and Development 

(CRAD) services include the on-line Job Bank, special Job 

Bank activities at the Annual Meeting, career development 

seminars and resources, and employer ads in SOT’s newsletter, 

the Communiqué, which reaches the entire SOT membership 

and beyond. 

On-Line Mentor Match Program 

Career Planning is Never Over: Lend a Hand or 

Receive One at Mentor Match! 

The Society of Toxicology recognizes the importance of 

mentoring in the scientific and professional development of its 

members. The objective of the new on-line mentoring program, 

Mentor Match, is to provide a service that matches mentees 

with potential mentors from the SOT membership to provide 

advice on career path selection, professional development, 

and life/work balance issues. SOT members are encouraged 

to share their professional knowledge and experience by 

serving as mentors for colleagues and for the next generation 

of toxicologists. The SOT Annual Meeting provides a great 

opportunity for the mentor and mentee to meet in person. We 

strongly encourage members of the Society to visit the Mentor 

Match site and register on-line as mentors and/or mentees. The 

Mentor Match program will develop as individuals register, 

allowing the quantity of profiles to increase to a robust 

combination of both mentors and mentees. The Mentor Match 

program is accessible to all active SOT members by visiting 

www.toxicology.org/ai/newcrad/mentormatch.asp. 

to provide them with a robust database of candidates available 

for career opportunities, ranging from junior- to senior-level 

positions. 

The Job Bank helps streamline the process for candidates and 

employers. Candidates can gain access to a variety of positions 

suited to their experience, areas of expertise, and desired 

geographical location. In addition, job seekers can see which 

sectors are hiring and stay abreast of new and emerging areas. 

Employers can attract potential candidates in a targeted 

and cost-effective manner through this SOT service. By 

having access to detailed candidate resumes, employers can 

determine the right match for a specific position and expedite 

the recruitment process. SOT Corporate Affiliates receive 

a reduced rate for position posting in appreciation for 

supporting the Society in achieving its objectives. 

Job Seeker Registration 

for SOT On-Line Job Bank 

Candidate Types 

Fees 

SOT Member $ 0 

Non-SOT Member $80 

Non-SOT Member—Postdoctoral $45 

Non-SOT Member—Student $30 

CarEEr ServICES 

SOT On-Line Job Bank 

Take Advantage of This Free Member Benefit 

SOT Members can register as a job seeker and access the 

positions posted on the Job Bank at no charge. 

The Society’s on-line SOT Job Bank makes it easy for 

candidates and employers alike to access this resource 

year-round, any time, any place via the SOT Web site at 

www.toxicology.org/jobbank. 

This forum links job candidates with employment positions in 

toxicology and related biological sciences. The SOT Job Bank 

allows you to: 

• Register as an employer or candidate 

• Post employment positions 

• Search the Job Bank database 

• Contact candidates or employers 

The on-line Job Bank lists positions available at corporations, 

academic institutions, government agencies, and private 

research organizations. Employers rely on this on-line service 

Employer Registration 

for SOT On-Line Job Bank 

Employer Types 

Fees 

SOT Affiliate $200 

Corporation $400 

University or Government $110 

Nonprofit Organization $110 



Career Resources and Development Services (Continued) 

Annual Meeting On-Site Job Bank Center 

Located in the Walter E. Washington Convention Center, the 

on-site Job Bank Center provides Annual Meeting attendees 

with access to the SOT Job Bank system as well as assistance 

in facilitating interviews at the SOT Annual Meeting. All 

users with current registrations at the time of the Annual 

Meeting will be permitted to use this service. 

A bank of computers will be available in the SOT Job Bank 

Center for last minute updates to your account information 

or posting, as well as printers for producing paper copies of 

candidate profiles and position descriptions. If you are a 

candidate attending the Annual Meeting, you should bring 

multiple copies of your personal resume for interested 

interviewers. All candidates and positions will be sought 

on-line. 

Employers recognize and appreciate that the Annual Meeting 

On-Site Job Bank Center provides a cost-effective and 

efficient way to interview a distinguished pool of candidates. 

Employers and candidates may take advantage of the multiple 

spaces available in Rooms 157 and 158 for interviews. Some 

rooms were available to be scheduled in advance, and others 

are on a first-come, first-served basis. To ensure privacy for 

candidates, the SOT Job Bank Center is located away from the 

scientific sessions. Also, the Job Bank interview rooms will 

be fitted with modular hard walls to increase privacy when 

interviews are conducted. 

It is up to the registrants of this service to exercise the 

confidentiality options that are offered. SOT is not responsible 

if any information contained in the Job Bank database is 

released. 

Although you are encouraged to pre-register before entering 

the Job Bank Center, you can register on-site in Rooms 157 

and 158. 

The Center is available during the following 

hours of operation: 

Sunday, March 6.......................................... 1:00 PM–4:30 PM 

Monday, March 7........................................ 9:00 AM–4:30 PM 

Tuesday, March 8........................................ 8:30 AM–4:30 PM 

Wednesday, March 9.................................. 8:30 AM–4:30 PM 

On-line Job Bank access will be available—as always— 

through your personal computer and at the Annual Meeting 

E-mail Center. Access to the on-line Job Bank in the Center is 

limited to short searches for updates or new information. 

For additional information, contact John Bae at SOT 

Headquarters: 703.438.3115 ext. 1660 or e-mail: johnb@ 

toxicology.org. 

Employer Ads in SOT Communiqué 

The Society’s newsletter, the Communiqué, is published four 

times annually. It includes career opportunity advertisements 

for employers from corporate, university, governmental, 

and nonprofit organizations wishing to reach the entire SOT 

membership and beyond. For more information, contact 

Marcia Lawson at SOT Headquarters: 703.438.3115 ext. 1446 

or e-mail: marcia@toxicology.org. 

SOT’s Career Development Program Track 

To help you develop your near-term and long-term career 

pathway, plan on attending the Education-Career Development 

Sessions scheduled this year that will be of special interest to 

you. Sessions include the following: 


Toxicologists—Monday, March 7, 12:10 PM–1:30 PM, 

Room 147 

• From Pilot Grants to High-End Journals: The Science of 

Writing—Wednesday, March 9, 6:30 AM–7:50 AM, 

Room 144 

• Polishing Today’s Job Candidate in a Tough Economy— 

Wednesday, March 9, 1:30 PM–4:15 PM, Room 202A 

• Bringing Toxicology to the Decision-Makers Table: 

Opportunities for Science Policy Positions in Washington, 

D.C.—Thursday, March 10, 6:30 AM–7:50 AM, Room 145 

CarEEr ServICES 


61

SOT Encourages the Recruitment of Undergraduates to Toxicology 

Undergraduates can sign up on the SOT Web site for special status 

as Undergraduate Student Affiliates 

Special Programs for Undergraduates at the SOT Annual Meeting 

These are coordinated by the SOT Education Committee and 

Committee on Diversity Initiatives. 

• Undergraduate Education Program for students from groups 

underrepresented in the sciences and their advisors 

• Undergraduate Education Program for students at institutions that 

receive low federal funding in science, math, engineering, and technology 

• Pfizer Undergraduate Student travel award for outstanding students 

presenting abstracts 

Support for toxicology career presentations through the ToxScholar 

and Guest Lecturer Programs 

Toxicologists receive travel support for visits to campuses to present seminars 

and meet informally with students to introduce toxicology and discuss career 

pathways. Funds are also available for international career presentation. 

SOT Recognizes Undergraduate Educators 

Endowment Fund 50th Anniversary 

Undergraduate Educator Award 

—Joan B. Tarloff— 

Find more information at 




SOT 2011 Award Recipients 

Achievement Award 

Arnold J. Lehman Award 

SPECIal Events 

Nathan 

Cherrington 

Nathan Cherrington, Ph.D., 

Associate Professor of Pharmacology 

and Toxicology, College of Pharmacy, 

and Associate Professor, Community 

Environment and Policy Division, Mel 

& Enid Zuckerman College of Public 

Health, University of Arizona, is the 

recipient of the SOT 2011 Achievement 

Award for his significant early career 

contributions to toxicology. 

Dr. Cherrington’s research focuses 

primarily on the role of disease 

states such as non-alcoholic steatohepatitis in the interindividual 

variability in drug metabolism and disposition. 

He has also extended his interest to examine the critical 

role that transporters play in the blood-testis barrier. 

Dr. Cherrington’s acclaim as an expert in transporter 

research has resulted in his inclusion as a member of various 

NIH Study Sections (NIDDK, NCCAM, XNDA, HBPP). 

For his studies, he has garnered support from NIH (NIDDK, 

NIAID, NICHD, NIEHS) and the Arizona State Disease 

Control Commission, as well as industrial support from 

AstraZeneca. The value of his research studies are further 

demonstrated in the competitive awards that his students 

have received via pre-doctoral NIH Awards and in student 

poster sessions at regional and national SOT meetings, 

including both Mechanisms and Drug Discovery Toxicology 

Specialty Sections. 

Dr. Cherrington is an active member of SOT, serving on 

the Committee on Diversity Initiatives as well as having 

Regional Chapter assignments. He also serves on the 

Editorial Boards of Toxicological Sciences and other 

prominent journals in the field. He is an outstanding teacher 

and a prodigious author with numerous articles and a book 

chapter to his credit. 

Dr. Cherrington earned his B.S. from Brigham Young 

University (1993), a Ph.D. in Toxicology from North 

Carolina State University (1997) with Ernst Hodgson, 

and completed a successful postdoctoral fellowship at 

the University of Kansas Medical Center (2002) with 

Curtis Klaassen. He was recruited to the University 

of Arizona as an Assistant Professor in 2002 where, 

in addition to his current responsibilities as Associate 

Professor, he serves as the Director of the Pharmacology- 

Toxicology Graduate Program and as a Council member 

of the University’s Graduate College. For the significant 

contributions to toxicology that he has made in the 

early stages of his career, the Society of Toxicology is 

pleased to present the SOT 2011 Achievement Award to 

Dr. Nathan Cherrington. 

Bette Meek, Ph.D., is recognized as 

the 2011 Arnold J. Lehman Award 

recipient for her contributions to risk 

assessment and regulation of chemical 

agents. 

Dr. Meek is Associate Director, 

Chemical Risk Assessment, 

McLaughlin Centre for Population 

Health, University of Ottawa, having 

recently completed an Interchange 

Bette Meek 

from Health Canada, where she 

continues to develop opportunities for 

mutually beneficial interactions among the regulatory and 

academic communities and agencies such as the World 

Health Organization regarding health risk assessment, risk 

management, and risk communication. 

Widely recognized as a major driving force for the 

development and application of new technologies and 

approaches for improving the practice of human health risk 

assessment, Dr. Meek is especially distinguished as one of 

the key individuals who have consistently led international 

efforts to move human health risk assessment forward 

scientifically. A prime example of her leadership has been 

her role in fostering the use of science-based methods 

including weight of evidence frameworks for incorporation 

of mode of action information and pharmacokinetic data and 

physiologically based pharmacokinetic (PBPK) modeling 

for determining the relationship between external exposure 

and internal (target tissue) exposure. 

A tireless, motivated, and committed contributor and 

leader, Dr. Meek has clearly demonstrated sustained and 

outstanding contributions to the knowledge and practice of 

hazard characterization, dose response assessment, exposure 

assessment and risk characterization. Her efforts have led to 

major progress in the use of new methodologies in the health 

assessments conducted by Health Canada, and, through her 

work for national and international agencies, around the 

world. Among other attributes Bette is articulate, erudite, 

humorous, forward thinking, tenacious, and steely, making 

her a savvy opponent in any argument using well thought 

out, logical, and consistent thinking with the latest science 

or the appropriate application of the newer methods. 

Dr. Meek has moved the field of regulatory toxicology and 

risk assessment significantly forward though innovative 

thinking and principled risk assessment practice. In 

recognition of her achievements, the SOT Awards Committee 

is pleased to announce Dr. Bette Meek as the recipient of the 

2011 Arnold J. Lehman Award. 


63



SOT 2011 Award Recipients (Continued) 

Best Postdoctoral Publication Awards 

The Postdoctoral Assembly recognizes these three 

recipients of their 2011 awards: 

Dieldrich S. 

Bermudez 

Joshua A. 

Harrill 

Jordan Ned 

Smith 

Dieldrich S. Bermudez, Ph.D., 

U.S. EPA/NCSU, Raleigh, NC 

Bermudez, D.S., Gray, L.E., 

and Wilson, V.S. 

Modeling the Interaction of Binary 

and Ternary Mixtures of Estradiol 

with Bisphenol A and Bisphenol AF 

in an In Vitro Estrogen-Mediated 

Transcriptional Activation Assay 

(T47D-KBluc) 

Toxicological Sciences 2010, 116 (2): 

477–487 

Joshua A. Harrill, Ph.D., U.S. EPA, 

Research Triangle Park, NC 

Harrill, J.A., Freudenrich, T.M., 

Machacek, D.W., Stice, S.L., 

and Mundy, W.R. 

Quantitative Assessment of Neurite 

Outgrowth in Human Embryonic 

Stem Cell Derived hN2 Cells Using 

Automated High-Content Image 

Analysis 

Neurotoxicology 201, 31(3):277–90 

Jordan Ned Smith, Ph.D., Pacific 

Northwest National Laboratory, 

Richland, WA 

Smith, J. N., Wang, J., Lin, Y., and 

Timchalk, C. 

Pharmacokinetics of the Chlorpyrifos 

Metabolite 3,5,6-Trichloro-2-Pyridinol 

(TCPy) in Rat Saliva 

Toxicological Sciences 2010, 

113(12):315–325 

Board of Publications Award for the Best 

Paper in Toxicological Sciences 

The Board of Publications has selected 

the paper entitled “Distribution of DNA 

Adducts Caused by Inhaled 

Formaldehyde Is Consistent with 

Induction of Nasal Carcinoma but Not 

Leukemia” as the best paper published 

in Toxicological Sciences in the past 

year (Toxicol. Sci. 2010, 116: 441–451). 

The authors of the paper are Kun Lu, 

Leonard B. Collins, Hongyu Ru, Edilberto Bermudez, and 

James A. Swenberg. 

In this paper, the authors used high performance liquid 

chromatographic-electrospray ionization-tandem mass 

spectrometry methods with selective ion monitoring 

(LC-ESI-MS/MS-SRM) to quantify formaldehyde-DNA 

adducts in various tissues. Furthermore, by exposing rats 

to [ 13 CD 2 

]-formaldehyde, they distinguished endogenous 

formaldehyde-DNA adducts from those resulting from 

inhalation exposure. With this approach, the authors 

determined that DNA adducts in the respiratory nasal 

epithelium resulting from exogenous exposure to 

formaldehyde (10 ppm; 5 days at 6 hr/day) were similar in 

abundance to those formed via endogenous formation of 

formaldehyde. The relative abundance of the exogenous and 

endogenously-formed adducts is notable new information 

as no previous research differentiated the precise source 

of DNA damage in the nose, and confirmation of DNA 

adducts from [ 13 CD 2 

]-formaldehyde support a causal role 

for genotoxicity in nasal carcinoma. In addition, whereas 

adducts from the inhaled stable-labeled formaldehyde were 

detected in the nasal epithelium, no adducts attributed to 

exogenous exposure to formaldehyde were detected in other 

tissues, including bone marrow. These observations offer 

important perspective on whether DNA adducts can be 

associated with the potential risk of formaldehyde-induced 

leukemia. 

The paper is being recognized because it provides important 

new data that is both timely and salient to enhancing the 

mechanistic understanding of the carcinogenic mode 

of action of inhaled formaldehyde in respiratory nasal 

epithelium. The results are also directly applicable to 

improving the scientific basis of human health risk 

assessment. 

SOT Sponsored Awards 




Oliver 

Hankinson 

Distinguished Toxicology Scholar Award 

Oliver Hankinson, Ph.D., Professor, 

Department of Pathology and 

Laboratory Medicine, and Director, 

Interdepartmental Doctoral Program 

in Molecular Toxicology, at the 

University of California, Los Angeles, 

is the recipient of the 2011 

Distinguished Toxicology Scholar 

Award. 

For over thirty years, Dr. Hankinson 

has had a record of making seminal 

contributions to research in 

Toxicology. One of his most outstanding contributions being 

the identification, cloning and functional characterization 

of the Aryl Hydrocarbon Receptor Nuclear Translocator 

(ARNT) protein, which presaged a transformational 

explosion in our understanding of the mechanisms of 

2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin) and polycyclic 

aromatic hydrocarbon carcinogenesis and toxicity, and the 

organism’s response to hypoxia. 

Dr. Hankinson is the founding and current Director of the 

UCLA Molecular Toxicology interdepartmental Ph.D. 

program (IDP). In 2000 he secured a training grant for 

the Molecular Toxicology program from the University 

of California Toxic Substances Research and Teaching 

Program (UC TSR&TP). This grant was considered seed 

funding, and expired in June, 2008, when he was awarded 

a training grant in Molecular Toxicology from the National 

Institutes of Environmental Health Sciences (NIEHS) in 

July, 2008. The NIEHS grant supports 4 pre-docs and 2 

postdocs. This was the only new training grant awarded by 

the NIEHS in 2008. 

The research of Dr. Hankinson’s laboratory has provided, 

and continues to provide, fundamental insights into the 

mechanisms whereby mammals respond to chemical 

carcinogens and hypoxia. For example, his recent research 

has documented roles for coactivator proteins and for 

chromatin modification during the activation of gene 

transcription by dioxin and hypoxia. The observations his 

group has made are highly relevant to diseases responsible 

for a major proportion of human mortality in the U.S.A, 

including cancer, heart attack, stroke, asthma and chronic 

lung disease. Furthermore, his laboratory has been an 

important source of reagents for other research groups. 

In recognition of his substantial and seminal scientific 

contributions to our understanding of the science of 

toxicology, Dr. Hankinson is presented the 2011 SOT 

Distinguished Toxicology Scholar Award. 

Distinguished Toxicology Scholar Award Lecture: 



Tuesday, March 8, 12:15 PM–1:05 PM, Room 201 

Education Award 

Michael Gallo, Ph.D., ATS, DABT, 

Professor, Environmental and 

Occupational Medicine; Adjunct 

Professor, Pharmacology and 

Toxicology, and Member of the 

Graduate Faculty, Rutgers College of 

Pharmacy, is the recipient of the SOT 

2011 Education Award. Professor 

Gallo continues to enjoy a long and 

distinguished career in Toxicology. His 

Michael Gallo pre-doctoral and postdoctoral training 

were conducted at the Albany Medical 

School of Union University, Albany, New York, under the 

tutelage of Professor Fred Coulston, a Founding member 

and Past President of the SOT. 

Having begun his career in 1972 as a toxicologist in 

the drug industry, he was appointed Director of the 

Toxicology Division in the Department of Occupational and 

Environmental Medicine at the Rutgers (now Robert Wood 

Johnson) Medical School of the University of Medicine and 

Dentistry of New Jersey (UMDNJ), New Brunswick , NJ, 

in 1980. Most of his research career has focused on dioxin, 

its receptor, and its biological activities and he has authored 

more than 90 research articles. Among his most significant 

contributions to toxicology are as a mentor and role model 

to graduate students. Among his many accomplishments, he 

was instrumental in the inception, development, and success 

of the Joint Graduate Program in Toxicology sponsored by 

Rutgers the State University of New Jersey and the Robert 

Wood Johnson Medical School of UMDNJ, which has 

successfully graduated more than 100 Ph.D. candidates in 

Toxicology. 

Professor Gallo’s educational activities go beyond the 

university. He has been very active in resurrecting the 

the Gordon Conference on Toxicology, one of the most 

important educational opportunities available to the 

toxicological community. He has also served on numerous 

national committees, including NAS/NRC Committees, the 

EPA Science Advisory Board, and the National Toxicology 

Program Board of Scientific Counselors, among others. 

He brings his experiences on these panels directly to the 

students to insure that they have an appreciation of the part 

that their own research may play in deciding upon national 

policies relating to chemicals. 



65




As he truly represents the best and most important aspects 

of the toxicology educator, the Society is pleased to name 

Dr. Michael Gallo the recipient of the SOT 2011 Education 

Award. 


50th Anniversary Undergraduate 


Joan B. Tarloff, Ph.D., Professor, 

Department of Pharmaceutical 

Sciences, Philadelphia College of 

Pharmacy, University of the Sciences in 

Philadelphia, is the recipient of the 2011 

SOT Endowment Fund 50th 

Anniversary Undergraduate Educator 

Award. 

Throughout her career, Dr. Tarloff has 

exemplified the philosophy that in order 

Joan B. Tarloff to build for the future of toxicology, 

one must first excite the students 

at the undergraduate level. As one of the few programs 

offering a B.S. level program in toxicology, the University 

of the Sciences in Philadelphia (USP) has provided many 

opportunities for Dr. Tarloff to influence undergraduates. She 

has been active in shaping this program, especially the core 

coursework in Biochemical Pharmacology and Toxicology, 

Research Techniques in Pharmacology and Toxicology 

and Biomethods in Pharmacology and Toxicology, and has 

served as Program Director from 1988 to 1996. 

Dr. Tarloff traditionally has carried a heavy teaching load for 

several course classes at USP. She is the course coordinator 

and a lecturer for Pharmacology I and II, and is an integral 

lecturer in Physiology, with approximately 20 contact hours 

teaching in renal physiology. In addition, Dr. Tarloff is a 

course coordinator and lecturer for Principles of Medicinal 

Chemistry and Molecular Pharmacology. 

Dr. Tarloff is consistently accessible and works with the 

students to solidify concepts that are critical to their success 

as pharmacists and scientists. For those students in the 

Pharm/Tox program, Dr. Tarloff invests additional time 

mentoring them, preparing them for careers and encouraging 

them to pursue graduate degrees. Dr. Tarloff also has an 

active research program and has received NIH grant support. 

She inspires people, and this is evident in the quality of her 

former students that have completed graduate school. 

Dr. Tarloff has also been active in the Society of 

Toxicology, serving in the Mechanisms Specialty Section, 

and the Communications Committee. In appreciation and 

recognition of her achievements, the Society is pleased to 

present Dr. Joan Tarloff with the 2011 SOT Endowment 

Fund 50th Anniversary Undergraduate Educator Award. 

Joseph 

Borzelleca 

Founders Award 

Joseph Borzelleca, Ph.D., is presented 

the SOT 2011 Founders Award in 

recognition of his outstanding 

leadership in fostering the role of 

toxicological sciences in safety 

decision-making through the 

development and application of stateof-the-art 

approaches that elucidate, 

with a high degree of confidence, the 

distinctions for humans between safe 

and unsafe levels of exposures to 

chemical and physical agents. 

One of the early leaders in the Society and an enthusiastic 

participant in all of its affairs, Dr. Borzelleca has served 

as a Councilor, Secretary, and President (1973–1974) of the 

Society. 

As an effective and persuasive spokesman for our 

discipline, he has represented SOT and our discipline in 

various governmental agencies—including the Food and 

Drug Administration, Environmental Protection Agency, 

National Cancer Institute, Occupational Safety and Health 

Administration and National Institute for Mental Health 

—and has been a vigorous proponent for good science 

and toxicology in several prominent roles in the National 

Academy of Sciences, the World Health Organization and a 

variety of other national and international organizations. 

He has served as the editor of Food and Chemical 

Toxicology since 1992 and is on the editorial board of 

nine other journals. His contributions to food safety are 

especially noteworthy. A review of his many publications 

in the peer-reviewed literature reveals many that deal with 

food additives or contaminants. His work did not stop with 

the publication of the results of well-designed and conducted 

studies. He regularly took the next step and championed 

the use of the science in safety evaluations. He personally 

contributed to evaluations of the health aspects of over 100 

compounds used as food ingredients or having the potential 

to contaminant foods. 

A passionate and dedicated teacher of graduate and medical 

students and an advocate for toxicology in all of his many 

scientific activities, Dr. Borzelleca is recognized both 

nationally and internationally as a distinguished expert in 

food toxicology. He is a mentor to his fellow toxicologists, an 

example to follow for his students and a joy for all who know 

and work with him. 




For his extraordinary achievements and contributions to 

ensuring the safety of food, the Society recognizes Joseph 

F. Borzelleca as the 2011 Founders Award recipient. His 

career epitomizes the use of toxicological science to create 

a healthier world. 


In recognition of his accomplishments and impact on the 

field of toxicology, the Society of Toxicology recognizes 

Dr. Masayuki Yamamoto with the SOT 2011 Leading Edge 

in Basic Science Award. 

Leading Edge in Basic Science Award Lecture: 

Roles of Keap1-Nrf2 in Environmental Response, 

Tuesday, March 8, 7:00 AM–7:50 AM, Room 201 


Masayuki 

Yamamoto 

Masayuki Yamamoto, M.D., Ph.D., is 

awarded the 2011 SOT Leading Edge 

in Basic Science Award for his 

discovery and characterization of the 

Keap1-Nrf2 signaling pathway, a 

seminal scientific advance that is 

having a profound and pervasive 

impact on the field of toxicology. 

Currently Vice President, Tohoku 

University, and Dean of the Tohoku 

University Graduate School of 

Medicine, Sendai, Japan, he is an 

incredibly productive scientist, 

publishing regularly in high impact journals. 

Over the past decade, the transcription factor Nrf2 has 

become recognized as a master regulator of adaptive 

responses to oxidative and electrophilic stresses. Expression 

levels, polymorphisms and mutations in the pathway all 

affect susceptibility of mammals to a wide range of toxicants. 

Dr. Yamamoto has been at the forefront of defining both the 

molecular details of signal transduction via Nrf2 and the 

mechanisms underlying cell survival via this pathway. He 

and his colleagues have recently used the tools of molecular 

biology, mouse genetics and structural biology to describe 

the intricate details of how chemical signals are transduced 

through Keap1 to allow Nrf2 to accumulate in the nucleus 

and activate or repress its target genes. 

Dr. Yamamoto has identified and characterized to a 

remarkable level of depth in a short period a signaling 

pathway that influences the toxicological responses of a wide 

range of agents. The importance of this pathway in human 

disease, especially that with underlying environmental 

etiologies, is only beginning to emerge, but will be a topic of 

intense investigation over the next few years. 

Dr. Yamamoto has clearly shown his dedication to basic 

toxicological research throughout his scientific career. He 

has published more than 400 research articles, including 

199 Nrf2 papers, in which 113 are toxicology related. He 

continues to make seminal and significant contributions 

to the Nrf2 field, having published 124 papers (71 with 

toxicology topics) in the past five years alone. 

Merit Award 

Michael Aschner, Ph.D., ATS, is the 

recipient of the 2011 SOT Merit Award 

in recognition of his distinguished 

contributions to toxicology throughout 

his career. He is currently the Gray E. 

B. Stahlman Chair of Neuroscience 

and Full Professor of Pediatrics and 

Pharmacology at Vanderbilt University 

Medical Center, where he also directs 

the Division of Pediatric Clinical 

Michael Aschner Pharmacology and Toxicology and 

serves as a Senior Scientist in the 

Kennedy Center for Research on 

Human Development. 

Dr. Aschner is a worldwide authority in the field of metal 

neurotoxicity, particularly with regard to methylmercury 

and manganese. Over the years, he has characterized the 

molecular mechanisms of methylmercury neurotoxicity, 

particularly in glial cells. His pioneer work has allowed 

shifting the “neuronocentric” theory of neurotoxicity to 

the understanding of the important roles that glial cells 

play in modulating the neurotoxicity of this organometal 

and of other compounds. His research in this area has been 

supported continuously by NIEHS for the past twenty years, 

and his major R01 grant on this topic was recently renewed 

for another five years. 

In addition to another NIEHS grant that has supported 

his research on manganese over the years, Dr. Aschner 

has also served as the Principal Investigator of a major 

Department of Defense Research Program (Manganese 

Health Research Program) which has funded his research 

as well as that of several other laboratories under his 

guidance and administration. He has also made many other 

innovative contributions in related fields, showing his ability 

to identify new trends and needs in neurotoxicology. His 

early recognition of the potential of “omics” technologies in 

neurotoxicology has led to important and thought-provoking 

commentaries on this topic. An extremely productive 

scientist, he has authored almost 300 peer-reviewed 

publications, dozens of book chapters, and several books, 

among other publications. 


67




Dr. Aschner’s contributions to toxicology go beyond his 

successful research and mentoring of students and younger 

colleagues; his service to the profession, and organizations 

involved in toxicology and risk assessment, including the 

Society of Toxicology, have been highly remarkable. It 

is a distinct pleasure to honor and recognize Dr. Michael 

Aschner with the 2011 SOT Merit Award. 

Merit Award Lecture: Living with Passion— 

Neurotoxicology Goes Global: Scientific Collaboration 

and Mentorship, Monday, March 7, 12:15 PM–1:05 PM, 

Room 201 

Eva A. 

Amouzougan 

Perry J. Gehring 

Diversity Student Travel Award 

Eva A. Amouzougan, 

Boise State University, Boise, ID 

Abstract Number: 1855 

Poster Board Number: 139 

Abstract Title: Regulation of 

Carbonyl Reductase Activity by Ah 

Receptor Ligands 

SOT/AstraZeneca/IUTOX Travel 

Fellowship 

Sonali Das, Ph.D., Strand Life Sciences Pvt. Ltd., 

Bangalore, India 

David K. Essumang, M.Phil., University of Cape Coast, 

Cape Coast, Ghana 

Rawiwan Maniratanachote, Ph.D., National 

Nanotechnology Center, Klong Luang, Thailand 

Anoka A. Njan, Ph.D., Aiida-4 Medical Consultants, 

Abuja, Nigeria 

Osman S. Shaik, Ph.D., Strand Life Sciences Pvt. Ltd., 

Bangalore, India 

Songsak Srianujata, Ph.D., Institute of Nutrition, Mahidol 

University, Bangkok, Thailand 

Dexter Tagwireyi, Ph.D., University of Zimbabwe, Harare, 

Zimbabwe 

Qinli Zhang, Ph.D., Shanxi Medical University, Taiyuan, 

China 

Bin Zhao, Ph.D., State Key Laboratory of Environmental 

Chemistry and Ecotoxicology, Beijing, China 

SOT Endowment Fund/ 

IUTOX Travel Fellowship 

Daam Settachan, Ph.D., Chulabhorn Institute, Bangkok, 

Thailand 

Omoniyi Kayode Yemitan, Ph.D., State University College 

of Medicine, Lagos, Nigeria 





Translational Impact Award 

Weida Tong, Ph.D., Director, Center 

for Bioinformatics, Division of 

Systems Biology, National Center for 

Toxicological Research (NCTR), Food 

and Drug Administration, is the 2011 

Translational Impact Award recipient. 

Dr. Tong is internationally recognized 

for his leadership in the area of 

computer modeling and bioinformatics 

which are areas critical to the 

Weida Tong development of “omic” biomarkers. 

These evolving classes of biomarkers 

generate large quantities of data which 

must be digested and translated into useful information for 

risk assessment purposes. One clear example of his 

leadership in this area as the Director of the Center for 

Bioinformatics in the Division of Systems Biology, NCTR, 

has been the development of the Array-Track system for 

managing genomic data sets which has gained acceptance 

and been adopted by a number of Federal agencies, 

universities, and the private sector. With this software, FDA 

has been able to analyze animal and clinical genomic data 

submitted as part of the Voluntary Genomic Data 

Submissions (VGDS) process and in regulatory filings. This 

system, developed under his leadership, has hence had a 

major public health impact as a translational tool for 

genomic data sets. 

Dr. Tong has been involved in many cross-agency and 

intra-FDA center efforts. His ability to work between the 

realm of molecular biology and computational methods 

has been critical to the ongoing success of interagency/ 

interdisciplinary collaborative projects involving scientists 

from U.S. FDA, ATSDR, U.S. EPA, and NIH/NCGC. 

Dr. Tong has a long history of successfully organizing large 

groups of individuals from different backgrounds to address 

areas of common concern relevant to the use of genomic data 

in translational medicine. He is well-known and respected 

within the genomics community and has been invited 

to present at many national and international meetings. 

Based on his exemplary leadership and accomplishments 

and considerable contributions, the Society recognizes 

Dr. Weida Tong as the recipient of the 2011 SOT 

Translational Impact Award. 

Translational Impact Award Lecture: Integration of 

Bioinformatics into Regulatory Decision Making, 

Wednesday, March 9, 12:15 PM–1:05 PM, Room 151 

Creating a Safer and Healthier World 

by Advancing the Science of Toxicology 

Do you know a toxicologist 

who deserves to be recognized? 

SOt recognizes distinguished 

toxicologists and students with many 

prestigious awards each year. 

In addition to receiving the specific award, 

recipients are honored at a special 

awards Ceremony at the 

SOt annual Meeting and their names are 

listed in SOt publications. 

Most award nominations and applications 

are submitted through a quick on-line 

process. 

Applications for 2012 national 

SOT awards are due October 9, 2011. 

Regional Chapter Awards, 

Special Interest Group Awards, and 

Specialty Section Awards have various 

deadlines throughout the year. 

visit the awards and Fellowships section 

of the Web site for award descriptions, 

additional information, and 

to make nominations. 



69



2011 Award Recipients 

AstraZeneca Traveling Lectureship Award 

Saber Hussain, Ph.D., ATS, is the 

2011 AstraZeneca Traveling 

Lectureship Award recipient. The 

award recognizes excellence in 

research and service in toxicology and 

enables a lecture tour of Europe to 

promote collaborations between 

European and North American 

toxicologists. 

Dr. Hussain is Group Leader for the 

Saber Hussain Nanotoxicology Section at the Air 

Force Research Laboratory where 

he leads a team of fifteen members in conducting in vitro 

toxicity evaluation of nanomaterials. His current research 

assesses toxicity of engineered nanomaterials in unique 

in vitro co-culture models representative of potential target 

organs using a spectrum of toxicity end points. 

Since 1999, Dr. Hussain has been an adjunct faculty member 

at the Wright State University (WSU), University of Dayton 

(UD) and Air Force Institute of Technology (AFIT) where 

he has been involved in teaching toxicology courses and 

presenting training courses. He is a recognized mentor 

at the Wright State University and University of Dayton 

where he is affiliated as faculty, and in the Wright Scholar 

program, NRC, and DAGSI. 

Dr. Hussain’s lecture itinerary will serve to familiarize 

research related to nanotoxicity at both industrial and 

academic institutions in Europe with the objective to 

establish productive relationships and collaborations 

with European Scientists. His goal is to gain a better 

understanding of the European view points on nanotoxicity 

testing using in vitro models, risk assessment and policy 

of nanomaterials in particular; strengthen collaboration 

with European colleagues; and provide great opportunities 

to leverage cutting-edge technology that benefits the U.S. 

The Society recognizes Dr. Saber Hussain with the 2011 

AstraZeneca Traveling Lectureship Award. 

Colgate-Palmolive Awards for Student Research 

Training in Alternative Methods 

Vijay More, M.S., University of Rhode 

Island, Kingston, RI 

Project Title: Modeling Diabetes, 

Obesity, and Non-Alcoholic Fatty Liver 

Disease in Mouse Hepatocytes to Aid in 

Prediction of Drug-Induced Liver Injury 

Host Institution: University of North 

Carolina at Chapel Hill, Chapel Hill, NC 

Colgate-Palmolive Grants for Alternative Research 

Patrick Allard, Ph.D., Harvard School of 

Public Health, Boston, MA 

Project Title: Design of a High- 

Throughput Screen for Chemicals That 

Cause Meiotic Aneuploidy 

Hao Zhu, Ph.D., University of North 

Carolina at Chapel Hill, Chapel Hill, NC 

Project Title: Predictive Quantitative 

Structure Activity Relationship 

(QSAR) Modeling of Reproductive and 

Developmental Toxicity Using Integrated 

Chemical and Biological (HTS Profiles) 

Descriptors of Molecules 

Colgate-Palmolive Postdoctoral Fellowship Award 

in In Vitro Toxicology 

Cassandra Deering Rice, Ph.D., 

University of Utah, Salt Lake City, UT 

Project Title: TRPA1 As a Molecular 

Mediator of Toxicities by Diesel Exhaust 

Particles (DEP) 

Host Institution: University of Utah, 

Salt Lake City, Utah 



2011 Award Recipients (Continued) 

Pfizer Undergraduate Student Travel Award 

Brandon Haghverdian, University of 

California Irvine, Irvine, CA 



Abstract Title: Changes in Mouse 

Pulmonary Response As a Function of 

Methacholine Aerosol Characteristics 

Jessica Hartman, University of Arkansas 

Little Rock, Little Rock, AR 

Research conducted at University of 

Arkansas for Medical Sciences 



Abstract Title: Butadiene Epoxide 

Metabolites Inhibit CYP2E1 Activity 

Camilla Odio, Kenyon College, 

Gambier, OH 



Abstract Title: Specific Amino Acid 

Residues within the Ligand Binding 

Domain Confer Low Responsiveness to 

2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin 

(TCDD) to an Aryl Hydrocarbon 

Receptor (AHR) from the Frog Xenopus 

laevis. 

Syngenta Fellowship Award in Human Health 

Applications of New Technologies 

Michelle C. DeSimone, B.S., 

University of North Carolina at 

Chapel Hill, Chapel Hill, NC 

Project Title: Using Population- 

Based Genetic Models to Investigate 

Mode-of-Action and Susceptibility to 

Environmentally-Linked Kidney Disease 

The following scientist was selected for a fellowship 

at the 2010 SOT Annual Meeting. 

2010 Novartis Graduate Student Fellowship 

Eric N. Liberda, B.E.S, M.E.S, M.A.Sc., 

New York University School of Medicine, 

Tuxedo, NY 



Abstract Title: Inhaled Nickel 

Nanoparticles and Murine Endothelial 

Progenitor Cells 


Viviana Vidal Anaya, University of 

Puerto Rico Cayey, Cayey, PR 

Research conducted at Michigan State 

University 



Abstract Title: Different Susceptibilities 

to MeHg-Induced Cell Death between 

Non-Neuronal and Neuronal Cells 

Phillip A. Wages, Ashland University, 

Ashland, OH 



Abstract Title: Joint Toxicity of 

Permethrin and Atrazine on Zebrafish 

(Danio rerio) 


71



SOT 2011 Honorary Memberships 

Honorary membership is awarded by the Society of Toxicology to persons who are not members of the Society in 

recognition of outstanding and sustained contributions to advancing the science and field of toxicology. The 2011 SOT 

Honorary Members are William C. Hays, Esq., and Dr. Frances Oldham Kelsey. 

William (Bill) C. Hays Esq., has 

represented the Society of Toxicology 

as Councilor for five decades and has 

been central to all the activities of the 

Society. As a Counsellor-at-Law with 

offices in Boston, Massachusetts, he has 

extensive experience in all aspects of 

estate planning, the administration of 

trusts, and in the settlement of estates. 

His practice, Hays & Skerry, also 

William C. Hays extends into the fields of real estate and 

general business law. Bill acts as trustee 

on many family trusts and also serves 

on the boards of numerous charitable and civic organizations. 

As Counsellor for the Society, he has studiously reviewed all 

changes to the Constitution and By-Laws of the Society, 

making key recommendations and providing judicious 

guidance and astute advice in all matters, from the 

development of new Membership classes to the shaping of 

the strategic vision of the Society to create a safer and 

healthier world by advancing the science of toxicology. Bill’s 

influence can be traced to the very forming and foundations 

of the Society and will no doubt extend to the future well 

being of the Society as well. 

Mr. Hays has lectured extensively in eastern Massachusetts 

on estate planning and affordable housing. He is a past 

chairman of the Regional Planning Subcommittee and the 

Land-Use Committee of the Boston Bar Association. He is a 

1955 graduate of Bowdoin College and earned his law degree 

from Harvard Law School in 1960. The Martindale Hubbell 

National Law Directory has awarded Mr. Hays an AV rating, 

the highest rating for legal ability and professional ethics. 

Frances Oldham 

Kelsey 

Frances Oldham Kelsey, Ph.D., M.D., 

is a pharmacologist who is famous for 

her diligence in evaluating the drug 

Thalidomide while a physician at the 

U.S. FDA. The U.S. FDA withheld 

approval of the drug based on her 

recommendations and the drug was 

later found to cause birth defects. 

Born on Vancouver Island in British 

Columbia on June 24, 1914, she 

graduated from high school at 15 

and enrolled at McGill University, 

Montreal, Canada, where she would receive both a Bachelors 

(1934) and Masters (1935) of Science in pharmacology. 

In 1938, she earned her Ph.D. in Pharmacology from the 

University of Chicago where she later taught from 1938 

to 1950. During this period Dr. Frances Oldham married 

Dr. Fremont Ellis Kelsey, a faculty member at the University 

of Chicago, (becoming Dr. Frances Kelsey) and had two 

daughters. Also, it was during this time that Dr. Frances 

attended the University of Chicago’s Medical School and 

received her M.D. (1950). She interned at Sacred Heart 

Hospital in Yankton, South Dakota, and from 1954 to 1957 

was an associate professor of pharmacology at the University 

of South Dakota. In 1955 she became a nationalized citizen. 

From 1957 to 1960 she ran a private practice in South 

Dakota. 

During her first month at the U.S. Food and Drug 

Administration, Dr. Frances Oldham Kelsey took a bold 

stance against inadequate testing and corporate pressure 

when she refused to approve release of thalidomide in the 

United States. For this she was awarded the highest honor 

given to a civilian in the United States, the President’s 

Award for Distinguished Federal Civilian Service, by 

President John F. Kennedy. She went on to help shape 

and enforce amendments to U.S. FDA drug regulation 

laws to institutionalize protection of the patient in drug 

investigations. These regulations required that drugs be 

shown to be both safe and effective, that informed consent be 

obtained from patients when used in clinical trials, and that 

adverse reactions be reported to the U.S. FDA. 

In 2005, Dr. Kelsey retired from the U.S. FDA at the age of 

90. She was recently honored by the U.S. FDA by presenting 

her with the first annual “Dr. Frances O. Kelsey Award for 

Excellence and Courage in Protecting the Public Health.” 


Endowment Awardees for SOT’s 50 th Anniversary 

Over 30 Endowment Fund Awards Given in 2010 

Plans to Fund Nine Additional Awards in 2011 

The Endowment Fund Needs Your Support to Achieve This Goal 

Our thanks and deep appreciation to all the members and friends of the Society who have contributed 

to our previous goal of reaching $1 million in donations by the 50th anniversary year. 

the number of named funds has grown to 30 at the time of this printing. 

Students are the main beneficiaries of the awards from the various Funds. 

Help exhaust the SOT Council Approved $750,000 

50th Anniversary Match. 

Your contribution can have twice the IMPACT. 

Matches will be made for all contributions to the four 

General Purpose funds: 

• Educational activities Fund 

• International activities Fund 

• SOt Priorities Fund 

• Student travel Fund 

InDIVIDuAL COnTRIBuTIOnS 

Recognition 

Level 

Paracelsus Circle 

Contribution 

in a fiscal year 

$500 or more 

Gold $250–$499 

Silver $100–$249 

Bronze $40–$99 

For a full listing of all the Funds and to make a contribution today to 

the SOt Endowment Fund of your choice, please visit 

www.toxicology.org/ai/csot/contributions.asp 

1 

Endowment Fund Contribution Donor Form can be fond on page 415. 


73



SOT Endowment Fund 2010 Award Recipients 

Mary Amdur Student Award Fund 

Mehdi S. Hazari, 

M.Sc., Ph.D., 

U.S. EPA, Research 

Triangle Park, NC 

Laxman S. Desai Association of 

Scientists of Indian Origin Student 

Award Fund 

Arunkumar 

Asaithambi, 

B.S., Iowa State 

University, Ames, IA 

Perry J. Gehring Biological Modeling 

Student Award Fund 

Sheppard A. Martin, 

B.S., M.P.H., 

University of 

Georgia, Athens, GA 

Eric N. Liberda, 

Ph.D., New York 

University, School of 

Medicine, Tuxedo, 

NY 

Young Soo Choi Student Scholarship 

Award Fund 

Do Hyung Kim, 

M.S.P.H., San Diego 

State University, 

San Diego, CA 

Founders Fund 

James S. Bus, 

Ph.D., DABT, ATS, 

Dow Chemical 

Company, Midland, 

MI 

Marc-André Verner, 

M.Sc., University of 

Quebéc, Montréal, 

QC, Canada 

Join Us for the Announcement of 2011 Endowment Fund Award Recipients 

2011 Endowment Fund Awards............................................................................................................................................................Awarded by 

Mary Amdur Student Award..........................................................................................................................................Inhalation and Respiratory SS 

Young Soo Choi Student Scholarship Award................................................................................ Korean Toxicologists Association in America SIG 

Laxman S. Desai ASIO Student Award................................................................................................Association of Scientists of Indian Origin SIG 

Diversity Initiatives................................................................................................................................................. Committee on Diversity Initiatives 

John Doull Student Award..............................................................................................................................................................Risk Assessment SS 

Founders Fund...................................................................................................................... Founders Fund recipient selected by Awards Committee 

Perry J. Gehring Biological Modeling Student Award.............................................................................................................Biological Modeling SS 

Perry J. Gehring Diversity Student Travel Award.................................................................................................. Committee on Diversity Initiatives 

Perry J. Gehring Risk Assessment Student Award.........................................................................................................................Risk Assessment SS 

Health and Environmental Science Institute Immunotoxicology Young Investigator Student Award..................................... Immunotoxicology SS 

Vera W. Hudson and Elizabeth K. Weisburger Scholarship................................................................................................ Women in Toxicology SIG 

Frank C. Lu Food Safety Student Award................................................................................................................................................Food Safety SS 

Jean Lu Student Scholarship Award.......................................................................................... American Association of Chinese in Toxicology SIG 

Roger O. McClellan Student Award............................................... Comparative and Veterinary SS and Toxicologic and Exploratory Pathology SS 

Harihara Mehendale ASIO Student Award..........................................................................................Association of Scientists of Indian Origin SIG 

Metals Specialty Section Graduate Student/Postdoc Award......................................................................................................................... Metals SS 

Molecular Biology Student Award...............................................................................................................................................Molecular Biology SS 

Pacific Northwest Toxicology Development.................................................................................................................................Pacific Northwest RC 

Emil A. Pfitzer Drug Discovery Student Award..........................................................................................................Drug Discovery Toxicology SS 

Gabriel L. Plaa Education Award..........................................................................................................................................................Mechanisms SS 

Renal Toxicology Fellowship Award.....................................................................................................................................................Mechanisms SS 

Robert J. Rubin Student Travel Award..........................................................................................................Mechanisms SS and Risk Assessment SS 

Dharm V. Singh ASIO Student Award.................................................................................................Association of Scientists of Indian Origin SIG 

Dharm V. Singh Carcinogenesis Award........................................................................................................................................... Carcinogenesis SS 

Carl C. Smith Student Mechanisms Award...........................................................................................................................................Mechanisms SS 

Please refer to the Daily Pocket Calendar, Event Listing, or Program Description for date, time, and location of the Committee on Diversity Initiative 

Reunion, Regional Chapter, Special Interest Group, and Specialty Section receptions where the Endowment Fund Awards are conferred. 



SOT Endowment Fund 2010 Award Recipients (Continued) 

Perry J. Gehring Diversity Student 

Travel Award Fund 

Nygerma L. 

Dangleben, B.S., 


California Berkeley, 

Berkeley, CA 

Frank C. Lu Food Safety Student Award 

Fund 

Alicia Marroquin- 

Cardona, D.V.M., 

M.Sc., Texas A&M, 

College Station, TX 

Molecular Biology Student Award Fund 

Jill Franzosa, 

M.S., Oregon State 

University, Corvallis, 

OR 


Perry J. Gehring Risk Assessment 

Student Award Fund 

Anne Loccisano, 

Ph.D., The Hamner 

Institutes, Research 


Kun Lu, M.S., 

University of North 

Carolina at Chapel 

Hill, Chapel Hill, NC 

Health and Environmental Science 

Institute Immunotoxicology Young 

Investigator Student Award Fund 

Megumi Maeda, 

Ph.D., Kawasaki 

Medical School, 

Kurashiki, Okayama, 

Japan 

Jean Lu Student Scholarship 

Award Fund 

Haitian Lu, M.S., 

Michigan State 

University, East 

Lansing, MI 

Roger O. McClellan Student Award Fund 

Yogesh Saini, M.S., 

B.V.Sc., Michigan 


East Lansing, MI 

Harihara Mehendale Association of 

Scientists of Indian Origin Student 

Award Fund 

Indira Devi Jutooru, 

B.V.Sc., Texas A&M, 

College Station, TX 

Raymond Lo, B.Sc., 

University of Toronto, 

Toronto, ON, Canada 

Lauren Mordasky 

Markell , B.S., 

Penn State University, 

University Park, PA 

Melissa Barhoover, 

Ph.D., The Hamner 

Institutes for Health 

Sciences, Research 


Tamara Tal, Ph.D., 

Oregon State 

University, Corvallis, 

OR 

Vera W. Hudson and Elizabeth K. 

Weisburger Scholarship Fund 

Natalie Malek 

Johnson, B.S., 

Texas A&M, College 

Station, TX 

Peili Yao, Ph.D., 

University of Texas at 

Austin, Austin, TX 


75



SOT Endowment Fund 2010 Award Recipients (Continued) 

Emil A. Pfitzer Drug Discovery Student 

Award Fund 

Arunkumar 

Asaithambi, 

B.S., Iowa State 

University, Ames, IA 

Renal Toxicology Fellowship Award 

Fund 

Jennifer Cohen, 

Ph.D., University of 

Arizona, Tucson, AZ 

Dharm V. Singh Carcinogenesis 

Award Fund 

Lauren Mordasky 

Markell , B.S., 

Penn State University, 

University Park, PA 

Peter Bui, B.S., 


California Los 

Angeles, Los 

Angeles, CA 

David Castro, Ph.D., 

Sanford-Burnham 

Medical Research 

Institute, La Jolla, 

CA 

Xiaoling Zhang, 

MS, University of 

Georgia, Athens, GA 

Robert J. Rubin Student Travel Award 

Fund 

David Szabo, Ph.D., 

University of North 

Carolina at Chapel 

Hill, Chapel Hill, NC 

Carl C. Smith Student Mechanisms 

Award Fund 

Donald S. Backos, 

B.S., M.P.H., 


Colorado, Denver, 

CO 

Neal S. Gould, 

B.S., University of 

Colorado, Denver, 

CO 

Harriet Kamendi, 

Ph.D., AstraZenica, 

Wilmington, DE 

(not pictured) 

Christina Powers, 

B.A., Duke 

University, Durham, 

NC and 

Sumitra Sengupta, 

B.S., M.Sc., Oregon 


Corvallis, OR 

Dharm V. Singh Association of Scientists 

of Indian Origin Student Award Fund 

Mayurranjan S. 

Mitra, B.Pharm, 

Ph.D., Washington 

University, Saint 

Louis, MO 

Bradley P. Sullivan, 

B.S., University of 

Kansas Medical 

Center, Kansas City, 

KS 



Recognition and Special Events 

All activities will be held at the Walter E. Washington 

Convention Center in Washington, D.C., unless otherwise 

noted. 


Live on SOT Web site on February 1 

(Access on-site in the E-mail Center or via your Internet 

connection) 

Chairperson(s): Anne Loccisano, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC. 

Sponsor: 

Postdoctoral Assembly 

In honor of the 50th Anniversary of SOT, the Postdoctoral 

Assembly is organizing the 50th Anniversary Silent Auction. 

Bid on vacation get-a-ways or purchase items of historical 

significance to SOT and toxicology (such as books, laboratory 

items, memorabilia, photographs) as well as other items of 

general interest. Bids for some items will close in the E-mail 

Center Monday, March 7, from 4:45 PM–5:45 PM. Join the 

excitement! Cash bar available. Bring your laptop or smart 


Bids for remaining items will close beginning at 10:00 AM 

Wednesday and conclude at 1:00 PM. All proceeds from the 

Silent Auction will go to the Endowment Priorities Fund. 

Regional Chapter, Special Interest Group, 

and Specialty Section Receptions 

Sunday, March 6 through Wednesday, March 9, 

Various Times 

Many of the SOT RC, SIG, and SS meet during the SOT 

Annual Meeting. All current and prospective RC, SIG, and SS 

members are encourage to attend. More information can be 

found on pages 80–82. 

SATuRDAy 

Smithsonian Seminar: Poisons: When Good 



S. Dillon Ripley Center 

To commemorate SOT’s 50th Anniversary, the Smithsonian 

Institution is holding an all day seminar for the public featuring 

the latest research in the science of toxicology, and information 

about the positive and adverse effects that chemical, biological, 

and physical substances can have on people, animals, and 

the environment. We are surrounded by chemicals that may 

be beneficial, harmful, or neither depending on the dose. 

This day-long session, which features several SOT Members, 

is open to the public and requires separate registration. SOT 

members receive the Smithsonian member discount. To learn 

more please visit www.toxicology.org/ai/meet/am2011. 

Protecting You and Your Pet 

through the Science of Toxicology: 

Paracelsus Goes to Washington 




Chairperson(s): Maureen Gwinn, U.S. EPA, Washington, D.C. 

Sponsors: 

Education Committee 

K–12 Task Force 

SOT is sponsoring a free Family Day at the Marion Koshland 

Science Museum of the National Academy of Sciences. We 

invite meeting attendees and their families, as well as D.C. 

visitors and residents, to experience this science museum near 

the Walter E. Washington Convention Center. In addition to 

the activities that are on display, SOT will supplement the 

topic areas of Wonders of Science, Safe Drinking Water, 

Global Warming, and Infectious Disease with toxicologyrelated 

activities. Toxicologists from a variety of employment 

sectors will be available to engage with visitors to learn more 

about toxicology. 

Dr. Reimschuessel, V.M.D., Ph.D., is Program 

Director of the Veterinary Laboratory Response 

Network, Center for Veterinary Medicine, U.S. 

FDA. She will speak at 12:00 NOON on 

“Poisoned Pet Food—Unraveling the Melamine 

Mystery.” Prior to 2007 melamine was considered 

a relatively non-toxic chemical. During 2007, 

many dogs and cats became ill, developing kidney failure. 

When food testing laboratories found melamine in the pet 

food, scientists were puzzled. First, why was this chemical in 

the food, and second, was it the melamine that was causing the 

kidney failure? 

She will describe her investigation into these questions and 

how her scientific background in both human and veterinary 

medicine helped her recognize key aspects of the pathology 

to solve this mystery. She will also describe the difference 

between the pet food recall and the Chinese infant formula 

melamine events, and the studies U.S. FDA is conducting to 

gain more insight into this unusual form of toxicity. 



77



Recognition and Special Events (Continued) 

Dr. Reimschuessel was co-author on the paper published 

from these investigations that was recognized as the 2010 

SOT Board of Publications Award for the Best Paper in 

Toxicological Sciences, “Identification and Characterization of 

Toxicity of Contaminants in Pet Food Leading to an Outbreak 

of Renal Toxicity in Cats and Dogs” (Toxicological Sciences 

2008, 106: 251–262). 

More information about the Koshland Science Museum event 

is on the Web Site, including how to volunteer to assist that 

day. 

Committee on Diversity Initiatives Reunion 

Saturday, March 5, 8:00 PM–9:00 PM 

Room 103 

Awards Ceremony Music 

Performed by Gail Shanta 


Room 207 

Gail Shanta was raised and educated in England, Germany 

and France. She began playing piano at the age of four and 

later studied organ while attending the University of Aix-en- 

Provence in southern France. Gail began studying the harp 

while working on a doctorate at the University of Colorado. 

She has been performing with Mount Vernon Orchestra and 

Fairfax City Band. In addition, she has played for fund-raising 

events such as Alexandria Symphony, The Lyceum, Ronald 

McDonald House, and others. 

Hosted by: 

Committee on Diversity Initiatives 

The Committee on Diversity Initiatives (CDI) will host 

the CDI Reunion from 8:00 PM–9:00 PM on Saturday, 

March 5. Whether as a student, peer mentor, host mentor, 

speaker, or organizer, anyone who has ever been involved in 

the SOT Undergraduate Program is invited to attend. Visit 

with colleagues who have been involved in the program over 

the last 22 years, meet with program alums, and greet the 

undergraduate students who are attending the program this 

year. The 2011 Endowment Gehring Diversity Student Travel 

Award will be presented. Enjoy dessert, coffee, and tea. Start 

off your 50th Anniversary meeting celebration by joining with 

the special people who have contributed to the diversity in 

SOT through this important activity. 

SunDAy 

Past Presidents 5K Fun Run 

Sunday, March 6, 6:00 AM 

In celebration of 50 years of moving the Society of Toxicology 

forward, the SOT Past Presidents have organized a 5K Fun 

Run at the 2011 SOT Annual Meeting. Can you keep up? SOT 

Past Presidents Jay Goodman (1999–2000) and Bill Greenlee 

(2002–2003) will be the pace presidents for an extremely fun, 

competitive, and entertaining 5K race at scenic Hains Point 

in East Potomac Park, where the Anacostia River joins the 

Potomac River. Past Presidents will cheer and greet you as you 

cross the finish line. 

Sign up on the SOT Annual Meeting Web site. Those who 

pre-register before February 15, 2011, will receive a free 

2011 Fun Run T-Shirt! Transportation to the Fun Run will 

depart at 6:00 AM from the L Street entrance of the Walter 

E. Washington Convention Center and return to the same 

location. Results will be announced on ToXchange, at the 50th 

Anniversary Member Celebration Meeting, as well as on the 

SOT Web site and in the Communiqué. 



Room 207 

SOT will recognize our prestigious award recipients at the 

SOT Awards Ceremony (pages 63–71). Please refer to the 

Awards and Fellowships section of the SOT Web site for 

complete details about the award recipients and criteria. In 

commemoration of the 50th Anniversary, two individuals 

who have significantly and positively influenced the fields of 

toxicology will be inducted as Honorary Members: William 

Hays, Esq. and Dr. Frances Kelsey. 

Endowment Fund 50th Anniversary 

Undergraduate Educator Award 


Room 207 

The new Endowment Fund Undergraduate Educator Award 

is being sponsored by the Endowment Education Fund 

and the Endowment SOT Priorities Fund in honor of the 

50th Anniversary and outstanding undergraduate education. 

The awardee, Joan B. Tarloff, will be recognized at the Sunday, 

March 6, Awards Ceremony. To learn more about the award 

criteria, please visit www.toxicology.org/ai/af/awards.aspx. 



Room 103 

If you have been a member of the Society of Toxicology for 

25 years or more, please join your colleagues to celebrate and 

recognize the scientists who established the Society. Be sure to 

sport your 25-year, 35-year, 45-year, or 50-year member pin. 



Recognition and Special Events (Continued) 

MOnDAy 

TUESDAy 


Landmarks Program Presentation to the 

National Academy of Science 



Michael P. Holsapple, SOT President, will present a landmark 

plaque to the leaders of the Committee on Toxicology, 

National Academy of Sciences (NAS), where the Society of 

Toxicology was founded March 4, 1961, and subsequently 

re-defined, fostered, and supported. The plaque represents the 

gratitude and appreciation of the leadership and membership 

of the Society of Toxicology. 


for Students: Full Speed into an Alternative 

Future 

Monday, March 7, 12:00 NOON–1:20 PM 

Salon G 


Lecturer: Robert E. Chapin, Pfizer, Groton, CT. 

Sponsor: 

Colgate-Palmolive Company 

Hosted by: 


Graduate students, undergraduates, postdoctoral scholars, and 

recipients of Colgate-Palmolive awards are among the guests 

at the In Vitro Toxicology Lecture and Luncheon. The goal of 

the In Vitro Toxicology Lecture series is to feature important 

research using in vitro and alternative techniques to study basic 

mechanisms, and to illustrate how these test methods benefit 

animal welfare by refining and reducing animal use. Students 

and postdocs can reserve a ticket for the luncheon with a $10 

deposit when they register for the SOT Annual Meeting. See 

page 83 for more information. 


Tuesday, March 8, 12:00 NOON–1:15 PM 

Salon G 


Sponsor: 


Amidst scrambling to attend all of the events at the meeting, 

this will be time for postdocs to kick back and relax! All 

postdoctoral scholars are invited to a casual luncheon 

organized by the Postdoctoral Assembly (PDA). We will 

announce the recipients of the Best Postdoctoral Publication 

Awards and acknowledge the postdocs who received awards 

this year from Regional Chapters, Special Interest Groups, 

and Specialty Sections. The PDA Board members will present 

an overview of accomplishments and future directions for the 

PDA, and will introduce the new board members for 2011– 

2012. There will be a drawing for prizes. Postdocs can reserve 

a ticket for $5 when they register for the Annual Meeting. 

50th Anniversary Member Celebration 

Meeting 


Room 207 

All members are invited to celebrate the Society’s first 50 years 

of accomplishments. This fun event will highlight the history 

and growth of the Society over the past 50 years recognizing 

the members who are responsible for the Society’s success. 

Come see what is going in the Time Capsule that will be 

opened in 2036 by current and future SOT members. Receive 

your copy of The Society of Toxicology: The First Fifty Years. 





Come celebrate the 50th Anniversary in style. Dance the night 

away with tunes from the Beatles as performed by BeatleMania 

Live. Dress in your favorite decade’s attire (60’s to the future)! 

Additional entertainment plans include festive decorations, 

games, delicious food stations, and beverages. This is truly 

an event you will not want to miss! Purchase your ticket now 

by signing up on the 2011 Annual Meeting registration form. 

A limited number of discounted tickets have been set aside 

for trainees (undergraduate students, graduate students, and 

postdocs). All tickets will be sold on a first-come, first-served 

basis and are non-refundable after February 11, 2011. 


79



RC, SIG, and SS Receptions (as of January 7) 

Regional Chapter Meetings/Luncheons or Receptions 

Sunday, March 6 through Wednesday, March 9, Various Times 

Many of the SOT Regional Chapters meet during the SOT Annual Meeting. All current and prospective Regional Chapter 

members are encourage to attend. 

Event Date Time Location Room 

Central States Regional Chapter Meeting/Luncheon Monday, March 7 12:00 NOON to 2:00 PM Embassy Suites Capital 

Ballroom B 

Gulf Coast/South Central Regional Chapters Joint 

Reception 

Michigan Regional Chapter Reception (Happy Hour/Social 

Gathering) 

Mountain West/Southern California Regional Chapters 

Joint Reception 

National Capital Area Regional Chapter/NRC Committee on 


Monday, March 7 5:00 PM to 6:30 PM Fado Irish Pub 

Wednesday, Mar 9 5:00 PM to 6:30 PM TBD 

Monday, March 7 6:00 PM to 7:30 PM RFD Restaurant 

Monday, March 7 5:30 PM to 7:30 PM Embassy Suites Capital 

Ballroom A 

Northeast Regional Chapter Student Luncheon Tuesday, March 8 12:30 PM to 2:00 PM Renaissance Congressional A 

Northern California Regional Chapter Reception Monday, March 7 6:30 PM to 8:30 PM District Chophouse 

Restaurant 

Regional Chapter Governance Committee Meeting Wednesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 304 

Regional Chapter Presidents and Officers Meeting Tuesday, Mar 8 7:00 AM to 8:30 AM Convention Center Room 103 




Special Interest Group Meetings or Receptions 


Each of the six Special Interest Groups will hold a meeting/reception during the 2011 SOT Annual Meeting. All current and 

prospective SOT Special Interest Group members are encouraged to attend. 


AACT Distinguished Chinese Toxicologist Lectureship Monday, March 7 5:00 PM to 6:00 PM 

Renaissance 


South 

American Association of Chinese in Toxicology 



6:00 PM to 8:00 PM 

Renaissance 


South 

ASIO Lunch and Learn Program Tuesday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 141 

Association of Scientists of Indian Origin Special Interest 



6:00 PM to 7:30 PM 


Salon H 

Hispanic Organization of Toxicologists Special Interest 



6:30 PM to 8:30 PM 


Korean Toxicologists Association in America 



6:30 PM to 8:30 PM 


(continued to next page) 



RC, SIG, and SS Receptions (Continued) (as of January 7) 

Special Interest Group Meetings/Luncheons or Receptions (Continued) 






Special Interest Group Collaboration Group Meeting Monday, Mar 7 1:00 PM to 1:30 PM Convention Center Room 103 

Special Interest Group Presidents and Officers Meeting Monday, Mar 7 12:00 NOON to 1:00 PM Convention Center Room 103 

Toxicologists of African Origin Special Interest Group 



6:00 PM to 8:00 PM 

Embassy Suites 

Capital Ballroom 

B 

Women in Toxicology Special Interest Group Meeting/ 

Reception 


4:30 PM to 6:30 PM 

Renaissance 

Ballroom 

West A&B 

Specialty Section Meetings/Luncheons or Receptions 


Each of the 26 SOT Specialty Sections will hold either a luncheon or early evening meeting/reception during the 

SOT 2011 Annual Meeting. All current and prospective SOT Specialty Section members are encouraged to attend. 


Biological Modeling Specialty Section Meeting/Reception Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Room 149 

Biotechnology Specialty Section Meeting/Reception Monday, March 7 6:00 PM to 7:30 PM Convention Center Room 140B 

Carcinogenesis Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 146A 

Carcinogenesis Specialty Section Officers Meeting Monday, March 7 6:30 AM to 8:00 AM Convention Center Salon G 

Cardiovascular Toxicology Specialty Section Meeting/ 

Reception 

Comparative and Veterinary Specialty Section Meeting/ 

Luncheon 

Monday, March 7 6:00 PM to 7:30 PM Convention Center Room 102 

Tuesday, March 8 12:00 NOON to 1:30 PM Convention Center Room 149 

Dermal Toxicology Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 203 

Dermal Toxicology Specialty Section Officers Meeting Sunday, March 6 4:00 PM to 6:00 PM Convention Center Room 203 

Drug Discovery Toxicology Specialty Section Meeting/ 

Reception 

Ethical, Legal, and Social Issues Specialty Section Meeting/ 

Reception 

Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Room 103 


Food Safety Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 140A 

Food Safety Specialty Section Officers Meeting Sunday, March 6 12:00 NOON to 1:30 PM Convention Center Room 140A 

Immunotoxicology Specialty Section Meeting/Reception Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Salon H 

In Vitro and Alternative Methods Specialty Section Meeting/ 

Luncheon 

In Vitro and Alternative Methods Specialty Section Officers 

Meeting 

Wednesday, March 9 12:00 NOON to 1:30 PM Convention Center Salon G 

Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

(continued to next page) 


81



RC, SIG, and SS Receptions (Continued) (as of January 7) 

Specialty Section Meetings/Luncheons or Receptions (Continued) 


Inhalation and Respiratory Specialty Section Meeting/ 

Reception 


Mechanisms Specialty Section Meeting/Reception Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Salon I 

Mechanisms Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Medical Device Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 156 

Medical Device Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Metals Specialty Section Meeting/Reception Sunday, March 6 6:00 PM to 8:00 PM District Chophouse 

Restaurant 

Mixtures Specialty Section Meeting/Reception Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Room 140A 

Mixtures Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Molecular Biology Specialty Section Meeting/Reception Monday, March 7 6:00 PM to 7:30 PM Convention Center Room 159 

Nanotoxicology Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 143 

Nanotoxicology Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Neurotoxicology Specialty Section Meeting/Reception Monday, March 7 6:00 PM to 7:30 PM Convention Center Salon G 

Neurotoxicology Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Occupational and Public Health Specialty Section 


Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 144 

Ocular Toxicology Specialty Section Meeting/Reception Sunday, March 6 6:30 PM to 8:00 PM Convention Center Room 142 

Regulatory and Safety Evaluation Specialty Section 

Meeting/Reception on Capitol Hill—The Great Debate, 

Sen. Johnny Isakson, Honorary Host (Limited Seating) 

Reproductive and Developmental Toxicology Specialty 


Reproductive and Developmental Toxicology Specialty 

Section Officers Meeting 

Monday, March 7 5:00 PM to 6:30 PM Russell Senate Building SR-325 

(Buses Depart CC at L Street beginning 

at 4:00 PM) 

Wednesday, March 9 6:00 PM to 7:30 PM Convention Center Salon G 

Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Risk Assessment Specialty Section Meeting/Reception Monday, March 7 6:00 PM to 7:30 PM Convention Center Salon I 

Risk Assessment Specialty Section Officers Meeting Monday, March 7 6:30 AM to 7:45 AM Convention Center Salon G 

Specialty Section Governance Group Meeting Monday, March 7 3:00 PM to 4:00 PM Convention Center Room 103 

Specialty Section Graduate Committee Meeting Tuesday, March 8 7:00 AM to 8:30 AM Convention Center Room 142 

Specialty Section Presidents and Officers Meeting Monday, March 7 4:30 PM to 6:00 PM Convention Center Room 103 

Stem Cells Specialty Section Inaugural Meeting/Reception Monday, March 7 6:00 PM to 7:30 PM Convention Center Room 149 





Monday, March 7 12:00 NOON to 1:30 PM Convention Center Room 149 

Monday, March 7 6:30 AM to 7:45 AM Convention Center Room 302 



Student and Postdoctoral Scholar Events 


Sunday–Thursday, time varies by group 

(Meet at the Lunch with an Expert Bulletin Board in 

Registration Area) 



Room 304 

(Ticket Required; Postdoctoral Scholars only, limited seating) 


Sponsor: 


The purpose of Lunch with an Expert is to provide graduate 

students and postdoctoral scholars the opportunity to network 

informally with well-established toxicologists while obtaining 

career advice and meeting new colleagues. Small groups are 

composed by matching research interests of students and 

postdocs with those of an Expert. The Expert for each group 

identifies a time and place for a meal, and the group meets at 

the Lunch with an Expert Bulletin Board before going to the 

restaurant. New this year: Meeting Room 16 in the Renaissance 

Hotel has been reserved for Lunch with an Expert groups from 

11:30 AM–1:30 PM. You may pick up food in the food court 

below the hotel and then proceed to the reserved room if you 

prefer this option to meeting in a restaurant. Sign up via the 

Graduate Student section of the SOT Web site. Details for each 

group meeting will be sent to participants in advance of the 

meeting. 



Salon G 


Sponsor: 


The Student Advisory Council and Graduate Committees 

host this opportunity for students and postdoctoral scholars to 

gather, to meet new colleagues, and to reestablish relationships 

in an informal atmosphere at the beginning of the meeting. 

Tickets are obtained at no cost by registering for this event on 

the Annual Meeting Registration Form. Ticket and meeting 

badge are required. Complimentary refreshments and a cash 

bar will be available. 

Chairperson(s): Michele La Merrill, Mount Sinai School of 

Medicine, New York, NY. 

Sponsor: 


Dr. Collins will meet informally for discussion with 

postdoctoral scholars after his Plenary Lecture. Room size 

is limited, and participants will be selected by lottery from 

among postdoctoral meeting registrants who request a ticket 

by January 21. 


for Students: Full Speed into an Alternative 

Future 

Monday, March 7, 12:00 NOON–1:20 PM 

Salon G 



Chairperson(s): Aaron Barchowsky, University of 

Pittsburgh, Pittsburgh, PA. 

Sponsor: 


Hosted by: 


The purpose of this lecture is to discuss the importance of 

animal research to biomedical sciences and toxicology, and 

the ethical obligations of the scientific community to follow 

the “3R’s” of animal testing (refine, reduce, replace) whenever 

it is feasible. 

Graduate students, undergraduates, postdoctoral scholars, 

and recipients of Colgate-Palmolive awards are among the 

guests at the In Vitro Toxicology Lecture and Luncheon. The 

goal of the In Vitro Toxicology Lecture series is to feature 

important research using in vitro and alternative techniques 

to study basic mechanisms and to illustrate how these test 

methods benefit animal welfare by refining and reducing 

animal use. Students and postdocs can reserve a ticket for the 

luncheon with a $10 deposit when they register for the SOT 

Annual Meeting. Lunch is served at the beginning of the event 

and service concludes before the talk/main program begins. 

Meal service may not be available to guests who arrive after 

12:30 PM. 

 

(continued on next page) 


83



Student and Postdoctoral Scholar Events (Continued) 

The “Toxicity Testing in the 21st Century” vision promulgates 

an in vitro approach to safety assessment based heavily 

on knowing the pathways responding in a cell and then 

correctly relating that to an in vivo exposure and response to 

predict the likely health outcome. But we are now much like 

Galileo was with our Moon: seeing the goal is many, many 

times easier than actually getting there. However, given that 

animal models correctly predict only 40–70% of human 

responses, in vitro models won’t actually have to do that 

well to be better than the current in vivo models. Thus, for 

both animal-use issues and for correct-predictivity issues, an 

in vitro future is a worthy and achievable goal. Meanwhile, 

there is much trial and error to pursue. This talk will quickly 

reprise an in vitro testing vision, and then put it into an 

industry perspective. It will soon become clear that we’re a 

long way from where we want to be. After this stage-setting, 

the audience will be asked to discuss and then present their 

answers to a set of related questions. 

• What are the limitations (and “costs”) of the current 

approach using animals? 

• What are the limitations of the proposed safety 

assessments using cell cultures and predictive models? 

• What are some possible explanations for the less-thanhoped-for 

predictivity? Which is most likely, and why? 

• How long will it take to implement this new paradigm? 

Why will it take longer than that? 

• What role might stem cells play in this future? What 

are the assumptions (and thus, possible pitfalls) in their 

playing that role? 

• List the benefits and drawbacks of having multiple cell 

types in the culture vs. having one cell type. 

• What would be the motivations of industry to embrace this 

new toxicity testing vision? What conditions need to be 

met for that marriage to happen? 

• Why might one solution to the predictivity problem be to 

use multiple predictive models? How would those models 

have to differ from each other to make that work? 


Live on SOT Web site by February 1 


connection) 



Sponsor: 


In honor of the 50th Anniversary of SOT, the Postdoctoral 

Assembly is organizing the 50th Anniversary Silent Auction. 

Bid on vacation get-a-ways or purchase an item of historical 

significance to SOT and toxicology (such as books, laboratory 

items, memorabilia, photographs) as well as other items of 

general interest. Bids for some items will close in the E-mail 

Center Monday, March 7, from 4:45 PM–5:45 PM. Join the 

excitement! Cash bar available. Bring your laptop or smart 


Bids for remaining items will close beginning a 10:00 AM 

Wednesday and conclude at 1:00 PM. All proceeds from the 

Silent Auction will go to the Endowment Priorities Fund. 


Tuesday, March 8, 12:00 NOON–1:15 PM 

Salon G 


Chairperson(s): Sarah Campion, Brown University, Providence, 

RI. 

Sponsor: 


Amidst scrambling to attend all of the events at the meeting, 

this will be time for postdocs to kick back and relax! All 

postdoctoral scholars are invited to a casual luncheon 

organized by the Postdoctoral Assembly (PDA). We will 

announce the recipients of the Best Postdoctoral Publication 

Awards and acknowledge the postdocs who received awards 

this year from Specialty Sections and Regional Chapters. 

The PDA Board members will present an overview of 

accomplishments and future directions for the PDA and will 

introduce the new board members for 2011–2012. There will 

be a drawing for door prizes. Postdocs can purchase a ticket 

for $5 when they register for the Annual Meeting. The ticket 

charge is not refundable, reserves your place, and defrays 

some of the expenses for the luncheon. Lunch is served at the 

beginning of the event and service concludes before the main 

program begins. Meal service may not be available to guests 

who arrive after 12:30 PM. 



Outreach Activities and Events 

SOT Pavilion 

Do you know all the resources available through SOT 

and where to find them? Stop by the SOT Pavilion, Booth 

#464, centrally located in the Exhibit Hall and learn about 

SOT services and membership benefits, and SOT Regional 

Chapters, Specialty Sections, and Special Interest Groups. 

Find out about the SOT Endowment Fund, Toxicological 

Sciences, awards and fellowships, educational resources and 

more. Special presentations will be given on SOT activities 

and member benefits, including ToXchange, so be sure to 

stop by for the schedule of SOT Pavilion events. The SOT 

Pavilion is the one-stop shop for all of your SOT questions 

and membership needs. Make the SOT Pavilion your meeting 

place on the exhibit floor. 

Undergraduate Education Program 

Saturday, March 5 through Monday, March 7 

Chairperson(s): Adrian Nanez, Amgen, Thousand Oaks, CA. 

Sponsor: 

Committee for Diversity Initiatives 

Saturday, March 5 

This evening event is for undergraduate students and advisors 

receiving 2011 SOT Travel funding and SOT program 

volunteers. 

4:15 PM–5:45 PM Orientation for SOT Hosts, Peer 

Mentors, and Advisors 

Jennifer Rayner, Oak Ridge National 

Laboratory, Oak Ridge, TN, and Enrique 

Fuentes-Mattei, University of Puerto 

Rico, San Juan, PR 

5:15 PM–5:45 PM Registration for Students 

Kim Daniel, Texas A&M, College 

Station, TX 

5:45 PM–6:15 PM Opening Event 

Convener: Adrian Nanez, Amgen, 

Thousand Oaks, CA 

6:15 PM–6:45 PM Lecture: Introduction to Toxicology 

José Manautou, University of 

Connecticut, Storrs, CT 

6:45 PM–7:15 PM Dinner (By Invitation Only) 

7:30 PM–8:00 PM Perspectives on the History of 


John Doull, University of Kansas 

Medical Center, Kansas City, MO 

8:00 PM–9:00 PM CDI Reunion (Dessert and 

Networking) 

Open to all past program participants 

Presentation of the 2011 Perry J. 

Gehring Diversity Student Travel 

Award 


85 


The Sunday program is open to undergraduate students 

who are registered for this event on the Annual Meeting 

Registration Form, the undergraduate students receiving SOT 

and Pfizer travel funding, and the SOT program volunteers. 

8:00 AM–11:30 AM Introductions and Special 

Toxicology Lectures 

Chairperson(s): Adrian Nanez, Amgen, 

Thousand Oaks, CA, and Nathan 

Cherrington, University of Arizona, 

Tucson, AZ 

8:00 AM–8:15 AM Welcome 

Michael P. Holsapple, SOT President, 

ILSI Health and Environmental Sciences 

Institute, Washington, D.C. 

8:15 AM–8:55 AM Exposure to Cigarette Smoke 

In Utero: Fetal Injury and Life Long 

Consequences 

Judith Zelikoff, New York University 

School of Medicine, Tuxedo Park, NY 

9:00 AM–9:45 AM Absorption, Distribution, Metabolism, 

and Excretion Principles in Toxicology 

Nathan Cherrington, University of 

Arizona, Tucson, AZ 

10:00 AM–10:40 AM Optical Nanotechnologies for 

Imaging of Cellular Processes and 

Neurosurgery 

Martin Philbert, University of Michigan, 

Ann Arbor, MI 

10:45 AM–11:30 AM Identifying the Poison: Case Study in 


Lauren Aleksunes, Rutgers University, 

Piscataway, NJ 

11:45 AM–12:45 PM Lunch and Networking 


Breakout Sessions For Students 

(3 concurrent sessions) 

12:45 PM–1:45 PM What is Graduate School and What 

Can I Expect? 

How to Get into Graduate School: An 

Academic Advisor’s Perspective 

Academic Advisor Facilitators: 

Charlene McQueen, Auburn University, 

Auburn, AL, James Luyendyk, 

University of Kansas Medical Center, 

Kansas City, KS, and Katherine Squibb, 

University of Maryland, College Park, 

MD 

For Advisors 

12:45 PM–1:45 PM Tips for Advising Prospective 

Graduate Students or How to get your 

students accepted to graduate school!! 

Speaker: William D. Atchison, Michigan 

State University, East Lansing, MI 

SPECIal Events



Outreach Activities and Events (Continued) 

All Participants 

2:00 PM–2:40 PM Career Opportunities in Toxicology— 

Panel Discussion 

Moderator: Les Recio, Integrated 

Laboratory Systems Inc., Research 


Academic: Alvaro Puga, University of 

Cincinnati, OH 

Government: Marquea King, U.S. EPA, 


Industry: Mari Stavanja, Celanese 

International Corporation, Dallas, TX 

For Host Mentors and Peer Mentors 

3:00 PM–3:30 PM Host Mentor and Peer Mentor 

Meeting 

Chairperson(s): Jennifer Rayner, 

Oak Ridge National Laboratory, Oak 

Ridge, TN, and Adrian Nanez, Amgen, 


For Students and Advisors 

3:00 PM–5:00 PM Open time with Academic Toxicology 

Program Directors and Internship 

Sponsors 

Chairperson(s): Kim Daniel, Texas 

A&M, College Station, TX 

8:00 PM–9:30 PM Student/Postdoctoral Scholar Mixer 



Monday activities are for undergraduate students and advisors 

receiving 2011 SOT Travel funding and SOT program 

volunteers. 

7:20 AM–7:30 AM Meeting for Students, Advisors, Peer 

Mentors, and SOT Hosts 

Chairperson(s): Adrian Nanez, Amgen, 


Undergraduate Toxicology Faculty Meeting 


Room 103 

Chairperson(s): Aaron Barchowsky, University of Pittsburgh, 

Pittsburgh, PA. 

Sponsors: 


Undergraduate Education Subcommittee 

The Education Committee and the Undergraduate Education 

Subcommittee are hosting the Undergraduate Toxicology 

Faculty Meeting for all faculty involved in the teaching 

of toxicology to undergraduates, or for those interested in 

including toxicology at the undergraduate level. Hear an 

update on initiatives for undergraduate faculty, provide your 

input, and network. 

High School Research Poster Presentations 

Tuesday, March 8 and Wednesday, March 9 

Chairperson(s): Kathleen Gabrielson, Johns Hopkins University, 

Baltimore, MD. 

Sponsors: 



High school students will display their research posters in 

a special area in the SOT Pavilion. This activity recognizes 

student effort and provides the high school students who have 

engaged in research with scientific meeting experience. A 

schedule will be available on the SOT Annual Meeting Web 

site. 

8:00 AM–9:00 AM Plenary Lecture 

Francis S. Collins, National Institutes of 

Health, Bethesda, MD 

9:30 AM–10:50 AM Poster Session for Visiting Students 

Chairperson(s): Julio Davila, 

Chesterfield, MO, Yolanda Banks 

Anderson, North Carolina Central 

University, Durham, NC, and Javier 

Avalos, TopTox, Sacramento, CA 

11:00 AM–11:45 AM Program Wrap Up 

12:00 NOON–1:20 PM In Vitro Toxicology Lecture and 

Luncheon for Students—Full Speed 

into an Alternative Future 


Speaker: Robert E. Chapin, Pfizer, 

Groton, CT 



Satellite Meetings 

Johns Hopkins Center for Alternatives to 

Animal Testing—Evidence-Based Toxicology 

(EBT) Collaboration Kick-Off Meeting 

Thursday, March 10, 12:00 NOON–3:00 PM 

Room 206 


Presented by: 

The Johns Hopkins Center for Alternatives 

to Animal Testing 

A group of toxicologists with backgrounds in industry, 

government oversight, academia, and animal welfare have 

created the EBT Collaboration to foster the development of 

a process, based on the Cochrane Collaboration in Evidencebased 

Medicine (EBM), for quality assurance of new 

toxicity tests for the assessment of safety in humans and the 

environment. To start the collaboration and solicit input from 

the stakeholder community, the EBT Collaboration steering 

group is organizing a workshop to take place on March 10, 

2011, immediately following the Society of Toxicology Annual 

Meeting in Washington, D.C. At the workshop, speakers will 

present the concept of EBT as it pertains to decision-making 

about the utility of new toxicity tests and their implementation 

into the risk assessment process. EBT promises to provide a 

quality, science-driven approach to assessing the effects of 

drugs and chemicals on human health and the environment, 

and provides principles of how to incorporate published 

information into the decision-making process. The methods 

of EBM, to be applied to EBT, include the systematic review 

of relevant literature, scoring tools to prioritize published 

reports, and meta-analysis of data. This transparent process 

will represent another approach toward evaluation and quality 

assurance of new testing methodologies 

For further information and to register, go to caat.jhsph.edu. 

Meeting is open and free to all registrants. 


87


Continuing Education (Continued) 

Continuing Education Courses 

The Continuing Education Program offers a wide range of courses that 

cover established knowledge in toxicology, as well as new developments 

in toxicology and related disciplines. Courses can be applied toward 

certifying and licensing board requirements and may also be used for 

recertification with the American Board of Toxicology (ABT). Both basic 

and advanced course topics are offered. The basic course is intended to 

provide a broad overview of an area or to assist individuals in learning 

new techniques or approaches. The advanced course is intended to be of 

interest to individuals with previous knowledge of the subject or already 

working in the field. 

Target Areas 

The Continuing Education Program offers a wide range of courses that 

cover established knowledge in toxicology, as well as new developments 

in toxicology and related disciplines. Continuing Education courses 

related to these Target Areas appear under each target description. The 

Target Areas will be identified throughout the Program with a . 

Continuing Education Courses will also be tracked by Scientific Program 

Theme and identified throughout the Program with a . An Overview of 

the Scientific Thematic Track is located on the Front Fold-Out. 


CE 

All courses will be held on Sunday, March 6, 2011, at the Walter E. 

Washington Convention Center. Please check the signage in the registration 

area and at the CE Booths for room assignments. Note: Your course 

materials will be available in the room immediately prior to the course 

(they will not be available at the registration area). If you have your 

course ticket, go directly to the assigned course room. If you have not 

received your course ticket or have not registered, please go to the registration 

area on Saturday afternoon/evening or on Sunday morning. If you 

have misplaced your ticket, please go to a Continuing Education Booth 

at the Convention Center on Sunday. The booths will be open from 6:30 

AM–5:30 PM. 

7:00 AM–7:45 AM Continuing Education Sunrise Mini-Course: 

1. Biodegradable Materials for Tissue Engineering: Applications and 

Safety Assessment 

8:15 AM–12:00 NOON Continuing Education Morning (AM) Courses: 

2. Best Practices for Developing, Characterizing, and Applying 

Physiologically Based Pharmacokinetic Models in Risk 

Assessment 

3. Current Nonclinical Strategies and Methods for Evaluating 

Drug-Induced Cardiovascular Toxicity 

4. Dealing with the Data Deluge: A Live Data Discovery and Analysis 

Course (Note: Participants will be asked to supply their own 

computer with Internet access) 

5. Epigenetics in Toxicology: Introduction, Mechanistic 

Understanding, and Applications in Safety Assessment 

6. Protecting Human Health: Use of Toxicological and 


Exposure 

7. Drug Hypersensitivity Reactions: Risk Assessment and 

Management 

8. Toxicology and Risk Assessment of Chemical Mixtures 

1:15 PM–5:00 PM Continuing Education Afternoon (PM) Courses: 

9. Applications of Computational Systems Biology for Toxicology 

10. Evaluating Toxicity of Engineered Nanomaterials: Issues with 

Conventional Toxicology Approaches 

11. New Technologies and Approaches in Genetic Toxicology 

and Their Expanding Role in General Toxicology and Safety 

Assessment 

12. Practical How-To and Pitfalls Associated with Current Epigenetic 

Studies 

13. Quantitative In Vitro to In Vivo Extrapolation: The Essential 

Element of In Vitro Assay-Based Risk Assessment 

14. Stem Cell Utility in Toxicology Screening 

15. The Biology and Toxicology of the Peri- and Post-Natal 

Development 

Registration for the Annual Meeting and a separate CE course ticket are 

required. 

The cardiovascular system comprises heart muscle and the vascular 

system. Proper maintenance of blood pressure and flow is a fundamental 

requirement for life. Insult to the cardiovascular system may occur by 

direct or indirect mechanisms, such as perturbations of the central nervous 

system or endocrine system. A basic understanding of cardiovascular 

toxicology is fundamental for naturally occurring substances, drugs, 

industrial compounds and environmental contaminants. The importance 

of this system and a testament to the need for further understanding is 

supplied by the fact that cardiac toxicity alone has been implicated in 28% 

of drug withdrawals in the United States over the last 30 years, including 

20 major drugs withdrawn in that period. Special consideration will be 

given to course proposals that present general concepts of cardiovascular 

toxicology and fundamental understanding of experimental design and 

data interpretation for toxicity testing that can be extrapolated to humans. 

• AM03: Current Nonclinical Strategies and Methods for Evaluating 


• Poster Session: Cardiovascular Toxicology 


The field of epigenetics encompasses the study of heritable changes in 

gene expression that vary as a result of both mutational and non-mutational 

events. Histone modification, DNA methylation, and nucleosomal 

remodeling are a few examples of cellular processes that, when subtly 

perturbed, may drive or facilitate a critical shift in genotype-phenotype 

relationship in fundamental physiological processes. Epigenetic 

mechanisms have been implicated in myriad disease states including 

cancer, autoimmune disorders, and drug resistance/drug hypersensitivity, 

and are recognized as key determinants of individual responses to and 

susceptibility to xenobiotics. Identifying and understanding the relative 

contribution of epigenetic mechanisms in “normal” and altered cellular 

function may be a key step in developing new strategies for diagnosing 

and treating pathological disorders and toxicities. This solicitation is for 

continuing education courses taught by a panel of experts in the field. A 

basic course would present fundamentals of epigenetics, including mechanisms, 

as they relate to “normal” physiological development and function 

and gender, age and species-specific differences in determining the mode 

of xenobiotic action and sensitivity to toxic effects, and the relationship 

between epigenetic changes and the development and progression of 

certain disease states, and the role of epigenetic changes in determining 

the mode of action of toxicants. An advanced course would present, in 

addition to these basic principles, practical applications of epigenetics in 

toxicological, biomedical research and/or clinical medicine. 

• AM05: Epigenetics in Toxicology: Introduction, Mechanistic 


• Poster Session: Epigenetic Mechanisms 

• Platform Session: Epigenetic Mechanisms in Development and 

Disease 

• PM12: Practical How-To and Pitfalls Associated with Current 

Epigenetic Studies 





2011 Continuing Education Courses 

In the context of toxicology, a systems-level understanding of biology 

utilizes “a set of principles and methodologies that links the behavior of 

molecules to system characteristics and functions.” Simply put, information 

at different levels of organization within an organism is integrated 

to obtain an understanding of the organism as a whole and its response to 

chemical perturbations. Molecules such as DNA, RNA, and proteins are 

organized through a framework of knowledge into signaling pathways 

that determine cellular behavior. The cells are organized in the same 

manner into tissues, tissues organized into organs, and so on until the 

individual functional components that make up an organism are arranged 

within multiple, interacting layers. The interrelationships of the individual 

components and organizational layers dictate the response of the system 

to chemical perturbation. Due to the diversity in the types of data required 

for understanding these relationships and the computational tools necessary 

for assembling and simulating the flow of information through the 

different levels of organization, an interdisciplinary team and collaborative 

environment are required. This solicitation is for continuing education 

courses taught by interdisciplinary teams with expert knowledge in the 

field. A basic-level course would present an overview of systems biology 

and demonstrate the types of experimental data, analysis methods, and 

simulation approaches that are necessary for success. An advanced level 

course would, in addition, extend this knowledge base by addressing 

additional technical points like choosing types of data and identifying data 

sets for evaluation and choosing computational methods for integration. 

Course proposals should contain sufficient examples to demonstrate key 

points. 

• AM04: Dealing with the Data Deluge: A Live Data Discovery and 

Analysis Course (Note: Participants are asked to bring their own 

computer with Internet access) 

• Poster Session: ‘Omics in Toxicology Research 

• AM09: Applications of Computational Systems Biology for 


Sunday Morning, March 6 

7:00 AM to 7:45 AM 

First Level 

(See signage at CE Booth for room location) 

Biodegradable Materials for Tissue Engineering: Applications 

and Safety Assessment 

SR01 

CE Basic 

Chairperson(s): Ronald P. Brown, U.S. FDA, Silver Spring, MD, 

and Richard W. Hutchinson, Ethicon Inc., Johnson & Johnson, The 

Woodlands, TX. 

Sponsor: 


Endorsed by: 


The incorporation of biodegradable materials as a fundamental component 

in tissue regeneration strategies began in the early 1980’s and 

continues today. The function of a biodegradable material is to act as a 

temporary support matrix for transplanted or host cells so as to restore, 

maintain, or improve tissue. In order for this function to be achieved, 

biodegradable materials must undergo a number of critical examinations 

to define their properties. For example, degradation rate, degradation 

products, and the tissue response to these products must all be characterized. 

In this presentation we will introduce a number of natural and 

synthetic biodegradable materials that are commonly considered in regenerative 

medicine, as well as some recently developed novel materials. The 

techniques utilized to describe their physical properties and the relationship 

between physical properties and tissue response will be examined, 

and advanced techniques for material characterization and toxicological 

effects will be considered. Finally, the application of these biodegradable 

materials in tissue engineering strategies will be described. 

CE 

Stay Competitive 

with SOT On-Line Courses 

Selected 2009 and 2010 Continuing 

Education Courses Available On-Line 

Toxicology is an ever-changing field. SOT Continuing 

Education courses are an excellent way to enhance your 

professional development and learn new techniques. SOT 

is dedicated to providing such opportunities and resources 

to the scientific community and the Continuing Education 

Committee is excited to offer on-line CE courses through 

the SOT Web site. Currently there are six on-line courses 

from the 48th Annual Meeting in Baltimore, 2009 and the 

49th Annual Meeting in Salt Lake City, 2010. Whether you 

want a refresher course, or to expand your knowledge, the 

on-line Continuing Education courses offer you a convenient 

way to stay competitive! 

Visit the SOT Web site for more information. 

• Biodegradable Materials for Tissue Engineering: Applications and 

Safety Assessment, John P. Fisher, University of Maryland, College 

Park, MD 


8:15 AM to 12:00 NOON 

First and Second Level (See signage at CE Booths for room 

locations) 

Best Practices for Developing, Characterizing, and Applying 

Physiologically Based Pharmacokinetic Models in Risk 

Assessment 

AM02 

CE Advanced 

Chairperson(s): M.E. (Bette) Meek, University of Ottawa, Ottawa, 

Ontario, Canada, and John C. Lipscomb, U.S. EPA, Cincinnati, OH. 

Sponsor: 


Endorsed by: 


This course is aimed at increasing confidence in the evaluation and application 

of PBPK models in quantitative health risk assessments, through 

systematic consideration of relevant criteria for their development and 

documentation, based on guidance. These principles (Best Practices for 

PBPK Modeling Applied to Health Risk Assessment) have been recently 

collected and expanded upon in guidance published by the WHO International 

Programme on Chemical Safety (2010), and have been the 


89



CE 

subject of several other peer-reviewed publications. The course comprises 

lectures describing the link between mode of action, dose-response characterization 

and risk assessment, and the role of PBPK models in reducing 

and characterizing uncertainty and variability. The course will present 

principles for the development, characterization, and communication and 

criteria for evaluation of PBPK models for risk assessment applications. 

A novel inclusion will be a projected demonstration of real-time changes 

in model outcome that depend on choice of model parameter values (e.g., 

breathing rate, metabolic activity). The demonstration of user-friendly 

model development software will be demonstrated in the final lecture. 

This will show the impact of choices for parameter values, and models 

will be exercised and the results interpreted to produce quantitative values 

to be used in place of uncertainty factors in health risk assessments. 

• Toxicokinetics in Risk Assessment, John C. Lipscomb, U.S. EPA, 

Cincinnati, OH 

• Developing a PBPK Model, Hugh Barton, Pfizer, Inc., Groton, CT 

• Characterizing a PBPK Model, Kannan Krishnan, Université de 

Montréal, Montréal, Québec, Canada 

• Applying PBPK Models in Risk Assessment, George Loizou, Health 

and Safety Laboratory, Buxton, United Kingdom 

• Case Study 1, Bette Meek, University of Ottawa, Ottawa, Ontario, 

Canada 

• Case Study 2, Jos Bessems, RIVM, Bilthoven, Netherlands 


8:15 AM to 12:00 NOON 


locations) 


Current Nonclinical Strategies and Methods for Evaluating 


AM03 

CE Basic 

Chairperson(s): Hong Wang, Genentech Inc., South San Francisco, 

CA, and Dennis J. Murphy, GlaxoSmithKline Pharmaceuticals, King of 

Prussia, PA. 

Sponsor: 

Cardiovascular Toxicology Specialty Section 

Endorsed by: 

Drug Discovery Toxicology Specialty Section 


Cardiovascular (CV) toxicity is among the major causes of withdrawal 

of drugs or restriction in their labeling and has had an impact on public 

health and the rising cost of developing new drugs. Early identification 

and characterization of CV liabilities, better understanding of the predictive 

values of nonclinical models, and an integrated and iterative approach 

during drug development could greatly facilitate the development of safe 

and effective medicines for patients. This course will describe the current 

in vitro and in vivo methods for evaluation of functional and structural 

CV liabilities, and discuss the strategies that can be applied at early 

stages of drug development to help reduce attrition and to avoid unanticipated 

liabilities at later development stages in either animal studies 

or in the clinic. Study design and data interpretation will be discussed, 

as well as the advantages, limitations, and future directions of current 

methods involving both functional and structural assessments. Specific 

topics such as integration of functional CV endpoints into repeat-dose 

toxicity studies, methods for identification and characterization of cardiac 

arrhythmia, and special considerations for testing oncology and diabetes 

drugs and biologics will be covered. In addition, case study examples 

will be provided to highlight how these data can be used to inform decisions 

at different stages of development. A regulatory perspective on the 

challenges and gaps of CV safety evaluations and opportunities available 

to improve the overall CV safety assessment paradigm will also be 

presented. Overall, this course will provide participants with a broad overview 

of the types of drug-induced CV liabilities, the current nonclinical 

strategies and methodologies for early detection of CV liabilities, and a 

regulatory perspective on the impact of CV toxicity on the drug-development 

process. 

• Opening Remarks and Overview of Cardiovascular Toxicity, 

Dennis J. Murphy, GlaxoSmithKline Pharmaceuticals, King of Prussia, 

PA 

• Early Identification of Cardiovascular Functional Liabilities: 

Role of In Vitro Assays, Derek Leishman, Eli Lilly & Company, 

Indianapolis, IN 

• Integrated Assessment of Cardiovascular Functional Liabilities: In 

Vivo Animal Models, R. Dustan Sarazan, Data Sciences International, 

St. Paul, MN 

• Assessment of Cardiovascular Injury: Morphological Evaluations 

and Biomarkers, Brian Berridge, GlaxoSmithKline Pharmaceuticals, 


• A Regulatory Perspective on Drug-Induced Cardiovascular 

Liabilities: Challenges, Gaps, and Opportunities, John Koerner, 

U.S. FDA, Silver Spring, MD 


8:15 AM to 12:00 NOON 


locations) 


Dealing with the Data Deluge: A Live Data Discovery and 

Analysis Course 

AM04 

CE Basic 

Chairperson(s): Marc E. Gillespie, St. Johns University, Jamaica, NY, 

and Susan M. Bello, Jackson Laboratory, Bar Harbor, ME. 

Sponsor: 


NOTE: Due to the unique “hands on” nature of this course, it is critical 

for AM04 course attendees to bring their own laptop computer as well 

as their own Internet network connection. The Walter E. Washington 

Convention Center offers Internet service for a nominal fee if attendees 

prefer to buy connectivity on-site. 

Using Web based resources and tools to gain novel scientific insights 

and advance your research is a significant step for all researchers. As 

the pace of science accelerates, experimental technologies continue 

to evolve and the quantity of data increases. With the evolution in 

biological research comes an increasing reliance on database resources 

and computational analysis tools to parse and integrate this growing 

mass of biological data. The field of toxicology is not exempt from these 

challenges. In this course, representatives from a diverse group of data 

resources have joined their efforts to present a unique series of handson 

tutorials. The tutorials follow a hypothetical researcher through the 

various stages of experimental design and data analysis, demonstrating 

how the different workshop resources can be used to facilitate all steps 

of the research process. Participants will identify orthologous biological 

information across different species; identify biological trends (pathway, 

function, phenotype, xenobiotic interactions) within a submitted data 

set; investigate an individual data set with on-line resources, identifying 

supplementary information available across multiple data sets; and gain 

hands on experience with formatting and submitting data to a diverse set 

of on-line data resources. 




Today toxicologists must select appropriate model organisms, manage 

abundant high-throughput data, understand legacy data, and develop 

pathway-based understanding of environmental factors influencing 

biological systems. Mastery of these concepts improves toxicity prediction 

while providing insights into environmentally influenced diseases 

and phenotypes. A clear understanding of the diverse on-line data resource 

aims and limitations equips the researcher with the best combination of 

resources to effectively address their questions. 

• Reactome Knowledgebase, Marc E. Gillespie, St. Johns University, 

Jamaica, NY 

• Comparative Toxicogenomics Database (CTD), Carolyn J. 

Mattingly, Mount Desert Island Biological Laboratory, Salisbury Cove, 

ME 

• PharmGKB, Teri E. Klein and Li Gong, Stanford University Medical 

Center, Stanford, CA 

• Mouse Genome Informatics Database, Susan M. Bello, Jackson 

Laboratory, Bar Harbor, ME 


8:15 AM to 12:00 NOON 


locations) 


Epigenetics in Toxicology: Introduction, Mechanistic 


AM05 

CE Basic 

Chairperson(s): Mayurranjan S. Mitra, Washington University School of 

Medicine, St. Louis, MO, and Thomas Sussan, Johns Hopkins University 

Bloomberg School of Public Health, Baltimore, MD. 

Sponsor: 


Endorsed by: 




Epigenetics refers to molecular mechanisms that cause heritable changes 

in gene expression without altering the DNA sequence. The most 

widely studied epigenetic mechanisms encompass DNA methylation, 

histone modifications, and gene regulation by non-coding RNAs, such 

as microRNAs. Typically, these mechanisms are required for normal 

cellular development and differentiation; however, perturbations in 

them can lead to diseases, notably cancer. Increasing evidence suggest 

that environmental factors such as diet, stress, and exposure to radiation 

and xenobiotics can induce heritable changes in the epigenetic status, 

potentially affecting the health of the present and future generations. 

Importantly, the long-term and life-threatening consequences of environment/chemical-induced 

changes in epigenetics, makes this field a critical 

area for future exploration by toxicologists. The course will begin by 

introducing the fundamental concepts of epigenetics and reviewing the 

various underlying mechanisms. Methods to assess epigenetic changes 

will be discussed, followed by a discussion of the role of DNA cytosine 

methylation in the regulation of carcinogen-inducible CYP450 genes. 

Mechanistic understanding of the role of microRNAs in the regulation 

of cellular toxicity and the influence of environment on epigenetics that 

cause developmental effects will also be presented. Finally, the future of 

epigenetics in toxicology and its potential applications for safety assessment 

will be discussed. Students as well as toxicologists working in 

academia, federal and pharmaceutical industries, and researchers interested 

in mechanistic toxicology will benefit from taking this course. 

• Introduction, Mayurranjan S. Mitra, Washington University School of 

Medicine, St. Louis, MO 

• Introduction and Overview of Epigenetics, James G. Herman, The 

Johns Hopkins School of Medicine, Baltimore, MD 

• Role of Epigenetics in the Regulation of Carcinogen-Metabolizing 

Enzymes, Oliver Hankinson, University of California Los Angeles, 

Los Angeles, CA 

• Retroelements and MicroRNAs in the Epigenetic Regulation of 

Cellular Differentiation, Proliferation, and Toxicity, Kenneth S. 

Ramos, University of Louisville, Louisville, KY 

• Epigenetic Gene Regulation: Linking Early Developmental 

Environment to Adult Disease, Dana Dolinoy, University of 

Michigan, Ann Arbor, MI 

• What We Need to Know Prior to Incorporating an Epigenetic 

Evaluation into Safety Assessments, Jay I. Goodman, Michigan State 

University, East Lansing, MI 


8:15 AM to 12:00 NOON 


locations) 

Integration of Toxicological and Epidemiological Evidence 

to Understand Human Risk 

Protecting Human Health: Use of Toxicological and 


Exposure 

AM06 

CE Basic 

Chairperson(s): Eileen P. Hayes, EP Hayes Toxicology Services LLC, 

Longmont, CO, and Terry Gordon, New York University School of 

Medicine, Tuxedo Park, NY. 

Sponsor: 


Toxicological and epidemiological data are the basis for risk assessment 

processes used to determine acceptable levels of exposure. This is the 

case for the general public who may be exposed to pollutants via ambient 

air and/or drinking water, for workers who may be exposed to chemicals 

in the workplace, and for patients who may have exposure to both active 

pharmaceutical ingredients (API) and impurities that may be present in 

the product. The goal of this course is to provide students with an understanding 

of the regulatory background and the practical application of 

both toxicological and epidemiological information in setting exposure 

levels considered to be protective of public health. The objectives of this 

course are 1) to describe the regulatory requirements that underlie development 

of acceptable levels of exposure for either the general population 

or select populations (workers, patients) via the media described above; 

and 2) to describe the evaluation of toxicological and epidemiological 

data in determining acceptable levels of exposure. Case studies of representative 

compounds will illustrate the processes. The U.S. Environmental 

Protection Agency (U.S. EPA) has well-defined processes for establishing 

both National Ambient Air Quality Standards (NAAQS) under the Clean 

Air Act and drinking water Maximum Contaminant Levels (MCLs) under 

the Safe Drinking Water Act. The Occupational Health and Safety Administration 

(OSHA) promulgates permissible exposure limits (PELs) for the 

workplace. The American Conference of Government Industrial Hygienists 

(ACGIH), a nonprofit, non-governmental organization publishes 

Threshold Limit Values (TLVs) that are used globally by many public and 

private-sector employers to protect the health of their employees. Additionally, 

many employers have established programs to derive acceptable 

levels of workplace exposure for compounds not specifically regulated 

by government agencies. Acceptable identification, reporting, and safety 

thresholds for impurities in drug products are governed under guidance 

CE 


91



CE 

documents issued by the International Committee on Harmonization 

(ICH), the U.S. Food and Drug Administration and the European Medicines 

Agency. The course will highlight legal and customary definitions 

of “acceptable risk,” as well as risk assessment methods for evaluating 

data to estimate risk levels under these programs. The regulations and/ 

or guidances will be detailed and approaches used to comply with them 

will be described. This course will begin with a description methods 

underlying U.S. EPA actions to protect the general public, i.e., establishment 

of NAAQS and MCLs. The course will then detail requirements, 

guidance, and processes to protect specific populations, i.e., workers and 

patients. In each case representative examples will be used to illustrate the 

processes. The application of toxicological and epidemiological data in 

these programs will be described. 

• Introduction, Eileen P. Hayes, EP Hayes Toxicology Services LLC, 

Longmont, CO 

• Clean Air Regulation: Science and the Process, Daniel L. Costa, 

U.S. EPA, Research Triangle Park, NC 

• Drinking Water Regulation: Science and the Process, Rita Schoeny, 

U.S. EPA, Washington, D.C. 

• Setting Occupational Exposure Limits, Bruce D. Naumann, Merck 

& Co., Inc., Whitehouse Station, NJ 

• Qualification of Impurities in Drug Products, Timothy J. 

McGovern, SciLucent, LLC, Herndon, VA 


8:15 AM to 12:00 NOON 


locations) 

Drug Hypersensitivity Reactions: Risk Assessment and 

Management 

AM07 

CE Basic 

Chairperson(s): Marija Popovic, Eli Lilly & Company, Indianapolis, 

IN, and Jessica Whritenour, Pfizer Global Research and Development, 

Groton, CT. 

Sponsor: 


Drug hypersensitivity reactions are not a common problem in drug development; 

however, when they do occur they can have a significant impact 

on the drug candidate’s developmental success. Drug hypersensitivity 

reactions are usually discovered in Phase II or III clinical trials, or in the 

post-marketing phase. Once allergic reactions are observed in patients, 

one needs to determine if the reaction is mediated by an immune response 

to the drug, or another mechanism. There are a few ex vivo diagnostic 

methods that can be used to identify immune-mediated reactions, but one 

needs to be aware of the limitations and advantages of each approach. 

In vitro methods, or animal models presently being developed to predict 

drug’s potential to trigger hypersensitivity reaction in the patient population 

are being developed, but at present, they have significant limitations. 

Risk management strategies may include selection of patient populations 

based on the HLA haplotype. This course is intended as an introduction 

for those with limited background in the area of hypersensitivity, or 

allergic reaction to drugs. The focus of the course will be on systemic 

hypersensitivity reactions (drug administered orally or parenterally) 

and will include discussions both on drugs that are small molecules and 

biologics. 

• Impact and Issues Associated with Drug Hypersensitivity 

Reactions on Drug Development and Commercialization, Thomas 

T. Kawabata, Pfizer Global Research and Development, Groton, CT 

• Clinical Overview: Description of the Types of Drug 

Hypersensitivity Reactions, Franklin Adkinson, Johns Hopkins 

University, Baltimore, MD 

• Mechanisms of Drug Hypersensitivity Reactions: Types I-IV 

Mechanisms, Hapten, PI, and Danger Hypotheses, Cynthia Ju, 

University of Colorado, Denver, Aurora, CO 

• Pseudoallergic and Anaphylactoid Drug Hypersensitivity 

Reactions, Jessica Whritenour, Pfizer Global Research and 

Development, Groton, CT 

• Risk Management of Drug Hypersensitivity Reactions: Application 

of Diagnostic Testing and Pharmacogenomic Approaches, Thomas 

T. Kawabata, Pfizer Global Research and Development, Groton, CT 

• Predictive Testing: Different Animal Models and Future 

Possibilities, Marija Popovic, Eli Lilly & Company, Indianapolis, IN 


8:15 AM to 12:00 NOON 


locations) 

Toxicology and Risk Assessment of Chemical Mixtures 

AM08 

CE Basic 

Chairperson(s): Jane Ellen Simmons, U.S. EPA, Research Triangle Park, 

NC, and Christopher J. Borgert, Applied Pharmacology Toxicology, Inc., 

Gainesville, FL. 

Sponsor: 


Endorsed by: 


Occupational Health and Public Health Specialty Section 

Assessment of the safety and risk of environmental chemicals, pharmaceuticals, 

consumer and personal care products, pesticides, and food 

additives increasingly requires consideration of the potential pharmacological 

and toxicological interactions that might occur as these agents 

are encountered as mixtures by patients, consumers, and through environmental 

exposures (e.g., mixtures present in air, water, soil). Both 

toxicological evaluations and risk assessments of mixtures of chemicals 

are complex due to the potential pharmacokinetic and pharmacodynamic 

mechanisms that might result in nonadditive interactions. While greater 

than expected toxicity is of most concern for environmental exposures, 

both less than and greater than additive toxicity are of pharmacological 

concern. Toxicological evaluation of chemical mixtures necessitates study 

designs, methods of analysis, and limits on interpretation not required 

for single chemicals. This course will cover the fundamentals of study 

design and data analysis for mixtures that apply to all classes and categories 

of chemicals encountered by humans and animals, regardless of 

market application. The objectives of this course are to 1) describe the 

basic principles that underlie modern concepts of the toxicology and risk 

assessment of chemical mixtures; 2) survey the basic tools and techniques 

needed to design, conduct, analyze and interpret experimental data with 

defined or complex mixtures of chemicals; and 3) review the guidance, 

underlying assumptions, and techniques used in risk assessment of chemical 

mixtures. This course will be of interest to experimentalists who wish 

to conduct studies on mixtures that are meaningful for evaluation of risk 

as well as safety and risk assessors who must evaluate and apply data on 

mixtures and interactions in assessments. 

• Basic Principles of Additivity Underyling Methods, Designs, and 

Techniques for Evaluation of Mixtures, Jane Ellen Simmons, U.S. 

EPA, Research Triangle Park, NC 




• The Intersection of Design and Interpretation of Mixtures Data, 

Christopher J. Borgert, Applied Pharmacology Toxicology, Inc., 

Gainesville, FL 

• Pharmacokinetic and Pharmacodynamic Mechanisms of 

Interactions in Mixtures, Sami Haddad, Université de Montréal, 

Montréal, Québec, Canada 

• Applications of Mixtures Data in Health Risk Assessment, Moiz 

Mumtaz, CDC-ATSDR, Atlanta, GA 

• From Dynamics to Decisions: Quantitative Modeling of the 

Mammalian DNA Damage Response, Jared E. Toettcher, University 

of California San Francisco, San Francisco, CA 

• Dynamic Regulation of Growth Factor Signaling Networks, Jason 

M. Haugh, North Carolina State University, Raleigh, NC 

• Stochastic Gene Expression and Heterogeneous Cellular Response, 

Sudin Bhattacharya, The Hamner Institutes for Health Sciences, 


Sunday Afternoon, March 6 

1:15 PM to 5:00 PM 


locations) 


System Biology 

Applications of Computational Systems Biology for 


PM09 

CE Basic 

Chairperson(s): Melvin E. Andersen, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, and Rory B. Conolly, U.S. EPA, 

Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 


The field of toxicity testing and risk assessment is undergoing a shift from 

reliance on high dose animal studies towards increased use of human 

in vitro systems that promise to provide mechanistic understanding 

of toxicity for environmentally relevant low dose exposure. For this 

fundamental change, toxicologists will need to adopt more integrated 

experimental and computational approaches to resolve the structures 

of key signaling pathways, which are composed of functional network 

motifs, and to understand the consequences of chemical perturbation on 

the dynamic and steady-state behaviors of these pathways. This course 

introduces state-of-the-art computational systems biology tools that are 

being used for organizing and understanding molecular circuits under 

both physiological and perturbed conditions. A broad overview will first 

provide a historical context of dose-response studies based on understanding 

mode of action through cellular pathway perturbation. The 

course will describe signaling properties of a suite of recurring network 

motifs, including ultrasensitivity, feedback, and feedforward loops, to 

appreciate the basic building blocks of complex biochemical pathways 

and networks. Secondly, focusing on the DNA damage response and cell 

cycle progression pathways, we will illustrate how these network motifs 

are organized into molecular circuits to give rise to higher-level cellular 

functions and if perturbed, how functional aberrations result. Signal transduction 

networks activated by growth factors are then examined to show 

how pathway cross-talk and feedback loops define the activation logic of 

the downstream MAPK, which is a key determinant of cell growth and 

survival. Finally, we will shows how stochastic gene expression and the 

resulting non-genetic cell-to-cell variability plays a role in influencing 

dose-response curves using examples such as B cell differentiation and 

its disruption by dioxin. The course concludes with a short summary and 

suggestions for applying these computational systems biology tools to 

future toxicity testing. 

• Introduction, Melvin E. Andersen, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC 

• Network Signaling Motifs, Qiang Zhang, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC 


1:15 PM to 5:00 PM 


locations) 

Toxicity Testing: State of Science and Strategies to 

Improve Public Health 

Evaluating Toxicity of Engineered Nanomaterials: Issues with 

Conventional Toxicology Approaches 

PM10 

CE Basic 

Chairperson(s): Srikanth S. Nadadur, NIEHS, Research Triangle Park, 

NC, and Frank A. Witzmann, Indiana University School of Medicine, 

Indianapolis, IN. 

Sponsor: 


Endorsed by: 



Inhalation and Respiratory Specialty Section 

Engineered nanomaterials (ENMs) have become an integral part of 

numerous consumer products, cosmetics, building materials, medical 

devices, therapeutic agents, and environmental remediation. Global 

demand for nanomaterials and nano-enabled devices has been projected 

to surpass $3.1 trillion by 2015. The widespread use of nanotechnologyderived 

products presents opportunities for intentional and unintentional 

exposure to ENMs. The size and size-dependent novel physical and chemical 

properties that make ENMs unique compared to micro-scale products 

of similar chemical composition makes it difficult to determine their interaction 

with biological matrices. The recent flood of toxicology literature 

without proper physical and chemical characterization of ENMs proposes 

adverse to no health effects for certain common ENMs such as carbon 

nanotubes and metal oxide nanoparticles. The course will provide an 

overview of the issues facing nanotechnology that the scientific community 

must grapple with in regard to predicting toxicity and biological 

outcomes associated with nanoscale properties and the need to identify 

and integrate novel approaches for safety of ENMs. To begin, focus will 

be placed on the importance of incorporating physical and chemical 

characteristics of ENMs in interpreting biological data; high throughput 

in vitro approaches using multiple parameters to classify ENMs toxicity 

profile will then be covered. Altered proteomic profiles in a model in 

vitro system to understand molecular alterations will be explored. Finally, 

the interpretation of data from in vivo studies using inhalational routes of 

exposure will be discussed. The goal of this course is to encourage both 

the novice and the toxicologist trained in conventional toxicity assessment 

to think outside the box to design rational toxicology studies in evaluating 

the safety of ENMs that are currently in use, and to develop models to 

predict potential toxicity of second and third generation ENMs. 

• Engineered Nanomaterials (ENMs) Toxicity Evaluation: Issues 

with Conventional Approaches, Srikanth S. Nadadur, NIEHS, 


CE 


93



CE 

• Importance of Integrating Physicochemical Characterization 

Information in Toxicity Assessment of Engineered Nanomaterials, 

Scott McNeil, National Cancer Institute, Bethesda, MD 

• Emergence of High Content Screening for Assessment of 

Nanotoxicity, Chris Vulpe, University of California Berkeley, 

Berkeley, CA 

• Proteomic Profiling of the Biological Effects of Engineered 

Nanomaterial Exposure Using In Vitro Models, Frank A. Witzmann, 

Indiana University School of Medicine, Indianapolis, IN 

• Correlating In Vitro and In Vivo Nanotoxicity: Limitations and 

Challenges, Günter Oberdörster, University of Rochester Medical 

Center, Rochester, NY 


1:15 PM to 5:00 PM 


locations) 



New Technologies and Approaches in Genetic Toxicology 

and Their Expanding Role in General Toxicology and Safety 

Assessment 

PM11 

CE Basic 

Chairperson(s): Jeffrey C. Bemis, Litron Laboratories, Rochester, NY, and 

Jennifer C. Sasaki, Johnson & Johnson, Raritan, NJ. 

Sponsor: 


Endorsed by: 


For decades, genetic toxicology and the “genetox battery” have been 

a well-established part of safety testing for pharmaceuticals and other 

chemical agents. Recent advances in experimental methodologies are 

contributing to a change in the way that genetic toxicology data are 

generated and incorporated in the disciplines of toxicology and safety 

testing. The intention of this course is to illustrate the broader impact that 

new genetic toxicology approaches are having on drug/chemicals safety 

assessment and human risk analysis. The structure of the course will 

provide examples of (1) Early discovery/high-throughput genotoxicity 

screening of chemical entities; (2) Integration of genetic toxicology assays 

with repeat-dose in vivo toxicology studies; and (3) New approaches for 

genotoxicity risk assessment, and conclude with an update on genotoxic 

impurity management strategies for pharmaceuticals. Speaker presentations 

will illustrate how genotoxicity testing is evolving from a hazard 

identification based-discipline to an integrated approach that may ultimately 

yield quantitative information that can be used for human risk 

assessment. 

This course should be of interest to experienced genetic toxicologists as 

well as those involved in general toxicology who want to learn about how 

incorporation of new genotoxicity methods can improve test predictivity, 

lower costs, reduce animal use, and may ultimately be applied to human 

risk assessment 

• Introduction, Jeffrey C Bemis, Litron Laboratories, Rochester, NY 

• High-Throughput Genetic Toxicity Screening Assays in Discovery 

Research & Development, Richard Walmsley, Gentronix, Ltd., and 

The University of Manchester, United Kingdom 

• The In Vitro Micronucleus Assay in Mammalian Cells: A High 

Content Assay, Anthony M. Lynch, GlaxoSmithKline, Hertfordshire, 

United Kingdom 

• Genetic Toxicity and Thresholds: State of the Science, B. Bhaskar 

Gollapudi, The Dow Chemical Company, Midland, MI 

• Integration of Genetic Toxicology Endpoints into Repeat-Dose 

Toxicity Studies, Maik Schuler, Pfizer PGRD, Groton, CT 

• Risk Assessment of Genotoxic Impurities in Pharmaceuticals, Lutz 

Mueller, Hoffmann La Roche, Inc., Basel, Switzerland 


1:15 PM to 5:00 PM 


locations) 


Practical How-To and Pitfalls Associated with Current 

Epigenetic Studies 

PM12 

CE Advanced 

Chairperson(s): Reza John Rasoulpour, The Dow Chemical Company, 

Midland, MI, and Chunhua Qin, Merck & Co., Inc., West Point, PA. 

Sponsor: 


The study of toxicant-induced epigenetic modifications is greatly 

expanding in complexity and scope as new tools of measuring these 

changes become available. Fundamental questions (e.g., how best to 

quantify changes) become enigmatic with DNA methylation, histone 

modifications, and microRNA epigenetic modifications that can affect 

imprinted, coding, non-coding, and global regions of the genome. 

Understanding these questions is important in interpreting species/ 

strain-specific responses. This advanced course is a practical guide to 

techniques used in epigenetic research with respect to toxicology for 

in vivo/ex vivo screening of rodent models, post-fertilization, embryos, 

developmental biology, and human disease states. Topics range from 

advancements in techniques to screening strategies and tools, and include 

techniques to correlate epigenetic changes to gene expression and apical 

end points, use of imprinted genes as biomarkers, and profiling DNA 

methylation in human population-based research. For screening tools to 

determine species-specific responses, a variety of novel technologies will 

be analyzed such as epigenomic profiling of DNA methylation in mouse 

tumors, pyrosequencing to examine the activity of endogenous retroviruses 

(e.g., IAP), and assays to explore miRNA and histone modification 

changes. In addition, cutting-edge techniques such as deep sequencing 

technologies of bisulfite-converted DNA will be discussed as these have 

enabled the characterization of methylation changes at the genome level; 

however, the significant challenge in using this technology is dealing 

with the massive amount of information obtained and making sense of 

the observed methylation changes. Scientists in academia, industry, and 

government will leave this course with an understanding of the strengths 

and weaknesses of available epigenetic tools, how these tools can be best 

used in screening and mode-of-action experiments, as well as insight into 

future potential of mechanistic epigenetic toxicology. 

• Screening Tools and Approaches for Methylation Analysis of 

Imprinted Genes, Reza John Rasoulpour, The Dow Chemical 

Company, Midland, MI 

• Profiling Epigenetic Changes in Rodent Tumor Models, Chunhua 

Qin, Merck & Co., Inc., West Point, PA 

• Evaluating Epigenetic Changes in Germ Cells and Early Embryos, 

Barbara F. Hales, McGill University, Montréal, Québec, Canada 




• Evaluating Epigenetic Changes Using Bisulfite Deep Sequencing, 

Russell S. Thomas, The Hamner Institutes for Health Sciences, 


• Population-Based DNA Methylation Profiling in Exposure-Related 

Disease, Carmen Marsit, Brown University, Providence, RI 


1:15 PM to 5:00 PM 


locations) 



Quantitative In Vitro to In Vivo Extrapolation: The Essential 

Element of In Vitro Assay-Based Risk Assessment 

PM13 

CE Basic 

Chairperson(s): Harvey J. Clewell, III, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, and Bastiaan Johan Blaauboer, 

Utrecht University, Utrecht, Netherlands. 

Sponsor: 


Endorsed by: 




There is increasing recognition of the need to use efficient approaches to 

assess the risk assessment of high numbers of chemicals in a short time. 

The reliance on approaches consisting of animal experimentation has its 

drawbacks in terms of ethical, economical, and—not least—scientific 

limitations in assessing risks in a high-throughput mode. The quantitative 

interpretation of toxic effects of compounds in in vitro studies, using 

in silico approaches such as systems biological descriptions of toxicity 

pathways and physiologically based pharmacokinetic modeling (PBPK), 

are a necessary component of the National Academy of Sciences vision 

on toxicity testing in the 21st Century. The limited studies performed with 

this approach to date have shown that good predictions for the risk of the 

use of chemicals can be made. However, a number of limitations have 

also become clear and more standardization of methods is needed before 

implementation of quantitative in vitro-in vivo extrapolations (QIVIVE) in 

risk assessments can be achieved. 

In this course, the following elements of the approach for assessing risks 

on the basis of in vitro toxicity data will be discussed: 

1. How can we improve the applicability of in vitro methods by determining 

the real concentrations that come into contact with the cells 

in vitro, both for chemical compounds and for particles? 

2. How can we effectively and efficiently integrate the metabolism of 

compounds, for clearance as well as for bioactivation? 

3. How can we provide a flexible and yet robust scheme for integrating 

the different elements in a high-throughput environment? 

• The Use of In Vitro Metabolism Data and Biokinetic Modeling to 

Conduct QIVIVE for Chemicals, Bastiaan Johan Blaauboer, Utrecht 

University, Utrecht, Netherlands 

• Characterizing Free Test Chemical Concentration during In 

Vitro Toxicity Assays, Nynke Kramer, Utrecht University, Utrecht, 

Netherlands 

• Particokinetic Modeling to Support QIVIVE for Particle Toxicity 

Assays, Justin G. Teeguarden, Pacific Northwest National Laboratory, 

Richland, WA 

• QIVIVE in a High-Throughput Environment, Harvey J. Clewell, 

III, The Hamner Institutes for Health Sciences, Research Triangle 

Park, NC 


1:15 PM to 5:00 PM 


locations) 


Bridging the Gap between Discovery and the Clinic through 

Translational Toxicology 

Stem Cell Utility in Toxicology Screening 

PM14 

CE Basic 

Chairperson(s): Manu M. Sebastian, Columbia University, New York, NY, 

and Zaher A. Radi, Pfizer Global Research and Development, Cambridge, 

MA. 

Sponsors: 

Society for Toxicologic Pathology 


The development of toxicological screening tools for evaluating toxicity 

of new drug candidates has been a major focus in the pharmaceutical 

industry. Human embryonic stem (hESC) cells and induced pluripotent 

stem (iPS) cells and their lineage cells can be used as tools to predict 

developmental and other toxicities of drug candidates since several of 

the human biochemical pathways are active in these cells. In addition, 

stem cells can also be used to help in the mechanistic understanding of 

how a specific class of compounds leads to toxicity. Participation in this 

course will provide a basic overview of the utility of stem cells in drug 

discovery and update toxicologists on a variety of stem cells applications 

as screening tool for evaluating toxicity in multiple organ systems, 

thereby giving toxicologists a better understanding of the potential practical 

application of these in vitro methods for safety and risk assessment. 

• Introduction: Stem Cells As Tools for Toxicology Screening, Manu 

M. Sebastian, Columbia University, New York, NY 

• Metabolomics of Human Embryonic Stem Cells and Predictive 

Biomarkers of Developmental Toxicity, Gabriela Cezar, University 

of Wisconsin, Madison, WI 

• Stem Cells and Mice with Humanized Livers: New Tools for Drug 

Metabolism and Toxicology, Stephen Strom, University of Pittsburgh 

Medical School, Pittsburgh, PA 

• Using Embryonic Stem Cell Models to Profile Potential 

Developmental Toxicants, E. Sidney Hunter III, U.S. EPA, Research 


• Stem Cells in Preclinical Drug Development, Hirdesh Uppal, 

Genentech, Inc., South San Francisco, CA 

• Concluding Remarks, Zaher A. Radi, Pfizer Global Research and 

Development, Cambridge, MA 

CE 


95




1:15 PM to 5:00 PM 


locations) 

The Biology and Toxicology of the Peri- and Post-Natal 

Development 

PM15 

CE Basic 

Chairperson(s): Gregg D. Cappon, Pfizer Global Research and 

Development, Groton, CT, and Gary J. Chellman, Charles River 

Laboratories, Reno, NV. 

Thank You 

Speakers 

CE 

Sponsor: 


The susceptibility to toxicity of organ systems during in utero and 

post-natal development is a concern for both drugs and environmental 

chemicals. While developmental toxicity can be manifested by death, 

structural abnormalities, and altered growth, alterations in the functional 

competence are of special concern during post-natal development. The 

primary focus in the past has been on functional toxicity to the CNS and 

reproduction, but the potential for developmental exposure to impact 

function of other systems such as the cardiovascular, respiratory, immune, 

endocrine, and digestive systems is now widely recognized. This basic 

course will begin with a review of post-natal development of major organ 

systems in humans and how those developmental processes might translate 

to sensitive periods for toxicity. Focus will be placed on study designs 

for evaluation of pharmaceuticals during the pre- and post-natal development 

period and designs for juvenile animal toxicity studies to support 

pediatric drug development. Next, designs will be presented for assessment 

of post-natal and juvenile toxicity studies in non-human primates, a 

rapidly expanding area given the increase in biopharmaceutical research. 

The course will wrap up with a discussion of multigenerational studies 

used to assess potential toxicity of environmental chemicals. Attendees 

will leave this course with an appreciation of the complex biology of 

pre- and post-natal development periods and an overview of current 

approaches to evaluating safety during this period. 

On behalf of the SOT Council and 

the entire membership of the Society 

of Toxicology (SOT), thank you to 

all of the speakers who graciously 

agreed to come to Washington, D.C., 

to participate in the 2011 Annual 

Meeting. SOT’s Annual Meeting 

is the largest international forum 

to highlight novel discoveries and 

emerging fields and how they apply to 

toxicology. You played an important 

role in helping SOT showcase this 

year’s achievements in research and 

education and your time, efforts, and 

expertise are truly appreciated. 

• Post-Natal Maturation of Major Organ Systems, Christopher J. 

Bowman, Pfizer Inc., Groton, CT 

• Post-Natal and Juvenile Toxicity Studies: Basic Study Designs and 

Practical Approaches, Donald G. Stump, WIL Research Laboratories 

LLC, Ashland, OH 

• Post-Natal and Juvenile Toxicity Studies in Non-Human Primates, 

Gary J. Chellman, Charles River Laboratories, Reno, NV 

• One and Two-Generation Studies for Assessment of 

Environmental Chemicals, Sue Marty, The Dow Chemical Company, 

Midland, MI 



Scientific Session Index (Continued) 

All sessions will be held at the Walter E. Washington Convention Center. 

General Scientific Sessions 

(Listed by type, then date and time) 

Education-Career 

Development Sessions 

Featured Sessions 


Informational Sessions 

Platform Sessions 


Regional Interest Session 

Roundtable Sessions 

Symposium Sessions 

Thematic Sessions 

Workshop Sessions 

Exhibitor Hosted Sessions are informative sessions developed by 

an exhibiting company. The Exhibitor Hosted Session Index is located on 

pages 41–42. 


Monday 

Date/Time Topic/Abstract # Room Page 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 


Emerging Issues at the 

Intersection of Reproductive and 

Mixtures Toxicology #16–21 

Environmental Oxidative 

Pollutant-Induced Pulmonary 

Toxicity #22–27 

High Content Imaging— 

Applications in Toxicology and 

Toxicity Testing #28–33 

Ribotoxic Stress: Mechanisms 

and Models for Human Disease 

#34–39 

Room 143 116 

Room 151 117 

Room 150 118 

Room 207 118 


Monday 

9:15 AM 

Monday 

9:15 AM 


Disease Prevention: The Next 50 

Years #40–46 

New Approaches for 

Integrating Toxicological and 

Epidemiological Data to Better 

Inform Risk Assessment #47–52 

Room 144 119 

Room 145 120 


Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Nanotoxicology—Carbon 

Nanotubes and Carbon 

Nanoparticles #53–61 

New Insights into Male 

Reproductive Toxicology #62–70 

Use of Embryonic Stem Cells in 

Toxicology #71–79 

Room 206 120 

Room 202A 121 

Room 204 122 


*Author attended 9:30 AM–11:00 AM; otherwise author attended 

11:00 AM–12:30 PM. Poster Board Surface Maps are on pages 104–107. 


Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

* Hypersensitivity: Methods and 

Mechanisms #80–98 

Poster Boards 101–119 

Epigenetic Mechanisms #99–110 


* DNA Replication and Repair 

#111–122 


Bioinformatic Profiling and 

Computational Pathway 

Prediction #123–159 


* Neurodegenerative Diseases 

#160–182 



#183–218 


* Carcinogenesis I #219–250 


Inflammatory Mediators in 

Disease Pathogenesis #251–264 


* Metals I #265–292 


Metals II #293–314 

Poster Boards 537–548 and 

601–610 

* Genotoxicity #315–343 


Receptor and Receptor- 

Mediated Toxicity #344–379 


* Cell Signaling and Gene 

Regulation #380–416 


ROUNDTABLE SESSION 

Exhibit Hall 123 














Monday 

12:10 PM 

Reforming the Toxic Substances 

Control Act (TSCA): Challenges, 

Opportunities, and Timing #417 

Room 144 151 

SESSion index 


97



SESSion index 



Monday 

12:10 PM 

The International Cooperation 

on Alternative Test Methods 

(ICATM): Translating Science to 

Provide Improved Public Health 

Safety Assessment Tools #418 

Room 143 152 



Monday 

12:10 PM 


Social Media and Informatics 

Essentials for Toxicologists #419 

Room 147 152 

*Author attended 1:00 PM–2:45 PM; otherwise author attended 

2:45 PM–4:30 PM. Poster Board Surface Maps are on pages 104–107. 


Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

* Drug Induced Liver Injury 

#420–443 


Acetaminophen Hepatotoxicity 

#444–463 


* Risk Assessment: Computational 

Approaches, Analyses, and 

Applications #464–505 


Animal Models in Toxicological 

Research #506–534 


* Animal Models in Toxicology 

#535–562 


Inhalation and Cardiopulmonary 



* Children’s Health/Juvenile 



Skin #631–648 


* Immunotoxicity: Methods and 

Evaluation #649–667 


601–617 

Mechanisms of Immunotoxicity 

#668–698 


* Biological Modeling: 

Computational Approaches, 

Mixtures, Multiroute and 

Lifestage Applications #699–737 


846–848 












Monday 

1:00 PM 

Monday 

1:00 PM 

Kidney #738–774 


* Pharmaceutical Safety 

Assessment: Therapeutic Agents 

#775–812 






Monday 

2:00 PM 

Monday 

2:00 PM 

Monday 

2:00 PM 

Monday 

2:00 PM 

Monday 

2:00 PM 


Epigenetics, Metals, and Cancer 

#813–818 

Human Variability in 

Susceptibility to Environmental 

Toxicants #819–824 

Toxicological Considerations 

in the Gulf of Mexico Oil Spill 

#825–830 

Translational Toxicology: 

Molecules to Global Health 

#831–835 

Vascular Developmental Toxicity: 

Identification, Prioritization, and 

Application #836–840 

Room 151 184 

Room 207 185 

Room 204 185 

Room 147 186 

Room 206 186 


Monday 

2:00 PM 

Monday 

2:00 PM 

Monday 

2:00 PM 


Protein Aggregation As a 

Common Mechanism of Toxicity 

in Neurodegenerative Diseases 

#841–845 

Technical Characterization 

and Dosimetry Challenges 

Associated with Conducting 

or Interpreting Nanotoxicity 

#846–851 

Understanding Structural 

and Physical Chemical Drivers 

of Drug Toxicity: Utility and 

Translatable Value #852–857 

Room 143 187 

Room 145 187 

Room 144 188 


Monday 

2:00 PM 

Monday 

2:00 PM 

Monday 

2:00 PM 

Advancing Assessment 

Approaches: Pesticides and 

Other Key Contaminants 

#858–866 


in Developmental 

Neurotoxicology: Validation and 

Application #867–873 

Biomarkers of Carcinogenesis 

#874–880 

Room 202B 189 

Room 201 189 

Room 202A 190 




ROUNDTABLE SESSIONS 

Tuesday 


Tuesday 

6:30 AM 

Tuesday 

6:30 AM 

Current Uses and Understanding 

of the Tissue Cross Reactivity 

Assay #881 

Risk and Risk Management of 

Potentially Toxic Compounds 

Formed by Cooking Food #882 


Room 144 193 

Room 143 193 


Tuesday 

6:30 AM 

Emerging Science for 

Environmental Health Decisions: 

Tools, Strategies, and Evidence 

#883 

Room 147 194 

REGIONAL INTEREST SESSION 


Tuesday 

9:00 AM 


Bombs in Our Backyards? 

Historical Military Activities and 

Current Public Health Issues in 

the U.S. Capital Region #927–933 

Room 150 199 


Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Computational Approaches to 

Address DILI and Hepatoxicity 

#934–941 

Epigenetic Mechanisms in 

Development and Disease 

#942–950 

Gene Regulatory Mechanisms of 

Carcinogenesis #951–958 

Room 204 200 

Room 201 200 

Room 202B 201 



Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 


Metabolic Basis of Respiratory 

Tract Chemical Toxicity #884–889 

Stem Cell Biology and Cell 

Therapy Approaches to 

Understanding Cellular Injury 

and Wound Healing in Dermal, 

Ocular, and Pulmonary Injury 

#890–895 

Uncovering the Role of 

Non-Coding RNAs in Toxicology 

#896–901 


Room 206 195 

Room 202A 196 

Room 147 196 


Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Identification of Chemical 

Respiratory Allergens: Principles 

and New Developments 

#902–907 

Safer Products for a Sustainable 

World: Linking Chemical Design 

and Toxicology #908–913 

Using Mode of Action Data 

to Guide Quantitative Cancer 

Risk Assessment: A Case Study 

of Hexavalent Chromium in 

Drinking Water #914–921 

HISTORICAL HIGHLIGHTS SESSION 

Room 207 197 

Room 144 197 

Room 143 198 


Tuesday 

9:00 AM 

1961 to 2011 and Beyond: 

The Evolution of Toxicology 

#922–926 

Room 151 199 

99 





Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

* Alternative Approaches to 

Animal Testing for Toxicological 

Research #959–989 


Alternatives to Mammalian 

Models for Testing #990–1021 


* Reproductive Toxicology I 

#1022–1048 


Reproductive Toxicology II 

#1049–1076 


* Hepatotoxicity #1077–1107 


Cholestasis, Lipid Homeostasis, 

and Liver Toxicity #1108–1120 


* Ah Receptor in Immune 

Regulation and Toxicity #1121– 

1139 


ImmunoSafety Methods in 

Non-Rodents #1140–1152 


* Stem Cell Toxicology #1153– 

1173 


Nanotoxicology: Carbon 

Nanotubes, Carbon 

Nanoparticulates, and Quantum 

Dots #1174–1197 












SESSion index



SESSion index 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

* Epidemiology and Exposure 

Evaluations #1198–1229 


Exposure Assessments and 

Biomonitoring Applications 

#1230–1268 


* Oxidative Stress and Redox 

Biology #1269–1308 







Tuesday 

12:00 PM 

Integrating Alternative Test 

Methods into the Federal 

Regulatory Framework #1309 

INFORMATIONAL SESSIONS 

Room 143 230 


Tuesday 

12:00 PM 

Tuesday 

12:00 PM 


Coordinating Global Chemical 

Safety: The Big Four #1310 

Livers on a Plate: Next 

Generation Hepatocyte Models 

for High-Throughput Screening 

and Mode of Action Prediction 

#1311 

Room 144 231 

Room 147 231 




Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

* Medical Devices #1312–1323 


Neurotoxicity of Pesticides 

#1324–1358 


* Genetic Polymorphisms #1359– 

1374 


Metal Neurotoxicity: 

Methylmercury and General 

#1375–1402 


* Mutagenecity #1403–1422 


Methods in Biomarker Discovery 

and Validation #1423–1452 


* Nanotoxicology #1453–1496 


Drug Allergy, Pseudoallergy, 

IDRH, and Autoimmunity 

#1497–1515 










Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

* Risk Assessment and Regulatory 

Policy Applications #1516–1540 


Safety and Risk Assessment: 

Critical Characterizations for 

Chemicals and New Concerns 

#1541–1582 


* ’Omics in Toxicology Research 

#1583–1606 


Developmental Toxicology 

#1607–1647 


* Apoptosis/Cell Death #1648– 

1673 



Biomarkers of Environmental 

Exposures #1674–1696 


843–848 and 930–940 








Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Developmental Origins of Adult 

Disease: The Effects of Low-Dose 

Lead #1697–1701 

Does the Clock Make the Poison? 

Influence of the Circadian Clock 

on Toxicological Mechanisms 

and Outcomes #1702–1708 

Macrophages: Regulators 

of Toxicity and Disease 

Pathogenesis #1709–1714 

When Is Exposure Not Exposure? 

Defining the Dose-Response 

Region between “Effect” and 

“Adverse Effect” Implications for 

Human Health Risk Assessment 

#1715–1721 

Room 144 263 

Room 204 263 

Room 143 264 

Room 147 265 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Nonclinical to Clinical Abuse 

Liability Assessment of Drugs: 

Current Practices, Challenges, 

and Impact of Recent Regulatory 

Guidance #1722–1727 

Risk Assessment for Proteins 

Introduced into Genetically 

Modified Crops #1728–1733 

The Spectrum of Systems 

Biology #1734–1739 

Room 150 265 

Room 207 266 

Room 151 267 






Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Application of Zebrafish Models 

in Toxicology #1740–1747 

Chemical and Biological 

Weapons—Sulfur Mustard 

Effects #1748–1756 

Nanotoxicology—Nanosilver 

Particulates #1757–1764 

Wednesday 

HISTORICAL HIGHLIGHTS SESSION 

Room 202B 267 

Room 145 268 

Room 202A 268 


Wednesday 

6:30 AM 

50 Years of “the Pill”: Risk 

Reduction and Discovery of 

Benefits Beyond Contraception 

#1765 

Room 147 271 



Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

PLATFORM SESSION 

Approaches for Incorporating 

Non-Chemical Stressors into 

Cumulative Risk Assessments 

#1792–1796 

Extending Pulmonary Toxicity 

Findings for Nanomaterials 

#1797–1803 

Understanding the Implications 

of Preclinical Seizures for Clinical 

Drug Development #1804–1808 

Room 204 276 

Room 206 276 

Room 145 277 


Wednesday 

9:00 AM 

QSAR Approaches and Predictive 

Pathways #1809–1816 

Room 147 278 



Wednesday 

6:30 AM 

Wednesday 

6:30 AM 

Precision Cut Tissue Slices 

Revisited: A Classical Method 

Meets New Challenges #1766 

The Application of the 

Threshold of Toxicological 

Concern Concept to the 

Preclinical Safety Assessment 

of Non-Pharmaceutical Medical 

Products, Including Medical 

Devices and Combination 

Drug-Device Products #1767 

Room 145 271 

Room 150 272 



Wednesday 

6:30 AM 


From Pilot Grants to High-End 

Journals: The Science of Writing 

#1768 

Room 144 272 


Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Autism: Genetic, Epigenetic, 

and Environmental Factors 

Influencing Neural Networks 

#1769–1773 

Gene-Environment Disease 

Interactions in Fish Models of 

Human Disease #1774–1779 

Mechanisms of Inflammation in 

Skin Carcinogenesis #1780–1785 

Room 202A 273 

Room 144 274 

Room 150 275 

Wednesday New Insights into the Nrf2– Room 143 275 

9:00 AM 

Keap1 Pathway and Its Impact 

on Human Disease #1786–1791 


101 





Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

• Xenobiotic Biotransformation 

#1817–1836 


Phase I and II Biotransformation 

Enzymes #1837–1864 


* Toxicology Education: K–12 and 

Beyond #1865–1880 


Safety Testing of 

Pharmaceuticals #1881–1893 


* Pharmaceutical Safety 

Assessment: Novel Methods 

#1894–1932 


Risk Assessment: Conceptual 

Constructs and Current 

Controversies #1933–1967 


* Arsenic #1968–2009 


Chemical and Biological 

Weapons #2010–2050 


* Nanotoxicology: Metal 

Oxides, Silver, Gold, and Silica 

Nanoparticle Toxicity #2051– 

2085 











SESSion index



Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Pesticides: General #2086–2120 


* Metal Neurotoxicity: Manganese 

and Lead #2121–2151 




Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

* Aquatic and Ecotoxicology 

#2378–2409 


Food Safety and Nutrition 

#2410–2443 




SESSion index 



Wednesday 

12:00 PM 


’Omics in Toxic Tort #2152 Room 144 307 


Wednesday 

12:00 PM 


Current and Changing 

Perspectives on Mycotoxins 

and Their Potential Health Risks 

Worldwide #2153 

Room 145 307 




Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

* Nanotoxicology: In Vitro or 

Ex Vivo Studies #2154–2184 


Developmental Basis of Adult 

Disease #2185–2203 


* Cellular Effects of Natural 

Product Extracts #2204–2236 


Persistent Organic Compounds 

(POPs) #2237–2256 


* Pharmacokinetics and 

Disposition #2257–2285 


Risk Assessment: Models and 

Approaches for Inhaled Agents 

#2286–2302 


* Mechanistic Assessment of 

Chemical Mixtures #2303–2316 


Mechanisms of Aspiration Injury 

and Airway Disease #2317–2337 


* Toxicology of the Gulf Oil Spill 

#2338–2342 


Endocrine Toxicology #2343– 

2377 














Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Autophagy in Toxicology: 

Essential Process, Adaptive 

Process, and Disease Process 

#2444–2449 

Human Pluripotent Stem Cells 

and Neural Progenitors as 

Models of Gene-Environment 

Interactions in Neurological 

Disease #2450–2455 

The Use of Epidemiological Data 

and PBPK Modeling in a Risk 

Assessment: Manganese As a 

Case Study #2456–2461 

Room 147 331 

Room 150 331 

Room 145 332 


Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Advancing Predictive 

Ecotoxicology Testing and 

Environmental Risk Assessment 

in the 21st Century #2462–2467 

De-Risking the Potential for 

Cardiovascular Toxicity of Type-2 

Diabetic Drugs: Preclinical and 

Clinical Strategies #2468–2473 

Meeting the Challenges of 

Respiratory Toxicology Testing— 

In Search of Best Practices 

#2474–2480 

Polishing Today’s Job Candidate 

in a Tough Economy #2481–2486 

Room 144 333 

Room 204 333 

Room 206 334 

Room 202A 335 


Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Airborne Particulates and Health 

Effects #2487–2495 

Nrf2 and Antioxidant Response 

Networks #2496–2503 

Room 143 335 

Room 202B 336 






Wednesday 

4:30 PM 

Assessment of Nanoparticle 

Exposure in Occupational 

Settings and in Inhalation 

Toxicology Studies: Is There a 

Best Dosemetric to Use? #2504 


Room 144 337 


Wednesday 

4:30 PM 

Wednesday 

4:30 PM 

Progress of the Tox21 

Consortium in High-Throughput 

Bioactivity Profiling of Chemicals 

#2505 

Toxicological Considerations 

of Pharmacotherapy during 

Pregnancy #2506 

Room 143 338 

Room 145 338 



10:15 AM–12:00 NOON. Poster Board Surface Maps are on pages 104–107. 


Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

* Alternatives to Mammalian 

Models #2509–2542 


Alternatives to Animal Models in 



* Disease Prevention #2576–2593 


Developmental Neurotoxicity: 

General #2594–2629 


* Cancinogenesis II #2630–2661 


East Salon 341 






Thursday 


Thursday 

6:30 AM 

Beyond Science and Decisions: 

From Problem Formulation to 

Dose-Response #2507 

Room 143 340 



Thursday 

9:00 AM 

Thursday 

9:00 AM 

Developmental Exposure to 

Environmental Toxicants: From 

Persistent Toxicities to Diseases 

#2662–2668 

Vascular Injury: A Figment of 

Your Inflammation? #2669–2674 

Room 143 354 

Room 150 354 

SESSion index 



Thursday 

6:30 AM 

Bringing Toxicology to the 

Decision-Makers Table: 

Opportunities for Science Policy 

Positions in Washington, D.C. 

#2508 

Room 145 341 



Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Are We There Yet? Attrition in 

the Pharmaceutical Industry 

and Impactful Strategies for 

Reducing Failure #2675–2681 

Autoimmunity versus Systemic 

Hypersensitivity: Commonalities 

Useful for Immunotoxicity 

Testing #2682–2687 

PBPK Model Use in Risk 

Assessment: Why Being 

Published Is Not Enough 

#2688–2693 

Role of Biomarkers in Assessing 

Tobacco Harm Reduction: 

A Toxicological Perspective 

#2694–2699 

Room 151 355 

Room 201 355 

Room 145 356 

Room 144 357 


103

SES 


Poster Session Board Surface Maps 

Monday, March 7–Wednesday, March 9—Exhibit Hall—Second Level 

MondAY 

Morning, March 7—9:30 AM to 12:30 PM 

Poster Set Up—7:30 AM to 9:30 AM 

Afternoon, March 7—1:00 PM to 4:30 PM 

Poster Set Up—12:30 PM to 1:00 PM 

TUESDAY 





WEdnESDAY 





Poster Reclamation Table 

POSTERS 

1677 

1679 

1681 

1683 

1685 

1687 

1689 

POSTERS (18) 

BOARD 

700s 

1572 

1570 

1566 

1473 

1469 

1372 

1370 

1368 

1273 

1271 

1269 

POSTER 

POSTERS BOARD (30) 

300s 

1072 

1070 

1068 

POSTERS (24) 

BOARD 

800s 

1258 

1256 

1249 

1247 

1243 

1241 

1254 

1250 

1159 

1157 

1155 

1153 

1151 

1154 

1152 

1150 

1053 

1051 

1649 

1647 

1444 

U.S. 

EPA 

1341 

1346 

1344 

1340 

POSTERS (20) 

BOARD 

1232 

1230 

1135 

1133 

POSTERS (24) 

400s 

Meso Scale 

Discovery 

1031 

1038 

1032 

1631 

1629 

1627 

1625 

1617 

AISLE 1600 

1626 

1624 

1620 

1618 

1527 

1525 

1521 

1519 

1522 

1558 

1552 

1546 

1544 

1542 

1540 

1459 

1455 

1453 

1449 

1447 

1445 

1443 

1441 

1416 

1414 

1412 

POSTER 

BOARD 

500s 

POSTERS (24) 

POSTER 

BOARD 

900s 

POSTERS POSTER 

(24) 

BOARD 

600s 

1223 

1228 

1224 

1129 

1127 

1125 

1126 

1124 

1027 

1025 

1026 1024 

1022 

761 

759 

757 

755 

749 

747 

745 

743 

741 

787 

785 

783 

771 

767 

765 

756 

754 

752 740 

782 

770 

1515 

Thermo Fisher 

657 

653 

641 

Scientific 

683 

675 

671 

Huntington 

1512 

AISLE 1500 

Life 

678 676 

674 

670 

668 

666 

Sciences 

WIL 

656 

652 

Research 

1409 

1403 

543 

AISLE 1400 

575 

571 

567 

561 

557 

1410 

1406 

1404 

1402 551 

549 

547 

545 

542 

1323 

1319 

1317 

1313 

1311 

1307 

451 

449 

447 

445 

441 

433 

419 

415 

413 

407 

403 

401 

AISLE 1300 

SOT 

PAVILION 

737 

729 

728 

727 

723 

721 

715 

713 

711 

707 

703 

LAB 

AISLE 700 

Research 

726 

724 

720 

716 

706 

704 

702 

635 

625 

621 

619 

617 

603 

638 

636 

634 

632 

AISLE 600 

539 

537 

535 

533 

515 

513 

507 

501 

AISLE 500 

538 

536 

534 

Charles River 

514 

512 

500 

AISLE 400 

1320 

1318 

1314 

1308 

1306 

446 

432 

422 

420 

418 

416 

406 

402 

Harlan 

Covance 

1221 

1219 

1217 

1215 

1211 

1209 

464 

327 

325 

323 

321 

317 

313 

311 

309 

307 

AISLE 1200 

AISLE 300 

1218 

1214 

1210 

374 

368 362 

346 

344 

342 

338 

324 

322 

320 

318 

314 

312 

310 

300 

BATTELLE 

Toxikon 

SNBL 

1121 

1119 

1115 

1113 

279 277 

275 

265 

263 

257 

245 241 

239 

233 

227 

223 

221 

217 

213 

205 203 

201 

AISLE 1100 

AISLE 200 

1120 1118 

1116 

276 

274 

262 

256 

254 

250 

242 

238 

220 

218 

214 

WuXi 

Southern 

MPI 

Apptec 

Research 

Research 

1021 

1019 

181 

177 

175 

165 

163 

157 

155 

153 

151 

149 

139 

133 

125 

121 

119 

101 

AISLE 1000 

AISLE 100 

180 

176 

174 

162 

160 

158 

156 154 

152 

144 

142 

140 

138 

136 

134 

128 

120 

116 

110 

108 106 

104 102 

100 

ToxExpo 

Exhibition 

Entrance 

L Street 

Bridge 

973 971 

969 

POSTER 

POSTERS BOARD 

(24) 

100s 

POSTER 

BOARD 

POSTERS 200s 

(26) 

945 

943 

941 

939 

935 

933 

927 

925 

942 

940 

938 

936 

934 

932 

930 

928 

841 

839 

837 

835 

833 

831 

AISLE 800 

ELECTRICAL 

INTERNET/ 

TELEPHONE 

AISLE 900 

PHOTOGRAPHY 

FLORAL 

SES LOGISTICS 

SES POSTER 

PICK UP 

909 

907 

903 

901 

908 

906 

904 

902 

900 

CONCESSION 

SEATING 



Poster Session Board Surface Maps (Continued) 

Monday, March 7–Wednesday, March 9—Exhibit Hall—Second Level (continued) 

700s 

736 735 734 733 732 731 848 847 846 845 844 843 940 939 938 937 936 935 934 

725 726 727 728 729 730 837 838 839 840 841 842 927 928 929 930 931 932 933 

724 723 722 721 720 719 836 835 834 833 832 831 926 925 924 923 922 921 920 

713 714 715 716 717 718 825 826 827 828 829 830 913 914 915 916 917 918 919 

712 711 710 709 708 707 824 823 822 821 820 819 912 911 910 909 908 907 

701 702 703 704 705 706 813 814 815 816 817 818 901 902 903 904 905 906 

812 811 810 809 808 807 

801 802 803 804 805 806 

500s 

800s 

900s 

600s 

506 507 518 519 530 531 542 543 648 647 646 645 644 643 

505 508 517 520 529 532 541 544 637 638 639 640 641 642 

504 509 516 521 528 533 540 545 

503 510 515 522 527 534 539 546 636 635 634 633 632 631 

502 511 514 523 526 535 538 547 625 626 627 628 629 630 

501 512 513 524 525 536 537 548 

624 623 622 621 620 619 

613 614 615 616 617 618 

280 

265 

264 

249 

248 

233 

232 

217 

216 

201 

180 

165 

164 

149 

300s 

400s 

360 359 358 357 356 355 448 447 446 445 444 443 

349 350 351 352 353 354 437 438 439 440 441 442 

348 347 346 345 344 343 436 435 434 433 432 431 

337 338 339 340 341 342 425 426 427 428 429 430 

612 611 610 609 608 607 

601 602 603 604 605 606 

148 

133 

132 

117 

116 

101 

336 335 334 333 332 331 424 423 422 421 420 419 

325 326 327 328 329 330 413 414 415 416 417 418 

324 323 322 321 320 319 412 411 410 409 408 407 

313 314 315 316 317 318 401 402 403 404 405 406 

312 311 310 309 308 307 

301 302 303 304 305 306 

200s 

248 247 246 245 244 243 

100s 

237 238 239 240 241 242 

148 147 146 145 144 143 236 235 234 233 232 231 

137 138 139 140 141 142 225 226 227 228 229 230 

136 135 134 133 132 131 224 223 222 221 220 219 

125 126 127 128 129 130 213 214 215 216 217 218 

124 123 122 121 120 119 212 211 210 209 208 207 

113 114 115 116 117 118 201 202 203 204 205 206 

Photography in the Exhibit Hall and all poster sessions 

is prohibited without the consent of exhibitors or 

poster presenter(s)/author(s). Please respect your 

colleagues’ right to privacy. 

The numbers listed refer to the poster location that does 

not change throughout the week. Presenters ONLY should 

display posters on the date and time communicated in 

your acceptance notice. A list of poster session dates 

and times with abstract numbers can be found on pages 

108–111. The ToxExpo Exhibit floor plan with a mock 

layout of the Poster Board Surface Maps can be found on 

pages 104–107 to assist you in finding poster sessions. 

POSTERS 

112 111 110 109 108 107 

101 102 103 104 105 106 


105

197 196 195 194 193 192 191 

184 185 186 187 188 189 190 

183 182 181 180 179 178 177 279 278 277 276 275 274 

171 172 173 174 175 176 268 269 270 271 272 273 

170 169 168 167 166 165 267 266 265 264 263 262 

158 159 160 161 162 163 164 255 256 257 258 259 260 261 

157 156 155 154 153 152 151 254 253 252 251 250 249 248 

144 145 146 147 148 149 150 241 242 243 244 245 246 247 

143 142 141 140 139 138 137 240 239 238 237 236 235 234 

131 132 133 134 135 136 228 229 230 231 232 233 

130 129 128 127 126 125 227 226 225 224 223 222 

116 117 118 119 120 121 122 123 124 214 215 216 217 218 219 220 221 

115 114 113 112 111 110 109 108 107 213 212 211 210 209 208 207 206 

101 102 103 104 105 106 201 202 203 204 205 



Thursday, March 10—East Salon—First Level 

THURSDAY 

Morning, March 10—8:00 AM to 12:00 noon—Poster Set Up—7:00 AM to 8:00 AM 

SINGLE SIDED USE 

197 196 195 194 193 192 191 

184 185 186 187 188 189 190 


183 182 181 180 179 178 177 279 278 277 276 275 274 

171 172 173 174 175 176 268 269 270 271 272 273 

170 169 168 167 166 165 267 266 265 264 263 262 

158 159 160 161 162 163 164 255 256 257 258 259 260 261 

157 156 155 154 153 152 151 254 253 252 251 250 249 248 

144 145 146 147 148 149 150 241 242 243 244 245 246 247 

143 142 141 140 139 138 137 240 239 238 237 236 235 234 

131 132 133 134 135 136 228 229 230 231 232 233 

130 129 128 127 126 125 227 226 225 224 223 222 

116 117 118 119 120 121 122 123 124 214 215 216 217 218 219 220 221 

115 114 113 112 111 110 109 108 107 213 212 211 210 209 208 207 206 

101 102 103 104 105 106 201 202 203 204 205 



POSTERS 

Escalators 

up to 

Sciencitific 

Sessions and 

ToxExpo 

WEST SALON 



Photography in the Exhibit Hall and all poster 

sessions is prohibited without the consent of exhibitors 

or poster presenter(s)/author(s). Please respect 

your colleagues’ right to privacy. 

The numbers listed refer to the poster location that does 

not change throughout the week. Presenters ONLY 

should display posters on the date and time communicated 

in your acceptance notice. A list of poster 

session dates and times with abstract numbers can be 

found on pages 108–111. The full maps of the Walter E. 

Washington Convention Center can be found on pages 

24–25 to assist you in finding poster sessions. 

Main Entrance 




BUSINESS 

CENTER 

UNDER 

STAIRS 

7th Street 




Thursday, March 10—Room 202—Second Level 

THURSDAY 

Morning, March 10—8:00 AM to 12:00 noon—Poster Set Up—7:00 AM to 8:00 AM 

*All accepted Late Breaking and Grace Period Abstracts will be available on-line through the Itinerary Planner. 

However, a printed supplemental list of the abstract titles will be available on-site in the Registration area. 

280 279 278 277 276 275 274 273 

265 266 267 268 269 270 271 272 

264 263 262 261 260 259 258 257 

249 250 251 252 253 254 255 256 

248 247 246 245 244 243 242 241 

233 234 235 236 237 238 239 240 


197 196 195 194 193 192 191 

184 185 186 187 188 189 190 

183 182 181 180 179 178 177 

171 172 173 174 175 176 26 

170 169 168 167 166 165 26 

232 231 230 229 228 227 226 225 

217 218 219 220 221 222 223 224 

216 215 214 213 212 211 210 209 

201 202 203 204 205 206 207 208 

180 179 178 177 176 175 174 173 

165 166 167 168 169 170 171 172 

164 163 162 161 160 159 158 157 

149 150 151 152 153 154 155 156 

148 147 146 145 144 143 142 141 

133 134 135 136 137 138 139 140 

132 131 130 129 128 127 126 125 

117 118 119 120 121 122 123 124 

116 115 114 113 112 111 110 109 

101 102 103 104 105 106 107 108 

Escalators 

down to 

Registration 

and 

E-mail Center 

158 159 160 161 162 163 164 25 

157 156 155 154 153 152 151 25 

144 145 146 147 148 149 150 24 

143 142 141 140 139 138 137 24 

131 132 133 134 135 136 22 

130 129 128 127 126 125 22 

116 117 118 119 120 121 122 123 124 21 

115 114 113 112 111 110 109 108 107 21 


101 102 103 104 105 106 


POSTERS 

Photography in the Exhibit Hall and all poster sessions 

is prohibited without the consent of exhibitors or poster 

presenter(s)/author(s). Please respect your colleagues’ right to 

privacy. 

The numbers listed refer to the poster location that does not change 

throughout the week. Presenters ONLY should display posters on 

the date and time communicated in your acceptance notice. A list 

of poster session dates and times with abstract numbers can be 

found on pages 108–111. The full maps of the Walter E. Washington 

Convention Center can be found on pages 24–25 to assist you in 

finding poster sessions. 


107 


Room 

202


Poster Session Schedule 

Monday Morning, March 7—9:30 AM to 12:30 PM—Exhibit Hall 

Poster Set Up 7:30 AM to 9:30 AM 

SESSION TITLE ABSTRACT NUMBERS POSTER BOARD NUMBERS 

Hypersensitivity: Methods and Mechanisms 80–98 101–119 

Epigenetic Mechanisms 99–110 125–136 

DNA Replication and Repair 111–122 137–148 

Bioinformatic Profiling and Computational Pathway Prediction 123–159 212–248 

Neurodegenerative Diseases 160–182 301–323 

Cardiovascular Toxicology 183–218 325–360 

Carcinogenesis I 219–250 401–432 

Inflammatory Mediators in Disease Pathogenesis 251–264 435–448 

Metals I 265–292 501–528 

Metals II 293–314 537–548 and 601–610 

Genotoxicity 315–343 613–641 

Receptor and Receptor-Mediated Toxicity 344–379 701–736 

Cell Signaling and Gene Regulation 380–416 801–837 

Visiting Student Poster Session BY INVITATION ONLY 901–933 

Monday Afternoon, March 7—1:00 PM to 4:30 PM—Exhibit Hall 

Poster Set Up 12:30 PM to 1:00 PM 

POSTERS 


Drug Induced Liver Injury 420–443 101–124 

Acetaminophen Hepatotoxicity 444–463 129–148 

Risk Assessment: Computational Approaches, Analyses, and Applications 464–505 207–248 

Animal Models in Toxicological Research 506–534 301–329 

Animal Models in Toxicology 535–562 333–360 

Inhalation and Cardiopulmonary Toxicology 563–609 401–447 

Children’s Health/Juvenile Toxicology 610–630 501–521 

Skin 631–648 525–542 

Immunotoxicity: Methods and Evaluation 649–667 547–548 and 601–617 

Mechanisms of Immunotoxicity 668–698 618–648 

Biological Modeling: Computational Approaches, Mixtures, Multiroute and Lifestage 699–737 701–736 and 846–848 

Applications 

Kidney 738–774 801–837 

Pharmaceutical Safety Assessment: Therapeutic Agents 775–812 901–938 

Photography in the Exhibit Hall and all poster sessions is prohibited without the consent of exhibitors or poster presenter(s)/author(s). 

Please respect your colleagues’ right to privacy. 



Poster Session Schedule (Continued) 

Tuesday Morning, March 8—9:00 AM to 12:30 PM—Exhibit Hall 



*Late Breaking Abstracts TBD 101–112 

Alternative Approaches to Animal Testing for Toxicological Research 959–989 118–148 


Alternatives to Mammalian Models for Testing 990–1021 217–248 

Reproductive Toxicology I 1022–1048 301–327 

Reproductive Toxicology II 1049–1076 333–360 

Hepatotoxicity 1077–1107 401–431 

Cholestasis,Lipid Homeostasis, and Liver Toxicity 1108–1120 436–448 

Ah Receptor in Immune Regulation and Toxicity 1121–1139 501–519 

ImmunoSafety Methods in Non-Rodents 1140–1152 522–534 


Stem Cell Toxicology 1153–1173 601–621 

Nanotoxicology: Carbon Nanotubes, Carbon Nanoparticulates, and Quantum Dots 1174–1197 625–648 

Epidemiology and Exposure Evaluations 1198–1229 701–732 

Exposure Assessments and Biomonitoring Applications 1230–1268 801–839 

Oxidative Stress and Redox Biology 1269–1308 901–940 

Tuesday Afternoon, March 8—1:00 PM to 4:30 PM—Exhibit Hall 



Medical Devices 1312–1323 101–112 

Neurotoxicity of Pesticides 1324–1358 114–148 

Genetic Polymorphisms 1359–1374 201–216 

Metal Neurotoxicity: Methylmercury and General 1375–1402 221–248 

Mutagenecity 1403–1422 301–320 

Methods in Biomarker Discovery and Validation 1423–1452 331–360 

Nanotoxicology 1453–1496 401–444 

Drug Allergy, Pseudoallergy, IDRH, and Autoimmunity 1497–1515 501–519 

Risk Assessment and Regulatory Policy Applications 1516–1540 524–548 

Safety and Risk Assessment: Critical Characterizations for Chemicals and New Concerns 1541–1582 601–642 

‘Omics in Toxicology Research 1583–1606 701–724 

Developmental Toxicology 1607–1647 801–841 

Apoptosis/Cell Death 1648–1673 901–926 

Biomarkers of Environmental Exposures 1674–1696 731–736 and 843–848 and 930–940 

POSTERS 



Photography in the Exhibit Hall and all poster sessions is prohibited without the consent of exhibitors or poster presenter(s)/ 

author(s). Please respect your colleagues’ right to privacy. 


109



Wednesday Morning, March 9—9:00 AM to 12:30 PM—Exhibit Hall 



Xenobiotic Biotransformation 1817–1836 101–120 

Phase I and II Biotransformation Enzymes 1837–1864 121–148 

Toxicology Education: K–12 and Beyond 1865–1880 201–216 


Safety Testing of Pharmaceuticals 1881–1893 301–313 

Pharmaceutical Safety Assessment: Novel Methods 1894–1932 322–360 

Risk Assessment: Conceptual Constructs and Current Controversies 1933–1967 407–441 

Arsenic 1968–2009 501–542 

Chemical and Biological Weapons 2010–2050 601–641 

Nanotoxicology: Metal Oxides, Silver, Gold, and Silica Nanoparticle Toxicity 2051–2085 701–735 

Pesticides: General 2086–2120 801–835 


Metal Neurotoxicity: Manganese and Lead 2121–2151 901–931 

Wednesday Afternoon, March 9—1:00 PM to 4:30 PM—Exhibit Hall 


POSTERS 



Nanotoxicology: In Vitro or Ex Vivo Studies 2154–2184 118–148 


Developmental Basis of Adult Disease 2185–2203 230–248 

Cellular Effects of Natural Product Extracts 2204–2236 301–333 

Persistent Organic Compounds (POPs) 2237–2256 341–360 

Pharmacokinetics and Disposition 2257–2285 401–429 

Risk Assessment: Models and Approaches for Inhaled Agents 2286–2302 432–448 

Mechanistic Assessment of Chemical Mixtures 2303–2316 501–514 

Mechanisms of Aspiration Injury and Airway Disease 2317–2337 516–536 


Toxicology of the Gulf Oil Spill 2338–2342 601–605 

Endocrine Toxicology 2343–2377 614–648 

Aquatic and Ecotoxicology 2378–2409 701–731 

Food Safety and Nutrition 2410–2443 801–834 









Thursday Morning, March 10—8:00 AM to 12:00 noon—East Salon 



Alternatives to Mammalian Models 2509–2542 101–134 

Alternatives to Animal Models in Toxicology 2543–2575 137–169 

Disease Prevention 2576–2593 177–194 

Developmental Neurotoxicity: General 2594–2629 201–236 

Cancinogenesis II 2630–2661 241–272 

Thursday Morning, March 10—8:00 AM to 12:00 noon—Room 202 



Grace Period Abstracts TBD 101–140 




POSTERS 






111


Historical Posters Floor Plan 

Second Level 

L Street Bridge: 

SOT Component 

Group Posters 


Food Court 

Escalators 

down to 

CE Courses and 


L Street Bridge 

Escalators 

down to 

Registration 

and E-mail Center 


Meeting Rooms > 

POSTERS 

Escalators down to CE Courses 

and Scientific Sessions 



Registration and E-mail Center 




Program Description (Continued) 

Abstract # 

The Program Description layout is ordered by date and start time. 

All scientific sessions and special events will be held in the Walter E. 

Washington Convention Center unless otherwise noted. 

50th Anniversary Event 

SOT general events and functions are displayed with a grey background. 

Scientific Session Types: Exhibitor Hosted Sessions are 

informative sessions developed by an exhibiting company. See 

page 41 for the Exhibitor Hosted Session Index. 

Education-Career 

Development Sessions 

Exhibitor Hosted Sessions 




Platform Sessions 







SATURDAY Morning 

Saturday Morning, March 5 

9:30 AM to 4:30 PM 

Smithsonian S. Dillon Ripley Center 

Smithsonian Seminar: Poisons: When Good Chemicals 

Turn Bad 

To commemorate SOT’s 50th Anniversary, the Smithsonian Institution 

and SOT are holding an all-day seminar for the public featuring the latest 

research in the science of toxicology, and information about the positive 

and adverse effects that chemical, biological, and physical substances 

can have on people, animals, and the environment. We are surrounded by 

chemicals that may be beneficial, harmful, or neither depending on the 

dose. This day-long session, which features several SOT Members, is open 

to the public and requires separate registration. SOT members receive 

the Smithsonian member discount. To learn more please visit www.toxicology.org/ai/meet/am2011. 


10:00 AM to 5:00 PM 



K–12 Outreach: Protecting You and Your Pet through the 

Science of Toxicology: Paracelsus Goes to Washington 


Abstract # 

SATURDAY Afternoon 


12:00 NOON to 1:00 PM 



K–12 Outreach: Poisoned Pet Food—Unraveling the 

Melamine Mystery 

Lecturer: Renate Reimschuessel, U.S. FDA, Laurel, MD. 


Sponsors: 



Please see page 77 for more details. 

Saturday Afternoon, March 5 

4:15 PM to 5:45 PM 

Room 302 

SATURDAY Evening 

Undergraduate Education Program: Orientation for SOT 

Hosts, Peer Mentors, and Advisors 

Chairperson(s): Jennifer Rayner, Oak Ridge National Laboratories, 

Oak Ridge, TN. 

Sponsor: 


This event is for advisors, peer mentors, and mentors assisting with the 

Undergraduate Program. Full program details are found pages 85–86. 

Saturday Afternoon, March 5 

5:45 PM to 9:00 PM 

Room 103 


Undergraduate Education Program Opening Event 


Sponsor: 


This event is for undergraduate students and advisors receiving 2011 SOT 

travel funding, and SOT program volunteers assisting with the Undergraduate 

Program. Full program details are found pages 85–86. 

Sponsors: 



SOT is sponsoring a free Family Day at the Marion Koshland Science 

Museum of the National Academy of Sciences. We invite meeting 

attendees and their families, as well as D.C. visitors and residents, to experience 

this science museum near the Walter E. Washington Convention 

Center. In addition to the activities that are on display, SOT will supplement 

the topic areas of Wonders of Science, Safe Drinking Water, Global 

Warming, and Infectious Disease with toxicology-related activities. Toxicologists 

from a variety of employment sectors will be available to engage 

with visitors to learn more about toxicology. 

Saturday Evening, March 5 

8:00 PM to 9:00 PM 

Room 103 

CDI Reunion (Networking and Dessert) 

Anyone involved with the SOT Undergraduate Education Program 

through the years should plan to attend. 

SATURDAY 







113


Sunday 


Abstract # Abstract # 

sunday MORNING 


7:00 AM to 7:45 AM 

First Level 

(Ticket Required; See signage at CE Booth for room location) 

Continuing Education Sunrise Mini-Course 

Full Continuing Education Course details may be found on pages 88–96. 

Sunday Morning and Afternoon, March 6 

8:00 AM to 5:00 PM 

(See pages 3–11 for room information) 



Sponsor: 


The Sunday program is open to undergraduate students who register for 

this event using the Annual Meeting Registration Form, the undergraduate 

students and advisors receiving SOT travel funding, and SOT program 

volunteers. Full program details are found pages 85–86. 


3:00 PM to 5:00 PM 

Room 102 

Undergraduate Education Program: Open Time with 

Academic Program Directors and Internship Sponsors 


Sponsor: 


The Sunday program is open to undergraduate students who register for 

this event using the Annual Meeting Registration Form, the undergraduate 

students and advisors receiving SOT travel funding, and SOT program 

volunteers. Full program details are found pages 85–86. 


4:00 PM to 6:00 PM 

Room 203 

Specialty Section Officers Meeting: Dermal Toxicology 

Sunday Evening 


8:15 AM to 12:00 NOON 

First and Second Levels 


Continuing Education Morning Courses 

Full Continuing Education details may be found on pages 88–96. 


12:00 NOON to 1:30 PM 

Room 104A 

Sunday Afternoon 

Specialty Section Officers Meeting: Food Safety 


1:15 PM to 5:00 PM 

First and Second Levels 


Continuing Education Afternoon Courses 

Full Continuing Education Course details may be found on pages 88–96. 


1:30 PM to 3:30 PM 


Sunday Evening, March 6 

5:15 PM to 6:30 PM 

Room 207 

(All Attendees and Registered Guests Welcome) 


Join us as SOT honors our prestigious award winners at the SOT Awards 

Ceremony. Please refer to the Awards and Fellowship section of the SOT 

Web site for complete details and the nominating information for next 

year. 


6:00 PM to 8:00 PM 


Specialty Section Meeting/Reception: 

Metals 


6:30 PM to 7:30 PM 

Room 103 



Have you been a member of the Society of Toxicology for 25 years 

(or more)? If so, please join you colleagues in celebration and recognition 

of the scientists who established the Society. 

SOT Committee/Task Force Chair Orientation 

If you will be a Committee/Task Force Chairperson in 2011–2012, please 

make plans to attend the Committee/Task Force Chair Meeting scheduled 

from 1:30 PM–3:30 PM, on Sunday, March, 6. With new assignments 

taking effect on May 1, 2011, the meeting is intended to provide new 

chairpersons with a jump start on operating a committee or task force 

to achieve SOT strategic goals. 2010–2011 Chairpersons are invited to 

provide input on current and planned activities. 

114 

Education-Career Development Sessions 





Platform Sessions



Abstract # 


6:30 PM to 8:30 PM 


Special Interest Group Meetings/Reception: Hispanic 

Organization of Toxicologists 


6:30 PM to 8:00 PM 

See room listing below. 

Specialty Section Meetings/Receptions: Carcinogenesis 

(Room 146A), Dermal Toxicology (Room 203), Food Safety 

(Room 140A), Medical Device (Room 156), NanoToxicology 

(Room 143), Occupational and Public Health (Room 144), 

Ocular Toxicology (Room 142) 

Abstract # 


8:00 PM to 9:30 PM 

Salon G 



Sponsor: 


The Student Advisory Council and Graduate Committees host this 

opportunity for students and postdoctoral scholars to gather, meet new 

colleagues, and reestablish relationships in an informal atmosphere at the 

beginning of the meeting. Tickets are obtained at no cost by registering for 

this event on the Annual Meeting Registration Form. Ticket and meeting 

badge are required. Complimentary refreshments and a cash bar will be 

available. 

SUNDAY 

Explore Federal Research Funding 

Opportunities and Strategies with Federal Agency Staff 

All meeting attendees invited 

Meet with Agency Review Administrators and Program Officers 

Research Funding 

Resource Room 

9:00 AM–4:30 PM 

Tuesday and Wednesday 

Room 203 

Make appointments or drop by 


12:00 NOON–1:15 PM 

Tuesday 

Salon I 

Grantsmanship 

Informal conversation with NIH, 

U.S. EPA, DOE, and other agency staff 

See pages 228 and 304 for more information 

See page 230 for more information 







115



MONday 


Monday Morning, March 7 

6:30 AM to 7:45 AM 

Salon G 

Monday Morning 

Specialty Section Officers Meetings: Carcinogenesis, 

In Vitro and Alternative Methods, Mechanisims, Medical 

Device, Mixtures, Nanotoxicology, Neurotoxicology, 

Reproductive and Developmental Toxicology, Risk 

Assessment 


6:30 AM to 7:45 AM 

Room 302 

Specialty Section Officers Meeting: Toxicologic and 



6:45 AM to 7:45 AM 

Room 103 



Monday Morning and Afternoon, March 7 

7:20 AM to 1:20 PM 

Room 102 



Sponsor: 



travel funding and SOT program volunteers assisting with the Undergraduate 



7:45 AM to 8:00 AM 


Landmarks Program Presentation to the National Academy 

of Science 

Michael P. Holsapple, SOT President, will present a landmark plaque 

to the leaders of the Committee on Toxicology, National Academy of 

Sciences (NAS), where the Society of Toxicology was founded 

March 4, 1961, and subsequently re-defined, fostered, and supported. 

The plaque represents the gratitude and appreciation of the leadership and 

membership of the Society of Toxicology. 


8:00 AM to 9:00 AM 


Plenary Opening Lecture: NIH Vision 

Lecturer: Francis S. Collins, National Institutes of 

Health, Bethesda, MD. 

Francis S. Collins, M.D., Ph.D., has served as the 

Director of the National Institutes of Health (NIH) since 

August 17, 2009. Dr. Collins is a physician-geneticist 

noted for his landmark discoveries of disease genes 

and his leadership of the Human Genome Project, which successfully 

completed the first sequence of the human DNA instruction book in 

2003. 

Dr. Collins received a B.S. in chemistry from the University of Virginia, 

a Ph.D. in physical chemistry from Yale University, and an M.D. with 

honors from the University of North Carolina at Chapel Hill. Prior 

to coming to the NIH in 1993 to lead the National Human Genome 

Research Institute, he spent nine years on the faculty of the University of 

Michigan. He is an elected member of the Institute of Medicine and the 

National Academy of Sciences. Dr. Collins was awarded the Presidential 

Medal of Freedom in 2007 and the National Medal of Science in 2009. 


9:15 AM to 12:00 NOON 

Room 143 

Symposium Session: Emerging Issues at the Intersection of 

Reproductive and Mixtures Toxicology 

Chairperson(s): Cynthia Rider, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC, and Vickie Wilson, U.S. 

EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 



Environmental contaminants have been implicated as having a role in 

reproductive toxicity observed in both humans and wildlife. For example, 

estrogenic and antiandrogenic chemicals have been hypothesized to be 

involved in the observed rise in the incidence of testicular dysgenesis 

syndrome noted as a suite of related pathologies including decreased semen 

quality, increased incidence of male reproductive tract malformations, and 

testicular cancer. Additionally, endocrine disruptors from concentrated 

animal feedlot operations and sewage effluent have been associated with 

observed reproductive anomalies in aquatic species. While toxicological 

studies and regulatory action have traditionally focused on individual 

chemicals, it is clear that realistic exposures are made University of multiple 

chemicals. Sources of exposure to endocrine active compounds are varied 

and include personal care products, pharmaceuticals, agricultural, and 

industrial compounds. Many of these sources may lead to constant, low dose 

exposures. Although individual chemicals are typically present at low levels 

within the exposure milieu, the impact of mixtures of these chemicals has 

only recently begun to be examined. Our panel of experts will provide an 

overview of potential exposures to endocrine active mixtures and describe 

current work on mixtures of reproductive and developmental toxicants from 

both a human health and ecotoxicological perspective. In conclusion, we 

will address emerging contaminants of concern and discuss the reproductive 

effects of relevant chemical mixtures in humans and wildlife. 

116 






Platform Sessions



Abstract # 

#16 9:15 EMERGING ISSUES AT THE 

INTERSECTION OF REPRODUCTIVE AND 

MIXTURES TOXICOLOGY. V. S. Wilson 1 and 

C. V. Rider 2 . 1 Reproductive Toxicology Branch, TAD, 

NHEERL, ORD, U.S. EPA, Research Triangle Park, 

NC and 2 Toxicology Branch, NIEHS-NTP, Research 

Triangle Park, NC. 

9:15 INTRODUCTION. Cynthia Rider 

#17 9:20 BIOASSAY USE IN IDENTIFYING 

ENDOCRINE DISRUPTORS IN THE 

ENVIRONMENT. D. Schlenk. Environmental 

Toxicology Program, University of California 

Riverside, Riverside, CA. 

#18 9:52 DIAGNOSTIC ASSESSMENT OF THE 

ECOLOGICAL RISK OF EDCS IN COMPLEX 

MIXTURES. G. Ankley. Med., NHEERL, ORD, 

U.S. EPA, Duluth, MN. Sponsor: L. Gray. 

#19 10:24 MOLECULAR ENDPOINTS AND MIXTURES 

OF ENDOCRINE DISRUPTING CHEMICALS 

IN FISH. N. D. Denslow 1 , N. Garcia-Reyero 2 , K. 

J. Kroll 1 , E. F. Orlando 3 , K. H. Watanabe 4 , M. S. 

Sepúlveda 5 , D. L. Villeneuve 6 , E. J. Perkins 7 and 

G. T. Ankley 6 . 1 Physiological Sciences, University 

of Florida, Gainesville, FL, 2 Chemistry, Jackson 

State University, Jackson, MS, 3 Animal and Avian 

Sciences, University of Maryland, College Park, 

MD, 4 Division of Environmental and Biomolecular 

System, Oregon Health & Science University, 

Beaverton, OR, 5 Forestry and Natural Resources, 

Purdue University, West Lafayette, IN, 6 ORD, 

NHEERL, Med., U.S. EPA, Duluth, MN and 

7 

Environmental Laboratory, U.S. Army Engineer 

Research and Development Center, Vicksburg, MS. 

#20 10:56 EFFECTS OF MIXTURES OF PHTHALATES, 

PESTICIDES, AND TCDD ON SEXUAL 

DIFFERENTIATON IN RATS: A RISK 

FRAMEWORK BASED UPON DISRUPTION 

OF COMMON DEVELOPING SYSTEMS. 

L. E. Gray. Reproductive Toxicology Branch, 

NHEERL, U.S. EPA, Research Triangle Park, NC. 

#21 11:28 ESTROGENIC CHEMICAL MIXTURES AND 

ENDOGENOUS HORMONES – A ROLE IN 

BREAST CANCER DEVELOPMENT? A. 

Kortenkamp and E. Silva. Centre for Toxicology, The 

School of Pharmacy, University of London, London, 

United Kingdom. Sponsor: C. Rider. 

Abstract # 


9:15 AM to 12:00 NOON 

Room 151 


Symposium Session: Environmental Oxidative Pollutant- 

Induced Pulmonary Toxicity 

Chairperson(s): Lin Mantell, St. John’s University, Queens, NY, and 

Judith Zelikoff, New York University School of Medicine, Tuxedo Park, 

NY. 

Sponsor: 


Endorsed by: 



Environmental oxidant toxicants remain a major public health concern in 

industrialized cities throughout the world. Population and epidemiological 

studies have associated oxidant air pollutant exposures with morbidity and 

mortality outcomes, and underscore the important detrimental effects of 

these pollutants on the lung. A well-orchestrated lung inflammation induced 

by cytokines is critical to optimizing host defense capabilities, while 

avoiding or minimizing potential damage to lung tissues. Normally, pulmonary 

inflammation plays a pivotal role during positive immune responses 

against microbial and small particle pathogens. Unfortunately, certain 

inhaled toxicants, such as asbestos, can non-specifically induce dysregulated 

chronic and acute inflammation within the respiratory tract. Our pannel 

of experts will emphasize and examine the types of immunomodulatory 

events that occur in the lungs in response to environmental agents and 

pathogens, and to demonstrate how these disparate challenges can lead 

to similar outcomes. In addition, cutting edge studies on the regulation of 

reactive oxygen species (ROS) production will be discussed. In conclusion, 

summaries will be provided that will allow for the recognition of the 

major putative mediators involved in induction of pulmonary inflammation; 

describe signaling pathways that mediate inflammatory responses to inhaled 

toxicants and pathogens; characterize reactive oxygen/nitrogen species 

(ROS/RNS) from exposure to environmental toxicants; better understand 

the inter-relationship between ROS/RNS, inflammatory responses and their 

impact on diseases; and, identify potential targets and therapeutic strategies 

for further development for the amelioration of acute lung inflammatory 

injury and chronic diseases. 

#22 9:15 ENVIRONMENTAL OXIDATIVE 

POLLUTANTS-INDUCED PULMONARY 

TOXICITY. L. L. Mantell 1 and J. T. Zelikoff 2 . 1 St. 

John’s University College of Pharmacy, Queens, 

NY and 2 New York University School of Medicine, 

Tuxedo, NY. 

9:15 INTRODUCTION. Lin Mantell 

#23 9:20 A SHORT OVERVIEW ON 

ENVIRONMENTAL OXIDATIVE 

POLLUTANTS-INDUCED PULMONARY 

TOXICITY. L. Mantell. Pharmaceutical Sciences, 

St. John’s University/The Feinstein Institute for 

Medical Research, Queens, NY. 

#24 9:35 PRO-INFLAMMATORY RESPONSES TO 

OXIDIZED MATRIX COMPONENTS IN 

RESPONSE TO ASBESTOS INJURY. T. 

Oury. Pathology, University of Pittsburgh School of 

Medicine, Pittsburgh, PA. Sponsor: L. Mantell. 

#25 10:12 USE OF OXIDATIVE LIPIDOMICS AND 

SIGNALING BY OXIDIZED LIPIDS IN 

SAFETY SCREENING OF NANOPARTICLES. 

V. E. Kagan. Environmental and Occupational, 

University of Pittsburgh, Pittsburgh, PA. 

MONday 







117



MONday 


#26 10:49 DIFFERENTIAL MECHANISMS OF 

SUSCEPTIBILITY TO OXIDANT-INDUCED 

LUNG DISEASE. E. M. Postlethwait. 

Environmental Health Sciences, University of 

Alabama at Birmingham, Birmingham, AL. 

#27 11:25 TARGETING INFLAMMATION AND THE 

INFLAMMASOME USING ANAKINRA, A 

POTENTIAL THERAPEUTIC AGENT FOR 

MESOTHELIOMA. B. Mossman. Pathology, 

University of Vermont College of Medicine, 

Burlington, VT. Sponsor: L. Mantell. 


9:15 AM to 12:00 NOON 

Room 150 


Bridging the Gap between Discovery and the Clinic 

through Translational Toxicology 

Symposium Session: High Content Imaging—Applications in 

Toxicology and Toxicity Testing 

Chairperson(s): William Mundy, U.S. EPA, Research Triangle Park, NC, 

and Joseph Trask, The Hamner Institutes for Health Sciences, Research 


Sponsor: 


Endorsed by: 



High Content Imaging (HCI) often referred as high content screening 

(HCS), combines state-of-the-art microscopy, robotics, and computerassisted 

image analysis to measure multiple cellular and sub-cellular 

features. The technology produces information (digital images and metadata) 

on cellular response or morphological changes at a high level of detail. 

Assays are amenable to high-throughput automation generating hundreds of 

measurements per cell and millions of data points from a single microtiter 

plate. Introduction of this technology in the pharmaceutical industry led to 

analysis of cell signaling and processes such as receptor internalization. The 

technology has expanded to include applications in angiogenesis, wound 

healing, cell cycle regulation, cell death, neurodegeneration, regeneration, 

and genotoxicity, etc. Using these approaches, measurements are made at 

the single cell or population level. HCI assays are generally conducted using 

cell lines, primary cells, and stem cells. Ex vivo tissue and whole organisms 

such as Drosophila, C. elegans, and zebrafish can also be imaged providing 

knowledge from intact specimens. Novel strategies for toxicity testing 

are likely to expand with HCI studies examining biologically significant 

cellular perturbations by linking genetic, phenotypic, or functional cellular 

changes with adverse outcomes from exposure to environmental chemicals 

or pharmaceutical compounds. HCI is likely to become a key technology 

for developing toxicity pathway assays as outlined by the 2007 NRC report 

Toxicity Testing in the 21st Century: A Vision and A Strategy. Furthermore, 

it is now evident toxicology programs in the pharmaceutical industry have 

adopted this technology in an effort to expedite the fate of compound 

candidate selection in preclinic and clinical trials using key measurements 

generated with HCI. Therefore it is important to provide an overview of this 

technology and its applications in toxicity testing relative to the HCI field 

from academia, biopharma, and government agencies with examples and 

case studies to gain knowledge and insight into toxicity pathways. 

#28 9:15 HIGH CONTENT IMAGING – 

APPLICATIONS IN TOXICOLOGY AND 

TOXICITY TESTING. W. Mundy. Integrated 

Systems Toxicology Division, U.S. EPA, Research 


9:15 INTRODUCTION. William Mundy 

#29 9:25 AN INTRODUCTION TO HIGH CONTENT 

IMAGING TECHNOLOGIES AND 

APPLICATIONS IN TOXICOLOGY. O. Joseph 

Trask. The Hamner Institutes for Health Sciences, 

Research Triangle Park, NC. Sponsor: R. Thomas. 

#30 9:45 HIGH CONTENT ANALYSIS OF 

CYTOTOXICITY FOR PREDICTION, 

MECHANISTIC ELUCIDATION, AND 

BLOOD BIOMARKERS OF HUMAN 

TOXICITY. P. J. O’Brien. University College 

Dublin, Belfield, Dublin, Ireland. Sponsor: J. Trask. 

#31 10:15 QUANTITATIVE IN VITRO MEASUREMENT 

OF CELLULAR PROCESSES CRITICAL 

TO THE DEVELOPMENT OF NEURAL 

CONNECTIVITY USING HCA. J. A. Harrill. 

Integrated Systems Toxicology Division, U.S. EPA, 


#32 10:45 BEYOND DECREASING ATTRITION: HIGH 

CONTENT IMAGING (HCI) IN GENETIC 

TOXICOLOGY. E. Rubitski. Genetic Toxicology, 

Pfizer, Groton, CT. Sponsor: J. Aubrecht. 

#33 11:15 HIGH CONTENT SCREENING (HCS) IN 

EARLY SAFETY ASSESSMENT: FROM DATA 

TO PREDICTIVE MODELS. M. Kansy 1 and 

A. Hoffman 2 . 1 Nonclinical Safety, F. Hoffmann-La 

Roche Ltd., Basel, Switzerland and 2 Discovery 

Technologies, F. Hoffmann-La Roche Ltd., Nutely, 

NJ. 

11:45 PANEL DISCUSSION/Q&A. 


9:15 AM to 12:00 NOON 

Room 207 

Symposium Session: Ribotoxic Stress: Mechanisms and 

Models for Human Disease 

Chairperson(s): James Pestka, Michigan State University, East Lansing, 

MI, and Yuseok Moon, Pusan National University School of Medicine, 

Yangsan, Japan. 

Sponsor: 


Endorsed by: 




Many xenobiotics evoke toxicity and cause disease by modifying critical 

mitogen-activated protein kinase (MAPK) signaling pathways that regulate 

growth, differentiation, and cell survival. A number of plant, fungal, 

bacterial, and algal toxins can aberrantly activate the P38, ERK, and JNK 

MAPKs by targeting the ribosome via a process termed the ribotoxic stress 

response. Examples of ribotoxic agents include natural toxins produced 

by plants (ricin), fungi (trichothecenes), bacteria (Shiga toxins), and algae 

(palytoxin). These agents can be encountered in food and water and are 

of further concern because of their potential use in chemical terrorism. 

Cells involved in the innate immunity appear to be particularly sensitive to 

ribotoxic stress. Ribotoxic stress is not completely understood but possible 

mechanisms activation of intracellular signaling pathways by sensors of 

damage-associated molecular patterns (DAMPs) or endoplasmic reticulum 

stress. From a translational perspective, exposure of experimental animals 

to ribotoxic stressors can result in downstream pathologic sequelae that 

remarkably mimic clinical signs associated with inflammatory human 

diseases such as acute respiratory distress, ulcerative colitis, IgA nephropathy, 

and hemolytic uremic syndrome. To address these issues, our panel of 

experts will explore commonalities and differences in upstream mechanisms 

118 






Platform Sessions



Abstract # 

of ribotoxic stress by different biotoxins and relate these to downstream 

sequelae associated with human inflammatory diseases. 

#34 9:15 RIBOTOXIC STRESS: MECHANISMS AND 

MODELS FOR HUMAN DISEASE. J. J. 

Pestka 1 , V. L. Tesh 2 , B. E. Magun 3 , Y. Moon 4 and N. 

Tumer 5 . 1 Michigan State University, East Lansing, 

MI, 2 Texas A&M University Health Science Center, 

College Station, TX, 3 Oregon Health and Science 

University, Portland, OR, 4 Pusan National University 

School of Medicine, Yangsan, Republic of Korea and 

5 

Rutgers University, New Brunswick, NJ. 

9:15 INTRODUCTION. James J. Pestka 

#35 9:20 RICIN MEDIATES ACUTE RESPIRATORY 

DISTRESS THROUGH IL-1BETA. B. Magun. 

Oregon Health and Science University, Portland, OR. 

Sponsor: J. Pestka. 

#36 9:52 MUCOSAL RIBOTOXIC STRESS AND 

INTESTINAL INFLAMMATORY DISEASES. 

Y. Moon. Department of Microbiology and 

Immunology, Pusan National University School of 

Medicine, Yangsan, Republic of Korea. 

#37 10:24 SHIGA TOXINS AND THE HEMOLYTIC 

UREMIC SYNDROME. V. L. Tesh. Microbial 

and Molecular Pathogenesis, Texas A&M University 

Health Science Center, College Station, TX. Sponsor: 

J. Pestka. 

#38 10:56 ROLE OF RIBOTOXIC STRESS AND 

INNATE IMMUNE ACTIVATION IN 

TRICHOTHECENE-INDUCED IGA 

NEPHROPATHY. J. J. Pestka. Microbiology and 

Molecular Genetics, Michigan State University, East 

Lansing, MI. 

#39 11:28 RICIN AND SHIGA TOXINS INTERACT 

DIFFERENTLY WITH THE RIBOSOMAL 

STALK. N. Tumer 1 , J. Chiou 1 , X. Li 1 , M. Remacha 2 

and J. P. Ballesta 2 . 1 Rutgers University, New 

Brunswick, NJ and 2 Universidad Autonoma de 

Madrid, Madrid, Spain. Sponsor: J. Pestka. 


9:15 AM to 12:00 NOON 

Room 144 


Workshop Session: Disease Prevention: The Next 50 Years 

Chairperson(s): Helmut Zarbl, University of Medicine and Dentistry New 

Jersey, Piscataway, NJ, and Dean P. Jones, Emory University, Atlanta, 

GA. 

Sponsor: 

Disease Prevention Task Force 

Endorsed by: 



The science of toxicology has had a tremendous impact on preventing 

adverse effects of environmental toxicants, consumer products, and drugs 

on human health. The Society of Toxicology played a pivotal role in developing 

the practice of toxicology as a profession and a research discipline. 

As the Society embarks on its next fifty years, new opportunities and challenges 

will no doubt change the role of toxicology in the improving human 

health. High- throughput genomic technologies are increasingly providing 

mechanistic insights into how exposure to toxicants interacts with other 

exposures, genetic background, diet, lifestyle, co-morbid disease and 

Abstract # 

numerous other factors to modulate the disease risk. The Society thus has an 

opportunity to once again play a leading role in improving public health by 

not only preventing toxicity, but by developing approaches to predicting and 

preventing disease in those already exposed and, by identifying individuals 

or populations at increased risk from exposures. Therefore, the future of 

toxicology should include an increasing presence in disease prevention 

through biomarker based exposure and risk assessment, and individualized 

intervention, chemoprevention, and predictive toxicology. These emerging 

approaches will be reviewed to provide a roadmap for increasing the role 

of mechanistically based, predictive toxicology and ‘omics technologies in 

disease prevention. 

#40 9:15 DISEASE PREVENTION: THE NEXT 50 

YEARS. H. Zarbl. Environmental and Occupational 

Health Sciences Institiute, Robert Wood Johnson 

Medical School, Piscataway, NJ. 

9:15 INTRODUCTION. Helmut Zarbl 

#41 9:20 ASSESSING THE IMPACT OF INTER- 

INDIVDUAL GENETIC VARIABILITY ON 

TOXICITY THROUGH TOXICOGENOMIC 

DATA. I. Rusyn. Environmental Science and 

Engineering, University of North Carolina at Chapel 

Hill, Chapel Hill, NC. 

#42 9:47 COMBINING THE GENOME WITH ITS 

EXPOSOME FOR MECHANISTICALLY- 

BASED DISEASE PREVENTION. C. P. Wild, 

International Agency for Cancer Research, Lyon, 

France. Sponsor: H. Zarbl. 

#43 10:14 TOP-DOWN EXPOSOMIC STRATEGIES 

TO CHARACTERIZE THE HUMAN 

EXPOSOME. M. Smyth. University of California 

Berkeley, CA. 

#44 10:41 HIGH-THROUGHPUT METABOLOMICS 

FOR IDENTIFICATION OF QUANTITATIVE 

EXPOSURE BIOMARKERS. D. Jones. Emory 

University, Atlanta, GA. 

#45 11:08 ROLE OF THE HUMAN MICROBIOME IN 

HUMAN ENVIRONMENTAL EXPOSURE 

AND DISEASE PREVENTION. E. Holmes. 

Imperial College, London, United Kingdom. 

Sponsor: H. Zarbl. 

#46 11:34 PUBLIC HEALTH OPPORTUNITIES AND 

CHALLENGES IN DISEASE PREVENTION. 

J. D. Groopman. Bloomberg School of Public 

Health, Johns Hopkins University, Baltimore, MD. 

MONday 







119



MONday 



9:15 AM to 12:00 NOON 

Room 145 



Workshop Session: New Approaches for Integrating 

Toxicological and Epidemiological Data to Better Inform Risk 

Assessment 

Chairperson(s): Daland Juberg, Dow AgroSciences, Indianapolis, IN, 

and Anna Lowit, U.S. EPA, Washington, D.C. 

Sponsor: 


Endorsed by: 



There is increasing scientific and regulatory interest in determining how 

to better integrate animal toxicological data and epidemiological evidence 

into the risk assessment process. This need stems from the growing body 

of literature on environmental epidemiology and the frequent disparity 

observed in human and animal data relative to reported outcomes. This 

workshop will identify the expectations and limitations that are inherent in 

animal and epidemiological studies and how existing and emerging tools, 

technologies, and study designs may be better utilized for scientificallydefensible 

and informed risk assessments. We will review the challenges 

that exist with both data types (i.e., animal and epidemiologic) and identify 

the types of tools and data that would allow improved integration of 

epidemiology and experimental toxicology studies through exploration of a 

common marker of dosimetry that would facilitate cross-comparison of data 

sets. A perspective on study design and dosing regimes used in regulatory 

studies will be presented as well as review of advancements that improve 

our ability to compare animal data with known or modeled human exposures. 

Epidemiology study design and the opportunities and limitations that 

exist for simultaneously characterizing exposures and risks in humans will 

be reviewed. Insight on some of the new tools and technologies that enable 

a more refined analysis of biological plausibility and mode of action, both 

critical when assessing animal and human data for use in risk assessment, 

will be provided. Finally, advancements in exposure science within the 

context of some U.S. EPA projects and research aimed at utilizing multiple 

sources of information (i.e., exposure data, internal biomarkers, and PBPK 

modeling) for improvements in our knowledge on chemical exposures to 

humans will be discussed. 

#47 9:15 NEW APPROACHES FOR 

INTEGRATING TOXICOLOGICAL AND 

EPIDEMIOLOGICAL DATA TO BETTER 

INFORM RISK ASSESSMENT. D. R. Juberg. 

Dow AgroSciences, Indianapolis, IN. 

9:15 INTRODUCTION. Daland Juberg 

#48 9:20 USING EPIDEMIOLOGY IN HUMAN 

HEALTH RISK ASSESSMENT: RECENT 

ADVANCES. A. Lowit. Office of Pesticide 

Programs, U.S. EPA, Washington, D.C. 

#49 9:46 NEW APPROACHES TO TOXICOLOGY 

STUDY DESIGN: LINKING TESTING DOSE 

RESPONSE AND DOSIMETRY TO HUMAN 

EXPOSURE AND HEALTH OUTCOMES. J. 

Bus. The Dow Chemical Company, Midland, MI. 

#50 10:12 THE ROLE OF EPIDEMIOLOGIC 

RESEARCH IN RISK ASSESSMENT: SOME 

CHALLENGES AND OPPORTUNITIES. S. 

A. Harris 1,2,3 . 1 Population Studies and Surveillance, 

Cancer Care Ontario, Toronto, ON, Canada, 

2 

Occupational Cancer Research Centre, Toronto, 

ON, Canada and 3 Dalla Lana School of Public 

Health, Divisions of Epidemiology and Occupational 

and Environmental Health, University of Toronto, 

Toronto, ON, Canada. Sponsor: D. Juberg. 

#51 10:38 NEW TOOLS AND APPROACHES TO LINK 

TOXICOLOGICAL MODELS TO HUMAN 

HEALTH EFFECTS. R. S. Thomas. The Hamner 

Institutes for Health Sciences, Research Triangle 

Park, NC. 

#52 11:04 THE ITERATIVE ROLE OF EXPOSURE 

SCIENCE IN RISK ASSESSMENT. R. Tornero- 

Velez. U.S. EPA, Research Triangle Park, NC. 

Sponsor: D. Juberg. 



9:15 AM to 12:00 NOON 

Room 206 

Platform Session: Nanotoxicology—Carbon Nanotubes and 

Carbon Nanoparticles 

Chairperson(s): Galya Orr, Pacific Northwest National Laboratory, 

Richland, WA, and Harald Krug, EMPA—Materials and Technology, St. 

Gallen, Switzerland. 

#53 9:15 ACUTE PULMONARY RESPONSES TO 

MWCNT INHALATION. M. G. Wolfarth 1 , W. 

McKinney 1 , B. T. Chen 1 , V. Castranova 1,2 and D. W. 

Porter 1,2 . 1 HELD/PPRB, NIOSH, Morgantown, WV 

and 2 Physiology and Pharmacology, West Virginia 

University, Morgantown, WV. 

#54 9:34 BIODEGRADATION OF CARBON 

NANOTUBES BY EOSINOPHIL 

PEROXIDASE. A. A. Kapralov 1 , N. Yanamala 1 , W. 

H. Feng 1 , B. Fadeel 2 , A. Star 3 , A. A. Shvedova 4 and V. 

E. Kagan 1 . 1 Center for Free Radical and Antioxidant 

Health, EOH, University of Pittsburgh, Pittsburgh, 

PA, 2 Division of Biochemical Toxicology, Karolinska 

Institutet, Stockholm, Sweden, 3 Department of 

Chemistry, University of Pittsburgh, Pittsburgh, PA 

and 4 Pathology and Physiology Research Branch, 

NIOSH, Morgantown, WV. 

#55 9:53 LONG, FIBROUS CARBON NANOTUBES 

ACTIVATE THE NLRP3 INFLAMMASOME 

IN HUMAN MACROPHAGES AND INDUCE 

NEUTROPHILIA IN MICE LUNGS AFTER 

INTRATRACHEAL ADMINISTRATION. J. 

Palomäki, E. M. Rossi, K. Savolainen, S. Matikainen 

and H. Alenius. Finnish Institute of Occupational 

Health, Helsinki, Finland. 

#56 10:12 PULMONARY FIBROTIC RESPONSE TO 

SUB-CHRONIC MULTI-WALLED CARBON 

NANOTUBE EXPOSURE. R. R. Mercer, A. 

F. Hubbs, J. F. Scabilloni, L. Wang, L. A. Battelli, 

V. Castranova and D. W. Porter. PPRB, NIOSH, 

Morgantown, WV. 

120 






Platform Sessions



Abstract # 

#57 10:30 THE ROLE OF IL-1β SIGNALING IN 

NICKEL ASSOCIATED MULTI-WALLED 

CARBON NANOTUBE-INDUCED 

PULMONARY INFLAMMATION. T. A. 

Girtsman. CEHS, University of Montana, Missoula, 

MT. 

#58 10:48 PULMONARY INFLAMMATION, 

EPITHELIAL HYPERPLASIA, AND 

LYMPH NODE TRANSLOCATION AFTER 

MULTI-WALLED CARBON NANOTUBE 

INHALATION. A. Hubbs, V. Castranova, B. T. 

Chen, D. G. Frazer, W. McKinney, R. R. Mercer, 

M. L. Kashon, L. A. Battelli, P. Willard and D. W. 

Porter. HELD, NIOSH, Morgantown, WV. 

#59 11:06 UNDERSTANDING CARBON NANOTUBE 

GENOTOXICITY. L. M. Sargent 1 , S. H. 

Reynolds 1 , A. F. Hubbs 1 , S. A. Benkovic 1 , D. T. 

Lowry 1 , M. L. Kashon 1 , K. J. Siegrist 1 , J. Mastovich 2 , 

J. L. Sturgeon 2 , K. L. Bunker 2 and C. Z. Dinu 3 . 

1 

Toxicology and Molecular Biology, CDC/NIOSH, 

Morgantown, WV, 2 RJLeeGroup, Pittburgh, PA and 

3 

Chemical Engineering, West Virginia Univeristy, 


#60 11:24 IMPACTS OF STRUCTURE AND 

FUNCTIONALIZATION ON 

TOXICOLOGICAL RESPONSE OF THE 

MODEL ORGANISM DAPHNIA MAGNA. 

D. A. Arndt and R. Klaper. School of Freshwater 

Sciences, University of Wisconsin Milwaukee, 

Milwaukee, WI. Sponsor: R. Hutz. 

#61 11:42 TOXICOGENOMICS EFFECTS OF WATER- 

SOLUBLE CARBON NANOTUBES. D. A. 

Sarigiannis 1,2 , G. Cimino Reale 1 , A. Collotta 1 , R. 

Brustio 1 , B. Casati 1 , E. Roda 3 , A. Profumo 6 , D. 

Merli 6 , E. Quartarone 5 , P. Mustarelli 5 , M. Fagnoni 5 , 

T. Coccini 4 , L. Manzo 3,4 and E. Marafante 1 . 1 Institute 

for Health and Consumer Protection, European 

Commission - Joint Research Centre, Ispra, Varese, 

Italy, 2 Chemical Engineering Department, Aristotle 

University of Thessaloniki, Thessaloniki, Greece, 

3 

Department of Internal Medicine and Therapeutics, 

University of Pavia, Pavia, Italy, 4 Toxicology 

Division, Salvatore Maugeri Foundation IRCCS, 

Pavia, Italy, 5 Department of Physical Chemistry, 

University of Pavia, Pavia, Italy and 6 Department of 

General Chemistry, University of Pavia, Pavia, Italy. 

Sponsor: L. Birnbaum. 


9:15 AM to 12:00 NOON 

Room 202A 

Platform Session: New Insights into Male Reproductive 


Chairperson(s): Evan Thackaberry, Genetech, and Melanie Fraites, 

U.S. EPA, Research Triangle Park, NC. 

#62 9:15 DECIPHERING MECHANISMS 

UNDERLYING PROLONGED MALE 

INFERTILITY FOLLOWING A CLINICALLY- 

RELEVANT MULTI-CYCLE CISPLATIN 

TREATMENT. J. Harman 1,2 and J. Richburg 1,2 . 

1 

College of Pharmacy, Division of Pharmacology/ 

Toxicology, University of Texas at Austin, Austin, 

TX and 2 Center for Molecular and Cellular 


TX. 

Abstract # 

#63 9:34 DRAMATIC STRAIN DIFFERENCES IN 

SENSITIVITY OF RAT SPERMATOGENESIS 

TO IRRADIATION AND OTHER GONADAL 

TOXICANTS. M. Meistrich, C. Weng and M. 

AbuElhija. Experimental Radiation Oncology, MD 

Anderson Cancer Center, Houston, TX. 

#64 9:53 THE EFFECTS OF NEONATAL EXPOSURE 

TO DECA-BROMINATED DIPHENYL 

ETHER ON APICAL ECTOPLASMIC 

SPECIALIZATION IN MOUSE TESTIS. 

H. Miyaso 1 , Y. Matsuno 1,2 , M. Komiyama 1 , S. 

Ochiai 1 , Y. Igoshi 1 and C. Mori 1,2 . 1 Department 

of Bioenvironmental Medicine, Graduate School 

of Medicine, Chiba University, Chiba, Japan and 

2 

Center for Preventive Medical Science, Chiba 

University, Chiba, Japan. 

#65 10:12 GENE EXPRESSION CHANGES IN THE 

TESTIS FOLLOWING X-RADIATION AND 2, 

5-HEXANEDIONE EXPOSURE. N. Catlin, S. 

N. Campion and K. Boekelheide. Brown University, 

Providence, RI. 

#66 10:30 C/EBP AND C-MYC COOPERATE FOR 

THE TRANSCRIPTIONAL SUPPRESSION 

OF SERTOLI CELL TIMP-2 IN RODENTS 

FOLLOWING MEHP EXPOSURE. P. Yao, Y. 

Lin and J. H. Richburg. Center for Molecular and 

Cellular Toxicology, Division of Pharmacology and 

Toxicology, College of Pharmacy, The University of 

Texas at Austin, Austin, TX. 

#67 10:48 IN UTERO DIBUTYL PHTHALATE 

EXPOSURE CONCOMITANTLY INHIBITS 

FETAL TESTIS STEROIDOGENIC 

AND SREBP2-DEPENDENT 

CHOLESTEROLOGENIC PATHWAYS. K. 

Johnson 1 , M. Viereck 1 , E. McDowell 1 and Q. Xia 2 . 

1 

Biomedical Research, Alfred I. duPont Hospital for 

Children, Wilmington, DE and 2 National Institutes of 

Statistical Sciences, Research Triangle Park, NC. 

#68 11:06 ACRYLAMIDE AND GLYCIDAMIDE ARE 

MUTAGENIC IN SPERMATOGONIAL 

STEM CELLS OF BIG BLUE MICE. N. Mei 1 , 

R. Wang 1,3 , L. P. McDaniel 1 , S. D. Shelton 1 , D. R. 

Doerge 2 and M. G. Manjanatha 1 . 1 Division of Genetic 

and Molecular Toxicology, NCTR /U.S. FDA, 

Jefferson, AR, 2 Division of Biochemical Toxicology, 

NCTR /U.S. FDA, Jefferson, AR and 3 Division of 

Health Effects Research, Japan National Institute of 

Occupational Safety and Health, Kawasaki, Japan. 

#69 11:24 1, 3-DINITROBENZENE: REVISITING THE 

POSTULATED MODE OF ACTION FOR 

ITS TESTICULAR TOXICITY. S. Ludwig, 

H. Tinwell, D. Rouquié and R. Bars. Research 

Toxicology, Bayer SAS, Sophia Antipolis Cedex, 

France. 

#70 11:42 ITCH PROMOTES MEHP-INDUCED GERM 

CELL APOPTOSIS. J. L. Dwyer 1 , Y. Lin 2 , P. Yao 2 

and J. H. Richburg 2,1 . 1 Institute for Cellular and 

Molecular Biology, University of Texas at Austin, 

Austin, TX and 2 Center for Molecular and Cellular 


TX. 

MONday 







121



MONday 



9:15 AM to 12:00 NOON 

Room 204 

Platform Session: Use of Embryonic Stem Cells in Toxicology 

Chairperson(s): Blake Anson, Cellular Dynamics International, Madison, 

WI, and Patrick McNutt, USAMRICD, Aberdeen Proving Ground, MD. 

#71 9:15 COMPARISON OF THE EMBRYONIC 

STEM CELL TEST, THE WHOLE EMBRYO 

CULTURE AND THE ZEBRAFISH EMBRYO 

TEST AS ALTERNATIVE METHODS FOR 

DEVELOPMENTAL TOXICITY TESTING 

OF TRIAZOLES. E. de Jong 1,2 , M. Barenys 3 , 

S. Hermsen 2,4 , A. Verhoef 2 and A. H. Piersma 1,2 . 

1 

Institute for Risk Assessment Sciences, Utrecht 

University, Utrecht, Netherlands, 2 National Institute 

for Public Health and the Environment, Bilthoven, 

Netherlands, 3 Toxicology Unit, Public Health 

Department, School of Pharmacy, University of 

Barcelona, Barcelona, Spain and 4 Department of 

Health Risk Analysis and Toxicology, NUTRIM, 

University of Maastricht, Maastricht, Netherlands. 

Sponsor: H. van Loveren. 

#72 9:34 PREDICTING DEVELOPMENTAL 

TOXICITY OF TOXCAST PHASE I 

CHEMICALS USING HUMAN EMBRYONIC 

STEM CELLS AND METABOLOMICS. N. C. 

Kleinstreuer 2 , P. R. West 1 , A. M. Weir-Hauptman 1 , 

A. M. Smith 1 , T. B. Knudsen 2 , E. L. Donley 1 and G. 

G. Cezar 1,3 . 1 Stemina Biomarker Discovery, Inc., 

Madison, WI, 2 ORD/NCCT, U.S. EPA, Durham, NC 

and 3 University of Wisconsin Madison, Madison, WI. 

#73 9:53 TESTING OF PRO-TERATOGENS 

IN THE EMBRYONIC STEM CELL 

TEST: SIMULATION OF METABOLIC 

CONVERSION BY TREATMENT WITH 

DEFINED MIXTURES OF PARENT 

COMPOUNDS AND THEIR RESPECTIVE 

METABOLITES. A. E. Seiler, J. Kaltenhaeuser, 

U. Gruber and A. Luch. ZEBET, Federal Institute 

for Risk Assessment, Berlin, Germany. Sponsor: R. 

Chapin. 

#74 10:12 COREXIT EC9527A INHIBITS RETINOL 

SIGNALING IN P19 MOUSE PLURIPOTENT 

CELLS. Y. Chen and D. H. Reese. DMB, OARSA, 

CFSAN, U.S. FDA, Laurel, MD. Sponsor: S. Sahu. 

#75 10:30 TERATOGENICITY OF VALPROIC 

ACID DERIVATIVES: EVALUATION OF 

STRUCTURE-ACTIVITY RELATIONSHIPS 

USING THE EMBRYONIC STEM CELL 

TEST. C. Riebeling 1 , A. E. Seiler 1 , K. Becker 2 , R. 

Buesen 1,6 , D. Eickel 5 , J. Kaltenhaeuser 1 , F. Meyer 3 , H. 

Nau 4 , R. Pirow 1 , B. Slawik 1 , A. Visan 1 , J. Volland 3 , H. 

Spielmann 1 and A. Luch 1 . 1 ZEBET, Federal Institute 

for Risk Assessment, Berlin, Germany, 2 Nonclinical 

Drug Safety, Bayer Schering Pharmacology AG, 

Berlin, Germany, 3 Nycomed GmbH, Barsbüttel, 

Germany, 4 Department of Food Toxicology and 

Chemical Analysis, University of Veterinary 

Medicine Hannover, Hannover, Germany, 5 Product 

Application Laboratory, Advion BioSystems, 

Ithaca, NJ and 6 Mechanistic Toxicology, BASF, 

Ludwigshafen, Germany. Sponsor: R. Chapin. 

#76 10:48 The roles of MKK4 and MKK7 in 

developmental toxicity. J. Wang 1,2 , 

L. Chen 1 , L. Zhang 2 and Y. Xia 1 . 1 Environmental 

Health, University of Cincinnati, Cincinnati, OH 

and 2 Histology & Embryology, Southern Medical 

University, Guangzhou, China. 

#77 11:06 DEVELOPMENT OF EMBRYONIC 

STEM CELL-DERIVED NEURONS FOR 

BOTULINUM NEUROTOXIN RESEARCH 

AND DRUG DISCOVERY. P. McNutt and M. 

Mesngon. USAMRICD, Gunpowder, MD. Sponsor: 

G. Rockwood. 

#78 11:24 TCDD INDUCED MODIFICATION OF 

TRANSCRIPTION FACTOR SIGNALING 

AND CARTILAGE DYSMORPHOGENESIS 

IN VIVO. W. Dong 1,2 and S. W. Kullman 1 . 

1 

Department of Environmental and Molecular 

Toxicology, North Carolina State University, Raleigh, 

NC and 2 College of Animal Science and Technology, 

Inner Mongolia University for the Nationalities, 

Tongliao, Inner Mongolia, China. 

#79 11:42 METHYL MERCURY INDUCED 

PERTURBATION OF NEURAL 

DIFFERENTIATION OF MURINE 

EMBRYONIC STEM CELLS OVER TIME 

DESCRIBED BY TRANSCRIPTOMICS. P. 

T. Theunissen 1,2 , J. L. Pennings 1 , J. C. Kleinjans 2 , 

J. F. Robinson 1 and A. H. Piersma 1,3 . 1 Laboratory 

for Health Protection Research, National Institute 

of Public Health and the Environment (RIVM), 

Bilthoven, Netherlands, 2 Department of Health Risk 

Analysis and Toxicology, University of Maastricht, 

Maastricht, Netherlands and 3 Institute for Risk 

Assessment Sciences, Utrecht University, Utrecht, 

Netherlands. 


9:15 AM to 10:15 AM 

Room 156 

Exhibitor Hosted Session: Logistic and Technical Challenges 

of Conducting Developmental Toxicity Studies in Nonhuman 

Primates 

Presented by: MPI Research 

The preclinical safety testing of biotherapeutics poses a particular challenge 

in selecting a relevant animal species for use in toxicology studies. 

The nonhuman primates are most frequently used for developmental and 

reproductive toxicity testing when commonly used rodents and/or rabbits are 

not pharmacologically relevant species. In this presentation, the logistical 

and technical challenges when conducting developmental toxicity testing in 

nonhuman primates will be presented and discussed. 


9:15 AM to 10:15 AM 

Room 140A 

Exhibitor Hosted Session: Phototoxicology: Current Practices 

and Regulatory Status 

Presented by: Charles River 

Phototoxic risk can be assessed during drug development from candidate 

screening through Phase IV. When and how to evaluate for phototoxic 

potential is not always clear and the changing regulatory status adds additional 

uncertainty. The tools for phototoxicity testing and how current/ 

upcoming regulations may affect these approaches will be presented. 

122 






Platform Sessions



Abstract # 


9:30 AM to 10:30 AM 

Room 304 

(Ticket Required; Postdoctoral Scholars only, 

limited seating) 


Chairperson(s): Michelle La Merrill, Mount Sinai School of Medicine, 

New York, NY. 

Sponsor: 


Dr. Collins will meet informally for discussion with postdoctoral scholars 

after his Plenary Lecture. 


9:30 AM to 10:50 AM 

Room 304 

Undergraduate Education Program: Poster Session for 

Visiting Students 

Chairperson(s): Julio Davila, Chesterfield, MD. 

Sponsors: 




travel funding and SOT program volunteers assisting with the Undergraduate 



9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Hypersensitivity: Methods and Mechanisms 

Chairperson(s): Victor Johnson, NIOSH, Morgantown, WV. 

Displayed: 9:30 AM–12:30 PM 

Author Attended: 9:30 AM–11:00 AM 

#80 Poster Board Number.....................................101 

VALIDATION OF THE CANDIDA 

ALBICANS DELAYED-TYPE 

HYPERSENSITIVITY (DTH) MODEL 

IN THE B6C3F1 MOUSE FOLLOWING 

EXPOSURE TO AZATHIOPRINE 

(AZA), CYCLOPHOSPHAMIDE 

(CPS), CYCLOSPORIN A (CSA), 

DEXAMETHASONE (DEX), OR BENZO[E] 

PYRENE (B[E]P) FOR 28 DAYS. M. J. 

Smith, C. E. McLoughlin, W. Auttachoat and K. 

L. White. Pharmacology and Toxicology, Virginia 

Commonwealth University, Richmond, VA. 


A RETROSPECTIVE OF THE REGULATORY 

USE OF THE LOCAL LYMPH NODE 

ASSAY FOR THE NOTIFICATION OF NEW 

CHEMICALS IN EUROPE. S. Casati, A. Angers- 

Loustau and L. Tosti. European Commission (Joint 

Research Centre), Ispra, Italy. Sponsor: D. Basketter. 

Abstract # 


COMPARISON OF 3H-THYMIDINE 

INCORPORATION AND NON- 

RADIOACTIVE CELL COUNTEND AS 

ENDPOINTS OF THE LOCAL LYMPH NODE 

ASSAY (LLNA) IN ROUTINE TESTING. S. 

N. Kolle, A. O. Gamer, A. Schrage, N. Honarvar, 

V. Strauss, R. Landsiedel and B. van Ravenzwaay. 

Experimental Toxicology and Ecology, BASF SE, 

Ludwigshafen, Germany. Sponsor: A. Van Cott. 


VEHICLE-DEPENDENT EFFECTS ON 

HEXYLCINNAMALDEHYDE RESPONSES 

IN THE LLNA. G. L. DeGeorge, M. Carathers, J. 

Tao and D. R. Cerven. MB Research Laboratories, 

Spinnerstown, PA. 


RESPIRATORY TRACT RESPONSES IN 

WISTAR AND BN RATS, SENSITIZED 

AND CHALLENGED BY INHALATION 

WITH THE CONTACT ALLERGEN 

DINITROCHLOROBENZENE (DNCB). J. 

van Triel 1 , J. Arts 1,2 and F. Kuper 1 . 1 Toxicology and 

Applied Pharmacology, TNO, Zeist, Netherlands and 

2 

Technology & Engineering, Akzo Nobel, Arnhem, 

Netherlands. Sponsor: R. Woutersen. 


STEPS TOWARDS THE DEVELOPMENT OF 

AN INTEGRATED APPROACH FOR THE 

PREDICTION OF SKIN SENSITIZATION 

POTENTIAL USING DATA FROM SEVERAL 

ALTERNATIVE TEST SYSTEMS. C. Ryan 1 , J. 

Jaworska 2 , P. Kern 2 , J. Chaney 1 and F. Gerberick 1 . 

1 

Procter & Gamble Company, Cincinnati, OH and 

2 

Procter & Gamble Company, Brussels, Belgium. 


DIFFERENTIATION OF PROHAPTENS 

FROM DIRECT ACTING CONTACT 

CHEMICAL ALLERGENS USING A 

CYTOCHROME P450 REDUCTASE 

DEFICIENT MOUSE MODEL. I. Chipinda, F. 

M. Blachere, S. E. Anderson and P. D. Siegel. HELD, 

CDC/NIOSH, Morgantown, WV. 


PLASMACYTOID DENDRITIC CELL-BASED 

ASSAY AS AN IN VITRO ALTERNATIVE FOR 

CHEMICAL ALLERGENICITY SCREENING. 

M. Spratt, M. Klausner, S. Ayehunie and M. Child. 

MatTek Corp, Ashland, MA. Sponsor: P. J. 


CELL LINE-BASED PREDICTION 

OF SENSITIZATION BY COUPLING 

KERATINOCYTE METABOLISM AND 

DENDRITIC CELL ACTIVATION. J. Hennen 1 , 

P. Aeby 2 , C. Goebel 3 , T. Schettgen 4 , A. Oberli 5 , 

M. Kalmes 1 and B. Blömeke 1 . 1 Environmental 

Toxicology, University Trier, Trier, Germany, 

2 

Consultant, Marly, Switzerland, 3 Procter & 

Gamble Co., Darmstadt, Germany, 4 RWTH Aachen 

University, Aachen, Germany and 5 Federal Office of 

Public Health (FOPH), Bern, Switzerland. 

MONday 







123



MONday 



DEVELOPMENT OF A MOUSE MODEL 

TO ASSESS THE ALLERGENICITY OF 

HYDROLYSED COW’S MILK BASED 

INFANT FORMULAE. B. C. van Esch 1 , J. H. 

Van Bilsen 2 , P. V. Jeurink 3 , J. Garssen 3 , J. Smit 4 , 

R. Pieters 4 and L. M. Knippels 3 . 1 Utrecht Institute 

for Pharmaceutical Sciences, Utrecht University, 

Utrecht, Netherlands, 2 Quality of Life, TNO, Zeist, 

Netherlands, 3 Immunology, Danone Research Centre 

for Specialized Nutrition, Wageningen, Netherlands 

and 4 IRAS, Utrecht University, Utrecht, Netherlands. 


PREFERENTIAL REACTIVITY OF 

CONTACT AND RESPIRATORY LOW 

MOLECULAR WEIGHT CHEMICAL 

ALLERGENS UNDER COMPETITIVE 

CONDITIONS. J. F. Lalko 1,3 , I. Kimber 1 , R. J. 

Dearman 1 , F. Gerberick 2 , A. Api 3 and L. W. Smith 3 . 

1 

The University of Manchester, Manchester, United 

Kingdom, 2 Procter & Gamble Company, Cincinnati, 

OH and 3 RIFM, Inc., Woodcliff Lake, NJ. 


ALLERGEN EXPOSURE RESULTS 

IN CHANGES IN THE LEVEL OF 

EXPRESSION AND FREQUENCY OF B220 + 

LYMPHOCYTES. S. Khan 1 , I. Kimber 1 , R. J. 

Dearman 1 , J. F. Lalko 1,2 and A. Api 2 . 1 The University 

of Manchester, Manchester, United Kingdom and 

2 

RIFM Inc., Woodcliff Lake, NJ. 


PROTEIN ALLERGENICITY AND 

DIGESTIBILITY : COMPARISONS OF 

PEPSIN AND CATHEPSIN. E. Foster, I. Kimber 

and R. J. Dearman. University of Manchester, 

Manchester, United Kingdom. 


INHALATION OF ORTHO- 

PHTHALALDEHYDE VAPOR CAUSES 

SYSTEMIC SENSITIZATION AND 

ALLERGIC INFLAMMATION IN THE 

LYMPH NODES, NASAL MUCOSA, AND 

LUNG OF MICE. V. J. Johnson, W. Wang, K. 

Fluharty, B. Yucesoy and J. S. Reynolds. CDC/ 



CONTACT SENSITIZING POTENTIAL OF 

HEPTACHLOR IN FEMALE BALB/C MICE. 

R. P. Frawley 1 , W. Auttachoat 2 , M. J. Smith 2 , R. 

D. Brown 2 , T. L. Guo 2 , K. L. White Jr 2 and D. R. 

Germolec 1 . 1 National Toxicology Program, National 

Institute of Environmental Health Sciences, Research 

Triangle Park, NC and 2 Department of Pharmacology 

and Toxicology, Virginia Commonwealth University, 

Richmond, VA. 


9:30 AM to 12:30 PM 

Exhibit Hall 


THE SURVIVAL OF DENDRITIC 

CELLS IS CONTROLLED BY THE 

TRANSCRIPTIONAL FACTOR NRF2 IN 

RESPONSE TO CHEMICAL SENSITIZERS. 

S. Kerdine-Römer, Z. El ALi, M. Damiens and 

M. Pallardy. Toxicologie, Université Paris Sud- 

INSERM UMR 996, Châtenay-Malabry, France. 


CHRONIC EXPOSURE OF MICE TO 

CHEMICAL ALLERGEN IS ASSOCIATED 

WITH A TH17 PHENOTYPE. R. J. Dearman, 

M. D. Hayes and I. Kimber. Faculty of Life Sciences, 

Manchester University, Manchester, Greater 

Manchester, United Kingdom. 


ALLERGEN-INDUCED LANGERHANS’ 

CELL AND DENDRITIC CELL 

MIGRATION: COMPARISONS BETWEEN 

2, 4-DINITROCHLOROBENZENE AND 2, 

4-DINITROTHIOCYANOBENZENE. M. 

Cumberbatch, C. F. Portsmouth, I. Kimber and R. J. 

Dearman. University of Manchester, Manchester, 

United Kingdom. 


DIFFERENTIAL REGULATION OF 

LANGERHANS’ CELL (LC) MIGRATION BY 

THIOREDOXIN AND LACTOFERRIN. R. 

Almond 1 , M. Cumberbatch 1 , G. del Val 2 , I. Kimber 1 

and R. J. Dearman 1 . 1 University of Manchester, 

Manchester, United Kingdom and 2 Syngenta Biotech, 

Bracknell, United Kingdom. 


Poster Session: Epigenetic Mechanisms 

Chairperson(s): Narendra Singh, University of South Carolina School of 

Medicine, Columbia, SC. 


Author Attended: 11:00 AM–12:30 PM 


HUMAN LINE1 PROMOTER ACTIVITY IS 

ENHANCED BY CHEMICAL AND DRUG- 

INDUCED STRESS IN HEPG2 CELLS. N. 

Terasaki, M. Kajikawa and N. Okada. Department of 

Biological Science, Graduate School of Bioscience 

and Biotechnology, Tokyo Institute of Technology, 

Yokohama, Japan. Sponsor: J. Sugimoto. 


IN UTERO BISPHENOL A EXPOSURE 

ALTERS METASTABLE EPIALLELE 

AND GLOBAL DNA METHYLATION 

PATTERNS IN MOUSE OFFSPRING. M. S. 

Nahar, C. Weinhouse, O. S. Anderson, T. R. Jones, 

S. A. Liberman, L. S. Rozek and D. C. Dolinoy. 

Environmental Health Science, University of 

Michigan, Ann Arbor, MI. 


IDENTIFICATION OF CANCER SPECIFIC 

METHYLATED PROMOTER REGION IN 

MOUSE BONE MARROW ORIGINATED 

TUMOR CELLS. H. Shin 1 , S. Jeong 2 , J. Kang 1 , 

Y. Park 1 , S. Son 1 and H. Kang 1 . 1 Toxicology & 

Chemistry Division, NVRQS, Anyang, Republic of 

Korea and 2 GLP Research Center, College of Natural 

Sciences, Hoseo University, Asan City, Republic of 

Korea. 

124 






Platform Sessions



Abstract # 


DOSE-DEPENDENT SHIFTS IN AVY COAT 

COLOR DISTRIBUTION FOLLOWING 

MATERNAL DIETARY EXPOSURE TO 

BISPHENOL A. O. S. Anderson, M. Nahar, T. 

R. Jones and D. C. Dolinoy. Environmental Health 

Science, University of Michigan, AnnArbor, MI. 


THE UP-REGULATION OF AHR AND STAT1 

GENE EXPRESSION IN LONG-TERM 

ESTROGEN EXPOSED MCF-7 CELLS: 

POTENTIAL ROLES OF AUTOCRINE 

SIGNALING AND EPIGENETIC 

MECHANISMS. N. A. Englert 1,2 , B. C. Spink 1 

and D. C. Spink 1,2 . 1 Laboratory of Molecular 

Toxicology, Wadsworth Center, New York State 

Department of Health, Albany, NY and 2 Department 

of Environmental Health Sciences, School of Public 

Health, University at Albany, State University of 

New York, Albany, NY. 


EPIGENETIC INACTIVATION OF 

P16 INK4A GENE IS ASSOCIATED WITH 

RESISTANCE OF GUERIN CARCINOMAS 

TO DOXORUBICIN AND CISPLATIN. S. 

Sarfaraz 1 , S. Shpyleva 1 , I. Todor 2 , N. Yanova 2 , V. 

Chekhun 2 and I. Pogribny 1 . 1 Biochemical Toxicology, 

NCTR /U.S. FDA, Jefferson, AR and 2 Oncology 

and Radiobiology, R.E. Kavetsky Institute of 

Experimental Pathology, Kyiv, Ukraine. Sponsor: V. 

Tryndyak. 


EPIGENETIC ALTERATIONS FOLLOWING 

DEVELOPMENTAL EXPOSURE 

TO THE PYRETHROID PESTICIDE 

DELTAMETHRIN. A. L. Green 1,2 and J. R. 

Richardson 2 . 1 The Joint Graduate Program in 

Toxicology, Piscataway, NJ and 2 Rutgers University, 

University of Medicine and Dentistry of New 

Jersey, The Environmental and Occupational Health 

Sciences Institute, Piscataway, NJ. 


EFFECTS OF CHRONIC EXPOSURE TO 

17β-ESTRADIOL ON CELL MORPHOLOGY, 

GROWTH PATTERN, AND EXPRESSION 

OF EPIGENETIC REGULATORY GENES. J. 

Treas and K. Singh. The Institute of Environmental 

and Human Health, Texas Tech, Lubbock, TX. 


DISRUPTION OF MITOSIS BY 

OCHRATOXIN A INVOLVES ALTERED 

ACETYLATION OF CORE HISTONES. K. 

Czakai, W. Dekant and A. Mally. Department of 

Toxicology, University of Wuerzburg, Wuerzburg, 

Germany. 


EPIGENETIC EFFECTS OF CRUDE OIL 

RECOVERED FROM THE DEEPWATER 

HORIZON SPILL ON HUMAN KIDNEY 

CELLS. H. Kim 1 , P. J. Lioy 2 , C. P. Weisel 2 , R. 

Portier 3 , N. Thakkar 1 , J. D. Laskin 2 and D. Heck 1 . 

1 

New York Medical College, Valhalla, NY, 2 UMDNJ- 

Robert Wood Johnson Medical School, Piscataway, 

NJ and 3 Lousiana State University, Baton Rouge, LA. 

Abstract # 


CD4+ T CELL INTRINSIC TNF RECEPTOR 

2 SIGNALING: AN EPIGENETIC TARGET 

FOR TRANSCRIPTIONAL REGULATION 

OF IL-2? J. K. Dey 4 , R. S. Schondelmeyer 3 , E. 

N. Sellers 3 , P. G. Miller 3 , G. Lin 5 , M. B. Bonn 4 and 

S. C. McKarns 1,2 . 1 Surgery, University of Missouri 

School of Medicine, Columbia, MO, 2 Molecular 

Microbiology & Immunology, University of Missouri 

School of Medicine, Columbia, MO, 3 Biochemistry, 

University of Missouri, Columbia, MO, 4 Biological 

Sciences, University of Missouri, Columbia, MO 

and 5 Biological Engineering, University of Missouri, 

Columbia, MO. 


EPIGENETIC MODULATION OF 

XENOESTROGEN INDUCED BREAST 

CANCER. L. Wang, W. Jiang, B. Moorthy and S. 

R. Kondraganti. Department of Pediatrics, Baylor 

College of Medicine, Houston, TX. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: DNA Replication and Repair 

Chairperson(s): Huaxian Ma, University of Texas Medical Branch, 

Galveston, TX. 




THE ROLE OF NICOTINE IN THE 

INDUCTION OF GENOMIC INSTABILITY 

IN BREAST CELLS. C. L. Clemens and J. W. 

DuMond. Environmental Science and Technology, 

Texas Southern University, Houston, TX. 


INDUCTION OF BASE EXCISION REPAIR 

ENZYMES APE1 AND NTH1 IN RAT SPLEEN 

FOLLOWING ANILINE EXPOSURE. H. Ma, 

J. Wang and M. Khan. Pathology, University of Texas 

Medical Branch, Galveston, TX. 


ENHANCED NUCLEOTIDE EXCISION 

REPAIR OF COMBINED 17ALPHA- 

ETHINYLESTRADIOL AND UV IN 

ZEBRAFISH LIVER CELLS. S. Tang 1 , E. 

G. Notch 2 , V. Allagadda 1 and G. D. Mayer 1 . 1 The 

Institute of Environmental and Human Health, Texas 

Tech University, Lubbock, TX and 2 Department of 

Physiology, Dartmouth Medical School, Hanover, 

NH. 


HOMOLOGOUS RECOMBINATION IN 

THE CELLULAR RESPONSE TO SULPHUR 

MUSTARD. P. A. Jowsey, F. M. Williams and P. 

G. Blain. Medical Toxicology Centre, Newcastle 

University, Newcastle Upon Tyne, United Kingdom. 

MONday 







125



MONday 



ARSENIC INHIBITS THE NUCLEOTIDE 

EXCISION REPAIR PATHWAY IN 

HUMAN LUNG CELLS AND MOUSE 

KERATINOCYTES. N. Holcomb, M. Goswami, 

T. Scott, T. Bhattarai, J. D’Orazio, D. Orren, 

G. Gairola and I. Mellon. Graduate Center for 

Toxicology, University of Kentucky, Lexington, KY. 


EXPLORING THE ROLE OF NUCLEOTIDE 

EXCISION REPAIR (NER) AND HELICASE 

IN ZIDOVUDINE (AZT)-INDUCED 

GENOTOXICITY. D. Momot, T. A. Nostrand, 

K. John, M. C. Poirier and O. A. Olivero. LCBG, 

National Cancer Institute, Bethesda, MD. 


DOSE-RESPONSE EVALUATION OF P53 

AND H2AX DNA DAMAGE RESPONSE 

BY METHYL METHANESULFONATE, 

ETOPOSIDE, AND QUERCETIN. B. Sun 1 , 

K. Daniels 1 , S. Ross 1 , Q. Zhang 1 , M. Andersen 1 , P. 

Carmichael 2 and R. Clewell 1 . 1 The Hamner Institute, 

Durham, NC and 2 Unilever SEAC, Bedfordshire, 



TO STUDY THE SIGNAL TRANSDUCTION 

ON 2-ABP & 4-ABP INDUCED DNA DAMAGE 

IN HEP G2 CELL. J. Wong 1 , J. Wu 2 , S. Chen 1 

and L. Chen 3 . 1 Department of Biotechnology, 

National Kaohsiung Normal University, Kaohsiung, 

Taiwan, 2 Department of Applied Chemistry, Fooyin 

University, Kaohsiung, Taiwan and 3 Department of 

Medical Nutrition, I-Shou University, Kaohsiung, 

Taiwan. 


GENOTOXICITY AND CHANGES IN GENE 

EXPRESSION PROFILES INDUCED BY 

AIRBORNE PARTICLES IN HUMAN CELL 

LINES. J. Topinka, K. Uhlirova, H. Libalova, A. 

Milcova, J. Schmuczerova and R. J. Sram. Genetic 

Ecotoxicology, Institute of Experimental Medicine 

AS CR, Prague 4, Czech Republic. 


MOLECULAR DETERMINANTS OF DNA 

POLYMERASE ETA FIDELITY. S. C. Suarez 

and S. D. McCulloch. Environmental and Molecular 

Toxicology, North Carolina State University, 

Raleigh, NC. 


MECHANISMS OF THE WERNER 

SYNDROME PROTEIN IN PROTECTING 

AGAINST CR(VI) INDUCED TELOMERE 

LOSS. F. Liu, K. E. Knickelbein, A. Barchowsky 

and P. L. Opresko. Environmental and Occupational 

Health, University of Pittsburgh, Pittsburgh, PA. 


ANALYSIS OF MOLECULAR SPLINT 

MUTANTS OF HUMAN DNA POL η AND 

THEIR EFFECT ON POLYMERASE 

PROPERTIES. R. A. Beardslee and S. D. 

McCulloch. Department of Environmental and 

Molecular Toxicology, North Carolina State 

University, Raleigh, NC. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Bioinformatic Profiling and Computational 

Pathway Prediction 

Chairperson(s): Hao Zhu, University of North Carolina at Chapel Hill, 

Chapel Hill, NC, and Imran Shah, U.S. EPA, Chapel Hill, NC. 




COMMONALITY AND STOCHASTICITY IN 

GENE EXPRESSION PROFILES DURING 

AGING PROCESS. T. Inoue 1 and Y. Hirabayashi 2 . 

1 

Center for Biological Safety & Research, National 

Institute of Health Sciences, Tokyo, Japan and 

2 

Division of Cellular & Molecular Toxicology, 

Center for Biological Safety & Research, National 

Institute of Health Sciences, Tokyo, Japan. 


COMPARISON OF TOXICOGENOMICS 

PROFILES TO DISCOVER CO-REGULATED 

GENES. Y. Igarashi 1 , N. Nakatsu 1 , H. Yamada 1 , 

A. Ono 2 , Y. Ohno 2 and T. Urushidani 1,3 . 1 National 

Institute of Biomedical Innovation, Ibaraki-City, 

Osaka, Japan, 2 National Institute of Health Sciences, 

Setagaya-ku, Tokyo, Japan and 3 Doshisha Women’s 

College of Liberal Arts, Kyotanabe-City, Kyoto, 

Japan. 


USE OF PATHWAY ANALYSES TO IDENTIFY 

POTENTIAL TARGET SAFETY RISKS FOR 

ANTIBODY DRUG CONJUGATES (ADC). B. 

Lu 1 , L. Obert 1 , A. Hooper 2 and M. Gosink 1 . 1 Drug 

Safety Research & Dev, Pfizer, Groton, CT and 

2 

Center for Integrative Biology & Biotherapeutics, 

Pfizer, Pearl River, NY. 


COMPARISON OF NEXT GENERATION 

SEQUENCING AND MICROARRAY 

ANALYSES OF GENE EXPRESSION IN 

KIDNEY OF THE RATS TREATED WITH 

CARCINOGEN ARISTOLOCHIC ACID. T. 

Chen 1 , Z. Li 1 , Z. Su 2 and L. Shi 3 . 1 Division of Genetic 

and Molecular Toxicology, U.S. FDA NCTR, 

Jefferson, AR, 2 Z-Tech, U.S. FDA NCTR, Jefferson, 

AR and 3 Division of System Biology, U.S. FDA 

NCTR, Jefferson, AR. 


THE ARYL HYDROCARBON RECEPTOR 

PROTEIN INTERACTION NETWORK (AHR- 

PIN). J. J. LaPres 1,2 , D. M. Tappenden 1,2 , L. Yang 3 

and R. S. Thomas 3 . 1 Biochemistry, Michigan State 

University, East Lansing, MI, 2 Center for Integrative 

Toxicology, Michigan State University, East Lansing, 

MI and 3 The Hamner Institutes for Health Sciences, 


126 






Platform Sessions



Abstract # 


SEQUENCE TAGGING REVEALS 

UNEXPECTED MODIFICATIONS IN 

TOXICOPROTEOMICS. S. Dasari 1 , M. C. 

Chambers 1 , D. C. Liebler 2 , F. P. Guengerich 2 and 

D. L. Tabb 1,2 . 1 Biomedical Informatics, School of 

Medicine, Vanderbilt University, Nashville, TN 

and 2 Biochemistry, School of Medicine, Vanderbilt 

University, Nashville, TN. 


PROTEOMIC PROFILING OF DYNAMIC 

CELLULAR RESPONSES TO SILICA 

NANOPARTICLES USING STABLE ISOTOPE 

AMINO ACID LABELING. B. Thrall 1 , B. Webb- 

Robertson 2 , K. Burnham 3 , M. H. Littke 1 , N. J. Karin 3 , 

J. Jacobs 3 and K. M. Waters 2 . 1 Cell Biology & 

Biochemistry, PNNL, Richland, WA, 2 Computational 

Biology & Bioinformatics, PNNL, Richland, WA 

and 3 Biological Separations & Mass Spectrometry 

Groups, Pacific Northwest National Laboratory, 

Richland, WA. 


ENVIRONMENTAL CHEMICALS AND 

HUMAN HEALTH: UNCOVERING THE 

CONNECTIONS WITH CTD. C. Mattingly, C. 

G. Murphy, C. A. Saraceni-Richards, S. Mockus, 

M. C. Rosenstein, T. C. Wiegers, B. King and A. P. 

Davis. Bioinformatics, MDI Biological Laboratory, 

Salisbury Cove, ME. 


GENERATING A GENE NETWORKS 

ASSOCIATED WITH KOLA ACUMINATA- 

BIZZY NUT INDUCE APOPTOSIS. R. Ledet 

and W. G. Gray. Chemistry, Southern University 

A&M College, Baton Rouge, LA. 


VIRTUAL SCREENING OF DIFFERENTIAL 

PROTEIN TARGETS FOR TROVAFLOXACIN 

AND LEVOFLOXACIN. J. Olivero-Verbel, 

C. Ortega-Zuñiga and M. Cabarcas-Montalvo. 

Environmental and Computational Chemistry 

Group, University of Cartagena, Cartagena, Bolivar, 

Colombia. 


THE MOUSE GENOME INFORMATICS 

DATABASE: INTEGRATING INFORMATION 

TO FACILITATE DISCOVERY. S. M. Bello, C. 

L. Smith, H. Dene, D. L. Burkart, L. L. Washburn, 

M. Tomczuk, A. Anagnostopoulos, B. Richards- 

Smith, H. Onda, R. P. Babiuk, M. Knowlton, J. 

Xu, J. A. Bubier and J. T. Eppig. Mouse Genome 

Informatics, The Jackson Laboratory, Bar Harbor, 

ME. 


FINDING CLUSTERS OF CHEMICALS 

AFFECTING SUB-NETWORKS OF THE 

PROTEIN INTERACTOME. R. Thomas 1 , 

I. Gerlovina 1 , A. Hubbard 1 , M. North 2 and C. 

Vulpe 2 . 1 Biostatistics, University of California, 

Berkeley, Berkeley, CA and 2 Nutritional Science 

and Toxicology, University of California, Berkeley, 

Berkeley, CA. 

Abstract # 


A BIOINFORMATICS-BASED PIPELINE 

FOR BIOMARKER DISCOVERY UTILIZING 

BOTH IN VITRO AND IN VIVO DATA. 

R. C. Grafström 1,2 , R. Ceder 1 , C. A. Staab 3 , J. 

Höög 3 , H. Jörnvall 3 , M. Nees 2 , B. Fadeel and K. 

Roberg 4 . 1 Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden, 2 Medical 

Biotechnology, VTT Technical Research Centre of 

Finland, Turku, Finland, 3 Department of Medical 

Biochemistry and Biophysics, Karolinska Institutet, 

Stockholm, Sweden and 4 Department of Clinical 

and Experimental Medicine, Linköping University, 

Linköping, Sweden. 


CHARACTERIZATION OF A QSAR MODEL 

FOR PHOSPHOLIPIDOSIS USING A 

HIERARCHICAL SCAFFOLD TREE OF 

SIGNIFICANT MOLECULAR FEATURES. 

N. L. Kruhlak 1 , K. Cross 2 and A. M. Orogo 1,3 . 1 U.S. 

FDA/CDER/OTR/DAPR, Silver Spring, MD, 

2 

Leadscope Inc., Columbus, OH and 3 GlobalNet 

Services Inc., Rockville, MD. Sponsor: R. Benz. 


IN SILICO PREDICTIVE MODEL FOR 

DRUG-INDUCED PHOSPHOLIPIDOSIS 

USING BIOEPISTEME SOFTWARE. S. S. 

Choi, L. G. Valerio and N. Sadrieh. U.S. FDA, Silver 

Spring, MD. 


PREDICTION OF DRUG-INDUCED 

LIVER INJURY IN HUMANS WITH 

TOXICOGENOMICS. M. Zhang, Q. Shi, M. 

Chen and W. Tong. NCTR, U.S. FDA, Jefferson, AR. 


PREDICTIVE VALUE OF CHEMICAL AND 

TOXICOGENOMIC DESCRIPTORS FOR 

DRUG-INDUCED HEPATOTOXICITY. Y. 

Low 1,5 , T. Uehara 1,2 , Y. Minowa 2 , H. Yamada 2 , 

Y. Ohno 3 , T. Urushidani 2,4 , A. Sedykh 5 , D. 

Fourches 5 , H. Zhu 5 , I. Rusyn 1 and A. Tropsha 5 . 

1 

Environmental Sciences & Engineering, University 

of North Carolina at Chapel Hill, Chapel Hill, NC, 

2 

Toxicogenomics Informatics Project, National 

Institute of Biomedical Innovation, Osaka, Japan, 

3 

National Institute of Health Sciences, Tokyo, Japan, 

4 

Doshisha Women’s College of Liberal Arts, Kyoto, 

Japan and 5 Eshelman School of Pharmacy, University 

of North Carolina at Chapel Hill, Chapel Hill, NC. 


CLASSIFICATION OF HUMAN 

CYTOCHROME 3A4 LIGANDS BY MEANS 

OF MOLECULAR DOCKING. Y. Tie 1 , B. T. 

McPhail 1 , H. Hong 2 , R. D. Beger 2 , B. A. Fowler 1 and 

E. Demchuk 1 . 1 Division Toxicology & Environmental 

Medicine, ATSDR/CDC, Atlanta, GA and 2 Division 

Systems Biology, NCTR/U.S. FDA, Jefferson, AR. 


BUILDING STRUCTURE FEATURE-BASED 

MODELS FOR PREDICTING ISOFORM- 

SPECIFIC HUMAN CYTOCHROME P450 

(HCYP 3A4, 2D6 AND 2C9) INHIBITION 

ASSAY RESULTS IN TOXCAST. P. Volarath 1 , B. 

Bienfait 2 , J. Gasteiger 2 , K. Houck 1 and A. Richard 1 . 

1 

NCCT, U.S. EPA, Research Triangle Park, NC and 

2 

Molecular Networks GmbH, Erlangen, Germany. 

MONday 







127



MONday 



EFFECTS OF GENETIC VARIATION IN 

ENZYME CYTOCHROME P450 2D6 ON 

XENOBIOTIC METABOLISM THROUGH IN 

SILICO MOLECULAR DOCKING MODELS. 

C. B. Tolson 1,2 , Y. Tie 1 and E. Demchuk 1 . 1 Division 

Toxicology & Environmental Medicine, ATSDR/ 

CDC, Atlanta, GA and 2 Biomedical Engineering, 

Georgia Institute of Technology, Atlanta, GA. 

Sponsor: B. Fowler. 


INCORPORATION OF TOXCAST IN VITRO 

ASSAY DATA AND RELEVANT TOXICITY 

PATHWAY INFORMATION IMPROVES THE 

EXTERNAL PREDICTION ACCURACY OF 

QUANTITATIVE STRUCTURE-ACTIVITY 

RELATIONSHIP (QSAR) MODELS OF 

CHEMICAL HEPATOTOXICITY. H. Zhu, L. 

Zhang, J. Staab, A. Sedykh, H. Tang, S. Gomez, I. 

Rusyn and A. Tropsha. University of North Carolina 

at Chapel Hill, Chapel Hill, NC. 


COMPUTATIONAL DOCKING OF THE 

ISOMERS OF NONYLPHENOL TO THE 

LIGAND BINDING DOMAIN OF THE 

ESTROGEN RECEPTOR. J. Rabinowitz and S. 

Little. NCCT/ORD /U.S. EPA, Research Triangle 

Park, NC. 


ANALYSIS OF RELATIVE 

ROSIGLITAZONE, PIOGLITAZONE, AND 

EPIRUBICIN CARDIOTOXICITY IN RATS 

USING HISTORICAL MICROARRAY DATA. 

H. Zhou and T. J. Colatsky. CDER/OPS/OTR/DAPR, 

U.S. FDA, Silver Spring, MD. 


COMPUTATIONAL MODELING 

FOR QT PROLONGATION: A DRUG 

CARDIOVASCULAR SAFETY ENDPOINT OF 

PARAMOUNT IMPORTANCE. L. G. Valerio 1 , 

J. Prous Blancafort 2 , A. Valencia 2 and X. Mensa 2 . 

1 

CDER/OPS, U.S. FDA, Silver Spring, MD and 

2 

Prous Institute for Biomedical Research, Barcelona, 

Spain. Sponsor: N. Sadrieh. 


TRANSLATABILITY OF DRUG-INDUCED 

CARDIOTOXICITY MOLECULAR 

MECHANISMS FROM IN VIVO TO IN 

VITRO. A. Enayetallah 1 , D. Puppala 1 , D. Ziemek 2 , 

N. Greene 1 , Y. Will 1 and M. Pletcher 1 . 1 Compound 

Safety Prediction-PGRD, Pfizer Inc., Groton, CT 

and 2 Computational Sciences CoE, Pfizer Inc., 

Cambridge, MA. 


ASSOCIATION NETWORKS AND 

VISUALIZATION TOOLS TO CORRELATE 

PRECLINICAL SIGNALS TO DRUG- 

INDUCED NAUSEA IN MAN. J. Glab 1 , 

M. Clark 2 , J. Valentin 1 and L. Ewart 1 . 1 Safety 

Pharmacology, AstraZeneca, Alderley Park, United 

Kingdom and 2 Discovery Information, AstraZeneca, 

Wilmington, DE. 


DDT AND TCDD INTERACT WITH 

PROTEINS INVOLVED IN THE INSULIN 

RECEPTOR SIGNALING. M. Cabarcas- 

Montalvo, D. Montes-Grajales and J. Olivero-Verbel. 

Environmental and Computational Chemistry Group, 

University of Cartagena, Cartagena, Colombia. 


COMPUTATIONAL BASED APPROACHES 

FOR IDENTIFYING AND UNDERSTANDING 

KINASES ASSOCIATED WITH 

CARDIOTOXICITY. D. Puppala 1 , V. Bonato 2 , 

K. Leach 1 , S. Louise-May 1 , K. J. McConnell 3 , M. 

Gosink 4 and M. T. Pletcher 1 . 1 Compound Safety 

Prediction, Pfizer Inc., Groton, CT, 2 Biostatistics 

Group, Pfizer Inc., Groton, CT, 3 Computational 

Science CoE, Pfizer Inc., Groton, CT and 4 DSRD, 

Pfizer Inc., Groton, CT. 


DISCOVERY OF NOVEL MICRO-RNAS 

FROM RAT LYMPHOCYTES DURING 

GLUCOCORTICOID INDUCED APOPTOSIS. 

R. Shah 1 , S. Vasa 1 , L. Smith 2 and J. Cidlowski 2 . 1 SRA 

International, Durham, NC and 2 National Institute 

of Environmental Health Science, Research Triangle 

Park, NC. 


AUTOMATIC IN SILICO ASSESSMENT OF 

GENOTOXIC POTENTIAL IMPURITIES. A. 

Brigo, G. Gerebtzoff, M. Kansy, T. Weiser and T. 

Singer. Nonclinical Safety, F. Hoffmann-La Roche 

Ltd., Basel, Switzerland. 


AUTOMATED IDENTIFICATION OF 

STRUCTURE-TOXICITY RELATIONSHIPS 

USING ATOM SIGNATURES. L. Carlsson, 

E. Ahlberg Helgee and S. Boyer. Computational 

Toxicology, AstraZeneca, Mölndal, Sweden. 


COMPUTATIONAL ASSESSMENT OF 

REACTIVE METABOLITE RISK IN DRUG 

DISCOVERY USING MECHANISTIC 

ENSEMBLE MODELLING. S. Boyer 1 , C. 

Hasselgren 1 , L. Peterlin-Masic 2 , O. Spjuth 3 and L. 

Carlsson 1 . 1 Computational Toxicology, AstraZeneca, 

Mölndal, Sweden, 2 Faculty of Pharmacy, University 

of Ljubljana, Ljubljana, Slovenia and 3 Department 

of Pharmaceutical Biosciences, Uppsala University, 

Uppsala, Sweden. 


DESIGN AND DEVELOPMENT OF AN 

INSTITUTIONAL KNOWLEDGE-BASE 

AT FDA’S CENTER FOR FOOD SAFETY 

AND APPLIED NUTRITION. K. Arvidson, A. 

McCarthy, C. Yang and D. Hristozov. CFSAN, U.S. 

FDA, College Park, MD. 


PHARMACOLOGICAL PROFILE 

SIMILARITY – A RELEVANT METHOD 

FOR ANTICIPATION OF IN VIVO SAFETY? 

D. Muthas 1 , M. Rolf 2 , S. Matis-Mitchell 3 and S. 

Boyer 1 . 1 Global Safety Assessment, AstraZeneca 

R&D, Mölndal, Sweden, 2 Global Safety Assessment, 

AstraZeneca R&D, Alderly Park, United Kingdom 

and 3 Discovery Information, AstraZeneca R&D, 


128 






Platform Sessions



Abstract # 


DEVELOPMENT OF QSAR MODEL FOR 

HIGH-SPEED IN SILICO IDENTIFICATION 

OF POTENTIALLY PHOTOTOXIC 

ORGANIC COMPOUNDS. W. Plonka 1 and J. M. 

Ciloy 2 . 1 Life Science, FQS Poland, Cracow, Poland 

and 2 Life Science, Fujitsu Kyushu Systems Ltd., 

Fukuoka, Japan. Sponsor: K. Hayamizu. 


THE POWER OF AN ONTOLOGY-DRIVEN 

DEVELOPMENTAL TOXICITY DATABASE 

FOR DATA MINING AND COMPUTATIONAL 

MODELING. A. Richard 1 , E. Julien 2 , E. Busta 3 , 

M. Wolf 4 and C. Yang 3 . 1 NCCT (D343-03), U.S. 

EPA, Research Triangle Park, NC, 2 LifeSci Research 

Service, Rockville, MD, 3 HFS-2775, U.S. FDA 

CFSA, College Park, Maryland, MD and 4 Lockheed- 

Martin, U.S. EPA, Research Triangle Park, NC. 


USE OF C. ELEGANS GROWTH ASSAY DATA 

IN NOVEL TWO-STEP HIERARCHICAL 

QSAR MODELING WORKFLOW 

ENHANCES IN VIVO TOXICITY 

PREDICTION FOR TOXCAST PHASE I 

CHEMICALS. A. Golbraikh 1,2 , R. Shah 1,4 , W. 

Boyd 3 , M. Smith 4 , A. Tropsha 1,2 and J. Freedman 3 . 

1 

SciOme LLC, Research Triangle Park, NC, 

2 

University of North Carolina at Chapel Hill, Chapel 

Hill, NC, 3 National Institute of Environmental Health 

Science, Research Triangle Park, NC and 4 SRA 

International, Durham, NC. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Neurodegenerative Diseases 

Chairperson(s): Richard Nass, Indiana University School of Medicine, 





EVALUATION OF JP-8 JET FUEL INDUCED 

HEARING LOSS IN RATS. L. D. Fechter 1 , J. 

W. Fisher 2 , G. D. Chapman 3 , V. P. Mokashi 3 , J. E. 

Reboulet 3 , J. E. Stubbs 4 , A. M. Lear 3 , S. L. Prues 3 , 

C. A. Gearhart 1 , S. Fulton 1 and D. R. Mattie 5 . 1 Jerry 

Pettis Memorial VA Medical Center, Loma Linda, 

CA, 2 U.S. FDA NCTR, Jefferson, AR, 3 NHRC/ 

EHEL, Wright-Patterson AFB, OH, 4 AFIT/ENV, 

Wright-Patterson AFB, OH and 5 711 HPW/RHPBA, 

Wright-Patterson AFB, OH. 


1, 3-DICARBONYL ENOLATES: A NEW 

CLASS OF NEUROPROTECTANTS. R. 

M. LoPachin 1 , T. Gavin 2 , D. Casper 3 and D. S. 

Barber 4 . 1 Department of Anesthesia Research, 

Montefiore Medical Center, Bronx, NY, 2 Chemistry, 

Iona College, New Rochelle, NY, 3 Neurosurgery, 

Montefiore Medical Center, Bronx, NY and 4 CEHT, 

University of Florida, Gainesville, FL. 

Abstract # 


MOLECULAR MODELING OF 1, 

3-DINITROBENZENE (1, 3-DNB) 

INTERACTIONS WITH ADENOSINE 

DEAMINASE (ADA). R. J. Richardson 1 , S. 

J. Wijeyesakere 2 , Y. Wang 1 and M. A. Philbert 1 . 

1 

Department of Environmental Health Sciences, 

Toxicology Program, University of Michigan, Ann 

Arbor, MI and 2 Department of Microbiology and 

Immunology, University of Michigan, Ann Arbor, 

MI. 


1, 3-DINITROBENZENE (1, 3-DNB) INHIBITS 

ADENOSINE DEAMINASE (ADA) LEADING 

TO INCREASED ADENOSINE LEVELS IN 

IMMORTALIZED DI TNC-1 ASTROCYTES. 

Y. Wang 1 , X. Liu 2 , B. Schneider 1 , E. A. Zverina 4 , 

K. A. Russ 1 , C. A. Fierke 3 , R. J. Richardson 1 and 

M. A. Philbert 1 . 1 Department of EHS, Toxicology, 

University of Michigan, Ann Arbor, MI, 2 Department 

of Chemistry, University of Michigan, Ann Arbor, 

MI, 3 Department of Biological Chemistry, University 

of Michigan, Ann Arbor, MI and 4 Chemical Biology 

Program, University of Michigan, Ann Arbor, MI. 


TRANSLOCATOR PROTEIN (18 KDA) 

(TSPO): A Preclinical BIOMARKER OF 

NEURODEGENERATION IN SANDHOFF 

DISEASE MICE. J. Choi 1 , H. Wang 2 , C. J. 

Endres 2 , J. J. Fox 2 , G. Green 2 , M. G. Pomper 2 and 

T. R. Guilarte 1 . 1 Environmental Health Sciences, 

Columbia University Mailman School of Public 

Health, New York, NY and 2 Radiology, Johns 

Hopkins Hospital, Baltimore, MD. 


THE CYANOBACTERIAL NEUROTOXIN 

β-N-METHYLAMINO-L-ALANINE (BMAA) 

INDUCES UNFOLDED PROTEIN RESPONSE 

(UPR) AND CHANGES OF SOD ACTIVITY 

LEVELS IN HUMAN NEURONAL CELLS. 

O. Okle 1 , M. Helmer 1 , K. Stemmer 1,2 and D. R. 

Dietrich 1 . 1 Human & Environmental Toxicology, 

University of Konstanz, Konstanz, Germany and 

2 

Obesity Research Centre at the Metabolic Disease 

Institute, University of Cincinnati, Cincinnati, OH. 


CYTOTOXICITY OF β-N-METHYLAMINO- 

L-ALANINE (L-BMAA) AND 

METHYLAZOXYMETHANOLACETATE 

(MAMAC) AND ASSOCIATED 

DIFFERENTIAL MRNA EXPRESSION IN 

HUMAN NEURONAL CELLS. M. Helmer 1 , O. 

Okle 1 , K. Stemmer 1,2 and D. R. Dietrich 1 . 1 Human & 

Environmental Toxicology, University of Konstanz, 

Konstanz, Germany and 2 Obesity Research Centre 

at the Metabolic Disease Institute, University of 

Cincinnati, Cincinnati, OH. 


PERTURBATION OF REGIONAL 

BRAIN METABOLISM IN F344 RATS 

AFTER LOW LEVEL EXPOSURE TO 

DIISOPROPYLFLUOROPHOSPHATE (DFP). 

D. Mahle 1 and N. V. Reo 2 . 1 AFRL/RHPB, Wright- 

Patterson AFB, OH and 2 Wright State University, 

Fairborn, OH. 

MONday 







129



MONday 



INVESTIGATING GENE-ENVIRONMENT 

INTERACTIONS RELEVANT TO 

PARKINSON’S DISEASE USING 

DROSOPHILA. C. A. Remillard, H. O. Lawal and 

D. E. Krantz. University of California, Los Angeles, 

Los Angeles, CA. 


IDENTIFYING LESS TOXIC TRIARYL 

PHOSPHATES FOR JET ENGINE 

LUBRICANTS. P. E. Baker 1 , T. B. Cole 1,2 , K. E. 

Thummel 3 , Y. S. Lin 3 , A. L. Co 1 , A. E. Rettie 3 , J. 

H. Kim 4 and C. E. Furlong 1 . 1 Medicine, Medical 

Genetics & Genome Sciences, University of 

Washington, Seattle, WA, 2 Environmental & 

Occupational Health Sciences, University of 

Washington, Seattle, WA, 3 Pharmaceutics and 

Medicinal Chemistry, University of Washington, 

Seattle, WA and 4 Anesthesiology & Pain Medicine, 

University of Washington, Seattle, WA. 


LIPOPOLYSACCHARIDE INCREASES 

SODIUM INFLUX AND DOWN-REGULATES 

VOLTAGE GATED SODIUM CHANNEL 

MRNA EXPRESSION IN ACTIVATED 

MICROGLIA. M. M. Hossain and J. R. 

Richardson. Environmental and Occupational 

Medicine, Robert Wood Johnson Medical School, 

University of Medicine and Dentistry of New Jersey, 

Piscataway, NJ. 


LIPOPOLYSACCHARIDE ACTIVATION 

OF MICROGLIA DIFFERENTIALLY 

REGULATES mRNA EXPRESSION OF ABC 

EFFLUX TRANSPORTERS. C. J. Gibson 1 , M. 

M. Hossain 2 , J. R. Richardson 2 and L. Aleksunes 1 . 

1 

Pharmacology and Toxicology, Rutgers University, 

Piscataway, NJ and 2 Environmental and Occupational 

Medicine, University of Medicine and Dentistry of 

New Jersey, Piscataway, NJ. 


EFFECTS OF ESTROGEN-DERIVED 

COMPOUNDS IN A MURINE MODEL OF 

ALZHEIMER’S DISEASE. A. E. Schlappal 1,2,3 , 

R. Schuh 3,4 , L. Prokai 5 and M. Ottinger 1 . 1 Animal and 

Avian Sciences, University of Maryland, College 

Park, MD, 2 Neuroscience and Cognitive Sciences 

Program, University of Maryland, College Park, MD, 

3 

Research and Development Service, Veterans Affairs 

Maryland Health Care System, Baltimore, MD, 

4 

Department of Neurology, University of Maryland 

School of Medicine, Baltimore, MD and 5 Department 

of Molecular Biology and Immunology, University 

of North Texas Health Science Center, Fort Worth, 

TX. 


THE INTERACTION OF MANGANESE 

WITH PRION PROTEIN AND ITS ROLE IN 

THE PROPAGATION OF PRION DISEASE. 

D. P. Martin 1,2 , V. Anantharam 1,2 , A. Kanthasamy 1,2 

and A. G. Kanthasamy 1,2 . 1 Department of Biomedical 

Sciences, Iowa State University, Ames, IA and 2 Iowa 

Center for Advanced Neurotoxicology, Iowa State 

University, Ames, IA. 


CHRONIC NEUROTOXICITY AFTER 

CHRONIC MOLD EXPOSURE. R. M. Singer. 

Raymond Singer, Ph.D., Professional Association, 

Santa Fe, NM. 


HYPERPHOSPHATEMIA AND 

HYPOZINCEMIA AFFECT PERIPHERAL 

NERVOUS SYSTEM IN SHR/NDMCR-CP, A 

MODEL OF METABOLIC SYNDROME. Y. 

Suzuki 1 , S. Ichihara 1 , A. Kato 1 , T. Yamaguchi 1 , Y. 

Yamada 1 and G. Ichihara 2 . 1 Life Science Reseach 

Center, Mie University, Tsu, Japan and 2 Nagoya 

University Graduate School of Medicine, Nagoya, 

Japan. 


EFFECTS OF 1-BROMOPROPANE 

EXPOSURE ON MYELINATION AND 

ASTROGLIA IN RAT BRAIN. S. Sheik 

Mohideen 1 , S. Ichihara 2 , Z. Huang 1 , L. Zhang 1 , 

K. Subramanian 1 , J. Kitoh 3 and G. Ichihara 1 . 

1 

Department of Occupational & Environmental 

Health, Nagoya University Graduate School of 

Medicine, Nagoya, Japan, 2 Mie University Graduate 

School of Regional Innovation Studies, Tsu, Mie, 

Japan and 3 Nagoya University, Nagoya, Japan. 


EXPOSURE TO 1-BROMOPROPANE 

DEGENERATES NORADRENERGIC 

AXONS IN THE RAT BRAIN. G. Ichihara 1 , S. 

Sheik Mohideen 1 , S. Ichihara 2 and S. Nakamura 3 . 

1 

Department of Occupational & Environmental 

Health, Nagoya University Graduate School of 

Medicine, Nagoya, Japan, 2 Mie University, Tsu, 

Japan and 3 Neuroscience, Yamaguchi University 

Graduate School of Medicine, Ube, Japan. 


CHRONIC EXPOSURE TO 

GLUCOCORTICOIDS PRIMES THE CNS 

PROINFLAMMATORY RESPONSE IN 

METHAMPHETAMINE NEUROTOXICITY. 

K. A. Kelly, D. B. Miller and O. P. James. Health 

Effects Laboratory Division, CDC-NIOSH, 



GST-PI INHIBITS DOPAMINE NEURON 

DEGENERATION IN C. ELEGANS 

MODELS OF PARKINSON’S DISEASE 

AND MANGANISM. R. Settivari, J. LeVora, 

N. VanDuyn, S. Zhou, G. Sinclair and R. Nass. 

Pharmacology and Toxicology, Indiana University 

School of Medicine, Indianapolis, IN. 


ROLE OF GLIAL ACTIVATION IN A 

PROGRESSIVE NEUROINFLAMMATORY 

MODEL OF PARKINSON’S DISEASE USING 

MPTP AND PROBENECID. B. R. Trout 1,2 , J. 

A. Miller 1,2 , K. A. Popichak 1 and R. B. Tjalkens 1,2 . 

1 

Environmental Radiological and Health Science, 

Colorado State University, Fort Collins, CO and 

2 

Molecular, Cellular, and Integrative Neurosciences, 

Colorado State University, Fort Collins, CO. 

130 






Platform Sessions



Abstract # 


DEVELOPMENT OF A HIGH-THROUGHPUT 

SCREENING PLATFORM FOR 

MONOAMINE TOXICITY. A. I. Bernstein 1 , 

K. A. Stout 1 , J. D. de Gastyne 1 and G. W. Miller 1,2 . 

1 

Environmental Health, Emory University, Atlanta, 

GA and 2 Center for Neurodegenerative Disease, 

Emory University, Atlanta, GA. 


SEROTONERGIC AND NORADRENERGIC 

SYSTEMS ARE DISRUPTED IN THE VMAT2- 

DEFICIENT PARKINSON’S DISEASE 

MOUSE MODEL. S. P. Alter, T. N. Taylor, K. R. 

Shepherd and G. W. Miller. Environmental Health, 



9:30 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Cardiovascular Toxicology 

Chairperson(s): Wenyue Hu, Pfizer, Inc., San Diego, CA, and Mary 

Walker, University of New Mexico, Albuquerque, NM. 




VASCULAR IMPLICATIONS OF NRTI- 

INDUCED MITOCHONDRIAL TOXICITY. 

V. Y. Hebert, S. Xue, M. Glover and T. Dugas. 

Pharmacology, Toxicology, and Neuroscience, 

Louisiana State University Health Sciences Center, 

Shreveport, LA. 


DRUG-INDUCED CARDIAC LEFT 

VENTRICULAR DYSFUNCTION AND 

ARRHYTHMIA ASSOCIATED WITH 

MITOCHONDRIAL IMPAIRMENT. P. J. 

Acton, K. Derakhchan, R. W. Chui, Y. Qu, M. Fang, 

B. Gao, I. Senal, R. Hernandez, D. Robert, H. M. 

Vargas and J. W. Lawrence. Comparative Biology 

and Safety Sciences, Amgen, Thousand Oaks, CA. 


INTERFERON SIGNALING, SYSTEMIC 

INFLAMMATION, AND ATHEROSCLEROSIS 

FOLLOWING WELDING FUME 

INHALATION EXPOSURE: FROM 

THE LUNG TO THE BLOOD TO THE 

VASCULATURE. A. Erdely, T. Hulderman, A. 

L. Liston, R. Salmen-Muniz, S. Stone, B. T. Chen, 

D. G. Frazer, S. Li, M. L. Kashon, J. M. Antonini, 

P. P. Simeonova and P. C. Zeidler-Erdely. NIOSH, 



A COMMON LINK FOR PULMONARY 

INFLAMMATION TO VASCULAR EFFECTS 

OF ENVIRONMENTAL TOBACCO SMOKE 

AND BENZO-A-PYRENE IN BOTH PIGS 

AND RATS. L. P. Weber, A. N. Al-Dissi and N. J. 

Gentner. Toxicology Graduate Program, University 

of Saskatchewan, Saskatoon, SK, Canada. 

Abstract # 


CIGARETTE SMOKE-DEPENDENT 

CHANGES IN THE RESPIRATORY 

AND CARDIOVASCULAR SYSTEM OF 

SPONTANEOUSLY HYPERTENSIVE (SH) 

RATS AND THE EFFECT OF SMOKING 

CESSATION. M. Lietz 1 , B. Friedrichs 1 , I. Gallitz 1 , 

S. Quadt-Humme 1 , Y. Steffen 1 , K. Stolle 1 , S. Lebrun 2 

and A. Berges 3 . 1 Philip Morris Research Laboratories 

GmbH, Cologne, Germany, 2 Philip Morris Products 

S.A., Neuchatel, Switzerland and 3 Philip Morris 

Research Laboratories Bvba, Leuven, Belgium. 

Sponsor: T. Mueller. 


INHALATION OF ENVIRONMENTALLY 

PERSISTENT FREE RADICALS ALTER 

LEFT VENTRICULAR FUNCTION IN VIVO. 

S. Mahne 1 , G. Raman 1 , B. Dellinger 2 and K. J. 

Varner 1 . 1 Pharmacology, Louisiana State University 

Health Science Center, New Orleans, LA and 

2 

Chemistry, Louisiana State University A&M, Baton 

Rouge, LA. Sponsor: T. Dugas. 


EFFECTS OF INHALED NITRIC OXIDE 

AND CARBON MONOXIDE ON VASCULAR 

RESPONSIVENESS. J. G. Buntz, S. N. Lucas and 

M. Campen. Pharmaceutical Sciences, University of 

New Mexico, Albuquerque, NM. 


EXPOSURE TO ACROLEIN ENHANCES 

PLATELET ACTIVATION AND 

EXACERBATES ATHEROSCLEROSIS. S. 

Srivastava, S. D. Sithu, E. N. Vladykovskaya, P. 

Haberzettl, D. J. Hoetker, M. A. Siddiqui, D. J. 

Conklin, A. Bhatnagar and S. E. D’Souza. School of 

Medicine, University of Louisville, Louisville, KY. 


SOLUBLE COMPONENTS OF ULTRAFINE 

PARTICULATE MATTER ACTIVATE 

CORONARY ENDOTHELIAL CELLS. S. 

J. Snow 1 and M. Carraway 2 . 1 Curriculum of 

Toxicology, University of North Carolina at Chapel 

Hill, Chapel Hill, NC and 2 Human Studies Facility, 

National Health and Environmental Effects Research 

Laboratory, U.S. EPA, Chapel Hill, NC. 


THE EFFECTS OF CERIA NANOPARTICLES 

ON THE REACTIVITY OF RAT MESENTERY 

AND CORONARY ARTERIOLES. V. C. 

Minarchick 1 , E. M. Sabolsky 2 and T. R. Nurkiewicz 1 . 

1 

Center for Cardiovascular and Respiratory Sciences, 

West Virginia University, Morgantown, WV and 

2 

Mechanical and Aerospace Engineering, West 

Virginia University, Morgantown, WV. 


EXPOSURE TO MULTI-WALLED CARBON 

NANOTUBES DOSE-DEPENDENTLY 

EXACERBATES CARDIAC INJURY AND 

DEPRESSES CORONARY FLOW. L. C. 

Thompson 1 , C. R. Frasier 1 , R. C. Sloan 1 , D. A. 

Brown 1 , B. Harrison 3 , J. M. Brown 2 and C. J. 

Wingard 1 . 1 Physiology, East Carolina University, 

Greenville, NC, 2 Pharmacology and Toxicology, 

East Carolina University, Greenville, NC and 3 Wake 

Forest University Institute of Regenerative Medicine, 

Winston-Salem, NC. 

MONday 







131



MONday 



TIME-COURSE OF IMPAIRED CORONARY 

ARTERIOLAR ENDOTHELIUM- 

DEPENDENT DILATION AFTER 


INHALATION. P. G. Stapleton 1,3 , V. C. 

Minarchick 1,3 , A. Cumpston 2 , W. McKinney 2 , B. 

T. Chen 2 , D. Frazer 2 , V. Castranova 2 and T. R. 

Nurkiewicz 1,3 . 1 Center for Cardiovascular and 

Respiratory Sciences, West Virginia University, 

Morgantown, WV, 2 Pathology and Physiology 

Research Branch, Health Effects Laboratory 

Division, National Institute for Occupational Safety 

and Health, Morgantown, WV and 3 Physiology 

and Pharmacology, West Virginia University, 



PROLONGATION OF QT INTERVALS BY 

MOXIFLOXACIN TREATMENT IN 2 AND 8 

WEEK OLD JUVENILE BEAGLE DOGS. M. 

Peschar 1 , N. Lourens 1 , K. Scase 1 , A. Zmarowski 1 , 

M. De Raaf 1 , E. Padgett 2 , B. Van Rozendaal 1 and 

H. Emmen 1 . 1 Toxicology, NOTOX B.V., DD‘s- 

Hertogenbosch, Netherlands and 2 Toxicology, WIL 

Research Laboratories LLC, Ashland, OH. 


REGULATION OF CARDIAC 

CARDIOTROPHIN-1 GENE EXPRESSION 

BY VALSARTAN AND SPIRONOLACTONE 

IN RAT, A POSSIBLE MECHANISM OF 

CARDIOPROTECTION. H. A. Al-Mazroua, N. 

M. Al-Rasheed and H. M. Korashy. Pharmacology 

& Toxicology, College of Pharmacy, King Saud 

University, Riyadh, Saudi Arabia. Sponsor: A. 

El-Kadi. 


TCDD MISREGULATES CELL MIGRATION 

AND THE EXTRACELLULAR MATRIX IN 

THE REGENERATING ZEBRAFISH HEART. 

P. J. Hofsteen 1 , M. Kim 1 , D. Nesbit 1 , V. Mehta 2 , R. E. 

Peterson 1,2 and W. Heideman 1,2 . 1 School of Pharmacy, 

University of Wisconsin Madison, Madison, WI 

and 2 Molecular and Environmental Toxicology, 

University of Wisconsin, Madison, WI. 


TCDD EXPOSURE ALTERS THE GENE 

EXPRESSION RESPONSE TO HEART 

REGENERATION IN ADULT ZEBRAFISH 

(DANIO RERIO). M. Kim, R. E. Peterson and W. 

Heideman. Division of Pharmaceutical Sciences, 

School of Pharmacy, University of Wisconsin, 

Madison, WI. 


2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN INDUCES PRO-HYPERTENSIVE 

AND -ADIPOGENIC GENE EXPRESSION 

IN MESENTERIC ARTERIOLES PRIOR TO 

THE ONSET OF HYPERTENSION. M. K. 

Walker, J. A. Scott and J. R. Boberg. Pharmaceutical 

Sciences, University of New Mexico, Albuquerque, 

NM. 


GLUCOCORTICOID INDUCED LEUCINE 

ZIPPER PREVENTS APOPTOSIS BY 

CARDIAC TOXINS. D. C. Aguilar, J. Strom, 

B. Xu and Q. Chen. Pharmacology, University of 

Arizona, Tucson, AZ. 


IS STRUCTURAL DAMAGE TO THE 

HEART ASSOCIATED WITH FUNCTIONAL 

CHANGES? L. Ewart, A. Hargreaves, T. 

Hammond, P. Lainee, J. Harleman and J. Valentin. 

AstraZeneca, Macclesfield, United Kingdom. 


USE OF NATRIURETIC PEPTIDES TO 

DETECT COMPOUND RELATED CHANGES 

IN BLOOD PRESSURE IN RODENTS. S. K. 

Engle, L. Huber, D. Sall, M. Uhlik and D. E. Watson. 

Lilly Research Laboratories, Eli Lilly and Company, 



THE C-TERMINUS OF THE CARDIAC 

ELECTRONEUTRAL SODIUM 

BICARBONATE COTRANSPORTER 

HHNBCN1 IS CYTOTOXIC. N. Magilnick, 

N. Abuladze, P. Ge, I. Atanasov and A. Pushkin. 

D. Geffen School of Medicine at University of 

California Los Angeles, Los Angeles, CA. Sponsor: 

W. Dekant. 


USING SOD2 HETEROZYGOUS MOUSE 

MODEL TO STUDY THE MECHANISM 

OF DOXORUBICIN INDUCED CARDIAC 

TOXICITY. W. Hu, W. Collette, L. Liu, M. 

Hemkens, J. Heyen, S. Aquirre, L. Marroquin, B. 

Jessen and V. Torti. DSRD, Pfizer, San Diego, CA. 


INDUCTION OF CARDIOTOXICITY BY 

PERFLUOROOCTANOIC ACID IN AN AVIAN 

MODEL. Q. Jiang and J. DeWitt. East Carolina 

University, Greenville, NC. 


CHRONIC OVEREXPRESSION OF 

RECEPTOR TYROSINE KINASE ERBB2 

INDUCES CELLULAR OXIDATIVE STRESS 

IN THE HEARTS OF MICE. F. Belmonte 1 , Y. 

Xu 1 , S. Polina 1 , C. Steenbergen 2 , S. Das 2 , X. Guo 1 , 

S. Pin 1 , D. Bedja 1 and K. Gabrielson 1 . 1 Molecular 

and Comparative Pathobiology, Johns Hopkins 

University, Baltimore, MD and 2 Cardiovascular 

Pathology, Johns Hopkins University, Baltimore, 

MD. 


RECOVERY OF CYTOCHROME C 

OXIDASE ACTIVITY IS REQUIRED FOR 

DIETARY COPPER SUPPLEMENTATION- 

INDUCED REGRESSION OF CARDIAC 

HYPERTROPHY IN MICE. L. Zhan 1 , L. 

Hussain 1 , Y. Yao 1 , W. Feng 2 , K. Bourcy 1 , J. Eaton 2 , W. 

Johnson 3 , C. Moraes 4 and Y. Kang 1 . 1 Pharmacology 

& Toxicology, University of Louisville, Louisville, 

KY, 2 Medicine, University of Louisville, Louisville, 

KY, 3 Human Nutrition Research Center, U.S. 

Department of Agriculture, Grand Forks, ND and 

4 

Cell Biology and Anatomy, University of Miami 

Miller School of Medicine, Miami, FL. 

132 






Platform Sessions



Abstract # 


THE INVOLVEMENT OF VIMENTIN IN 

THE CU INDUCED REGRESSION OF 

HYPERTROPHY IN HUMAN CARDIAC 

MYOCYTES. K. S. Bourcy 1 , W. Feng 2 and Y. 

Kang 1 . 1 Pharmacology & Toxicology, University of 

Louisville, Louisville, KY and 2 Medicine, University 

of Louisville, Louisville, KY. 


DIRECT EFFECTS OF NRTIS ON 

MITOCHONDRIA CONTRIBUTE TO 

ENDOTHELIAL DYSFUNCTION. M. C. 

Glover, S. Xue, V. Y. Hebert, J. H. Zavecz and 

T. R. Hebert. Pharmacology, Toxicology, and 

Neuroscience, Lousiana State University Health 

Sciences Center, Shreveport, LA. 


ANG II INDUCED PKC/NOX ACTIVATION- 

ASSOCIATED NITROSATIVE DAMAGE 

PLAYS A CRITICAL ROLE IN CHRONIC 

ALCOHOL-CAUSED CARDIAC CELL 

DEATH AND CARDIOMYOPATHY. Y. Tan, Z. 

Zhou and L. Cai. Pediatrics/Medicine, University of 

Louisville, Louisville, KY. 


ASSESSMENT OF THE VARIATION IN 

TROPONIN I LEVELS IN THE DOG DURING 

THE PERIOD PRIOR TO TOXICOLOGICAL 

STUDY DOSING. C. J. Betts, T. Child, S. J. 

Bickerton, M. Moores, N. Derbyshire, H. T. Thomas, 

M. C. Jacobsen and S. Robinson. Safety Assessment, 

AstraZeneca, Macclesfield, Cheshire, United 

Kingdom. 


EGCG DECREASES POLYCHLORINATED 

BIPHENYL-INDUCED EXPRESSION 

OF CYP1A1 AND ENDOTHELIAL 

INFLAMMATORY PARAMETERS 

VIA INDUCTION OF ANTIOXIDANT 

ELEMENTS. B. Hennig 1 , S. Han 1 and M. Toborek 2 . 

1 

Animal and Food Sciences, University of Kentucky, 

Lexington, KY and 2 Department of Neurosurgery, 

University of Kentucky, Lexington, KY. 


QUANTITATIVE PROTEOMICS REVEALS 

RAPID CHANGES IN NA+/K+ ATPASE AND 

NCX1 LEVELS IN ADULT ZEBRAFISH 

HEART FOLLOWING TCDD EXPOSURE. 

K. Lanham 1 , J. Zhang 2 , R. Peterson 2 , W. Heideman 2 

and L. Li 2 . 1 Biomolecular Chemistry, University 

of Wisconsin Madison, Madison, WI and 2 School 

of Pharmacy, University of Wisconsin Madison, 

Madison, WI. 


HSP90-BETA OVEREXPRESSION IN THE 

MOUSE HEART INDUCES HEART FAILURE. 

Y. Xu 1 , D. Bedja 1 , X. Guo 1 , M. Mei 1 , P. Sysa Shah 1 , 

S. Das 2 , C. Steenbergen 2 and K. Gabrielson 1 . 

1 

Molecular and Comparative Pathobiology, Johns 

Hopkins University, Baltimore, MD and 2 Cardiac 

Pathology, Johns Hopkins University, Baltimore, 

MD. 

Abstract # 


HUMAN INDUCED PLURIPOTENT STEM 

CELL DERIVED CARDIOMYOCYTES FOR 

ASSESSING DRUG-INDUCED CARDIAC 

ARRHYTHMIAS. B. Anson 1 , J. Ma 1 , L. Guo 2 , 

S. Fiene 1 , R. Adams 2 , T. Weiser 3 , T. Singer 3 and K. 

Kolaja 2 . 1 Cellular Dynamics International, Madison, 

WI, 2 Nonclinical Safety, F. Hoffman-La Roche, 

Nutley, NJ and 3 Pharmacology Research and Early 

Development, F. Hoffman-La Roche AG, Basel, 

Switzerland. 


ISIS 416858, AN ANTISENSE INHIBITOR OF 

FACTOR XI, IS WELL TOLERATED AND 

PRODUCES NO RISK OF BLEEDING IN 

THE CYNOMOLGUS MONKEY FOR UP TO 

13 WEEKS OF TREATMENT. H. S. Younis 1 , J. 

Crosby 2 and S. P. Henry 1 . 1 Preclinical Development, 

ISIS Pharmaceuticals, Carlsbad, CA and 2 Drug 

Discovery, ISIS Pharmaceuticals, Carlsbad, CA. 


BENZO[A]PYRENE AUGMENTS 

INFLAMMATORY AND PROTEOLYTIC 

CHANGES IN MOUSE MODEL OF 

ABDOMINAL AORTIC ANEURYSM. P. A. 

Prins 1 , P. R. Perati 1 , A. Ramesh 2 , Z. Guo 2 and U. K. 

Sampson 1 . 1 Cardiovascular Medicine, Vanderbilt 

University, Nashville, TN and 2 Meharry Medical 

College, Nashville, TN. 


ARYL HYDROCARBON RECEPTOR 

AGONIST - PCB 77 - INCREASES 

THE INCIDENCE AND SEVERITY OF 

ABDOMINAL AORTIC ANEURYSM. V. 

Arsenescu, R. Arsenescu and L. Cassis. GCNS, 

University of Kentucky, Lexington, KY. Sponsor: H. 

Swanson. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Carcinogenesis I 

Chairperson(s): John Wisler, Amgen Inc., Thousand Oaks, CA. 




NNK, A TOBACCO-SPECIFIC 

CARCINOGEN, INHIBITS THE 

EXPRESSION OF LYSYL OXIDASE: A 

TUMOR SUPPRESSOR GENE. Y. Zhao, S. Gao, 

J. Zhou, P. Toselli and W. Li. Biochemistry, Boston 

University School of Medicine, Boston, MA. 


GT-094, A NO-NSAID, INHIBITS COLON 

CANCER CELL GROWTH BY ACTIVATION 

OF A REACTIVE OXYGEN SPECIES (ROS)- 

MICRORNA-27A:ZBTB10-SPECIFICITY 

PROTEIN (SP) PATHWAY. S. Pathi 1 and S. 

Safe 1,2 . 1 Veterinary Physiology and Pharmacology, 

Texas A&M University, College Station, TX and 

2 

Institute of Biosciences and Technology, Texas 

A&M Health Science Center, Houston, TX. 

MONday 







133



MONday 



MOLECULAR MECHANISM OF ACTION 

OF INSULIN SENSITIZING DRUG- 

METFORMIN AS ANTICANCER AGENT IN 

PANCREATIC CANCER. V. Vasanthakumari 1 

and S. Safe 1,2 . 1 Veterinary Physiology & 

Pharmacology, Texas A&M University, College 

Station, TX and 2 Institute of Biosciences and 

Technology, Houston, TX. 


PHARMACOLOGICAL INHIBITION OF 

THE TGFβ1 TYPE I RECEPTOR INDUCES 

PREMALIGNANT KERATINOCYTE 

TERMINAL DIFFERENTIATION. K. E. 

Masiuk, L. Mordasky Markell, N. Blazanin and 

A. B. Glick. Center for Molecular Toxicology and 

Carcinogenesis, Penn State University, University 

Park, PA. 


PHENOBARBITAL-LIKE MODE OF 

ACTION FOR LIVER TUMORS IN CD1 

MICE AND F344 RATS EXPOSED TO A 

NEW DEVELOPMENTAL COMPOUND 

(X11422208). D. Geter 1 , L. H. Kan 1 , A. Wood 1 , M. 

J. LeBaron 1 , B. B. Gollapudi 1 , J. Murray 1 , C. Terry 3 , 

R. Rasoulpour 1 , C. Elcombe 2 , A. Vardy 2 , J. Ross 2 

and R. Billington 3 . 1 The Dow Chemical Company, 

Midland, MI, 2 CXR BioSciences, Dundee, United 

Kingdom and 3 Dow AgroSciences, Abingdon, 

Oxfordshire, United Kingdom. 


NON-HUMAN RELEVANCE OF A CAR- 

MEDIATED TUMOR FORMATION IN 

RATS INDUCED BY THE HERBICIDE 

METAZACHLOR. C. Wiemann 1 , N. Honarvar 1 , 

M. Göttel 1 , S. Gröters 2 , E. Fabian 2 , B. van 

Ravenzwaay 2 and I. Fegert 1 . 1 Regulatory Toxicology 

Pesticides, BASF SE, Ludwigshafen, Germany and 

2 


Ludwigshafen, Germany. Sponsor: R. Landsiedel. 


LIGAND-DEPENDANT ACTIVATION AND 

DEACTIVATION OF NUCLEAR RECEPTOR 

SUBFAMILY 4 MEMBERS IN PANCREATIC 

CANCER CELLS. X. Li 1 and S. Safe 2,3 . 1 College 

of Medicine, Texas A&M Health Science Center, 

College Station, TX, 2 Veterinary Physiology and 

Pharmacology, Texas A&M University, College 

Station, TX and 3 Institute of Biosciences & 

Technology, Texas A&M Health Science Center, 

Houston, TX. 


CANNABINOIDS INDUCE TYROSINE 

PHOSPHATASES AND INHIBIT SP 

TRANSCRIPTION FACTORS IN COLON 

AND PROSTATE CANCER CELLS. S. 

Sreevalsan 1 , N. Kaminski 3 and S. Safe 1,2 . 1 Veterinary 

Physiology and Pharmacology, Texas A&M 

University, College Station, TX, 2 Institute of 

Biosciences and Technology, Texas A&M Health 

Science Center, Houston, TX and 3 Center for 

Integrative Toxicology, Michigan State University, 

East Lansing, MI. 


HOPS (Humulus lupulus) INHIBITS 

ESTROGEN METABOLISM IN NON- 

TUMORIGENIC HUMAN BREAST 

EPITHELIAL CELLS (MCF-10A CELLS). L. 

P. Hemachandra, R. P. Chandrasena, B. M. Dietz, 

S. Chen, G. F. Pauli, N. R. Farnsworth, G. R. 

Thatcher and J. L. Bolton. Medicinal Chemistry & 

Pharmacognosy, University of Illinois at Chicago, 

Chicago, IL. 


ENDOCRINE TOXICANTS PROMOTE 

RESISTANCE TO ANOIKIS AND 

INVASIVENESS OF BREAST CANCER 

CELLS IN VITRO. W. G. Foster and H. L. 

Cameron. Obstetrics and Gynecology, McMaster 

University, Hamilton, ON, Canada. 


ENVIRONMENTAL CHEMICALS AND 

BREAST CANCER: GEOGRAPHIC 

ASSOCIATION BETWEEN LIVESTOCK 

WASTE, CONTAMINATED SURFACE 

WATER, AND BREAST CANCER 

INCIDENCE IN THE SAN FRANCISCO BAY 

AREA. H. Larson 1 , M. Mun 1 , W. Onyenwe 1 and D. 

E. Johnson 1,2 . 1 Nutritional Sciences & Toxicology, 

University of California, Berkeley, Berkeley, CA 

and 2 California Breast Cancer & Chemicals Policy 

Project, San Francisco, CA. 


NOVEL P450 REDUCTASE KNOCKOUT 

MOUSE MODELS FOR STUDYING 

CHEMICAL CARCINOGENESIS IN THE 

MAMMARY GLAND. Y. Yao 1 , S. Liu 1 , W. Yang 1 , 

B. Moorthy 2 , X. Ding 1 and J. Gu 1 . 1 Wadsworth 

Center, New York State Department of Health, and 

School of Public Health, State University of New 

York at Albany, Albany, NY and 2 Baylor College of 

Medicine, Houston, TX. 


IDENTIFYING INHIBITION PATHWAYS 

OF MAMMARY CANCER STEM CELLS BY 

CHEMICAL GENETICS. D. Castro, J. Maurer 

and R. Oshima. Tumor Development Program, 

Sanford-Burnham Medical Research Institute, La 

Jolla, CA. 


SEVERE URINARY BLADDER 

CYTOTOXICITY AND REGENERATIVE 

HYPERPLASIA WITH DOSE 

RESPONSE INDUCED BY ARSENITE 

IN ARSENIC (+3 OXIDATION STATE) 

METHYLTRANSFERASE KNOCKOUT 

MICE. M. Yokohira 2,1 , L. L. Arnold 2 , K. L. 

Pennington 2 , S. Suzuki 2 , S. Kakiuchi-Kiyota 2 , K. 

Herbin-Davis 3 , D. J. Thomas 3 , K. Imaida 1 and S. M. 

Cohen 2 . 1 Oncopathology, Kagawa University, Faculty 

of Medicine, Kita-gun, Kagawa, Japan, 2 Pathology 

and Microbiology, University of Nebraska Medical 

Center, Omaha, NE and 3 Pharmacokinetics Branch, 

Integrated Systems Toxicology Division, National 

Health and Environmental Effects Research 

Laboratory, U.S. EPA, Omaha, NE. 

134 






Platform Sessions



Abstract # 


TUMORS AND PROLIFERATIVE LESIONS 

IN ADULT OFFSPRING AFTER MATERNAL 

EXPOSURE TO METHYLARSONOUS ACID 

DURING GESTATION IN CD1 MICE. M. 

Waalkes 2,1 , B. A. Diwan 3 , E. J. Tokar 2,1 and D. J. 

Thomas 4 . 1 NCI at NIEHS, Research Triangle Park, 

NC, 2 NTP, NIEHS, Research Triangle Park, NC, 

3 

IRSP, SAIC, NCI, Frederick, MD and 4 U.S. EPA, 



ACTIVATION OF PPARα BY PHTHALATES 

IS A NECESSARY KEY EVENT IN THE 

MODE OF ACTION (MOA) LEADING TO 

INDUCTION OF RODENT LIVER TUMORS 

– A REEXAMINATION OF DATA AND DATA 

GAPS. A. Bachman 1 , R. David 2 , J. Butala 3 and 

J. Deyo 4 . 1 ExxonMobil Biomedical Sciences Inc., 

Annandale, NJ, 2 BASF Corporation, Florham Park, 

NJ, 3 Consultant for Ferro Corporation, Gibsonia, PA 

and 4 Eastman Chemical Company, Kingsport, TN. 


TOXICOLOGY STUDY OF SENNA IN 

C3B6F1/N TRP53 HAPLOINSUFFICIENT 

MICE. I. Surh 1 , A. Brix 2 , J. French 3 and J. 

Dunnick 1 . 1 Toxicology Branch, National Toxicology 

Program, National Institute of Environmental Health 

Sciences, Research Triangle Park, NC, 2 Pathology 

Group, National Toxicology Program, National 


Triangle Park, NC and 3 Host Susceptibility Branch, 

National Toxicology Program, National Institute of 

Environmental Health Sciences, Research Triangle 

Park, NC. 


GLOBAL DE-REGULATION OF GENE 

EXPRESSION, OVER-EXPRESSION OF 

MICROTUBULES/MICROFILAMENTS, 

AND ALTERED CA+2 GRADIENTS, IN 

NI-TRANSFORMED 10T1/2 MOUSE 

EMBRYO CELLS. J. R. Landolph 1,2,3 , A. 

T. Pehl-DeSilva 2,3 , D. Mai 1,3 , J. K. Lin 1 and J. 

Zheng 1 . 1 Department of Molecular Microbiology/ 

Immunology, Keck School of Medicine, University 

of Southern California, Los Angeles, California, 

CA, 2 Department of Pathology, Keck School of 

Medicine, University of Southern California, Los 

Angeles, CA and 3 University of Southern California 

Comprehensive Cancer Center, University of 

Southern California, Los Angeles, CA. 


SKIN TUMOR INITIATION / PROMOTION 

EVALUATION OF OXIDIZED ASPHALT 

(BITUMEN) FUME CONDENSATE. J. J. 

Freeman 1 , C. A. Schreiner 2 , E. W. Arp 3 , D. M. 

Burnett 4 , C. R. Clark 5 , S. Mahagaokar 6 , C. M. 

Parker 7 , C. W. Stewart 8 and M. S. Swanson 7 . 

1 

ExxonMobil Biomedical Sciences, Inc., Annandale, 

NJ, 2 C & C Consulting in Toxicology, Meadowbrook, 

PA, 3 Asphalt Institute, Lexington, KY, 4 BP 

Corporation, Naperville, IL, 5 ConocoPhillips, 

Bartlesville, OK, 6 Shell Oil Company, Houston, 

TX, 7 Marathon Petroleum, Findlay, OH and 8 MPI 

Research, Mattawan, MI. 

Abstract # 


TUMOR NECROSIS FACTOR-α IS 

INVOLVED IN INFLAMMATION- 

MEDIATED SYSTEMIC GENOTOXICITY. 

A. M. Westbrook 1 , B. Wei 2 , K. Hacke 2 , J. Braun 2 and 

R. H. Schiestl 1,2 . 1 Molecular Toxicology, University 

of California Los Angeles, Los Angeles, CA and 

2 

Pathology and Laboratory Medicine, University of 

California, Los Angeles, Los Angeles, CA. 


IDENTIFYING ONCOMUTATIONS THAT 

WILL BE USEFUL QUANTITATIVE 

BIOMARKERS OF CARCINOGENIC 

EFFECT SUITABLE FOR SUB-CHRONIC 

TOXICITY TESTING. M. B. Myers, Y. Wang, 

F. Meng, P. B. McKinzie, K. L. McKim and B. 

L. Parsons. Division of Genetic and Molecular 

Toxicology, National Center for Toxicological 

Research /U.S. FDA, Jefferson, AR. 


AEROSOL DELIVERED-AKT KD 

ATTENUATED CLARA CELL INJURY 

INDUCED BY NAPHTHALENE. A. Minai 

Tehrani and M. Cho. Laboratory of Toxicology, 

College of Veterinary Medicine, Seoul National 

University, Seoul, Republic of Korea. 


ABCB1 PROTECTS KIDNEY PROXIMAL 

TUBULE CELLS AGAINST CADMIUM- 

INDUCED APOPTOSIS: ROLES OF 

CADMIUM TRANSPORT AND CERAMIDE 

METABOLISM. W. Lee, B. Torchalski, N. 

Kohistani and F. Thévenod. Physiology & 

Pathophysiology, University of Witten/Herdecke, 

Witten, NRW, Germany. 


EVALUATION OF THE TUMORIGENIC 

POTENTIAL OF A MIXTURE OF FIVE 

PESTICIDES USING A MEDIUM-TERM 

HEPATOCARCINOGENESIS ASSAY WITH 

THE LEWIS RATS. J. V. de Camargo, C. S. 

Franchi and M. F. Martinez. Pathology, Sao Paulo 

State University - UNESP - Medical School, 

Botucatu, Brazil. Sponsor: D. Wolf. 


PRELIMINARY EVALUATION OF THE 

HUMAN RELEVANCE OF RESPIRATORY 

TUMORS OBSERVED IN RODENTS 

EXPOSED TO NAPHTHALENE. V. Piccirillo 1 , 

M. G. Bird 2 , R. Lewis 2 and W. Bover 2 . 1 VJP 

Consulting, Inc., Ashburn, VA and 2 ExxonMobil 

Biomedical Sciences, Inc., Annandale, NJ. 


SMALL MOLECULE RAF INHIBITORS 

CAUSE EXTENSIVE MULTIPLE TISSUE 

HYPERPLASIA AND AN INCIDENCE OF 

URINARY BLADDER TRANSITIONAL 

CARCINOMA IN THE RAT WITHIN 

28-DAYS. J. Wisler 1 , C. Afshari 1 , M. Fielden 1 , 

C. Zimmermann 1 , S. Taylor 1 , J. Carnahan 2 and S. 

Vonderfecht 1 . 1 Comparative Biology Safety Sciences, 

Amgen, Thousand Oaks, CA and 2 Hematology & 

Oncology Research, Amgen, Thousand Oaks, CA. 

MONday 







135



MONday 



PATHWAY DIRECTED MOLECULAR 

ANALYSIS OF LARGE INTESTINAL 

TUMORS INDUCED IN FISHER 344 RATS 

EXPOSED TO ALOE VERA WHOLE LEAF 

EXTRACT IN DRINKING WATER. A. R. 

Pandiri 1,2 , R. C. Sills 1 , M. J. Hoenerhoff 1 , T. T. 

Ton 1 , H. L. Hong 1 , G. P. Flake 1 , D. E. Malarkey 1 , 

I. Pogribny 4 , N. J. Walker 3 and M. D. Boudreau 4 . 

1 

Cellular and Molecular Pathology Branch, National 

Toxicology Program (NTP), National Institute of 

Environmental Health Sciences (NIEHS), Research 

Triangle Park, NC, 2 Experimental Pathology 

Laboratories, Inc., Research Triangle Park, NC, 

3 

NTP/NIEHS, Research Triangle Park, NC and 

4 

National Center for Toxicological Research, 

Jefferson, AR. 


EFFECTS OF CHRONIC ACRYLAMIDE 

EXPOSURE ON SYSTEMIC HORMONAL 

ENVIRONMENT AND CARCINOGENIC 

TARGET ORGANS IN F344 FEMALE RATS. 

T. Imai 1 , T. Watari 1 , T. Hayakawa 2 and T. Kitahashi 1 . 

1 

Central Animal Laboratory, National Cancer 

Center Research Institute, Tokyo, Japan and 2 Cancer 

Prevention Basic Research Project, National Cancer 

Center Research Institute, Tokyo, Japan. Sponsor: A. 

Nishikawa. 


CO-CARCINOGENESIS OF N, 

N-DIETHYLNITROSAMINE AND CARBON 

TETRACHLORIDE IN MOUSE LIVER. G. 

Ainslie 1 , T. Uehara 1 , O. Kosyk 1 , B. Bradford 1 , 

G. Boorman 2 and I. Rusyn 1 . 1 Department of 

Environmental Sciences and Engineering, University 

of North Carolina at Chapel Hill, Chapel Hill, NC 

and 2 Covance, Princeton, NJ. 


KNOCK DOWN OF AHR IN HUMAN 

BREAST CANCER CELL LINE 

UPREGULATES THE EXPRESSION OF 

PROAPOPTOTIC FACTOR BAK. G. Goode 

and S. E. Eltom. Biochemistry & Cancer Biology, 

Meharry Medical College, Nashville, TN. 


A NOVEL SMALL MOLECULE INHIBITOR 

OF WNT/β-CATENIN SIGNAL PATHWAY 

INDUCES CELL CYCLE ARREST IN 

HUMAN NON-SMALL LUNG CANCER 

CELLS. J. Choi 1 , S. Lee 1 , Y. Gong 2 , Y. Park 1 and 

M. Dong 1 . 1 School Lifesciences and Biotechnology, 

Korea University, Seoul, Republic of Korea and 

2 

Department of Chemistry, Dongguk University, 

Seoul, Republic of Korea. Sponsor: B. Lee. 


ARISTOLOCHIC ACID NEPHROPATHY: 

AN ENVIRONMENTAL AND IATROGENIC 

DISEASE. A. Grollman 1 , B. Jelakovic 2 , Y. Pu 3 and 

C. Chen 3 . 1 State University of New York at Stony 

Brook, Stony Brook, NY, 2 University of Zagreb, 

Zagreb, Croatia and 3 National Taiwan University, 

Taiwan, China. Sponsor: J. Swenberg. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Inflammatory Mediators in Disease 

Pathogenesis 

Chairperson(s): Saurabh Chatterjee, NIEHS, Research Triangle Park, 

NC. 




VITAMIN E DEFICIENCY IN MICE 

TREATED WITH DICHLOROACETATE 

OR TRICHLOROACETATE MODULATES 

THE BIOMARKERS OF PHAGOCYTIC 

ACTIVATION AND ANTIOXIDANT ENZYME 

ACTIVITIES IN THE PERITONEAL 

LAVAGE CELLS. E. Hassoun and A. Al-Dieri. 

Pharmacology, Pharmacy, University of Toledo, 

Toledo, OH. 


XENOBIOTIC-INDUCED ENDOPLASMIC 

RETICULUM STRESS TRIGGERS PRO- 

INFLAMMATORY NF-κB SIGNALS 

VIA REPRESSION OF PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR γ. 

Y. Moon and S. Park. Microbiology and Immunology, 

Pusan National University School of Medicine and 

Medical Research Institute, Yangsan, Republic of 

Korea. 


PRO-INFLAMMATORY CYTOKINE AND 

COMPLEMENT RECEPTOR 3 (CR3) 

RESPONSES TO FUNGAL CELL WALL 

MANNAN AND MANNAN BINDING LECTIN 

(MBL) IN HUMAN WHOLE BLOOD AND 

MONOCYTES. A. M. Nilsen 1 , I. Rauk 1 , M. 

Løvik 1,2 and L. N. Johannessen 1 . 1 Cancer Research 

and Molecular Medicine, Norwegian University of 

Science and Technology, Trondheim, Norway and 

2 

Division of Environmental Medicine, Norwegian 

Institute of Public Health, Oslo, Norway. 


ANTIBACTERIAL AGENT TRICLOSAN 

INHIBITS IgE RECEPTOR-MEDIATED 

MAST CELL DEGRANULATION. R. K. 

Palmer 1,2 , B. Burpee 2 , L. Hutchinson 2 , Z. Kormendy 2 , 

E. Tupper 2 , J. Pelletier 2 , E. Malay 2 and J. A. 

Gosse 1,2 . 1 Graduate School of Biomedical Sciences, 

University of Maine, Orono, ME and 2 Molecular and 

Biomedical Sciences, University of Maine, Orono, 

ME. 


TRANSACTIVATION OF GENE 

EXPRESSION BY NFκB IS DEPENDENT ON 

THIOREDOXIN REDUCTASE ACTIVITY. W. 

Watson and J. Heilman. Department of Medicine/GI, 

University of Louisville, Louisville, KY. 

136 






Platform Sessions



Abstract # 


TLR3 PROTECTS AGAINST MYOCARDITIS 

BY PROMOTING A TH1 RESPONSE, 

DECREASING VIRAL REPLICATION, 

PREVENTING SYSTOLIC FAILURE. E. 

Abston, A. Bucek, A. Frisancho, M. Coronado, J. 

Shin and D. Fairweather. Environmental Health 

Sciences, Johns Hopkins Bloomberg School of 

Public Health, Baltimore, MD. 


S-NITROSYLATION OF SURFACTANT 

PROTEIN-D OCCURS IN BLEOMYCIN- 

INDUCED INJURY AND IS A 

PRO-INFLAMMATORY MEDIATOR VIA 

ACTIVATION OF NF-κB DEPENDENT 

PATHWAYS. C. Guo and A. Gow. Pharmacology 

& Toxicology, Rutgers University, Piscataway, NJ. 


UTILIZATION OF EXTRACELLULAR 

GLUTATHIONE BY PHAGOCYTOSIS 

REDUCES TUMOR NECROSIS FACTOR α 

RELEASE IN MACROPHAGES. N. S. Gould 1,2 , 

E. Min 1 and B. J. Day 1,2,3 . 1 Medicine, National Jewish 

Health, Denver, Co., 2 Pharmaceutical Sciences, 

University of Colorado AMC, Aurora, CO and 

3 

Immunology, University of Colorado AMC, Aurora, 

CO. 


ACROLEIN INHIBITS THE CLEAVAGE OF 

ADHESION MOLECULES IN CYTOKINE- 

STIMULATED ENDOTHELIAL CELLS. S. D. 

Sithu, A. Bhatnagar, S. Srivastava and S. E. D’Souza. 

School of Medicine, University of Louisville, 

Louisville, KY. 


INDUCTION OF PROINFLAMMATORY 

MEDIATORS FACILITATES PCB- 

MEDIATED ENHANCEMENT OF BRAIN 

METASTASIS FORMATION. E. Bodone 

Sipos, L. Chen, I. Andras, B. Zhang, J. Wrobel, M. 

Park, J. Choi, S. Eum and M. Toborek. Molecular 

Neuroscience and Vascular Laboratory, Department 

of Neurosurgery, University of Kentucky, Lexington, 

KY. 


NITRIC OXIDE ENHANCES BACTERIAL 

CLEARANCE IN HYPEROXIA. A. Gore. St. 

John’s University, Queens, NY. 


ENDOTHELIAL ACTIVATION BY 4, 

HYDROXY TRANS-2-NONENAL: ROLE OF 

ENDOPLASMIC RETICULUM STRESS. E. 

N. Vladykovskaya, S. D. Sithu, P. Haberzettl, N. S. 

Wickramasinghe, O. A. Barski, S. E. D’Souza, A. 

Bhatnagar and S. Srivastava. School of Medicine, 



LOVASTATIN ATTENUATES HYPEROXIA- 

INDUCED HMGB1 RELEASE AND 

RESCUES MACROPHAGE FUNCTION VIA 

INACTIVATION OF NF-κB P65 PATHWAY. 

R. Malla 1 and L. Mantell 1,2 . 1 St. John’s University, 

Queens, NY and 2 The Feinstein Institute for 

Medical Research, North Shore-LIJ Health System, 

Manhasset, NY. 

Abstract # 


SELECTIVE ALPHA7 NICOTINIC 

ACETYLCHOLINE RECEPTOR AGONIST 

GTS-21 ENHANCES HYPEROXIC 

MACROPHAGE FUNCTION. R. A. Sitapara. 

Department of Pharmaceutical Sciences, St. Johns 

University, Jamaica, NY. Sponsor: L. Mantell. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Metals I 

Chairperson(s): Jaclyn Goodrich, University of Michigan, Ann Arbor, MI. 




METALLOTHIONEIN AND ACUTE 

CADMIUM-INDUCED DNA OXIDATIVE 

DAMAGE. W. Qu 1 , L. Cheng 1 , Y. Sun 1 , R. P. 

Mason 2 and M. Waalkes 1 . 1 NTP Laboratories, NTP, 

NIEHS, Research Triangle Park, NC and 2 Laboratory 

of Toxicology and Pharmacology, NIEHS, Research 



SEXUAL DIMORPHISM OF CADMIUM- 

INDUCED TOXICITY IN RATS: 

INVOLVEMENT OF PROGESTERONE. H. 

Shimada 1 , T. Hashiguchi 1 , A. Yasutake 2 , M. P. 

Waalkes 3 and Y. Imamura 4 . 1 Kumamoto University, 

Kumamoto, Japan, 2 National Institute for Minamata 

Disease, Kumamoto, Japan, 3 NIEHS, Research 

Triangle Park, NC and 4 Nihon Pharmaceutical 

University, Saitama, Japan. 


CADMIUM ACCUMULATES WITHIN 

PANCREATIC ISLETS RESULTING IN 

IMPAIRED GLUCOSE STIMULATED 

INSULIN SECRETION IN AN ANIMAL 

MODEL OF SUBCHRONIC EXPOSURE. J. 

Edwards, R. Fitzgerald and A. Olsen. Department 

of Pharmacology, Midwestern University, Downers 

Grove, IL. 


CADMIUM ALTERS MICRORNA 

EXPRESSION IN HUMAN A549 ALVEOLAR 

EPITHELIAL CELLS. M. J. Fay, P. Rodriguez, 

L. A. Alt and W. C. Prozialeck. Pharmacology, 

Midwestern University, Downers Grove, IL. 


SUPPRESSION OF IRON TRANSPORT 

SYSTEM IN DUODENUM BY CADMIUM. 

M. Satoh, H. Banno and Y. Fujiwara. Laboratory 

of Pharmaceutical Health Sciences, School of 

Pharmacy, Aichi Gakuin University, Nagoya, Japan. 

MONday 







137



MONday 



COMBINED EFFECT OF ABDOMINAL 

SURGERY AND CHRONIC CADMIUM 

ADMINISTRATION ON HEPATIC 

RIBONUCLEASE ACTIVITY, 

METALLOTHIONEIN, AND ALPHA-2- 

MACROGLOBULIN CONCENTRATION. 

E. Brambila, M. R. Vieyra-Lobato, B. A. Leon- 

Chavez and P. Aguilar-Alonso. Clinical Chemistry, 

University of Puebla, Puebla, Mexico. 


CIRCADIAN VARIATION OF CADMIUM- 

INDUCED MORTALITY IN MICE. N. Miura. 

Japan National Institute of Occupational Safety and 

Health (JNIOSH), Kawasaki, Japan. Sponsor: M. 

Satoh. 


TOXIC EFFECTS OF CADMIUM ON 

HUMAN PERIPHERAL LUNG CELLS. R. 

Person 1 , E. Tokar 2 and M. Waalkes 2 . 1 NCI at 

NIEHS, Research Triangle Park, NC and 2 National 

Toxicology Program, NIEHS, Research Triangle 

Park, NC. 


GENETIC TOXICITY OF HEXAVALENT 

CHROMIUM IN THE GASTROINTESTINAL 

TRACT FOLLOWING ORAL EXPOSURE. T. 

J. O’Brien 1 , H. Ding 1 , S. R. Patierno 1 , R. D. May 2 

and C. D. Hébert 2 . 1 Pharmacology and Physiology, 

George Washington University, Washington, D.C. 

and 2 Southern Research Institute, Birmingham, AL. 


IDENTIFICATION OF CADMIUM- 

RESPONSIVE TRANSCRIPTIONAL 

REGULATORS OF THE C. ELEGANS GENE, 

CDR-1. L. E. Fuhrman and J. H. Freedman. 

NIEHS, Durham, NC. 


CHARACTERIZATION OF THE 

MOLECULAR MECHANISM OF CADMIUM 

AND NICKEL-INDUCED TOXICITY. B. 

Longwell and M. Reynolds. Biology, Washington 

College, Chestertown, MD. 


CADMIUM EXPOSURE ALTERS THE 

EXPRESSION OF KEY REGULATORY 

GENES IN OSTEOBLASTIC CELLS VIA 

ACTIVATION OF THE ERK SIGNALING 

PATHWAY. M. A. Simmonds, C. M. Christensen, 

D. L. Filer, D. E. Haggard and S. J. Heggland. 

Biology, The College of Idaho, Caldwell, ID. 


EFFECTS OF CIGARETTE SMOKE 

CADMIUM AND SMOKING CESSATION 

ON URINARY CALCIUM EXCRETION 

IN POSTMENOPAUSAL WOMEN. M. H. 

Bhattacharyya 1,2 and S. Bozorgnia 2 . 1 Medicine, 

Medical College of Georgia, Augusta, GA and 

2 

Orthopedic Surgery, Medical College of Georgia, 

Augusta, GA. 


CHRONIC EXPOSURE TO PARTICULATE 

CHROMATE INDUCES NUMERICAL 

CHROMOSOME INSTABILITY AND 

CENTROSOME AMPLIFICATION IN 

HUMAN LUNG CELLS. A. L. Holmes 1,2,3 , S. S. 

Wise 1,2,3 , S. Pelsue 2,3 , W. Lingle 4 , J. Salisbury 4 and 

J. P. Wise 1,2,3 . 1 Wise Laboratory of Environmental 

and Genetic Toxicology, University of Southern 

Maine, Portland, ME, 2 Maine Center for Toxicology 

and Environmental Health, University of Southern 

Maine, Portland, ME, 3 Department of Applied 

Medical Science, University of Southern Maine, 

Portland, ME and 4 Mayo Clinic and Foundation, 

Rochester, MN. 


BOWHEAD WHALE LUNG CELLS 

ARE RESISTANT TO CR(IV)-INDUCED 

GENOTOXICITY. J. Martino 1,2 , S. S. Wise 1,2 , 

A. L. Holmes 1,2 , H. Xie 1,2,3 and J. P. Wise 1,2,3 . 

1 

Wise Laboratory of Environmental and Genetic 

Toxicology, University of Southern Maine, 

Portland, ME, 2 Maine Center for Toxicology and 

Environmental Health, University of Southern 

Maine, Portland, ME and 3 Department of Applied 


Portland, ME. 


THE IMPACT OF ALTERED GRAVITY 

ON CHROMATE GENOTOXICITY: 

USING A BIOREACTOR TO SIMULATE 

MICROGRAVITY IN CELL CULTURE. J. 

P. Wise Jr. 1,2 , C. Wheeler 1,2 and J. P. Wise Sr. 1,2,3 . 

1 







Portland, ME. 


GENOTOXIC EFFECTS OF DEPLETED 

URANIUM IN EXPOSED GULF WAR 

VETERANS WITH EMBEDDED 

FRAGMENTS. M. McDiarmid 1 , R. Albertini 2 , 

M. Oliver 1 and K. Squibb 1 . 1 University of Maryland 

School of Medicine, Baltimore, MD and 2 University 

of Vermont School of Medicine, Burlington, VT. 


PARTICULATE DEPLETED URANIUM 

INDUCES SELECTIVE X-CHROMOSOME 

FRAGMENTATION DEPENDENT ON 

XRCC3 IN CHINESE HAMSTER OVARY 

CELLS. K. Joyce 1,2 , C. LaCerte 1,2 and J. P. 

Wise 1,2,3 . 1 Wise Laboratory of Environmental and 

Genetic Toxicology, University of Southern Maine, 




Medical Sciences, University of Southern Maine, 

Portland, ME. 

138 






Platform Sessions



Abstract # 


EFFECTS OF DEPLETED URANIUM ON 

ETOPOSIDE-INDUCED DNA DAMAGE 

AND REPAIR IN HUMAN BRONCHIAL 

EPITHELIAL CELLS. M. Yellowhair 1 and D. 

Lantz 2 . 1 Pharmacology & Toxicology, The University 

of Arizona, Tucson, AZ and 2 Cell Biology & 

Anatomy, The University of Arizona, Tucson, AZ. 


THROMBOPOIETIN (TPO) AND ITS 

RECEPTOR (MPL) ARE INVOLVED IN 

MEGAKARYOPOIESIS STIMULATION 

AFTER VANADIUM PENTOXIDE 

INHALATION. T. I. Fortoul, A. Gonzalez- 

Villalva, P. Diaz-Bech and P. Diaz-Fuentes. Biologia 

Celular y Tisular, UNAM, Mexico City, Mexico. 


NON-CILIATED BRONCHIOLAR 

CELL POPULATION CHANGES 

AFTER VANADIUM INHALATION. C. 

I. Falcon-Rodriguez 1,4 , N. Lopez-Valdez 1,4 , S. 

Hernandez-Ojeda 2 , J. Espinoza-Aguirre 2 , T. I. 

Fortoul 1 and M. Altamirano-Lozano 3 . 1 Biologia 

Celular y Tisular, UNAM, Mexico City, Mexico, 

2 

Departamento de Medicina Genómica y Toxicología 

Ambiental; Insituto de Investigaciones Biomedicas, 

UNAM, Mexico City, Mexico, 3 Unidad de 

Investigación en Genética y Toxicología ambiental, 

Bioterio, Campo-II, Facultad de Estudios Superiores 

Zaragoza, UNAM, Mexico City, Mexico and 

4 

Posgrado Ciencias Biológicas, UNAM, Mexico 

City, Mexico. 


VANADIUM PENTOXIDE INHALATION 

EFFECT IN A MURINE MODEL OF LUNG 

CANCER. N. Lopez-Valdez 1,2 , C. I. Falcon- 

Rodriguez 1,2 , M. Gonsebatt-Bonaparte 3 , M. 

Altamirano-Lozano 4 and T. I. Fortoul 1 . 1 Biologia 

Celular y Tisular, UNAM, Mexico City, Mexico, 

2 

Posgrado de Ciencias Biologicas, UNAM, Mexico 

City, Mexico, 3 Departamento de Toxicología y 

Medicina Genómica. Instituto de Investigaciones 

Biomédicas, UNAM, Mexico City, Mexico and 

4 

Unidad de Investigación en Genética y Toxicología 

Ambiental, Bioterio, Campo-II. Facultad de Estudios 

Superiores-Zaragoza, UNAM, Mexico City, Mexico. 


CHANGES IN SPLEEN LYMPHOCYTES 

PROLIFERATION PATTERN IN MALE 

MICE CAUSED BY V2O5 INHALATION. V. 

Rodriguez-Lara 1 , A. Muñiz Rivera-Cambas 2 and 

T. I. Fortoul 1 . 1 Biologia Celular y Tisular, UNAM, 

Mexico City, Mexico and 2 Facultad de Ciencias, 

Biologia, UNAM, Mexico City, Mexico. 


MORPHO-PHYSIOLOGICAL ALTERATIONS 

IN LYMPH NODE DUE TO VANADIUM 

PENTOXIDE INHALATION. L. S. Lopez- 

Zepeda and T. I. Fortoul. Biologia Celular y Tisular, 

UNAM, Mexico City, Mexico. 

Abstract # 


FIRST STEPS TOWARDS AN 

UNDERSTANDING OF A MODE OF 

CARCINOGENIC ACTION FOR VANADIUM 

PENTOXIDE. D. McGregor 1 , D. Schuler 2 , K. 

Morgenthal 2 , H. J. Chevalier 3 , M. Merker 4 , J. L. 

Ravanat 5 , P. Sagelsdorf 2 , M. Walter 2 and K. Weber 2 . 

1 

Toxicity Evaluation Consultants, Aberdour, United 

Kingdom, 2 Harlan Laboratories Ltd., Füllinsdorf, 

Switzerland, 3 AnaPath GmbH, Oberbuchsiten, 

Switzerland, 4 Harlan Cytotest Cell Research GmbH, 

Rossdorf, Germany and 5 INAC/SCIB/LAN, CEA- 

Grenoble, Grenoble, France. 


TISSUE BURDEN AND HISTOPATHOLOGY 

IN SPRAGUE-DAWLEY RATS AFTER 

INHALATION OF TUNGSTEN ALLOY. P. 

A. Ortiz 1 , C. U. Parkinson 2 , V. P. Mokashi 1 , M. G. 

Stockelman 1 and B. A. Wong 1,2 . 1 Naval Medical 

Research Unit - Dayton, Wright-Patterson AFB, OH 

and 2 The Hamner Institutes for Health Sciences, 



EFFECTS OF TUNGSTEN CHEMICAL 

SPECIES ON PHOSPHATE-DEPENDENT 

PATHWAYS IN AN OSTEOBLAST CELL 

LINE. D. R. Johnson 1 and C. Ang 2 . 1 Environmental 

Laboratory, U.S. Army Engineer Research & 

Development Center, Vicksburg, MS and 2 Badger 

Testing Services, Vicksburg, MS. 


THE INFLUENCE OF GENETIC 

POLYMORPHISMS ON MERCURY 

BIOMARKER DISTRIBUTION IN MEXICAN 

MOTHER-CHILD PAIRS. J. Goodrich 1 , D. 

Cantonwine 1 , B. N. Sánchez 2 , M. Hernández- 

Avila 3 , H. Hu 1 , M. M. Téllez-Rojo 4 and N. Basu 1 . 

1 


Michigan, Ann Arbor, MI, 2 Biostatistics, University 

of Michigan, Ann Arbor, MI, 3 Ministry of Health, 

México, Districto Federal, Mexico and 4 Statistics, 

Center for Evaluation Research and Surveys, 

National Institute of Public Health, Cuermavaca, 

Morelos, Mexico. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Metals II 

Chairperson(s): Wei Zheng, Purdue University, West Lafayette, IN. 




LEAD CAUSES BONE LOSS BY 

DEPRESSION OF OSTEOBLASTIC 

FUNCTION THROUGH INHIBITION OF 

WNT SIGNALING. E. E. Beier 1,2 , E. Puzas 1,2 , 

M. Zuscik 2 , D. Cory-Slechta 1 and T. Sheu 2 . 

1 

Environmental Medicine, University of Rochester, 

Rochester, NY and 2 Orthopedics, University of 

Rochester, Rochester, NY. 

MONday 







139



MONday 



LOW LEVEL OF LEAD CAN INDUCE 

PHOSPHATIDYLSERINE-EXPOSURE 

AND ERYTHROPHAGOCYTOSIS: A NEW 

MECHANISM UNDERLYING LEAD- 

ASSOCIATED ANEMIA. J. Noh, K. Kim, W. 

Jang, K. Lim, S. Kang, O. Bae and J. Chung. College 

of Pharmacy, Seoul National University, Seoul, 

Republic of Korea. 


ACUTE ORAL LEAD BULLET FRAGMENT 

EXPOSURE IN NORTHERN BOBWHITE 

QUAIL. R. Kerr 1 , J. Hollady 1 , T. Jarrett 1 , S. D. 

Holladay 1 , B. Selcer 1 , B. Meldrum 2 , S. Williams 3 , 

L. Tannenbaum 4 and R. M. Gogal 1 . 1 Department of 

Anatomy and Radiology, University of Georgia, 

Athens, GA, 2 Department of Biomedical Sciences 

& Pathobiology, Virginia Tech, Blacksburg, VA, 

3 

Poultry Diagnostic & Research Center, University 

of Georgia, Athens, GA and 4 U.S. Army Center 

for Health Promotion & Preventive Medicine, 

Department of Defense, Aberdeen, MD. 


ORAL LEAD PELLET EXPOSURE IN 

NORTHERN BOBWHITE QUAIL: A 56-DAY 

STUDY. R. M. Gogal 1 , R. Kerr 1 , J. Holladay 1 , S. 

D. Holladay 1 , L. Tannenbaum 2 , B. Meldrum 3 and S. 

Williams 4 . 1 Department of Anatomy and Radiology, 

University of Georgia, Athens, GA, 2 Department 

of Biomedical Sciences and Pathobiology, Virginia 

Maryland Regional College, Blacksburg, VA, 3 U.S. 

Army Center for Health Promotion and Preventative 

Medicine, Department of Defense, Aberdeen, MD 

and 4 Poultry Diagnostic and Research Center, 

University of Georgia, Athens, GA. 


ALUMINIUM TOXICITY AND ELEMENTAL 

COMPOSITION CHANGES IN 

CAENORHABDITIS ELEGANS. K. E. Page 1,2 , 

D. W. Killilea 3 , K. N. White 2 , C. R. McCrohan 2 and 

G. J. Lithgow 1 . 1 The Buck Institute for Age Research, 

Novato, CA, 2 Faculty of Life Sciences, University 

of Manchester, Manchester, United Kingdom and 

3 

Children’s Hospital Oakland Research Institute, 

Oakland, CA. 


BIOACCESSIBILITY-BASED READ-ACROSS 

ASSESSMENT OF NICKEL COMPOUNDS 

FOR ORAL SYSTEMIC TOXICITY. R. G. 

Henderson 1 , D. Cappellini 2 , S. Seilkop 3 , A. R. Oller 1 

and H. K. Bates 1 . 1 NiPERA, Inc., Durham, NC, 

2 

Kirby Memorial Health Center, Wilkes-Barre, PA 

and 3 SKS Consulting Services, Siler City, NC. 


NICKEL(II) CHLORIDE CAUSES 

PANCREATIC ISLET β-CELL DEATH VIA 

A JNK-REGULATED MITOCHONDRIAL 

APOPTOTIC PATHWAY. D. Hung 2,1 , K. Chen, 

H. Wu 3 , Y. Chen 4 , C. Su 5 , C. Yen 6 , T. Lu 1 , Y. Yang 1 , 

T. Ho 7 and C. Huang 7 . 1 Graduate Institute of 

Drug Safety, China Medical University, Taichung 

City, Taiwan, 2 Toxicology Center, China Medical 

University Hospital, Taichung, Taiwan, 3 Department 

of Urology, China Medical University Hospital, 

Taichung, Taiwan, 4 Department of Physiology, China 

Medical University, Taichung, Taiwan, 5 Department 

of Otorhinolaryngology, Head and Neck Surgery, 

Changhua Christian Hospital, Changhua, Taiwan, 

6 

Department of Occupational Safety and Health, 

Chung Shan Medical University, Taichung, Taiwan 

and 7 School of Chinese Medicine, China Medical 

University, Taichung, Taiwan. 


LOW-DOSE PYRROLIDINE 

DITHIOCARBAMATE/COPPER COMPLEX 

INDUCES LUNG EPITHELIAL CELL 

APOPTOSIS VIA THE ER-STRESS-RELATED 

SIGNALING PATHWAYS. Y. Chen 1 , K. Chen 2 , 

C. Chen 3,4 , H. Wu 2 , C. Su 5 , D. Hung 6,4 , C. Yen 7 , Y. 

Yang 4 and T. Lu 4 . 1 Department of Physiology, China 


of Urology, China Medical University Hospital, 

Taichung, Taiwan, 3 Department of Emergency, 

China Medical University Hospital, Taichung, 

Taiwan, 4 Graduate Institute of Drug Safety, China 




6 

Toxicology Center, China Medical University 

Hospital, Taichung, Taiwan and 7 Department of 

Occupational Safety and Health, Chung Shan 

Medical University, Taichung, Taiwan. 


CHEMICAL FORM OF METALS IN 

TRADITIONAL MEDICINES UNDERLINES 

POTENTIAL TOXICITY IN CELL 

CULTURES. Q. Wu 1 , Y. Lu 1 , J. Shi 3 , J. Liu 1,2 and J. 

Shi 1 . 1 Pharmacology, Zunyi Medical College, Zunyi, 

Guizhou, China, 2 Pharmacology, Toxicology & 

Therapeutics, University of Kansas Medical Center, 

Kansas City, KS and 3 Pharmacology, Guiyang 

Traditional Medical College, Guiyang, Guizhou, 

China. 


INVESTIGATION OF TELLURIUM 

TOXICITY IN HT-29 AND CACO-2 HUMAN 

COLON CELLS. P. Vij and D. Hardej. 

Department of Pharmaceutical Sciences, St. John’s 

University, Queens, NY. 

140 






Platform Sessions



Abstract # 


LUNAR DUST SIMULANT IS CYTOTOXIC 

BUT NOT GENOTOXIC TO HUMAN SKIN 

FIBROBLAST CELLS. R. Duffy 1,2 , J. Wise 1,2 , H. 

Xie 1,2,3 , A. Jeevaragen 4 , W. Wallace 6 , D. Hammond 4 , 

T. Shehata 5 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 

Environmental and Genetic Toxicology, University 

of Southern Maine, Portland, ME, 2 Maine Center for 

Toxicology and Environmental Health, University 

of Southern Maine, Portland, ME, 3 Department of 

Applied Medical Science, University of Southern 

Maine, Portland, ME, 4 NASA Johnson Space Center, 

Houston, TX, 5 Maine Space Consortium, Augusta, 

ME and 6 Wyle Integrated Science and Engineering, 

Houston, TX. 


COMPARATIVE CYTOTOXICITY OF 

SIMULATED MOON AND MARS DUSTS, 

EARTH DUST, AND SELECTED LUNAR 

DUST COMPONENTS IN HUMAN LUNG 

EPITHELIAL CELLS. M. Braun 1,2 , Q. Qin 1,2 , H. 

Xie 1,2,3 , R. Leighton 1,2 , M. Mason 2,4 , A. Jeevaragen 5 , 

W. Wallace 5 , D. Hammond 5 , T. Shehata 6 and J. P. 

Wise 1,2,3 . 1 Wise Laboratory of Environmental and 

Genetic Toxicology, University of Southern Maine, 





Portland, ME, 4 Department of Chemical and 

Biological Engineering, University of Maine, Orono, 

ME, 5 NASA Johnson Space Center, Houston, TX and 

6 

Maine Space Consortium, Augusta, ME. 


MECHANISMS OF CELLULAR 

TOXICITY FOR DUAL EXPOSURE TO 

NICL2 AND COCL2 IN H460 HUMAN 

LUNG EPITHELIAL CELLS. C. Lynch 

and M. Reynolds. Biology, Washington College, 

Chestertown, MD. 


RAD23, A FACTOR INVOLVED IN 

UBIQUITIN-PROTEASOME SYSTEM, 

REDUCES METHYLMERCURY TOXICITY 

THROUGH INHIBITION OF DEGRADATION 

OF N-GLYCANASE IN BUDDING YEAST. 

G. Hwang and A. Naganuma. Graduate School of 

Pharmaceutical Sciences, Tohoku University, Sendai, 

Miyagi, Japan. 


METHYLMERCURY INDUCED 

PANCREATIC β-CELL APOPTOSIS 

THROUGH ENDOPLASMIC RETICULUM 

STRESS. T. Lu 1 , D. Hung 1,2 , C. Chen 1,3 , C. 

Yen 4 , C. Su 5 , Y. Chen 6 and C. Huang 7 . 1 Graduate 

Institute of Drug Safety, China Medical University, 

Taichung, Taiwan, 2 Toxicology Center, China 

Medical University Hospital, Taichung, Taiwan, 

3 

Department of Emergency, China Medical 

University Hospital, Taichung, Taiwan, 4 Department 

of Occupational Safety and Health, Chung Shan 




6 

Department of Physiology, China Medical 

University, Taichung, Taiwan and 7 School of Chinese 

Medicine, China Medical University, Taichung, 

Taiwan. 

Abstract # 


ROLES OF RIP1 AND YIL006W, 

MITOCHONDRIAL PROTEINS, IN 

METHYLMERCURY TOXICITY IN 

BUDDING YEAST. J. Lee, G. Hwang and A. 

Naganuma. Graduate School of Pharmaceutical 

Sciences, Tohoku University, Sendai, Japan. 


MERCURY MODULATE THE 

CYTOCHROME P450 1A1 IN C57BL/6 

MICE: IN VIVO AND IN VITRO STUDIES. I. 

Amara and A. El-Kadi. Faculty of Pharmacy and 

Pharmaceutical Sciences, University of Alberta, 

Edmonton, AB, Canada. 


ASSESSING METAL LEVELS IN CHILDREN 

FROM THE MECHANISTIC INDICATORS 

OF CHILDHOOD ASTHMA (MICA) STUDY. 

A. Sanders 1 , J. Gallagher 2 , J. McGee 2 , S. Rhoney 2 , E. 

Hugens 2 , H. Özkaynak 3 and R. Fry 1 . 1 Environmental 

Sciences and Engineering, Gillings School of 

Global Public Health, University of North Carolina 

at Chapel Hill, Chapel Hill, NC, 2 National Health 

Environmental Effects Research Laboratory, U.S. 

EPA, Research Triangle Park, NC and 3 National 

Exposure Research Laboratory, U.S. EPA, Research 



BRIDGING THE MISSING LINK IN 

PRINCIPLE THEORY – SELENIUM 

TRANSPORT IN ENTEROCYTES AND 

HEPATOCYTES. S. Misra 1 , R. W.M. Kwong 2 and 

S. Niyogi 1 . 1 Biology, University of Saskatchewan, 

Saskatoon, Saskatchewan, Canada and 2 Toxicology 

Centre, University of Saskatchewan, Saskatoon, 

Saskatchewan, Canada. 


THE IRON TRANSPORTER FERROPORTIN 

CAN ALSO FUNCTION AS A MANGANESE 

EXPORTER. M. S. Madejczyk and N. Ballatori. 

Environmental Medicine, University of Rochester 

School of Medicine, Rochester, NY. 


CHARACTERIZATION OF ZIP8 AND ZIP14 

ZINC/BICARBONATE SYMPORTERS IN 

XENOPUS OOCYTES: CADMIUM AND ZINC 

UPTAKE AND INHIBITION BY VARIOUS 

METALS. M. Gálvez-Peralta, E. B. Hay, H. Li, 

M. Soleimani, E. Johansson, L. He, B. Wang and D. 

W. Nebert. University Cincinnati Medical Center, 

Cincinnati, OH. 


ZIP8 AND ZIP14 ZINC/BICARBONATE 

SYMPORTERS: THEIR POSSIBLE ROLES 

DURING INFLAMMATION. Z. Wang 1 , M. 

Gálvez-Peralta 1 , C. M. Williams 1 , M. Liu 2 , D. L. 

Knoell 2 and D. W. Nebert 1 . 1 Environmental Health, 

University of Cincinnati Medical Center, Cincinnati, 

OH and 2 David Heart and Lung Research Institute, 

Ohio State University, Columbus, OH. 

MONday 







141



MONday 



9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Genotoxicity 

Chairperson(s): Lynn Pottenger, Dow Chemical Company, Midland, MI. 




EVALUATION OF MUTAGENICITY, 

CHROMOSOME BREAKAGE, AND DNA 

DAMAGE BY PIG-A, MICRONUCLEUS AND 

COMET ASSAYS IN 28-DAY REPEATED 

DOSE TOXICITY STUDIES. J. Shi 1 , M. 

Paranjpe 1 , S. W. Bruce 1 , T. Kelley 1 , S. Springer 1 , 

J. Sly 1 , M. Klug 1 , M. Arevaro 1 , S. Atta-Safoh 1 , 

F. Debelie 1 , L. Krsmanovic 1 , P. Sareen 1 and S. 

Dertinger 2 . 1 BioReliance Corporation, Rockville, 

MD and 2 Litron Laboratories, Rochester, NY. 


A NOVEL HIGH-THROUGHPUT IN VITRO 

MNT PROFILING ASSAY FOR SUSPENSION 

CELLS. S. Kirchner, M. Prummer, S. Marget- 

Müller, J. Muller, C. McGinnis, K. Kolaja, R. 

Werder, K. Christensen, S. Zoffmann, T. Enderle, R. 

Rietmann, D. Vögelin, P. Iaiza, C. Fattinger and T. 

Weiser. F. Hoffmann-La Roche Ltd., CH-4070 Basel, 

Switzerland. 


THE HUNT FOR MISLEADING POSITIVES: 

CAN NON-GENOTOXIC REGULATION 

OF GADD45A INTERFERE WITH 

GREENSCREEN HC? C. Topham 2 and 

R. Walmsley 1,2 . 1 Life Sciences, University of 

Manchester, Manchester, United Kingdom and 

2 

Gentronix Ltd., Manchester, United Kingdom. 


COMPARATIVE DNA DAMAGE AND 

CHRONIC LIVER TOXICITY OF BENZO[A] 

PYRENE IN TWO POPULATIONS OF 

THE ATLANTIC KILLIFISH (FUNDULUS 

HETEROCLITUS) WITH DIFFERENT 

EXPOSURE HISTORIES. R. Di Giulio 1 , D. 

Jung 2,1 and L. Wills 3,1 . 1 Nicholas School of the 

Environment, Duke University, Durham, NC, 

2 

Department of Physiology, Dartmouth Medical 

School, Lebanon, NH and 3 Medical University of 

South Carolina, Charleston, SC. 


DNA DAMAGE CAUSED BY TRICYCLIC 

ANTIDEPRESSANTS. E. A. Korobkova and A. 

K. Williams. Science, John Jay College of Criminal 

Justice, New York. Sponsor: B. Shane. 


EVALUATION OF DIRECT AND INDIRECT 

DNA DAMAGE INDUCED BY OCHRATOXIN 

A IN CHO AND TK6 CELLS USING THE 

COMET ASSAY. R. Ali 1,2 , J. G. Shaddock 2 , W. 

Ding 2 , J. A. Bhalli 2 , Q. M. Khan 1 and R. H. Heflich 2 . 

1 

Environmental Biotechnology Division, National 

Institute for Biotechnology and Genetic Engineering 

(NIBGE), Faisalabad, Pakistan and 2 Division of 

Genetic and Molecular Toxicology, National Center 

for Toxicological Research/U.S. FDA, Jefferson, AR. 

Sponsor: M. Moore. 


THE IN VIVO RAT COMET ASSAY OF 

DIETHYLNITROSAMINE: RELEVANCE 

BETWEEN CARCINOGENESIS AND DNA 

DAMAGE IN THE TARGET ORGANS. Y. 

Uematsu, C. Hirogaki, H. Adachi, K. Kijima, T. 

Yamada, Y. Michimae, I. Matsumoto, T. Koujitani, 

H. Oishi, H. Funabashi and T. Seki. Safety Research 

Laboratory, Dainippon Sumitomo Pharmacology Co., 

Ltd., Suita-City, Osaka, Japan. 


OPTIMAL CONDITIONS FOR 

PERFORMANCE OF THE COMET ASSAY 

USING A THREE-DIMENSIONAL HUMAN 

EPIDERMAL MODE. H. Kojima and M. Hojyo. 

Division of Pharmacology, National Institute of 

Health Sciences, Tokyo, Japan. 


GENOTOXICITY OF STYRENE- 

ACRYLONITRILE TRIMER IN WEANLING 

F344 RATS. R. S. Chhabra 1 , C. A. Hobbs 2 , L. 

Recio 2 , J. Winters 2 , K. Shepard 2 , P. Allen 2 , M. 

Prajapati 2 , M. Streicker 3 and K. L. Witt 1 . 1 National 

Toxicology Program, NIEHS, Research Triangle 

Park, NC, 2 Genetic and Molecular Toxicology, ILS, 

Inc., Research Triangle Park, NC and 3 Investigative 

Toxicology, ILS, Inc., Research Triangle Park, NC. 


THE EVALUATION OF MN AND SCE 

FREQUENCIES AND OXIDATIVE 

STRESS STATUS OF HOSPITAL STAFF 

OCCUPATIONALLY EXPOSED TO LOW 

DOSES OF IONIZING RADIATION. DOES 

THE LOW DOSE STIMULATE DEFENSE 

STATUS? A. Aydin 1 , A. Eken 2 , O. Erdem 2 , C. 

Akay 2 , B. Soykut 2 , A. Sayal 2 and I. Somuncu 3 . 

1 

Toxicology, Yeditepe University, Faculty of 

Pharmacy, Istanbul, Turkey, 2 Toxicology, Gulhane 

Military Medical Academy, Ankara, Turkey and 

3 

Radiology, Gulhane Military Medical Academy, 

Ankara, Turkey. Sponsor: A. Karakaya. 


GENOTOXICITY TESTING OF GATIFOLIA 

(GUM GHATTI). C. A. Hobbs 1 , C. Swartz 1 , R. 

Maronpot 2 , J. Davis 3 , M. Prajapati 1 , K. Shepard 1 , 

P. Allen 1 , C. Lentz 1 , P. Garibaldi 1 , L. Recio 1 and 

S. Hayashi 4 . 1 Genetic and Molecular Toxicology, 

ILS, Inc., Research Triangle Park, NC, 2 Maronpot 

Consulting LLC, Raleigh, NC, 3 Investigative 

Toxicology, ILS, Inc., Research Triangle Park, NC 

and 4 San-Ei Gen F.F.I., Inc., Osaka, Japan. 

142 






Platform Sessions



Abstract # 


COMPARISON OF TWO DIFFERENT 

TEST PROTOCOLS FOR AN ACCURATE 

ASSESSMENT OF THE IN VITRO 

MICRONUCLEUS TEST IN HUMAN 

LYMPHCYTES. S. Bohnenberger, A. H. Poth, 

C. Hall and W. Voelkner. Genetic and Alternative 

Toxicology, Harlan Cytotest Cell Research GmbH, 

Rossdorf, Germany. 


TOXICOLOGICAL EVALUATION OF 

COMPLEX MIXTURES FROM RESIDUES 

USED ON AGRICULTURAL LAND 

APPLICATION. A. Pillco 1,2 , E. de la Peña 1 and 

M. Hazen 3 . 1 Centro de Ciencias Medioambientales, 

Consejo Superior de Investigaciones Científicas, 

Madrid, Spain, 2 Facultad de Bioquímica, Universidad 

Mayor de San Andrés, La Paz, Bolivia and 

3 

Departamento de Biología, Universidad Autónoma 

de Madrid, Madrid, Spain. Sponsor: E. Vilanova. 


CYTOTOXIC AND GENOTOXIC EFFECTS 

OF MAGNETITE ON HUMAN A549 LUNG 

CELLS IN VITRO–INFLUENCE OF ROS, 

JNK, AND NF-κB. M. Könczöl 1 , V. Mersch- 

Sundermann 1 , S. Ebeling 2 , E. Goldenberg 3 , B. 

Grobéty 4 , R. Gieré 3 , I. Merfort 2 , B. Rothen- 

Rutishauser 5 and R. Gminski 1 . 1 Department of 

Environmental Health Sciences, University Medical 

Center Freiburg, Freiburg, Germany, 2 Department 

of Pharmaceutical Biology, University Freiburg, 

Freiburg, Germany, 3 Department of Geosciences, 

University Freiburg, Freiburg, Germany, 4 Institute 

of Geosciences, University Fribourg, Fribourg, 

Switzerland and 5 Institute of Anatomy, University 

Bern, Bern, Switzerland. Sponsor: J. Pauluhn. 


THE PROTECTIVE EFFECT OF TROLOX 

AND RESVERATROL ON DNA DAMAGE 

INDUCED BY CYCLOPHOSPHAMIDE AND 

TAMOXIFEN IN HUMAN LEUKOCYTES. 

R. Naravaneni, S. Sharma, D. Bhaumick and R. D. 

Mehta. Genetic Toxicology, PBR Laboratories Inc., 



EVALUATION OF THE GENOTOXICITY 

OF 1, 2-DICHLOROETHANE (EDC). D. 

O. Johns 2 , M. R. Gwinn 1 , T. F. Bateson 1 and K. Z. 

Guyton 1 . 1 Office of Research & Development, U.S. 

EPA, Washington, D.C. and 2 Office of Research & 

Development, U.S. EPA, Research Triangle Park, 

NC. 


INTEGRATION OF PIG-A, MICRONUCLEUS, 

CHROMOSOME ABERRATION, AND 

COMET ASSAY ENDPOINTS INTO 

RODENT TOXICITY STUDIES WITH 

4-NITROQUINOLINE-1-OXIDE (4NQO): 

EFFECT OF DOSE FRACTIONATION ON 

GENOTOXIC RESPONSES. L. F. Stankowski, 

D. J. Roberts, H. Chen, T. E. Lawlor, M. McKeon, H. 

Murli, A. Thakur and Y. Xu. Covance Laboratories, 

Inc., Vienna, VA. 

Abstract # 


CASE STUDY ON DOSE-RESPONSES FOR 

MUTAGENICITY AND CLASTOGENICITY 

INDUCED BY DNA-REACTIVE 

CHEMICALS. L. H. Pottenger 1 , M. M. Moore 2 , T. 

Zhou 3 and E. Zeiger 4 . 1 The Dow Chemical Company, 

Midland, MI, 2 U.S. FDA NCTR, Jefferson, AR, 

3 

U.S. FDA/CVM, Rockville, MD and 4 Errol Zeiger 

Consulting, Chapel Hill, NC. 


HIGH-THROUGHPUT IN VITRO 

MICRONUCLEUS ASSAY: AUTOMATED 

SCORING OF 384-WELL PLATES. S. Bryce, 

S. Avlasevich and S. Dertinger. Litron Laboratories, 

Rochester, NY. 


PHOTO-CLASTOGENICITY TESTING 

IN HUMAN PERIPHERAL BLOOD 

LYMPHOCYTES. S. Roy, H. Murli, M. Chan, 

L. F. Stankowski Jr. and T. Lawlor. Genetic & 

Molecular Toxicology, Covance Laboratories Inc., 

Vienna, VA. Sponsor: M. McKeon. 


PCB3 METABOLITES INDUCE SPINDLE 

ABERRATIONS AND REDUCE TUBULIN 

POLYMERIZATION. S. Flor and G. Ludewig. 

University of Iowa, Iowa City, IA. 


EVALUATION OF THE GENOTOXICITY 

AND MUTAGENICITY OF THE DYE 

REACTIVE ORANGE 16. G. R. Oliveira 1 , M. 

B. Zanoni 2 and D. P. Oliveira 1 . 1 Departamento de 

Análises Clínicas, Toxicológicas e Bromatológicas, 

Faculdade de Ciências Farmacêuticas de Ribeirão 

Preto - FCFRP/USP, Ribeirão Preto, São Paulo, 

Brazil and 2 Departamento de Química Analítica, 

Instituto de Química - UNESP, Araraquara, São 

Paulo, Brazil. 


COMPARISON OF ANEUPLOIDIES OF 

CHROMOSOMES X, Y, AND 21 IN THE 

PERIPHERAL BLOOD LYMPHOCYTES AND 

SPERM CELLS OF WORKERS EXPOSED TO 

BENZENE. Z. Ji 1 , R. H. Weldon 1 , F. Marchetti 2 , H. 

Chen 1 , G. Li 3 , C. Xing 2,3 , E. Kurtovich 1 , S. Young 1 , 

T. E. Schmid 2 , S. Waidyanatha 4 , S. Rappaport 1 , A. J. 

Wyrobek 2 , L. Zhang 1 and B. Eskenazi 1 . 1 School of 

Public Health, University of California at Berkeley, 

Berkeley, CA, 2 Life Sciences Division, Lawrence 

Berkeley National Laboratory, Berkeley, CA, 3 China 

CDC, Beijing, China and 4 National Toxicology 

Program, NIEHS, Research Triangle Park, NC. 


IN VITRO GENOTOXIC MECHANISMS 

OF ARSENIC TRIOXIDE IN HUMAN 

HEPATOCELLULAR CARCINOMA (HEPG2) 

CELLS: INVOLVEMENT IN OXIDATIVE 

STRESS. E. T. Brown, C. G. Yedjou and P. B. 

Tchounwou. Jackson State University, Jackson, MS. 

MONday 







143



MONday 



EFFICIENT SCORING OF MICRONUCLEI 

AND CELL CYCLE STATUS IN THE 

RECONSTRUCTED SKIN MICRONUCLEUS 

(RSMN) ASSAY USING FLOW CYTOMETRY. 

M. Crosby 1 , E. Dahl 2 , S. Bryce 3 , A. Allemang 1 , 

S. Brown 1 and S. Pfuhler 1 . 1 Procter & Gamble 

Company, Cincinnati, OH, 2 Institute for In 

Vitro Sciences, Gaithersburg, MD and 3 Litron 

Laboratories, Rochester, NY. 


NEXT GENERATION DEL ASSAY: RAPID 

AND ACCURATE ASSESSMENT OF 

TOXICITY. Y. Rivina and R. H. Schiestl. 


California, Los Angeles, Los Angeles, CA. 


THE RECONSTRUCTED SKIN COMET 

ASSAY SHOWS GOOD INTRA- AND INTER- 

LABORATORY REPRODUCIBILITY: 

RESULTS FROM THREE LABORATORIES. 

T. Downs 1 , A. Reus 2 , K. Reisinger 3 , C. Krul 2 and S. 

Pfuhler 1 . 1 Procter & Gamble Company, Cincinnati, 

OH, 2 TNO Quality of Life, Zeist, Netherlands and 

3 

Henkel AG & Co KgaA, Düsseldorf, Germany. 

Sponsor: G. Daston. 


CHLORPYRIFOS DOES NOT INDUCE 

RAT BRAIN DNA DAMAGE OR BONE 

MARROW MICRONUCLEUS FORMATION 

IN A MICRONUCLEUS AND COMET 

COMBINATION ASSAY. Y. Xu, K. Carl and L. 

Timothy. Covance, Vienna, VA. 


GENOTOXICITY TESTING USING THE 

MICRONUCLEUS AND COMET ASSAYS 

IN NORMAL HUMAN CELL BASED 3D 

EPITHELIAL MODELS. J. DeLuca, Y. 

Kaluzhny, P. J. Hayden, A. Armento, V. Karetsky and 

M. Klausner. MatTek Corp, Ashland, MA. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Receptor and Receptor-Mediated Toxicity 

Chairperson(s): Angela Slitt, University of Rhode Island, Kingston, RI. 




COLOCALIZATION OF CANNABINOID 

RECEPTOR SUBTYPES IN CULTURED 

RAT CORTICAL ASTROGLIAL CELLS. J. 

A. Torres 1,2 and A. Shivachar 2 . 1 Environmental 

Toxicology, Texas Southern University, Houston, 

TX and 2 College of Pharmacy and Health Sciences, 

Texas Southern University, Houston, TX. 


PEROXISOME PROLIFERATOR 

ACTIVATED RECEPTOR γ IS 

ACTIVATED BY 15-DEOXY-PGJ 2 

-G, 

A PUTATIVE METABOLITE OF THE 

ENDOCANNABINOID, 2-ARACHIDONYL 

GLYCEROL. P. Raman 1,2 , B. Kaplan 1,2 , J. 

Thompson 3 , J. Vanden Heuvel 3 and N. Kaminski 1,2 . 

1 

Pharmacology & Toxicology, Michigan State 



MI and 3 Veterinary Science & Biomedical Sciences, 

Center for Molecular Toxicology and Carcinogenesis, 

Pennsylvania State University, University Park, PA. 


PHARMACOLOGICAL STUDY OF 

SEROTONIN AND DOPAMINE POST- 

SYNAPTIC RECEPTORS OF THE LATERAL 

CILIATED CELLS OF THE GILL AND 

VISCERAL GANGLIA OF CRASSOSTREA 

VIRGINICA. C. Brown, Z. Bandaogo, E. J. 

Catapane, M. A. Carroll, A. Hernandez and D. 

Adebesin. Biology, Medgar Evers College, Brooklyn, 

NY. 


SPECIFIC AMINO ACID RESIDUES 

WITHIN THE LIGAND BINDING DOMAIN 

CONFER LOW RESPONSIVENESS TO 2, 3, 

7, 8-TETRACHLORODIBENZO-P-DIOXIN 

(TCDD) TO AN ARYL HYDROCARBON 

RECEPTOR (AHR) FROM THE FROG 

XENOPUS LAEVIS. C. Odio 1 , S. A. Holzman 1 , M. 

S. Denison 2 , L. Bonati 3 and W. H. Powell 1 . 1 Biology, 

Kenyon College, Gambier, OH, 2 Environmental 

Toxicology, University of California Davis, Davis, 

CA and 3 Scienze dell’Ambiente e del Territorio, 

Universita` degli Studi di Milano-Bicocca, Milano, 

Italy. 


THE NOVEL DAPHNIA NUCLEAR 

RECEPTOR, HR97G, IS ACTIVATED BY 

JUVENILE HORMONE ANALOGS. G. 

Ginjupalli 2 , Y. Li 2 and W. S. Baldwin 2,1 . 1 Biological 

Sciences, Clemson University, Clemson, SC and 

2 

Environmental Toxicology Program, Clemson 

University, Clemson, SC. 


LIGAND-ACTIVATED AHR ALTERS 

THE EXPRESSION OF GENES IN THE 

HUMAN EPIDERMAL DIFFERENTIATION 

COMPLEX. C. H. Sutter, S. Bodreddigari, 

C. Campion, R. Wible and T. Sutter. Biological 

Sciences, University of Memphis, Memphis, TN. 


ACTIVATING PKCβ1 AT THE BLOOD- 

BRAIN BARRIER (BBB) REVERSES 

INDUCTION OF P-GLYCOPROTEIN (PGP) 

ACTIVITY BY DIOXIN AND RESTORES 

DRUG DELIVERY TO THE CNS. X. 

Wang, B. Hawkins and D. Miller. Laboratory of 

Toxicology and Pharmacology, National Institute of 


Park, NC. 

144 






Platform Sessions



Abstract # 



ANTAGONISTS INHIBIT ADIPOCYTE- 

BREAST CANCER CELL INTERACTIONS. 

T. Salisbury, R. Jones, M. Hodge, K. Geronilla 

and N. Santanam. Marshall University School of 

Medicine, Huntington, WV. Sponsor: M. Valentovic. 


DUAL PPAR/RXR AGONIST TRIBUTYLTIN 

UNIQUELY IMPACTS BONE INTEGRITY 

AND MARROW MICROENVIRONMENT. 

A. H. Baker 1 , B. D. Meeks 2 , K. K. Mann 3 , L. C. 

Gerstenfeld 2 and J. J. Schlezinger 4 . 1 Medicine, 

Boston University, Boston, MA, 2 Orthopedic 

Surgery, Boston University, Boston, MA, 3 Oncology, 

McGill University, Montréal, QC, Canada and 

4 

Environmental Health, Boston University, Boston, 

MA. 


MOLECULAR AND FUNCTIONAL 

CHARACTERIZATION OF ARYL 

HYDROCARBON RECEPTOR REPRESSOR 

(AHRR) FROM THE CHICKEN (GALLUS 

GALLUS). H. Iwata 1 , J. Lee 1 , E. Kim 2 and K. 

Nomaru 1 . 1 Center for Marine Environmental 

Studies, Ehime University, Matsuyama, Japan 

and 2 Department of Life and Nanopharmaceutical 

Science and Department of Biology, Kyung Hee 



STABLE OVER-EXPRESSION OF PPAR/ 

AND PPAR TO EXAMINE RECEPTOR 

SIGNALING IN HUMAN HaCaT 

KERATINOCYTES. P. S. Palkar 1 , M. G. 

Borland 1 , C. Khozoie 1 , B. Zhu 1 , C. Lee 1 , F. J. 

Gonzalez 2 and J. M. Peters 1 . 1 Veterinary Sciences, 

Pennsylvania State University, State College, PA 

and 2 Laboratory of Metabolism, National Cancer 

Institute, Bethesda, MD. 


PPAR/MODULATES AHR SIGNALING IN 

MOUSE AND HUMAN KERATINOCYTES. J. 

Morales 1 , M. G. Borland 1 , C. Lee 1 , F. J. Gonzalez 2 

and J. M. Peters 1 . 1 Department of Veterinary and 

Biomedical Sciences, The Pennsylvania State 

University, University Park, PA and 2 Laboratory of 

Metabolism, National Cancer Institute, Bethesda, 

MD. 


ROLE OF 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN- 

INDUCIBLE POLY(ADP-RIBOSE) 

POLYMERASE IN DIOXIN-INDUCED ARYL 

HYDROCARBON RECEPTOR SIGNALING. 

L. M. MacPherson and J. Matthews. Pharmacology 

and Toxicology, University of Toronto, Toronto, ON, 

Canada. 


PPARβ/δ INHIBITS VIRAL HRAS1 

(V-HRAS1)-INDUCED NEOPLASTIC/ 

MALIGNANT TRANSFORMATION OF 

MOUSE PRIMARY KERATINOCYTES. B. 

Zhu 1 , C. Khozoie 1 , M. T. Bility 1 , N. Blazanin 1 , A. B. 

Glick 1 , F. J. Gonzalez 2 and J. M. Peters 1 . 1 Molecular 

Toxicology, University Park, PA and 2 Laboratory of 


MD. 

Abstract # 


CHARACTERIZATION OF 

GENOME-WIDE PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR-/ 

(PPAR/) BINDING AND TRANSCRIPTIONAL 

REGULATION. C. Khozoie 1 , M. G. Borland 1 , B. 

Zhu 1 , F. J. Gonzalez 2 and J. M. Peters 1 . 1 Department 

of Veterinary and Biomedical Sciences and The 

Center for Molecular Toxicology and Carcinogenesis, 

The Pennsylvania State University, University Park, 

PA and 2 Laboratory of Metabolism, National Cancer 



FUNCTIONAL CHARACTERIZATION 

OF PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-/(PPAR/) 

EXPRESSION IN COLON CANCER. J. 

E. Foreman 1 , W. Chang 2 , J. L. Williams 3 , M. 

L. Clapper 2 , F. J. Gonzalez 4 and J. M. Peters 1 . 

1 

Department of Veterinary and Biomedical Sciences 

and The Center for Molecular Toxicology and 

Carcinogenesis, Pennsylvania State University, 

University Park, PA, 2 Cancer Prevention and Control 

Program, Fox Chase Cancer Center, Philadelphia, 

PA, 3 Cancer Prevention Laboratory, State University 

of New York at Stony Brook, Stony Brook, NY 

and 4 Laboratory of Metabolism, National Cancer 



REDEFINING ARYL HYDROCARBON 

RECEPTOR ANTAGONISM THROUGH 

CHARACTERIZATION OF A NEW LIGAND. 

K. J. Smith 1 , I. A. Murray 1 , R. Tanos 1 , Y. Wang 2 , J. 

E. Tellew 2 , A. E. Boitano 2 , M. P. Cooke 2 and G. H. 

Perdew 1 . 1 Pennsylvania State University, University 

Park, PA and 2 Genomics Institute of the Novartis 

Foundation, San Diego, CA. 


COMPARISON OF EFFECTS OF 

DIFFERENT LIGANDS AND Y322 ON ARYL 

HYDROCARBON RECEPTOR SIGNALING. 

M. L. Powis, T. Celius and J. Matthews. Department 

of Pharmacology and Toxicology, University of 

Toronto, Toronto, ON, Canada. 


IMMUNOMODULATORY EFFECT OF 


ANTAGONISM ALTERS INFLAMMATORY 

PHENOTYPE IN HFLS-RA CELLS. T. S. 

Lahoti, I. A. Murray and G. H. Perdew. Veterinary 

Sciences, The Pennsylvania State University, 

University Park, PA. 


AH RECEPTOR ANTAGONIST TREATMENT 

CAN ALTER THE AGGRESSIVE 

PHENOTYPE OF HEAD AND NECK 

SQUAMOUS CELL CARCINOMA CELL 

LINES. B. DiNatale and G. H. Perdew. 


MONday 







145



MONday 



ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN INFLAMMATORY BOWEL 

DISEASES. H. Swanson 1 , V. Arsenescu 2 , E. Choi 1 , 

R. Dingle 1 and R. Arsenescu 3 . 1 Department of 

Molecular and Biomedical Pharmacology, University 

of Kentucky, Lexington, KY, 2 Graduate Center 

for Nutritional Sciences, University of Kentucky, 

Lexington, KY and 3 Digestive Diseases and 

Nutrition, University of Kentucky, Lexington, KY. 


MULTIPLE INTRACELLULAR SIGNAL 

MODULATORS AS EFFECTORS OF HUMAN 

CONSTITUTIVE ANDROSTANE RECEPTOR 

ACTIVATION. T. Chen, E. M. Laurenzana and 

C. J. Omiecinski. Center for Molecular Toxicology, 

Penn State University, University Park, PA. 


CONSTRUCTING A PPARα-MEDIATED 

TRANSCRIPTIONAL NETWORK 

IN PRIMARY HUMAN AND RAT 

HEPATOCYTES. C. G. Woods 1 , K. M. 

Yarborough 1 , L. J. Pluta 1 , J. Pi 2 , R. S. Thomas 1 

and M. E. Andersen 1 . 1 Computational Biology, The 

Hamner Institutes for Health Sciences, Research 

Triangle Park, NC and 2 Translational Biology, The 




MODE OF ACTION (MOA) AND DOSE- 

RESPONSE APPROACHES FOR NUCLEAR 

RECEPTORS. D. Schrenk 5 , R. Budinsky 1 , J. 

Corton 3 , C. Elcombe 2 , J. Klaunig 4 and D. Wolf 3 . 

1 

Dow, Midland, MI, 2 CRX Bioscience, Dundee, 

Scotland, United Kingdom, 3 U.S. EPA, Research 

Triangle Park, NC, 4 Indiana University, Indianapolis, 

IN and 5 University of Kaiserslautern, Kaiserslautern, 

Germany. 


TESTING STRUCTURE-BINDING 

PREDICTIONS FROM COMPARATIVE 

MODELING OF THE AHR LIGAND- 

BINDING DOMAIN: STUDIES WITH 

ZEBRAFISH AHR1a. S. I. Karchner 1 , D. G. 

Franks 1 , A. Pandini 3 , A. A. Soshilov 2 , L. Bonati 3 , 

M. S. Denison 2 and M. E. Hahn 1 . 1 Woods Hole 

Oceanographic Institution, Woods Hole, MA, 

2 

University of California Davis, CA and 3 Universita’ 

degli Studi di Milano-Bicocca, Milan, Italy. 


DISCOVERING TRANSCRIPTIONAL 

REGULATORS OF CYTOCHROME P450 1A 

THROUGH SIRNA HIGH-THROUGHPUT 

SCREENINGS. P. Solaimani 1 , O. Hankinson 1 

and R. Damoiseaux 2 . 1 Molecular Toxicology 

IDP, University of California Los Angeles, Los 

Angeles, CA and 2 California NanoSystems Institute, 

University of California Los Angeles, Los Angeles, 

CA. 


EPITHELIAL REGULATION OF 

PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR γ BY CHEMICAL 

RIBOSOME-INACTIVATING STRESS. S. 

Park, H. Choi, H. Yang and Y. Moon. Department 

of Microbiology and Immunology, Pusan National 

University School of Medicine and Medical Research 

institute, Yangsan, Republic of Korea. 


FOXA1 IS ESSENTIAL FOR THE AHR- 

DEPENDENT REGULATION OF CYCLIN 

G2. S. Ahmed, S. Al-Saigh and J. Matthews. 

Pharmacology & Toxicology, University of Toronto, 

Toronto, ON, Canada. 


DIVERGENT ROLES FOR THE ARYL 

HYDROCARBON RECEPTOR AND ARYL 

HYDROCARBON RECEPTOR NUCLEAR 

TRANSLOCATOR IN ESTROGEN 

SIGNALING. M. P. Labrecque 1 , K. J. Tam 1 , B. D. 

Hollingshead 2 , G. G. Prefontaine 1 , G. H. Perdew 2 

and T. V. Beischlag 1 . 1 Faculty of Health Sciences, 

Simon Fraser University, Burnaby, BC, Canada 

and 2 Veterinary and Biomedical Sciences, The 




INTERACTS WITH ATP5α1, A SUBUNIT 

OF THE ATP SYNTHASE COMPLEX, 

AND MODULATES MITOCHONDRIAL 

FUNCTION. D. M. Tappenden 1,2 , S. Lynn 1,2 , R. 

B. Crawford 3 , N. E. Kamniski 2,3 , R. S. Thomas 4 

and J. J. LaPres 1,2 . 1 Biochemistry, Michigan State 



MI, 3 Department of Pharmacology and Toxicology, 

Michigan State University, East Lansing, MI and 

4 

The Hamner Institutes for Health Sciences, Research 



REGULATION OF CHOLESTEROL 

BIOSYNTHETIC GENE EXPRESSION 

BY AH RECEPTOR THROUGH A DNA- 

INDEPENDENT MECHANISM. R. Tanos, R. 

D. Patel and G. H. Perdew. Penn State University, 



MULTI-SPECIES ANALYSES OF DIRECT 

ACTIVATORS OF THE CONSTITUTIVE 

ANDROSTANE RECEPTOR. C. Omiecinski 1 , 

D. M. Coslo 1 , T. Chen 1 and R. C. Peffer 2 . 1 Center 

for Molecular Toxicology, Penn State University, 

University Park, PA and 2 Syngenta Crop Protection, 

Inc., Greensboro, NC. 


A FUNCTIONAL CROSSTALK BETWEEN 

CAR AND LXR LINKS XENOBIOTIC 

RESPONSE AND LIPOGENESIS. W. Xie, 

T. Wada and Y. Zhai. University of Pittsburgh, 


146 






Platform Sessions



Abstract # 


SPECIES-DEPENDENT AND RECEPTOR- 

SELECTIVE EFFECT OF BILOBALIDE 

ON THE ACTIVITY OF CONSTITUTIVE 

ANDROSTANE RECEPTOR AND 

PREGNANE X RECEPTOR. A. Lau 1 , G. Yang 1 , 

G. Rajaraman 2 , C. C. Baucom 3 and T. K. Chang 1 . 

1 

Faculty of Pharmaceutical Sciences, The University 

of British Columbia, Vancouver, BC, Canada, 

2 

CellzDirect - Life Technologies, Austin, TX and 

3 

CellzDirect - Life Technologies, Durham, NC. 


THE HUMAN XENORECEPTOR CAR AND 

ITS NATURALLY-OCCURRING SPLICE 

VARIANTS DISPLAY DIFFERENTIAL 

PROTEIN-PROTEIN INTERACTIONS WITH 

RXRα AND SRC1. E. M. Laurenzana and C. 

J. Omiecinski. Center for Molecular Toxicology 

and Carcinogenesis, Department of Veterinary and 

Biomedical Sciences, Pennsylvania State University, 



EFFECTS OF TRICLOSAN ON CELL 

PROLIFERATION AND PPARα ACTIVATION 

IN MOUSE AND HUMAN CELLS. Q. Wu, F. 

A. Beland and J. Fang. Division of Biochemical 




9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Cell Signaling and Gene Regulation 

Chairperson(s): Joseph Landolph, University of Southern California, Los 

Angeles, CA. 




GLOBAL PANCREATIC GENE EXPRESSION 

ANALYSIS OF FISHER-344 MALE 

RATS INDICATES SLC2A4 (GLUCOSE 

TRANSPORTER) GENE TO PLAY 

IMPORTANT ROLE IN THE TOXICITY 

EFFECTS OF 2-AMINOANTHRACENE 

EXPOSURE. W. E. Gato and J. C. Means. 

Chemistry&Biochemistry, Southern Illinois 

University Carbondale, Carbondale, IL. 


EFFECTS OF RIFAMPIN ON DRUG 

METABOLIZING ENZYME AND 

TRANSPORTER GENE EXPRESSION 

IN HUMAN HEPATOCYTES. Q. Yang, U. 

Doshi and A. P. Li. In Vitro ADMET Laboratories, 

Advanced Pharmaceutical Sciences, Columbia, MD. 


MICROTUBULE ACETYLATION 

ENHANCES BINDING AND 

INTRACELLULAR TRAFFICKING OF 

PLASMID DNA IN GENE TRANSFER. M. A. 

Badding and D. A. Dean. Pediatrics, University of 

Rochester Medical Center, Rochester, NY. Sponsor: 

B. Lawerence. 

Abstract # 


INHIBITION OF A549 LUNG CANCER CELL 

MIGRATION BY PRECURSOR LET-7G 

MICRORNA. S. Park, A. Minai Tehrani and M. 

Cho. Laboratory of Toxicology, College of Veterinary 

Medicine, Seoul National University, Seoul, 



ELUCIDATING THE CONSTITUTIVE 

ACTIVITY OF THE HUMAN TNIP1 

PROMOTER. P. C. Encarnacao, C. Zhang and 

B. J. Aneskievich. Pharmacology/Toxicology, 

University of Connecticut, Storrs, CT. 


GESTATIONAL UDP- 

GLUCURONOSYLTRANSFERASE 1A GENE 

REGULATION IS CONTROLLED BY THE 

PREGNANE X RECEPTOR. S. Chen and R. H. 

Tukey. Pharmacology, University of California San 

Diego, La Jolla, CA. 


BREAST MILK SUPPRESSES UDP- 

GLUCURONOSYLTRANSFERASE 1A1 GENE 

EXPRESSION IN THE GASTROINTESTINAL 

TRACT AND INCREASES THE RISK FOR 

SEVERE HYPERBILIRUBINEMIA AND 

BRAIN DAMAGE. R. Fujiwara, S. Chen and R. H. 

Tukey. Pharmacology, University of California San 

Diego, La Jolla, CA. 


TRANSCRIPTOMIC ANALYSIS 

REVEALS MECHANISM UNDERLYING 

THE OFF-TARGET EFFECT OF THE 

CHOLESTERYL-ESTER TRANSFER 

PROTEIN INHIBITOR TORCETRAPIB. J. 

Hoflack, N. Flint, M. Haiker, A. Stauffer, L. Suter- 

Dick, A. Roth, T. Weiser, T. Singer, L. Müller, E. 

J. Niesor and R. G. Clerc. F Hoffmann La Roche, 

Basel, Switzerland. 


TRANSCRIPTIONAL INDUCTION OF 

GLUTATHION S-TRANSFERASE BY 

CHLORPYRIFOS IN HEPG2 CELLS. I. M. 

Medina 1 , M. C. Martinez 1 , M. Rubio 1 , A. E. Rojas 1 , 

M. L. Robledo 1 , M. I. Giron 1 and G. Elizondo 2 . 

1 

Secretaria de Investigacion y Posgrado, Universidad 

Autonoma de Nayarit, Tepic, Nayarit, Mexico and 

2 

bDepartamento de Biología Celular, Centro de 

Investigación y de Estudios Avanzados del IPN, 

Mexico, DF, Mexico. Sponsor: B. Quintanilla. 


IDENTIFICATION OF TRANSCRIPTIONAL 

REGULATORS OF C. ELEGANS 

METALLOTHIONEIN GENE EXPRESSION. 

J. Hall and J. H. Freedman. NIEHS, Durham, NC. 


ANILINE-INDUCED CELL CYCLE 

PROGRESSION OF SPLENOCYTES: 

RESPONSE OF CYCLINS AND CYCLIN- 

DEPENDENT KINASES IN G1/S AND G2/M 

PHASES. J. Wang, G. Wang and M. Khan. 

University of Texas Medical Branch, Galveston, TX. 

MONday 







147



MONday 



ENHANCED PDE4B EXPRESSION 

AUGMENTS LPS-INDUCIBLE TNF-α 

IN GLUCOSE-PRIMED MONOCYTES: 

A POTENTIAL PATHOGENIC ROLE 

FOR PHOSPHODIESTERASES (PDES) 

IN THE DEVELOPMENT OF DIABETIC 

COMPLICATIONS. E. Chambers 1 , L. 

Gobejishvili 1 , S. Joshi-Barve 1 , C. McClain 1,2 and S. 

Barve 1 . 1 Department of Medicine/GI, University of 

Louisville, Louisville, KY and 2 Robley Rex Veterans 

Administration Medical Center, Louisville, KY. 


CURCUMIN EPIGENETICALLY 

REACTIVATES SILENCED TUMOR 

SUPPRESSOR GENE - TISSUE FACTOR 

PATHWAY INHIBITOR-2 AND DECREASES 

CELL SURVIVAL AND INVASIVENESS IN 

HEPATOCELLULAR CARCINOMA CELLS. 

A. Moghe 1 , A. S. Barve 1 , D. Barker 1 , S. Ghare 1 , L. 

Gobejishvili 1 , S. Joshi-Barve 1 , C. McClain 1,2 and S. 





THE HEPATOCYTE AUTONOMOUS CLOCK 

MODULATES THE CHRONOTOXICITY OF 

ACETAMINOPHEN. B. P. Johnson 1 , J. Walisser 1 , 

Y. Liu 1 , A. Shen 1 , E. McDearmon 2 , B. McIntosh 2 , A. 

Schook 2 , J. Takahashi 2 and C. Bradfield 1 . 1 Oncology, 

University of Wisconsin Madison, Madison, WI and 

2 

Northwestern University, Evanston, IL. 


ARSENITE EXPOSURE DOWN-REGULATES 

GLUTAMATE TRANSPORTER EXPRESSION 

IN GLIAL CELLS. Y. Castro-Coronel 1,2 , A. 

Ortega 1 , L. Del Razo 2 and E. Lopez-Bayghen 1 . 

1 

Department Genetica y Biol.Mol., CINVESTAV, 

México, Mexico and 2 Department Toxicología, 

CINVESTAV, México, Mexico. 


DOWN-REGULATION OF TWO HSP 

FAMILIES BY TNIP1 IN HACAT 

KERATINOCYTES. V. P. Ramirez, C. Zhang, 

W. Krueger and B. J. Aneskievich. Department 

of Pharmaceutical Sciences, School of Pharmacy, 



SEXUALLY DIMORPHIC ROLE FOR THE 

CIRCADIAN CLOCK IN MODULATING 

XENOBIOTIC METABOLISM. L. A. 

Hooven, K. Sherman, E. Chow, L. Beaver and J. 

Giebultowicz. Oregon State University, Corvallis, 

OR. 


CHARACTERIZATION OF THE 

PROMOTER-PROXIMAL REGION OF 

HUMAN MULTIDRUG RESISTANCE- 

ASSOCIATED PROTEIN 4 GENE. J. E. 

Manautou and X. Gu. Pharmaceutical Sciences, 



HIGH CONTENT ANALYSIS USING 

REDISTRIBUTION® TECHNOLOGY. A. 

M. Peters, D. Miller, B. Samson and Y. Fedorov. 

Life Science Research - Cellomics, Thermo Fisher 

Scientific, Pittsburgh, PA. Sponsor: J. Haskins. 


ASSESSMENT OF NUCLEAR FACTOR 

KAPPA B (NF-κB) SIGNALING IN THE 

HIPPOCAMPUS DURING KANIC ACID 

EXPOSURE USING TRANSGENIC 

REPORTER MICE. J. A. Miller 1 , R. A. Bialecki 2 

and R. B. Tjalkens 1 . 1 Center for Environmental 

Medicine, Colorado State University, Fort Collins, 

CO and 2 Safety Assessment U.S., AstraZeneca, 



ALTERATIONS OF SIGNALING PROTEIN 

INTERACTIONS IN RESPONSE TO 

INCREASING DOSE. C. Kinzer, H. Williams, X. 

Gao, N. Rubenstein, A. Cook, J. Vrana and J. Boyd. 

Bennett Department of Chemistry, West Virginia 



IMPACT OF ENERGY METABOLISM ON 

THE DESIGN OF KINASE-TARGETED 

THERAPEUTICS. A. Cook, H. Williams, X. Gao 

and J. Boyd. Bennett Department of Chemistry, West 



cAMP-DEPENDENT PATHWAY(S) 

INCREASE P27 KIP -CYCLIN D1 THROUGH 

THE RAP-GTP/B-RAF MAPK SIGNALING 

PATHWAY IN RENAL CANCER. N. 

Mastrandrea, K. Y. Tham, J. D. Cohen, T. J. Monks 

and S. S. Lau. Pharmacology/Toxicology, University 

of Arizona, Tucson, AZ. 


EFFECT OF P, P’-DDE ON JAK2, 

STAT1α, AND NFκB ACTIVATION IN 

MACROPHAGES J774A.1. N. A. Torres- 

Aviles 1 , L. C. Acosta-Saavedra 1 , A. L. Luna 1 , E. K. 

Silbergeld 2 and E. S. Calderon-Aranda 1 . 1 Department 

of Toxicologia, Cinvestav, Mexico, Mexico and 

2 

BSPH, Johns Hopkins University, Baltimore, MD. 


A ROLE FOR STRESS-RESPONSIVE 

SIGNALING IN THE REGULATION OF ERK 

OSCILLATIONS. T. J. Weber 1 , H. Shankaran 2 , K. 

M. Waters 2 , W. B. Chrisler 1 and R. L. Sontag 1 . 1 Cell 

Biology & Biochemistry, PNNL, Richland, WA and 

2 

Computational Biology, PNNL, Richland, WA. 


HARMINE MODULATES DIOXIN- 

INDUCED CYP1A1 ENZYME THROUGH 

TRANSCRIPTIONAL AND POST 

TRANSLATIONAL MECHANISMS. M. El 

Gendy and A. El-Kadi. Faculty of Pharmacy and 

Pharmaceutical Sciences, University of Alberta, 


148 






Platform Sessions



Abstract # 


E7 VIRAL ONCOPROTEIN NEGATIVELY 

INFLUENCES THE TRANSCRIPTIONAL 

ACTIVITY OF THE L1MD 

RETROTRANSPOSON PROMOTER UNDER 

CONDITIONS OF CELLULAR STRESS. 

D. E. Montoya-Durango 1,2 and K. S. Ramos 1,2 . 

1 

Biochemistry and Molecular Biology, University of 

Louisville, Louisville, KY and 2 Center for Genetics 

and Molecular Medicine, University of Louisville, 



NEOPLASTIC LUNG CELL 

PROLIFERATION, STIMULATED BY 

ALVEOLAR MACROPHAGE-DERIVED 

IGF-1, CAN BE ABROGATED BY THE 

COMBINED INHIBITION OF MEK AND 

PI3K. J. M. Fritz, L. D. Dwyer-Nield and A. M. 

Malkinson. Department of Pharmaceutical Sciences, 

University of Colorado Denver, Aurora, CO. 


MASS SPECTROMETRY TECHNIQUES TO 

STUDY PROTEIN-LIGAND INTERACTIONS 

AND MOLECULAR TOXICOLOGY 

PATHWAYS. K. E. Yamada 1,2 , C. M. Ryan 3 , J. 

P. Whitelegge 3 and C. D. Eckhert 1,2 . 1 Molecular 

Toxicology IDP, University of California Los 

Angeles, Los Angeles, CA, 2 Environmental Health 

Sciences, University of California Los Angeles, Los 

Angeles, CA and 3 The Pasarow Mass Spectrometry 

Laboratory, The NPI-Semel Institute, David Geffen 

School of Medicine, University of California Los 

Angeles, Los Angeles, CA. 


DICLOFENAC INHIBITS TNF-INDUCED 

NF-B NUCLEAR SHUTTLING CAUSING 

SYNERGISTIC HEPATOCYTE APOPTOSIS 

VIA CASPASE-8. L. Fredriksson, B. Herpers, Z. 

Di and B. van de Water. Toxicology, LACDR, Leiden 

University, Leiden, Netherlands. 


NRF2B: A NOVEL NRF2 PARALOG IN 

ZEBRAFISH. A. R. Timme-Laragy 1 , S. I. 

Karchner 1 , D. G. Franks 1 , M. J. Jenny 2 and M. 

E. Hahn 1 . 1 Biology, Woods Hole Oceanographic 

Institution, Woods Hole, MA and 2 University of 

Alabama, Tuscaloosa, AL. 


CRITICAL CYSTEINE RESIDUES OF 

KEAP1 IN SUPPRESSION OF NRF2 BASAL 

ACTIVITY AND ARSENIC-SENSING BY 

REGULATING THE UBIQUITINATION- 

PROTEASOMAL DEGRADATION OF NRF2 

PROTEIN. X. He 1 and Q. Ma 1,2 . 1 Receptor Biology 

Lab. /TMBB/HELD, NIOSH, Morgantown, WV and 

2 

Biochemistry, West Virginia University, School of 

Medicine, Morgantown, WV. 

Abstract # 


THE KEAP1-NRF2 SYSTEM REGULATES 

METALLOTHIONEIN EXPRESSION AND 

PROTECTS VASCULAR ENDOTHELIAL 

CELLS FROM CADMIUM CYTOTOXICITY. 

Y. Shinkai 1 , Y. Kumagai 1 , T. Kimura 2 , C. Yamamoto 3 , 

M. Yamamoto 4 , H. Jinno 5 , T. Tanaka-Kagawa 5 and T. 

Kaji 6 . 1 Graduate School of Comprehensive Human 

Sciences, University of Tsukuba, Tsukuba, Japan, 

2 

Faculty of Pharmaceutical Sciences, Setsunan 

University, Osaka, Japan, 3 Faculty of Pharmaceutical 

Sciences, Hokuriku University, Kanazawa, Japan, 

4 

Graduate School of Medicine, Tohoku University, 

Sendai, Japan, 5 Division of Environmental 

Chemistry, National Institute of Health Sciences, 

Tokyo, Japan and 6 Faculty of Pharmaceutical 

Sciences, Tokyo University of Science, Noda, Japan. 

Sponsor: A. Naganuma. 


MECHANISTIC INVOLVEMENT OF THE 

NRF2/KEAP1 ANTI-OXIDANT RESPONSE 

IN THE REGULATION OF HUMAN ABCC3. 

M. D. Merrell 1 , M. J. Canet 1 , F. Zhao 1 , T. Wu 1 , J. 

M. Maher 2 and N. J. Cherrington 1 . 1 Pharmacology 

and Toxicology, University of Arizona, Tucson, AZ 

and 2 Department of Medical Biochemistry, Tohoku 

University, Sendai, Japan. 


ATTENUATION OF THE NRF2 SIGNALING 

PATHWAY IN HEPATOCYTES LACKING 

SIRTUIN 1 (SIRT1). W. Wei 1 , J. Xu 1 , S. Kulkarni 1 , 

X. Li 2 and A. Slitt 1 . 1 BPS, University of Rhode 

Island, Kingston, RI and 2 National Institute of 


Park, NC. 


RESPONSE OF NRF2-MODULATED GENES 

TO CIGARETTE SMOKE. B. Kosmider, E. 

Messier, H. Chu and R. J. Mason. National Jewish 

Health, Denver, CO. 


INDIRUBIN-3’-(2, 3 DIHYDROXYPROPYL)- 

OXIMETHER (E804) IS A POTENT 

AHR-AGONIST AND MODULATOR OF 

INFLAMMATION PROFILES IN LPS- 

TREATED RAW264.7 MACROPHAGES. A. 

S. Babcock and C. D. Rice. Biological Sciences, 

Clemson University, Clemson, SC. 


10:30 AM to 11:30 AM 

Room 156 

Exhibitor Hosted Session: First in Human Monoclonal 

Antibody Development Strategies for the Treatment of 

Cancer Patients 

Presented by: Huntingdon Life Sciences 

Monoclonal antibodies have demonstrated to provide huge healthcare 

benefits in treatment of cancer. Designing and performing the optimal IND 

enabling nonclinical safety package is very important. Some non-standard 

approaches are discussed which highlight the need for focus upon the pathophysiology 

of disease, the biology of the drug target and the risks that need 

to be considered with drug intervention. 

MONday 







149



MONday 



10:30 AM to 11:30 AM 

Room 140B 

Exhibitor Hosted Session: From Guidelines to Protocol: 

Lessons from EDSP Validation 

Presented by: Harlan Laboratories, Inc. 

This session will discuss the challenges faced in developing laboratory test 

protocols from the original OPPTS guidelines that were issued, as well as 

the final resolution of those challenges. A summary of validation data will 

be presented along with a perspective on interpreting results obtained from 

the assays. 


11:00 AM to 11:45 AM 

Room 102 

Undergraduate Education Program Wrap Up 



11:45 AM to 12:45 PM 

Room 156 

Exhibitor Hosted Session: Urine and Blood Based Biomarkers 

for Detecting Nephrotoxicity 

Presented by: Rules-Based Medicine 

Hear the pertinent facts from a recent set of publications by the Predictive 

Safety Testing Consortium (PSTC) Nephrotoxicity Working Group on qualifying 

a panel of seven biomarkers for preclinical studies of nephrotoxicity. 

Data demonstrating the utility of the biomarkers for human kidney injury 

will also be presented. 

Sponsor: 


The Monday Undergraduate Education Program events are for those 

undergraduate students and advisors receiving SOT travel funding and 

SOT program volunteers. Full program details can be found on pages 

85–86. 


11:45 AM to 12:45 PM 

Room 140B 

Exhibitor Hosted Session: Knockout Rats As More Effective 

Preclinical Models 

Presented by: Sigma Life Science 

Knockout models for disease have been limited mostly to mice, which 

may not accurately reflect the physiology in humans. Advances in genetic 

engineering have extended the species available, enabling the creation of 

targeted knock-outs in rats, rabbits, zebrafish, and swine. An expert panel 

will discuss genetic engineering technologies used to develop more relevant 

translational animal models. 


11:45 AM to 12:45 PM 

Room 140A 

Exhibitor Hosted Session: Nonclinical Evaluation of Drug- 

Abuse Liability 

Presented by: Porsolt & Partners Pharmacology 

Evaluation of abuse liability is currently a major topic in drug safety. Recent 

documents from European and U.S. authorities provide guidance as to how 

to address this issue but many issues remain. This session will explore this 

topic from the point of view of pharma companies, regulatory agencies, and 

CROs. 

150 






Platform Sessions



Abstract # 

Monday Afternoon, March 7 

12:00 NOON to 1:20 PM 

Salon G 


Monday Afternoon 

In Vitro Toxicology Lecture and Luncheon for 

Students: Full Speed into an Alternative 

Future 


Chairperson(s): Aaron Barchowsky, University of 

Pittsburgh, Pittsburgh, PA. 

Sponsor: 


The purpose of this lecture is to discuss the importance of animal research 

to biomedical sciences and toxicology and the ethical obligations of 

the scientific community to follow the “3R’s” of animal testing (refine, 

reduce, replace) whenever it is feasible. 

Graduate students, undergraduates, postdoctoral scholars, and 

recipients of Colgate-Palmolive awards are among the guests at the 

In Vitro Toxicology Lecture and Luncheon. The goal of the In Vitro 

Toxicology Lecture series is to feature important research using 

in vitro and alternative techniques to study basic mechanisms and to 

illustrate how these test methods benefit animal welfare by refining and 

reducing animal use. Students and postdocs can reserve a ticket for the 

luncheon with a $10 deposit when they register for the SOT Annual 

Meeting. Lunch is served at the beginning of the event and service 

concludes before the talk/main program begins. Meal service may not be 

available to guests who arrive after 12:30 PM. 

The “Toxicity Testing in the 21st Century” vision promulgates an 

in vitro approach to safety assessment based heavily on knowing the 

pathways responding in a cell and then correctly relating that to an in 

vivo exposure and response to predict the likely health outcome. But we 

are now much like Galileo was with our Moon: seeing the goal is many, 

many times easier than actually getting there. However, given that animal 

models correctly predict only 40–70% of human responses, in vitro 

models won’t actually have to do that well to be better than the current in 

vivo models (i.e., the bar is low). Thus, for both animal-use issues and for 

correct-predictivity issues, an in vitro future is a worthy and achievable 

goal. Meanwhile, there is much trial and error (and error) (and error) to 

pursue. 

This talk will quickly reprise an in vitro testing vision, and then put it into 

an industry perspective. It will soon become clear that we’re a long way 

from where we want to be. After this stage-setting, the audience will be 

asked to discuss and then present their answer to a set of related questions. 

 


12:00 NOON to 1:00 PM 

Room 103 

(See page 84 for more information) 

Special Interest Group Presidents and Officers Meeting 

If you will be a President or a Vice President of a Special Interest Group 

in 2011–2012, please make plans to attend the Special Interest Groups 

Presidents and Officers meeting. The agenda for the meeting will include 

an overview of the SOT Strategic Plan, SOT Headquarters administrative 

support information, ToXchange, a review of 2010–2011 activities and 

plans for the future. 

Abstract # 


12:00 NOON to 2:00 PM 

Embassy Suites, Capital Ballroom B 

Regional Chapter Meeting/Luncheon: Central States 


12:00 NOON to 1:00 PM 

Room 149 

Specialty Section Meeting/Luncheon: Toxicologic and 



12:10 PM to 1:30 PM 

Room 144 

Roundtable Session: Reforming the Toxic Substances Control 

Act (TSCA): Challenges, Opportunities, and Timing 

Chairperson(s): Thomas Lewandowski, Gradient, Seattle, WA, and 

Stanley Barone, U.S. EPA, Washington, D.C. 

Sponsor: 


Endorsed by: 



The Toxic Substances Control Act (TSCA) of 1976 significantly changed 

the regulatory landscape for chemicals in the United States. It gave the 

federal government greater powers to track the introduction of new chemicals 

into the consumer marketplace, provided the U.S. EPA with limited 

powers to require testing of new chemicals, and allowed for case-by-case 

restriction of chemicals shown to be particularly hazardous. Yet the basic 

provisions of TSCA are now 35 years old, and unlike most major environmental 

laws passed in the 1970s, the TSCA legal framework remains 

essentially unchanged. Achieving the goals of TSCA, namely to ensure that 

adequate data are available to allow assessment of the effect of chemical 

substances and mixtures on health and the environment has also proven 

difficult. The regulatory apparatus has been unable to cope with the large 

number of chemicals requiring evaluation, has focused on new rather than 

existing chemicals, has largely ignored the potential interaction of chemicals 

occurring in mixtures, and has generally failed to keep up with advances 

in technology. While once a model regulation for other nations, the TSCA 

framework has now been superseded by chemical safety regulations adopted 

by other jurisdictions (e.g., REACH). Given the dramatic changes in chemical 

technology, toxicology, and risk assessment that are expected to occur 

in the near future, reform of TSCA is seen as a high priority by many stakeholders. 

Issues that are likely to be addressed by reform of TSCA include 

the distinct toxicology and exposure scenarios posed by nanotechnology, the 

possibility of basing hazard identification for the large number of chemicals 

requiring assessment on mechanistic and in vitro data rather than standard 

animal tests, and consideration of special population groups (not only 

children but also those with genetic susceptibilities or chronic health conditions). 

Reform of TSCA has the potential to greatly affect the way chemical 

risks are assessed in the U.S. and may therefore have a significant impact on 

the daily lives of society members. 

#417 12:10 REFORMING THE TOXIC SUBSTANCES 

CONTROL ACT (TSCA): CHALLENGES, 

OPPORTUNITIES, AND TIMING. T. 

Lewandowski 1 and S. Barone 2 . 1 Gradient, Seattle, WA 

and 2 U.S. EPA, Washington, D.C. 

12:10 TSCA:TIME FOR A CHANGE. Thomas 

Lewandowski 

MONday 







151



MONday 


12:25 EPA’S ENHANCED CHEMICAL 

MANAGEMENT PROGRAM. Tala Henry 

12:40 TSCA REFORM AND REACH: WHAT WE 

CAN LEARN AND WHAT WE NEED TO 

AVOID. George Rusch 

12:55 LEGISLATION FOR TSCA REFORM: THE 

POSSIBLE AND THE PROBABLE. James 

Votaw 



12:10 PM to 1:30 PM 

Room 143 



Informational Session: The International Cooperation on 

Alternative Test Methods (ICATM): Translating Science to 

Provide Improved Public Health Safety Assessment Tools 

Chairperson(s): William S. Stokes, NIEHS, Research Triangle Park, NC, 

and Marilyn Wind, U.S. Consumer Product Safety Commission, Bethesda, 

MD. 

Sponsor: 


Endorsed by: 




In 2009, the United States, Canada, the European Union, and Japan signed a 

Memorandum of Cooperation for International Cooperation on Alternative 

Test Methods (ICATM). This agreement provides for enhanced international 

collaborations for the validation, evaluation, and development of internationally 

harmonized recommendations for new and alternative safety testing 

methods and strategies. The initial participating validation organizations 

are the NICEATM and ICCVAM, ECVAM, JaCVAM, and Health Canada’s 

Environmental Health Science and Research Bureau. A Korean Center for 

the Validation of Alternative Methods (KoCVAM) has recently also been 

established and is in the process of becoming an ICATM participant. The 

ICATM organizations work collaboratively to promote the validation and 

regulatory acceptance of new, revised, and alternative test methods that are 

based on sound science and that will provide continued or improved protection 

of people, animals, and the environment while reducing, refining, and 

replacing the use of animals where scientifically feasible. The participating 

validation organizations seek to expand and strengthen cooperation, collaboration, 

and communications on the scientific validation and evaluation of 

new alternative testing methods proposed for regulatory health and safety 

assessments. Consistent collaborations are critical to the design and conduct 

of validation studies, the evaluation and independent scientific peer review 

of proposed test methods and the development of harmonized recommendations 

for national and international regulatory consideration. The enhanced 

international cooperation in these three areas is expected to result in more 

efficient test method validation and review, and more rapid national and 

international acceptance of scientifically valid test methods. We will provide 

an overview of the ICATM process along with an introduction to each 

participating validation organization and highlights of recent and planned 

ICATM contributions. 

#418 12:10 THE INTERNATIONAL COOPERATION ON 

ALTERNATIVE TEST METHODS (ICATM): 

TRANSLATING SCIENCE TO PROVIDE 

IMPROVED PUBLIC HEALTH SAFETY 

ASSESSMENT TOOLS. W. Stokes 1 and M. 

Wind 2 . 1 NICEATM, NIEHS, Research Triangle Park, 

NC and 2 Consumer Product Safety Commission, 

Bethesda, MD. 

12:10 THE INTERNATIONAL COOPERATION ON 

ALTERNATIVE TEST METHODS (ICATM): 

TRANSLATING SCIENCE INTO PUBLIC 

HEALTH SAFETY ASSESSMENT TOOLS. 

William S. Stokes 

12:20 THE NTP INTERAGENCY CENTER FOR 

THE EVALUATION OF ALTERNATIVE 

TOXICOLOGICAL METHODS (NICEATM) 

AND THE INTERAGENCY COORDINATING 

COMMITTEE ON THE VALIDATION OF 

ALTERNATIVE METHODS (ICCVAM): 

RECENT ICATM CONTRIBUTIONS AND 

FUTURE PLANS. Marilyn Wind 

12:30 THE EUROPEAN CENTER FOR THE 

VALIDATION OF ALTERNATIVE METHODS 

(ECVAM): RECENT CONTRIBUTIONS TO 

ICATM AND REACH AND FUTURE PLANS. 

Joachim Kreysa 

12:40 THE JAPANESE CENTER FOR THE 

VALIDATION OF ALTERNATIVE 

METHODS (JACVAM): RECENT ICATM 

CONTRIBUTIONS AND FUTURE PLANS. 

Hajime Kojima 

12:50 HEALTH CANADA’S ROLE IN ICATM. David 

Blakey 

1:00 THE KOREAN CENTER FOR THE 

VALIDATION OF ALTERNATIVE METHODS 

(KOCVAM): RECENT PROGRESS AND 

FUTURE PLANS. Soon Young Han 



12:10 PM to 1:30 PM 

Room 147 

Education-Career Development Session: Social Media and 

Informatics Essentials for Toxicologists 

Chairperson(s): Lyle Burgoon, U.S. EPA, Durham, NC, and Sneha 

Bhatia, Research Institute for Fragrance Materials Inc., Woodcliff Lake, 

NJ. 

Sponsor: 

Ethical, Legal & Social Issues Specialty Section 

Endorsed by: 

Career Resource and Development Committee 

Communications Committee 


How many times a day do we use Google or a search engine? Its use has 

become so intuitive that we have coined this term as a verb and simply 

cannot imagine functioning without it. Information that was once confined 

to libraries and various periodicals is now free and easily accessible since 

the advent of Internet technology. Furthermore, it has broken cultural and 

language barriers and enabled one to communicate and collaborate with 

people all over the world. The combination of social media, open source 

programs, and bioinformatics has transformed the role of the computer in 

152 






Platform Sessions



Abstract # 

the modern scientist’s life. Video journals, blogging, open access journals, 

social network websites, and podcasts have become the new channels of 

communication—enabling first hand transfer of free knowledge and an ease 

by which to carry out many collaborative efforts. A familiarity with simple 

Internet searching, word processing, and expansive spreadsheets is simply 

not an adequate preparation. Furthermore, the software tools used to deal 

with data arising from in silico models, toxicogenomics, or high-throughput 

screens require an understanding of basic concepts in computer science, 

database design, bioinformatics, and statistics. To bridge the gap between 

these two worlds our panel of experts will provide toxicologists with the 

basic knowledge of the informatics and various open source tools available. 

In closing, we’ll discuss innovative strategies including the use of social 

media as a communication, collaboration, networking, and a career advancement 

tool. 

#419 12:10 Social Media and Informatics Essentials for 

Toxicologists, L. Burgoon 2 , S. Bhatia 1 , P. Wexler 3 

and M. Price 4 . 1 Human Health Sciences, RIFM, 

Woodcliff Lake, NJ, 2 Biostatistics and Bioinformatics 

Research Core (BBRC), U.S. EPA, Durham, NC, 

3 

Toxicology and Environmental Health Information 

Program, National Library of Medicine, Bethesda, 

MD and 4 Membership and Social Media Marketing, 

Society of Toxicology, Reston, VA. 

12:15 The Cloud, Open Source, and Data 

Democratization: Innovating Computational 

Toxicology and Bioinformatics, Lyle D. Burgoon 

12:30 Hazard Communication in the 21 st Century: Use 

of Social Media and Internet Technologies to 

Communicate Hazard, Phil Wexler 

12:50 Social Media Essentials for Toxicologists, 

Matthew Price 

1:10 Social Media as a Career Advancement Tool: 

Your Virtual Resume, Sneha Bhatia 


12:15 PM to 1:05 PM 

Room 201 

Merit Award Lecture: Neurotoxicology Goes 

Global: Scientific Collaboration and 

Mentorship 

Lecturer: Michael Aschner, Vanderbilt University, 

Nashville, TN. 

Methylmercury (MeHg) is a potent neurotoxin 

disrupting multiple homeostatic pathways within both the developing 

and mature central nervous system (CNS). Since the 1980s, our efforts 

have been directed at addressing the role of glia in modulating MeHg 

neurotoxicity. We have focused on astrocytes, and more recently 

microglia, two cell types that assume multiple roles in maintaining 

an optimally-suited milieu for neuronal function. Collaborative work 

with multiple groups, both nationally and internationally, has led us 

to recognize that reactive oxygen species (ROS) are key mediators 

of MeHg’s toxic effects. Collectively, these studies have shown that 

(i) in cultured astrocytes and neurons, as well as in vivo, F 2 

-IsoPs and 

F 4 

-NeuropsPs (isoprostanes) can be reliably quantified as oxidative 

damage markers; (ii) MeHg inhibits astrocytic uptake systems for cystine 

and cysteine transport, compromising glutathione (GSH) synthesis; 

(iii) MeHg-induced ROS formation is attenuated by antioxidants, 

reversing MeHg’s functional effects on glutamate uptake inhibition; 

(iv) cytosolic phospholipase A 2 

(cPLA 2 

) is a target for MeHg toxicity, 

supporting the notion that cPLA 2 

-stimulated hydrolysis and arachidonic 

acid release play a central role in MeHg-induced ROS generation; (v) 

consistent with oxidative stress, MeHg leads to reduced ATP production 

and collapse of the mitochondrial membrane potential (ΔΨ m 

); 

 

(continued to next column) 

Abstract # 

(vi) in vivo, prenatal MeHg exposure in mice alters CNS GSH antioxidant 

system ontogenesis, causing long-lasting oxidative stress; and (vii) 

nuclear factor erythroid 2-related factor 2 (Nrf2) coordinates the upregulation 

of cytoprotective genes that combat MeHg-induced oxidative 

injury, suggesting that genetic and biochemical changes that negatively 

impact upon Nrf2 function may increase MeHg’s neurotoxicity. My 

talk will address the functions of astrocytes and microglia, emphasizing 

their varied roles in mediating MeHg-induced neurotoxicity, while highlighting 

the global nature of these studies and crucial input of faculty and 

students alike (supported by NIEHS 07331). 


1:00 PM to 1:30 PM 

Room 103 

Special Interest Group Collaboration Group Meeting 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Drug Induced Liver Injury 

Chairperson(s): Yvonne Dragen, Astra Zeneca, DE. 

Displayed: 1:00 PM–4:30 PM 

Author Attended: 1:00 PM–2:45 PM 


DEVELOPING A SCREENING SYSTEM 

FOR HEPATOTOXICITY BY COMBINING 

THE HEPARG CELL MODEL WITH HIGH 

CONTENT IMAGING. M. Mennecozzi, M. 

Tsaneva, L. Saavedra and M. Whelan. Sistems 

Toxicology Unit, European Commission-Joint 

Research Centre, Ispra, Varese, Italy. Sponsor: D. 

Dix. 


USING PRECISION-CUT LIVER SLICES 

TO PROFILE BIOCHEMICAL CHANGES 

OF DRUG-INDUCED HEPATOTOXICITY. 

R. Hernandez, J. W. Lawrence and M. A. Lafleur. 

Amgen, Thousand Oaks, CA. Sponsor: S. Sawant. 


CYTOTOXICITY OF 3-(3, 

5-DICHLOROPHENYL)-2, 

4-THIAZOLIDINEDIONE (DCPT) AND 

ANALOGUES IN WILD TYPE AND CYP3A4- 

TRANSFECTED HEPG2 CELLS. D. M. 

Frederick, E. Y. Jacinto, T. H. Rushmore, R. Tchao 

and P. J. Harvison. Department of Pharmaceutical 

Sciences, University of the Sciences, Philadelphia, 

PA. 


DEVELOPMENT OF AN ANIMAL MODEL 

OF AMODIAQUINE-INDUCED LIVER 

INJURY. P. Cai, T. Nakgawa and J. Uetrecth. 

Faculty of Pharmacy, University of Toronto, Toronto, 

ON, Canada. 


DEVELOPMENT OF AN ANIMAL MODEL 

OF ISONIAZID-INDUCED LIVER INJURY. 

I. G. Metushi 1 and J. P. Uetrecht 2,1 . 1 Pharmacology, 

University of Toronto, Toronto, ON, Canada and 

2 

Faculty of Pharmacy, University of Toronto, 


MONday 







153



MONday 



APPROACH FOR DETECTING 

FLUTAMIDE-INDUCED HEPATOTOXICITY 

USING GLUTATHIONE DEPLETED RATS. 

H. Horie, I. Miyawaki, I. Matsumoto, T. Kai, M. 

Aoki, T. Yamada, J. Kimura, H. Funabashi and T. 

Seki. Dainippon Sumitomo Pharmacology Co., Ltd., 

Osaka, Japan. 


A 3-DIMENSIONAL LIVER MODEL FOR 

THE SAFETY-EVALUATION OF DRUG 

CANDIDATES. R. M. Kostadinova, F. Boess, 

L. Suter-Dick, T. Weiser, T. Singer and A. Roth. F. 

Hoffmann-La Roche Ltd., Basel, Switzerland. 


A BENCHMARK DRUG LIST FOR THE 

STUDY OF DRUG-INDUCED LIVER INJURY. 

V. Vijay, M. Chen, Q. Shi and W. Tong. Systems 

Biology, NCTR /U.S. FDA, Jefferson, AR. 


MONOCYTE TO MACROPHAGE 

DIFFERENTIATION-ASSOCIATED 2 

(MMD2) IS A NEW CANDIDATE GENE 

FOR HEPATOPROTECTIVE EFFECT OF 

TAMOXIFEN AGAINST DRUG-INDUCED 

LIVER INJURY. T. Yokoi 1 , Y. Yoshikawa 1 , Y. 

Toyoda 1 , S. Higuchi 1 , T. Tsukui 2 , K. Tsuneyama 3 , 

T. Fukami 1 and M. Nakajima 1 . 1 Graduate School of 

Medical Science, Kanazawa University, Kanazawa, 

Ishikawa, Japan, 2 Research Center for Genomic 

Medicine, Saitama Medical University, Hidaka, 

Saitama, Japan and 3 Department of Diagnostic 

Pathology, Toyama University, Toyama, Japan. 


INVESTIGATING LIVER MITOCHONDRIAL 

TOXICITY USING PRIMARY RAT 

HEPATOCYTES AND A LIVER CELL LINE. 

C. Summers, K. Abbott, J. I. Goodman and A. Foster. 

Safety Assessment, Astrazeneca, Alderley Park, 

Cheshire, United Kingdom. Sponsor: D. Brown. 


IN VITRO METHOD DEVELOPMENT TO 

ASSESS THE ROLE OF KUPFFER CELLS 

IN DRUG-INDUCED HEPATOTOXICTY. 

N. Shangari 1 , M. Dong 2 , A. Reising 1 , O. Weber 2 , 

E. Cruz 1 , S. Sampath 1 , P. Patel 1 , M. Gurnani 1 , 

C. Buono-Dalton 4 , V. Richard 4 , T. Wang 3 , M. 

Uteng 2 , J. Scheumann 2 , S. Chibout 2 , F. Pognan 2 

and A. Wolf 2 . 1 iTOX, Preclinical Safety, Novartis 

Institutes of Biomedical Research, East Hanover, 

NJ, 2 iTOX, Preclinical Safety, Novartis Institutes 

of Biomedical Research, Basel, Switzerland, 

3 

Preclinical Safety, Novartis Institutes of Biomedical 

Research, Emeryville, CA and 4 iTOX, Preclinical 

Safety, Novartis Institutes of Biomedical Research, 



AUTOMATED IMAGING, 

QUANTIFICATION, AND CLASSIFICATION 

OF NF-KAPPA B AND NRF2 RESPONSES TO 

IDENTIFY ADVERSE DRUG REACTIONS 

IN HEPG2 CELLS. B. Herpers, L. Fredriksson, 

Z. Di and B. van de Water. Division of Toxicology - 

LACDR, Leiden University, Leiden, Netherlands. 


MECHANISTIC STUDIES ON THE 

CYTOTOXICITY OF LEFLUNOMIDE 

AND ITS MAJOR METABOLITES IN RAT 

HEPATIC CELLS. Q. Shi, X. Yang and W. F. 

Salminen. Division of Systems Biology, U.S. FDA, 



THE HEMOSTATIC SYSTEM AND 

NEUTROPHILS IN AMIODARONE/ 

LIPOPOLYSACCHARIDE-INDUCED LIVER 

INJURY IN RATS. J. Lu 1 , R. A. Roth 2 and P. 

E. Ganey 2 . 1 Department of Biochemistry and 

Molecular Biology, Michigan State University, East 

Lansing, MI and 2 Department of Pharmacology and 


MI. 


STUDY OF LIVER LYMPHOCYTES 

IN AMODIAQUINE-INDUCED 

HEPATOTOXICITY IN BROWN NORWAY 

RATS. F. Liu 1 , P. Cai 1 , J. Li 2 and J. Uetrecht 1 . 

1 

Faculty of Pharmacy, University of Toronto, 

Toronto, ON, Canada and 2 Immunotoxicology, 

Bristol-Myers Squibb Company, New Brunswick, 

NJ. 


SIGNIFICANT RELATIONSHIP EXISTS 

BETWEEN ORAL DRUG EXPOSURE LEVEL 

AND ITS POTENTIAL RISK FOR HUMAN 

HEPATOTOXICITY. M. Chen, V. Vijay and W. 

Tong. Division of Systems Biology, U.S. FDA’s 



EVALUATION OF PHOSPHOLIPIDOSIS- 

INDUCING POTENTIAL OF DRUGS FROM 

ORAL SINGLE-DOSE RAT LIVER GENE 

EXPRESSION PROFILING. T. Kai 2 , H. T. 

Yudate 1 , Y. Minowa 3 , M. Aoki 4 , T. Yamada 5 , T. 

Kimura 4 , A. Ono 6 , H. Yamada 3 , Y. Ohno 7 and T. 

Urushidani 3,8 . 1 Strategic Planning & Management, 

Dainippon Sumitomo Pharmacology Co., Ltd., 

Osaka, Japan, 2 Genomic Science Laboratories, 


Osaka, Japan, 3 Toxicogenomics-Informatics Project, 

National Institute of Biomedical Innovation, 

Osaka, Japan, 4 Research Planning & Management, 


Osaka, Japan, 5 Safety Research Laboratories, 


Osaka, Japan, 6 Division of Risk Assessment, 

National Institute of Health Sciences, Tokyo, Japan, 

7 

National Institute of Health Sciences, Tokyo, Japan 

and 8 Department of Pathophysiology, Doshisha 

Women’s College of Liberal Arts, Kyoto, Japan. 


EVALUATION OF 3 BILE ACIDS AS 

POTENTIAL BIOMARKERS OF DRUG- 

INDUCED LIVER INJURY. L. Luo, C. A. Fritz 

and J. L. Colangelo. Drug Safety R&D, Pfizer Inc., 

Groton, CT. 

154 






Platform Sessions



Abstract # 


UNTARGETED METABOLOMICS 

IDENTIFIED A PANEL OF MARKERS FOR 

DRUG-INDUCED LIVER INJURY. L. Guo 1 , 

N. Masutomi 2 , M. Miyake 2 , M. Yamazaki 2 , H. Sato 2 , 

K. A. Lawton 1 , M. V. Milburn 1 and J. A. Ryals 1 . 

1 

Metabolon, Durham, NC and 2 Mitsubishi Tanabe 

Pharmacology Corporation, Chiba, Japan. 


EVALUATION OF ALT ISOZYMES 

AS REFINED BIOMARKERS OF 

DRUG-INDUCED LIVER DAMAGE: 

CHARACTERIZATION AND 

DEVELOPMENT OF METHODS FOR 

ANALYZING ALT1 AND ALT2 ISOZYMES. 

M. S. Mondal 1 , J. Gabriels 1 , K. Zhu 2 and F. Pognan 3 . 

1 

Investigative Toxicology, Preclinical Safety, 

Novartis Institute of Biomedical Research, Inc., 

Cambridge, MA, 2 Analytical Sciences, Novartis 

Institute of Biomedical Research, Inc., Cambridge, 

MA and 3 Investigative Toxicology, Preclinical Safety, 

Novartis Institute of Biomedical Research, Inc., 



SORBITOL DEHYDROGENASE AND 

GLUTAMATE DEHYDROGENASE ARE 

NOT SUPERIOR TO TRADITIONAL 

BIOMARKERS OF LIVER INJURY: A 

HEALTHY VOLUNTEER STUDY OF 

HEPARINS. A. H. Harrill 1 , S. Eaddy 1 , J. Roach 2 , 

I. D. Fier 2 and P. B. Watkins 1,3 . 1 University of North 

Carolina-Hamner Institute for Drug Safety Sciences, 

The Hamner Institutes, Research Triangle Park, NC, 

2 

Momenta Pharmaceuticals, Cambridge, MA and 

3 

University of North Carolina, Chapel Hill, Chapel 

Hill, NC. 


IMPORTANCE OF IL-6 SIGNALING FOR 

MITOCHONDRIAL STAT3 EXPRESSION 

AND MITOCHONDRIAL FUNCTION IN 

MOUSE LIVER. F. Boess, A. Roth, K. Schad, C. 

Zihlmann, M. Bellot, A. Olaharski, L. Suter, S. Platz, 

T. Weiser, T. Singer and L. Mueller. F. Hoffmann-La 

Roche AG, Basel, Switzerland. 


GENE EXPRESSION AND 

MORPHOLOGICAL ANALYSIS OF HEART 

AND LIVER FROM IL-6 KO MICE. A. Roth, 

F. Boess, J. Hoflack, C. Landes, M. Bellot, A. 

Olaharski, L. Suter, S. Platz, T. Weiser, T. Singer 

and L. Mueller. F. Hoffmann-La Roche AG, Basel, 

Switzerland. 


TROVAFLOXACIN ENHANCEMENT 

OF LPS-MEDIATED SIGNALING IS 

ASSOCIATED WITH REDUCED SOCS- 

1 EXPRESSION. R. Singhal, K. L. Poulsen, 

P. E. Ganey and R. A. Roth. Pharmacology and 


MI. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Acetaminophen Hepatotoxicity 

Chairperson(s): Hartmut Jaeschke, University of Kansas Medical Center, 

Kansas City, KS, and Daniel Ferreira, University of Connecticut, Storrs, 

CT. 




ENHANCED ACETAMINOPHEN 

HEPATOTOXICITY IN VANIN-1 NULL 

MICE IS INDEPENDENT OF DIFFERENCES 

IN BASAL HEPATIC GLUTATHIONE 

LEVELS AND GENE EXPRESSION OF 

DRUG METABOLIZING ENZYMES AND 

TRANSPORTERS. D. W. Ferreira 1 , P. Naquet 2 , 

F. Galland 2 and J. E. Manautou 1 . 1 Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT and 

2 

Centre d’Immunologie de Marseille-Luminy CNRS- 

INSERM-Université de la Méditerranée, Marseille, 

France. 


DIFFERENTIAL HEPATIC EXPRESSION 

OF ID GENES BY ACETAMINOPHEN 

TREATMENT IN MICE. X. Gu and J. E. 

Manautou. University of Connecticut, Storrs, CT. 


PROFILING THE HEPATIC PROTEOME 

TO EXPLORE THE MOLECULAR 

BASIS OF THE CHRONOTOXICITY OF 

ACETAMINOPHEN. P. J. Starkey Lewis 1 , C. 

E. Goldring 1 , V. Platt 1 , A. M. Obeng 1 , L. Randle 1 , 

C. Rowe 1 , J. Moggs 2 and K. Park 1 . 1 Molecular & 

Clinical Pharmacology, University of Liverpool, 

Liverpool, Merseyside, United Kingdom and 

2 

Investigative Toxicology, Novartis, Basel, CH-4132, 

Switzerland. Sponsor: D. Mendrick. 


ACUTE LIVER TOXICITY OF 

ACETAMINOPHEN IS NOT POTENTIATED 

IN HCV TRANSGENIC MICE. T. Uehara 1 , O. 

Kosyk 1 , E. Jeannot 1 , B. Bradford 1 , J. Grimes 2 , T. 

O’Connell 2 , G. Boorman 3 , S. Melnyk 4 , S. Weinman 5 

and I. Rusyn 1 . 1 Department of Environmental 

Sciences and Engineering, University North 

Carolina, Chapel Hill, NC, 2 The Hamner Institutes, 

Research Triangle Park, NC, 3 Covance, Princeton, 

NJ, 4 University of Arkansas for Medical Sciences, 

Little Rock, AR and 5 University of Kansas Medical 

Center, Kansas City, KS. 


INTRAVITAL IMAGING OF 

ACETAMINOPHEN (APAP) 

HEPATOTOXICITY. J. Hu 1 , V. K. Ramshesh 1 , H. 

Jaeschke 2 and J. J. Lemasters 1 . 1 Medical University 

of South Carolina, Charleston, SC and 2 University of 

Kansas Medical Center, Kansas City, KS. 

MONday 







155



MONday 



THE ALPHA MUPA MICE, A MODEL OF 

CALORIC RESTRICTION, ARE MORE 

SUSCEPTIBLE TO ACETAMINOPHEN 

HEPATOTOXICITY. Z. Fu 1 , Y. Zhang 1 , R. Miskin 2 

and C. D. Klaassen 1 . 1 Department of Pharmacology, 

Toxicology and Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Department 

of Biological Chemistry, The Weizmann Institute of 

Science, Rehovot, Israel. 


ACTIVATION OF CASPASES DURING 

ACETAMINOPHEN TOXICITY IS A STRAIN 

DEPENDENT PHENOMENON. H. Jaeschke, 

M. Koerner and C. D. Williams. University of Kansas 

Medical Center, Kansas City, KS. 


INHIBITION OF THE MITOCHONDRIAL 

MEMBRANE PERMEABILITY 

TRANSITION PORE PROTECTS 

AGAINST ACETAMINOPHEN-INDUCED 

MITOCHONDRIAL OXIDANT STRESS AND 

LIVER INJURY IN VIVO. A. Ramachandran 1 , 

M. Lebofsky 1 , C. Baines 2 , S. A. Weinman 1 , J. J. 

Lemasters 3 and H. Jaeschke 1 . 1 Pharmacology, 

Toxicology & Therapeutics, University of Kansas 

Medical Center, Kansas City, KS, 2 University of 

Missouri, Columbia, MO and 3 Medical University of 

South Carolina, Charleston, SC. 


ROLE OF THE NALP3 INFLAMMASOME 

IN NEUTROPHIL ACTIVATION AND CELL 

INJURY DURING ACETAMINOPHEN- 

INDUCED HEPATOTOXICITY. C. D. 

Williams 1 , P. J. Shaw 2 and H. Jaeschke 1 . 1 University 

of Kansas Medical Center, Kansas City, KS and 

2 

New York University, New York, NY. 


ACETAMINOPHEN HEPATOTOXICITY 

IN HUMANS: MITOCHONDRIAL 

INJURY AND DNA FRAGMENTATION IN 

OVERDOSE PATIENTS. M. R. McGill 1 , M. R. 

Sharpe 2 , C. Williams 1 , M. Taha 2 and H. Jaeschke 1 . 

1 

Pharmacology, Toxicology, and Therapeutics, 

University of Kansas Medical Center, Kansas City, 

KS and 2 Internal Medicine, University of Kansas 



KAVA EXTRACT, AN HERBAL 

ALTERNATIVE FOR ANXIETY RELIEF, 

POTENTIATES ACETAMINOPHEN- 

INDUCED CYTOTOXICITY IN RAT 

HEPATIC CELLS. X. Yang and W. F. Salminen. 

Division of Systems Biology, U.S. FDA, NCTR, 



HEPATIC ENDOTHELIAL CELLS 

REGULATE LIVER CELL REPAIR 

FOLLOWING ACETAMINOPHEN 

INTOXICATION. Y. Liu, C. R. Gardner, M. 

Francis, J. D. Laskin and D. L. Laskin. Pharmacology 



NEGATIVE REGULATION OF CLASSICAL 

MACROPHAGE ACTIVATION BY THE STK 

RECEPTOR DURING ACETAMINOPHEN- 

INDUCED HEPATOTOXICITY. C. R. 

Gardner 1 , Y. Liu 1 , P. A. Hankey 2 , J. D. Laskin 3 and 

D. L. Laskin 1 . 1 Rutgers University, Piscataway, NJ, 

2 

Pennsylvania State University, University Park, PA 

and 3 UMDNJ-Robert Wood Johnson Medical School, 



ROLE OF MACROPHAGE-DERIVED 

GALECTIN-3 IN ACETAMINOPHEN- 

INDUCED HEPATOTOXICITY. A. Dragomir 1 , 

R. Sun 1 , J. D. Laskin 2 and D. L. Laskin 1 . 

1 



Medicine, UMDNJ-Robert Wood Johnson Medical 

School, Piscataway, NJ. 


TARGETING OF THIOREDOXIN 

REDUCTASE BY THE ACETAMINOPHEN 

METABOLITE N-ACETYL-P- 

BENZOQUINONE IMINE. Y. Jan 1 , D. E. Heck 2 , 

D. L. Laskin 3 , Y. Liu 3 , A. Dragomir 3 and J. D. 

Laskin 1 . 1 Environmental & Occupational Medicine, 

UMDNJ-Robert Wood Johnson Medical School, 

Piscataway, NJ, 2 Environmental Health, New York 

Medical College, Valhalla, NY and 3 Pharmacology & 

Toxicology, Rutgers University, Piscataway, NJ. 


TRIFLUOPERAZINE MEDIATED 

HEPATOPROTECTION AND REDUCTION 

OF HIF-1α IN ACETAMINOPHEN 

MEDIATED TOXICITY IN MICE. S. 

Chaudhuri 1 , S. S. McCullough 1 , A. Brown 1 , 

J. A. Hinson 2 and L. P. James 1,2 . 1 Pediatrics/ 

Clinical Pharmacology, Arkansas Childrens 

Hospital Research Institute, Little Rock, AR and 

2 

Pharmacology and Toxicology, University of 

Arkansas for Medical Sciences, Little Rock, AR. 


SULFORAPHANE PREVENTS 

ACETAMINOPHEN-INDUCED HEPATIC 

INJURY IN MICE. R. Schmidt 1,2 , K. C. Falkner 2,3 , 

J. Beier 1,2 and G. Arteel 1,2 . 1 Pharmacology & 

Toxicology, University of Louisville, Louisville, KY, 

2 

Alcohol Research Center, University of Louisville, 

Louisville, KY and 3 Medicine, University of 

Louisville, Louisville, KY. Sponsor: C. States. 


ACETAMINOPHEN (APAP) AND 

S-ADENOSYL-L-METHIONINE (SAME) 

EFFECTS ON OXIDATIVE STRESS 

ENZYMES: ATTENUATION BY SAME. J. 

Brown, J. G. Ball, T. Ahmad and M. Valentovic. 

Pharmacology, Physiology, and Toxicology, Marshall 

University School of Medicine, Huntington, WV. 


NERVE GROWTH FACTOR (NGF) IN 

MOUSE LIVER HAS AN AUTOCRINE 

ACTIVITY AND ITS TRANSCRIPTION IS 

MODULATED BY BSO, ACETAMINOPHEN, 

AND ARSENIC. C. Valdovinos and M. E. 

Gonsebatt. Instituto de Investigaciones Biomedicas, 

Universidad Nacional Autónoma de México, Mexico, 

D.F., Mexico. 

156 






Platform Sessions



Abstract # 


URINE PROTEOMIC PROFILING FOR 

BIOMARKERS OF ACETAMINOPHEN- 

INDUCED ACUTE LIVER INJURY IN 

MICE AND HUMANS. R. P. van Swelm 1 , C. 

M. Laarakkers 2 , R. Masereeuw 1 and F. G. Russel 1 . 

1 

Pharmacology and Toxicology, Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands 

and 2 Laboratory Medicine, Radboud University 

Nijmegen Medical Centre, Nijmegen, Netherlands. 

Sponsor: R. Pieters. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment: Computational Approaches, 

Analyses, and Applications 

Chairperson(s): MaryJane Selgrade, ICF International, Durham, NC, 

and Lynne Haber, Toxicology Excellence for Risk Assessment (TERA), 





DEVELOPMENT OF A MECHANISTIC 

SAR MODEL FOR THE DETECTION OF 

PHOTOTOXIC CHEMICALS AND USE IN 

AN INTEGRATED TESTING STRATEGY. S. 

Ringeissen 1 , L. Marrot 1 , R. R. Note 1 , A. Labarussiat 1 , 

S. Imbert 1 , M. Todorov 2 , O. Mekenyan 2 and J. 

Meunier 1 . 1 L’Oreal, Aulnay Sous Bois, France and 

2 

Laboratory of Mathematical Chemistry, Bourgas, 

Bulgaria. Sponsor: H. Toutain. 



RELATIONSHIP MODELING OF SKIN 

SENSITIZERS TESTED IN LOCAL LYMPH 

NODE ASSAY. D. Pu 1 , H. Zhu 1 , G. Zhao 1 , J. 

Strickland 2 , E. Salicru 2 and A. Tropsha 1 . 1 University 

of North Carolina, Chapel Hill, NC and 2 ILS, 



3D ORGANOTYPIC EPIOCULAR EYE 

IRRITATION TEST (EIT) RESULTS – USE OF 

ALTERNATIVE TISSUE CULTURE INSERTS. 

M. Klausner, Y. Kaluzhny, P. J. Hayden, L. 

d’Argembeau-Thornton and H. Kandarova. MatTek 

Corp, Ashland, MA. 


GUIDING FORMULA DEVELOPMENT 

UTILIZING THE CLINICAL CUMULATIVE 

IRRITATION CLINICAL TESTING WHEN 

INGREDIENTS INTERFERE WITH IN VITRO 

IRRITATION ASSAY. D. Orak, P. Kazmi, V. 

Srinivasan and T. A. Re. Safety Evaluation, L’Oreal 

USA, Clark, NJ. 

Abstract # 


A WEIGHT OF EVIDENCE APPROACH 

TO IMPROVING SAR PREDICTION OF 

ALLERGIC CONTACT DERMATITIS. 

C. Seaman 1 , A. Quayson 2 , M. J. Olson 3 and F. 

Guerriero 4 . 1 HS&P, GlaxoSmithkline, Ware, Herts, 

United Kingdom, 2 School of Biosciences, University 

of Birmingham, Birmingham, West Midlands, United 

Kingdom, 3 HS&P, GlaxoSmithKline, Research 

Triangle Park, NC and 4 HS&P, GlaxoSmithKline, 

Philadelphia, PA. 


A MECHANISTIC RATIONALE FOR 

THE PREDICTION OF SKIN IRRITANCY 

EFFECTS IMPLEMENTED IN A 

WORKFLOW PROCESS. C. Yang 2 , S. 

Ringeissen 1 , J. F. Rathman 2,3 , B. Prunier 1 , R. Note 1 

and J. Meunier 1 . 1 L’Oreal Recherche, Aulany-sous- 

Bois, 93600, France, 2 Altamira LLC, Columbus, OH 

and 3 The Ohio State University, Columbus, OH. 


DECISION TREES FOR EVALUATING 

SKIN AND RESPIRATORY SENSITIZING 

POTENTIAL OF CHEMICALS FOR REACH. 

M. Selgrade 1 , K. Sullivan 1 , R. Boyles 1 , E. Dederick 1 , 

T. Serex 2 and S. Loveless 2 . 1 ICF International, Fairfax, 

VA and 2 DuPont Haskell Global Centers for Health & 

Environmental Sciences, Newark, DE. 


DEVELOPMENT OF A MICROBIAL RISK 

ASSESSMENT GUIDELINE. Microbial Risk 

Assessment Guideline Workgroup. The Federal 

Interagency. USDA, U.S. EPA, DHHS and other 

Federal Agencies, Washington, D.C. Sponsor: A. 

Kadry. 


PRELIMINARY SENSITIVITY EVALUATION 

FOR CUMULATIVE IMPACTS ANALYSIS. 

G. V. Alexeeff, J. Faust, L. Meehan and L. Zeise. 

OEHHA, California/U.S. EPA, Oakland, CA. 


CATEGORICAL REGRESSION: 

STRENGTHS, WEAKNESSES, AND 

APPLICATIONS. L. T. Haber 1 , R. Danzeisen 2 

and J. S. Gift 3 . 1 Toxicology Excellence for Risk 

Assessment (TERA), Cincinnati, OH, 2 International 

Copper Association, New York, NY and 3 U.S. EPA 

ORD NCEA, Research Triangle Park, NC. 


USE OF POWER LAW MODELING 

TO ESTIMATE LOW DOSE HUMAN 

RELATIVE POTENCIES OF DIOXIN- 

LIKE COMPOUNDS (DLCS). T. B. Starr 1 , 

E. A. Carlson 3 , C. H. Sutter 2 , T. R. Sutter 2 and 

J. B. Silkworth 3 . 1 TBS Associates, Raleigh, NC, 

2 

University of Memphis, Memphis, TN and 3 General 

Electric, Niskayuna, NY. 


NON-THRESHOLD BIOLOGICAL 

PROCESSES AND THE ASSUMPTION OF 

LOW-DOSE LINEARITY: CONSIDERATION 

OF RECEPTOR-MEDIATED EVENTS 

IN RISK ASSESSMENT. P. D. White, M. A. 

Spassova, R. P. Subramaniam and L. Kopylev. U.S. 

EPA, Washington, D.C. Sponsor: S. Vulimiri. 

MONday 







157



MONday 



THE HUMAN-RELEVANT-POTENCY- 

THRESHOLD: UNCERTAINTY ANALYSIS 

AND HUMAN CALIBRATION FOR 

CUMULATIVE RISK ASSESSMENTS. E. 

Sargent 2 , R. Golden 4 , D. Dietrich 3 , G. Casella 5 and 

C. Borgert 1 . 1 Applied Pharmacology & Toxicology, 

Inc., Gainesville, FL, 2 EV Sargent LLC, Clearwater, 

FL, 3 Faculty of Biology, University of Konstanz, 

Konstanz, Germany, 4 ToxLogic, Potomac, MD and 

5 

Department of Statistics, University of Florida, 



THRESHOLD ANALYSES FOR 

ACRYLONITRILE AND BRAIN TUMORS 

IN RATS. D. E. Strother 1 and C. R. Kirman 2 . 

1 

ToxSolve LLC, Manassas, VA and 2 Summit 

Toxicology LLP, Orange, OH. 


EFFICIENT DESIGN OF BIOLOGICAL 

EXPERIMENTS FOR DOSE-RESPONSE 

MODELING IN TOXICOLOGY STUDIES. 

F. Yang 1 and D. Porter 2 . 1 West Virginia University, 

Morgantown, WV and 2 NIOSH, Morgantown, WV. 


PHARMACOKINETIC AND 

TOXICOLOGICAL PROFILING OF 

NATURAL PRODUCTS AND DRUGS. C. 

Hasselgren 1 , H. Chen 2 , Y. Yang 2 , S. Boyer 1 , 

T. I. Oprea 3 and S. Muresan 2 . 1 Global Safety 

Assessment, AstraZeneca, Mölndal, Sweden, 2 DECS, 

AstraZeneca, Mölndal, Sweden and 3 Division 

of Biocomputing, University of New Mexico, 

Albuquerque, NM. 


A FLEXIBLE METHOD FOR BUILDING AND 

USING PREDICTIVE MODELS APPLIED TO 

SAFETY ENDPOINTS. O. Spjuth 2 , L. Carlsson 1 , 

M. Eklund 2 , E. Ahlberg Helgee 1 and S. Boyer 1 . 

1 

Computational Toxicology, AstraZeneca, Mölndal, 

Sweden and 2 Department of Pharmaceutical 

Biosciences, Uppsala University, Uppsala, Sweden. 


ASSESSING DOSE-RESPONSE OF 

ENVIRONMENTAL CHEMICALS 

INTERACTION WITH DNA USING 

A SYSTEM BIOLOGY MODELING 

APPROACH. J. M. Gavina, Y. Feng and A. Nong. 

Environmental Health Science and Research Bureau, 

Health Canada, Ottawa, ON, Canada. 


USING A MULTIPLE STAGE DECISION 

TREE TO MAKE ACTIVITY CALLS IN 

QUANTITATIVE HIGH-THROUGHPUT 

SCREENING (QHTS) DATA. K. R. Shockley 1 , 

G. E. Kissling 1 , R. Huang 2 , M. Xia 2 , C. P. Austin 2 

and R. R. Tice 1 . 1 National Toxicology Program/ 

National Inistitute of Environmental Health Sciences, 

Research Triangle Park, NC and 2 NIH Chemical 

Genomic Center, Bethesda, MD. 


TESTING MULTIPLE AVAILABLE QSARS 

FOR REPRODUCTIVE TOXICITY AND 

CARCINOGENICITY TO DRINKING WATER 

CONTAMINANTS. M. Heringa 1 , A. Roncaglioni 2 , 

R. Benigni 3 and A. Worth 4 . 1 KWR Watercycle 

Research Institute, Nieuwegein, Netherlands, 2 Istituto 

di Ricerche Farmacologiche “Mario Negri”(IRFMN), 

Milan, Italy, 3 Istituto Superiore di Sanita (ISS), 

Rome, Italy and 4 European Commission - Joint 

Research Centre (JRC), Ispra, Italy. 


CONSENSUS MULTIPLE-POTENCY QSAR 

MODELING FOR PREDICTION OF RODENT 

CARCINOGENICITY. E. J. Matthews 2 and K. P. 

Cross 1 . 1 Leadscope, Inc., Columbus, OH and 2 U.S. 

FDA/CFSAN/OFAS, College Park, MD. Sponsor: 

R. Tice. 


DECISION ANALYSIS APPROACH TO 

MODE-OF-ACTION MODELS: EXPLICIT 

EXPRESSION OF DATA QUALITY AND 

RELIABILITY TO EVALUATE CAUSALITY. 

A. M. Jarabek 1,2 and D. Crawford-Brown 2 . 1 U.S. 

EPA, Research Triangle Park, NC and 2 DESE 

University North Carolina, Chapel Hill, NC. 


CASE STUDIES ON THE ROLE OF 

DNA ADDUCT DATA IN CANCER RISK 

ASSESSMENT: CONTEXT IS KEY. J. Skare 1 , 

L. H. Pottenger 2 , L. Andrews 2 , A. Bachman 3 , P. J. 

Boogaard 4 , J. Cadet 5 , P. Farmer 6 , M. Himmelstein 7 , 

A. Jarabek 8 , J. Kim 9 , E. Martin 10 , R. Mauthe 11 , R. 

Persaud 12 , J. Preston 8 , R. Schoeny 8 , J. Swenberg 13 , 

G. Williams 14 , F. Zhang 2 and E. Zeiger 15 . 1 Procter 

& Gamble, Cincinnati, OH, 2 The Dow Chemical 

Company, Midland, MI, 3 EMBSI, Annandale, NJ, 

4 

Shell International, The Hague, Netherlands, 5 CEA/ 

Grenoble, Grenoble, France, 6 U. Leicester, Leicester, 

United Kingdom, 7 DuPont, Newark, DE, 8 U.S. EPA, 

Research Triangle Park, NC, 9 HESI, Washington, 

D.C., 10 AstraZeneca, Macclesfield, United 

Kingdom, 11 Pfizer, Groton, CT, 12 L’Oreal, Clark, NJ, 

13 

University of North Carolina, Chapel Hill, NC, 

14 

NY Medical College, Valhalla, NY and 15 E. Zeiger 

Consulting, Chapel Hill, NC. 


QSAR PREDICTION OF CARCINOGENIC 

POTENCY (TD50) AND THE RISK SPECIFIC 

DOSE(RSD) ADJUSTED THRESHOLD 

OF TOXICOLOGICAL CONCERN (TTC) 

FOR GENOTOXIC CHEMICALS AND 

PHARMACEUTICAL IMPURITIES. J. F. 

Contrera. Computational Toxicology Services LLC, 

Rockville, MD. 


VIRTUAL CHEMICAL-PROTEIN 

RECEPTOR INTERACTIONS CAN 

DIFFERENTIATE TUMOR SITE SELECTIVE 

CARCINOGENS. N. Malik, S. Qamar, C. 

Carrasquer and A. R. Cunningham. James Graham 

Brown Cancer Center, University of Louisville, 


158 






Platform Sessions



Abstract # 


USE OF 'OMICS DATA TO IMPROVE PAH 

MIXTURES CANCER RISK ASSESSMENT. 

P. McClure 1 , H. Carlson-Lynch 1 , J. Stickney 1 , 

K. Salinas 1 , I. Cote 2 and L. Flower 2 . 1 Chemical, 

Biological, and Environmental Center, SRC, Inc., 

North Syracuse, NY and 2 Office of Research and 

Development, U.S. EPA, Washington, D.C. 


SOME TRICKS FOR STATISTICAL 

ANALYSIS OF NEOPLASTIC LESIONS 

USING PROC MULTTEST IN SAS. A. K. 

Thakur and H. Chen. Nonclinical Safety Assessment, 

Covance Laboratories, Vienna, VA. 


A GROUP APPROACH FOR HUMAN 

HEALTH SAFETY ASSESSMENT OF 

FRAGRANCE INGREDIENTS. A. Api, S. 

Bhatia, C. Letizia, D. McGinty, J. Scognamiglio 

and L. W. Smith. Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ. 


IMPLEMENTING COMPUTATIONAL 

METHODS IN AN INSTITUTIONAL 

KNOWLEDGE-BASE AT FDA’S CENTER 

FOR FOOD SAFETY AND APPLIED 

NUTRITION: A MODE-OF-ACTION-BASED 

APPROACH TO BUILDING QSAR MODELS. 

L. Ye, R. Brown, E. Busta, K. Arvidson and C. Yang. 

CFSAN, U.S. FDA, College Park, MD. 


ASSESSMENT OF MITOCHONDRIAL 

TOXICITY OF ENVIRONMENTAL 

CHEMICALS USING A QUANTITATIVE 

HIGH-THROUGHPUT SCREENING 

APPROACH. M. S. Attene-Ramos 1 , R. Huang 1 , S. 

Sakamuru 1 , S. Shahane 1 , L. Shou 1 , K. L. Witt 2 , R. R. 

Tice 2 , C. P. Austin 1 and M. Xia 1 . 1 National Institutes 

of Health Chemical Genomics Center (NCGC), 

Rockville, MD and 2 National Toxicology Program 

(NTP). National Institute of Environmental Health 

Sciences (NIEHS), Research Triangle Park, NC. 



RELATIONSHIP (QSAR) MODELING OF 

ESTROGEN RECEPTOR (ER) BINDING 

AFFINITY AND VIRTUAL SCREENING FOR 

POTENTIAL ENDOCRINE DISRUPTING 

COMPOUNDS (EDCS). L. Zhang 1 , H. Zhu 1 , A. 

Afantitis 2 , G. Melagraki 2 , H. Sarimveis 2 , I. Rusyn 3 

and A. Tropsha 1 . 1 Eshelman School of Pharmacy, 


Hill, NC, 2 NovaMechanics Ltd., Nicosia, Cyprus 

and 3 Environmental Sciences and Engineering, 


Hill, NC. 


A COLLABORATIVE PROJECT FOR DATA 

SHARING AND HARMONIZATION OF 

DEVELOPMENTAL TOXICITY DATABASES. 

E. Busta 1 , S. Espada 2 , M. Martin 3 , D. Hristozov 1 , K. 

Arvidson 1 , D. Mattison 4 and C. Yang 1 . 1 U.S. FDA, 

College Park, MD, 2 Pennsylvania State University, 

College Station, PA, 3 U.S. EPA, Research Triangle 

Park, NC and 4 NICHD, Bethesda, MD. 

Abstract # 


DEHP: COMPARISON OF IN SILICO 

PREDICTIONS WITH IN VITRO AND IN 

VIVO TOXICITY. M. M. Dingemans 1 , E. Rorije 2 , 

A. Efremenko 3 , H. Clewell 3 and B. Blaauboer 1 . 

1 

Institute for Risk Assessment Sciences (IRAS), 

Utrecht University, Utrecht, Netherlands, 2 National 

Institute for Public Health and the Environment 

(RIVM), Bilthoven, Netherlands and 3 The Hamner 

Institutes, Research Triangle Park, NC. 


CHEMICALS IN CONTEXT: EPA DESIGN 

FOR THE ENVIRONMENT GREEN 

CHEMISTRY EVALUATIONS FOR SAFER 

CONSUMER PRODUCTS. C. Baier-Anderson 1 , 

C. Davies 1 , D. DiFiore 1 , K. Grant 1 , D. Johnson 2 , E. 

Lavoie 1 , L. Morlacci 2 , E. Sommer 1 and M. Vrabel 1 . 

1 

Design for the Environment Branch, U.S. EPA, 

Washington, D.C. and 2 SRC, Inc., Arlington, VA. 


APPLICATION OF AGE-SPECIFIC 

ADJUSTMENTS TO CANCER POTENCY 

FOR CHILDREN AT CALIFORNIA SCHOOL 

SITES. S. A. Knadle 1 , H. Bolstad 2 , M. S. Sandy 1 , M. 

A. Marty 1 and J. Carlisle 1 . 1 Cal /U.S. EPA, OEHHA, 

Sacramento, CA and 2 Environmental Toxicology, 

University of California at Davis, Davis, CA. 


DERMAL DNEL SETTING: USING QSAR 

PREDICTIONS FOR DERMAL ABSORPTION 

FOR A REFINED ROUTE-TO-ROUTE 

EXTRAPOLATION. V. Mostert and A. Goergens. 

Toxicology/Human Exposure, Knoell Consult 

GmbH, Leverkusen, Germany. 


AN ASSESSMENT OF THE IMPACT OF 

EXPOSURE DURATION AND INTENSITY 

ON THE HUMAN KINETIC ADJUSTMENT 

FACTOR (HKAF). K. Krishnan 1 and M. Valcke 1,2 . 

1 

Santé environnementale et Santé au travail, 

Université de Montréal, Montréal, QC, Canada and 

2 

Direction de la Santé environnementale et de la 

Toxicologie, Institut national de santé publique du 

Québec, Montréal, QC, Canada. 


EVALUATION OF THE IMPACT OF 

DEMOGRAPHY ON THE ADEQUACY OF 

THE HUMAN KINETIC ADJUSTMENT 

FACTOR (HKAF). M. Valcke 1,2 and K. Krishnan 1 . 

1 

Santé environnementale et Santé au travail, 


2 

Direction de la Santé environnementale et de la 

Toxicologie, Institut national de santé publique du 

Québec, Montréal, QC, Canada. 


DEVELOPMENT OF SURROGATE 

REFERENCE CONCENTRATIONS FOR 

VOLATILE ORGANIC COMPOUNDS 

COMMONLY ENCOUNTERED AT 

HAZARDOUS WASTE SITES. K. Fehling 1 , T. 

Copeland 3 , J. Otani 4 and B. Kerger 2 . 1 The Fehling 

Group, LLC, Novato, CA, 2 Health Science Resource 

Integration, Inc., Tallahassee, FL, 3 Consultant, 

Agoura Hills, CA and 4 Consultant, Menlo Park, CA. 

MONday 







159



MONday 



EFFECTS OF AN ASYMMETRY 

PARAMETER ON CURVE-FITTING FOR 

SINGLE CHEMICAL AND MIXTURE 

CONCENTRATION-RESPONSE DATA: 3) 

MONO-HALOGENATED ACETONITRILES 

AND ETHYL ACETATES. D. A. Dawson 1 , G. 

Pöch 2 and T. W. Schultz 3 . 1 Biology/Toxicology, 

Ashland University, Ashland, OH, 2 Pharmacology 

and Toxicology, University of Graz, Graz, Austria 

and 3 Comparative Medicine, College of Veterinary 

Medicine, The University of Tennessee, Knoxville, 

TN. Sponsor: D. Fort. 






TWENTY RANDOMLY SELECTED SOFT 

ELECTROPHILE-CONTAINING MIXTURES. 

N. Genco 1 , H. Bensinger 1 , Z. Il’Giovine 1 , D. A. 

Dawson 1 , T. W. Schultz 2 and G. Pöch 3 . 1 Biology/ 

Toxicology, Ashland University, Ashland, OH, 

2 

Comparative Medicine, College of Veterinary 


TN and 3 Pharmacology and Toxicology, University 

of Graz, Graz, Austria. Sponsor: D. Fort. 






MONO-, DI- AND TRI-HALOGENATED 

ACETONITRILE COMBINATIONS. D. 

Guinn 1 , D. A. Dawson 1 , T. W. Schultz 2 and G. Pöch 3 . 

1 

Biology/Toxicology, Ashland University, Ashland, 

OH, 2 Comparative Medicine, College of Veterinary 


TN and 3 Pharmacology and Toxicology, University 

of Graz, Graz, Austria. Sponsor: D. Fort. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Animal Models in Toxicological Research 

Chairperson(s): Lori Moilanen, 3M, St. Paul, MN. 




PROPENTOFYLLINE ATTENUATES 

METHAMPHETAMINE–INDUCED 

DOPAMINE RELEASE IN THE RAT 

CAUDATE-PUTAMEN. Z. Binienda 1 , B. Gough 1 , 

F. C. Pereira 2 and S. F. Ali 1,2 . 1 Neurotoxicology, 

U.S. FDA NCTR, Little Rock, AR and 2 Medicine, 

University of Coimbra, Coimbra, Portugal. 


A DOSE VOLUME TOLERABILITY STUDY 

TO EVALUATE WHETHER CD-1 MICE ARE 

EXTRAORDINARILY SENSITIVE TO LIPID- 

BASED DRUG DELIVERY VEHICLES: 

CAPMUL PG-12, CAPMUL MCM, AND 

CREMOPHOR EL. R. Yeager 1 , B. Padden 2 , J. 

Lipari 2 , J. Maher 3 , K. Desino 4 , P. Katavolos 5 , D. 

Weddle 5 and K. Sachdeva 1 . 1 Toxicology, Abbott, 

Abbott Park, IL, 2 Pharmaceutics, Abbott, Abbott 

Park, IL, 3 Investigative Toxicology and Pathology, 

Abbott, Abbott Park, IL, 4 Drug Metabolism, Abbott, 

Abbott Park, IL and 5 Pathology, Abbott, Abbott Park, 

IL. 


ESTABLISHMENT OF 2-STEP ULTRA- 

SHORT-TERM CARCINOGENICITY TEST 

IN CB6F1 TG RASH2 MICE - STUDY ON 

SEVERAL PROMOTERS-. K. Urano 1 , M. 

Kawabe 2 , M. Suguro 2 , T. Numano 2 , M. Yasuda 1 , H. 

Tsutsumi 1 and F. Furukawa 2 . 1 Central Institute for 

Experimental Animals, Kawasaki, Japan and 2 DIMS 

Institute of Medical Science, Inc., Ichinomiya, Japan. 


THE EFFECT OF CLOZAPINE TREATMENT 

ON NEUTROPHIL KINETICS IN SPRAGUE- 

DAWLEY RATS. A. Lobach and J. Uetrecht. 

Pharmaceutical Sciences, University of Toronto, 



TROGLITAZONE-INDUCED LIVER INJURY 

IN CHIMERIC MICE WITH HUMANIZED 

LIVER. M. Kakuni 1 , M. Morita 2 , Y. Katoh 1 , M. 

Nakajima 2 , C. Tateno 1 and T. Yokoi 2 . 1 Study Service 

Department, PhoenixBio Co., Ltd., Higashi- 

Hiroshima, Japan and 2 Division of Pharmaceutical 

Sciences, Faculty of Pharmaceutical Sciences, 

Kanazawa University, Kanazawa, Japan. 


CHARACTERIZATION OF IRON 

OVERLOAD IN RATS AS A POTENTIAL 

MODEL OF HUMAN HEMOCHROMATOSIS. 

S. J. Wildt 1 , T. Bartnikas 2 , M. D. Fleming 2 and D. 

M. Cooper 1 . 1 Laboratory Animal Medicine, Harlan 

Laboratories, Indianapolis, IN and 2 Department of 

Pathology, Children’s Hospital Boston, Boston, MA. 

Sponsor: A. Jackson. 


PAIN ASSESSMENT IN MONOSODIUM 

IODOACETATE (MIA)-INDUCED 

OSTEOARTHRITIS (OA) MODEL. R. 

Samadfam, L. Chouinard and S. Y. Smith. 

Toxicology, Charles River Preclinical Services, 

Montréal, QC, Canada. Sponsor: M. Vézina. 


PROTEOMIC ANALYSIS OF MAINSTREAM 

CIGARETTE SMOKE-EXPOSED FISHER 

RAT NOSES IN A SHORT-TERM STUDY. C. 

A. Carter and M. Misra. Life Sciences, Lorillard 

Tobacco Company, Greensboro, NC. 

160 






Platform Sessions



Abstract # 


FIRST IN MONKEY (FIM) PERFORMED 

TRACKING OF MAGNETIC CAPSULE 

INSIDE THE GASTROINTESTINAL TRACT 

WITH 3D-MAGMA. H. Richert 2 , S. H. Korte 1 and 

S. Abert 2 . 1 Covance Laboratories GmbH, Muenster, 

Germany and 2 Matesy GmbH, Jena, Germany. 

Sponsor: G. Weinbauer. 


TOXIC EFFECTS OF ETHYL TERTIARY 

BUTYL ETHER EXPOSURE IN CYP2E1 

KNOCKOUT MICE. R. Wang 1 , Y. Yanagiba 1 , 

K. Ohtani 1 , M. Suda 1 , Z. Weng 1 and T. Nakajima 2 . 

1 

Japan National Institute of Occupational Safety and 

Health, Kawasaki, Japan and 2 Nagoya University 

School of Medicine, Nagoya, Japan. Sponsor: N. 

Mei. 


THE INDIVIDUAL AND INTERACTIVE 

EFFECTS OF LIPOPOLYSACCHARIDE 

AND DEOXYNIVALENOL ON FREE FATTY 

ACIDS IN THE LIVER AND BRAIN OF RATS. 

I. Ross 1 , T. Boyle 1 , W. D. Johnson 1 , L. H. Garthoff 1 , 

S. M. Ahn 1 , M. W. O’Donnell 2 and C. S. Kim 1 . 1 U.S. 

FDA, Laurel, MD and 2 Biostatistics Branch, Laurel, 

MD. Sponsor: H. Luu. 


FEASIBILITY OF APPLYING DRIED BLOOD 

SPOT (DBS) SAMPLING IN EXPLORATORY 

TOXICITY STUDIES IN THE RAT. W. Scott 1 , 

R. Hunter 2 , Z. Shen 2 , J. May 1 , L. Liu 1 , S. Vekich 2 , 

W. Huang 1 , R. Rahavendran 2 and A. Sacaan 1 . 1 Drug 

Safety Research and Development, Pfizer Inc., San 

Diego, CA and 2 Pharmacokinetics Dynamics and 

Metabolism, Pfizer Inc., San Diego, CA. 


APPLICATION OF PREDICTION INTERVAL 

BASED MIXED-EFFECT MODELS TO 

EVALUATE MONKEY BODY WEIGHT 

CHANGE IN PRECLINICAL TOXICOLOGY 

STUDIES. D. Zhao 1 , R. Yeager 1 , Y. Lan 2 , C. Lin 2 

and M. Duvall 1 . 1 Toxicology, Abbott, Abbott Park, IL 

and 2 Statistics, Abbott, Abbott Park, IL. 


LONGITUDINAL COMPARISON OF 

SPONTANEOUS OCULAR LESIONS IN THE 

NORMAL RAT AND MOUSE ON CHRONIC 

TOXICOLOGY STUDIES. K. Tenneson, N. 

Cicciu and M. Vézina. Toxicology, Charles River 

Preclinical Services, Montréal, QC, Canada. 


COMPARISON OF ANESTHETIC EFFECTS 

ON ELECTRORETINOGRAMS (ERG) IN 

DOGS. G. Glazier, D. Martel, T. Halle, S. Duval, 

T. Bryant and M. Vézina. Toxicology, Charles River 

Preclinical Services, Montréal, QC, Canada. 


APPLICATION OF THE rasH2 MOUSE IN 

CARCINOGENESIS AND BIOMARKER 

STUDIES. Y. Shimamura 1 , R. Arai1, A. Sunohara 1 , 

F. Baba1, K. Urano 2 , H. Tsutsumi 2 , M. Ito 2 , A. 

Hirayama 1 , M. Sugimoto 1 , T. Soga 1 , T. Nomura 2 and 

M. Tomita 1 . 1 Institute for Advanced Biosciences, 

Keio University, Tsuruoka, Yamagata, Japan 

and 2 Central Institute for Experimental Animals, 

Kawasaki, Kanagawa, Japan. 

Abstract # 


DEVELOPMENT OF INDUCIBLE IN VIVO 

RNAi MOUSE MODELS FOR TARGET 

VALIDATION. J. Hitchcock 1 , V. Beuger 2 , 

H. Kissel 2 , N. Pullen 1 and A. Rossi 1 . 1 Pfizer 

Ltd., Sandwich, Kent, United Kingdom and 

2 

TaconicArtemis GmbH, Cologne, Germany. 

Sponsor: M. Sharpe. 


METABOLOMIC ASSESSMENT OF 

TEMPORAL CHANGES INDUCED DURING 

THE COURSE OF A TYPICAL OVERNIGHT 

FAST IN THE SD RAT. D. G. Robertson, S. 

Stryker and J. Vassallo. Discovery Toxicology, 

Bristol-Myers Squibb Company, Princeton, NJ. 


BACKGROUND OCULAR CHANGES 

FOLLOWING TRANSVITREAL 

SUBRETINAL DOSING IN THE RHESUS 

AND CYNOMOLGUS MONKEY. A. 

Préfontaine, M. Bussières and M. Vézina. 


Montréal, QC, Canada. 


DOSE RESPONSE OF DIURON-INDUCED 

URINARY BLADDER HYPERPLASIA IN 

MALE WISTAR RATS. A. F. Cardoso, S. M. 

Ihlaseh, M. S. da Rocha, M. G. Nascimento, J. V. 

de Camargo and M. C. de Oliveira. Pathology, Sao 

Paulo State University - UNESP - Medical School, 

Botucatu, Brazil. 


BIOAVAILABILITY AND DISTRIBUTION 

OF SOIL BOUND POLYCYCLIC AROMATIC 

HYDROCARBONS IN SWINE. R. E. Peters 1 , 

S. D. Siciliano 1,2 and M. Wickstrom 2 . 1 Soil Science, 

University of Saskatchewan, Saskatoon, SK, Canada 

and 2 Toxicology Centre, University of Saskatchewan, 

Saskatoon, SK, Canada. Sponsor: L. Weber. 


CENTELLA ASIATICA AN EMERGING 

ALTERNATIVE TO ALZHEIMER’S 

DISEASE. M. Ahuja, M. Dhanasekaran, M. A. 

Buabeid, V. Suppiramaniam and E. A. AbdelRahman. 

Harrison School of Pharmacy, Auburn, AL. 


CHARACTERIZATION OF LYMPHOCYTE 

SUBSETS IN PERIPHERAL BLOOD OF 

HEALTHY, OBESE, AND TUMOR-BEARING 

DOGS. M. Ko 1 , Q. Peng 1 , A. Gonzales 2 , E. 

McCandless 2 , M. Aleo 2 , R. McCall 2 , S. Kamerling 2 , 

Q. Zong 1 , D. Sace 1 , R. Yafawi 1 , J. Wang 1 and 

A. John-Baptiste 1 . 1 Drug Safety, Research & 

Developement, Pfizer, San Diego, CA and 2 Animal 

Health, Pfizer, Kalamazoo, MI. Sponsor: W. Huang. 


INVESTIGATION, OPTIMIZATION, 

AND VALIDATION OF MINIPIG 

IMMUNOPHENOTYPING BY FLOW 

CYTOMETRY. A. Shen and S. Sokolowski. Drug 

Safety R&D, Pfizer, Inc., Groton, CT. Sponsor: J. 

Colangelo. 

MONday 







161



MONday 



IGE POSITIVITY IN B LYMPHOCYTES: A 

VALUABLE BIOMARKER FOR DIAGNOSIS 

OF CANINE ALLERGY. Q. Peng 1 , M. Ko 1 , A. 

Gonzales 1,2 , E. McCandless 1,2 , Q. Zong 1 , F. Sace 1 , 

R. Yafawi 1 , J. Wang 1 and A. John-Baptiste 1 . 1 DSRD, 

Pfizer, San Diego, CA and 2 Animal Health, Pfizer, 

Kalamazoo, MI. Sponsor: G. Stevens. 


INFLUENCE OF A MIXTURE OF FIVE 

PESTICIDES ON THE REPRODUCTIVE 

SYSTEM OF FEMALE SPRAGUE-DAWLEY 

RATS. V. M. Pacotto 1 , M. T. Guerra 2 , J. V. de 

Camargo 1 and C. S. Franchi 1 . 1 Pathology, Sao 


Botucatu, San Paulo, Brazil and 2 Graduate Program 

in Cell and Structural Biology, State University of 

Campinas, Campinas, Sao Paulo, Brazil. Sponsor: S. 

Cohen. 


BIOLOGICAL PATHWAY ANALYSES OF 

HEPATOTOXICANT-INDUCED CHANGES 

IN HEPATIC GENE EXPRESSION IN 

CHIMERIC PXB-MOUSE ® WITH HIGHLY 

HUMANIZED LIVER. S. Nagatsuka 1 , D. Hynes 1 , 

S. Ninomiya 1 , M. Kakuni 2 , C. Tateno-Mukaidani 2 , 

T. Shimada 2 and Y. Yamazoe 3 . 1 R&D, Sekisui 

Medical Co., ADME & Toxicology Research 

Institute, Tokai-mura, Ibaraki, Japan, 2 PhoenixBio 

Co., Higashi-Hiroshima, Hiroshima, Japan and 

3 

Graduate School of Pharmaceutical Sciences, 

Tohoku University, Sendai, Miyagi, Japan. Sponsor: 

T. Miyaoka. 


THE EFFECTS OF CILOSTAZOL ON MOUSE 

OOCYTE MEIOTIC MATURATION AND 

MORPHOLOGY. A. M. Taiyeb 1 , D. Kraemer 1 , 

V. Fajt 1 and C. M. Sayes 1,2 . 1 Veterinary Physiology 

& Pharmacology, Texas A&M University, College 

Station, TX and 2 Interdisciplinary Program in 

Toxicology, Texas A&M University, College Station, 

TX. 


3D LIVER CO-CULTURES MAINTAIN 

PHASE I, II, AND III METABOLISM 

ACTIVITY IN LONG-TERM CULTURE. J. 

Llamas Vidales 1 , L. New 1 , C. I. Pearson 1 , A. H. 

Roter 2 , B. A. Naughton 1 and D. R. Applegate 1 . 1 R&D, 

RegeneMed, Inc., San Diego, CA and 2 Entelos, Inc., 

Foster City, CA. Sponsor: R. Thomas. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Animal Models in Toxicology 

Chairperson(s): Jessica Whritenour, Pfizer Global Research and 

Development, Groton, CT. 




ATP-BINDING-CASSETTE TRANSPORTER 

KNOCKOUT RAT MODELS. I. D. Carbery, L. 

C. Little, E. J. Weinstein and X. Cui. SAGE, Sigma- 

Aldrich, St. Louis, MO. 


PATHOLOGY OF A BROWN-NORWAY RAT 

MODEL OF AMODIAQUINE-INDUCED 

LIVER INJURY. H. C. Workman 1 , J. Li 2 , P. 

Cai 3 , M. Odin 1 , M. David 1 and J. Uetrecht 3,4 . 

1 

Nonclinical Safety, Hoffmann-La Roche, Nutley, 

NJ, 2 Immunotoxicology, Bristol-Myers Squibb, New 

Brunswick, NJ, 3 Pharmacy, University of Toronto, 

Toronto, ON, Canada and 4 Medicine, University of 



ALTERED BEHAVIOR, BODY WEIGHT, 

AND BRAIN CHEMISTRY IN PAK5-/-, PAK6 

-/-AND PAK5-/-/PAK6-/-MICE. M. A. Furnari 1 , 

M. L. Jobes 1 , T. Nekrasova 2 , A. Minden 2 and G. C. 

Wagner 1,3 . 1 Joint Graduate Program in Toxicology, 

Rutgers University, Piscataway, NJ, 2 Susan Lehman 

Cullman Laboratory for Cancer Research, Rutgers 

University, Piscataway, NJ and 3 Psychology, Rutgers 

University, Piscataway, NJ. 


THE TOXICITY OF METHIMAZOLE IN 

THE MOUSE OLFACTORY MUCOSA IS AT 

LEAST PARTLY MEDIATED THROUGH 

TARGET-TISSUE METABOLIC ACTIVATION 

BY CYP2A5. J. Gu 1 , F. Xie 1 , X. Zhou 1 , M. Genter 2 

and X. Ding 1 . 1 Wadsworth Center, New York State 

Department of Health, Albany, NY and 2 Department 

of Environmental Health, University of Cincinnati, 



MODELS OF ACUTE LUNG 

INFLAMMATION IN NON HUMAN 

PRIMATES: LPS, MECHANICAL 

VENTILATION, PSEUDOMONAS 

AERUGINOSA, AND CIGARETTE SMOKE. 

R. W. Spindle, M. Doyle-Eisele, O. Denise, J. Tipper, 

K. Harrod, R. Jaramillo and J. McDonald. LRRI, 



EVALUATING THE CELLULAR CHANGES 

IN BLEOMYCIN-INDUCED PULMONARY 

FIBROSIS MODELS: IT VS. INHALATION. 

M. Doyle-Eisele, R. W. Spindle, A. Gigliotti and J. D. 

McDonald. LRRI, Albuquerque, NM. 


THE PATHOPHYSIOLOGY OF 

PROGRESSIVE EXPOSURE TO TOBACCO 

SMOKE IN A RODENT MODEL OF 

CHRONIC OBSTRUCTIVE PULMONARY 

DISEASE (COPD). L. Wang 1 , S. Bolton 2 and 

K. E. Pinkerton 1 . 1 Center for Health and the 

Environment, University of California, Davis, Davis, 

CA and 2 Safety Assessment, AstraZeneca R&D, 

Loughborough, United Kingdom. 


USE OF MOUSE MODEL AS AN EARLY 

SCREENING TOOL FOR PDE4 INHIBITOR- 

INDUCED GASTROINTESTINAL TOXICITY. 

C. Chen, H. Sexton, K. Jarnagin, X. Fan, W. Bu, A. 

Wu, Y. Freund and S. Chanda. Toxicology, Anacor 

Pharmaceuticals, Palo Alto, CA. 

162 






Platform Sessions



Abstract # 


EFFICACY OF PHARMACEUTICAL DRUG 

COCKTAILS FOR TREATING CHLORINE 

VAPOR INDUCED CUTANEOUS LESIONS. 

J. Rhone 1 , J. L. Plahovinsak 1 , E. M. Benson 1 , R. 

C. Hamilton 1 , F. M. Reid 1 , J. F. Dillman 2 and J. S. 

Graham 2 . 1 Biomedical Research Center, Battelle, 

Columbus, OH and 2 U.S. Army Medical Research 

Institute of Chemical Defense, Aberdeen, MD. 


EFFICACY OF PHARMACEUTICAL 

DRUG COCKTAILS FOR AMELIORATION 

OF CUTANEOUS SULFUR MUSTARD 

INJURIES. F. M. Reid 1 , J. L. Plahovinsak 1 , M. 

D. Etheridge 1 , J. Rhone 1 , J. F. Dillman 2 and J. S. 

Graham 2 . 1 Biomedical Research Center, Battelle, 




BEHAVIORAL EFFECTS OF REPIN IN 

MICE. W. K. Rumbeiha and J. Nunez. Michigan 

State University, East Lansing, MI. 


INTRAVITREOUS INJECTION-RELATED 

RESPONSES AND THEIR MANAGEMENT IN 

NON-HUMAN PRIMATE - A CASE STUDY. 

T. T. Lam, J. Seeman and B. J. Christian. Covance, 

Madison, WI. 


DIURON-INDUCED DECREASE OF CD4+ 

LYMPHOCYTES IN THE SPLEEN OF MALE 

WISTAR RATS. S. M. Ihlaseh, A. Domingues, 

A. F. Cardoso, A. T. Spinardi-Barbisan, M. C. de 

Oliveira and J. V. de Camargo. Pathology, Sao 


Botucatu, Brazil. 


INCREASED SECONDARY BILE ACIDS 

IN OATP1A1-NULL MICE CAN BE 

EXPLAINED BY AN OVERGROWTH OF 

INTESTINAL BACTERIA. P. B. Limaye 1 , Y. 

Zhang 1 , I. L. Csanaky 1 , L. Lehman-McKeeman 2 and 

C. D. Klaassen 1 . 1 Department of Pharmacology, 

Toxicology, and Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Discovery 

Toxicology, Bristol-Myers Squibb Co., Princeton, 

NJ. 


TREATMENT PARADIGM FOR 

ASSESSMENT OF ETIOLOGIES OF 

PAFURAMDINE-INDUCED KIDNEY AND 

LIVER TOXICITY. K. D. DeSmet 1 , A. Harrill 1 , 

J. Hall 2 , M. Paine 3 , M. Wang 3 , R. Tidwell 2 and P. 

Watkins 1 . 1 Institute for Drug Safety Sciences, The 


Triangle Park, NC, 2 Department of Pathology and 

Laboratory Medicine, University of North Carolina 

at Chapel Hill, Chapel Hill, NC and 3 Eshelman 

School of Pharmacy, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 

Abstract # 


CO-EXPOSURE OF A NOVEL 

MOUSE MODEL TO LOW-DOSE 

TRICHLOROETHYLENE AND INORGANIC 

ARSENIC: INTERACTIONS, GENETICS, 

AND RENAL TOXICITY. M. C. DeSimone 1,2 , G. 

Glavich 2 , A. Bohn 2 and D. Threadgill 1,2 . 1 Curriculum 

in Toxicology, University of North Carolina at 

Chapel Hill, Chapel Hill, NC and 2 Department of 

Genetics, North Carolina State University, Raleigh, 

NC. 


LIPIDOMIC CHANGES IN THE LIVERS OF 

HEPATIC ALCOHOL DEHYDROGENASE- 

DEFICIENT DEER MICE AFTER 

SUBCHRONIC EXPOSURE TO ETHANOL. 

H. Fernando, K. K. Bhopale, G. A. Ansari and B. S. 

Kaphalia. Department of Pathology, University of 

Texas Medical Branch, Galveston, TX. 


DEVELOPMENT AND EVALUATION OF 

A MUCOCILIARY CLEARANCE MODEL 

IN BEAGLE DOGS VIA PLANAR GAMMA 

CAMERA IMAGE ANALYSIS. P. Kuehl, R. 

Chand, M. Doyle-Eisele and J. McDonald. LRRI, 



REPRESSION OF MULTIPLE CYP2B 

MEMBERS BY RNAI IN MICE. B. Damiri, X. 

Yu, E. Holle and W. S. Baldwin. Biology/ Clemson 

University, Environmental Toxicology, Clemson, SC. 


ENDOTHELIAL CELL-SPECIFIC ARYL 

HYDROCARBON RECEPTOR KNOCKOUT 

MICE ARE HYPOTENSIVE AND 

EXHIBIT DIMINISHED RESPONSES TO 

ANGIOTENSIN II. L. N. Agbor, M. T. Walsh and 

M. K. Walker. Pharmaceutical Sciences, University 

of New Mexico, Albuquerque, NM. 


STUDY DESIGN CONSIDERATIONS 

FOR ACCURATE CARDIAC TROPONIN 

EVALUATION IN NON-HUMAN PRIMATES 

AND RATS. W. J. Reagan, D. Blackwell, L. 

Correia, K. Alger, C. Kaplan and F. Geoly. Pfizer, 

Groton, CT. 


EFFECTS OF TRAINING ON BLOOD 

PRESSURE MEASUREMENT BY HDO IN 

CYNOMOLGUS MONKEYS. B. Niggemann, 

M. Niehoff, J. Luft and G. Weinbauer. Covance 

Laboratories GmbH, Muenster, Germany. 


RELIABLE DETECTION OF 

HYPERTENSION AND HYPOTENSION 

IN CONSCIOUS, FREELY MOVING 

CYNOMOLGUS MONKEYS (MACACA 

FASCICULARIS). M. Niehoff, B. Niggemann, J. 

Sternberg, U. Zuehlke and G. Weinbauer. Covance 

Laboratories GmbH, Muenster, Germany. 

MONday 







163



MONday 



STATISTICAL ANALYSIS OF 

ELECTROCARDIOGRAPHIC (ECG) DATA 

COLLECTED BY JACKETED EXTERNAL 

TELEMETRY (JET) AND IMPLANTED 

TELEMETRY (IMPTLM) IN NONHUMAN 

PRIMATES. J. J. Kremer, M. A. Osinski, Z. Xiang, 

E. Lemke, T. W. Beck and C. M. Foley. Covance 

Laboratories Inc., Madison, WI. 


MINIMALLY-INVASIVE TELEMETRIC 

MEASUREMENT OF ARTERIAL BLOOD 

PRESSURE IN THE FREELY MOVING 

MINIPIG. ISOPRENALINE VALIDATION. S. 

Baudet 1 , S. Milano 1 , O. Boucheix 1 , E. Chalencon 1 , 

P. Lege 1 , C. Bory 1 , C. Dupuis 1 , E. Rieux 2 and S. 

Tiesma 2 . 1 Ricerca Biosciences SAS, Lyon, France 

and 2 Data Sciences International, St. Paul, MN. 


CLINICAL AND HISTOPATHOLOGICAL 

OUTCOMES FOLLOWING AMBULATORY 

INTRAVENOUS INFUSION FOR USE IN 

PRECLINICAL STUDIES IN THE BEAGLE 

DOG. J. Briffaux, C. Gerhardy, M. Chopinaud 

and N. Pickersgill. Ricerca Biosciences SAS, Lyon, 

France. 


HIGH DEFINITION OSCILLOMETRY 

(HDO) IN MONKEYS: ACCLIMATION 

REQUIREMENTS AND SENSITIVITY 

ASSESSMENT OF HDO VERSUS 

TELEMETRY. A. Mitchell, A. Lee and T. W. 

Beck. Safety Pharmacology, Covance Laboratories 

Inc., Madison, WI. Sponsor: P. Kruzich. 


TELEMETRY ECG LEAD PLACEMENT 

IN CYNOMOLGUS MONKEYS (MACACA 

FASCICULARIS): METHOD TO MAXIMIZE 

SIGNAL QUALITY. S. Authier 1,4 , M. Stonerook 2 , 

S. Fournier 1 , B. Moon 3 and E. Troncy 3 . 1 Lab. 

Research Inc., Laval, QC, Canada, 2 Vertex 

Pharmaceuticals, Cambridge, MA, 3 Data Science 

International, St. Paul, MN and 4 Faculty of 

Veterinary Medicine, University of Montréal, St. 

Hyacinthe, QC, Canada. Sponsor: K. Draper. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Inhalation and Cardiopulmonary Toxicology 

Chairperson(s): Mehdi Hazari, U.S. EPA, Research Triangle Park, NC, 

and Jonathan Shannahan, University of North Carolina Chapel Hill, 

Chapel Hill, NC. 




CHARACTERIZATION OF WELDING 

AEROSOLS GENERATED BY RESISTANCE 

SPOT WELDING. A. Afshari, B. T. Chen, D. 

Schwegler-Berry, J. Cumpston, A. Cumpston, D. 

Leonard, S. Friend, P. C. Zeidler-Erdely, D. G. Frazer 

and J. M. Antonini. NIOSH, Morgantown, WV. 


ACUTE INHALATION STUDY OF ALLYL 

ALCOHOL FOR DERIVATION OF ACUTE 

EXPOSURE GUIDELINE LEVELS (AEGL). 

A. Li 1 , J. Fowles 2 , M. Banton 2 , C. Picut 3 and D. 

Kirkpatrick 3 . 1 Exponent Inc., San Francisco, CA, 

2 

LyondellBasell, Rotterdam, Netherlands and 3 WIL 

Research Laboratories, LLC, Ashland, OH. 


COMPARING ELECTROSTATIC AEROSOL 

IN VITRO EXPOSURE SYSTEM (EAVES) TO 

TRADITIONAL PARTICULATE MATTER 

EXPOSURE TECHNIQUE. K. Lichtveld 1 , 

S. Ebersviller 1 , K. G. Sexton 1 , H. Jeffries 1 and I. 

Jaspers 2 . 1 Environmental Sciences & Engineering, 


Hill, NC and 2 CEMALB, Chapel Hill, NC. 


VITAMIN C YELLOWING ASSAY 

STUDIES WITH TITANIUM DIOXIDE AND 

NONFIBROUS POTASSIUM TITANATE 

SAMPLES. D. B. Warheit 1 , K. L. Reed 1 and S. 

Sakai 2 . 1 DuPont Haskell Lab., Wilmington, DE and 

2 

Otsuka Chemical Company, Osaka, Japan. 


SUSTAINED TRANSCRIPTIONAL 

RESPONSES ACCOMPANY PULMONARY 

ACROLEIN EXPOSURE IN MICE. P. 

C. Burcham, B. Lauder, A. Raso and P. Henry. 

Pharmacology Unit, University of Western Australia, 

Nedlands, WA, Australia. 


GAS-PHASE AND PARTICULATE 

COMPONENTS OF DIESEL EXHAUST 

PRODUCE DIFFERENTIAL 

CARDIOPHYSIOLOGICAL IMPAIRMENTS 

IN HEALTHY RATS. C. Gordon 1 , Q. Krantz 2 , P. J. 

Rowsey 3 , M. C. Schladweiler 2 , A. D. Ledbetter 2 and 

U. P. Kodavanti 2 . 1 Toxicity Asessment Division, U.S. 

EPA, Research Triangle Park, NC, 2 Environmental 

Public Health Divsion, U.S. EPA, Research Triangle 

Park, NC and 3 University of North Carolina, Chapel 

Hill, NC. 


A POSSIBLE MECHANISM ASSOCIATED 

WITH AMIODARONE-INDUCED 

PULMONARY TOXICITY. B. M. ALShammari 1 , 

S. AlBakheet 2 and M. Khalifa 2 . 1 National Food and 

Drug Authority, Saudi Food and Drug Authority, 

Riyadh, Saudi Arabia and 2 Pharmacology, King Saud 

University, Riyadh, Saudi Arabia. 


VARIABILITY IN ONSET OF ECG CHANGES 

INDICATIVE OF ISCHEMIA AFTER 

EXPOSURE TO WHOLE VS FILTERED 

DIESEL EXHAUST IN HYPERTENSIVE 

RATS—INSIGHT ON MECHANISM? C. 

M. Lamb 1 , N. Haykal-Coates 2 , A. P. Carll 3 , M. S. 

Hazari 2 , D. W. Winsett 2 , D. L. Costa 4 and A. K. 

Farraj 2 . 1 Toxicology, University of North Carolina 

at Chapel Hill, Chapel Hill, NC, 2 EPHD, U.S. EPA, 

Research Triangle Park, NC, 3 EHE, University of 

North Carolina School of Public Health, Chapel Hill, 

NC and 4 ORD, U.S. EPA, Research Triangle Park, 

NC. 

164 






Platform Sessions



Abstract # 


THE ROLE OF RELMα (RESISTIN LIKE 

MOLECULE α) IN THE RESPONSES OF THE 

LUNG’S VASCULATURE TO ANTIGEN AND 

URBAN PARTICULATE MATTER. G. Grunig, 

M. Sisco, T. Gordon and C. Hoffman. Environmental 

Medicine, New York University, Tuxedo, NY. 


TOXIC LOAD METHOD FOR 

CALCULATING INHALATION DOSES 

FOLLOWING TOXIC VAPOR EXPOSURES. 

S. Chesler 1 , H. Salem 1 and J. Moser 2 . 1 Edgewood 

Chemical Biological Center, Gunpowder, MD and 

2 

Chemical Security Analysis Center, Aberdeen 

Proving Ground, MD. 


PRELIMINARY ASSESSMENT OF 

PULMONARY TOXICITY OF MIDDLE 

EASTERN SOIL EXTRACT IN A RAT 

MODEL. M. L. Foster 1 , K. H. Taylor 1 , M. G. 

Stockelman 2 , J. A. Centeno 3 and D. C. Dorman 1 . 

1 

College of Veterinary Medicine, North Carolina 

State University, Raleigh, NC, 2 Naval Medical 

Research Unit, Dayton, Wright-Patterson AFB, 

OH and 3 Armed Forces Institute of Pathology, 



THE CIGARETTE ADDITIVE MENTHOL 

BLOCKS THE RESPIRATORY TRACT 

IRRITATION RESPONSE TO ACROLEIN, 

A PRIMARY IRRITANT IN CIGARETTE 

SMOKE. D. N. Willis 1 , B. Liu 2 , J. B. Morris 1 

and S. Jordt 2 . 1 Toxicology Program, University of 

Connecticut, Storrs, CT and 2 Pharmacology, Yale 

University Medical School, New Haven, CT. 


THE USE OF E-CADHERIN 

IMMUNOFLUORESCENCE IN PULMONARY 

TOXICOLOGIC PATHOLOGY STUDIES. L. 

A. Battelli, V. Castranova, D. W. Porter, S. Friend, 

D. Schwegler-Berry, P. Willard and A. F. Hubbs. 

HELD, NIOSH, Morgantown, WV. 


TELEMETERED THORACIC IMPEDANCE 

PNEUMOGRAPHY: COMPARISON 

WITH AMBULATORY RESPIRATION 

MEASUREMENT STANDARDS IN THE 

ANESTHETIZED BEAGLE DOG AND 

PHARMACOLOGICAL VALIDATION. S. 

Milano 1 , C. Bory 1 , S. Baudet 1 and B. Moon 2 . 1 Ricerca 

Biosciences SAS, Lyon, France and 2 Data Sciences 

International, St. Paul, MN. 


INHALATION CAPSULE DOSER- 

CONSERVING TEST ARTICLE IN SMALL 

SCALE INHALATION EXPOSURES. S. A. 

Moore 1 , R. Goodway 1 , C. Hardy 1 , D. Coombs 1 , 

A. Allen 1 , S. Cracknell 2 , G. Paul 3 , G. Somers 3 , A. 

Smith 3 , A. Taylor 3 , S. Sparrow 3 and D. Hassall 3 . 

1 

Inhalation, Huntingdon Life Sciences, Huntingdon, 

United Kingdom, 2 Huntingdon Life Sciences, East 

Millstone, NJ and 3 GlaxoSmithKline (GSK), Ware, 


Abstract # 


IN VITRO MACROPHAGE CYTOTOXICITY 

OF INDIUM-PHOSPHIDE AND INDIUM- 

TIN OXIDE PARTICLES IS DEPENDENT 

UPON PHAGOSOME ACIDIFICATION 

AFTER PARTICLE UPTAKE. W. M. Gwinn 1 , 

C. J. Shines 1 , R. W. Bousquet 2 and D. L. Morgan 1 . 

1 

Laboratory of Toxicology and Pharmacology, 

NIEHS, Research Triangle Park, NC and 2 Alion 

Science and Technology Corporation, Research 



THE EFFECT OF PARTICLE SIZE AND 

SEASON ON THE TOXICITY OF URBAN 

AND RURAL PM. J. E. Mirowsky 1 , C. Hickey 1 , 

M. Lippmann 1 , R. Peltier 2 , L. Horton 1 , K. Galdanes 1 

and T. Gordon 1 . 1 Environmental Medicine, New York 

University, Tuxedo Park, NY and 2 Environmental 

Health, University of Massachusetts, Amherst, MA. 


BIOMARKERS FOR NASAL RESPONSE 

TO NAPHTHALENE VAPOR. J. B. Morris 1 , 

L. S. Van Winkle 2 , J. Cichocki 1 and A. R. Buckpitt 2 . 

1 

Toxicology Program, University of Connecticut, 

Storrs, CT and 2 Veterinary Medicine, University 

California Davis, Davis, CA. 


AMBIENT PARTICLE COMPOSITION 

AND MECHANISMS OF ENDOTHELIAL 

DYSFUNCTION IN A MURINE MODEL. A. 

Cuevas, E. Liberda and L. Chen. Environmental 

Medicine, New York University School of Medicine, 

Tuxedo, NY. 


GENERATION AND CHARACTERIZATION 

OF A CYP2F2-NULL MOUSE MODEL AND 

STUDIES ON THE ROLE OF CYP2F2 IN 

NAPHTHALENE-INDUCED TOXICITY IN 

THE LUNG AND NASAL MUCOSA. L. Li 1,2 , 

Y. Wei 1,2 , L. Van Winkle 3 , X. Zhou 1 , J. Hu 1 , F. Xie 1,2 , 

K. Kluetzman 1 and X. Ding 1 . 1 Wadsworth Center, 

New York State Department of Health, Albany, NY, 

2 


York at Albany, Albany, NY and 3 Center for Health 

and the Environment, University of California Davis, 

Davis, CA. 


GENDER-RELATED DIFFERENCES IN AIR 

POLLUTION – MEDIATED EXPRESSION 

OF FACTORS ASSOCIATED WITH 

PROGRESSION OF ATHEROSCLEROSIS. 

A. K. Lund, J. Lucero, L. Blair and J. D. McDonald. 

Lovelace Respiratory Research Institute, 



CHANGES IN MOUSE PULMONARY 

RESPONSES AS A FUNCTION 

OF METHACHOLINE AEROSOL 

CHARACTERISTICS. B. A. Haghverdian 1 , 

L. Mendez 2 , A. Keebaugh 1 , G. Gookin 1 and M. 

Kleinman 1 . 1 Medicine, University of California 

Irvine, Irvine, CA and 2 Microbiology and Molecular 

Genetics, University of California Irvine, Irvine, CA. 

MONday 







165



MONday 



ACUTE INHALATION SAFETY 

ASSESSMENT OF ACETYLATED LECITHIN. 

S. A. MacKenzie, T. A. Kegelman and M. P. 

DeLorme. Inhalation Toxicology, DuPont Haskell 

Global Centers for Health and Environmental 

Sciences, Newark, DE. 


6:2 FLUOROTELOMER ALCOHOL: 

INHALATION EXPOSURE ATMOSPHERE 

CHARACTERIZATION AND ACUTE 

INHALATION TOXICITY. D. P. Kelly, T. L. 

Serex, R. C. Buck, S. E. Loveless and M. P. DeLorme. 

Inhalation Toxicology, DuPont Haskell Global 

Centers for Health and Environmental Sciences, 

Newark, DE. 


6:2 FLUOROTELOMER ALCOHOL: ONE- 

WEEK INHALATION TOXICITY STUDY. 

M. P. DeLorme, T. L. Serex, S. R. Frame, R. C. 

Buck and S. E. Loveless. Inhalation Toxicology, 

DuPont Haskell Global Centers for Health and 

Environmental Sciences, Newark, DE. 


BEHAVIORAL EFFECT OF CHRONIC 

INHALATION EXPOSURE TO 

MOTORCYCLE EXHAUST IN RATS. H. 

Yu, T. Li and T. Ueng. National Taiwan University, 

Taipei, Taiwan. 


STUDY OF GENERATING AND 

MONITORING PROTEIN AEROSOL FOR 

INHALATION STUDY. J. Song, H. Yang, S. 

Kwon, K. Jung, Y. Yang, K. Lee, J. Heo, C. Kim and 

C. Song. Koeran Institute of Toxicology, Jeong-Up, 



A MOUSE VIDEO INSTILLATOR (MOVI) 

FOR INTRATRACHEAL INSTILLATION 

IN THE MOUSE. K. Lee 1 , B. Lee 2 , K. Cho 1 , C. 

Kim 1 and C. Song 1 . 1 Korea Institute of Toxicology, 

Jeongup, Republic of Korea and 2 Doobae System, 

Seoul, Republic of Korea. 


IN VITRO AND IN VIVO ANALYSIS 

OF SIZE-FRACTIONATED PM FROM 

DIFFERENT U.S. CITIES. C. A. Hickey, L. 

Horton, K. Galdanes, M. Lippmann and T. Gordon. 

Environmental Medicine, New York University 

School of Medicine, Tuxedo, NY. 


TOBACCO SMOKE MODULATES THE 

PULMONARY AND CNS EFFECTS OF 

OZONE INHALATION IN RATS. V. 

Bhoopalan 1 , M. M. Shah 1,3 , D. M. Thomas 1,3 , S. Han 2 

and D. K. Bhalla 1 . 1 Pharmaceutical Sciences, Wayne 

State University, Detroit, MI, 2 Animal and Food 

Sciences, University of Kentucky, Lexington, KY 

and 3 R&D Service, John D. Dingell VAMC, Detroit, 

MI. 


CYTOPROTECTIVE GENE EXPRESSION BY 

ACTIVATION OF NRF2 TRANSCRIPTION 

FACTOR IN LUNG OF RATS EXPOSED 

TO FINE AND ULTRAFINE AMBIENT 

PARTICULATE MATTER IN MEXICO CITY. 

A. Valdés-Arzate 1 , M. Uribe-Ramirez 1 , O. G. Aztatzi- 

Aguilar 1 , M. Tinoco-Mendez 2 , C. Gómez-Ruiz 2 , I. 

Gracia-Mora 3 , M. T. Kleinman 4 and A. De Vizcaya- 

Ruiz 1 . 1 Department of Toxicology, Cinvestav, Mexico 

City, Mexico, 2 Unidad de Experimentación Animal, 

Facultad de Quimica, UNAM, Mexico City, Mexico, 

3 

Departamento de Quimica Inorganica y Nuclear, 

Facultad de Quimica, UNAM, Mexico City, Mexico 

and 4 Division of Occupational and Environmental 

Medicine, Department of Medicine, University of 

California Irvine, Irvine, CA. 


DETERMINATION OF HAZARD 

ASSOCIATED WITH AMINE AND AMINE 

DEGRADATION PRODUCTS FROM 

CARBON SEQUESTRATION PROCESSES. V. 

Naik 1 , J. McDonald 1 , M. Doyle-Eisele 1 , E. Knipping 2 

and A. Rohr 2 . 1 Lovelace, Albuqueruque, NM and 

2 

Electric Power Research Institute, Palo Alto, CA. 


TRACHEOBRONCHIAL AIRWAY 

MORPHOMETRY FOR THE C57BL/6 

MOUSE: IMPLICATIONS IN INHALED 

DOSIMETRY PREDICTIONS. L. B. Mendez 1,2 , 

R. F. Phalen 2 and G. J. Ramirez 3 . 1 Microbiology and 

Molecular Genetics, University of California Irvine, 

Irvine, CA, 2 Medicine, University of California 

Irvine, Irvine, CA and 3 East Los Angeles College, 

Monterey Park, CA. 


DECREMENTS IN HEART RATE 

VARIABILITY IN A ATHEROSCLEROTIC 

MOUSE MODEL DUE TO EXPOSURE 

TO SEMI-VOLATILE COMPONENTS OF 

ULTRAFINE CONCENTRATED AMBIENT 

PARTICULATES. A. J. Keebaugh 1 , G. Gookin 1 , 

M. MacKinnon 1 , K. Salazar 1 , L. Mendez 2 , D. 

Meacher 1 , C. Sioutas 3 and M. Kleinman 1 . 1 Medicine, 

University of California Irvine, Irvine, CA, 

2 

Microbiology and Molecular Genetics, University 

of California Irvine, Irvine, CA and 3 Civil and 

Environmental Engineering, University of Southern 

California, Los Angeles, CA. 


DERIVATION OF PHYSIOLOGICAL 

INHALATION RATES IN CHILDREN, 

ADULTS, AND ELDERLY BASED ON 

NIGHTTIME AND DAYTIME RESPIRATORY 

PARAMETERS. P. Brochu, K. Krishnan and J. 

Brodeur. Université de Montréal, Montréal, QC, 

Canada. 


DERIVATION OF CARDIAC OUTPUT 

AND ALVEOLAR VENTILATION RATE 

BASED ON ENERGY EXPENDITURE 

MEASUREMENTS IN HEALTHY MALES 

AND FEMALES. B. Pierre, K. Krishnan and J. 

Brodeur. Université de Montréal, Montréal, QC, 

Canada. 

166 






Platform Sessions



Abstract # 


EFFECT OF ETHANOL VAPORS, OZONE, 

AND NANOPARTICLES ON PULMONARY 

INFLAMMATION IN A RAT MODEL OF 

ALLERGIC ASTHMA. A. Scarino 1 , R. Tardif 2 , 

P. Renzi 2 and M. Charbonneau 1 . 1 INRS-Institut 

Armand-Frappier, Université du Québec, Laval, QC, 

Canada and 2 Université de Montréal, Montréal, QC, 

Canada. 


QUANTIFICATION OF THE 

PATHOLOGICAL RESPONSE AND FATE IN 

THE LUNG AND PLEURA OF CHRYSOTILE 

IN COMBINATION WITH FINE PARTICLES 

COMPARED TO AMOSITE-ASBESTOS 

FOLLOWING SHORT-TERM INHALATION 

EXPOSURE. D. M. Bernstein 1 , R. A. Rogers 2 

and H. E. Stewart 3 . 1 Consultant in Toxicology, 

Geneva, Switzerland, 2 Rogers Imaging Corporation, 

Needham, MA and 3 Georgia-Pacific, LLC, Atlanta, 

GA. 


TWO-WEEK INHALATION EXPOSURE OF 

RATS TO LIBBY AMPHIBOLE (LA) AND 

AMOSITE ASBESTOS. S. H. Gavett 1 , A. M. 

Jarabek 1 , E. W. Tewksbury 2 , E. Bermudez 2 , V. A. 

Wong 2 , E. A. Gross 2 , G. A. Willson 3 , H. G. Wall 3 and 

D. E. Dodd 2 . 1 U.S. EPA, Research Triangle Park, NC, 

2 

The Hamner Institutes for Health Sciences, Research 

Triangle Park, NC and 3 Experimental Pathology 

Laboratories, Inc., Research Triangle Park, NC. 


LONG TERM RESPONSE OF RATS TO 

SINGLE INTRATRACHEAL EXPOSURE OF 

LIBBY AMPHIBOLE (LA) OR AMOSITE. 

J. M. Cyphert 1 , D. J. Padilla-Carlin 1 , M. C. 

Schladweiler 2 , A. Nyska 3 , J. H. Shannahan 1 , U. 

P. Kodavanti 2 and S. H. Gavett 2 . 1 Curriculum in 

Toxicology, University of North Carolina School 

of Medicine, Chapel Hill, NC, 2 EPHD, NHEERL, 

U.S. EPA, Research Triangle Park, NC and 3 Sackler 

School of Medicine, Tel Aviv University, Tel Aviv, 

Israel. 


LIBBY AMPHIBOLE-INDUCED 

INFLAMMATION IS MODULATED BY IN 

IRON IN VITRO AND IN VIVO. J. Shannahan 1 , 

M. Schladweiler 2 , J. McGee 2 , J. Richards 2 , S. 

Gavett 2 , A. Ghio 2 and U. Kodavanti 2 . 1 University of 

North Carolina Chapel Hill, Chapel Hill, NC and 

2 



INHALATION OF OZONE AND DIESEL 

EXHAUST PARTICLES (DEP) INDUCES 

ACUTE AND REVERSIBLE CARDIAC GENE 

EXPRESSION CHANGES. U. P. Kodavanti 1 , B. 

Vallanat 2 , M. C. Schladweiler 1 and A. D. Ledbetter 1 . 

1 

EPHD, NHEERL, U.S. EPA, Research Triangle 

Park, NC and 2 RCU, NHEERL, U.S. EPA, Research 


Abstract # 


MODULATION BY NANO-SIZED 

CERIUM OXIDE OF THE TOXICITY OF 

INHALED DIESEL ENGINE EXHAUST 

IN ATHEROSCLEROSIS-PRONE 

APOLIPOPROTEIN E-DEFICIENT MICE. 

F. R. Cassee 1 , J. F. Boere 1 , P. H. Fokkens 1 , D. L. 

Leseman 1 , P. Krystek 3 , I. Gosens 1 and M. R. Miller 2 . 

1 

Centre for Environmental Health, National Institute 

for Public Health and the Environment (RIVM), 

Bilthoven, Netherlands, 2 Centre for Cardiovascular 

Science, University of Edinburgh, Edinburgh, 

United Kingdom and 3 MiPlaza Material Analysis, 

Eindhoven, Netherlands. 


COMPARISON OF TOXICITY OF 

BIODIESEL VERSUS PETROLEUM- 

DIESEL-FUELED ENGINE EXHAUST IN 

AN ASTHMA MOUSE MODEL. G. R. Gookin 1 , 

A. Keebaugh 1 , L. M. Mendez 2,1 , B. Haghverdian 1 , 

D. Meacher 1 , S. Nakao 3 , D. R. Cocker 3 and M. T. 

Kleinman 1 . 1 Medicine, University of California 

Irvine, Irvine, CA, 2 Microbiology and Molecular 

Genetics, University of California Irvine, Irvine, 

CA and 3 Chemical and Environmental Engineering, 

University of California Riverside, Riverside, CA. 


HYPOTENSION AND AV BLOCK AFTER 

DIESEL EXHAUST EXPOSURE IN 

HEART FAILURE-PRONE RATS: ROLE 

OF GASEOUS AND PARTICULATE 

COMPONENTS. A. P. Carll 1 , C. Lamb 2 , M. 

S. Hazari 3 , N. Haykal-Coates 3 , D. W. Winsett 3 , 

Q. T. Krantz 3 , D. L. Costa 4 and A. K. Farraj 3 . 

1 

Environment Sciences & Engineering, University 


2 

CURTOX, University of North Carolina Chapel 

Hill, Chapel Hill, NC, 3 Environmental Public Health 

Division, U.S. EPA, Research Triangle Park, NC and 

4 

ORD, U.S. EPA, Research Triangle Park, NC. 


A SINGLE EXPOSURE TO DIESEL 

EXHAUST INCREASES THE RISK OF 

TRIGGERED CARDIAC ARRHYTHMIAS IN 

CONSCIOUS RATS DURING DOBUTAMINE 

CARDIAC “STRESS” TEST. M. S. Hazari, D. 

W. Winsett, N. Haykal-Coates, D. L. Costa and A. K. 

Farraj. Environmental Public Health Division, U.S. 



COMBINED EFFECTS OF DIESEL 

EXHAUST PARTICLES AND HIGH 

GLUCOSE ON MMP-2 EXPRESSION 

IN HUMAN MONOCYTES. R. Wan 1 , Y. 

Mo 1 , S. Chien 2 , D. J. Tollerud 1 and Q. Zhang 1 . 

1 

Environmental and Occupational Health Sciences, 

University of Louisville, Louisville, KY and 

2 

Surgery, University of Louisville, Louisville, KY. 

MONday 







167



MONday 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Children’s Health/Juvenile Toxicology 

Chairperson(s): Christopher Bowman, Pfizer Drug Safety Research and 





DISORDERED PORPHYRIN METABOLISM 

AMONG AUTISTIC CHILDREN IS NOT 

ASSOCIATED WITH MERCURY EXPOSURE. 

J. S. Woods 1 , S. E. Armel 1,2 , D. Echeverria 1,3 and N. 

J. Heyer 3 . 1 Environmental and Occupational Health 

Sciences, University of Washington, Seattle, WA, 

2 

Veritox, Inc., Redmond, WA and 3 Battelle Centers 

for Public Health Research and Evaluation, Seattle, 

WA. 


PRENATAL EXPOSURE TO DIOXINS AND 

PCBS IS ASSOCIATED WITH INCREASED 

RISK OF WHEEZING AND INCREASED 

NUMBER OF UPPER AIRWAY INFECTIONS 

IN ONE YEAR-OLD CHILDREN. S. B. 

Stølevik 1 , B. Granum 1 , U. C. Nygaard 1 , E. Namork 1 , 

M. Haugen 1 , H. E. Kvalem 1 , H. M. Meltzer 1 , J. 

Alexander 1 , H. van Loveren 2,3 , J. H. van Delft 3 and 

M. Løvik 1,4 . 1 Norwegian Institute of Public Health, 

Oslo, Norway, 2 National Institute of Public Health 

and the Environment, Bilthoven, Netherlands, 

3 

Maastricht University, Maastricht, Netherlands and 

4 

Norwegian University of Science and Technology, 

Trondheim, Norway. 


EVOLUTION OF MITOCHONDRIAL 

FUNCTION IN HEALTHY INFANTS 

IN UTERO EXPOSED TO HIV AND 

ANTIRETROVIRALS. C. Morén 1 , G. Garrabou 1 , 

A. Noguera-Julian 2 , N. Rovira 2 , M. Nicolàs 1 , E. 

Corrales 2 , F. Cardellach 1 , C. Fortuny 2 and. Miró 1 . 

1 

Mitochondrial Research Laboratory, Muscle 

Research Unit, Internal Medicine Department, 

IDIBAPS-University of Barcelona (Barcelona, 

Spain) and Centro de Investigación Biomédica en 

Red de Enfermedades Raras (CIBERER, Valencia, 

Spain), Barcelona, Spain and 2 Infectious Diseases, 

Pediatrics Department, Hospital Sant Joan de Déu, 

University of Barcelona, Barcelona, Spain. Sponsor: 

J. Domingo. 


ADVERSE PERINATAL OUTCOME AND 

MITOCHONDRIAL TOXICITY IN HIV- 

INFECTED PREGNANT WOMEN AND 

THEIR NEWBORN. G. Garrabou 1 , A. S. 

Hernandez 2 , C. Moren 1 , M. Lopez 2 , M. Nicolas 1 , 

O. Coll 2 , F. Cardellach 1 , E. Gratacos 2 and O. Miro 1 . 

1 

Mitochondrial Research Laboratory, Internal 

Medicine Department, IDIBAPS-University of 

Barcelona, Hospital Clinic Barcelona (HCB, 

Barcelona, Spain) and Centro de Invest.Biomédica 

en Red de Enfermedades Raras (CIBERER, Valencia, 

Spain), Barcelona, Spain and 2 Materno-Fetal Medical 

Service (HCB, Barcelona, Spain), Barcelona, Spain. 

Sponsor: J. Domingo. 


TOBACCO CAUSES MITOCHONDRIAL 

TOXICITY AND REDUCED BIRTH WEIGHT 

IN NEWBORN OF SMOKING PREGNANT 

MOTHERS. F. Cardellach 1 , G. Garrabou 1 , A. S. 

Hernandez 2 , C. Moren 1 , M. Nicolas 1 , O. Coll 2 and 

O. Miro 1 . 1 Mitochondrial Research Laboratory, 

Internal Medicine Department, IDIBAPS-University 

of Barcelona, Hospital Clinic of Barcelona (HCB, 

Barcelona, Spain) and Centro de Investigación 

Biomédica en Red de Enfermedades Raras 

(CIBERER, Valencia, Spain), Barcelona, Spain and 

2 

Materno-Fetal Medical Service, (HCB, Barcelona, 

Spain), Barcelona, Spain. Sponsor: J. Domingo. 


MOLECULAR MECHANISMS REGULATING 

DRUG METABOLIZING ENZYME 

ONTOGENY. R. N. Hines 1,2 , M. Le 1,2 , J. D. 

Shadley 1,2 , N. Giebel 1,2 , K. Dorko 3 and S. C. Strom 3 . 

1 

Pediatrics & Pharmacology/Toxicology, Medical 

College of Wisconsin, Milwaukee, WI, 2 Children’s 

Research Institute, Children’s Hospital and Health 

Systems, Milwaukee, WI and 3 Pathology, University 

of Pittsburgh School of Medicine, Pittsburgh, PA. 


PRENATAL EXPOSURE TO FLAVONOIDS: 

IMPLICATION FOR CANCER RISK. K. 

Vanhees, L. de Bock, R. W. Godschalk, F. J. van 

Schooten and S. Barjesteh van Waalwijk van Doorn- 

Khosrovani. Health Risk Analysis and Toxicology, 

Maastricht University, Maastricht, Netherlands. 

Sponsor: H. van Loveren. 


EFFECTS OF INTRAVENOUS AND ORAL 

ADMINISTRATION OF DEHP IN THE 

LUNGS OF NEONATAL MALE RATS. J. R. 

Latendresse 2 , L. Camacho 1 , L. Muskhelishvili 2 , S. 

J. Moon 1 and K. Delclos 1 . 1 Division Biochemical 


Research. U.S. FDA, Jefferson, AR and 2 Toxicologic 

Pathology Associates, Jefferson, AR. 


JUVENILE TOXICITY ASSESSMENT OF 

ANIDULAFUNGIN IN RATS. G. Chmielewski 1 , 

C. J. Bowman 1 , S. L. Ripp 1 , E. M. Lewis 2 , C. M. 

Sawaryn 1 and D. M. Cross 3 . 1 Pfizer Inc., Groton, CT, 

2 

Charles River Laboratories Preclinical Services, 

Horsham, PA and 3 Pfizer Inc., Sandwich, United 

Kingdom. 


ORGAN SYSTEM ASSESSMENTS IN 

JUVENILE DOG TOXICOLOGY STUDIES. 

K. Robinson, H. Penton, S. Y. Smith and M. Adamo. 


Montréal, QC, Canada. Sponsor: M. Vézina. 


CHEMICAL INTOLERANCE, ATTENTION 

DEFICIT/HYPERACTIVE DISORDER, AND 

AUTISM—A LINK? L. P. Heilbrun, R. F. Palmer 

and C. S. Miller Family Community Medicine, 

University of Texas Health Center at San Antonio, 

San Antonio, TX. Sponsor: G. Gould. 

168 






Platform Sessions



Abstract # 


ANALYSIS OF TRANSFER RATE OF 

CONGENERS OF PCBS AND OH-PCBS 

FROM MOTHER TO FETUS THROUGH 

PLACENTA IN HUMAN. C. Mori 1,2 , E. 

Todaka 1,2 , Y. Matsuno 1,2 , T. Fujisaki 1 , M. Shimoda 2 , 

H. Nakaoka 1,2 and M. Hanazato 2 . 1 Department of 

Bioenvironmental Medicine, Graduate School 

of Medicine, Chiba University, Chiba, Japan and 

2 

Center for Preventive Medical Science, Chiba 

University, Chiba, Japan. 


ENDOCRINE EFFECTS OF A NOVEL HIV- 

NNRTI IN SEXUALLY IMMATURE FEMALE 

CYNOMOLGUS MONKEYS. F. van Velsen 4 , 

J. Sternberg 1 , B. Niggemann 1 , S. Friderichs- 

Gromoll 1 , G. Weinbauer 1 , I. Vanwelkenhuysen 2 , L. 

Grooten 2 , S. Lachau-Durand 4 , S. De Jonghe 2 , L. De 

Schaepdrijver 2 , T. Coogan 3 , L. Lammens 2 , A. Raoof 4 

and W. Coussement 2 . 1 Covance Laboratories GmbH, 

Muenster, Germany, 2 GPCD, Janssen Pharmaceutica, 

Beerse, Belgium, 3 PCD, Centocor, Radnor, PA and 

4 

PCD, Tibotec, Beerse, Belgium. 


IMPAIRED REPRODUCTION IN ADULT 

MALE, BUT NOT FEMALE, RATS 

FOLLOWING JUVENILE TREATMENT 

WITH THE AROMATASE INHIBITOR, 

EXEMESTANE. G. Cappon 1 , M. E. Hurtt 1 , R. E. 

Chapin 1 and L. Burns-Naas 2 . 1 DSRD, Pfizer, Groton, 

CT and 2 DSRD, Pfizer, LaJolla, CA. 


MOST BPA-FREE PLASTICS RELEASE 

CHEMICALS HAVING ESTROGENIC 

ACTIVITY (EA): BPA-FREE DOES NOT 

MEAN EA-FREE. G. Bittner 1,2,3 , C. Z. Yang 1 , S. 

Yaniger 2 and D. Klein 2 . 1 CertiChem, Inc., Ausin, 

TX, 2 PlastiPure, Inc., Austin, TX and 3 University of 

Texas, Austin, TX. Sponsor: R. Tice. 


MANGANESE LEVELS IN CARPET DUST 

ARE ASSOCIATED WITH PROXIMITY TO 

AGRICULTURAL USE OF MANEB AND 

MANCOZEB. R. Gunier 1 , D. R. Smith 2 , A. 

Bradman 1 and B. Eskenazi 1 . 1 University of California 

Berkeley, Berkeley, CA and 2 University of California 

Santa Cruz, Santa Cruz, CA. 


BLOOD LEAD LEVELS AND IQ AMONG 

PRESCHOOL CHILDREN. J. Liu 1 , L. A. 

McCauley 2 , J. Pinto-Martin 1 , C. Yan 3 , X. Shen 3 

and H. Needleman 4 . 1 University of Pennsylvania, 

Philadelphia, PA, 2 Emory University, Atlanta, GA, 

3 

Shanghai Jiaotong University, Shanghai, China and 

4 

University of Pittsburgh, Pittsburgh, PA. 


CHARACTERISTICS OF 

HISTOPATHOLOGICAL CHANGES 

INDUCED BY SEMICARBAZIDE 

HYDROCHLORIDE IN RATS. M. Takahashi, 

M. Yoshida, K. Inoue, T. Morikawa and A. 

Nishikawa. Pathology, National Institute of Health 

Sciences, Tokyo, Japan. 

Abstract # 


EFFECTS OF BLOOD LEAD LEVEL ON 

COGNITIVE AND PERSONAL ABILITY IN 

SCHOOL CHILDREN. D. Kim 1 , S. Yu 2 and J. 

Cha 3 . 1 Department Environmental Health, National 

Institute of Environmental Research, Inchon, 

Republic of Korea, 2 Department Environmental 

Health, National Institute of Environmental 

Research, Inchon, Republic of Korea and 3 Lab. 

Industrial Environment, Research Institute of 

Industrial health and Environment, Korean Industrial 

Health Association, Seoul, Republic of Korea. 

Sponsor: J. Park. 


NEUROMOTOR AND SENSORY CHANGES 

IN ITALIAN CHILDREN RESIDENT IN THE 

VICINITY OF FERROALLOY INDUSTRY. 

R. Lucchini 2,1 , F. Donna 2 , S. Zoni 2 , S. Guazzetti 3 , 

E. Bontempi 2 , D. R. Smith 1 and N. Zimmerman 4 . 

1 

University of California Santa Cruz, Santa Cruz, 

CA, 2 University of Brescia, Brescia, Italy, 3 PHS, 

Reggio Emilia, Italy and 4 Purdue University, West 

Lafayette, IN. 


JUVENILE (IMMUNO) DEVELOPMENT 

STUDY IN GÖTTINGEN MINIPIGS®. A. 

Wolterbeek, G. van Mierlo, C. Snel, F. Kuper and A. 

Penninks. Toxicology and Applied Pharmacology, 

TNO Quality of Life, Zeist, Netherlands. Sponsor: R. 

Woutersen. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Skin 

Chairperson(s): Ronaldo Baynes, North Carolina State University, 

Raleigh, NC, and Nancy Monteiro-Riviere, North Carolina State 





NOVEL DUOX INDUCTION IN EPIDERMAL 

KERATINOCYTES BY IFN-γ AND IL-4. T. 

Hill and R. H. Rice. Environmental Toxicology, 

University of California at Davis, Davis, CA. 


IN VIVO DERMAL UPTAKE PATTERN 

FOR 20 DILUTE AQUEOUS ORGANIC 

CHEMICALS IS POORLY PREDICTED BY 

MODELS BASED ON IN VITRO DATA. K. T. 

Bogen. Health Sciences, Exponent, Inc., Oakland, 

CA. 


PREDICTING SKIN PERMEABILITY FROM 

COMPLEX CHEMICAL MIXTURES: THE 

IMPACT OF BIOLOGICAL SKIN MODEL 

SYSTEMS ON QUANTITATIVE STRUCTURE 

PERMEATION RELATIONSHIPS (QSPR). J. 

E. Riviere and J. D. Brooks. Center for Chemical 

Toxicology Research and Pharmacokinetics, North 

Carolina State University, Raleigh, NC. 

MONday 







169



MONday 



IN VITRO EVALUATION OF THE EFFECT 

OF DOSE, RECEPTOR FLUID, AND 

VEHICLE ON THE ABSORPTION OF FIVE 

PHYSICOCHEMICALLY DIFFERENT 

COMPOUNDS IN PORCINE SKIN. D. 

Karadzovska, E. L. Koivisto, J. D. Brooks and J. E. 

Riviere. Center for Chemical Toxicology Research 

and Pharmacokinetics, North Carolina State 



CHARACTERIZATION OF NORMAL 

SKIN THICKNESS FOR VARIOUS BODY 

REGIONS, AGES, AND GENDERS OF 

YUCATAN MINIATURE SWINE. L. Brown 1 , 

D. Kim 2 , C. Hanks 1 , D. Brocksmith 1 , M. Hodges 1 , J. 

Liu 1 and G. Bouchard 1 . 1 Sinclair Research Center, 

Columbia, MO and 2 VMDL CVM University of 

Missouri, Columbia, MO. 


NORMAL PHYSIOLOGICAL RANGES FOR 

HANFORD MINIATURE SWINE. M. Ross, 

L. Brown, D. Unterreiner, C. Hanks, J. Liu, M. 

Hodges and G. Bouchard. Sinclair Research Center, 

Columbia, MO. 


ROLE OF MAP KINASES IN REGULATING 

EXPRESSION OF KERATINOCYTE 

ANTIOXIDANTS BY THE ELECTROPHILIC 

NITRO-FATTY ACIDS DERIVATIVES 9- 

AND 10-NITROOLEIC ACID. R. Zheng 1 , A. 

T. Black 1 , A. Gow 1 , D. E. Heck 3 , D. L. Laskin 1 and 

J. D. Laskin 2 . 1 Rutgers University, Piscataway, NJ, 

2 


Piscataway, NJ and 3 New York Medical College, 

Valhalla, NY. 


A STUDY OF PHOTOTOXICITY 

FOLLOWING INTRAVENOUS 

ADMINISTRATION OF CIPROFLOXACIN 

HYDROCHLORIDE IN THE 

MICROMINIPIG. H. Kawaguchi 1 , N. Miyoshi 1 , 

A. Tanimoto 1 , Y. Takahashi 2 , S. Utsunomiya 2 , T. 

Motokado 2 , Y. Ooshima 2 , H. Izumi 2 , T. Sukamoto 2 

and R. Nagata 2 . 1 Kagoshima University, Kagoshima, 

Japan and 2 Shin Nippon Biomedical Laboratories 

(SNBL), Ltd., Kagoshima, Japan. 


INFLUENCE OF THE ARYL 

HYDROCARBON RECEPTOR ON 

PROLIFERATION OF HUMAN 

KERATINOCYTES (HACAT). M. Kalmes, J. 

Hennen, J. Clemens and B. Blömeke. Environmental 

Toxicology, University of Trier, Trier, Germany. 


WHAT IS THE BEST SKIN PREPARATION 

FOR DERMAL PENETRATION STUDIES 

IN VITRO? A COMPARISON OF FULL- 

THICKNESS SKIN AND DERMATOMED 

SKIN. K. Guth 1 , M. Schaefer-Korting 2 , E. 

Fabian 1 , B. van Ravenzwaay 1 and R. Landsiedel 1 . 

1 

BASF SE, Experimental Toxicology and Ecology, 

Ludwigshafen, Germany and 2 Freie Universitaet, 

Berlin, Germany. 


ANTI-INFLAMMATORY DRUG EFFICACY 

FOR TREATING SULFUR MUSTARD 

INDUCED CUTANEOUS LESIONS. J. L. 

Plahovinsak 1 , M. D. Etheridge 1 , J. Rhone 1 , F. M. 

Reid 1 , J. F. Dillman 2 and J. S. Graham 2 . 1 Battelle, 




DERMAL ABSORPTION OF 

DICYCLOHEXYLAMINE (DCHA) IN METAL 

WORKING FLUID FORMULATIONS. R. 

Baynes, A. Linthicum, J. Yeatts, J. Brooks and E. 

Koivisto. North Carolina State University, Raleigh, 

NC. 


INTERLEUKIN 6 EXPRESSION 

MODULATES IRRITANT DERMATITIS 

SEVERITY. E. G. Lee, B. M. Mickle and R. 

Gallucci. Pharmaceutical Sciences, Oklahoma 

University State Health Sciences Center College of 

Pharmacy, Oklahoma City, OK. 


THE EPIOCULAR ASSAY FOR TESTING 

EYE IRRITATION IN VITRO: IN HOUSE 

VALIDATION WITH 60 TEST SUBSTANCE 

IN A ROUTINE LAB OF THE CHEMICAL 

INDUSTRY. A. Schrage 1 , S. Kolle 1 , B. Wareing 1 , 

R. B. Tacou 1,2 , B. van Ravenzwaay 1 , H. Kanderova 3 

and R. Landsiedel 1 . 1 Experimental Toxicology 

and Ecology, BASF SE, Ludwigshafen am Rhein, 

Germany, 2 Master Program in Toxicology, Technical 

University of Kaiserslautern, Kaiserslautern, 

Germany and 3 MatTek Corporation, Ashland, MA. 


EVALUATION OF THE IN VITRO EPISKIN 

AND SKINETHIC RHE SKIN IRRITATION 

TEST METHODS FOR HAZARD 

IDENTIFICATION OF CHEMICALS. D. 

Lelièvre 1 , N. Alépée 1 , J. Cotovio 1 , M. H. Grandidier 1 , 

A. De Brugerolle de Fraissinette 2 , C. Tornier 2 and J. 

R. Meunier 1 . 1 L’Oréal, Aulnay sous Bois, France and 

2 

SkinEthic Laboratories, Lyon, France. Sponsor: H. 

Toutain. 


ADAPTATION OF THE VALIDATED 

SKINETHIC RHE SKIN CORROSION TEST 

METHOD TO 0.5 CM2 TISSUE SAMPLE. C. 

Tornier 1 , M. Roquet 1 , N. Alépée 2 , J. R. Meunier 2 

and A. De Brugerolle de Fraissinette 1 . 1 SkinEthic 

Laboratories, Lyon, France and 2 L’Oréal, Aulnay 

sous Bois, France. Sponsor: H. Toutain. 


EXPRESSION AND INDUCTION OF 

XENOBIOTIC METABOLISM GENES 

IN THE STRATATEST® HUMAN SKIN 

MODEL. C. Rasmussen, K. Gratz, N. Simon, M. 

VanderZanden, C. Johnston and L. Allen-Hoffmann. 

Stratatech Corporation, Madison, WI. 

170 






Platform Sessions



Abstract # 


INTRAMUSCULAR INJECTION SITES: 

IS THE QUALITY OF THE DIAGNOSIS 

IMPROVED WHEN MORE THAN ONE 

TISSUE SECTION IS EXAMINED? C. 

Thuilliez, M. Perron-Lepage, C. Clément, J. Briffaux 

and C. Botteron. Ricerca Biosciences SAS, Lyon, 

France. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Immunotoxicity: Methods and Evaluation 

Chairperson(s): Raj Krishnaraj, Covance Inc., Madison, WI. 




ESTABLISHMENT OF T-CELL 

INDEPENDENT ANTIBODY RESPONSE 

IN RATS AS AN IMMUNOTOXICITY 

EVALUATION METHOD. S. Ito, H. Hattori, 

R. Kawai, S. Komatsu, K. Muramatsu, M. Yagi, 

T. Matsuyama, T. Furukawa and A. Sanbuissho. 

Medicinal Safety Research Laboratories, Daiichi 

Sankyo Co., LTD., Fukuroi, Shizuoka, Japan. 

Sponsor: M. Teranishi. 


ANALYTICAL VALIDATION OF 

IMMUNOPHENOTYPING FOR CD5 IN 

PERIPHERAL BLOOD, SPLEEN, AND 

THYMUS FOR CD 1 MICE. P. Sims 2 , P. Joshi 2 , 

J. E. Arrington 1 and J. Puchalski 2 . 1 Toxicology 

Study Direction, Covance, Madison, WI and 

2 

Immunotoxicology, Covance, Madison, WI. 


ANALYTICAL VALIDATION OF 

SPLEEN, THYMUS, AND MESENTERIC 

AND MANDIBULAR LYMPH NODE 

IMMUNOPHENOTYPING FOR SPRAGUE- 

DAWLEY RATS. J. E. Arrington and P. Joshi. 

Immunotoxicology, Covance, Madison, WI. 


IN VITRO MODEL FOR IMMUNOTOXICITY: 

SURFACE MARKER EXPRESSION AND 

CYTOKINE RELEASE IN NORMAL HUMAN 

DENDRITIC CELLS. T. Landry, M. Klausner, A. 

Hunter, J. Sheasgreen, P. J. Hayden and S. Ayehunie. 

MatTek Corp, Ashland, MA. 


USE OF AN ELECTROSPUN 

POLYCAPROLACTONE NANOFIBROUS 

SCAFFOLD AS A POTENTIAL 

DRUG DELIVERY SYSTEM FOR 

IMMUNOMODULATORY COMPOUNDS. C. 

E. McLoughlin, M. J. Smith, W. Auttachoat, G. L. 

Bowlin and K. L. White. Virginia Commonwealth 

University, Richmond, VA. 

Abstract # 


TCDD ADSORBED ONTO NATURAL 

AND SYNTHETIC SILICA SUPPRESSES 

HUMORAL IMMUNITY IN MICE. N. 

Kovalova 1,2 , R. Crawford 2 , B. Kaplan 2 , S. Kim 3 , S. 

Boyd 3 , B. Teppen 3 , C. Johnston 5 , T. Pinnavaia 4 and N. 

Kaminski 1,2 . 1 Pharmacology & Toxicology, Michigan 

State University, East Lansing, MI, 2 Center for 


East Lansing, MI, 3 Crop & Soil Science, Michigan 

State University, East Lansing, MI, 4 Chemistry, 


5 

Soil Chemistry & Mineralogy, Purdue University, 

W. Lafayette, IN. 


TITANIUM DIOXIDE NANOPARTICLES: 

LACK OF IMMUNOSUPRESSIVE AND 

CONTACT HYPERSENSITIVITY EFFECTS 

IN FEMALE MICE. W. Auttachoat 1 , C. E. 

McLoughlin 2 , M. J. Smith 1 and K. L. White 1 . 

1 

Pharmacology & Toxicology, Virginia 

Commonwealth University, Richmond, VA and 

2 

Biomedical Engineering, Virginia Commonwealth 



ACTIVATED CYTOTOXIC AND HELPER 

T-CELLS ARE REDUCED IN C57BL6 MICE 

EXPOSED TO TUNGSTATE IN A ONE- 

GENERATION EXPOSURE. A. R. Osterburg 1 , 

C. T. Robinson 2 , V. P. Mokashi 1 , M. G. Stockelman 1 

and G. F. Babcock 2 . 1 Naval Medical Research Unit 

- Dayton, Wright-Patterson AFB, OH and 2 Shriners 

Hospitals for Children and the University of 

Cincinnati, Cincinnati, OH. Sponsor: K. Mumy. 


ASSOCIATIONS OF 

PERFLUOROCHEMICALS (PFCS) 

WITH IMMUNE, BIOCHEMICAL, AND 

HEMATOLOGICAL PARAMETERS IN 

BOTTLENOSE DOLPHINS. P. Fair 1 , T. 

Romano 2 , T. Hulsey 3 , J. Reif 4 , G. Bossart 5 , J. Adams 1 , 

M. Houde 6 , D. Muir 6 , C. Rice 7 and P. Margie 8 . 

1 

NOAA/NOS, Charleston, SC, 2 Mystic Aquarium, 

Mystic, CT, 3 Medical University of South Carolina, 

Charleston, SC, 4 Colorado State University, Fort 

Collins, Co., 5 Harbor Branch Oceanographic Institute 

at Florida Atlantic University, Fort Pierce, FL, 

6 

Environment Canada, Burlington, ON, Canada, 

7 

Clemson University, Clemson, SC and 8 University 

of Nevada Las Vegas, Las Vegas, NV. 


COMPARISON EFFECTS OF IN VITRO PFOS 

EXPOSURE ON BOTTLENOSE DOLPHIN 

AND MURINE IMMUNE FUNCTION. J. R. 

Wirth 1 , M. M. Peden-Adams 2 , N. Henry 3 and P. A. 

Fair 3 . 1 Graduate Program of Marine Biology, College 

of Charleston, Charleston, SC, 2 Harry Reid Center 

for Environmental Science, University of Nevada 

Las Vegas, Las Vegas, NV and 3 NOAA/NOS/ 

CCEBHR, Charleston, SC. 

MONday 







171



MONday 



THE ROLE OF T-CELL IL-2 AND 

MACROPHAGE IL-10 PRODUCTION 

IN PFOS-INDUCED HUMORAL 

IMMUNOSUPPRESSION. M. M. Peden- 

Adams 1 , J. Berger-Ritchie 2,1 , S. Young 3 , N. Ayala 4 

and D. Keil 5 . 1 Harry Reid Center for Enivronmental 

Studies, University of Nevada Las Vegas, Las Vegas, 

NV, 2 School of Community Health, University of 

Nevada Las Vegas, Las Vegas, NV, 3 Department of 

Anthropology, University of Nevada Las Vegas, 

Las Vegas, NV, 4 Clinical Laboratory Sciences, 

University of Nevada Las Vegas, Las Vegas, NV and 

5 

Department of Medical Laboratory Sciences, School 

of Medicine, University of Nevada Las Vegas, Salt 

Lake City, UT. 


THE T CELL DEPENDENT ANTIBODY 

RESPONSE AS A PREDICTOR OF THE TYPE 

OF IMMUNOSUPPRESSION ASSOCIATED 

WITH PERIPHERAL MULTIFOCAL 

LEUKOENCEPHALOPATHY. E. R. Fedyk, P. 

F. Smith and V. J. Kadambi. Drug Safety Evaluation, 

Millennium Pharmaceuticals Inc., Cambridge, MA. 


IMMUNOTOXICOLOGIC EVALUATION 

OF RITUXIMAB AND CYCLOSPORINE 

IN CYNOMOLGUS MONKEYS. J. Legrand 1 , 

E. Grosdidier 1 , R. Fleurance 1 , C. Mimouni 1 , A. 

N’Guyen 1 , F. Gervais 1 and J. Descotes 2 . 1 CIT, 

Evreux, France and 2 Poison Center, Lyon, France. 


DISCHARGING A THEORETICAL RISK 

OF INTEGRASE INHIBITOR-INDUCED 

IMMUNOTOXICITY IN JUVENILE RATS. M. 

Rhodes 1 , S. Laffan 2 , C. Genell 2 , J. Gower 2 , C. Maier 2 , 

G. Nichols 1 , T. Fukushima 3 , J. Chism 1 , G. Tabolt 1 and 

A. Bassiri 2 . 1 GlaxoSmithKline, Research Triangle 

Park, NC, 2 GlaxoSmithKline, King of Prussia, PA 

and 3 Shionogi Pharmaceuticals, Osaka, Japan. 


THE EFFECTS OF TRIBUTYLTIN (TBT) 

ON SPLENOCYTES IN F1 RATS EXPOSED 

TO TBT VIA PLACENTA, THEIR DAM’S 

MILK, AND/OR FOOD. M. Tsunoda 1 , T. 

Kido 1 , R. Ikeuchi 1 , T. Kaido 1 , M. Hosokawa 2,1 , C. 

Sugaya 1 , H. Ohta 1 , H. Katagiri 3 , K. Hayashi 4 , T. 

Kosaka 4 , Y. Takeuchi 5 , T. Tashiro 5 and Y. Aizawa 1 . 

1 

Preventive Medicine and Public Health, Kitasato 

University School of Medicine, Sagamihara, 

Japan, 2 Juntendo University Faculty of Medicine, 

Tokyo, Japan, 3 Kitasato University School of Allied 

Health Sciences, Sagamihara, Japan, 4 Institute 

of Environmental Toxicology, Tokyo, Japan and 

5 

Aoyama Gakuin University School of Science and 

Engineering, Sagamihara, Japan. 


USE OF TDAR (SRBC) IMMUNOTOXICITY 

MONITORING IN AN EXTENDED ONE 

GENERATION REPRODUCTIVE TOXICITY 

TEST WITH LEAD ACETATE. J. Hargitai 1 , D. J. 

Esdaile 1 , R. Kubaszky 1 , T. Hanley 2 , D. Minnema 2 and 

R. Lewis 3 . 1 LAB Research Ltd., Veszprem, Hungary, 

2 

Syngenta Crop Protection LLC, Greensboro, NC and 

3 

Syngenta, Jealotts Hill, Bracknell, United Kingdom. 


LONG-TERM IMMUNOTOXIC EFFECTS OF 

COMBINED PRENATAL AND NEONATAL 

ATRAZINE EXPOSURE IN BALB/C MICE. I. 

Holaskova, R. Schafer, K. Brundage, E. Lukomska 

and J. B. Barnett. Microbiology, Immunology & Cell 

Biology, West Virginia University, Morgantown, WV. 


EFFECTS OF CIGARETTE SMOKE ON 

INFECTIOUS BURDEN, RESPIRATORY 

INFECTION, AND INFLAMMATORY 

RESPONSE WITH CHLAMYDIA 

PNEUMONIAE IN A MOUSE MODEL. S. 

P. Doherty-Lyons 1 , C. Hoffman 1 , S. Kumar 2 , S. 

Kolhoff 2 , M. R. Hammerschlag 2 and J. T. Zelikoff 1 . 

1 


School of Medicine, Tuxedo, NY and 2 Pediatrics, 

State University of New York Downstate, Brooklyn, 

NY. 


EVALUATION OF THE 

IMMUNOMODULATORY POTENTIAL 

OF DIETHYL PHTHALATE FOLLOWING 

DERMAL EXPOSURE IN A MURINE 

MODEL. J. L. Franko, E. Lukomska, B. J. Meade 

and S. E. Anderson. NIOSH, Morgantown, WV. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Mechanisms of Immunotoxicity 

Chairperson(s): Alhaji Njai, University of Wisconsin Madison, Madison, 

WI, and Marc Williams, U.S. EPA, Durham, NC. 




AFRICAN DUST ENDOTOXINS AND THEIR 

PRO-INFLAMMATORY ROLE IN HUMAN 

BRONCHIAL EPITHELIAL CELLS. M. G. 

Ortiz-Martínez 1,3 , E. Rivera 4,3 , L. B. Méndez 2 and 

B. D. Jiménez Vélez 1,3 . 1 Biochemistry, University 

of Puerto Rico Medical Sciences Campus, San 

Juan, 2 Department of Microbiology and Molecular 

Genetics, University of California Irvine, Irvine, 

CA, 3 Center for Environmental and Toxicological 

Research, University of Puerto Rico San Juan and 

4 

Department of Biology, University of Puerto Rico 

Río Piedras, San Juan. 


AFRICAN DUST PM 2.5 

REACHING PUERTO 

RICO INDUCES OXIDATIVE STRESS AND 

PRO-INFLAMMATORY MEDIATORS IN 

HUMAN LUNG CELLS. R. I. Rodríguez 1,3 , 

L. B. Méndez Torres 2 and B. D. Jiménez Vélez 1,3 . 

1 

Biochemistry, University of Puerto Rico Medical 

Sciences Campus, San Juan, Puerto Rico, 

2 

Department of Microbiology and Molecular 

Genetics, University of California Irvine, Irvine, CA 

and 3 Center for Environmental and Toxicological 

Research, University of Puerto Rico, San Juan. 

172 






Platform Sessions



Abstract # 


HEALTH EFFECTS DUE TO ACUTE 

EXPOSURE OF DUST SAMPLES 

COLLECTED FROM NELLIS DUNES 

RECREATIONAL AREA. S. Proper 1 , M. Peden- 

Adams 2 , N. Ayala 2 , J. Berger-Ritchie 2 , S. Labahn 2 , 

S. Young 2 , B. Buck 2 , D. Goossens 2,3 , D. Soukup 4 , 

R. Sudowe 2 , Y. Teng 2 , D. Baron 2 , J. R. Harkema 1 

and D. E. Keil 5,2 . 1 Michigan State University, East 

Lansing, MI, 2 University of Nevada, Las Vegas, 

NV, 3 Katholieke Universiteit, Leuven, Belgium, 

4 

California State University, Bakersfield, CA and 

5 

University of Utah, Salt Lake City, UT. 


INFLAMMATION AND TISSUE DAMAGE IN 

THE MOUSE LUNG INDUCED BY WOOD 

SMOKE PARTICULATE MATTER FROM 

NEW AND OLD TECHNOLOGY HEATING 

APPLIANCES. O. Uski 1 , M. Happo 2 , P. Jalava 1,2 , 

K. Joachim 3 , T. Brunner 3,4,5 , I. Obernberger 3,4,5 , M. 

Tapanainen 1 , J. Jokiniemi 2,6 and M. Hirvonen 1,2 . 

1 

National Institute for Health and Welfare, Kuopio, 

Finland, 2 University of Eastern Finland, Kuopio, 

Finland, 3 Bioenergy 2020+ GmbH, Graz, Austria, 

4 

Graz University of Technology, Graz, Austria, 

5 

Bios Bioenergiesysteme GmbH, Graz, Austria and 

6 

VTT Technical Research Centre of Finland, Espoo, 

Finland. Sponsor: M. Viluksela. 


COMBUSTION CONDITIONS AFFECT 

TOXICOLOGICAL AND CHEMICAL 

PROPERTIES OF WOOD COMBUSTION 

PARTICLES. M. Tapanainen 1 , P. Jalava 1,2 , H. 

Lamberg 2 , P. Hakulinen 1 , P. Yli-Pirilä 2 , J. Ruusunen 2 , 

J. Mäki-Paakkanen 1 , R. Hillamo 3 , J. Jokiniemi 2,4 and 

M. Hirvonen 1,2 . 1 National Institute for Health and 

Welfare, Kuopio, Finland, 2 University of Eastern 

Finland, Kuopio, Finland, 3 Finnish Meteorological 

Institute, Helsinki, Finland and 4 VTT Technical 

Research Centre of Finland, Espoo, Finland. 

Sponsor: M. Viluksela. 


DENDRITIC CELLS IN ALLERGIC ASTHMA 

EXHIBIT HEIGHTENED FUNCTIONAL 

INFLAMMATORY RESPONSES ON 

ACTIVATION BY AMBIENT PARTICULATE 

MATTER. M. A. Williams 1 , S. M. Bauer 2 and S. N. 

Georas 2 . 1 NHEERL - EPHD, U.S. EPA, Research 

Triangle Park, NC and 2 Department of Medicine, 

University of Rochester, Rochester, NC. 


CHEMOKINE-MEDIATED INDUCTION 

OF CD11b + Gr1 + MYELOID-DERIVED 

SUPPRESSOR CELLS (MDSCs) BY 

CANNABINOIDS AND THEIR ROLE IN 

IMMUNOSUPPRESSION. V. L. Hegde, P. 

S. Nagarkatti and M. Nagarkatti. Pathology, 

Microbiology & Immunology, University of South 

Carolina, Columbia, SC. 

Abstract # 


Δ 9 -TETRAHYDROCANNABINOL 

DECREASES ANTIGEN PRESENTATION ON 

DENDRITIC CELLS AFTER INFLUENZA 

INFECTION IN VIVO AND TOLL-LIKE 

RECEPTOR STIMULATION IN VITRO. 

P. Karmaus 1,3 , W. Chen 2,3 , B. Kaplan 3,4 and N. 

Kaminski 4,3 . 1 Cell & Molecular Biology Program, 

Michigan State University, East Lansing, MI, 

2 

Microbiology & Molecular Genetics, Michigan State 



MI and 4 Pharmacology & Toxicology, Michigan 



ANTI-INFLAMMATORY PROPERTIES 

OF ENDOGENOUS CANNABINOIDS 

CAN BE ATTRIBUTED TO INDUCTION 

OF A TRANSIENT POPULATION OF 

IMMUNOSUPPRESSIVE MYELOID 

DERIVED SUPPRESSOR CELLS 

THAT PROGRESS INTO IMMATURE 

MACROPHAGES. A. R. Jackson, V. Hegde, 

P. Nagarkatti and M. Nagarkatti. Pathology, 

Microbiology, and Immunology, University of South 



Δ 9 -TETRAHYDROCANNABINOL 

MODULATES ELICITATION AND 

FUNCTION OF CYTOTOXIC T 

LYMPHOCYTE (CTL) DIRECTED AGAINST 

HIV GP120. W. Chen 1,4 , S. Pike 4 , P. Karmaus 2,4 , 

B. Kaplan 4,3 and N. Kaminski 3,4 . 1 Microbiology & 


Lansing, MI, 2 Cell & Molecular Biology, Michigan 

State University, East Lansing, MI, 3 Pharmacology & 


MI and 4 Center for Integrative Toxicology, Michigan 



EFFECTS OF CANNABINOIDS ON 

ANTI-HIV-TAT INDUCED ANTIBODY 

PRODUCTION. E. Velez 1,3 , R. Dasgupta 1 , N. 

E. Kaminski 1,2 and B. F. Kaplan 1,2 . 1 Center for 


East Lansing, MI, 2 Pharmacology and Toxicology, 


3 

Chemistry, University of Puerto Rico at Cayey, 

Cayey, PR. 


GLOBAL AND TEMPORAL GENE 

EXPRESSION ANALYSIS OF PERITONEAL 

MACROPHAGES IN A MOUSE ALCOHOL 

BINGE DRINKING MODEL WITH 

REDUCED RESISTANCE TO SEPSIS. 

X. Deng 1 , B. Cheng 2 , R. Fan 2 and S. Pruett 1 . 

1 

Department of Basic Sciences, Mississippi State 

University, Mississippi State, MS and 2 Cellular 

Biology and Anatomy, Lousiana State University 

Health Sciences Center, Shreveport, LA. 

MONday 







173



MONday 



METAL OXIDE NANOPARTICLES 

MODULATE EXOSOMES. B. Andersson 1 , 

T. Bürki-Thurnherr 2 , H. Krug 2 , B. Fadeel 3 , A. 

Scheynius 1 and S. Gabrielsson 1 . 1 Clinical Allergy 

Research Unit, Karolinska Institutet, Stockholm, 

Sweden, 2 Federal Laboratories for Material Science 

and Technology, St. Gallen, Switzerland and 

3 

Institute of Environmental Medicine, Karolinska 

Institutet, Stockholm, Sweden. 


ROLE OF NEUTROPHILS IN A MOUSE 

MODEL OF CHEMICAL-INDUCED 

ASTHMA. S. Smulders 1 , V. De Vooght 1 , 

G. Opdenakker 2 , B. Nemery 1 , P. Hoet 1 and J. 

Vanoirbeek 1 . 1 Research Unit for Lung Toxicology, 

K.U. Leuven, Leuven, Belgium and 2 Rega Institute 

for Medical Research, Laboratory of Immunobiology, 

K.U. Leuven, Leuven, Belgium. 


EFFECTS OF PENICILLIUM MYCOTOXINS 

ON BOVINE MACROPHAGES IN VITRO. H. 

J. Boermans 2 , S. Oh 1 , N. A. Karrow 1 , B. Sharma 1 and 

S. Haladi 3 . 1 Animal and Poultry Sciences, University 

of Guelph, Guelph, ON, Canada, 2 Biomedical 

Sciences, University of Guelph, Guelph, ON, Canada 

and 3 Alltech, Guelph, ON, Canada. 


EFFECT OF ASBESTOS EXPOSURE 

ON PRODUCTION OF CYTOKINES, 

APOPTOSIS, AND CELL PROLIFERATION 

RELATED WITH DIFFERENTIATION OF 

HUMAN CTL. N. Kumagai, Y. Nishimura, 

M. Maeda, H. Hayashi and T. Otsuki. Hygiene, 

Kawasaki Medical School, Kurashiki, Japan. 


1, 3-DIBROMOPROPANE UP-REGULATES 

INDUCIBLE NITRIC OXIDE SYNTHASE 

EXPRESSION VIA NF-KB ACTIVATION IN 

MACROPHAGES. J. Yang 1 , E. Han 1 , J. Im 1 , K. 

Lee 2 , T. Jeong 3 and H. Jeong 1 . 1 Pharmacy, Chungnam 

National University, Daejeon, Republic of Korea, 

2 

Pharmacy, Chonnam National University, Gwangju, 

Republic of Korea and 3 Pharmacy, Yeungnam 

University, Kyungsan, Republic of Korea. 


SYNERGISM OF LEPTIN SIGNALING 

AND POST TRANSLATIONAL 

PROTEIN OXIDATION IN 

BROMODICHLOROMETHANE EXPOSURE 

IS KEY TO THE DEVELOPMENT OF 

STEATOHEPATITIS OF OBESITY. S. 

Chatterjee, J. Clark, M. Kadiiska and R. P. Mason. 

Laboratory of Toxicology and Pharmacology, 

NIEHS, Research Triangle Park, NC. 


EFFECT OF LEAD EXPOSURE ON THE 

MACROPHAGES ACTIVATION THROUGH 

TLR4. A. L. Luna 1,2 , N. A. Torres-Aviles 1 , L. 

C. Acosta-Saavedra 1 , E. K. Silbergeld 3 and E. 

S. Calderon-Aranda 1 . 1 Department Toxicologia, 

Cinvestav, Mexico, Mexico, 2 Biomedicina Molecular, 

ENMH-IPN, Mexico, Mexico and 3 BSPH, Johns 

Hopkins University, Baltimore, MD. 


CONTINUOUS AND LOW-DOSE EXPOSURE 

TO ASBESTOS ENHANCES TGF-β1 

PRODUCTION IN A HUMAN ADULT T 

CELL LEUKEMIA VIRUS-IMMORTALIZED 

T CELL LINE, MT-2. T. Otsuki, M. Maeda, N. 

Kumagai, N. Miyahara, M. Katoh, S. Yamamoto, 

T. Hatayama and Y. Nishimura. Hygiene, Kawasaki 

Medical School, Kurashiki, Japan. 


EFFECT OF VIBRIO VULNIFICUS 

LIPOPOLYSACCHARIDE (LPS) ON RAT 

BRAIN MICROGLIA: CYTOKINE AND 

CHEMOKINE EXPRESSION PROFILING 

BY ANTIBODY ARRAY TECHNOLOGY. L. 

D. Ottenhoff 1 , N. Patel 1 , M. L. Hall 1 , K. B. Glaser 2,1 , 

P. B. Jacobson 2 , D. Rowley 3 , C. De Castro 4 , A. 

Molinaro 4 and A. M. Mayer 1 . 1 Pharmacology, 

Midwestern University, Downers Grove, IL, 

2 

Abbott Laboratories, Chicago, IL, 3 Biomedical and 

Pharmaceutical Sciences, University of Rhode Island, 

Kingston, RI and 4 Chimica Organica e Biochimica, 

Università di Napoli Federico II, Naples, Italy. 


ENHANCED SUPPRESSIVE FUNCTION ON 

REGULATORY T CELL-LIKE CELL LINE, 

MT-2, BY CONTINUOUS EXPOSURE TO 

ASBESTOS. M. Maeda 1 , Y. Chen 1 , Y. Nishimura 1 , 

N. Kumagai 1 , H. Hayashi 1 , Y. Miura 2 and T. Otsuki 1 . 

1 

Hygiene, Kawasaki Medical School, Kurashiki, 

Okayama, Japan and 2 Molecular Genetics, Kyushu 

University, Fukuoka, Japan. 


HISTONE DEACETYLASES PLAY A 

CRITICAL ROLE IN REGULATING IFNα- 

MEDIATED ANTI-HCV GENE EXPRESSION. 

S. Mathews 1 , S. Joshi-Barve 1 , C. McClain 1,2 and S. 





ZIRAM INDUCES APOPTOSIS IN HUMAN 

IMMUNE CELLS. Q. Li, M. Kobayashi and T. 

Kawada. Nippon Medical School, Tokyo, Japan. 


ENHANCEMENT OF HUMORAL 

IMMUNITY BY THE ENDOCRINE 

DISRUPTER PROPANIL IS NOT ALTERED 

BY NEONATAL ANDROGEN TREATMENT. 

R. Schafer 1 , S. Hileman 2 , R. Goodman 2 and I. 

Holaskova 1 . 1 Microbiology, Immunology, and Cell 

Biology, West Virginia University, Morgantown, WV 

and 2 Physiology and Pharmacology, West Virginia 



ASBESTOS EXPOSURE CAUSES DECREASE 

IN PRODUCTION OF CYTOKINES 

RELATED TO NK CELL ACTIVATION. Y. 

Nishimura, N. Kumagai, M. Maeda, H. Hayashi 

and T. Otsuki. Hygiene, Kawasaki Medical School, 

Kurashiki, Japan. 

174 






Platform Sessions



Abstract # 


IFN PRODUCTION BY RESTIMULATED 

NRF2-NULL T CELLS IS MODULATED BY 

PRESENCE OF WILD-TYPE ANTIGEN- 

PRESENTING CELLS. C. E. Rockwell 1 , P. 

E. Fields 2 and C. D. Klaassen 1 . 1 Department of 



KS and 2 Department of Pathology & Laboratory 

Medicine, University of Kansas Medical Center, 

Kansas City, KS. 


TBTO INHIBITS MTOR SIGNALING IN 

HUMAN T CELLS, A NOVEL PUTATIVE 

IMMUNOTOXIC MECHANISM OF TBTO. 

O. L. Volger 1 , J. Shao 1 , A. A. Peijnenburg 1 and H. 

van Loveren 2 . 1 Toxicology and Effect Monitoring, 

RIKILT Institute of Food Safety, Wageningen, 

Netherlands and 2 Laboratory for Health Protection 

Research, National Institute of Public Health and the 

Environment, Bilthoven, Netherlands. 


CHARACTERIZATION OF ACUTE EFFECTS 

OF METHYLISOTHIOCYANATE (MITC) 

IN AN IN VITRO AND AN IN VIVO MODEL. 

W. Tan, B. Jan, X. Deng and S. Pruett. Department 

of Basic Sciences, Mississippi State University, 

Mississippi State, MS. 


SODIUM METHYLDITHIOCARBAMATE- 

INDUCED OXIDATIVE STRESS ON 

NF-KAPPAB REPORTER MICE. M. Gadson, 

W. Tan, X. Deng and S. Pruett. Department of Basic 

Sciences, Mississippi State University, Mississippi 

State, MS. 


IMMUNOMODULATORY ROLES OF THE 

PROKARYOTIC METALLOTHIONEIN. 

K. Pietrosimone 1 , S. Davis 1 , D. Laukens 2 , D. A. 

Lawrence 3 and M. Lynes 1 . 1 University of Connecticut, 

Storrs, CT, 2 University of Ghent, Ghent, Belgium and 

3 

Wadsworth Laboratory, Albany, NY. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Biological Modeling: Computational 

Approaches, Mixtures, Multiroute and Lifestage Applications 

Chairperson(s): Andy Nong, Health Canada, Ottawa, Ontario, Canada, 

and John Wambaugh, U.S. EPA, Research Triangle Park, NC. 




PROGRESS IN DEVELOPMENT 

OF PHYSIOLOGICALLY BASED 

PHARMACOKINETIC MODELS FOR PAHS. 

S. R. Crowell 1 , J. Soelberg 1 , S. G. Amin 2 , K. A. 

Anderson 3 , D. E. Williams 3 and R. A. Corley 1 . 1 Pacific 

Northwest National Laboratory, Richland, WA, 2 Penn 

State College of Medicine, Hershey, PA and 3 Oregon 

State University, Corvallis, OR. 

Abstract # 


DOSIMETRY ASSESSMENT OF 

SILOXANES IN COSMETIC PRODUCTS 

USING PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC MODELING. A. Nong, 

R. Wang and J. Zhu. Environmental Health Science 

and Research Bureau, Health Canada, Ottawa, ON, 

Canada. 


PHYSIOLOGICALLY BASED 

PHARMACOKINETIC MODELING OF 

MANGANESE EXPOSURE IN HUMANS 

DURING FETAL AND NEONATAL 

DEVELOPMENT. M. Yoon 1 , J. D. Schroeter 1 , A. 

Nong 1 , M. Taylor 2 , D. C. Dorman 1,3 , M. E. Andersen 1 

and H. J. Clewell 1 . 1 The Hamner Institutes for Health 

Sciences, Durham, NC, 2 Afton Chemical, Richmond, 

VA and 3 North Carolina State University, Raleigh, 

NC. 


A BBDR-HPT AXIS MODEL FOR THE 

LACTATING RAT AND NURSING PUP: 

EVALUATION OF IODIDE DEFICIENCY. S. 

Li 1 , M. E. Gilbert 2 , R. T. Zoeller 3 , K. M. Crofton 2 , 

E. D. McLanahan 4 , D. R. Mattie 5 , B. C. Blount 6 , L. 

Valentin-Blasini 6 , K. Kurunthachalam 7 , T. Kunisue 7 

and J. W. Fisher 1 . 1 College of Public Health, 

University of Georgia, Athens, GA, 2 NHEERL, 

U.S. EPA, Research Triangle Park, NC, 3 Biology 

Department, University of Massachusetts, Amherst, 

MA, 4 NCEA, U.S. EPA, Research Triangle Park, 

NC, 5 711 HPW/RHPBA, Wright-Patterson AFB, OH, 

6 

CCEHIP/NCEH, CDC, Atlanta, GA and 7 Wadsworth 

Center, New York State Department of Health, 

Albany, NY. 


AGE-DEPENDENT METABOLISM OF 

CHLOPYRIFOS AND CHLORPYRIFOS- 

OXON IN HUMAN PLASMA AND HEPATIC 

MICROSOMES. T. S. Poet 1 , C. Timchalk 1 , M. J. 

Bartels 2 and J. N. Smith 1 . 1 Biological Monitoring 

& Modeling, Battelle, Pacific Northwest Division, 

Richland, WA and 2 The Dow Chemical Company, 

Midland, MI. 


DEVELOPMENT OF A LIFESTAGE 


PHARMACOKINETIC AND 

PHARMACODYNAMIC (PBPK/PD) MODEL 

FOR CHLORPYRIFOS IN RATS AND 

HUMANS. J. N. Smith 1 , P. M. Hinderliter 1 , C. 

Timchalk 1 , M. J. Bartels 2 and T. S. Poet 1 . 1 Biological 

Monitoring & Modeling, Battelle, Pacific Northwest 

Division, Richland, WA and 2 The Dow Chemical 

Company, Midland, MI. 


EFFECT OF PARAMETER VARIABILITY 

AND UNCERTAINTY IN A LIFESTAGE 

PBPK MODEL FOR CHLORPYRIFOS. P. M. 

Hinderliter 1 , J. N. Smith 1 , M. J. Bartels 2 , P. S. Price 2 

and T. S. Poet 1 . 1 Biological Monitoring & Modeling, 

Battelle, Pacific Northwest Division, Richland, WA 

and 2 The Dow Chemical Company, Midland, MI. 

MONday 







175



MONday 



DEVELOPMENT OF HUMAN GESTATION 

AND LACTATION PBPK MODELS FOR 

PERFLUOROOCTANOATE (PFOA) AND 

PERFLUOROOCTANESULFONATE (PFOS). 

A. E. Loccisano 1 , M. E. Andersen 1 , J. Butenhoff 2 and 

H. J. Clewell 1 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 3M 

Corporation, St. Paul, MN. 


LIFE-STAGE PBPK MODELS FOR 

MULTIPLE ROUTES OF ETHANOL 

EXPOSURE IN THE RAT. S. A. Martin 1,7 , J. L. 

Campbell 2 , K. Choi 2 , H. J. Clewell 2 , H. El-Masri 3,7 , 

W. R. LeFew 3,7 , T. E. Beasley 1,7 , W. M. Oshiro 1,7 , 

L. L. Degn 1,7 , P. A. Evansky 4,7 , A. Ledbetter 4,7 , J. 

Ford 5,7 , D. W. Herr 1,7 , W. K. Boyes 1,7 , P. J. Bushnell 1,7 

and E. D. McLanahan 6,7 . 1 NB/TAD/NHEERL/ORD, 

Research Triangle Park, NC, 2 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC, 

3 

SBB/ISTD/NHEERL/ORD, Research Triangle 

Park, NC, 4 ITFB/EPHD/NHEERL/ORD, Research 

Triangle Park, NC, 5 ACRC/RCU/NHEERL/ORD, 

Research Triangle Park, NC, 6 NCEA/ORD, Research 

Triangle Park, NC and 7 U.S. EPA, Research Triangle 

Park, NC. 


ANALYSIS OF BISPHENOL A KINETICS 

AND METABOLISM IN NEONATAL AND 

ADULT MONKEYS AND RATS USING A 

PBPK MODEL. J. Fisher, N. C. Twaddle, M. 

Vanlandingham and D. R. Doerge. Biochemical 

Toxicology Division, U.S. FDA NCTR, Jefferson, 

AR. 



PHARMACOKINETIC MODELING 

(PBPK) AS A TOOL TO PREDICT 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN 

(TCDD) PHARMACOKINETICS (PK) 

DURING GESTATION AND LACTATION. C. 

Emond 1,2 , M. J. Devito 3 , M. Warner 4 , B. Eskenazi 4 , 

P. Mocarelli 5 and L. S. Birnbaum 6 . 1 BioSimulation 

Consulting Inc., Newark, DE, 2 University of 

Montréal, Montréal, QC, Canada, 3 NIEHS & NTP, 

Research Triangle Park, NC, 4 School of Public 

Health, University of California, Berkeley, CA, 

5 

Department of Laboratory Medicine, University 

of Milano-Bicocca, School of Medicine, Hospital 

of Desio, Desio, Desio-Milano, Italy and 6 NCI & 



DEVELOPMENT OF PHYSIOLOGICALLY 

BASED PHARMACOKINETIC (PBPK) 

MODEL TO PREDICT TULATHROMYCIN 

DISTRIBUTION IN GOATS. T. L. Leavens 1 , 

L. A. Tell 2 , K. A. Clothier 2 , R. W. Griffith 3 , R. E. 

Baynes 1 and J. E. Riviere 1 . 1 Center for Chemical 


Carolina State University, Raleigh, NC, 2 Department 

of Medicine and Epidemiology, University of 

California Davis, CA and 3 Department of Veterinary 

Microbiology and Preventive Medicine, Iowa State 



APPLICATION OF A MULTIROUTE 

HUMAN PBPK MODEL FOR 

BROMODICHLOROMETHANE (BDCM). 

E. M. Kenyon 1 , T. L. Leavens 2 , C. Eklund 1 and R. 

A. Pegram 1 . 1 ORD/NHEERL/ISTD, U.S. EPA, 

Durham, NC and 2 Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina State 



A PHYSIOLOGICALLY BASED 

PHARMACOKINETIC (PBPK) TOOL 

KIT TO EVALUATE EXPOSURES TO 

ENVIRONMENTAL POLLUTANTS. M. 

Mumtaz 1 , P. Ruiz 1 , M. Ray 2 , J. Fisher 3 and S. Hays 4 . 

1 

Department of Toxicology and Environmental 

Medicine, ATSDR, Atlanta, GA, 2 University of 

South Carolina, Columbia, SC, 3 U.S. FDA, National 

Center for Toxicological Research, Jefferson, AR and 

4 

Summit Toxicology Inc., Lyons, CO. 


DERIVATION OF CHEMICAL-SPECIFIC 

ADJUSTMENT FACTORS FOR HUMAN 

VARIABILITY IN TOXICOKINETICS OF 

ACETONE. G. Johanson and A. Mörk. Work 

Environment Toxicology, Karolinska Institute, 

Stockholm, Sweden. 


PRIORITIZING TOXCAST CHEMICALS 

ACROSS MULTIPLE SECTORS OF 

TOXICITY USING TOXPI. D. Reif, M. Martin, 

M. Holly, S. Gangwal, A. Wang, R. Judson, P. 

Volarath, R. Kavlock and D. Dix. National Center for 

Computational Toxicology, U.S. EPA, Durham, NC. 


INTEGRATION OF HIGH-THROUGHPUT 

SCREENING DATA WITH DOSIMETRY AND 

HUMAN EXPOSURE IN THE TOXICITY 

ASSESSMENT OF ENVIRONMENTAL 

CHEMICALS. B. A. Wetmore 1 , J. F. Wambaugh 2 , 

D. M. Rotroff 2,3 , H. J. Clewell 1 , M. E. Andersen 1 , 

S. Ferguson 4 , D. J. Dix 2 and R. S. Thomas 1 . 

1 

The Hamner Institutes for Health Sciences, 

Research Triangle Park, NC, 2 National Center for 

Computational Toxicology, U.S. EPA, Research 

Triangle Park, NC, 3 Department of Environmental 

Sciences and Engineering, University of North 

Carolina at Chapel Hill, Chapel Hill, NC and 4 Life 

Technologies, Inc., Durham, NC. 


A BIOLOGICALLY INFORMED 

FRAMEWORK FOR THE ANALYSIS OF 

THE PPAR SIGNALING PATHWAY USING A 

BAYESIAN NETWORK. A. Beam 1,2 , W. John 1 , R. 

Setzer 1 , K. Houck 1 , S. Imran 1 , D. Dix 1 and R. Judson 1 . 

1 

U.S. EPA/ORD/NCCT, Research Triangle Park, 

NC and 2 Statistics, North Carolina State University, 

Raleigh, NC. 


MODELING REPRODUCTIVE TOXICITY 

FOR CHEMICAL PRIORITIZATION INTO 

AN INTEGRATED TESTING STRATEGY. 

M. T. Martin, T. Knudsen, K. Houck, R. Judson, R. 

Kavlock and D. Dix. NCCT, U.S. EPA, Research 


176 






Platform Sessions



Abstract # 


BIOLOGICALLY-BASED LUMPING 

METHODOLOGY (BBLM) TO INVESTIGATE 

TOXICOLOGICAL INTERACTIONS OF 

COMPLEX CHEMICAL MIXTURES. W. 

LeFew and H. El-Masri. U.S. EPA, Durham, NC. 


A PBPK MODEL OF MICRO AND NANO 

SIZED FLUORESCENT POLYSTYRENE 

SPHERES IN RATS. X. Chang 1 , K. Sarlo 2 , N. 

Walker 1 , K. Blackburn 2 , E. Clark 2 , J. Grothaus 2 and 

C. Portier 1 . 1 NIEHS, Reseach Triangle Park, NC 

and 2 Miami Valley Laboratories, Procter & Gamble, 



PHARMACOKINETICS-ENABLED 

REVERSE DOSIMETRY APPROACH 

IMPROVES THE ACCURACY OF 

BISPHENOL A (BPA) EXPOSURE 

ASSESSMENT. R. Gunawan and J. Teeguarden. 

Biological Monitoring/Modeling, Pacific Northwest 

National Laboratory, Richland, WA. 


A SHOW OF HANDS FOR MODERN RISK 

ASSESSMENT: SPECIES-TO-SPECIES 

EXTRAPOLATIONS OF STEREOISOMERIC 

MIXTURES WITH PROVISIONAL PBPK 

MODELS. R. Goldsmith 1 , J. Kenneke 2 , C. Mazur 2 , 

D. Chang 1 , Y. Tan 1 , R. Tornero-Velez 1 , C. Dary 3 and 

E. Ulrich 1 . 1 U.S. EPA, Durham, NC, 2 U.S. EPA, 

Athens, GA and 3 U.S. EPA, Las Vegas, NV. 


MARKOV CHAIN MONTE CARLO 

ANALYSIS OF RAT TISSUE:AIR PARTITION 

COEFFICIENTS. T. Peyret and K. Krishnan. 

Département de Santé Environnementale et Santé 

au Travail, Université de Montréal, Montréal, QC, 

Canada. 


INTEGRATED KNOWLEDGE-DRIVEN 

IN SILICO WORKFLOW IN SUPPORT 

OF PBPK/PD MODEL DEVELOPMENT: 

ESTABLISHING PRIORS FOR 

PYRETHROID CLASS INSECTICIDES. X. 

Zhang 1 , D. Chang 2 , R. Goldsmith 2 , J. B. Knaak 3 , 

C. Tan 2 , R. Tornero-Velez 2 , J. Johnson 4 and C. C. 

Dary 4 . 1 General Dynamics Information Technology, 

Henderson, NV, 2 NERL, U.S. EPA, Research 

Triangle Park, NC, 3 Department of Pharmacology 

and Toxicology, State University of New York at 

Buffalo, Buffalo, NY and 4 NERL, U.S. EPA, Las 

Vegas, NV. 


GROUPING OF CHEMICALS IN THE 21 ST 

CENTURY: A BIOLOGY BASED APPROACH 

USING METABOLOMICS. B. van Ravenzwaay 2 , 

M. Herold 1 , H. Kamp 2 , M. Kapp 2 , E. Fabian 2 , R. 

Looser 1 , G. Krennrich 2 , W. Mellert 2 , A. Prokoudine 1 , 

V. Strauss 2 , T. Walk 1 and J. Wiemer 1 . 1 Metanomics 

GmbH, Berlin, Germany and 2 Experimental 

Toxicology, BASF SE, Ludwigshafen, Germany. 

Sponsor: R. David. 

Abstract # 


STATISTICAL APPROACHES TO 

ANALYZING A LARGE, MULTI- 

TREATMENT, TIME COURSE STUDY 

OF METAL PELLETS IMPLANTED 

INTO MOUSE MUSCLE: CLINICAL 

MEASUREMENTS AND PREDICTIVE 

MODELING. W. Bao 2 , C. Tsu-Ming 2 , R. D. 

Wolfinger 2 , E. J. Perkins 3 and D. I. Bannon 1 . 

1 

Directorate of Toxicology, U.S. Army Public Health 

Command, APG, Aberdeen, MD, 2 SAS Institute, 

Inc., Cary, NC and 3 Environmental Laboratory, U.S. 

Army Engineer Research and Development Center, 

Vicksburg, MS. 


UPDATED ALUMINUM 

PHARMACOKINETICS IN INFANTS 

FOLLOWING EXPOSURES THROUGH 

DIET AND VACCINATION. R. J. Mitkus, M. 

O. Walderhaug and M. Hess. U.S. FDA/CBER, 

Rockville, MD. 


ASSESSING THE ROBUSTNESS OF 

CHEMICAL PRIORITIZATIONS BASED 

ON TOXCAST CHEMICAL PROFILING. A. 

Wilson, S. Gangwal, M. Martin, R. Judson, D. Dix 

and D. Reif. National Center for Computational 

Toxicology, Office of Research and Development, 



TOXPLORER: A COMPREHENSIVE 

KNOWLEDGEBASE OF TOXICITY 

PATHWAYS USING ONTOLOGY-DRIVEN 

INFORMATION EXTRACTION. I. Shah 1 , A. 

Singh 2 , C. Haugh 1 , J. Jack 1 , R. Judson 1 , T. Knudsen 1 , 

M. Martin 1 and J. Wambaugh 1 . 1 NCCT, U.S. EPA, 

Research Triangle Park, NC and 2 Lockheed Martin, 



BELIEF THEORY IN MECHANISTIC 

PHARMACOVIGILANCE: USING THE 

BIOMEDICAL LITERATURE TO CONFIRM 

ADVERSE DRUG EVENT REPORTS FROM 

ELECTRONIC HEALTH RECORDS. E. 

Ahlberg Helgee and S. Boyer. Computational 

Toxicology, AstraZeneca and EU-ADR Consortium, 

Mölndal, Sweden. 


PREDICTING ADAPTIVE RESPONSE 

TO FADROZOLE EXPOSURE: 

COMPUTATIONAL MODEL OF THE 

FATHEAD MINNOWS HYPOTHALAMIC- 

PITUITARY-GONADAL AXIS. M. Breen 1,2 , D. 

Villeneuve 1 , G. Ankley 1 , K. Watanabe 3 , M. Breen 1 , 

A. Lloyd 2 and R. Conolly 1 . 1 U.S. EPA, Research 

Triangle Park, NC, 2 North Carolina State University, 

Raleigh, NC and 3 Oregon Health and Science 

University, Beaverton, OR. 

MONday 







177



MONday 



APPLICATION OF A HUMAN 

PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC MODEL TO 

EVALUATE BENZENE BLOOD LEVELS FOR 

PUBLIC HEALTH CONCERN. D. A. Fowler 1 , 

R. R. Worley 1 , J. S. Wheeler 1 , C. Welsh 1 , D. Moffett 1 

and J. Fisher 2 . 1 Agency for Toxic Substances and 

Disease Registry, CDC/ATSDR/NCEH, Atlanta, GA 

and 2 National Center for Toxicological Research, 

U.S. FDA, Jefferson, AR. 


CHARACTERIZATION OF STRAIN & DOSE- 

DEPENDENT ROUTES OF ELIMINATION 

FOR BENZENE & ITS METABOLITES IN 

4 MOUSE STRAINS. G. A. Knudsen 1 , R. K. 

Kuester 1 , M. L. Cunningham 2 , J. E. French 2 and 

I. G. Sipes 1 . 1 Medical Pharmacology, University 

of Arizona, Tucson, AZ and 2 National Toxicology 

Program, National Institutes of Environmental Health 



VIRTUAL LIVER: EVALUATING THE 

IMPACT OF HEPATIC MICRODOSIMETRY 

FOR TOXCAST CHEMICALS. J. F. 

Wambaugh 1 , J. Jack 1 , C. Haugh 1 , J. Zaldívar 

Comenges 2 and I. Shah 1 . 1 National Center for 

Computational Toxicology, U.S. EPA, Research 

Triangle Park, NC and 2 Institute for Health and 

Consumer Protection, European Commission, Joint 

Research Centre, Ispra, Italy. 


MOLECULAR DYNAMICS STABILITY 

STUDY OF THE WILD-TYPE AND MUTANTS 

OF THE HEPTAPEPTIDE (NNFGAIL) 

SEGMENT OF AMYLIN AGGREGATE. W. 

M. Berhanu 1,2 and A. E. Masunov 1,2 . 1 Chemistry, 

University of Central Florida, Orlando, FL and 

2 

Nanoscience Technology Center, University of 

Central Florida, Orlando, FL. 


MECHANISTIC UNDERSTANDING OF 

DRUG EFFECTS USING METABOLOMICS: 

A COMPUTATIONAL APPROACH BASED 

ON A RAT LIVER MODEL. O. Shaikh, S. Das, 

R. Kumar, S. Raghavan and K. Subramanian. Strand 

Life Sciences, Bangalore, India. 


DEVELOPMENT OF A PHYSIOLOGICALLY 


MODEL FOR RDX (HEXAHYDRO-1, 3, 

5-TRINITRO-1, 3, 5-TRIAZINE) IN FEMALE 

B6C3F1 MICE. M. L. Gargas 1 , C. P. Gut 1 , M. 

R. Okolica 1 , A. Ntamack 1 , L. M. Sweeney 1 , L. R. 

Williams 2 , G. Reddy 2 and M. S. Johnson 2 . 1 Naval 

Medical Research Unit - Dayton, Wright-Patterson 

AFB, OH and 2 U.S. Army Public Health Command, 

Aberdeen Proving Ground, MD. 


BIOMARKERS OF EXPOSURE VERSUS 

PBPK MODEL ESTIMATES OF 

INTERNAL DOSE: A CASE STUDY WITH 

ACRYLAMIDE. R. S. DeWoskin. U.S. EPA, 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Kidney 

Chairperson(s): Sue Ford, St. Johns University, Jamaica, NY, and 

Vijay Kale, Medical University of South Carolina, Charleston, SC. 




IN VITRO 3, 5-DICHLOROANILINE 

NEPHROTOXICITY IN FRESHLY ISOLATED 

RAT RENAL CORTICAL CELLS. C. 

Smurthwaite, S. Baksi, T. Ferguson, C. Schuetz, 

D. Anestis and G. O. Rankin. Pharmacology, 

Physiology, and Toxicology, Marshall University, 

Huntington, WV. 


IN VITRO ANALYSIS OF CYCLOSPORINE 

A-INDUCED NEPHROTOXICITY BY 

GENE EXPRESSION AND 1H-NMR- 

METABONOMICS OF CELL LYSATES. K. 

Herrgen 1 , O. Schmal 1 , C. J. Burek 1 , M. Gruene 2 , 

P. Jennings 3 and W. Dekant 1 . 1 Department of 

Toxicology, University of Wuerzburg, Wuerzburg, 

Germany, 2 Department of Organic Chemistry, 

University of Wuerzburg, Wuerzburg, Germany and 

3 

Department of Physiology and Medical Physics, 

Medical University of Innsbruck, Innsbruck, Austria. 


EVALUATION OF MRP2 TRANSPORTER- 

MEDIATED PROTECTION AGAINST 

CISPLATIN-INDUCED NEPHROTOXICITY 

USING IN VITRO AND IN VIVO 

APPROACHES. X. Wen 1 , M. Goedken 2 , C. D. 

Klaassen 3 , J. E. Manautou 4 and L. M. Aleksunes 1 . 

1 


Piscataway, NJ, 2 Pathology, Merck & Co., Inc., 

Lafayette, NJ, 3 Pharmacology, University of 

Kansas Medical Center, Kansas City, KS and 

4 

Pharmaceutical Sciences, University of Connecticut, 

Storrs, CT. 


MODULATION OF CISPLATIN MEDIATED 

OXIDATIVE STRESS BIOMARKERS BY 

RESVERATROL. M. Valentovic, J. G. Ball and J. 

Brown. Pharmacology, Physiology, and Toxicology, 

Marshall University School of Medicine, Huntington, 

WV. 


URINARY BIOMARKERS FOR THE EARLY 

PREDICTION OF CISPLATIN-INDUCED 

CHANGES IN KIDNEY FUNCTION AND 

INJURY IN RATS. Y. Chen, D. Brott, P. 

Bentley, D. Thurman, L. Kinter and R. Bialecki. 

Safety Assessment, AstraZeneca Pharmaceuticals, 



STATE-OF-THE-ART DETECTION OF 

NEPHROTOXICITY BY URINARY PROTEIN 

BIOMARKERS. B. Emde, P. Hewitt, S. Czasch, F. 

v. Landenberg and T. C. Fuchs. Toxicology, Merck 

Serono, Darmstadt, Germany. 

178 






Platform Sessions



Abstract # 


URINARY FIBRINOGEN: A MECHANISTIC 

TRANSLATIONAL BIOMARKER FOR 

VASCULAR DYSFUNCTION AND 

INFLAMMATION IN THE KIDNEY. D. 

Hoffmann 1 , A. Krishnamoorthy 1 , V. Ramirez 

Gonzalez 1 , Q. Zhang 2 , P. L. Goering 2 , R. B. Brown 2 , 

S. Waikar 1 and V. S. Vaidya 1 . 1 Renal Division, 

Brigham and Women’s Hospital, Harvard Medical 

School, Boston, MA and 2 CDRH, U.S. FDA, Silver 

Spring, MD. 


METABOLOMICS ANALYSIS SUGGESTS 

ROLE OF 3-INDOXYL SULFATE IN 

CENTRAL NERVOUS SYSTEM TOXICITY 

AND AN EARLY INDICATOR OF 

CHEMICALLY-INDUCED RENAL FAILURE. 

M. V. Milburn 1 , D. Alexander 1 , J. R. Zgoda-Pols 2 , 

S. Chowdhury 2 , M. Wirth 2 and K. B. Alton 2 . 

1 

Metabolon, Durham, NC and 2 Department of Drug 

Metabolism and Pharmacokinetics, Merck Research 

Laboratories, Kenilworth, NJ. Sponsor: G. Vansant. 


SHORT-TERM TOXICITY OF MELAMINE 

AND ITS MIXTURE WITH CYANURIC ACID 

IN F344 NEONATAL RATS AND SEARCHING 

FOR NOVEL KIDNEY BIOMARKERS. H. 

Kang 1 , Y. Park 1 , S. Jeong 2 , J. Seo 1 , Y. Jean 1 , J. 

Kang 1 , H. Shin 1 and S. Son 1 . 1 Veterinary Toxicology 

and Chemistry, National Veterinary Research and 

Quarantine Service, Anyang, Republic of Korea 

and 2 GLP Research Center, Hoseo University, Asan, 



TRANSCRIPTION LEVELS OF 

BIOMARKERS OF ACUTE RENAL INJURY 

IN F344 RATS CO-EXPOSED TO MELAMINE 

AND CYANURIC ACID FOR SEVEN DAYS. 

L. Camacho, K. Kelly and G. Gamboa da Costa. 

Division Biochemical Toxicology, National Center 

for Toxicological Research. U.S. FDA, Jefferson, 

AR. 


THE USE OF FLOW CYTOMETRY 

TO STUDY MECHANISMS OF 

MITOCHONDRIAL BIOGENESIS IN RENAL 

CELLS. V. Kale and R. Schnellmann. Department 

of Pharmaceutical and Biomedical Sciences, Medical 

University of South Carolina, Charleston, SC. 


OXIDANT INJURY INDUCES RAPID 

DEGRADATION OF MITOCHONDRIAL 

CALPAIN 10 IN RENAL PROXIMAL 

TUBULE CELLS. M. A. Smith and R. G. 

Schnellmann. Pharmaceutical Sciences, Medical 



MITOCHONDRIAL HOMEOSTASIS AFTER 

ACUTE KIDNEY INJURY: SUSTAINED 

ALTERATIONS IN MITOCHONDRIAL 

PROTEINS, FUSION/FISSION, AND 

BIOGENESIS. J. A. Funk, B. E. Shaner and R. 

G. Schnellmann. Pharmaceutical and Biomedical 

Sciences, Medical University of South Carolina, 

Charleston, SC. 

Abstract # 


IDENTIFICATION AND 


MITOCHONDRIAL TOXICANTS. L. P. Wills, 

G. C. Beeson, R. Trager, C. Lindsey, Y. K. Peterson, 

C. C. Beeson and R. G. Schnellmann. Department of 

Pharmaceutical and Biomedical Sciences, Medical 



MITOCHONDRIAL GSH STATUS IN 

COMPENSATORY RENAL HYPERTROPHY 

DUE TO UNINEPHRECTOMY AND 

DIABETIC NEPHROPATHY. L. H. Lash, B. 

Benipal, D. A. Putt and Q. Zhong. Pharmacology, 

Wayne State University School of Medicine, Detroit, 

MI. 


THE CYTOPROTECTIVE EFFECT 

OF N-ACETYLCYSTEINE AGAINST 

ROS-INDUCED CYTOTOXICITY IS 

INDEPENDENT OF ITS ABILITY TO 

ENHANCE GLUTATHIONE SYNTHESIS. F. 

Zhang, S. S. Lau and T. J. Monks. Department of 

Pharmacology and Toxicology, College of Pharmacy, 

University of Arizona, Tucson, AZ. 


PLASMA, URINE, AND TISSUE 

CONCENTRATIONS OF HEXAVALENT 

CHROMIUM ASSOCIATED ACUTE KIDNEY 

INJURY IN SPRAGUE-DAWLEY RATS. R. P. 

Brown 1 , Q. Zhang 1 , D. S. Barber 2 , A. C. Komiyama 1 

and P. L. Goering 1 . 1 CDRH, U.S. FDA, Silver Spring, 

MD and 2 University of Florida, Gainesville, FL. 


COVALENT MODIFICATIONS OF KIDNEY 

PROTEINS BY S-(1, 2-DICHLOROVINYL)-L- 

CYSTEINE SULFOXIDE (DCVCS): IN VITRO 

CHARACTERIZATION USING N-BIOTINYL- 

DCVCS (NB-DCVCS). R. M. Irving 1 , M. S. 

Brownfield 2 and A. A. Elfarra 1,2 . 1 Molecular and 

Environmental Toxicology Center, University of 

Wisconsin Madison, Madison, WI and 2 Department 

of Comparative Biosciences, University of Wisconsin 

Madison, Madison, WI. 


ZINC DEFICIENCY EXACERBATES 

DIABETES-INDUCED RENAL OXIDATIVE 

DAMAGE, INFLAMMATION, AND 

FIBROSIS. B. Li 1,2 , L. Miao 2 and L. Cai 1 . 

1 


2 

Nephrology, Jilin University, Changchun, Jilin, 

China. 


ROLE OF OXIDATIVE STRESS INDUCED 

BY CHROMATE IN THE ACTIVATION 

OF MAPK IN NRK-52E CELLS. L. Arreola- 

Mendoza 1,2 , J. L. Reyes 3 , E. I. Sanchez 3 and L. 

M. Del Razo 2 . 1 Biosciences and Engineering, 

CIIEMAD-IPN, Mexico D.F., Mexico, 2 Toxicology, 

Cinvestav-Ipn, Mexico D.F., Mexico and 3 Physiology 

& Biophysics, Cinvestav-Ipn, Mexico D.F., Mexico. 

MONday 







179



MONday 



ALUMINUM CITRATE AND COM: 

MECHANISMS FOR DECREASED RENAL 

INJURY IN A RAT MODEL OF ETHYLENE 

GLYCOL POISONING. L. M. Besenhofer, M. 

C. McLaren and K. E. McMartin. Pharmacology, 

Toxicology, and Neuroscience, Louisiana State 

University Health Sciences Center Shreveport, 

Shreveport, LA. 


SUB-CHRONIC ETHANOL EXPOSURE 

INDUCES ACUTE RENAL INJURY AND 

FIBROSIS IN RATS. C. Latchoumycandane 1 , 

J. Liu 1 , L. E. Nagy 2 , A. E. Feldstein 1 and T. M. 

McIntyre 1 . 1 Cell Biology, Lerner Research Institute, 

Cleveland Clinic, Cleveland, OH and 2 Pathobiology 

and Gastroenterology, Lerner Research Institute, 

Cleveland Clinic, Cleveland, OH. 


BODY ADIPOSITY AND DIETARY FATTY 

ACIDS INDUCE CYTOKINE EXPRESSION 

AND ACTIVATION OF TUMOR 

PROMOTING PATHWAYS IN THE RAT 

KIDNEY. A. Bort 1,2 , G. Ananthakrishnan 1 , D. 

Perez-Tilve 1 , D. R. Dietrich 2 , M. H. Tschöp 1 , P. T. 

Pfluger 1 and K. Stemmer 1,2 . 1 Department of Internal 

Medicine, University of Cincinnati, Cincinnati, 

OH and 2 Human and Environmental Toxicology, 

University of Konstanz, Konstanz, Germany. 


TRANSPORT OF MERCURIC SPECIES 

IN RABBIT RENAL BRUSH-BORDER 

MEMBRANE VESICLES. C. Bridges, L. 

Joshee and R. K. Zalups. Division of Basic Medical 

Sciences, Mercer University School of Medicine, 

Macon, GA. 


KIDNEY PROXIMAL TUBULE-ON-A-CHIP 

FOR DRUG TRANSPORTER STUDIES AND 

NEPHROTOXICITY ASSESSMENT. K. Jang 1,2 , 

D. Huh 1,3 , G. A. Hamilton 1 , A. Bahinski 1 , K. Suh 2 

and D. E. Ingber 1,3,4 . 1 Wyss Institute for Biologically 

Inspired Engineering at Harvard University, Boston, 

MA, 2 Interdisciplinary Program in Nano-Science 

and Technology, Seoul National University, Seoul, 

Republic of Korea, 3 Vascular Biology Program, 

Departments of Pathology and Surgery, Children’s 

Hospital, Boston, MA and 4 School of Engineering 

and Applied Sciences, Harvard University, 



ATTENUATION OF OCHRATOXIN A 

TOXICITY BY INHIBITION OF ORGANIC 

ANION TRANSPORT. A. Sarma and S. M. Ford. 

Toxicology Program, St. Johns University, Queens, 

NY. 


EXPRESSION OF THE ZINC/CADMIUM 

TRANSPORTER, SCL39A8 (ZIP8), IN 

NORMAL AND TRANSFORMED CELLS OF 

THE PROSTATE AND BLADDER, AND IN 

RENAL CORTICAL TISSUE AND DERIVED 

CELL CULTURE. A. Ajjimaporn, S. H. Garrett, S. 

Somji, X. Zhou, S. Satarug, M. Sens and D. A. Sens. 

Pathology, University of North Dakota, Grand Forks, 

ND. 


FIBRINOGEN IS SYNTHESIZED BY THE 

KIDNEY AND MODULATES TISSUE 

REPAIR FOLLOWING RENAL INJURY. A. 

Krishnamoorthy 1 , A. K. Ajay 1 , D. Hoffmann 1 , T. 

Kim 2 , S. Selvakumar 1 , V. Ramirez 1 , N. Bobadilla 3 , 

P. Park 2 and V. S. Vaidya 1 . 1 Renal Division, Brigham 

and Women’s Hospital, Harvard Medical School, 

Boston, MA, 2 Center for Biomedical Informatics, 

Harvard Medical School, Boston, MA and 3 National 

Autonomous University of Mexico, Mexico City, 

Mexico. 


ETHANOL(ETOH)EXPOSURE IN VIVO 

POTENTIATES DICLOFENAC(DCLF)- 

INDUCED NEPHROTOXICITY BY 

DESTABILIZING GENOMIC INTEGRITY 

AND PRO- AND ANTIAPOPTOTIC GENES. 

S. D. Pravasi, S. N. Desai and S. D. Ray. Molecular 

Toxicology Labs, Division of Pharmaceutical 

Sciences, Arnold & Marie Schwartz College of 

Pharmacology & Health Sciences, Brooklyn, NY. 


DIVERGENT ASSOCIATIONS OF BLOOD 

AND URINE CADMIUM LEVELS WITH 

KIDNEY FUNCTION. V. Weaver 1,2 , M. Tellez- 

Plaza 1 , A. Navas-Acien 1 , B. Jaar 1,2 , J. Fadrowski 2 , P. 

Muntner 4 , E. Silbergeld 1 and E. Guallar 1,2,3 . 1 Johns 

Hopkins Bloomberg School of Public Health, 

Baltimore, MD, 2 Johns Hopkins University School 

of Medicine, Baltimore, MD, 3 Centro Nacional 

de Investigaciones Cardiovasculares School 

of Medicine, Madrid, Spain and 4 University of 

Alabama, Birmingham, AL. 


PARADOXICAL ASSOCIATIONS OF URINE 

CADMIUM WITH SERUM CREATININE 

BUT NOT CYSTATIN-C-BASED eGFR. J. 

Fadrowski 1 , N. Kim 3 , B. Jaar 1,2 , J. Spector 4 , P. 

Parsons 5 , A. Steuerwald 5 , A. Todd 6 , D. Simon 7 , B. 

Lee 3 , B. Schwartz 1,2 and V. Weaver 1,2 . 1 Johns Hopkins 

University School of Medicine, Baltimore, MD, 

2 

Johns Hopkins Bloomberg School of Public Health, 

Baltimore, MD, 3 SoonChunHyang University, Asan, 

Republic of Korea, 4 University of Washington, 

Seattle, WA, 5 New York State Department of Health, 

Albany, NY, 6 Mount Sinai School of Medicine, New 

York and 7 Biostatistical Consulting, Cincinnati, OH. 


TISSUE DEPOSIT AND TOXIC MECHANISM 

OF CADMIUM IN THE KIDNEY OF 

FE-DEPLETED RATS. J. Park 1 , D. Kim 1 , H. 

Bae 1 , T. Lee 2 and B. Choi 1 . 1 Preventive Medicine, 

Chung-Ang University, Seoul, Republic of Korea and 

2 

Pathology, Chung-Ang University, Seoul, Republic 

of Korea. 

180 






Platform Sessions



Abstract # 


CADMIUM CAUSES OVER- 

ACCUMULATION OF P53 THROUGH THE 

SUPPRESSION OF GENE EXPRESSION 

OF UBE2D FAMILY IN RAT PROXIMAL 

TUBULE CELLS. M. Tokumoto 1,2 , Y. Fujiwara 2 , 

T. Hasegawa 3 , Y. Seko 3 , H. Nagase 1 and M. Satoh 2 . 

1 

Laboratory of Hygienic Chemistry and Molecular 

Toxicology, Gifu Pharmaceutical University, Gifu, 

Japan, 2 Laboratory of Pharmaceutical Health Science, 

School of Pharmacy, Aichi Gakuin University, 

Nagoya, Japan and 3 Department of Environmental 

Biochemistry, Yamanashi Institute of Environmental 

Sciences, Fujiyoshida, Japan. 


CHANGES TO CONNEXIN EXPRESSION 

IN METALLOTHIONEIN-3 POSITIVE AND 

NEGATIVE HUMAN PROXIMAL TUBULE 

CELLS AFTER CADMIUM TREATMENT. 

L. C. Burgess, T. E. Bhobho, J. R. Murray and 

M. C. McCoy. Natural Sciences, Dickinson State 

University, Dickinson, ND. 


STATISTICAL ANALYSIS OF 

LONGITUDINAL GENE EXPRESSION 

PROFILES IN HUMAN PROXIMAL TUBULE 

CELLS EXPOSED TO CADMIUM. S. H. 

Garrett, K. Clarke, D. A. Sens, S. Somji, M. Sens and 

K. Zhang. Pathology, University of North Dakota, 

Grand Forks, ND. 


ASSOCIATIONS OF MULTIPLE METALS 

WITH KIDNEY OUTCOMES IN LEAD 

WORKERS. R. L. Shelley 1 , N. Kim 2 , P. J. Parsons 3 , 

J. Agnew 1 , A. J. Steuerwald 3 , B. G. Jaar 1 , B. Lee 2 , B. 

S. Schwartz 1 , G. Matanoski 1 , A. C. Todd 4 , D. Simon 5 

and V. Weaver 1 . 1 Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD, 2 SoonChunHyang 

University, Asan, Republic of Korea, 3 New York 

State Department of Health, Albany, NY, 4 Mount 

Sinai School of Medicine, New York, NY and 

5 

Biostatistical Consulting, Cincinnati, OH. 


GENDER DIFFERENCES IN THE 

MOLECULAR MECHANISMS OF BROMATE 

INDUCED NEPHROTOXICITY IN F344 

RATS. N. Kolisetty 1 , D. A. Delker 2 , C. Nelson 2 , 

S. Muralidhara 1 , R. J. Bull 3 , O. Quinones 4 , G. 

Zhongxian 5 , S. Snyder 4 , J. Cotruvo 6 , J. W. Fisher 7 , C. 

Ong 8 and B. S. Cummings 1 . 1 University of Georgia, 

Athens, GA, 2 University of Utah, Salt Lake City, 

UT, 3 Mo Bull Consulting, Richland, WA, 4 Water 

Quality Research and Development, Henderson, 

NV, 5 Center for Advanced Water Technology, 

Singapore, Singapore, 6 Joseph Cotruvo & Assoc., 

LLC, Washington, D.C., 7 University of Georgia, 

Athens, GA and 8 National University of Singapore, 

Singapore, Singapore. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 




Poster Session: Pharmaceutical Safety Assessment: 

Therapeutic Agents 

Chairperson(s): Anne Gilson, Forest Research Institute, Jersey City, NJ. 




NKTR-181, A NOVEL POLYMER 

CONJUGATED OPIOID AGONIST, 

DEMONSTRATES REDUCED TOXICITY 

AND CNS SIDE EFFECTS RELATIVE TO 

OXYCODONE. E. Tonkin, S. Wong, A. Odinecs 

and T. D. Sweeney. Nektar Therapeutics, San Carlos, 

CA. 


RELATIVE TOXICITY ANALYSIS OF 

DL11F, A HER3, AND EGFR DUAL ACTION 

ANTIBODY, AND CETUXIMAB IN 

CYNOMOLGUS MONKEYS. R. Prell 1 , D. 

Danilenko 1 , C. Wang 1 , A. Kamath 1 , G. Schaefer 1 , 

P. Allen 2 , J. Roberts 2 and W. Halpern 1 . 1 Genentech, 

South San Francisco, CA and 2 Valley Biosystems, 

West Sacramento, CA. 


NONCLINICAL CARCINOGENICITY 

ASSESSMENT OF PRASUGREL. L. A. 

Buckley 2 , A. Sanbuissho 1 , J. J. Starling 2 , M. Knadler 2 

and J. A. Jakubowski 2 . 1 Daiichi Sankyo Co., Ltd., 

Tokyo, Japan and 2 Eli Lilly & Co., Indianapolis, IN. 


OFF-TARGET PLATELET ACTIVATION 

IN MACAQUES BY A THERAPEUTIC 

MONOCLONAL ANTIBODY. M. J. 

Santostefano 1 , N. E. Everds 2 , H. M. Vargas 3 , M. Fort 4 , 

P. Narayanan 4 , D. Tran 2 , W. Pan 5 , J. Kirchner 6 , C. 

Vissinga 6 and G. S. Elliott 7 . 1 CBSS - Toxicology, 

Amgen, Seattle, WA, 2 CBSS - Pathology, Amgen, 

Seattle, WA, 3 CBSS - Investigative Toxicology, 

Amgen, Thousand Oaks, CA, 4 CBSS - Investigative 

Toxicology, Amgen, Seattle, WA, 5 Pharmacokinetics 

and Drug Metabolism, Amgen, Seattle, WA, 

6 

Inflammation Research, Amgen, Seattle, WA and 

7 

Clinical Pathology, Charles River Laboratories, 

Reno, NV. 


CINACALCET HCL: 6-MONTH ORAL 

TOXICITY STUDY IN JUVENILE BEAGLE 

DOGS. K. Black 1 , C. Dean 1 , N. Everds 1 , E. Lesage 2 

and M. Loomis 1 . 1 Amgen Inc., Thousand Oaks, CA 

and 2 Charles River Laboratories Preclinical Services, 

Senneville, QC, Canada. 

MONday 







181



MONday 



QUANTIFIED TRACKING AND 

MONITORING OF DIAZEPAM TREATED 

SOCIALLY HOUSED CYNOMOLGUS 

MONKEYS. C. Rose 1 , J. E. van der Harst 2 , R. C. 

de Heer 2 , B. M. Spruijt 2 and S. H. Korte 1 . 1 Covance 

Laboratories GmbH, Muenster, Germany and 2 Delta 

Phenomics BV, Utrecht, Netherlands. Sponsor: G. 

Weinbauer. 


28-DAY TOXICITY STUDY WITH THE NON- 

TRADITIONAL VEHICLE SOLUTOL 

HS15 AND POLYETHYLENE GLYCOL 

400 IN FEMALE BEAGLE DOGS. D. Kemp, 

J. Hailey, H. Jordan, R. Brown and D. Bailey. 

GlaxoSmithKline, Research Triangle Park, NC. 


TOXICITY OF MDL72, 527 ADMINISTERED 

ORALLY TO RATS AND DOGS. S. D. Grimes 1 , 

R. W. Watkins 1 , J. F. Mann 1 , H. S. Basu 2 , I. M. 

Kapetanovic 3 and C. D. Hebert 1 . 1 Southern Research 

Institute, Birmingham, AL, 2 Colby Pharmaceutical 

Company, Menlo Park, CA and 3 National Cancer 



SAFETY ASSESSMENT OF PHOSPHO- 

IBUPROFEN AS A POTENTIAL CANCER 

CHEMOPREVENTIVE AGENT. R. W. 

Watkins 1 , J. F. Mann 1 , S. D. Grimes 1 , R. Fulton 2 , 

C. V. Rao 3 , I. M. Kapetanovic 4 and C. D. Hebert 1 . 

1 

Southern Research Institute, Birmingham, AL, 

2 

FVClinPath Consulting, Birmingham, AL, 

3 

University of Oklahoma Health Sciences Center, 

Oklahoma City, OK and 4 National Cancer Institute, 

Bethesda, MD. 


EARLY SAFETY ASSESSMENT 

CONSIDERATIONS AND STRATEGIES IN 

DRUG DISCOVERY. S. Mohr 1 , A. J. Olaharski 2 , 

F. Crameri 1 , T. Singer 1 and T. Weiser 1 . 1 Nonclinical 

Safety, F. Hoffmann-La Roche, Basel, Switzerland 

and 2 Nonclinical Safety, F. Hoffmann-La Roche, 

Nutley, NJ. 


ASSESSMENT OF HEMATOLOGICAL 

TOXICITY ASSOCIATED WITH 

COMBINING CLASSICAL 

CHEMOTHERAPEUTIC AND TARGETED 

CANCER DRUGS. S. Khoh-Reiter, D. Lee and B. 

Jessen. Pfizer Inc., San Diego, CA. 


HUMAN NON-RELEVANCE OF MOTILIN 

AGONIST INDUCED ANAPHYLACTOID 

REACTIONS IN BEAGLE DOGS. P. 

Chowdhury and C. Powell. Safety Assessment, 

GlaxoSmithKline, Ware, United Kingdom. 


AN IMPROVED ORAL TOXICITY PROFILE 

OF A NOVEL BOTULINUM TOXIN TYPE 

A FORMULATION. H. F. Stone, T. D. Thach, 

L. Garcia and C. L. Ruegg. Revance Therapeutics, 

Newark, CA. 


NONCLINICAL TOXICOLOGY OF 

BIIB022, AN ANTI-IGF-1R MONOCLONAL 

ANTIBODY. K. Stickland 1 , E. Polack 1 , J. Galluppi 1 , 

J. Morrow 1 , J. Clarke 1 , S. Chuang 2 , S. Tichenor 2 , L. 

Huard 3 and S. Rose 2 . 1 Biogen Idec, Cambridge, MA, 

2 

Charles River Laboratories, Reno, NV and 3 Charles 

River Laboratories, Montréal, QC, Canada. 


PPD10558: AN ORALLY EFFECTIVE STATIN 

WITHOUT MYOTOXIC EFFECTS. R. A. 

Lopez 1 , D. Prohaska 1 , G. McIntyre 1 and M. Griggs 2 . 

1 

Furiex Pharmaceuticals, Inc., Morrisville, NC and 

2 

MPI Research, Mattawan, MI. 


COMPREHENSIVE INVESTIGATION OF 

PROPYLENE GYLCOL, POLYSORBATE 

80, AND HYDROXYPROPYL-BETA- 

CYCLODEXTRIN FOR USE IN GENERAL, 

REPRODUCTIVE, AND DEVELOPMENTAL 

TOXICOLOGY STUDIES. E. A. Thackaberry 1 , 

S. Kopytek 2 , P. Sherratt 3 , K. Trouba 4 , B. McIntyre 5 , K. 

A. Treinen 2 and B. P. Enright 6 . 1 Safety Assessment, 

Genentech, South San Francisco, CA, 2 Safety 

Assessment, Merck Research Laboratories, Summit, 

NJ, 3 Toxicology, Celgene Corporation, Summit, NJ, 

4 

Drug Safety Evaluation, Bristol-Myers Squibb, Mt. 

Vernon, IN, 5 National Toxicology Program, National 

Institute of Environmental Health Science, Research 

Triangle Park, NC and 6 Preclinical Safety, Abbott 

Laboratories, Abbott Park, IL. 


NONCLINICAL DEVELOPMENT 

OF BMN 110, AN ENZYME 

REPLACEMENT THERAPY FOR 

MUCOPOLYSACCHARIDOSIS TYPE IVA 

(MPS IVA). F. Lorget, D. Kennedy, Y. Qi, L. 

Argento Martell, A. Van Tuyl, M. Dvorak-Ewell, 

E. Paysinger, C. O’Neill and L. Tsuruda. BioMarin 

Pharmaceuticals Inc., Novato, CA. 


GASTROINTESTINAL TOXICITY IN RATS 

FOLLOWING ORAL ADMINISTRATION 

OF AURORA KINASE INHIBITORS. M. J. 

Anderton 1 , H. Mellor 1 , J. Barnes 1 , T. Child 1 , N. 

Barrass 1 , P. Cotton 1 , S. Green 2 , J. Foster 1 and R. 

Roberts 1 . 1 Safety Assessment UK, AstraZeneca, 

Cheshire, United Kingdom and 2 Cancer Research 

Department, AstraZeneca, Cheshire, United 

Kingdom. 


HSP90 INHIBITORS REDUCE 

ELECTRORETINOGRAM RESPONSES IN 

DOGS. C. Somps 1 , C. Liu 1 , N. Poy 3 , J. Marcek 1 and 

V. Torti 2 . 1 Drug Safety R&D, Pfizer, Inc., Groton, 

CT, 2 Drug Safety R&D, Pfizer, Inc., La Jolla, CA and 

3 

World Wide Comparative Medicine, Pfizer, Inc., 

Groton, CT. 


SUBCHRONIC ORAL TOXICITY 

EVALUATION OF CP31398, A P53 

STABILIZER, IN RATS. D. L. McCormick 1 , 

W. D. Johnson 1 , M. Muzzio 1 , C. J. Detrisac 2 , L. 

Kopelovich 3 and I. M. Kapetanovic 3 . 1 IIT Research 

Institute, Chicago, IL, 2 Pathology Associates, 

Chicago, IL and 3 National Cancer Institute, Bethesda, 

MD. 

182 






Platform Sessions



Abstract # 


SUBCHRONIC ORAL TOXICITY 

EVALUATION OF CP31398, A P53 

STABILIZER, IN DOGS. W. D. Johnson 1 , M. 

Muzzio 1 , C. J. Detrisac 2 , L. Kopelovich 3 , I. M. 

Kapetanovic 3 and D. L. McCormick 1 . 1 IIT Research 

Institute, Chicago, IL, 2 Pathology Associates, 

Chicago, IL and 3 National Cancer Institute, Bethesda, 

MD. 


SUBCUTANEOUS ADMINISTRATION 

STUDY TO DETERMINE THE INFLUENCE 

OF AN ANTI-MOUSE IL-12/IL-23P40 

ANTIBODY ON PHOTOCARCINOGENESIS 

IN HAIRLESS MICE. W. M. Bracken 1 , D. Learn 2 , 

G. Blaich 1 and G. M. Veldman 3 . 1 Global Preclinical 

Safety, Abbott, Abbott Park, IL, 2 Photobiology, CRL, 

Horsham, PA and 3 Biologics Generation, Abbott 

Bioresearch Center, Worcester, MA. 


ANTIBODY-MEDIATED VASCULITIS: 

IN VIVO INVESTIGATIONS INTO THE 

MECHANISM OF TOXICITY. K. Mackay 1 , 

T. Sullivan 1 , M. Carioto1, J. Senn 1 , J. Lane 2 , J. S. 

Michaelson 3 and J. C. Clarke 1 . 1 Pharmacotoxicology, 

Biogen Idec, Cambridge, MA, 2 Comparative 

Pathology, Biogen Idec, Cambridge, MA and 

3 

Immunobiology, Biogen Idec, Cambridge, MA. 


INHIBITION OF THE ENZYME 

S-NITROSOGLUTATHIONE (GSNO) 

REDUCTASE DOES NOT CAUSE 

MECHANISM-BASED TOXICITY. D. B. 

Colagiovanni, X. Sun, J. Qiu, A. Stout, A. Patton, L. 

Green, J. Richards and G. J. Rosenthal. Research, 

N30 Pharmaceuticals, Boulder, CO. 


ORAL TWO WEEK (3X/WEEK) DOSE 

RANGE FINDING STUDY OF DECITABINE 

AND TETRAHYDROURIDINE IN CD-1 

MICE. K. Engelke 1 , E. Hanan 1 , J. Covey 2 , Y. 

Ling 3 , K. Chan 3 , Y. Saunthararajah 4 and P. Terse 2 . 

1 

AVANZA Laboratories, LLC, Gaithersburg, MD, 

2 

National Cancer Institute, Bethesda, MD, 3 Ohio 

State University, Columbus, OH and 4 Cleveland 

Clinic, Cleveland, OH. 


CONSEQUENCES OF REPEATED 

COMPLEMENT ACTIVATION AFTER 

CHRONIC TREATMENT IN CYNOMOLGUS 

MONKEYS. L. Shen 1 , T. Machemer 1 , P. Giclas 2 

and S. Henry 1 . 1 ISIS Pharmaceuticals, Inc., Carlsbad, 

CA and 2 National Jewish Health, Denver, CO. 


SINGLE INTRACEREBROVENTRICULAR 

INFUSION TOXICITY, TOXICOKINETICS, 

AND DISTRIBUTION STUDY OF 

TRIPEPTIDYL PEPTIDASE-1 IN 

CYNOMOLGUS MONKEYS. B. Vuillemenot 1 , 

L. Tsuruda 1 , D. Kennedy 1 , D. Musson 1 , S. Keve 1 , R. 

Reed 2 , R. Boyd 2 , M. Butt 3 and C. O’Neill 1 . 1 BioMarin 

Pharmaceutical Inc., Novato, CA, 2 Northern 

Biomedical Research, Inc., Muskegon, MI and 

3 

ToxPath Specialists, LLC, Hagerstown, MD. 

Abstract # 


THE SAFETY OF CBD IN SOCIAL ANXIETY 

DISORDER PATIENTS. M. M. Bergamaschi 1,2 , 

M. Chagas 2 , D. Oliveira 2 , B. Martinis 3 , J. Hallak 2 , 

A. Zuardi 2 , J. Crippa 2 and R. Queiroz 1 . 1 School of 

Pharmaceutical Science of Ribeirão Preto, University 

of São Paulo, Ribeirão Preto, SP, Brazil, 2 School of 

Medicine of Ribeirão Preto, University of São Paulo, 

Ribeirão Preto, SP, Brazil and 3 School of Philosophy, 

Science and Literature of Ribeirão Preto, University 

of São Paulo, Ribeirão Preto, SP, Brazil. 


IN VITRO MABEL APPROACH FOR 

NONCLINICAL SAFETY ASSESSMENT 

OF MEDI-565 (MT111), A NOVEL CEA/ 

CD3-BISPECIFIC SINGLE-CHAIN BITE 

ANTIBODY. P. C. Ryan 1 , S. A. Hammond 1 , S. 

Ren 1 , P. Lutterbuese 2 , M. Amann 2 , M. D. Oberst 1 , 

K. Mulgrew 1 , R. Criste 1 , S. Fuhrmann 1 , N. Lee 1 , 

R. Gross 1 , M. Liang 1 , A. Schneider 1 , R. Dixit 1 , P. 

A. Baeuerle 2 , B. Rattel 2 , S. Coats 1 , L. Roskos 1 , K. 

Bosslet 1 , B. Jallal 1 and L. Richman 1 . 1 MedImmune, 

Gaithersburg, MD and 2 Micromet, Bethesda, MD. 


HEAT SHOCK PROTEIN 90 INHIBITORS 

CAN INDUCE VISUAL CHANGES AND 

RETINAL DEGENERATION INCLUDING 

IRREVERSIBLE PHOTORECEPTOR LOSS 

IN DOGS. V. Torti 1 , J. Marcek 3 , K. Muravnick 3 , 

S. Aguirre 1 , J. Fortner 3 , J. Render 3 , T. Schmahai 3 , 

S. Yamazaki 2 , L. Nguyen 2 , Z. Shen 2 and L. Burns- 

Naas 1 . 1 DSRD, Pfizer Inc., La Jolla, CA, 2 PDM, 

Pfizer Inc., La Jolla, CA and 3 DSRD, Pfizer Inc., 

Groton, CT. 


BIOEQUIVALENCY OF TWO DIFFERENT 

METHOTREXATE FORMULATIONS IN 

HEPATIC GENE EXPRESSION OF PXB- 

MOUSE ® WITH HIGHLY HUMANIZED 

LIVER. M. Nakashima 1 , H. Tachiki 2 , T. Shimada 3 , 

D. Hynes 4 and S. Nagatsuka 4 . 1 Graduate School of 

Biomedical Sciences, Nagasaki University, Nagasaki, 

Japan, 2 Research & Development Division, Towa 

Pharmaceutical Co., Ltd., Kadoma, Osaka, Japan, 

3 

PhoenixBio Co., Higashi-Hiroshima, Hiroshima, 

Japan and 4 R&D, Sekisui Medical Co., ADME & 

Toxicology Research Institute, Tokai-mura, Ibaraki, 

Japan. Sponsor: T. Miyaoka. 


PRECLINICAL ASPECTS OF BIOSIMILAR 

DEVELOPMENT – PRACTICAL 

CONSIDERATIONS. P. Baldrick and R. 

Donninger. Covance Laboratories Ltd., Harrogate, 

United Kingdom. Sponsor: S. Kirk. 


THE INCIDENCE OF TOXICOKINETIC 

CONTROL SAMPLE CONTAMINATION IN 

REGULATORY TOXICOLOGY STUDIES. S. 

Cahill and R. Turcan. Covance Laboratories Ltd., 

Harrogate, United Kingdom. Sponsor: S. Kirk. 

MONday 







183



MONday 



PHARMCOKINETICS AND 14-DAY 

TOXICITY OF INHALED BREVENAL 

IN CD-1 MICE. G. Wang 1 , D. G. Baden 2 , D. 

C. Esparza 1 , T. H. March 1 , P. J. Kuehl 1 and J. 

M. Benson 1 . 1 Lovelace Respiratory Research 

Institute, Albuquerque, NM and 2 Center for Marine 

Science, University of North Carolina Wilmington, 

Wilmington, NC. 


NONCLINICAL SAFETY ASSESSMENT OF 

AN ANTITHROMBOTIC THERAPEUTIC 

PROTEIN ON FERTILITY AND EMBRYO- 

FETAL DEVELOPMENT. V. H. Chen 1 , S. 

Jacobs 1 , H. Ulrichts 1 , S. Priem 1 , S. Rossenu 1 , J. 

Leuschner 2 , J. Baumeister 1 and J. Holz 1 . 1 Ablynx, 

Zwijnaarde, Belgium and 2 LPT, Hamburg, Germany. 


TOPIRAMATE AND BIRTH DEFECTS: AN 

UPDATE. J. M. DeSesso 1 , A. Lavin Williams 1 and 

G. Koren 2 . 1 Exponent, Alexandria, VA and 2 The 

Motherisk Program, The Hospital for Sick Children, 



LONG-TERM PULMONARY SAFETY 

ASSESSMENT OF AFREZZA IN RATS 

AND DOGS. S. Greene 1 , K. Nikula 2 , J. Reynolds 3 , 

D. Poulin 4 , K. McInally 5 , D. Townson 1 and P. 

Richardson 1 . 1 MannKind Corp, Valencia, CA, 

2 

Seventh Wave Laboratories, Chesterfield, MO, 

3 

J.A. Reynolds & Associates, Madison, CT, 4 Charles 

River Laboratories, Montréal, QC, Canada and 5 ITR 

Laboratories, Montréal, QC, Canada. 



LMI1195, A NOVEL SYMPATHETIC 

NERVOUS SYSTEM PET IMAGING AGENT. 

M. Mistry 1 , Y. Tang 1 , D. Onthank 1 , E. Cheesman 1 , K. 

Baghdadi 2 , S. Watson 3 , K. Beard 3 and S. Robinson 1 . 

1 

Lantheus Medical Imaging, North Billerica, MA, 

2 

Analytical Chemistry, Charles River Laboratories, 

Senneville, QC, Canada and 3 ITR Laboratories, Baie 

d’Urfé, QC, Canada. Sponsor: W. Ruddock. 


2:00 PM to 4:45 PM 

Room 151 


Symposium Session: Epigenetics, Metals, and Cancer 

Chairperson(s): Max Costa, New York University School of Medicine, 

Tuxedo Park, NY, and Scott Garrett, University of North Dakota, Grand 

Forks, ND. 

Sponsor: 


of how metals alter epigenetic programs at a variety of levels ranging from 

inhibition of histone demethylases, miRNA, DNA methylation, and histone 

acetylation. Although the focus is mostly on cancer other toxicities can also 

be manifested as a result of these epigenetic effects. Thus, we will being by 

presenting recent evidence that sustained exposure to low environmental 

doses of chromium leads to gradual changes in histone marks and signal 

transduction pathways that cumulatively affect gene expression, silencing 

expression of tumor suppressor genes and of PAH-induced detoxification 

genes. We will then examine miRNA and protein-coding gene promoter 

microarrays to determine the extent and temporal nature of changes in DNA 

methylation and histone modification in a human urothelial cell model of 

arsenical-induced malignant transformation. Before concluding a member 

of the panel will demonstrate that dioxygenases such as the histone demethylases 

and DNA repair enzymes ABH2 are major targets of nickel ions in 

cells. Data will be presented that suggest that the alteration of H4K16 acetylation 

affects arsenic toxicity in both yeast and human cells. Finally, detailed 

studies on the epigenetic regulation of MT-3 expression in normal, tumorigenic 

and metal-transformed cell types will be highligthed. Mt-3 expression 

is repressed in normal bladder and breast cells but increased in expression 

in the respective tumors. In summary, we will detail state of the art methodology 

that examines the epigenetic mechanisms of metal carcinogenesis. 

#813 2:00 EPIGENETICS, METALS, AND CANCER. M. 

Costa. Department of Environmental Medicine, New 

York University School of Medicine, Tuxedo, NY. 

2:00 INTRODUCTION. Max Costa 

#814 2:05 CHROMIUM-INDUCED CHROMATIN 

REMODELING. A. Puga. Department of 

Environmental Health, University of Cincinnati, 


#815 2:37 EPIGENETIC REMODELING BY 

ENVIRONMENTAL ARSENICALS. B. 

W. Futscher. Department of Pharmacology & 

Toxicology, The University of Arizona, College of 

Pharmacy, Tucson, AZ. 

#816 3:09 OXIDATIVE HISTONE DEMETHYLASES 

AND ABH2 DNA DEMETHYLASE AS 

TARGETS OF NICKEL IONS. M. Costa. 

Department of Environmental Medicine and 

Department of Pharmacology, New York University 

School of Medicine, New York, NY. 

#817 3:41 YEAST FUNCTIONAL GENOMICS REVEAL 

ROLE FOR ARSENICALS IN HISTONE 

ACETYLATION. C. Vulpe 1 , W. Jo 1 , F. Chu 4 , X. 

Ren 2 , A. Burlingame 3 , M. Smith 2 and L. Zhang 2 . 

1 

Nutritional Science and Toxicology, University 

of California Berkeley, Berkeley, CA, 2 School of 

Public Health, University of California Berkeley, 

Berkeley, CA, 3 Department of Pharmaceutical 

Chemistry, University of California San Francisco, 

San Francisco, CA and 4 Molecular, Cellular & 

Biomedical Sciences, University of New Hampshire, 

Durham, NH. 

#818 4:13 THE ROLE OF EPIGENETICS IN THE 

INDUCTION OF METALLOTHIONEIN-3 

DURING BLADDER AND BREAST 

TUMORIGENESIS. S. Garrett. Department of 

Pathology, University of North Dakota, School of 

Medicine & Health Sciences, Grand Forks, ND. 

Endorsed by: 



Mounting experimental data indicates that epigenetic programs of gene 

expression are altered following exposure to carcinogenic chemicals. Carcinogenic 

metals such as nickel, chromate, and arsenite are excellent examples 

of agents that cause cancer and induce alterations in epigenetic marks. To 

better understand these alterations, it is important to address the mechanisms 

184 






Platform Sessions



Abstract # 


2:00 PM to 4:45 PM 

Room 207 


Symposium Session: Human Variability in Susceptibility to 

Environmental Toxicants 

Chairperson(s): Holly Mortensen, U.S. EPA, Durham, NC, and 

Susan Euling, U.S. EPA, Washington, D.C. 

Sponsor: 


Endorsed by: 



Defining the differing levels of susceptibility across human populations 

in response to environmental chemicals can provide information to define 

population risk factors and in turn, allow for risk levels to be based on the 

most susceptible populations. Data from high-throughput/high content (HT/ 

HC) technologies, including 'omics, have been integral in the identification 

and characterization of drug-target or disease loci and have the potential 

to be informative for characterizing the effects and dose-response assessment 

of chemical exposure and outcomes within genetically heterogeneous 

populations. Many of the same 'omics technologies have been successfully 

utilized to provide data that informs the mechanism of action for 

environmental chemicals, including the identification of perturbed toxicity 

pathways. In addition, large scale population genotyping studies, such as the 

HapMap, can help to establish levels of variability at chemical-associated, 

target loci across human populations, and in comparison to genome-wide 

patterns. Individual genotype-phenotype combinations can then be verified 

using in vitro methods, or extrapolation from animal models. This session 

includes talks on some of the latest approaches to informing population 

variability and the identification of susceptible populations through the use 

of HT/HC data, particularly from genomics technologies. We will discuss 

how 'omics data in combination with data from enhanced animal models, 

publically available datasets and related computational tools can be used 

to identify biomarkers, and subsequently define risk for genetically heterogeneous 

populations, and how this variability translates to human risk and 

progression of disease. 

#819 2:00 HUMAN VARIABILITY IN SUSCEPTIBILITY 

TO ENVIRONMENTAL TOXICANTS. H. 

Mortensen. NCCT, U.S. EPA, Research Triangle 

Park, NC. 

2:00 INTRODUCTION. Holly Mortensen 

#820 2:05 POPULATION-BASED DISCOVERY OF 

TOXICOGENOMICS BIOMARKERS FOR 

HEPATOTOXICITY. I. Rusyn. Environmental 

Sciences and Engineering, University of North 

Carolina at Chapel Hill, Chapel Hill, NC. 

#821 2:37 EXPERIMENTALLY DEFINING TOXICITY 

PATHWAYS USING IN VITRO HIGH- 

CONTENT SCREENING OF EMBRYONIC 

FIBROBLASTS FROM THE MOUSE 

DIVERSITY PANEL. R. Thomas. Genomic 

Biology and Bioinformatics, The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC. 

#822 3:09 HERITABILITY IN DOSE RESPONSE - 

PUTTING THE HORSE BEFORE THE CART. 

A. Motsinger-Reif. Department of Statistics, North 

Carolina State University, Raleigh, NC. Sponsor: H. 

Mortensen. 

Abstract # 

#823 3:41 ASSOCIATION OF GENETIC 

POLYMORPHISMS, MRNA EXPRESSION 

OF P53 AND P21 WITH CHRONIC 

BENZENE POISONING IN A CHINESE 

OCCUPATIONAL POPULATION. N. Rothman. 

Division of Cancer Epidemiology and Genetics, 

National Cancer Institute, Bethesda, MD. Sponsor: 

H. Mortensen. 

#824 4:13 PERSONALIZED MEDICINE, 

INDIVIDUALIZED DRUG THERAPY: 

CAN THESE GOALS BE REALISTICALLY 

ACHIEVED? D. W. Nebert. Departments of 

Environmental Health & Pediatrics, Division of 

Human Genetics, University Cincinnati Medical 

Center, Cincinnati, OH. 


2:00 PM to 4:45 PM 

Room 204 

Symposium Session: Toxicological Considerations in the Gulf 

of Mexico Oil Spill 

Chairperson(s): Michael Madden, U.S. EPA, Chapel Hill, NC, and 

Michael Ottlinger, U.S. EPA, Cincinnati, OH. 

Sponsor: 

Occupational Public Health Specialty Section 

The Deepwater Horizon oil rig explosion on April 20, 2010 resulted in a 

release of petroleum crude oil into Gulf of Mexico waters. The release, 

41 miles offshore, was about 1 mile in Department Oil dispersants were 

employed to change surface oil and underwater properties. Surface oil was 

also combusted and physical barriers deployed. Oil was estimated to have 

spread to an estimated 2500 square mile in the Gulf. On July 15, the well 

head was capped reducing oil flow to a minimum. A number of exposure 

uncertainties have arisen as a result of the spill related to the locations 

the oil has dispersed to, including volatilization to the atmosphere; and 

the dose of contaminant reaching wildlife, humans, and vegetation in the 

affected areas, and physicochemical properties of the dispersant-treated 

and aged oil. We will present findings related to understanding the migration 

of the spill components, the habitats and organisms contaminated, and 

the characteristics of altered crude. Routes of exposure for humans to oil 

components will be presented in part based on data from other studied oil 

spills. Knowledge of these currently unsure parameters will assist in understanding 

the potential biological and health effects induced by the spill. The 

major possible ecological effects will be described and compared to the 

normal Gulf ecosystem dynamics. The choice of the specific oil dispersants 

utilized will be discussed with an emphasis on the toxicity assays employed; 

toxicity endpoints still not fully examined will be identified. The types and 

likelihood of possible human adverse health effects, both acute and latent, 

will be presented in light of what will be known of the exposure routes 

and the conditions (e.g. heat). In order to comprehend possible effects in a 

comprehensive manner in order to develop estimates of various risks, the 

data sources available to perform such an assessment will be identified (e.g., 

estimates of contaminated seafood consumption). Finally, data deficiencies 

needed for risk assessment will be described. 

#825 2:00 TOXICOLOGICAL CONSIDERATIONS IN 

THE GULF OF MEXICO OIL SPILL. M. C. 

Madden. ORD, NHEERL, HSD, Clinical Research 

Branch, U.S. EPA, Chapel Hill, NC. 

#826 2:00 THE GULF OF MEXICO ECOSYSTEM: 

CONSEQUENCES OF THE BP OIL SPILL. W. 

Benson, S. Jordan, R. Greene, V. Engle, M. Hemmer 

and M. Barron. Gulf Ecology Division, U.S. EPA, 

Gulf Breeze, FL. 

MONday 







185



MONday 


#827 2:00 THE FATE, BEHAVIOR, AND WEATHERING 

OF SPILLED OIL FROM THE DEEPWATER 

HORIZON SPILL. J. Michel. Research Planning, 

Inc., Columbia, SC. Sponsor: M. Madden. 

#828 2:00 OIL SPILL CHEMICAL DISPERSANTS: 

THE GOOD, THE BAD, OR THE UGLY? C. 

L. Mitchelmore. Center for Environmental Science, 

University of Maryland, Solomons, MD. Sponsor: M. 

Madden. 

#829 2:00 SHORT-TERM HEALTH EFFECTS FROM 

OIL SPILLS. N. Sathiakumar. University of 

Alabama Birmingham, Birmingham, AL. Sponsor: 

M. Madden. 

#830 2:00 RISK ASSESSMENT OF THE SPILL: 

CRITICAL INFORMATION NEEDS. W. H. 

Farland. Colorado State University, Fort Collins, 

CO. 


2:00 PM to 4:45 PM 

Room 147 


Symposium Session: Translational Toxicology: Molecules to 

Global Health 

Chairperson(s): Thomas Kensler, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD, and John Groopman, Johns Hopkins 


Sponsor: 


Endorsed by: 


The appreciation that the environment plays a universal role in human health 

has evolved rapidly in recent decades, drawing largely on new analytic technologies, 

advanced data acquisition, informatics and modeling, mechanistic 

studies in toxicology, and the conceptual framework of risk assessment. 

To adequately explore rapidly evolving issues, we will highlight four case 

studies detailing exposures through the vectors of air, food and water to 

agents, natural and anthropogenic that impact health across the lifespan of 

millions of people across the globe. Specific attention will be given relative 

to the use of toxicologic and epidemiologic data with improved techniques 

for quantifying exposure of biologically effective dose produce estimates of 

risks from environmental hazards to selected target populations. The global 

health implications of these exposures and possible intervention strategies 

to mitigate these exposures and their consequent health effects will also be 

discussed. In conclusion, the panelists will discuss the current status of toxicology 

and global health and a consideration of the challenges emerging in 

the next 50 years. 

#831 2:00 TRANSLATIONAL TOXICOLOGY: 

MOLECULES TO GLOBAL HEALTH. T. W. 

Kensler 1,2 and J. D. Groopman 2 . 1 Pharmacology 

& Chemical Biology, University of Pittsburgh, 

Pittsburgh, PA and 2 Environmental Health Sciences, 



2:00 INTRODUCTION. Thomas Kensler 

#832 2:05 MYCOTOXINS: IMPACTS ON CANCER AND 

CHILDREN’S HEALTH. C. P. Wild. International 

Agency for Research on Cancer, Lyon, France. 

Sponsor: T. Kensler. 

#833 2:40 ARSENIC: RECENT FINDINGS FROM 

THE HEALTH EFFECTS OF ARSENIC 

LONGITUDINAL STUDY IN BANGLADESH. 

J. H. Graziano. Environmental Health Sciences, 

Columbia University, New York, NY. 

#834 3:15 SECONDHAND TOBACCO SMOKE: USING 

BIOMARKERS TO INFORM PUBLIC 

POLICY. S. S. Hecht. Masonic Cancer Center, 

University of Minnesota, Minneapolis, MN. Sponsor: 

T. Kensler. 

#835 3:50 STRUCTURAL AND FUNCTIONAL CNS 

EFFECTS OF LEAD IN ADULTS. B. S. 

Schwartz. Environmental Health Sciences, Johns 

Hopkins Bloomberg School of Public Health, 




2:00 PM to 4:45 PM 

Room 206 

Symposium Session: Vascular Developmental Toxicity: 

Identification, Prioritization, and Application 

Chairperson(s): Nicole Kleinstreuer, U.S. EPA, Research Triangle Park, 

NC, and Thomas Knudsen, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




Advanced research approaches to vascular developmental toxicity, including 

new computational modeling methods, high-throughput in vitro tests, 

alternative platforms such as embryonic stem cells and zebrafish reporter 

gene constructs, and potential chemical prioritization, risk-assessment, and 

clinical applications to human health are important issues. The formation 

of the vascular network during embryogenesis is crucial to all aspects of 

development, both through maternal placental oxygen and nutrient delivery 

as well as direct effects on morphogenesis. Disruption in local signal-flow 

phenomena during development alters morphogenetic gradients that control 

endothelial cell differentiation, proliferation, chemotaxis, and subsequent 

signals. This, in turn, affects the distribution of nutrients, metabolic products 

and/or chemicals, and seriously impacts organogenesis. Due to the 

centralized role and complexity of the signaling networks underlying 

blood vessel formation and remodeling and their centralized role across 

all embryonic systems, developmental defects mediated by disruption of 

the vascular network can be manifested in diverse ways and attributed to a 

variety of factors. Associated severe developmental effects include embryonic 

lethality and in less severe cases, phenotypes such as preeclampsia, 

microphthalmia, and limb defects. Traditional prenatal animal testing is not 

informative for resolving and attributing the inherent phenotypic ambiguity 

that arises due to various vascular network perturbations, prompting a new 

paradigm for toxicity testing (NRC 2007). There is a need to deepen current 

understanding of developmental vascular biology, to identify biologically 

significant perturbations in potential toxicity pathways that may lead to 

vascular disruption, and to develop and implement new testing strategies 

with greater specificity and predictive power to identify the many vascular 

signaling pathways during developmental angiogenesis that are highly 

conserved and factor heavily in pathogenesis of adult vascular disease. 

#836 2:00 VASCULAR DEVELOPMENTAL TOXICITY: 

IDENTIFICATION, PRIORITIZATION, 

AND APPLICATION. T. B. Knudsen and N. C. 

Kleinstreuer. ORD / NCCT, U.S. EPA, Research 


2:00 INTRODUCTION. Nicole Kleinstreuer 

186 






Platform Sessions



Abstract # 

#837 2:05 CELLULAR AND MOLECULAR 

NETWORKS UNDERLYING NORMAL AND 

PATHOLOGICAL EMBRYONIC VASCULAR 

DEVELOPMENT: INSIGHTS GAINED FROM 

STEM CELL RESEARCH. K. Hirschi. Baylor 

College of Medicine, Houston, TX. Sponsor: T. 

Knudsen. 

#838 2:45 BIOMARKERS OF DRUG-INDUCED 

VASCULAR INJURY. M. Lawton. Pfizer, Inc., 

New York, NY. 

#839 3:25 RESOLVING THE THALIDOMIDE 

PUZZLE: IDENTIFYING EFFECTS ON THE 

VASCULATURE AND DEVELOPMENTAL 

CONSEQUENCES. N. Vargesson. School of 

Medical Sciences, University of Aberdeen, Aberdeen, 

United Kingdom. Sponsor: N. Kleinstreuer. 

#840 4:05 COMPUTATIONAL MODELING OF 

EMBRYONIC VASCULAR DEVELOPMENT: 

AN IN SILICO TESTING PLATFORM FOR 

VDC PRIORITIZATION. N. C. Kleinstreuer. 

ORD/NCCT, U.S. EPA, Durham, NC. 


2:00 PM to 4:45 PM 

Room 143 

Workshop Session: Protein Aggregation As a Common 

Mechanism of Toxicity in Neurodegenerative Diseases 

Chairperson(s): Gary Miller, Emory University, Atlanta, GA, and 

Anumantha Kanthasamy, Iowa State University, Ames, IA. 

Sponsor: 


Endorsed by: 


Women in Toxicology Special Interest Group 

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s 

disease, Huntington disease, prion diseases, and amyotrophic lateral sclerosis 

(ALS) afflict millions of U.S. citizens. In each of theses diseases, 

aggregation of various disease-specific proteins appears to play a primary 

role in the pathology. This process of protein aggregation now appears to 

be a fundamental element of disease. Recent discoveries over the past few 

years have greatly advanced our understanding of this important neurotoxic 

mechanism. Thus we will use this platform to explore the potential role 

of environmental factors in the protein aggregation process, potentially 

opening up a new avenue of research in toxicology. 

#841 2:00 PROTEIN AGGREGATION AND 

NEURODEGENERATION. G. W. Miller. 

Environmental Health, Emory University, Atlanta, 

GA. 

2:00 INTRODUCTION. Gary Miller 

#842 2:05 PROTEIN MISFOLDING AND 

NEURODEGENERATION. S. L. Ackerman. 

Jackson Laboratory, HHMI, Bar Harbor, ME. 

Sponsor: G. Miller. 

#843 2:45 PROTEIN AGGREGATION IN 

ALZHEIMER’S DISEASE AND 

PARKINSON’S DISEASE. M. Lee. University of 

Minnesota, Minneapolis, MN. 

Abstract # 

#844 3:25 THE ROLE OF LIPID-PROTEIN 

INTERACTION IN THE PATHOGENESIS OF 

PRION DISEASE. J. Ma. Molecular and Cellular 

Biochemistry, Ohio State University, Columbus, OH. 

Sponsor: A. Kanthasamy. 

#845 4:05 ROLE OF DIVALENT METALS IN 

PRION PROTEIN UPREGULATION AND 

AGGREGATION. A. Kanthasamy, C. Choi, 

D. Martin, V. Anantharam, J. A. Richt and A. 

Kanthasamy. Biomedical Sciences, Iowa State 



2:00 PM to 4:45 PM 

Room 145 

Workshop Session: Technical Characterization and Dosimetry 

Challenges Associated with Conducting or Interpreting 

Nanotoxicity 

Chairperson(s): Syed Ali, National Center for Toxicological Research, 

Jefferson, AR, and Saber Hussain, Wright-Patterson Air Force Base, 

Dayton, OH. 

Sponsor: 


Recent developments in nanotechnology have generated a degree of apprehension 

concerning the potential risk to human health and the environment 

from manufactured engineered nanomaterials (MEN). The unique chemical 

and physical properties of MEN coupled with their high surface area per unit 

mass require a re-assessment of exposure protocols and models to assess the 

toxicity of MEN. Based on ultrafine particle toxicity knowledge and recent 

toxicity studies on new forms of MEN, the biological activity of MEN will 

depend on specific physicochemical characteristics that are not usually 

considered in dissolution chemical toxicological studies. Not only must the 

size and surface area of the MEN be characterized prior to dose but the size 

distribution, chemical composition, crystallinity, surface structure, shape, 

and solubility must be determined. Additionally, the MEN in solution may 

be destabilized before, during, or after dosing resulting in an agglomeration 

rate that is dependent on MEN preparation methods and the biological 

system that the MEN are introduced into. Since agglomeration can modify 

uptake rates, transport, and clearance by the cell model or organ system, it is 

critical to interpret the data from MEN toxicity experiments with a detailed 

knowledge of the physicochemical properties of the MEN at all experimental 

time points. Therefore we must consider the toxicity assessment of 

MEN and address technical challenges associated with conducting or interpreting 

in vitro or in vivo toxicity studies. We will also discuss the technical 

challenges associated with obtaining accurate and reproducible results and 

the selection of appropriate controls. Optimal methods for dispersing MEN 

in solution, monitoring agglomeration, and methods of tracking and visualizing 

MEN after internalization will be presented. Overall, this important 

forum will provide for the discussion of these critical issues in the newly 

emerging field of nanotoxicity. 

#846 2:00 TECHNICAL CHARACTERIZATION AND 

DOSIMETRY CHALLENGES ASSOCIATED 

WITH CONDUCTING OR INTERPRETING 

NANOTOXICITY. S. F. Ali 1 and S. Hussain 2 . 

1 

Neurotoxicology, NCTR, Jefferson, AR and 2 HED 

Air Force Research Laboratory, Wright-Patterson 

AFB, Dayton, OH. 

2:00 INTRODUCTION. Syed Ali 

#847 2:10 ROBUST CHARACTERIZATION OF 

NANOMATERIALS IS NECESSARY BEFORE 

TOXICITY STUDIES/ASSESSMENTS CAN 

BE UNDERTAKEN. D. B. Warheit. DuPont 

Haskell Global Centers, Newark, DE. 

MONday 







187



MONday 


#848 2:36 MINIMUM MATERIAL 

CHARACTERIZATIONS FOR 

NANOTOXICOLOGY STUDIES: A 

NECESSITY OR A NUISANCE? N. J. Walker. 

National Toxicology Program, NIEHS, Research 


#849 3:02 THE SELECTION AND 


NANOMATERIALS FOR DEVELOPING 

TOXICOLOGICAL QSARS. S. Oldenburg 1 , A. 

Neigh 1 , O. Nguyen 1 and S. Ali 2 . 1 nanoComposix, San 

Diego, CA and 2 NCTR /U.S. FDA, Jefferson, AR. 

#850 3:28 DOSIMETRIC CONSIDERATIONS FOR 

EXPLORING THE CYTOTOXICITY OF 

SILICA NANOPARTICLES IN VITRO. 

D. F. Lison 1 , V. Rabolli 1 and L. Thomassen 2 . 

1 

Louvain Centre for Toxicology and Applied 

Pharmacology, Brussels, Belgium and 2 Centrum 

voor Oppervlaktechemie en Katalyse, Katholieke 

Universiteit Leuven, Leuven, Belgium. 

#851 3:54 ENABLING PREDICTION AND 

EXTRAPOLATION: A NEW PARADIGM FOR 

NANOMATERIAL DOSIMETRY IN VITRO. 

J. G. Teeguarden 1 , P. M. Hinderliter 2 , G. Orr 3 , K. R. 

Minard 2 , B. D. Thrall 2 and J. G. Pounds 2 . 1 Biological 

Monitoring and Modeling, Pacific Northwest 

National Laboratory, Richland, WA, 2 Biological 

Sciences, Pacific Northwest National Laboratory, 

Richland, WA and 3 Environmental and Molecular 

Sciences Laboratory, Pacific Northwest National 

Laboratory, Richland, WA. 



2:00 PM to 4:45 PM 

Room 144 

Workshop Session: Understanding Structural and Physical 

Chemical Drivers of Drug Toxicity: Utility and Translatable 

Value 

Chairperson(s): Dylan Hartley, Genentech, South San Francisco, CA, 

and Manfred Kansy, F. Hoffman-LaRoche, Basel, Switzerland. 

Sponsor: 


Endorsed by: 



Given the demands on drug discovery teams to produce effective, specific, 

and safe new molecules, toxicologists are now finding themselves with 

new responsibilities in the drug discovery setting as part of lead optimization 

teams. To be effective members of these teams, toxicologists are 

now required to gain awareness and experience in recognizing potential 

structural and physicochemical properties of compounds that often lend to 

certain off-target toxicities, such as off-target receptor activities, QT-interval 

prolongation, phospholipidosis, enzyme induction, liver injury, and genotoxicity. 

The understanding of structural attributes of compounds that may 

drive specific liabilities will enhance the toxicologist’s contributions by 

enabling active collaboration with chemists to inform synthesis of new 

molecules to gain a safety advantage over previous molecules. To this 

end, in vitro assays (e.g., hERG channel inhibition, pharmacology ligand 

binding panels, enzyme induction, and transporter inhibition), coupled with 

specific mathematical or statistical models, and pharmacophore models 

(e.g., hERG channel and PXR activation) can be effective at instructing 

chemical modifications to attenuate the potential for activity against specific 

toxicological endpoints a priori. Furthermore, new in silico approaches in 

chemoinformatics are proving useful for predicting off-target polypharmacology 

by mapping potential drug-target interactions through ligand-based 

similarities. Similarly, mapping adverse drug reactions to chemical space 

may hold promise for predicting specific features of compounds that lead to 

adverse drug reactions in humans. Finally, detailed assessments of pharmacokinetic 

or physical chemical drivers of tissue accumulation are improving 

our understanding of in vitro—in vivo correlations. Overall these approaches 

demonstrate the importance and utility of understanding structural motifs 

and physicochemical properties of compounds that lead to off-target activity. 

#852 2:00 UNDERSTANDING STRUCTURAL AND 

PHYSICAL CHEMICAL DRIVERS OF DRUG 

TOXICITY: UTILITY AND TRANSLATABLE 

VALUE. D. P. Hartley 1 and M. Kansy 2 . 1 Genentech, 

South San Francisco, CA and 2 F. Hoffmann-LaRoche 

AG, Basel, Switzerland. 

2:00 INTRODUCTION. Dylan Hartley 

#853 2:05 CLINICAL TRANSLATIONAL VALUE OF 

PHARMACOLOGICAL PROMISCUITY 

OBSERVED IN IN VITRO SAFETY 

PROFILING. L. A. Urban 1 , S. Whitebread 1 , J. 

Hamon 2 , K. Azzaoui 2 and D. Mikhailov 1 . 1 Center 

for Proteomic Chemistry, NIBR, Cambridge, MA 

and 2 Center for Proteomic Chemistry, NIBR, Basel, 

Switzerland. 

#854 2:37 PREDICTING DRUG OFF-TARGETS 

UNDERLYING ADVERSE EVENTS. 

M. Keiser 1,2 and B. Shoichet 2 . 1 SeaChange 

Pharmaceuticals, Inc., San Francisco, CA and 

2 

Pharmaceutical Chemistry, University of California, 

San Francisco, San Francisco, CA. Sponsor: D. 

Hartley. 

#855 3:09 EARLY SAFETY PROFILING IN DRUG 

DISCOVERY: HOW STRUCTURAL AND 

PHYSICOCHEMICAL COMPOUND 

CHARACTERISTICS INFLUENCE THE 

SAFETY PROFILE OF DRUG CANDIDATES. 

M. Kansy and H. Fischer. Nonclinical Safety, F. 

Hoffmann-La Roche Ltd., Basel, Switzerland. 

#856 3:41 PHARMACOKINETIC DRIVERS OF 

TOXICITY FOR SMALL MOLECULES: 

EVALUATING PLASMA-TISSUE 

CONCENTRATION RELATIONSHIPS. D. 

Diaz. Investigative Safety Assessment, Genentech, 

South San Francisco, CA. 

#857 4:13 MAPPING ADVERSE DRUG REACTIONS IN 

CHEMICAL SPACE. J. Scheiber. Pharmacology 

Research & Early Development Informatics, 

Disease & Translational Informatics, Pharmacology 

Research and Early Development (pRED), Penzberg, 

Germany. Sponsor: D. Hartley. 

188 






Platform Sessions



Abstract # 


2:00 PM to 4:45 PM 

Room 202B 

Platform Session: Advancing Assessment Approaches: 

Pesticides and Other Key Contaminants 

Chairperson(s): Jeanelle Martinez, U.S. EPA, Cincinnati, OH, and Paul 

Price, The Dow Chemical Company, Midland, MI. 

#858 2:00 INNOVATIONS IN TOXICITY TESTING – AN 

INTEGRATED APPROACH TO TESTING 

OF A NEW AGROCHEMICAL BASED 

ON SOUND SCIENCE AND THE “3RS” 

PRINCIPLES ON ANIMAL RESEARCH. C. 

Terry 1 , R. J. Rasoulpour 2 , B. Gollapudi 2 and R. 

Billington 1 . 1 Dow AgroSciences LLC, Oxfordshire, 

United Kingdom and 2 The Dow Chemical Company, 

Midland, MI. 

#859 2:19 CROSS-SPECIES GENE EXPRESSION 

CHANGES IN PRIMARY 

HEPATOCYTES EXPOSED TO 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN. J. 

Rowlands 1 , R. A. Budinsky 1 , A. A. Dombkowski 2 

and R. S. Thomas 3 . 1 Toxicology and Environmental 

Research & Consulting, The Dow Chemical 

Company, Midland, MI, 2 Department of Pediatrics, 

Wayne State University School of Medicine, 

Detroit, MI and 3 Center for Genomic Biology and 

Bioinformatics, The Hamner Institutes for Health 


#860 2:38 COMPARATIVE QSAR STUDIES OF MONO- 

HYDROXYLATED POLYCHLORINATED 

BIPHENYLS AND THEIR POTENTIAL 

ESTROGENIC EFFECTS. P. Ruiz, O. Faroon, B. 

Fowler and M. Mumtaz. Department of Toxicology 

and Environmental Medicine, ATSDR, Atlanta, GA. 

#861 2:57 MOLECULAR FIELD TOPOLOGY 

ANALYSIS OF STRUCTURAL 

DETERMINANTS FOR ACUTE AND 

DELAYED NEUROTOXICITY OF 

O-PHOSPHORYLATED OXIMES. G. F. 

Makhaeva 1 , E. V. Radchenko 2 , V. B. Sokolov 1 , V. 

A. Palyulin 2 , N. S. Zefirov 1,2 and R. J. Richardson 3 . 

1 

Institute of Physiologically Active Compounds, 

Russian Academy of Sciences, Chernogolovka, 

Russian Federation, 2 Chemistry Department, M.V. 

Lomonosov Moscow State University, Moscow, 

Russian Federation and 3 Toxicology Program, 

Department of Environmental Health Sciences, 

University of Michigan, Ann Arbor, MI. 

#862 3:15 FRAMEWORK FOR INTEGRATION OF 

HUMAN AND ANIMAL DATA FOR RISK 

ASSESSMENT PURPOSES: CHLORPYRIFOS 

NEUROBEHAVIORAL DATA AS CASE- 

STUDY. A. A. Li 1 , K. Lowe 1 , L. McIntosh 1 and 

P. Mink 2 . 1 Health Sciences, Exponent Inc., San 

Francisco, CA and 2 Epidemiology, Emory University, 

Atlanta, GA. 

#863 3:33 DEVELOPMENT OF SURFACE CLEAN 

UP LEVELS FOR ACUTE AND CHRONIC 

EXPOSURE TO TARGET CHEMICALS. J. M. 

Martinez 1 , S. A. Hines 2 and D. J. Chappie 2 . 1 Office of 

Emergency Management, U.S. EPA, Cincinnati, OH 

and 2 Battelle, Cincinnati, OH. 

Abstract # 

#864 3:51 USING PBPK/PD MODELS TO 

INCORPORATE CHEMICAL AND 

NON-CHEMICAL STRESSORS INTO 

CUMULATIVE RISK ASSESSMENT: A CASE 

STUDY OF PESTICIDE EXPOSURES. S. C. 

Wason 1,2 , T. J. Smith 1 , M. J. Perry 1 and J. I. Levy 1 . 

1 

Environmental Health, Harvard School of Public 

Health, Boston, MA and 2 Gradient, Cambridge, MA. 

Sponsor: A. Lewis. 

#865 4:09 ASSESSMENT OF AGGREGATE PERINATAL 

EXPOSURE TO BPA. D. A. Sarigiannis 1,2 

and S. Karakitsios 1 . 1 Institute for Health and 

Consumer Protection, European Commission - Joint 

Research Centre, Ispra, Varese, Italy and 2 Chemical 

Engineering, Aristotle University of Thessaloniki, 

Thessaloniki, Greece. Sponsor: L. Birnbaum. 

#866 4:27 USE OF A PBPK/PD MODEL TO DERIVE 

AGE-SPECIFIC INTERSPECIES (UF A 

) AND 

INTERINDIVIDUAL (UF H 

) UNCERTAINTY 

FACTORS FOR CHLORPYRIFOS. P. S. Price 1 , 

P. M. Hinderliter 2 and T. S. Poet 2 . 1 Toxicology & 

Environmental Research & Consulting, The Dow 

Chemical Company, Midland, MI and 2 Battelle 

Pacific Northwest Division, Richland, WA. 


2:00 PM to 4:45 PM 

Room 201 

Platform Session: Alternative Methods in Developmental 


Chairperson(s): Abby Li, Exponent Health Sciences, San Francisco, CA, 

and Merle Paule, U.S. FDA, Jefferson, AR. 

#867 2:00 ASSESSMENT OF 16 CHEMICALS ON 

PROLIFERATION AND APOPTOSIS IN 

HUMAN NEUROPROGENITOR CELLS 

USING HIGH-CONTENT IMAGE ANALYSIS 

(HCA). M. E. Culbreth, J. A. Harrill, T. M. 

Freudenrich, W. R. Mundy and T. J. Shafer. Integrated 

Systems Toxicology, U.S. EPA, Research Triangle 

Park, NC. 

#868 2:24 TOXIC ALTERATIONS OF DOPAMINERGIC 

NEURON DEVELOPMENT FROM 

PLURIPOTENT STEM CELLS AFTER 

CHRONIC LOW-DOSE EXPOSURE TO 

METALS DURING THE LATE MATURATION 

PHASE. M. Leist, S. Schildknecht, S. Kadereit and 

B. Zimmer. In Vitro Toxicology and Biomedicine, 

University Konstanz, Konstanz, Germany. 

#869 2:48 IS THE PENTABDE REPLACEMENT, 

TRIS (1, 3-DICHLORO-2-PROPYL) 

PHOSPHATE (TDCPP), A DEVELOPMENTAL 

NEUROTOXICANT? STUDIES IN PC12 

CELLS. L. Dishaw 1 , C. M. Powers 2 , I. T. Ryde 1 , S. 

C. Roberts 1 , F. J. Seidler 2 , T. A. Slotkin 2 and H. M. 

Stapleton 1 . 1 Nicholas School of the Environment, 

Duke University, Durham, NC and 2 Pharmacology 

and Cancer Biology, Duke University, Durham, NC. 

#870 3:12 MULTIPARAMETRIC LIVE CELL IMAGING 

OF IMPAIRED NEURITE OUTGROWTH IN 

HIGH-DENSITY CULTURES OF HUMAN 

NEURONAL PRECURSORS. M. Daneshian, N. 

Stiegler, F. Matt and M. Leist. In Vitro Toxicology 

and Biomedicine, University Konstanz, Konstanz, 

Germany. 

MONday 







189



MONday 


#871 3:36 STUDIES OF THE VARIABLES AFFECTING 

BEHAVIOR OF LARVAL ZEBRAFISH FOR 

DEVELOPMENTAL NEUROTOXICITY 

SCREENING. S. Padilla 1 , D. L. Hunter 1 , B. 

Padnos 1 , S. Frady 3 and R. C. MacPhail 2 . 1 ISTD, U.S. 

EPA, Research Triangle Park, NC, 2 TAD, U.S. EPA, 

Research Triangle Park, NC and 3 NCCT, U.S. EPA, 


#872 3:59 DRUGS THAT TARGET DOPAMINE 

RECEPTORS: CHANGES IN LOCOMOTOR 

ACTIVITY IN LARVAL ZEBRAFISH. T. D. 

Irons 2,1 , P. Kelly 3 , D. L. Hunter 1 , R. C. MacPhail 1 

and S. Padilla 1 . 1 U.S. EPA, Research Triangle Park, 

NC, 2 Curriculum in Toxicology, University of 

North Carolina at Chapel Hill, Chapel Hill, NC and 

3 

Biology Department, University of North Carolina 


#873 4:22 EMBRYONIC EXPOSURE TO 

DELTAMETHRIN RESULTS IN 

DOPAMINERGIC GENE EXPRESSINON 

CHANGES AND ALTERED SWIM ACTIVITY 

IN THE ZEBRAFISH. T. S. Kung, J. R. 

Richardson, K. R. Cooper and L. A. White. EOHSI, 

Rutgers University/UMDNJ, New Brunswick, NJ. 


2:00 PM to 4:45 PM 

Room 202A 

Platform Session: Biomarkers of Carcinogenesis 

Chairperson(s): John Wisler, Amgen Inc., Thousand Oaks, CA, and 

Wesley Gray, Southern University A&M College, Baton Rouge, LA. 

#874 2:00 DYSREGULATION OF HEPATIC 

MICRORNA PROFILES ARE ASSOCIATED 

WITH EARLY STAGES OF CHEMICAL 

CARCINOGENESIS. C. Koufaris 1 , J. Wright 2 , 

R. A. Currie 2 and N. J. Gooderham 1 . 1 Biomolecular 

Medicine, Imperial College London, London, 

United Kingdom and 2 Syngenta, Bracknell, United 

Kingdom. Sponsor: R. Peffer. 

#875 2:24 A LIPIDOMIC INVESTIGATION OF EARLY 

METABOLIC CHANGES CAUSED BY NON- 

GENOTOXIC CARCINOGENS. Z. Ament 1 , R. 

A. Currie 2 , J. Wright 2 and J. L. Griffin 1 . 1 Department 

of Biochemistry and Cambridge Systems Biology 

Centre, University of Cambridge, Cambridge, 

United Kingdom and 2 Syngenta, Bracknell, United 

Kingdom. Sponsor: R. Peffer. 

#876 2:48 DEVELOPMENT AND EVALUATION 

OF A GENOMIC SIGNATURE FOR THE 

PREDICTION OF NON-GENOTOXIC 

HEPATOCARCINOGENS IN THE RAT. R. T. 

Dunn 1 , A. Adai 2 , A. Olaharski 3 , G. H. Searfoss 4 , J. 

Sina 5 , J. Aubrecht 6 , E. Boitier 7 , P. Nioi 1 , D. Jacobson 

Kram 8 , N. Raghavan 9 , B. Car 10 , S. Chen 10 , Y. Yang 11 , 

A. Kinkaid 12 , J. Sherlock 12 , S. Auerbach 13 and M. 

Fielden 1 . 1 Amgen, Thousand Oaks, CA, 2 Asuragen, 

Inc., Austin, TX, 3 F. Hoffman-LaRoche, Nutley, 

NJ, 4 Lilly Research Laboratories, Indianapolis, IN, 

5 

Merck, West Point, PA, 6 Pfizer, Groton, CT, 7 sanofi 

aventis, Vitry-Sur-Seine Cedex, France, 8 U.S. FDA, 

Silver Spring, MD, 9 J&J PRD, Raritan, NJ, 10 BMS, 

Princeton, NJ, 11 Abbott, Abbott Park, IL, 12 Life 

Technologies, Foster City, CA and 13 NIEHS-NTP, 


#877 3:12 REDOX STATES OF THIOREDOXIN-1 

DIFFERENTIATE HUMAN CANCER FROM 

ITS ADJACENT BENIGN TISSUES. W. Shan 1,2 , 

W. Zhong 2,3 and T. D. Oberley 2,3 . 1 Molecular and 

Environmental Toxicology Center, University of 

Wisconsin, Madison, WI, 2 Department of Pathology 

and Laboratory Medicine, University of Wisconsin, 

Madison, WI and 3 Pathology and Laboratory 

Medicine Service, William S. Middleton Veterans 

Memorial Hospital, Madison, WI. Sponsor: C. 

Bradfield. 

#878 3:36 TROVAFLOXACIN PROMOTES DNA 

DOUBLE-STRAND BREAKS IN A 

MACROPHAGE CELL LINE. K. L. Poulsen 1,2 , 

K. Beggs 1,2 , R. Singhal 1 , P. E. Ganey 1,2 and R. A. 

Roth 1,2 . 1 Pharmacology and Toxicology, Michigan 

State University, East Lansing, MI and 2 Center for 



#879 3:59 EFFECT OF IONIZING RADIATION ON 

K- ras CODON 12 POINT MUTATIONS IN 

LUNG AND LIVER OF THE F344 RAT. P. B. 

McKinzie, J. G. Shaddock, M. G. Pearce and V. N. 

Dobrovolsky. Division of Genetic and Molecular 


Research, Jefferson, AR. Sponsor: B. Parsons. 

#880 4:22 ASSOCIATION OF ESTROGEN 

METABOLISM AND RISK OF NON- 

HODGKIN LYMPHOMA: DETECTION 

OF NOVEL BIOMARKERS FROM CASE- 

CONTROL STUDY. L. Yang 1,2 , N. W. Gaikwad 3 , 

D. D. Weisenburger 3 , J. Vose 3 , E. Rogan 3 and E. 

Cavalieri 3 . 1 Department of Pharmacology and 

Chemical Biology, University of Pittsburtgh, 

Pittsburgh, PA, 2 Department of Environmental, 

Agricultural and Occupational Health, College of 

Public Health, University of Nebraska Medical 

Center, Omaha, NE and 3 Eppley Institute for 

Research in Cancer and Allied Diseases, University 

of Nebraska Medical Center, Omaha, NE. 


2:15 PM to 3:15 PM 

Room 140A 

Exhibitor Hosted Session: How to Comply with the EPA’s 

Endocrine Disruption Screening Program 

Presented by: WIL Research Laboratories 

The U.S. EPA’s Endocrine Disruption Screening Program (EDSP) was 

established in response to growing concern that humans and animals may 

exhibit adverse endocrine effects due to environmental chemicals. The first 

tier in the U.S. EPA’s EDSP includes a suite of specific assays designed to 

look at endocrine effects at the molecular, receptor, and functional levels. 

These assay will be reviewed in this session. 

190 






Platform Sessions



Abstract # 


2:15 PM to 3:15 PM 

Room 140B 

Exhibitor Hosted Session: Nonhuman Primate (NHP) Infant 

Age and Relevance of Postnatal and Juvenile Assessments: 

Principles for Understanding Specific Endpoints in Study 

Designs Supporting Biologics Regulatory Submissions 

Presented by: SNBL USA, Ltd. 

In regulatory-mandated NHP pre-/post-natal and juvenile studies, infant 

development milestones and test compound pharmacology dictate the types 

of parameters to monitor. The pertinent question is how to identify critical 

parameters from the numerous possibilities that exist. This presentation will 

highlight approaches to take and provide examples of background data and 

interpretation. 


3:30 PM to 4:30 PM 

Room 140B 

Exhibitor Hosted Session: Announcing EPA’s Clean 

Air Research Centers: Science to Protect Health in a 

Multipollutant Atmosphere 

Presented by: U.S. EPA 

The U.S. Environmental Protection Agency is investing $32 million in new 

Clean Air Research Centers (CLARCs). The CLARCs will investigate exposures 

to air pollution mixtures, atmospheric transformation products, and 

associated health outcomes to determine impacts across life stages, amongst 

vulnerable populations, and within high-risk communities. 


3:30 PM to 4:30 PM 

Room 140A 

Exhibitor Hosted Session: Screening of Drug Candidates with 

Idiosyncratic Hepatoxic Potential: Concepts and Approaches 

Presented by: In Vitro ADMET Laboratories, LLC (IVAL) 

Experimental assessment of idiosyncratic drug toxicity is elusive due to the 

rarity of the events and the lack of appropriate animal models. The multiple 

parameter hypothesis of idiosyncratic drug toxicity and promising experimental 

approaches based on the hypothesis will be described. 


2:15 PM to 3:15 PM 

Room 156 

Exhibitor Hosted Session: Utility of Hematopoietic Colony 

Forming Cell (CFC) Assays in Drug Development 

Presented by: STEMCELL Technologies, Inc. 

A potential side effect of anticancer and some antiviral/antimicrobial drugs 

is damage to the hematopoietic (blood) system. Compounds that impair 

cell proliferation and differentiation can result in neutropenia, anemia or 

thrombocytopenia. This talk outlines the value of hematopoietic in vitro 

clonogenic assays for prediction of hematotoxicity. 

Abstract # 


3:00 PM to 4:00 PM 

Room 103 

Specialty Section Governance Group Meeting 


4:30 PM to 6:00 PM 

Room 103 

Specialty Section Presidents and Officers Meeting 

If you will be a President or a Vice President of a Specialty Section in 

2011–2012, please make plans to attend the Specialty Section Presidents 

and Officers meeting. The agenda for the meeting will include an overview 

of the SOT Strategic Plan, SOT Headquarters administrative support 

information, ToXchange, a review of 2010–2011 activities and plans for 

the future. 


4:35 PM to 5:55 PM 

Room 150 

SOT/EUROTOX Debate: Biomarkers from Blood 

and Urine Will Replace Traditional Histopathological 

Evaluation to Determine Adverse Responses 

Chairperson(s): William Slikker, Jr., U.S. FDA, Jefferson, AR, and 

Ruth Roberts, AstraZeneca, Macclesfield, United Kingdom. 

SOT Debater: Kim Boekelheide, Brown University, Providence, RI. 

EUROTOX Debater: Ina Schuppe Koistinen, AstraZeneca R&D 

Södertälje, Södertälje, Sweden. 

Endorsed by: 

Society of Toxicology (SOT) 

European Societies of Toxicology (EUROTOX) 

Each year the SOT Annual Meeting includes a debate that continues a 

tradition that originated in the early 1990s in which leading toxicologists 

advocate opposing sides of an issue of great toxicological importance. 

This year, our debaters will address the proposition: Biomarkers from 

Blood and Urine Will Replace Traditional Histopathological Evaluation 

to Determine Adverse Responses. 

The strengths and limitations of histopathological and existing renal or 

hepatic tests (BUN, ALT, etc.) have been examined over the years. These 

endpoints may have advantages such as long term use but do they offer 

sufficient potential for early detection and tissue specificity? And now 

there exists a new generation of potential biomarkers spawned from the 

promise of genomics, proteomics, metabolomics and imaging. Yet do the 

data from these potentially minimally invasive, mechanistically-based 

and time course endpoints provide information appropriate to define 

adverse response? The debate will present some of the challenges that 

researchers and regulators are facing in the development and integration 

of new and existing biomarkers to determine adverse responses. 

Regardless of framework differences and personal convictions, each 

scientific delegate will present relevant evidence and compelling scientific 

arguments to persuade and appeal to the response of the audience in 

order to obtain the approval or refusal of the motion. In addition to being 

a featured session at the SOT Annual Meeting, this debate will again take 

place in Paris, France during the 2011 Eurotox Annual Congress, August 

28–31, 2011. 

MONday 







191




MONday 


4:45 PM to 5:45 PM 

E-mail Center, East Salon 


connection) 




In honor of the 50th Anniversary of SOT, the Postdoctoral Assembly is 

organizing the 50th Anniversary Silent Auction. Bid on vacation get-aways 

or purchase items of historical significance to SOT and toxicology 

(such as books, laboratory items, memorabilia, photographs) as well 

as other items of general interest. Bids for some items will close in the 

E-mail Center Monday, March 7, from 4:45 PM–5:45 PM. Join the excitement! 

Cash bar available. Bring your laptop or smart phone to join in the 

bidding. 

Bids for remaining items will close beginning at 10:00 AM Wednesday 

and conclude at 1:00 PM. All proceeds from the Silent Auction will go to 

the Endowment Priorities Fund. 

Monday Evening, March 7 

5:30 PM to 7:30 PM 

Embassy Suites Capital Ballroom A 

Regional Chapter Joint Reception: National Capital Area/ 

NRC Committee on Toxicology 


6:00 PM to 7:30 PM 


Regional Chapter Joint Reception: Mountain West/Southern 

California 


6:00 PM to 8:00 PM 


Special Interest Group Meeting/Reception: American 

Association of Chinese in Toxicology 


5:00 PM to 7:00 PM 

Fado Irish Pub 

Monday Evening 


5:00 PM to 6:00 PM 


AACT Distinguished Chinese Toxicologist Lectureship: 

Oxidative Stress and Metal Carcinogenesis 

Regional Chapter Joint Reception: Gulf Coast/South 

Central 


5:00 PM to 6:00 PM 

(Buses Depart CC from L Street beginning at 4:00 PM) 

Capital Hill, Russell Senate Building 

Specialty Section Meeting/Reception: Regulatory and 

Safety Evaluation—The Great Debate—Hazard Information 

Provides an Adequate Basis for Restricting Chemical Use 

Moderator: James Lamb 

Debaters: George Gray and Lorenz Rhomberg 

Honorary Host: Senator Johnny Isakson (R-GA) 

The reception and debate will take place on Capitol Hill in Suite 325, the 

Kennedy Caucus Room, of the Russell Senate Office Building. Space is 

limited and attendance is on a first come first served basis. Buses depart 

for the event beginning at 4:00 PM at the L Street entrance of the Convention 

Center. Guests must have valid photo identification. Please wear your 

SOT Annual Meeting badge to gain entrance. 


6:00 PM to 7:30 PM 

Salon H 

Special Interest Group Meeting/Reception: Association of 

Scientists of Indian Origin in America 


6:00 PM to 8:00 PM 

Embassy Suites Capital Ballroom B 

Special Interest Group Meeting/Reception: Toxicologists of 

African Origin 


6:00 PM to 7:30 PM 

See room listings below. 

Specialty Section Meeting/Reception: Biotechnology (Room 

140B), Cardiovascular Toxicology (Room 102), Molecular 

Biology (Room 159), Neurotoxicology (Salon G), Risk 

Assessment (Salon I), Stem Cells Inaugural (Room 149) 


6:30 PM to 8:30 PM 


Regional Chapter Reception: Northern California 


6:30 PM to 8:30 PM 


Special Interest Group Meeting/Reception: Korean 

Toxicologists Association in America 

192 






Platform Sessions



Abstract # 

Tuesday Morning, March 8 

6:30 AM to 7:50 AM 

Room 144 

Tuesday Morning 

Roundtable Session: Current Uses and Understanding of the 

Tissue Cross Reactivity Assay 

Chairperson(s): Jeanine Bussiere, Amgen, Inc., Thousand Oaks, CA, and 

Michael Leach, Pfizer, Andover, MA. 

Sponsor: 


Endorsed by: 


Tissue cross-reactivity (TCR) studies are screening assays conducted 

with monoclonal antibodies and related antibody-like biopharmaceuticals 

primarily to identify off-target binding, and secondarily to identify sites of 

on-target binding that were not previously identified. As presently utilized 

by the biopharmaceutical industry and regulatory agencies, TCR studies 

usually involve the ex vivo immunohistochemical (IHC) staining of a 

panel of frozen tissues from humans and animals. However, other methods 

of conducting TCR studies are possible. While ex vivo TCR studies have 

become routine in the development of antibody therapeutics, their value 

for the purpose of making safety assessment decisions by both industry and 

regulatory agencies has been questioned as experience with the assay has 

increased. Recently, an industry white paper was published to review the 

use of tissue cross-reactivity studies in the development of antibody-based 

biopharmaceuticals: history, experience, methodology, and future directions. 

In addition, a multinational pharmaceutical and biotechnology company 

survey was conducted to gain a better understanding of the use and value of 

the TCR assay in the development of biotherapeutic molecules. The information 

from this survey can be used to help understand the appropriate use 

and interpretation of this assay in a nonclinical drug development program. 

Our panel of experts will address the following issues of importance 

including how we got to where we are today; the technical aspects of the 

TCR assay and issues with interpretation; case studies and summary from 

white paper on use of TCR; industry survey results on use of the TCR assay; 

and, the new technologies for identifying off-target binding of monoclonal 

antibodies. 

#881 6:30 CURRENT USES AND UNDERSTANDING 

OF THE TISSUE CROSS REACTIVITY 

ASSAY. J. L. Bussiere 1 , J. Cavagnaro 5 , E. 

Galbreath 3 , T. Machlachlan 6 , N. Dybdal 4 and M. 

Leach 2 . 1 Toxicology, Amgen, Inc., Thousand Oaks, 

CA, 2 Drug Safety Research and Development, 

Pfizer, Andover, MA, 3 Toxicology, Lilly Research 

Laboratories, Indianapolis, IN, 4 Safety Assessment, 

Genentech, Inc., South San Francisco, CA, 

5 

AccessBio, Boyce, VA and 6 Pharmacology and 

Toxicology, Genzyme, Framingham, MA. 

6:30 TCR: HOW WE GOT TO WHERE WE ARE 

TODAY. Joy Cavagnaro 

6:45 TECHNICAL ASPECTS OF THE TCR ASSAY 

AND ISSUES WITH INTERPRETATION. 

Elizabeth Galbreath 

7:00 CASE STUDIES AND SUMMARY FROM 

THE WHITE PAPER ON USE OF TCR. Tim 

MacLachlan 

7:15 INDUSTRY SURVEY RESULTS ON USE OF 

THE TCR ASSAY. Jeanine L. Bussiere 


Abstract # 


6:30 AM to 7:50 AM 

Room 143 


Roundtable Session: Risk and Risk Management of 

Potentially Toxic Compounds Formed by Cooking Food 

Chairperson(s): Steven Hermansky, ConAgra Foods, Inc., Omaha, NE, 

and Wu Li, Frito-Lay, Inc., Plano, TX. 

Sponsor: 


Endorsed by: 



The discovery of acrylamide in food in 2002 by Swedish researchers initiated 

an international effort to assess exposure and manage risk to the public. 

Millions of dollars and countless hours of resources have been dedicated to 

this effort around the world. The concept that cooking changes the chemistry 

of food is not new but the presence of acrylamide across a wide variety of 

foods brought a new perspective to food safety for the international regulatory 

community. This issue continues to develop as different research groups 

focus on multiple heat-formed chemicals and various aspects of toxicology 

of these naturally occurring compounds. From the recent completion of the 

European Union HEATOX (Heat-Generated Food Toxicants: Identification, 

Characterization, and Risk Minimization) project to the development of 

increasingly sensitive and refined analytical methods that are able to detect 

ever lower concentrations of compounds in foods, it is becoming increasingly 

clear that acrylamide only represents one compound of many. This 

revelation presents challenges to both the scientific and regulatory communities. 

Just as importantly, resources are more frequently stretched thin 

as scientific debates are played out in the mass media and the credibility 

of the scientific and regulatory process is challenged. We will discuss the 

challenges and opportunities presented by risk management of compounds 

formed in food during cooking. 

#882 6:30 RISK AND RISK MANAGEMENT OF 

POTENTIALLY TOXIC COMPOUNDS 

FORMED BY COOKING FOOD. S. J. 

Hermansky 1 , W. Li 8 , R. Lane 2 , N. Rachman 4 , S. 

Olin 5 , T. Troxell 3 , M. Bolger 6 and A. Tritscher 7 . 

1 

ConAgra Foods, Omaha, NE, 2 Pepsico, Valhalla, 

NY, 3 Exponent, Washington, D.C., 4 Grocery 

Manufacturer’s Association, Washington, D.C., 5 ILSI 

Research Foundation, Washington, D.C., 6 U.S. FDA 

Center for Food Safety and Nutrition, Washington, 

D.C., 7 World Health Organization, Geneva, 

Switzerland and 8 Frito Lay, Plano, TX. 

6:30 INTRODUCTORY REMARKS AND 

SUMMARY OF NEW DATA. Steven J. 

Hermansky 

6:35 THE POLITICS OF CHEMICAL FOOD 

SAFETY. Richard Lane 

6:47 THE NEW FOOD LANDSCAPE: 

BALANCING THE BENEFITS WITH THE 

CHEMICAL RISKS OF COOKING. Nancy J. 

Rachman 

6:59 EVALUATING THE TOXICOLOGY OF 

CHEMICALS IN FOOD: DO WE NEED A 

NEW PARADIGM? Steve S. Olin 

7:11 ESTABLISHING A FUTURE RISK 

MANAGEMENT VISION FOR COOKING 

TOXINS. Terry Troxell 

7:23 PANEL DISCUSSION. Mike Bolger and 

Angelika Tritscher 

Tuesday 







193



Tuesday 



6:30 AM to 7:50 AM 

Room 147 



Informational Session: Emerging Science for Environmental 

Health Decisions: Tools, Strategies, and Evidence 

Chairperson(s): William Farland, Colorado State University, Fort 

Collins, CO, and John Balbus, NIEHS, Bethesda, MD. 

Sponsor: 


Endorsed by: 

Association of Scientist of Indian Origin Special Interest Group 


The last year was very productive for the National Research Council’s 

(NRC) Standing Committee on Emerging Science for Environmental Health 

Decisions, sponsored by the National Institutes of Environmental Health 

Science. A number of timely, topical sessions were held that included SOT 

members that were of special relevance to toxicology, risk assessment, and 

public health. These topics were designed to extend discussion contained 

in two 2007 NRC reports—Toxicity Testing in the 21st Century: A Vision 

and a Strategy and Application of Toxicogenomics Technologies to Predictive 

Toxicology and Risk Assessment. These sessions brought together 

government, industry, environmental groups, and the academic community 

to discuss emerging scientific concepts and advances and their potential 

implications for environmental health decisions. Specifically, these sessions 

have explored emerging tools and technologies for epigenetics, computational 

toxicology, stem cell models, and exposome research and their 

potential roles in identifying, quantifying, and mitigating environmental 

impacts on human health. In follow up to these dynamic sessions we will 

highlight many aspects of this important topic. Our panel of experts will 

address what was learned linking specifically to the common threads among 

the sessions, such as bioinformatics and expanding input information for 

systems approaches to toxicology. In closing, we’ll synthesize how to best 

integrate data across these emerging and evolving areas of research and 

explore potential next steps for using such data and insights in environmental 

health decisions and policy. 

#883 6:30 EMERGING SCIENCE FOR 

ENVIRONMENTAL HEALTH DECISIONS: 

TOOLS, STRATEGIES, AND EVIDENCE. W. 

H. Farland. Colorado State University, Fort Collins, 

CO. 

6:30 WELCOME AND INTRODUCTION. William 

H. Farland 

6:35 THE EPIGENETICS LINK. Helmut Zarbl 

6:50 THE EXPOSOME: EXPLORING THE 

ENVIRONMENTAL ETIOLOGY OF HUMAN 

DISEASE. Elaine Cohen Hubal 

7:05 STEM CELL MODELS AND 

ENVIRONMENTAL HEALTH. Tom Gasiewicz 

7:20 INTEGRATING EMERGING SCIENCE: 

COMPUTATIONAL TOXICOLOGY. Ivan 

Rusyn 

7:35 THE PATH TO INCORPORATING 

EMERGING SCIENCE IN 

ENVIRONMENTAL HEALTH DECISIONS. 

Linda Birnbaum 


7:00 AM to 7:50 AM 

Room 201 


Lecture: Roles of Keap1-Nrf2 in 

Environmental Response 

Lecturer: Masayuki Yamamoto, Tohoku University 

Graduate School of Medicine, Sendai, Japan. 

Studies of the erythroid gene expression identified the 

NF-E2 motif and CNC family of transcription factors. As the NF-E2 

motif and antioxidant responsive element (ARE) share high-level 

sequence similarity, a CNC factor Nrf2 was identified as a key transcriptional 

activator interacting with ARE. Targeted disruption of the 

Nrf2 gene revealed that Nrf2 is essential for the coordinated induction 

of cellular defense enzymes. Keap1 was identified as a sensor for xenobiotic 

and oxidative stresses and a component of ubiquitin E3 ligase. 

The two-site substrate recognition model proposed for the Keap1-Nrf2 

system describes the regulation of nuclear accumulation of Nrf2 by a 

Keap1-dependent mechanism. Both high-affinity ETGE and low-affinity 

DLG motifs of the Nrf2 Neh2 domain bind to two Keap1-DC domains of 

the Keap1 homodimer. This allows correct positioning of the ubiquitintarget 

lysines within Neh2 for efficient ubiquitination. Oxidative or 

electrophilic stress modifies multiple reactive cysteines of Keap1, and 

these modifications lead to alteration of the local conformation, resulting 

in the dissociation of either lower-affinity DLG motif or an E3 component 

Cul3 from Keap1. We recently found cancer-related mutations of the 

Keap1-Nrf2 system. These mutations are activating mutations of Nrf2 

and concentrated in the Keap1-Nrf2 interface, strongly supporting the 

two-site recognition model. 


7:00 AM to 8:30 AM 

Room 103 

Regional Chapter Presidents and Officers Meeting 

If you will be a President or a Vice President of a Regional Chapter in 

2011–2012, please make plans to attend the Regional Chapter Presidents 

and Officers meeting. The agenda for the meeting will include an overview 

of the SOT Long-Range Plan. SOT Headquarters support services 

and 50th Anniversary Celebration Events, SAC, and PDA Representatives 

recruitment and involvement, Regional Chapter funding, RC Communities 

on ToXchange, RC Governance Group, and discussion of face-to-face 

summer leadership meeting. 


7:00 AM to 8:30 AM 

Room 142 

Speciality Section Graduate Committee Meeting 

194 






Platform Sessions



Abstract # 


8:00 AM to 9:00 AM 


Keynote Plenary Lecture: Increasing the 

Prestige of Regulatory Sciences 

Lecturer: Margaret Hamburg, U.S. FDA, Washington, 

D.C. 

Described as “an inspiring public health leader with 

broad experience in infectious disease, bioterrorism, 

and health policy” by HHS Secretary Kathleen Sebelius we are delighted 

to have Dr. Margaret A. Hamburg, the 21st U.S. FDA Commissioner 

present a keynote plenary lecture at the Society’s 50th Anniversary 

Annual Meeting. Dr. Hamburg is exceptionally qualified by her training 

and experience as a medical doctor, scientist, and public health executive. 

Dr. Hamburg graduated from Harvard Medical School, and completed 

her residency in internal medicine at what is now New York Presbyterian 

Hospital-Weill Cornell Medical Center, one of the top-ten hospitals in the 

nation. She conducted research on neuroscience at Rockefeller University 

in New York, studied neuropharmacology at the National Institute of 

Mental Health on the National Institutes of Health campus in Bethesda, 

Maryland, and later focused on AIDS research as Assistant Director of 

the National Institute of Allergy and Infectious Diseases. 

During her career she has been widely praised for her initiatives, decisive 

leadership, and significant public health measures. As a public health 

official she is credited with improving services for women and children, 

a needle-exchange program to reduce the spread of HIV (the AIDS 

virus), and the initiation the first public health bio-terrorism defense 

program in the nation. Her most celebrated achievement, however, was 

curbing the spread of tuberculosis in the 1990s. 

In 1994, Dr. Hamburg was elected to the membership in the Institute of 

Medicine, one of the youngest persons to be so honored. Three years 

later, at the request of President Clinton, she accepted the position of 

Assistant Secretary for Policy and Evaluation in the U.S. Department of 

Health and Human Services (HHS). 


9:00 AM to 11:45 AM 

Room 206 


Symposium Session: Metabolic Basis of Respiratory Tract 

Chemical Toxicity 

Chairperson(s): Laura Van Winkle, University of California Davis, Davis, 

CA, and Xinxin Ding, New York State Department of Health, Albany, NY. 

Sponsor: 


Endorsed by: 



The respiratory tract, including both the lung and the nasal tissue, has 

substantial metabolic activity, which can influence the distribution and 

action of drugs and xenobiotics, either inhaled or ingested. The metabolic 

enzymes that are active in the respiratory tract include cytochrome P450 

monooxygenases, esterases, oxidoreductases, and dehydrogenases. Their 

distribution and activity can vary greatly with anatomic location, by species, 

sex and history of prior exposure. Respiratory tract metabolic activity can 

either enhance, or inhibit, local and systemic chemical toxicity. While 

this basic principle has been understood and investigated for many years, 

recent new approaches have allowed more in-Department investigation of 

Abstract # 

the mechanisms of toxicity in the respiratory tract following exposure to 

bioactivated toxicants. Significant advances have been made, with the use 

of novel animal models, new detection methods, application of site-specific 

approaches to colocalize toxicity and metabolism, recombinant human 

enzymes, and modeling, which enhance our understanding of the contributions 

of xenobiotic metabolism in the respiratory tract to toxicity in humans. 

Several examples highlighting recent progress in this area will be presented. 

#884 9:00 METABOLIC BASIS OF RESPIRATORY 

TRACT CHEMICAL TOXICITY. L. S. Van 

Winkle 1 and X. Ding 2 . 1 Center for Health and the 

Environment/Veterinary Medicine, Anatomy, 

Physiology, and Cell Physiology, University of 

California Davis, Davis, CA and 2 Division of 

Environmental Health Sciences, Laboratory of 

Molecular Toxicology, Wadsworth Center, New York 

State Department of Health, Albany, NY. 

9:00 INTRODUCTION. Laura Van Winkle 

#885 9:05 ROLE OF CYP2A AND CYP2F ENZYMES 

IN RESPIRATORY TRACT CHEMICAL 

TOXICITY – INSIGHTS FROM P450 

KNOCKOUT AND HUMANIZED MOUSE 

MODELS. X. Ding 1,2 . 1 Laboratory of Molecular 

Toxicology, Wadsworth Center, New York State 

Department of Health, Albany, NY and 2 School 

of Public Health, State University of New York at 

Albany, Albany, NY. 

#886 9:36 METABOLISM OF INHALED 

GLUCOCORTICOIDS IN LUNG: 

SELECTIVE INACTIVATION OF CYP3A5. 

G. S. Yost. Deptartment of Pharmacology and 

Toxicology, University of Utah, Salt Lake City, UT. 

#887 10:07 SEX DIFFERENCES IN METABOLISM AND 

TOXICITY IN THE LUNG. L. S. Van Winkle, K. 

Sutherland, D. Morin, P. Edwards and A. Buckpitt. 

University of California Davis, Davis, CA. 

#888 10:38 DEVELOPMENT OF ADDUCTED PEPTIDE 

BIOMARKERS TO ADDRESS THE 

CONSEQUENCES OF HUMAN EXPOSURE 

TO RODENT PULMONARY TOXICANTS. A. 

Buckpitt, N. Pham, D. Krawiec, D. Morin, W. Jewell 

and L. Van Winkle. University of California Davis, 

Davis, CA. 

#889 11:09 RESPIRATORY TRACT METABOLISM AND 

INHALATION DOSIMETRY OF VAPORS. 

J. B. Morris. Toxicology Program, University of 

Connecticut, Storrs, CT. 

11:40 SUMMARY. 

Tuesday 







195



Tuesday 



9:00 AM to 11:45 AM 

Room 202A 

Symposium Session: Stem Cell Biology and Cell Therapy 

Approaches to Understanding Cellular Injury and Wound 

Healing in Dermal, Ocular, and Pulmonary Injury 

Chairperson(s): Jeffrey Yourick, Defense Threat Reduction Agency, Fort 

Belvoir, VA, and John Graham, U.S. Army Medical Research Institute of 

Chemical Defense, Aberdeen Proving Ground, MD. 

Sponsor: 


Endorsed by: 

Ocular Toxicology Specialty Section 

Thermal and chemical burns as well as chemical injury to the skin, eye, and 

lung invoke a vast tissue and cellular response followed by the initiation of 

wound healing mechanisms. Stem cells may be defined as undifferentiated 

cells that have the capacity for self-renewal and may differentiate into many 

different cell types when stimulated by specific cellular signals. Injury to 

stem cell tissue populations has immense implications for normal repair and 

restoration of tissue function after chemical injury. Research on stem cells, 

such as epidermal stem cells, dermal stem cells, mesenchymal stem cells 

and embryonic stem cells all have potential to repair and restore structure 

and function to the skin and eye after extensive injury. An overview of 

recent advances in dermal, ocular, and pulmonary induced injury related to 

stem cells will be presented along with potential stem cell and other cellbased 

therapies as they relate to tissue repair and wound healing. 

#890 9:00 STEM CELL AND CELL THERAPY 

APPROACHES FOR UNDERSTANDING 

CELLULAR INJURY AND WOUND 

HEALING IN DERMAL, OCULAR, AND 

LUNG INJURY. J. J. Yourick. Medical Chemical 

Countermeasure, Defense Threat Reduction Agency, 

Fort Belvior, VA. 

9:00 INTRODUCTION. Jeffrey Yourick 

#891 9:05 THE INVOLVEMENT OF EPITHELIAL 

STEM CELLS IN THE PATHOGENESIS 

OF SULFUR MUSTARD INJURIES: 

MECHANISM AND POTENTIAL THERAPY. 

T. Kadar, V. Horwitz, L. Cohen, M. Cohen, R. Sahar, 

H. Gutman, L. Tveria, R. Gez, S. Dachir and A. 

Amir. Pharmacology, Israel Institute for Biological 

Research, Ness Ziona, Israel. Sponsor: J. Yourick. 

#892 9:37 CELL-BASED THERAPEUTICS IN BURN 

MEDICINE. J. S. Graham. U.S. Army Medical 

Research Institute of Chemical Defense, Aberdeen 

Proving Ground, MD. Sponsor: J. Yourick. 

#893 10:09 STEM CELLS AND DAUGHTER CELLS 

IN REGENERATION OF EPITHELIAL 

SURFACES. M. Simon 1 , J. Tafrova 1 , L. Wan 1 , J. 

S. Graham 2 , J. Azeke 2 , E. Braue 2 and S. McClain 3 . 

1 

Stony Brook University, Stony Brook, NY, 2 U.S. 

Army Medical Research Institute of Chemical 

Defense, Aberdeen Proving Ground, MD and 

3 

McClain Laboratories, LLC, Smithtown, NY. 

Sponsor: J. Yourick. 

#894 10:41 EMBRYONIC, MESENCHYMAL, AND 

PHARMACOLOGICAL MODULATION OF 

STEM CELLS FOR THE TREATMENT OF 

CUTANEOUS VESICANT INJURY. M. P. 

Nambiar. Closed Head Injury, Water Reed Army 

Institute of Research, Silver Spring, MD. 

#895 11:13 CONTROL OF STEM CELL 

DIFFERENTIATION IN THE LUNG. J. 

D. Laskin 1,3 and D. L. Laskin 2,3 . 1 Environmental 

& Occupational Medicine, UMDNJ-Robert 

Wood Johnson Medical School, Piscataway, NJ, 

2 



Health Sciences Institute, Piscataway, NJ. 


9:00 AM to 11:45 AM 

Room 147 

Symposium Session: Uncovering the Role of Non-Coding 

RNAs in Toxicology 

Chairperson(s): Mark Hahn, Woods Hole Oceanographic Institute, 

Woods Hole, MA, and Tamara Tal, Oregon State University, Corvallis, 

OR. 

Sponsor: 


Endorsed by: 



Over the past ten years non-coding RNAs (ncRNAs) have emerged as 

pivotal players in fundamental physiological and cellular processes and have 

been increasingly implicated in cancer, immune disorders, and cardiovascular, 

neurodegenerative, and metabolic diseases. MicroRNAs (miRNAs) 

represent a class of ncRNA molecules that are predicted to post-transcriptionally 

regulate the expression of 30–60% of all human protein-coding 

genes and as such, miRNAs play key roles in cellular and developmental 

processes, human health, and disease. Recently, miRNAs have surfaced as 

targets of developmental, hepatic, neurological, and carcinogenic toxicological 

agents, and have increasingly been identified as putative regulators 

of phase I xenobiotic-metabolizing enzymes. We will highlight impactful 

research demonstrating the growing understanding of the role of miRNAs in 

toxicological modes of action, study the mechanisms of miRNA-mediated 

toxicity in a variety of emerging model systems. 

#896 9:00 UNCOVERING THE ROLE OF NON- 

CODING RNAS IN TOXICOLOGY. M. 

E. Hahn 1 and T. Tal 2 . 1 Biology, Woods Hole 

Oceanographic Institution, Woods Hole, MA and 

2 

Environmental and Molecular Toxicology, Oregon 

State University, Corvallis, OR. 

9:00 INTRODUCTION. Mark Hahn 

#897 9:05 EXPLORING THE ROLE OF MICRORNAS 

AS MEDIATORS OF DEVELOPMENTAL 

NEUROBEHAVIORAL TOXICITY IN 

ZEBRAFISH. T. L. Tal 1 , J. A. Franzosa 1 , S. Tilton 2 , 

K. Waters 2 and R. L. Tanguay 1 . 1 Environmental and 

Molecular Toxicology, Oregon State University, 

Corvallis, OR and 2 Computational Biology & 

Bioinformatics Group, Pacific Northwest National 

Laboratories, Richland, WA. 

#898 9:35 DEFINING THE DEVELOPMENTAL ROLE 

OF MICRORNAS IN ORCHESTRATING 

TOXICOLOGICAL RESPONSES. J. A. 

Franzosa, T. L. Tal and R. L. Tanguay. Environmental 

and Molecular Toxicology, Oregon State University, 

Corvallis, OR. 

#899 10:05 IDENTIFICATION OF NEW NON-CODING 

SMALL RNA IN BREAST CANCER. C. Rovira. 

Clinical Sciences, Department of Oncology, Lund 

University, Lund, Sweden. Sponsor: T. Tal. 

196 






Platform Sessions



Abstract # 

#900 10:35 ONCOGENIC MICRORNAS AS DRUG 

TARGETS FOR CANCER CHEMOTHERAPY. 

S. Safe. Veterinary Physiology, Texas A&M 

University, College Station, TX. 

#901 11:05 MICRORNA REGULATION OF DEP- 

INDUCED INFLAMMATION IN AIRWAY 

EPITHELIAL CELLS. M. J. Jardim, L. Dailey 

and D. Diaz-Sanchez. U.S. EPA, Chapel Hill, NC. 

Sponsor: T. Tal. 

11:35 PANEL DISCUSSION/Q&A. Mark Hahn 


9:00 AM to 11:45 AM 

Room 207 

Workshop Session: Identification of Chemical Respiratory 

Allergens: Principles and New Developments 

Chairperson(s): Ian Kimber, University of Manchester, Manchester, 

United Kingdom, and Takahiko Yoshida, Asahikawa Medical College, 

Asahikawa, Japan. 

Sponsor: 


Japanese Society of Immunotoxicology 

There are several new developments and opportunities in chemical respiratory 

allergy. This is an important occupational health problem associated 

with significant morbidity, and occasionally mortality. The identification 

and characterization of chemical respiratory allergens has presented toxicologists 

with some significant challenges, not least because there remains 

uncertainty about the immunological mechanisms that may result in allergic 

sensitization of the respiratory tract. Moreover, there is continuing debate 

about the relevant routes of exposure for the acquisition of sensitization. 

Previously attention focused primarily on the development of predictive 

test methods based upon animal, mainly guinea pig and mouse models, or 

through exploitation of (quantitative) structure-activity relationships. More 

recently, however, other strategies have been proposed and developed, 

included among which are modified peptide reactivity assays, and the 

identification of altered gene expression signatures specific for chemical 

respiratory allergens. Recent progress will be reviewed critically and prospects 

for the development of widely accepted methods for the identification 

and characterization of chemical respiratory allergens will be discussed. 

#902 9:00 IDENTIFICATION OF CHEMICAL 

RESPIRATORY ALLERGENS: PRINCIPLES 

AND NEW DEVELOPMENTS. I. Kimber 1 and 

T. Yoshida 2 . 1 Faculty of Life Sceinces, University of 

Manchester, Manchester, UK, United Kingdom and 

2 

Asahikawa Medical College, Asahikawa, Japan. 

9:00 INTRODUCTION. Ian Kimber 

#903 9:05 IDENTIFICATION AND 

CHARACTERIZATION OF CHEMICAL 

RESPIRATORY ALLERGENS:CHALLENGES 

AND OPPORTUNITIES. I. Kimber. Faculty of 

Life Sceinces, University of Manchester, Manchester, 

UK, United Kingdom. 

#904 9:37 ANIMAL MODELS OF CHEMICAL 

RESPIRATORY ALLERGY. J. Pauluhn. 

Toxicology, Bayer HealthCare, Wuppertal, Germany. 

#905 10:09 PEPTIDE REACTIVITY OF CHEMICAL 

RESPIRATORY ALLERGENS. J. F. Lalko 1,2 . 

1 

The University of Manchester, Manchester, United 

Kingdom and 2 Research Institute for Fragrance 

Materials Inc., Woodcliff Lake, NJ. Sponsor: I. 

Kimber. 

Abstract # 

#906 10:41 GENE EXPRESSION CHANGES AND 

THE IDENTIFICATION OF CHEMICAL 

RESPIRATORY ALLERGENS. D. R. Boverhof. 

The Dow Chemical Company, Midland, MI. 

#907 11:13 A MODIFIED LOCAL LYMPH NODE ASSAY 

FOR HAZARD IDENTIFICATION OF 

CHEMICAL RESPIRATORY ALLERGENS. 

T. Yoshida. Health Science, Asahikawa Medical 

University, Asahikawa, Hokkaido, Japan. 


9:00 AM to 11:45 AM 

Room 144 


Workshop Session: Safer Products for a Sustainable World: 

Linking Chemical Design and Toxicology 

Chairperson(s): Patricia Beattie, SciVera, Inc. and Arcalis Scientific, 

LLC, West Bloomfield, MI, and Hal Zenick, U.S. EPA, Research Triangle 

Park, NC. 

Sponsor: 


Endorsed by: 



There is no more greatly studied characteristic of molecules than their 

ability to exhibit biological activity and major industries, including pharmaceuticals 

and pesticides, are based on this science. Billions of dollars 

are spent to evaluate the risk of chemicals in the environment and billions 

more are to discover new chemicals that have beneficial biological effects. 

One of the goals of green chemistry first introduced by Paul Anastas and 

John Warner in 1998, is to reduce or eliminate the use and generation of 

hazardous substances throughout the design, manufacture, and use of chemical 

products. The principles of green chemistry and engineering are now 

being widely embraced beyond the traditional chemical and pharmaceutical 

industries, into formulators and manufacturers of consumer products. Information 

on the potential hazards of the substances that are incorporated into 

final products is needed in order to assess and design safer products and 

processes. Recent advances in understanding the mechanisms of toxicity, 

the development of in vitro high-throughput screening (HTS) assays as well 

as other predictive and in silico methods allow for rapid assessment and 

screening of many more chemicals than had been possible in the past using 

traditional whole animal models. With the reform of the Toxic Substances 

Control Act (TSCA) and other state and global regulations requiring toxicity 

information and assessment of safer alternatives on thousands of chemicals, 

it is imperative that these predictive toxicology methods be incorporated 

into the assessment paradigm. As new industrial chemicals are designed 

with green chemistry and engineering principles, these toxicology screening 

methods can be used to efficiently evaluate substances, minimizing potential 

adverse health effects both in the workplace and to the final consumer. 

#908 9:00 SAFER PRODUCTS FOR A SUSTAINABLE 

WORLD: LINKING CHEMICAL DESIGN 

AND TOXICOLOGY. H. Zenick 1 and P. Beattie 2 . 

1 

National Health Environmental Effects Research 

Lab., U.S. EPA, Research Triangle Park, NC and 

2 

SciVera, Inc. and Arcalis Scientific, LLC, West 

Bloomfield, MI. 

9:00 INTRODUCTION. Patricia Beattie 

#909 9:05 GREEN CHEMISTRY DONE RIGHT: A 

PARTNERSHIP BETWEEN CHEMICAL 

DESIGN AND TOXICOLOGY. P. Anastas. 

Office of Research and Development, U.S. EPA, 

Washington, D.C. Sponsor: H. Zenick. 

Tuesday 







197



Tuesday 


#910 9:37 IMPLEMENTING CALIFORNIA’S 

GREEN CHEMISTRY INITIATIVE: THE 

TOXICOLOGICAL, TECHNICAL, AND 

EDUCATIONAL QUESTIONS. M. Schwarzman. 

Centers for Occupational and Environmental Health 

and Green Chemistry, University of California 

Berkeley School of Public Health, Berkeley, CA. 

Sponsor: P. Beattie. 

#911 10:09 PUTTING WORKERS’ SAFETY AND 

HEALTH INTO GREEN CHEMISTRY. P. A. 

Schulte. Centers for Disease Control and Prevention, 

NIOSH, Cincinnati, OH. Sponsor: H. Zenick. 

#912 10:41 DIFFERENTIAL TOXICITY 

CHARACTERIZATION OF GREEN 

ALTERNATIVE CHEMICALS. R. Judson. 

National Center for Computational Toxicology, U.S. 


#913 11:13 DESIGN FRAMEWORK FOR SAFER 

CHEMICALS – RECENT RESEARCH AND 

COMMERCIAL APPLICATIONS. T. G. 

Osimitz. Science Strategies Institute and SciVera, 

Inc., Charlottesville, VA. 


9:00 AM to 11:45 AM 

Room 143 



Workshop Session: Using Mode of Action Data to Guide 

Quantitative Cancer Risk Assessment: A Case Study of 

Hexavalent Chromium in Drinking Water 

Chairperson(s): Deborah Proctor, ToxStrategeis, Inc., Rancho Santa 

Margarita, CA, and Bette Meek, University of Ottowa, Ottawa, Ontario, 

Canada. 

Sponsor: 


Endorsed by: 



Current cancer risk assessment guidance recommends that mode-of-action 

(MOA) data be used to inform the qualitative and quantitative assessment of 

human health risk. However, the ideal MOA data rarely exist, and as a result 

there are few examples for which MOA information has been used quantitatively 

in risk assessment. A comprehensive MOA research program was 

recently undertaken for hexavalent chromium [Cr(VI)] to better understand 

the key events underlying the tumorigenic response observed in rodents 

exposed chronically to Cr(VI) in drinking water. In 2009, and at the direction 

of an independent science advisory board, MOA Framework guidance 

was used to identify data gaps and develop a research program that included 

a pharmacokinetic (PK) study to generate the data necessary to model tissue 

dose, dose-response and quantify interspecies variability, and a subchronic 

study in both rats and mice (including an interim 7 day time point), with 

evaluation of the toxicogenomics in target tissues, histopathology, biochemical 

measures of immune response and oxidative stress, analyses of DNA 

damage (8-OH-dG and Cr-DNA adducts), and in vivo mutation. The findings 

of these studies are used to identify and temporally sequence key events 

in the MOA and provide information for extrapolation across species and 

doses. The use of these MOA and PK studies for Cr(VI) cancer risk assessment 

are discussed as an example case study for using MOA data to refine 

human health risk assessment. 

#914 9:00 USING MODE OF ACTION DATA TO 

GUIDE QUANTITATIVE CANCER RISK 

ASSESSMENT: A CASE STUDY OF 

HEXAVALENT CHROMIUM IN DRINKING 

WATER. D. Proctor 1 and B. Meek 2 . 1 ToxStrategies, 

Inc., Rancho Santa Margarita, CA and 2 University of 

Ottawa, Ottawa, ON, Canada. 

9:00 INTRODUCTION. Deborah Proctor and Bette 

Meek 

#915 9:05 NTP TOXICOLOGY AND CARCINOGENESIS 

STUDIES OF CHROMIUM. M. D. Stout and M. 

J. Hooth. NTP/NIEHS, Research Triangle Park, NC. 

#916 9:20 RESEARCH PLAN TO FILL DATA GAPS 

IN THE MODE OF ACTION FOR CANCER 

RISK ASSESSMENT OF HEXAVALENT 

CHROMIUM IN DRINKING WATER. L. 

Haws 3 , D. Proctor 1 , C. Thompson 2 and M. Harris 2 . 

1 

ToxStrategies, Inc., Rancho Santa Margarita, CA, 

2 

ToxStrategies, Inc., Houston, TX and 3 ToxStrategies, 

Inc., Austin, TX. 

#917 9:35 TOXICOGENOMIC ANALYSIS OF CR(VI) 

EFFECTS ON INTESTINAL AND ORAL 

EPITHELIUM. T. R. Zacharewski 1 , A. K. Kopec 1 , 

A. L. Forgacs 1 , S. Kim 1 , S. D. Grimes 2 and C. D. 

Hébert 2 . 1 Biochemistry & Molecular Biology and 

Center for Integrative Toxicology, Michigan State 

University, East Lansing, MI and 2 Southern Research 

Institute, Birmingham, AL. 

#918 10:00 GENETIC TOXICITY OF HEXAVALENT 

CHROMIUM IN THE GASTROINTESTINAL 

TRACT FOLLOWING ORAL EXPOSURE. 

T. J. O’Brien 1 , H. Ding 1 , C. D. Hébert 2 , R. D. May 2 

and S. R. Patierno 1 . 1 Department of Pharmacology 

and Physiology, The George Washington University 

Medical Center, Washington, D.C. and 2 Southern 

Research Institute, Birmingham, AL. 

#919 10:25 A FRAMEWORK FOR EVALUATING DATA 

IN SUPPORT OF A MUTAGENIC MOA. R. 

Schoeny. Office of Water, U.S. EPA, Washington, 

D.C. Sponsor: D. Proctor. 

#920 10:50 PHARMACOKINETICS OF INGESTED 

CR(VI) IN RODENTS: EXTRAPOLATIONS 

TO TARGET TISSUE DOSE IN HUMANS. 

S. Hays 1 , L. Aylward 2 and C. Kirman 3 . 1 Summit 

Toxicology, Inc., Lyons, Co., 2 Summit Toxicology, 

Inc., Falls Church, VA and 3 Summit Toxicology, Inc., 

Orange Village, OH. 

#921 11:15 USE OF MODE OF ACTION AND 

PHARMACOKINETICS TO INFORM THE 

CANCER RISK ASSESSMENT OF INGESTED 

CR(VI): A CASE STUDY. D. Proctor 1 , L. Haws 2 , 

C. Thompson 3 and M. Harris 3 . 1 ToxStrategies, Inc., 

Rancho Santa Margarita, CA, 2 ToxStrategies, Inc., 

Austin, TX and 3 ToxStrategies, Inc., Houston, TX. 

11:35 PANEL DISCUSSION. 

198 






Platform Sessions



Abstract # 


9:00 AM to 11:45 AM 

Room 151 

Historical Highlights Session: 1961 to 2011 and Beyond: The 

Evolution of Toxicology 

Chairperson(s): Steven G. Gilbert, Institute of Neurotoxicology & 

Neurological Disorders, Seattle, WA, and Joel G. Pounds, Battelle, PNNL, 

Richland, WA. 

Sponsor: 


Endorsed by: 



Toxicology has contributed enormously to environmental and human health. 

During the past 50 years significant rules and regulations were enacted to 

protect and enhance human and ecological health, often following a serious 

toxicological event. Most notably, toxicological sciences have shaped drug 

development through the U.S. FDA and chemical use through the U.S. EPA. 

Workplace exposure and health issues are addressed by OSHA and NIOSH. 

There is increasing concern about low-dose effects on the developing organisms 

of not only humans but also animals. Our panel of experts will review 

how advances in toxicological sciences over the past 50 years have driven 

the regulatory, societal, and medical view of key toxicants. After examination 

of some key contributions to the field, we will reflect on how advances 

in the science of toxicology will shape the future environment regarding 

drug and chemical development and use. 

#922 9:00 LOOKING BACK 50 YEARS OF 

TOXICOLOGY TO LOOK FORWARD. S. G. 

Gilbert 1 and J. G. Pounds 2 . 1 INND, Seattle, WA and 

2 

Cell Biology & Biochemistry, Pacific Northwest 


9:00 INTRODUCTION. Steven Gilbert 

#923 9:10 METALS 50 YEARS OF EXPLORATION. B. 

Weiss. Department of Environmental Medicine, 

University of Rochester, Rochester, NY. 

#924 9:45 HALOGENATED AROMATIC 

HYDROCARBONS (PCBS, PBB, DDT, 

DIOXIN). D. L. Eaton. Department of 



#925 10:20 RISK ASSESSMENT AND BEYOND. E. 

M. Faustman. Department of Environmental 

and Occupational Health Sciences, University of 

Washington, Seattle, WA. 

#926 10:55 CHEMICAL CARCINOGENESIS 50 YEARS 

TO WHERE. C. C. Harris. National Cancer 

Institute, National Institute of Health, Bethesda, MD. 

Sponsor: S. Gilbert. 


Abstract # 


9:00 AM to 11:45 AM 

Room 150 

Regional Interest Session: Bombs in Our Backyards? 

Historical Military Activities and Current Public Health 

Issues in the U.S. Capital Region 

Chairperson(s): Laurie Roszell, U.S. Army-CHPPM, Aberdeen Proving 

Ground, MD, and Erik Janus, Steptoe & Johnson, LLP, Washington, D.C. 

Sponsor: 

National Capital Area Regional Chapter 

#927 9:00 A BRIEF INTRODUCTION TO UXO IN THE 

CAPITAL REGION: SESSION OVERVIEW. 

E. R. Janus 2 and L. E. Roszell 1 . 1 Environmental 

Health Risk Assessment, USA PHC (P), Aberdeen 

Proving Ground, MD and 2 Regulatory & Industry 

Affairs, Steptoe & Johnson LLP, Washington, D.C. 

#928 9:15 ENVIRONMENTAL RISK ISSUES 

ASSOCIATED WITH A MUNITIONS 

RESPONSE SITE IN NORTHWEST 

WASHINGTON, D.C. THE SPRING VALLEY 

FORMERLY USED DEFENSE SITE. D. G. 

Noble. Baltimore District, U.S. Army Corps of 

Engineers, Baltimore, MD. Sponsor: L. Roszell. 

#929 9:40 MUNITIONS AND EXPLOSIVES OF 

CONCERN (MEC) IN SPRING VALLEY AND 

THE WASHINGTON, D.C. AREA. P. Greene. 

U.S. Army Corps of Engineers, Baltimore, MD. 

Sponsor: L. Roszell. 

#930 10:05 TOXICITY OF WWI ERA CHEMICALS 

STUDIED AT SPRING VALLEY, 

WASHINGTON, D.C. C. Opdyke. Baltimore 

District, U.S. Army Corps of Engineers, Baltimore, 

MD. Sponsor: L. Roszell. 

#931 10:30 A PUBLIC HEALTH APPROACH TO A WW 

I LEGACY: TRACKING HEALTH AND 

ENVIRONMENT IN SPRING VALLEY. M. A. 

Fox 1 , F. Curriero 2 , R. Chari 1 , E. Janus 4 , K. Kulbicki 3 , 

R. Neff 2 , J. Zablotsky 5 , B. Resnick 1 and T. Burke 1 . 

1 

Health Policy and Management, Johns Hopkins 

University, Baltimore, MD, 2 Environmental Health 

Sciences, Johns Hopkins University, Baltimore, 

MD, 3 Westat, Rockville, MD, 4 Steptoe and 

Johnson, Washington, D.C. and 5 Food Safety and 

Inspection Service, U.S. Department of Agriculture, 


#932 10:55 THE ROLE OF TRUST AT MUNITIONS/ 

CHEMICAL WEAPONS SITES. L. Siegel. 

Center for Public Environmental Oversight, 

Mountain View, CA. Sponsor: L. Roszell. 

#933 11:20 ADDRESSING PUBLIC PERCEPTIONS: 

COMMUNICATING PUBLIC HEALTH 

ISSUES EFFECTIVELY. L. S. Geckle. Health 

Risk Communication program, U.S. Army Public 

Health Center (Prov), Aberdeen Proving Ground, 

MD. Sponsor: L. Roszell. 

Tuesday 







199



Tuesday 



9:00 AM to 11:45 AM 

Room 204 

Platform Session: Computational Approaches to Address 

DILI and Hepatoxicity 

Chairperson(s): Amy Wang, U.S. Environmental Protection Agency, 

Research Triangle Park, NC, and Raymond Kemper, Boehringer 

Ingelheim Pharmaceuticals, Ridgefield, CT. 

#934 9:00 THE FDA’S LIVER TOXICITY 

KNOWLEDGE BASE (LTKB) PROJECT. W. 

Tong 1 , M. Chen 1 , V. Vikrant 1 , Q. Shi 1 , M. Zhang 1 , L. 

Guo 2 , Z. Liu 1 , J. Zhang 1 and E. Bearden 1 . 1 Division 

of Systems Biology, U.S. FDA NCTR, Jefferson, AR 

and 2 Division of Biochemical Toxicology, U.S. FDA 


#935 9:21 VALIDATION OF CELLCIPHR 

CELLULAR SYSTEMS BIOLOGY (CSB) 

TECHNOLOGY. CELLCIPHR2— 

BUILDING ON EXPERIENCE OF IN VIVO 

RAT LIVER INJURY PREDICTION TO 

DEVELOP THE HUMAN DILI PREDICTION. 

S. Thomas 2 , J. Mein 2 , R. Annand 1 , P. Walker 2 , M. 

Jacewicz 1 , D. Steen 3 , C. Chesne 3 , J. Gilbert 1,2 and K. 

Tsaioun 1,2 . 1 Apredica, Watertown, MA, 2 Cyprotex, 

Macclesfield, United Kingdom and 3 Biopredic, 

Rennes, France. 

#936 9:42 INVESTIGATING THE ROLE OF 

MITOCHONDRIAL TOXICITY IN DRUG- 

INDUCED LIVER INJURY VIA CONGRUENT 

STRUCTURE-ACTIVITY RELATIONSHIPS. 

M. L. Patel 1 , L. Fisk 1 , N. Greene 2 and R. T. Naven 2 . 

1 

Lhasa Limited, Leeds, United Kingdom and 

2 

Worldwide Medicinal Chemistry, Pfizer Inc., 

Groton, CT. 

#937 10:03 QUANTITATIVE SIMULATION OF 

INTRACELLULAR SIGNALING CASCADES 

IN A VIRTUAL LIVER: ESTIMATING 

DOSE DEPENDENT CHANGES IN 

HEPATOCELLULAR PROLIFERATION 

AND APOPTOSIS. J. Jack 1 , M. Mennecozzi 2 , C. 

Haugh 1 , J. Wambaugh 1 and I. Shah 1 . 1 National Center 

for Computational Toxicology, U.S. EPA, Research 

Triangle Park, NC and 2 Joint Research Centre, 

European Commission, Ispra, Italy. 

#938 10:24 PHYSIOLOGICALLY BASED 

PHARMACOKINETIC (PBPK) 

MODELING TO PREDICT PLASMA 

PHARMACOKINETICS FOR LIVER 

TRANSPORTER SUBSTRATES. H. A. 

Barton 1 , H. Jones 2 and Y. Lai 1 . 1 Pharmacokinetics, 

Pharmacodynamics, and Metabolism, Pfizer, 

Inc., Groton, CT and 2 Pharmacokinetics, 

Pharmacodynamics, and Metabolism, Pfizer, Inc., 

Sandwich, United Kingdom. 

#939 10:45 A NOVEL PREDICTIVE PLATFORM FOR 

DILI: A COMBINATION OF IN SILICO 

AND IN VITRO METHODS TO PREDICT 

TOXICITY MECHANISMS IN VIVO. S. Das, 

R. Kumar, S. Raghavan and K. Subramanian. Strand 

Life Sciences, Bangalore, India. 

#940 11:05 APPLICATIONS OF A COMPUTATIONAL 

MODEL FOR PREDICTING DRUG- 

INDUCED LIVER INJURY (DILI). B. A. 

Howell 1 , R. Kumar 3 , L. Wennerberg 3 , Y. Yang 2 , R. 

Ho 3 , A. Harrill 1 , C. L. Kurtz 1 , M. E. Andersen 2 , H. J. 

Clewell 2 , S. Q. Siler 3 and P. B. Watkins 1 . 1 Drug Safety 

Sciences, The Hamner Institutes, Research Triangle 

Park, NC, 2 Chemical Safety Sciences, The Hamner 

Institutes, Research Triangle Park, NC and 3 Entelos, 

Inc., Foster City, CA. 

#941 11:25 DEVELOPMENT OF A PBPK/PD MODEL 

FOR ACETAMINOPHEN TOXICITY IN 

RATS. Y. Yang, B. Howell, M. Yoon, M. Andersen 

and H. J. Clewell. The Hamner Institutes for Health 



9:00 AM to 11:45 AM 

Room 201 


Platform Session: Epigenetic Mechanisms in Development 

and Disease 

Chairperson(s): Yanan Tian, Texas A&M University, College Station, TX, 

and Xiefan Fang, University of Mississippi, University, MS. 

#942 9:00 USING ZEBRAFISH TO STUDY BENZO(A) 

PYRENE-MEDIATED CHANGES IN 

DNA METHYLATION STATUS DURING 

DEVELOPMENT. X. Fang 1 , C. Thornton 1 , B. 

E. Scheffler 2 and K. L. Willett 1 . 1 Department of 

Pharmacology and Toxicology, the University of 

Mississippi, University, MS and 2 Genomics and 

Bioinformatics Research Unit, USDA Mid South 

Area Genomics Laboratory, Stoneville, MS. 

#943 9:19 GENOME-WIDE DNA METHYLATION 

DIFFERENCES BETWEEN LATE- 

ONSET ALZHEIMER’S DISEASE AND 

COGNITIVELY NORMAL CONTROLS 

IN THE HUMAN FRONTAL CORTEX. K. 

Bakulski 1 , D. C. Dolinoy 1 , M. A. Sartor 1 , H. L. 

Paulson 2 , A. P. Lieberman 2 , R. L. Albin 2 , H. Hu 1,2 and 

L. S. Rozek 2 . 1 School of Public Health, University 

of Michigan, Ann Arbor, MI and 2 Medical School, 


#944 9:38 EPIGENETIC CHANGES DURING 

CO-CARCINOGENESIS OF N, 

N-DIETHYLNITROSAMINE AND CARBON 

TETRACHLORIDE IN MOUSE LIVER. K. 

Kutanzi 1 , I. Koturbash 1 , T. Uehara 2 , O. Kosyk 2 , 

I. Pogribny 1 and I. Rusyn 2 . 1 National Center for 

Toxicological Research, U.S. FDA, Jefferson, AR 

and 2 Department of Environmental Sciences and 


Hill, Chapel Hill, NC. 

#945 9:57 AH RECEPTOR INHIBITS GENE 

EXPRESSION OF DELETED IN LIVER 

CANCER (DLC1) THROUGH REGULATION 

OF MICRORNA IN MOUSE LIVER CELLS. 

Y. Tian 1 , S. Ke 1 , M. Huang 2 , B. Zhou 1 and Z. Zhou 2 . 

1 

Program of Toxicology, Texas A&M University, 

College Station, TX and 2 School of Public Health, 

Fudan University, Shanghai, China. 

200 






Platform Sessions



Abstract # 

#946 10:15 INTER-STRAIN DIFFERENCES IN 

SUSCEPTIBILITY TO 1, 3-BUTADIENE- 

INDUCED DNA DAMAGE, EPIGENETIC 

AFFECTS, AND HEPATOTOXICITY. I. 

Pogribny 1 , K. Igor 1 , A. Scherhag 1 , J. Sorrentino 2 , S. 

Kennet 2 , W. Bodnar 2 , S. A. James 2 , B. A. Frederick 1 

and R. Ivan 2 . 1 National Center for Toxicological 

Research, Jefferson, AR and 2 University of North 

Carolina, Chapel Hill, NC. 

#947 10:33 ALTERED DNA METHYLATION PATTERNS 

IN INDIVIDUALS WITH ARSENICOSIS. 

L. Smeester 1 , J. Rager 1 , L. Zhang 6 , X. Guan 3 , 

N. Smith 1 , G. Garcia-Vargas 4 , L. Del Razo 5 , Z. 

Drobna 2 , H. Kelkar 3 , G. Schroth 6 , M. Styblo 2 and 

R. Fry 1 . 1 Environmental Sciences and Engineering, 

Gillings School of Global Public Health University 


2 

Nutrition, Gillings School of Global Public Health 


Hill, NC, 3 Center for Bioinformatics, University 


4 

Faculty of Medicine, Juarez University of Durango 

State, Juarez, Mexico, 5 Department of Toxicology, 

Cinvestav-Ipn, Mexico City, Mexico and 6 Illumina, 

Inc., Hayward, CA. 

#948 10:51 HDAC INHIBITORS, ENTINOSTAT, 

AND VORINOSTAT SYNERGIZE WITH 

ADAPHOSTIN, A TYRPHOSTIN KINASE 

INHIBITOR, INCREASING OXIDATIVE 

STRESS AND APOPTOSIS IN LEUKEMIA 

CELLS. N. Rivera-Del Valle and J. Chandra. 

Pediatric Research, University of Texas M.D. 

AndersonCancer Center, Houston, TX. 

#949 11:09 AHR-MEDIATED IMMUNE REGULATION 

RESULTS FROM EPIGENETIC EFFECTS. P. 

Nagarkatti, N. P. Singh, U. Singh and M. Nagarkatti. 

Pathology, Microbiology, and Immunology, 

University of South Carolina School of Medicine, 

Columbia, SC. 

#950 11:27 DNA METHYLATION AND HISTONE 

MODIFICATION CHANGES IN THE 

LIVERS OF C57BL/6J MICE EXPOSED 

TO 1, 3-BUTADIENE BY INHALATION. I. 

Koturbash 1 , A. Scherhag 1 , S. Jessica 2 , B. Wanda 2 , 

S. A. James 2 , B. A. Frederick 1 , P. Igor 1 and R. 

Ivan 2 . 1 Biochemical Toxicology, National Center 

for Toxicological Research, Jefferson, AR and 

2 

University of North Carolina, Chapel Hill, NC. 


9:00 AM to 11:45 AM 

Room 202B 

Platform Session: Gene Regulatory Mechanisms of 


Chairperson(s): David Castro, Sanford-Burnham Medical Research 

Institute, La Jolla, CA, and B. Bhaska Gollapudi, The Dow Chemical 


#951 9:00 PROPICONAZOLE ENHANCES CELL 

PROLIFERATION BY DYSREGULATION 

OF RAS FARNESYLATION AND THE MAPK 

PATHWAY. L. Murphy, T. Moore and S. Nesnow. 

U.S. EPA, Research Triangle Park, NC. Sponsor: S. 

Hester. 

Abstract # 

#952 9:21 ANALYSIS OF MOLECULAR, CELLULAR, 

AND BIOCHEMICAL CHANGES IN THE 

LIVER OF MALE B6C3F1 MICE TREATED 

WITH NITRAPYRIN—A NITROGEN 

STABILIZER. M. J. LeBaron 1 , M. R. Schisler 1 , 

H. L. Kan 1 , J. Thomas 1 , D. L. Eisenbrandt 2 and B. B. 

Gollapudi 1 . 1 The Dow Chemical Company, Midland, 

MI and 2 Dow AgroSciences, Indianapolis, IN. 

#953 9:42 THE FRY TUMOR SUPPRESSOR ENCODES 

AN INHIBITOR OF EPITHELIAL 

MESENCHYMAL TRANSITION. J. Graham 1 , 

X. Ren 2 and H. Zarbl 1 . 1 Toxicology, UMDNJ- 

RWJMS, Piscataway, NJ and 2 University of 

California, Berkeley, CA. 

#954 10:03 REDUCTION OF PTEN DOSE IMPAIRS 

DNA REPAIR AND PREDISPOSES TO UVB- 

INDUCED SKIN TUMORIGENESIS. Y. He 1 , 

M. Ming 1 , L. Feng 2 , C. Shea 1 , K. Soltani 1 , B. Zhao 2 , 

W. Han 1 , R. Smart 3 , C. Trempus 2 and J. Pritchard 2 . 

1 

Medicine/Dermatology, University of Chicago, 

Chicago, IL, 2 Laboratory of Pharmacology, National 

Institute of Environmental Health Sciences, National 

Institute of Health, Research Triangle Park, NC 

and 3 Department of Environmental and Molecular 

ToxicologyGroup, North Carolina State University, 

Raleigh, NC. 

#955 10:24 TOLFENAMIC ACID INHIBITS GROWTH 

AND SURVIVAL OF MULTIPLE TUMORS 

AND DOWNREGULATES SPECIFICITY 

PROTEIN (SP) TRANSCRIPTION FACTORS. 

G. Chadalapaka 1 , I. Jutooru 1 , S. Sreevalsan 1 , 

S. Pathi 1 and H. Wilson 2 . 1 VTPP, Texas A&M 

University, College Station, TX and 2 Department 

of Small Animal Clinical Sciences, Texas A&M 


#956 10:45 ROLE OF SPECIFICITY PROTEIN 

(SP) TRANSCRIPTION FACTORS IN 

REGULATION OF STAT3 IN PANCREATIC 

CANCER CELLS. I. D. Jutooru 1 , G. 

Chadalapaka 1 and S. H. Safe 1,2 . 1 Veterinary 


University, College Station, TX and 2 Institute of 

Biosciences & Technology, Houston, TX. 

#957 11:05 PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR (PPAR)γ IN 

MAMMARY SECRETORY EPITHELIAL 

CELLS STOPS DMBA-MEDIATED BREAST 

TUMOURIGENESIS. A. J. Apostoli 1 , N. 

Peterson 1 , R. Rubino 1 , S. SenGupta 1 , M. Schneider 1 

and C. Nicol 1,2 . 1 Pathology & Molecular Medicine, 

Queen’s University, CRI, Kingston, ON, Canada and 

2 

Division of Cancer Biology & Genetics, Queen’s 

University, CRI, Kingston, ON, Canada. 

#958 11:25 MITOCHONDIAL UNCOUPLING PROTEIN 

3 ANTAGONIZES TUMOR PROMOTION BY 

ALTERING CANONICAL KERATINOCYTE 

GROWTH AND DIFFERENTIATION 

SIGNALING PATHWAYS. S. M. Nowinski 1 , J. E. 

Rundhaug 2 , O. Rho 1 , J. Digiovanni 1 and E. M. Mills 1 . 

1 

Division of Pharmacology and Toxicology, College 

of Pharmacy, The University of Texas at Austin, 

Austin, TX and 2 Science Park - Research Division, 

The University of Texas M.D. AndersonCancer 

Center, Smithville, TX. 

Tuesday 







201



Tuesday 



9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Alternative Approaches to Animal Testing for 

Toxicological Research 

Chairperson(s): Adrian Nanez, Amgen Inc., Thousand Oaks, CA. 




EFFECTS OF LOW LEVELS OF BISPHENOL 

A IN HUMAN ENDOTHELIAL CELLS. 

H. Andersson and E. Brittebo. Pharmaceutical 

Biosciences, Faculty of Pharmacy, Uppsala, Sweden. 

Sponsor: M. Stigson. 


CIGARETTE SMOKE EXPOSED 

PRECISION-CUT LUNG SLICES (PCLS) AS 

A NEW IN VITRO MODEL FOR SMOKE- 

INDUCED TOXICITY. S. Switalla, D. Ritter, J. 

Knebel, C. Dasenbrock, A. Braun and K. Sewald. 

Fraunhofer Institute for Toxicology and Experimental 

Medicine, Hannover, Germany. Sponsor: H. Muhle. 


LONG-TERM CULTURE OF H9C2 RAT 

CARDIOMYOCYTES WITH NUCLEOSIDE 

REVERSE TRANSCRIPTASE INHIBITORS 

(NRTIS) ALTERS RESPIRATORY CAPACITY 

AND MITOCHONDRIAL BIOGENESIS. Y. 

Liu, P. Nguyen, T. Baris and M. C. Poirier. National 

Cancer Institute, Bethesda, MD. 


INTERROGATING GENETIC PATHWAYS 

OF TOXICITY USING IN VITRO HIGH- 

CONTENT SCREENING OF EMBRYONIC 

FIBROBLASTS FROM THE MOUSE 

DIVERSITY PANEL. T. Wiltshire 1 , O. Suzuki 1 , N. 

Butz 1 , A. Frick 1 , B. Parks 2 , J. Trask 2 and R. Thomas 2 . 

1 

University of North Carolina, Chapel Hill, NC and 

2 

The Hamner Institute for Health Sciences, Durham, 

NC. 


VEHICLE EFFECTS ON RESULTS OF 

LOCAL LYMPH NODE ASSAYS. T. Anzai 1,2 , 

D. Hayashi 1,2 , S. Corney 1 , K. Sato 2 and T. Satoh 3,1 . 

1 

Harlan Laboratories, Tokyo, Japan, 2 Showa 

University School of Medicine, Tokyo, Japan and 

3 

HAB Research Institute, Chiba City, Japan. 


EFFECTS OF 5-HT 1A 

OR 

ENDOCANNABINOID RECEPTOR 

AGONISTS ON ZEBRAFISH BEHAVIOR IN 

NOVEL ENVIRONMENTS. K. A. Connors 1 , 

T. W. Vallenti 1 , K. N. Prosser 1 , B. W. Brooks 1 , E. S. 

Onaivi 2 and G. G. Gould 3 . 1 Environmental Science, 

Baylor University, Waco, TX, 2 Biology, William 

Paterson University, Wayne, NJ and 3 Physiology, 

University of Texas Health Science Center at San 

Antonio, San Antonio, TX. 


IMPLEMENTATION OF THE NCTC2544 

IL-18 ASSAY TO IDENTIFY IN VITRO 

CONTACT ALLERGENS. V. Galbiati 1 , M. 

Mitjans 2 , F. Colleoni 1 , C. L. Galli 1 , M. Marinovich 1 

and E. Corsini 1 . 1 Department of Pharmacological 

Sciences, Università degli Studi di Milano, Milano, 

Italy and 2 Dpt Fisiologia, Facultat de Farmacia, 

Universitat de Barcelona, Barcelona, Spain. 


DIFFERENT REGULATION OF 

INTERLEUKIN-8 EXPRESSION IN HUMAN 

THP-1 CELLS AFTER EXPOSURE TO 

ISOEUGENOL VERSUS OTHER CONTACT 

ALLERGENS. E. Corsini 1 , A. Carne 1 , V. Galbiati 1 , 

M. Mitjans 2 , C. L. Galli 1 and M. Marinovich 1 . 

1 

Department of Pharmacological Sciences, Università 

degli Studi di Milano, Milano, Italy and 2 Dpt 

Fisiologia, Facultat de Farmacia, Universitat de 

Barcelona, Barcelona, Spain. 


IN VITRO DETECTION OF CONTACT 

ALLERGENS: DEVELOPMENT OF 

AN OPTIMIZED PROTOCOL AND 

PERFORMING OF AN INTERNATIONAL 

RING STUDY USING HUMAN PERIPHERAL 

BLOOD MONOCYTE DERIVED DENDRITIC 

CELLS. A. G. Schepky, J. Spieker, S. Gerlach, H. 

Wenck, K. Wittern and H. J. Reuter. 4218-Research 

Toxicology, Beiersdorf AG, Hamburg, Germany. 

Sponsor: R. Fautz. 


ASIAN GINSENG (PANAX GINSENG) 

AGGRAVATES ETHANOL TOXICITY IN 

JAPANESE MEDAKA (ORYZIAS LATIPES) 

EMBRYOGENESIS. M. H. Haron 1,3,2 , L. A. 

Walker 1 , I. A. Khan 1 and A. K. Dasmahapatra 1,2,3 . 

1 

National Center for Natural Product Research, 

University of Mississippi, University, MS, 

2 

Environmental Toxicology Research Program, 

University of Mississippi, University, MS and 

3 

Department of Pharmacology, University of 

Mississippi, University, MS. 


CYTOTOXICITY OF TOBACCO SMOKE 

AEROSOLS IN VITRO : COMPARISON OF 

ISO AND HCI SMOKING REGIMES. K. 

Scott 1 , J. Kilford 2 , P. Fowler 2 , J. Young 2 , I. Crooks 1 , 

D. Dillon 1 and C. Meredith 1 . 1 Group R&D, British 

American Tobacco, Southampton, United Kingdom 

and 2 Covance Laboratories Ltd., Harrogate, North 

Yorkshire, United Kingdom. 


APPLICATION OF SILAC QUANTITATIVE 

PROTEOMICS FOR PATHWAY DISCOVERY 

OF IDIOSYNCRATIC DRUG-INDUCED 

LIVER INJURY COMPOUNDS. K. L. Leach 1 , S. 

Nadanaciva 1 , C. Vazquez-Martin 2 , A. Lamond 2 and P. 

Ajuh 2 . 1 Compound Safety Prediction, Pfizer, Groton, 

CT and 2 Dundee Cell Products, Dundee, United 

Kingdom. 

202 






Platform Sessions



Abstract # 


EXPERIENCES WITH CYTOTOXICITY 

ASSAYS TO SELECT STARTING DOSES 

FOR ACUTE ORAL TOXICITY TESTING. 

K. Hempel, A. Schrage, S. Kolle, M. Schulz, B. 

van Ravenzwaay and R. Landsiedel. BASF SE, 

Ludwigshafen, Germany. Sponsor: A. Doi. 


FURAN AND 1, 3-PROPANEDIOL PRODUCE 

DNA CROSS-LINKS IN TURKEY FOETAL 

LIVER. A. M. Jeffrey 1 , J. Duan 1 , K. D. 

Brunnemann 1 , J. R. Schlatter 2 and G. M. Wiliams 1 . 

1 

Department of Pathology, New York Medical 

College, Valhalla, NY and 2 Swiss Federal Office 

of Public Health, Stauffacherstrasse 101, Zürich, 

CH-8004, Switzerland. 


RETINOIC ACID DIFFERENTIATED H9C2 

RAT CARDIAC CELLS AS A MODEL FOR 

TOXICITY SCREENING. H. P. Behrsing, 

J. Hamre III, M. J. Furniss, D. Mesa and R. E. 

Parchment. SAIC-Frederick/NCI-Frederick, 

Frederick, MD. 


IDENTIFICATION AND CLASSIFICATION 

OF SKIN SENSITIZER USING PEPTIDE 

BINDING ASSAY BY LC-MS. T. Morimoto, 

T. Higaki, M. Ota, K. Inawaka and S. Kawamura. 

Sumitomo Chemical Co., Ltd., Osaka, Japan. 

Sponsor: T. Yamada. 


A NEW RECONSTITUTED HUMAN 

CORNEAL EPITHELIUM MODEL FOR THE 

ALTERNATIVE EYE IRRITATION TEST. K. 

Jung 1 , S. Lee 2 , Y. Ryu 2 , H. Jung 2 , W. Jang 1 , J. Han 3 , 

S. Seok 3 , J. Park 3 , Y. Son 4 , J. Chung 3 , Y. Park 1 and K. 

Lim 1 . 1 Amorepacific. Co. R&D Center, Gyeonggido, 

Republic of Korea, 2 Modern Cell&Tissue 

Technologies Inc., Seoul, Republic of Korea, 3 Seoul 

National University, Seoul, Republic of Korea and 

4 

Kyung Hee University, Gyeonggi-do, Republic of 

Korea. 


AN ACUTE 1 HOUR EXPOSURE TO 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN (2, 

3, 7, 8-TCDD) INHIBITED VITELLOGENIN 

(ZFVTG 1-3) INDUCTION BY 

17α-ETHYNYLESTRADIOL IN ZEBRAFISH 

(DANIO RERIO). S. M. Bugel 1 , L. A. White 2 

and K. R. Cooper 2 . 1 Department of Environmental 

Sciences, Rutgers University, New Brunswick, NJ 

and 2 Department of Biochemistry and Microbiology, 

Rutgers University, New Brunswick, NJ. 

Abstract # 


TOXICOLOGICAL INVESTIGATION OF 

VOLATILE ORGANIC COMPOUNDS 

ON NON-MAMALIAN MODEL SPECIES, 

DROSOPHILA MELANOGASTER AND 

CAENORHABDITIS ELEGANS FOR INDOOR 

AIR POLLUTANTS BIOMONITORING. Y. 

Chung 1 , H. Eom 1 , K. Song 2 , S. Kim 3 , M. Rhee 4 , T. 

Chon 5 and J. Choi 1 . 1 University of Seoul, Seoul, 

Republic of Korea, 2 Korea Conformity Laboratories, 

Seoul, Republic of Korea, 3 Seoul National 

University, Seoul, Republic of Korea, 4 Chungnam 

National University, Seoul, Republic of Korea and 

5 

Pusan National University, Pusan, Republic of 

Korea. Sponsor: D. Ryu. 


DETERMINING SKIN SENSITIZATION 

POTENTIAL OF MEDICAL DEVICE 

MATERIALS USING A NEW IN VITRO 

METHOD. D. Keller 1 , B. Wallace 1 , H. Wagner 1 , 

J. Gorski 2 and J. M. McKim 1 . 1 CeeTox, Inc., 

Kalamazoo, MI and 2 North American Scientific 

Associates, Inc. (NAMSA), Northwood, OH. 


NEUROPATHY TARGET ESTERASE (NTE) 

CODIFYING GEN AS BIOINDICATOR OF 

EMBRYOTOXICITY IN IN VITRO TESTS. 

M. A. Sogorb, A. C. Romero, D. Pamies, C. Estevan 

and E. Vilanova. Unidad de Toxicología y Seguridad 

Química, Instituto de Bioingeniería, Universidad 

Miguel Hernández de Elche, Elche, Alicante, Spain. 


CO-CULTURE OF HUMAN DOPAMINERGIC 

NEURONS AND RAT GLIA CELLS AS 

IN VITRO MODEL FOR PARKINSONS 

DISEASE. S. Schildknecht, D. Poeltl and M. Leist. 

University of Konstanz, Konstanz, Germany. 


POPULATION-BASED QUANTITATIVE 

HIGH-THROUGHPUT SCREENING (QHTS) 

FOR CHEMICAL TOXICITY. S. O’Shea 1 , 

O. Kosyk 1 , N. Abdo 1 , E. Lock 1 , F. Wright 1 , R. 

Huang 2 , M. Xia 2 , C. Austin 2 , R. Tice 3 and I. Rusyn 1 . 

1 

Department of Environmental Sciences and 


Hill, Chapel Hill, NC, 2 NIH Chemical Genomics 

Center, NHGRI/NIH, Bethesda, MD and 3 National 

Toxicology Program, NIEHS/NIH, Research Triangle 

Park, NC. 


HIGH-THROUGHPUT SCREENING OF 

TOXCAST PHASE I CHEMICALS IN A 

MOUSE EMBRYONIC STEM CELL ASSAY 

REVEALS DISRUPTION OF POTENTIAL 

TOXICITY PATHWAYS. K. J. Chandler 1 , S. 

Hunter 1 , S. Jeffay 1 , H. Nichols 1 , M. Hoopes 1 , M. 

Barrier 1 , N. Sipes 1 , N. Kleinstreuer 1 , A. Singh 2 and 

T. Knudsen 1 . 1 U.S. EPA, Research Triangle Park, NC 

and 2 Lockheed Martin, Research Triangle Park, NC. 

Tuesday 







203



Tuesday 



EVALUATION OF A NOVEL CELL CULTURE 

EXPOSURE SYSTEM WITH CELL MODELS 

OF DIFFERENT COMPLEXITY. F. Glahn 1 , A. 

Rogers 2 , S. Kerwien 1 , J. Wiese 1 , S. Thomas 1 and H. 

W. Foth 1 . 1 Institute of Environmental Toxicology, 

Martin-Luther-University, Halle/Saale, Saxony- 

Anhalt, Germany and 2 TSE Systems GmbH, Bad 

Homburg, Germany. 


COMPARATIVE REPRODUCTIVE 

AND DEVELOPMENTAL TOXICITY 

OF AFLATOXIN B1 IN THE WILD 

TYPE AND MUTANTS OF NEMATODE 

CAENORHABDITIS ELEGANS. L. Tang 1 , 

S. Xue 2 , G. Qian 1 , H. Ma 1 , P. L. Williams 1 and J. 

Wang 1 . 1 Environmental Health Science, University 

of Georgia, Athens, GA and 2 University of Texas at 

Austin, Austin, TX. 


β-CATENIN ACTIVATION IS NECESSARY 

FOR SURVIVAL OF HUMAN BRONCHIAL 

EPITHELIAL CELLS EXPOSED TO 

CIGARETTE SMOKE CONDENSATE. W. W. 

Polk. Research and Development, Lorillard Tobacco 

Company, Greensboro, NC. Sponsor: C. Carter. 


MOLECULAR EFFECTS OF INORGANIC 

AND ORGANIC MERCURY IN 

CAENORHABDITIS ELEGANS AND HUMAN 

CELLS. M. K. McElwee and J. H. Freedman. 

NIEHS, Durham, NC. 


3D CELL CULTURE IMPROVES 

DETECTION OF OXAZOLIDIONE 

TOXICITY. J. Yang 1 , X. Xu 1 , K. Howe 2 , J. Dykens 2 

and Z. Cui 1 . 1 Department of Engineering Science, 

University of Oxford, Oxford, United Kingdom and 

2 

Drug Safety Research and Development, Pfizer, 

Sandwich, United Kingdom. Sponsor: M. Sharpe. 


NNK-INDUCED CYTOKINE ALTERATIONS 

IN LUNG SLICES FROM LEAN AND DIET- 

INDUCED OBESE C57BL/6J MICE. T. Liberati 

and M. Randle. Internal Medicine, Southern Illinois 

University School of Medicine, Springfield, IL. 


IRRITATION IN THE LLNA: 2000 MICE 

EAR THICKNESS MEASUREMENTS 

DEPENDENCE ON VEHICLE AND HCA 

TREATMENT. J. L. Moore, M. R. Carathers, 

D. R. Cerven and G. L. DeGeorge. MB Research 

Laboratories, Spinnerstown, PA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Alternatives to Mammalian Models for 

Testing 

Chairperson(s): Susan M. Bello, Jackson Laboratories, Bar Harbor, ME. 




THE CYTOTOXIC AND INFLAMMATORY 

RESPONSE OF BRONCHIAL EPITHELIAL 

CELLS EXPOSED TO CIGARETTE WHOLE 

SMOKE AND VAPOUR AT THE AIR-LIQUID 

INTERFACE. G. J. Phillips, L. E. Haswell, G. 

Foss-Smith, K. Hewitt, S. Corke, D. Azzopardi, 

M. D. Gaca and C. Meredith. Group R&D, British 

American Tobacco, Southampton, United Kingdom. 


THE USE OF IN VITRO TOXICITY DATA 

AND PHYSIOLOGICALLY BASED KINETIC 

MODELING TO PREDICT DOSE-RESPONSE 

CURVES FOR IN VIVO DEVELOPMENTAL 

TOXICITY OF GLYCOL ETHERS IN RAT 

AND MAN. J. Louisse 1,2,3 , E. de Jong 4,5 , J. J. van 

de Sandt 2 , B. J. Blaauboer 5 , R. A. Woutersen 1,2,3 , 

A. H. Piersma 4,5 , I. M. Rietjens 1,3 and M. Verwei 2,3 . 

1 

Division of Toxicology, Wageningen University, 

Wageningen, Netherlands, 2 TNO Quality of 

Life, Zeist, Netherlands, 3 WUR/TNO Centre for 

Innovative Toxicology, Wageningen, Netherlands, 

4 

National Institute of Public Health and the 

Environment (RIVM), Bilthoven, Netherlands and 

5 

Institute for Risk Assessment Sciences (IRAS), 

Utrecht University, Utrecht, Netherlands. 


EVALUATION OF MEDAKA AS AN ANIMAL 

MODEL TO STUDY AUTISM SPECTRUM 

DISORDER. M. Wu 2,1 , I. A. Khan 1 and A. K. 

Dasmahapatra 1,2 . 1 National Center for Natural 

Product Research, University of Mississippi, 

University, MS and 2 Department of Pharmacology, 

University of Mississippi, University, MS. 


CHLORPYRIFOS DISRUPTS THE 

BLOOD-BRAIN BARRIER BY ALTERING 

TIGHT JUNCTION AND TRANSIENT 

RECEPTOR POTENTIAL CHANNEL GENE 

EXPRESSIONS. W. Li and M. Ehrich. Virginia- 

Maryland Regional College of Veterinary Medicine, 

Virginia Tech, Blacksburg, VA. 


CAENORHABDITIS ELEGANS AS AN 

ALTERNATIVE MODEL TO EVALUATE 

NANOMATERIAL TOXICITY. L. Komatsu 1 , 

N. Olejnik 1 , K. M. Tyner 2 and R. L. Sprando 1 . 1 U.S. 

FDA, Laurel, MD and 2 U.S. FDA, CDER, Silver 

Spring, MD. Sponsor: T. Flynn. 

204 






Platform Sessions



Abstract # 


EFFECTS OF DIETARY PHENOLICS 

AND BOTANICAL EXTRACTS ON 

HEPATOTOXICITY-RELATED ENDPOINTS 

IN HUMAN AND RAT HEPATOMA CELLS 

AND STATISTICAL MODELS FOR 

PREDICTION OF HEPATOTOXICITY. Y. 

Liu 2 , T. Flynn 1 , M. Ferguson 3 , E. Hoagland 1 and L. 

Yu 2 . 1 Division of Toxicology, U.S. FDA, Laurel, MD, 

2 

Nutrition & Food Science, University of Maryland, 

College Park, MD and 3 Division of Public Health & 

Biostatistics, U.S. FDA, College Park, MD. 


EXPANDED PREVALIDATION FOR THE 

ISOLATED RABBIT EYE (IRE) ASSAY. F. 

Guerriero 1 , C. Seaman 2 , A. Whittingham 3 , A. Else 3 , 

E. Adriaens 4 , R. Guest 3 and M. Olson 1 . 1 H, S&P, 

GlaxoSmithKline, Research Triangle Park, NC, 2 H, 

S&P, GlaxoSmithKline, Ware, United Kingdom, 

3 

Harlan Laboratories, Shardlow, United Kingdom 

and 4 Adriaens Consulting, Aalter, Belgium. 


CYTOTOXICITY AND GENOTOXICITY OF 

PHENAZINE IN HUMAN CELL LINES. C. 

F. McGuigan 1 , S. Gabos 2 and X. Li 1 . 1 Division of 

Analytical & Environmental Toxicology, University 

of Alberta, Edmonton, AB, Canada and 2 Alberta 

Health and Wellness, Edmonton, AB, Canada. 

Sponsor: R. Bull. 


IN VITRO EXPOSURE OF 

ORGANOTYPICAL 3D EPITHELIAL 

TISSUES TO CIGARETTE SMOKE AS A 

POTENTIAL ALTERNATIVE TO RODENT 

INHALATION STUDIES. D. Weisensee, B. 

Kurkowsky, M. Hebestreit and S. Wagner. Philip 

Morris Research and Development, Philip Morris 

Research Laboratories GmbH, Cologne, Germany. 

Sponsor: E. Roemer. 


EVALUATION OF MALE RAT ENDOCRINE 

TOXICITY USING THE IN VITRO RAT 

TESTICULAR CELL LINE R2C. R. 

Kuk 1 , P. S. Giffen 2 , S. B. Laffan 1 and D. J. 

Stanislaus 1 . 1 Reproductive Toxicology, Safety 

Assessment, GlaxoSmithKline, King of Prussia, 

PA and 2 SA Pathology, Preclinical Development, 

GlaxoSmithKline, Ware, Hertfordshire, United 

Kingdom. 


THE DEVELOPMENT OF AN IN VITRO 

ASSAY TO PREDICT SKIN SENSITIZATION 

BASED ON ROS PRODUCTION. K. Saito, 

M. Miyazawa, Y. Nukada, H. Sakaguchi and N. 

Nishiyama. Kao Corporation, Tochigi, Japan. 

Sponsor: J. Avalos. 


A TIERED APPROACH COMBINING FOUR 

IN VITRO ASSAYS FOR PREDICTING EYE 

IRRITATION POTENTIAL OF CHEMICALS. 

K. Hayashi 1 , T. Abo 1 , K. Ooshima 2 , T. Hayashi 2 , T. 

Komano 2 , R. Fautz 3 , T. Simion 4 and H. Sakaguchi 1 . 

1 

Kao Corporation, Tochigi, Japan, 2 Kanebo 

Cosmetics Inc., Kanagawa, Japan, 3 Kao Professional 

Salon Services GmbH, Darmstadt, Germany and 

4 

Kao Brands Company, Cincinnati, OH. 

Abstract # 


TOWARDS ANIMAL-FREE TESTING 

FOR SKIN SENSITIZATION: IN-HOUSE 

VALIDATION OF FOUR METHODS: MUSST, 

H-CLAT, KERATINOSENS, AND DPRA. C. 

Bauch 1,2 , T. Eltze 1 , E. Fabian 1 , S. N. Kolle 1 , C. 

Pachel 1,3 , T. R. Hernandez 1 , B. Wiench 1,4 , C. J. 

Wruck 2 , R. Landsiedel 1 and B. van Ravenzwaay 1 . 

1 

Experimental Toxicology and Ecology, BASF 

SE, Ludwigshafen, Germany, 2 Department of 

Anatomy and Cell Biology, RWTH Aachen 

University, Aachen, Germany, 3 Technical University 

Kaiserslautern, Kaiserslautern, Germany and 4 Faculty 

of Chemistry, Pharmaceutics, and Geosciences, 

Johannes Gutenberg University Mainz, Mainz, 

Germany. Sponsor: A. Van Cott. 


ASSESSMENT OF AIRWAY GENOTOXICITY 

POTENTIAL USING THE EPIAIRWAY IN 

VITRO HUMAN AIRWAY MODEL AND 

THE COMET ASSAY. A. Armento, J. DeLuca, 

Y. Kaluzhny, H. Kandarova, M. Klausner and P. J. 

Hayden. MatTek Corp., Ashland, MA. 


APPLICATION OF PRECISION-CUT 

LIVER SLICES FOR THE INVESTIGATION 

OF XENOBIOTIC-INDUCED CELL 

PROLIFERATION. E. Fabian 1 , F. Schuck 2,1 , C. 

Jaeckh 1 , S. Groetters 1 , B. van Ravenzwaay 1 and R. 

Landsiedel 1 . 1 Expermental Toxicology and Ecology, 

BASF SE, Ludwigshafen, Germany and 2 Johannes 

Gutenberg-University, Mainz, Germany. 


EVALUATION OF XENOBOTIC 

METABOLISM IN HUMAN 

RECONSTRUCTED SKIN MODELS FOR 

GENOTOXICITY TESTING. C. Jaeckh 1 , 

V. Blatz 1 , E. Fabian 1 , K. Reisinger 2 , B. van 

Ravenzwaay 1 , S. Trappe 3 and R. Landsiedel 1 . 

1 


Ludwigshafen, Germany, 2 Henkel AG and Co., 

KGaA, Duesseldorf, Germany and 3 Bundesinstitut 

for Risikobewertung, Berlin, Germany. 


CUTANEOUS METABOLISM. J. Eilstein, G. 

Léreaux, J. Meunier, J. Leclaire and D. Duché. Life 

Sciences Research-Safety Research Department, 

L’Oréal Advance Research, Aulnay-sous-Bois, 

France. Sponsor: H. Toutain. 


ASSESSMENT OF COMBINATIONS 

OF ANTIANDROGENIC COMPOUNDS 

VINCLOZOLIN AND FLUTAMIDE IN A 

YEAST BASED REPORTER ASSAY. S. 

Kolle 1 , G. Krenrich 2 , B. van Ravenzwaay 1 and R. 

Landsiedel 1 . 1 BASF SE, Experimental Toxicology 

and Ecology, Ludwigshafen, Germany and 2 BASF 

SE, GVC/S Scientific Computing, Ludwigshafen, 

Germany. Sponsor: A. Doi. 


SCREENING FOR ENDOCRINE 

DISRUPTORS IN PRODUCT 

DEVELOPMENT: TIERED TESTING USING 

IN VITRO AND IN VIVO ASSAYS. B. van 

Ravenzwaay, S. Kolle, R. Buesen, H. Kamp and R. 

Landsiedel. BASF SE, Experimental Toxicology and 

Ecology, Ludwigshafen, Germany. Sponsor: A. Doi. 

Tuesday 







205



Tuesday 



THE KERATINOSENS ASSAY TO 

DETECT SKIN SENSITIZERS BASED ON 

NRF2-DEPENDENT GENE ACTIVITY: 

EXPLORING THE INTER-LABORATORY 

REPRODUCIBILITY AND THE 

APPLICABILITY DOMAIN. A. Natsch 1 , C. 

Bauch 2 , G. Ellis 1 , L. Foertsch 4 , F. Gerberick 4 , K. 

Norman 3 , R. Landsiedel 2 , S. Onken 5 , H. Reuter 5 , A. 

Schepky 5 and R. Emter 1 . 1 Givaudan Schweiz AG, 

Duebendorf, Switzerland, 2 BASF SE, Ludwigshafen, 

Germany, 3 The Institute for In Vitro Sciences, Inc. 

(IIVS), Gaithersburg, MD, 4 Procter & Gamble Inc., 

Cincinnati, OH and 5 Beiersdorf AG, Hamburg, 

Germany. 


THE MYELOID U937 SKIN SENSITIZATION 

TEST (MUSST) FOR THE PREDICTION 

OF SKIN SENSITIZATION POTENTIAL. 

J. Ovigne, C. Piroird, D. Verda, F. Rousset, S. 

Martinozzi-Teissier and J. Meunier. L’Oréal 

Research, Aulnay-sous-Bois, France. Sponsor: H. 

Toutain. 


IN VITRO GENE EXPRESSION PROFILING 

TO PREDICT SKIN SENSITIZING 

POTENTIAL. J. van der Veen 1,2 , J. Ezendam 1 , 

T. Pronk 1,2 , R. Vandebriel 1 , J. Pennings 1 and H. 

van Loveren 1,2 . 1 Laboratory for Health Protection 

Research, National Institute for Public Health 

and the Environment, Bilthoven, Netherlands and 

2 

Department of Health Risk Analysis and Toxicology, 

Maastricht University, Maastricht, Netherlands. 


COMPARATIVE INVESTIGATION OF 

PHOTOTOXICITY OF CHEMICAL 

COMPOUNDS BY USING THE STANDARD 

BALB 3T3 NRU PHOTOTOXICITY TEST 

AND A THREE-DIMENSIONAL HUMAN 

SKIN MODEL (EST 1000). A. Heppenheimer 

and A. H. Poth. Genetic and Alternative Toxicology, 

Harlan Cytotest Cell Research GmbH, Rossdorf, 

Germany. 


FUNCTIONAL IN VITRO ASSAYS 

OF DIFFERENT CELL SOURCES 

ARE ABLE TO PREDICT SPECIFIC 

IMMUNOSUPPRESSIVE PROPERTIES OF 

CHEMICAL COMPOUNDS. A. Fischer, L. 

Koeper and H. Vohr. Toxicology, Bayer Schering 

Pharmacology Wuppertal, Germany. Sponsor: H. 

Ellinger-Ziegelbauer. 


PRECISION-CUT LIVER SLICES AS AN EX 

VIVO MODEL TO STUDY IDIOSYNCRATIC 

HEPATOTOXICITY IN MOUSE AND 

HUMAN. M. Hadi 1 , Y. Chen 1 , M. Stitzinger 2 , H. 

Emmen 2 and G. Groothuis 1 . 1 Pharmacokinetics, 

Toxicology & Targeting, University of Groningen, 

Groningen, Netherlands and 2 Toxicology, NOTOX 

BV, s’-Hertogenbosch, Netherlands. Sponsor: A. 

Vickers. 


TRANSPORT OF CHLORPROMAZINE 

ACROSS CACO-2 CELLS AND MEASURING 

THE FREE CONCENTRATION BY ND-SPME. 

J. Broeders, B. Blaauboer and J. Hermens. Institute 

for Risk Assessment Sciences, Utrecht University, 

Utrecht, Netherlands. 


INTERNATIONAL VALIDATION STUDY 

OF AN IN VITRO CELL PROLIFERATION 

TEST METHOD FOR SCREENING 

POTENTIAL ESTROGENIC AGONISTS 

AND ANTAGONISTS IN MCF-7 CELLS. F. 

Deal 2 , W. Casey 1 , P. Ceger 2 , D. Allen 2 , C. Yang 3 , 

M. Nakamura 4 , H. Kojima 5 , A. Ono 5 , H. Yoon 6 , 

S. Han 7 and W. Stokes 1 . 1 NICEATM, NIEHS, 

Research Triangle Park, NC, 2 ILS, Inc., Research 

Triangle Park, NC, 3 CertiChem Inc., Austin, TX, 

4 

Hiyoshi Corp., Omihachiman, Japan, 5 JaCVAM, 

Tokyo, Japan, 6 NIFDS, KFDA, Seoul, Democratic 

People’s Republic of Korea and 7 KoCVAM, Seoul, 

Democratic People’s Republic of Korea. 


FINAL RESULTS OF AN INTERNATIONAL 

VALIDATION STUDY OF AN IN VITRO ER 

TA TEST METHOD IN BG-1 CELLS. W. 

Casey 1 , P. Ceger 2 , D. Allen 2 , G. Clark 3 , P. Pazos 4 , E. 

Grignard 4 , J. de Lange 4 , S. Bremer 4 , M. Nakamura 5 , 

H. Kojima 6 and W. Stokes 1 . 1 NICEATM, NIEHS, 

Research Triangle Park, NC, 2 ILS, Inc., Research 

Triangle Park, NC, 3 XDS, Inc., Durham, NC, 

4 

ECVAM, Ispra, Italy, 5 Hiyoshi Corp., Omihachiman, 

Japan and 6 JaCVAM, Tokyo, Japan. 


AFLATOXIN B 1 

INDUCED DNA DAMAGE 

IN TURKEY AND CHICKEN EGG FOETAL 

LIVER CELLS. J. G. Williams 1 , U. Deschl 2 and 

G. M. Williams 1 . 1 Department of Pathology, New 

York Medical College, Valhalla, NY and 2 Boehringer 

Ingelheim Pharmacology KG, Boehringer Ingelheim 

Pharmacology KG, Biberach/Riss, Germany. 


TRACE METALS ALTER HISTONE 

METHYLATION PATHWAYS IN MOUSE 

EMBRYONIC STEM CELLS. S. R. Gadhia and 

F. A. Barile. Pharmaceutical Sciences, St. John’s 

University College of Pharmacy, Queens, NY. 


MICRO ELECTRODE CHIP ASSAY (MEA) AS 

METHOD TO DETECT NEUROTOXICITY 

IN VITRO. S. Vogel 1 , A. Novellino 2 , E. De 

Franchi 2 , B. van Ravenzwaay 1 and R. Landsiedel 1 . 

1 


Ludwigshafen, Germany and 2 ETTs.r.l, Genova, Italy. 


EFFECT OF METALS ON β-ACTIN 

AND TOTAL PROTEIN SYNTHESIS 

IN CULTURED HUMAN INTESTINAL 

EPITHELIAL CELLS. A. R. Calabro and F. 

A. Barile. Pharmaceutical Sciences, St. John’s 

University College of Pharmacy, Queens, NY. 

206 






Platform Sessions



Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Reproductive Toxicology I 

Chairperson(s): Kembra Howdeshell, NIEHS, Research Triangle Park, 

NC. 




FETAL PHTHALATE SCREEN: 

ASSESSMENT OF SEVERAL PHTHALATE 

ESTERS (PE) ON FETAL RODENT 

TESTOSTERONE (T) PRODUCTION AND 

GENE EXPRESSION FOLLOWING IN 

UTERO EXPOSURE. C. Lambright 1 , J. Furr 1 , M. 

Cardon 1 , B. Hannas 2 , D. Bermudez 5 , N. Wrench 3 , 

V. Wilson 1 , P. Foster 4 and E. Gray, Jr 1 . 1 ORD/TAD, 

U.S. EPA, Durham, NC, 2 NRC Postdoctoral Fellow, 

Durham, NC, 3 Student Contractor, Durham, NC, 

4 

NTP, NIEHS, Durham, NC and 5 North Carolina 

State Postdoctoral, U.S. EPA, Durham, NC. 


DETERMINING ESTROGENIC 

ACTIVITY IN SERUM FROM 

OVARIECTOMIZED RATS TREATED WITH 

ENVIRONMENTAL COMPOUNDS USING 

AN IN VITRO ESTROGEN-MEDIATED 

TRANSCRIPTIONAL ACTIVATION ASSAY 

(T47D-KBLUC). N. Wrench 1,3 , L. Gray 1 , D. S. 

Bermudez 2 , J. Furr 1 and V. S. Wilson 1 . 1 NHEERL, 

TAD, U.S. EPA, Durham, NC, 2 Postdoctoral Fellow, 

North Carolina State University, Raleigh, NC and 

3 

Student Contractor, U.S. EPA, Durham, NC. 


REPRODUCTIVE ENDPOINTS OF 

FEMALE WISTAR RATS EXPOSED TO 

TESTOSTERONE IN UTERO AND DURING 

LACTATION. M. T. Guerra 1 , R. F. Silva 2 , M. 

Sanabria 2 , A. C. Gaspar 2 and W. G. Kempinas 2 . 

1 

Unicamp, Campinas, São Paulo, Brazil and 

2 

Morphology, Unesp, Botucatu, São Paulo, Brazil. 

Sponsor: S. Cohen. 


EFFECTS OF PREIMPLANTATION 

BISPHENOL-A EXPOSURE ON EMBRYO 

TRANSPORT, EMBRYO IMPLANTATION, 

AND POSTNATAL BODY WEIGHT IN 

C57BL6 MICE. X. Ye, S. Xiao, H. Diao and F. 

Zhao. University of Georgia, Athens, GA. 


CIGARETTE SMOKE EXPOSURE RESULTS 

IN SIGNIFICANT FOLLICLE LOSS VIA 

AN ALTERNATIVE OVARIAN CELL 

DEATH PATHWAY. A. M. Mulligan Tuttle 1 , 2 , 

M. Stämpfli 3 and W. G. Foster 2 . 1 Faculty of Health 

Sciences, McMaster University, Hamilton, ON, 

Canada, 2 Obstetrics and Gynecology, McMaster 

University, Hamilton, ON, Canada and 3 Pathology 

and Molecular Medicine, McMaster University, 

Hamilton, ON, Canada. 

Abstract # 


ASSESSING POTENTIAL NON-SPECIFIC 

IMMUNE-MEDIATED EFFECTS IN 

REPRODUCTIVE TOXICITY STUDIES 

WITH VACCINES. L. Segal 1 , D. Stannard 2 , D. 

Myers 2 , D. Morelle 1 , S. Veenstra 1 and B. Baras 1 . 

1 

GlaxoSmithKline Biologicals, Rixensart/Wavre, 

Belgium and 2 Huntingdon Life Sciences, Eye, 

Suffolk, United Kingdom. 


COMPARISON OF THE REPRODUCTIVE 

PERFORMANCE OF THE HARLAN AND 

CHARLES RIVER SPRAGUE-DAWLEY RAT. 

E. Mylchreest and K. K. Daniels. Southern Research, 

Birmingham, AL. 


DEVELOPMENTAL AND REPRODUCTIVE 

TOXICITY OF ISODECYL BENZOATE. 

K. L. Pavkov 1 and E. D. Sloter 2 . 1 Department 

of Toxicology and Environmental Sciences, 

ExxonMobil Biomedical Sciences, Inc., Annandale, 

NJ and 2 Developmental and Reproductive 

Toxicology, WIL Research Laboratories, LLC., 

Ashland, OH. 


EXTENDED ONE GENERATION 

REPRODUCTIVE TOXICITY TEST WITH 

LEAD ACETATE. R. Kubaszky 1 , D. J. Esdaile 1 , 

T. Hanley 2 , P. Maslej 1 , D. Minnema 2 , J. Wright 3 and 

R. Lewis 3 . 1 Lab. Research Ltd., Veszprem, Hungary, 

2 

Syngenta Crop Protection, LLC, Greensboro, NC 

and 3 Syngenta, Jealotts Hill, Bracknell, United 

Kingdom. 


DISTRIBUTION OF ATRAZINE (ATR) 

AND METABOLITES IN THE WISTAR 

RAT FOLLOWING GESTATIONAL/ 

LACTATIONAL EXPOSURES. T. E. Stoker 1 , 

A. Kamel 2 , Y. Qian 2 , L. Podhorniak 2 , R. Cooper 1 

and L. Strader 1 . 1 Endocrinology Branch, U.S. 

EPA, Research Triangle Park, NC and 2 Analytical 

Chemistry Branch, U.S. EPA, Ft. Meade, D.C. 


LOW-DOSE, GESTATIONAL EXPOSURE TO 

ATRAZINE DOES NOT ALTER POSTNATAL 

REPRODUCTIVE DEVELOPMENT OF 

MALE OFFSPRING. M. J. Fraites, D. S. Best, 

M. G. Narotsky and R. L. Cooper. Toxicology 

Assessment Division, NHEERL, ORD, U.S. EPA, 



BISPHENOL A INDUCES ATRESIA IN 

MOUSE ANTRAL FOLLICLES. J. Peretz, R. 

K. Gupta and J. A. Flaws. Comparative Biosciences, 

University of Illinois Urbana-Champaign, Urbana, 

IL. 

Tuesday 







207



Tuesday 



EVALUATION OF A COMBINED DERMAL 

DEVELOPMENTAL AND PERINATAL/ 

POSTNATAL REPRODUCTION TOXICITY 

STUDY OF PEA (PHENETHYL ALCOHOL) 

IN RATS—INCLUDING AN EXAMINATION 

SKELETAL VARIANTS POSTNATALLY. V. 

T. Politano 1 , E. M. Lewis 2 , A. M. Hoberman 2 , R. M. 

Diener 3 and A. Api 1 . 1 Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ, 2 Charles River 

Laboratories Preclinical Services, Horsham, PA and 

3 

Argus International, Inc., Horsham, PA. 


PREGNENOLONE CO-TREATMENT DOES 

NOT RESTORE GROWTH OF MOUSE 

ANTRAL FOLLICLES TREATED IN VITRO 

WITH THE MONO-HYDROXYLATED 

METABOLITE OF METHOXYCHLOR. Z. R. 

Craig, P. R. Hannon and J. A. Flaws. Comparative 

Biosciences, University of Illinois, Urbana, IL. 


DI-(2-ETHYLHEXYL) PHTHALATE AND 

MONO-(2-ETHYLHEXYL) PHTHALATE 

INHIBIT GROWTH OF OVARIAN ANTRAL 

FOLLICLES THROUGH AN OXIDATIVE 

STRESS PATHWAY. W. Wang, Z. R. Craig, M. 

S. Basavarajappa, R. K. Gupta and J. A. Flaws. 

Comparative Bioscience, University of Illinois, 

Urbana, Urbana, IL. 


METHOXYCHLOR ALTERS 

STEROIDOGENIC ENZYMES IN 

CULTURED MOUSE ANTRAL FOLLICLES. 

M. Basavarajappa, Z. Craig, B. Karman, W. Wang 

and J. Flaws. Comparative Biosciences, University 

of Illinois, Urbana, IL. 


ESTROGEN RECEPTOR ALPHA 

OVEREXPRESSING MOUSE OVARIES MAY 

BE SUSCEPTIBLE TO METHOXYCHLOR 

AND ITS METABOLITES BECAUSE 

OF REDUCED METABOLISM OF THE 

CHEMICALS. T. Paulose, I. Hernández-Ochoa, 

M. S. Basavarajappa, J. Peretz, Z. R. Craig and J. 

A. Flaws. Comparative Biosciences, University of 

Illinois Urbana-Champaign, Urbana, IL. 


MONO- AND DI-ESTER PHTHALATES 

ALTER TESTOSTERONE PRODUCTION 

IN MOUSE BLTK1 MURINE LEYDIG 

TUMOR CELLS. Q. Ding 1 , N. A. Rahman 2 , I. T. 

Huhtaniemi 2 and T. R. Zacharewski 1 . 1 Department of 

Biochemistry & Molecular Biology and Center for 


East Lansing, MI and 2 Department of Physiology, 

University of Turku, Turku, Finland. 


A STUDY OF FERTILITY IN SPRAGUE- 

DAWLEY RATS WITH XOMA 052, A NOVEL 

MONOCLONAL ANTIBODY TARGETING 

IL-1 BETA. C. Gasper 1 , B. Thorsrud 2 , J. 

Ma 1 , L. Cao 1 , K. Der 1 and K. Meyer 1 . 1 Product 

Development, XOMA (U.S.) LLC, Berkeley, CA and 

2 

Developmental & Reproductive Toxicology, MPI 



IMMUNOHISTOCHEMICAL AND CHIP 

MICROARRAY ANALYSIS OF PPARα 

IN FETAL RAT TESTES EXPOSED TO 

DIBUTYLPHTHALATE (DBP). S. M. Plummer 1 , 

D. Dan 1 , J. Quinney 1 , M. Millar 3 , M. Sheila 3 , N. 

Hallmark 2 , R. D. Phillips 2 and C. R. Elcombe 1 . 1 CXR 

Biosciences, Dundee, United Kingdom, 2 ExxonMobil 

Petroleum & Chemical, Hermeslaan, Belgium 

and 3 MRC Human Reproductive Sciences Unit, 

Edinburgh, United Kingdom. 


GESTATIONAL EXPOSURE TO ATRAZINE 

HAS LITTLE EFFECT ON FEMALE 

REPRODUCTIVE PARAMETERS IN 

SPRAGUE-DAWLEY (SD) RATS. L. K. Davis, 

A. S. Murr, T. E. Stoker, M. Narotsky, J. M. Goldman 

and R. L. Cooper. Endocrine Toxicology Branch, 



THE EFFECTS OF ENDOCRINE 

DISRUPTION ON THE DEVELOPING 

HUMAN FETAL PROSTATE. C. Saffarini, 

S. J. Hall and K. Boekelheide. Brown University, 



TWO-GENERATION REPRODUCTIVE 

TOXICITY STUDY OF ALUMINIUM 

SULFATE ADMINISTERED VIA DRINKING 

WATER TO RATS. M. Hirata-Koizumi 1 , S. 

Fujii 2 , A. Ono 1 , A. Hirose 1 , R. Hasegawa 1 , T. Imai 3 , 

K. Ogawa 1 , M. Ema 1 and A. Nishikawa 1 . 1 National 

Institute of Health Sciences, Tokyo, Japan, 2 Safety 

Research Institute for Chemical Compounds Co., 

Ltd., Sapporo, Japan and 3 Central Animal Laboratory, 

National Cancer Center Research Institute, Tokyo, 

Japan. 


APPLICATION OF IN VIVO AND IN 

VITRO TOOLS FOR DETECTION OF 

EMBRYOTOXICITY: THE EXAMPLE OF 

ARTEMISININ-TYPE COMPOUNDS. P. 

Colombo, M. Longo, S. Zanoncelli and M. Brughera. 

Preclinical Development, Accelera Srl, Nerviano - 

Milano, Italy. 


DEVELOPMENT OF REPRODUCTIVE 

ORGANS IN MALE CYNOMOLGUS 

MONKEYS. E. Haruyama 1,2 , Y. Ayukawa 1 , 

K. Kamura 1 , M. Mizutamari 1 , Y. Ooshima 1 , T. 

Sukamoto 1 , R. Nagata 1 and A. Tanimoto 2 . 1 Shin 

Nippon Biomedical Laboratories, Ltd., Kagoshima, 

Japan and 2 Kagoshima University, Kagoshima, 

Japan. 


INTERACTIONS OF ENDOCRINE 

DISRUPTING CHEMICALS WITH THE 

BCRP TRANSPORTER: POTENTIAL 

MECHANISM FOR DICTATING FETAL 

EXPOSURE. L. Aleksunes and X. Wen. 

Pharmacology & Toxicology, Rutgers University, 


208 






Platform Sessions



Abstract # 


THE EFFECTS OF TRIS (2-ETHYLHEXYL) 

TRIMELLITATE (TOTM) ON GENE 

EXPRESSION ASSOCIATED WITH 

TESTICULAR MAL-DEVELOPMENT (TMD) 

IN RAT FETAL TESTES. C. R. Elcombe 1 , D. 

Dan 1 , D. G. Farrar 2 and S. M. Plummer 1 . 1 CXR 

Biosciences, Dundee, United Kingdom and 2 INEOS 

Chlor Limited, Runcorn, United Kingdom. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Reproductive Toxicology II 

Chairperson(s): Cathy Yang, CertiChem, Inc., Austin, TX. 




EPIVAGINAL TISSUE MODEL FOR 

PRECLINICAL SCREENING OF SINGLE 

OR REPEAT EXPOSURE TO VAGINALLY 

APPLIED CHEMICALS/FORMULATIONS. 

C. Cannon, M. Klausner, S. Ayehunie, A. Wang, K. 

LaRosa and T. Landry. MatTek Corp, Ashland, MA. 

Sponsor: P. J. 


IVOS AND HISTOPATHOLOGY 

PROCEDURES FOR GLP-COMPLIANT 

TOXICOLOGY STUDIES IN NONHUMAN 

PRIMATES. R. E. Watson 1 , D. Thompson 1 , M. 

Novilla 1 , N. Makori 1 , R. Eyre 1 and R. Nagata 2 . 

1 

SNBL USA, Seattle, WA and 2 SNBL Laboratories, 

Kagoshima, Japan. 


GOLD NANOPARTICLE EFFECTS ON RAT 

OVARIAN GENE EXPRESSION. J. Larson 1,3 , 

M. J. Carvan III 2,3 , R. Klaper 2,3 and R. J. Hutz 1,3 . 

1 

University of Wisconsin Milwaukee, Milwaukee, 

WI, 2 University of Wisconsin Milwaukee Great 

Lakes WATER Institute, Milwaukee, WI and 3 NIEHS 

Children’s Environmental Health Sciences Core 

Center at University of Wisconsin Milwaukee and 

Medical College of Wisconsin, Milwaukee, WI. 


MONO-2-ETHYLHEXYL PHTHALATE 

INCREASES OXIDANT SPECIES 

PRODUCTION AND MODIFIES 

EXPRESSION OF REDOX-SENSITIVE 

GENES IN HUMAN PLACENTAL CELLS. L. 

M. Tetz and R. Loch-Caruso. Environmental Health 

Sciences, University of Michigan School of Public 

Health, Ann Arbor, MI. 


RELATIONSHIP BETWEEN LOW 

METABOLIC CAPABILITY OF LIGNANS 

AND IDIOPATHIC MALE INFERTILITY. Y. 

Xia, P. Zhu, M. Chen, C. Lu, S. Wang and X. Wang. 

Institute of Toxicology, Nanjing Medical University, 

Nanjing, China. 

Abstract # 


INHIBITION OF OVARIAN KIT 

AUTOPHOSPHORLATION BY THE 

OVOTOXICANT 4-VINYLCYCLOHEXENE 

DIEPOXIDE. C. J. Kappeler 1 , L. McKee 1 , I. 

Sipes 2 , J. Konhilas 1 and P. B. Hoyer 1 . 1 Physiology, 

University of Arizona, Tucson, AZ and 

2 

Pharmacology, University of Arizona, Tucson, AZ. 


A DOSE-RESPONSE STUDY FOLLOWING 

LATE GESTATIONAL EXPOSURE TO 

THE PHTHALATE METABOLITE, 

MONO-2-ETHYLHEXYL PHTHALATE 

(MEHP): EFFECTS ON FEMALE MOUSE 

REPRODUCTIVE DEVELOPMENT. B. 

J. Moyer and M. L. Hixon. Brown University, 



TETRABROMOBISPHENOL A STIMULATES 

SECRETION OF INTERLEUKIN 6 

FROM HUMAN FIRST TRIMESTER 

TROPHOBLASTS. P. W. Kimani and R. Loch- 

Caruso. Environmental Health Sciences, University 

of Michigan, Ann Arbor, MI. 


OXIDANT-INDUCED INFLAMMATORY 

RESPONSE IN HUMAN PLACENTAL CELLS 

IS DEPENDENT ON MITOGEN ACTIVATED 

PROTEIN KINASES (MAPKS). C. S. Korte 

and R. Loch-Caruso. Environmental Health Science, 



REGULATION OF HUMAN PLACENTAL 

DRUG TRANSPORTERS IN RESPONSE TO 

BACTERIAL CELL WALL COMPONENTS. 

L. Yacovino 1 , A. Vetrano 2 , N. Hanna 3 and L. M. 

Aleksunes 1 . 1 Pharmacology & Toxicology, Rutgers 

University, Piscataway, NJ, 2 Pediatrics, University 

of Medicine and Dentistry of New Jersey, New 

Brunswick, NJ and 3 Pediatrics, Winthrop University 

Hospital, Mineola, NY. 


ALCOHOL DRINKING-PROMOTED 

ACETALDEHYDE ACCUMULATION AND 

OXIDATIVE STRESS IN RAT TESTES. G. 

D. Castro, L. N. Quintans, F. M. Bietto, M. I. Díaz 

Gómez and J. A. Castro. CEITOX, CONICET- 

UNSAM, San Martín, Buenos Aires, Argentina. 


NONHUMAN PRIMATE POSTNATAL 

DEVELOPMENT: HISTORICAL CONTROL 

DATA IN NONCLINICAL TOXICOLOGY 

STUDIES. N. Lalayeva 1 , J. Kenfield 1 , J. Cowan 2 , 

S. Oneda 1 , N. Makori 1 , R. Eyre 1 , H. Tsusaki 1 and R. 

Nagata 3 . 1 SNBL USA, Ltd., Everett, WA, 2 Consultant 

for NHP Infant Behavior, San Francisco, CA and 

3 

Shin Nippon Biomedical Laboratories, Ltd., 

Kagoshima, Japan. 


MENSTRUAL CYCLE AND SERUM 

HORMONE DATA IN MATURE 

CYNOMOLGUS MONKEYS. S. Oneda 1 , N. 

Lalayeva 1 , R. Watoson 1 , N. Makori 1 , R. Eyre 1 , H. 

Tsusaki 1 and R. Nagata 2 . 1 SNBL USA, Ltd., Everett, 

WA and 2 Shin Nippon Biomedical Laboratories, Ltd., 

Tokyo, Japan. 

Tuesday 







209



Tuesday 



ESTROGENIC IMPACTS OF A STANDARD 

RODENT CHOW DIET ON RAT 

REPRODUCTION AND DEVELOPMENT. H. 

Aoyama 1 , K. L. Takahashi 1 , N. Endo 1 , A. Sato 1 , M. 

Araki 1 , M. Harigae 1 , M. Mitsutani 1 , C. Urakawa 1 , 

T. Nakamura 1 , N. Sakai 1 , K. Sakasai 1 , S. Teramoto 1 , 

F. Horio 2 , A. Murai 2 , M. Kobayashi 2 and H. Hojo 1 . 

1 

Toxicology Division, Institute of Environmental 

Toxicology, Joso, Japan and 2 Graduate School 

of Bioagricultural Sciences, Nagoya University, 

Nagoya, Japan. Sponsor: M. Kuwagata. 


EFFECTS OF NEONATAL BISPHENOL-A 

EXPOSURE ON PERIPUBERTAL 

DEVELOPMENT OF FEMALE RAT 

HYPOTHALAMUS. S. M. Losa, K. L. Todd, K. 

McCaffrey, M. Radford and H. B. Patisaul. Biology, 

North Carolina State University, Raleigh, NC. 


IMPACT OF NEONATAL BPA EXPOSURE 

ON SEXUALLY DIMORPHIC GENE 

EXPRESSION IN THE POSTNATAL RAT 

HYPOTHALAMUS. J. Cao, J. A. Mickens, K. 

McCaffrey, K. L. Todd and H. Patisaul. Biology, 


Sponsor: G. LeBlanc. 


BENZO(A)PYRENE-INDUCED OVARIAN 

DYSFUNCTION RESULTS FROM 

SUPPRESSED E 2 

SYNTHESIS. A. E. 

Archibong 1 , A. Ramesh 2 , M. S. Niaz 2 and D. J. 

Alcendor 3 . 1 Physiology, Meharry Medical College, 

Nashville, TN, 2 Biochemistry & Cancer Biology, 

Meharry Medical College, Nashville, TN and 

3 

Microbiology and Center for Health Disparities 

Research in HIV, Meharry Medical College, 



IN UTERO EXPOSURE TO DIBUTYL 

PHTHALATE ALTERS GENE EXPRESSION 

LEVELS IN THE FETAL RAT FORESKIN. 

J. Pike, S. McCahan and K. Johnson. Nemours 

Biomedical Research, Alfred I. duPont Hospital for 

Children, Newark, DE. 


INHALED CADMIUM OXIDE (CDO) 

NANOPARTICLES (NP) REACHES THE 

PLACENTA AND DECREASES PREGNANCY 

INCIDENCE AND GROWTH RATES IN 

NEONATAL OFFSPRING IN FEMALE MICE. 

L. K. Rosenblum, J. L. Blum, J. Q. Xiong and J. T. 

Zelikoff. College of Medicine, New York University, 

Tuxedo, NY. 


A MECHANISTIC APPROACH TO 

THE ROLE OF TRIBUTYLTIN IN THE 

DEVELOPMENT OF MALE-TYPE GENITAL 

ORGANS IN FEMALE QUEEN CONCH 

(STROMBUS GIGAS). O. S. Phillip 2,1 , K. 

Thomas 3 , C. O’Neal 1 and W. Gray 2 . 1 Marine Biology, 

H. Lavity Stoutt Community College, Road Town, 

Tortola, BVI, United Kingdom, 2 Chemistry, Southern 

University and A&M College, Baton Rouge, LA and 

3 

Center for Environment, Fisheries and Aquaculture 

Science, Burnham on Crouch, Essex, United 

Kingdom. 


TOXICOGENOMIC RESOLUTION OF 

EARLY BIOMARKERS FOR LATER LIFE 

DISEASE ONSET RELATED TO CANCER, 

PRO-INFLAMMATORY DISORDERS, AND 

OBESITY IN MICE EXPOSED IN UTERO TO 

MAINSTREAM CIGARETTE SMOKE. J. L. 

Blum 1 , K. Sexton 2 , C. Hoffman 1 , K. BéruBé 2 and J. 

T. Zelikoff 1 . 1 Environmental Medicine, New York 

University School of Medicine, Tuxedo, NY and 

2 

School of Biosciences, Cardiff University, Wales, 



FOXO1 ASSOCIATED P27KIP1 DECREASE 

IS ESSENTIAL FOR FENVALERATE- 

INDUCED CELL GROWTH IN HUMAN 

UTERINE LEIOMYOMA (UTLM) AND 

SMOOTH MUSCLE CELLS (UTSMCS). X. 

Gao, L. Yu, L. Castro, A. B. Moore, M. I. Sifre, C. 

D. Bortner and D. Dixon. NIEHS, Research Triangle 

Park, NC. 


INVESTIGATING THE IMPACT OF 

CHRONIC HERBICIDE EXPOSURE ON 

SEXUAL DEVELOPMENT IN ZEBRAFISH. 

M. M. Corvi 1 , K. A. Stanley 1 , J. K. LaDu 1 , T. S. 

Peterson 3 , S. W. Feist 2 , M. L. Kent 2,4 and R. L. 

Tanguay 1 . 1 Environmental and Molecular Toxicology, 

Oregon State University, Corvallis, OR, 2 Weymouth 

Laboratory, Centre for Environment, Fisheries & 

Aquaculture Science, Weymouth, United Kingdom, 

3 

Microbiology, Oregon State University, Corvallis, 

OR and 4 Environmental Health Sciences Center, 

Oregon State University, Corvallis, OR. 


CIGARETTE SMOKE CONDENSATE 

INHIBITS FOLLICULAR DEVELOPMENT, 

OOCYTE MATURATION AND 

DYSREGULATES STEROIDS SYNTHESIS 

IN VITRO : IMPLICATIONS FOR HUMAN 

FECUNDITY. J. Sadeu and W. G. Foster. 

Department of Obstetrics and Gynecology, McMaster 

University, Hamilton, ON, Canada. 


TREATMENT OF CAENORHABDITIS 

ELEGANS WITH GLYPHOSATE SUGGESTS 

DEVELOPMENTAL AND REPRODUCTIVE 

TOXICITY. M. B. Johnson and V. A. Fitsanakis. 

Biology, King College, Bristol, TN. 


MITOGENIC AND APOPTOTIC 

INTERACTIONS OF BENZO[A]PYRENE 

IN JEG3 HUMAN TROPHOBLAST CELLS: 

IMPLICATIONS FOR INTRAUTERINE 

GROWTH RESTRICTION. I. N. Olomu and B. 

V. Madhukar. Pediatrics and Human Development, 

Michigan State University, East Lansing, MI. 


CARBON MONOXIDE TOXICITY AND 

THE MATERNAL-FETAL ENVIRONMENT. 

T. Dodd-Butera 1 and M. Broderick 2 . 1 Nursing, 

California State University San Bernardino, College 

of Natural Sciences, San Bernardino, CA and 

2 

California Poison Control System, San Diego, CA. 

210 






Platform Sessions



Abstract # 


CHARACTERIZATION OF A NOVEL 

SERIES OF ENDOTHELIN-A RECEPTOR 

ANTAGONISTS IN THE SETTING OF 

INFECTION ASSOCIATED PRETERM 

BIRTH. N. S. Olgun, H. J. Patel, R. A. Stephani 

and S. E. Reznik. Pharmaceutical Science, St. John’s 

University, Jamaica, NY. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Hepatotoxicity 

Chairperson(s): Angela Slitt, University of Rhode Island, Kingston, RI. 




AFFECTS OF ALCOHOL CIRRHOSIS AND 

DIABETES ON DRUG TRANSPORTER 

EXPRESSION IN HUMAN LIVER. V. R. More 1 , 

Z. Lu 2 , N. Cherrington 3 and A. Slitt 1 . 1 Biomedical and 

Pharmaceutical Sciences, University of Rhode Island, 

Kingston, RI, 2 Statistical Consulting Laboratory, 

University of Arizona, Tucson, AZ and 3 Department 




PERINATAL BISPHENOL A (BPA) 

EXPOSURE ALTERS LIVER ATP-BINDING 

CASSETTE (ABC) TRANSPORTER 

EXPRESSION IN MICE. A. C. Donepudi 1 , M. 

Meloon 1 , P. T. Sieli 3 , C. S. Rosenfeld 2 and A. L. Slitt 1 . 

1 

Department of Biomedical and Pharmaceutical 

Sciences, University of Rhode Island, Kingston, RI, 

2 

Department of Biomedical Sciences, University of 

Missouri, Columbia, MO and 3 Bond Life Sciences 

Center, University of Missouri, Columbia, MO. 


OPPOSING EFFECTS OF DIABETES 

AND PREGNANCY ON HEPATOBILIARY 

EFFLUX TRANSPORTER EXPRESSION. A. 

L. Slitt 1 , J. Xu 1 and L. M. Aleksunes 2 . 1 Biomedical 

and Pharmaceutical Sciences, University of Rhode 

Island, Kingston, RI and 2 Pharmacology and 



EFFECT OF TROGLITAZONE (TRO) 

ON ENDOGENOUS BILE ACID (BA) 

DISPOSITION IN RAT AND HUMAN 

SANDWICH-CULTURED HEPATOCYTES 

(SCH). T. Marion 1 , C. Perry 2 , R. L. St. Claire 

III 2 and K. Brouwer 1,3 . 1 Curriculum in Toxicology, 


Hill, NC, 2 Qualyst, Inc., Research Triangle Park, NC 

and 3 Eshelman School of Pharmacy, University of 

North Carolina at Chapel Hill, Chapel Hill, NC. 

Abstract # 


EFFECTS OF SEEDING DENSITY AND DAYS 

IN CULTURE ON BILE ACID TRANSPORT 

AND Mrp4 EXPRESSION IN SANDWICH- 

CULTURED MOUSE HEPATOCYTES ARE 

NOT A RESULT OF OXIDATIVE STRESS. B. 

C. Ferslew 1 , X. Gu 2 , B. Swift 3 , J. E. Manautou 2 and 

K. L. Brouwer 1 . 1 Eshelman School of Pharmacy, 


Hill, NC, 2 Department of Pharmaceutical Sciences, 

University of Connecticut, Storrs, CT and 3 PKPD 

and Drug Metabolism, Allergan, Inc., Irvine, CA. 


THE CELL SURFACE MARKER CD90 

IDENTIFIES A SUBSET OF HEPATOCYTES 

PRIMED FOR INCREASED MATRIX 

PRODUCTION: IMPLICATIONS FOR 

ETHANOL-INDUCED LIVER FIBROSIS. 

B. A. Hocevar, Z. Wang and L. M. Kamendulis. 

Department of Environmental Health, Indiana 

University, Bloomington, IN. 


INVESTIGATING ER STRESS PATHWAY 

ACTIVATION IN LIVER CELLS AND TISSUE 

AS A TOXICOLOGICAL TOOL. M. Lafleur, 

R. Hernandez and J. W. Lawrence. Investigative 

Toxicology, Amgen, Thousand Oaks, CA. Sponsor: 

S. Sawant. 


PROFILING IMPAIRED HEPATIC 

ENDOPLASMIC RETICULUM 

GLYCOSYLATION AS A CONSEQUENCE 

OF ETHANOL INGESTION. J. Galligan 1 , K. 

S. Fritz 2 , H. Tipney 1 , R. L. Smathers 2 , C. T. Shearn 2 , 

L. J. Hunter 1 and D. R. Petersen 2 . 1 Pharmacology, 

University of Colorado Denver, Aurora, CO and 

2 

Toxicology, University of Colorado Denver, Aurora, 

CO. 


CO-INVOLVEMENT OF MITOCHONDRIA 

AND ENDOPLASMIC RETICULUM IN 

ACROLEIN-INDUCED HEPATOCYTE 

APOPTOSIS. D. Avila 1 , J. Zhang 1 , C. McClain 1,2 , 

S. Barve 1 and S. Joshi-Barve 1 . 1 Department of 

Medicine/GI, University of Louisville, Louisville, 

KY and 2 Robley Rex Veterans Administration 

Medical Center, Louisville, KY. 


FRUCTOSE INDUCES URIC ACID 

GENERATION AND MITOCHONDRIAL 

DYSFUNCTION IN LIVER CELLS DURING 

THE DEVELOPMENT OF METABOLIC 

SYNDROME. M. A. Lanaspa, L. G. Sanchez- 

Lozada, C. A. Roncal-Jimenez, N. Li, C. Cicerchi 

and R. J. Johnson. Renal Medicine, University of 

Colorado AMC, Denver, CO. 


DIBENZOFURAN EXPOSURE AFFECTS 

MITOCHONDRIAL PERMEABILITY 

TRANSITION INDUCTION. C. M. Palmeira, 

F. V. Duarte, A. P. Gomes, A. M. Simões, A. T. 

Varela, J. S. Teodoro and A. P. Rolo. Center for 

Neurosciences and Cell Biology, Department of Life 

Sciences, University of Coimbra, Coimbra, Portugal. 

Tuesday 







211



Tuesday 



REGULATION OF LIVER FLAVIN- 

CONTAINING MONOOXYGENASE 3 (FMO3) 

GENE EXPRESSION UNDER OXIDATIVE 

STRESS CONDITIONS. S. Rudraiah 1 , X. Gu 1 , L. 

M. Aleksunes 2 , S. Campion 1 , R. N. Hines 3 and J. E. 

Manautou 1 . 1 Department of Pharmaceutical Sciences, 

University of Connecticut, Storrs, CT, 2 Department 

of Pharmacology & Toxicology, Rutgers University, 

Piscataway, NJ and 3 Department of Pediatrics, 

Medical College of Wisconsin, Milwaukee, WI. 


PFOA-INDUCED LIVER EFFECTS IN CD-1 

AND PPAR-ALPHA KNOCK-OUT C57BL/6 

MICE. A. J. Filgo 1,2 , M. J. Hoenerhoff 2 , G. E. 

Kissling 2 , S. S. White 2 , E. P. Hines 3 , J. P. Stanko 2 

and S. E. Fenton 2 . 1 Toxicology, University of North 

Carolina at Chapel Hill, Chapel Hill, NC, 2 CMPB, 

NTP, NIEHS, Research Triangle Park, NC and 

3 

NCEA, ORD, U.S. EPA, Research Triangle Park, 

NC. 


INVOLVEMENT OF CONSTITUTIVE 

ANDROSTANE RECEPTOR (CAR) IN THE 

PROCESS OF LIVER HYPERTROPHY AND 

HEPATOCARCINOGENESIS-INDUCED 

BY CYP2B-INDUCING NON-GENOTOXIC 

HEPATOCARCINOGENS IN MICE (1). Y. 

Sakamoto 1 , M. Yoshida 1 , K. Inoue 1 , M. Takahashi 1 , Y. 

Taketa 1 , S. Hayashi 1 , S. Ozawa 2 and A. Nishikawa 1 . 

1 

Division Pathology, NIHS, Setagaya, Tokyo, 

Japan and 2 School of Pharmacology, Iwate Medical 

University, Morioka, Iwate, Japan. 


EXPOSURE TO TCDD INCREASES HEPATIC 

STELLATE CELL PROLIFERATION AND 

ACTIVATION. W. A. Harvey, C. J. Doolittle and 

K. A. Mitchell. Biology, Boise State University, 

Meridian, ID. 


DETERMINATION OF IN VIVO KUPFFER 

CELL FUNCTIONS BY CONTRAST 

ENHANCED ULTRASOUND (CEUS) 

IMAGING. V. Joaquin 1 , T. Tomoo 1 , E. Skuba 5 , 

T. Wang 3 , V. Richard 4 , S. Chibout 2 , F. Pognan 2 , N. 

Shangari 1 and A. Wolf 2 . 1 iTOX, Preclinical Safety 

(PCS), Novartis Institutes of Biomedical Research 

(NIBR), East Hanover, NJ, 2 iTOX, PCS, NIBR, 

Basel, Switzerland, 3 PCS, NIBR, Emmeryville, CA, 

4 

iTOX, PCS, NIBR, Cambridge, MA and 5 PCS, 

NIBR, East Hanover, NJ. 


TCDD ENHANCES THE RESPONSE 

OF INNATE IMMUNE CELLS TO 

CONCANAVALIN A ADMINISTRATION. 

A. M. Fullerton, R. A. Roth and P. E. Ganey. 

Department Pharmacology & Toxicology, Center for 




A MICROPATTERNED HUMAN 

HEPATOCYTE CO-CULTURE MODEL 

ALLOWS DETERMINATION OF TOXICITY 

AT MORE RELEVANT CONCENTRATIONS 

THAN HEPATOCYTE SANDWICH 

CULTURES. D. Keller 1 , S. Krzyzewski 2 and S. 

Khetani 2 . 1 Preclinical Safety, sanofi-aventis U.S., 

Malvern, PA and 2 Hepregen Corp., Medford, MA. 


DEVELOPMENT OF AN IN VITRO 

HEPATOCYTE MODEL TO INVESTIGATE 

CHEMICAL MODE OF ACTION. S. D. Hester 1 , 

J. Harrill 1 , C. Corton 1 and L. Murphy 2 . 1 Systems 

Biology Branch, U.S. EPA, Durham, NC and 

2 

Carcinogenesis, U.S. EPA, Durham, NC. 


QUANTITATIVE (Q)PCR ANALYSIS OF 

RNA EXTRACTED FROM FORMALIN- 

FIXED PARAFFIN EMBEDDED (FFPE) 

LIVER FROM AFLATOXIN B1 (AFB1) 

TREATED RATS: CORRELATION WITH 

MICROARRAY DATA. B. A. Merrick, S. S. 

Auerbach, P. S. Stockton, J. F. Foley, D. E. Malarkey, 

R. C. Sills, R. D. Irwin and R. R. Tice. National 

Toxicology Program, NIEHS/NIH, Research Triangle 

Park, NC. 


SIMILARITIES AND DIFFERENCES IN THE 

EXPRESSION OF DRUG METABOLIZING 

ENZYMES BETWEEN HUMAN HEPATIC 

CELL LINES AND PRIMARY HUMAN 

HEPATOCYTES. L. Guo, S. Dial, L. Shi, W. 

Branham, J. Fang, B. Green, J. Kaput and B. Ning. 



ENHANCEMENT OF NATURALLY 

OCCURRING BASOPHILIC FOCI IN THE 

LIVERS OF HAN WISTAR RATS TREATED 

WITH AZD9056. P. A. Duffy, J. G. Evans, P. 

J. Kerry, M. O’Donovan, M. Coulson and H. 

Powell. Global Safety Assessment, AstraZeneca, 

Macclesfield, Cheshire, United Kingdom. 


THE EFFECT OF VITAMIN E DEFICIENCY 

ON D.C.A- AND TCA-INDUCED OXIDATIVE 

STRESS IN THE LIVERS OF MALE B6C3F1 

MICE FOLLOWING SUBCHRONIC 

EXPOSURE. J. Cearfoss and E. Hassoun. 

Pharmacology, University of Toledo, Toledo, OH. 


O- AND N-DEMETHYLATION OF 

LEVOMETHORPHAN BY HUMAN 

CYTOCHROME P450 ENZYMES. M. 

Sunouchi 1 , A. Miyajima-Tabata 2 , R. Kikura-Hanajiri 3 

and Y. Goda 3 . 1 Division of Pharmacology, National 

Institute of Health Sciences, Tokyo 158-8501, Japan, 

2 

Division of Medical Devices, National Institute 

of Health Sciences, Tokyo 158-8501, Japan and 

3 

Division of Pharmacognosy and Phytochemistry, 

National Institute of Health Sciences, Tokyo 158- 

8501, Japan. Sponsor: A. Hirose. 

212 






Platform Sessions



Abstract # 


EFFECT OF ACARBOSE ON ALANINE 

AMINOTRANSFERASE 1 AND 2 PROTEINS 

AND GLUCONEOGENESIS IN RAT TISSUES. 

K. Kumagai, S. Arakawa, T. Matsuyama, K. Kai, 

M. Teranishi and A. Sanbuissho. Medicinal Safety 

Research Laboratories, Daiichi Sankyo Co., Ltd., 

Shizuoka, Japan. 


ENZYMES AND OXIDATIVE DAMAGE 

INDICATORS IN RATS FOLLOWING 

SUBACUTE OR SUBCHRONIC 

MANGANESE CHLORIDE EXPOSURE. 

P. Huang 1 , G. Li 2 and Z. Sun 1 . 1 Department of 

Toxicology and Sanitary Chemistry, School of 

Public Health and Family Medicine, Capital Medical 

University, Beijing, China and 2 Beijing Research 

Center for Preventive Medicine, Beijing, China. 

Sponsor: W. Zheng. 


THE ROLE OF 3, 3’, 4, 4’, 

5-PENTACHLOROBIPHENYL (PCB 126) 

IN COPPER DISPOSITION IN RODENT 

LIVER. M. Li 1,2 , I. Lai 1,2 , B. Wels 3 , D. Simmons 3 , 

G. Ludewig 1,2 and L. Robertson 1,2 . 1 Interdisciplinary 

Program in Human Toxicology, University of Iowa, 

Iowa City, IA, 2 Occupation and Environmental 

Health, University of Iowa, Iowa City, IA and 3 State 

Hygienic Laboratory, University of Iowa, Iowa City, 

IA. 


ENTEROHEPATIC CIRCADIAN RHYTHM 

IN MICE: CONTRIBUTIONS OF BILE 

ACIDS. Y. J. Zhang, G. L. Guo and C. D. Klaassen. 



KS. 


MYELOPEROXIDASE-DEPENDENT 

METABOLISM OF P-CRESOL: A NOVEL 

PATHWAY FOR XENOBIOTIC AND 

ENDOBIOTIC BIOTRANSFORMATION 

DURING INFLAMMATION. J. Houghton 1 , K. 

Hayakawa 1 , D. DeGroot 2 , B. Zhao 2 , M. Denison 2 

and J. P. Eiserich 1 . 1 Department of Internal 

Medicine, University of California Davis, Davis, 

CA and 2 Department of Environmental Toxicology, 



TOXICITY, TOXICOGENOMIC, 

AND METABOLOMIC STUDY OF 

PENTAMETHYLCHROMANOL. T. Parman 1 , 

D. Bunin 1 , H. H. Ng 1 , T. Harrison 1 , J. McDunn 2 , I. 

M. Kapetanovic 3 and C. E. Green 1 . 1 Biosciences, 

SRI International, Menlo Park, CA, 2 Metabolon, 

Inc., Durham, NC and 3 National Cancer Institute, 

Bethesda, MD. 


EVIDENCE OF PEPPERMINT OIL SKIN 

PENETRATION AND CYTOTOXICITY ON 

RAT HEPATOCYTES IN VITRO. M. Dong 1 , 

O. Weber 1 , E. Di Lenarda 1 , P. End 2 , S. Chibout 1 , A. 

Wolf 1 and F. Pognan 1 . 1 Preclinical Safety, Novartis, 

Basel, Switzerland and 2 Drug Metabolism and 

Pharmacokinetics, Novartis, Basel, Switzerland. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Cholestasis, Lipid Homeostasis, and Liver 

Toxicity 

Chairperson(s): Rhiannon Hardwick, University of Arizona, Tucson, AZ. 




MOLECULAR MECHANISM OF ALTERED 

EZETIMIBE DISPOSITION IN NON- 

ALCOHOLIC STEATOHEPATITIS. R. N. 

Hardwick, C. D. Fisher, S. M. Street, M. J. Canet and 

N. J. Cherrington. Pharmacology and Toxicology, 



DIETARY N-ACETYLCYSTEINE (NAC) 

REDUCES HEPATOCELLULAR LIPID 

ACCUMULATION FOLLOWING 3, 3’, 4, 4’, 

5-PENTACHLOROBIPHENYL (PCB 126) 

EXPOSURE. I. Lai 1,2 , A. Olivier 3 , M. Li 1,2 , K. 

Dhakal 1,2 and L. Robertson 1,2 . 1 Occupation and 

Environmental Health, University of Iowa, Iowa 

City, IA, 2 Interdisciplinary Program in Human 

Toxicology, University of Iowa, Iowa City, IA and 

3 

Department of Pathology, University of Iowa, Iowa 

City, IA. 


SERUM CYTOKERATIN 18 AND 

CYTOKINE ELEVATIONS SUGGEST A 

HIGH PREVALENCE OF OCCUPATIONAL 

LIVER DISEASE IN ELASTOMER / 

POLYMER WORKERS HIGHLY-EXPOSED 

TO ACRYLONITRILE, BUTADIENE, 

AND STYRENE. M. Cave 1,2 , K. Falkner 1 , B. 

Costello 1 , B. Gregory 1 , L. Henry 1 and C. McClain 1,2 . 

1 

Department of Medicine/GI, University of 




MITOCHONDRIAL TOXICITY OF 

CHLOROACETALDEHYDE IN HEPG2 

CELLS. K. Falkner 1 , B. Hill 1 , B. Sansbury 1 , J. 

Gaurdiola 1 , C. McClain 2 and M. Cave 2 . 1 Department 

of Medicine/GI, University of Louisville, Louisville, 

KY and 2 Louisville VA Medical Center, Louisville, 

KY. 


HGF ALTERED RESPONSE IN 

HIGH CHOLESTEROL FEED MICE 

HEPATOCYTES. M. Dominguez, N. Nuño, D. 

Clavijo, C. Enriquez, V. Souza, L. Bucio, L. Gomez 

Quiroz and C. Gutierrez-Ruiz. Health Sciences, 

Universidad Autónoma Metropolitana Iztapalapa, 

Mexico, Mexico. 

Tuesday 







213



Tuesday 



NRF2 ACTIVATION PROMOTES 

HYPERCHOLESTEROLEMIA AND 

GALLSTONE FORMATION. M. A. Paranjpe 1 , 

Q. Cheng 1 , J. Moscovitz 1 , D. Ajay 1 , M. Yamamoto 2 

and A. Slitt 1 . 1 Biomedical and Pharmaceutical 

Sciences, University of Rhode Island, Kingston, 

RI and 2 Medical Biochemistry, Tohoku University, 

Sendai, Miyagi, Japan. 


NRF2 PROTECTS MOUSE LIVER 

FROM OXIDATIVE INJURY AND 

STEATOHEPATITIS INDUCED BY 

PERSISTENT ACTIVATION OF AHR. H. Lu 

and C. D. Klaassen. University of Kansas Medical 



TCDD EFFECTS ON HEPATIC LIPID 

COMPOSITION IN MICE. M. M. Angrish 1,2 , 

B. D. Mets 2,3 , D. Wright 3 and T. R. Zacharewski 1,2,3 . 

1 

Genetics Program, Michigan State University, East 

Lansing, MI, 2 Center for Integrative Toxicology, 


3 

Biochemistry & Molecular Biology, Michigan State 

University, East Lansing, MI. 


PHARMACOLOGIC NRF2 ACTIVATION 

PROMOTES HYPERCHOLESTEROLEMIA 

IN MICE. J. Moscovitz, M. Paranjpe and A. Slitt. 

University of Rhode Island, Kingston, RI. 


BERBERINE INDUCES HEPATIC 

STEATOSIS VIA C/EBPβ ACTIVATION. B. 

Lee 1 , Y. Choi 1 , H. Suh 1 , S. Jeoung 1 and K. Lee 2 . 

1 

Seoul National University, Seoul, Republic of Korea 

and 2 Sungkyunkwan University, Suwon, Republic 



EFFECTS OF MEDICINAL HERBS 

AND THEIR COMPONENTS ON THE 

STEATOGENIC HEPATOTOXICITY. Y. 

Choi 1 , S. Jeoung 1 , H. Suh 1 , H. Choi 1 , S. Park 1 , S. 

Oh 1 , J. Choi 2 , S. Lee 3 , K. Lee 4 and B. Lee 1 . 1 Seoul 

National University, Seoul, Republic of Korea, 

2 

Pukyong National University, Pusan, Republic of 

Korea, 3 Yeungnam University, Gyeongbuk, Republic 

of Korea and 4 Sungkyunkwan University, Suwon, 



FIBRINOGEN DEFICIENCY INCREASES 

LIVER INJURY AND EARLY GROWTH 

RESPONSE-1 EXPRESSION IN A MODEL 

OF CHRONIC XENOBIOTIC-INDUCED 

CHOLESTASIS. J. P. Luyendyk 1 , K. M. Kassel 1 , 

K. Allen 1 , G. L. Guo 1 , G. Li 1 , G. H. Cantor 2 and 

B. L. Copple 1 . 1 Pharmacology, Toxicology, and 

Therapeutics, The University of Kansas Medical 

Center, Kansas City, KS and 2 Discovery Toxicology, 

Bristol-Myers Squibb, Princeton, NJ. 


ENDOGENOUS CYP1B1 METABOLISM IN 

VIVO CONTROLS ENDOGENOUS LIVER 

PPAR ACTIVITY WITHOUT EXPRESSION 

IN HEPATOCYTES. J. R. Bushkofsky 1,2 , 

M. L. Larsen 3 , S. Wang 3 and C. R. Jefcoate 1,2,3 . 

1 

Endocrinology and Reproductive Physiology, 

University of Wisconsin Madison School of 

Medicine and Public Health, Madison, WI, 

2 

Molecular and Environmental Toxicology Center, 

University of Wisconsin Madison, Madison, WI 

and 3 Department of Pharmacology, University of 

Wisconsin Madison, Madison, WI. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Ah Receptor in Immune Regulation and 

Toxicity 

Chairperson(s): Qing Li, Nippon Medical School, Tokyo, Japan. 




EVIDENCE OF AhR-DEPENDENT 

SUPPRESSION OF IMMUNOGLOBULIN 

EXPRESSION. M. J. Wourms and C. Sulentic. 

Pharmacology and Toxicology, Boonshoft School of 

Medicine Wright State University, Dayton, OH. 


TCDD-INDUCED MODULATION OF THE 

hs1, 2 ENHANCER WITHIN THE 3’IgHRR 

IN MOUSE AND HUMAN. J. Liu, T. Fernando, 

S. Ochs and C. E. Sulentic. Pharmacology and 

Toxicology, Boonshoft School of Medicine, Wright 

State Unversity, Dayton, OH. 


PAX5 MAY MEDIATE TCDD-INDUCED 

DIFFERENCES IN TRANSCRIPTIONAL 

REGULATION OF THE MOUSE AND 

HUMAN hs1, 2 ENHANCER. S. Ochs, J. Liu and 

C. Sulentic. Pharmacology and Toxicology, Wright 

State Unversity, Dayton, OH. 


ROLE OF THE 3’IgHRR IN TCDD- 

INDUCED SUPPRESSION OF THE 

IMMUNOGLOBULIN HEAVY CHAIN. J. L. 

Panchal, E. Romer, T. Fernando and C. Sulentic. 


Medicine, Wright State University, Dayton, OH. 


NF-B/REL AND THE AhR IN MODULATING 

THE 3́IgHRR. R. Salisbury and C. Sulentic. 


Medicine, Wright State University, Dayton, OH. 


PERSISTENT DEVELOPMENTAL 

ARYLHYDROCARBON RECEPTOR 

ACTIVATION MODULATES NOTCH1- 

DEPENDENT T-CELL BUT NOT B-CELL 

DIFFERENTIATION POTENTIAL. L. 

Ahrenhoerster, P. Lakatos and M. Laiosa. School of 

Public Health, University of Wisconsin Milwaukee, 

Milwaukee, WI. 

214 






Platform Sessions



Abstract # 


THE ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN WOOD SMOKE-INDUCED 

MACROPHAGE SUPPRESSION. C. T. 

Migliaccio, E. Kobos, V. Porter and T. Ward. Center 

for Environmental Health Sciences, University of 

Montana, Missoula, MT. 


TCDD TREATMENT ENHANCES THE 

M1 PHENOTYPE IN J774 MURINE 

MACROPHAGES. A. E. McCartney, R. A. 

Aguayo, P. V. Hamilton and K. A. Mitchell. 

Biological Sciences, Boise State University, Boise, 

ID. 



MODULATES PHENOTYPE AND FUNCTION 

OF DENDRITIC CELLS. G. Jin and B. 

Lawrence. Environmental Medicine, University of 



MODULATION OF NF-KB MEDIATED 

DENDRITIC CELL DIFFERENTIATION 

AND FUNCTION BY ARYL HYDROCARBON 

RECEPTOR ACTIVATION. C. Vogel 1,3 , S. 

Goth 2 , D. Wu 3 , V. Kou 3 , A. Lollies 3 , I. Pessah 2 

and F. Matsumura 1,3 . 1 Environmental Toxicology, 

University of California, Davis, CA, 2 Molecular 

Biosciences, University of California, Davis, CA and 

3 

Center for Health and the Environment, University 

of California, Davis, CA. 


AH RECEPTOR ACTIVATION GENERATES 

REGULATORY DENDRITIC CELLS 

CAPABLE OF INDUCING CD4+ CD25+ 

FOXP3+ REGULATORY T CELLS. T. 

Simones, J. Bankoti and D. M. Shepherd. Center 

for Environmental Health Sciences, University of 

Montana, Missoula, MT. 


ALL AHR LIGANDS ARE NOT CREATED 

EQUAL: THE DURATION OF AHR 

ACTIVATION IS A KEY PARAMETER IN 

MODULATING THE IMMUNE RESPONSE 

TO INFLUENZA VIRUS INFECTION. J. 

Head 1 and B. Lawrence 1,2 . 1 Environmental Medicine, 

University of Rochester, Rochester, NY and 

2 

Microbiology and Immunology, University of 



TCDD AMELIORATES COLITIS IN MICE 

BY INDUCTION OF REGULATORY T CELLS 

(TREGS) VIA AHR ACTIVATION. N. P. Singh 1 , 

U. Singh 1 , B. Singh 2 , L. Hofseth 3 , M. Nagarkatti 1 

and P. Nagarkatti 1 . 1 Pathology, Microbiology, and 

Immunology, University of South Carolina School of 

Medicine, Columbia, SC, 2 Primate Research Center, 

Emory University, Atlanta, GA and 3 South Carolina 

College of Pharmacy, University of South Carolina, 

Columbia, SC. 



ACTIVATION SUPPRESSES INTESTINAL 

INFLAMMATION. J. M. Benson and D. M. 

Shepherd. Biomedical and Pharmaceutical Sciences, 

University of Montana, Missoula, MT. 

Abstract # 


BACH2 BINDING TO Prdm1 

AS A MECHANISM OF 2, 3, 7, 

8-TETRACHLORODIBENZO-P- 

DIOXIN(TCDD)-MEDIATED IMMUNE 

SUPPRESSION. A. S. Phadnis 1,3 , K. DeAbrew 4 , 

R. S. Thomas 4 and N. E. Kaminski 2,3 . 1 Genetics 

Program, Michigan State University, East Lansing, 

MI, 2 Pharmacology & Toxicology, Michigan State 



MI and 4 Hamner Institutes for Health Sciences, 



DIDOX (DIHYDROXYBENZOHYDROXAMIC 

ACID) AMELIORATES MACROPHAGE AHR 

ACTIVATION, CYP1A1/AHR INDUCTION, 

AND OXIDATIVE STRESS PROFILES 

INDUCED BY PCB-126. C. D. Rice, V. S. 

Gallichio and T. M. Matsebatlela. Biological 

Sciences, Clemson University, Clemson, SC. 


MECHANISTIC INVESTIGATION OF TCDD 

EFFECTS ON CD40 LIGAND-INDUCED 

ACTIVATION OF PRIMARY HUMAN B 

CELLS: PERTURBATION OF IMMEDIATE 

AND PERSISTENT SIGNALING. H. Lu 1,2 , 

R. Crawford 1,2 and N. E. Kaminski 1,2 . 1 Center for 


East Lansing, MI and 2 Pharmacology & Toxicology, 



AH RECEPTOR MEDIATED RESTORATION 

OF SPLEEN AND BONE MARROW 

FOLLOWING THE CYP1B1-DEPENDENT 

ADVERSE EFFECTS OF POLYCYCLIC 

AROMATIC HYDROCARBONS (PAHS). A. 

U. N’jai 1,3 , M. Larsen 2 , C. R. Jefcoate 2,3 and C. J. 

Czuprynski 1,3,4 . 1 Pathobiological Sciences, University 

of Wisconsin Madison, Madison, WI, 2 Pharmacology, 

University of Wisconsin Madison, Madison, WI, 

3 

METC, University of Wisconsin Madison, Madison, 

WI and 4 Food Research Institute, University of 

Wisconsin Madison, Madison, WI. 


ACTIVATION OF THE ARYL 

HYDROCARBON RECEPTOR BY TCDD 

SUPPRESSES SENSITIZATION IN A MOUSE 

PEANUT ALLERGY MODEL. V. J. Schulz 1 , J. 

Smit 1,2 , L. Boon 3 , M. van den Berg 1 , M. van Duursen 1 

and R. Pieters 1 . 1 Immunotoxicology, Institute of Risk 


Netherlands, 2 Utrecht Center for Food Allergy, 

Utrecht, Netherlands and 3 Bioceros B.V., Utrecht, 

Netherlands. 

Tuesday 







215



Tuesday 



9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: ImmunoSafety Methods in Non-Rodents 

Chairperson(s): Melissa Rhodes, GlaxoSmithKline, Research Triangle 

Park, NC. 




VALIDATION OF AN IN VITRO SCREENING 

METHOD FOR THE INDUCTION OF DRUG 

CYTOKINE RELEASE IN CYNOMOLGUS 

MONKEY. M. S. Piché, S. Lavallée, S. Legris, R. 

Falvo, K. Eliacin and L. LeSauteur. Immunology, 

Charles River Preclinical Services, Montréal, QC, 

Canada. 


EVALUATING THE SECONDARY IMMUNE 

RESPONSE TO KLH IN CYNOMOLGUS 

MACAQUES: AN EX VIVO APPROACH. S. H. 

Cole, P. Gorman, T. T. Kawabata, M. Collinge and S. 

Casinghino. Immunotoxicology, Pfizer Global R&D, 

Groton, CT. 


DEVELOPMENT OF AN ASSAY TO 

MEASURE NATURAL KILLER CELL 

FUNCTION IN CYNOMOLGUS MACAQUES. 

S. Haskett, C. Donovan, C. Thiffeault, T. Kawabata 

and C. Kamperschroer. Pfizer, Groton, CT. 


FLOW CYTOMETRY AND REPORTABLE 

COMBINATIONS: WHEN IS ENOUGH 

TRULY ENOUGH? A. R. Mcintyre, T. Salewsky, 

T. Warren, C. Cornwall, N. Pratt, R. Eyre and H. 

Tsusaki. SNBL USA, Ltd., Everett, WA. 


QUALIFCATION OF FLOW CYTOMETRY 

IMMUNOPHENOTYPING FOR Preclinical 

APPLICATIONS IN NON-HUMAN 

PRIMATES. T. Salewsky, A. R. Mcintyre, T. 

Warren, A. Charzynska, N. Clark, R. Eyre and H. 

Tsusaki. SNBL USA, Ltd., Everett, WA. 


DELAYED-TYPE HYPERSENSITIVITY 

(DTH) REACTION WITH TETANUS TOXOID 

(TTX) IN CYNOMOLGUS MONKEYS. Y. 

Takahashi, Y. Otsubo, K. Nagatomo, T. Nakamura, T. 

Sukamoto, K. Fukuzaki and R. Nagata. Shin Nippon 

Biomedical Laboratories (SNBL), Ltd., Kagoshima, 

Japan. 


IMMUNOTOXICITY ASSESSMENT IN 

INFANT CYNOMOLGUS MONKEYS BY 

MEASUREMENT OF HUMORAL IMMUNITY 

(TDAR) TO KLH AND INNATE IMMUNITY 

(NATURAL KILLER (NK) CELL ACTIVITY). 

F. G. Burleson 1 , N. Makori 2 , N. Lalayeva 2 , G. R. 

Burleson 1 and H. Tsusaki 2 . 1 BRT-Burleson Research 

Technologies, Inc., Morrisville, NC and 2 SNBL, 

Everett, WA. 


REPRODUCTIVE TOXICOLOGY AND 

INFANT IMMUNOPHENOTYPING: 

REFERENCE RANGES FOR T-CELL 

ASSESSMENT IN INFANTS. C. Cornwall, A. R. 

Mcintyre, T. Salewsky, T. Warren, N. Pratt, R. Eyre 

and H. Tsusaki. SNBL USA, Ltd., Everett, WA. 


DEVELOPMENT OF AN ASSAY TO 

DETECT CMV AND LCV SPECIFIC 

T-CELLS TO EVALUATE IMMUNE STATUS 

IN CYNOMOLOGUS MONKEYS. P. A. 

Schneider, L. O’Donnell, T. T. Kawabata and C. 

Kamperschroer. Pfizer, Groton, CT. 


VIRAL LOAD AND LYTIC GENE 

EXPRESSION ASSAYS TO DETECT 

REACTIVATION OF LCV IN CYNOMOLGUS 

MACAQUES. K. R. Tartaro 1 , S. W. Kumpf 2 , 

T. T. Kawabata 1 and C. Kamperschroer 1 . 

1 

Immunotoxicology, Pfizer, Groton, CT and 2 DART, 

Pfizer, Groton, CT. 


IMMUNOGENICITY TESTING OF 

INFLIXIMAB (REMICADE®) AND 

ADALIMUMAB (HUMERA®) IN 

GOTTINGEN MINIPIGS®. G. J. van Mierlo 1 , 

A. H. Penninks 1 , J. Wolthoorn 1 , N. H. Cnubben 1 , 

L. Aarden 2 and D. Wouters 2 . 1 Toxicology and 

Applied Pharmacology, TNO-Quality of Life, Zeist, 

Netherlands and 2 Sanquin Research, Amsterdam, 

Netherlands. Sponsor: R. Woutersen. 


IMMUNOGENICITY TESTING OF 

KINERET® IN GOTTINGEN MINIPIGS®. 

A. H. Penninks 1 , J. Wolthoorn 2 , N. H. Cnubben 1 

and G. J. van Mierlo 1 . 1 Toxicology and Applied 

Pharmacology, TNO-Quality of Life, Zeist, 

Netherlands and 2 Analytical Research, TNO Quality 

of Life, Zeist, Netherlands. Sponsor: R. Woutersen. 


ASSESSMENT OF IMMUNE FUNCTION 

IN CELLS ISOLATED FROM 

BRONCHOALVELOAR LAVAGE (BAL) 

FLUID, OBTAINED IN-LIFE IN THE DOG. V. 

Leighton, A. Head, G. Hale and S. A. Kirk. Covance 

Laboratories Ltd., Harrogate, United Kingdom. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Stem Cell Toxicology 

Chairperson(s): Rakesh Ranjan, Bayer CropScience, Research Triangle 

Park, NC. 




TRANSIENT KNOCK DOWN OF CHK1 

IN BONE MARROW HEMATOPOIETIC 

PROGENITORS IS LINKED TO BONE 

MARROW TOXICITY. B. Jessen and W. Hu. 

DSRD, Pfizer, San Diego, CA. 

216 






Platform Sessions



Abstract # 


RADIATION AND SENESCENCE: 

DECELERATION OF CELL-CYCLE IN 

PRIMITIVE HEMOPOIETIC PROGENITORS 

(CFU-S13) WAS ONLY SIGNIFICANT 

PARAMETER DURING AGING, WHICH 

WAS REACTIVELY ACCELERATED AFTER 

2GY WHOLE-BODY IRRADIATION. Y. 

Hirabayashi 1 , I. Tsuboi 2 , K. Sekita 1 , J. Kanno 1 , Y. 

Kusunoki 3 and T. Inoue 1,2,3 . 1 NCBCR, NIHS, Tokyo, 

Japan, 2 School of Medicine, Nihon University, 

Tokyo, Japan and 3 RERF, Hiroshima, Japan. 


CADMIUM-INDUCED TRANSFORMATION 

OF HUMAN STEM CELLS. E. Tokar and M. 

Waalkes. National Toxicology Program, NIEHS, 



GROWTH HORMONE VS. PEGYLATED GH 

LIPOATROPHY IN HUMAN STEM CELL 

DERIVED ADIPOCYTES. P. M. Bartholomew 1 , 

C. Donahue 2 , M. Thiede 2 , S. Martin 3 and J. Vajdos 2 . 

1 

Drug Safety R&D, Pfizer Inc., Groton, CT, 

2 

Genetically Modified Models, Pfizer Inc., Groton, 

CT and 3 Pharm R&D, Pfizer Inc., Groton, CT. 


DIOXIN, A POTENT LIGAND OF THE 

ARYL HYDROCARBON RECEPTOR, 

ALTERS MIGRATION OF MURINE 

HEMATOPOIETIC STEM CELLS. F. L. 

Casado-Pena, K. P. Singh and T. A. Gasiewicz. 

Environmental Medicine, University of Rochester, 




AGONIST DIOXIN PRODUCES 

ALTERATIONS IN EARLY HEMATOPOIESIS 

IN MOUSE FETAL LIVER. K. P. Singh, F. 

L. Casado and T. A. Gasiewicz. Environmental 

Medicine, University of Rochester Medical Center, 



INVOLVEMENT OF AMPK IN SUNITINIB 

MEDIATED CARDIOTOXICITY IN 

HUMAN STEM CELL DERIVED 

CARDIOMYOCYTES. J. D. Cohen, S. Kameoka, 

J. Babiarz, T. Weiser, T. Singer and K. Kolaja. 

Nonclinical Safety, Hoffmann-La Roche, Nutley, NJ. 


HYPOTHERMOSOL—DERISKING A 

VEHICLE. C. Potter 1 , K. Hedley 1 , M. Sharpe 1 , P. 

Cleall 1 , A. Raber 2 , W. Vant Hof 2 , R. Deans 2 and A. 

Mathew 3 . 1 Pfizer, Sandwich, Kent, United Kingdom, 

2 

AtherSys, Cleveland, OH and 3 Biolife Solutions, 

Bothell, WA. 


CARDIAC TROPONIN I AS A MARKER 

OF CARDIOTOXICITY IN HUMAN- 

INDUCED PLURIPOTENT STEM CELL 

CARDIOMYOCYTES. R. Abrams 1 , M. Dunn 1 , 

D. Coluccio 1 , G. Hirkaler 1 , J. Babiarz 1 , R. Nicklaus 1 , 

W. Geng 1 , I. Mikaelian 1 , T. Singer 2 and K. Kolaja 1 . 

1 

Nonclinical Safety, Roche, Nutley, NJ and 

2 

Nonclinical Safety, Roche, Basel, Switzerland. 

Abstract # 


IN VITRO TOXICITY OF (THIO)ARSENATES 

FOR HUMAN UROTHELIAL CELLS 

(UROTSA) AND HEPATOCYTES (HEPG2). S. 

Rabieh 1 , R. Lohmayer 1 , S. Hinrichsen 1 , E. Dopp 2 and 

B. Planer–Friedrich 1 . 1 Environmental Geochemistry, 

University of Bayreuth, Bayreuth, Germany and 

2 

Institute of Hygiene and Occupational Medicine, 

University Hospital Essen, Essen, Germany. 


THE MRNA AND MIRNA PROFILE OF 

HUMAN IPS-CELLS DIFFERENTIATING TO 

CARDIOMYOCYTES. J. Babiarz 1 , M. Ravone 2 , 

B. Anson 3 , C. Kendrick-Parker 3 , E. Nuywasir 3 , T. 

Weiser 2 , T. Singer 2 , E. Chiao 1 , U. Certa 2 and K. 

Kolaja 1 . 1 Nonclinical Safety, F. Hoffman-La Roche, 

Nutley, NJ, 2 Nonclinical Safety, F. Hoffman-La 

Roche, Basel, Switzerland and 3 Cellular Dynamics 

International, Madison, WI. 


USE OF INDUCED PLURIPOTENT 

CELL-DERIVED CARDIOMYOCYTES 

TO PREDICT AND INVESTIGATE DRUG- 

INDUCED CARDIAC INJURY. S. Kameoka 1 , 

J. Babiarz 1 , B. Anson 3 , C. Kendrick-Parker 3 , E. 

Nuwaysir 3 , T. Weiser 2 , T. Singer 2 , E. Chiao 1 and K. 

Kolaja 1 . 1 Nonclinical Safety, F. Hoffman-La Roche, 

Nutley, NJ, 2 Nonclinical Safety, F. Hoffman-La 

Roche, Basel, Switzerland and 3 Cellular Dynamics 

International, Madison, WI. 


FAST IMPEDANCE ANALYSIS IN HIPSC- 

DERIVED CARDIOMYOCYTES FOR EARLY 

IDENTIFICATION OF CARDIAC DRUG 

LIABILITY. L. Guo 1 , R. Abramas 1 , T. Singer 2 , 

T. Weiser 1,2 , J. Babiarz 1 , E. Chiao 1 and K. Kolaja 1 . 

1 

NCS Early & Investigative Safety, F. Hoffmann-La 

Roche, Inc., Nutley, NJ and 2 Nonclinical Safety, F. 

Hoffmann–La Roche Ltd., Basel, Switzerland. 


VARDENAFIL INCREASES THE BEAT 

RATE OF HUMAN CARDIOMYOCYTES 

VIA POTENTIATION OF HCN4 CHANNEL 

CURRENTS. A. Bruening-Wright, Y. A. Kuryshev, 

J. W. Kramer, A. MacCormack, T. Yang, W. Pei and 

A. M. Brown. ChanTest Corp., Cleveland, OH. 


GENERATION AND VALIDATION OF 

CELL BASED REPORTER SYSTEM TO 

MONITOR EPIGENETIC CHANGES IN 

HUMAN EMBRYONIC AND INDUCED 

PLURIPOTENT STEM CELLS. I. Gurevich, 

W. Krueger and T. P. Rasmussen. Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT. 


DIFFERENTIAL PAH EFFECTS MEDIATED 

BY CYP1A1 AND CYP1B1 IN THE BONE 

MARROW SPECIFICALLY TARGET 

HEMATOPOIETIC PROGENITORS. M. L. 

Larsen 1 , A. U. N’Jai 3 , C. J. Czuprynski 3,2 and C. R. 

Jefcoate 1,2 . 1 Pharmacology, University of Wisconsin, 

Madison, WI, 2 Molecular and Environmental 

Toxicology Center, University of Wisconsin, 

Madison, WI and 3 School of Veterinary Medicine, 

University of Wisconsin, Madison, WI. 

Tuesday 







217



Tuesday 



IMMUNOMODULATORY RESPONSE 

OF MOUSE BONE MARROW-DERIVED 

MESENCHYMAL STROMAL CELLS 

(MBMSCS) TO STIMULATION WITH 

LIPOPOLYSACCHARIDES (LPS). N. V. 

Gorbunov, B. R. Garrison, G. Ledney and J. G. 

Kiang. Radiation Combined Injury Program, Armed 

Forces Radiobiology Research Institute, Bethesda, 

MD. 


FINE PARTICULATE MATTER (PM 2.5 

) 

EXPOSURE AFFECTS CIRCULATING 

AND BONE MARROW ENDOTHELIAL 

PROGENITOR CELLS. P. Haberzettl, J. Lee, D. 

Duggineni, J. McCracken, A. Bhatnagar and D. J. 

Conklin. Diabetes and Obesity Center, University of 



ALDH1B1 IS A MARKER FOR HUMAN 

COLON CANCER. Y. Chen 1 , A. Matsumoto 1 , D. 

Orlicky 2 , S. Singh 1 and V. Vasiliou 1 . 1 Pharmaceutical 

Sciences, University of Colorado Denver, Aurora, 

CO and 2 Pathology, University of Colorado Denver, 

Aurora, CO. 


DIFFERENTIAL TOXICITIES OF KINASE 

INHIBITORS (KI) ON BONE MARROW 

PROGENITORS FROM DIFFERENT 

SPECIES. E. Clarke and G. dos Santos. ReachBio, 

Seattle, WA. Sponsor: R. Steigerwalt. 


DEVELOPMENT AND 

CHARACTERIZATION OF HUMAN 

HEPATOCYTES DERIVED FROM INDUCED 

PLURIPOTENT STEM CELLS (IPSC): 

A NOVEL IN VITRO MODEL SYSTEM 

FOR ASSESSING DRUG-INDUCED 

HEPATOTOXICITY. V. L. Ott, P. Fuhrken, J. 

Luebke-Wheeler, C. Kannemeier, B. Swanson, 

W. Wang and E. Nuwaysir. Cellular Dynamics 

International, Madison, WI. Sponsor: K. Kolaja. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology: Carbon Nanotubes, Carbon 

Nanoparticulates, and Quantum Dots 

Chairperson(s): Anita Patlolla, Jackson State University, Jackson, MS. 




BIOLOGICAL SURFACE ADSORPTION 

INDEX (BSAI) FOR CHARACTERIZING 

CARBON NANOMATERIALS WITH 

DIFFERENT SURFACE CHEMISTRIES 

IN BIOLOGICAL SYSTEMS. X. Xia, 

N. A. Monteiro-Riviere and J. E. Riviere. 

Center for Chemical Toxicology Research and 

Pharmacokinetics, North Carolina State University, 

Raleigh, NC. 


CELLULAR UPTAKE MECHANISMS AND 

CYTOTOXICITY OF QUANTUM DOT 

NANOPARTICLES IN PORCINE DENDRITIC 

CELLS. L. W. Zhang and N. A. Monteiro-Riviere. 



Raleigh, NC. 


EVALUATION OF TOXICITY AND 

INFLAMMATION IN THREE DIFFERENT 

HYDROXYLATED FULLERENES 

(C 60 

(OH) X 

) IN HUMAN CELLS. J. G. 

Saathoff 1 , X. Xia 1 , J. E. Riviere 1 , A. O. Inman 1 , 

A. R. Badireddy 2 , M. R. Wiesner 2 and N. A. 

Monteiro-Riviere 1 . 1 Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina 

State University, Raleigh, NC and 2 Civil and 

Environmental Engineering, Duke University, 

Durham, NC. 


THE TRANSCRIPTIONAL PROFILING IN 

RESPONSE TO C(60) FULLERENES OF RAT 

LUNGS FOR IDENTIFICATION POTENTIAL 

BIOMARKERS. K. Fujita 1 , Y. Morimoto 2 , 

S. Endoh 1 , K. Uchida 1 , H. Fukui 1 , A. Ogami 2 , I. 

Tanaka 2 , M. Horie 1 , Y. Yoshida 1 , H. Iwahashi 1 and 

J. Nakanishi 1 . 1 National Institute of Advanced 

Industrial Science and Technology, Tsukuba, Japan 

and 2 University of Occupational and Environmental 

Health, Kitakyushu, Japan. Sponsor: M. Takahashi. 


EFFECT OF SURFACE MODIFICATION 

ON THE BIOAVAILABILITY AND 

INFLAMMATORY POTENTIAL OF MULTI- 

WALLED CARBON NANOTUBES. T. M. 

Sager 1,2 , M. Wolfarth 1 , D. Porter 1 , V. Castranova 1 , 

N. Wu 3 and A. Holian 2 . 1 Pathology/Physiology 

Reasearch Branch, Health Effects Laboratory 

Division, NIOSH, Morgantown, WV, 2 Center 

for Environmental Health Sciences, University 

of Montana School of Medicine, Missoula, MT 

and 3 Department of Mechanical and Aerospace 

Engineering, West Virginia University, Morgantown, 

WV. 


OXIDATIVE LIPIDOMICS REVEALS 

SELECTIVE, BUT NOT RANDOM, 

PULMONARY PHOSPHILIPID 

PEROXIDATION AFTER INHALATION 

OF CARBON NANOTUBES. Y. Tyurina 1 , V. 

Tyurin 1 , L. Sparvero 1 , A. Amoscato 1 , V. Kapralova 1 , 

E. Kisin 2 , A. Murray 2 , J. Shi 3 , B. Fadeel 3 , A. 

Shvedova 2 and V. Kagan 1 . 1 Center for Free Radical 

and Antioxidant Health, Department of EOH, 

University of Pittsburgh, Pittsburgh, PA, 2 Pathology 

and Physiology Research Branch, Health Effects 

Laboratory Division, NIOSH, Morgantown, WV 

and 3 Division of Biochemical Toxicology, Institute 

of Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden. 

218 






Platform Sessions



Abstract # 


COMPARATIVE GENOTOXICITY 

OF FIBROUS PARTICLES: CARBON 

NANOFIBERS, SINGLE-WALLED CARBON 

NANOTUBES, AND ASBESTOS. E. Kisin 1 , A. 

R. Murray 1 , L. Sargent 2 , D. Lowry 2 , K. Siegrist 2 , 

M. Chirila 3 , D. Schwegler-Berry 1 , S. Leonard 1 , V. 

Castranova 1 , B. Fadeel 4 , V. E. Kagan 5 and A. A. 

Shvedova 1 . 1 PPRB, NIOSH, Morgantown, WV, 

2 

TMBB, NIOSH, Morgantown, WV, 3 AEB, NIOSH, 

Morgantown, WV, 4 Institute of Environmental 

Medicine, Karolinska Instituet, Stockholm, Sweden 

and 5 University of Pittsburgh, Pittsburgh, OR. 


ELUCIDATION OF FACTORS 

DETERMINING CARBON NANOTUBES’ 

ABILITY TO PENETRATE ALVEOLAR 

EPITHELIAL BARRIER AND INTERACT 

WITH LUNG FIBROBLASTS IN VITRO. R. 

Derk 1 , A. Mishra 1 , T. Stueckle 1 , Y. Rojanasakul 2 , V. 

Castranova 1 and L. Wang 1 . 1 HELD/PPRB, CDC/ 

NIOSH, Morgantown, WV and 2 School of Pharmacy, 

West Virginia University, Morgantown, WV. 


IN VITRO ASSESSMENT OF POTENTIAL 

TUMORGENICITY OF CHRONIC SWCNT 

AND MWCNT EXPOSURE TO LUNG 

EPITHELIUM. T. A. Stueckle 1 , A. Mishra 1 , R. 

Derk 1 , Y. Rojanasakul 2 , V. Castranova 1 and L. Wang 1 . 

1 

HELD/PPRB, CDC/NIOSH, Morgantown, WV 

and 2 School of Pharmacy, West Virginia University, 



ASSESSMENT OF FIBROGENIC 

BIOMARKERS INDUCED BY MULTI WALL 

CARBON NANOTUBES. A. Mishra 1,2 , Y. 

Rojanasakul 2 , V. Castranova 1,2 , R. Mercer 1 and L. 

Wang 1,2 . 1 HELD/PPRB, CDC/NIOSH, Morgantown, 

WV and 2 Pharmaceuticals & Pharmacological 

Sciences, West Virginia University, Morgantown, 

WV. 


DIFFERENTIAL EFFECTS OF SINGLE- 

WALLED CARBON NANOTUBES 

ON HUMAN HEPATIC, RENAL, AND 

COLORECTAL CARCINOMA CELL LINES. 

K. Hitoshi 1 , M. Katoh 1 , T. Suzuki 2 , Y. Ando 1 and 

M. Nadai 2 . 1 Faculty of Pharmacy, Meijo University, 

Nagoya, Japan and 2 Faculty of Science and 

Technology, Meijo University, Nagoya, Japan. 


MULTI-WALL CARBON NANOTUBE 

(MWCNT)-INDUCED GENE EXPRESSION 

IN THE MOUSE LUNG: IMPLICATION OF 

CARCINOGENESIS RISK. M. Pacurari 2,1 , 

Y. Qian 1 , A. Hubbs 1 , D. Porter 1 , M. Wolfarth 1 , 

D. Luo 2 , Y. Wan 2 , V. Castranova 1 and N. Guo 2,3 . 

1 

Pathology and Physiology Research Branch, 

NIOSH, Morgantown, WV, 2 MBR Cancer Center, 

West Virginia University, Morgantown, WV and 

3 

Department of Community Medicine, West Virginia 


Abstract # 



INSTILLATION IN C57BL/6 MICE INDUCES 

CHANGES IN PULMONARY FUNCTION. 

P. Katwa 1 , A. Aldossari 1 , S. C. Hilderbrand 1 , C. 

J. Wingard 2 , D. M. Walters 2 and J. M. Brown 1 . 

1 

Pharmacology & Toxicology, East Carolina 

University, Greenville, NC and 2 Physiology, East 

Carolina University, Greenville, NC. 


CARBON NANOTUBES INDUCE APOPTOSIS 

RESISTANCE THROUGH FLICE- 

INHIBITORY PROTEIN. V. Pongrakhananon 1 , 

Y. Lu 1 , L. Wang 2 , T. Stueckle 2 , S. Luanpitpong 1 

and Y. Rojanasakul 1 . 1 West Virginia University, 

Morgantown, WV and 2 National Institute for 

Occupational Safety and Health, Morgantown, WV. 


POTENTIAL CARCINOGENICITY OF 

CARBON NANOTUBES. Y. Rojanasakul 2 , Y. Lu 2 , 

S. Luanpitpong 2 , V. Castranova 1 , V. Pongrakhananon 2 

and L. Wang 1 . 1 National Institute for Occupational 

Safety and Health, Morgantown, WV and 2 West 



PULMONARY EXPOSURE TO 

CARBONACEOUS NANOPARTICLES 

AFFECTS LOCAL AND SYSTEMIC 

IMMUNITY. A. Tkach 1 , E. Kisin 1 , A. R. Murray 1 , 

G. V. Shurin 2 , M. R. Shurin 2 , S. H. Young 1 , A. Star 2 , 

B. Fadeel 3 , V. E. Kagan 2 and A. A. Shvedova 1 . 1 PPRB, 

NIOSH, Morgantown, WV, 2 University of Pittsburgh, 

Pittsburgh, PA and 3 Institute of Environmental 

Medicine, Karolinska Institute, Stockholm, Sweden. 


PULMONARY RESPONSE OF CIGARETTE 

SMOKE-EXPOSED MICE TO CARBON 

NANOPARTICLES. C. Gairola 1 , S. Han 1 and D. 

Bhalla 2 . 1 Graduate Center for Toxicology, University 

of Kentucky, Lexington, KY and 2 Wayne State 

University, Detroit, MI. 


INHALATION OF SINGLE-WALL CARBON 

NANOTUBES INCREASES APOPTOSIS AND 

ENDOTHELIN-1 LEVELS IN HAMSTER 

LUNGS. K. H. Bijlani, H. R. Sukhija, J. O. Cantor 

and J. M. Cerreta. PHS, St. Johns University, Queens, 

NY. Sponsor: L. Trombetta. 


INHALED SINGLE-WALL CARBON 

NANOTUBES INCREASE LEVELS OF 5– 

LIPOXYGENASE AND LTB4 IN HAMSTER 

LUNGS. H. R. Sukhija, K. H. Bijlani, J. O. Cantor 

and J. M. Cerreta. PHS, St. Johns University, Queens, 

NY. Sponsor: L. Trombetta. 


AMPHIPHILIC POLYMER-COATED CdSe 

/ZnS QUANTUM DOTS INDUCE LUNG 

INFLAMMATION IN MICE WHICH 

IS MODULATED BY GLUTATHIONE 

STATUS. D. Botta, C. C. White, C. S. Weldy, L. A. 

McConnachie, J. Wilkerson, S. E. Gill, X. Hu, W. 

C. Parks, X. Gao and T. J. Kavanagh. University of 


Tuesday 







219



Tuesday 



BIO-DISTRIBUTION OF FULLERENE 

INTRAVENOUS ADMINISTRATED IN RAT. 

T. Nishimura 1 , R. Kubota 1 , M. Tahara 1 , K. Shimizu 1 , 

T. Obama 1 , N. Sugimoto 1 and A. Hirose 2 . 1 Division 

of Environmental Chemistry, National Institute of 

Health Sciences, Tokyo, Japan and 2 Division of Risk 

Assessment, Biological Safety Research Center, 

National Institute of Health Sciences, Tokyo, Japan. 


AIRWAY INFLAMMATION IN MICE 

EXPOSED TO OVALBUMIN ALLERGEN 

AND MULTI-WALLED CARBON 

NANOTUBES (MWCNT) IS REGULATED 

BY CYCLOOXYGENASE-2 (COX-2). B. C. 

Sayers 1 , E. E. Glista 1 , A. J. Taylor 1 , R. Langenbach 2 

and J. C. Bonner 1 . 1 Environmental and Molecular 


NC and 2 Laboratory of Molecular Carcinogenesis, 



RESPIRATORY EFFECTS OF INHALED 

SINGLE-WALLED CARBON NANOTUBES: 

THE ROLE OF IRON AND PARTICLE 

MORPHOLOGY. A. K. Madl, A. Tsumura, K. 

Johnson, V. Seshachellam, P. C. Edwards, S. V. 

Teague, T. Guo, L. S. Van Winkle, J. E. Evans and K. 

E. Pinkerton. University of California Davis, Davis, 

CA. 


IN VIVO TOXICITY STUDY OF QUANTUM 

DOT NANOPARTICLES FOLLOWING 

INTRAVENOUS ADMINISTRATION IN 

MICE. J. Treadway 2 , J. Bartel 2 , J. Schatz 3 and S. 

Kim 1 . 1 Design-for-Environment, Life Technologies, 

Foster City, CA, 2 Life Technologies, Eugene, OR 

and 3 Design-for-Environment, Life Technologies, 

Madison, WI. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Epidemiology and Exposure Evaluations 

Chairperson(s): Monica Lind, Uppsala University, Uppsala, Sweden, and 

Guadalupe Ocampo-Gomez, University of Coahuila, Coahuila, Mexico. 




EXPOSURE AND DISEASE 

SUSCEPTIBILITY DIFFERENCES IN 

U.S. AND SWEDISH POPULATIONS: 

IMPLICATIONS FOR ASSESSMENT 

OF RISKS FROM USE OF TOBACCO 

PRODUCTS. C. Ward, G. Mariano and A. 

Santamaria. Environ International, Arlington, VA. 


PULMONARY FUNCTION TESTING IN 

BOAT MANUFACTURER WORKERS. G. 

T. Johnson, S. C. Harbison, J. D. McCluskey, P. 

Xu, L. Thomas, S. Goldman and R. D. Harbison. 

Environmental and Occupational Health, University 

of South Florida, Tampa, FL. 


CIRCULATING LEVELS OF PERSISTENT 

ORGANIC POLLUTANTS ASSOCIATE 

IN DIVERGENT WAYS TO FAT MASS IN 

HUMANS. M. Rönn 1 , L. Lind 1 , B. van Bavel 2 , 

S. Salihovic 2 , K. Michaelsson 3 and M. P. Lind 1 . 

1 

Department of Medical Sciences, Uppsala 

University, Uppsala, Sweden, 2 MTM Research 

Center, Örebro University, Örebro, Sweden 

and 3 Department of Surgical Sciences, Uppsala 

University, Uppsala, Sweden. 


CIRCULATING LEVELS OF PHTHALATES, 

BISPHENOL A, AND ABDOMINAL OBESITY. 

M. P. Lind 1 , M. Rönn 1 , K. Michaelsson 2 , D. A. 

Birkholz 3 , L. Johansson 4 , H. Ahlström 4 and L. Lind 5 . 

1 

Department of Medical Sciences, Occupational 

and Environmental Medicine, Uppsala University, 

Uppsala, Sweden, 2 Department of Surgical 

Sciences, Uppsala University, Uppsala, Sweden, 

3 

Environmental Division, ALS, Edmonton, AB, 

Canada, 4 Department of Radiology, University 

Hospital, Uppsala, Sweden and 5 Department of 

Medical Sciences, Acute and Internal Medicine, 

Uppsala University, Uppsala, Sweden. 


ATHEROSCLEROSIS IS RELATED TO 

CIRCULATING LEVELS OF PERSISTENT 

ORGANIC POLLUTANTS (POPS) IN THE 

ELDERLY. L. Lind 1 , B. van Bavel 2 , S. Salihovic 2 

and M. P. Lind 3 . 1 Acute and Internal Medicine, 

Department of Medical Sciences, Uppsala University 

Hospital, Uppsala, Sweden, 2 MTM Research 

Centre, School of Science and Technology, Örebro 

University, Örebro, Sweden and 3 Occupational and 

Environmental Medicine, Department of Medical 

Sciences, Uppsala University, Uppsala, Sweden. 


SERUM LEVELS OF POLYCHLORINATED 

BIPHENYLS IN MEXICAN WOMEN AND 

BREAST CANCER RISK. R. Recio-Vega 1 , 

V. Velasco-Rodriguez 2,1 , G. Ocampo-Gomez 1 and 

S. Hernandez-Gonzalez 1 . 1 Environmental Health, 

University of Coahuila, Torreon, Coahuila, Mexico 

and 2 Clinical Epidemiology, IMSS, Torreon, Mexico. 

Sponsor: M. Cebrian-Garcia. 


THE MODIFIER EFFECT OF ALAD 2 ON 

THE ASSOCIATION BETWEEN BLOOD 

LEAD AND HEMATOLOGIC OUTCOMES. 

F. Scinicariello 1 , B. A. Fowler 1 , A. Yesupriya 2 , M. 

Chang 2 and N. F. Dowling 2 . 1 Division Toxicology 

and Environmental Medicine, ATSDR/CDC, Atlanta, 

GA and 2 Office of Public Health Genomics, Centers 

for Disease Control and Prevention, Atlanta, GA. 


LEAD AND CHILDHOOD COGNITIVE 

DEFICITS: EXPLORING THE ROLE OF 

GENDER AND SOCIAL STRESS. D. A. 

Cory-Slechta 1 , K. Merchant-Borna 1 and E. Van 

Wjingaarden 2 . 1 Department of Environmental 


Rochester, NY and 2 Community and Preventive 



220 






Platform Sessions



Abstract # 


OCCUPATIONAL EXPOSURE 

TO POLYCYCLIC AROMATIC 

HYDROCARBONS DECREASES SPERM 

QUALITY AND INDUCE DNA DAMAGE. G. 

Ocampo-Gomez 1 , E. Olivas-Calderon 1 , R. Recio- 

Vega 1 , G. Garcia-Arenas 2 , R. Martinez-Salinas 3 , 

J. Espinosa-Fematt 2 and M. Gallegos-Arreola 4 . 

1 

University of Coahuila, Coahuila, Mexico, 

2 

University of Durango, Gomez Palacio, Durango, 

Mexico, 3 University of San Luis Potosi, SLP, Mexico 

and 4 University of Guadalajara, Guadalajara, Mexico. 

Sponsor: M. Cebrian-Garcia. 


THREE DECADES OF LOW- 

LEVEL EXPOSURE TO SPRAYED 

ORGANOPHOSPHATES: 

NEUROBEHAVIORAL OUTCOMES 

IN AGRICULTURAL WORKERS AND 

RESIDENTS OF RURAL COMMUNITIES. Y. 

Finkelstein 1 , A. Ophir 1,2 , M. Aschner 4 , E. Doitsch 1 , 

U. Wormser 2 and E. D. Richter 3 . 1 Neurology 

and Toxicology Service and Unit, Shaare Zedek 

Medical Center, Jerusalem, Israel, 2 Institute of 

Drug Research, School of Pharmacy, Hebrew 

University, Jerusalem, Israel, 3 The Department of 

Occupational and Environmental Medicine, Faculty 

of Medicine, Hebrew University, Jerusalem, Israel 

and 4 Department of Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN. 


PRENATAL EXPOSURE TO DDT AND ITS 

EFFECT ON REPRODUCTIVE OUTCOME 

MEASURES. I. Al-Saleh 1 , I. Al-Doush 1 , A. 

Alshabbaheen 1 and A. Rabbah 2 . 1 Environmental 

Health Section, BMR Department, King Faisal 

Specialist Hospital & RC, Riyadh, Saudi Arabia and 

2 

King Khalid Hospital, Al-Kharj, Saudi Arabia. 


TRENDS IN PARAOXONASE 1 ACTIVITY 

AND LIFESTYLE FACTORS IN A RURAL 

POPULATION OVER TIME. L. Badtke 1 , K. M. 

Kelly 2 , K. Wang 3 , J. A. Merchant 2 and G. Ludewig 1,2 . 

1 

Graduate Program in Human Toxicology, The 

University of Iowa, Iowa City, IA, 2 Occupational and 

Environmental Health, The University of Iowa, Iowa 

City, IA and 3 Biostatistics, The University of Iowa, 

Iowa City, IA. 


A CASE CONTROL STUDY OF CHRONIC 

MYELOMONOCYTIC LEUKEMIA IN 

SHANGHAI, CHINA. S. A. Gross 1,2 , R. D. 

Irons 1,3,4 , D. Galbraith 5 and D. Paustenbach 5 . 1 Fudan- 

Cinpathogen Clinical and Molecular Research 

Center, Institutes of Biomedical Sciences, Fudan 

University, Shanghai, China, 2 ChemRisk, Boulder, 

Co., 3 School of Pharmacy, School of Medicine, 

University of Colorado, Denver, Denver, Co., 

4 

Cinpathogen, Boulder, CO and 5 ChemRisk, San 

Francisco, CA. 

Abstract # 


NEW FOOD-BORNE HAZARD PARASITE 

TOXIN. D. Irikura 2 , M. Saito 1 , Y. Yahata 3 , Y. 

Sugita-Konishi 2 and Y. Kamata 2 . 1 Kumagaya Meat 

Inspection Center Saitama Prefecture, Kumagaya, 

Saitama, Japan, 2 Division of Microbiology, National 

Institute of Health Sciences, Setagaya-Ku, Tokyo, 

Japan and 3 Infectious Disease Surveillance Center, 

National Institute of Infectious Diseases, Shinjiku- 

Ku, Tokyo, Japan. 


LEVELS OF EXHALED BREATH 

CONDENSATE PH AND FRACTIONAL 

EXHALED NITRIC OXIDE IN RETIRED 

COAL MINERS. J. Lee, J. Shin, J. Lee, K. Lee, 

J. Kim and B. Choi. Occupational Lung Diseases 

Institute, COMWEL, Ansan, Republic of Korea. 

Sponsor: I. Yu. 


IN VITRO TOXICITY CHARACTERIZATION 

OF WOOD COMBUSTION PARTICLES. D. 

R. Dietrich 1 , B. Pieterse2, B. van der Burg 2 and S. 

Gauggel 1 . 1 Human & Environmental Toxicology, 


2 

BioDetection Systems BV, Amsterdam, Netherlands. 


SULFUR EMISSIONS FROM CHINESE 

DRYWALL IN CHAMBERS AND HOMES. J. 

Matheson 1 , M. Babich 1 , T. Thomas 1 , K. Hatlelid 1 , J. 

Recht 1 , R. Maddalena 2 , M. Apte 2 , J. McCarthy 3 , B. 

Baker 3 , J. Allen 3 , D. MacIntosh 3 and L. Saltzman 1 . 

1 

U.S. Consumer Product Safety Commission, 

Bethesda, MD, 2 LBNL, Berkeley, CA and 3 EH&E, 

Needham, MA. 


EXPOSURE MODEL FOR INDIVIDUALS 

(EMI) IN HUMAN HEALTH STUDIES: 

PREDICTING RESIDENTIAL INDOOR 

EXPOSURES TO FINE AIRBORNE 

PARTICLES. M. Breen 1 , M. Breen 1,2 , B. Schultz 1 , 

T. Long 1 , R. Williams 1 , A. Vette 1 and R. Devlin 1 . 

1 

U.S. EPA, Research Triangle Park, NC and 2 North 



EXPOSURE TO PHTHALATES AMONG 

PREMENSTRUAL GIRLS FROM RURAL 

AND URBAN, GHARBIAH, EGYPT. J. 

Colacino 1,2 , A. Soliman 2,3 , M. Nahar 1 , A. Hablas 4 , 

I. Seifeldin 4 , A. Van Zomeren-Dohm 1 , L. S. Rozek 1 

and D. C. Dolinoy 1 . 1 Environmental Health Sciences, 

University of Michigan School of Public Health, Ann 

Arbor, MI, 2 Center for Global Health, University of 

Michigan, Ann Arbor, MI, 3 Epidemiology, University 

of Michigan, Ann Arbor, MI and 4 Tanta Cancer 

Center, Gharbiah, Egypt. 


BLOOD ANALYSIS OF SWEDISH FIRE 

VICTIMS 1992–2009 SUGGEST HYDROGEN 

CYANIDE AS AN IMPORTANT CAUSE OF 

DEATH. K. Stamyr 1 , G. Thelander 2 , L. Ernstgård 1 

and G. Johanson 1 . 1 Work Environment Toxicology, 


Institutet, Stockholm, Sweden and 2 Department of 

Forensic Genetics and Forensic Toxicology, National 

Board of Forensic Medicine, Linköping, Sweden. 

Tuesday 







221



Tuesday 



DERMAL AND INHALATION EXPOSURE OF 

EGYPTIAN COTTON WORKERS DURING 

CHLORPYRIFOS APPLICATIONS. R. 

Fenske 1 , F. M. Farahat 2 , K. Galvin 1 , J. R. Olson 3 , 

D. S. Rohlman 4 and W. K. Anger 4 . 1 University of 

Washington, Seattle, WA, 2 Menoufia University, 

Shebin Elkom, Egypt, 3 University at Buffalo, 

Buffalo, NY and 4 Oregon Health & Science 

University, Portland, OR. 


CIGARETTE SMOKING AND GENETIC 

POLYMORPHISMS IN THE ARYL 

HYDROCARBON RECEPTOR MAY BE 

ASSOCIATED WITH MENOPAUSAL HOT 

FLASHES. A. Ziv-Gal 1 , L. Gallicchio 2,3 , S. R. 

Miller 3 , H. Zacur 3 and J. A. Flaws 1 . 1 Comparative 

Biosciences, University of Illinois, Urbana, IL, 2 The 

Prevention and Research Center, Mercy Medical 

Center, Baltimore, MD and 3 School of Medicine, 

Johns Hopkins University, Baltimore, MD. 


EVALUATION OF NEUROLOGICAL, 

CARDIAC, AND ENDOCRINE EFFECTS 

OF CARBON DISULFIDE EXPOSURE 

IN HUMANS. S. B. Diwan, J. C. Lipscomb, 

J. Whalan, N. Keshava and C. Shoaf. Office of 

Research and Development, NCEA-W, U.S. EPA, 

Washington, D.C. Sponsor: B. Diwan. 


OCURRENCE OF PERFLUORINATED 

COMPOUNDS IN WATER SUPPLY 

NETWORKS OF CATALONIA, SPAIN. M. 

Nadal 1 , J. L. Domingo 1 , I. Ericson Jogsten 2 , G. 

Perelló 1 , E. Bigas 3 , B. van Bavel 2 and X. Lleberia 3 . 

1 

Toxicology, Rovira i Virgili University, Reus, Spain, 

2 

Örebro University, Örebro, Sweden and 3 Catalan 

Public Health Agency, Department of Health, 

Barcelona, Spain. 


AGRICULTURAL USE OF MANEB 

INCREASES SOIL MN LEVELS IN AN 

EXPERIMENTAL STUDY: IMPLICATIONS 

FOR ENVIRONMENTAL MN EXPOSURE. 

T. Cobban 1 , J. van den Berg 1 , A. Bradman 2 , B. 

Eskenazi 2 and D. R. Smith 1 . 1 University of California, 

Santa Cruz, CA and 2 University of California, 

Berkeley, CA. 


ENVIRONMENTAL AND HEALTH EFFECTS 

RESULTING FROM HEAVY METALS 

EXPOSURE IN LUANDA SOIL FROM 

ANGOLA, AFRICA. M. E. Gomes, C. G. Yedjou 

and P. B. Tchounwou. Biology, Jackson State 

University, Jackson, MS. 


CIGARETTE SMOKING IN CHINA AND THE 

U.S. : AN EVALUATION USING THE CHINA 

HEALTH AND NUTRITION SURVEY AND 

THE NATIONAL HEALTH AND NUTRITION 

EXAMINATION SURVEY. S. J. Kathman 1 , K. 

M. Marano 1 , Z. S. Naufal 1 , H. Gan 1 , J. Xie 2 , H. Liu 2 , 

X. Li 2 , P. Shang 2 , C. D. Garner 1 and C. L. Wilson 1 . 

1 

RJ Reynolds Tobacco Co., Winston Salem, NC and 

2 

Zhengzhou Tobacco Research Institute, Zhengzhou, 

China. 


AN APPROACH TO “CHEMILESS OFFICE” 

WHICH AIMS TO PREVENT SICK- 

BUILDING SYNDROME BY IMPROVING 

THE OFFICE INDOOR AIR. H. Nakaoka 1,2 , E. 

Todaka 3,1 , M. Hanazato 2,4 , H. Seto 5 and C. Mori 1,2,3 . 

1 

Department of Bioenvironmental Medicine, 

Graduate School of Medicine, Chiba University, 

Chiba, Japan, 2 Center for Preventive Medical 

Science, Chiba University, Chiba, Japan, 3 Center 

for Environment, Health and Field Sciences, 

Chiba University, Chiba, Japan, 4 Department of 

Architecture, Graduate School of Engineering, Chiba 

University, Chiba, Japan and 5 Tokyo Kenbikyo-in 

Foundation, Tachikawa, Tokyo, Japan. 


ARE PEAK WORKPLACE EXPOSURES 

ASSOCIATED WITH STYRENE 

NEUROTOXICITY? N. El Majidi, A. Vyskocil, 

R. Thuot, C. Beaudry, G. Charest-Tardif, R. Tardif, F. 

Gagnon, B. Ska, A. Turcot and C. Viau. Université de 

Montréal, Montréal, QC, Canada. 


UTILITY OF C6-GLIOMA CELLS FOR 

EXPLORATORY RISK ASSESSMENT OF 

MIXTURES OF INSECTICIDES. D. M. 

Romero 1 , M. L. Kotler 1 and M. J. Wolansky 1,2 . 

1 

Biological Chemistry (Toxicology), ARG NRC 

/ University of Buenos Aires School of Science, 

Buenos Aires, Argentina and 2 ARG National Agency 

for Scientific and Technological Promotion, Buenos 

Aires, Argentina. 


BARIUM INTAKE IN THE CANARY 

ISLANDS: A TOTAL DIET STUDY. C. Rubio, 

D. González-Weller,. J. Gutiérrez and A. Hardisson. 

Toxicology, University of La Laguna, La Laguna, 

Spain. Sponsor: A. Anadon. 


HOUSE DUST-MEDIATED PAH EXPOSURES 

RELATED TO SEALED PARKING LOTS 

MAY EXCEED DIETARY INTAKES IN 

CHILDREN. E. S. Williams 1 , B. J. Mahler 2 and P. 

C. Van Metre 2 . 1 Center for Reservoir and Aquatic 

Systems Research, Baylor University, Waco, TX and 

2 

U.S. Geologic Survey, Austin, TX. 

222 






Platform Sessions



Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Exposure Assessments and Biomonitoring 

Applications 

Chairperson(s): David Dodge, Gradient Corporation, Bend, OR, and Tim 

Fennell, RTI International, Research Triangle Park, NC. 




DIRECT COMPARISON OF DRIED BLOOD 

SPOT (DBS) ANALYSIS TO PLASMA 

AND WHOLE BLOOD ANALYSIS IN 

TOXICOKINETIC STUDIES OF RATS. L. 

Patrone 1 , G. Liu 2 , H. M. Snapp 2 , A. Batog 1 , J. 

Valentine 1 , R. S. Mangipudy 1 , A. Tymiak 2 , Q. C. 

Ji 2 and M. E. Arnold 2 . 1 Drug Safety Evaluation, 

Bristol-Myers Squibb, New Brunswick, NJ and 

2 

Bioanalytical Sciences, Bristol-Myers Squibb, 

Lawrenceville, NJ. 


DRIED BLOOD SPOT (DBS): A POTENTIAL 

APPROACH TO MONITORING DRUG 

EXPOSURE IN RAT FOETUSES. S. Cinelli 1 , 

F. Pastori 2 , R. Cicalese 3 , S. Villa 4 and G. Oberto 1 . 

1 

Scientific Direction, Research Toxicology Centre 

RTC, Pomezia, Rome, Italy, 2 Analytical Chemistry, 

Research Toxicology Centre, Pomezia - Rome, Italy, 

3 

Toxicology, Research Toxicology Centre, Pomezia, 

Rome, Italy and 4 Operative Direction, Research 

Toxicology Centre, Pomezia, Rome, Italy. Sponsor: 

J. Brightwell. 


COMPARATIVE KINETICS USING DRIED 

BLOOD SPOT TECHNIQUE (DBS) IN THE 

CYNOMOLGUS MONKEY. S. Grote-Wessels 1 , 

M. Niehoff 1 , W. Wilbois 1 , T. Pfaff 2 , H. Fischer 3 , A. 

Welbers 2 and W. Mueller 1 . 1 Covance Laboratories 

GmbH, Muenster, Germany, 2 AiCuris GmbH & 

Co.KG, Wuppertal, Germany and 3 A&M Labor, 

Bergheim, Germany. Sponsor: G. Weinbauer. 


CHARACTERISATION OF BIOLOGICALLY 

AVAILABLE WOOD COMBUSTION 

PARTICULATES IN CELL CULTURE 

MEDIUM. S. Gauggel 1 , C. Derreza-Greeven 1 , 

J. Wimmer 1 , M. Wingfield 2 and D. R. Dietrich 1 . 

1 

Human & Environmental Toxicology, University 

of Konstanz, Konstanz, Germany and 2 Malvern 

Instruments GmbH, Herrenberg, Germany. 


DIESEL EXHAUST PARTICLE TOXICITY 

TO HUMAN LUNG EPITHELIAL CELL 

LINE: SINGLE CELL EXPOSURE 

ASSESSMENT WITH MORPHOLOGICAL 

AND BIOPHYSICAL ANALYSIS. G. D. 

McEwen 1 , Y. Wu 1 , R. A. Coulombe 2 and A. Zhou 1 . 

1 

Biological Engineering, Utah State University, 

Logan, UT and 2 Animal, Dairy, and Veterinary 

Sciences, Utah State University, Logan, UT. 

Abstract # 


SUPERCOARSE WORLD TRADE CENTER 

PARTICLE EFFECTS ON RAT BRONCHIAL 

AIRWAY FUNCTION. B. Garrett, J. Vaughan, M. 

Cohen and L. Chen. Environmental Health Science, 

New York University, New York, NY. 


ASSESSMENT OF PUBLIC HEALTH RISKS 

ASSOCIATED WITH NAPHTHALENE 

ENTERING RESIDENCES AND 

COMMERCIAL SPACE FROM VAPOR 

INTRUSION AT MGP SITES. R. B. DeHate 1 , B. 

Skelly 1 , G. T. Johnson 2 and R. D. Harbison 2 . 1 GEI 

Consultants, Tampa, FL and 2 Environmental and 

Occupational Health, University of South Florida, 

Tampa, FL. 


EARLY LIFE MANGANESE EXPOSURE 

ESTIMATED USING DECIDUOUS TOOTH 

DENTINE AS A BIOMARKER. M. Arora 1,2 , A. 

Bradman 3 , K. Harley 3 , M. Vedar 3 , J. Chevrier 3 , N. 

Holland 3 , B. Eskenazi 3 and D. R. Smith 1 . 1 University 

of California, Santa Cruz, CA, 2 University of 

Sydney, Sydney, NSW, Australia and 3 University of 

California, Berkeley, CA. 


VALIDATION OF HAIR MANGANESE AS A 

EXPOSURE BIOMARKER : ANALYTICAL 

CONSIDERATIONS AND ASSOCIATIONS 

WITH OTHER EXPOSURE MARKERS. D. 

R. Smith 1 , T. Jursa 1 , F. Donna 4 , N. Zimmerman 2 , E. 

Hoffman 3 , R. Wright 3 and R. Lucchini 4 . 1 University 

of California, Santa Cruz, CA, 2 Purdue University, 

West Lafayette, IN, 3 Harvard University, Boston, MA 

and 4 University of Brescia, Brescia, Italy. 


THE VALUE OF INFORMATION FROM 

PROVISIONAL PBPK MODELS IN SUPPORT 

OF BIOMONITORING: THE CASE OF 

ATRAZINE. Y. Tan 1 , R. Goldsmith 1 , C. Daniel 1 , X. 

Zhang 3 , R. Tornero-Velez 1 , J. Johnson 2 and C. Dary 2 . 

1 

U.S. EPA, Durham, NC, 2 U.S. EPA, Las Vegas, NV 

and 3 General Dynamics Information Technology, 

Henderson, NV. 


A TOXICOKINETIC MODEL TO ASSESS 

EXPOSURE TO FOLPET FUNGICIDE FROM 

URINARY BIOMARKERS. R. Heredia Ortiz 1 , 

A. Berthet 1,2 and M. Bouchard 1 . 1 Department of 


of Montréal, Montréal, QC, Canada and 2 Institute for 

Work and Health, Lausanne University, Lausanne, 

Switzerland. 


EVALUATION OF CARDIOVASCULAR 

DISEASE BIOMARKERS IN ADULT 

TOBACCO CONSUMERS: A COMPARISON 

BETWEEN THE NATIONAL HEALTH AND 

NUTRITION EXAMINATION SURVEY AND 

A SINGLE SITE CROSS-SECTIONAL STUDY. 

K. M. Marano, S. J. Kathman, B. A. Jones, B. G. 

Brown and M. F. Borgerding. RJ Reynolds Tobacco 

Co., Winston Salem, NC. Sponsor: C. Garner. 

Tuesday 







223



Tuesday 



AN ANALYSIS OF PERFLUOROCHEMICAL 

CONCENTRATIONS IN AMERICAN RED 

CROSS ADULT BLOOD DONORS, 2000 TO 

2010. G. W. Olsen 1 , D. C. Mair 2 , C. C. Lange 3 , 

M. E. Ellefson 3 and W. K. Reagen 3 . 1 Medical, 

3M Company, St. Paul, MN, 2 North Central 

Region, American Red Cross, St. Paul, MN and 

3 

Environmental Laboratory, 3M, St. Paul, MN. 


PLASTICIZER MIGRATION FROM TOYS 

AND CHILD CARE ARTICLES. M. A. Dreyfus 

and M. A. Babich. U.S. Consumer Product Safety 

Commission, Bethesda, MD. 


RESIDENTIAL EXPOSURE MODELING FOR 

OZONE-GENERATING AIR CLEANERS. M. 

A. Babich, K. R. Carlson and T. A. Thomas. U.S. 

Consumer Product Safety Commission, Bethesda, 

MD. 


SEASONAL CHARACTERIZATION 

OF HEALTH RISKS DERIVED FROM 

EXPOSURE TO VOLATILE ORGANIC 

COMPOUNDS AND BIOAEROSOLS 

FOR RESIDENTS NEAR A WASTE 

MANAGEMENT FACILITY. L. Vilavert, 

J. L. Domingo, M. Schuhmacher and M. Nadal. 

Toxicology, Rovira i Virgili University, Reus, Spain. 


ENVIRONMENTAL IMPACT OF THE USE 

OF ALTERNATIVE FUELS IN CEMENT 

PLANTS: BASELINE STUDY IN TWO 

FACILITIES. J. L. Domingo, J. Rovira, M. Mari, 

M. Schuhmacher and M. Nadal. Toxicology, Rovira i 

Virgili University, Reus, Spain. 


ASBESTOS EXPOSURE ASSOCIATED WITH 

FIRE SLEEVE MATERIALS. C. L. Blake 1 , S. 

C. Harbison 2 , G. T. Johnson 2 and R. D. Harbison 2 . 

1 

Bureau Veritas, Atlanta, GA and 2 Environmental and 

Occupational Health, University of South Florida, 

Tampa, FL. 


CHARACTERIZATION OF AN ARS ANIMAL 

MODEL OF WHOLE-BODY IRRADIATION 

IN THE MINIPIG. S. Harbo 2 , L. Staska 2 , M. 

Murphy 1 , J. Lovaglio 2 and K. D. Thrall 1 . 1 Battelle, 

Pacific Northwest Division, Richland, WA and 

2 

Biological Monitoring & Modeling, Battelle 

Toxicology Northwest, Richland, WA. 


THE ARCTIC DILEMMA: COMMUNITY- 

BASED OUTREACH RELATED TO 

PISCIVORY AND MERCURY. C. Lieske and T. 

O’Hara. University of Alaska Fairbanks, Fairbanks, 

AK. 


IMPACT OF TOXICITY OF SELECTED 

PESTICIDES ON SURVIVILITY AND 

EFFICACY OF AN ENTOMOPATHOGENIC 

NEMATODE HETERORHABDITIS MINUTUS. 

R. Paul and C. Girish. Department of Post-Graduate 

Studies in Zoology, Gulbarga University, Gulbarga, 

Karnataka, India. Sponsor: C. Chetty. 


THE ROLE OF BOUND, SKIN RESIDUES IN 

DERMAL ABSORPTION OF PESTICIDES. 

R. C. Cochran 1 and J. H. Ross 2 . 1 Risk Assessment, 

GemQualityRisk, Inc., Sacramento, CA and 

2 

GemQualityRisk, Inc., Carmichael, CA. 


BISPHENOL A (BPA) AND 

HEXABROMOCYCLODODECANE (HBCD) 

STEREOISOMERS IN U.S. FOOD. A. 

Schecter 1 , N. Malik 1 , O. Paepke 2 and L. Birnbaum 3 . 

1 


University of Texas School of Public Health, Dallas, 

TX, 2 Eurofins Gfa GmbH Laboratory, Hamburg, 

Germany and 3 National Institute for Environmental 



SECOND-HAND, SMOKE-INDUCED 

PRO-INFLAMMATORY CYTOKINE 

PRODUCTION AND OXIDATIVE STRESS 

IN MICE. T. Muthumalage 2 , K. Hunter 3,2 , D. 

Redelman 4 , K. Pritsos 1 and C. Pritsos 1,2 . 1 Nutrition, 

University of Nevada, Reno, NV, 2 Environmental 

Sciences Graduate Program, University of Nevada, 

Reno, NV, 3 Microbiology and Immunology, 

University of Nevada, Reno, NV and 4 Physiology 

and Cell Biology, University of Nevada, Reno, NV. 


COMMONLY USED AIR FILTERS DO NOT 

SUBSTANTIALLY REDUCE EXPOSURE TO 

SECONDHAND SMOKE CONSTITUENTS. 

C. Pritsos 1,2 and T. Muthumalage 2 . 1 Nutrition, 

University of Nevada, Reno, NV and 2 Environmental 

Science Graduate Program, University of Nevada, 

Reno, NV. 


URINARY T, T MUCONIC ACID LEVELS 

ARE MODULATED BY EPXH1H139R AND 

NQO1*2 POLYMORPHISMS IN CHILDREN. 

E. Jiménez-Mendoza 1,2 , M. Sánchez-Guerra 1 , N. A. 

Pelallo-Martínez 3 , F. Díaz-Barriga 3 , L. Carrizales- 

Yánez 3 and B. Quintanilla-Vega 1 . 1 Toxicology 

Department, Cinvestav-Ipn, Mexico City, D.F., 

Mexico, 2 FES-Iztacala-UNAM, Mexico City, Mexico 

and 3 Faculty of Medicine, UASLP, San Luis Potosi, 

Mexico. 


BLOOD MERCURY CONCENTRATION 

AND RELATED FACTORS IN AN URBAN 

COASTAL AREA IN KOREA. Y. S. Hong 1 , D. S. 

Kim 2 , E. M. Jo 1 , B. G. Kim 1 , Y. M. Kim 1 , C. H. You 1 , 

S. D. Yu 2 and J. D. Park 3 . 1 Preventive Medicine, 

Dong-A University, Busan, Republic of Korea, 

2 

Environmental Epidemiology, National Institute of 

Environmental Research, Seoul, Republic of Korea 

and 3 Preventive Medicine, Chung-Ang University, 



HIGH PERFORMANCE METABOLIC 

PROFILING (HPMP) FOR 

ENVIRONMENTAL TOXICOLOGY. Y. H. 

Park. Medicine, Emory University, Atlanta, GA. 

Sponsor: D. Jones. 

224 






Platform Sessions



Abstract # 


EVALUATING CHEMICAL EXPOSURES 

USING HEMOGLOBIN ADDUCTS FOR 

ACRYLAMIDE AND 1, 3-BUTADIENE. J. 

M. Shimek 1 , B. McCarthy 2 , S. Erdal 1 and F. Davis 2 . 

1 


University of Illinois at Chicago, Chicago, IL and 

2 

Epidemiology and Biostatistics, University of 

Illinois at Chicago, Chicago, IL. 


A FISHING LINE GENERATOR TO 

DELIVER WTC DUST PARTICLES FOR 

INHALATION EXPOSURE. J. M. Vaughan, B. 

J. Garrett, M. D. Cohen and L. Chen. Environmental 

Health Science, New York University, Tuxedo, NY. 


SENSING OF THE CYANIDE METABOLITE 

2, 4 AMINOTHIAZOLINE CARBOXYLIC 

ACID WITH SURFACE ENHANCED RAMAN 

SPECTROSCOPY – STEPS TOWARD A 

PORTABLE SENSOR. D. E. Thompson 1 , 

A. Parbatani 1 , T. Tessema 2 , A. Meyers 1 and I. 

Petrikovics 1 . 1 Chemistry, Sam Houston State 

University, Huntsville, TX and 2 Chemistry, Villanova 

University, Villanova, PA. 


BTEX SERUM LEVELS IN THE GENERAL 

U.S. POPULATION: AN ANALYSIS OF THE 

2003–2004 NHANES DATASET. J. D. Urban, 

L. Fitzgerald, B. Burkhalter, D. Staskal-Wikoff, M. 

Harris and L. Haws. ToxStrategies, Inc., Austin, TX. 


PROFILING THE INTERNAL DOES 

OF REACTIVE AGENTS AND THEIR 

METABOLITES USING N-TERMINAL 

VALINE ADDUCTS. S. Goel, N. I. Georgieva, 

M. Thompson and G. Boysen. Environmental and 

Occupational Health, University of Arkansas for 

Medical Sciences, Little Rock, AR. 


EVALUATION OF AIRBORNE TOXICANT 

CONCENTRATIONS FROM THE 

DEEPWATER HORIZON OIL SPILL. J. 

Keenan 1 , H. Avens 2 , K. Unice 3 and D. Paustenbach 1 . 

1 

ChemRisk, San Francisco, CA, 2 ChemRisk, Boulder, 

CO and 3 ChemRisk, Pittsburgh, PA. 


IDENTIFYING AND COMMUNICATING 

EXPOSURES AND HEALTH RISKS FROM 

MICROCONSTITUENTS AT BIOSOLIDS 

LAND APPLICATION SITES. V. B. Mylavarapu 1 

and P. V. Cline 2 . 1 E E & S, CH2M Hill, Orlando, FL 

and 2 EE&S, CH2M Hill, Gainesville, FL. 


SITE EVALUATION OF BIOACCESSIBILITY 

OF DIOXINS/FURANS FROM SOIL. Y. W. 

Lowney 1 , G. Brorby 2 and R. Kalmes 2 . 1 Exponent, 

Boulder, CO and 2 Exponent, Oakland, CA. 

Abstract # 


ASSESSMENT OF BENZENE SHOWER 

EXPOSURES - IMPLICATIONS FOR SOIL 

AND WATER QUALITY GUIDELINE 

DEVELOPMENT. A. L. Knafla 1 , S. Hays 2 , 

J. Campbell 1 and M. Morden 3 . 1 Equilibrium 

Environmental Inc., Calgary, AB, Canada, 2 Summit 

Toxicology, Lyons, CO and 3 Suncor Energy Inc., 

Calgary, AB, Canada. 


ERIONITE MINERAL FIBERS IN ROAD 

GRAVEL: A POTENTIAL OCCUPATIONAL 

HAZARD IN THE WESTERN UNITED 

STATES. C. R. Partridge 1 , P. H. Ryan 2 , S. Adjei 3 , 

J. E. Lockey 3 and S. Griffin 1 . 1 U.S. EPA Region 8, 

Denver, Co., 2 Environmental Health, University of 

Cincinnati College of Medicine, Cincinnati, OH and 

3 

Internal Medicine, University of Cincinnati College 

of Medicine, Cincinnati, OH. 


RISK CHARACTERIZATION OF THE 

BROMINATED FLAME RETARDANT 

DECABROMODIPHENYL ETHANE IN 

INDOOR DUST. D. G. Dodge 1 , M. C. Pollock 2 , 

S. N. Sax 2 , C. Petito Boyce 3 and J. E. Goodman 2 . 

1 

Gradient, Bend, OR, 2 Gradient, Cambridge, MA and 

3 

Gradient, Seattle, WA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Oxidative Stress and Redox Biology 

Chairperson(s): Alexandria Lau, University of Arizona, Tucson, AZ, and 

Monica Valentovic, Marshall University School of Medicine, Huntington, 

WV. 




LIPOSOMAL-NAC PROTECTS 

AGAINST ACETAMINOPHEN-INDUCED 

HEPATOTOXICITY. K. Pucaj 1 , C. Buonocoro 2 , 

M. Alipour 2 , A. Omri 2 , M. Zsabo 2 and Z. Suntres 2 . 

1 

Nucro-Technics, Scarborough, ON, Canada and 

2 

Medical Sciences Division, Northern Ontario School 

of Medicine, Thunder Bay, ON, Canada. Sponsor: 

G. Shopp. 


PARAOXONASE 2 (PON 2) IN THE 

CENTRAL NERVOUS SYSTEM: A 

NEUROPROTECTIVE ROLE? L. G. Costa 1,3 , 

G. Giordano 1 , T. B. Cole 2 and C. E. Furlong 2 . 

1 

Department of Environmental and Occupational 

Health Sciences, University of Washington, Seattle, 

WA, 2 Division of Medical Genetics and Department 

of Genome Sciences, University of Washington, 

Seattle, WA and 3 Department of Human Anatomy, 

Pharmacology and Forensic Science, University of 

Parma Medical School, Parma, Italy. 

Tuesday 







225



Tuesday 



COMPARATIVE EVALUATION OF TAURINE 

AND THIOTURINE FOR THEIR EFFECTS 

ON ETHANOL-INDUCED OXIDATIVE 

STRESS IN THE RAT. M. C. Parikh and C. 

A. Lau-Cam. Pharmaceutical Sciences, St. John’s 

University, Jamaica, NY. 


THE EFFECT OF ESTROGEN ON 

MACROPHAGES RESPONSE TO 

OXIDATIVE STRESS. T. Entezarizaher 1 , M. 

Javdan 2 and Z. Zakeri 3 . 1 LaGuardia Community 

College, Long Island City, NY, 2 The Feinstein 

Institute for Medical Research, Manhasset, NY 

and 3 Queens College and Graduate Center of City 

University of New York, Flushing, NY. 


DOSE-RESPONSE ANALYSIS OF 

POTASSIUM BROMATE-INDUCED DNA 

DAMAGE IS CONSISTENT WITH LOW- 

DOSE LINEAR, NON-THRESHOLD 

PROCESSES. M. A. Spassova 1 , D. J. Miller 1 , J. 

Caldwell 1 , S. V. Vulimiri 1 , D. A. Eastmond 2 , C. Chen 1 

and P. D. White 1 . 1 NCEA, U.S. EPA, Washington, 

D.C. and 2 Cell Biology & Neuroscience, University 

of California Riverside, Riverside, CA. 


ALL-TRANS-RETINOIC ACID PROTECTS 

AGAINST ROS INDUCED KIDNEY INJURY. 

S. S. Lau, J. L. Lord-Garcia, L. W. Lai, K. Y. Yong, 

Y. H. Lien and T. J. Monks. Pharmacology and 

Toxicology, University of Arizona, Tucson, AZ. 


TEMPOL AND TEMPOL-H PROTECT 

CARDIOMYOCYTES FROM NUCLEOSIDE 

REVERSE TRANSCRIPTASE INHIBITOR 

(NRTI)-INDUCED MITOCHONDRIAL 

TOXICITY. P. Nguyen 1 , Y. Liu 1 , J. B. Mitchell 2 

and M. C. Poirier 1 . 1 Carcinogen-DNA Interactions 

Section, LCBG, National Cancer Institute, National 

Institutes of Health, Bethesda, MD and 2 Tumor 

Biology Section, RBB, National Cancer Institute, 

National Institutes of Health, Bethesda, MD. 


NOVEL FUNCTIONS OF ALDH7A1 AGAINST 

HYPEROSMOTIC STRESS. C. Brocker 1 , M. 

Cantore 2 , P. Failli 2 and V. Vasiliou 1 . 1 Department 

of Pharmaceutical Sciences, University of 

Colorado Denver, Aurora, CO and 2 Department of 

Pharmacology, University of Florence, Florence, 

Italy. 


PROTECTIVE ROLE OF ATP BINDING 

CASSETTE TRANSPORTER ABCB6 IN 

ARSENIC TOXICITY. H. Chavan, M. Oruganti 

and P. Krishnamurthy. Pharmacology, Toxicology & 




ARSENIC ACTIVATES THE NRF2 

ANTIOXIDANT RESPONSE PATHWAY 

VIA AUTOPHAGY. A. Lau and D. D. Zhang. 


Arizona, College of Pharmacy, Tucson, AZ. 


HISTONE DEACETYLASE 6 ASSOCIATES 

WITH THE POLYSOME DURING 

ARSENITE-INDUCED STRESS. K. Kappeler, J. 

Zhang and Q. Chen. University of Arizona, Tucson, 

AZ. 


POST-TRANSLATIONAL MODIFICATION 

AND REGULATION OF GLUTAMATE 

CYSTEINE LIGASE BY THE α, 

β-UNSATURATED ALDEHYDES ACROLEIN 

AND 4-HYDROXYNONENAL. D. S. Backos 1 , 

K. S. Fritz 1 , J. R. Roede 2 , D. R. Petersen 1 and C. C. 

Franklin 1 . 1 Department of Pharmaceutical Sciences, 

University of Colorado Denver, Denver, CO and 

2 

Department of Medicine, Pulmonary Division, 



IDENTIFICATION OF 

HYDROIMIDAZOLONE AND 

ARGPYRIMIDINE ADDUCTS AS 

GLYCOOXIDATIVE BIOMARKERS IN 

TYPE 2 DIABETIC SUBJECTS. O. Kinsky 1 , 

M. J. Kimzey 1 , H. N. Yassine 2 , C. S. Stump 2 , G. 

Tsaiprailis 1 , T. J. Monks 1 and S. S. Lau 1 . 1 Southwest 

Environmental Health Sciences Center, Department 

of Pharmacology and Toxicology, College of 

Pharmacy, University of Arizona, Tucson, AZ and 

2 

College of Medicine, University of Arizona, Tucson, 

AZ. 



CHARACTERIZATION OF 4-HNE 

MODIFIED LIVER FATTY ACID BINDING 

PROTEIN IN A RODENT MODEL OF 

EARLY ALCOHOLIC LIVER DISEASE. R. L. 

Smathers, K. S. Fritz, J. J. Galligan, C. T. Shearn and 

D. R. Petersen. Pharmaceutical Sciences, University 

of Colorado Denver, Aurora, CO. 


EXTENSIVE OXIDATIVE PROTEIN 

MODIFICATIONS OBSERVED IN HUMAN 

PLASMA AND CANDIDATE BIOMARKERS 

OF SYSTEMIC CHRONIC INFLAMMATORY 

AND OXIDATIVE STRESS. X. Zhang, M. A. 

Gritsenko, B. Webb-Robertson, K. M. Waters, D. J. 

Bigelow, W. Qian, J. G. Pounds and J. M. Jacobs. 

Biological Sciences Division, Pacific Northwest 



EXTENSIVE OXIDATIVE PROTEIN 

MODIFICATIONS OBSERVED IN HUMAN 

PLASMA AND CANDIDATE BIOMARKERS 

OF SYSTEMIC CHRONIC INFLAMMATORY 

AND OXIDATIVE STRESS. B. Webb-Robertson, 

X. Zhang, K. M. Waters, W. Qian, J. M. Jacobs, D. 

J. Bigelow, R. Corley and J. G. Pounds. Biological 

Sciences Division, Pacific Northwest National 


226 






Platform Sessions



Abstract # 


DEVELOPMENT OF MALDI-TOF 

METHODOLOGY FOR SELECTIVE 

MS-ANALYSIS AND IMAGING OF 

CARDIOLIPINS IN LIPID EXTRACTS AND 

TISSUES. L. J. Sparvero 1,3 , A. Amoscato 1,3 , B. R. 

Pitt 1,3 , H. Bayir 2,3 and V. E. Kagan 1,3 . 1 Center for Free 

Radical and Antioxidant Health, Environmental and 

Occupational Health, Pittsburgh, PA, 2 Critical Care 

Medicine, Safar Center for Resuscitation Research, 

Pittsburgh, PA and 3 University of Pittsburgh, 



PROTEOMIC IDENTIFICATION OF 

NITRATED PROTEINS IN THE SPLEEN OF 

ANILINE EXPOSED RATS. X. Fan 1 , J. Wang 1 , 

K. Soman 2 , G. Ansari 1,2 and M. Khan 1 . 1 Pathology, 

University of Texas Medical Branch, Galveston, TX 

and 2 BMB, University of Texas Medical Branch, 

Galveston, TX. 


CIRCULATING LEVELS OF NITRATED 

PROTEINS ARE SUPPRESSED BY 

CIGARETTE SMOKING. R. Zangar 1 , H. Jin 1 , 

B. Webb-Robertson 1 , D. Bigelow 1 , M. Scholand 2 , J. 

Hoidal 2 and J. Pounds 1 . 1 Pacific Northwest National 

Laboratory, Richland, WA and 2 Health Sciences 

Center, University of Utah, Salt Lake City, UT. 


URINARY 8-OXO-DEOXYGUANOSINE IN 

SMOKERS: ASSOCIATIONS WITH RACE, 

SEX, AND MENTHOL SMOKING. M. 

Misra and D. Ergle. Lorillard Tobacco Company, 

Greensboro, NC. 


IMBALANCED EPITHELIAL ANTI-VIRAL 

RESPONSES INDUCED BY CIGARETTE 

SMOKE (CS). S. Tao and Y. Chen. Pharmacology 

and Toxicology, School of Pharmacy, Tucson, AZ. 


NITRITE AND METHEMOGLOBIN 

FORMATION UPON NO2 EXPOSURE 

MAY TRIGGER OXIDANT STRESS AND 

CARDIOVASCULAR DYSFUNCTION. 

POSSIBLE MECHANISM FOR TRAFFIC- 

INDUCED ADVERSE EFFECTS. C. Monteil 1 , 

C. Crochemore 1 , V. Keravec 2 , D. Preterre 2 and J. 

Morin 1 . 1 U644, Inserm, Rouen, France and 2 Certam, 

Certam, Saint Eienne du Rouvray, France. Sponsor: 

R. Forster. 


PARTICULATE MATTER-INDUCED LIPID 

PROFILE ALTERATIONS IN HUMAN 

ENDOTHELIAL CELLS. L. Yu 1 and A. Jeng 2 . 

1 

Biomedical Sciences Program, Old Dominion 

University, Norfolk, VA and 2 Community and 

Environmental Health, Old Dominion University, 

Norfolk, VA. 

Abstract # 


HYDROXYL RADICAL FORMATION 

BY REDOX CYCLING OF QUINONES 

IN DIESEL EXHAUST PARTICLES. R. G. 

Udasin 1 , K. C. Fussell 1 , Y. Wang 2 , V. Mishin 3 , 

D. E. Heck 4 , D. L. Laskin 1,3 and J. D. Laskin 1,2 . 

1 

Joint Graduate Program in Toxicology, Rutgers 

University/UMDNJ, Piscataway, NJ, 2 Environmental 

& Occupational Medicine, UMDNJ-RW Johnson 

Medical School, Piscataway, NJ, 3 Pharmacology & 

Toxicology, Rutgers University, Piscataway, NJ and 

4 

Department of Environmental Health Science, New 

York Medical College, Valhalla, NY. 


TRANSFORMING GROWTH FACTOR 

BETA MEDIATES OZONE-INDUCED 

AIRWAY WALL FIBROSIS. R. Liu 1 , A. Katre 1 , 

C. Ballinger 1 , H. Akhter 1 , M. Fanucchi 1 , D. Kim 2 

and E. Postlethwait 1 . 1 University of Alabama at 

Birmingham, Birmingham, AL and 2 Ewha Womans 



ANGIOTENSIN II PLAYS A CRITICAL 

ROLE IN DIABETIC LUNG FIBROSIS 

VIA ACTIVATION OF NADPH OXIDASE- 

MEDIATED NITROSATIVE DAMAGE. L. 

Cai 1,2 , J. Yang 2,1 , Y. Tan 1 and L. Miao 2 . 1 Pediatrics, 

University of Louisville, Louisville, KY and 2 Second 

Hospital of Jilin University, Changchun, China. 


THE ROLE OF NITRIC OXIDE SYNTHASE 

IN PARAQUAT-INDUCED OXIDATIVE 

STRESS IN A SKELETAL MUSCLE CELL 

LINE. P. Venkatakrishnan, S. Panda, L. Roman and 

B. S. Masters. Biochemistry, University of Texas 

Health Science Center, San Antonio, TX. 


GENERATION OF ACETYL RADICAL 

AND SINGLET OXYGEN BY REACTIVE 

ALPHA-OXOALDEHYDES LINKED TO 

AGING AND DIABETES. J. Massari 1 and E. J. 

Bechara 1,2 . 1 Ciências Exatas e da Terra, Universidade 

Federal de São Paulo, Diadema, São Paulo, Brazil 

and 2 Biochemistry, São Paulo University, São Paulo, 

Brazil. Sponsor: S. Berlanga Barros. 


CARBONYLATION AND INACTIVATION OF 

MITOCHONDRIAL COMPLEX I DURING 

KAINATE-INDUCED EPILEPTOGENESIS. 

K. Ryan and M. Patel. Pharmaceutical Sciences, 

University of Colorado Denver, Aurora, CO. 


TOLUENE EFFECTS ON OXIDATIVE 

STRESS IN BRAIN REGIONS OF YOUNG- 

ADULT, MIDDLE-AGE, AND SENESCENT 

BROWN NORWAY RATS. P. S. Kodavanti, 

J. E. Royland, J. H. Richards, J. Besas and R. C. 

MacPhail. NHEERL, U.S. EPA, Research Triangle 

Park, NC. 

Tuesday 







227



Tuesday 



MERCURY-INDUCED PHOSPHATIDIC 

ACID LIPID SIGNALING IN VASCULAR 

ENDOTHELIAL CELLS IS REDOX- 

REGULATED. J. D. Secor 1,2 , R. B. Patel 1,2 , S. 

R. Kotha 1,2 , R. M. Uppu 3 and N. L. Parinandi 1,2 . 

1 

The Ohio State University College of Medicine, 

Columbus, OH, 2 Pulmonary, Dorothy M. Davis Heart 

and Lung Research Institute, Columbus, OH and 

3 

Environmental Toxicology, Southern University and 

A&M College, Baton Rouge, LA. 


GENETIC ABLATION OF IPLA 2 

γ 

INCREASED URINARY MARKERS OF 

OXIDATIVE STRESS AND INCREASED 

LIPID PEROXIDATION IN KIDNEY 

CORTEX OF AGED MICE. A. C. Eaddy, V. 

M. Kale, J. L. Blakely and R. G. Schnellmann. 

Pharmaceutical and Biomedical Sciences, Medical 



FREE FATTY ACIDS SENSITIZE 

HEPATOCYTES TO ETHANOL 

METABOLISM-INDUCED DAMAGE. I. 

Hernandez Resendiz, L. Gomez Quiroz, L. Bucio, 

V. Souza and C. Gutierrez-Ruiz. Health Sciences, 

Universidad Autónoma Metropolitana Iztapalapa, 

Mexico, Mexico. 


ALCOHOL-INDUCED BONE LOSS IS 

BLOCKED IN P47PHOX -/- MICE LACKING 

FUNCTIONAL NADPH OXIDASES. K. 

Mercer 2 , R. Wynne 1,2 , C. Moutos 2 , C. Lumpkin 1 , 

L. Suva 1 , T. Badger 1,2 , J. Chen 1,2 and M. J. Ronis 1,2 . 

1 

University of Arkansas for Medical Sciences, Little 

Rock, AR and 2 Arkansas Children’s Nutrition Center, 

Little Rock, AR. 


INDUCTION OF OXIDATIVE DNA DAMAGE 

BY MESALAMINE IN THE PRESENCE OF 

COPPER: A POTENTIAL MECHANISM FOR 

MESALAMINE ANTICANCER ACTIVITY. Z. 

Jia 1,2 , R. P. Zimmerman 1 , H. Zhu 1 , N. Vandjelovic 1 , 

H. P. Misra 1 , J. Wang 1 and Y. Li 1,2 . 1 Edward Via 

Virginia College of Osteopathic Medicine, Virginia 

Tech Corporate Research Center, Blacksburg, VA and 

2 

Department of Biomedical Sciences & Pathobiology, 

Virginia Polytechnic Institute and State University, 

Blacksburg, VA. 


EFFECT OF ZIDOVUDINE ON 

MITOCHONDRIAL OXIDATIVE 

PHOSPHORYLATION PROTEIN LEVELS 

AND ENZYME COMPLEX ACTIVITIES. J. 

Fang and F. A. Beland. Division of Biochemical 




MECHANISMS BY WHICH 

GLYCERALDEHYDE-3-PHOSPHATE 

DEHYDROGENASE PROTECTS ITSELF 

AGAINST A CHEMICAL MODIFICATION. 

T. Miura 1 , Y. Egara 2 , R. Hirose 1 , N. Iwamoto 1 , Y. 

Shinkai 1 , A. K. Cho 3 and Y. Kumagai 1,3 . 1 Doctoral 

Programs in Medical Sciences, Graduate School 

of Comprehensive Human Sciences, University of 

Tsukuba, Tsukuba, Ibaraki, Japan, 

2 

Master’s Program in Environmental Sciences, 

Graduate School of Life and Environmental 

Sciences, University of Tsukuba, Tsukuba, Ibaraki, 

Japan and 3 Southern California Particle Center, 


CA. Sponsor: A. Naganuma. 


METABOLISM DEPENDENT 

MODULATION OF 3, 4-(±)-METHYLENE 

DIOXYMETHAMPHETAMINE-INDUCED 

NEUROTOXICITY: POTENTIAL ROLE 

OF THIOETHER METABOLITES IN THE 

NEUROINFLAMMATORY RESPONSE. J. M. 

Herndon, A. B. Cholanians, G. V. Erives, X. Li, S. 

S. Lau and T. J. Monks. Pharmacology/Toxicology, 

University of Arizona - College of Pharmacy, 

Tucson, AZ. 


PRO-OXIDANT ACTIONS OF APOCYNIN 

AND ITS OXIDATIVE METABOLITES 

DIAPOCYNIN AND 5-NITROAPOCYNIN. L. 

A. Laynes 1 , A. C. Raghavamenon 1 and R. M. Uppu 1,2 . 

1 

Environmental Toxicology, Southern University and 

A&M College, Baton Rouge, LA and 2 Chemistry, 

Southern University and A&M College, Baton 

Rouge, LA. 


GLUTATHIONE AND AMINO ACID FLUX 

MEASUREMENT UNDER NORMAL 

AND OXIDATIVE STRESS CONDITIONS 

USING HPLC AND ACCELERATOR MASS 

SPECTROMETRY. B. Stewart 1 , A. Navid 2 , R. Le 1 , 

K. Turteltaub 2 and G. Bench 1 . 1 Center for Accelerator 

Mass Spectrometry, Lawrence Livermore National 

Laboratory, Livermore, CA and 2 Bioscience and 

Biotechnology Division, Lawrence Livermore 

National Laboratory, Livermore, CA. 


9:00 AM to 4:30 PM 

Room 203 


Chairperson(s): Joel G. Pounds, Pacific Northwest National 

Laboratory, Richland, WA, and Nancy Kerkvliet, Oregon State 

University, Corvallis, OR. 

Sponsor: 

Research Funding Committee 

Representatives from federal agencies that fund research will be available 

in the Research Funding Room. Individual conversations can occur 

in a quiet, informal space whether you want to discuss research plans, 

a current grant application, or previous reviews. Representatives from 

NIH, including program officers and Center for Scientific Review staff, 

NIEHS, NHLBI, and other institutes, as well as U.S. EPA ORD, DOE, 

and other agencies will be available at various times. 

Make an appointment with your program officer in advance or at their 

exhibit booth, or check the posted schedule to meet with the staff 

member of your choice. New investigators are especially encouraged to 

meet with program staff. Handouts will be available. 

228 






Platform Sessions



Abstract # 


9:15 AM to 10:15 AM 

Room 140B 

Exhibitor Hosted Session: LiverPool: Pooled Human 

Cryopreserved Hepatocytes and Their Advantages Across 

Diverse ADME-Tox Applications 

Presented by: Celsis In Vitro Technologies 

The patented LiverPool TM pooled hepatocyte product, provides an average 

response that is optimal for ADME-Tox studies. Advances in pre-pooling 

have further increased the usefulness of pooled human hepatocytes 

including their ability to meet targeted activity profiles. Applications like 

transporter and inhibition will be discussed. 


9:15 AM to 10:15 AM 

Room 140A 

Exhibitor Hosted Session: Preclinical Cellular Therapeutic 

Safety Testing 


Cell-based therapies present unique challenges for the evaluation of safety, 

cell survival, differentiation and distribution, and the potential for tumor 

formation in the appropriate animal model. These specifically designed 

preclinical studies with different approaches provide valuable information 

for assessment of potential clinical and regulatory risks of these promising 

therapies. 


9:15 AM to 10:15 AM 

Room 156 

Exhibitor Hosted Session: Predicting the Human 

Clinical Dose 


Allometric scaling has been the primary technique for human dose prediction. 

The development of humanized ADME reagents has led to techniques 

where the metabolic characteristics of a drug are taken into account to 

improve the accuracy of predicting human clinical doses and potential drug/ 

drug interaction issues. 

Abstract # 


10:30 AM to 11:30 AM 

Room 156 

Exhibitor Hosted Session: Developing a Noval Vaccine/ 

Adjuvant Combination for the Prophylaxis and Treatment of 

Infectious Disease 


Novel vaccine/adjuvant combinations introduce new risks that need to be 

assessed during safety assessment. Standard paradigms do not exist and 

approaches must be designed on a case by case basis with a good understanding 

of the predicted clinical immunogenicity of the vaccine candidate. 

Case studies will be discussed which highlight varying approaches for both 

prophylactic and therapeutic vaccines. 


10:30 AM to 11:30 AM 

Room 140B 

Exhibitor Hosted Session: Diets for GLP Studies, Including 

Those for REACH 


In vivo testing as part of REACH programs further challenges the toxicologist 

to make scientifically-sound decisions on what is appropriate diet 

in terms of nutrient levels and ingredients for GLP work, in light of the wellestablished 

evidence that diet can adversely impact on endocrine disruptor 

studies. 


10:30 AM to 11:30 AM 

Room 140A 

Exhibitor Hosted Session: National Toxicology Program 

Chemical Effects in Biological Systems 

Presented by: National Toxicology Program 

NTPCEBS (National Toxicology Program Chemical Effects in Biological 

Systems), the NTP public database, now contains data from legacy NTP 

studies, making this data available in cross-study queries. Recently the NTP 

also made DrugMatrix (Entelos) available in NTPCEBS. This session will 

introduce NTPCEBS and how to use it. 

Tuesday 


11:45 AM to 12:45 PM 

Room 140A 

Exhibitor Hosted Session: A Battery of Toxicity Screening 

Assays for Selection of Dermal Drug Candidates 

Presented by: LAB Research 

This session will describe a battery of in silico, in vitro, and in vivo toxicity 

screening assays that—prior to selecting the final drug candidate for clinical 

development—are useful to screen out candidate molecules for their potential 

to cause local irritancy, contact sensitization or photototoxicity reactions. 







229



Tuesday 



11:45 AM to 12:45 PM 

Room 156 

Exhibitor Hosted Session: A Systems Toxicology Approach 

to Understanding Drug Toxicity and Compound Prioritization 

Presented by: Ingenuity Systems, Inc. 

This session will demonstrate using an industry relevant case study, how 

IPA’s rich molecular toxicity content and functionality, such as toxicity pathways, 

pathology endpoints, clinical chemistry, and hematology assay data 

associations can add to the understanding and evaluation of drug mechanisms 

and compound prioritization. Presented by: Kevin T. Morgan, Ph.D., 

Independent Consultant. 


11:45 AM to 12:45 PM 

Room 140B 

Exhibitor Hosted Session: New Applications of Latest 

Telemetry Technology in Toxicology and Safety Pharmacology 

Presented by: Data Sciences International 

Advances in wireless technology have enabled new non-invasive and 

plantable telemetric physiological monitoring to provide additional new 

parameters. Leading researchers will present their latest validation data from 

recent work with new innovative combined applications in toxicology and 

safety pharmacology. Data from rodent, canine, and NHP model studies will 

be presented. 

Tuesday Afternoon, March 8 

12:00 NOON to 1:30 PM 

Room 141 

Tuesday Afternoon 

Special Interest Group Luncheon: ASIO Lunch and Learn 



12:00 NOON to 1:30 PM 

Room 149 

Specialty Section Meeting/Luncheon: Comparative and 

Veterinary 


12:00 NOON to 1:15 PM 

Salon I 


Sponsor: 





This event is focused on new investigators such as new assistant professors 

on tenure track. Participants will be able to speak informally with 

federal funding agency program officers and more senior investigators, 

including members of the Research Funding Committee. After a brief 

grantsmanship talk by Sally J. Rockey, Ph.D., NIH Deputy Director for 

Extramural Research, discussion will continue with the program officers 

at each table. Ask your questions and benefit from conversation resulting 

from the questions of others. You can also arrange at this time to meet 

these representatives later in the Research Funding Resource Room for 

an individual discussions. A limited number of box lunches and seats will 

be available. 


12:00 NOON to 1:15 PM 

Salon G 



Chairperson(s): Sarah Campion, Brown University, Providence, RI. 

Sponsor: 


Amidst scrambling to attend all of the events at the meeting, this will be 

time for postdocs to kick back and relax! All postdoctoral scholars are 

invited to a casual luncheon organized by the Postdoctoral Assembly 

(PDA). We will announce the recipients of the Best Postdoctoral Publication 

Awards and acknowledge the postdocs who received awards this year 

from Regional Chapters, Special Interest Groups, and Specialty Sections. 

The PDA Board members will present an overview of accomplishments 

and future directions for the PDA, and will introduce the new board 

members for 2011–2012. There will be a drawing for prizes. Postdocs can 

reserve a ticket for $5 when they register for the Annual Meeting. 


12:00 NOON to 1:20 PM 

Room 143 



Roundtable Session: Integrating Alternative Test Methods 

into the Federal Regulatory Framework 

Chairperson(s): Suzanne Fitzpatrick, U.S. FDA, Rockville, MD, and 

Leonard Schechtman, Innovative Toxicology Testing, Lake Worth, FL. 

Sponsor: 


Endorsed by: 


Current regulatory testing paradigms require certain sets of data needed for 

regulatory evaluation and risk assessment. Many of the methodologies used 

230 






Platform Sessions



Abstract # 

today in the traditional approach to toxicity testing originated over a half 

century ago and are both time and animal intensive. In 2007, the National 

Academy of Sciences report described a new vision and strategy for toxicity 

testing in the 21st century that would be based on human biology rather 

than animal biology and would be less expensive and less time consuming. 

This strategy would also involve a strong commitment to the 3Rs—replacement, 

reduction, and refinement of animal use in research, testing, and 

education. Being responsive to this progressive scientific perspective would 

necessitate moving forward in developing, validating, and incorporating 

alternative toxicological test methods into the federal regulatory framework. 

This transformational toxicological approach would also entail an active 

dialogue and collaboration between stakeholders, NGOs, academics, and 

federal scientists. Our panel of experts will offer the opportunity for such a 

discourse between U.S. FDA and U.S. EPA and their stakeholders about the 

type of data needed from alternative methods to demonstrate that they are 

scientifically valid and address the fundamental questions of human safety 

and efficacy. 

#1309 12:00 INTEGRATING ALTERNATIVE TEST 

METHODS INTO THE FEDERAL 

REGULATORY FRAMEWORK. S. C. 

Fitzpatrick 1 and L. Schechtman 2 . 1 Office of the 

Commissioner, U.S. FDA, Silver Spring, MD and 

2 

Innovative Consulting, LLC, Lake Worth, FL. 

12:00 THE 3 R’S: MORE IMPORTANT NOW THAN 

EVER. Andrew N. Rowan 

12:05 INTEGRATED TESTING AND EMPLOYING 

ADVANCED METHODS FOR BIOLOGICAL 

PROFILING IN THE MODERNIZED TSCA. 

Richard A. Becker 

12:20 REGULATORY ACCEPTANCE 

OF ALTERNATIVE METHODS— 

PHARMACEUTICALS IN THE U.S. Abigail 

Jacobs 

12:35 CURRENT APPROACHES TO ANIMAL 

TESTING IN REGULATION OF BIOLOGICS 

AND VACCINES BY U.S. FDA/CBER. Richard 

D. McFarland 

12:50 CONSIDERATIONS FOR ACCEPTANCE OF 

ALTERNATIVES FOR PESTICIDES AND 

CHEMICALS. John R. Fowle 



12:00 NOON to 1:20 PM 

Room 144 


Informational Session: Coordinating Global Chemical Safety: 

The Big Four 

Chairperson(s): Philip Wexler, National Library of Medicine, Bethesda, 

MD, and Harihara Mehendale, University of Louisiana Monroe, Monroe, 

LA. 

Sponsor: 

Global Strategy Task Force 

Endorsed by: 



As the toxicology community is well aware, chemicals are both a global 

benefit and concern. They routinely cross national borders in the marketplace 

and in planned or accidental pollution streams. With increasing 

production comes increasing opportunity for exposure. Novel chemical 

entities, such as those derived from nanotechnology, simply up the ante 

Abstract # 

with still undetermined effects. It has been nearly 40 years since the United 

Nations (Stockholm) Conference on the Human Environment stated in its 

declaration that ‘The protection and improvement of the human environment 

is a major issue which affects the well-being of peoples and economic 

development throughout the world; it is the urgent desire of the peoples of 

the whole world and the duty of all Governments.’ Principle 6 of this declaration 

also indirectly advocated control of chemicals by calling for a halt 

to the discharge of toxic substances which exceed the capacity of the environment 

to render them harmless. The strengthened global will to manage 

chemicals responsibly has been facilitated by advances in information and 

communications technologies, chief among them being the Internet. Many 

multilateral efforts, both legally binding vehicles and policy frameworks, 

can at least, in some respect, trace their lineage back to the Stockholm 

Conference. These three major international legal instruments dealing with 

chemicals including the transboundary movement of hazardous wastes and 

their disposal, prior informed consent, and persistent organic pollutants 

will be our focus. We will highlight the Strategic Approach to International 

Chemicals Management (SAICM), today’s major international policy 

framework. Finally, our panel of experts will offer a summary relative to the 

provisions of these multilateral environmental agreements (MEAs), highlight 

major successes and challenges, discuss future outlooks, and indicate 

the relevance of global chemical policy to toxicologists, and how they, in 

turn, can influence such policy. 

#1310 12:00 COORDINATING GLOBAL CHEMICAL 

SAFETY: THE BIG FOUR. P. Wexler 1 , P. 

Whiting 2 , D. Downie 3 , H. Selin 4 and L. Onyon 5 . 

1 

National Library of Medicine, Bethesda, MD, 

2 

U.S. EPA, Washington, D.C., 3 Fairfield University, 

Fairfield, CT, 4 Boston University, Boston, MA and 

5 

UNEP, Geneva, Switzerland. 

12:00 Introduction. Philip Wexler 

12:05 BASEL CONVENTION. Patricia Whiting 

12:22 ROTTERDAM CONVENTION. David Downie 

12:39 STOCKHOLM CONVENTION. Henrik Selin 

12:56 STRATEGIC APPROACH TO 

INTERNATIONAL CHEMICALS 

MANAGEMENT. Lesley Onyon 



12:00 NOON to 1:20 PM 

Room 147 




Informational Session: Livers on a Plate: Next Generation 

Hepatocyte Models for High-Throughput Screening and 

Mode-of-Action Prediction 

Chairperson(s): Chris Corton, U.S. EPA, Research Triangle Park, NC, 

and Susan Hester, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 



The liver is a common target for chemicals and drugs, due in part to the 

role of the liver in xenobiotic metabolism. Because the liver is frequently 

the most sensitive target in two-year bioassays, chemical regulation is often 

based on adverse liver effects. Drugs withdrawn from the market are more 

often due to unforeseen hepatotoxicity. Given the number of chemicals that 

need to be assessed for hepatotoxicity by the pharmaceutical and chemical 

Tuesday 







231



Tuesday 


industries, many investigators currently use primary hepatocytes or transformed 

hepatocyte-derived cell lines in lieu of animal studies. These models 

have serious limitations including major differences in the expression of 

xenobiotic metabolizing enzymes compared to the intact liver. There is a 

clear need for the identification and characterization of biologically-relevant 

in vitro models that can recapitulate the functions, cell interactions, and 

responses to chemicals found in vivo. A number of exciting in vitro models 

of the liver have been recently developed which make them potentially 

better models for predicting responses in vivo than conventional cultures. 

We will characterize the use of a number of in vitro models of the liver 

including 2D and 3D co-cultures containing hepatocytes and other cell 

types. Our panel of experts have an extensive experience in the characterization 

and use of these models and will discuss applications of the models 

including toxicity screening, metabolic activation, mode-of-action determination 

using toxicogenomics and species extrapolation. This particular topic 

will be useful to those interested in high-throughput screening, hepatotoxicity, 

and mode-of-action research. 

#1311 12:00 LIVERS ON A PLATE: NEXT GENERATION 

HEPATOCYTE MODELS FOR HIGH- 

THROUGHPUT SCREENING AND 

MODE-OF-ACTION PREDICTION. C. 

Corton 1 , S. Khetani 4 , L. Griffith 3 , D. Applegate 2 

and S. D. Hester 1 . 1 Integrated Systems Toxicology 

Division, U.S. EPA, Durham, NC, 2 RegeneMed, 

Inc., San Diego, CA, 3 MIT, Cambridge, MA and 

4 

HepreGen Corporation, Medford, MA. 

12:00 INTRODUCTION. Chris Corton 

12:05 IN VITRO TOXICOGENOMICS AND 

CHRONIC TOXICITY ASSESSMENT USING 

3D LIVER CO-CULTURE. Dawn Applegate 

12:25 PERFUSED MULTIWELL PLATE FOR 3D 

LIVER TISSUE ENGINEERING. Linda Griffith 

12:45 APPLICATIONS OF MICROSCALE ANIMAL 

AND HUMAN IN VITRO LIVER MODELS IN 

TOXICOLOGY. Salman Khetani 

1:05 HEPATOCYTE MODELS FOR 

PRIORITIZATION AND MODE-OF-ACTION 

PREDICTION OF ENVIRONMENTALLY- 

RELEVANT CHEMICALS. Susan Hester 


12:15 PM to 1:05 PM 

Room 201 

Distinguished Toxicology Scholar Award 

Lecture: Cloning and Functional Analysis of 

the Aryl Hydrocarbon Nuclear Translocator 

(ARNT) 

Lecturer: Oliver Hankinson, University of California, 


In 1991 we cloned ARNT, which we knew to be required for activity of 

the Aryl Hydrocarbon Receptor (AHR). We subsequently showed that 

ARNT is the obligate dimerization partner for AHR. ARNT represented 

a new class of transcription factor, the basic helix-loop-helix-Per-Arnt- 

Sim (bHLH-PAS) family. AHR, which was cloned the following year, 

also proved to be a bHLH-PAS protein. These observations were very 

surprising, since most investigators expected that AHR and its dimerization 

partner would be members of the nuclear receptor superfamily. 

Further studies by our group and others identified functional domains 

of these proteins, and lead to a broad understanding of their roles in 

transcriptional activation and chemical carcinogenesis. In 1995, Hypoxia 

Inducible Factor (HIF) was cloned, and shown to be a dimer of ARNT 

and another bHLH-PAS protein. Studies by us and others have shown 

that ARNT is directly involved in tumor growth, angiogenesis, wound 

healing, diabetes and stroke through its role as a component of HIF. Our 

recent studies have focused on defining the roles of coactivator and other 

facilitator proteins in the AHR/ARNT- and HIF-dependent induction of 

gene transcription. Such proteins may represent nodal points for crosstalk 

between these pathways and other pathways of gene regulation. 


12:30 NOON to 2:00 PM 


Regional Chapter Student Luncheon: Northeast Regional 

Chapter 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Medical Devices 

Chairperson(s): Lori Moilanen, 3M, St. Paul, MN. 




EVALUATION OF THE SENSITIVITY 

OF ENDPOINTS IN THE ISO 10993-11 

SYSTEMIC TOXICITY STANDARD USING 

POSITIVE CONTROL COMPOUNDS. A. 

Freeman 1,2 , A. Komiyama 1 , J. Fazio 1,3 , S. Hamilla 1,4 , 

H. Dinesdurage 1 and R. P. Brown 1 . 1 U.S. FDA, Silver 

Spring, MD, 2 University of Maryland, College Park, 

MD, 3 Western New England College, Springfield, 

MA and 4 University of Connecticut, Storrs, CT. 


RAPID TOXICITY SCREENING OF 

POLYMERIC MATERIALS USING THE 

MICROTOX ASSAY. P. Kulkarni, H. Dinesdurage 

and R. P. Brown. CDRH, U.S. FDA, Silver Spring, 

MD. 

232 






Platform Sessions



Abstract # 


USE OF AN IN VITRO SCREEN FOR 

ASSESSING THE VAGINAL IRRITATION 

POTENTIAL OF INTIMATE CARE 

PRODUCTS. P. Clay 1 and N. Belot 2 . 1 SSL 

International, Manchester, United Kingdom and 

2 

Straticell, Gembloux, Belgium. Sponsor: D. Kent. 


DETERMINATION OF BISPHENOL-A 

COMPOUNDS LEACHABLE FROM 

POLYCARBONATE- AND POLYSULFONE- 

BASED HEMODIALYZERS. J. Guo, 

S. Cho and H. D. Luu. Division of Chemistry and 

Materials Sciences, U.S. FDA, Center for Devices 

and Radiological Health, Office of Science and 

Engineering Laboratories, Silver Spring, MD. 


HUMAN BIOKINETIC MODEL OF NICKEL 

RELEASE FROM MEDICAL DEVICES. J. S. 

Tsuji 1 and K. T. Bogen 2 . 1 Exponent, Bellevue, WA and 

2 

Exponent, Oakland, CA. 


PRECLINICAL SAFETY ASSESSMENT OF 

DESMA (CASRN 1101874-33-2) FOR USE IN 

PROLONGED SURFACE CONTACT DENTAL 

PRODUCTS. B. D. Bagley 1 , L. H. Moilanen 1 and 

K. Stefan 2 . 1 Medical Department, 3M, St. Paul, MN 

and 2 3M ESPE, Seefeld, Germany. 


REPRODUCTIVE TOXICITY EVALUATION 

OF THE RESIN MONOMER TRIETHYLENE 

GLYCOL DIMETHACRYLATE (TEGDMA) 

IN MICE. L. H. Moilanen 1 , J. K. Dahms 3 and 

A. Hoberman 2 . 1 Medical Department, 3M, St. Paul, 

MN, 2 Charles River Laboratories, Horsham, PA and 

3 

3M ESPE, St. Paul, MN. 


PRECLINICAL BIOCOMPATIBILITY 

ASSESSMENT OF A NEW NANO-FILLED 

FLOWABLE DENTAL COMPOSITE. E. F. 

Hope 1 , L. H. Moilanen 1 and A. Bogdan 2 . 1 Medical 

Department, 3M, St. Paul, MN and 2 3M ESPE, St. 

Paul, MN. 


POLYPHENOL-ELUTING STENT 

COATING, A NOVEL APPROACH FOR THE 

PREVENTION OF RESTENOSIS WITH 

REDUCED SIDE EFFECTS. J. J. Kleinedler 1 , 

A. W. Orr 2 , V. Hebert 1 , A. Yurdagul 2 , J. D. Foley 3 

and T. R. Dugas 1 . 1 Pharmacology, Toxicology, and 

Neuroscience, Louisiana State University Health 

Sciences Center, Shreveport, LA, 2 Pathology, 

Louisiana State University Health Sciences Center, 

Shreveport, LA and 3 Biomaterials Research, 

Nanocopoeia, Inc., St. Paul, MN. 


CYTOTOXICITY TESTING STRATEGY 

OF CONTACT LENS DISINFECTING 

SOLUTIONS. S. Kostrubsky, K. Bullard and J. 

Wegrzyn. Vistakon, Division of J&J Vision Care, 

Jacksonville, FL. 

Abstract # 


TRANSLATIONAL IMAGING OF AN 

INJECTABLE POLY-L-LACTIC ACID 

DERMAL FILLER. N. J. Barlow 1 , D. Wilson 1 , 

R. Rimsky 1 , L. Wachsmuth 1 , T. Coulthard 2 and X. 

Ying 1 . 1 Disposition, Safety, and Animal Research, 

sanofi-aventis U.S., Inc., Bridgewater, NJ and 

2 

VisualSonics, Inc., Toronto, ON, Canada. 


EVALUATION OF EXTRACTABLES/ 

LEACHABLES FROM IMPLANTED 

MEDICAL DEVICES. L. A. Haighton 1,2 , 

H. Fikree 2 , L. Sarkissian 2 and J. W. Card 2 . 1 Cantox 

Health Sciences International, Mississauga, ON, 

Canada and 2 Ashuren Health Sciences, Mississauga, 

ON, Canada. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Neurotoxicity of Pesticides 

Chairperson(s): Russell Carr, Mississippi State University, Mississippi 

State, MS, and Kimberly Jarema, U.S. EPA, Research Triangle Park, NC. 




AGE-RELATED DIFFERENCES IN 

CHOLINESTERASE (CHE) INHIBITION 

IN IMMATURE AND ADULT RATS AFTER 

ACUTE OR REPEATED EXPOSURES TO 

CHLORPYRIFOS (CPF) OR CPF-OXON 

(CPFO). M. S. Marty 1 , A. K. Andrus 1 , M. P. Bell 1 , 

J. K. Passage 1 , A. W. Perala 1 , K. A. Brzak 1 , S. N. 

Fishman 1 , M. J. Bartels 1 and D. R. Juberg 2 . 1 The 

Dow Chemical Company, Midland, MI and 2 Dow 

AgroSciences, Indianapolis, IN. 


REPEATED DEVELOPMENTAL 

CHLORPYRIFOS EXPOSURE INCREASES 

ENDOCANNABINOID LEVELS IN THE 

BRAIN OF JUVENILE RATS. R. L. Carr, A. 

B. Ward and M. K. Ross. Center for Environmental 

Health Sciences, Mississippi State University, 

Mississippi State, MS. 


PON1 STATUS MODULATES CEREBELLAR 

GENE EXPRESSION CHANGES 

ASSOCIATED WITH DEVELOPMENTAL 

EXPOSURE TO CHLORPYRIFOS OXON. 

T. B. Cole 1,2 , R. P. Beyer 2 , T. K. Bammler 2 , S. S. 

Park 1 , F. M. Farin 2 , L. G. Costa 2 and C. E. Furlong 1 . 

1 

Genome Sciences and Medicine, Division of 

Medical Genetics, University of Washington, Seattle, 

WA and 2 Environmental and Occupational Health 

Sciences, University of Washington, Seattle, WA. 


CHLORPYRIFOS AND CHLORPYRIFOS 

OXON ALTER RYANODINE RECEPTOR 

FUNCTION. Y. Niknam, A. Ghogha, P. Lein and I. 

Pessah. Molecular Biosciences, School of Veterinary 

Medicine, University of California Davis, Davis, CA. 

Tuesday 







233



Tuesday 



OCCUPATIONAL PESTICIDE EXPOSURE 

AND NEUROBEHAVIORAL DEFICITS 

IN AN ADOLESCENT POPULATION. D. 

Rohlman 1 , A. Ismail 2 , J. R. Olson 3 , O. Hendy 3 and G. 

Abdel Rasoul 3 . 1 CROET, Oregon Health & Science 

University, Portland, OR, 2 Menoufia University, 

Shebin Elkom, Egypt and 3 State University of New 

York at Buffalo, Buffalo, NY. 


BEHAVIORAL DEFICITS IN EGYPTIAN 

APPLICATION TEAMS WITH CHRONIC 

ORGANOPHOSPHORUS PESTICIDE 

EXPOSURES. W. K. Anger 1 , F. M. Farahat 2 , P. 

J. Lein 3 , J. R. Olson 4 and D. S. Rohlman 1 . 1 CROET, 

Oregon Health & Science University, Portland, OR, 

2 

Menoufia University, Shebin Elkom, Menoufia, 

Egypt, 3 University of California, Davis, CA and 

4 

State University of New York at Buffalo, Buffalo, 

NY. 


BIOMARKERS OF NEUROTOXICITY 

IN A RAT MODEL OF OCCUPATIONAL 

CHLORPYRIFOS (CPF) EXPOSURE. N. 

Hussainzada 1,2 , D. Jackson 2 , D. Bruun 3 , D. 

Milatovic 4 , J. Lewis 2 , C. Banks 3 , M. Aschner 4 , 

R. Browne 5 , J. R. Olson 5 and P. Lein 3 . 1 Orise 

Postdoctoral Fellow, Fort Detrick, MD, 2 U.S. 

Army Corps of Engineers HR, U.S. Army, Fort 

Detrick, MD, 3 University of California, Davis, CA, 

4 

Vanderbilt University, Nashville, TN and 5 State 

University of New York, Buffalo, NY. 


ORAL EXPOSURE TO THE PESTICIDE 

CHLORPYRIFOS IN TG2576 MICE, AN 

ANIMAL MODEL OF ALZHEIMER’S 

DISEASE. T. Colomina 1,2 , J. G. Salazar 1 , I. 

Reverte 1,2 , M. Cabré 1 , F. Sánchez-Santed 3 and J. L. 

Domingo 1 . 1 Toxicology, Rovira i Virgili University, 

Reus, Spain, 2 Psychobiology CRAM, Rovira i 

Virgili University, Tarragona, Catalonia, Spain and 

3 

Neuroscience, University of Almeria, Almeria, 

Spain. 


EFFECTS OF DIAZINON AND DIAZOXON 

ON NEURONAL DIFFERENTIATION. D. 

Pizzurro 1 , G. Giordano 1 , K. Dao 1 and L. G. Costa 1,2 . 

1 


Health Sciences, University of Washington, 


Pharmacology, and Forensic Science, University of 



ORGANOPHOSPHATE (OP) PESTICIDES 

INDUCE OXIDATIVE STRESS AND 

OXIDATIVE DNA DAMAGE IN HUMAN 

SH-SY5Y NEUROBLASTOMA CELLS. J. 

Muniz 1 , L. A. McCauley 2 and G. E. Kisby 3 . 1 School 

of Nursing, University of Pennsylvania, Philadelphia, 

PA, 2 School of Nursing, Emory University, Atlanta, 

GA and 3 Center for Research on Occupational and 

Environmental Toxicology, Oregon Health & Science 

University, Portland, OR. 


GLOBAL GENE EXPRESSION ANALYSIS 

OF THE CENTRAL NERVOUS SYSTEM 

OF SARIN EXPOSED RATS (SIX MONTHS 

POST TREATMENT) SUGGESTS EVOLVING 

MOLECULAR PATHWAYS. M. B. Abou-Donia 2 

and T. V. Damodaran 1,2 . 1 Biology, North Carolina 

Central University, Durham, NC and 2 Pharmacology 

and Cancer Biology, Duke University Medical 

Center, Durham, NC. 


IN VITRO EVALUATION OF INHIBITION 

OF BUTYRYLCHOLINESTERASE AND 

NEUROPATHY TARGET ESTERASE 

CAUSED BY THE ENANTIOMERS OF 

METHAMIDOPHOS IN BLOOD OF HENS. 

G. L. Emerick 1,2 , R. V. Oliveira 2 , K. A. Belaz 2 , M. 

Gonçalves 1 and G. H. DeOliveira 1 . 1 Department of 

Natural Active Principles and Toxicology, University 

Estadual Paulista, Araraquara, Sao Paulo, Brazil and 

2 

Department of Chemistry, Universidade Federal de 

São Carlos, Sao Carlos, Sao Paulo, Brazil. 


CLUSTERING OF SERINE HYDROLASES 

BY SIMILARITIES OF INHIBITION 

PATTERNS TOWARD THE 4 

STEREOISOMERS OF ISOMALATHION 

AGREES WITH PHYLOGENETIC 

PROXIMITIES INFERRED FROM 

SEQUENCE ALIGNMENTS. S. J. Wijeyesakere 1 , 

S. Jianmongkol 1 , J. A. Doorn 1 , B. R. Marable 1 , C. 

M. Thompson 2 , I. I. Baskin 3 , V. A. Palyulin 3 , G. 

F. Makhaeva 4 and R. J. Richardson 1 . 1 Toxicology 

Program, Department of Environmental Health 

Sciences, University of Michigan, Ann Arbor, 

MI, 2 Department of Pharmaceutical Sciences, 

University of Montana, Missoula, MT, 3 Department 

of Chemistry, M.V. Lomonosov Moscow State 

University, Moscow, Russian Federation and 

4 

Institute of Physiologically Active Compounds, 

Russian Academy of Sciences, Chernogolovka, 

Russian Federation. 


AGE-RELATED BEHAVIORAL EFFECTS OF 

METHOMYL IN BROWN NORWAY RATS. 

R. C. MacPhail, K. A. Jarema and P. M. Phillips. 



AGE-RELATED DIFFERENCES IN 

ACQUISTION, STEADY-STATE 

PERFORMANCE, AND CARBARYL 

EFFECTS ON THE OPERANT BEHAVIOR 

OF BROWN NORWAY RATS. K. A. Jarema, 

P. M. Phillips and R. C. MacPhail. NHEERL, U.S. 



CARBARYL NEUROTOXICITY ACROSS 

THE LIFE-SPAN OF THE BROWN-NORWAY 

RAT. V. C. Moser, P. M. Phillips and K. L. 

McDaniel. Toxicity Assessment Division, U.S. EPA, 


234 






Platform Sessions



Abstract # 


EFFECTS OF GESTATIONAL & 

LACTATIONAL EXPOSURE TO THE 

PYRETHROID PESTICIDE DELTAMETHRIN 

ON NEURAL DEVELOPMENT. M. Pine, B. 

Reimers, R. Mariano, D. DeVillier, T. Wagner and G. 

Ko. Texas A&M University, College Station, TX. 


AGE-DEPENDENT MODULATION OF 

SODIUM CHANNEL LEVELS AND CALPAIN 

ACTIVATION FOLLOWING ACUTE 

DELTAMETHRIN EXPOSURE. J. P. Magby 1,2 

and J. R. Richardson 1,2 . 1 Joint Graduate Program in 

Toxicology, Rutgers University/UMDNJ, Piscataway, 

NJ and 2 Graduate School of Biomedical Sciences, 

RWJMS, Piscataway, NJ. 


DELTAMETHRIN INHIBITS HUMAN 

VOLTAGE-SENSITIVE CALCIUM CHANNEL 

ISOFORMS EXPRESSED IN XENOPUS 

OOCYTES. D. Galluzzo, E. M. Mutanguha, 

Z. Valentine and S. B. Symington. Biology and 

Biomedical Science, Salve Regina University, 

Newport, RI. 


DIFFERENTIAL SENSITIVITY OF RAT 

VOLTAGE-GATED SODIUM CHANNEL 

ISOFORMSS TO THE PYRETHROID 

INSECTICIDE TEFLUTHRIN. D. M. 

Soderlund 1 , J. Choi 2 and J. Tan 3 . 1 Entomology, 

Cornell University, Geneva, NY, 2 Neurology, Yale 

University School of Medicine, New Haven, CT and 

3 

Monsanto Company, St. Louis, MO. 


CHARACTERIZATION OF DIFFERENTIAL 

EFFECTS OF ALLETHRIN ON 

N- AND L-TYPE NEURONAL VOLTAGE- 

GATED CALCIUM CHANNELS IN 

DIFFERENTIATED PC12 CELLS. A. P. Neal 1 , 

S. M. Fox 1 , D. Wiwatratana 2 , Y. Yuan 1 and W. D. 

Atchison 1 . 1 Pharmacology and Toxicology, Michigan 

State University, East Lansing, MI and 2 Neuroscience 

Program, Michigan State University, East Lansing, 

MI. 


PYRETHROID EFFECTS ON MUSCARINIC 

ACETYLCHOLINE RECEPTOR 

EXPRESSION IN N1E-115 AND PC12 CELLS. 

J. M. Diaz Otero 1 , A. P. Neal 2 and W. D. Atchison 2 . 

1 

University of Puerto Rico at Cayey, Cayey, Puerto 

Rico and 2 Pharmacology and Toxicology, Michigan 



TIME, DOSE, AND STRUCTURE 

DEPENDENT ACTIONS OF 

PYRETHROID INSECTICIDES ON RAT 

THERMOREGULATION. A. M. Pato 1 , C. Sosa- 

Holt 1 and M. J. Wolansky 1,2,3 . 1 Biological Chemistry 

(Toxicology), University of Buenos Aires School of 

Science, Buenos Aires, Argentina, 2 Argentine NRC, 

Buenos Aires, Argentina and 3 ARG National Agency 

for Scientific Technological Promotion, Buenos 

Aires, Argentina. 

Abstract # 


ROLE OF DOPAMINE TRANSPORTER IN 

MANEB AND MANCOZEB TOXICITY. S. 

Cheng, J. Quinones and C. Cuellar. Sciences, John 

Jay College, New York. 


USE OF NON-BIASED STEREOLOGY 

TO ESTIMATE THE NUMBER OF TH+ 

NEURONS IN THE SUBSTANTIA NIGRA OF 8 

AND 16 MONTH OLD MALE AND FEMALE 

C57BL/6 MICE REPEATEDLY EXPOSED TO 

PARAQUAT AND MANEB. J. P. O’Callaghan 1 , 

K. A. Kelly 1 , D. B. Miller 1 , R. C. Switzer 2 , E. C. 

Lau 3 , A. A. Li 3 and L. J. McIntosh 3 . 1 Neurotoxicology 

Laboratories, Centers for Disease Control, 

Morgantown, WV, 2 NeuroScience Associates, 

Knoxville, TN and 3 Exponent, Inc., Menlo Park, CA. 


PARAQUAT AND MANEB ALTER 

CELLULAR REDOX STATUS BY NON- 

REDUNDANT MECHANISMS IN SH-SY5Y 

NEUROBLASTOMA CELLS. J. Roede and D. P. 

Jones. Medicine, Emory University, Atlanta, GA. 


MANEB (MANGANOUS 

ETHYLENEBIS[DITHIOCARBAMATE]) 

EXPOSURE IN RAT HIPPOCAMPAL 

ASTROCYTES LEADS TO ACTIVATION 

OF INTRINSIC APOPTOTIC PATHWAY. 

M. Akhtar and L. D. Trombetta. Pharmaceutical 

Sciences, St. John’s University, Queens, NY. 


THE NEUROTOXIC EFFECTS OF MANEB 

ON THE HIPPOCAMPUS OF NRF2 (-/-) 

MICE. D. M. Kurzatkowksi and L. D. Trombetta. 

Pharmaceutical Sciences, St. John’s University, 

Queens, NY. 


DEVELOPMENTAL EXPOSURE TO 

AMITRAZ ALTERS THE SEROTONIN 

SYSTEM. M. R. Martínez-Larrañaga, J. Del 

Pino, M. A. Martínez, E. Ramos and A. Anadón. 

Department of Toxicology and Pharmacology, 

Faculty of Veterinary Medicine, Universidad 

Complutense, Madrid, Spain. 


SODIUM CHANNEL BLOCKER 

INSECTICIDES (SCBIS) ARE STATE- 

DEPENDENT INHIBITORS OF 

MAMMALIAN VOLTAGE-GATED SODIUM 

CHANNELS. R. T. von Stein and D. M. Soderlund. 

Entomology, Cornell University, Geneva, NY. 


GABA A 

RECEPTOR ANTAGONISTS 

INCREASE FIRING, BURSTING, AND 

SYNCHRONY OF SPONTANEOUS 

ACTIVITY IN NEURONAL NETWORKS 

GROWN ON MICROELECTRODE ARRAYS 

(MEAS): A STEP TOWARDS CHEMICAL 

“FINGERPRINTING”. A. M. Johnstone 1 , J. 

Turner 1 , C. Mack 1 , L. Burgoon 2 and T. J. Shafer 1 . 

1 

Integrated Systems Toxicology, U.S. EPA, Research 

Triangle Park, NC and 2 Research Cores Unit, U.S. 


Tuesday 







235



Tuesday 



EFFECTS OF FIPRONIL ON THE EEG 

OF LONG-EVANS RATS. D. F. Lyke, K. L. 

McDaniel, V. C. Moser and D. W. Herr. NB/TAD/ 

NHEERL/ORD, U.S. EPA, Research Triangle Park, 

NC. 


TREATMENT OF CAENORHABDITIS 

ELEGANS WITH GLYPHOSATE OR 

MANCOZEB SUGGESTS SELECTIVE 

NEURONAL DEGENERATION. R. Negga, M. 

Machen, J. Salva and V. A. Fitsanakis. Biology, King 

College, Bristol, TN. 


EFFECTS OF ATRAZINE 

AND ITS METABOLITE 

DIAMINOCHLOROTRIAZINE 

ON UNDIFFERENTIATED AND 

DIFFERENTIATING N27 DOPAMINERGIC 

CELLS. Z. Lin, C. A. Dodd, I. I. Georgieva and 

N. M. Filipov. Physiology and Pharmacology, 



EFFECT OF HEXACHLOROBENZENE(HCB) 

ON THE NEURONAL DIFFERENTIATION 

OF MOUSE EMBRYONIC STEM CELLS. C. 

Addae and E. Martinez-Ceballos. Environmental 

Toxicology, Southern University and A&M College, 

Baton Rouge, LA. Sponsor: R. Uppu. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Genetic Polymorphisms 

Chairperson(s): Melanie Young, U.S. EPA, Washington, D.C. 




INCREASED FREQUENCIES OF 

MICRONUCLEATED RETICULOCYTES 

RELATED TO ALDH2 POLYMORPHISMS 

IN NON-SMOKING AND NON-DRINKING 

WORKERS EXPOSED TO STYRENE. 

Z. Weng 1 , D. Guan 2 , X. Zhang 4 , P. Zhao 3 , Y. 

Zheng 4 and R. Wang 1 . 1 Japan National Institute of 

Occupational Safety and Health, Kawasaki, Japan, 

2 

Beijing Fengtai Health Inspection Institute, Beijing, 

China, 3 Beijing Guoji Zhongyi Hospital, Beijing, 

China and 4 National Institute of Occupational Health 

and Poison Control, China, Beijing, China. Sponsor: 

N. Mei. 


MODULATION OF DNA REPAIR CAPACITY 

BY XPC HAPLOTYPES. C. M. Rondelli 1 , J. K. 

Wickliffe 2 and S. Z. Abdel-Rahman 1 . 1 NCB & ObGyn, 

University of Texas Medical Branch, Galveston, 

TX and 2 Environmental Health Sciences, Tulane 

University, New Orleans, LA. 


DRUG METABOLIZING ENZYME 

POLYMORPHISMS, RESPONSE TO 

CHEMOTHERAPY, AND SURVIVAL IN 

LUNG CANCER PATIENTS. A. O. Ada 1 , S. 

C. Kunak 2 , F. Hancer 1 , S. Bilgen 1 , T. G. Ada 1 , V. 

Karacaoglan 1 , S. Suzen 1 , S. Alpar 3 , M. Gulhan 3 , 

B. Kurt 3 and M. Iscan 1 . 1 Toxicology, Ankara 

University, Faculty of Pharmacy, Ankara, Turkey, 

2 

Pharmacology, Giresun University, Medical Faculty, 

Giresun, Turkey and 3 Pulmonary Diseases Clinic, 

Ataturk Pulmonary Diseases and Thoracic Surgery 

Hospital, Ankara, Turkey. 


CYP AND GST GENE POLYMORPHISMS 

IN A TURKISH POPULATION. M. Iscan 1 , V. 

Karacaoglan 1 , S. H. Kunak 2 , E. Soydas 1 , T. G. Ada 1 

and A. O. Ada 1 . 1 Department of Toxicology, Ankara 

University, Faculty of Pharmacy, Ankara, Turkey and 

2 

Department of Pharmacology, Giresun University, 

Faculty of Medicine, Giresun, Turkey. 


INFLUENCE OF GENETIC VARIATION 

IN THE SEROTONIN TRANSPORTER ON 

SMOKING CESSATION SUCCESS USING 

ANTIDEPRESSANT THERAPY. M. Quaak 1,2 , 

C. P. van Schayck 2 , D. S. Postma 3 , E. J. Wagena 2,4 

and F. J. van Schooten 1 . 1 Health Risk Analysis and 

Toxicology, Maastricht University, Maastricht, 

Netherlands, 2 General Practice, Maastricht 

University, Maastricht, Netherlands, 3 Pulmonology, 

University Medical Center Groningen, Groningen, 

Netherlands and 4 Kiadis Pharmacology Amsterdam, 

Netherlands. Sponsor: H. van Loveren. 


TOXICOGENOMICS OF NEVIRAPINE- 

ASSOCIATED CUTANEOUS AND HEPATIC 

ADVERSE EVENTS AMONG POPULATIONS 

OF AFRICAN, ASIAN, AND EUROPEAN 

DESCENT. J. Yuan 1 , S. Guo 1 , D. Hall 1 , A. 

Cammett 1 , S. Jayadev 1 , M. Distel 2 , S. Storfer 1 , Z. 

Huang 1 , P. Mootsikapun 3 , K. Ruxrungtham 4 , D. 

Podzamczer 5 and D. Haas 6 . 1 Boehringer Ingelheim 

Pharmaceuticals, Inc., Ridgefield, CT, 2 Boehringer 

Ingelheim GmbH, Ingelheim, Germany, 3 Khon Kaen 

University, Khon Kaen, Thailand, 4 Chulalongkorn 

University, Bangkok, Thailand, 5 Hospital Universitari 

de Bellvitge, Barcelona, Spain and 6 Vanderbilt 

University School of Medicine, Nashville, TN. 


AN EVALUATION OF SINGLE NUCLEOTIDE 

POLYMORPHISMS IN THE HUMAN ARYL 

HYDROCARBON RECEPTOR NUCLEAR 

TRANSLOCATOR GENE. R. Budinsky 1 , J. 

D. Urban 2 and J. Rowlands 1 . 1 The Dow Chemical 

Company, Midland, MI and 2 ToxStrategies, Inc., 

Austin, TX. 


SINGLE NUCLEOTIDE POLYMORPHISMS 

IN THE HUMAN ARYL HYDROCARBON 

RECEPTOR INTERACTING PROTEIN (AIP) 

GENE FROM SIX ETHNIC POPULATIONS. 

D. Staskal-Wikoff 1 , R. Budinsky 2 and J. Rowlands 2 . 

1 

ToxStrategies, Inc., Austin, TX and 2 The Dow 

Chemical Company, Midland, MI. 

236 






Platform Sessions



Abstract # 


ASSOCIATION OF GENETIC VARIATIONS 

IN ANTIOXIDANT ENZYME GENES WITH 

DIISOCYANATE-INDUCED ASTHMA IN 

EXPOSED WORKERS. B. Yucesoy 1 , V. J. 

Johnson 1 , K. Fluharty 1 , J. Slaven 1 , Z. L. Lummus 2 , 

G. E. Kissling 3 , D. R. Germolec 3 , M. I. Luster 1 

and D. I. Bernstein 2 . 1 NIOSH/CDC, Morgantown, 

WV, 2 University of Cincinnati, Cincinnati, OH and 

3 



SULT1A1 GENE COPY NUMBER 

VARIATION (CNV) REAL-TIME 

QUANTITATIVE PCR (qPCR) ASSAY: 

AN OPPORTUNITY FOR POPULATION 

GENETIC COPY NUMBER VARIATION 

MEASUREMENT FOR ENHANCEMENT 

OF HUMAN HEALTH RISK ASSESSMENT 

OF GENETICALLY SENSITIVE SUB- 

POPULATIONS. M. Young. U.S. EPA, Office 

of Science and Technology, Human Health Risk 

Assessment Branch, Washington, D.C. 


CHARACTERIZATION OF WHOLE 

GENOME AMPLIFIED (WGA) DNA FOR USE 

IN GENOTYPING ASSAY DEVELOPMENT. 

T. Han 1 , C. Chang 2 , J. Kwekel 1 , Y. Chen 3 , F. 

Martinez-Murillo 4 , D. Roscoe 4 , Z. Tezak 4 , R. Philip 4 , 

K. Bijwaard 4 and J. C. Fuscoe 1 . 1 Division of Systems 

Biology, National Center for Toxicological Research 

/U.S. FDA, Jefferson, AR, 2 DPNM NCTR /U.S. 

FDA, Jefferson, AR, 3 DGMT NCTR /U.S. FDA, 

Jefferson, AR and 4 ODDES/CDRH /U.S. FDA, 

Silver Spring, MD. 


MUTAGENICITY OF RARE METAL 

AND METAL OXIDE NANOPARTICLES: 

COMPONENTS AND PARTICLE SIZES. 

G. Hasegawa 1 , M. Shimonaka 2 and Y. Ishihara 1 . 

1 

Department of Public Health, School of Medicine, 

Kurume University, Kurume, Fukuoka, Japan and 

2 

Department of Chemistry, Tokyo University of 

Science, Tokyo, Japan. 


PON1 Q192R POLYMORPHISM ANALYSIS 

IN SOUTHERN CARDIAC PATIENTS. M. 

Dail, A. Crow, H. Coombes, E. Meek, H. Chambers 

and J. Chambers. Center for Environmental Health 

Sciences, Mississippi State University, MS State, 

MS. 


ANALYSIS OF POLYMORPHISMS 

OF ASTHMATIC CHILDREN FROM 

COAHUILA, MEXICO EXPOSED TO 

ENVIRONMENTAL TOBACCO SMOKE 

(ETS). B. Muñoz-Soto 1 , B. S. Barrón-Vivanco 1 , 

A. López-Moya 1 , I. Romero-Toledo 1 , C. López- 

Campos 2 , J. J. Magaña-Aguirre 3 and A. Albores 1 . 

1 

Toxicology, Cinvestav-Ipn, México, Mexico, 

2 

Pediatrics, UMAE-IMSS 71, Torreon, Coahuila, 

Mexico and 3 Human Genetics, INR, Mexico City, 

Mexico. 

Abstract # 


CYP1A1*2C, EPHX1T113H, EPHX1H139R 

AND NQO1*2 POLYMORPHISMS ARE 

INVOLVED IN THE GENETIC DAMAGE 

CAUSED IN CHILDREN EXPOSED TO PAHS 

AND BENZENE. M. Sánchez-Guerra 1 , N. A. 

Pelallo-Martínez 2 , F. Díaz-Barriga 2 , L. Carrizales- 

Yáñez 2 , L. Hernández-Cadena 3 , M. E. Gonsebatt 4 

and B. Quintanilla-Vega 1 . 1 Toxicology Department, 

Cinvestav-Ipn, Mexico City, Mexico, 2 Faculty 

of Medicine, UASLP, San Luis Potosí, Mexico, 

3 

National Institute of Public Health, Cuernavaca, 

Morelos, Mexico and 4 IIB, UNAM, Mexico City, 

Mexico. 


USING OF PCR-RFLP OF CYTOCHROME 

B GENE FOR HAIR IDENTIFICATION 

IN HUMAN AND SOME NON-DOMESTIC 

ANIMALS. M. H. Ghoneim, A. A. Abou-Hadeed, 

A. M. Alkelch and M. R. Awad-allah. Toxicology 

& Forensic Medicine, Zagazig University, Zagazig, 

Egypt. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Metal Neurotoxicity: Methylmercury and 

General 

Chairperson(s): William Atchison, Michigan State University, East 

Lansing, MI, and Edward Levin, Duke University Medical Center, 

Durham, NC. 




STEM CELL REPONSES OF MURINE 

HIPPOCAMPUS FOLLOWING 

TRIMETHYLTIN INTOXICATION. B. C. 

Weig, K. R. Reuhl and H. E. Lowndes. Pharmacology 



EFFECTS OF DIFFERENT FORMS OF 

COPPER ON HUMAN CNS DERIVED 

CELL LINES. S. S. Shaligram and A. Campbell. 

Pharmaceutical Sciences, Western University of 

Health Sciences, Pomona, CA. 


MECHANISM OF BRAIN COPPER (CU) 

TRANSPORT AND ACCUMULATION: 

INFLUENCE OF IRON DEFICIENCY. A. D. 

Monnot 1 , S. Ho 1 , G. Robinson 2 , Y. Pushkar 2 and W. 

Zheng 1 . 1 Health Sciences, Purdue University, West 

Lafayette, IN and 2 Physics, Purdue University, West 


Tuesday 







237



Tuesday 



PERSISTING NEUROCHEMICAL EFFECTS 

OF DEVELOPMENTAL COPPER EXPOSURE 

IN WILDTYPE AND METALLOTHIONEIN 

1 AND 2 KNOCKOUT MICE. A. Petro 1 , H. 

Sexton 1 , C. Miranda 1 , A. Rastogi 1 , J. H. Freedman 3 

and E. D. Levin 1,2 . 1 Psychiatry, Duke University 

Medical Center, Durham, NC, 2 Integrated Toxicology 

and Environmental Health Program, Duke 

University, Durham, NC and 3 NIEHS, Research 



PERSISTENT OLFACTORY DEFICITS 

FOLLOWING INTRANASAL CADMIUM 

EXPOSURE CAN BE REHABILITATED 

BY TRAINING ON AN OLFACTORY 

DETECTION TASK. D. J. Turkel, A. H. Moberly, 

L. Czarnecki and J. P. McGann. Psychology 

Department, Rutgers University, Piscataway, NJ. 


IN VIVO OPTICAL VISUALIZATION OF 

DOSE-DEPENDENT PATHOPHYSIOLOGY 

INDUCED BY INTRANASAL CADMIUM 

EXPOSURE IN THE MOUSE OLFACTORY 

SYSTEM. L. Czarnecki, A. H. Moberly, J. 

Pottackal, D. J. Turkel, T. Rubinstein and J. 

P. McGann. Psychology Department, Rutgers 



PERIPHERAL CADMIUM EXPOSURE 

INDUCES SECONDARY PATHOLOGY IN 

DOWNSTREAM BRAIN REGIONS IN THE 

MOUSE OLFACTORY SYSTEM. J. Pottackal, 

D. J. Turkel, T. Rubinstein, M. D. Kass, L. Czarnecki 

and J. P. McGann. Psychology Department, Rutgers 



FAILURE TO REGENERATE OLFACTORY 

NERVE FUNCTION AFTER ACUTE 

INTRANASAL CADMIUM EXPOSURE IN 

THE MOUSE. T. Rubinstein, L. Czarnecki, D. J. 

Turkel, J. Pottackal and J. P. McGann. Psychology 

Department, Rutgers University, Piscataway, NJ. 


THE EFFECT OF TUNGSTEN ALLOY 

SURROGATES ON PC12 CELL GENE 

EXPRESSION. V. H. Adams 1 , D. I. Bannon 1 , M. G. 

Stockelman 2 and V. P. Mokashi 2 . 1 Army Institute of 

Public Health, U.S. Army Public Health Command 

(Prov), Aberdeen Proving Ground-EA, MD and 

2 

Naval Medical Research Unit, Dayton (NAMRU- 

Dayton), Wright-Patterson AFB, OH. 


DIFFERENT SUSCEPTIBILITIES TO 

MEHG-INDUCED CELL DEATH BETWEEN 

NON-NEURONAL AND NEURONAL CELLS. 

V. Vidal 1 , S. M. Fox 2 and W. D. Atchison 2 . 1 University 

of Puerto Rico at Cayey, Cayey, Puerto Rico and 

2 

Pharmacology and Toxicology, Michigan State 



EFFECTS OF ACUTE EXPOSURE TO 

METHYLMERCURY ON INTRACELLULAR 

CA2+ IN PRIMARY CEREBELLAR 

GRANULE CELLS OF TOTTERING AND 

LETHARGIC MICE. B. Marrero-Rosado 1 and 

W. D. Atchison 2 . 1 Genetics Program, Michigan State 

University, East Lansing, MI and 2 Pharmacology and 


MI. 


METHYLMERCURY DECREASES 

NEURONAL MIGRATION, VINCULIN 

LEVELS, AND LOCATION IN FOCAL 

ADHESION OF A NEUROBLASTOMA CELL 

LINE. D. Albores-Garcia 1 , L. C. Acosta-Saavedra 1 , 

E. K. Silbergeld 2 and E. S. Calderon-Aranda 1 . 

1 

Department Toxicologia, Cinvestav, Mexico, 

Mexico and 2 BSPH, Johns Hopkins University, 



EFFECT OF METHYLMERCURY ON 

THE NEURONAL MIGRATION AND 

ON ACTIVITY OF FAK IN HUMAN 

NEUROBLASTOMA CELLS. G. T. Rodriguez- 

Kessler 1 , D. Albores-Garcia 1 , L. C. Acosta-Saavedra 1 , 

B. Luque 1 , D. Arias-Salvatierra 1 , E. K. Silbergeld 2 

and E. S. Calderon-Aranda 1 . 1 Toxicologia, Cinvestav, 

Mexico, Mexico and 2 BSPH, Johns Hopkins 

University, Baltimore, MD. 


DIFFERENTIAL EFFECTS OF 

NEUROTOXIC MERCURIALS ON 

ANGIOGENESIS (AG). M. Nash 1 , E. Robinson 1 , 

B. J. Zaffo 1 , S. Obhan 2 , N. F. Alrowaily 1 , L. A. 

Shaiba 1 , S. A. Mousa 2 and H. A. El-Fawal 1 . 1 Health 

Sciences, Albany College of Pharmacy and Health 

Sciences, Albany, NY and 2 Pharmaceutical Research 

Institute, Albany College of Pharmacy and Health 

Sciences, Albany, NY. 


ANTAGONISTIC EFFECTS OF 

NEUROTOXIC MERCURIALS ON TUMOR- 

INDUCED ANGIOGENESIS (AG). B. J. 

Zaffo 1 , M. Yalcin 2 , E. Robinson 1 , L. A. Shaiba 1 , N. 

F. Alrowaily 1 , S. A. Mousa 2 and H. A. El-Fawal 1 . 

1 

Health Sciences, Albany College of Pharmacy and 

Health Sciences, Albany, NY and 2 Pharmaceutical 

Research Institute, Albany College of Pharmacy and 

Health Sciences, Albany, NY. 


METHYLMERCURY AFFECTS 

HIPPOCAMPAL NEURAL STEM CELLS 

LEADING TO LATER CELL LOSS AND 

MEMORY DEFICITS. K. B. Sokolowski 1,3,4 , 

K. Robinson 2 and E. DiCicco-Bloom 4,3,1 . 1 JGPT, 

Rutgers, New Brunswick, NJ, 2 CBN, Rutgers, New 

Brunswick, NJ, 3 GSBS, UMDNJ, Piscataway, NJ and 

4 

NCB, RWJMS, Piscataway, NJ. 

238 






Platform Sessions



Abstract # 


PRENATAL EXPOSURE TO 

METHYLMERCURY NEGATIVELY 

AFFECTS BDNF CONCENTRATION IN 

CORD BLOOD. S. Spulber 1 , T. Rantamäki 2 , O. 

Nikkilä 2 , E. Castrén 2 , P. Weihe 3 , P. Grandjean 4,5 

and S. Ceccatelli 1 . 1 Neuroscience, Karolinska 

Institutet, Stockholm, Sweden, 2 Neuroscience Center, 

University of Helsinki, Helsinki, Finland, 3 Faroese 

Hospital System, Tørshavn, Faroe islands, 4 Institute 

of Public Health, University of Southern Denmark, 

Odense, Denmark and 5 Environmental Health, 

Harvard School of Public Health, Boston, MA. 


A ROLE FOR CYTOCHROME P450 (CYP) 

ENZYMES IN METHYLMERCURY (MEHG) 

TOLERANCE. M. D. Rand and C. Mahapatra. 

Anatomy and Neurobiology, University of Vermont, 

Burlington, VT. 


OXIDATIVE STRESS-MEDIATED ERK1/2, 

P38 AND MITOCHONDRIAL-DEPENDENT 

SIGNALING PATHWAYS INVOLVE IN 

METHYLMERCURY INDUCES THE 

NEURONAL CELL APOPTOSIS. C. Chen 1,2 , 

T. Lu 2 , C. Yen 3 , D. Hung 4,2 , T. Ho 5 , C. Su 6 , Y. Chen 7 , 

C. Huang 5 and W. Chen 1 . 1 Emergency Department, 


Taiwan, 2 Graduate Institute of Drug Safety, China 


of Occupational Safety and Health, Chung Shan 

Medical University, Taichung, Taiwan, 4 Toxicology 

Center, China Medical University Hospital, 

Taichung, Taiwan, 5 School of Chinese Medicine, 

China Medical University, Taichung, Taiwan, 

6 

Department of Otorhinolaryngology, Head and Neck 

Surgery, Changhua Christian Hospital, Changhua, 

Taiwan and 7 Department of Physiology, China 

Medical University, Taichung, Taiwan. 


COMPARATIVE EFFECTS OF 

METHYLMERCURY AND 1-METHYL- 

4-PHENYLPYRIDINIUM ON THE 

DOPAMINERGIC SYSTEM IN MN9D CELLS. 

Y. Shao and H. Chan. Community Health Science 

Program, University of Northern British Columbia, 

Prince George, BC, Canada. 


CA 2+ CHANNEL α 1 

SUBUNITS 

DIFFERENTIALLY MODULATE 

METHYLMERCURY (MEHG)-INDUCED 

CA 2+ DYSREGULATION IN HEK-293 CELLS. 

H. Hannon, E. M. Sparkenbaugh, K. Krcmarik and 

W. D. Atchison. Pharmacology/Toxicology, Michigan 




CHARACTERIZATION OF MOLECULAR 

MODULATORS OF METHYLMERCURY- 

INDUCED DOPAMINE NEURON 

PATHOLOGY IN C. ELEGANS. N. VanDuyn, R. 

Settivari, G. Sinclair and R. Nass. Pharmacology and 

Toxicology, Indiana University School of Medicine, 


Abstract # 


ION CHANNEL GENE TRANSCRIPTION 

IS AFFECTED DIFFERENTIALLY IN 

RAT CEREBELLUM AFTER POSTNATAL 

METHYLMERCURY EXPOSURE. A. 

Colón-Rodriguez, R. K. Hajela, Y. Yuan and W. D. 

Atchison. Pharmacology/Toxicology, Michigan State 



MOLECULAR MECHANISMS 

OF IRREVERSIBLE INHIBITION 

OF SELENOENZYMES BY HIGH 

METHYLMERCURY EXPOSURES. N. V. 

Ralston and L. J. Raymond. Energy & Environmental 

Research Center, University of North Dakota, Grand 

Forks, ND. 


SEPIAPTERIN REDUCTASE AS A TARGET 

FOR METHYL MERCURY TOXICITY. S. 

Yang 1 , J. R. Richardson 1 , K. Reuhl 2 , V. Mishin 2 

and J. D. Laskin 1 . 1 Environmental & Occupational 


School, Piscataway, NJ and 2 Pharmacology & 



LACK OF EFFECT OF ACUTE 

METHYLMERCURY EXPOSURE ON 

TYROSINE HYDROXYLASE ACTIVITY IN 

NIGROSTRIATAL DOPAMINE NEURONS 

IN MICE. C. Tiernan 1 , M. A. Bernard-Flores 3 , 

J. L. Goudreau 1,2 , K. J. Lookingland 1,2 and W. D. 

Atchison 1,2 . 1 Neuroscience Program, Michigan State 

University, East Lansing, MI, 2 Pharmacology & 


MI and 3 RISE Program, University of Puerto Rico- 

Cayey, Cayey. 


CHRONIC METHYLMERCURY EXPOSURE 

OF ADULT MICE DISRUPT HIPPOCAMPAL 

GLUTAMATERGIC FUNCTIONS. F. 

O. Johnson, S. M. Fox and W. D. Atchison. 

Pharmacology and Toxicology, Michigan State 



CHRONIC METHYLMERCURY EXPOSURE 

DISRUPTS HIGH-RATE RESPONDING ON 

TWO OPERANT TASKS. J. Johnson 2 and M. C. 

Newland 1 . 1 Auburn University, Auburn University, 

AL and 2 Duke University Medical Center, Durham, 

NC. 

Tuesday 







239



Tuesday 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Mutagenecity 

Chairperson(s): Leslie Recio, ILSIntegrated Laboratory Systems Inc., 





GENOTOXICITY AND PRE- 

NEOPLASTIC LESIONS INDUCED BY 2, 

4-DIAMINOTOLUENE IN THE LIVER OF 

F344 GPT DELTA TRANSGENIC RATS. 

T. Nohmi 1 , N. Toyoda-Hokaiwado 1 , T. Inoue 2 , 

K. Masumura 1 , H. Hayashi 3 , Y. Kawamura 3 , Y. 

Kurata 3 , M. Takamune 1 , M. Yamada 1 , H. Sanada 4 , 

T. Umemura 2 and A. Nishikawa 2 . 1 Division of 

Genetics and Mutagenesis, National Institute of 

Health Sciences, Setagata, Tokyo, Japan, 2 Division 

of Pathology, National Institute of Health Sciences, 

Setagata, Tokyo, Japan, 3 Meiji Seika Kaisha, Ltd., 

Yokohama, Kanagawa, Japan and 4 Safety Research 

Department, Central Research Laboratories, Kaken 

Pharmaceutical Co., Ltd., Fujieda, Shizuoka, Japan. 


CHEMOPREVENTIVE 

EFFECTS OF SILYMARIN ON 1, 

2-DIMETHYLHYDRAZINE-INDUCED 

MUTAGENESIS AND CARCINOGENESIS IN 

THE COLON OF GPT DELTA TRANSGENIC 

RATS. K. Masumura 1 , N. Toyoda-Hokaiwado 1 , 

Y. Yasui 2 , M. Muramatsu 1,3 , M. Takamune 1 , M. 

Yamada 1 , T. Tanaka 4 and T. Nohmi 1 . 1 Division of 

Genetics and Mutagenesis, National Institute of 

Health Sciences, Tokyo, Japan, 2 School of Veterinary 

Medicine, Rakuno Gakuen University, Hokkaido, 

Japan, 3 Tokyo University of Pharmacy and Life 

Sciences, Tokyo, Japan and 4 Tohkai Cytopathology 

Institute, Gifu, Japan. Sponsor: A. Nishikawa. 


EXAMINING THE MUTAGENICITY OF 

ETHYL METHANESULFONATE IN MICE 

USING THE PIG-A, HPRT, AND GPT 

DELTA ASSAYS. X. Cao, J. G. Shaddock, R. A. 

Mittelstaedt, V. N. Dobrovolsky, S. D. Shelton, M. 

Manjanatha and R. H. Heflich. DGMT, NCTR /U.S. 

FDA, Jefferson, AR. Sponsor: T. Chen. 


MANIFESTATION AND PERSISTENCE OF 

PIG-A MUTANT FREQUENCY IN C57BL/6 

MICE TREATED WITH DIFFERENT DOSES 

OF ENU. J. A. Bhalli, M. G. Pearce, V. N. 

Dobrovolsky and R. H. Heflich. NCTR, U.S. FDA, 

Jefferson, AR. Sponsor: B. Parsons. 


NITROXIDES TEMPO AND TEMPOL 

INDUCE TK MUTATIONS IN MOUSE 

LYMPHOMA CELLS. X. Guo 1 , L. Guo 2 , M. 

M. Moore 1 and N. Mei 1 . 1 Division of Genetic and 

Molecular Toxicology, NCTR /U.S. FDA, Jefferson, 

AR and 2 Division of Biochemical Toxicology, NCTR 

/U.S. FDA, Jefferson, AR. 


GENOTOXICITY OF 3, 

5-DIMETHYLANILINE AND ITS 

METABOLITES. M. Chao, L. J. Trudel and G. 

N. Wogan. Biological Engineering, Massachusetts 

Institute of Technology, Cambridge, MA. 


COMPARISON OF THE BACTERIAL 

MUTAGENICITY OF MAINSTREAM 

WHOLE SMOKE FROM CIGARETTES 

WITH DIFFERENT LEVELS OF MENTHOL. 

R. Leverette. Lorillard, Greensboro, NC. 


A NOVEL IN VITRO SYSTEM FOR THE 


GENOTOXIC COMPOUNDS. S. O. Mueller, 

K. Boehme, Y. Dietz and P. G. Hewitt. Toxicology, 

Merck KGaA, Darmstadt, Germany. 


COMPARATIVE MUTAGENICITY OF 

CYCLOPHOSPHAMIDE IN F344 MALE 

RATS USING THE PIG-A AND HPRT 

ASSAYS. V. N. Dobrovolsky, J. G. Shaddock, M. 

Pearce and R. H. Heflich. NCTR, Jefferson, AR. 

Sponsor: B. Parsons. 


INTERNATIONAL, INTERLABORATORY 

PIG-A MUTATION ASSAY TRIAL: 

EVALUATION OF TRANSFERABILITY. S. 

Dertinger 1 , S. Phonethepswath 1 , P. Weller 1 , L. 

Stankowski 2 , D. Roberts 2 , J. Shi 3 , L. Krsmanovic 3 , 

H. Vohr 4 , L. Custer 5 , C. Gleason 5 , A. Henwood 5 , K. 

Sweder 5 , A. Giddings 6 , A. Lynch 6 , W. Gunther 7 , C. 

Thiffeault 7 , T. Shutsky 7 , R. Fiedler 7 , J. Bhalli 8 , R. 

Heflich 8 , J. Nicolette 9 , P. Sonders 9 , J. Murray 9 , T. 

Kimoto 10 and J. MacGregor 11 . 1 Litron Laboratories, 

Rochester, NY, 2 Covance Laboratories, Vienna, 

VA, 3 BioReliance, Rockville, MD, 4 Bayer Schering 

Pharmacology AG, Wuppertal, Germany, 5 Bristol- 

Myers Squibb, Syracuse, NY, 6 GlaxoSmithKline, 

Ware, United Kingdom, 7 Pfizer Global R&D, Groton, 

CT, 8 U.S. FDA NCTR, Jefferson, AR, 9 Abbott 

Laboratories, Abbott Park, IL, 10 Teijin Pharmacology 

Tokyo, Japan and 11 Toxicology Consulting Services, 

Arnold, MD. 


TOXICOLOGICAL CHARACTERIZATION 

OF DIESEL ENGINE EMISSIONS USING 

BIODIESEL AND A CLOSED SOOT FILTER. 

I. M. Kooter, M. A. van Vugt, A. D. Jedynska, R. P. 

Verbeek and C. A. Krul. TNO, Utrecht, Netherlands. 

Sponsor: R. Woutersen. 


IN VITRO PREDICTIONS OF IN VIVO 

GENOTOXICITY ARE BETTER THAN 

PREDICTIONS OF CARCINOGENICITY. 

R. Walmsley 1,2 . 1 Life Sciences, University of 

Manchester, Manchester, United Kingdom and 

2 

Gentronix Ltd., Manchester, United Kingdom. 

240 






Platform Sessions



Abstract # 


CYTOTOXICITY AND GENE EXPRESSION 

ALTERATIONS FOLLOWING TREATMENT 

OF TK6 CELLS WITH ETOPOSIDE AND 

SODIUM CHLORIDE. Y. Chen 1 , M. M. Moore 1 

and J. C. Fuscoe 2 . 1 Division of Genetic and 

Molecular Toxicology, U.S. FDA NCTR, Jefferson, 

AR and 2 Division of Systems Biology, U.S. FDA 



PIG-A MUTATION AND 

MICRONUCLEATED RETICULOCYTE 

ASSAYS DISCRIMINATE THE MUTAGENIC/ 

NON-MUTAGENIC PAIR: BENZO[A] 

PYRENE/PYRENE. D. Torous 1 , J. MacGregor 2 , 

S. Phonethepswath 1 , P. Weller 1 , J. Bemis 1 and S. 

Dertinger 1 . 1 Litron Laboratories, Rochester, NY and 

2 

Toxicology Consulting Services, Arnold, MD. 


THE MUTAGENIC POTENTIAL OF CIS-2- 

BUTENE-1, 4-DIAL. A. Terrell 1 , M. Huynh 2 and 

L. A. Peterson 1,3 . 1 Environmental Health Sciences, 

University of Minnesota, Minneapolis, MN, 

2 

Biochemistry, Molecular Biology, and Biophysics, 

University of Minnesota, Minneapolis, MN and 

3 

Masonic Cancer Center, University of Minnesota, 

Minneapolis, MN. 


THE METABOLITES OF THE AZO DYE 

DISPERSE RED 1 CAN REPRESENT HUMAN 

RISKS CONSIDERING THE INGESTION 

OF CONTAMINATED WATER AND FOOD. 

F. D. Chequer 1 , T. M. Lizier 2 , M. B. Zanoni 2 , R. 

Marcos 3 and D. P. Oliveira 1 . 1 Faculdade de Ciências 

Farmacêuticas de Ribeirão Preto - Universidade 

de São Paulo, Ribeirão Preto, São Paulo, Brazil, 

2 

(2) Universidade Paulista Júlio de Mesquita Filho, 

Araraquara, São Paulo, Brazil and 3 (3) Universitat 

Autònoma de Barcelona, Barcelona, Spain. 


MUTATION SPECTRUM IN HPRT-/ 

GPT+ V79 CELLS TREATED WITH 

TEAK WOOD EXTRACT AND 

2-METHYLANTHRAQUINONE, AN 

ABUNDANT BIQUINONE IN TEAK WOOD. 

M. J. Wilson 1 , C. Miller 1,2 , G. Sabbioni 1,2 and R. 

Rando 1 . 1 Environmental Health Sciences, Tulane 

University, New Orleans, LA and 2 Tulane Cancer 

Center, Tulane University, New Orleans, LA. 


GENOTOXICITY ASSESSMENT OF 

ETHYLENEDIAMINE DINITRATE (EDDN) 

AND DIETHYLENETRIAMINE TRINITRATE 

(DETN). G. Reddy 1 , J. Song 2 , P. Kirby 2 and M. S. 

Johnson 1 . 1 Directorate of Toxicology, U.S. Army 

Public Health Command, Aberdeen Proving Ground, 

MD and 2 SITEK Research Laboratories, Rockville, 

MD. 


DOSE-RESPONSE OF NAPHTHALENE– 

INDUCED GENOTOXICITY AND 

GLUTATHIONE DETOXIFICATION IN 

HUMAN TK6 LYMPHOBLASTS. L. Recio 1 , 

K. Shepard 1 , C. Swartz 1 and G. Kedderis 2 . 1 ILS, 

Research Triangle Park, NC and 2 Consultant, Chapel 

Hill, NC. 

Abstract # 


DIMETHYLSULFOXIDE (DMSO) 

INHIBITION OF NAPHTHALENE-INDUCED 

CYTOTOXICITY AND GENOTOXICITY IN 

HUMAN TK6 CELLS. K. Shepard 1 , G. Kedderis 2 , 

C. Swartz 1 and L. Recio 1 . 1 ILS, Research Triangle 

Park, NC and 2 Consultant, Chapel Hill, NC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Methods in Biomarker Discovery and 

Validation 

Chairperson(s): Michael Dunn, Roche, Nutley, NJ. 




IN VIVO MRI OF RAT THYROID 

GLANDS AND CORRELATION WITH 

HISTOPATHOLOGY. M. Stephan-Gueldner, B. 

Kuenekke, B. Lenz, A. Braendli-Baiocco, J. Funk, 

M. vonKienlin and T. Pfister. F. Hoffmann-La Roche 

AG, Basel, Switzerland. 


INTERPRETATION OF NHANES VOC 

BLOOD DATA USING HEALTH-BASED 

SCREENING VALUES. L. L. Aylward 1 , B. 

Blount 2 , D. Pyatt 3 , C. Kirman 4 and S. Hays 5 . 1 Summit 

Toxicology, LLP, Falls Church, VA, 2 Centers for 

Disease Control and Prevention, Atlanta, GA, 

3 

Summit Toxicology, LLP, Superior, Co., 4 Summit 

Toxicology, LLP, Orange Village, OH and 5 Summit 

Toxicology, LLP, Lyons, CO. 


THE UTILITY OF NEUTROPHIL 

GELATINASE-ASSOCIATED LIPOCALIN 

AND KIDNEY INJURY MOLECULE-1 

FOR DETECTION AND SCREENING OF 

NEPHROTOXIC AGENTS IN PRECLINICAL 

DRUG DEVELOPMENT. D. Kitchel, D. Ackley, 

A. McGuinty, T. Magee, W. J. Raegan and J. 

Aubrecht. Drug Safety Research and Development, 



SERUM LEVELS OF THE PHOSPHOLIPID 

BIS(MONOACYLGLYCEROL) PHOSPHATE 

AS AN INDICATOR OF PHOSPHOLIPIDOSIS 

INDUCED IN THE RAT BY CORALGIL. 

K. Thompson 1 , K. Haskins 1 , N. Hartman 2 , B. 

Rosenzweig 1 , S. Stewart 1 , D. Peters 1 , D. Mans 3 and T. 

Colatsky 1 . 1 DAPR, CDER, U.S. FDA, Silver Spring, 

MD, 2 LCP, CDER, U.S. FDA, Silver Spring, MD and 

3 

DPA, CDER, U.S. FDA, St. Louis, MO. 


INVESTIGATION OF PREDICTIVE 

GASTROINTESTINAL TOXICITY 

BIOMARKERS FOR ONCOLOGY DRUG 

DEVELOPMENT IN RATS. W. Huang 1 , W. 

Scott 1 , M. Twamley 1 , E. Kindt 2 , A. Wu 2 , A. Sacaan 1 , 

A. Vitsky 1 and A. John-Baptiste 1 . 1 Drug Safety, Pfizer 

Global Research and Development, San Diego, CA 

and 2 PDM, Pfizer Global Research and Development, 

San Diego, CA. 

Tuesday 







241



Tuesday 



EVALUATION OF A TEST METHOD FOR 

THE MEASUREMENT OF THE URINARY 

BIOMARKERS S-BENZYLMERCAPTURIC 

ACID AND S-PHENYLMERCAPTURIC ACID. 

C. B’Hymer and J. E. Snawder. BHAB, NIOSH, 



MIR-34A EXPRESSION WAS 

UP-REGULATED BY SEVEN DIFFERENT 

GENOTOXIC AGENTS IN A DOSE- 

DEPENDENT MANNER IN TK6 CELLS. Z. 

Li, J. Yan and T. Chen. Division of Genetic and 

Molecular Toxicology, U.S. FDA NCTR, Jefferson, 

AR. 


VALIDATION OF DIKI BIOMARKERS IN 

CYNOMOLGUS MONKEY. M. Guha 1 , A. 

Heier 4 , S. Price 4 , M. Balenstein 5 , R. Caccese 1 , T. 

Simpson 2 , D. Stong 1 , L. Kinter 1 , Y. Dragan 1 and 

E. Bodes 3 . 1 Safety Assessment, Astra Zeneca, 

Wilmington, DE, 2 Medicinal Chemistry, AstraZeneca 

Pharmaceuticals, Wilmington, DE, 3 Emerging 

Product Team, AstraZeneca Pharmaceuticals, 

Wilmington, DE, 4 Safety Assessment, AstraZeneca 

Pharmaceuticals, Alderly Park, Manchester, United 

Kingdom and 5 Clinical Pharmacology &DMPK, 

AstraZeneca Pharmaceuticals, Sodertalje, Sweden. 


SHIPPING OF NONCLINICAL 

SPECIMENS: THE IDEAL CONDITION 

FOR CONSISTENCY OF SAMPLE 

HANDLING THROUGHOUT THE DRUG 

DEVELOPMENT PROCESS. J. J. Stewart, D. 

Efterfield, A. Powell and L. Brown. Flow Contract 

Site Laboratory, LLC, Kirkland, WA. Sponsor: J. 

Hill. 


VALIDATION OF BIOMARKERS FOR 

ASSESSMENT OF CARDIAC EFFECTS 

IN RATS. J. C. Mirsalis, N. Chini, D. Vuong, 

K. Altera, B. Schneider and H. Ng. Preclinical 

Development, SRI International, Menlo Park, CA. 


INSTABILITY OF QUINONE 

ELECTROPHILE ADDUCTS ON 

CYSTEINE RESIDUES: A BASIS FOR 

THE PREFERENTIAL DETECTION OF 

COVALENT MODIFICATION OF LYSINES 

AND ARGININES. C. L. Kuhlman 1 , M. L. 

Labenski 1 , A. A. Fisher 1 , B. Z. Olenyuk 2 , T. J. Monks 1 

and S. S. Lau 1 . 1 Southwest Environmental Health 

Sciences Center, Department of Pharmacology/ 

Toxicology, College of Pharmacy, University of 

Arizona, Tucson, AZ and 2 Department of Chemistry/ 

Biochemistry, College of Science, University of 



URINARY BIOMARKER DETECTION OF 

MELAMINE-CYANURIC ACID-INDUCED 

KIDNEY DAMAGE IN RATS. Q. Zhang 1 , G. 

Gamboa da Costa 2 , R. Beger 2 , L. Schnackenberg 2 , J. 

Sun 2 , L. Pence 2 , S. Bhattacharyya 2 , C. Jacob 2 , R. P. 

Brown 1 and P. L. Goering 1 . 1 CDRH, U.S. FDA, Silver 

Spring, MD and 2 NCTR, U.S. FDA, Jefferson, AR. 


VALIDATION OF BEST DETECTION 

METHODS FOR MEASURING OXIDATIVE 

STRESS. M. B. Kadiiska. NIEHS/NIH, Research 



STEROID HORMONE PROFILING 

BY MASS SPECTROMETRY IN RAT 

BLOOD COLLECTED VIA THE CULEX® 

AUTOMATED IN VIVO SAMPLING 

SYSTEM. C. Penno 1,2 , L. Morawiec 1 , M. Schwald 1 , 

N. Zamurovic 1 , S. Busch 1 , A. Wolf 1 , F. Pognan 1 , S. 

Chibout 1 , A. Odermatt 2 and M. Dong 1 . 1 Preclinical 

Safety, Novartis, Basel, Switzerland and 2 Department 

of Pharmaceutical Sciences, University of Basel, 



SERUM CARDIAC TROPONIN I 

CONCENTRATION AS AN EARLY 

BIOMARKER OF MYOCARDIAL 

HYPERTROPHY IN THE ROSIGLITAZONE 

OR 3, 3’, 5-TRIIODO-L-THYRONINE 

TREATED RAT. M. Dunn 1 , D. Coluccio 1 , R. 

Fernandes 1 , D. Knapp 1 , R. Nicklaus 1 , G. Hirkaler 1 , 

W. Geng 1 , M. Sanders 1 , T. Singer 2 and I. Mikaelian 1 . 

1 

Nonclinical Safety, Roche, Nutley, NJ and 

2 

Nonclinical Safety, Roche, Basel, Switzerland. 

Sponsor: K. Kolaja. 


CHARACTERISATION OF THE 

PRODROMAL AND REVERSIBILITY VALUE 

OF NOVEL RENAL SAFETY BIOMARKERS 

IN GENTAMICIN-TREATED RATS. J. Wood 1 , 

A. Shoieb 1 , A. McGuinty 1 , P. Cleall 1 , D. Hardy 1 , 

D. Collins 1 , C. Dubray 1 , R. Williams 1 , A. Moody 1 , 

K. Lynch 2 , D. Ennulat 2 , T. Sellars 2 , T. Lambert 2 , 

S. Beushausen 3 , E. Harpur 4 , M. Guffroy 1 and 

D. Brees 1 . 1 Pfizer, Sandwich, United Kingdom, 

2 

GlaxoSmithKline, King of Prussia, PA, 3 Pfizer, St. 

Louis, MO and 4 Sanofi-Aventis, Alnwick, United 

Kingdom. Sponsor: D. Robinson Gravatt. 


EVALUATION OF NOVEL BIOMARKERS 

OF NEPHROTOXICITY IN MICE. J. Gautier 1 , 

T. Gury 1 , J. Léonard 1 , O. Dorchies 1 , L. Stimmer 1 , E. 

Harpur 2 , S. Küsters 3 , J. Mapes 3 and M. Guffroy 1 . 

1 

sanofi-aventis, Paris, France, 2 sanofi-aventis, 

Alnwick, United Kingdom and 3 Rules-Based 

Medicine, Austin, TX. 


IMPACT OF NUTRITION ON THE PLASMA 

METABOLOME IN RATS. W. Mellert 1 , M. 

Kapp 1 , V. Strauss 1 , J. Wiemer 2 , E. Leibold 1,2 , H. 

G. Kamp 1,2 , T. Walk 2 , R. Looser 2 , A. Prokoudine 2 , 

E. Fabian 1 , G. Krennrich 1 , M. Herold 2 and B. van 

Ravenzwaay 1 . 1 Experimental Toxicology and 

Ecology, BASF SE, Ludwigshafen am Rhein, 

Germany and 2 Metanomics GmbH, Berlin, Germany. 

Sponsor: R. Landsiedel. 


UTILITY OF MICRORNAS AS POTENTIAL 

BIOMARKERS OF TESTICULAR TOXICITY. 

H. Lin 3 , J. Milano 1 , L. Barone 1 , J. Stewart 2 , S. 

Ramaiah 3 and Y. Dragan 1 . 1 Safety Assessment, 

AstraZeneca Pharmaceuticals, Wilmington, 

DE, 2 Reproductive Toxicology, AstraZeneca 

Pharmaceuticals, Alderley Park, Cheshire, United 

Kingdom and 3 DSRD, Pfizer Inc., Cambridge, MA. 

242 






Platform Sessions



Abstract # 


SURFACE PLASMON-BASED CELL 

AND PROTEIN MICROARRAYS FOR 

THE IDENTIFICATION OF STRESS AND 

DISEASE BIOSIGNATURES. J. M. Rice 1 , C. 

Rich 1 , P. E. Reinhold 1 , D. A. Lawrence 2 and M. A. 

Lynes 1 . 1 Molecular and Cell Biology, University 

of Connecticut, Storrs, CT and 2 New York State 

Department of Health, Wadsworth Center, Albany, 

NY. 


INITIAL BIOLOGICAL QUALIFICATION OF 

SBDP-145 IN CEREBROSPINAL FLUID AS 

A BIOMARKER OF COMPOUND-INDUCED 

NEURODEGENERATION IN THE RAT. M. 

L. Pritt 1 , W. H. Jordan 2 , D. G. Hall 1 , D. W. Ballard 1 , 

U. W. Muller 3 , K. W. Wang 3 and D. E. Watson 1 . 

1 

Lilly Research Laboratories, Eli Lilly and Company, 

Indianapolis, IN, 2 VetPath Services, Mason, OH and 

3 

Banyan Biomarkers, Alachua, FL. 


PET IMAGING OF TRANSLOCATOR 

PROTEIN 18 kDa (TSPO) REVEALS 

DELAYED NEUROINFLAMMATION 

COINCIDENT WITH PERSISTENT 

BEHAVIORAL DEFICITS IN RATS ACUTELY 

INTOXICATED WITH DFP. D. A. Bruun 1 , 

D. Rowland 2 , Y. Li 1 , B. Ford 3 and P. Lein 1 . 

1 

Molecular Biosciences, University of California, 

Davis, CA, 2 Center for Molecular and Genomic 

Imaging, University of California, Davis, CA and 

3 

Anatomy and Neurobiology, Neuroscience Institute, 

Morehouse School of Medicine, Atlanta, GA. 


MOVING BEYOND THE 

ORTHODOX ‘TBNK’ PANEL: NEW 

IMMUNOPHENOTYPING STRATEGIES 

FOR IMMUNE-TOXICOLOGICAL 

ASSESSMENTS IN PRECLINICAL AND 

CLINICAL PHARMACEUTICAL STUDIES. 

T. Warren, A. R. Mcintyre, T. Salewsky, R. Eyre and 

H. Tsusaki. SNBL USA, Ltd., Everett, WA. 


GENOMICS AND PROTEOMICS ANALYSIS 

IDENTIFIED THE PROTEINS ASSOCIATED 

WITH ADIPOCYTE LIPOLYSIS AS A KEY 

REGULATOR FOR THE PATHOGENESIS 

OR PROGRESSION OF METABOLIC 

SYNDROME. J. Chang 2 , S. Oikawa 4 , C. Ando 1 , 

K. Kuzuya 1 , G. Ichihara 3 and S. Ichihara 2,1 . 1 Life 

Science Research Center, Mie University, Tsu, Japan, 

2 

Graduate School of Regional Innovation Studies, 

Mie University, Tsu, Japan, 3 Nagoya University 

Graduate School of Medicine, Nagoya, Japan and 

4 

Department of Environmental and Molecular 

Medicine, Mie University Graduate School of 

Medicine, Tsu, Japan. 

Abstract # 


DEVELOPMENTAL CONTAMINANT 

EXPOSURE IMPACTS PHYSIOLOGICAL 

FUNCTION IN AMERICAN ALLIGATORS, 

ALLIGATOR MISSISSIPPIENSIS. M. A. 

Pickett 1 , J. T. Martin 1 , S. S. Smith 1 , E. J. Hulse 1 , 

A. Boggs 2 , L. J. Guillette 2,3 and M. P. Gunderson 1 . 

1 

Biology, The College of Idaho, Caldwell, ID, 

2 

Biology, University of Florida, Gainesville, FL 

and 3 Marine Biomedicine and Environmental 

Sciences Center Medical University South Carolina, 

Charleston, SC. Sponsor: S. Heggland. 


DEVELOPMENT OF A METHOD FOR 

QUANTITATING SPHINGOID BASE 

1-PHOSPHATES IN BLOOD SPOTS. R. T. 

Riley 1,2 , N. C. Zitomer 1 and J. Gelineau van Waes 3 . 

1 

Toxicology and Mycotoxin Research Unit, USDA- 

ARS, Athens, GA, 2 Interdisciplinary Toxicology 

Program, University of Georgia, Athens, GA and 

3 

Creighton University School of Medicine, Omaha, 

NE. 


DEVELOPMENT OF HUMAN EPITHELIAL 

CELL-BASED ALTERNATIVE 

MONITORING OF XENOBIOTIC-INDUCED 

ENDOPLASMIC RETICULUM STRESS. H. 

Choi, H. Yang, J. Kim and Y. Moon. Department 

of Microbiology and Immunology, Pusan National 

University School of Medicine and Medical Research 

Institute, Yangsan, Republic of Korea. 


INTEGRATION OF TRANSCRIPTOMIC 

AND PROTEOMIC DATA TO IDENTIFY 

SUSCEPTIBILITY FACTORS FOR 

PULMONARY INFECTION DURING DIET- 

INDUCED OBESITY IN MICE EXPOSED TO 

LIPOPOLYSACCHARIDE. S. C. Tilton, K. M. 

Waters, B. Webb-Robertson, N. J. Karin, X. Zhang, 

J. M. Jacobs, J. G. Pounds and R. A. Corley. Pacific 

Northwest National Laboratory, Richland, WA. 


CERIVASTATIN INDUCES THE MUSCLE 

ATROPHY PROGRAM IN A TIME- AND 

FIBER-DEPENDENT MANNER WITH 

AN INCREASE IN BIOMARKERS OF 

MYOPATHY. J. D. Vassallo 1,2 , J. A. Rathmacher 3 , 

E. B. Janovitz 1 , S. Stryker 1 , D. Robertson 1 , L. J. 

Lowe-Krentz 2 and L. D. Lehman-McKeeman 1 . 

1 

Discovery Toxicology, Bristol-Myers Squibb, 

Princeton, NJ, 2 Biological Sciences, Lehigh 

University, Bethlehem, PA and 3 Metabolic 

Technologies, Ames, IA. 


USE OF A QUANTITATIVE 

IMMUNOHISTOCHEMICAL METHOD 

FOR DIAGNOSING PHOSPHOLIPIDOSIS. 

K. A. Haskins 1 , S. Stewart 1 , D. Mans 2 , J. Zhang 1 , 

D. Peters 1 , T. Colatsky 1 and K. L. Thompson 1 . 

1 

Division of Applied Pharmacology Research, 

CDER, U.S. FDA, Silver Spring, MD and 2 Division 

of Pharmaceutical Analysis, CDER, U.S. FDA, St. 

Louis, MO. 

Tuesday 







243



Tuesday 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology 

Chairperson(s): Laura Braydich-Stolle, AFRL/RHPB, Dayton, OH. 




BIOCHEMICAL MODULATION OF COPPER 

NANOPARTICLE UPTAKE DIMINISHES 

CYTOTOXICITY. J. B. Lin, A. Schrand and S. 

M. Hussain. Applied Biotechnology, AFRL/RHPB, 



EFFECT OF ENGINEERED TITANIUM 

DIOXIDE NANOPARTICLE SHAPE ON 

TOXICITY IN VIVO. D. W. Porter 1,2 , M. G. 

Wolfarth 1 , N. Wu 3 , A. Holian 4 , A. Hubbs 1 , K. A. 

Funk 5 and V. Castranova 1,2 . 1 HELD/PPRB, NIOSH, 

Morgantown, WV, 2 Physiology and Pharmacology, 

West Virginia University, Morgantown, WV, 

3 

Mechanical and Aerospace Engineering, West 

Virginia University, Morgantown, WV, 4 Center 

for Environmental Health Sciences, University 

of Montana, Missoula, MT and 5 Experimental 

Pathology Laboratories, Inc., Sterling, VA. 


INFLUENCE OF THE AGGLOMERATION 

STATE ON IN VIVO PULMONARY 

INFLAMMATION AND CYTOTOXICITY OF 

INHALED NANO-AEROSOLS OF TIO2. A. 

Noel 1 , K. Maghni 2 , Y. Cloutier 3 , C. Dion 3 , R. Tardif 1 

and G. Truchon 3 . 1 Environmental and Occupational 

Health, University of Montréal, Montréal, QC, 

Canada, 2 University of Montréal, Montréal, QC, 

Canada and 3 Institut de Recherche Robert-Sauvé 

en Santé et en Sécurité du Travail, Montréal, QC, 

Canada. 


EFFECT OF SILVER NANOPARTICLES 

ON NITRIC OXIDE RELEASE IN THE RAT 

TRACHEA SMOOTH MUSCLE. C. Gonzalez 1 , 

S. Salazar-Garcia 1 , P. P. Martinez-Cuevas 1 , A. 

Ramirez-Lee 1 , S. E. Jimenez-Badillo 1 , H. Rosas- 

Hernandez 1 and S. F. Ali 2 . 1 Faculty of Chemistry, 

Autonomous University of San Luis Potosi, San Luis 

Potosi, SLP, Mexico and 2 Neurochem Lab., Division 

of Neurotoxicology, NCTR/U.S. FDA, Jefferson, AR. 


GLOBAL GENE PROFILING REVEALS 

DOSE AND TIME PROGRESSION OF KEY 

BIOLOGICAL RESPONSES OF LUNG 

EPITHELIAL CELLS TO NANOSCALE 

AMORPHOUS SILICA IN VITRO. N. J. 

Karin 1,3 , K. M. Waters 1,3 , J. G. Teeguarden 1,3 , W. 

Wang 2,3 , J. A. Price 3 , R. D. Quesenberry 1,3 and B. D. 

Thrall 1,3 . 1 Pacific Northwest National Laboratory, 

Richland, WA, 2 Oak Ridge National Laboratory, Oak 

Ridge, TN and 3 Battelle Center for Fundamental and 

Applied Systems Toxicology, Columbus, OH. 


PULMONARY TOXICITY OF AMORPHOUS 

SILICA NANOMATERIAL: A COMPARISON 

OF INHALATION AND INSTILLATION 

STUDIES. L. Ma-Hock 1 , M. Wiemann 3 , S. Brill 1 , 

W. Wohlleben 2,1 , V. Strauss 1 , S. Treumann 1 , B. van 

Ravenzwaay 1 and R. Landsiedel 1 . 1 Experimental 

Toxicology and Ecology, BASF SE, Ludwigshafen 

am Rhein, Germany, 2 ibe, Marl, Germany and 

3 

Polymer Physics, BASF SE, Ludwigshafen am 

Rhein, Germany. 


NANOPARTICLE INHALATION ENHANCES 

CARDIAC PROTEIN PHOSPHORYLATION 

AND NEUROTRANSMITTER SYNTHESIS IN 

THE NODOSE GANGLIA OF RATS. H. Kan 1 , 

Z. Wu 2 , S. Young 1 , T. B. Chen 1 , J. L. Cumpston 1 , F. 

Chen 1 and V. Castranova 1 . 1 HELD/PPRB, NIOSH, 

Morgantown, WV and 2 Department of Neurobiology 

and Anatomy, West Virginia University, 



DISTRIBUTION, ELIMINATION, AND 

BIOPERSISTENCE TO 90 DAYS OF A 

SYSTEMICALLY-INTRODUCED 30 NM 

CERIA ENGINEERED NANOMATERIAL 

IN RATS. R. A. Yokel 1 , T. C. Au 1 , M. Dan 1 , R. 

L. Florence 1 , J. M. Unrine 2 , R. C. MacPhail 4 , 

M. T. Tseng 3 , D. Butterfield 2 , S. S. Hardas 2 , R. 

Sultana 2 , U. M. Graham 2 , P. Wu 2 and E. A. Grulke 2 . 

1 

Pharmaceutical Sciences, University of Kentucky, 

Lexington, KY, 2 University of Kentucky, Lexington, 

KY, 3 University of Louisville, Louisville, KY and 

4 



PHOTO-ACTIVATION OF MULTISIZED 

TITANIUM DIOXIDE NANOPARTICLES 

(TIO 2 

NPS) RESULTS IN DIFFERENT ROS 

PRODUCTION AND OXIDATIVE TOXICITY 

PROFILES IN ZEBRAFISH EMBRYOS. O. 

Bar-Ilan 1,2 , K. Louis 2 , S. Yang 2 , J. Pedersen 2 , R. 

Hamers 2 , R. E. Peterson 1,2 and W. Heideman 1,2 . 

1 

Division of Pharmaceutical Sciences, University of 

Wisconsin, Madison, WI and 2 NSEC, University of 

Wisconsin, Madison, WI. 


PULMONARY TOXICITY OF BIODIESEL 

PARTICULATE MATTER. A. A. Shvedova 1 , 

E. Kisin 1 , A. R. Murray 1 , A. Tkach 1 , D. Schwegler- 

Berry 1 , S. H. Young 1 , V. E. Kagan 2 and A. D. 

Bugarski 3 . 1 PPRB, NIOSH, Morgantown, WV, 

2 


Health, University of Pittsburgh, Pittsburgh, PA and 

3 

OMSHR, NIOSH, Pittsburgh, PA. 


ENGINEERED SILICA NANOPARTICLES 

ACT AS ADJUVANTS TO ENHANCE 

ALLERGIC AIRWAY DISEASE IN MICE. J. 

R. Harkema 1 , N. Rowley 1 , L. Bramble 1 , Q. Zhang 2 , 

D. Jackson-Humbles 1 , G. Baker 2 , J. Wagner 1 

and M. Worden 3 . 1 Pathobiology, Michigan State 

University, East Lansing, MI, 2 Chemistry, Michigan 

State University, East Lansing, MI and 3 Chemical 

Engineering, Michigan State University, East 

Lansing, MI. 

244 






Platform Sessions



Abstract # 


COPPER NANOPARTICLES INDUCE 

CEREBRAL MICROVASCULATURE 

PROLIFERATION OR TOXICITY THAT 

AFFECT BLOOD-BRAIN BARRIER 

PERMEABILITY. W. J. Trickler 1 , S. M. Lantz 1 , B. 

L. Robinson 1 , G. D. Newport 1 , P. C. Howard 2 , J. J. 

Schlager 3 , M. G. Paule 1 , W. Slikker 1 , S. M. Hussain 3 

and S. F. Ali 1 . 1 Neurochemistry Laboratory, Division 

of Neurotoxicology, NCTR/U.S. FDA, Jefferson, 

AR, 2 Office of Scientific Coordination, NCTR/U.S. 

FDA, Jefferson, AR and 3 AB Branch, AFRL, Wright- 

Patterson AFB, Dayton, OH. 


IN VITRO TOXICITY OF AMPHIPHILIC 

POLYMER-COATED CD/SE/ZNS QUANTUM 

DOTS IN MULTIPLE HUMAN AND MOUSE 

CELL TYPES. L. McConnachie, C. White, D. 

Botta, M. Zadworny, D. Cox, R. Beyer, X. Hu, 

D. Eaton, X. Gao and T. Kavanagh. University of 



DEVELOPMENT OF NANO-AEROSOL 

GENERATION TEST PLATFORM FOR 

INHALATION TOXICOLOGY STUDIES. V. 

B. Mikheev 1,4 , W. S. Forsythe 1,4 , B. N. Swita 1,4 , K. 

R. Minard 2,4 and W. Wei 3,4 . 1 Battelle Toxicology 

Northwest, Richland, WA, 2 Pacific Northwest 

National Laboratory, Richland, WA, 3 Oak Ridge 

National Laboratory, Oak Ridge, TN and 4 B-FAST, 

Battelle Center for Fundamental and Applied 

Systems Toxicology, Columbus, OH. Sponsor: R. 

Meng. 


TOXICITY STUDY OF SILVER 

NANOPARTICLES IN DROSOPHILA 

MELANOGASTER USING STRESS 

SENSITIVE MUTANTS AND GAL4 

ENHANCER TRAP SCREENING. H. Tian, H. 

Eom, G. Lee, Y. Chung and J. Choi. University of 

Seoul, Seoul, Republic of Korea. Sponsor: D. Ryu. 


SHORT-TERM RAT INHALATION STUDY 

WITH AEROSOLS GENERATED FROM 

ACRYLIC ESTER POLYMERS WITH A 

PROPORTION OF NANOPARTICLES. K. 

Wiench 1 , L. Ma-Hock 2 , V. Strauss 2 , S. Gertrud 3 , 

B. van Ravenzwaay 2 and R. Landsiedel 2 . 1 Product 

Safety, BASF SE, Ludwigshafen, Germany, 

2 

Experimental Toxicology and Ecology, BASF 

SE, Ludwigshafen, Germany and 3 Dispersions 

for Adhesives & Construction Europe, BASF SE, 

Ludwigshafen, Germany. 


GENOTOXIC EFFECTS OF 

NANOMATERIALS IN LUNG TISSUE IN 

VITRO AND IN VIVO. M. Schulz 2 , K. Wiench 1 , K. 

Chodakowski 2 , A. Hartwig 3 , S. Brill 2 , L. Ma-Hock 2 , 

B. van Ravenzwaay 2 and R. Landsiedel 2 . 1 Product 

Safety, BASF SE, Ludwigshafen, Germany, 

2 


Ludwigshafen, Germany and 3 Food Chemistry and 

Toxicology, Technical University Berlin, Berlin, 

Germany. 

Abstract # 


COMPARATIVE GENE EXPRESSION 

PROFILE IN TISSUES OF RATS 

INTRATRACHEALLY EXPOSED TO 

CADMIUM-DOPED NANOPARTICLES. 

T. Coccini 1 , E. Roda 2 , M. Fabbri 3 , M. Sacco 3 , L. 

Manzo 1,2 and L. Gribaldo 3 . 1 Toxicology Division, 

Maugeri Foundation IRCCS, Institute of Pavia, 

Pavia, Italy, 2 European Centre for Nanomedicine, 

University of Pavia, Pavia, Italy and 3 IHCP, 

European Commission, Joint Research Centre, Ispra, 

Italy. 


NANOPARTICLES ALTER 

CYCLOOXYGENASE ACTIVITY IN 

MICROVASCULAR DYSFUNCTION. T. L. 

Knuckles 1 , J. Yi 1 , D. Frazer 2 , J. Cumpston 2 , B. Chen 2 , 

V. Castranova 2 and T. R. Nurkiewicz 1 . 1 Physiology 

and Pharmacology, West Virginia University, 

Morgantown, WV and 2 National Institute of 

Occupational Safety and Health, Morgantown, WV. 


HUMAN CLINICAL STUDIES OF 

DIESEL EXHAUST PARTICULATE AND 

IMPLICATION FOR NANOPARTICLE 

EXPOSURES. P. A. Valberg 2 , T. W. Hesterberg 1 , C. 

M. Long 2 , C. A. Lapin 3 and A. K. Hamade 2 . 1 Navistar, 

Inc., Chicago, IL, 2 Gradient, Inc., Cambridge, MA 

and 3 Lapin and Associates, Glendale, CA. 


PULMONARY AND HEMATOLOGICAL 

EFFECTS IN RATS FOLLOWING A SINGLE 

INHALATION EXPOSURE TO CEO2 

NANOPARTICLES. K. Dreher, A. Ledbetter, R. 

Jaskot, M. Odegaard, R. Snyder, J. Richards and 

N. Coates. ORD, NHEERL, U.S. EPA, Research 



EFFECTS OF COPPER NANOPARTICLE 

EXPOSURE ON HOST DEFENSE IN 

MURINE PULMONARY INFECTION 

MODEL OF KLEBSIELLA PNEUMONIAE. J. 

Kim 1 , A. Adamcakova-Dodd 2 , P. T. O’Shaughnessy 2 , 

V. H. Grassian 1 and P. S. Thorne 1,2 . 1 Interdisciplinary 

Graduate Program in Human Toxicology, University 

of Iowa, Iowa City, IA and 2 Occupational and 


City, IA. 


MAGNETIC PARTICLE DETECTION (MPD) 

FOR RAPID CELL & TISSUE DOSIMETRY. 

K. R. Minard 1,4 , B. D. Thrall 1,4 , J. G. Teeguarden 1,4 , 

M. H. Littke 1,4 , V. B. Mikheev 2,4 and W. Wang 3,4 . 

1 

Pacific Northwest National Laboratory, Richland, 

WA, 2 Battelle, Richland, WA, 3 Oak Ridge National 

Lab., Oak Ridge, TN and 4 B-FAST, Battelle Center 

for Fundamental and Applied Systems Toxicology, 

Columbus, OH. 


SYNTHESIS, CHARACTERIZATION, AND 

TOXICITY STUDIES OF DISCRETE SIZE 

NANOPARTICLE-PESTICIDE CONJUGATE 

FOR NOVEL PESTICIDE DELIVERY. A. 

Sooresh, H. Kwon, P. Pietrantonio, M. Pine and C. 

Sayes. Texas A&M University, College Station, TX. 

Tuesday 







245



Tuesday 



NANOPARTICLE TOXICITY ON AIRWAY 

EPITHELIAL CELLS. M. M. McCorkel 1,2 and S. 

Boitano 1,2,3 . 1 Biomedical Engineering, University of 

Arizona, Tucson, AZ, 2 Arizona Respiratory Center, 

Arizona Health Sciences Center, Tucson, AZ and 

3 

Physiology, University of Arizona, Tucson, AZ. 

Sponsor: R. Lantz. 


TRANSPORT MECHANISM OF 

NANOPARTICLE INTO THE BRAIN. B. Choi, 

D. Kim and J. Park. Preventive Medicine, Chung- 

Ang University, Seoul, Republic of Korea. 


EMBRYONIC GENE EXPRESSION 

IS IMPACTED BY SURFACE 

FUNCTIONALITIES OF GOLD 

NANOPARTICLES. L. Truong 1,2 , T. Zaikova 2,3 , 

J. Miller 2,3 , J. Hutchison 2,3 and R. Tanguay 1,3 . 

1 

Environmental & Molecular Toxicology, Oregon 

State University, Corvallis, OR, 2 The Oregon 

Nanoscience and Microtechnologies Institute and 

the Safer Nanomaterials and Nanomanufacturing 

Initiative, Eugene, OR and 3 Chemistry, University of 

Oregon, Eugene, OR. 


DISPERSIBILITY CONTROL AFFECTS THE 

RESULT OF CYTOTOXICITY TEST FOR 

NANOMATERIAL. H. Yang 1 , K. Lee 1 , C. Lee 2 , 

K. Cho 1 , C. Kim 1 and C. Song 1 . 1 Korea Institute 

of Toxicology, Jeongup, Republic of Korea and 

2 

Battelle Korea, Seoul, Republic of Korea. 


SILICA NANOPARTICLES CAUSE 

GENOTOXIC ACTIVITY IN THE IN VIVO 

COMET AND MICRONUCLEUS ASSAYS 

WHILE GOLD OR POLYSTYRENE 

NANOMATERIALS DO NOT. S. Pfuhler, T. 

Downs, M. Crosby, J. Jester, A. Allemang and K. 

Sarlo. Central Product Safety, Procter & Gamble, 



USE OF MICROCOSMS TO EVALUATE 

FATE AND EFFECTS OF NANOMATERIALS 

IN AQUATIC SYSTEMS. D. S. Barber, J. Gao, 

L. C. Smith and K. W. Powers. University of Florida, 



IMPACT OF DISSOLVED ORGANIC 

MATTER ON THE TOXICITY OF TITANIUM 

DIOXIDE NANOPARTICLES IN ZEBRAFISH 

EMBRYOS. S. Yang 1 , O. Bar-Ilan 2 , K. M. Louis 3 , 

R. E. Peterson 2 , W. Heideman 2 , R. J. Hamers 3 and 

J. A. Pedersen 1 . 1 Molecular and Environmental 

Toxicology, University of Wisconsin Madison, 

Madison, WI, 2 School of Pharmacy, University of 

Wisconsin Madison, Madison, WI and 3 Department 

of Chemistry, University of Wisconsin Madison, 

Madison, WI. 


NANOTOXICOLOGY AND NANOHEALTH 

BIBLIOMETRY FROM 2000 TO 2009. W. 

Waissmann 1 , M. M. Alencar 2 , M. Moura 1 , A. B. 

Veggi 1 , T. Pastorello 1 and R. B. Santana 1 . 1 Sergio 

Arouca National School of Public Health, Oswaldo 

Cruz Foundation, Rio de Janeiro, Brazil and 2 Institute 

of Scientific and Technological Communication and 

Information in Health, Oswaldo Cruz Foundation, 

Rio de Janeiro, Brazil. Sponsor: E. Silbergeld. 


DISRUPTION OF MUSCARINIC RECEPTOR 

MEDIATED SIGNAL TRANSDUCTION BY 

OXIDATIVE STRESS. C. Wu, J. Erickson, H. 

Wang, Y. Huang and R. S. Aronstam. Biological 

Sciences, Missouri University of Science and 

Technology, Rolla, MO. 


SYSTEMATIC EVALUATION OF THE 

TOXICITY OF CARBON-COATED AND 

NON-COATED COPPER AND NICKEL 

NANOPARTICLES. S. Minocha, A. Sarangi, 

A. Tropsha and R. J. Mumper. University of North 

Carolina Eshelman School of Pharmacy, Chapel Hill, 

NC. Sponsor: A. Ghio. 


THE OCCUPATIONAL HEALTH SURVEY 

ON WORKERS AND NANOPARTICLE 

NUMBER IN THE FACTORY HANDLING 

NANO-TITANIUM DIOXIDE. S. Ichihara 1 , W. 

Li 2 , T. Kobayashi 3 , S. Omura 3 , Y. Hiraku 5 , X. Ding 2 

and G. Ichihara 4 . 1 Life Science Research Center, 

Mie University, Tsu, Japan, 2 Shanghai Institute of 

Planned Parenthood Research, Shanghai, China, 

3 

Tokyo Institute of Technology, Yokohama, Japan, 

4 

Nagoya University Graduate School of Medicine, 

Nagoya, Japan and 5 Mie University Graduate School 

of Medicine, Tsu, Japan. 


QUANTITATIVE PROTEOMICS ANALYSIS 

OF ADSORBED PLASMA PROTEINS 

CLASSIFIES NANOPARTICLES WITH 

DIFFERENT SURFACE PROPERTIES AND 

SIZE. H. Zhang, K. E. Burnum, M. L. Luna, B. 

O. Petritis, J. Kim, W. Qian, R. J. Moore, B. Webb- 

Robertson, R. D. Smith, B. D. Thrall, J. G. Pounds 

and T. Liu. Biological Sciences Division, Pacific 



EFFECTS OF CERIUM OXIDE 

NANOPARTICLES ON GLYCINE MAX 

GROWN IN HYDROPONICS. A. De La Rosa 1 , 

J. R. Peralta 1 , J. Gardea-Torresdey 1 and J. Terry 2 . 

1 

Chemistry, University of Texas at El Paso, El Paso, 

TX and 2 Physics, Illinois Institute of Technology, 

Chicago, IL. 


EFFECTS OF 12-WEEK-INHALATION 

EXPOSURE TO ETHYL TERT-BUTYL 

ETHER (ETBE) ON BEHAVIOR AND BRAIN 

IN C57BL/6J AND ALDH2(-/-) MICE. R. Hojo, 

H. Kubota, M. Suda, Y. Yanagiba and R. Wang. 

JNIOSH, Kawasaki, Kanagawa, Japan. Sponsor: C. 

Tohyama. 

246 






Platform Sessions



Abstract # 


OXIDATIVE STRESS ASSOCIATED 

WITH ULTRAFINE MODEL PARTICLE 

SYSTEMS CONTAINING CHEMISORBED 

ENVIRONMENTALLY PERSISTENT FREE 

RADICALS. M. A. Kelley 1 , V. Y. Hebert 1 , S. 

A. Cormier 2 , B. Dellinger 3 , S. Lomnicki 3 and 

T. R. Dugas 1 . 1 Pharmacology, Toxicology, and 

Neuroscience, Louisiana State University Health 

Sciences Center, Shreveport, LA, 2 Pharmacology 

& Experimental Therapeutics, Louisiana State 

University Health Sciences Center, New Orleans, LA 

and 3 Chemistry, Louisiana State University, Baton 

Rouge, LA. 


IDENTIFICATION OF SYSTEMIC 

MARKERS FROM A PULMONARY CARBON 

NANOTUBE EXPOSURE. T. Hulderman, A. L. 

Liston, R. Salmen-Muniz, S. H. Young, P. C. Zeidler- 

Erdely, V. Castranova, P. P. Simeonova and A. 

Erdely. NIOSH, Morgantown, WV. 


IN VITRO VASCULAR TOXICITY OF METAL 

OXIDE NANOPARTICLES. M. Odegaard and K. 

Dreher. Environmental Public Health Division, U.S. 



ACUTE PHASE PROTEINS AS 

BIOMARKERS FOR PREDICTING 

THE EXPOSURE AND SAFETY OF 

NANOMATERIALS. Y. Yoshioka 1,2,3 , K. 

Higashisaka 1,3 , K. Yamashita 1,3 , M. Fujimura 1,3 , Y. 

Morishita 1,3 , P. Huiyan 1,3 , T. Ogura 1,3 , H. Nabeshi 1,3 , 

K. Nagano 3 , Y. Abe 3 , H. Kamada 2,3 , S. Tsunoda 2,3,4 , 

N. Itoh 1,3 , T. Yoshikawa 1,3 and Y. Tsutsumi 1,2,3 . 

1 

Department of Toxicology and Safety Science, 


Osaka University, Osaka, Japan, 2 The Center for 

Advanced Medical Engineering and Informatics, 

Osaka University, Osaka, Japan, 3 Laboratory of 

Biopharmaceutical Research, National Institute 

of Biomedical Innovation, Osaka, Japan and 

4 

Department of Biomedical Innovation, Graduate 

School of Pharmaceutical Sciences, Osaka 

University, Osaka, Japan. 


TOLL-LIKE RECEPTOR 4 IS INVOLVED IN 

THE CEREBROVASCULAR TOXICITY OF 

PCB153 BOUND TO NANOPARTICLES. B. 

Zhang 1,2 , L. Chen 2 , B. Hennig 1,3 and M. Toborek 1,2 . 

1 

Graduate Center for Nutritional Sciences, University 

of Kentucky, Lexington, KY, 2 Department of 

Neurosurgery, University of Kentucky, Lexington, 

KY and 3 College of Agriculture, University of 

Kentucky, Lexington, KY. 


ASSESSMENT OF PULMONARY TOXICITY 

IN MICE AFTER INHALATION EXPOSURE 

TO ZINC OXIDE. A. Adamcakova-Dodd 1 , 

J. Kim 2 , S. U. Vorrink 2 , L. V. Stebounova 3 , P. T. 

O’Shaughnessy 1 , V. H. Grassian 3,2 and P. S. Thorne 1,2 . 

1 

Occupational and Environmental Health, University 

of Iowa, Iowa City, IA, 2 Interdisciplinary Graduate 

Program in Human Toxicology, University of Iowa, 

Iowa City, IA and 3 Chemistry, University of Iowa, 


Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Drug Allergy, Pseudoallergy, IDRH, and 

Autoimmunity 

Chairperson(s): Raymond Pieters, Utrecht University, Utrecht, 

Netherlands. 




DEVELOPMENT OF A MOUSE MODEL FOR 

PREDICTING DRUG HYPERSENSITIVITY 

REACTIONS. A. Hudson, S. H. Cole, T. T. 

Kawabata and J. Whritenour. Immunotoxicology, 

Pfizer Global R&D, Groton, CT. 


HLA-SPECIFIC T-CELL ACTIVATION 

AS AN UNDERLYING CAUSE OF DRUG- 

INDUCED HYPERSENSITIVITY. J. M. 

Goodwin 1 , T. Kawabata 2 and M. T. Pletcher 1 . 

1 

Compound Safety Prediction, Pfizer, Groton, CT 

and 2 Immunotoxicology CoE, Pfizer, Groton, CT. 


EARLY CHANGES IN AROMATIC AMINE- 

INDUCED IDIOSYNCRATIC DRUG 

REACTIONS. W. Ng and J. Uetrecht. Pharmacy, 

University of Toronto, Toronto, ON, Canada. 


THE USE OF MAST CELLS DERIVED FROM 

HUMAN CD34+ HEMATOPOIETIC STEM 

CELLS AS A TOOL FOR PREDICTING 

PSEUDOALLERGIC DRUG REACTIONS. J. 

Whritenour 1 , C. Homiski 1 , K. Haskell 2 , M. Thiede 2 

and T. T. Kawabata 1 . 1 Immunotoxicology CoE, Drug 

Safety Research and Development, Pfizer, Inc., 

Groton, CT and 2 Genetically Modified Mice CoE, 

Pfizer, Inc., Groton, CT. 


EFFECT OF RETINOIC ACID ON 

NEVIRAPINE-INDUCED SKIN RASH AND 

THE INVOLVEMENT OF TH17 CELLS. X. 

Chen and J. P. Uetrecht. Faculty of Pharmacy, 

University of Toronto, Toronto, ON, Canada. 


IMMUNOLOGICAL ASPECTS OF AN 

ANIMAL MODEL OF AMODIAQUINE- 

INDUCED LIVER TOXICITY. J. Li 1 , H. 

C. Workman 2 , P. Cai 3 , G. Kourteva 4 , H. Hilton 4 , 

H. Haggerty 1 , D. Moore 2 and J. Uetrecht 3,5 . 

1 

Immunotoxicology, Bristol-Myers Squibb Company, 

New Brunswick, NJ, 2 Nonclinical Safety, F. 

Hoffmann-La Roche Inc., Nutley, NJ, 3 Pharmacy, 

University of Toronto, Toronto, ON, Canada, 4 TRS- 

RNA Biomarker Technology, F. Hoffmann-La 

Roche Inc., Nutley, NJ and 5 Medicine, University of 


Tuesday 







247



Tuesday 



CHANGES IN HEPATIC GENE EXPRESSION 

INDUCED BY AMODIAQUINE IN RATS. J. 

Uetrecht 3,5 , J. Li 1 , G. Kourteva 2 , H. Hilton 2 , P. Cai 3 , 

H. C. Workman 4 , H. Haggerty 1 and D. Moore 4 . 

1 

Immunotoxicology, Bristol-Myers Squibb Company, 

New Brunswick, NJ, 2 TRS-RNA Biomarker 

Technology, F. Hoffmann-La Roche Inc., Nutley, 

NJ, 3 Pharmacy, University of Toronto, Toronto, 

ON, Canada, 4 Nonclinical Safety, F. Hoffmann-La 

Roche Inc., Nutley, NJ and 5 Medicine, University of 



COVALENT BINDING OF NEVIRAPINE IN 

VITRO AND IN VIVO. A. Sharma and J. Uetrecht. 

Pharmaceutical Sciences, University of Toronto, 



DANGER SIGNALS IN NEVIRAPINE- 

INDUCED SKIN RASH. X. Zhang and J. 

Uetrecht. Pharmaceutical Science, University of 



INVOLVEMENT OF T HELPER 17 (TH17) 

PATHWAY IN D-PENICILLAMINE-INDUCED 

AUTOIMMUNITY. X. Zhu 1 , J. Li 3 and J. P. 

Uetrecht 1,2 . 1 Faculty of Pharmacy, University of 

Toronto, Toronto, ON, Canada, 2 Faculty of Medicine, 

University of Toronto, Toronto, ON, Canada and 

3 

Department of Immunotoxicology, R&D, Drug 

Safety Evaluation, Bristol-Myers Squibb Company, 

New Brunswick, NJ. 


INDOLES MITIGATE THE DEVELOPMENT 

OF EXPERIMENTAL AUTOIMMUNE 

ENCEPHALOMYELITIS BY ACTIVATION 

AHR AND ER, RECIPROCAL INDUCTION 

OF REGULATORY T CELLS AND TH17 

CELLS, AND INDUCTION OF APOPTOSIS. 

M. Rouse, M. Nagarkatti and P. Nagarkatti. 

University of South Carolina, Columbia, SC. 


TNF RECEPTOR 2 (TNFR2)-DEFICIENT 

MYELIN OLIGODENDROCYTE 

GLYCOPROTEIN (MOG)-SPECIFIC T 

CELL RECEPTOR (TCR) TRANSGENIC 

MICE DEVELOP SPONTANEOUS 

AUTOIMMUNITY. P. G. Miller 3 , E. N. Sellers 3 , 

R. S. Schondelmeyer 3 , M. B. Bonn 4 , J. K. Dey 4 , J. 

A. Cascio 2 , C. Franklin 2 , H. Braley-Mullen 2 , N. H. 

Ruddle 5 and S. C. McKarns 1,2 . 1 Surgery, University of 

Missouri, Columbia, MO, 2 Molecular Microbiology 

& Immunology, University of Missouri, Columbia, 

MO, 3 Biochemistry, University of Missouri, 

Columbia, MO, 4 Biological Sciences, University 

of Missouri, Columbia, MO and 5 Biological & 

Biomedical Sciences, Yale University, New Haven, 

CT. 


ANTI-MESOTHELIAL CELL 

AUTOANTIBODIES ASSOCIATED WITH 

ASBESTOS EXPOSURE AND PLEURAL 

DISEASE. L. S. Marchand 2 , J. C. Pfau 1 , S. 

Sophie 1 and E. A. Putnam 3 . 1 Biological Sciences, 

Idaho State University, Pocatello, ID, 2 School of 

Medicine, University of Washington, Seattle, WA and 

3 

Biomedical & Pharmaceutical Sciences, University 

of Montana, Missoula, MT. 


INVOLVEMENT OF OXIDATIVE STRESS 

IN TRICHLOROETHENE-MEDIATED 

AUTOIMMUNITY: DOSE- AND TIME- 

RESPONSE STUDY. G. Wang, J. Wang, X. 

Fan and M. Khan. Pathology, University of Texas 

Medical Branch, Galveston, TX. 


EFFECTS OF LIBBY AMPHIBOLE 

ASBESTOS EXPOSURE ON TWO RAT 

MODELS OF RHEUMATOID ARTHRITIS. 

K. D. Salazar, C. B. Copeland and R. W. Luebke. 

Cardiopulmonary and Immunotoxicology Branch, 

Environmental Public Health Division, NHEERL, 



ESR SPIN-TRAPPING INVESTIGATION OF 

LUNG FREE RADICALS IN AN ANIMAL 

MODEL OF INTERSTITIAL PNEUMONIA 

ASSOCIATED WITH AUTOIMMUNE 

DISEASE. M. B. Kadiiska, H. Miyakawa, J. Jiang 

and R. Mason. NIEHS/NIH, Research Triangle Park, 

NC. 


B1A CELL ACTIVATION BY GLUTAMATE. 

R. Marcum and J. C. Pfau. Biological Sciences, 

Idaho State University, Pocatello, ID. 


SEX HORMONES DETERMINE WHETHER 

IL-33 PROTECTS OR EXACERBATES 

AUTOIMMUNE HEART DISEASE. M. 

Coronado, D. Bedja, A. Bucek, K. Gabrielson and D. 

Fairweather. Johns Hopkins University, Baltimore, 

MD. 


EFFECT OF TISSUE TRANSGLUTAMINASE 

ANTIBODIES ON CELIAC DISEASE. 

R. N. Ndeto and B. Fraij. Biology, Chemistry, 

Environmental Health Science, Benedict College, 

Columbia, SC. Sponsor: B. Cummings. 

248 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment and Regulatory Policy 

Applications 

Chairperson(s): Angelina Duggan, Exponent Inc., Philadelphia, PA, and 

Christopher Teaf, Florida State University, Tallahassee, FL. 




THE USE OF DMELS IN REACH RISK 

CHARACTERIZATION. R. Roy, L. Milchak, 

N. Pechacek, J. Walton and R. Skoglund. Medical 

Department, 3M Company, St. Paul, MN. 


THE ROLE OF ANNUAL VALIDATION 

IN RISK MANAGEMENT IN BIOSAFETY 

LEVEL 3 LABORATORIES. D. Harbourt 1,2 , J. 

Glass 2,3 , J. Osorio-Sanchez 2,3 , T. J. Traum 2,3 and D. 

Wilson 2,3 . 1 National Biosafety and Biocontainment 

Training Program, National Institutes of Health, 

Bethesda, MD, 2 Division of Occupational Health and 

Safety, National Institutes of Health, Bethesda, MD 

and 3 Office of Research Services, National Institutes 

of Health, Bethesda, MD. 


ICCVAM EVALUATION AND 

RECOMMENDATIONS ON THE NON- 

RADIOACTIVE LLNA: BRDU-ELISA FOR 

EVALUATING ALLERGIC CONTACT 

DERMATITIS HAZARDS. A. Jacobs 1 , J. 

Matheson 2 , M. Wind 3 , V. Malshet 2 , J. Toy 2 and W. 

Stokes 4 . 1 U.S. FDA, Silver Spring, MD, 2 Consumer 

Product Safety Commission, Bethesda, MD, 

3 


MD and 4 NICEATM, NIEHS, Research Triangle 

Park, NC. 


ICCVAM EVALUATION OF THE LOCAL 

LYMPH NODE ASSAY (LLNA) FOR 

POTENCY CATEGORIZATION OF 

CHEMICALS CAUSING ALLERGIC 

CONTACT DERMATITIS IN HUMANS. P. 

Brown 1 , J. Matheson 2 , A. Jacobs 1 , T. McMahon 3 , D. 

Germolec 4 , M. Wind 5 and W. Stokes 6 . 1 U.S. FDA, 

Silver Spring, MD, 2 Consumer Product Safety 

Commission, Bethesda, MD, 3 U.S. EPA, Washington, 

D.C., 4 NIEHS, Research Triangle Park, NC, 

5 


MD and 6 NICEATM, NIEHS, Research Triangle 

Park, NC. 


ICCVAM EVALUATION AND 

RECOMMENDATIONS ON THE 

NON-RADIOACTIVE LLNA: DA FOR 

EVALUATING ALLERGIC CONTACT 

DERMATITIS HAZARDS. J. Mathesono 1 , 

A. Jacobs 2 , M. Wind 3 , P. Brown 4 , R. Ward 4 , E. 

Margosches 4 and W. Stokes 5 . 1 CPSC, Bethesda, MD, 

2 

U.S. FDA, Silver Spring, MD, 3 CPSC, Bethesda, 

MD, 4 U.S. EPA, Washington, D.C. and 5 NICEATM, 


Abstract # 


USING FEWER ANIMALS TO IDENTIFY 

CHEMICAL EYE HAZARDS: REVISED 

CLASSIFICATION CRITERIA NECESSARY 

TO MAINTAIN EQUIVALENT HAZARD 

LABELING. W. Stokes 1 , J. Haseman 2 , E. 

Lipscomb 3 , J. Truax 3 , N. Johnson 3 , B. Jones 3 and 

D. Allen 3 . 1 NICEATM, NIEHS, Research Triangle 

Park, NC, 2 Consultant, Raleigh, NC and 3 ILS, Inc., 



FROM HAZARD-BASED TO TISSUE DOSE- 

BASED TESTING—REDUCTION AND 

REFINEMENT. J. Bessems. National Institute 

for Public Health and the Environment (RIVM), 

Bilthoven, Netherlands. 


PRACTICAL IMPLEMENTATION OF THE 

THRESHOLD OF CONCERN AND NOAEL- 

TO-LC50 RATIO FACTOR APPROACH TO 

DETERMINE ACUTE EFFECTS SCREENING 

LEVELS. T. D. Phillips, S. E. Ethridge and R. L. 

Grant. Toxicology Division, Texas Commission on 

Environmental Quality, Austin, TX. 


REPEATED-DOSE PRECLINICAL TOXICITY 

STUDIES: HIGHEST DOSE TESTED = 

NOAEL—WHAT TO DO? R. Garg, W. Bracken, 

D. Bury and K. Marsh. Abbott Laboratories, Abbott 

Park, IL. 


SAFETY ASSESSMENT OF FOOD AND 

FEED FROM BIOTECHNOLOGY-DERIVED 

CROPS WITH MODIFICATIONS THAT 

REGULATE ENDOGENOUS GENE 

EXPRESSION. J. S. Petrick 1 , W. Parrott 2 , B. 

Chassy 3 , J. Ligon 4 , L. Meyer 5 , J. Zhou 6 , R. Herman 7 , 

B. Delaney 8 and M. Levine 9 . 1 Product Safety Center, 

Monsanto Company, Saint Louis, MO, 2 Crop and 

Soil Sciences, University of Georgia, Athens, GA, 

3 

College of ACES, University of Illinois, Urbana, IL, 

4 

Bayer CropScience, Research Triangle Park, NC, 

5 

Syngenta Biotechnology, Inc., Research Triangle 

Park, NC, 6 Johnson & Johnson, Raritan, NJ, 7 Dow 

AgroSciences, Indianapolis, IN, 8 Pioneer, A DuPont 

Company, Johnston, IA and 9 International Life 

Sciences Institute, Washington, D.C. 


USE OF CLUSTER ANALYSIS IN PESTICIDE 

INERT INGREDIENT RISK ASSESSMENT. 

A. S. Duggan 1 , J. Johnston 2 , J. Messina 2 , K. Akkari 3 , 

D. Hillebold 4 , G. Lindner 5 and P. McCain 6 . 1 Health 

Practice Center for Toxicology and Mechanistic 

Biology, Exponent, Inc., Philadelphia, PA, 2 Health 

Practice Center for Chemical Regulation and Food 

Safety, Exponent, Inc., Washington, D.C., 3 APD/RD, 

BASF Corp., Research Triangle Park, NC, 4 Surface 

Chemistry, Akzo Nobel, LLC, Chicago, IL, 5 Crop 

Care Applications, Croda, Inc., New Castle, DE and 

6 

Regulatory Affairs, Syngenta Crop Protection, Inc., 


Tuesday 







249



Tuesday 



OPTIONS FOR INCREASED REGULATORY 

OVERSIGHT OF COSMETICS IN THE U.S. 

N. Beck 1 , K. Sullivan 1 and C. Willet 2 . 1 Physicians 

Committee for Responsible Medicine, Washington, 

D.C. and 2 People for the Ethical Treatment of 

Animals, Norfolk, VA. 


THE SHE CELL TRANSFORMATION 

ASSAY—ITS USE IN HAZARD AND RISK 

ASSESSMENT FOR REACH. A. H. Poth. 

Genetic and Alternative Toxicology, Harlan Cytotest 

Cell Research GmbH, Rossdorf, Germany. 


DEVELOPMENT OF A HEALTH RISK- 

BASED SURFACE CONTAMINATION 

CLEAN-UP STANDARD FOR 

OCCUPATIONAL EXPOSURE TO 

BERYLLIUM. P. Damian. SCS Engineers, West 

Sacramento, CA. 


MINIMAL RISK LEVELS FOR STYRENE. S. 

Chou 1 and L. Ingerman 2 . 1 Division Toxicology and 

Env.Med., ATSDR/CDC, Atlanta, GA and 2 SRC, 

Inc., Syracuse, NY. Sponsor: B. Fowler. 


RISK ASSESSMENT FOR ETHYL TERTIARY- 

BUTYL ETHER (ETBE) TO DETERMINE 

ACCEPTABLE DRINKING WATER LEVELS. 

V. S. Bhat, G. L. Ball and C. J. McLellan. NSF 

International, Ann Arbor, MI. 


HEALTH RISK ASSESSMENT FOR 

HYDROGEN PEROXIDE TO DETERMINE 

ACCEPTABLE DRINKING WATER LEVELS. 

G. L. Ball, J. C. English and C. J. McLellan. NSF 



LEAD SOIL SCREENING LEVELS AND 

CLEAN-UP AT CALIFORNIA HAZARDOUS 

WASTE SITES. T. Behrsing 1 , J. Carlisle 2 , E. 

Sciullo 1 , J. Spearow 1 , B. Davis 1 , K. Day 1 and M. 

Wade 1 . 1 Department of Toxic Substances Control 

(DTSC), CalEPA, Sacramento, CA and 2 Office 

of Environmental Health Hazard Assessment 

(OEHHA), CalEPA, Sacramento, CA. 


MYCOTOXINS: U.S., CANADIAN, 

EUROPEAN, AND JECFA REGULATORY 

STRATEGIES. S. H. Henry. Center for Food 

Safety and Applied Nutrition, U.S. FDA, Greenbelt, 

MD. 


GENERATION OF ELECTRICAL POWER 

WITH WOODY BIOMASS: A SITE-SPECIFIC 

TECHNICAL EVALUATION OF EMISSIONS 

AND POTENTIAL HEALTH RISKS. C. Teaf 1,5 , 

T. Davis 2 , J. Doolittle 2 , G. Morris 3 , J. Levine 4 and D. 

Covert 5 . 1 Florida State University, Tallahassee, FL, 

2 

ECT, Inc., Gainesville, FL, 3 Green Power Institute, 

Berkeley, CA, 4 American Renewables, LLC, Boston, 

MA and 5 Hazardous Substance & Waste Management 

Research, Tallahassee, FL. 


EMERGENCY DO NOT CONSUME/DO 

NOT USE PUBLIC NOTIFICATIONS FOR 

DIRECT DRINKING WATER ADDITIVES. C. 

J. McLellan, C. C. Willhite, V. S. Bhat and G. L. Ball. 

NSF International, Ann Arbor, MI. 


ENDPOINT SENSITIVITY IN FISH 

ENDOCRINE DISRUPTION ASSAYS: 

REGULATORY IMPLICATIONS. Z. Dang. 

RIVM, Bilthoven, Netherlands. Sponsor: J. Bessems. 


MODELING THE IMPACT OF SHORT 

TERM LEAD EXPOSURE ON BLOOD LEAD 

LEVELS IN YOUNG CHILDREN. J. Donohue 1 , 

W. Mendez 2 and A. Shapiro 2 . 1 Office of Water, U.S. 

EPA, Washington, D.C. and 2 ICF International, 

Fairfax, VA. Sponsor: E. Doyle. 


THE COUNCIL OF CANADIAN ACADEMIES 

EXPERT PANEL ON THE INTEGRATED 

TOXICITY TESTING OF PESTICIDES. M. 

Trainer and L. Ritter 1,2 . 1 Council of Canadian 

Academies, Ottawa, ON, Canada and 2 School of 

Environmental Sciences, University of Guelph, 

Guelph, ON, Canada. 


THE PROS AND CONS OF USING 

DATABASES TO SUPPORT 

TOXICOLOGICAL DECISION MAKING. T. 

Allio. Office of Pediatric Therapeutics, U.S. FDA, 

Silver Spring, MD. Sponsor: D. Jacobson-Kram. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Safety and Risk Assessment: Critical 

Characterizations for Chemicals and New Concerns 

Chairperson(s): Sven Korte, Covance Laboratories GmbH, Muenster, 

Germany. 




NEW RESULTS ON A UNIQUE PSYCHO- 

TOXICOGENOMIC DRUG SCREENING 

ASSAY TO ASSESS TREATMENT- 

EMERGENT SUICIDALITY RISK 

PRECLINICALLY. D. Weissmann, L. Vincent, L. 

Cavarec, C. Plusquellec, C. Leborgne, F. Allemand 

and J. Pujol. Biocortech, Paris, France. Sponsor: E. 

Bush. 


DERIVATION OF AN ORAL REFERENCE 

DOSE AND DRINKING WATER SCREENING 

LEVEL FOR SULFOLANE USING 

BENCHMARK DOSE MODELING. 

C. Thompson 1 , C. Perry 2 , D. Gaylor 3 , A. Tachovsky 2 , 

B. Burkhalter 2 and L. Haws 2 . 1 ToxStrategies, Inc., 

Katy, TX, 2 ToxStrategies, Inc., Austin, TX and 

3 

Gaylor and Associates, LLC, Eureka Springs, AR. 

250 






Platform Sessions



Abstract # 


ASSESSMENT OF POPULATION HEALTH 

RISKS FROM ENVIRONMENTAL 

POLLUTION BY EMISSIONS OF A 

CHEMICAL WEAPONS DESTRUCTION 

FACILITY. M. Kombarova 1 , I. Lomteva 2 , A. 

Radilov 1 , E. Tsibul’skaya 1 , N. Goncharov 1 and N. 

Khlebnikova 1 . 1 RIHOPHE, Saint Petersburg, Russian 

Federation and 2 Institute for Applied Ecology and 

Hygiene, Saint Petersburg, Russian Federation. 

Sponsor: R. Gupta. 


INITIAL TOXICOLOGIC 


TRIAMINOGUANIDINIUM-1-METHYL-5- 

NITRIMINOTETRAZOLATE (TAG-MNT) IN 

FEMALE RATS AND IN VITRO ASSAYS. L. R. 

Williams, C. J. Cao, E. LaFiandra, L. C. Crouse, M. 

A. Bazar, W. S. Eck and M. S. Johnson. Directorate 

of Toxicology Health Effects Research Program 

(MCHB-TS-THE), U.S. Army Public Health 

Command (Provisional), Aberdeen Proving Ground, 

MD. 


HUMAN HEALTH RISKS FROM EXPOSURE 

TO 1, 4-BUTANEDIOL IN CRAFT KIT 

BEADS. R. Mattuck, M. Seeley, K. R. Reid and J. 

E. Goodman. Gradient, Cambridge, MA. 


SAFETY OF COMPOUNDS RELEASED 

FROM DEGRADING CARPET MATERIALS 

IN SCHOOL BUILDINGS. B. J. Kelman 1 , M. W. 

Krause 1 , L. J. Swenson 2 and C. A. Robbins 1 . 1 Veritox, 

Inc., Redmond, WA and 2 Veritox, Inc., Portland, OR. 


HEPATOTUMORIGENICITY OF ETHYL 

TERTIARY-BUTYL ETHER (ETBE) BY 

INHALATION EXPOSURE BUT NOT ORAL 

ADMINISTRATION IN F344 RATS. K. 

Nagano 1 , T. Nishizawa 1 , K. Yamazaki 1 , T. Noguchi 1 , 

A. Hagiwara 2 , F. Nishimaki 3 , S. Iida 3 , K. Komiya 3 

and S. Fukushima 1 . 1 Japan Bioassay Research Center, 

Japan Industrial Safety and Health Association, 

Kanagawa, Japan, 2 DIMS Institute of Medical 

Science, Nagoya, Japan and 3 Japan Petroleum Energy 

Center, Tokyo, Japan. 


GENOTOXITY OF FURAN IN F344 RATS 

USING THE IN VIVO COMET AND 

MICRONUCLEUS ASSAYS. W. Ding 1 , R. 

H. Heflich 1 , M. G. Pearce 1 , G. White 2 , R. A. 

Mittelstaedt 1 , J. G. Shaddock 1 , P. L. McDaniel 1 , D. R. 

Doerge 3 , M. G. Manjanatha 1 and A. Aidoo 1 . 1 DGMT, 

U.S. FDA NCTR, Jefferson, AR, 2 Toxicology 

Pathology Associates, U.S. FDA NCTR, Jefferson, 

AR and 3 DBT, U.S. FDA NCTR, Jefferson, AR. 


ACUTE ORAL TOXICITY STUDIES OF 

A NEW PESTICIDE-AMTS18 IN MICE. 

J. Zhang, Y. Pang and S. Brimijoin. Molecular 

Pharmacology and Experimental Therapeutics, Mayo 

Clinic, Rochester, MN. 


SKIN BIOCOMPATIBILITY TESTING OF A 

POLYISOPRENE ELASTOMER. N. Pechacek, 

T. Brunshidle and L. Eichinger. 3M, St. Paul, MN. 

Abstract # 


CONSIDERATIONS FOR DEMONSTRATING 

THE INTER-LABORATORY RELIABILITY 

OF CHORIOALLANTOIC MEMBRANE 

VASCULAR ASSAY (CAMVA) AND THE 

BOVINE CORNEAL OPACITY AND 

PERMEABILITY ASSAY (BCOP). G. Mun 2 , N. 

Wilt 2 , D. A. Donahue 1 , J. Avalos 1 , K. Norman 2 , A. 

Hilberer 2 , F. A. Simion 1 and H. Raabe 2 . 1 Research 

and Development, Kao Brands Company, Cincinnati, 

OH and 2 Institute for In Vitro Sciences, Inc., 

Gaithersburg, MD. 


SAFETY EVALUATION OF β-HYDROXY 

CYCLODEXTRIN IN WISTAR RATS. R. 

Nirogi, V. Goyal, R. Vedamurthy, M. A. Mulla, S. 

Pandey, S. Jana and A. Gothi. Toxicology, Suven Life 

Sciences Limited, Hyderabad, Andhra Pradesh, India. 

Sponsor: V. Reddy. 


ICCVAM RECOMMENDATIONS ON THE 

USEFULNESS AND LIMITATIONS OF THE 

CYTOSENSOR MICROPHYSIOMETER® 

(CM) TEST METHOD FOR OCULAR 

SAFETY TESTING. J. Merrill 1 , D. Lowther 1 , A. 

Layton 2 , J. Redden 3 , M. Wind 4 and W. Stokes 5 . 1 U.S. 

FDA, Silver Spring, MD, 2 U.S. CPSC, Bethesda, 

MD, 3 U.S. EPA, Washington, D.C., 4 U.S. CPSC 

(Retired), Bethesda, MD and 5 NICEATM, NIEHS, 



L’OREAL COMMITMENT IN THE 

DEVELOPMENT, EVALUATION, AND 

VALIDATION OF SCREENING AND 

TESTING APPROACHES CONTRIBUTING 

TO THE 3RS. J. R. Meunier, N. Alépée, J. Cotovio, 

D. Duché, G. Ouedraogo, L. Marrot, S. Teissier, J. 

M. Ovigne and J. Leclaire. L’Oréal, Aulnay sous 

Bois, France. Sponsor: H. Toutain. 


TOXICITY OF SMALL 50CC ENGINE 

EMISSIONS ON ORGANOTYPIC CULTURES 

OF RAT LUNG TISSUE: 2-STROKE, 

4-STROKE ENGINES, AND LUBE OIL (LO) 

QUALITY IMPACTS. J. Morin 1 , D. Preterre 2 , 

V. Keravec 2 , C. Monteil 1 and F. Dionnet 2 . 1 U644, 

INSERM - School of Medicine Pharmacy, Rouen, 

France and 2 Certam, Saint Etienne du Rouvray, 

France. Sponsor: R. Forster. 


HISTORY OF SAFE USE OF CRY1C 

PROTEIN. R. Ranjan 1 and C. Herouet-Guicheney 2 . 

1 

Regulatory Toxicology, BayerCrop Science LP, 

Durham, NC and 2 Regulatory Toxicology, Bayer 

SAS, Bayer CropScience, Sophia Antipolis, France. 


LOCAL AND SYSTEMIC TOXICITY OF 

IMPLANTED ACCELERATOR-FREE 

POLYCHLOROPRENE-TYPE AND LATEX 

SURGICAL GLOVE MATERIAL. M. 

Goravanahally, A. F. Hubbs, P. H. Nicolaysen, M. L. 

Kashon, L. A. Battelli, B. F. Law, P. A. Willard and P. 

D. Siegel. HELD, National Institute for Occupational 

Safety and Health, Morgantown, WV. 

Tuesday 







251



Tuesday 



DETAILED CHEMICAL COMPARISONS 

OF NEW AND OLD SERIES REFERENCE 

SMOKELESS TOBACCO PRODUCTS (STP). 

J. H. Lauterbach 1 and D. A. Grimm 2 . 1 Chemistry & 

Toxicology, Lauterbach & Associates, LLC, Macon, 

GA and 2 Coordinated Instrumentation Facility, 

Tulane University, New Orleans, LA. 


IN-DEPARTMENT EVALUATION OF 

THE VARIABILITY IN CHEMICAL 

COMPOSITION OF CHAMOMILE 

ESSENTIAL OIL (CEO) DUE TO 

GEOGRAPHICAL ORIGIN OF THE 

SOURCE PLANT: IMPLICATIONS FOR 

SAFETY EVALUATION. R. Persaud 1 , T. Re 1 , V. 

Srinivasan 1 , E. Antignac 2 and G. Nohynek 2 . 1 Product 

Safety, L’Oreal USA, Clark, NJ and 2 Global Safety 

Evaluation, L’Oreal R&D, Asnieres, France. 


ORAL (GAVAGE) ONE-GENERATION 

REPRODUCTION STUDY OF 

CITRONELLYL NITRILE IN RATS, WITH 

AN EVALUATION THROUGH SEXUAL 

MATURITY IN THE F1 GENERATION. J. 

Scognamiglio, D. McGinty, V. T. Politano and A. Api. 

Research Institute for Fragrance Materials, Woodcliff 

Lake, NJ. 


REPEAT ORAL DOSE TOXICITY OF 

MELAMINE IN RATS. X. Mu, Q. Kong, H. Yu, 

J. Zhou, H. Xu, X. Yang and Y. Jiang. WuXiAppTec 

(Suzhou), Suzhou, China. 


REPRODUCIBILITY OF METABOLOMICS 

PERFORMED IN PLASMA SAMPLES 

OF 28 DAY RAT SYSTEMIC TOXICITY 

STUDIES. H. G. Kamp 1 , E. Fabian 1 , M. Herold 3 , 

M. Kapp 1 , G. Krennrich 2 , R. Looser 3 , W. Mellert 1 , 

A. Prokoudine 3 , V. Strauss 1 , T. Walk 3 , J. Wiemer 3 

and B. van Ravenzwaay 1 . 1 Experimental Toxicology 

and Ecology, BASF SE, Ludwigshafen, Germany, 

2 

Computational Chemistry, BASF SE, Ludwigshafen, 

Germany and 3 Metanomics GmbH, Berlin, Germany. 

Sponsor: C. Shelp. 


OPPORTUNITIES TO MINIMISE ANIMAL 

USE IN REGULATORY TOXICOLOGY: A 

CROSS-COMPANY REVIEW. S. Sparrow 1 , S. 

Robinson 2 , C. Bruce 3 , A. Danks 4 , D. Everett 5 , R. Hill 6 , 

H. Palmer 7 and K. Chapman 8 . 1 GlaxoSmithKline, 

Ware, United Kingdom, 2 AstraZeneca, Macclesfield, 

Cheshire, United Kingdom, 3 Pfizer, Sandwich, Kent, 

United Kingdom, 4 Charles River, Tranent, Scotland, 

United Kingdom, 5 Covance Laboratories, Harrogate, 

United Kingdom, 6 Sequani, Ledbury, United 

Kingdom, 7 HLS, Huntingdon, United Kingdom and 

8 

NC3Rs, London, United Kingdom. 


THE LIMITED VALUE OF ACUTE 

TOXICITY TESTS IN SAFETY ASSESSMENT. 

S. Robinson 1 , S. Creton 2 and K. Chapman 2 . 

1 

AstraZeneca, Macclesfield, Cheshire, United 

Kingdom and 2 NC3Rs, London, United Kingdom. 


RISK ASSESSMENT OF ACETALDEHYDE 

(A TOBACCO SMOKE TOXICANT): 

INTEGRATION OF MARGIN OF EXPOSURE 

(MOE) AND MODE-OF-ACTION (MOA) 

EVALUATIONS. F. H. Cunningham, S. Fiebelkorn 

and C. Meredith. Group R&D, British American 

Tobacco, Southampton, United Kingdom. 


CONTINUOUS INTRAVENOUS INFUSION 

STUDIES WITH IMPLANTED PORT 

CATHETER SYSTEMS IN FREE RANGING 

CYNOMOLGUS MONKEYS—A 20 YEAR 

EXPERIENCE REPORT. S. H. Korte, P. Nowak, 

S. Friderichs-Gromoll, J. Kaspareit and E. Buse. 

Covance Laboratories GmbH, Muenster, Germany. 

Sponsor: G. Weinbauer. 


ENVIRONMENTAL PREDICTORS OF U.S. 

COUNTY MORTALITY PATTERNS ON A 

NATIONAL BASIS. M. P. Chan 1 , R. S. Weinhold 2 , 

R. Thomas 3 , J. M. Gohlke 4 and C. J. Portier 5 . 1 NTP/ 

NIEHS, Research Triangle Park, NC, 2 Independent 

Researcher & Journalist, Colorado City, Co., 3 School 

of Public Health, University of California, Berkeley, 

CA, 4 School of Public Health, University of Alabama 

at Birmingham, Birmingham, AL and 5 NCEH & 

ATSDR, CDC, Atlanta, GA. 


FIELD INVESTIGATION AND RISK 

ASSESSMENT OF FIVE CRUMB 

RUBBER ARTIFICIAL TURF FIELDS IN 

CONNECTICUT. G. L. Ginsberg 1 , B. Toal 1 , 

N. Simcox 2 , A. Bracker 2 and B. Golembiewski 3 . 

1 

Environmental & Occupational Health, Connecticut 

Department of Public Health, Hartford, CT, 

2 

University of Connecticut Health Center, 

Farmington, CT and 3 Connecticut Department of 

Environmental Protection, Hartford, CT. 


CRITICAL EVALUATION OF THE 

TOXICITY DATA FOR SELECTED 

PHTHALATE ESTERS. K. R. Carlson, D. J. 

Williams, C. A. Osterhout and M. A. Babich. U.S. 

Consumer Product Safety Commission (CPSC), 

Bethesda, MD. 


TOXICITY OF PARTICULATE MATTER 

FROM AFGHANISTAN AND IRAQ IN A 

TWO-WEEK INHALATION STUDY IN RATS. 

B. A. Wong 1,2 , K. C. Roberts 2 , C. U. Parkinson 2 , V. P. 

Mokashi 1 and P. A. Ortiz 1 . 1 Naval Medical Research 

Unit - Dayton, Wright-Patterson AFB, OH and 2 The 




TOXICITY OF EXCITATORY AMINO 

ACIDS IN RED ALGAE FOR PARASITIC 

COPEPODES OF CULTURED PUFFERFISH. 

K. Yasui 1 and M. Asakawa 2 . 1 Graduate School of 

Biosphere Science, Hiroshima University, Hiroshima 

Prefecture, Japan and 2 Graduate School of Biosphere 

Science, Hiroshima University, Higashi-Hiroshima, 

Hiroshima Prefecture, Japan. 

252 






Platform Sessions



Abstract # 


RESULTS OF A ONE-YEAR FISH 

CONSUMPTION SURVEY IN ALABAMA. E. 

S. Ebert 1 , N. Wilson 2 , M. Wacksman 1 , A. Fowler 3 , 

J. Schell 4 and J. Loper 5 . 1 ARCADIS, Portland, ME, 

2 

ARCADIS, Brighton, MI, 3 ARCADIS, Beverly, 

MA, 4 Entrix, Houston, TX and 5 The Loper Group, 

Seabrook, TX. 


ANALYSIS OF TOP 10 VOLATILE ORGANIC 

COMPOUNDS (VOCS) TO EVALUATE 

THE INDOOR AIR QUALITY WHICH MAY 

CAUSE SICK BUILDING SYNDROME. M. 

Hanazato 1,2 , E. Todaka 3,4 , H. Nakaoka 1,4 and C. 

Mori 1,3,4 . 1 Center for Preventive Medical Science, 

Chiba University, Chiba, Japan, 2 Department of 

Architecture, Graduate School of Engineering, 

Chiba University, Chiba, Japan, 3 Center for 

Environment, Health and Field Sciences, Chiba 

University, Kashiwa, Japan and 4 Department of 

Bioenvironmental Medicine, Graduate School of 

Medicine, Chiba University, Chiba, Japan. 


EFFECT OF FEED RESTRICTION ON 

ROUTINE TOXICITY PARAMETERS IN 

WISTAR RATS. S. Jana, R. Nirogi, M. A. Mulla, 

S. Pandey, V. Goyal, A. Gothi, R. Vedamurthy and 

R. Mishra. Toxicology, Suven Life Sciences Limited, 

Hyderabad, Andhra Pradesh, India. Sponsor: V. 

Reddy. 


ACUTE NEUROBEHAVIORAL EFFECTS 

OF INHALATION EXPOSURE TO ETHYL 

ACETATE—A PILOT STUDY IN HUMAN 

VOLUNTEERS USING EVENT-RELATED 

POTENTIALS. S. A. Juran 1,2 , S. Kleinbeck 2 , M. 

Schäper 2 , G. Johanson 1 and C. van Thriel 2 . 1 Work 

Environment Toxicology, Karolinska Institutet, 

Stockholm, Sweden and 2 Unit for Neurobehavioral 

Toxicology and Chemosensation, Leibniz Research 

Centre for Working Environment and Human Factors 

(IfADo), Dortmund, Germany. 


CASE STUDY: RISK ASSESSMENT WITH 

A MULTI-KINASE INHIBITOR WITH 

ONCOLOGICAL INDICATION. M. Brughera, 

R. Pulci, P. Colombo and A. Giusti. Preclinical 

Development, Accelera Srl, Nerviano - Milano, Italy. 


AN IN VITRO MODEL SYSTEM FOR 

ASSESSING THE EFFECTS OF OIL 

DISPERSANTS IN HUMAN HEPATOCYTES. 

O. Bandele, M. Santillo and P. Wiesenfeld. 

Toxicology, Office of Applied Research and Safety 

Assessment, Center for Food Safety and Applied 

Nutrition, U.S. FDA, Laurel, MD. 


CHARACTERIZATION OF IONIC LIQUID 

COMPOUNDS FOR TOXICOLOGICAL 

EVALUATION. J. W. Algaier 1 , C. C. Pearson 1 , A. 

D. Ammenhauser 1 , Q. Lawrence 1 , J. L. Cookinham 1 , 

L. G. Siemann 1 , R. K. Harris 1 , B. Jayaram 2 and C. 

S. Smith 2 . 1 Midwest Research Institute, Kansas City, 

MO and 2 NIH, NIEHS, Research Triangle Park, NC. 

Abstract # 


ANALYSIS OF ACUTE AND CHRONIC 

EFFECTS OF HETEROCYCLIC AROMATIC 

AMINES IN DIFFERENTIATED HUMAN 

HEPATOMA HEPARG CELLS. J. Dumont 1,2 , R. 

Josse 1,2 , C. Lambert 1,2 , S. Anthérieu 1,2 , C. Guguen- 

Guillouzo 1,2 , A. Guillouzo 1,2 and M. Robin 1,2 . 

1 

UMR991, INSERM, Rennes, France and 2 University 

of Rennes 1, Rennes, France. Sponsor: M. Pallardy. 


THE MAXIMUM CUMULATIVE RATIO 

(MCR): A TOOL FOR ASSESSING THE NEED 

FOR CUMULATIVE RISK ASSESSMENTS. 

X. Han and P. S. Price. Toxicology & Environmental 

Research & Consulting, The Dow Chemical 



EVALUATION OF THE POTENTIAL 

IMPACT OF INHIBITION OF 

TRICHLOROETHYLENE METABOLISM 

IN THE LIVER ON EXTRAHEPATIC 

TOXICITY. C. R. Eklund, M. V. Evans and J. 

Simmons. NHEERL, U.S. EPA, Research Triangle 

Park, NC. 


A COMPUTATIONAL FRAMEWORK FOR 

CUMULATIVE RISK ASSESSMENT. D. A. 

Sarigiannis 1,2 , A. Gotti 3 and S. Karakitsios 1 . 1 Institute 

for Health and Consumer Protection, European 

Commission - Joint Research Centre, Ispra, Varese, 

Italy, 2 Chemical Engineering Department, Aristotle 

University of Thessaloniki, Thessaloniki, Greece 

and 3 CPERI, CERTH, Thermi, Greece. Sponsor: T. 

Hartung. 


1:00 PM to 4:30 PM 

Exhibit Hall 


Poster Session: ‘Omics in Toxicology Research 

Chairperson(s): Scott Auerbach, NIEHS, Research Triangle Park, NC. 




USE OF A CUSTOM RT-PCR ARRAY TO 

ANALYZE TOXICITY PATHWAYS AT 

DIFFERENT LIFE STAGES IN BROWN 

NORWAY RAT BRAIN FOLLOWING ACUTE 

TOLUENE EXPOSURE. J. E. Royland 1 , P. R. 

Kodavanti 2 , G. W. Knapp 1 and R. C. MacPhail 2 . 

1 

Integrated Systems Toxicology Division U.S. 

EPA, Research Triangle Park, NC and 2 Toxicity 

Assessment Division, U.S. EPA, Research Triangle 

Park, NC. 


COMPARATIVE ANALYSIS OF TCDD- 

ELICITED GENE EXPRESSION PROFILES 

IN HUMAN, MOUSE, AND RAT PRIMARY 

HEPATOCYTES. E. Dere, A. L. Forgacs and T. 

R. Zacharewski. Michigan State University, East 

Lansing, MI. 

Tuesday 







253



Tuesday 



DESCRIPTIVE ’OMICS OF 

ACETAMINOPHEN IN HUMANS. M. Jetten 1 , 

S. Gaj 1 , A. Ruiz-Aracama 2 , T. de Kok 1 , J. van 

Delft 1 , S. Claessen 1 , A. Lommen 2 , A. Peijnenburg 2 , 

L. Pellis 3 , E. van Someren 3 , R. Stierum 3 and J. 

Kleinjans 1 . 1 Health Risk Analysis & Toxicology, 

Maastricht University, Maastricht, Netherlands, 

2 

Institute of Food Safety, RIKILT, Wageningen, 

Netherlands and 3 Quality of Life, TNO, Zeist, 

Netherlands. Sponsor: H. van Loveren. 


CISPLATIN-INDUCED GENOTOXIC STRESS 

IN PRIMARY MOUSE HEPATOCYTES, 

MOUSE EMBRYONIC STEM CELLS, AND 

HEPG2 CELLS. L. Rieswijk 1,2 , D. Lizárraga 1,2 , 

K. Brauers 1 , B. van de Water 2,3 , H. Vrieling 2,3 , J. van 

Delft 1,2 and J. Kleinjans 1,2 . 1 Health Risk Analysis 

and Toxicology, Maastricht University, Maastricht, 

Netherlands, 2 Netherlands Toxicogenomics Centre, 

Maastricht, Netherlands and 3 Toxicogenetics, LUMC, 

Leiden, Netherlands. Sponsor: H. van Loveren. 


USING A TRANSCRIPTIONAL 

GENE SIGNATURE TO PREDICT 

NEPHROTOXICITY in vitro. D. DeSilver 1 , 

V. Bonato 2 , M. Kuhn 2 and M. T. Pletcher 1 . 

1 

Compound Safety Prediction, Pfizer, Inc., Groton, 

CT and 2 Biostatistics, Pfizer, Inc., Groton, CT. 


TOXICOGENOMIC COMPARISON OF THE 

TOXIC EFFECTS OF DIETARY TCDD IN 

RAINBOW TROUT AND ZEBRAFISH. Q. 

Liu 1,2 , M. L. Rise 3 , C. A. Struble 4 , J. M. Spitsbergen 5 , 

G. Goetz 1 , R. J. Hutz 2 and M. J. Carvan 6,1 . 1 Great 

Lakes WATER Institute, Milwaukee, WI, 2 Biological 


Milwaukee, WI, 3 Ocean Sciences Centre, Memorial 

University of Newfoundland, St. John’s, NF, Canada, 

4 

Department of Math, Statistics, and Computer 

Science, Marquette University, Milwaukee, WI, 

5 

Microbiology, Oregon State University, Corvallis, 

OR and 6 School of Freshwater Sciences, University 

of Wisconsin Milwaukee, Milwaukee, WI. 


IDENTIFICATION OF MECHANISTIC 

BIOMARKERS OF CARDIAC AND 

SKELETAL MUSCLE TOXICITY TO AID 

THE DEVELOPMENT OF TISSUE-SPECIFIC 

IN VITRO MODELS. W. Dott 1 , P. Mistry 2 , J. 

Wright 2 and K. Herbert 1 . 1 Cardiovascular Sciences, 

University of Leicester, Leicester, United Kingdom 

and 2 Syngenta, Bracknell, United Kingdom. Sponsor: 

R. Peffer. 


RETROSPECTIVE GENE EXPRESSION 

ANALYSIS USING FORMALIN-FIXED 

TISSUE BLOCKS FROM TOXICOLOGICAL 

STUDIES. F. v. Landenberg, P. Hewitt, S. 

O. Mueller and C. S. Schmitt. Merck Serono, 

Darmstadt, Germany. 


TRANSCRIPTIONAL DOSE RESPONSE 

ANALYSIS IN FEMALE MOUSE AND 

RAT LUNGS FOLLOWING REPEATED 

INHALATION EXPOSURE TO 2-CHLORO-1, 

3-BUTADIENE. M. W. Himmelstein 1 and R. S. 

Thomas 2 . 1 DuPont Haskell Global Centers, Newark, 

DE and 2 The Hamner Institutes for Health Sciences, 



GENE EXPRESSION PROFILING OF LXR- 

MEDIATED HEPATIC STEATOSIS IN RATS. 

J. M. Maher, W. R. Buck, M. J. Liguori, J. Lai- 

Zhang, T. Sharapova, S. J. Morgan, E. A. Blomme 

and Y. Yang. Investigative Toxicology and Pathology, 

Abbott Laboratories, Abbott Park, IL. 


CHARACTERIZATION OF THE HEPATIC 

TRANSCRIPTOME RESPONSE TO A 

MIXTURE OF LOW MOLECULAR WEIGHT 

POLYBROMINATED DIPHENYL ETHERS: 

DISEASE, SIGNATURE, NETWORK AND 

PATHWAY ANALYSIS. S. S. Auerbach 1 , K. 

R. Shockley 1 , R. Thomas 2 , N. J. Machesky 4 , M. 

K. Vallant 1 , C. D. Hebert 3 , H. C. Cunny 1 and J. K. 

Dunnick 1 . 1 National Toxicology Program, National 


Triangle Park, NC, 2 Environmental Health Sciences, 

University of California, Berkeley, CA, 3 Southern 

Research Institute, Birmingham, AL and 4 Battelle 

Columbus Operations, Columbus, OH. 


AGE AND SEX DIFFERENCES IN RENAL 

GENE EXPRESSION DURING THE RAT 

LIFE CYCLE. J. C. Kwekel, V. G. Desai, T. 

Han, W. S. Branham, C. L. Moland and J. C. 

Fuscoe. Systems Toxicology/Center for Functional 

Genomics, U.S. FDA/National Center for 

Toxicological Research, Jefferson, AR. 


GENE EXPRESSION PROFILE OF RAT 

PRIMARY HEPATOCYTES EXPOSED TO 

DI(2-ETHYLHEXYL) PHTHALATE OR 

DIISONONYL PHTHALATE, THE PATH 

TO GENERATE TOXIGENOMICS DATA AS 

SUPPORT FOR STRUCTURE ACTIVITY 

RELATIONSHIPS ASSESSMENTS. J. M. 

Naciff, G. J. Overmann, R. Adams, G. J. Carr, J. 

P. Tiesman and G. P. Daston. Procter & Gamble, 



PERCELLOME TOXICOGENOMICS 

PROJECT AND ITS APPLICATION TO 

STUDIES ON ANTICANCER AGENTS. J. 

Kanno, K. Aisaki, K. Igarashi and S. Kitajima. 

Division of Cellular and Molecular Toxicology, 

National Institute of Health Sciences, Tokyo, Japan. 

Sponsor: N. Ryoichi. 


COMPARISON OF BASAL AND CRVI- 

MEDIATED SOLUTE CARRIER GENE 

EXPRESSION IN RODENT DUODENAL 

EPITHELIUM. S. Kim 1 , C. M. Thompson 2 , A. 

K. Kopec 1 , M. A. Harris 2 and T. R. Zacharewski 1 . 

1 

Biochemistry & Molecular Biology and Center 

for Integrative Toxicology, East Lansing, MI and 

2 

ToxStrategies, Inc., Katy, TX. 

254 






Platform Sessions



Abstract # 


NOVEL SHORT TERM PREDICTION 

SYSTEM FOR CARCINOGENICITY OF 

CHEMICALS BY HEPATIC TRANSCRIPT 

PROFILING IN A 28-DAY REPEAT-DOSE 

TOXICITY STUDY. F. Saito 1 , H. Matsumoto 1 , M. 

Takeyoshi 1 , Y. Yakabe 1 and T. Shirai 2 . 1 Chemicals 

Assessment and Research Center, Chemicals 

Evaluation and Research Institute (CERI), Japan, 

Saitama, Japan and 2 Department of Experimental 

Pathology and Tumor Biology, Nagoya City 

University Graduate School of Medical Sciences, 

Nagoya, Japan. 


TIME AND CONCENTRATION DEPENDENT 

REGULATION OF THE TRANSCRIPTOME 

AND THE PHENOTYPE OF A MOUSE 

LIVER CELL LINE EXPOSED TO BAP. D. 

Jannuzzi Madureira 1,2 , J. Michaelson 3 , A. Beyer 3 , S. 

Trump 4 , I. Lehmann 4 and K. Schirmer 1,2 . 1 Eawag, 

Swiss Federal Institute of Aquatic Science and 

Technology, Duebendorf, Switzerland, 2 Swiss 

Federal Institute of Technology Zürich, Switzerland, 

Zuerich, Switzerland, 3 Biotechnology Center TU 

Dresden, Dresden, Germany and 4 Helmholtz Centre 

for Environmental Research, Leipzig, Germany. 

Sponsor: M. R. Embry. 


TRANSCRIPTOMICS ANALYSIS OF 

NANOPARTICLE-CONTAINING HAIR 

DYES. D. A. Sarigiannis, G. Cimino Reale, E. 

Marafante, B. Casati, R. Brustio and A. Collotta. 

Institute for Health and Consumer Protection, 

European Commission - Joint Research Centre, Ispra, 

Varese, Italy. Sponsor: L. Birnbaum. 


A TOXICOGENOMIC COMPARISON OF 

PRIMARY VERSUS PHOTOCHEMICALLY 

ALTERED AIR POLLUTANTS IN HUMAN 

LUNG CELLS. J. E. Rager 1 , K. G. Sexton 1 , L. 

Smeester 1 , I. Jaspers 2 and R. C. Fry 1 . 1 Environmental 

Sciences and Engineering, Gillings School of 

Global Public Health, University of North Carolina 

at Chapel Hill, Chapel Hill, NC and 2 Center for 

Environmental Medicine, Asthma, and Lung Biology, 

School of Medicine, University of North Carolina at 



UNCOVERING TRANSCRIPTIONAL 

REGULATORS OF KIDNEY INJURY 

MOLECULE-1 IN CISPLATIN-INDUCED 

KIDNEY TOXICITY. M. P. Wagoner, J. Milano, 

D. Brott, D. Thurman, Y. Dragan, L. B. Kinter and 

B. Jeffy. Safety Assessment U.S., AstraZeneca, 



CORRELATION BETWEEN 

TOXICOGENOMIC PROFILING AND 

TRADITIONAL SAFETY BIOMARKERS. T. 

Wang 1 , M. Papoutsi 2 , M. Decristofaro 3 , M. Keselica 3 , 

E. Skuba 3 , R. Spaet 3 , P. Moulin 2 , F. Pognan 2 , A. 

Wolf 2 and W. Kluwe 1 . 1 Translational Sciences, 

Novartis Institute of Biomedical Research-USA, 

Emeryville, CA, 2 Translational Sciences, Novartis 

Institute of Biomedical Research-Switzerland, Basel, 

Switzerland and 3 Novartis Institute of Biomedical 

Research-USA, Easter Hanover, NJ. 

Abstract # 


MUSCLE IMPLANTED PELLETS OF 

TUNGSTEN/NICKEL/COBALT, NICKEL, 

OR TANTALUM: A 12 MONTH STUDY 

OF METAL MOBILIZATION AND 

MICROARRAY EXPRESSION. D. I. Bannon 1 , 

A. B. Rosencrance 2 , W. E. Dennis 2 , W. Bao 3 , C. 

Tsu-Ming 3 , R. D. Wolfinger 3 and E. J. Perkins 4 . 

1 

Directorate of Toxicology, U.S. Army Public Health 

Command, APG, Aberdeen, MD, 2 Department of 

Chemistry, U.S. Army Center for Environmental 

Health Research, Fort Detrick, MD, 3 SAS Institute, 

Inc., Cary, NC and 4 Environmental Laboratory, U.S. 

Army Engineer Research and Development Center, 

Vicksburg, MS. 


EXPOSURE TO HEAVY METALS CAUSES 

DISTINCT CHANGES IN THE GENE 

EXPRESSION PATTERN OF A RAT LIVER- 

DERIVED CELL LINE. M. Permenter 2 , J. A. 

Lewis 1 and D. A. Jackson 1 . 1 U.S. Army Center for 

Environmental Health Research, Fort Detrick, MD 

and 2 Excet, Inc., Fort Detrick, MD. 


TRANSCRIPTIONAL SIGNATURES FOR 

CHEMICALLY INDUCED HEPATOXICITY: 

IN VIVO PREDICTIVE POWER OF 3D LIVER 

CO-CULTURE OVER 2D HEPATOTOXICITY. 

B. A. Naughton 1 , R. S. Thomas 3 , L. New 1 , C. 

I. Pearson 1 , A. H. Roter 2 and D. R. Applegate 1 . 

1 

RegeneMed Inc., San Diego, CA, 2 Entelos, Inc., 

Foster City, CA and 3 Genomics, The Hamer Institutes 

for Health Sciences, Research Triangle Park, NC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Developmental Toxicology 

Chairperson(s): Jyotshna Kanungo, U.S. FDA, Jefferson, AR. 




COMPARISON OF BDE-47 AND ITS 

HYDROXYLATED ANALOGUES ON 

THE DEVELOPMENT OF EMBRYONIC 

ZEBRAFISH. C. Y. Usenko 1,2 and E. D. 

Bruce 1,3 . 1 Biology, Baylor University, Waco, TX, 

2 

Biomedical Studies, Baylor University, Waco, TX 

and 3 Department of Environmental Science, Baylor 

University, Waco, TX. 

Tuesday 







255



Tuesday 



STUDY OF ANTI-DIABETICS AND LMA BY 

MMP CHANGES ON HEPG2 CELLS USING 

LASER SCANNING CYTOMETER AND 

HYPERCYT-CYAN FLOW CYTOMETER. A. 

Juan-Garcia 1 , J. Robinson 1,2 , V. Davisson 3 , C. Juan 4 , 

M. Ruiz 4 and G. Font 4 . 1 Basic Medical Science- 

PUCL, Purdue University, West Lafayette, IN, 

2 

Biomedical Engineering-PUCL, Purdue University, 

West Lafayette, IN, 3 Medicinal Chemistry and 

Molecular Pharmacology, Purdue University, West 

Lafayette, IN and 4 Medicina Preventiva i Salut 

Publica, Ciencies de l’ Alimentació, Toxicologia 

I Medicina Legal, Valencia University, Burjassot, 

Valencia, Spain. 


EFFECTS OF GESTATIONAL EXPOSURE 

TO PFOA ON PPAR PROTEIN AND MRNA 

EXPRESSION IN VITAL ORGANS OF FETAL 

AND POSTNATAL MICE. A. M. Watkins, C. R. 

Wood, K. P. Das, C. Lau and B. D. Abbott. U.S. EPA, 



DEVELOPMENTAL TOXICITY OF 

LEFLUNOMIDE AND ITS METABOLITE 

TERIFLUNOMIDE IN ZEBRAFISH 

EMBRYOS. A. Mattsson, K. Vikholm, E. Ullerås 

and A. Oskarsson. Biomedical Sciences and 

Veterinary Public Health, The Swedish University of 

Agricultural Sciences, Uppsala, Sweden. 


IMPACT OF DIFFERENT OILY VEHICLES 

ON TESTICULAR TOXICITY OF DI-BUTYL 

PHTHALATE (DBP). A. J. Martino-Andrade 1,2 , 

A. S. Lourenço 2 , B. C. Minatovicz 1 , M. F. Kienast 1 , 

R. N. Morais 1 and P. R. Dalsenter 2 . 1 Physiology, 

Universidade Federal do Paraná, Curitiba, Brazil and 

2 

Pharmacology, Universidade Federal do Paraná, 

Curitiba, Brazil. Sponsor: R. Landsiedel. 


IN UTERO EXPOSURE TO BISPHENOL A 

INDUCES CHANGES IN THE DEVELOPING 

MAMMARY GLAND. J. LaRocca, J. Pietruska 

and M. Hixon. Brown University, Providence, RI. 


AN INVESTIGATION OF THE CLEARANCE 

OF 14 C-LABELLED VITAMIN K IN 

CONTROL AND MCCP-TREATED FEMALE 

CD RATS. R. H. Powrie 1 , D. G. Farrar 2 and C. R. 

Elcombe 1 . 1 CXR Biosciences Ltd., Dundee, United 

Kingdom and 2 Ineos Chlor Ltd., Runcorn, United 

Kingdom. 


KETAMINE INDUCES MOTOR NEURON 

TOXICITY AND ATTENUATION OF 

HEART RATE IN ZEBRAFISH. J. Kanungo, 

E. M. Cuevas, Z. He, S. F. Ali and M. G. Paule. 

Neurotoxicology, National Center for Toxicological 



NEUROCHEMICAL EFFECTS OF 

MATERNAL HALOPERIDOL EXPOSURE 

ON THE DEVELOPING RAT. R. Williams. 

Florida A&M University, Tallahassee, FL. 


HISTIOTROPHIC NUTRITION INFORMS 

DNA METHYLATION IN THE RAT 

CONCEPTUS. K. E. Sant, M. Nahar, D. Dolinoy 

and C. Harris. Environmental Health Sciences, 



A DEVELOPMENTAL TOXICITY STUDY 

IN SPRAGUE-DAWLEY RATS WITH XOMA 

052, A NOVEL MONOCLONAL ANTIBODY 

TARGETING IL-1 BETA. K. Meyer 1 , C. Gasper 1 , 

J. Ma 1 , L. Cao 1 , J. Chen 1 , K. Der 1 and B. Thorsrud 2 . 

1 

Product Development, XOMA (U.S. ) LLC, 

Berkeley, CA and 2 Developmental & Reproductive 

Toxicology, MPI Research, Mattawan, MI. 


DEVELOPMENTAL HYPOTHYROIDISM 

DISRUPTS PERFORMANCE OF A SIGNAL 

DETECTION TASK IN RATS. M. Hasegawa 1,2 

and H. Wada 1 . 1 Psychology, Hokkaido University, 

Sapporo, Japan and 2 Japan Society for the Promotion 

of Science, Tokyo, Japan. Sponsor: K. Crofton. 


PROBING THE TOXCAST CHEMICAL 

LIBRARY FOR PREDICTIVE SIGNATURES 

OF DEVELOPMENTAL TOXICITY. N. S. 

Sipes 1 , N. C. Kleinstreuer 1 , R. S. Judson 1 , D. M. Reif 1 , 

A. V. Singh 3 , K. J. Chandler 1,2 , M. R. Rountree 1 , D. J. 

Dix 1 , R. J. Kavlock 1 and T. B. Knudsen 1 . 1 U.S. EPA/ 

ORD/NCCT, Research Triangle Park, NC, 2 U.S. EPA 

/ORD/NHEERL, Research Triangle Park, NC and 

3 

Lockheed Martin, Research Triangle Park, NC. 


IN OVO EXPOSURE TO 

PERFLUOROOCTANOIC ACID DECREASES 

HATCHING MUSCLE GLYCOGEN IN 

CHICKEN EMBRYOS. J. DeWitt 1 , I. Bryan 2 

and J. Loftis 3 . 1 Pharmacology and Toxicology, East 

Carolina University, Greenville, NC, 2 Biology and 

Chemistry, East Carolina University, Greenville, NC 

and 3 Summer Ventures in Science and Mathematics, 

East Carolina University, Greenville, NC. 


ARSENIC DELAYS THE MUSCLE 

DIFFERENTIATION AND REPRESSES 

MYOGENIN EXPRESSION BY RECRUITING 

EZH2 AND SUPPRESSING MEF2C IN 

MOUSE MUSCLE CELLS. G. Hong and L. Bain. 

Biological Sciences, Clemson University, Clemson, 

SC. 


EFFECTS OF LOW-DOSE PRENATAL 

PFOA EXPOSURE ON THE MAMMARY 

GLAND OF CD-1 MICE. M. B. Macon 1,2 , L. R. 

Villanueva 3,4 , R. D. Zehr 5 , K. Tatum-Gibbs 1,4 , M. 

J. Strynar 5 , J. P. Stanko 2 , S. S. White 2 , L. Helfant 5 

and S. E. Fenton 2 . 1 Toxicology, University of North 

Carolina at Chapel Hill, Chapel Hill, NC, 2 NTP, 

NIEHS, Research Triangle Park, NC, 3 Chemistry, 

North Carolina Central University, Durham, NC, 

4 

TAD, NHEERL, ORD, U.S. EPA, Research Triangle 

Park, NC and 5 HEASD, NERL, ORD, U.S. EPA, 


256 






Platform Sessions



Abstract # 


PYRIMETHAMINE—INVESTIGATIVE 

EMBRYO-FETAL DEVELOPMENT STUDY 

BY THE ORAL ROUTE (GAVAGE) IN THE 

MINIPIG WITH MID-TERM CAESAREAN 

SECTIONS. E. C. Marsden, C. Pique and P. C. 

Barrow. Ricerca Biosciences SAS, Lyon, France. 


WNT INHIBITORY FACTOR 1 (WIF1) 

PROMOTES PROSTATIC BUD FORMATION 

AND MAY PARTIALLY PROTECT AGAINST 

DEFECTS IN PROSTATE DEVELOPMENT 

CAUSED BY TCDD EXPOSURE. A. Branam 1 , 

R. W. Moore 1 , L. L. Abler 2 , S. H. Allgeier 1 , V. 

Mehta 2 , C. M. Vezina 2 and R. E. Peterson 1 . 1 School 

of Pharmacy, University of Wisconsin, Madison, 

WI and 2 Comparative Biosciences, University of 

Wisconsin, Madison, WI. 


EFFECTS OF PERFLUORINATED 

PHOSPHONIC ACID EXPOSURE DURING 

PREGNANCY IN THE MOUSE. K. R. Tatum- 

Gibbs 1 , K. P. Das 2 , B. Grey 2 , M. Strynar 3 , A. 

Lindstrom 3 and C. Lau 2 . 1 Curriculum in Toxicology, 

University of North Carolina at Chapel Hill, 

Research Triangle Park, NC, 2 Developmental 

Toxicology Branch, U.S. EPA, Research Triangle 

Park, NC and 3 HEASD, U.S. EPA, Research Triangle 

Park, NC. 


IDENTIFICATION OF Wnt AND Rspo 

GENES WHOSE EXPRESSION PATTERNS 

IN FETAL MOUSE UROGENITAL 

SINUS (UGS) ARE ALTERED BY 2, 3, 7, 

8-TETRACHLORODIBENZO- p -DIOXIN 

(TCDD). R. W. Moore 1 , L. L. Abler 2 , V. Mehta 2 , C. 

M. Vezina 2 and R. E. Peterson 1 . 1 School of Pharmacy, 

University of Wisconsin, Madison, WI and 

2 

Comparative Biosciences, University of Wisconsin, 

Madison, WI. 


ZEBRAFISH EMBRYOS SEQUESTER 

PETROCHEMICAL COMBUSTION 

PRODUCTS IN LIPID DROPLETS, 

WITH UP-REGULATION OF 

BIOTRANSFORMATION, OXIDATIVE 

STRESS, AND INFLAMMATION-RELATED 

GENES. R. Xiao, A. Bui, K. Kleinow and A. Penn. 

Louisiana State University School of Veterinary 

Medicine, Baton Rouge, LA. 


PRENATAL TCDD AND POSTNATAL 

AUTOIMMUNE DISEASE: A COMPARISON 

OF TWO MURINE STRAINS. S. D. Holladay, 

A. Mustafa and R. M. Gogal. Department of 

Anatomy and Radiology, University of Georgia, 

Athens, GA. 


EFFECT OF LOW-DOSE MERCURIC 

CHLORIDE EXPOSURE ON EARLY 

ZEBRAFISH EMBRYO DEVELOPMENT. 

L. C. Abbott 1 , E. A. Moussa 2 and S. A. Hassan 3 . 

1 

Integrative Biosciences, Texas A&M University, 

College Station, TX, 2 Anatomy and Embryology, 

Suez Canal University, Ismailia, Egypt and 3 Anatomy 

and Embryology, Suez Canal University, Ismailia, 

Egypt. 

Abstract # 


DEVELOPMENTAL TOXICITY OF THE 

HMG-COA REDUCTASE INHIBITOR 

(PPD10558) IN RATS AND RABBITS. A. S. 

Faqi 1 , D. Prohaska 2 , R. Lopez 2 and G. McIntyre 2 . 

1 

Drug Safety Evaluation, MPI Research, 

Mattawan, MI and 2 Drug Safety Evaluation, Furiex 

Pharmaceuticals, Morrisville, NC. 


FOXQ1: A BRIDGE BETWEEN THE AHR 

AND HEDGEHOG SIGNALING PATHWAYS. 

A. Planchart. Mount Desert Island Biological 

Laboratory, Salisbury Cove, ME. 


CLEFT PALATE IN RATS TREATED 

WITH A COMPOUND THAT HAS STEROL 

ANTISYNTHESIS ACTION. N. Ikemi 1 , T. 

Oota 2 and K. Kawashima 2 . 1 Otsuka AgriTechno Co., 

Ltd., Tokushima, Japan and 2 Mitsubishi Chemical 

Medience Co., Ltd., Kumamoto, Japan. 


CHEMICAL FORM MATTERS: 

DIFFERENTIAL ACCUMULATION OF 

ORGANIC AND INORGANIC MERCURY 

IN ZEBRAFISH LARVAE. T. C. MacDonald, 

M. Korbas, I. J. Pickering, G. N. George and P. H. 

Krone. University of Saskatchewan, Saskatoon, SK, 

Canada. 


ABERRANT LIGAND-INDUCED 

ACTIVATION OF G-PROTEIN-COUPLED 

ESTROGEN RECEPTOR 1 (GPER) RESULTS 

IN DEVELOPMENTAL MALFORMATIONS 

DURING VERTEBRATE EMBRYOGENESIS. 

B. S. Jayasinghe and D. C. Volz. Department of 

Environmental Health Sciences, Arnold School 

of Public Health, University of South Carolina, 

Columbia, SC. 


PRENATAL BISPHENOL-A ALTERS 

LUNG EPITHELIAL SECRETORY CELL 

MATURATION. S. Murphy, M. Boetticher, C. 

VandeVoort and L. Van Winkle. California National 

Primate Research Center, University of California 

Davis, Davis, CA. 


ESTIMATED DIETARY EXPOSURE 

AND PREDICTORS OF SERUM 

CONCENTRATIONS OF PERFLUORINATED 

COMPOUNDS IN 119 PREGNANT 

NORWEGIAN WOMEN. A. Brantsaeter, M. 

Haugen, L. S. Haug, H. K. Knutsen, H. E. Kvalem, 

C. Thomsen, G. Becher, J. Alexander and H. Meltzer. 

Environmental Medicine, Norwegian Institute of 

Public Health, Oslo, Norway. Sponsor: M. Løvik. 


EFFECTS OF PCBS ON EMBRYONIC 

CARDIAC DEVELOPMENT IN GALLUS 

(GALLUS DOMESTICUS). T. Carro and M. 

Ottinger. Animal and Avian Sciences, University of 

Maryland, College Park, MD. Sponsor: R. Schuh. 

Tuesday 







257



Tuesday 



POLYCYCLIC AROMATIC 

HYDROCARBONS EXERT STRUCTURE- 

DEPENDENT DIFFERENTIAL 

MECHANISMS OF TOXICITY IN 

DEVELOPING ZEBRAFISH. B. C. Goodale 1 , 

J. K. La Du 1 , S. C. Tilton 2 , K. M. Waters 2 and R. L. 

Tanguay 1 . 1 Environmental and Molecular Toxicology, 

Oregon State University, Corvallis, OR and 2 Pacific 



GENE EXPRESSION EVALUATION OF 

THE RELATIVE SAFETY OF PRENATAL 

STRESS AND/OR ANTIDEPRESSANT 

EXPOSURE. C. H. Bourke, C. F. Capello and M. J. 

Owens. Psychiatry and Behavioral Sciences, Emory 

University, Atlanta, GA. 


FACIAL ANOMALIES IN A RAT MODEL 

WITH ETHANOL: ANIMAL FRIENDLY 

MARKERS FOR FETAL ALCOHOL 

SYNDROME (FAS). R. Slieker, L. vd Horst, R. 

Nederlof, M. Otto and D. De Groot. TNO Quality of 

Life, Zeist, Netherlands. Sponsor: R. Woutersen. 


DEVELOPMENTAL ARSENIC EXPOSURE 

INCREASES PERINATAL MORTALITY 

AND CAUSES LIVER INFLAMMATION IN 

FEMALE MICE. M. W. Carmody, A. R. King, A. 

E. Hill and R. J. Sommer. Biology Department, Bates 

College, Lewiston, ME. 


MICRORNA EXPRESSION PROFILES 

AFTER DEVELOPMENTAL EXPOSURE OF 

ZEBRAFISH (DANIO RERIO) EMBRYOS TO 

TCDD. N. Aluru 1 , M. J. Jenny 1,2 and M. E. Hahn 1 . 

1 

Biology Department, Woods Hole Oceanographic 

Institution, Woods Hole, MA and 2 Department 

of Biological Sciences, University of Alabama, 

Tuscaloosa, AL. 


MIRNAS ARE ESSENTIAL FOR BILE 

ACID HOMEOSTASIS DURING LIVER 

DEVELOPMENT. Y. J. Cui, J. Liu, Z. Fu, Y. Guo 

and C. D. Klaassen. Department of Pharmacology, 

Toxicology and Therapeutics, University of Kansas 



AN INHALATION DEVELOPMENTAL 

TOXICITY STUDY OF N-ETHYL 

ACETAMIDE IN RATS. J. Domoradzki 1 , T. 

Edwards 2 and D. Kirkpatrick 2 . 1 Dow Corning 

Corporation, Auburn, MI and 2 WIL Research 

Laboratories, LLC, Ashland, OH. 


EFFECTS OF THALIDOMIDE ON NORMAL 

FETAL GROWTH AND HEART RATE IN 

CYNOMOLGUS MONKEYS. C. Diabo, M. 

Kob, C. Cohle, K. Griffin, B. Lewis, A. Kuzmin, S. 

Magness and A. S. Faqi. Drug Safety Evaluation, 

MPI Research, Mattawan, MI. 


COMPARATIVE EVALUATION OF 

LEARNING AND MEMORY IN RATS 

USING MORRIS MAZE VIDEO TRACKING 

SYSTEM AND PASSIVE AVOIDANCE. C. 

Lanphear, A. Terpstra, A. Rohr and A. S. Faqi. Drug 

Safety Evaluation, MPI Research, Mattawan, MI. 



DIOXIN (TCDD) INHIBITS EPICARDIAL 

DEVELOPMENT IN THE EMBRYONIC 

ZEBRAFISH HEART. J. S. Plavicki, W. 

Heideman and R. E. Peterson. School of Pharmacy, 

University of Wisconsin at Madison, Madison, WI. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Apoptosis/Cell Death 

Chairperson(s): Salmaan Inayat-Hussain, Universiti Kebangsaan 

Malaysia, Kuala Lumpur, Malaysia, and Sidhartha Ray, UAMS College of 

Pharmacy & Health Sciences, Brooklyn, NY. 




MINOCYCLINE AND DOXYCYLINE, 

BUT NOT TETRACYCLINE, DECREASE 

LIVER AND KIDNEY INJURY 

AFTER HEMORRHAGIC SHOCK 

AND RESUSCITATION IN MICE. A. 

Kholmukhamedov 1 , C. Czerny 1 , J. Hu 1 , J. Schwartz 1 

and J. J. Lemasters 1,2 . 1 Pharmaceutical & Biomedical 


Charleston, SC and 2 Biochemistry & Molecular 

Biology, Medical University of South Carolina, 



DOXYCYCLINE AND MINOCYCLINE, 

BUT NOT OTHER TETRACYCLINE 

DERIVATIVES, INHIBIT THE 

MITOCHONDRIAL PERMEABILITY 

TRANSITION AND MITOCHONDRIAL IRON 

UPTAKE. J. Schwartz 1 , E. Holmuhamedov 1 and 

J. J. Lemasters 1,2 . 1 Pharmaceutical & Biomedical 


Charleston, SC and 2 Biochemistry & Molecular 

Biology, Medical University of South Carolina, 



LYSOSOMES, COMPOUND 

ACCUMULATION, AND IN VITRO 

TOXICITY. S. Lu 1 , 1 S. Nadanaciva 2 , R. Swiss 2 , 

B. Jessen 1 and Y. Will 2 . 1 Drug Safety Research 

and Development, Pfizer Inc., San Diego, CA and 

2 

Compound Safety Prediction, Pfizer Inc., Groton, 

CT. 

258 






Platform Sessions



Abstract # 


LYSOSOMAL IRON RELEASE AND 

MITOCHONDRIAL IRON UPTAKE 

CONTRIBUTE TO ISCHEMIA- 

REPERFUSION INJURY TO RAT 

HEPATOCYTES. X. Zhang and J. J. Lemasters. 

Medical University of South Carolina, Charleston, 

SC. 


THE CYTOTOXIC INTERACTION 

BETWEEN HYPOXIA AND NEUTROPHIL 

ELASTASE IN A MURINE HEPATOMA 

CELL LINE IS INDEPENDENT OF HIF-1α 

SIGNALING. E. M. Sparkenbaugh, M. A. Nothem, 

P. E. Ganey and R. A. Roth. Pharmacology and 

Toxicology, Michigan State University, Lansing, MI. 


THE ROLE OF MITOCHONDRIA IN 

AMIODARONE-INDUCED APOPTOSIS IN 

RAT PLEURAL MESOTHELIAL CELLS. E. S. 

Taneva and J. M. Cerreta. PHS, St. Johns University, 

Queens, NY. Sponsor: L. Trombetta. 


ACUTE SINGLE-MITOCHONDRION 

RESPONSES TO 1, 3-DINITROBENZENE 

IN ASTROCYTES. L. Maurer 1 , I. C. Speirs 1 , 

J. Fernandez 1 , D. Song 2 , T. Epstein 3 , A. Jureziz 1 , 

S. Steiner 1 and M. A. Philbert 1 . 1 Department of 

Environmental Health Sciences, Toxicology, 

University of Michigan, Ann Arbor, MI, 2 Mechanical 

Engineering Department, University of Michigan, 

Ann Arbor, MI and 3 Chemistry Department, 



ARE REACTIVE OXYGEN SPECIES 

REQUIRED FOR AUTOPHAGY? J. Jiang 1 , 

D. A. Stoyanovsky 1 , A. Maeda 1 , J. S. Greenberger 2 

and V. E. Kagan 1 . 1 Environmental and Occupational 

Health, University of Pittsburgh, Pittsburgh, PA 

and 2 Radiation Oncology, University of Pittsburgh, 



CONNEXIN32 HEMICHANNELS 

FACILITATE THE APOPTOTIC-TO- 

NECROTIC TRANSITION DURING 

FAS-MEDIATED HEPATOCYTE CELL 

DEATH. M. Vinken 1 , E. Decrock 2 , E. De Vuyst 2 , 

M. De Bock 2 , V. Roosmarijn 3 , B. De Geest 4 , J. 

Demeester 4 , N. Sanders 5 , T. Vanhaecke 1 , L. Leybaert 2 

and V. Rogiers 1 . 1 Toxicology, Free University 

Brussels, Brussels, Belgium, 2 Basic Medical 

Sciences/Physiology Group, Ghent University, 

Ghent, Belgium, 3 Molecular Biomedical Research, 

Ghent University, Ghent, Belgium, 4 General 

Biochemistry and Physical Pharmacy, Ghent 

University, Ghent, Belgium and 5 Gene Therapy, 

Ghent University, Ghent, Belgium. 


DECIPHERING THE ROLE OF FASL IN 

REGULATING C-FLIP EXPRESSION IN 

GERM CELLS. Y. Lin, P. Yao and J. H. Richburg. 

Center for Molecular and Cellular Toxicology, 

College of Pharmacy, Division of Pharmacology 

and Toxicology, The University of Texas at Austin, 

Austin, TX. 

Abstract # 


APOPTOSIS AND CELL PROLIFERATION 

IN HEPG2 CELLS TREATED WITH 

TROVAFLOXACIN AND TUMOR NECROSIS 

FACTOR. K. M. Beggs, P. E. Ganey and R. A. 

Roth. Pharmacology and Toxicology, Michigan State 



CAFFEINE PROMOTES UVB-INDUCED 

APOPTOSIS THROUGH INHIBITING THE 

AKT/COX-2 PATHWAYS. W. Han, M. Ming 

and Y. He. Medicine/Dermatology, University of 

Chicago, Chicago, IL. 


NEUROTOXIC SIGNALING PATHWAY 

OF BISPHENOL AF IN HIPPOCAMPAL 

NEURONAL CELLS: ROLE OF CALCIUM- 

INDUCED ROS, MAPKS, AND NF-κB. S. Kim 2 

and S. Lee 1 . 1 Department of Pharmacology, School of 

Medicine, Kyungpook National University, Daegu, 

Republic of Korea and 2 Toxicology Branch, National 

Toxicology Program, Morrisville, NC. 


QUANTITATIVE ASSESSMENT OF 

[18F]-DFNSH UPTAKE BY MICROPET 

IMAGING AS A BIOMARKER OF 

ANESTHETIC-INDUCED NEURONAL 

DEATH. X. Zhang 1 , C. Wang 1 , G. D. Newport 1 , M. 

G. Paule 1 , F. Liu 1 , M. S. Berridge 2 , S. M. Apana 2 , 

G. Kabalka 3 and W. Slikker 1 . 1 NCTR /U.S. FDA, 

Jefferson, AR, 2 3D Imaging, Little Rock, AR and 

3 

The University of Tennessee, Knoxville, TN. 


INDUCTION OF APOPTOSIS- 

ASSOCIATED RIBOSOMAL RNA (RRNA) 

CLEAVAGE BY THE TRICHOTHECENE 

DEOXYNIVALENOL. K. He 1,2 , H. Zhou 3 and 

J. Pestka 1,2,3 . 1 Department of Microbiology & 


Lansing, MI, 2 Center for Integrative Toxicology, 


3 

Food Science & Human Nutrition, Michigan State 



DEVELOPMENT OF NOVEL 

INDOLEQUINONE ANTI-TUMOR AGENTS: 

MECHANISM OF TOXICITY IN HUMAN 

PANCREATIC CANCER. C. Yan 1 , D. Siegel 1 , M. 

Colucci 2 , A. Chilloux 2 , J. Newsome 2 , C. J. Moody 2 

and D. Ross 1 . 1 Pharmaceutical Sciences, University 

of Colorado Denver, Aurora, CO and 2 Chemistry, 

University of Nottingham, Nottingham, United 

Kingdom. 


SDF-1β PROTECTS CARDIAC CELLS FROM 

PALMITATE-INDUCED NITROSATIVE 

STRESS-MEDIATED ER STRESS AND CELL 

DEATH THROUGH ACTIVATION OF AMPK- 

MEDIATED IL-6 EXCRETION. Y. Zhao 2,1 , 

W. Li 2 and L. Cai 1,2 . 1 University of Louisville, 

Louisville, KY and 2 The Fist Hospital of Jilin 

University, Changchun, China. 

Tuesday 







259



Tuesday 



THE MECHANISMS OF PARAQUAT- 

INDUCED LUNG TOXICITY IN VIVO AND 

IN VITRO. Y. Yang 1 , D. Hung 1,2 , C. Chen 1,3 , H. 

Wu4, K. Chen 4 , C. Su 5 , C. Huang 6 and Y. Chen 7 . 

1 

Graduate Institute of Drug Safety, China Medical 

University, Taichung, Taiwan, 2 Toxicology Center, 


Taiwan, 3Department of Emergency, China 


4 

Department of Urology, China Medical University 

Hospital, Taichung, Taiwan, 5 Department of 

Otorhinolaryngology, Head and Neck Surgery, 


6 

School of Chinese Medicine, China Medical 

University, Taichung, Taiwan and 7 Department of 

Physiology, China Medical University, Taichung, 

Taiwan. 


ROLE OF CANNABINOID RECEPTORS IN 

CANNABIDIOL-MEDIATED APOPTOSIS IN 

LIPOPOLYSACCHARIDE(LPS) ACTIVATED 

B LYMPHOCYTES. R. Rao, P. Nagarkatti and M. 

Nagarkatti. University of South Carolina, Columbia, 

SC. 


EFFECTS OF PBDES CONGENERS (BDE- 

209 AND BDE-47) ON HUMAN HEPATOMA 

CELLS (HEPG2) PROLIFERATION AND 

VIABILITY. D. J. Dorta and A. O. de Souza. 

Quimica, Faculdade de Filosofia, Ciências e Letras 

de Ribeirão Preto - Universidade de Sao Paulo, 

Ribeirão Preto, SP, Brazil. 


HYDROXYL RADICALS MEDIATES 

CISPLATIN-INDUCED APOPTOSIS IN 

HUMAN HAIR FOLLICLES DERMAL 

PAPILLA CELLS AND KERATINOCYTES 

THROUGH BCL-2-DEPENDENT 

MECHANISM. S. Luanpitpong 1,3 , P. 

Chanvorachote 3 , V. Pongrakhananon 1,3 , L. Wang 2 , 

U. Nimmannit 4 and Y. Rojanasakul 1 . 1 West Virginia 

University, Morgantown, WV, 2 National Institute 

for Occupational Safety and Health, Morgantown, 

WV, 3 Chulalongkorn University, Bangkok, Thailand 

and 4 National Nanotechnology Center, Pathumthani, 

Thailand. 


LC-ESI/MS REVEALS UNUSUAL 

OXYGENATED LYSO- 

PHOSPHATIDYLSERINES PRODUCED 

AFTER OXIDATION AND HYDROLYSIS 

BY PLASMA LIPOPROTEIN-ASSOCIATED 

PHOSPHOLIPASE A2 OF SN-1, SN-2- 

DILINOLEOYL-PS. V. A. Tyurin 1,2 , Y. Y. 

Tyurina 1,2 , C. H. Macphee 3 and V. E. Kagan 1,2 . 

1 

Center for Free Radical and Antioxidant 

Health, University of Pittsburgh, Pittsburgh, PA, 

2 


of Pittsburgh, Pittsburgh, PA and 3 GlaxoSmithKline, 

King of Prussia, PA. 


GROWTH INHIBITION OF BENZO(A) 

PYRENE (BAP)-EXPOSED HT29 

HUMAN COLON CANCER CELLS BY 

RESVERATROL. A. C. Huderson, J. N. Myers 

and A. Ramesh. Biochemistry & Cancer Biology, 

Meharry Medical College, Nashville, TN. 


CYTOTOXICITY COMPARISON OF 

DIFFERENT ORGAN TOXICANTS IN 

ORGAN SPECIFIC CELL LINES. Z. Lin, R. 

Swiss, Y. Will and M. Pletcher. Compound Safety 

Prediction, Pfizer Global Research & Development, 

Groton, CT. 


STORE-OPERATED CALCIUM CHANNELS 

PLAY A SIGNIFICANT ROLE IN ROS- 

INDUCED NECROTIC CELL DEATH. F. 

M. Ramirez, R. Xie, S. S. Lau and T. J. Monks. 

Southwest Environmental Health Sciences Center, 

Department of Pharmacology & Toxicology, College 

of Pharmacy, University of Arizona, Tucson, AZ. 


PROTECTION OF HYDROQUINONE- 

INDUCED APOPTOSIS BY FAU IS 

MEDIATED BY NQO1 IN W7.2 MOUSE 

THYMOMA CELLS. S. H. Inayat-Hussain 1 , L. 

E. Siew 1 , M. K. Chan 1 , N. F. Rajab 1 , D. Ross 2 and 

G. T. Williams 3 . 1 Environmental Health Program, 

Universiti Kebangsaan Malaysia, Kuala Lumpur, 

Malaysia, 2 School of Pharmacy, University of 

Colorado at Denver, Denver, CO and 3 Institute for 

Science and Technology in Medicine and School 

of Life Sciences, Keele University, Keele, United 

Kingdom. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Biomarkers of Environmental Exposures 

Chairperson(s): Joel G. Pounds, Battelle, PNNL, Richland, WA. 




AFLATOXIN PREVALENCE AND 

HEPATOCELLULAR CARCINOMA IN 

GHANA: A REGIONAL ANALYSIS. N. J. 

Mitchell 1 , P. E. Jolly 2 , C. M. Jolly 3 , A. Marroquin- 

Cardona 1 and T. D. Phillips 1 . 1 College of Veterinary 

Medicine, Texas A&M University, College Station, 

TX, 2 Department of Epidemiology, School of Public 

Health, University of Alabama at Birmingham, 

Birmingham, AL and 3 Department of Agricultural 

Economics and Rural Sociology, Auburn University, 

Auburn, AL. 


CYTOCHROME P4501A PROMOTER 

POLYMORPHISMS AND ACTIVITY IN 

NATURAL POPULATIONS ADAPTED TO 

CHRONIC POLLUTION. L. Williams 1 and 

M. Oleksiak 2 . 1 Environmental and Molecular 


NC and 2 University of Miami, Miami, FL. 

260 






Platform Sessions



Abstract # 


TWO BIOMARKERS FOR EVALUATION OF 

ORGANOPHOSPHATE (OP) POISONING 

IN HUMANS. G. H. DeOliveira 1 , G. L. Emerick 1 , 

K. A. Belaz 2 , M. Gonçalves 1 and R. V. Oliveira 2 . 

1 

Natural Actives Principles and Toxicology, UNESP 

Sao Paulo State University, Araraquara, Sao Paulo, 

Brazil and 2 Department of Chemistry, University 

Federal of Sao Carlos, Sao Carlos, SP, Brazil. 


GLOBAL GENE EXPRESSION CHANGES 

BY HUMAN UROEPITHELIAL 

CELLS EXPOSED TO LOW-LEVEL 

MONOMETHYLARSONOUS ACID. X. Zheng, 

P. Novak, S. M. Wnek, M. K. Medeirous, V. Chyan 

and J. A. Gandolfi. Pharmacology/Toxicology, 



METABOLIC PROFILING OF SERUM FROM 

RATS DOSED WITH ACETAMINOPHEN 

AND CARBON TETRACHLORIDE. R. D. 

Beger, L. Pence, L. K. Schnackenberg, J. Sun, T. 

Schmitt, X. Yang, J. Greenhaw, S. Bhattacharyya, W. 

Salminen and D. L. Mendrick. Division of Systems 

Biology, NCTR, U.S. FDA, Jefferson, AR. 


CHARACTERIZATION OF PEPTIDE 

ADDUCTS OF REACTIVE NAPHTHALENE 

METABOLITES IN THE URINE OF MALE 

MICE BY MASS SPECTROMETRY. N. 

Pham 2,1 , A. Buckpitt 1,2 , D. Morin 1 and W. T. Jewell 2 . 

1 

Veterinary Medicine: Molecular Biosciences, 

University of California Davis, Davis, CA and 

2 




INSECTICIDE RESIDUES AND THEIR 

SELECTED BIOMARKERS IN PRODUCE: 

FIELD STUDIES USING MALATHION AND 

FENPROPATHRIN IN STRAWBERRIES. L. 

Chen 1 , Z. Chen 1,2 , Y. Liu 1 , T. Lopez 1,2 , G. Sankaran 1,2 , 

H. Vega 1 and R. I. Krieger 1,2 . 1 Personal Chemical 

Exposure Program, Department of Entomology, 

University of California, Riverside, CA and 

2 

Environmental Toxicology Graduate Program, 

University of California, Riverside, CA. 


QUANTITATION OF THE BENZO[A] 

PYRENE (B[A]P) METABOLOME BY A 

STABLE ISOTOPE DILUTION TANDEM 

MASS SPECTROMETRY METHOD 

AND ITS APPLICATION TO HUMAN 

BRONCHOALVEOLAR CELLS. D. Lu 1,2 , R. 

Harvey 4 , I. Blair 1,3 and T. Penning 1,2 . 1 Department 

of Pharmacology, University of Pennsylvania, 

Philadelphia, PA, 2 Center of Excellence in 

Environmental Toxicology, University of 

Pennsylvania, Philadelphia, PA, 3 Center for 

Cancer Pharmacology, University of Pennsylvania, 

Philadelphia, PA and 4 The Ben May Department for 

Cancer Research, University of Chicago, Chicago, 

IL. 

Abstract # 


MALDI IMAGING OF PROSTATE CANCER 

TISSUE TOWARD VALIDATION OF 

BIOMARKER IDENTIFICATION. C. M. 

Hattan 1 , N. J. Mastrandrea 1 , J. M. C Gard 2 , R. 

Nagle 2 , T. J. Monks 1 and S. S. Lau 1 . 1 Southwest 

Environmental Health Sciences Center, Department 

of Pharmacology/Toxicology, College of Pharmacy, 

University of Arizona, Tucson, AZ and 2 College of 

Medicine, University of Arizona, Tucson, AZ. 


MOLECULAR DOSIMETRY OF 

N 2 -HYDROXYMETHYL-dG ADDUCTS 

FOLLOWING FORMALDEHYDE 

EXPOSURE TO NON-HUMAN PRIMATES. B. 

C. Moeller 1 , K. Lu 2 , M. Doyle-Eisele 3 , J. McDonald 3 , 

A. Gigliotti 3 and J. A. Swenberg 1,2 . 1 Curriculum 

in Toxicology, University of North Carolina at 

Chapel Hill, Chapel Hill, NC, 2 Department of 

Environmental Sciences and Engineering, University 

of North Carolina at Chapel Hill, Chapel Hill, 

NC and 3 Lovelace Respiratory Research Institute, 




DIOXIN RESPONSIVE TRANSCRIPTS 

IN AVIAN EMBRYONIC LIVER, 

IDENTIFIED BY LARGE-SCALE 

DIFFERENTIAL DISPLAY SYSTEM WITH 

VERTEBRATE-COMMON DEGENERATE 

OLIGONUCLEOTIDE PRIMERS. H. Teraoka 1 , 

S. Ito 1 , N. Ukai 1 , E. Kim 2,3 , H. Iwata 3 , T. Kitazawa 1 , 

T. Hiraga 1 and D. Endoh 1 . 1 School of Veterinary 

Medicine, Rakuno Gakuen University, Ebetsu, 

Hokkaido, Japan, 2 Department of Biology, Kyung 

Hee University, Seoul, Republic of Korea and 

3 

Center for Marine Environmental Studies, Ehime 

University, Matsuyama, Ehime, Japan. 


IS TRICHLOROETHYLENE-INDUCED 

FORMIC ACIDURIA A BIOMARKER OF 

EXPOSURE RATHER THAN A SIGN OF 

TOXICITY? E. A. Lock, N. Yaqoob and A. Evans. 

School of Pharmacy and Biomolecular Sciences, 

Liverpool John Moores University, Liverpool, United 

Kingdom. 


VALIDATION OF A PORTABLE X-RAY 

FLUORESCENCE (XRF) TECHNOLOGY 

TO QUANTIFY LEAD IN BONE IN VIVO. 

S. Sanchez 1 , M. G. Weisskopf 2 and L. H. Nie 1 . 

1 

School of Health Sciences, Purdue University, West 

Lafayette, IN and 2 Harvard School of Public Health, 

Boston, MA. 


USE OF GLOBIN ADDUCTS FOR 1, 

3-BUTADIENE INTERNAL DOSIMETRY 

THAT REFLECTS EXPOSURE AND 

METABOLISM. N. K. Bordeerat 1 , S. Carro 1 , L. 

Collins 1 , W. Bodnar 1 , P. Upton 1 , V. Walker 2 and J. A. 

Swenberg 1 . 1 Environmental Science and Engineering, 

The University of North Carolina at Chapel Hill, 

Chapel Hill, NC and 2 University of Vermont, 

Burlington, VT. 

Tuesday 







261



Tuesday 



AFLATOXIN EXPOSURE IN RURAL 

RESIDENTS OF BURKINA FASO, WEST 

AFRICA. P. A. Nikiema, G. Qian, L. Tang, J. 

H. Williams and J. Wang. University of Georgia, 

Athens, GA. 


EMPLOYING A NEW ANALYTICAL 

METHOD FOR MEASURING THE CYANIDE 

METABOLITE, 2-AMINOTHIAZOLINE- 

4-CARBOXYLIC ACID, IN BIOLOGICAL 

SAMPLES. J. C. Yu 2 , I. Petrikovics 1 , S. Martin 1,2 , 

J. Nasr 1 , D. Thompson 1 and S. Holmes 1 . 1 Chemistry, 

Sam Houston State University, Huntsville, TX and 

2 

Forensic Science, Sam Houston State University, 

Huntsville, TX. 


MOLECULAR DOSIMETRY AND HALF LIFE 

OF N2-HYDROXYMETHYL-DG ADDUCT IN 

RATS EXPOSED TO FORMALDEHYDE. K. 

Lu 1 , B. Moeller 2 , M. Doyle-Eisele 3 , J. McDonald 3 

and J. A. Swenberg 1,2 . 1 Environmental Sciences and 


Hill, Chapel Hill, NC, 2 Curriculum in Toxicology, 


Hill, NC and 3 Lovelace Respiratory Research 

Institute, Albuquerque, NM. 


FORMALDEHDYE-INDUCED 

HYDROXYMETHYL DNA ADDUCTS IN 

RATS EXPOSED TO ISOTOPE LABELED 

METHANOL. H. Gul, K. Lu, P. Upton and J. A. 

Swenberg. Environmental Sciences and Engineering, 


Hill, NC. 


HUMAN BIOMARKERS FOR TRICRESYL 

PHOSPHATE EXPOSURE. J. Marsillach 

Lopez 1,2 , R. J. Richter 1,2 , T. B. Cole 1,3 , J. H. Kim 4 , 

R. C. Stevens 1,2 , M. J. MacCoss 2 , D. Tomazela 2 , 

E. J. Hsieh 2 , S. M. Suzuki 1,2 , L. M. Schopfer 5 , O. 

Lockridge 5 and C. E. Furlong 1,2 . 1 Medicine, Division 

of Medical Genetics, University of Washington, 

Seattle, WA, 2 Genome Sciences, University 

of Washington, Seattle, WA, 3 Environmental 

and Occupational Health Sciences, University 

of Washington, Seattle, WA, 4 Anesthesiology, 

University of Washington, Seattle, WA and 

5 

University of Nebraska Medical Center, Omaha, NE. 


VOC SERUM LEVELS IN THE GENERAL 

U.S. POPULATION: AN ANALYSIS OF THE 

2003–2004 NHANES DATASET. L. Fitzgerald, 

B. Burkhalter, J. Urban, D. Staskal, M. Harris and L. 

Haws. ToxStrategies, Austin, TX. 


IDENTIFICATION OF URINARY 

METABOLIC PROFILES ASSOCIATED 

WITH METHYLMERCURY EXPOSURE 

USING A METABOLOMIC APPROACH. P. 

Tremblay 1,2 ,. Gaudreau 2 ,. Dewailly 1 and P. Ayotte 1,2 . 

1 

Axe de Recherche en Santé des Populations et 

Environnementale, CRCHUQ-CHUL and Université 

Laval, Québec, Canada and 2 Laboratoire de 

Toxicologie, Institut National de Sante Publique du 

Québec, Québec, Canada. 


QUANTIFICATION OF BENZO(A)PYRENE 

IN HAIR AS A BIOMARKER OF EXPOSURE 

USING GAS CHROMATOGRAPHY/MASS 

SPECTROMETRY—SELECTIVE ION 

MONITORING (GC/MS-SIM). S. C. Campbell 1 , 

D. E. Rollins 1 , S. G. Tiffany 2 and D. G. Wilkins 1 . 

1 

Pharmacology and Toxicology, University of Utah, 

Salt Lake City, UT and 2 Psychiatry, University of 

Buffalo, Buffalo, NY. 


BIOMARKERS OF CARDIOVASCULAR 

RISK IN NAVAJO POPULATIONS EXPOSED 

TO CONTAMINATED URANIUM MINING 

SITES. M. Harmon 1 , M. Channell 1 , M. Campen 1 , 

E. Erdei 2 , M. Downs 2 , B. Pacheco 2 , D. Malony 3 , M. 

Cajero 2 , J. DeGroat 2 , C. Shuey 4 , S. Henio-Adeky 4 , 

S. Ramone 4 , T. Nez 4 and J. Lewis 2 . 1 Pharmaceutical 

Sciences, University of New Mexico, Albuquerque, 

NM, 2 Community Environmental Health Program, 

University of New Mexico, Albuquerque, NM, 

3 

Nephrology, University of Texas Houston Medical 

Center, Houston, TX and 4 Southwest Research and 

Information Center, Albuquerque, NM. 


1:00 PM to 2:00 PM 

Room 156 

Exhibitor Hosted Session: Latest Advances in Arrhythmia 

Detection and in Non-Invasive Blood Pressure Monitoring 

from Ambulatory Animals 

Presented by: emka TECHNOLOGIES 

An alternative to implantable telemetry for measuring blood pressure (BP) 

in ambulatory animals, will be presented. We will explain how improvements 

in hardware and in software algorithms enabled higher efficiency 

and reliability in the noninvasive study of BP. Finally we will describe 

computerized methods that optimize efficiency and minimize resources in 

the detection of arrhythmia. 


1:00 PM to 2:00 PM 

Room 140B 

Exhibitor Hosted Session: The Marmoset As an Experimental 

Model for the Development of Biopharmaceuticals 

Presented by: RTC Research Toxicology Centre 

Pharmaceuticals are now often represented by biotechnology-derived products. 

For biopharmaceuticals NHP are usually the only relevant model. 

Marmosets with their small size and early sexual maturation represent an 

interesting alternative to macaque for toxicity testing and could speed up 

development, requiring a limited amount of product to start safety evaluation. 

262 






Platform Sessions



Abstract # 


1:00 PM to 2:00 PM 

Room 140A 

Exhibitor Hosted Session: Uses for Stereology in Toxicologic 

Pathology 

Presented by: WIL Research Laboratories 

Unbiased stereological analysis is required for documentation of shifts in 

neuronal and other cell populations as well as changes in lung parameters 

such as aleveolar counts and size estimations. This session will introduce 

the specialized terminology and basic mathematical and technical concepts 

involved in stereological sampling and analysis. 


1:30 PM to 4:15 PM 

Room 144 


Symposium Session: Developmental Origins of Adult Disease: 

The Effects of Low-Dose Lead 

Chairperson(s): Erin Hines, U.S. EPA, Research Triangle Park, NC, and 

Andrew Rooney, NIEHS, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




Numerous epidemiology and animal toxicology studies support an association 

between an adverse prenatal environment and the development of 

diseases in later life. Experimentally, prenatal exposure to lead (Pb) at low, 

environmentally-relevant doses causes physiological changes that increase 

the likelihood of diseases in adulthood such as obesity, hypertension, and 

neurological disorders. Although human epidemiological data also support 

an association between increased Pb exposure and hypertension or cognitive 

impairment, the exact mechanisms by which lead exerts these effects 

in epidemiologic studies is unknown. We will discuss experimental animal 

toxicology data that suggest several possible mechanisms for developmental 

origins of adult diseases (DOAD) associated with exposure to low levels 

of lead. Data support a sex-dependent mechanism resulting in increased 

fat deposition and late-onset obesity, retinal degeneration, and motor 

activity aberrations following low dose gestational lead exposure in male 

mice. Lead-induced hypothalamic pituitary adrenal axis dysfunction is a 

potential mechanism for a range of adult diseases and disorders, including 

hypertension, diabetes, metabolic syndrome, schizophrenia, and cognitive 

dysfunction. Epigenetic mechanisms have also been implicated, and 

epigenetic pathways may present a mechanistic link between developmental 

lead exposure and the etiology of Alzheimer’s disease. These data highlight 

the importance of exposure windows for the development of adverse health 

effects associated with low-level lead and have possible risk assessment 

implications for ongoing assessments such as the NTP Monograph on Low- 

Level Lead and the U.S. EPA Integrated Science Assessment for Lead. 

#1697 1:30 DEVELOPMENTAL ORIGINS OF ADULT 

DISEASE: THE EFFECT OF LOW-DOSE 

LEAD (PB). E. P. Hines 1 and A. Rooney 2 . 1 EMAG, 

NCEA, U.S. EPA, Research Triangle Park, NC 

and 2 National Toxicology Program, Center for the 

Evaluation of Risks to Human Reproduction, NIEHS, 


1:30 INTRODUCTION. Erin Hines 

Abstract # 

#1698 1:35 LOW-LEVEL GESTATIONAL LEAD 

EXPOSURE IS A RISK FACTOR FOR LATE- 

ONSET METABOLIC SYNDROME AND 

NEURODEGENERATION. D. A. Fox. University 

of Houston, Houston, TX. 

#1699 2:15 DEVELOPMENTAL LEAD (PB) 

EXPOSURE AND PERMANENT HPA 

AXIS DYSFUNCTION: A POTENTIAL 

UNIFYING BIOLOGICAL MECHANISM 

FOR PB-ASSOCIATED DISEASES AND 

DISORDERS. D. A. Cory-Slechta. Department of 

Environmental Medicine, University of Rochester 

Medical Center, Rochester, NY. 

#1700 2:55 EARLY LIFE EXPOSURE TO PB AND 

PROGRAMMED SUSCEPTIBILITY TO 

NEURODEGENERATIVE DISEASE. N. Zawia. 

Biomedical Sciences, University of Rhode Island, 

Kingston, RI. 

#1701 3:35 CONTRASTING THE DEVELOPMENTAL 

AND ADULT ORIGINS OF ADVERSE 

EFFECTS FROM LEAD IN THE DRAFT NTP 

MONOGRAPH ON LOW-LEVEL LEAD. A. 

A. Rooney. Center for the Evaluation of Risks to 

Human Reproduction, NIEHS, National Toxicology 

Program, Research Triangle Park, NC. 


1:30 PM to 4:15 PM 

Room 204 

Symposium Session: Does the Clock Make the Poison? 

Influence of the Circadian Clock on Toxicological 

Mechanisms and Outcomes 

Chairperson(s): Helmut Zarbl, University of Medicine and Dentistry New 

Jersey, Piscataway, NJ, and Louisa Hooven, Oregon State University, 

Corvallis, OR. 

Sponsor: 


Endorsed by: 


The daily biochemical, physiological, and behavioral activities of many 

organisms are synchronized by light/dark cycles. These temporal oscillations 

are maintained by the circadian clock, which has intrinsic periodicity 

of approximately 24 hours. The circadian rhythm of cells is controlled by 

the interaction of multiple positive and negative feedback loops comprising 

a molecular oscillator, which modulates expression through transcriptional 

and epigenetic means. Environmental and occupational exposures leading 

to disruption of circadian rhythm, including jet lag, light-at-night, and 

shift work are associated with an increased risk of endometriosis, breast 

cancer, and prostate cancer, prompting the International Agency for Cancer 

Research to classify shift work as a probable human carcinogen (type 2A). 

Disruption of the circadian clock is also associated with increased risk of 

cancer, cardiovascular disease, diabetes, obesity, reproductive problems, 

sleep disorders, drug and alcohol addiction, and psychiatric disorders. 

Accumulating evidence indicates that the dynamic influence of the circadian 

clock profoundly affects many critical pathways in toxicology. Exposure to 

stressors, carcinogens, chemotherapeutic agents, and other xenobiotics can 

alter circadian function in cells, rodents, and humans, while some chemopreventive 

agents my reset the rhythm. Targeted disruption of clock gene 

expression is advancing our ability to understand and manipulate the circadian 

clock. Our panel of experts will review the state of this emerging area 

and explore opportunities for disease prevention. 

Tuesday 







263



Tuesday 


#1702 1:30 DOES THE CLOCK MAKE THE POISON? 

INFLUENCE OF THE CIRCADIAN CLOCK 

ON TOXICOLOGICAL MECHANISMS AND 

OUTCOMES. H. Zarbl 1 and L. A. Hooven 2 . 

1 

Environmental and Occupational Health Sciences 

Institiute, Robert Wood Johnson Medical School, 

Piscataway, NJ and 2 Department of Zoology, Oregon 

State University, Portland, OR. 

1:30 INTRODUCTION. Helmut Zarbl 

#1703 1:35 ENVIRONMENTAL INFLUENCES 

UNCOUPLE PERIPHERAL CLOCKS FROM 

SCN CLOCKS. U. Schibler. Molecular Biology, 

University of Geneva, Geneva, Switzerland. Sponsor: 

H. Zarbl. 

#1704 2:00 TICK-TOXICOLOGY: CLOCK GENE 

EXPRESSION AND INTERACTIONS 

BETWEEN THE MOLECULAR PATHWAYS 

FOR THE REGULATION OF CIRCADIAN 

RHYTHMS, AND TOXIN METABOLISM. 

D. J. Earnest. Neuroscience and Experimental 

Therapeutics, Texas A&M Health Sciences Center, 

College Station, TX. Sponsor: H. Zarbl. 

#1705 2:25 THE HEPATOCYTE AUTONOMOUS CLOCK 

MODULATES THE CHRONOTOXICITY 

OF ACETAMINOPHEN. C. A. Bradfield 1 , J. 

A. Walisser 1 , B. P. Johnson 1 , Y. Liu 1 , A. Shen 1 , E. 

L. McDearmon 1 , B. McIntosh 1 , A. Vollrath 1 , A. 

C. Schook 2 and J. S. Takahashi 2 . 1 The McArdle 

Laboratory for Cancer Research, University of 

Wisconsin School of Medicine and Public Health, 

Madison, WI and 2 Northwestern Univeristy, 

Evanston, IL. 

#1706 2:50 CIRCADIAN EXPRESSION OF DRUG 

PROCESSING GENES IN MICE. C. D. 

Klaassen. Pharmacology, University of Kansas 


#1707 3:15 RELEVANCE OF CIRCADIAN DISRUPTION 

AND CIRCADIAN INDUCTION FOR 

CANCER CONTROL. F. Levi. Rhythmes 

Biologiques et Cancer, INSERM, Villejuif, France. 

Sponsor: H. Zarbl. 

#1708 3:40 METHYLSELENOCYSTEINE RESETS THE 

RHYTHMIC EXPRESSION OF CIRCADIAN 

AND GROWTH REGULATORY GENES 

DISRUPTED BY NITROSOMETHYLUREA 

IN VIVO. M. Fang and H. Zarbl. Environmental 

and Occupational Health Sciences Institiute, Robert 

Wood Johnson Medical School, Piscataway, NJ. 



1:30 PM to 4:15 PM 

Room 143 

Symposium Session: Macrophages: Regulators of Toxicity 

and Disease Pathogenesis 

Chairperson(s): Debra Laskin, Rutgers University, Piscataway, NJ, and 

Andrew Gow, Rutgers University, Piscataway, NJ. 

Sponsor: 


Endorsed by: 




Macrophages function as control switches of the immune system, providing 

a balance between pro- and anti-inflammatory responses. To accomplish 

this, they develop into different subsets: classically (M1) or alternatively 

(M2) activated macrophages. Whereas M1 macrophages display a cytotoxic, 

proinflammatory phenotype, M2 macrophages, suppress immune 

and inflammatory responses and participate in wound repair and angiogenesis. 

Critical to the actions of these divergent or polarized macrophage 

subpopulations is the regulated release of inflammatory mediators. When 

properly controlled, classically activated M1 macrophages effectively 

destroy invading pathogens, tumor cells, and foreign materials. However, 

when M1 activation becomes uncontrolled, these cells release excessive 

quantities of cytotoxic mediators that contribute to disease pathogenesis. 

The activity of M1 macrophages is countered by alternatively activated 

M2 macrophages which release mediators that down regulate M1 cells, and 

stimulate growth, extracellular matrix turnover, and tissue repair. Aberrant 

functioning of M2 macrophages can lead to fibrosis and tumor metastasis 

and progression. Ultimately, it is the balance in the production of mediators 

by these two cell types that determines the outcome of the tissue response to 

chemical toxicants and disease progression. These different models will be 

presented to illustrate this divergent role of macrophages in disease pathogenesis 

and toxicity. 

#1709 1:30 MACROPHAGES: REGULATORS OF 

TOXICITY AND DISEASE PATHOGENESIS. 

D. Laskin and A. Gow. Pharmacology and 


1:30 INTRODUCTION. Debra Laskin 

#1710 1:35 MACROPHAGES AND HEPATOTOXICITY: 

A BATTLE OF FORCES. D. Laskin 1 , C. 

Gardner 1 , Y. Liu 1 and J. Laskin 2 . 1 Pharmacology and 


2 

UMDNJ-RWJ Medical School, Piscataway, NJ. 

#1711 2:05 LUNG MACROPHAGE RESPONSES 

TO BIOACTIVE ENGINEERED 

NANOMATERIALS (ENM) INVOLVES 

ACTIVATION OF THE NLRP3 

INFLAMMASOME. A. Holian and C. Migliaccio. 

Center for Environmental Health Sciences, 

University of Montana, Missoula, MT. 

#1712 2:35 MACROPHAGE DIVERSITY AND 

POLARIZATION IN IMMUNOPATHOLOGY. 

A. Mantovani. Istituto Clinico Humanitas IRCCS, 

University of Milan, Milan, Italy. Sponsor: D. 

Laskin. 

#1713 3:05 MECHANISMS OF MICROGLIAL 

ACTIVATION IN RESPONSE TO 

TOXICANTS. A. Gow. Pharmacology and 


Sponsor: D. Laskin. 

264 






Platform Sessions



Abstract # 

#1714 3:35 MACROPHAGE DIVERSITY PROMOTES 

TUMOR PROGRESSION AND METASTASIS. 

J. W. Pollard. Department of Developmental and 

Molecular Biology, Albert Einstein College of 

Medicine Yeshiva University, New York. Sponsor: D. 

Laskin. 



1:30 PM to 4:15 PM 

Room 147 



Symposium Session: When Is Exposure Not Exposure? 

Defining the Dose-Response Region between “Effect” and 

“Adverse Effect” Implications for Human Health Risk 

Assessment 

Chairperson(s): Caroline English, NSF International, Ann Arbor, MI, and 

Edward Ohanian, U.S. EPA, Washington, D.C. 

Sponsor: 


Endorsed by: 


‘Omics technologies demonstrate global changes in gene regulation and 

expression following chemical exposure, causing toxicologists to revisit the 

question, what is an adverse effect and what isn’t. Dose-dependent transitions 

in genomic and related responses reflect the levels of exposure that 

cause detectable perturbations to the biological system under study. We 

will focus on two transitions, having both dose and temporal dimensions, 

which are advanced as being pivotal to understanding mode of action and 

prediction of toxicity. The first transition is from no-detectable-effect on the 

biological system relative to unexposed controls, to the first-perceptibleeffect 

at the global genome level; observed as up- and down-regulation 

of genes that regulate adaptive responses. The second transition is from 

the adaptive response region to the first adverse response or critical effect 

region of the dose-response relationship. We will explore if and how ‘omic 

phenomena elicited by chemical exposures translate into useful information 

for risk assessors. Consideration of the adaptive capacity of the biological 

system and severity of the effect might further inform our definition of 

the term adverse and inform the magnitude of traditional uncertainty 

factors used. Understanding dose-dependent transitions combined with 

dosimetry models that characterize the exposure-tissue concentration relationship 

might permit risk assessors to define exposures delimited by safe 

and adverse boundaries. We will conclude by describing emerging advances 

in high-throughput quantitative ‘omic technologies, and findings from 

studies with endogenous and exogenous compounds and nanoparticulates, to 

address how we move from the vast array of ‘omic data generated to practical 

risk assessment applications. 

#1715 1:30 WHEN IS EXPOSURE NOT EXPOSURE? 

DEFINING THE DOSE-RESPONSE REGION 

BETWEEN “EFFECT” AND “ADVERSE 

EFFECT” IMPLICATIONS FOR HUMAN 

HEALTH RISK ASSESSMENT. C. English. NSF 


1:30 INTRODUCTION. Caroline English 

#1716 1:39 USE OF THE HIERARCHICAL OXIDATIVE 

STRESS PARADIGM FOR HAZARD AND 

RISK ASSESSMENT IN RESPONSE TO 

AMBIENT ULTRAFINE AND ENGINEERED 

NANOPARTICLE TOXICITY. A. E. Nel. 

Medicine, University of California Los Angeles, Los 

Angeles, CA. Sponsor: A. Nel. 

Abstract # 

#1717 2:05 HUMAN EXPOSURE CONTEXT FOR 

NANOPARTICLE TOXICITY ASSESSMENT 

BY BIOLOGICAL PATHWAY BASED DOSE- 

RESPONSE MODELING. J. G. Teeguarden 1 , 

M. N. Costa 2 , K. M. Waters 2 and J. E. McDermott 2 . 

1 

Biological Monitoring and Modeling, Pacific 

Northwest National Laboratory, Richland, WA and 

2 

Computational Biology and Bioinformatics, Pacific 


#1718 2:31 TIME-DEPENDENT CHANGES IN THE 

TRANSCRIPTOME: AN APPROACH FOR 

IDENTIFYING TRANSCRIPTIONAL 

PROFILES ASSOCIATED WITH THE ONSET 

OF CHRONIC PHENOTYPIC CHANGES. 

D. C. Wolf. NHEERL/ORD, U. S. EPA, Research 


#1719 2:57 FORMALDEHYDE: DOSE-DEPENDENT 

TRANSITIONS FOR AN ENDOGENOUS 

COMPOUND WITH HIGH DOSE 

CARCINOGENICITY. M. E. Andersen. 

Computational Biology, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC. 

#1720 3:23 ENVIRONMENTAL EPIGENOMICS AND 

RISK ASSESSMENT: WHAT CONSTITUTES 

AN ADVERSE EFFECT AND ISSUES OF 

NONLINEARITY. D. C. Dolinoy. Environmental 

Health Sciences, University of Michigan, Ann Arbor, 

MI. 

#1721 3:49 INTERPRETING DOSE-RESPONSE 

INFORMATION ON INTERMEDIATE 

STAGES OF CAUSAL CASCADES IN 

TOXICITY MODE OF ACTION. L. R. 

Rhomberg. Gradient, Cambridge, MA. 


1:30 PM to 4:15 PM 

Room 150 

Workshop Session: Nonclinical to Clinical Abuse Liability 

Assessment of Drugs: Current Practices, Challenges, and 

Impact of Recent Regulatory Guidance 

Chairperson(s): Brian Gemzik, Bristol-Myers Squibb, Princeton, NJ, and 

Carrie Markgraf, Merck, Lafayette, NJ. 

Sponsor: 


Endorsed by: 



An increased level of attention has been focused on the assessment of abuse 

liability for drugs that affect the central nervous system as a consequence 

of recent regulatory guidances from the EMEA, ICH, as part of M3(R2), 

and U.S. FDA (draft). It is therefore critical to understand the current 

issues facing the pharmaceutical research and regulatory communities in 

the evaluation of new drug candidates for abuse and dependence potential. 

Nonclinical and clinical evaluations each contribute to the assessment of 

a drug for class scheduling, and to the information in the product label. 

Animal models for the study of drugs with pharmacologic mechanisms 

known to be associated with abuse are well characterized, and clinical trial 

protocols enrolling experienced users of abused drugs have been widely 

utilized in risk assessment. However, unique challenges are encountered 

in both nonclinical and clinical discovery and development settings when 

evaluating drugs with novel mechanisms of action. In recognition of the 

need for a broad and integrated understanding in the toxicology community, 

this symposium will blend current topics in this field of growing interest, 

Tuesday 







265



Tuesday 


and present the scientific background and challenges in the context of the 

emerging regulatory landscape. Speakers will discuss the translational 

aspects of nonclinical and clinical findings to regulatory and scheduling 

processes. Emphasis will be placed on presentation and discussion of issues, 

with specific examples, that bridge these areas of interest and enhance 

overall awareness of the topic. 

#1722 1:30 NONCLINICAL TO CLINICAL ABUSE 

LIABILITY ASSESSMENT OF DRUGS: 

CURRENT PRACTICES, CHALLENGES, 

AND IMPACT OF RECENT REGULATORY 

GUIDANCES. B. Gemzik. Discovery Toxicology, 

Bristol-Myers Squibb Company, Princeton, NJ. 

1:30 INTRODUCTION. Brian Gemzik 

#1723 1:35 NEUROPHARMACOLOGY OF DRUGS 

OF ABUSE AND IMPLICATIONS ACROSS 

DIVERSE DRUG DISCOVERY PROGRAMS. 

D. R. Compton. Preclinical Safety - Toxicology, 

sanofi-aventis U.S. Inc., Bridgewater, NJ. Sponsor: 

B. Gemzik. 

#1724 2:05 ANIMAL MODELS FOR ASSESSMENT OF 

ABUSE POTENTIAL: TRNSLATION TO 

CLINICAL EVALUATION. M. J. Kallman. 

Covance Inc., Greenfield, IN. 

#1725 2:35 DESIGN AND INTERPRETATION OF 

CLINICAL TRIALS EVALUATING ABUSE 

POTENTIAL OF DRUGS: WHERE ARE 

THE GAPS? M. Sokolowska. Grünenthal USA, 

Bedminster, NJ. Sponsor: B. Gemzik. 

#1726 3:05 CURRENT CHALLENGES IN ABUSE 

LIABILITY ASSESSMENT: DRUGS WITH 

NOVEL MECHANISMS OF ACTION. K. E. 

Cannon. Global Safety Pharmacology CoE, Pfizer, 

Inc., Groton, CT. Sponsor: T. Brabham. 

#1727 3:35 REGULATORY AND SCHEDULING: 

PROCESSES AND CURRENT CONCERNS. 

M. Klein. CDER, U.S. FDA, Silver Spring, MD. 

Sponsor: B. Gemzik. 



1:30 PM to 4:15 PM 

Room 207 


Workshop Session: Risk Assessment for Proteins Introduced 

into Genetically Modified Crops 

Chairperson(s): Bruce Hammond, Monsanto Company, St. Louis, MO, 

and Joseph Jez, The Donald Danforth Plant Science Center, St. Louis, 

MO. 

safe use (HOSU) in food. For registration of GM crops in Europe, if there 

is no reliable safety information, IP without a HOSU must be tested in a 28 

day repeat dose toxicity study. Thus we will explore appropriate information 

that might resolve safety concerns for IP without a HOSU. Advances in the 

field of molecular biology over the last 30 years have increased our ability 

to modify the structure, stability, and activity of proteins of interest. These 

modified proteins may not have a HOSU. However, absence of HOSU 

does not mean absence of safety. Protein engineering and evolution studies 

suggest that changes in amino acid sequences of proteins not related to those 

with known toxicological hazards (i.e., toxins or allergens) will not make a 

protein potentially hazardous de novo. Modifications often exert little effect 

on biological function, and some substitutions are deleterious to protein 

structure and function. In regards to dietary risk assessment of proteins 

introduced into GM crops, risk assessors have generally made the highly 

conservative assumption that the IP remains functionally intact during the 

processing of the crop into human food fractions. However for crops such 

as corn or soy which are extensively processed, the IP that have been tested 

do not survive processing functionally intact. This information could be 

relevant to resolving concerns about the safety of IP that do not have a 

HOSU. However, if the IP is related to known mammalian toxins, remains 

functionally intact after processing or is not susceptible to digestion, then 

further toxicology testing may be needed. 

#1728 1:30 RISK ASSESSMENT FOR PROTEINS 

INTRODUCED INTO GENETICALLY 

MODIFIED (GM) CROPS. B. G. Hammond. 

Product Safety Center, Monsanto Company, St. 

Louis, MO. 

1:30 INTRODUCTION. Bruce Hammond 

#1729 1:35 NATURE’S BALANCING ACT: 

EVOLUTIONARY CHANGES IN PROTEIN 

FAMILIES. J. M. Jez. The Donald Danforth 

Plant Science Center, St. Louis, MO. Sponsor: B. 

Hammond. 

#1730 2:07 ENGINEERING PROTEINS TO IMPROVE 

BIOLOGICAL FUNCTION. S. J. Franklin. 

Protein Technologies, Monsanto Company, 

Cambridge, MA. Sponsor: B. Hammond. 

#1731 2:39 SAFETY ASSESSMENT OF NOVEL 

PROTEINS. J. L. Kough. Biopesticides and 

Pollution Protection Division, Office of Pesticide 

Programs, U.S. EPA, Washington, D.C. Sponsor: B. 

Hammond. 

#1732 3:11 EFSA’S UPDATED STRATEGY FOR THE 

RISK ASSESSMENT OF GM PLANTS AND 

DERIVED FOOD/FEED. H. A. Kuiper. Chair 

EFSA GMO Panel, European Food Safety Agency 

(EFSA), Parma, Italy. Sponsor: B. Hammond. 

#1733 3:43 RISK ASSESSMENT RECOMMENDATIONS 

FOR INTRODUCED PROTEINS. B. G. 

Hammond. Product Safety Center, Monsanto 

Company, Saint Louis, MO. 

Sponsor: 


Endorsed by: 



In 2009, there was 330 million acres of genetically modified (GM) crops 

planted in 25 countries. Despite rapid adoption, planting of GM crops 

remains controversial in some countries. GM crops undergo comprehensive 

food safety assessment before commercialization. This includes proteins 

introduced into the crop to achieve desired technical effects. One of the 

safety questions asked is if the introduced proteins (IP) have a history of 

266 






Platform Sessions



Abstract # 


1:30 PM to 4:15 PM 

Room 151 

Workshop Session: The Spectrum of Systems Biology 

Chairperson(s): William Mattes, PharmPoint Consulting, Poolesville, 

MD, and Lyle Burgoon, U.S. EPA, Durham, NC. 

Sponsor: 


Endorsed by: 


What is Systems Biology? While being hailed as the most promising 

approach for creating breakthroughs in scientific understanding in the wake 

of the ‘omics crush, systems biology is a phrase used to describe a multitude 

of approaches to understanding and/or predicting biological responses to 

stimuli. Decades ago systems biology invoked quantitative metabolic flux 

modeling, while today it is used to describe pathway analysis of ‘omic 

data, quantitative signaling network modeling, the integration of multiple 

‘omic data, and many other approaches. Our panel of experts are poised to 

discuss their divergent views of systems biology and will describe how their 

research addresses a holistic solution to biologic data. Before concluding a 

panel discussion will convene that will provide a more global (i.e., systems) 

view of systems biology. 

#1734 1:30 THE SPECTRUM OF SYSTEMS BIOLOGY. 

L. Burgoon 1 and W. Mattes 2 . 1 U.S. EPA, Durham, NC 

and 2 PharmPoint Consulting, Poolesville, MD. 

#1735 1:35 BIOSIMULATION OF DRUG-INDUCED 

LIVER INJURY. H. J. Clewell 1 , B. A. Howell 1 , Y. 

Yang 1 , S. Q. Siler 2 , R. Ho 2 , R. Kumar 2 , A. H. Harrill 1 , 

M. E. Andersen 1 and P. B. Watkins 1 . 1 The Hamner 


Park, NC and 2 Entelos, Inc., Foster City, CA. 

#1736 2:07 DEFINING SYSTEMS BIOLOGY IN A MODE- 

OF-ACTION CONTEXT. S. Edwards. U.S. EPA, 


#1737 2:39 PHARMGKB: THE PHARMCOGENOMICS 

KNOWLEDGE BASE. T. E. Klein. Department 

of Genetics, Stanford University Medical Center, 

Stanford, CA. Sponsor: L. Burgoon. 

#1738 3:11 THE INTERSECTOME: INTEGRATION OF 

KNOWLEDGE IN SYSTEMS BIOLOGY FOR 

HYPOTHESIS GENERATION. A. Ma’ayan. 

Pharmacology and Systems Therapeutics, Mount 

Sinai School of Medicine, New York. Sponsor: L. 

Burgoon. 

#1739 3:43 INTEGRATED ANALYSIS OF DISTINCT 

MOLECULAR AND PHENOTYPIC DATA 

TYPES IN XENOBIOTIC RESPONSE 

MODELING. R. J. Brennan. Toxicology, GeneGo 

Inc., San Jose, CA. 

Abstract # 


1:30 PM to 4:15 PM 

Room 202B 



Platform Session: Application of Zebrafish Models in 


Chairperson(s): Robert Chapin, Pfizer Global Research and 

Development, Groton, CT, and Colleen Doshna, Pfizer Inc., Groton, CT. 

#1740 1:30 ZEBRAFISH: A PREDICTIVE MODEL FOR 

ASSESSING CANCER DRUG-INDUCED 

ORGAN TOXICITY. L. D’Amico 1 , C. Li 1 , E. 

Glaze 2 , M. Davis 2 and W. L. Seng 2 . 1 Phylonix, 

Cambridge, MA and 2 NCI, NIH, Bethesda, MD. 

Sponsor: P. McGrath. 

#1741 1:51 MANIPULATION OF THE WNT/β-CATENIN 

PATHWAY BY PROTOTYPIC INHIBITORS 

COMPARED TO MORPHOLINO 

KNOCKDOWN IN ZEBRAFISH. S. M. Eddy, 

D. B. Stedman and M. D. Aleo. Drug Safety, Pfizer 

Global Research and Development, Groton, CT. 

#1742 2:12 ASSESSMENT OF DRUG-INDUCED 

SEIZURE-LIKE MOVEMENT IN 

ZEBRAFISH. D. Park, J. Meidenbauer, W. L. Seng 

and P. McGrath. Phylonix, Cambridge, MA. 

#1743 2:33 VALIDATION OF AN AUTOMATED 

SCREENING ASSAY BASED IN A 

ZEBRAFISH MODEL FOR THE DETECTION 

OF COMPOUNDS THAT INHIBIT 

ANGIOGENESIS. C. Quevedo, C. Callol and 

A. Letamendia. Scientific, Biobide, San Sebastian, 

Guipuzkoa, Spain. Sponsor: S. Tripathi. 

#1744 2:54 THE EFFECTS OF CHEMICALS IN 

THE U.S. EPA’S TOXCAST LIBRARY 

ON CAENORHABDITIS ELEGANS AND 

ZEBRAFISH DEVELOPMENT. W. A. Boyd 1 , M. 

V. Smith 2 and J. H. Freedman 1 . 1 NIEHS, Durham, 

NC and 2 SRA International, Durham, NC. 

#1745 3:15 A PROTEOMIC ANALYSIS OF ARSENIC 

EXPOSED ZEBRAFISH (DANIO RERIO) 

SUGGESTS ALTERED LIPID METABOLISM. 

P. Carlson 1 and R. J. Van Beneden 1 , 2 . 1 Graduate 

School of Biomedical Sciences, University of 

Maine, Orono, ME and 2 School of Marine Sciences, 

University of Maine, Orono, ME. Sponsor: G. 

Mayer. 

#1746 3:35 LOCALIZATION OF MEGALIN ALONG 

ZEBRAFISH LATERAL LINE. C. Doshna 1 , C. 

Nykyforchyn 2 , P. Burch 1 and M. D. Aleo 1 . 1 DSRD, 

Pfizer, Groton, CT and 2 University of CT, Storrs, CT. 

#1747 3:55 PERSISTENT LIFE HISTORY EFFECTS OF 

ATRAZINE EXPOSURE IN ZEBRAFISH: 

A MULTI-GENERATIONAL STUDY 

ENCOMPASSING GENE EXPRESSION, 

FITNESS, AND EPIGENETIC EFFECTS. S. 

Lewis 1 , G. J. Weber 2 , S. M. Peterson 2 , J. L. Freeman 2 

and M. S. Sepulveda 1 . 1 Forestry and Natural 

Resources, Purdue University, West Lafayette, IN 

and 2 School of Health Sciences, Purdue University, 

West Lafayette, IN. 

Tuesday 







267



Tuesday 



1:30 PM to 4:15 PM 

Room 145 

Platform Session: Chemical and Biological Weapons—Sulfur 

Mustard Effects 

Chairperson(s): JeanClare Seagrave, Lovelace Respiratory Research 

Institute, Albuquerque, NM, and Gunda Reddy, U.S. Army-CHPPM, 


#1748 1:30 MOLECULAR EVALUATION OF RABBIT 

CORNEAL OCULAR SULFUR MUSTARD 

INJURY: TOWARDS MECHANISMS OF 

PERSISTENT INJURY. D. Milhorn 2 , P. McNutt 1 , 

T. Hamilton 1 and R. Lawrence 1 . 1 USAMRICD, 

Aberdeen Proving Ground- Edgewood Area, MD 

and 2 Medical Research and Materiel Command, Fort 

Detrick, MD. Sponsor: G. Rockwood. 

#1749 1:49 INDUCTION OF AUTOPHAGY IN A MOUSE 

KERATINOCYTE CONSTRUCT MODEL BY 

THE VESICANT 2-CHLOROETHYL ETHYL 

SULFIDE; REGULATION BY MAP KINASES 

AND CAVEOLAE. A. T. Black 1 , R. P. Casillas 2 , 

D. E. Heck 3 , D. R. Gerecke 1 , D. L. Laskin 1 and J. 

D. Laskin 4 . 1 Rutgers University, Piscataway, NJ, 

2 

Battelle Biomedical Research Center, Columbus, 

OH, 3 New York Medical College, Valhalla, NY and 

4 


#1750 2:08 ROLE OF CAVEOLAE IN REGULATING 

EXPRESSION OF HSP27 AND HSP70 

FOLLOWING EXPOSURE OF HUMAN AND 

MOUSE SKIN MODELS TO THE VESICANT 

2-CHLOROETHYL ETHYL SULFIDE. J. D. 

Laskin 1 , A. T. Black 2 , P. J. Hayden 3 , R. P. Casillas 4 , 

D. E. Heck 5 , D. R. Gerecke 2 and D. L. Laskin 2 . 

1 


Piscataway, NJ, 2 Rutgers University, Piscataway, 

NJ, 3 MatTek Corporation, Ashland, MA, 4 Batelle 

Memorial Institute, Columbus, OH and 5 New York 

Medical College, Valhalla, NY. 

#1751 2:27 SULFUR MUSTARD VAPORS INDUCE DNA 

DAMAGE AND APOPTOSIS IN MOUSE 

SKIN. L. B. Joseph 1 , D. R. Gerecke 1 , A. T. Black 1 , R. 

P. Casillas 2 , N. D. Heindel 3 , P. J. Sinko 1 , D. E. Heck 4 , 

D. L. Laskin 1 and J. D. Laskin 5 . 1 Rutgers University, 

Piscataway, NJ, 2 Battelle, Columbus, OH, 3 Lehigh 

University, Bethlehem, PA, 4 New York Medical 

College, Valhalla, NY and 5 UMDNJ-Robert Wood 

Johnson Medical School, Piscataway, NJ. 

#1752 2:45 MECHANISMS OF VESICANT-INDUCED 

CYTOTOXICITY IN LUNG EPITHELIAL 

CELLS. Y. Wang 1 , D. E. Heck 3 , D. L. Laskin 2 

and J. D. Laskin 1 . 1 Environmental & Occupational 


School, Piscataway, NJ, 2 Pharmacology & 


3 

Environmental Health Sciences, New York Medical 

College, Valhalla, NY. 

#1753 3:03 HOUSEKEEPING GENE EXPRESSION 

IN NORMAL HUMAN EPIDERMAL 

KERATINOCYTES IS ALTERED BY SULFUR 

MUSTARD EXPOSURE. S. L. Beach, J. F. 

Dillman and A. L. Ruff. U.S. Army Medical Research 

Institute of Chemical Defense, Aberdeen Proving 

Ground, MD. 

#1754 3:21 DEVELOPMENT OF A SULFUR MUSTARD 

NON-HUMAN PRIMATE INHALATION 

EXPOSURE MODEL. W. M. Weber, J. D. 

McDonald, L. F. Blair, M. R. Lehman, D. A. Kracko, 

C. Cox, M. Duncan, J. Baldwin, J. Seagrave, T. 

March and G. R. Grotendorst. Lovelace Respiratory 

Research Institute, Albuquerque, NM. 

#1755 3:39 A TOXICOLOGICAL, BIOCHEMICAL, AND 

PHYSIOLOGICAL ASSESSMENT OF LUNG 

AND SYSTEMIC INJURY IN RATS EXPOSED 

TO INHALED SULFUR MUSTARD ACROSS 

DOSE AND TIME. D. S. Olivera 1 , K. A. Whitten 2 , 

R. K. Kan 3 , J. L. Collins 1 , J. B. Simons 1 , A. M. 

Rodriguez 1 , C. M. Bowens 1 , A. M. Witriol 1 and A. 

M. Sciuto 1 . 1 Analytical Toxicology, USAMRICD, 

Gunpowder, MD, 2 Research Support, USAMRICD, 

Gunpowder, MD and 3 Research, USAMRICD, 

Gunpowder, MD. 

#1756 3:57 THERAPEUTIC EFFICACY OF 

CATALYTIC ANTIOXIDANT AEOL 10150 

IN ATTENUATING SULFUR MUSTARD 

ANALOG 2-CHLOROETHYL ETHYL 

SULFIDE-INDUCED SKIN INJURY. N. 

Tewari-Singh 1 , A. K. Jain 1 , S. Inturi 1 , M. Gu 1 , C. 

Agarwal 1 , B. J. Day 2 , C. W. White 3 and R. Agarwal 1 . 

1 

Pharmaceutical Sciences, University of Colorado 

Denver, Aurora, CO, 2 Medicine, National Jewish 

Health, Denver, CO and 3 Pediatrics, National Jewish 

Health, Denver, CO. 


1:30 PM to 4:15 PM 

Room 202A 

Platform Session: Nanotoxicology—Nanosilver Particulates 

Chairperson(s): David Barber, University of Florida, Gainesville, FL, 

and William Waissmann, Oswaldo Cruz Foundation, Rio de Janeiro, 

Brazil. 

#1757 1:30 NANOSILVER MOVEMENT THROUGH 

BIOLOGICAL BARRIERS RELATES TO 

PHYSICOCHEMICAL PROPERTIES. B. 

Veronesi 1 , N. Nazo 1 , A. Tennant 1 , S. Simmons 1 , B. 

Baruwati 2 and R. Varma 2 . 1 NHEERL-ISTD, U.S. 

EPA, Research Triangle Park, NC and 2 NRMRL- 

STD, U.S. EPA, Cincinnati, OH. 

#1758 1:51 TOXICITY, CELLULAR UPTAKE, AND 

DIFFERENTIATION OF HUMAN ADULT 

STEM CELLS EXPOSED TO SILVER 

NANOPARTICLES. M. E. Samberg 1,2 , 

E. G. Loboa 2 and N. A. Monteiro-Riviere 1,2 . 

1 



Raleigh, North Carolina and 2 Joint Department of 

Biomedical Engineering at North Carolina State 

University and University of North Carolina at 

Chapel Hill, North Carolina State University, 

Raleigh, NC. 

#1759 2:12 PULMONARY TOXICITY FOLLOWING 

INTRATRACHEAL INSTILLATION OF 

DISPERSED SILVER NANOPARTICLES 

IN RATS. J. R. Roberts 1 , R. S. Chapman 1 , S. 

Young 1 , A. Kenyon 1 , D. Schwegler-Berry 1 , A. B. 

Stefaniak 2 , B. T. Chen 1 and J. M. Antonini 1 . 1 HELD, 

NIOSH, Morgantown, WV and 2 DRDS, NIOSH, 


268 






Platform Sessions



Abstract # 

#1760 2:33 OPTIMIZATION OF HIGH-THROUGHPUT 

NANOMATERIAL DEVELOPMENTAL 

TOXICITY TESTING IN ZEBRAFISH 

EMBRYOS. A. Wang 1 , C. Matson 2 , S. Frady 1 , M. 

Arnold 2 , S. Padilla 3 , R. T. Di Giulio 2 and K. Houck 1 . 

1 

National Center for Computational Toxicology, U.S. 

EPA, Research Triangle Park, NC, 2 Center for the 

Environmental Implications of NanoTechnology, 

Duke University, Durham, NC and 3 ISTD, NHEERL, 


#1761 2:54 TOXICITY OF INTRANASALLY- 

ADMINISTERED SILVER NANOPARTICLES. 

M. Genter 1 , N. C. Newman 1 , H. G. Shertzer 1 , S. F. 

Ali 2 , S. M. Hussain 3 and B. Bolon 4 . 1 Environmental 

Health, University of Cincinnati, Cincinnati, 

OH, 2 Neurochemistry Laboratory, Division of 

Neurotoxicology, NCTR/U.S. FDA, Jefferson, 

AR, 3 Applied Biotechnology Branch, AFRL, 

Wright-Patterson AFB, Dayton, OH and 4 GEMpath, 

Longmont, CO. 

#1762 3:15 RECOVERY FROM SILVER 

NANOPARTICLE EXPOSURE-INDUCED 

LUNG FUNCTION CHANGES IN SPRAGUE- 

DAWLEY RATS. I. Yu 1 , J. Sung 2 , J. Ji 3 , K. Song 2 , 

J. Lee 1 , J. Lee 4 , J. Park 5 , H. Park 6 , C. Kang 1 and 

K. Ahn 7 . 1 Hoseo University, Asan, Republic of 

Korea, 2 Korea Conformity Laboratories, Incheon, 

Republic of Korea, 3 Samung Electronics, Ltd., 

Suwon, Republic of Korea, 4 Occupational Lung 

Diseases Institute, COMWEL, Ansan, Republic of 

Korea, 5 Chung-Ang University, Seoul, Republic of 

Korea, 6 Korea Research Institute of Standards and 

Science, Daejeon, Republic of Korea and 7 Hanyang 


#1763 3:35 CLEARANCE OF ACCUMULATED 

SILVER AFTER CESSATION OF SILVER 

NANOPARTICLE (AGNP) EXPOSURE IN 

TISSUES OF SPRAGUE-DAWLEY RATS. 

J. Lee 1 , I. Yu 1 , Y. Kim 2 , K. Song 3 , H. Ryu 3 , J. 

Sung 3 , M. Kwon 1 , J. Park 4 , J. Lee 5 , H. Park 6 , C. 

Kang 1 and D. Marshak 7 . 1 Hoseo University, Asan, 

Republic of Korea, 2 KT&G, Daejeon, Republic of 

Korea, 3 Korea Conformity Laboratories, Incheon, 

Republic of Korea, 4 Chung-Ang University, Seoul, 

Republic of Korea, 5 Occupational Lung Diseases 

Institute, COMWEL, Ansan, Republic of Korea, 

6 

Korea Research Institute of Standards and Science, 

Daejeon, Republic of Korea and 7 PerkinElmer, 

Boston, MA. 

#1764 3:55 PREMATURE CELLULAR SENESCENCE- 

INDUCED BY NANOPARTICLE EXPOSURE: 

A NOVEL APPROACH TO NANOTOXICITY 

TESTING. D. Ellis and S. Hussain. Air Force 

Research Laboratory 711 HPW/RHPBA, Wright- 

Patterson AFB, OH. 


2:15 PM to 3:15 PM 

Room 140B 

Exhibitor Hosted Session: Automated GLP Infusion Studies: 

Improved Process Quality and Labor Utilization 

Presented by: Instech Solomon 

GLP infusion studies, rife with high labor content and opportunities for 

quality improvement, present a classic automation opportunity. This session 

describes the costs (investment) and benefits (reduced labor and improved 

process data quality) of moving from manual to Part 11 compatible automated 

processes. 

Abstract # 


2:15 PM to 3:15 PM 

Room 140A 

Exhibitor Hosted Session: Machine Learning and Exposure 

to Modeling in the Prediction of In Vivo Toxicity from High 

Content Screening (HCS) Data 

Presented by: Cyprotex Discovery 

High content screening (HCS) is a powerful tool for generating insight into 

changes arising from exposure of cells to potentially toxic xenobiotics. 

Linking these changes to in vivo toxic responses enables the creation of 

predictive models for in vivo drug-mediated toxicity. In this presentation, 

novel developments in modeling of drug-induced hepatotoxicity from HCS 

data will be described. 


2:15 PM to 3:15 PM 

Room 156 

Exhibitor Hosted Session: Predictive Analysis of Cell 

Viability, Apoptosis and ADME/Tox Properties Using 

Multiparametric In Vitro Assays and Human Induced 

Pluripotent Stem (iPS) Cell-Derived Cardiomyocytes and 

Hepatocytes 

Presented by: Promega Corporation 

This seminar will highlight the use of multiplexed bioluminescent and fluorescent 

cell-based assays with human iPS cell-derived cardiomyocytes and 

hepatocytes that offer a powerful new approach to predictive analysis of cell 

viability, apoptosis and ADME/Tox properties while enabling streamlined 

data collection, high data quality and robust interpretation with biologically 

relevant human cell model systems. 


3:00 PM to 4:15 PM 

CC Room 103 

Undergraduate Faculty Meeting 

Chairperson(s): Aaron Barchawsky, University of Pittsburgh, 


Sponsor: 


The Education Committee and the Undergraduate Education Subcommittee 

are hosting the Undergraduate Toxicology Faculty Meeting for all 

faculty involved in the teaching of toxicology to undergraduates, or for 

those interested in including toxicology at the undergraduate level. Hear 

an update on initiatives for undergraduate faculty, provide your input, and 

network. 


3:30 PM to 4:30 PM 

Room 140B 

Exhibitor Hosted Session: Cryopreserved HepaRG: An 

Alternative In Vitro Screening Tool for Human Hepatic Drug 

Metabolism, and Safety Applications 

Presented by: Life Technologies 

The use of primary human hepatoxytes in screening applications is limited 

by tissue availability, donor variability, cost and a relative short lifespan in 

culture. The use of HepaRG cells solves these limitations without sacrificing 

many of the critical hepatocyte traits such as drug metabolizing enzyme 

expression, functional transport proteins, and expression of key nuclear 

receptor pathways. 

Tuesday 







269





3:30 PM to 4:30 PM 

Room 156 

Exhibitor Hosted Session: HepaRG, Novel Human Hepatic 

Cells for In Vitro Tox 

Presented by: Biopredic Inc 

Biologics present an ongoing challenge to both PK/PD assessment and 

safety/immunotoxic effects. This session will discuss issues around assay 

development, impact of immunogenicity on PK/efficacy, and risk-based 

approach to determine what, if any, additional safety immune-based 

endpoints should be assessed. 

Notes 


3:30 PM to 4:30 PM 

Room 140A 

Exhibitor Hosted Session: The Use of Minipigs in the 

Development of New Medicines 

Presented by: Ellegaard Göttingen Minipigs A/S 

This session provides an overview of marketed drug products where minipigs 

were used for safety and/or efficacy assessment. General trends of use 

are identified, furthermore its predictivity towards select clinical adverse 

reactions is evaluated. 

Tuesday 


4:30 PM to 6:00 PM 

Room 207 

(SOT Members Only) 

50th Anniversary Member Celebration Meeting 

All members are invited to celebrate the Society’s first 50 years of 

accomplishments. This fun event will highlight the history and growth 

of the Society over the past 50 years recognizing the members who are 

responsible for the Society’s success. Come see what is going in the Time 

Capsule that will be opened in 2036 by future SOT members. Receive 

your copy of The Society of Toxicology: The First Fifty Years. 

Tuesday Evening, March 8 

6:30 PM to 9:30 PM 



Tuesday Evening 

50th Anniversary Celebration Event 

Come celebrate the 50th Anniversary in style. Dance the night away with 

tunes from the Beatles as preformed by BeatleMania Live. Dress in your 

favorite decade’s attire (60’s to the future)! Additional entertainment plans 

include festive decorations, games, delicious food stations, and beverages. 

This is truly an event you will not want to miss! All tickets will be sold on 

a first-come, first-served basis and are non-refundable after February 11, 

2011. 

270 






Platform Sessions



Abstract # 

Wednesday Morning, March 9 

6:30 AM to 7:50 AM 

Room 147 

Wednesday Morning 

Historical Highlights Session: 50 Years of “the Pill”: Risk 

Reduction and Discovery of Benefits Beyond Contraception 

Chairperson(s): Brinda Mahadevan, Abbott Laboratories, Abbott Park, 

IL, and Kristina Chadwick, Bristol-Myers Squibb, New Brunswick, NJ. 

Sponsor: 


Endorsed by: 




Widely regarded as a revolutionary drug in its early years, “the pill” might 

retrospectively be considered as the first designer or lifestyle drug. Since the 

introduction of oral contraceptives (OCs) in the 1960s, both health benefits 

and safety concerns have been attributed to their use. In most instances, 

the non-contraceptive benefits of OCs outweigh the potential risks. OCs 

are highly effective, safe, and widely used; approximately 85% of women 

in the United States will use an OC for an average of five years. However, 

widespread use of OC formulations by women throughout their reproductive 

life cycle has given rise to concerns about the effects of OCs on risk factors 

for coronary heart disease. As with many drug firsts, many lessons can be 

learned from its development and use. Indeed, “the pill” played a significant 

role in reshaping pharmacology, social perceptions of medication, and 

the regulatory process for new drugs during the second half of the 20th 

century. In addition to the history and side effects/toxicity of OCs, the noncontraceptive 

health benefits that women experience that expand far beyond 

pregnancy prevention will be illuminated. 

#1765 6:30 50 YEARS OF “THE PILL”: RISK 

REDUCTION AND DISCOVERY OF 

BENEFITS BEYOND CONTRACEPTION. B. 

Mahadevan 1 , K. D. Chadwick 2 , R. T. Burkman 3 and 

D. Nicholson 4 . 1 Abbott Laboratories, Abbott Park, 

IL, 2 Drug Safety Evaluation, Bristol-Myers Squibb, 

New Brunswick, NJ, 3 Department of Obstetrics and 

Gynecology, Tufts University School of Medicine, 

Springfield, MA and 4 Worldwide Licensing 

and Knowledge Management, Merck Research 

Laboratories, Rahway, NJ. 

6:30 INTRODUCTION. Brinda Mahadevan 

6:35 “THE PILL”: HISTORICAL OVERVIEW 

1961–2011. Kristina D. Chadwick 

6:55 ORAL CONTRACEPTIVES: A 50 

YEAR EXPERIENCE OF OVERALL 

CARDIOVASCULAR SAFETY. Ronald T. 

Burkman 

7:15 NOVEL APPROACHES FOR 

CONTRACEPTION: REFLECTIONS AND 

FORECAST. Belen M. Tornesi 


Abstract # 


6:30 AM to 7:50 AM 

Room 145 




Informational Session: Precision Cut Tissue Slices Revisited: 

A Classical Method Meets New Challenges 

Chairperson(s): Armin Wolf, Novartis Institutes of Biomedical Research 

(NIBR), Basel, Switzerland, and Alison E. Vickers, Allergan, Irvine, CA. 

Sponsor: 


Endorsed by: 



The understanding of the underlying mechanisms of a potential drug safety 

liability and the prediction of a potential risk to man is important from a 

safety and regulatory perspective. Significant progress in molecular and 

cellular biology has lead to in vitro models being applied for this purpose. 

Precision-cut organ slices is an outstanding in vitro model, which maintains 

the in vivo tissue organization, contains all in vivo relevant cell types, 

architecture and functional heterogeneity. Historically, organ slice cultures 

have been applied to study drug metabolism, pharmacology, and compound 

toxicity. Recently, it has been used to provide information on immune and 

inflammatory responses, provide insight into pathways of organ injury, 

assess the involvement of specific cell types in toxicity, and differentiate 

between species specific responses, thus furthering our understanding in 

predicting human toxicities and their underlying mechanisms. We will 

review this latest state-of-the-art use of this technology by providing a 

forum for the users of precision-cut slices to share their experiences. Our 

panel of experts will discuss the strengths, opportunities, and limitations of 

the model to evaluate target organ toxicities. A focal point of our discussions 

will be the use of slice technology used as a predictive tool in drug development 

and bridging compound-related safety from different animal species 

to man. We will provide an overview of the innovative use of toxicity 

endpoints, functional markers, and demonstrate the use of the model for 

tailor-made assessment of mechanisms of drug-induced target organ toxicity. 

#1766 6:30 PRECISION-CUT TISSUE SLICES 

REVISITED: A CLASSICAL METHOD 

MEETS NEW CHALLENGES. A. Wolf 1 , 

A. Vickers 2 , P. Olinga 3 , A. Braun 5 , C. Martin 6 , 

G. Groothuis 7 and N. Shangari 4 . 1 Investigative 

Toxicology (iTOX), Novartis Institutes of 

Biomedical Research (NIBR), Basel, Switzerland, 

2 

Investigative Sciences, Allergan Inc., Irvine, CA, 

3 

GUIDE, University of Netherlands, Groningen 

Area, Netherlands, 4 iTOX, NIBR, East Hanover, 

NJ, 5 Department of Immunology, Allergology and 

Immunotoxicology, Fraunhofer Institute, Hanover, 

Germany, 6 Department of Pharmacology and 

Toxicology, RWTH Aachen, Aachen, Germany and 

7 

GUIDE, University of Netherlands, Groningen Area, 

Netherlands. 

6:30 INTRODUCTION. Armin Wolf 

6:35 MECHANISTIC INSIGHT INTO DRUG- 

INDUCED ORGAN INJURY WITH 

COMPARISONS OF ANIMAL AND HUMAN 

TISSUE. Alison E. Vickers 

6:45 TOXICOGENOMIC STUDIES IN HUMAN 

AND RAT PRECISION-CUT LIVER SLICES. 

Peter Olinga 

Wednesday 







271



Wednesday 


6:55 USE OF PRECISION-CUT LIVER SLICE 

CULTURES TO STUDY KUPFFER CELL- 

MEDIATED DRUG TOXICITY. Nandita 

Shangari 

7:05 EX VIVO LUNG CULTURE MODELS TO 

STUDY RESPIRATORY INFLAMMATION 

AND THEIR RELEVANCE FOR IN VIVO. 

Armin Braun 

7:15 CROSS-SPECIES COMPARISON 

ON PHARMACOLOGICAL AND 

TOXICOLOGICAL ACTIVITIES IN 

PRECISION-CUT LUNG SLICES. Christian 

Martin 

7:25 CROSS-SPECIES COMPARISON OF 

DRUG METABOLISM AND TOXICITY IN 

INTESTINAL SLICES. Genny M. Groothuis 



6:30 AM to 7:50 AM 

Room 150 



Informational Session: The Application of the Threshold 

of Toxicological Concern Concept to the Preclinical Safety 

Assessment of Non-Pharmaceutical Medical Products, 

Including Medical Devices and Combination Drug-Device 

Products 

Chairperson(s): Richard W. Hutchinson, Johnson & Johnson: Ethicon, 

Somerville, NJ, and Ronald P. Brown, U.S. FDA, Silver Spring, MD. 

Sponsor: 


Endorsed by: 



The Threshold of Toxicological Concern (TTC) is a concept used to estimate 

safe exposure levels for chemicals for which toxicological data are 

not available. It is based on chemical structure and known safety data for 

structurally related chemicals. This value represents a low level of exposure 

with negligible risk to humans. The process for demonstrating preclinical 

safety or biocompatibility of medical devices often involves a staged 

approach starting with a thorough understanding of the chemical composition 

of the device, then progressing through in vitro and in vivo bioassays 

and ultimately continuing the risk management process through the lifecycle 

of the product. The TTC concept is a tool that many risk assessors use to 

make decisions early in this staged process, and international committees are 

actively developing standardized methods for applying these techniques. In 

order to adequately explore this topic, we begin by discussing the history of 

the TTC concept along with an overview of the areas that this concept has 

been embraced up to this point. We will provide a description of how tolerable 

intake levels are set for medical device extractables when an adequate 

database of information about the extracted chemical is known. In addition, 

information will be provided on how the TTC concept can be used for 

extractable chemicals from medical devices for which structural information 

is known but the toxicological database is insufficient. Finally, the validation 

of a software package in the context of extractable chemicals known to be 

relevant to medical devices will be described. 

#1767 6:30 THE APPLICATION OF THE THRESHOLD 

OF TOXICOLOGICAL CONCERN 

CONCEPT TO THE PRECLINICAL SAFETY 

ASSESSMENT OF NON-PHARMACEUTICAL 

MEDICAL PRODUCTS, INCLUDING 

MEDICAL DEVICES AND COMBINATION 

DRUG-DEVICE PRODUCTS. R. W. 

Hutchinson 1 , R. Brown 2 , M. A. Cheeseman 3 and J. 

Cammack 4 . 1 Preclinical, Johnson&Johnson: Ethicon, 

Somerville, NJ, 2 CDRH, U.S. FDA, Silver Spring, 

MD, 3 CFSAN, U.S. FDA, Riverdale, MD and 4 ISIS 

Services, San Carlos, CA. 

6:30 INTRODUCTION. Richard W. Hutchinson 

6:35 HISTORY OF THE THRESHOLD OF 

TOXICOLOGICAL CONCERN CONCEPT. 

Mitchell Cheeseman 

6:50 USE OF ISO 10993-17 GUIDELINES FOR 

SETTING TOLERABLE EXPOSURE LIMITS. 

Jon Cammack 

7:05 THRESHOLD OF TOXICOLOGICAL 

CONCERN: APPLICATION TO MEDICAL 

DEVICES. Richard W. Hutchinson 

7:20 CATEGORIZATION OF COMPOUNDS 

RELEASED FROM MEDICAL DEVICE 

MATERIALS INTO CRAMER CLASSES 

USING TOXTREE SOFTWARE. Ron Brown 



6:30 AM to 7:50 AM 

Room 144 

Education-Career Development Session: From Pilot Grants to 

High-End Journals: The Science of Writing 

Chairperson(s): Marie C. Fortin, Environmental and Occupational 

Health Sciences Institute, Piscataway, NJ, and Anne Loccisano, The 

Hamner Institutes for Health Sciences, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




Want to learn how to write effective grants and publications, or sharpen 

your scientific writing skills to communicate better? As toxicologists, it is 

essential that we be able to articulate new ideas in the form of grants and 

to disseminate the results of research in the form of scientific publications. 

Thus effective communication through writing is fundamental therefore it is 

crucial for early career scientists to learn effective writing skills. Publishing 

is imperative in academic or non-profit sectors and obtaining sufficient 

funding is a necessity when establishing a career and reputation. However, 

most scientists do not receive any formal training in writing and these skills 

are usually learned by following the style of a mentor or other authors. This 

issue is particularly important for graduate students, postdoctoral fellows, 

and other early career scientists who would like to enhance their critical 

writing skills which are needed for good communication. Our panel of 

experts will provide the audience with tactics to write promising NIH grant 

applications, general approaches that enhance the publication success of 

scientific papers, as well as concrete scientific writing strategies from an 

author’s and reader’s standpoint. Attendees will be provided with tips to 

enhance their skills that will enable more effective communication of both 

their ideas and their science, from grant proposals to publication. 

272 






Platform Sessions



Abstract # 

#1768 6:30 FROM PILOT GRANTS TO HIGH-END 

JOURNALS: THE SCIENCE OF WRITING, 

M. C. Fortin 1 and A. E. Loccisano 2 . 1 Clinical 

Research and Occupational Medicine, Environmental 

and Occupational Health Sciences Institute, 

Piscataway, NJ and 2 The Hamner Institutes for 


6:30 Introduction. Marie Fortin 

6:34 Communicating Ideas Efficiently: An Essential 

Skill for All Researchers. Deborah A. Cory- 

Slechta 

6:53 Grantsmanship at NIH: How to Swim with the 

Sharks. Jerrold J. Heindel 

7:12 Writing for Success. Angela K. Eggleston 

7:31 Panel Discussion/Q&A. 


8:00 AM to 9:00 AM 


Keynote Medical Research Council (MRC) 

Lecture: Cellular Responses to DNA Damage: 

New Molecular Insights and New Approaches 

for Cancer Therapy 

Lecturer: Stephen P. Jackson, The Gurdon Institute 

and Department of Biochemistry, University of 

Cambridge, Cambridge, United Kingdom. 

Inherited or acquired defects in detecting, signalling or repairing DNA 

damage are associated with various human pathologies, including 

immuno-deficiencies, neurodegenerative diseases and various forms of 

cancer1. Our increasing knowledge of cellular DNA-damage responses 

(DDR) is therefore providing new insights into the aetiology of such 

diseases and, moreover, is presenting opportunities for novel diagnostic 

and therapeutic strategies. Work in Dr. Jackson’s laboratory aims to 

decipher the mechanisms by which cells detect DNA damage and signal 

its presence to the DNA-repair and cell-cycle machineries. In particular, 

much of the work focuses on DNA double-strand breaks (DSBs) that are 

generated by ionizing radiation and radiomimetic chemicals, and which 

can also arise when the DNA replication apparatus encounters other 

DNA lesions. 

In this talk, Dr. Jackson will first provide an overview of how cells 

respond to DNA damage and will describe the key protein players in 

these events. Next, he will discuss some of our recent work that has 

identified new proteins that mediate DSB responses, control DSB 

processing or modulate chromatin structure at DNA damage sites. He 

will then explain how this type of work identified therapeutic opportunities 

that led to me founding KuDOS Pharmaceuticals Ltd, whose 

mission was to develop DDR inhibitors for cancer therapy. Finally, He 

will use the example of the KuDOS drug olaparib (now owned by and 

being developed by AstraZeneca) to highlight the exciting potential for 

DDR inhibitors in treating many cancers. Specifically, Dr. Jackson will 

explain the molecular basis for how olaparib is exquisitely cytotoxic to 

cancer cells bearing DSB repair defects because of inherited mutations 

in BRCA1 or BRCA2 but is well tolerated by normal cells of cancer 

patients. In closing, he will explain how this and related mechanisms of 

“synthetic lethality” might be applied to a wider range of cancers that 

bear DDR defects. 

Abstract # 


9:00 AM to 11:45 AM 

Room 202A 

Symposium Session: Autism: Genetic, Epigenetic, and 

Environmental Factors Influencing Neural Networks 

Chairperson(s): Isaac Pessah, University of California Davis, Davis, CA, 

and Cindy Lawler, National Institute of Environmental Health Sciences, 

Durham, NC. 

Sponsor: 


Endorsed by: 



Our current knowledge about how genetic, epigenetic, and environmental 

factors contribute to autism susceptibility is ever changing. From a toxicologist’s 

perspective, the identity of defective genes and signaling pathways 

linked to autism provide important clues about exposures to environmental 

chemicals that influence autism susceptibility, severity, and/or treatment 

outcomes. One fundamental way by which heritable genetic vulnerabilities 

can amplify the adverse effects triggered by environmental exposures is 

if both factors (genes x environment) converge to dysregulate the same 

signaling systems at critical times of development. Thus, we will review 

current knowledge of genetic contributions to autism risk, and present new 

evidence that autism is associated with an appreciably increased level of 

genomic instability in low copy repeat (LCR) rich intervals of the genome 

and how environmental factors that affect genomic stability could contribute 

to the incidence and severity of autism. We will highlight new findings from 

both a mouse model of Rett Syndrome and human tissues that contribute to 

our understanding of how developmental exposures to brominated flame 

retardants (PBDEs) influence DNA methylation and neurobehavioral 

outcomes relevant to autism. An update will be provided on recent progress 

in understanding how impairments in neural connectivity contribute to 

autism including seminal findings of the role of MET polymorphisms play 

in autism risk and how polyaromatic hydrocarbons found in air pollution 

might influence MET signaling. Finally, we will review the major translational 

issues confronting autism research and provide information about 

current funding opportunities in autism research. 

#1769 9:00 AUTISM: GENETIC, EPIGENETIC, 

AND ENVIRONMENTAL FACTORS 

INFLUENCING NEURAL NETWORKS. I. N. 

Pessah. Department of Molecular and Biological 

Sciences, University of California Davis, Davis, CA. 

9:00 INTRODUCTION. Isaac Pessah 

#1770 9:15 COPY NUMBER BURDEN ASSOCIATED 

WITH AUTISM IN UNSTABLE SEGMENTS 

OF THE GENOME. S. B. Selleck 1,2,7 , R. L. 

Johnson 2 , J. Balciuniene 7,3 , C. M. Conboy 7 , T. B. 

Nauth 2 , A. N. Klossner 7 , M. Alsagabi 4 , A. Alqallaf 4 , 

R. Davis 5 , R. Hansen 5 , J. Gregg 5 , I. Hertz-PIcciotto 5 , 

A. Tewfik 4 and I. N. Pessah 6,5 . 1 Biochemistry 

and Molecular Biology, The Pennsylvania State 

University, University Park, PA, 2 Pediatrics, 

University of Minnesota, Minneapolis, MN, 

3 

Biology, Temple University, Philadephia, PA, 

4 

Electrical Engineering and Computer Science, 

University of Minnesota, Minneapolis, MN, 5 The 

Medical Investigations of Neurodevelopmental 

Disorders Institute, University of California, 

Davis, Sacramento, CA, 6 Department of Molecular 

Biosciences, School of Veterinary Medicine, 


7 

Genetics Cell Biology and Development, University 

of Minnesota, Minneapolis, MN. 

Wednesday 







273



Wednesday 


#1771 9:55 EPIGENETIC INTERACTION BETWEEN 

PERINATAL PBDE EXPOSURE AND 

MECP2308 MUTATION THROUGH X 

CHROMOSOME INACTIVATION. J. 

LaSalle 1 , R. O. Vallero 1 , M. Golub 3 , J. K. Suarez 1 , 

R. Woods 1 , T. Ta 4 , A. George 1 , P. J. Kostyniak 5 , I. 

N. Pessah 2 and R. Berman 4 . 1 Microbiology and 

Immunology, University of California Davis School 

of Medicine, Davis, CA, 2 Molecular Biosciences, 

University of California Davis School of Veterinary 

Medicine, Davis, CA, 3 Environmental Toxicology, 

University of California Davis School of Medicine, 

Davis, CA, 4 Neurological Surgery, University of 

California Davis School of Medicine, Davis, CA and 

5 

Toxicology Research, State University of New York, 

Buffalo, NY. 

#1772 10:35 PATHOGENESIS OF CIRCUIT 

DEVELOPMENT IN THE AUTISMS: 

EMERGENCE OF THE GENE- 

ENVIRONMENT AND THE 

DEVELOPMENTAL NEUROBIOLOGY 

INTERFACE. P. Levitt. Zilkha Neurogenetic 

Institute, Keck School of Medicine of University of 

Southern California, Los Angeles, CA. Sponsor: I. 

Pessah. 

#1773 11:15 AUTISM AND THE ENVIRONMENT: 

CHALLENGES AND OPPORTUNITIES FOR 

ADVANCING THE SCIENCE. C. Lawler. 

Division of Extramural Research and Training, 

NIEHS, Research Triangle Park, NC. Sponsor: I. 

Pessah. 



9:00 AM to 11:45 AM 

Room 144 


Symposium Session: Gene-Environment Disease Interactions 

in Fish Models of Human Disease 

Chairperson(s): Michael Carvan, University of Wisconsin Milwaukee, 

Milwaukee, WI, and Seth Kullman, North Carolina Sate University, 

Raleigh, NC. 

Sponsor: 


Endorsed by: 


Use of alternative species for toxicity testing is a fast growing field in toxicology 

and provides many distinct advantages as an adjunct to mammalian 

testing. Thus, we will hightlight the use of small aquarium fish as models 

to investigate mechanistic toxicity in relation to environment and disease 

etiology. It is clear that much insight into human health and safety can be 

gained through research involving various aquatic species. Much effort has 

been put into using fish species as translational models for detailed mechanistic 

investigation in cancer, aging, tissue regeneration, genetic diseases 

and disorders, and stem cell biology. These findings emphasize that most 

cellular, molecular, and biochemical processes are well conserved across 

vertebrate groups. The use of aquatic organisms as models in biomedical 

research has a rich and extensive history. Their research value is widely 

appreciated, comprising a taxonomically and environmentally diverse group, 

providing researchers with opportunities to investigate a wide range of 

systems and processes. New contributions to the toxicology literature reflect 

in part the strategic use of available resources and chronicle the advantages 

inherent when these models are coupled to modern experimental approaches 

in human disease. We will effectively communicate the current state of 

research with small aquarium fish models in mechanistic toxicology as it 

relates to molecular approaches addressing gene-environment and environmental-disease 

interactions. Focus areas will include ‘omic approaches, role 

of gene duplicates and polymorphic sequences in toxicity, and association of 

genetic and environment factors in disease susceptibility. In conclustion, we 

will provide a forum for investigators to exchange scientific information and 

encourage enhancement of the utility of aquatic models for studies of human 

disease. 

#1774 9:00 GENE-ENVIRONMENT DISEASE 

INTERACTIONS IN FISH MODELS 

OF HUMAN DISEASE. M. J. Carvan 1 , J. 

Postlethwait 2 , M. Hahn 3 , S. Kullman 4 and J. 

Bronstein 5 . 1 Great Lakes WATER Institute, 

Milwaukee, WI, 2 University of Oregon, Eugene, 

OR, 3 Woods Hole Oceanographic Institution, Woods 

Hole, MA, 4 North Carolina State University, Raleigh, 

NC and 5 University of California Los Angeles, Los 

Angeles, CA. 

9:00 INTRODUCTION. Seth Kullan 

#1775 9:05 SOX9, TCDD, GAR, AND DUPLICATE GENE 

EVOLUTION. J. H. Postlethwait, A. Amores and 

Y. Yan. University of Oregon, Eugene, OR. Sponsor: 

S. Kullman. 

#1776 9:36 GENE-ENVIRONMENT INTERACTIONS 

AND DIOXIN SENSITIVITY IN NATURAL 

AND LABORATORY POPULATIONS 

OF FISH. M. E. Hahn 1 , S. I. Karchner 1 , M. 

J. Jenny 3,1 , D. G. Franks 1 , A. M. Reitzel 1 , A. R. 

Timme-Laragy 1 , N. Aluru 1 , D. E. Nacci 2 and M. F. 

Oleksiak 4 . 1 Biology, Woods Hole Oceanographic 

Institute, Woods Hole, MA, 2 NHEERL, U.S. EPA, 

Narragansett, RI, 3 Biological Sciences, University 

Alabama, Tuscaloosa, AL and 4 RSMAS, University 

of Miami, Miami, FL. 

#1777 10:07 ALTERATION OF DEVELOPMENTAL 

PROGRAMS REGULATING CARTILAGE 

AND BONE FORMATION IN TCDD 

TREATED MEDAKA. S. W. Kullman 1 , W. Dong 1 

and D. E. HInton 2 . 1 Environmental and Molecular 


NC and 2 Nicholas School of the Environment, Duke 

University, Durham, NC. 

#1778 10:38 INFLUENCE OF HUMAN GENE VARIANTS 

ON THE EFFECTS OF DEVELOPMENTAL 

MEHG EXPOSURE. M. J. Carvan 1 , R. Klingler 1 

and J. Topczewski 2 . 1 School of Freshwater 

Sciences, Great Lakes WATER Institute, University 

of Wisconsin Milwaukee, Milwaukee, WI and 

2 

Children’s Memorial Research Center, Northwestern 

University, Chicago, IL. 

#1779 11:09 INVESTIGATING ENVIRONMENTAL 

AND GENETIC RISK FACTORS OF 

PARKINSON’S DISEASE USING 

ZEBRAFISH. J. Bronstein, A. Kotagiri, S. 

Prabhudesai, S. Sinha, S. Li and G. Bitan. Neurology, 

University of California Los Angeles School of 

Medicine, Los Angeles, CA. Sponsor: M. Carvan. 

11:40 CLOSING REMARKS/SUMMARY. 

274 






Platform Sessions



Abstract # 


9:00 AM to 11:45 AM 

Room 150 

Symposium Session: Mechanisms of Inflammation in Skin 


Chairperson(s): Lauren Mordasky Markell, Penn State University, 

University Park, PA, and Michael Borland, Penn State University, 


Sponsor: 


Endorsed by: 



The World Health Organization finds that 30% of all human cancers are 

cancer of the skin, and one in five Americans will develop skin cancer in 

their lifetime. Furthermore, increased cancer mortality has been linked to 

a history of non-melanoma skin cancer. The majority of skin cancers arise 

from chemical contact or exposure to ultraviolet radiation, but a complete 

understanding of the mechanisms involved in cancer development remain 

elusive. Chronic irritation and inflammation have also been observed at sites 

of tumorigenesis; this, coupled with the fact that tumors routinely present 

with deregulated proliferative signaling pathways, suggests inflammatory 

signaling may significantly contribute to skin carcinogenesis. Understanding 

how inflammation alters tumor development and progression could identify 

novel preventative and therapeutic strategies to treat or reduce skin cancer. 

Our divergent panel of experts will discuss the mechanisms by which the 

inflammatory micro-environment alters skin tumor formation and progression, 

the importance of epidermal homeostasis, the differential roles of 

key inflammatory cells that contribute to the tumor phenotype, how mouse 

models can be applied to human relevance, and how this research impacts 

risk assessment and regulation. Because inflammation has been implicated 

in other cancers, investigators can apply, exploit, and build upon the 

discussed strategies and mechanisms for other cancer models. For those 

investigators interested in the integrative and multi-disciplinary nature of 

cancer biology, this discussion and collaboration will lay the groundwork 

to help understand the novel mechanisms of skin carcinogenesis. In conclusion, 

exploration of this topic will enable U.S. to identify potential targets 

that can be related to the cause of cancer ultimately striving to decrease the 

incidence and mortality of this very common worldwide cancer. 

#1780 9:00 MECHANISMS OF INFLAMMATION IN 

SKIN CARCINOGENESIS. L. Mordasky Markell 

and M. G. Borland. Center for Molecular Toxicology 

and Carcinogenesis, Penn State University, 


9:00 INTRODUCTION. Lauren Mordasky Markell 

#1781 9:05 A SERIES OF AUTOCRINE AND 

PARACRINE FEEDBACK LOOPS IN 

INFLAMMATION PATHWAYS ARE 

REQUIRED FOR TUMOR FORMATION 

IN SKIN CARCINOGENESIS. S. H. Yuspa. 

National Cancer Institute, National Institutes of 

Health, Bethesda, MD. Sponsor: L. Markell. 

#1782 9:35 IKKα FUNCTION IN SKIN INFLAMMATION 

AND TURMORIGENESIS. Y. Hu. NCI, 

Frederick, MD. Sponsor: L. Markell. 

#1783 10:05 MODELING THE INFLAMMATORY TO 

IMMUNOSUPPRESSIVE SWITCH DURING 

PREMALIGNANT PROGRESSION. A. Glick 

and A. Gunderson. Veterinary and Biomedical 

Sciences, Penn State University, University Park, PA. 

Sponsor: L. Mordasky Markell. 

Abstract # 

#1784 10:35 DOES SEX MATTER IN THE 

DEVELOPMENT OF NON-MELANOMA 

SKIN CANCER? T. Oberyszyn 1 , N. J. Sullivan 1 , 

K. L. Tober 1 , M. A. Bill 2 , J. A. Riggenbach 1 , J. S. 

Schick 1 and G. B. Lesinski 2 . 1 Pathology, The Ohio 

State University, Columbus, OH and 2 Internal 

Medicine, The Ohio State University, Columbus, 

OH. Sponsor: L. Mordasky Markell. 

#1785 11:05 BIOMARKERS AS INDICATORS 

OF PHOTOTOXICITY: DO THEY 

HAVE A ROLE AS PREDICTORS OF 

PHOTOCARCINOGENESIS? D. B. Learn 1 , P. 

D. Forbes 2 , C. P. Sambuco 1 , A. M. Hoberman 1 and S. 

R. Eldridge 3 . 1 Charles River Laboratories Preclinical 

Services, Horsham, PA, 2 Toxarus, Inc., Malvern, PA 

and 3 Charles River-Pathology Associates, Frederick, 

MD. 



9:00 AM to 11:45 AM 

Room 143 

Symposium Session: New Insights into the Nrf2-Keap1 

Pathway and Its Impact on Human Disease 

Chairperson(s): Thomas Kensler, Johns Hopkins Bloomberg School of 

Public Health, Baltimore, MD, and Donna Zhang, University of Arizona, 

Tucson, AZ. 

Sponsor: 


Endorsed by: 




Damage mediated by reactive electrophilic intermediates can have a 

profound effect on many cellular functions, and has been implicated in 

cancer, inflammation, neurodegenerative diseases, cardiovascular diseases, 

and aging. Eukaryotic cells have evolved anti-oxidant defense mechanisms 

to neutralize reactive oxygen species (ROS) and maintain cellular redox 

homeostasis. Eukaryotic cells also express cofactors and enzymes for trapping 

reactive electrophiles. A key adaptive response system for protection 

against ROS and electrophilic intermediates is mediated by the transcription 

factor Nrf2, through the antioxidant responsive element (ARE) sequences 

in the promoter regions of dozens of cytoprotective genes. Basal levels of 

Nrf2 remain relatively low, due to its negative regulation by Keap1, which 

targets Nrf2 for ubiquitination and degradation. However, upon activation, 

cysteine residues of Keap1 are modified, leading to conformational 

changes that impair ubiquitination of Nrf2, thus allowing Nrf2 to translocate 

into the nucleus to activate the expression of its downstream genes. The 

activation of the Nrf2 pathway is not only important in protecting cells 

against the deleterious effects caused by carcinogens and environmental 

toxicants, but, also, Nrf2 protects against drug-induced organ toxicity and 

damage. Unfortunately, the dark-side of Nrf2 has been revealed indicating 

that constitutive activation of Nrf2, due to mutations in either Nrf2 or 

Keap1, creates an environment conducive to cancer cell growth and thus, 

contributes to chemoresistance. Our knowledge on the Nrf2 pathway has 

progressed rapidly, and new important insights into its complex regulation 

have emerged. Thus it is important to highlight the novel mechanisms that 

activate the Nrf2 pathway, cross-talk between Nrf2 with other essential cell 

signaling pathways to maintain cellular homeostasis, the protective role of 

Nrf2 in human diseases, and paradoxically its role as a hostage in cancer. 

In conclusion, we will explore the essential role of Nrf2 in disease and in a 

variety of biological processes that regulate the response to environmental 

exposures. 

Wednesday 







275



Wednesday 


#1786 9:00 NEW INSIGHTS INTO THE NRF2-KEAP1 

PATHWAY AND ITS IMPACT ON HUMAN 

DISEASE. D. D. Zhang 1 and T. W. Kensler 2 . 

1 

University of Arizona, Tucson, AZ and 2 University 

of Pittsburgh, Pittsburgh, PA. 

9:00 INTRODUCTION. Donna Zhang 

#1787 9:05 THE NRF2-KEAP1 STRESS RESPONSE 

PATHWAY: MOLECULAR BASIS 

OF ADAPTIVE RESPONSES AND 

PATHOGENESIS. M. Yamamoto, H. Kurokawa, 

T. Suzuki, K. Taguchi and H. Motohashi. Medical 

Biochemistry, Tohoku University Graduate School of 

Medicine, Sendai, Japan. Sponsor: T. Kensler. 

#1788 9:37 NRF2 IN TOXICOLOGY: FROM 

MONOFUNCTIONAL INDUCERS TO 

THERAPY. C. D. Klaassen. Pharmacology, 

University Kansas Medical Center, Kansas City, KS. 

#1789 10:09 NRF2: NOT JUST FOR PHASE 2 ENZYMES 

ANYMORE. T. W. Kensler 1,2 . 1 Pharmacology 

& Chemical Biology, University of Pittsburgh, 

Pittsburgh, PA and 2 Environmental Health Sciences, 



#1790 10:41 GAIN OF NRF2 FUNCTION AS A TARGET 

FOR ANTICANCER THERAPY? S. Biswal and 

A. Singh. Johns Hopkins University, Baltimore, MD. 

Sponsor: D. Zhang. 

#1791 11:13 GETTING CAUGHT IN THE WEB OF NRF2. 

D. D. Zhang. Pharmacology and Toxicology, 



9:00 AM to 11:45 AM 

Room 204 



Workshop Session: Approaches for Incorporating Non- 

Chemical Stressors into Cumulative Risk Assessments 

Chairperson(s): Cynthia Rider, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC, and Jane Ellen Simmons, 


Sponsor: 


Endorsed by: 



Realistic human exposures are comprised of multiple chemical as well as 

non-chemical stressors. Non-chemical stressors, such as poor diet and physiological 

or psychological stress, often elicit adverse effects by targeting 

the same signaling pathways as chemical stressors and, therefore, have the 

potential to significantly modify our responses to chemical exposures. In 

recent years, regulatory agencies have emphasized the need for conducting 

cumulative risk assessments in order to account for real-world, multichemical 

exposure scenarios; however, the incorporation of non-chemical 

stressors into these cumulative risk assessments represents a novel and 

complex challenge. Development of a systematic approach for assessing 

the joint action of chemical and non-chemical stressors is needed in order 

to prioritize non-chemical stressors for inclusion in cumulative risk assessments, 

determine the type of data needed to incorporate non-chemical 

stressors, and develop methods for assessing their contribution to overall 

risk. We will highlight key issues in order to provide a rational starting place 

for moving forward. Therefore it is important to put this issue in context, 

describe data needs, and propose methods for incorporating nonchemical 

stressors into cumulative risk assessments. Participants represent perspectives 

from regulatory agencies, industry, non-profit, and academia. 

#1792 9:00 APPROACHES FOR INCORPORATING 

NON-CHEMICAL STRESSORS INTO 

CUMULATIVE RISK ASSESSMENTS. C. 

V. Rider 1 and J. Simmons 2 . 1 Toxicology Branch, 

NIEHS-NTP, Research Triangle Park, NC and 

2 

Pharmacokinetics Branch, ISTD, NHEERL, ORD, 


9:00 INTRODUCTION. Cynthia Rider 

#1793 9:05 CURRENT REGULATORY PERSPECTIVE 

ON INCORPORATING NON-CHEMICAL 

STRESSORS INTO CUMULATIVE RISK 

ASSESSMENTS. M. M. Mumtaz. Computational 

Toxicology and Methods Development Laboratory, 

ATSDR, Atlanta, GA. 

#1794 9:37 A CONCEPTUAL FRAMEWORK FOR 

CHARACTERIZING FACTORS THAT 

INFLUENCE EXPOSURES TO CHEMICAL 

AND NON-CHEMICAL STRESSORS. P. S. 

Price. Toxicology & Environmental Research & 

Consulting, The Dow Chemical Company, Midland, 

MI. 

#1795 10:09 ISSUES WITH QUANTIFICATION OF 

THE JOINT IMPACT OF CHEMICAL 

AND NON-CHEMICAL STRESSORS 

FOR ENVIRONMENTAL HEALTH RISK 

ASSESSMENT. R. C. Hertzberg. Biomathematics 

Consulting, Atlanta, GA. Sponsor: C. Rider. 

#1796 10:41 COMPARATIVE DIETARY RISK 

ASSESSMENT: AN ALGORITHM WITH 

INCORPORATION OF CULTURAL 

BENEFITS OR STRESSORS. M. L. Dourson. 

Toxicology Excellence for Risk Assessment (TERA), 




9:00 AM to 11:45 AM 

Room 206 

Workshop Session: Extending Pulmonary Toxicity Findings 

for Nanomaterials 

Chairperson(s): Phil Sayre, U.S. EPA, Bethesda, MD, and David Warheit, 

DuPont Haskell Global Centers, Newark, DE. 

Sponsor: 


Endorsed by: 

Cardiovascular Toxicology SpecialtySection 



As the diversity of manufactured nanomaterials continues to increase, 

associated exposures may pose concerns for human health. Subchronic 

inhalation studies are often needed to evaluate the possible effects related to 

longer-term inhalation exposures. However, since all nanomaterials cannot 

be tested in this manner, additional methods need to be developed for use by 

industry screening at the research and development phase, and/or for regulatory 

review as part of a commercial submission. One such method is to 

consider extending the pulmonary toxicity findings from one material within 

a class of nanomaterial types to other materials within that same class. 

This may not be possible for the majority of eclectic particle-types within 

most nanoscale-related categories. However, there exists well-developed 

276 






Platform Sessions



Abstract # 

pulmonary toxicity testing data for two classes of materials—those for nano 

titania and multi-walled carbon nanotubes (MWCNTs). The hazard data 

were generated for these two classes by utilizing standardized regulatory 

guideline methodologies, which make such predictions for closely-related 

materials approachable. Additional methodologies which may facilitate 

broader-based conclusions or assist in screening include use of other in vivo 

-based testing approaches such as those involving shorter-term inhalation, 

or aspiration/intratracheal instillation protocols. We will highlight different 

perspectives, consistent with our panel of experts diverse backgrounds 

which are needed to address this complex need. In addition, we will offer 

the latest findings on the pulmonary toxicity of nano titania and MWCNTs. 

In addition, viewpoints will be offered on how generalizable the findings 

are to other types of titania and MWCNTs, given differing physicochemical 

properties, methods of particle generation and delivery, and current perspectives 

on modes of actions. Insights will be presented on how such data 

can be utilized in applications such as pre-screening, and establishment 

of protective levels for workers. We believe that the dialogue between 

the panelists and the audience will facilitate the identification of areas of 

agreement, and key information needs, in order to further develop these 

approaches. 

#1797 9:00 EXTENDING PULMONARY TOXICITY 

FINDINGS FOR NANOMATERIALS. D. 

Warheit 2 and P. Sayre 1 . 1 U.S. EPA, Washington, D.C. 

and 2 DuPont, Providence, RI. 

9:00 INTRODUCTION. Phil Sayre 

#1798 9:05 TESTING OF MWCNT FOR POSSIBLE 

HEALTH HAZARDS AND RELEASE FROM 

COMPOSITE MATERIALS. R. Landsiedel 1 , 

W. Wohlleben 1,2 , L. Ma-Hock 1 , S. Treumann 1 , K. 

Wiench 3 and B. van Ravenzwaay 1 . 1 Department of 


Ludwigshafen am Rhein, Germany, 2 Polymer Physics 

Department, BASF SE, Ludwigshafen am Rhein, 

Germany and 3 Product Safety Department, BASF 

SE, Ludwigshafen am Rhein, Germany. 

#1799 9:27 EXPERIMENTAL EVIDENCE FROM A 

90-DAY MWCNT INHALATION STUDY 

IN RATS: ANALYSIS OF COMMON 

DENOMINATORS OF MWCNT WITH 

SUBMICRONSIZED PARTICLES. J. Pauluhn. 

Toxicology, Bayer HealthCare, Wuppertal, Germany. 

#1800 9:49 FACTORS AFFECTING THE PULMONARY 

RESPONSE TO CARBON NANOTUBES. V. 

Castranova. Pathology & Physiology Branch, CDC 


#1801 10:11 TITANIA-CRYSTALLINITY AND SURFACE 

REACTIVITY EFFECTS ON TOXICITY 

—NOT ALL NANO TITANIUM DIOXIDE 

PARTICLES HAVE THE SAME HAZARD 

POTENTIAL. D. B. Warheit. DuPont Haskell 

Global Centers, Newark, DE. 

#1802 10:33 CHARACTERIZING MWCNTS AND 

TITANIA NANOSTRUCTURES: DIFFERENT 

MATERIALS REQUIRE DIFFERENT 

TECHNIQUES. C. Sayes. Texas A&M University, 

College Station, TX. 

#1803 10:55 CONSIDERATION FOR BROAD MULTI- 

WALL CARBON NANOTUBE AND TITANIA 

OCCUPATIONAL EXPOSURE LIMITS 

AND RELEVANT INSIGHTS FROM THE 

EUROPEAN PERSPECTIVE. L. Tran. Institute 

of Occupational Medicine, Edinburgh, Scotland, 

United Kingdom. Sponsor: P. Sayre. 


Abstract # 


9:00 AM to 11:45 AM 

Room 145 

Workshop Session: Understanding the Implications of 

Preclinical Seizures for Clinical Drug Development 

Chairperson(s): August Wilke, Eli Lilly and Company, Indianapolis, IN, 

and Mary Jeanne Kallman, Covance, Greenfield, IN. 

Sponsor: 


Endorsed by: 


Convulsions observed in animals during the drug development process 

require a thorough risk assessment to determine the implications for human 

dosing. The origin of an outwardly visible convulsion is generally considered 

to be a generalized seizure (i.e., an abnormal/sychronized electrical 

discharge in the brain). While seizures are sometimes due to the intended, 

or on-target pharmacology of the molecule, seizures are likely more often 

due to an unintended, or off-target central nervous system (CNS) effect. 

Seizures in humans are problematic given the potential safety impact of loss 

of motor control and/or consciousness. While the intent is to avoid seizures 

in humans, there is no published consensus on how to accomplish this 

(e.g., what exposure multiple is appropriate to ensure the safety of clinical 

subjects; how valuable are premonitory signs or EEG data for predicting 

seizures). Therefore we will review some of the available animal models 

and tools, and to build consensus on appropriate approaches to seizure risk 

assessment during drug development. 

#1804 9:00 UNDERSTANDING THE IMPLICATIONS OF 

PRECLINICAL SEIZURES FOR CLINICAL 

DRUG DEVELOPMENT. A. Wilke 1 and M. 

Kallman 2 . 1 Nonclinical Safety Assessment, Eli Lilly 

and Co., Indianapolis, IN and 2 Neuroscience and 

Investigative Toxicology, Covance, Inc., Greenfield, 

IN. 

#1805 9:00 AN OVERVIEW OF SEIZURES AND THE 

IMPACT OF DRUG-INDUCED SEIZURES 

ON DRUG DEVELOPMENT. M. J. Kallman. 

Covance Inc., Greenfield, IN. 

#1806 9:34 TRANSLATION OF EEG DATA FROM 

ANIMALS TO MAN. J. Arezzo. Department 

Neuroscience and Neurology, Albert Einstein College 

of Medicine, Bronx, NY. Sponsor: A. Wilke. 

#1807 10:08 APPROACHES TO SEIZURES IN DRUG 

DEVELOPMENT: AN INDUSTRY 

PERSPECTIVE. A. Wilke. Nonclinical Safety 

Assessment, Eli Lilly and Co., Indianapolis, IN. 

#1808 10:42 CONSIDERATIONS WHEN MANAGING 

SEIZURES IN DRUG DEVELOPMENT. 

A. Avila. Division of Psychiatry Drugs, U.S. FDA, 

Silver Spring, MD. Sponsor: A. Wilke. 


Wednesday 







277



Wednesday 



9:00 AM to 11:45 AM 

Room 147 

Platform Session: QSAR Approaches and Predictive 

Pathways 

Chairperson(s): Richard Judson, U.S. EPA, Research Triangle Park, NC, 

and Luis Valerio, U.S. FDA, Silver Spring, MD. 

#1809 9:00 A NEW COMPUTATIONAL TOOL TO 

DETERMINE TISSUE: BLOOD PARTITION 

COEFFICIENTS FOR A VARIETY OF 

CHEMICALS. E. E. Carpenter, A. N. Mayeno and 

B. Reisfeld. Department of Chemical and Biological 

Engineering, Colorado State University, Fort Collins, 

CO. 

#1810 9:21 A COMPUTATIONAL FRAMEWORK FOR 

CHARACTERIZING BIOMARKERS OF 

ORGANOPHOSPHORUS INSECTICIDE 

MIXTURE EXPOSURE. J. H. Ivy 1,2 , J. M. 

Wright 2 , J. L. Rogers 1,2 , A. N. Mayeno 1,2 , M. A. 

Lyons 1,2 and B. Reisfeld 1,2 . 1 Department of Chemical 

and Biological Engineering, Colorado State 

University, Fort Collins, CO and 2 Systems and 

Computational Biology Research Group, Colorado 

State University, Fort Collins, CO. 

#1811 9:42 QSAR ANALYSIS OF THE ATSDR 

DATABASE OF CHEMICAL HEALTH 

GUIDANCE VALUES. E. Demchuk 1 , Y. Tie 1 , T. 

Miller 2 and R. M. Garrett 2 . 1 Division of Toxicology 

& Environmental Medicine, ATSDR/CDC, Atlanta, 

GA and 2 Department of Defense, Washington, D.C. 

Sponsor: B. Fowler. 

#1812 10:03 SUPPORTING SAFETY ASSESSMENT 

OF DRUG IMPURITIES THROUGH 

EXAMINATION OF AN AMES ASSAY QSAR 

MODEL. G. Myatt 1 , K. P. Cross 1 and L. G. Valerio 2 . 

1 

Leadscope Inc., Columbus, OH and 2 CDER/OPS, 

U.S. FDA, Silver Spring, MD. Sponsor: N. Sadrieh. 

#1813 10:24 ESTIMATING TOXICITY-RELATED 

BIOLOGICAL PATHWAY ALTERING DOSES 

FOR HIGH-THROUGHPUT CHEMICAL 

RISK ASSESSMENTS. R. Judson, D. J. Dix, K. 

J. Robert, R. Setzer, E. A. Cohen Hubal and M. T. 

Martin. U.S. EPA, Research Triangle Park, NC. 

#1814 10:45 EVALUATION OF IN SILICO TOOLS FOR 

THE PREDICTION OF MUTAGENICITY. 

A. Hillebrecht, W. Muster, A. Brigo, M. Kansy, 

T. Weiser and T. Singer. Pharmacology Research 

Nonclinical Safety, F. Hoffmann-La Roche Ltd., 


#1815 11:05 MEASURING COMPOUND SELECTIVITY 

AND ITS LINK TO IN VIVO TOXICITY 

STUDY OUTCOME. X. Wang and N. Greene. 

Compound Safety Prediction, Pfizer, Groton, CT. 

#1816 11:25 IDENTIFICATION AND CLASSIFICATION 

OF GENOTOXIC AND NON- 

GENOTOXIC SCAFFOLDS IN RODENT 

CARCINOGENICITY QSAR MODELS. K. 

P. Cross 1 and E. J. Matthews 2 . 1 Leadscope, Inc., 

Columbus, OH and 2 U.S. FDA/CFSAN/OFAS, 

College Park, MD. Sponsor: R. Tice. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Xenobiotic Biotransformation 

Chairperson(s): James Bruckner, University of Gerogia, Athens, GA. 




EFFECTS OF ORAL DOSAGE REGIMEN 

ON FIRST-PASS ELIMINATION AND 

TOXICOKINETICS (TK) OF 1, 1, 

1-TRICHLOROETHANE (TRI) AND 

TRICHLOROETHYLENE (TCE). V. Srivatsan, 

S. Muralidhara, J. V. Bruckner and C. A. White. PBS, 



IN VITRO METABOLISM OF BDE-99 IN 

HUMAN LIVER MICROSOMES. C. Erratico 

and S. Bandiera. Faculty of Pharmaceutical Sciences, 

The University of British Columbia, Vancouver, BC, 

Canada. 


BIOTRANSFORMATION OF ETHANOL TO 

ETHYL GLUCURONIDE IN A RAT MODEL 

AFTER A SINGLE ORAL DOSAGE. T. Haupt 

and K. Ferslew. East Tennessee State University, 

Johnson City, TN. 


RAT LIVER MICROSOMES 

ENANTIOSELECTIVELY CATALYZE 

THE FORMATION OF HYDROXYLATED 

METABOLITES OF 2, 2’, 3, 3’, 6, 

6’-HEXACHLOROBIPHENYL (PCB136). I. 

Kania-Korwel 1 , M. W. Duffel 2 , S. Bandiera 3 and 

H. Lehmler 1 . 1 Department of Occupational and 


City, IA, 2 Division of Medicinal and Natural Products 

Chemistry, University of Iowa, Iowa City, IA and 

3 

Faculty of Pharmaceutical Sciences, University of 

British Columbia, Vancouver, BC, Canada. 


MYELOPEROXIDASE- 

MEDIATED BIOACTIVATION OF 

5-HYDROXYTHIABENDAZOLE: A 

POSSIBLE MECHANISM BEHIND 

THE TOXICITIES ASSOCIATED WITH 

THIABENDAZOLE. J. Jamieson, E. Smith, D. 

Dalvie, G. Stevens and G. Yanochko. Pfizer, Inc., San 

Diego, CA. 


METABOLISM OF 2-HYDROXY-4- 

METHOXYBENZOPHENONE DEPENDS 

ON SPECIES AND SEX. C. Wegerski 1 , S. S. 

Auerbach 2 , J. M. Sanders 2 , M. Doyle-Eisele 1 and 

J. D. McDonald 1 . 1 Lovelace Respiratory Research 

Institute, Albuquerque, NM and 2 NTP/NIEHS, 


278 






Platform Sessions



Abstract # 


THE IN VITRO METABOLISM OF METHYL 

AND PROPYL PARABENS IN HUMAN AND 

RAT. K. Choi, H. Joo, J. Campbell, M. Andersen 

and H. Clewell. The Hamner Institutes for Health 



PHASE II BIOTRANSFORMATION OF DI(2- 

EHTYLHEXYL) PHTHALATE IN HUMAN 

AND RAT. H. Joo 1 , K. Choi 1 , J. Grimes 1,2 , T. 

O’Connell 1,2 , R. Clewell 1 , J. Campbell 1 and H. 

Clewell 1 . 1 The Hamner Institutes for Health Sciences, 

Research Triangle Park, NC and 2 The University of 



EFFECTS OF METABOLISM BY 

INTESTINAL MICROORGANISM ON 

PHARMACOKINETICS OF BAICALIN IN 

VIVO. T. Jeong, M. Kang, G. Ko, S. Yoo, H. Ha, M. 

Kong and D. Lee. Pharmacy, Yeungnam University, 

Gyeongsan, Gyeongbuk, Republic of Korea. 


IMMUNOTOXIC EFFECTS OF ARBUTIN 

VIA METABOLISM BY INTESTINAL 

BACTERIA IN VITRO. M. Kang 1 , H. Ha 1 , H. 

Kim 2 , G. Ko 1 , S. Yoo 1 , D. Lee 1 , M. Kong 1 , Y. Ahn 3 , 

H. Jeong 2 and T. Jeong 1 . 1 Pharmacy, Yeungnam 

University, Gyeongsan, Gyeongbuk, Republic of 

Korea, 2 Pharmacy, Chungnam National University, 

Daejeon, Republic of Korea and 3 Yakult Co., Yongin, 



ROLE OF METABOLISM BY INTESTINAL 

BACTERIA IN GENIPOSIDE-INDUCED 

TOXICITY IN MAMMALIAN CELL 

CULTURES. M. Kong 1 , H. Ha 1 , H. Kim 2 , G. Ko 1 , 

S. Yoo 1 , D. Lee 1 , M. Kang 1 , H. Jeong 2 and T. Jeong 1 . 

1 

Pharmacy, Yeungnam University, Gyeongsan, 

Gyeongbuk, Republic of Korea and 2 Pharmacy, 

Chungnam National University, Daejeon, Republic 



METABOLIC CONVERSION OF 

AFLATOXIN B2 TO AFLATOXIN B1 IN 

DUCKS. A. Poapolathep 1 , S. Poapolathep 1 , 

S. Isariyodom 3 , K. Imsilp 1 , N. Klangkaew 1 , Y. 

Sugita-Konishi 4 and S. Kumagai 2 . 1 Department of 

Pharmacology, Faculty of Veterinary Medicine, 

Kasetsart University, Bangkok, Thailand, 2 Research 

Center for Food Safety, University of Tokyo, Tokyo, 

Japan, 3 Department of Animal Husbandry, Faculty of 

Agriculture, Kasetsart University, Bangkok, Thailand 

and 4 Division of Microbiology, National Institute of 

Health Sciences, Tokyo, Japan. 


THIOETHER METABOLITES 

OF 3, 4-METHY- 

LENEDIOXYMETHAMPHETAMINE ARE 

POTENT INHIBITORS OF THE HUMAN 

SEROTONIN TRANSPORTER (HSERT). L. 

E. Lizarraga, J. Herndon, S. S. Lau and T. J. Monks. 

Pharmacology/Toxicology, University of Arizona 

College of Pharmacy, Tucson, AZ. 

Abstract # 


METABOLISM OF 2, 2’, 3, 3’, 6, 

6’-HEXACHLOROBIPHENYL (PCB136) IN 

PRECISION-CUT RAT LIVER SLICES. X. 

Wu 1 , K. Dammanahalli 2 , M. Duffel 2 and H. Lehmler 1 . 

1 

Occupational and Environmental Health, The 

University of Iowa, Iowa City, IA and 2 Medicinal and 

Natural Products Chemistry, The University of Iowa, 



STRUCTURAL CHARACTERIZATION 

OF O-METHYLATED-CATECHOL 

METABOLITE OF BENZO[A]PYRENE-7, 

8-DIONE IN THREE HUMAN LUNG 

CELLS. M. Huang, L. Zhang, I. A. Blair and T. M. 

Penning. Centers of Excellence in Environmental 

Toxicology and Cancer Pharmacology, Department 

of Pharmacology, University of Pennsylvania, 

Philadelphia, PA. 


A MEANS TO STUDY CRITICAL ADDUCT 

PROTEIN TARGETS: COMPARISON OF 

TOXIC NAPHTHALENE AND NON-TOXIC 

DIETHYL MALEATE SHOWS EQUIVALENT 

IN VIVO COVALENT BINDING AND 

GLUTATHIONE DEPLETION IN AIRWAY 

EPITHELIUM. D. Krawiec 1 , D. Morin 1 , L. Van 

Winkle 2 and A. Buckpitt 1 . 1 Molecular Biosciences, 


2 

Anatomy Physiology and Cell Biology, University 

of California Davis, Davis, CA. 


EFFECT OF DDT ON TESTOSTERONE 

BIOTRANSFORMATION BY RAT BRAIN 

MICROSOMES. A. Sierra-Santoyo 1 , O. Horacio 2 

and M. L. Lopez-Gonzalez 1 . 1 Departamento de 

Toxicologia, Cinvestav-Ipn, Mexico, D.F., Mexico 

and 2 Departamento de Nefrologia, Inc., Mexico, D.F., 

Mexico. 


TWO MECHANISMS INVOLVED IN 

ECSTASY-INDUCED HEPATOTOXICITY. 

I. Antolino Lobo 1,2 , W. Strach 1 , D. A. Fiechter 1 , 

I. S. Ludwig 1 , M. van den Berg 1 , J. Meulenbelt 1,2 

and M. van Duursen 1 . 1 Endocrine Toxicology, 

IRAS, Utrecht, Netherlands and 2 National Poisons 

Information Centre, National Institute for Public 

Health and the Environment, Bilthoven, Netherlands. 


TOXICITY OF AMINONITRILES IN MALE 

SPRAGUE-DAWLEY RATS. M. Y. Farooqui and 

T. Lacy. Biology, University of Texas Pan American, 

Edinburg, TX. 


DRUGS INTERACTING WITH 

TRICHLOROETHYLENE METABOLISM IN 

RAT AND HUMAN. M. Cheikh-Rouhou 2 and S. 

Haddad 1 . 1 Environmental and Occupational Health, 


2 

Biological Sciences, TOXEN, Université du Québec 

à Montréal, Montréal, QC, Canada. 

Wednesday 







279



Wednesday 



9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Phase I and II Biotransformation Enzymes 

Chairperson(s): Bhagavatula Moorthy, Baylor College of Medicine, 

Houston, TX. 




HUMAN DIOXIN-INDUCIBLE 

CYTOCHROME P450, CYP2S1, 

METABOLIZES CYCLOOXYGENASE— 

AND LIPOXYGENASE—DERIVED 

EICOSANOIDS. P. H. Bui 1,2,3 , S. Imaizumi 4 , S. 

Beedanagari 1,2 , S. T. Reddy 4 and O. Hankinson 1,2,3 . 

1 

Pathology and Laboratory Medicine, University 

of California Los Angeles, Los Angeles, CA, 

2 

Molecular Toxicology Interdepartmental Program, 


CA, 3 Jonsson Comprehensive Cancer Center, 


CA and 4 Department of Molecular and Medical 

Pharmacology, University of California Los Angeles, 



CYTOCHROME P450’S VARY IN THEIR 

ABILITY TO GENERATE REACTIVE 

OXYGEN SPECIES. V. Mishin 1 , D. E. Heck 2 , 

D. L. Laskin 1 and J. D. Laskin 3 . 1 Pharmacology 

& Toxicology, Rutgers University, Piscataway, 

NJ, 2 Environmental Health Sciences, New York 

Medical College, Valhalla, NY and 3 Environmental 

& Occupational Medicine, UMDNJ-Robert Wood 

Johnson Medical School, Piscataway, NJ. 


BACKGROUND LEVELS OF THE 

TRYPTOPHAN PHOTOPRODUCT 

6-FORMYLINDOLO[3, 2-b]CARBAZOLE 

(FICZ) DETERMINE THE OUTCOME OF 

IN VITRO BIOASSAYS FOR AH-RECEPTOR 

ACTIVATION. U. Rannug 1 , E. Wincent 1,2 , 

A. Mohammadi Bardbori 2 , T. Alsberg 3 and A. 

Rannug2. 1 Department of Genetics, Microbiology, 

and Toxicology, Stockholm University, Stockholm, 

Sweden, 2 Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden and 

3 

Department of Applied Environmental Science, 

Stockholm University, Stockholm, Sweden. 


CYTOCHROME P450 CYP2AA, CYP3A, 

AND PREGNANE X RECEPTOR IN 

ZEBRAFISH (DANIO RERIO): EXPRESSION 

IN RESPONSE TO POTENTIAL AGONISTS 

FOR PXR. A. Kubota 1 , A. Bainy 2,1 , M. Siebert 2 , 

B. Woodin 1 , J. Goldstone 1 and J. Stegeman 1 . 

1 

Biology Department, Woods Hole Oceanographic 

Institution, Woods Hole, MA and 2 Departamento de 

Bioquímica, Universidade Federal de Santa Catarina, 

Florianopolis, SC, Brazil. 


TRANSCRIPTIONAL AND POST- 

TRANSCRIPTIONAL REGULATIONS 

OF CYP1A1 GENE BY LEAD IN HUMAN 

HEPATOMA HEPG2 CELL. H. M. Korashy 1 and 

A. O. El-Kadi 2 . 1 Pharmacology & Toxicology, King 

Saud University, Riyadh, Saudi Arabia and 2 Faculty 

of Pharmacy & Pharmaceutical Sciences, University 

of Alberta, Edmonton, AB, Canada. 


EFFECTS OF THE STANDARDIZED 

EXTRACT OF CENTELLA ASIATICA 

(ECA 233) ON HUMAN CYTOCHROME 

P450. S. T. Lawanprasert, N. Niwattisaiwong, W. 

Warisnoicharoen, P. Seeka, T. Winitthana and M. 

H. Tantisira. Faculty of Pharmaceutical Sciences, 

Chulalongkorn University, Bangkok 10330, 

Thailand. Sponsor: L. Robertson. 


BUTADIENE EPOXIDE METABOLITES 

INHIBIT CYP2E1 ACTIVITY. J. H. Hartman 1 , 

G. P. Miller 1 and G. Boysen 2 . 1 Biochemistry, 

University of Arkansas for Medical Sciences, Little 

Rock, AR and 2 Environmental and Occupational 

Health, University of Arkansas for Medical Sciences, 



EFFECTS OF HERBAL EXTRACTS ON 

CYTOCHROME P450-ASSOCIATED 

MONOOXYGENASE ACTIVITIES IN 

ENRICHED RAT LIVER MICROSOMES. D. 

Lee, M. Kong, G. Ko, S. Yoo, H. Ha, T. Jeong and M. 

Kang. Pharmacy, Yeungnam University, Gyeongsan, 

Gyeongbuk, Republic of Korea. 


IS THE PROMISCUITY OF THE ARYL 

HYDROCARBON RECEPTOR A MYTH? 

E. Wincent 1,2 , J. Bengtsson 2 , U. Rannug 2 and A. 

Rannug 1 . 1 Institute of Environmental Medicine, 


2 

Department of Genetics, Microbiology, and 

Toxicology, Stockholm University, Stockholm, 

Sweden. 


IN VITRO METABOLISM OF DI(2- 

ETHYLHEXYL) PHTHALATE (DEHP) 

BY VARIOUS HUMAN AND RAT ORGAN 

MICROSOMES, S9, AND CYP ISOFORMS. 

J. Campbell, K. Choi, H. Joo, R. Clewell and H. 

Clewell. The Hamner Institutes, Research Triangle 

Park, NC. 


USE OF ALTERNATIVE PROMOTERS AS 

REGULATORS OF HUMAN MICROSOMAL 

EPOXIDE HYDROLASE EXPRESSION. H. 

Nguyen, X. Yang and C. J. Omiecinski. Center 

for Molecular Toxicology, Penn State University, 



RESPECTIVE ROLES OF CYP2A5 AND 

CYP2F2 IN THE BIOACTIVATION 

OF 3-METHYLINDOLE IN MOUSE 

OLFACTORY MUCOSA AND LUNG. X. 

Zhou 1 , J. D’Agostino 1 , L. Li 1 , G. S. Yost 2 and 

X. Ding 1 . 1 Wadsworth Center, Albany, NY and 

2 


280 






Platform Sessions



Abstract # 


MICROSOMAL METABOLISM OF 

NAPHTHALENE (NA) IN TARGET AND 

NON-TARGET RODENT TISSUES: 

COMPARISON WITH NON-HUMAN 

PRIMATES. A. Buckpitt, D. Morin, P. Edwards and 

L. Van Winkle. Veterinary Medicine, University of 



CYTOCHROME P450S MEDIATE THE 

METABOLISM AND ARE REGULATED 

BY BERBERINE IN MICE AND HUMANS. 

Y. J. Guo 1 , F. Li 2 , Y. Chen 1 , Z. Tan 1 , C. Pope 3 , X. 

Chen 2 , X. Ma 2 , C. D. Klaassen 2 and H. Zhou 1 . 

1 

Pharmacogenetics Research Institute, Institute of 

Clinical Pharmacology, Central South University, 

Changsha, China, 2 University of Kansas Medical 

Center, Kansas and 3 XenoTech, LLC, Kansas City, 

KS. 


CYTOCHROME P450 2S1 MEDIATED 

REGULATION OF HUMAN LUNG CELL 

PROLIFERATION. A. M. Rowland, T. W. 

Madanayake, T. P. Fidler and L. Montoya. Chemistry 

and Biochemistry, New Mexico State University, Las 

Cruces, NM. 


NEW ROLES OF CYTOCHROME P4501A1 

(CYP1A1) AND THE ENDOGEONUS ARYL 

HYDROCARBON RECEPTOR (AHR) 

LIGAND 6-FORMYLINDOLO[3, 2-b] 

CARBAZOLE (FICZ) IN REGULATION 

OF CELL GROWTH. A. Rannug 1 , H. Mei 1 , A. 

Mohammmadi-Bardbori 1 , Y. Wei 2 and U. Rannug 3 . 

1 


Institutet, Stockholm, Sweden, 2 Department of 

Community Medicine, Mercer University School 

of Medicine, Macon, GA and 3 Department of 

Genetics, Microbiology, and Toxicology, Stockholm 

University, Stockholm, Sweden. 


TRANSCRIPTOMIC EVALUATION OF 

CANINE SUSPENSION-SHIPPED AND PRE- 

PLATED HEPATOCYTES: COMPARISON 

TO LIVER. A. Ditewig, M. Liguori, E. Blomme 

and Y. Yang. Cellular, Molecular, and Exploratory 

Toxicology, Abbott Laboratories, Abbott Park, IL. 


RAT CYTOCHROME P450 2S1 (CYP2S1) 

IS NOT INDUCED BY THE ARYL 

HYDROCARBON RECEPTOR (AHR) 

AGONIST PCB126. B. Wang 1 , L. Robertson 1,2 , 

K. Wang 3 and G. Ludewig 1,2 . 1 Human Toxicology, 

University of Iowa, Iowa City, IA, 2 Occupational 

& Environmental Health, University of Iowa, Iowa 

City, IA and 3 Biostatistics, University of Iowa, Iowa 

City, IA. 


REGULATION OF CARBONYL REDUCTASE 

EXPRESSION AND ACTIVITY BY AH 

RECEPTOR LIGANDS. E. A. Amouzougan 1 , 

C. R. Klocke 1 , H. A. Charlier 2 and K. A. Mitchell 1 . 

1 

Biological Sciences, Boise State University, Boise, 

ID and 2 Chemistry and Biochemistry, Boise State 

University, Boise, ID. 

Abstract # 


INCREASED LEVELS OF OXIDATIVE 

DNA ADDUCTS IN CYTOCHROME 

P450 (CYP)1A2-NULL MICE AND 

PREMATURE INFANTS EXPOSED TO 

HYPEROXIA: NOVEL BIOMARKERS FOR 

BRONCHOPULMONARY DYSPLASIA (BPD). 

B. Moorthy 1 , L. Wang 1 , C. Xanthi 1 , G. Zhou 2 and 

W. Jiang 1 . 1 Pediatrics, Baylor College of Medicine, 

Houston, TX and 2 Institute of Biotechnology, Texas 

A&M University, Houston, TX. 


ALTERATION IN EXPRESSION OF MOUSE 

CARBOXYLESTERASE ISOFORMS 

FOLLOWING DEVELOPMENTAL 

DELTAMETHRIN EXPOSURE: ROLE OF 

NUCLEAR RECEPTORS. A. A. Baker and 

J. R. Richardson. Toxicology, UMDNJ-Rutgers 



TRANSCRIPTIONAL REGULATION OF 

THE HUMAN MICROSOMAL EPOXIDE 

HYDROLASE GENE (EPHX1) DRIVEN 

BY A FAR UPSTREAM ALTERNATIVE 

PROMOTER. S. Su 1,2 and C. Omiecinski 2 . 1 Huck 

Institute of Life Sciences, Penn State University, 

University Park, PA and 2 Center for Molecular 

Toxicology and Carcinogenesis, Penn State 

University, University Park, PA. 


ROS PRODUCTION AND ENZYME 

INACTIVATION OF ZEBRAFISH CYP1S 

BY HALOGENATED AROMATIC 

HYDROCARBONS. J. V. Goldstone 1 , P. Urban 2 , 

D. Pompon 2 and J. J. Stegeman 1 . 1 Biology, Woods 

Hole Oceanographic Institution, Woods Hole, MA 

and 2 CNRS-Gif sur Yvette, Gif sur Yvette, France. 


OXIDATIVE METABOLISM OF STYRENE IN 

CYP2F2-NULL MOUSE LIVER AND LUNG 

MICROSOMES. S. Shen 1 , L. Li 2 , X. Ding 2 and J. 

Zheng 1,3 . 1 Center for Developmental Therapeutics, 

Seattle Children’s Research Institute, Seattle, WA, 

2 

Wadsworth Center, New York State Department of 

Health, and School of Public Health, State University 

of New York, NY and 3 Department of Pediatrics, 



DOWN REGULATION OF MOUSE CYP2DS 

IN PRIMARY HEPATOCYTES USING RNAI. 

O. Elraghy 1 , B. Damiri 2 and W. S. Baldwin 1,2 . 

1 

Biological Sciences, Clemson University, Clemson, 

SC and 2 Environmental Toxicology Program, 

Clemson University, Clemson, SC. 


DIFFERENTIAL SULFOTRANSFERASE 

EXPRESSION AFTER FASTING AND 

CALORIC RESTRICTION IN LIVERS OF 

LEAN (C57BL/6) AND OBESE (OB/OB) MICE. 

N. H. Knudsen 1 , S. R. Kulkarni 2 , J. Xu 2 , R. S. King 2 

and A. L. Slitt 2 . 1 Biochemistry, Moravian College, 

Bethlehem, PA and 2 Biomedical and Pharmaceutical 

Sciences, University of Rhode Island, Bethlehem, RI. 

Wednesday 







281



Wednesday 



NAT1 INTERACTION WITH PPD AND 

OXIDIZED PPD. J. Bonifas, D. Dierolf and B. 

Blömeke. Environmental Toxicology, University 

Trier, Trier, Germany. 


CHANGES IN PHASE I AND PHASE II 

ENZYME ACTIVITIES OVER TIME IN 

PLATED HUMAN HEPATOCYTES. T. Moeller, 

S. Heyward, J. Lee and R. Tolando. Celsis In Vitro 

Technologies, Halethorpe, MD. Sponsor: M. Xia. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Toxicology Education: K–12 and Beyond 

Chairperson(s): Sue Ford, St. Johns University, Jamaica, NY. 




INSPECTOR TOXICOLOGY : AN 

INNOVATIVE TOXICOLOGY AWARENESS 

PROGRAM. D. Hardej 1,2 and A. R. Schatz 1 . 

1 

Mid-Atlantic Society of Toxicology (MASOT), 

Bordentown, NJ and 2 Department of Pharmaceutical 

Sciences, St. John’s University, Jamaica, NY. 


TOTALLY TOXIC! A K-12 SCIENCE 

OUTREACH ACTIVITY USING CASE 

STUDIES TO TEACH BASIC PRINCIPLES 

OF TOXICOLOGY. C. P. Curran 1 and D. R. 

Mattie 2 . 1 Biological Sciences, Northern Kentucky 

University, Highland Heights, KY and 2 Nano/ 

Toxicology Section, AFRL/Wright-Patterson AFB, 

Dayton, OH. 


SCIENCE DAY: HANDS-ON SCIENTIFIC 

OUTREACH WITH THE GIRL SCOUTS. T. 

R. Hiltke 2 and M. R. Gwinn 1 . 1 U.S. EPA, Washington, 

D.C. and 2 Girl Scout Council National Chapter, New 

Market, MD. 


SCIENTIFIC OUTREACH – 

COLLABORATING WITH LOCAL 

PARTNERS. M. K. Stapleton 2 , M. R. Gwinn 1 and 

J. M. Matheson 3 . 1 U.S. EPA, Washington, D.C., 

2 

Towson University, Baltimore, MD and 3 Consumer 

Product Safety Commission, Bethesda, MD. 


THE IDAHO SCIENCE & ENGINEERING 

FESTIVAL: SATELLITE EVENT FOR K-12 

SCIENCE EDUCATION. J. C. Pfau, C. Evilia 

and L. DeVeaux. Biological Sciences, Idaho State 

University, Pocatello, ID. 


THE VOYAGE OF THE ODYSSEY: A 

UNIQUE PLATFORM FOR TOXICOLOGY 

RESEARCH AND EDUCATION. I. Kerr 1,3 

and J. P. Wise 1,2,3 . 1 Ocean Alliance, Lincoln, MA, 

2 



Portland, ME and 3 Maine Center for Toxicology 


Maine, Portland, ME. 


REINFORCING QUANTITATIVE SKILLS 

THROUGH DATA ANALYSIS IN AN 

UNDERGRADUATE TOXICOLOGY 

COURSE. V. A. Fitsanakis. Biology, King College, 

Bristol, TN. 


UNDERGRADUATE RESEARCH UTILIZING 

C. ELEGANS DURING A TOXICOLOGY 

COURSE. M. Pomeroy-Black. LaGrange College, 

LaGrange, GA. 


DEVELOPING UNDERGRADUATE 

ENVIRONMENTAL HEALTH 

AND TOXICOLOGY CURRICULA 

WITH RESEARCH EXPERIENCE 

OPPORTUNITIES. B. W. Brooks. Baylor 

University, Waco, TX. 


INTRODUCTION OF UNDERGRADUATE 

STUDENTS TO TOXICOLOGY-RELATED 

ISSUES THROUGH JOURNALING. S. M. 

Ford. Toxicology Program, St. Johns University, 

Queens, NY. 


TOXLEARN: AN NLM-SOT EDUCATIONAL 

COLLABORATION. P. Wexler 1 , M. Kamrin 2 , 

B. Eidemiller 3 and S. Ray 4 . 1 Toxicology and 

Environmental Health Information Program, National 

Library of Medicine, Bethesda, MD, 2 Center for 


East Lansing, MI, 3 Society of Toxicology, Reston, 

VA and 4 Pharmaceutical Sciences, AMS College 

of Pharmacology & Health Sciences, Long Island 

University, Brooklyn, NY. 


SO YOU WANT TO START A TOXICOLOGY 

GRADUATE PROGRAM? A. de Peyster. 

Graduate School of Public Health, San Diego State 

University, San Diego, CA. 


TRISK: A EUROPEAN ADVANCED RISK 

ASSESSORS TRAINING PROGRAMME FOR 

TOXICOLOGY EXPERTS. A. Moretto 1,2 , C. L. 

Galli 1 , H. Hakansson 3 , S. Price 4 , B. J. Blaauboer 5 , 

R. Kahl 6 and M. Gerevini 7 . 1 University of Milano, 

Milano, Italy, 2 ICPS, Ospedale Sacco, Milano, 

Italy, 3 Karolinska Institute, Stockholm, Sweden, 

4 

University of Surrey, Guildford, United Kingdom, 

5 

Universiteit Utrecht, Utrecht, Netherlands, 

6 

Universitatsklinikum Dusseldorf, Dusseldorf, 

Germany and 7 Tecnoalimenti, Milano, Italy. 

282 






Platform Sessions



Abstract # 


REGISTRATION OF SPECIALISTS IN 

TOXICOLOGY AND RISK ASSESSMENT IN 

AUSTRALASIA. P. Di Marco 1 and B. Priestly 2 . 

1 

Environment, Golder Associates, West Perth, WA, 

Australia and 2 Australian Centre for Human Health 

Risk Assessment, Monash University, Clayton, VIC, 

Australia. 


RESULTS OF THE 2010 SOCIETY OF 

TOXICOLOGY GLOBAL JOB OUTLOOK 

SURVEY. J. Kerzee 1 , M. Genter 2 , J. A. Popp 3 , R. 

D. Storer 4 and V. Vasiliou 5 . 1 Health and Life Sciences 

Global Business, Battelle Memorial Institute, 

Columbus, OH, 2 Department of Environmental 

Health and Safety, University of Cincinnati, 

Cincinnati, OH, 3 Stratoxon, Lancaster, PA, 

4 

Laboratory Sciences and Investigative Toxicology, 

Merck & Co., Inc., West Point, PA and 5 Department 

of Pharmaceutical Sciences, University of Colorado, 

Aurora, CO. 


PLACING TOXICOLOGICAL SCIENCE IN 

THE CONTEXT OF HISTORY, SOCIETY, 

AND CULTURE. S. Gilbert 1 and P. Wexler 2 . 

1 

INND, Seattle, WA and 2 National Library of 

Medicine, Bethesda, MD. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Safety Testing of Pharmaceuticals 

Chairperson(s): Kenneth Olivier, Merrimack Pharmaceuticals, 





ZEBRAFISH BEHAVIOR IN TESTS OF 

SOCIAL PREFERENCE AND SOCIAL 

NOVELTY FOLLOWING ACUTE 

PARACETAMOL, 5-HT 1A 

OR CB 1 

AGONIST 

EXPOSURES. P. A. Barba-Escobedo 1,2 and G. G. 

Gould 2,1 . 1 Arts & Sciences, Texas A&M San Antonio, 

San Antonio, TX and 2 Physiology, University of 

Texas Health Science Center at San Antonio, San 

Antonio, TX. 


TOXICITY EVALUATION OF INHALED 

LOXAPINE IN THE RAT. B. E. Stewart 1 , M. 

Garley 1 and A. Koester 2 . 1 Alexza Pharmaceuticals, 

Inc., Mountain View, CA and 2 Battelle, Columbus, 

OH. 


TOXICITY EVALUATION OF INHALED 

LOXAPINE IN THE DOG. M. K. Garley 1 , B. E. 

Stewart 1 and R. Matheson 2 . 1 Alexza Pharmaceuticals, 

Inc., Mountain View, CA and 2 Charles River 

Laboratories Preclinical Services Montréal, 

Senneville, QC, Canada. 

Abstract # 


DOXORUBICIN-INDUCED PLATELET 

PROCOAGULANT ACTIVITIES: AN 

IMPORTANT CLUE FOR CHEMOTHERAPY- 

ASSOCIATED THROMBOSIS? K. Kim, S. 

Kim, K. Lim, J. Noh, S. Kang, O. Bae and J. Chung. 

College of Pharmacy, Seoul National University, 



TOXICOLOGY ASSESSMENT OF 

SHETA2, A NOVEL CHEMOPREVENTIVE 

AGENT, IN RATS AFTER 28-DAY ORAL 

ADMINISTRATION. K. K. Kabirov 1 , I. M. 

Kapetanovic 2 , A. Banerjee 1 , A. D. Zakharov 1 , D. 

M. Benbrook 3 and A. V. Lyubimov 1 . 1 University of 

Illinois at Chicago, Chicago, IL, 2 National Cancer 

Institute, Bethesda, MD and 3 University of Oklahoma 

Health Sciences Center, Oklahoma City, OK. 


CALCIUM CHANNEL BLOCKERS DISRUPT 

LEARNING IN AN INCREMENTAL 

REPEATED ACQUISITION PROCEDURE. 

J. Bailey 1 , Y. Lin 2 , W. Ravis 2 and C. Newland 1 . 

1 

Psychology, Auburn University, Auburn, AL and 

2 

Pharmacal Sciences, Auburn University, Auburn, 

AL. 


APOPTOTIC MECHANISMS OF ARSENIC 

TRIOXIDE IN HUMAN PROMYELOCYTIC 

LEUKEMIA (HL-60) CELLS. C. G. Yedjou and 

P. B. Tchounwou. Biology, Jackson State University, 

Jackson, MS. 


MM-302, A HER2-TARGETED LIPOSOMAL 

DOXORUBICIN, LIMITS DOXORUBICIN 

ACCUMULATION IN CARDIOMYOCYTES, 

AND ENHANCES DOXORUBICIN UPTAKE 

INTO TUMOR CELLS IN VITRO. J. Reynolds 1 , 

B. Hendriks 1 , P. Lucker 2 , K. J. Olivier 1 , P. Zandstra 2 , 

C. Niyikiza 1 , J. Park 3 , C. Benz 4 , D. Drummond 1 , 

U. Nielsen 1 and T. J. Wickham 1 . 1 Merrimack 

Pharmaceuticals, Cambridge, MA, 2 University 

of Toronto, Toronto, ON, Canada, 3 University of 

California, San Francisco, CA and 4 Buck Institute, 

Novato, CA. 


MECHANISTIC INSIGHT AND SENSITIVITY 

OF HIGH-CONTENT SCREENING 

(HCS) OVER SINGLE-PARAMETER 

CYTOTOXICITY ASSAYS. P. Walker 2 , J. 

Mein 1,2 , M. Jacewicz 1,2 , J. Gilbert 1,2 , R. Annand 1,2 , H. 

Gill 2 and K. Tsaioun 1,2 . 1 Apredica, Watertown, MA 

and 2 Cyprotex, Macclesfield, United Kingdom. 


BIPHASIC REGULATION OF 

INTRACELLULAR CALCIUM BY 

GEMFIBROZIL CONTRIBUTED TO 

THE INHIBITING L6 MYOBLAST 

DIFFERENTIATION. R. Dai 1,3 , A. Liu 1 , J. 

Yang 1 and F. J. Gonzales 2 . 1 School of Biosciences 

and Bioengineering, South China University 

of Technology, Guangzhou, China, 2 Lab. of 


MD and 3 Zhongshan Pharmass Corporation, 

Zhongshan City, Guangdong, China. 

Wednesday 







283



Wednesday 



BINDING OF THE THERAPEUTIC 

ANTIBODY CP-751871 TO IGF-1R INDUCES 

PARTIAL AGONIST SIGNALING IN HUMAN 

AND MONKEY IMMUNE CELLS. D. U. Lee 

and B. Jessen. Drug Safety, Pfizer R&D, La Jolla, 

CA. 


A 5-DAY ORAL REPEAT-DOSE TOXICITY 

STUDY IN SPRAGUE-DAWLEY RATS TO 

EVALUATE THE TOLERABILITY OF AN S1P 

AGONIST. C. Hurst, T. Sullivan and J. Clarke. 

Biogen Idec, Cambridge, MA. 


THERAPEUTIC EFFICACY AND SAFETY 

EVALUATION OF UC-II ALONE OR IN 

COMBINATION WITH GLUCOSAMINE 

AND CHONDROITIN IN ARTHRITIC DOGS 

USING PIEZOELECTRIC SENSOR-BASED 

GROUND FORCE PLATE. R. C. Gupta 1 , T. D. 

Canerdy 1 , J. Lindley 1 , B. A. Carroll 1 , M. Konemann 1 , 

C. Hendricks 1 , M. Bagchi 2 , D. Bagchi 2 and J. T. 

Goad 1 . 1 Toxicology, Murray State University, 

Hopkinsville, KY and 2 InterHealth Research Center, 

Benicia, CA. 


9:00 AM to 12:30 PM 

Exhibit Hall 




Poster Session: Pharmaceutical Safety Assessment: Novel 

Methods 

Chairperson(s): Clement Yedjou, Jackson State University, Jackson, MS. 




AUTOMATIC SINGLE CELL CALCIUM 

TRANSIENT ANALYSIS FOR 

CARDIOTOXICITY SCREENING AND 

PHARMACOLOGICAL TESTING. F. 

Cerignoli 1,2 , D. Charlot 3,4 , R. Ingermanson 2 , K. Wei 1 , 

A. Savtchenko 2 , J. H. Price 2,3 , P. M. McDonough 2 

and M. Mercola 1 . 1 Muscle Development and 

Regeneration Program, Sanford-Burnham Medical 

Research Institute, La Jolla, CA, 2 Vala Sciences 

Inc., San Diego, CA, 3 Quantitative Microscopy 

Laboratory, Sanford-Burnham Medical Research 

Institute, La Jolla, CA and 4 Bioengineering, 

University of California, San Diego, CA. 


A STRATEGY COMBINING HIGH- 

CONTENT SCREENING AND ZEBRAFISH 

LARVAE TO PREDICT HUMAN DRUG- 

INDUCED HEPATOTOXICITY. N. Mesens, 

M. Steemans, F. Van Goethem and J. Van 

Gompel. Global Preclinical Development, Janssen 

Pharmaceutical Companies of Johnson&Johnson, 

Beerse, Belgium. 


MULTIPLEX DETECTION OF OXIDATIVE 

PHOSPHORYLATION AS A MECHANISTIC 

INDICATOR FOR DRUG-INDUCED 

MITOCHONDRIAL TOXICITY. W. Zheng 1 , 

L. Goretzki 1 , G. Korzus 1 , J. Wang 1 , J. Murray 2 and 

R. Capaldi 2 . 1 R&D, EMD Millipore, San Diego, CA 

and 2 R&D, MitoSciences, Eugene, OR. Sponsor: R. 

Wiese. 


IMPORTANCE OF RAT AND HUMAN 

SCREENS FOR ARYL HYDROCARBON 

RECEPTOR (AHR) ACTIVATION/CYP1A 

INDUCTION. H. J. Garside, S. Atwal, M. R. 

Brown, J. Bowes, M. Graham and J. Valentin. Global 

Safety Assessment, AstraZeneca, Macclesfield, 



NOVEL IN VITRO APPROACH FOR 

ASSESSING CARDIAC CONTRACTILE 

LIABILITIES USING MICROPATTERNED 

MUSCULAR THIN FILMS. A. Grosberg 1,2 , 

M. D. Brigham 1 , J. A. Goss 1 , P. W. Alford 1 and K. 

K. Parker 1,2 . 1 Harvard School of Engineering and 

Applied Sciences, Boston, MA and 2 Wyss Institute 

for Biologically Inspired Engineering at Harvard 

University, Boston, MA. Sponsor: A. Bahinski. 


A NOVEL IN VITRO APPROACH 

TO IDENTIFY MECHANISMS OF 

HEPATOTOXICITY. C. Hu, D. Pietrzak, 

K. French and K. Frazier. Safety Assessment, 

GlaxoSmithKline, King of Prussia, PA. 


GENERATION OF PRECISION CUT LIVER 

SLICES FROM PINCH BIOPSY SECTIONS. 

K. Kowalkowski, A. Lisowski, W. R. Buck, E. 

Blomme and Y. Yang. Abbott Laboratories, Abbott 

Park, IL. 


A HUMAN BREATHING LUNG-ON-A- 

CHIP FOR DRUG SCREENING AND 

NANOTOXICOLOGY APPLICATIONS. 

D. Huh 1,2 , B. D. Matthews 2 , A. Mammoto 2 , M. 

Montoya 1 , H. Hsin 2 and D. E. Ingber 1,2,3 . 1 Wyss 

Institute for Biologically Inspired Engineering 

at Harvard University, Boston, MA, 2 Children’s 

Hospital Boston and Harvard Medical School, 

Boston, MA and 3 School of Engineering and Applied 

Sciences, Harvard University, Cambridge, MA. 

Sponsor: A. Bahinski. 


IN VITRO PREDICTION OF INJECTION 

SITE REACTIONS USING L6 RAT 

SKELETAL MUSCLE CELLS. J. A. Willy 1 , N. 

Schulte 2 , E. Kreklau 1 , J. Walgren 1 , A. Stauber 1 , J. L. 

Stevens 1 and T. K. Baker 1 . 1 Toxicology, Eli Lilly and 

Co., Indianapolis, IN and 2 Preformulation, Eli Lilly 

and Co., Indianapolis, IN. 

284 






Platform Sessions



Abstract # 


HEPARG CELL MODEL IN HIGH-CONTENT 

SCREENING ASSAYS GIVES MECHANISTIC 

INSIGHT INTO METABOLISM-MEDIATED 

HEPATOTOXICITY. J. Mein 1,3 , P. Walker 3 , M. 

Jacewicz 1,3 , R. Annand 1,3 , D. Steen 2 , C. Chesne 2 , 

H. Gill 2 and K. Tsaioun 1,3 . 1 Apredica, Watertown, 

MA, 2 Biopredic, Rennes, France and 3 Cyprotex, 

Macclesfield, United Kingdom. 


A NOVEL RESAZURIN/RESORUFIN 

CELLULAR ASSAY TO DETECT AND 

CHARACTERIZE REACTIVE ACYL 

GLUCURONIDES. M. McMillian, J. Sasaki, 

M. Singer, F. Xu and H. Lim. Johnson & Johnson, 

Raritan, NJ. 


HEPATOTOXIC DRUGS THAT DISTURB 

MITOCHONDRIAL FUNCTIONS ARE 

DETECTED IN THE SPERMATOZOA 

MOTILITY ASSAY. I. Edebert 1 , L. Löfstedt 1 , I. 

Rafter 1 , I. Cotgreave 1 , P. Rigler 2 , A. Serov 2 and R. 

Rigler 2 . 1 Safety Assessment, Molecular Toxiclogy, 

AstraZeneca R&D Södertälje, Södertälje, Sweden 

and 2 Biophos SA, PSE-A EPFL, CH-1015, Lausanne, 

Switzerland. Sponsor: P. Moldeus. 


IDENTIFYING KEY KINASES ASSOCIATED 

WITH BONE MARROW TOXICITY. L. 

Marroquin, W. Hu and B. Jessen. Pfizer, San Diego, 

CA. 


A RAT HEART SLICE MODEL TO 

EVALUATE THE IMPACT OF DRUG- 

INDUCED INJURY ON CARDIAC HEALTH. 

J. Herrmann and A. Vickers. Allergan, Inc., Irvine, 

CA. 


DETECTION OF DRUG-INDUCED 

STRUCTURAL CARDIOTOXICITY 

IN THE RAT H9C2 CELL LINE: SUB- 

LETHAL ENDPOINTS OFFER GREATER 

SENSITIVITY THAN CYTOTOXICITY. 

A. Pointon, S. Dawson, N. Gerges and J. E. 

Sidaway. Global Safety Assessment, AstraZeneca, 

Macclesfield, United Kingdom. Sponsor: D. Brown. 


EX VIVO CYTOCHROME P450 INDUCTION 

ANALYSIS AS A TOOL TO CLARIFY 

MECHANISM OF LIVER DYSFUNCTION IN 

RODENT TOXICITY STUDIES. M. Graham 2 , 

C. Garner 1 , P. P. Lainee 1 , H. Garside 1 , A. Scally 2 , 

H. Marshall 2 and J. Valentin 1 . 1 Safety Assessment, 

AstraZeneca, Alderley Park, United Kingdom and 

2 

Safety Assessment, AstraZeneca, Charnwood, 



A FLOW CYTOMETRIC MULTIPLEX HIGH- 

THROUGHPUT APOPTOSIS ASSAY USING 

THE HTFC SYSTEM. C. Black 1 , B. Stout 1 , K. 

Luu 1 , T. Duensing 1 , P. Rana 2 and Y. Will 2 . 1 IntelliCyt 

Corporation, Albuquerque, NM and 2 Compound 

Safety Prediction, Pfizer Inc., Groton, CT. 

Abstract # 


POLYSORBATE 80 14.7% IS A SUITABLE 

VEHICLE IN LONG-TERM RAT 

TOXICOLOGY STUDIES. E. Lesage 1 , M. 

Awori 1 , F. Vlasseros 1 , S. Y. Smith 1 , T. Ahn 2 and K. 

Veverka 2 . 1 Toxicology, Charles River Preclinical 

Services, Montréal, QC, Canada and 2 GTx Inc., 

Memphis, TN. Sponsor: M. Vézina. 


FUNCTIONAL ASSESSMENTS IN REPEAT- 

DOSE TOXICITY STUDIES IN RODENTS 

AND NON-RODENTS: OVERCOMING 

PREJUDICES. W. S. Redfern, L. Ewart, P. Lainée, 

S. Robinson and J. Valentin. Safety Assessment UK, 

AstraZeneca R&D Alderley Park, Macclesfield, 

Cheshire, United Kingdom. 


AN IMPROVED SYSTEM FOR 

SURGICALLY IMPLANTED IN-DWELLING 

CATHETERIZATION FOR LONG 

TERM INTRAVENOUS INFUSION IN 

CYNOMOLGUS MONKEYS, USING 

2% TAUROLIDINE-CITRATE (TC) TO 

MAINTAIN CATHETER PATENCY. R. Tavcar 

and K. Draper. Laboratory Research, Laval, QC, 

Canada. 


VALIDATION OF RESPIRATORY 

INDUCTANCE PLETHYSMOGRAPHY IN 

CONSCIOUS CYNOMOLGUS MONKEYS. 

K. R. Kearney, M. R. Metea and P. R. Atterson. WIL 

Research Laboratories, LLC, Ashland, OH. 


DRUG DISPOSITION AND CARDIAC 

TOXICITY: A LITERATURE-BASED 

REVIEW. T. G. Hammond 1 , J. Bowes 1 , S. Boyer 3 , 

M. P. Burnham 1 , D. Cook 1 , C. Gavaghan 3 , M. 

Hance 4 , M. M. Haywood 1 , S. Matis 4 , S. Roberts 1 , B. 

Springthorpe 2 and J. Valentin 1 . 1 Safety Assessment, 

AstraZeneca, Alderley Park, United Kingdom, 

2 

Safety Assessment, Astrazeneca, Charnwood, United 

Kingdom, 3 Safety Assessment, Astrazeneca, Molndal, 

Sweden and 4 Safety Assessment, Astrazeneca, 



POLYSORBATE 80 14.7% IS A SUITABLE 

VEHICLE IN LONG-TERM NON-HUMAN 

PRIMATE TOXICOLOGY STUDIES. M. 

Awori 1 , E. Lesage 1 , F. Vlasseros 1 , S. Y. Smith 1 , T. 

Ahn 2 and K. Veverka 2 . 1 Toxicology, Charles River 

Preclinical Services, Montréal, QC, Canada and 

2 

GTx, Inc., Memphis, TN. Sponsor: M. Vézina. 


BACKGROUND DATA AND COMPARISON 

OF TWO LONG-TERM CONTINUOUS 

INTRAVENOUS INFUSION MODELS IN THE 

MOUSE USED FOR SAFETY ASSESSMENT 

STUDIES. H. Van Wijk and A. Fraser. Covance 

Laboratories Ltd., Harrogate, United Kingdom. 

Sponsor: S. Kirk. 

Wednesday 







285



Wednesday 



INTEGRATION OF PIG-A, MICRONUCLEUS, 

CHROMOSOME ABERRATION, AND 

COMET ASSAY ENDPOINTS IN A 28-DAY 

RODENT TOXICITY STUDY WITH 

4-NITROQUINOLINE-1-OXIDE (4NQO). M. 

McKeon, H. Chen, T. E. Lawlor, H. Murli, D. J. 

Roberts, A. Thakur, Y. Xu and L. F. Stankowski. 

Covance Laboratories, Inc., Vienna, VA. 


COMPUTERIZED ARRHYTHMIA 

DETECTION IN LARGE TELEMETERED 

ANIMALS: A NOVEL STRATEGY TO ASSESS 

DRUG LIABILITIES. R. Mikaelian 1 , S. Authier 1,3 , 

F. Koeppel 2 , F. Rossi 2 , D. Labarre 2 , S. Fournier 1 and 

E. Troncy 3 . 1 Laboratory Research Inc., Laval, QC, 

Canada, 2 Notocord, Paris, France and 3 Faculty of 

Veterinary Medicine, University of Montréal, St. 

Hyacinthe, QC, Canada. Sponsor: K. Draper. 


HOW TO IMPROVE SENSITIVITY OF 

RESPIRATORY SAFETY PHARMACOLOGY 

STUDIES IN CYNOMOLGUS MONKEYS 

USING IMPEDANCE MONITORED BY 

IMPLANTABLE TELEMETRY: THE USE OF 

SUPER-INTERVALS. F. Duguay 1 , S. Authier 1,2 , S. 

Fournier 1 and B. Moon 3 . 1 Laboratory Research Inc., 

Laval, QC, Canada, 2 Faculty of Veterinary Medicine, 

University of Montréal, St. Hyacinthe, QC, Canada 

and 3 Data Science International, St. Paul, MN. 

Sponsor: K. Draper. 


RESPIRATORY SAFETY PHARMACOLOGY 

MONITORING IN CONSCIOUS GÖTTINGEN 

MINIPIGS: QUALIFICATION OF A NEW 

MODEL. C. Ponzi 1 , J. Gervais 1,2 , E. Troncy 2 and 

S. Authier 1,2 . 1 Laboratory Research Inc., Laval, 

QC, Canada and 2 Faculty of Veterinary Medicine, 

University of Montréal, St. Hyacinthe, QC, Canada. 

Sponsor: K. Draper. 


SUBCUTANEOUS LOCAL TOLERANCE 

FOR BIOLOGIC DRUG DEVELOPMENT: 

COMPARISON OF TWO APPROACHES. S. 

Fleming-Weis 1 , L. M. Diehl 2 , D. Aleksandrowicz 1 , J. 

Morrow 1 , K. J. Zokowski 4 , K. Ishida 1 , L. E. Beebe 1 , 

J. M. Pletcher 3 , W. P. Davis 4 and J. B. Clarke 1 . 

1 

Pharmacotoxicology, Biogen Idec, Cambridge, 

MA, 2 Toxicology, Charles River Laboratories, 

Spencerville, OH, 3 Pathology Associates, Charles 

River Laboratories, Frederick, MD and 4 Comparative 

Pathology, Biogen Idec, Cambridge, MA. 


CYNOMOLGUS MONKEYS: FACTORS 

AND ISSUES FOR CONSIDERATION IN 

THE SELECTION OF SEXUALLY MATURE 

MALES AND FEMALES FOR PRECLINICAL 

SAFETY STUDIES. D. Mitchell, H. Palmer, 

R. Davis and C. Chesher. Safety Assessment, 

Huntingdon Life Sciences, Cambridgeshire, United 

Kingdom. 


SERIAL COLLECTION OF 

CEREBROSPINAL FLUID VIA A 

SURGICALLY OR PERCUTANEOUSLY 

IMPLANTED CATHETER IN 

CYNOMOLGUS MONKEYS. J. K. Herman, 

R. Avery, M. Taschwer, P. Love, J. Fohey, M. 

Abdelhameed and W. Meier. Nonclinical Safety 

Assessment, Covance Laboratories, Madison, WI. 


TEMPERATURE REGULATION AND THE 

ASSESSMENT OF TOXICITY. K. L. Hastings 1 

and M. D. Green 2 . 1 Corporate Regulatory Affairs, 

sanofi-aventis, Bethesda, MD and 2 OVRR, DVRPA, 

U.S. FDA, Bethesda, MD. 


APPLICATION OF THE DRIED BLOOD 

SPOT TECHNIQUE IN THE BIOANALYSIS 

OF SULPIRIDE. R. Forster, R. Michaud, S. 

Laurent and T. Ameller. CIT, EVREUX Cedex, 

France. 


INTRAVITREOUS ADMINISTRATION IN 

THE RABBIT AND MINIPIG. R. Forster, V. 

Haag, J. Legrand and B. Palate. CIT, EVREUX 

Cedex, France. 


ASSESSMENT OF COMMON PRECLINICAL 

VEHICLE FORMULATIONS USED IN DRUG 

DISCOVERY BY MAGNETIC RESONANCE 

SPECTROSCOPY (MRS). R. Sriram and S. 

Liachenko. Pfizer Inc., Groton, CT. Sponsor: M. 

Paule. 


DEVELOPMENT AND VALIDATION OF A 

PHARMACOKINETIC LIGAND BINDING- 

ASSAY FOR THE DETECTION OF A 

HUMANIZED THERAPEUTIC IN MULTIPLE 

SPECIES. A. Neaga, Y. Boyle-Holmes, J. E. 

Coash, Y. Q. Xiao and L. D. Albee. Department 

of Immunology, MPI Research, Mattawan, MI. 

Sponsor: A. Faqi. 


A THOROUGH CHARACTERIZATION OF 

THE THE FREQUENCY RESPONSE OF 

VARIOUS IN VIVO BLOOD PRESSURE 

MEASUREMENT TECHNOLOGIES. J. P. 

Kroehle, J. Grenwis and R. Sarazan. DSI, St. Paul, 

MN. 


OPTIMIZATION OF INTRAVENOUS 

CYNOMOLGUS MONKEY INFUSION VIA 

VASCULAR ACCESS PORT. A. M. Brooks and 

A. N. Alexander. Department of Toxicology, Covance 

Inc., Madison, WI. 


CONTROLLING FOR CROSS 

CONTAMINATION IN TOXICOLOGY 

STUDIES. M. M. Peet, C. J. Dean, C. Diabo, E. 

St. Peter and S. E. Boley. General Toxicology, MPI 


286 






Platform Sessions



Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment: Conceptual Constructs and 

Current Controversies 

Chairperson(s): David Eastmond, University of California Riverside, 

Riverside, CA, and Julie Goodman, Gradient Corporation, Cambridge, 

MA. 




PATHOLOGICAL LESIONS OF RODENTS 

LACKING HUMAN RELEVANCE IN RISK 

ASSESSMENT. M. A. Mulla, R. Nirogi, S. Jana, 

V. Goyal and S. Pandey. Toxicology, Suven Life 

Sciences Limited, Hyderabad, Andhra Pradesh, India. 

Sponsor: V. Reddy. 


AN EVALUATION OF FACTORS FOR 

CLASSIFYING A CHEMICAL AS INDUCING 

CANCER IN EITHER RODENTS OR 

HUMANS VIA A MUTAGENIC MODE OF 

ACTION USING A WEIGHT OF EVIDENCE 

APPROACH. D. A. Eastmond 1 , S. V. Vulimiri 2 and 

B. Sonawane 2 . 1 Environmental Toxicology Program, 

University of California Riverside, Riverside, CA 

and 2 National Center for Environmental Assessment, 

U.S. EPA, Washington, D.C. 


A WEIGHT-OF-EVIDENCE EVALUATION 

OF ASBESTOS EXPOSURE AND 

MESOTHELIOMA RISK AMONG 

ELECTRICIANS. M. Peterson, L. A. Bailey, D. G. 

Dodge, J. E. Goodman and P. A. Valberg. Gradient, 

Seattle, WA. 


STATE-OF-THE-SCIENCE ASSESSMENT OF 

NON-FIBROUS AMPHIBOLE EXPOSURE: IS 

THERE A HEALTH HAZARD? C. A. Williams, 

R. Adams, D. Podraza, C. Simmons, T. Rose and L. 

Dell. Environ International, Tampa, FL. 


ARSENIC SPECIATION IN AIR: AN 

EVALUATION OF THE CURRENT STATE 

OF KNOWLEDGE AND RESEARCH NEEDS. 

A. S. Lewis 1 , K. R. Reid 1 , M. C. Pollock 1 and S. 

Campleman 2 . 1 Gradient, Cambridge, MA and 

2 

Electric Power Research Institute, Palo Alto, CA. 


THE ROLE OF IRON IN THE REDUCED 

BIOAVAILABILITY OF ARSENIC IN SOIL. V. 

L. Mitchell 1 , C. N. Alpers 2 , N. T. Basta 3 , T. Burlak 4 , 

S. W. Casteel 5 , R. L. Fears 1 , A. L. Foster 6 , C. S. Kim 7 , 

P. A. Myers 1 and E. Petersen 8 . 1 Toxic Substances 

Control, Cal EPA, Sacramento, CA, 2 U.S. Geological 

Survey, Sacramento, CA, 3 Ohio State University, 

Columbus, OH, 4 California State University, 

Sacramento, CA, 5 University of Missouri, Columbia, 

MO, 6 U.S. Geological Survey, Menlo Park, CA, 

7 

Chapman University, Orange, CA and 8 University of 

Utah, Salt Lake City, UT. 

Abstract # 


ARSENIC RISK ASSESSMENT FOLLOWING 

REMOVAL OF CONSTRAINING FACTORS— 

REFERENCE POPULATION AND MEDIAN 

EXPOSURE METRIC. S. H. Lamm 1,2 , S. 

Robbins 1 , J. Lu 3 , R. Chen 4 and M. Feinleib 5 . 

1 

Epidemiology, Consultants in Epidemiology and 

Occupational Health (CEOH), Washington, D.C., 

2 

Health Policy and Management, Johns Hopkins 

Bloomberg School of Public Health, Baltimore, MD, 

3 

Mathematics, American University, Washington, 

D.C., 4 Center for New Design in Learning and 

Scholarship, Georgetown University, Washington, 

D.C. and 5 Epidemiology, Johns Hopkins Bloomberg 

School of Public Health, Baltimore, MD. Sponsor: 

J. Tsuji. 


INTERPRETING NHANES DATA ON 

ARSENIC LEVELS IN URINE USING 

BIOMONITORING EQUIVALENTS. C. 

R. Kirman 1 , S. M. Hays 2 , L. L. Aylward 3 and R. 

Schoeny 4 . 1 Summit Toxicology LLP, Orange, OH, 

2 

Summit Toxicology LLP, Lyons, Co., 3 Summit 

Toxicology LLP, Falls Church, VA and 4 U.S. EPA, 



A REVIEW OF THE POTENTIAL 

ASSOCIATION BETWEEN CHILDHOOD 

LEUKEMIA AND BENZENE. D. Pyatt 1,2,3 and S. 

Hays 1,2 . 1 Summit Toxicology, Superior, Co., 2 School 

of Public Health, University of Colorado, Denver, 

CO and 3 MTEHS Program, University of Colorado, 

Denver, CO. 


USE OF IN VITRO BIOACCESSIBILITY 

ANALYSIS, HUMAN HEALTH RISK 

ASSESSMENT, AND URINARY ARSENIC 

MEASUREMENTS TO ASSESS EXPOSURE 

AND RISKS OF CHILDREN IN A NORTHERN 

CANADIAN SMELTER COMMUNITY. E. 

Sigal, A. M. Safruk and C. M. Bacigalupo. Intrinsik, 

Mississauga, ON, Canada. 


BLOOD AND URINARY ELIMINATION 

KINETICS OF BISPHENOL A IN HUMANS 

FOLLOWING DIETARY EXPOSURE. J. 

G. Teeguarden 1 , R. Gunawan 1 and A. Calafat 2 . 

1 

Biological Monitoring and Modeling, Pacific 

Northwest National Laboratory, Richland, WA and 

2 

Organic Analytical Toxicology Branch, National 

Center for Environmental Health, Centers for 

Disease Control, Atlanta, GA. 


WEIGHT-OF-EVIDENCE EVALUATION 

OF FORMALDEHYDE EXPOSURE AND 

LEUKEMIA RISK. J. E. Goodman, D. B. 

Mayfield, L. A. Bailey and L. R. Rhomberg. Gradient, 




OF NON-CANCER ANIMAL AND 

HUMAN STUDY OUTCOMES AFTER 

FORMALDEHYDE EXPOSURE. S. L. Makris, 

T. F. Bateson, D. DeVoney, S. Y. Euling, B. S. 

Glenn and K. C. Raffaele. ORD, NCEA, U.S. EPA, 


Wednesday 







287



Wednesday 



EFFECT OF FORMALDEHYDE EXPOSURE 

ON UPPER RESPIRATORY TRACT 

CANCERS: WEIGHT OF EVIDENCE. T. F. 

Bateson, J. Jinot, R. P. Subramanian, D. DeVoney, S. 

V. Vulimiri and J. Whalan. ORD/NCEA, U.S. EPA, 



EVIDENCE-BASED ANALYSIS 

DEFINING A FORMALDEHYDE VAPOR 

CONCENTRATION NOEL FOR IRRITANT 

RESPONSES IN HUMANS. J. K. Britt 1 , N. 

Halmes 2 , B. Kerger 3 and R. C. James 1 . 1 TERRA, Inc., 

Tallahassee, FL, 2 Halmes & Associates, Centennial, 

CO and 3 HSRI, Inc., Tallahassee, FL. 



OF A PLAUSIBLE MODE OF ACTION FOR 

LEUKEMOGENESIS FROM INHALATION 

EXPOSURE TO FORMALDEHYDE. L. 

Bailey, A. K. Hamade and L. R. Rhomberg. Gradient, 



DOES FORMALDEHYDE CAUSE 

HEMATOTOXICITY? A WEIGHT- 

OF-EVIDENCE EVALUATION OF 

HEMATOTOXICITY STUDIES IN HUMANS 

AND ANIMALS IN THE CONTEXT OF 

LEUKEMOGENICITY. A. Hamade, L. A. 

Bailey and L. R. Rhomberg. Toxicology, Gradient, 



IS MTBE GENOTOXIC OR MUTAGENIC? 

M. Seeley, L. A. Beyer and B. D. Beck. Gradient 

Corporation, Cambridge, MA. 


METHYL TERTIARY BUTYL ETHER 

(MTBE): TWO-YEAR DRINKING WATER 

STUDY IN WISTAR RATS. E. Bermudez 1 , D. 

K. Layko 1 , G. A. Willson 2 and D. E. Dodd 1 . 1 The 





A COMPARATIVE RISK EVALUATION 

OF MTBE AND OTHER COMPOUNDS 

(INCLUDING NATURALLY OCCURRING 

COMPOUNDS) IN DRINKING WATER IN 

NEW HAMPSHIRE. L. A. Beyer, R. L. Mattuck, 

S. Thakali and B. D. Beck. Gradient, Cambridge, 

MA. 


SUB-CHRONIC NAPHTHALENE 

INHALATION CAUSES A DECREASE IN P53 

CODON 271 CAT MUTANT FRACTION IN 

THE NASAL RESPIRATORY EPITHELIUM 

OF MALE RATS. F. Meng 1 , Y. Wang 1 , M. B. 

Myers 1 , B. A. Wong 2 , E. A. Gross 2 , H. J. Clewell 3 , D. 

E. Dodd 2 and B. L. Parsons 1 . 1 Division of Genetic 

and Molecular Toxicology, National Center for 

Toxicological Research/U.S. FDA, Jefferson, AR, 

2 

Division of Toxicology and Preclinical Studies, The 


Triangle Park, NC and 3 Center for Human Health 

Assessment, The Hamner Institutes for Health 



NASAL EPITHELIAL LESIONS IN F344 

RATS FOLLOWING A 90-DAY INHALATION 

EXPOSURE TO NAPHTHALENE. D. E. Dodd 1 , 

B. A. Wong 1 , E. A. Gross 1 and R. A. Miller 2 . 1 The 





KEY MODE-OF-ACTION ISSUES AND DATA 

GAPS FOR NAPHTHALENE –INDUCED 

CARCINOGENICITY. C. Keshava 1 , P. McClure 2 , 

J. Stickney 2 and L. Flowers 1 . 1 NCEA, ORD, U.S. 

EPA, Washington, D.C. and 2 SRC, Inc., Syracuse, 

NY. 


OVERVIEW OF EPIDEMIOLOGY DATA 

FOR INDUSTRIES WITH NAPHTHALENE- 

CONTAINING STREAMS. R. J. Lewis. 

ExxonMobil Biomedical Science Inc., Annandale, 

NJ. Sponsor: M. Bird. 


NAPHTHALENE RESEARCH: THE 

RELEVANCE OF TUMORS IN RODENTS TO 

HUMAN RISK ASSESSMENT. A. LeHuray 1 and 

K. Wise 2 . 1 Naphthalene Council, Alexandria, VA and 

2 

American Petroleum Institute, Washington, D.C. 


PUTATIVE MECHANISMS OF 

ENVIRONMENTAL CHEMICAL-INDUCED 

STEATOSIS. J. Kaiser. Oak Ridge Institute for 

Science and Education, Oak Ridge, TN. 


POLYCHLORINATED BIPHENYLS 

ARE NOT “DIOXINS”, AND OTHER 

INCONVENIENT TRUTHS RELEVANT 

TO THE USE OF TOXIC EQUIVALENCY 

FACTORS (TEFS) IN HUMAN HEALTH RISK 

ASSESSMENT. J. B. Silkworth and E. A. Carlson. 

General Electric, Niskayuna, NY. 


APPLICATION OF LINEAR AND NON- 

LINEAR, DOSE-RESPONSE MODELS FOR 

POLYCHLORINATED BIPHENYLS (PCBs) 

BASED ON A RECEPTOR-MEDIATED 

MODE OF ACTION (MOA) FOR TUMOR 

PROMOTION. R. E. Keenan 1 , P. O. Gwinn 1 , J. M. 

Hamblen 1 , J. Shoenfelt 2 and J. B. Silkworth 3 . 1 Integral 

Consulting Inc., Portland, ME, 2 Integral Consulting 

Inc., Annapolis, MD and 3 General Electric Global 

Research, Niskayuna, NY. 


TOXIC EQUIVALENCY FACTORS ARE 

NOT UNIVERSAL WITHIN VERTEBRATE 

CLASSES: EVIDENCE, MECHANISTIC 

REASONS, AND REGULATORY 

IMPLICATIONS. E. A. Carlson 1 , C. H. Sutter 2 , 

T. R. Sutter 2 and J. B. Silkworth 1 . 1 General Electric, 

Niskayuna, NY and 2 University of Memphis, 

Memphis, TN. 

288 






Platform Sessions



Abstract # 


LOW DOSE RESPONSE RELATIONSHIPS 

FOR NON-CANCER ENDPOINTS: OZONE, 

MERCURY, AND XENOESTROGENS. L. 

Zeise 2 , G. Ginsberg 1 and M. S. Sandy 2 . 1 Connecticut 

Department of Public Health, Hartford, CT and 

2 

Cal EPA Office of Environmental Health Hazard 

Assessment, Oakland, CA. 


ANALYZING THE SAFETY OF GULF 

SEAFOOD AFTER THE OIL SPILL BASED 

ON POPULATION SPECIFIC EXPOSURE 

SCENARIOS AND INCORPORATION 

OF DISPERSANT AND HEAVY METAL 

TOXICITY PARAMETERS. J. M. Gohlke. 


Alabama at Birmingham, Birmingham, AL. 


CORN OIL AS A CAUSATIVE FACTOR 

FOR PROLIFERATIVE LESIONS OF 

THE FORESTOMACH IN B6C3F1 MICE 

EXPOSED BY GAVAGE. L. M. Plunkett 1 , 

T. Starr 2 , J. A. MacGregor 3 and A. M. Jonyas 4 . 

1 

Integrative Biostrategies LLC, Houston, TX, 2 TBS 

Associates, Raleigh, NC, 3 Toxicology Consulting 

Services, Arnold, MD and 4 Amvac Chemical 

Corporation, Newport Beach, CA. 


ASSESSING RISKS FOR SEC- AND 

TERT-BUTYLBENZENE: A SURROGATE 

METHOD. N. Y. Wang 1 and C. J. Moudgal 2 . 

1 

National Center for Environmental Assessment, U.S. 

EPA, Cincinnati, OH and 2 Environmental Risk & 

Toxicology, ICF International, Dublin, CA. 


EVALUATING IN SILICO AND IN VITRO 

TECHNOLOGIES FOR PREDICTING 

HEPATOTOXICITY. W. J. Bailey 3 , A. Bahl 1 , E. 

Keough 2 , K. R. Leander 2 , C. Gretzula 4 , I. Pak 1 , M. 

C. Kuhls 3 , C. Kreatsoulas 5 , R. P. Sheridan 5 , A. G. 

Aslamkhan 3 , L. Kiss 4 , A. Bagchi 1 and B. J. Howell 2 . 

1 

Informatics IT, Merck & Co., Inc., West Point, PA, 

2 

RNA Therapeutics, Merck & Co., Inc., West Point, 

PA, 3 Analytical & Systems Toxicology, Merck & 

Co., Inc., West Point, PA, 4 In Vitro Pharmacology, 

Merck & Co., Inc., West Point, PA and 5 Chemistry 

Modeling & Informatics, Merck & Co., Inc., West 

Point, PA. 


CANCER HAZARD IDENTIFICATION 

UTILIZING STRUCTURE- 

ACTIVITY CONSIDERATIONS FOR 

1, 3-DICHLOROPROPANOL AND 

3-MONOCHLOROPROPANE-1, 2-DIOL. D. 

W. Morry, R. S. Tomar, F. C. Tsai, M. S. Sandy and 

L. Zeise. Office of Environmental Health Hazard 

Assessment, California EPA, Oakland, CA. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Arsenic 

Chairperson(s): Shawn Wnek, University of Arizona, Tucson, AZ, and 

Seema Somji, University of North Dakota, Grand Forks, ND. 




ARSENIC INDUCES METABOLIC 

REGULATORS AND DIFFERENTIATION IN 

ADIPOSE TISSUE. L. R. Klei, Y. Garciafigueroa, 

R. T. Cattley and A. Barchowsky. Environmental 

and Occupational Health, University of Pittsburgh, 



TRANSCRIPTIONAL REPRESSOR 

INVOLVED IN GLUCOSE METABOLISM 

PLAYS A KEY ROLE IN PROTECTION 

AGAINST ARSENITE TOXICITY. T. 

Takahashi, N. Miyanaga, T. Yano and A. Naganuma. 

Graduate School of Pharmaceutical Sciences, Tohoku 

University, Sendai, Miyagi, Japan. 


CHRONIC EXPOSURE TO MODERATE 

DOSES OF ARSENIC INCREASES 

ATHEROSCLEROSIS FORMATION OF 

UNSTABLE PLAQUES. M. Lemaire 1 , C. A. 

Lemarié 2 , M. Flores-Molina 1 , E. L. Schiffrin 2 , 

S. Lehoux 2 and K. K. Mann 1 . 1 Oncology, McGill 

University, Montréal, QC, Canada and 2 Medicine, 

McGill University, Montréal, QC, Canada. 


LOW DOSE ARSENIC EXPOSURE 

INCREASES MONOCYTE AND 

MACROPHAGE ADHESION AND PRO- 

ATHEROGENIC PHENOTYPE. M. 

Flores-Molina, M. Lemaire, C. A. Lemarié, S. 

Lehoux and K. K. Mann. McGill University, 

Montréal, QC, Canada. 


BIOMARKERS FOR THE EARLY 

DETECTION OF ATHEROSCLEROSIS 

IN A CHILDREN POPULATION 

ENVIRONMENTALLY EXPOSED TO 

INORGANIC ARSENIC. C. Osorio-Yáñez 1 , 

J. C. Ayllon-Vergara 2 , L. Arreola-Mendoza 1,3 , E. 

Hernández-Castellanos 1 , M. A. Sanchez-Guerra 1 , 

E. M. Melgar-Paniagua 1 , A. De Vizcaya-Ruiz 1 , G. 

Aguilar-Madrid 4 and L. M. Del Razo 1 . 1 Toxicology, 

Cinvestav-Ipn, Mexico D.F., Mexico, 2 Hospital 

Español, Mexico, Mexico, 3 Biosciences and 

Engineering, CIIEMAD-IPN, Mexico, Mexico and 

4 

Health and Work, IMSS, Mexico, Mexico. 


MITOGEN ACTIVATED PROTEIN 

KINASE PATHWAY IS INVOLVED IN 

THE UP-REGULATION OF KERATIN 

6 IN ARSENITE AND CADMIUM 

TRANSFORMED UROTSA CELLS. S. Somji, 

L. Cao, S. H. Garrett, M. Sens and D. A. Sens. 

Pathology, University of North Dakota, Grand Forks, 

ND. 

Wednesday 







289



Wednesday 



SEAFOOD INTAKE AND URINE 

CONCENTRATIONS OF TOTAL 

ARSENIC, DIMETHYLARSINATE, 

AND ARSENOBETAINE IN THE U.S. 

POPULATION. A. Navas-Acien 1,2 , K. A. 

Francesconi 3 , E. K. Silbergeld 1 and E. Guallar 2 . 

1 

Environmental Health Sciences, Johns Hopkins 

Bloomberg School of Public Health, Baltimore, MD, 

2 

Epidemiology, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD and 3 Institute of 

Chemistry, Karl-Franzens University Graz, Graz, 

Austria. 


DIFFERENTIAL MODULATION OF CYP1A1 

BY ARSENITE IN VIVO AND IN VITRO IN 

C57BL/6 MICE. A. Anwar-Mohamed and A. O. 

El-Kadi. Faculty of Pharmacy and Pharmaceutical 

Sciences, University of Alberta, Edmonton, AB, 

Canada. 


ROLE OF CONTINUOUS LOW-LEVEL 

MONOMETHYLARSONOUS ACID 

EXPOSURE IN THE INHIBITION OF PARP 

AND CONTRIBUTION TO INCREASED 

GENOTOXICITY IN THE MALIGNANT 

TRANSFORMATION OF UROTSA CELLS. 

S. M. Wnek, M. M. Medeiros, J. M. Camarillo, T. J. 

Jensen, X. Zheng, B. W. Futscher and A. Gandolfi. 




P53 RESPONSE TO 

MONOMETHYLARSONOUS ACID 

EXPOSURE IN HUMAN BLADDER 

EPITHELIAL CELLS. M. K. Medeiros and A. 

Gandolfi. Pharmacology and Toxicology, University 



IN VIVO CONSEQUENCES OF ARSENIC 

METHYLATION IN A DROSOPHILA MODEL. 

I. Cartwright 1 , J. Muñiz Ortiz 2 and J. Shang 1 . 

1 

Molecular Genetics, University of Cincinnati 

College of Medicine, Cincinnati, OH and 2 NHEERL, 



ASSOCIATION OF ARSENIC EXPOSURE 

AND GENETIC POLYMORPHISMS 

WITH ARSENIC METABOLISM IN A 

VIETNAMESE POPULATION. T. Agusa 1,2 , 

T. Kunito 3 , J. Fujihara 1 , H. Takeshita 1 , T. B. Minh 4 , 

P. K. Trang 4 , P. H. Viet 4 , S. Tanabe 2 and H. Iwata 2 . 

1 

Shimane University Faculty of Medicine, Izumo, 

Japan, 2 Ehime University, Matsuyama, Japan, 

3 

Shinshu University, Matsumoto, Japan and 4 Vietnam 

National University, Hanoi, Viet Nam. 


AS3MT/M287T POLYMORPHISM IS A RISK 

FACTOR FOR DIABETES ASSOCIATED 

WITH CHRONIC EXPOSURE TO 

INORGANIC ARSENIC. D. Loomis 1 , L. M. Del 

Razo 2 , G. G. Garcia-Vargas 3 , Z. Drobná 4 and M. 

Styblo 4 . 1 Medical Center, University of Nebraska, 

Omaha, NE, 2 Department of Toxicology, Cinvestav- 

Ipn, Mexico, Mexico, 3 Faculty of Medicine, Juarez 

University of Durango State, Gomez-Palacio, 

Mexico and 4 Nutrition, University of North Carolina 



METHYLATION OF ARSENIC BY 

RECOMBINANT HUMAN AS3MT/287M AND 

AS3MT/287T POLYMORPHS. L. Ding 1 , J. 

Saunders 1 , Z. Drobná 1 , D. J. Thomas 2 and M. Styblo 1 . 

1 

Nutrition, University of North Carolina at Chapel 

Hill, Chapel Hill, NC and 2 ETD, NHEERL, U.S. 



GST-T1 AND GST-M1 GENOTYPES 

MODULATE THE METABOLISM AND 

DIABETOGENIC EFFECTS OF INORGANIC 

ARSENIC. Z. Drobna 1 , L. Del Razo 2 , G. Garcia- 

Vargas 3 , D. Loomis 4 and M. Styblo 1 . 1 Nutrition, 

CB#7461, University of North Carolina at Chapel 

Hill, Chapel Hill, NC, 2 Toxicology, Cinvestav-Ipn, 

Mexico City, Mexico, 3 Faculty of Medicine, Juarez 

University of Durango State, Durango, Mexico and 

4 

Epidemiology, University of Nebraska Medical 

Center, Omaha, NE. 


ARSENIC METHYLATION IS ASSOCIATED 

WITH BREAST CANCER RISK IN 

NORTHERN MEXICO. M. E. Cebrián 1 , A. 

Gandolfi 2 , R. U. Hernandez 3 , J. M. Ornelas 4 , 

L. Torres-Sanchez 3 and L. Lopez-Carrillo 3 . 

1 

Toxicology, Cinvestav IPN, Mexico City, DF, 

Mexico, 2 Pharmacology and Toxicology, University 

of Arizona, Tucson, AZ, 3 CISP, INSP, Cuernavaca, 

Morelos, Mexico and 4 Pathology, IMSS, Ciudad 

Obregón, Sonora, Mexico. 


INFLUENCE OF INDIGENOUS AMERICAN 

ANCESTRY AND BODY MASS INDEX ON 

ARSENIC METHYLATION EFFICIENCY 

IN NORTHWEST MEXICO. P. Gomez-Rubio 1 , 

M. M. Meza-Montenegro 2 , E. Cantu-Soto 2 , Y. C. 

Klimentidis 3 and W. T. Klimecki 1 . 1 Pharmacology 

and Toxicology, University of Arizona, Tucson, AZ, 

2 

Environmental Sciences, Instituto Tecnologico de 

Sonora, Obregon, Sonora, Mexico and 3 Biostatistics, 

University of Alabama at Birmingham, Birmingham, 

AL. 


THE INFLUENCE OF GENETICS, 

NUTRITION, AND PREGNANCY 

ON ARSENIC METABOLISM: A 

LONGITUDINAL COHORT STUDY. R. M. 

Gardner 1 , K. Engström 2 , K. Broberg 2 and M. Vahter 1 . 

1 


Institutet, Stockholm, Sweden and 2 Department 

of Laboratory Medicine, Lund University, Lund, 

Sweden. 

290 






Platform Sessions



Abstract # 


DETECTION AND STABILITY OF 

METHYLATED TRIVALENT ARSENIC 

METABOLITES IN MOUSE LIVER 

HOMOGENATES. J. Currier 1 , J. Saunders 2 , Z. 

Drobná 2 and M. Styblo 2 . 1 Curriculum in Toxicology, 


Hill, NC and 2 Nutrition, University of North Carolina 



THE EFFECT OF PRENATAL FOLATE 

SUPPLEMENTATION ON DNA 

METHYLATION AND GENE EXPRESSION 

IN MALE CD1 MOUSE FETUSES EXPOSED 

IN UTERO TO ARSENIC. V. Tsang 1 , R. Fry 2 , M. 

Niculescu 3 , J. Saunders 1 , M. Waalkes 4 , M. Styblo 1 

and Z. Drobna 1 . 1 Nutrition, CB#7461, University 

of North Carolina at Chapel Hill, Chapel Hill, 

NC, 2 Environmental Sciences and Engineering, 


Hill, NC, 3 Nutrition Research Institute, Kannapolis, 

NC and 4 NTP at NIEHS, Research Triangle Park, 

NC. 


AUTOPHAGY: A CELLULAR PROCESS 

STRONGLY ASSOCIATED WITH ARSENITE- 

INDUCED IMMUNOTOXICITY IN HUMAN 

LYMPHOBLASTOID CELL LINES. A. M. Bolt, 

R. M. Douglas and W. T. Klimecki. Pharmacology 

and Toxicology, University of Arizona, Tucson, AZ. 


DEVELOPMENTAL IMMUNOTOXICITY 

OF LOW DOSE ARSENIC EXPOSURE. C. 

Kozul-Horvath 1 , J. W. Hamilton 2 and R. Enelow 1 . 

1 

Immunology, Dartmouth Medical School, Lebanon, 

NH and 2 Bay Paul Center for Comparative Molecular 

Biology & Evolution, Marine Biological Laboratory, 

Woods Hole, MA. 


ARSENIC ALTERS PURINERGIC TYPE 

2 (P2) RECEPTOR Ca 2+ SIGNALING 

ASSOCIATED WITH INNATE IMMUNITY 

IN HUMAN AIRWAY EPITHELIAL CELLS. 

C. L. Sherwood 1,2,5 , R. Lantz 2,4,5 , J. L. Burgess 4,6 and 

S. Boitano 1,3,4 . 1 Arizona Respiratory Center, Arizona 

Health Sciences Center, Tucson, AZ, 2 Cell Biology 

and Anatomy, Arizona Health Sciences Center, 

Tucson, AZ, 3 Physiology, Arizona Health Sciences 

Center, Tucson, AZ, 4 SWEHSC, Arizona Health 

Sciences Center, Tucson, AZ, 5 Bio5 Institute, Arizona 

Health Sciences Center, Tucson, AZ and 6 College 

of Public Health, Arizona Health Sciences Center, 

Tucson, AZ. 


SODIUM ARSENITE AND HYPERTHERMIA 

ALTER EXPRESSION OF XPA, XPC, AND 

MSH2 IN RESPONSE TO CISPLATIN- 

INDUCED DNA DAMAGE AND INCREASE 

ACCUMULATION OF PLATINUM IN 

OVARIAN CANCER. C. S. Muenyi 1 , V. A. 

States 1 , J. H. Masters 1 , T. Fan 1,2 , W. Helm 1,3 and J. 

States 1 . 1 Pharmacology & Toxicology, University of 

Louisville, Louisville, KY, 2 Chemistry, Univesity 

of Louisville, Louisville, KY and 3 Obstetrics, 

Gynecology & Women’s Health, Univesity of 


Abstract # 


EPITHELIA MALIGNANTLY 

TRANSFORMED BY ARSENIC OR 

CADMIUM DRIVES NEARBY NORMAL 

STEM CELLS TOWARDS A MALIGNANT 

PHENOTYPE. Y. Xu, E. Tokar and M. Waalkes. 

National Toxicology Program, NIEHS, Research 



OVERABUNDANCE OF PUTATIVE 

CANCER STEM CELLS IN HUMAN SKIN 

KERATINOCYTE CELLS MALIGNANTLY 

TRANSFORMED BY ARSENIC. Y. Sun, 

E. Tokar and M. Waalkes. National Toxicology 

Program, NIEHS, Research Triangle Park, NC. 


TRANSFORMATION OF NORMAL HUMAN 

BREAST EPITHELIAL (MCF-10A) CELLS 

BY ARSENITE AND CADMIUM INDUCES 

THE OVER-EXPRESSION OF NEURONAL 

SPECIFIC ENOLASE (ENOLASE-2). M. Soh, 

S. H. Garrett, C. Bathula, D. A. Sens, S. Somji and M. 

Sens. Pathology, University of North Dakota, Grand 

Forks, ND. 


SPARC GENE EXPRESSION IS REPRESSED 

IN HUMAN UROTHELIAL CELLS (UROTSA) 

EXPOSED TO OR MALIGNANTLY 

TRANSFORMED BY CADMIUM OR 

ARSENITE. J. L. Larson 1 , S. Somji 2 , D. A. 

Sens 2 , M. Sens 2 , S. H. Garrett 2 and J. R. Dunlevy 1 . 

1 

Anatomy and Cell Biology, University of North 

Dakota, Grand Forks, ND and 2 Pathology, University 

of North Dakota, Grand Forks, ND. 


DIFFERENCES IN THE EPIGENETIC 

REGULATION OF METALLOTHIONEIN-3 

GENE EXPRESSION BETWEEN PARENTAL 

AND CADMIUM- OR ARSENITE- 

TRANSFORMED HUMAN UROTHELIAL 

CELLS. D. A. Sens, S. H. Garrett, A. Ajjimaporn, 

M. Sens and S. Somji. Pathology, University of North 

Dakota, Grand Forks, ND. 


IL-8 OVER-EXPRESSION AND AUTOCRINE 

CELL ACTIVATION ARE KEY FACTORS 

IN MONOMETHYLARSENOUS ACID 

[MMA(III)]-INDUCED MALIGANT 

TRANSFORMATION OF HUMAN 

UROTHELIAL CELLS. C. Escudero 1,2 , T. Wu 2 , 

J. M. Camarillo 2 and A. Gandolfi 2 . 1 Inmunologia y 

Biologia Celular y Molecular/CIEP, Universidad 

Autonoma de San Luis Potosi, SLP, Mexico and 

2 

Department of Pharmacology and Toxicology, 


Wednesday 







291



Wednesday 



INORGANIC ARSENIC CAUSES APOPTOSIS 

IN MOUSE CEREBRUM THROUGH AN 

OXIDATIVE STRESS-INDUCED MAPKS 

AND ER STRESS PATHWAY. C. Huang 1 , M. 

Lee 2 , Y. Chen 3 , T. Ho 1 , C. Yen 4 and C. Su 5 . 1 School 

of Chinese Medicine, China Medical University, 

Taichung, Taiwan, 2 Department of Surgery, Penghu 

Hospital, Department of Health, Executive Yuan, 

Penghu, Taiwan, 3 Department of Physiology, China 


of Occupational Safety and Health, Chung 

Shan Medical University, Taichung, Taiwan and 

5 

Department of Otorhinolaryngology, Head and Neck 

Surgery, Changhua Christian Hospital, Changhua, 

Taiwan. 


ALTERED EXPRESSION PROFILES OF 

microRNAs UPON ARSENIC EXPOSURE OF 

HUMAN UMBILICAL VEIN ENDOTHELIAL 

CELLS. Y. Wei 1 , Y. Shi 2 , X. Ma 3 and R. Li 2 . 

1 

Department of Community Medicine, Mercer 

University School of Medicine, Macon, GA, 2 Key 

Laboratory of Pathobiology, Jilin University, 

Changchun, Jilin, China and 3 Department of 

Molecular and Cell Biology, Center for Systems 

Biology, University of Texas at Dallas, Richardson, 

TX. 


ARSENIC INDUCES EXPRESSION OF 

C-REACTIVE PROTEIN. I. Druwe, J. J. 

Sollome, P. Sanchez-Soria, T. D. Camenisch and 

R. R. Vaillancourt. Department of Pharmacology & 

Toxicology, The University of Arizona, Tucson, AZ. 


INORGANIC ARSENITE IMPAIRS INSULIN- 

STIMULATED GLUCOSE UPTAKE IN 

3T3-L1 ADIPOCYTES: INVOLVEMENT OF 

CELLULAR ADAPTIVE RESPONSE TO 

OXIDATIVE STRESS. P. Xue 1,2 , Y. Hou 1,2 , J. 

Fu 1 , C. G. Woods 1 , H. Liu 1 , Q. Zhang 1 , G. Sun 2 , M. 

E. Andersen 1 and J. Pi 1 . 1 The Hamner Institutes, 

Reaserach Triangle Park, NC and 2 China Medical 

University, Shenyang, China. 


CHRONIC LOW-DOSE ARSENIC 

EXPOSURE ENHANCES HEPATIC INJURY 

INDUCED BY HIGH FAT DIET IN MICE. 

M. Tan 1,2 , R. H. Schmidt 1,2 , H. Zhong 1,2 , J. States 1 

and G. E. Arteel 1,2 . 1 Pharmacology and Toxicology, 


2 

Alcohol Research Center, University of Louisville, 



ARSENIC-IRON INTERACTIONS IN 

FERRITIN: A NEW MODEL FOR ARSENIC 

TOXICITY. T. R. Radabaugh, T. J. Monks and S. 

S. Lau. Southwest Environmental Health Sciences 

Center, Department of Pharmacology/Toxicology, 

College of Pharmacy, The University of Arizona, 

Tucson, AZ. 


REALGAR- AND CINNABAR- CONTAINING 

AN-GONG-NIU-HUANG WAN (AGNH) 

IS MUCH LESS ACUTELY TOXIC THAN 

SODIUM ARSENITE AND MERCURIC 

CHLORIDE. Y. Lu 2 , J. Yan 2 , Q. Wu 2 , J. Shi 3 , J. 

Liu 1,2 and J. Shi 2 . 1 Pharmacology, Toxicology & 


Kansas City, KS, 2 Pharmacology, Zunyi Medical 

College, Zunyi, Guizhou, China and 3 Pharmacology, 

Guiyang Traditional Medicine College, Guiyang, 

Guizhou, China. 


CINNABAR-CONTAINING ZHU-SHA- 

AN-SHENG WAN IS MUCH LESS 

CHRONICALLY NEPHROTOXIC 

THAN MERCURY CHLORIDE AND 

METHYLMERCURY IN RATS. J. Shi 2 , F. 

Kang 2 , Q. Wu 3 , Y. Lu 3 , J. Liu 1,3 and J. Y. Kang 4 . 

1 

Pharmacology, Toxicology & Therapeutics, 


KS, 2 Pharmacology, Guiyang Traditional Medical 

College, Guiyang, Guizhou, China, 3 Pharmacology, 

Zunyi Medical College, Zunyi, Guizhou, China and 

4 

Medicine, University of Louisville, Lousville, KY. 


REALGAR AND REALGAR-CONTAINING 

LIU-SHEN-WAN ARE LESS ACUTELY 

TOXIC THAN ARSENITE AND ARSENATE. 

J. Liu 1,2 , S. Liang 2 , Y. Lu 2 , Q. Wu 2 , J. Miao 2 and J. 

Shi 2 . 1 Pharmacology, Toxicology & Therapeutics, 


KS and 2 Pharmacology, Zunyi Medical College, 

Zunyi, Guizhou, China. 


AQUAGLYCEROPORIN 3 IS AN ARSENIC 

TRANSPORTER IN THE ATLANTIC 

KILLIFISH (FUNDULUS HETEROCLITUS): 

EFFECTS OF SALINITY. D. Jung 1 , B. Jackson 1 , 

B. MacIver 2 , C. Chapline 3 , D. Sato 3 , J. R. Shaw 3,4 

and B. A. Stanton 1,3 . 1 Dartmouth Medical School, 

Hanover, NH, 2 Beth Israel Deaconess Medical Center 

and Havard Medical School, Boston, MA, 3 Mt. 

Desert Island Biological Laboratory, Salisbury Cove, 

ME and 4 Indiana University, Bloomington, IN. 


LOW-LEVEL ARSENITE EXPOSURE 

THROUGH DRINKING WATER INCREASES 

BLOOD PRESSURE AND PROMOTES 

CONCENTRIC LEFT VENTRICULAR 

HYPERTROPHY IN MICE. P. Sanchez Soria 1 , 

D. Broka 1 and T. D. Camenisch 1,2,3 . 1 Pharmacology 

and Toxicology, College of Pharmacy, University of 

Arizona, Tucson, AZ, 2 Steele Children’s Research 

Center, University of Arizona, Tucson, AZ and 

3 

Southwest Environmental Health Sciences Center, 

University of Arizona, Tucson, AZ. Sponsor: J. 

Gandolfi. 


RELATIVE BIOAVAILABILITY OF ARSENIC 

CONTAMINATED SOILS IN A MOUSE 

MODEL. M. F. Hughes 1 , K. D. Bradham 2 , K. G. 

Scheckel 3 , P. Seales 1 , G. Lee 1 , C. Nelson 2 , A. Yeow 4 , 

S. Harper 2 and D. J. Thomas 1 . 1 ORD/NHEERL, U.S. 

EPA, Research Triangle Park, NC, 2 ORD/NERL, 

U.S. EPA, Research Triangle Park, NC, 3 ORD/ 

NRMRL, U.S. EPA, Cincinnati, OH and 4 SAB, U.S. 

EPA, Washington, D.C. 

292 






Platform Sessions



Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Chemical and Biological Weapons 

Chairperson(s): Neera Tewari-Singh, University of Colorado Denver, 

Aurora, CO. 




EVALUATION OF A COMBINATION OF AN 

ISOFLAVONE AND AN ACE INHIBITOR 

FOR PREVENTION OF RADIATION- 

INDUCED INJURY. M. R. Landauer 1 , T. A. 

Davis 2 and R. M. Day 3 . 1 Armed Forces Radiobiology 

Research Institute, Bethesda, MD, 2 Department of 

Regenerative Medicine, Naval Medical Research 

Center, Silver Spring, MD and 3 Department of 

Pharmacology, Uniformed Services University of the 

Health Sciences, Bethesda, MD. 


IDENTIFICATION OF A NOVEL VX 

METABOLITE FROM MINIPIG LIVER 

MICROSOMES VIA LC-Q-TOF MASS 

SPECTROMETRY. J. M. McGuire 1 , M. E. 

Parrish 2 , E. M. Jakubowski 1 and S. A. Thomson 1 . 

1 

U.S. Army Edgewood CB Center, Aberdeen Proving 

Ground, MD and 2 SAIC, Gunpowder, MD. 


COMPARISON OF THE EFFECT UPON AND 

RECOVERY OF ACETYLCHOLINESTERASE 

(ACHE) ACTIVITY IN VARIOUS TISSUES 

AND BLOOD AFTER SUB-LETHAL 

INHALATION AND SUBCUTANEOUS 

CYCLOSARIN (GF) EXPOSURES. C. E. 

Whalley 1 , L. A. Lumley 2 , J. O’Donnell 2 , D. Miller 1 , 

W. Muse 1 and T. Shih 2 . 1 ECBC, Aberdeen Proving 

Ground, MD and 2 USAMRICD, Aberdeen Proving 

Ground, MD. 


A DEEP DERMAL SKIN INJURY 

FOLLOWING EXPOSURE OF HAIRLESS 

GUINEA PIGS TO SULFUR MUSTARD 

VAPOR. S. Dachir, M. Cohen, L. Tverya, R. Sahar, 

H. Gutman, R. Gez, R. Brandeis, V. Horwitz and T. 

Kadar. Pharmacology, Israel Institute for Biological 

Research, Ness Ziona, Israel. Sponsor: J. Graham. 


REACTIVATION OF ORGANOPHOSPHATE 

INHIBITED ACETYLCHOLINESTERASE 

(ACHE) BY NOVEL PYRIDINIUM OXIMES 

IN THE CENTRAL NERVOUS SYSTEM OF 

RATS. E. C. Meek 1 , H. W. Chambers 1 , J. Gearhart 2 , 

R. B. Pringle 1 and J. E. Chambers 1 . 1 Center for 

Environmental Health Sciences, Mississippi State 

University, Mississippi State, MS and 2 AFRL, 


Abstract # 


CATECHOLAMINE OVERLOAD AND 

CARDIAC LESION FORMATION IN RATS 

FOLLOWING EXPOSURE TO THE NERVE 

AGENT SOMAN. J. H. McDonough, K. E. Van 

Shura, M. E. Lyman, B. A. Capacio, J. C. O’Donnell 

and K. A. Whitten. U.S. Army Medical Research 

Institute of Chemical Defense, Aberdeen Proving 

Ground, MD. 


CENTRALLY ACTING THERAPEUTIC 

ADJUNCTS FOR NERVE AGENT 

INTOXICATION. I. Koplovitz, J. H. McDonough 

and T. Shih. Research Division, U.S. Army Medical 




RICIN TOXICITY IN BALB/C 3T3 CELLS: 

DOSE DEPENDENT PROTEIN EXPRESSION 

DETERMINED BY MASS SPECTROMETRY 

BASED PROTEOMICS. V. H. Bevilacqua 1 , S. 

Deshpande 2 , J. S. Madren-Whalley 3 , R. Jabbour 4 , K. 

Jones 5 , L. M. Reilly 6 and J. S. Rice 7 . 1 Point Detection 

Branch, Edgewood Chemical Biological Center, 

Aberdeen Proving Ground, MD, 2 STC, Edgewood, 

MD, 3 Biotechnology Branch, Edgewood Chemical 

Biological Center, Aberdeen Proving Ground, MD, 

4 

SAIC, Gunpowder, MD, 5 NuSep, Bogart, GA, 

6 

Physical Science Department, Bethany College, 

Bethany, WV and 7 Elona Biotechnologies, Inc., 

Greenwood, IN. Sponsor: J. Sekowski. 


ASSESSMENT OF PRO-2-PRALIDOXIME 

(PRO-2-PAM) THERAPY FOR EXPOSURE 

TO ORGANOPHOSPHATE AGENTS IN 

GUINEA PIGS. J. C. DeMar 1 , S. M. Somerville 1 , 

R. H. Ratcliffe 1 , T. C. Ku 1 , N. M. Nur 1 , B. M. Ursic 1 , 

S. M. Schulz 2 , K. H. Smith 2 , E. D. Clarkson 2 and R. 

K. Gordon 1 . 1 Regulated Laboratories, Walter Reed 

Army Institute of Research, Silver Spring, MD and 

2 

Medical Toxicology Branch, U.S. Army Medical 




SULFUR MUSTARD-INDUCED RESPONSES 

OF AIRWAY AND SKIN IN VITRO. J. Seagrave, 

W. Weber and G. Grotendorst. Lovelace Respiratory 

Research Institute, Albuquerque, NM. 


PREGABALIN REDUCES THE DURATION 

OF ACUTE SEIZURES INDUCED BY 

SOMAN EXPOSURE. M. Furtado 1 , F. Rossetti 1 , 

L. Lumley 2 , M. Addis 1 , M. Moffett 2 , B. Robertson 1 , 

K. Bailey 1 , S. Chanda 1 , N. Kelley 2 , M. Stone 2 , T. 

Pak 1 , S. Lichtenstein 1 and D. Yourick 1 . 1 Walter Reed 


2 

U.S. Army Medical Research Institute of Chemical 

Defense, Aberdeen Proving Ground, Edgewood, MD. 

Wednesday 







293



Wednesday 



CLOT & CLEAN: IN VIVO 

DEMONSTRATION OF A NOVEL 

DECONTAMINATION ROLE FOR A 

HAEMOSTATIC DRESSING. H. Lydon 1,2 , 

C. A. Hall 1,2 , J. K. Chipman 2 , R. P. Chilcott 1 and 

J. S. Graham 3 . 1 CBRN & Chemical Toxicology 

Group, Health Protection Agency, Salisbury, United 

Kingdom, 2 School of Biosciences, University 

of Birmingham, Birmingham, United Kingdom 

and 3 Medical Toxicology Branch, USAMRICD, 



TESTING THE ABILITY OF WOUNDSTAT 

TO PROTECT AGAINST THE CHEMICAL 

WARFARE AGENT VX. E. D. Clarkson 1 , K. 

H. Smith 1 , C. A. Hall 2 , H. L. Lydon 2 , C. H. Dalton 2 , 

J. S. Graham 1 , R. F. Railer 1 , R. S. Stevenson 1 , R. 

R. Deckert 1 , J. L. Devorak 1 , J. D. Boecker 1 , E. H. 

Braue 1 , H. L. Lumpkin 1 , B. F. Doxzon 1 and R. P. 

Chilcott 2 . 1 Analytical Toxicology Division U.S. Army 

Medical Research Institute of Chemical Defense, 

Aberdeen Proving Ground, MD and 2 CBRN and 

Chemical Toxicology Group, Health Protection 

Agency, Porton Down, Salisbury, United Kingdom. 


REDUCTION OF MECHLORETHAMINE 

TOXICITY BY STRUCTURALLY DIVERSE 

ANTIOXIDANTS. A. Lulla 1 , M. Pino 1 , C. Lau- 

Cam 1 , M. Pietka-Ottlik 2 , J. Mlochowski 2 and B. 

Billack 1 . 1 Pharmaceutical Sciences, St. John’s 

University, Jamaica, NY and 2 Faculty of Chemistry, 

Wroclaw University of Technology, Wroclaw, 

Poland. 


PROTECTIVE EFFICACY OF CATALYTIC 

BIOSCAVENGER, PARAOXONASE 1 

AGAINST SARIN AND SOMAN EXPOSURE 

IN GUINEA PIGS. M. Valiyaveettil, Y. Alamneh, 

L. Biggemann, I. Soojhawon, B. P. Doctor and M. 

P. Nambiar. Closed Head Injury, Walter Reed Army 



EVALUATION OF NOVEL NERVE AGENT 

ANTICONVULSANTS AND THEIR EFFECTS 

ON BRAIN GLUTAMATE CONCENTRATION 

IN RATS. J. Guarisco, R. K. Kan, J. K. Chandler, 

A. J. Wegener, T. M. Shih and J. H. McDonough. 

USAMRICD, Aberdeen Proving Ground, MD. 


THE HAIRLESS MOUSE BACK MODEL AND 

THE MEVM HAVE SIMILAR MOLECULAR 

PROFILES. J. D. Wang 2 , M. Soriano 1 , N. Singer 1 , 

R. P. Casillas 3 , D. R. Gerecke 1,2 and Y. Chang 1 . 

1 

Pharmacology & Toxicology, Ernest Mario 

School of Pharmacy, Rutgers University, EOHSI, 

Piscataway, NJ, 2 Pharmacology & Toxicology, 

Ernest Mario School of Pharmacy, Joint Graduate 

Program in Toxicology, Rutgers University, EOHSI, 

Piscataway, NJ and 3 Battelle Biomedical Research 

Center, Columbus, OH. 


USE OF GAMMA-H2AX AS A BIOMARKER 

TO EVALUATE THE ANTI-GENOTOXIC 

ACTIVITY OF COMPOUNDS IN CULTURED 

HUMAN SKIN CELLS FOLLOWING CEES 

EXPOSURE. A. L. Miller, N. K. Waraich, C. L. 

Gross, E. W. Nealley, O. E. Clark, K. L. Rodgers 

and W. J. Smith. Research, USAMRICD, Aberdeen 



ROLE OF ENDOGENOUS CANNABINOIDS 

IN VESICANT-INDUCED SKIN INJURY. I. 

M. Wohlman 1 , D. E. Heck 2 , N. D. Heindel 3 , M. 

Huang 4 , D. R. Gerecke 1 , P. J. Sinko 5 , C. J. Lacey 3 , 

D. L. Laskin 1 and J. D. Laskin 6 . 1 Pharmacology 

& Toxicology, Rutgers University, Piscataway, 

NJ, 2 Environmental Health Sciences, New York 

Medical College, Valhalla, NY, 3 Chemistry, 

Lehigh University, Bethlehem, PA, 4 Chemical 

Biology, Rutgers University, Piscataway, NJ, 

5 

Pharmaceutics, Rutgers University, Piscataway, 

NJ and 6 Environmental & Occupational Medicine, 




EFFICACY OF ENDOTRACHEAL 

ADMINISTRATION OF ADENOSINE 

RECEPTOR A1 ANTISENSE 

OLIGONUCLEOTIDE (EPI 2010) IN 

COMBINATION WITH ATROPINE 

METHYL BROMIDE AGAINST 

RESPIRATORY TOXICITY FOLLOWING 

MICROINSTILLATION INHALATION 

EXPOSURE TO SARIN. J. Song 1 , P. Rezk 2 , M. 

Perkins 2 , P. Sabnekar 2 , S. Oguntayo 1 , A. M. Scuito 2 , 

B. P. Doctor 1 and M. P. Nambiar 1,3 . 1 Closed Head 

Injury Branch, Center For Military Psychiatry 

and Neuroscience, Walter Reed Army Institute of 

Research, Silver Spring, MD, 2 Medical/Analytical 

Toxicology, USAMRICD, Aberdeen Proving 

Ground, MD and 3 Department of Medicine, Uniform 

Services University of Health Sciences, Bethesda, 

MD. 


CELL SURVIVAL AND APOPTOSIS 

MARKERS IN SULFUR MUSTARD 

EXPOSED MOUSE SKIN. Y. Chang 1 , J. D. 

Wang 1 , R. P. Casillas 2 , M. K. Gordon 1 and D. R. 

Gerecke 1 . 1 Department of Pharm and Toxicology, 

Ernest Mario School of Pharmacy, Rutgers 

University, Pisacataway, NJ and 2 Battelle Biomedical 

Research Center, Columbus, OH. 


SULFUR MUSTARD EXPOSURE OF THE 

CORNEA INDUCES AUTOPHAGY. L. 

Raman 1 , R. A. Hahn 1 , J. J. Schlager 2 , R. Gordon 3 , 

D. R. Gerecke 1 , M. C. Babin 4 and M. K. Gordon 1 . 

1 


Piscataway, NJ, 2 Air Force Research Laboratory, 

Wright-Patterson AFB, Dayton, OH, 3 Pathology, 

Mount Sinai School of Medicine, New York, NY 

and 4 Battelle Biomedical Research Center, West 

Jefferson, OH. 

294 






Platform Sessions



Abstract # 


NITROGEN MUSTARD-INDUCED 

CORNEAL INJURY IS AMELIORATED BY 

ADAM17/TACE INHIBITORS. A. S. DeSantis 1 , 

R. A. Hahn 1 , N. D. Heindel 2 , K. K. Svoboda 3 , D. R. 

Gerecke 1 and M. K. Gordon 1 . 1 Ernest Mario School 

of Pharmacy, Rutgers University, Piscataway, NJ, 

2 

Chemistry, Lehigh University, Bethlehem, PA and 

3 

Biomedical Sciences, Baylor College of Dentistry, 

Texas A&M Health Science Center, Dallas, TX. 


COMPARISON OF CORNEAL WOUND 

HEALING AFTER ULTRAVIOLET AND 

NITROGEN MUSTARD INJURY. I. P. Po 1 , 

A. S. DeSantis 1 , R. A. Hahn 1 , D. R. Gerecke 1 , J. D. 

Laskin 2 and M. K. Gordon 1 . 1 Ernest Mario School 

of Pharmacy, Rutgers University, Piscataway, NJ 

and 2 Environmental and Occupational Medicine, 




SIGNALING MECHANISMS THAT 

CAN CONTRIBUTE TO THE 

NEUROPROTECTION AFFORDED BY 

GALANTAMINE IN GUINEA PIGS EXPOSED 

TO THE NERVE AGENT SOMAN. G. 

Kulkarni 1 , M. Akkerman 1 , Y. Aracava 1 , E. X. 

Albuquerque 2,1 and E. R. Pereira 1,2 . 1 Department 

Epidemiology and Public Health, University of 

Maryland School of Medicine, Baltimore, MD and 

2 

Department of Pharmacology and Experimental 

Therapeutics, University of Maryland School of 

Medicine, Baltimore, MD. 


GALANTAMINE COUNTERACTS 

COGNITIVE DEFICITS IN GUINEA PIGS 

CHALLENGED WITH THE NERVE AGENT 

SARIN. J. Mamczarz 1 , Y. Aracava 1 , E. R. Pereira 1,2 

and E. X. Albuquerque 2,1 . 1 Department Epidemiology 

and Public Health, University of Maryland School 

of Medicine, Baltimore, MD and 2 Department of 

Pharmacology and Experimental Therapeutics, 

University of Maryland School of Medicine, 



ANALYSIS OF MAP KINASE SIGNALING 

IN SULFUR MUSTARD TOXICITY USING 

PHARMACOLOGIC INHIBITORS AND 

GENE EXPRESSION PROFILING. C. C. 

Rothwell, C. M. Crum, P. A. Everley and J. F. 

Dillman. Cell and Molecular Biology, USAMRICD, 



THE NEUROPROTECTANT EFFECTS OF 

DIAZEPAM ALONE AND COMBINATION 

WITH HISTONES DEACETILASES 

INHIBITORS IN A RAT MODEL OF 

STATUS EPILEPTICUS INDUCED BY 

ORGANOPHOSPHORUS EXPOSURE. F. 

Rossetti 1 , M. Furtado 1 , M. Addis 1 , B. Robertson 1 , M. 

Moffet 2 , L. Lumley 2 and D. Yourick 1 . 1 Walter Reed 


2 


Defense, Aberdeen Proving Ground, MD. 

Abstract # 


ACUTE CL2 INHALATION CAUSES 

NEUTROPHIL RECRUITMENT AND 

SURFACTANT INACTIVATION IN MICE. 

C. B. Massa, C. J. Guo, P. Scott and A. J. Gow. 



DURATION OF STATUS EPILEPTICUS DOES 

NOT AFFECT LEVEL OF BRAIN DAMAGE 

IN SOMAN EXPOSED RATS. K. Bailey 1 , L. 

Wierenga 1 , L. Yang 1 , L. West 1 , C. Wheeling 1 , M. 

Furtado 1 , D. Yourick 1 and L. Lumley 2 . 1 Walter Reed 


2 


Defense, Edgewood, MD. 


TWO-HIT MODEL OF CEES SKIN 

INJURY INVOLVING DNA DAMAGE 

AND INDUCTION OF INFLAMMATORY 

MEDIATORS, IN PART VIA OXIDATIVE 

STRESS, IN SKH-1 HAIRLESS MOUSE SKIN. 

A. K. Jain 1 , N. Tewari-Singh 1 , M. Gu 1 , S. Inturi 1 , 

C. W. White 2 and R. Agarwal 1 . 1 Pharmaceutical 

Sciences, University of Colorado Denver, Aurora, 

CO and 2 Pediatrics, National Jewish Health, Denver, 

CO. 


EFFICACY OF ENDOTRACHEAL 

AEROSOLIZATION OF SCOPOLAMINE 

FOLLOWING MICROINSTILLATION 

INHALATION EXPOSURE TO SOMAN IN 

GUINEA PIGS. M. W. Perkins 1 , Z. Pierre 1 , P. 

Rezk 1 , P. Sabnekar 1 , J. Song 2 , S. Oguntayo 2 , A. 

Sciuto 1 , B. Doctor 2 and M. P. Nambiar 2 . 1 Analytical 

Toxicology, USAMRICD, Aberdeen, MD and 

2 

Closed Head Injury Branch, Walter Reed Army 



MECHANISTICALLY-BASED 

COMPUTATIONAL MODEL OF THE HOST 

IMMUNE RESPONSE TO BIOLOGICAL 

WARFARE AGENTS: APPLICATION TO 

TULAREMIA. C. Hack, E. J. Fleming, P. E. 

Anderson and J. M. Gearhart. AFRL/711 HPW/ 

RHPB, Wright-Patterson Air Force Base, OH. 


ABSORPTION, DISPOSITION 

ELIMINATION KINETICS OF THE 

BIOLOGICAL TOXIN MYCROCYSTIN LR. 

D. Kracko, K. Turteltaub, R. Harris, M. Doyle-Eisele 

and J. McDonald. Lovelace, Albuqueruque, NM. 


ABSORPTION, DISPOSITION ELIMINATION 

KINETICS OF THE BIOLOGICAL TOXIN 

SEB. R. Harris, M. Doyle-Eisele, J. McDonald and 

K. Turteltaub. Lovelace, Albuqueruque, NM. 


CORRELATION OF LD50 AND 

CYTOCHROME C OXIDASE ACTIVITY 

IN MITOCHRONDRIA FROM BRAINS OF 

RODENTS TREATED WITH CYANIDE AND 

CYANIDE POISONING ANTIDOTES. D. 

Haines, I. Petrikovics, P. Guidry and M. Marziaz. 

Department of Chemistry, Sam Houston State 

University, Huntsville, TX. 

Wednesday 







295



Wednesday 



NOVEL SULFUR DONOR FORMULATIONS 

FOR CYANIDE ANTAGONISM. P. K. Jayanna 1 , 

I. Petrikovics 1 , J. C. Yu 2 , M. Zottola 3 , M. Ancha 1 

and G. A. Rockwood 3 . 1 Chemistry, Sam Houston 

State University, Huntsville, TX, 2 Forensic Science, 

Sam Houston State University, Huntsville, TX and 

3 

Analitical Toxicology, USAMRICD, Aberdeen 



ESTERASE ACTIVITIES AND HEMOSTASIS 

OF RAT BLOOD AT DIFFERENT STAGES 

AFTER ACUTE INTOXICATION WITH 

WARFARE ORGANOPHOSPHATES. N. 

Goncharov, V. Shmurak, V. Garnyuk, I. Kurdyukov, 

A. Nadeev, N. Voitenko, D. Prokofieva, Y. 

Pechenevskii, A. Radilov and V. Rembovskiy. 

RIHOPHE, Saint Petersburg, Russian Federation. 

Sponsor: R. Gupta. 


PROTECTION AGAINST ACHE - 

INHIBITION. I. Petrikovics 1 , R. J. Kern 2 , J. 

R. Wild 2 , G. Kuzmitcheva 1 and M. E. Wales 2 . 

1 

Chemistry, Sam Houston State University, 

Huntsville, TX and 2 Biochemistry, Biophysics, Texas 

A&M University, College Station, TX. 


REACTIVATION OF PHOSPHORYLATED 

ACETYLCHOLINESTERASE AND NEURAL 

PROTECTION IN THE CENTRAL NERVOUS 

SYSTEM USING NOVEL PYRIDINIUM 

OXIMES. R. Pringle 1 , E. Meek 1 , H. Chambers 1 , 

J. Gearhart 2 and J. Chambers 1 . 1 Mississippi State 

University, Mississippi State, MS and 2 AFRL, 



IMPROVED DECORPORATION OF 

THE ACTINIDE RADIOELEMENT 241 Am 

WITH A NOVEL ORALLY AVAILABLE 

FORMULATION OF DTPA. G. N. Shankar 1 , W. 

Weber 2 , M. Doyle-Eisele 2 , N. Bejugam 1 , S. Mutyam 1 

and R. A. Guilmette 2 . 1 Pharmaceutical Sciences, 

SRI International, Menlo Park, CA and 2 Center 

for Countermeasures Against Radiation, Lovelace 

Respiratory Research Institute, Albuquerque, NM. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology: Metal Oxides, Silver, Gold, 

and Silica Nanoparticle Toxicity 

Chairperson(s): Kevin Dreher, U.S. EPA, NC. 




EFFECTS OF COPPER DOPED TITANIUM 

DIOXIDE NANOPARTICLES IN VIVO: 

ROLE OF SOLUBLE METAL. B. L. Serke 1 , N. 

Corson 1 , P. Mercer 1 , R. Gelein 1 , M. Sahu 2 , P. Biswas 2 , 

G. Oberdörster 1 and A. Elder 1 . 1 Environmental 

Medicine, University of Rochester, Rochester, 

NY and 2 Energy, Environmental, and Chemical 

Engineering, Washington University, St. Louis, St. 

Louis, MO. 


GENE EXPRESSION PROFILING OF 

IMMUNE-COMPETENT CELLS EXPOSED 

TO METAL OXIDE NANOPARTICLES. B. 

Fadeel 1 , S. Tuomela 2 , R. Autio 3 , A. Kunzmann 1 , B. 

Andersson 4 , J. Shi 1 , T. Bürki-Thurnherr 5 , P. Wick 5 , 

O. Arslan 6 , S. Mathur 6 , A. Scheynius 4 , H. Krug 5 

and R. Lahesmaa 2 . 1 Institute of Environmental 

Medicine, Karolinska Institutet, Stockholm, 

Sweden, 2 University of Turku and Åbo Akademi 

University, Turku Centre for Biotechnology, 

Turku, Finland, 3 Department of Signal Processing, 

Tampere University of Technology, Tampere, 

Finland, 4 Department of Medicine Solna, Karolinska 

Institutet, Stockholm, Sweden, 5 Laboratory for 

Materials-Biology Interactions, Swiss Federal 

Laboratories for Material Science and Technology, 

St. Gallen, Switzerland and 6 Inorganic and Materials 

Chemistry, University of Cologne, Cologne, 

Germany. 


UPTAKE OF SILICA NANOPARTICLES AND 

QUANTUM DOTS IN DIFFERENTIATED 

AND UNDIFFERENTIATED THP-1 CELLS: 

AN ILLUSTRATION OF CHALLENGES IN 

MEASURING NANOPARTICLE UPTAKE BY 

CELLS. G. K. Hinkley 1 , D. Barber 1 , P. Sharma 2 , K. 

Powers 2 and S. Roberts 1 . 1 Center for Environmental 

and Human Toxicology, University of Florida, 

Gainesville, FL and 2 Particle Engineering Research 

Center, University of Florida, Gainesville, FL. 


THE TOXIC EFFECTS OF MESOPOROUS 

SILICA NANOPARTICLES IN 

MACROPHAGES. S. Lee 1 , H. Yun 2 and S. Kim 1 . 

1 

Pharmacology, Kyungpook National University, 

Daegu, Republic of Korea and 2 Engineering 

Ceramics Research Group, Functional Materials 

Division, Korea Institute of Materials Science 

(KIMS), Changwon, Republic of Korea. 


ZNO NANOPARTICLE NEUROTOXICITY 

REQUIRES CELLULAR INFLUX OF 

PARTICLES. A. M. Klim 1 , B. V. Madhukar 2 and P. 

Cobbett 1 . 1 Pharmacology and Toxicology, Michigan 

State University, East Lansing, MI and 2 Pediatrics 

and Human Development, Michigan State University, 



THE USE OF ACCELERATOR MASS 

SPECTROMETRY TO QUANTIFY 

THE ADMET PROPERTIES OF SIO2 

NANOPARTICLES IN VIVO. M. A. Malfatti 1,3 , 

E. Kuhn 1,3 , W. Wang 2,3 , S. Retterer 2,3 and K. 

Turteltaub 1,3 . 1 Lawrence Livermore National 

Laboratory, Livermore, CA, 2 Oak Ridge National 

Laboratory, Oak Ridge, TN and 3 Battelle Center 

for Fundamental and Applied Systems Toxicology 

(B-FAST), Battelle Memorial Institute, Columbus, 

OH. 


INHALED CADMIUM OXIDE (CDO) 

NANOPARTICLES CAUSES LUNG INJURY 

IN ADULT MALE MICE. L. K. Rosenblum, J. L. 

Blum, J. Q. Xiong and J. T. Zelikoff. Environmental 

Medicine, New York University School of Medicine, 

Tuxedo, NY. 

296 






Platform Sessions



Abstract # 


INHALED NICKEL NANOPARTICLES AND 

MURINE ENDOTHELIAL PROGENITOR 

CELLS. E. N. Liberda, A. K. Cuevas, Q. Qu and 

C. Lung Chi. Environmental Medicine, New York 

University, Tuxedo, NY. 


GOLD NANOSPHERES CAUSE SIZE- 

DEPENDENT CELLULAR ALTERATIONS IN 

HUMAN KERATINOCYTES. C. M. Garrett 1,2 , 

A. M. Schrand 2 and S. M. Hussain 2 . 1 Air Force 

Research Laboratory, Henry M. Jackson, Wright- 

Patterson AFB, OH and 2 Appli.ed Biotechnology 

Branch, 711th Human Performance Wing, Wright- 

Patterson AFB, Dayton, OH. 


IN VITRO MECHANISTIC STUDY ON THE 

TOXICITY OF COMMERCIAL ZINC OXIDE 

NANOPARTICLES. T. Bürki-Thurnherr 1 , L. 

Diener 1 , C. Waldmann 2 , O. Arslan 2 , X. Maeder- 

Althaus 1 , P. Wick 1 , S. Mathur 2 and H. F. Krug 1 . 

1 

Laboratory for Materials-Biology Interactions, 

EMPA - Swiss Federal Laboratories for Materials 

Testing and Research, St. Gallen, Switzerland and 

2 

Inorganic and Materials Chemistry, University of 

Cologne, Cologne, Germany. Sponsor: B. Fadeel. 


MACROPHAGE ACTIVATION AND 

MIGRATION ON TRANSPARENT TITANIUM 

NANOSTRUCTURE. D. Khang 2 , S. Lee 1 and 

S. Kim 1 . 1 Pharmacology, Kyungpook National 

University, Daegu, Republic of Korea and 2 Center 

for Nano-Morphic Biological Energy and School 

of Nano and Advanced Materials Science and 

Engineering, Gyeongsang National University, Jinju, 



ADHESIVE PROPERTIES OF HUMAN 

ENDOTHELIAL CELLS EXPOSED TO 

AMORPHOUS SILICA NANOPARTICLES. 

D. H. Napierska 1 , R. Quarck 2 , L. Thomassen 3 , 

L. Gonzalez 4 , V. Rabolli 5 , D. Lison 5 , M. Kirsch- 

Volders 4 , J. Martens 3 , M. Delcroix 2 , B. Nemery 1 and 

P. H. Hoet 1 . 1 Research Unit for Lung Toxicology, 

K.U. Leuven, Leuven, Belgium, 2 Pulmonary 

Circulation Unit, K.U. Leuven, Leuven, Belgium, 

3 

Center for Surface Chemistry & Catalysis, K.U. 

Leuven, Leuven, Belgium, 4 Free University of 

Brussels, Brussels, Belgium and 5 Catholic University 

of Louvain, Brussels, Belgium. 


CYTOTOXICITY OF SILVER 

NANOPARTICLES ON JURKAT T CELLS. 

H. Eom and J. Choi. University of Seoul, Seoul, 

Republic of Korea. Sponsor: D. Ryu. 


TOXICOLOGICAL INVESTIGATION 

OF SILVER NANOPARTICLES ON 

MAPK PATHWAYS AND RELATED 

TRANSCRIPTION FACTORS IN 

CAENOHABDITIS ELEGANS. J. Roh, D. Lim, 

H. Eom, J. An and J. Choi. University of Seoul, 

Seoul, Republic of Korea. Sponsor: D. Ryu. 

Abstract # 


BIODISTRIBUTION AND PERSISTENCE 

OF FOUR SIZES OF CERIA ENGINEERED 

NANOMATERIALS AFTER INTRAVENOUS 

ADMINISTRATION. M. Dan 1 , P. Wu 2 , M. 

T. Tseng 3 , U. M. Graham 2 , R. L. Florence 2 , J. 

M. Unrine 2 , E. A. Grulke 2 and R. A. Yokel 1 . 

1 

Pharmaceutical Sciences, University of Kentucky, 

Lexington, KY, 2 University of Kentucky, Lexington, 

KY and 3 University of Louisville, Louisville, KY. 


ENDOTHELIN-1 SECRETION IS INHIBITED 

IN VITRO BY TIO2 NANOPARTICLES. E. 

Alfaro-Moreno 1 , A. Montiel-Dávalos 1 , D. Napierska 2 

and R. Quarck 3 . 1 Investigacion Basica, Instituto 

Nacional de Cancerologia, Mexico, Distrito Federal, 

Mexico, 2 Lung Toxicology Unit, K.U. Leuven, 

Leuven, Belgium and 3 Pneumology Section, K.U. 

Leuven, Leuven, Belgium. 


BIOAVAILABILITY AND TISSUE 

DISTRIBUTION OF SILVER 

NANOPARTICLES IN SPRAGUE-DAWLEY 

RATS. M. D. Boudreau 1 , C. R. Cozart 1 , P. H. 

Siitonen 1 , M. V. Pogribna 1 and N. J. Walker 2 . 

1 

Division of Biochemical Toxicology, National 

Center for Toxicological Research, U.S. FDA, 

Jefferson, AR and 2 National Toxicology Program, 

National Institute of Environmental Health Sciences, 



CELLULAR ANTIOXIDANTS AND 

PREDISPOSITION TO DAMAGE BY 

METAL OXIDE NANOPARTICLES: 

A TOXICOLOGICAL COMPARISON 

BETWEEN HUMAN PULMONARY 

EPITHELIAL AND MESOTHELIAL CELL 

LINES. D. E. Figueroa 1 , J. Berg 2 , A. Romoser 2 and 

C. M. Sayes 1,2 . 1 Biomedical Engineering, Texas A&M 

University, College Station, TX and 2 Toxicology 

Program, Texas A&M University, College Station, 

TX. 


BUILDING MATHEMATICAL MODELS FOR 

NANOPARTICLE-INDUCED REACTIVE 

OXYGEN SPECIES PRODUCTION: A STUDY 

COMPARING SILVER, ZINC, COPPER, 

NICKEL, AND IRON NANOPARTICLES. 

P. A. Smith 1 , I. Ivanov 2 and C. M. Sayes 1,2 . 

1 

Biomedical Engineering, Texas A&M University, 

College Station, TX and 2 Veterinary Physiology 

& Pharmacology, Texas A&M University, College 

Station, TX. 


THE TOXICITY OF SILVER AND SILICA 

NANOPARTICLES IN COMPARABLE 

HUMAN AND MOUSE CELL LINES. R. 

Foldbjerg 1,2 , C. Beer 1 , D. S. Sutherland 2 and 

H. Autrup 1 . 1 Environmental and Occupational 

Medicine, Aarhus University, Aarhus, Denmark and 

2 

Interdisciplinary Nanoscience Center (iNANO), 

Aarhus University, Aarhus, Denmark. 

Wednesday 







297



Wednesday 



AN IN VITRO INVESTIGATION OF THE 

TOXICITY OF SILVER NANOPARTICLES. 

P. Sriwichai, F. M. Williams, C. Lye, A. Silmon, A. 

Groom and E. Mutch. Medical Faculty, Institute of 

Cellular Medicine, Newcastle Upon Tyne, Tyne and 

Wear, United Kingdom. Sponsor: M. Graham. 


IRON OXIDE NANOPARTICLES CAUSE 

OXIDATIVE STRESS AND DERMAL 

TOXICITY. A. R. Murray 1,2 , E. Kisin 1 , A. O. 

Inman 3 , S. H. Young 1 , M. Muhammed 4 , T. Burks 4 , 

A. Uheida 4 , A. Tkach 1 , M. Waltz 2 , V. Castranova 1 , B. 

Fadeel 5 , J. E. Riviere 3 , V. E. Kagan 6 , N. A. Monteiro- 

Riviere 3 and A. A. Shvedova 1,2 . 1 PPRB, NIOSH, 

Morgantown, WV, 2 West Virginia University, 

Morgantown, WV, 3 North Carolina State University, 

Raleigh, NC, 4 Royal Institute of Technology, 

Stockholm, Sweden, 5 Karolinska Institute, 

Stockholm, Sweden and 6 University of Pittsburgh, 



A TOXICOGENOMIC ANALYSIS OF 

GENE EXPRESSION CHANGES IN TIO2 

NANOPARTICLE-TREATED MICE. S. Liu, Y. 

Yao, W. Yang, X. Ding and J. Gu. Wadsworth Center, 

New York State Department of Health, and School 




GOLD NANOPARTICLES INCREASE THE 

LIVER TOXICITY OF ACETAMINOPHEN. 

A. M. Keene, A. Knapton, N. R. Hartman, D. Peters, 

G. Tobin, L. Zhang, S. Stewart, L. Xu, R. Rouse 

and K. M. Tyner. Center for Drug Evaluation and 

Research, U.S. FDA, Laurel, MD. 


SILVER NANOPARTICLES-INDUCED 

GENOTOXICITY IN BONE MARROW 

CELLS OF SPRAGUE-DAWLEY RATS. A. 

Patlolla 1 and D. Hackett 1,2 . 1 Molecular Toxicology 

Research Laboratory, Jackson State University, 

Jackson, MS and 2 Biology, Jackson State University, 

Jackson, MS. 


TOXICOLOGICAL ACTIVITY OF 

METAL OXIDE NANOPARTICLES UPON 

BIOLOGICAL MODELS IN VITRO. T. D. 

Palacios-Hernandez 1,2 , J. L. Garate-Morales 1 , F. 

Cordova-Lozano 2 , J. L. Sanchez-Salas 2 , C. C. Berry 3 , 

E. Gonzalez-Vergara 1 and M. A. Mendez-Rojas 2 . 

1 

Centre of Chemstry and Faculty of Chemical 

Sciences, Benemerita Universidad Autonoma de 

Puebla, Puebla, Mexico, 2 Chemical and Biological 

Sciences, Universidad de las Americas, Puebla, San 

Andres Cholula, Puebla, Mexico and 3 Centre for 

Cell Engineering, University of Glasgow, Glasgow, 

United Kingdom. Sponsor: O. Olivero. 


EVALUATION OF GENOTOXICITY OF 

TITANIUM DIOXIDE NANOPARTICLES 

USING THE AMES TEST AND IN VITRO 

COMET ASSAY. J. Yan 1 , R. S. Woodruff 2 , M. 

Y. Jones 3 , F. Watanabe 4 , A. Biris 4 and T. Chen 1 . 

1 

Division of Genetic and Molecular Toxicology, 

U.S. FDA NCTR, Jefferson, AR, 2 Division of 

Microbiology, Arkansas Regional Laboratory, U.S. 

FDA, Jefferson, AR, 3 Nanotechnology Facility, U.S. 

FDA NCTR, Jefferson, AR and 4 Nanotechnology 

Center, University of Arkansas at Little Rock, Little 

Rock, AR. 


A COMPARISON OF THE PHOTOTOXIC 

POTENCY OF SIX TYPES OF TIO2 

NANOPARTICLES. W. K. Boyes 1 , K. M. Sanders 1 , 

L. L. Degn 1 , R. M. Zucker 1 , W. R. Mundy 2 , B. 

Zhao 3 and J. E. Roberts 4,3 . 1 Toxicity Assessment 

Division, U.S. EPA, Research Triangle Park, NC, 

2 

Integrated Systems Toxicology Division, U.S. EPA, 

Research Triangle Park, NC, 3 National Institute of 


Park, NC and 4 Fordham University, New York, NY. 


INHIBITORY EFFECTS OF SILVER 

NANOPARTICLES ON RECOMBINANT 

CYTOCHROME P450 ENZYMES AND 

HUMAN LIVER MICROSOMES. R. 

Maniratanachote 1 , K. Kulthong 1 , Y. Kobayashi 2 , T. 

Fukami 2 and T. Yokoi 2 . 1 National Nanotechnology 

Center, National Science and Technology 

Development Agency, Klong Luang, Pathumthani, 

Thailand and 2 Faculty of Pharmaceutical Sciences, 

Kanazawa University, Kakuma-machi, Kanazawa, 

Japan. 


EFFECT OF ORALLY EXPOSURED 

AMORPHOUS NANOSILICA ON ANTIGEN- 

SPECIFIC IMMUNE RESPONSES. T. 

Yoshida 1,2 , T. Yoshikawa 1,2 , S. Tochigi 1,2 , T. Hirai 1,2 , 

M. Uji 1,2 , H. Nabeshi 1,2 , K. Nagano 2 , Y. Abe 2 , H. 

Kamada 2,3 , S. Tsunoda 2,3,4 , N. Itoh 1,2 , Y. Yoshioka 1,2,3 

and Y. Tsutsumi 1,2,3 . 1 Department of Toxicology and 

Safety Science, Graduate School of Pharmaceutical 

Sciences, Osaka University, Osaka, Japan, 

2 

Laboratory of Biopharmaceutical Research, National 


3 

The Center for Advanced Medical Engineering 

and Informatics, Osaka University, Osaka, Japan 

and 4 Department of Biomedical Innovation, 

Graduate School of Pharmaceutical Sciences, Osaka 



MATRIX METALLOPROTEINASES 2 

AND 9 AND TISSUE INHIBITORS OF 

METALLOPROTEINASE 1 IN CERIUM 

OXIDE INDUCED PULMONARY FIBROSIS. 

J. Y. Ma 1 , R. R. Mercer 1 , M. Barger 1 , J. K. Ma 2 and V. 

Castranova 1 . 1 PPRB/HELD, NIOSH, Morgantown, 

WV and 2 School of Pharmacy, West Virginia 


298 






Platform Sessions



Abstract # 


PULMONARY TOXICITY OF 

CRYSTALLINE SILICA AFTER A SINGLE 

INTRATRACHEAL INSTILLATION IN RATS. 

M. Naya 1 , N. Kobayashi 1 , S. Endoh 2 , K. Mizuno 3 , 

R. Nagaosa 1 , M. Ema 1 and J. Nakanishi 1 . 1 Research 

Institute of Science for Safety and Sustainability, 

National Institute of Advanced Industrial Science 

and Technology, Tsukuba, Japan, 2 Research Institute 

for Environmental Management Technology, 

National Institute of Advanced Industrial Science and 

Technology, Tsukuba, Japan and 3 Metrology Institute 

of Japan, National Institute of Advanced Industrial 

Science and Technology, Tsukuba, Japan. 


SIZE-DEPENDENT IMMUNE-MODULATING 

EFFECT OF AMORPHOUS NANOSILICA. T. 

Hirai 1,2 , T. Yoshikawa 1,2 , T. Yoshida 1,2 , H. Nabeshi 1,2 , 

S. Tochigi 1,2 , M. Uji 1,2 , K. Nagano 2 , Y. Abe 2 , H. 

Kamada 2,3 , S. Tsunoda 2,3,4 , N. Itoh 1,2 , Y. Yoshioka 1,2,3 

and Y. Tsutsumi 1,2,3 . 1 Department of Toxicology and 

Safety Science, Graduate School of Pharmaceutical 

Sciences, Osaka University, Osaka, Japan, 

2 

Laboratory of Biopharmaceutical Research, National 


3 


and Informatics, Osaka University, Osaka, Japan 

and 4 Department of Biomedical Innovation, 




DISTRIBUTION IN THE TESTIS 

AND REPRODUCTIVE EFFECTS OF 

NANOSILICA. Y. Morishita 1,2 , Y. Yoshioka 1,2,3 , 

K. Yamashita 1,2 , K. Higashisaka 1,2 , M. Fujimura 1,2 , 

H. Pan 1,2 , T. Ogura 1,2 , K. Nagano 2 , Y. Abe 2 , H. 

Kamada 2,3 , S. Tsunoda 2,3,4 , H. Nabeshi 1 , N. Itoh 1 , 

T. Yoshikawa 1,2 and Y. Tsutsumi 1,2,3 . 1 Department 

of Toxicology and Safety Science, Graduate 

School of Pharmaceutical Sciences, Osaka 

University, Suita, Osaka, Japan, 2 Laboratory of 

Biopharmaceutical Research, National Institute 

of Biomedical Innovation, Ibaraki, Osaka, Japan, 

3 


and Informatics, Osaka University, Suita, Osaka, 

Japan and 4 Department of Biomedical Innovation, 


University, Suita, Osaka, Japan. 


BIODISTRIBUTION AND REPRODUCTIVE 

TOXICITY OF NANOSILICA FOR 

ENSURING THE SAFETY OF 

NANOMATERIALS. K. Yamashita 1,2 , Y. 

Yoshioka 1,2,3 , K. Higashisaka 1,2 , M. Fujimura 1,2 , Y. 

Morishita 1,2 , H. Pan 1,2 , T. Ogura 1,2 , H. Nabeshi 1 , K. 

Nagano 2 , Y. Abe 2 , H. Kamada 2,3 , S. Tsunoda 2,3,4 , 

N. Itoh 1,2 , T. Yoshikawa 1,2 and Y. Tsutsumi 1,2,3 . 

1 

Department of Toxicology and Safety Science, 


Osaka University, Osaka, Japan, 2 Laboratory of 

Biopharmaceutical Research, National Institute of 

Biomedical Innovation, Osaka, Japan, 3 The Center 

for Advanced Medical Engineering and Informatics, 

Osaka University, Osaka, Japan and 4 Department 

of Biomedical Innovation, Graduate School of 

Pharmaceutical Sciences, Osaka University, Osaka, 

Japan. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Pesticides: General 

Chairperson(s): Diane Hardej, St. Johns University, Jamaica, NY, and 

Virginia Moser, U.S. EPA, Research Triangle Park, NC. 




INACTIVATION OF ENDOCANNABINOID 

METABOLISM IN HUMAN THP1 

MACROPHAGES FOLLOWING 

EXPOSURE TO ACTIVATED 

ORGANOPHOSPHOTHIONATES. M. K. 

Ross 1 , A. Borazjani 1 and P. M. Potter 2 . 1 Mississippi 

State University, Mississippi State, MS and 2 St. Jude 

Children’s Hospital, Memphis, TN. 


ETHYLENE BISDITHOCARBAMATE 

PESTICIDES MANEB AND MANCOZEB 

CAUSE TOXICITY IN NORMAL AND 

TRANSFORMED COLON CELLS. H. M. 

Lisa and D. Hardej. Department of Pharmaceutical 



RETINOIC ACID AND TESTOSTERONE 

LEVELS IN TESTIS AFTER MOLINATE: 

IN VITRO AND IN VITRO STUDIES. F. G. 

Zuno, B. S. Winder, D. Holstege and M. G. Miller. 

Environmental Toxicology, University of California, 

Davis, CA. 


CHARACTERIZATION OF CHLORPYRIFOS 

TOXICITY ON THE PANCREATIC BETA 

CELL LINE RINM5F. Z. Yan and D. R. Cool. 

Pharmacology/Toxicology, Wright State University, 

Dayton, OH. Sponsor: C. Sulentic. 


EARLY DEVELOPMENTAL EXPOSURE 

TO THE HERBICIDE ATRAZINE RESULTS 

IN ENRICHMENT OF GENE EXPRESSION 

ALTERATIONS ASSOCIATED WITH 

NEUROENDOCRINE DEVELOPMENT 

AND CARCINOGENESIS. G. J. Weber 1 , S. S. 

Lewis 2 , S. M. Peterson 1 , M. S. Sepúlveda 2 and J. L. 

Freeman 1 . 1 Health Sciences, Purdue University, West 

Lafayette, IN and 2 Forestry and Natural Resources, 

Purdue University, West Lafayette, IN. 


CHANGES IN EXPRESSION OF CRITICAL 

PROSTATE CANCER GENES UPON 

EXPOSURE TO ENVIRONMENTAL ANTI- 

ANDROGENIC PESTICIDE VINCLOZOLIN. 

S. Prasad 1 , M. Sienkiewicz 1 , B. Nguyen 1 , S. 

Ramoju 1 , P. O’Reilly 1 and J. Gomes 2,3 . 1 Cellular and 

Molecular Medicine, University of Ottawa, Ottawa, 

ON, Canada, 2 Health Science Program, University 

of Ottawa, Ottawa, ON, Canada and 3 Institute of 

Population Health, University of Ottawa, Ottawa, 

ON, Canada. 

Wednesday 







299



Wednesday 



PESTICIDE MIXTURES IN REPTILIAN 

AND AQUATIC MODELS. M. H. Feld and I. P. 

Callard. Department of Biology, Boston University, 

Boston, MA. 


JOINT TOXICITY OF PERMETHRIN AND 

ATRAZINE TO ZEBRAFISH (DANIO RERIO). 

P. Wages, A. Trimble and M. Posner. Biology/ 

Toxicology, Ashland University, Ashland, OH. 

Sponsor: P. Wages. 


2, 4-DICHLOROPHENOXYACETIC ACID 

(2, 4-D): EVALUATION OF ENDOCRINE 

MODULATING POTENTIAL. B. Neal 1 , M. 

S. Marty 2 , K. Coady 2 and J. C. Lamb 1 . 1 Center for 

Toxicology and Mechanistic Biology, Exponent, 

Alexandria, VA and 2 Toxicology & Environmental 

Research and Consulting, Dow Chemical Company, 

Midland, MI. 


LATE FETAL RESORPTIONS IN RATS 

INDUCED BY EPOXICONAZOLE OCCUR 

IN THE PRESENCE OF SIGNIFICANT 

MATERNAL TOXICITY AND CAN 

BE ANTAGONIZED BY ESTRADIOL 

CO-TREATMENT. S. Stinchcombe 1 , S. 

Schneider 2 , I. Fegert 1 , V. Strauss 2 , S. Gröters 2 , M. C. 

Rey Moreno 2 and B. van Ravenzwaay 2 . 1 Regulatory 

Toxicology Pesticides, BASF SE, Ludwigshafen, 

Germany and 2 Experimental Toxicology and 

Ecology, BASF SE, Ludwigshafen, Germany. 

Sponsor: R. Parod. 


MICROARRAY ANALYSIS OF GENE 

EXPRESSION CHANGES IN HUMAN 

HEPATOCYTES AFTER CHLORPYRIFOS 

EXPOSURE. A. D. Wallace 1 , R. Shah 2 , K. 

Choi 1 , H. Joo 1 and E. Hodgson 1 . 1 Environmental 

and Molecular Toxicology, North Carolina State 

University, Raleigh, NC and 2 Sciome LLC, Research 



HUMAN HEPATIC CYTOCHROME 

P450-SPECIFIC METABOLISM OF 

CHLORPYRIFOS, PARATHION, METHYL 

PARATHION, AND DIAZINON. Y. Tian, C. 

A. Ellison, R. J. Foxenberg, B. P. McGarrigle, 

J. B. Knaak and J. R. Olson. Pharmacology and 

Toxicology, University at Buffalo, Buffalo, NY. 


STUDY OF THE INHIBITION 

OF RECOMBINANT HUMAN 

CARBOXYLESTERASE 1 AND 2 BY 

CHLORPYRIFOS OXON, PARAOXON, AND 

METHYL PARAOXON. J. A. Crow 1 , V. Bittles 1 , 

K. Herring 1 , A. Borazjani 1 , P. M. Potter 2 and M. K. 

Ross 1 . 1 Mississippi State University, Mississippi 

State, MS and 2 St. Jude Children’s Hospital, 

Memphis, TN. 


GLOBAL TRANSCRIPTIONAL PROFILE OF 

DICHLORVOS EFFECTS IN DANIO RERIO. 

T. M. Bui Nguyen 1,2 , N. Hussainzada 1,2 , C. Baer 3 , 

J. Lewis 2 and D. Jackson 2 . 1 Oak Ridge Institute 

for Science and Education-U.S. Army Center for 

Environmental Health Research, Fort Detrick, 

MD, 2 U.S. Army Center for Environmental Health 

Research-Fort Detrick, Fort Detrick, MD and 3 Excet, 

Inc., Fort Detrick, MD. 


ABSORPTION AND LIMITED 

PHARMACOKINETICS OF INHALED 

SULFURYL FLUORIDE IN NEW ZEALAND 

WHITE RABBITS. D. L. Eisenbrandt 1 , M. J. 

Bartels 2 , S. M. Krieger 2 , D. A. Markham 2 , D. L. 

Rick 2 and J. A. Hotchkiss 2 . 1 Dow AgroSciences, 

LLC, Indianapolis, IN and 2 The Dow Chemical 



KINETIC INTERACTION OF 

SOLUBLE ESTERASES OF BRAIN 

AND PHENYLMETHYLSULPHONYL 

FLUORIDE (PMSF), AN INHIBITOR 

PROTECTING AND POTENTIATING 

THE ORGANOPHOSPHORUS DELAYED 

NEUROTOXICITY. E. Vilanova, I. Mangas and 

J. Estévez. Instituto de Bioingeniería, Universidad 

Miguel Hernández, Elche, Alicante, Spain. 


IMPACTS OF HYPERSALINE CONDITIONS 

ON ORGANOPHOSPHATE TOXICITY. 

L. A. Maryoung, R. Lavado and D. Schlenk. 

Environmental Toxicology, University of California, 

Riverside, Riverside, CA. 


METABOLISM OF CHLORPYRIFOS BY 

ALLELIC ISOFORMS OF CYP2B6, A KEY 

BIOACTIVATING ENZYME. A. L. Crane, B. 

P. McGarrigle and J. R. Olson. Pharmacology and 

Toxicology, University at Buffalo, Buffalo, NY. 


ALTERATIONS IN THE EXPRESSION OF 

PYRETHROID PESTICIDE METABOLIZING 

ENZYMES DURING GESTATION IN 

MICE. M. C. Fortin 1 , L. M. Aleksunes 2 and J. R. 

Richardson 1 . 1 Environmental and Occupational 

Medicine, Environmental and Occupational 

Health Sciences Institute, Piscataway, NJ and 

2 




ACUTE INHALATION OF AEROSOLIZED 

CHLORPYRIFOS BY ADULT SPRAGUE- 

DAWLEY RATS: ABSORPTION, 

METABOLISM, AND KINETICS OF 

CHOLINESTERASE INHIBITION IN RED 

BLOOD CELLS, PLASMA, BRAIN, AND 

LUNG. J. A. Hotchkiss 1 , S. M. Krieger 1 , D. L. 

Rick 1 , M. J. Bartels 1 , F. B. Selman 2 and D. R. 

Juberg 2 . 1 The Dow Chemical Company, Midland, MI 

and 2 Dow AgroSciences, LLC, Indianapolis, IN. 

300 






Platform Sessions



Abstract # 


CONSTRUCTION AND VALIDATION OF A 

HUMAN PBPK/PD MODEL FOR DERMAL 

CHLORPYRIFOS EXPOSURE UTILIZING 

HUMAN BIOMARKER DATA. C. A. Ellison 1 , 

J. B. Knaak 1 , R. McDougall 2 , P. J. Lein 3,4 , F. M. 

Farahat 5 , K. Anger 3 and J. R. Olson 1 . 1 University 

at Buffalo, Buffalo, NY, 2 University of Ontario 

Institute of Technology, Oshawa, ON, Canada, 

3 

Oregon Health & Science University, Portland, OR, 

4 


Medicine, Davis, CA and 5 Menoufia University, 

Shibin el Kom, Egypt. 


INTEGRATION OF TOXICOKINETICS (TK) 

INTO GUIDELINE TOXICITY STUDIES OF 

A NEW AGROCHEMICAL. S. A. Saghir 1 , D. L. 

Rick 1 , A. J. Clark 1 , J. L. Staley 1 , M. J. Bartels 1 , C. 

Terry 2 and R. Billington 2 . 1 The Dow Chemical Co., 

Midland, MI and 2 Dow AgroSciences, Milton Park, 



TOXICOKINETIC - TOXICODYNAMIC 

RELATIONSHIPS IN CASES OF 

GLYPHOSATE HERBICIDE EXPOSITION. 

A. Anadon, M. A. Martínez, I. Ares, E. Ramos, 

V. Castellano, M. Martínez and M. R. Martínez- 

Larrañaga. Department of Toxicology and 

Pharmacology, Faculty of Veterinary Medicine, 

Universidad Complutense, Madrid, Spain. 


PROPICONAZOLE INDUCES ALTERATIONS 

IN THE HEPATIC METABOLOME OF 

MICE: RELEVANCE TO PROPICONAZOLE- 

INDUCED HEPATOCARCINOGENESIS. S. 

Nesnow, T. Moore and W. Padgett. NHEERL/ISTD, 

U.S. EPA, Research Triangle Park, NC. Sponsor: S. 

Hester. 


EXPRESSION OF CYPS 2B1/2B2, BUT 

NOT CYPS 1A1 OR 1A2, ARE INDUCED IN 

THE LIVER FROM RATS FED MIXTURES 

OF THE PESTICIDES DIELDRIN, 

DICHLORVOS, PERMETHRIN, DICOFOL, 

AND ENDOSULFAN. S. Ramos da Silva, C. S. 

Franchi, J. V. de Camargo and D. Elgui de Oliveira. 

Pathology, São Paulo State University (UNESP) 

Medical School, Botucatu, SP, Brazil. Sponsor: D. 

Wolf. 


CYTOCHROME P450 3A5 

GENOTYPE IS CORRELATED WITH 

ACETYLCHOLINESTERASE INHIBITION 

LEVELS AFTER EXPOSURE TO 

ORGANOPHOSPHATE PESTICIDES. Z. 

Guerrette 1 , E. G. Moreira 1,3 , W. C. Griffith 1 , 

G. D. Coronado 2 , E. M. Vigoren 1 , X. Yu 1 , B. 

Thompson 1,2 and E. M. Faustman 1 . 1 Environmental 

and Occupational Health Sciences, University of 

Washington, Seattle, WA, 2 Fred Hutchinson Cancer 

Research Center, Seattle, WA and 3 State University 

of Londrina, Londrina, PR, Brazil. 

Abstract # 


GLUTATHIONE S-TRANSFERASE 

POLYMORPHISMS INFLUENCE THE 

LEVEL OF OXIDATIVE DNA DAMAGE IN 

SOYBEAN PESTICIDE APPLICATORS. M. 

A. Carballo 1 , M. Porcel de Peralta 2 , E. Kleinsorge 2 

and M. Simoniello 1,2 . 1 Bioquímica Clínica, Facultad 

de Farmacia y Bioquímica. Universidad de Buenos 

Aires, Buenos Aires, Argentina and 2 Bioquimica 

Clínica, CIGETOX. INFIBIOC. Facultad de 

Farmacia y Bioquímica. UBA, Buenos Aires, 

Argentina. Sponsor: O. Olivero. 


HYDROLYSIS OF ORGANOPHOSPHATE 

AND MODEL SUBSTRATES IN 

AFRICAN AMERICAN AND 

CAUCASIAN SOUTHERNERS BY 

SERUM PARAOXONASE-1 (PON1) AND 

RELATIONSHIP TO ATHEROSCLEROSIS. 

H. Coombes, A. Crow, M. Dail, H. Chambers, R. 

Wills, E. Meek and J. Chambers. Mississippi State 

University, Mississippi State, MS. 


INTRAVENTRICULAR CONDUCTION 

DELAY AFTER GLYPHOSATE- 

SURFACTANT HERBICIDES 

INTOXICATION. Y. Tseng 1 , C. Chen 1,2 , C. 

Huang 4 , W. Chen 1 and D. Hung 1,2,3 . 1 Department 

of Emergency, China Medical University Hospital, 

Taichung, Taiwan, 2 Toxicology Center, China 


3 

Graduate Institute of Drug Safety, College of 

Pharmacy, China Medical University, Taichung, 

Taiwan and 4 School of Chinese Medicine, College 

of Chinese Medicine, China Medical University, 

Taichung, Taiwan. 


GENETIC DAMAGE AND GENE 

EXPRESSION IN PESTICIDE RETAILERS 

FROM NAYARIT, MEXICO. E. Rojas 1 , S. 

Lara-Montoya 1 , P. Ostrosky 2 , M. Sordo 2 , M. Medina- 

Díaz 1 , L. Robledo-Marenco 1 , A. Benitez-Trinidad 1 , 

B. Quintanilla-Vega 3 and M. Bermúdez de León 4 . 

1 

Laboratorio de Contaminación y Toxicología 

Ambiental, Universidad Autónoma de Nayarit, 

Tepic, Nayarit, Mexico, 2 Instituto de Investigaciones 

Biomédicas, Universidad Nacional Autónoma de 

México, Mexico, D.F., D.F., Mexico, 3 Departamento 

de Toxicología, Centro de Investigación y de 

Estudios Avanzados del IPN, Mexico, D.F., D.F., 

Mexico and 4 Laboratorio de Biología Molecular, 

Centro de Investigación Biomédica del Noreste- 

IMSS, Monterrey, Nuevo León, Mexico. 

Wednesday 







301



Wednesday 



ACETYLCHOLINESTERASE ACTIVITY 

AND GENE EXPRESSION IN URBAN 

SPRAYERS FROM NAYARIT, MEXICO. 

M. Fuentes-Reyes 1 , E. Rojas 1 , P. Ostrosky 2 , M. 

Sordo 2 , M. Medina-Díaz 1 , L. Robledo-Marenco 1 , S. 

Lara-Montoya 1 , A. Benitez-Trinidad 1 , B. Quintanilla- 

Vega 3 , M. Bermúdez de León 4 , B. Barrón-Vivanco 1,3 , 

I. Girón-Pérez 1 , C. González-Arias 1 and F. 

Herrera-Moreno 1 . 1 Laboratorio de Contaminación 

y Toxicología Ambiental, Universidad Autónoma 

de Nayarit, Tepic, Nayarit, Mexico, 2 Instituto 

de Investigaciones Biomédicas, Universidad 

Nacional Autónoma de México, D.F., Mexico, D.F, 

Mexico, 3 Departamento de Toxicología, Centro de 

Investigación y de Estudios Avanzados del IPN, D.F., 

Mexico, D.F., Mexico and 4 Laboratorio de Biología 

Molecular, Centro de Investigación Biomédica del 

Noreste-IMSS, Monterrey, Nuevo León, Mexico. 


ESTIMATING EGYPTIAN COTTON 

FIELD WORKER EXPOSURE TO THE 

ORGANOPHOSPHORUS PESTICIDE 

PROFENOFOS. O. A. Dadson 1 , C. A. Ellison 1 , 

S. T. Singleton 1 , L. Chi 1 , F. M. Farahat 2 and J. R. 

Olson 1 . 1 University at Buffalo, Buffalo, NY and 

2 

Menoufia University, Shibin el Kom, Egypt. 


THE CONTRIBUTION OF HANDS TO 

THE DERMAL PESTICIDE EXPOSURE OF 

STRAWBERRY HARVESTERS. G. Sankaran 1,2 , 

L. Chen 2 , Z. Chen 1,2 , T. Lopez 1,2 , H. Vega 2 and R. 

I. Krieger 1,2 . 1 Environmental Toxicology Graduate 

Program, University of California, Riverside, CA and 

2 

Personal Chemical Exposure Program, Department 

of Entomology, University of California, Riverside, 

CA. 


PRELIMINARY RESEARCH FOR A 

MONITORING PROGRAM FOR PESTICIDE 

RESIDUES ON MARKET VEGETABLES 

IN MEXICO. M. L. Aldana-Madrid 1 , M. I. 

Silveira-Gramont 1 , A. I. Valenzuela-Quintanar 3 , G. 

Rodríguez-Olibarría 1 , P. Grajeda-Cota 3 , F. G. Zuno 2 

and M. G. Miller 2 . 1 Departamento de Investigación 

y Posgrado en Alimentos, Universidad de Sonora, 

Hermosillo, Sonora, Mexico, 2 Environmental 

Toxicology, University of California, Davis, CA 

and 3 Centro de Investigación en Alimentación y 

Desarrollo, Hermosillo, Sonora, Mexico. 


IMPLICATIONS OF ORGANOPHOSPHATE 

(OP) PESTICIDES IN FOOD GRAIN. R. 

Dufault 2 and S. Gilbert 1 . 1 INND, Seattle, WA and 

2 

Food Ingredient and Health Research Institute 

(FIHRI), Honolulu, HI. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Metal Neurotoxicity: Manganese and Lead 

Chairperson(s): Nikolay Filipov, University of Georgia, Athens, GA, and 

Dejan Milatovic, Vanderbilt University Medical Center, Nashville, TN. 




HIGH-THROUGHPUT ASSESSMENT 

OF CELLULAR MANGANESE (MN) 

IDENTIFIES NOVEL MECHANISM 

UNDERLYING A MN DEFICIT OF 

HUNTINGTON’S DISEASE MODEL. G. 

Kwakye 1 , D. Li 1 , O. Kabobel 1 , M. Wegrzynowicz 1 , 

K. M. Erikson 2 , M. Aschner 1 and A. B. Bowman 1 . 

1 

Neuroscience, Vanderbilt University Medical Center, 

Nashville, TN and 2 Nutrition, University of North 

Carolina, Greensboro, NC. 


CTR1, BUT LESS LIKELY DMT1, PLAYS A 

CRITICAL ROLE IN MANGANESE (MN)- 

INDUCED COPPER (CU) ACCUMULATION 

IN THE BLOOD-CSF BARRIER. G. Zheng 

and W. Zheng. School of Health Sciences, Purdue 

University, West Lafayette, IN. 


EXAMINING A POTENTIAL GENE- 

ENVIRONMENT INTERACTION BETWEEN 

THE PD-ASSOCIATED GENE PARKIN AND 

MANGANESE IN A C. ELEGANS MODEL. 

S. Chakraborty 1 and M. Aschner 2,3 . 1 Neuroscience 

Graduate Program, Vanderbilt University, Nashville, 

TN, 2 Pediatrics, Vanderbilt University, Nashville, 

TN and 3 Vanderbilt Kennedy Center, Vanderbilt 

University, Nashville, TN. 


HSPS ARE IMPORTANT MEDIATORS OF 

MN-INDUCED TOXICITY IN C. ELEGANS. 

D. Avila and M. Aschner. Pediatrics/Toxicology, 

Vanderbilt University, Nashville, TN. 


THE EFFECTS OF MANGANESE ON 

MITOCHONDRIAL ACONITASE AND 

CYTOCHROME C OXIDASE IN THE 

GILL OF THE BIVALVE CRASSOSTREA 

VIRGINICA. K. Huang, A. Hutchinson, H. Huang, 

Z. Nicholas, R. Desroches, E. J. Catapane and M. A. 

Carroll. Biology, Medgar Evers College, Brooklyn, 

NY. 


MN 2+ INHIBITION OF OXIDATIVE 

PHOSPHORYLATION IN LIVER, BRAIN, 

AND HEART MITOCHONDRIA. T. E. 

Gunter 1 , B. Gerstner 1 , C. Gavin 2 and K. Gunter 1 . 

1 

Biochemistry and Biophysics, University of 

Rochester School of Medicine, Rochester, NY and 

2 

Pfizer, Groton, CT. 

302 






Platform Sessions



Abstract # 


MECHANISM OF ENHANCED HEME 

OXYGENASE-1 (HO-1) ACTIVITY AND 

THE ROLE OF HO-1 IN CONTROLLING 

INFLAMMATORY CYTOKINE OUTPUT IN 

LPS-STIMULATED MICROGLIA. C. A. Dodd, 

I. I. Georgieva and N. M. Filipov. Physiology and 

Pharmacology, University of Georgia, Athens, GA. 


OXIDATIVE INJURY AND EP2 SIGNALING 

IN MANGANESE NEUROTOXICITY. D. 

Milatovic 1 , Y. Yu 1 , S. Zaja-Milatovic 2 and M. 

Aschner 1 . 1 Pediatrics, Vanderbilt University, 

Nashville, TN and 2 Medicine, Vanderbilt University, 



GLIAL INTERACTIONS AND 

NEUROINFLAMMATION IN MANGANESE 

NEUROTOXICITY. K. Sullivan 1 and R. 

Tjalkens 1,2 . 1 Environmental and Radiological Health 

Sciences, Colorado State University, Fort Collins, 

CO and 2 Molecular and Cellular Biology, Colorado 

State University, Fort Collins, CO. 


NOVEL NADPH OXIDASE 

MODULATOR PROTECTS AGAINST 

NEUROINFLAMMATION ASSOCIATED 

WITH MANGANESE NEUROTOXICITY. 

C. Hogan 1 , R. Gordon 1 , A. Kanthasamy 1 , V. 

Anantharam 1 , B. Kalyanaraman 2 and A. G. 

Kanthasamy 1 . 1 Biomedical Sciences, Iowa Center for 

Advanced Neurotoxicology, Iowa State University, 

Ames, IA and 2 Biophysics, Medical College of 

Wisconsin, Milwaukee, WI. 


PROTEIN KINASE C IS INVOLVED IN 

MANGANESE- MEDIATED DISRUPTION OF 

GLUTAMINE TURNOVER IN ASTROCYTES. 

M. Sidoryk-Wegrzynowicz 1 , E. Lee 2 and M. 

Aschner 1 . 1 Department of Pediatrics, Vanderbilt 

University Medical Center, Nashville, TN and 

2 

Department of Physiology, Meharry Medical 



EXPRESSION OF MUTANT HUNTINGTIN 

INCREASES ARGINASE ACTIVITY IN 

MOUSE STRIATUM, BUT DECREASES 

ITS SUSCEPTIBILITY TO MANGANESE 

EXPOSURE. M. Wegrzynowicz 1,2 , H. K. Holt 1,2 

and A. B. Bowman 1,2,3 . 1 Department of Neurology, 

Vanderbilt University Medical Center, Nashville, TN, 

2 

Vanderbilt Kennedy Center, Vanderbilt University 

Medical Center, Nashville, TN and 3 Center for 

Molecular Toxicology, Vanderbilt University Medical 

Center, Nashville, TN. 


NEUROTOXIC EFFECTS OF INTRANASAL 

MANGANESE EXPOSURE AND 

INTERACTION WITH CADMIUM 

EXPOSURE IN A MOUSE MODEL. A. H. 

Moberly, J. Pottackal, L. Czarnecki, T. Rubinstein, D. 

J. Turkel and J. P. McGann. Psychology Department, 

Rutgers University, Piscataway, NJ. 

Abstract # 


MANGANESE AND VANADIUM EXPOSURE 

INDUCES SEVERE NEUROTOXIC 

RESPONSE IN OLFACTORY SYSTEM 

OF AN ANIMAL MODEL: POTENTIAL 

RELEVANCE TO OLFACTORY 

DYSFUNCTION AND PARKINSON’S 

DISEASE (PD). H. Afeseh Ngwa, A. Kanthasamy, 

V. Anantharam and A. G. Kanthasamy. Iowa State 



CHRONIC MANGANESE ALTERS THYROID 

AND ESTROGEN LEVELS IN RATS BLOOD. 

O. Soldin 1 and M. Aschner 2 . 1 Departments of 

Oncology, Medicine, Physiology and Biophysics, 

Obstetrics and Gynegology, Georgetown University, 

Washington, D.C. and 2 Departments of Pediatrics and 

Pharmacology, Vanderbilt University, Nashville, TN. 


PEPTIDOME AND PROTEOME IN MURINE 

CHOROID PLEXUS-CEREBROSPINAL 

FLUID SYSTEM: EFFECT OF CHRONIC 

MANGANESE (MN) EXPOSURE. G. J. Li 1 , K. 

H. Wei 2 , H. M. Jing 1 , F. Yang 2 , C. Y. Zhao 1 , L. Ma 1 , 

T. Zhang 2 , X. Y. Zhang 2 , J. Z. Liu 1 , L. P. Liu 1 and W. 

Zheng 3 . 1 Beijing Center for Preventive Medicine, 

Beijing, China, 2 Beijing Proteome Research Center, 

Beijing, China and 3 Purdue University, West 



REDUCED COPPER CLEARANCE BY THE 

BLOOD-CSF BARRIER FOLLOWING IN 

VIVO MANGANESE AND THE ROLE OF CU 

TRANSPORTER ATP7A. X. Fu, Y. Zhang, W. 

Jiang, A. D. Monnot and W. Zheng. School of Health 

Sciences, Purdue University, West Lafayette, IN. 


INCREASED BETA-AMYLOID DEPOSITION 

IN TRANSGENIC APP MICE FOLLOWING 

CHRONIC LEAD (PB) EXPOSURE. W. 

Zheng 1 , H. Gu 2 , X. Wei 2 , A. D. Monnot 1 and Y. Du 1,2 . 

1 


Lafayette, IN and 2 Neurology, Indiana University 



NEUROIMAGING OF MANGANESE 

TOXICITY: EFFECT OF EXPOSURE TIME 

ON ACCUMULATION IN HUMAN BRAIN. J. 

Xu 1,2 , X. Li 3 , S. Streitmatter 1 , L. Long 3 , W. Zheng 1 , Y. 

Jiang 3 and U. Dydak 1,2 . 1 School of Health Sciences, 

Purdue University, West Lafayette, IN, 2 Indiana 

Univeristy School of Medicine, Indianapolis, IN and 

3 

Guangxi Medical University, Nanning, China. 



TOXICITY: GABA AND METABOLIC 

CHANGES IN THE HUMAN BRAIN. Z. 

Long 1,2 , Y. Jiang 3 , X. Li 3 , J. Xu 1,2 , L. Long 3 , W. 

Zheng 1 and U. Dydak 1,2 . 1 School of Health Sciences, 

Purdue University, West Lafayette, IN, 2 Indiana 

University School of Medicine, Indianapolis, IN and 

3 

Guangxi Medical University, Nanning, China. 

Wednesday 







303



Wednesday 



THE DEVELOPMENT OF A HUMAN 

MULTI-ROUTE PHYSIOLOGICALLY- 

BASED PHARMACOKINETIC MODEL FOR 

MANGANESE. M. D. Taylor 1 , J. D. Schroeter 2 , A. 

Nong 2 , M. Yoon 2 , D. C. Dorman 3 , M. E. Andersen 2 

and H. J. Clewell 2 . 1 Afton Chemical Corporation, 

Richmond, VA, 2 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 3 College 

of Veterinary Medicine, North Carolina State 



DEVELOPMENTAL LEAD EXPOSURE 

CAUSES TIME POINT SPECIFIC 

ALTERATIONS IN NERVOUS SYSTEM 

RELATED GENE AND PROTEIN 

EXPRESSION LEVELS. S. Peterson, J. Zhang, 

G. J. Weber and J. L. Freeman. Purdue University, 



LOW-LEVEL DEVELOPMENTAL LEAD 

(PB2+) EXPOSURES ALTERS C-START 

RESPONSE IN LARVAL ZEBRAFISH. D. 

Weber 1 and C. Rice 2 . 1 Children’s Environmental 

Health Sciences Center, University of Wisconsin- 

Milwaukee, Milwaukee, WI and 2 American 

University, Washington, D.C. 


NEURODEVELOPMENTAL TOXICITY OF 

LEAD (PB): A MORPHOLOGIC STUDY IN 

THE EMBRYONIC ZEBRAFISH BRAIN. J. 

Zhang, S. M. Peterson, W. Zheng and J. L. Freeman. 




EFFECTS OF DEVELOPMENTAL LEAD 

EXPOSURE ON GENE EXPRESSION IN THE 

HIPPOCAMPUS: GENE-ENVIRONMENT 

INTERACTIONS. W. Mettil, D. Anderson, L. 

Walinchus, R. Schray and J. Schneider. Pathology, 

Anatomy, and Cell Biology, Thomas Jefferson 

University, Philadelphia, PA. 


LEAD DIFFERENTIALLY AFFECTS GENE 

EXPRESSION PROFILES IN HIPPOCAMPUS 

AND FRONTAL CORTEX. J. Schneider, W. 

Mettil, D. Anderson, R. Shray and L. Walinchus. 

Thomas Jefferson University, Philadelphia, PA. 


CATALASE MANIPULATIONS MODIFY 

VOLUNTARY ETHANOL INTAKE IN 

DEVELOPMENTALLY LOW-LEVEL LEAD 

EXPOSED RATS. M. Virgolini, M. S. Mattalloni 

and L. M. Cancela. IFEC CONICET Department 

de Farmacologia., Fac. de Ciencias Quimicas. 

Universidad Nacional de Cordoba, Cordoba, 

Argentina. 


WATERBORNE MANGANESE EXPOSURE 

ALTERS STEREOTYPIC BEHAVIORS AND 

PLASMA METABOLITES IN DEVELOPING 

RATS. S. C. Fordahl 1 , P. Cooney 1 , Y. Qiu 2 , G. 

Xie 2 , W. Jia 2 and K. Erikson 1 . 1 Nutrition, University 

of North Carolina at Greensboro, Greensboro, NC 

and 2 Nutrition, University of North Carolina at 

Greensboro, North Carolina Research Campus, 

Kannapolis, NC. 


PRE-WEANING MN EXPOSURE LEADS TO 

PROLONGED ASTROCYTE ACTIVATION 

AND LASTING EFFECTS ON THE 

DOPAMINERGIC SYSTEM IN ADULT RATS. 

C. Kern and D. R. Smith. Environmental Toxicology, 

University of California, Santa Cruz, CA. 


EFFECTS OF PERINATAL LEAD EXPOSURE 

ON LEARNING AND MEMORY ARE 

MODIFIED BY SEX AND REARING 

CONDITION. K. Pothakos, D. Anderson, R. 

Schray, L. Walinchus and J. Schneider. Pathology, 

Anatomy, and Cell Biology, Thomas Jefferson 

University, Philadelphia, PA. 


A MOUSE MODEL OF Pb-STRESS 

INTERACTIONS AT BLOOD Pb < 10 g/dl. K. 

Merchant-Borna, S. Liu, D. Weston and D. A. Cory- 

Slechta. Department of Environmental Medicine, 

University of Rochester School of Medicine, 



9:00 AM to 4:30 PM 

Room 203 





Sponsor: 


Representatives from federal agencies that fund research will be available 

in the Research Funding Room. Individual conversations can occur 

in a quiet, informal space whether you want to discuss research plans, 

a current grant application, or previous reviews. Representatives from 

NIH, including program officers and Center for Scientific Review staff, 

NIEHS, NHLBI, and other institutes, as well as U.S. EPA ORD, DOE, 

and other agencies will be available at various times. 

Make an appointment with your program officer in advance or at their 

exhibit booth, or check the posted schedule to meet with the staff 

member of your choice. New investigators are especially encouraged to 

meet with program staff. Handouts will be available. 

304 






Platform Sessions



Abstract # 


9:15 AM to 10:15 AM 

Room 156 

Exhibitor Hosted Session: Developing Local and Systemic 

Biologics to Treat Inflammation of the Lung 


Pharmaceutical companies have investigated the respiratory route as a 

potential to deliver large molecular weight drugs systemically. Many companies 

are continuing to explore the respiratory route for the treatment of local 

inflammation. Equally a number of companies are using systemically delivered 

drugs to treat inflammation of the lung. Session highlights issues and 

assess how the safety might be addressed. 


9:15 AM to 10:15 AM 

Room 140B 

Exhibitor Hosted Session: Key Six Sigma Methods Applied to 

Surgical Services for Operational Excellence 


Harlan Laboratories removed non-value added steps and reduced sources of 

variation within our rodent surgical services processes using Lean Six Sigma 

methods. This was key to achieving operational excellence as toxicologists 

and others increased demand for our outsourced surgical services. 


9:15 AM to 10:15 AM 

Room 140A 

Exhibitor Hosted Session: Reproductive and Developmental 

Toxicity Testing of Vaccines and Biologics 


The regulatory-required testing of large molecules (vaccines and biologics) 

prior to marketing for effects on reproduction and development of the fetus 

presents unique problems in the selection of appropriate species, the timing 

of treatment, the evaluation of the response to treatment and the relevance of 

any findings to humans. 

Abstract # 


10:30 AM to 11:30 AM 

Room 156 

Exhibitor Hosted Session: Challenges of Assessing Biologics 

for Efficacy and Safety 


Biologics present an ongoing challenge to both PK/PD assessment and 

safety/immunotoxic effects. This session will discuss issues around assay 

development, impact of immunogenicity on PK/efficacy, and risk-based 

approach to determine what, if any, additional safety immune-based 

endpoints should be assessed. 


10:30 AM to 11:30 AM 

Room 140A 

Exhibitor Hosted Session: Drug Testing Using 3D 

Microtissues 

Presented by: InSphero AG 

More physiological in vitro cell models will foster the efficiency of the drug 

development process. InSphero provides an in-depth review of different 

3D-call-culture technologies used to create microtissue models. Applications 

in oncology and toxicology as well as examples of the successful use of 3D 

models up to the regulatory level for skin applications are presented. 


10:30 AM to 11:30 AM 

Room 140B 

Exhibitor Hosted Session: Overview, Design, and Review of 

Transgenic Carcinogenicity Studies 

Presented by: BioReliance ® Corporation 

Experience and design of Transgenic Carcinogenicity studies; as well as, 

date, statistics and histopathology from the largest database of spontaneous 

tumors from these studies will be presented. Discussion will include an 

overview of the history of specific models, validations and the efficacy for 

use in regulatory submissions. 


9:30 AM to 10:30 AM 

Room 201 

Meet the Director: NIEHS Director 

Chairperson(s): Jon C. Cook, Pfizer, Groton, CT. 

Lecturer: Linda Birnbaum, NIEHS, Research Park Triangle, NC. 

The National Institute of Environmental Health Sciences (NIEHS) seeks 

to understand how the environment infuences the development and 

progression of human disease. This session will be a particularly valuable 

opportunity to update SOT members on the future directions of 

the NIEHS and the National Toxicology Program (NTP). Dr. Birnbaum 

will talk about her plans for leading NIEHS and NTP in promoting the 

environmental public health of the United States and the world through 

research directed at preventing and treating disease. 

Wednesday 







305



Wednesday 



10:45 AM to 11:45 AM 

Room 201 

Meet the Director: CDC/NIOSH Director 

Chairperson(s): William Slikker, Jr., U.S. FDA, Jefferson, AR. 

Lecturer: John Howard, CDC/NIOSH, Washington, D.C. 

The National Institute for Occupational Safety and Health (NIOSH) is 

a component of the Centers for Disease Control and Prevention in the 

U.S. Department of Health and Human Services. NIOSH’s mission is to 

generate new knowledge in the field of occupational safety and health 

and transfer that knowledge globally. NIOSH was established along 

with the Occupational Safety and Health Administration (OSHA) by 

the Occupational Safety and Health Act of 1970. NIOSH is a founding 

member of the National Toxicology Program (NTP) along with the Food 

and Drug Administration and the National Institute for Environmental 

Health Sciences. 

Highlights of NIOSH’s current activities in the area of toxicology include 

two major programs. First, the National Occupational Research Agenda 

(NORA) is a partnership program to stimulate innovative research and 

improved workplace practices. NORA has become a research framework 

for NIOSH and the nation. Diverse parties collaborate to identify the 

most critical issues in workplace safety and health. Partners then work 

together to develop goals and objectives for addressing these needs. 

Participation in NORA is broad, including stakeholders from universities, 

large and small businesses, professional societies, government agencies, 

and worker organizations. The program entered its second decade with 

a new sector based structure to better move research to practice within 

workplaces. The national agenda will be developed and implemented 

through the NORA Sector Councils. NIOSH is the steward of NORA and 

facilitates the work of the Sector Councils, which develop and implement 

research agendas for the occupational safety and health community. 

Second, the Nanotechnology Research Center (NRC) developed a 

Strategic Plan, published Progress Reports, provided guidance of good 

handling practices for nanomaterials, and produced CIBs for nano TiO2 

and carbon nanotubes. Currently, there are 52 projects in the NTRC. 

Projects are in the areas of toxicology and internal dose, measurement 

methods, exposure assessment, epidemiology and surveillance, 

risk assessment, engineering controls and PPE, fire and explosivity, 

recommendations and guidance, communication and information, and 

applications. 

Finally, during the Deepwater Horizon Response—Gulf of Mexico Oil 

Cleanup NIOSH was involved in several activities including rostering 

efforts, exposure assessments using health hazard evaluations (HHEs), 

toxicity testing, and worker health surveillance. NIOSH’s efforts in 

assessing the toxicity of the oil spill have focused on the dispersant 

designed to break up the oil. There has been a lot of concern about 

the chemicals within the dispersant, as well as the mixture of the 

crude and the dispersant together. The toxicology studies are currently 

ongoing and are looking at pulmonary, cardiovascular, and central 

nervous system effects after inhalation of dispersant or oil as well 

as dermal and immune effects after topical exposure to dispersant 

or oil. Also, on May 28, 2010, BP requested a health hazard 

evaluation of Deepwater Horizon Response workers. The sixth in a 

series of interim reports from this health hazard evaluation was issued 

September 13, 2010. These reports can be found by clicking on the 

NIOSH Web site. In addition, you will also find at this site current 

spreadsheets containing quantitative industrial hygiene sampling data 

available to date from NIOSH’s health hazard evaluation of the Deepwater 

Horizon Response. 


11:45 AM to 12:45 PM 

Room 140B 

Exhibitor Hosted Session: Humanized Mouse Models for PK 

and Safety Profiling of Compounds 

Presented by: Taconic 

There are profound interspecies differences in levels and functions of 

proteins involved in absorption, distribution, metabolism, excretion and 

toxicology (ADMET). Thus, traditional mouse models can be poor predictors 

of ADMET in humans. Panels of transgenic mouse models with key 

murine ADMET genes knocked out or exchanged for their human counterparts 

are discussed. 


11:45 AM to 12:45 PM 

Room 140A 

Exhibitor Hosted Session: Toxicity Knowledge Bases and 

Pathway Analysis Tools for Systems Toxicology 

Presented by: GeneGo, Inc., a Thomson Reuters Business 

ToxHunter is a rich database and powerful suite of tools for analyzing 

high content molecular toxicology data. Capabilities of the system in a 

safety assessment will be demonstrated. Dr. Russell Thomas from the 

Hamner Institutes will follow with a presentation on Applications of 

Pathway Analysis to Chemical Risk Assessment. 

Wednesday Afternoon 

Wednesday Afternoon, March 9 

12:00 NOON to 1:30 PM 

Room 304 

Regional Chapter Governance Committee Meeting 


12:00 NOON to 1:30 PM 

Salon G 

Specialty Section Meeting/Luncheon: In Vitro and 


306 






Platform Sessions



Abstract # 


12:00 NOON to 1:00 PM 

Room 201 

Meet the Director: Eunice Kennedy Shriver National 

Institute of Child Health & Human Development Director 

Chairperson(s): Cheryl Lyn Walker, University of Texas M.D. 

Anderson Cancer Center, Smithville, TX. 

Lecturer: Yvonne Maddox, NICHD, Bethesda, MD. 

The mission of the Eunice Kennedy Shriver National Institute of Child 

Health & Human Development (NICHD) is to ensure that every person 

is born healthy and wanted, that women suffer no harmful effects from 

reproductive processes, and that all children have the chance to achieve 

their full potential for healthy and productive lives, free from disease or 

disability, and to ensure the health, productivity, independence, and wellbeing 

of all people through optimal rehabilitation. 

Dr. Yvonne Maddox is the deputy director of the NICHD at the National 

Institutes of Health (NIH), a position she has held since January 1995. 

Dr. Maddox guides the organizations and programs of the NICHD, 

advises the director on matters regarding the internal affairs of the institute 

budget, and oversees the extramural program that supports research 

on child development, developmental biology, nutrition, AIDS, mental 

retardation, population issues, reproductive biology, contraception, pregnancy, 

and medical rehabilitation. From January 2000, to June 2002, Dr. 

Maddox also served as the acting deputy director of the NIH. 


12:00 NOON to 1:20 PM 

Room 144 

Roundtable Session: ‘Omics in Toxic Tort 

Chairperson(s): Angela Harris, Center for Toxicology and Environmental 

Health, North Little Rock, AR, and Anne Chapelle, Chapelle Toxicology 

Consulting, Chadds Ford, PA. 

Sponsor: 


Endorsed by: 


In the past few years, there has been a growing influx of ‘omics data into the 

courtroom. Transcriptomic and proteomic data have already been submitted 

in toxic tort litigation as evidence of exposure to a chemical or toxic effect 

due to chemical exposure, as have data regarding the genetic polymorphisms 

of plaintiffs alleging toxic effects. Submission of ‘omics data will likely 

increase exponentially over the next decade, however, there has been little 

discussion in the scientific community about how appropriate these data 

currently are in proving exposure and effect in any individual or group of 

individuals. Issues regarding specificity, interindividual and intraindividual 

variation, and validation are addressed in the scientific community as the 

data are projected for use in making regulatory decisions, but there is a 

serious gap in gauging the sometimes limited datasets submitted as evidence 

on which to base causal decisions in a court of law. We will introduces 

topics related to ‘omics in toxic tort to open a dialogue among toxicologists 

interested in the transition of these data from research tools to causative 

tools in litigation. 

#2152 12:00 ‘OMICS IN TOXIC TORT. A. J. Harris. CTEH, 

North Little Rock, AR. 

12:00 ENTRY OF ‘OMICS DATA INTO THE 

COURTROOM: AN INTRODUCTION. Angela 

J. Harris 

Abstract # 

12:05 DO ‘OMICS DATA REQUIRE STRINGENT 

VALIDATION AND ARE THE DATA 

PREDICTIVE OF TOXICOLOGIC 

OUTCOME IN HUMANS? Dan Casciano 

12:25 POTENTIAL EFFECTS OF GENETIC 

PROFILING AND INDIVIDUAL 

SUSCEPTIBILITY TO REGULATION 

IN THE CHEMICAL AND PETROLEUM 

INDUSTRIES. Anne Chapelle 

12:45 THE USE OF DNA EVIDENCE IN TOXIC 

EXPOSURE LITIGATION. Anthony G. Hopp 

1:05 PANEL DISCUSSION. 


12:00 NOON to 1:20 PM 

Room 145 

Informational Session: Current and Changing Perspectives 

on Mycotoxins and Their Potential Health Risks Worldwide 

Chairperson(s): Kenneth Voss, U.S. Department of Agriculture, Athens, 

GA, and Michael Bolger, U.S. FDA, College Park, MD. 

Sponsor: 


Endorsed by: 




Mycotoxins are ubiquitous contaminants of cereals and other commodities. 

Interventions at the agricultural, commodity processing, or food preparation 

stages of the field to plate sequence have significantly contributed to 

reducing human exposures. However, establishment of tolerable intakes and 

regulatory policies limiting the levels of aflatoxins, fumonisins, ochratoxin 

A, deoxynivalenol, and other mycotoxins known or suspected to cause 

human disease continues as a first line of defense for protecting consumer 

health. Contrasting approaches to safety and risk assessment can lead to the 

establishment of different tolerable intakes or regulatory standards as, for 

example, between the U.S. and the E.U. Improved commodity sampling and 

monitoring procedures and additional toxicology data reduce uncertainty in 

risk assessment and allow refinement of regulations for mycotoxins, as illustrated 

by changes in limits for aflatoxins in tree nuts which have facilitated 

international trade without compromising public health. However, regulatory 

approaches are not globally consistent and may not effectively protect 

public health if enforcement is less stringent. Inconsistent standards can in 

some cases lead to exportation of the best quality commodities. Therefore, 

implementation of multifaceted bottom up approaches involving better 

pre-harvest and post-harvest practices, improved nutrition, and clinical 

interventions is also needed to effectively reduce exposures to aflatoxins 

and other mycotoxins. Recent research increases our understanding of how 

mycotoxins interact with commodity and food matrix constituents, describes 

improved biomarkers for exposure assessments, and provides new findings 

on the toxicology and mechanisms of action that are essential for both 

regulatory and bottom up approaches to reduce mycotoxin exposure and 

maintain safe food supplies worldwide. 

#2153 12:00 CURRENT AND CHANGING 

PERSPECTIVES ON MYCOTOXINS AND 

THEIR POTENTIAL HEALTH RISKS 

WORLDWIDE. K. A. Voss 1 , M. Bolger 2 , S. H. 

Henry 2 , J. G. Adams 3 and F. Wu 4 . 1 Toxicology & 

Mycotoxin Research Unit, USDA-ARS, Athens, 

GA, 2 Center for Food Safety and Applied Nutrition, 

U.S. FDA, College Park, MD, 3 Almond Board of 

California, Modesto, CA and 4 Environmental and 

Occupational Health, University of Pittsburgh, 


Wednesday 







307



Wednesday 


12:00 MICHAEL BOLGER. Introduction 

12:05 IMPROVING OUR UNDERSTANDING 

OF MYCOTOXINS: EMERGING ISSUES 

RELEVANT TO FOOD SAFETY AND PUBLIC 

HEALTH. Kenneth A. Voss 

12:20 MYCOTOXINS: U.S. AND EUROPEAN 

REGULATORY STRATEGIES. Sara H. Henry 

12:35 AFLATOXIN LIMITS: A CASE STUDY OF 

RISK MANAGEMENT APPROACHES IN 

THE COMMERCIAL ENVIRONMENT. Julie 

G. Adams 

12:50 RISKS IN LESS DEVELOPED COUNTRIES: 

FOCUS ON PUBLIC HEALTH 

INTERVENTIONS, NOT REGULATIONS. 

Felicia Wu 



12:15 PM to 1:05 PM 

Room 151 

Translational Impact Award Lecture: 


Decision Making 

Lecturer: Weida Tong, U.S. FDA, Jefferson, AR. 

Advanced high throughput and high content technologies 

such as genomics offer new opportunities 

for investigating disease and toxicity at the molecular level, and for 

discovery of corresponding biomarkers. Data from the new experimental 

platforms are both huge in number and noisy in content. Extraction of 

useful knowledge requires bioinformatics for data management, analysis 

and interpretation. The NCTR Center for Bioinformatics provides 

an array of informatics infrastructures and data analysis capability to 

address the U.S. FDA regulatory needs. The presentation highlights 

a diversity of projects developed in the center to address key bioinformatics 

issues associated with the omics research and predictive 

toxicology in FDA. Specifically, the following projects will be discussed 

with focused on lessons learned: (1) The U.S. FDA bioinformatics tool, 

Array-Track; (2) The FDA-led community wide effort, MicroArray 

Quality Control (MAQC) project; (3) Liver Toxicity Knowledge Base 

(LTKB); and (4) Endocrine Disruptor Knowledge Base (EDKB). 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology: In Vitro or Ex Vivo Studies 

Chairperson(s): Nan Mei, U.S. FDA, Jefferson, AR. 




TERPENE EFFECTS ON PENETRATION 

OF NANOPARTICLES IN HUMAN SKIN. N. 

A. Monteiro-Riviere 1 , A. O. Inman 1 , D. Erdmann 2 , 

X. Xia 1 and J. E. Riviere 1 . 1 Center for Chemical 


Carolina State University, Raleigh, NC and 2 Duke 

University Medical Center, Duke University, 

Durham, NC. 


SKIN PH EFFECTS THE PENETRATION 

OF QUANTUM DOT NANOPARTICLES IN 

PORCINE SKIN. A. O. Inman, N. A. Monteiro- 

Riviere and J. E. Riviere. Center for Chemical 




INFORMING SELECTION OF 

NANOMATERIAL CONCENTRATIONS FOR 

TOXCAST IN VITRO TESTING USING THE 

MULTIPLE-PATH PARTICLE DOSIMETRY 

MODEL. S. Gangwal 1 , J. S. Brown 2 , A. Wang 1 , 

K. A. Houck 1 , D. J. Dix 1 , R. J. Kavlock 1 and E. A. 

Cohen Hubal 1 . 1 National Center for Computational 

Toxicology (NCCT), U.S. EPA, Research Triangle 

Park, NC and 2 National Center for Environmental 

Assessment (NCEA), U.S. EPA, Research Triangle 

Park, NC. 


NANOTOXICOLOGY – QUO VADIS? H. F. 

Krug. Materials Meet Life, EMPA - Materials & 

Technology, St. Gallen, Switzerland. Sponsor: B. 

Fadeel. 


A NOVEL COMPREHENSIVE EVALUATION 

PLATFORM TO ASSESS NANOPARTICLE 

TOXICITY IN VITRO. C. Hirsch 1 , F. Wessling 1 , 

K. Fischer 1 , M. Roesslein 1 , P. Wick 1 , H. Hofmann 2 

and H. F. Krug 1 . 1 Materials-Biology Interactions, 

Empa, Swiss Federal Laboratories for Materials 

Science and Technology, St. Gallen, Switzerland and 

2 

Powder Technology Laboratory, EPFL, Lausanne, 

Switzerland. Sponsor: B. Fadeel. 


PROTEOME PROFILING OF BEAS-2B 

CELLS TREATED WITH TITANIUM 

DIOXIDE REVEALS POTENTIAL TOXICITY 

OF AND DETOXIFICATION PATHWAYS 

FOR NANOMATERIALS. M. E. Bruno, W. 

Winnik, K. Wallace, R. Prasad and Y. Ge. U.S. EPA, 

Research Triangle Park, NC. Sponsor: E. Kenyon. 


SWCNT EXPOSURE OF ALVEOLAR 

EPITHELIAL CELLS AND MACROPHAGES 

INDUCED OPN AND TGF-β1 RESPONSE. 

M. J. Waltz 1,2 , A. R. Murray 1,2 , E. Kisin 2 and A. A. 

Shvedova 1,2 . 1 West Virginia University, Morgantown, 

WV and 2 NIOSH, Morgantown, WV. 


MEMBRANE-MEDIATED MODES 

OF ENTRY OF C 60 

INTO CULTURED 

IMMORTALIZED MACROPHAGES. K. A. 

Russ 1 , I. C. Speirs 1 , P. Elvati 2 , J. A. Fernandez 1 , A. 

Violi 2 and M. A. Philbert 1 . 1 Department of EHS, 

Toxicology, University of Michigan, Ann Arbor, 

MI and 2 Department of Mechanical Engineering, 



IN VITRO TESTING STRATEGIES FOR 

ASSESSING PARTICLE-INDUCED GENETIC 

DAMAGE USING ALVEOLAR CELL LINES. 

K. P. Glover, A. Myhre, M. Laskowski, K. L. Reed, 

E. Donner and D. B. Warheit. DuPont Haskell Global 

Centers for Health and Environmental Sciences, 

Newark, DE. 

308 






Platform Sessions



Abstract # 


DEVELOPING AN IN VITRO MODEL OF 

THE ALVEOLO-CAPILLARY BARRIER TO 

STUDY TOXICITY AND TRANSLOCATION 

OF NANOPARTICLES. K. Luyts, B. Nemery and 

P. H. Hoet. Research Unit for Lung Toxicology, K.U. 

Leuven, Leuven, Belgium. 


CYTOTOXICITY AND GENOTOXICITY 

OF ACUTE AND CHRONIC EXPOSURE 

TO SILVER NANOPARTICLES IN HUMAN 

LUNG CELLS. H. Xie 1,2,3 , D. McGovern 1,2 , A. 

Sample 1,2 , S. Abramson 1,2 , A. Perez 1,2 , M. D. Mason 4 , 

G. Craig 4 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 






Maine, Portland, ME and 4 Department of Chemical 

and Biological Engineering, University of Maine, 

Orono, ME. 


INFLUENCE OF SURFACE 

FUNCTIONALIZATION ON PROTEIN 

ADSORPTION AND NANOPARTICLE 

UPTAKE BY INTESTINAL EPITHELIAL 

CELLS. P. N. Wiecinski 1 , K. M. Louis 2 , R. M. 

Albrecht 3 and J. A. Pedersen 1,4 . 1 Molecular and 

Environmental Toxicology, University of Wisconsin 

Madison, Madison, WI, 2 Chemistry, University of 

Wisconsin Madison, Madison, WI, 3 Animal Science, 

University of Wisconsin Madison, Madison, WI and 

4 

Soil Science, University of Wisconsin Madison, 

Madison, WI. Sponsor: R. Peterson. 


INTERNALIZATION OF CARBON BLACK 

AND IRON OXIDE NANOPARTICLE 

MIXTURES LEADS TO OXIDANT 

PRODUCTION. J. Berg and C. M. Sayes. Texas 

A&M University, Bryan, TX. 


IN VITRO PULMONARY TOXICITY OF 

METAL OXIDE NANOPARTICLES. R. J. 

Snyder and K. Dreher. U.S. EPA, Durham, NC. 


GENE EXPRESSION OF METAL UPTAKE 

GENES, USING CDSE/ZNS QUANTUM 

DOTS IN ZEBRAFISH LIVER CELLS. V. 

Allagadda, S. Tang and G. D. Mayer. The Institute 

of Environmental & Human Health, Texas Tech 

University, Lubbock, TX. 


ACCUMULATION AND TRANSLOCATION 

OF NANOMATERIALS ACROSS THE 

HUMAN PLACENTA. P. Wick 1 , A. Malek 2 , P. 

Diener 3 , A. Zisch 2 , H. F. Krug 1 and U. von Mandach 2 . 

1 

Laboratory for Materials-Biology Interaction, Empa 

Swiss Federal Laboratories for Materials Science and 

Technology, St. Gallen, Switzerland, 2 Department 

of Obstetrics, University Hospital Zurich, 

Zurich, Switzerland and 3 Institute of Pathology, 

Kantonsspital St. Gallen, St. Gallen, Switzerland. 

Sponsor: B. Fadeel. 

Abstract # 


CYTOTOXICITY AND BIOKINETICS 

OF POLYMERIC MAGHEMITE 

NANOPARTICLES IN VITRO. V. Sorribas 1 , 

L. Mohamed-Ahmed-Ali 1,2 , R. Villa-Bellosta 1 , A. 

Millan 1 , L. Gabilondo 2 , R. Piñol 2 and F. Palacio 2 . 

1 

Laboratory of Molecular Toxicology, University of 

Zaragoza, Zaragoza, Spain and 2 Insitute of Materials 

Science, CSIC, Zaragoza, Spain. Sponsor: A. 

Anadon. 


TOXICITY ASSESSMENT OF 

NANOMATERIALS IN ALVEOLAR 

EPITHELIAL CELLS AT THE AIR-LIQUID 

INTERFACE. Y. Xie, N. Williams, A. Tolic, J. 

Teeguarden, J. Pounds, A. Laskin and G. Orr. Pacific 



IN VITRO CYTOTOXICITY AND OXIDATIVE 

STRESS INDUCTION OF GA-IN-CU-SE 

NANOPARTICLES IN HUMAN ALVEOLAR 

EPITHELIAL A549 CELLS. J. Narvaez, M. 

Uribe-Ramirez, O. G. Aztatzi-Aguilar, O. C. Barbier 

and A. De Vizcaya-Ruiz. Department of Toxicology, 

CINVESTAV IPN, Mexico City, Mexico. 


TOXICITY AND GENOMIC PROFILING OF 

ENGINEERED NANOMATERIALS WITH 

DISTINCT GEOMETRY AND SURFACE 

FUNCTIONALIZATION IN HUMAN 

AORTIC ENDOTHEIAL CELLS. P. J. Moos, 

A. Mikkleson, H. Herd, G. Thiagrarjan and H. 

Ghandehari. University of Utah, Salt Lake City, UT. 


SUBCELLULAR DISTRIBUTION OF 

GOLD NANOPARTICLES AND LACK 

OF CYTOTOXICITY IN RAT PRIMARY 

HEPATOCYTE CELL CULTURE MODEL. Y. 

Zhang 1 , W. Salminen 2 , Q. Shi 2 , X. Yang 2 , Y. Jones 1 , 

S. Linder 3 , T. Mudalige 3 , B. Miller 1 , C. Weis 1 and P. 

Howard 1 . 1 Office of Scientific Coordination, NCTR 

/U.S. FDA, Jefferson, AR, 2 Division of Systems 

Biology, NCTR /U.S. FDA, Jefferson, AR and 

3 

Arkansas Regional Laboratory, ORA /U.S. FDA, 



THE ROLE OF SURFACE CHEMISTRY 

ON INTRACELLULAR OXIDANT 

GENERATION. S. H. Ho 1 , J. M. Berg 2 , B. Guo 3 

and C. M. Sayes 1,2 . 1 Department of Biomedical 

Engineering, Texas A&M University, College 

Station, TX, 2 Toxicology Program, Texas A&M 

University, College Station, TX and 3 Department of 

Mechanical Engineering, Texas A&M University, 

College Station, TX. 


NICKEL NANOPARTICLES AND PLATELET- 

DERIVED GROWTH FACTOR (PDGF) ACT 

COORDINATELY TO INCREASE PRO- AND 

ANTI-ANGIOGENIC FACTORS IN RAT 

PLEURAL MESOTHELIAL CELLS. E. E. 

Glista, B. C. Sayers, A. J. Taylor and J. C. Bonner. 

Environmental and Molecular Toxicology, North 


Wednesday 







309



Wednesday 



CONTRIBUTION OF PHYSICOCHEMICAL 

PROPERTIES OF 4TH PERIOD METAL 

OXIDE NANOPARTICLES TO THEIR 

CYTOTOXICITY IN CULTURED HUMAN 

LUNG CELLS. Y. Huang 1 , C. C. Chusuei 2 , 

S. Mallavarapu 2 , C. Wu 1 and R. S. Aronstam 1 . 

1 

Biological Sciences, Missouri University of Science 

and Technology, Rolla, MO and 2 Department of 

Chemistry, Middle Tennessee State University, 

Murfreesboro, TN. 


SURFACE MODIFICATION OF MULTI- 

WALLED CARBON NANOTUBES 

ENHANCES PDGF-INDUCED CHEMOKINE 

& GROWTH FACTOR PRODUCTION BY 

RAT PLEURAL MESOTHELIAL CELLS. A. 

J. Taylor 1 , C. K. Devine 2 , E. E. Glista 1 , B. C. Sayers 1 , 

G. N. Parsons 2 and J. C. Bonner 1 . 1 Environmental 


University, Raleigh, NC and 2 Chemical and 

Biomolecular Engineering, North Carolina State 



A COMPARISON BETWEEN ZINC OXIDE 

NANOPARTICLES AND ORGANIC UV 

FILTERS IN UV-IRRADIATED HUMAN 

SKIN AND IMMUNE CELLS. P. F. Wright 1,3 , 

G. J. D’Costa 1,3 , S. J. O’Keefe 1,3 , B. N. Feltis 1,2,3 , 

V. Muthusamy 1,3 , T. J. Piva 1,3 and T. W. Turney 2,3 . 

1 

School of Medical Science, RMIT University, 

Bundoora, VIC, Australia, 2 Center for Green 

Chemistry, Monash University, Clayton, VIC, 

Australia and 3 Nanosafe Australia, Melbourne, VIC, 

Australia. Sponsor: J. Ahokas. 


TITANIUM NANOPARTICLES INDUCE 

EXPRESSION OF ADHESION MOLECULES 

IN VASCULAR ENDOTHELIAL CELLS. S. 

Han, M. Toborek and B. Hennig. Superfund Research 

Program, University of Kentucky, Lexington, KY. 


SILVER NANOWIRES INDUCED 

INFLAMMATION IN AN IN VITRO HUMAN 

ALVEOLAR LUNG MODEL. N. M. Schaeublin 1 , 

C. A. Estep 1 , J. R. Roberts 2 and S. M. Hussain 1 . 1 711 

HPW; RHPB, Air Force Research Labs, Wright 

Patterson, OH and 2 CDC/NIOSH, Morgantown, WV. 


EVALUATING THE TOXICITY OF 

NANOMATERIALS USING A 3D NEURONAL 

CO-CULTURE MODEL. L. K. Braydich-Stolle 

and S. Hussain. AFRL/RHPB, Wright-Patterson 

AFB, OH. 


CYTOTOXICOLOGICAL AND PATHWAY- 

FOCUSED PERTURBATIONS IN DERMAL 

CELLS EXPOSED TO QUANTUM DOT 

SYSTEMS. A. A. Romoser and C. M. Sayes. VTPP- 

Toxicology, Texas A&M, College Station, TX. 


IN VITRO DNA DAMAGE, MUTATION, AND 

CYTOTOXICITY AND SUBCHRONIC CELL 

GROWTH STUDIES OF QUANTUM DOT 

NANOPARTICLES. J. Bartel 2 , J. Treadway 2 , J. 

Schatz 3 and S. Kim 1 . 1 Design-for-Environment, Life 

Technologies, Foster City, CA, 2 Life Technologies, 

Eugene, OR and 3 Design-for-Environment, Life 

Technologies, Madison, WI. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Developmental Basis of Adult Disease 

Chairperson(s): Lynette Rogers, University of Southern California, Los 

Angeles, CA. 




GLOBAL GENE EXPRESSION PROFILING 

ANALYSIS OF FOOD DEPRIVED 

MATERNAL AND FETAL MICE LIVERS. 

T. Ogawa 1,2 , R. Rakwal 1,2 , J. Shibato 2 , C. Sawa 1,2 , 

T. Saito 1 , A. Murayama 1 , M. Kuwagata 2,3 and S. 

Shioda 1,2 . 1 Anti-aging Medicine, Showa University, 

Tokyo, Japan, 2 Anatomy, Showa Unversity, Tokyo, 

Japan and 3 Laboratory of Pathology, Food and Drug 

Safety Center, Kanagawa, Japan. 


MATERNAL-CORD BLOOD LEVELS OF 

BISPHENOL-A (BPA) IN HUMAN AND 

FOLLOWING BPA ADMINISTRATION IN 

PREGNANT SHEEP. V. Padmanabhan 1 , S. 

Halubai 1 , V. Almudena 1 , C. Liao 2 , S. E. Domino 1 and 

K. Kurunthachalam 2 . 1 University of Michigan, Ann 

Arbor, MI and 2 Wadsworth Center, Albany, NY. 


ALZHEIMER’S DISEASE: EPIGENETIC 

INTERMEDIATES AND EARLY LIFE 

EXPOSURE TO PB IN PRIMATES. S. W. 

Bihaqi 1 , H. Huang 2 and N. H. Zawia 1 . 1 Biomedical 

and Pharmaceutical Science, University of Rhode 

Island, Kingston, RI and 2 School of Public Health, 

Zhengzhou University, Zhengzhou, Henan, China. 


GESTATIONAL DIETHYLSTILBESTROL 

IMPACTS ADULT MALE PROGENY HEART 

STRUCTURE, FUNCTION, AND GENE 

EXPRESSION IN MICE. R. Haddad, I. Sebag 

and L. Chalifour. Lady Davis Institute, Montréal, 

QC, Canada. Sponsor: K. Mann. 


TESTOSTERONE-MEDIATED 

PROGRAMMING OF ADULT FEMALE 

MOUSE HEART. W. Noiles, I. Sebag and L. 

Chalifour. Lady Davis Institute, Montréal, QC, 

Canada. Sponsor: K. Mann. 

310 






Platform Sessions



Abstract # 


EARLY LIFE PARTICLE AND OZONE 

INHALATION SENSITIZES THE LUNG AND 

BRAIN TO LATER LIFE CHALLENGES. C. J. 

Johnston 1,2 , J. Allen 2 , R. Gelein 2 , J. N. Finkelstein 1,2 , 

G. Oberdörster 2 and D. A. Cory-Slechta 2 . 1 Pediatrics, 

University of Rochester Medical Center, Rochester, 

NY and 2 Environmental Medicine, University of 

Rochester Medical Center, Rochester, NY. 


INTERSPECIES APPROACH TO 

THE ASSESSMENT OF HUMAN 

SUSCEPTIBILITY TO PHTHALATE- 

INDUCED ENDOCRINE DISRUPTION. 

N. Heger 1 , S. J. Hall 1 , M. A. Sandrof 1 , E. V. 

McDonnell 1 , J. B. Hensley 4 , K. J. Johnson 3 , E. 

Houseman 2 , K. W. Gaido 4 and K. Boekelheide 1 . 

1 

Pathology and Laboratory Medicine, Brown 

University, Providence, RI, 2 Community Health, 

Brown University, Providence, RI, 3 duPont Hospital 

for Children, Wilmington, DE and 4 The Hamner 


Park, NC. 


LACK OF TRANSGENERATIONAL EFFECT 

FOR VAGINAL PATENCY AND UTERINE 

WEIGHT IN CD-1 MICE EXPOSED TO 

DIETHYLSTILBESTROL OR 17BETA- 

ESTRADIOL. E. Carney, R. J. Rasoulpour, M. 

J. LeBaron, J. Murray, R. Sura, J. Passage, R. Ellis- 

Hutchings and B. Gollapudi. The Dow Chemical 



MATERNAL DHA SUPPLEMENTATION 

ATTENUATES HYPEROXIA-INDUCED 

LUNG DEVELOPMENTAL DEFICITS IN 

ADULT MICE. L. K. Rogers 1,2 , K. Dingess 1,2 , 

M. Velten 1 and T. E. Tipple 1,2 . 1 Center for Perinatal 

Research, The Research Institute at Nationwide 

Children’s Hospital, Columbus, OH and 2 Department 

of Pediatrics, The Ohio State University, Columbus, 

OH. 


PRENATAL AND POSTNATAL CIGARETTE 

SMOKE EXPOSURE INCREASES 

SUSCEPTIBILITY TO ADULT ONSET 

DISEASE. J. L. Lyon and T. Gordon. 


School of Medicine, Tuxedo, NY. 


A DIRECT LC/MS/MS METHOD FOR 

DETERMINATION OF β-ALANINE IN 

HUMAN PLASMA. C. Chen, C. Cunningham and 

J. E. Eble. Critical Path Services, Garnet Valley, PA. 

Sponsor: A. Chappelle. 


DIFFERENTIAL EFFECTS OF ADULT 

VERSUS PRENATAL HG EXPOSURE ON 

THE INNATE IMMUNE RESPONSE TO 

CVB3 INFECTION. K. L. Speiran 1 , D. L. Shirley 1 , 

E. K. Silbergeld 2 and J. F. Nyland 1,2 . 1 Pathology, 

Microbiology & Immunology, University of South 

Carolina School of Medicine, Columbia, SC and 

2 



Abstract # 


NEONATAL GENISTEIN EXPOSURE 

CAUSES IMPLANTATION FAILURE 

BECAUSE OF PERMANENT ALTERATIONS 

IN UTERINE MORPHOLOGY AND STEROID 

HORMONE RESPONSES. W. Jefferson, S. 

M. Wagner, E. Padilla-Banks and C. J. Williams. 



NEONATAL GENISTEIN EXPOSURE 

PERMANENTLY DISRUPTS OVIDUCT 

GENE EXPRESSION AND TISSUE 

ARCHITECTURE DURING PREGNANCY. E. 

Padilla-Banks, W. Jefferson, S. M. Wagner and C. J. 

Williams. NIEHS, Research Triangle Park, NC. 


DELAYED TEMPORAL INCREASE OF 

HEPATIC HSP70 IN APOE-/- MICE WITH 

ACCELERATED ATHEROSCLEROSIS 

INDUCED BY IN UTERO ARSENIC 

EXPOSURE. N. N. Ngalame, M. E. Feil, A. F. 

Micciche and J. States. Pharmacology/Toxicology, 



CORRELATION BETWEEN 

POLYBROMINATED DIPHENYL ETHERS 

(PBDES) AND PERSISTENT ORGANIC 

POLLUTANTS (POPS) OR HEAVY METALS 

DETECTED IN UMBILICAL CORDS. Y. 

Igoshi 1 , S. Ochiai 1 , E. Todaka 1,2 , Y. Matsuno 1 , S. 

Suzuki 4 , N. Shimojo 3 , Y. Kohno 3 and C. Mori 1,2 . 

1 

Bioenvironmental Medicine, Chiba University, 

Chiba City, Chiba, Japan, 2 Preventive Medical 

Science, Chiba University, Chiba, Japan, 3 Pediatrics, 

Chiba University, Chiba, Japan and 4 Pediatrics, 

Shimoshizu National Hospital, Yotsukaido, Japan. 


IN UTERO AND POSTNATAL 

EXPOSURE TO FLUORIDE PRODUCES 

HYPERINSULINEMIA AND IMPAIRED 

GLUCOSE TOLERANCE IN RAT. L. M. Del 

Razo, J. G. García-Lopez, A. Barrera-Hernandez 

and B. Olivier. Toxicology, Cinvestav-Ipn, Mexico, 

Distrito Federal, Mexico. 


METABOLOMICS: INVESTIGATING THE 

IMPACT OF GESTATIONAL EXPOSURE 

TO A PHTHALATE ON THE BRAIN AND 

REPRODUCTIVE ORGANS OF THE DAM 

AND PREPUBERTAL PUPS. R. Banerjee 1 , 

R. Snyder 2 , W. Pathmasiri 2 and S. J. Sumner 2 . 

1 

University of North Carolina Chapel Hill, Chapel 

Hill, NC and 2 RTI International, Research Triangle 

Park, NC. 


IN UTERO BAP-EXPOSURE LEADS 

TO DYSREGULATION OF THE 

CARDIOVASCULAR SYSTEM OF LEH 

RAT OFFSPRING IN LATE LIFE. G. E. 

Jules 1 , M. M. Maguire 1 , A. Ramesh 2 and D. B. 

Hood 1 . 1 Neuroscience and Pharmacology, Meharry 

Medical College, Nashville, TN and 2 Biochemistry 

and Cancer Biology, Meharry Medical College, 


Wednesday 







311



Wednesday 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Cellular Effects of Natural Product Extracts 

Chairperson(s): Minerva Mercado-Feliciano, National Institute of 

Environmental Health Sciences, Research Triangle Park, NC. 




MODULATION OF OXIDATIVE 

DNA DAMAGE BIOMARKER IN 

POSTMENOPAUSAL WOMEN BY GREEN 

TEA POLYPHENOLS AND TAI CHI. F. Wang 1 , 

L. Tang 1 , G. Qian 1 , S. Xue 1 , C. L. Shen 2 and J. 

Wang 1 . 1 Environmental Health Science, University 

of Georgia, Athens, GA and 2 Texas Tech University 

Health Science Center, Lubbock, TX. 


ANTI-INFLAMMATORY EFFECTS OF 

FRAGMENTS OF H2A HISTONE AND 

ORYZA SATIVA JAPONICA PROTEIN. U. 

Wormser 1 , M. Aschner 2 , B. Brodsky 1 , E. Proscura 1 , 

A. Erlanger-Rosengarten 1 , R. Feldman 1 , E. Shapira 1 

and Y. Schussheim 1 . 1 Institute of Drug Research, 

The Hebrew University, Jerusalem, Israel and 

2 

Department of Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN. 


THE ANALGESIC AND ANTI-PLASMODIAL 

ACTIVITIES AND TOXICOLOGY OF 

VERNONIA AMYGDALINA. A. A. Njan 1,2 , B. 

Adzu 5 , A. G. Agaba 2 , D. Byarugaba 4 , S. Diaz-Llera 3 

and D. R. Bangsberg 6 . 1 Research, Aiida4 Medical 

Consultants, Abuja, FCT, Nigeria, 2 Pharmacology 

and Therapeutics, Mbarara University of Science and 

Technology, Mbarara, Uganda, 3 Pharmacy, Mbarara 

University of Science and Technology, Mbarara, 

Uganda, 4 Biology, Mbarara University of Science 

and Technology, Mbarara, Uganda, 5 Pharmacology 

and Toxicology, National Institute for Pharmaceutical 

Research and Development, Abuja, Nigeria and 

6 

University of California San Francisco, San 

Francisco, CA. Sponsor: S. Areola. 


PLATYCODON GRANDIFLORUM ROOT- 

DERIVED SAPONINS SUPPRESSES 

DNCB-INDUCED ATOPIC DERMATITIS IN 

MICE. B. Park 1 , J. Choi 1 , E. Han 1 , Y. Hwang 1 , 

Y. Chung 2 and H. Jeong 1 . 1 Pharmacy, Chungnam 

National University, Daejeon, Republic of Korea and 

2 

Food Science, Korea International University, Jinju, 



SUPPRESSION OF PMA-INDUCED TUMOR 

CELL INVASION BY PIPERINE VIA 

INHIBITION OF PKCα/ERK AND NF-κB/ 

AP-1-DEPENDENT MECHANISMS. H. Yun 1,2 , 

Y. Hwang 1 , J. Choi 1,2 and H. Jeong 1 . 1 Pharmacy, 

Chungnam National University, Daejeon, Republic of 

Korea and 2 Pharmacy, Chosun University, Gwangju, 



INHIBITION OF DEVELOPMENT OF 

ATOPIC DERMATITIS BY SAPONIN 

FROM THE ROOTS OF PLATYCODON 

GRANDIFLORUM. E. Han 1 , J. Choi 1 , J. Im 1 , 

J. Yang 1 , Y. Chung 2 and H. Jeong 1 . 1 Pharmacy, 


of Korea and 2 Food Science, Korea International 

University, Jinju, Republic of Korea. 


CAPSAICIN SUPPRESSES FIBROSARCOMA 

CELL MIGRATION AND INVASION 

VIA EGFR-ERK AND P38 MAPK-AP-1 

SIGNALING. H. Jeong, Y. Hwang, J. Choi and 

B. Park. Pharmacy, Chungnam National University, 

Daejeon, Republic of Korea. 



DERIVED SAPONINS SUPPRESSES 

ACROLEIN-INDUCED MUC5AC 

PRODUCTION IN A549 CELLS. C. Ho 1 , B. 

Park 1 , E. Han 1 , H. Kim 1 , Y. Hwang 1 , Y. Chung 2 

and H. Jeong 1 . 1 Pharmacy, Chungnam National 

University, Daejeon, Republic of Korea and 2 Food 

Science, Korea International University, Jinju, 



ANTHOCYANIN ISOLATED FROM THE 

PURPLE-FLESHED SWEET POTATO 

PREVENTS HEPATIC FIBROSIS BY 

DMN AND HEPATIC STELLATE CELLS 

PROLIFERATION BY PDGF-BB. J. Choi 1 , 

Y. Hwang 1 , C. Choi 2 , Y. Chung 2 and H. Jeong 1 . 

1 

Pharmacy, Chungnam National University, Daejeon, 

Republic of Korea and 2 Food Science, Korea 

International University, Jinju, Republic of Korea. 



DERIVED SAPONINS SUPPRESSES HIGH 

FAT DIET-INDUCED STEATOSIS AND 

FIBROSIS IN RATS. Y. Chung 2 , J. Choi 1 , 

T. Khanal 1 , B. Park 1 , Y. Hwang 1 and H. Jeong 1 . 

1 


Republic of Korea and 2 Food Science, Korea 

International University, Jinju, Republic of Korea. 


ACTEOSIDE SUPPRESSES PHORBOL 

12-MYRISTATE 13-ACETATE-INDUCED 

MMP-9 EXPRESSIONS VIA CAMK/ERK- 

AND JNK/NF-KB SIGNALING PATHWAY IN 

HUMAN FIBROSARCOMA HT-1080 CELLS. 

Y. Hwang, J. Choi, E. Han, H. Kim, B. Park and H. 

Jeong. Pharmacy, Chungnam National University, 

Daejeon, Republic of Korea. 


AMP-ACTIVATED PROTEIN KINASE IS 

REQUIRED FOR THE LIPID-LOWERING 

EFFECT OF ANTHOCYANINS-RICH 

PURPLE SWEET POTATO IN INSULIN- 

RESISTANT HUMAN HEPG2 CELLS. J. 

Kim, Y. Hwang, J. Choi and H. Jeong. Pharmacy, 



312 






Platform Sessions



Abstract # 


ANTHOCYANINS FROM PURPLE SWEET 

POTATO PROTECTS AGAINST TERT- 

BUTYL HYDROPEROXIDE-INDUCED 

OXIDATIVE STRESS BY INCREASING 

EXPRESSION OF HEME OXYGENASE-1 

IN A PI3K AND ERK/NRF2-DEPENDENT 

MANNER. H. Pil 1 , J. Choi 1 , J. Seo 2 , Y. Chung 2 

and H. Jeong 1 . 1 Pharmacy, Chungnam National 

University, Daejeon, Republic of Korea and 2 Food 

Science, Korea International University, Jinju, 



SAPONINS FROM THE ROOTS OF 

PLATYCODON GRANDIFLORUM 

STIMULATE OSTEOBLAST 

DIFFERENTIATION VIA RUNX2 

ACTIVATION IN MESENCHYMAL STEM 

CELL. H. Jeong 2 , J. Kim 1 , E. Han 1 , B. Park 1 , 

Y. Chung 3 , K. Lee 2 and H. Jeong 1 . 1 Pharmacy, 


of Korea, 2 Pharmacy, Chonnam National University, 

Gwangju, Republic of Korea and 3 Food Science, 

Korea International University, Jinju, Republic of 

Korea. 


PSIDIUM GUAJAVA INHIBITS IGE- 

MEDIATED ALLERGIC RESPONSES BY 

BLOCKING FCεRI SIGNALING IN MAST 

CELLS. J. Im 1 , E. Han 1 , J. Park 1 , J. Yang 1 , J. Seo 2 , 

Y. Chung 2 and H. Jeong 1 . 1 Pharmacy, Chungnam 

National University, Daejeon, Republic of Korea and 

2 

Food Science, Korea International University, Jinju, 



NOVEL PHARMACOLOGICAL ACTIONS OF 

NATURAL ANTAGONISTS DERIVED FROM 

K. BREVIS (RED TIDE). W. M. Abraham 1 and D. 

G. Baden 2 . 1 Research, Mount Sinai Medical Center, 

Miami Beach, FL and 2 Marine Science, University of 

North Carolina Wilmington, Wilmington, NC. 


BIOACTIVATION EVALUATION OF 

HERBAL INGREDIENTS. Z. Fang, Y. Zhang, H. 

Ma, G. Li and L. Yang. Laboratory of Pharmaceutical 

Resource Discovery, Dalian Institute of Chemical 

Physics, Chinese Academy of Scienes, Dalian, 

Liaoning, China. Sponsor: P. Wells. 


CYTOTOXIC EFFECTS OF ARBUTIN IN 

MAMMALIAN CELLS AFTER ACTIVATION 

BY HUMAN INTESTINAL BACTERIA. H. 

Kim 1 , T. Khanal 1 , H. Ha 2 , T. Jeong 2 and H. Jeong 1 . 

1 


Republic of Korea and 2 Pharmacy, Yeungnam 

National University, Gyeonsgan, Republic of Korea. 


PREVENTION OF ADRIAMYCIN HEPATIC 

AND RENAL TOXICITY IN MALE BALB/C 

MICE BY A NUTRIENT MIXTURE. M. Roomi, 

N. W. Roomi, M. Rath and A. Niedzwiecki. Dr. Rath 

Research Institute, Santa Clara, CA. 

Abstract # 


ISOLATION AND DETECTION OF RICIN 

IN CASTOR BEANS USING A DUAL- 

FRACTIONATION TECHNIQUE AND 

MATRIX-ASSISTED LASER DESORPTION 

IONIZATION/TIME-OF-FLIGHT MASS 

SPECTROMETRY. C. Wilson, K. Meyerholtz 

and S. Hooser. Indiana Animal Disease Diagnostic 

Laboratory, Purdue University, West Lafayette, IN. 


PROTECTIVE EFFECT OF HOVENIA 

DULCIS EXTRACT ON THE TUNICAMYCIN 

INDUCED ER STRESS IN HEPG2 CELLS. M. 

Dong 1 , J. Choi 1 , C. Na 2 , D. Na 1 and Y. Park 1 . 1 School 

Lifesciences and Biotechnology, Korea University, 

Seoul, Republic of Korea and 2 Lifetree Biotech Co., 

Suwon, Republic of Korea. Sponsor: B. Lee. 


EFFECTS OF THE MARINE ALGAL TOXIN 

PECTENOTOXIN ON THE ACTIVITY OF 

VARIOUS ACTIN ISOFORMS. S. Butler 1 , C. O. 

Miles 2 , A. Karim 1 and M. Twiner 1 . 1 Natural Sciences, 

University of Michigan, Dearborm, MI and 2 Section 

for Chemistry, National Veterinary Institute, Oslo, 

Norway. 


COMPARATIVE CYTOTOXICITY OF 

VARIOUS ANALOGS OF THE MARINE 

ALGAL TOXIN AZASPIRACID. R. El-Ladki 1 , 

G. Doucette 2 and M. Twiner 1 . 1 Natural Sciences, 

University of Michigan, Dearborm, MI and 2 Marine 

Biotoxins Program, NOAA/National Ocean Service, 



ANALYSIS OF RESVERATROL AND ITS 

METABOLITES IN PREGNANT RATS, 

FETUSES, AND PUPS. B. L. Fletcher 1 , M. A. 

Silinski 1 , T. R. Fennell 1 , F. K. Thomas 1 , J. C. Blake 1 , 

S. D. Cooper 1 , R. A. Fernando 1 and B. J. Collins 2 . 

1 

RTI International, Research Triangle Park, NC and 

2 

NIEHS/NTP, Research Triangle Park, NC. 


AFB1 BINDING CAPACITIES OF 

EXCELERITE CLAY SAMPLES FROM 

PANACA, NEVADA. K. Zychowski 1 , A. 

Marroquin-Cardona 1 , Y. Deng 2 and T. D. Phillips 1 . 

1 

College of Veterinary Medicine, Texas A&M 

University, College Station, TX and 2 Soil and Crop 

Sciences, Texas A&M University, College Station, 

TX. 


THE ACUTE TOXICITY OF THE DEATH 

CAMAS (ZIGADENUS SPP.) ALKALOID 

ZYGACINE IN MICE, INCLUDING THE 

EFFECT OF METHYLLYCACONITINE 

CO-ADMINISTRATION ON ZYGACINE 

TOXICITY. K. Welch, K. Panter, D. Gardner, 

B. Stegelmeier, B. Green, J. Pfister and D. Cook. 

Poisonous Plant Research Laboratory, USDA-ARS, 

Logan, UT. 

Wednesday 







313



Wednesday 



TOXICOLOGICAL ASSESSMENT 

OF METHANOLIC ROOT EXTRACT 

OF CNESTIS FERRUGINEA: 

CHARACTERIZATION OF ANTIOXIDANT 

ENZYME ACTIVITY IN SPRAGUE-DAWLEY 

RAT. I. Ishola, J. Akindele and O. Adeyemi. 

Pharmacology, University of Lagos, Lagos, Nigeria. 


POMEGRANATE EXTRACT EXERTED 

CHEMOPREVENTIVE EFFECTS IN 

COLON CANCER CELLS AND TARGETED 

MICRORNA-21A AND MICRORNA-126. N. 

Banerjee 1 , G. Noratto 1 , L. Xiangrong 1 and S. M. 

Talcott 1,2 . 1 Nutrition and Food Science, Texas A&M 

University, College Station, TX and 2 Veterinary 




IN VITRO AND IN VIVO GENO – 

ANTIGENOTOXICITY EVALUATION 

OF WATERCRESS. N. A. Casanova, M. M. 

Lopez Nigro and M. A. Carballo. Bioquímica 

Clínica, Cigetox. Infibioc. Facultad de Farmacia y 

Bioquímica. Universidad de Buenos Aires, Buenos 

Aires, Argentina. Sponsor: O. Olivero. 


CURCUMIN DECREASES INFLAMMATION 

IN NORMAL CELLS AND EXERT 

CHEMOPREVENTIVE EFFECT ON COLON 

CANCER CELLS THROUGH REGULATION 

OF KEY MICRORNAS. G. D. Noratto 1,2,3 and 

S. U. Mertens-Talcott 1,2,3 . 1 Veterinary Physiology 

and Pharmacology, Texas A&M University, College 

Station, TX, 2 Nutrition and Food Science, Texas 

A&M University, College Station, TX and 3 Institute 

for Obesity Research and Program Evaluation, Texas 

A&M University, College Station, TX. 


13-WEEK GAVAGE EXPOSURE TO GUM 

GUGGUL EXTRACT (GGE) MODULATES 

ACTIVITY OF HEPATIC CYP2B AND CYP3A 

IN HARLAN SPRAGUE-DAWLEY RATS AND 

B6C3F1 MICE. C. A. Granville 1 , M. K. Vallant 2 , 

M. Hejtmancik 1 , D. K. Gerken 1 and M. E. Wyde 2 . 

1 

Battelle Memorial Institute, Columbus, OH and 

2 

NTP/NIEHS, Research Triangle Park, NC. 


CURCUMIN REGULATES CELL CYCLE 

PROGRESSION IN RESPONSE TO BPDE- 

INDUCED DNA DAMAGE. E. N. Rogers and J. 

States. Pharmacology and Toxicology, University of 



ACUTE TOXICITY (LC50)AGAINST 

ARTEMIA FRANCISCANA OF ESSENTIAL 

OILS FROM LANTANA ARMATA SCHAUER, 

XYLOPIA AROMATICA LAMARCK, AND 

SATUREJA BROWNEI BRIQ, COLLECTED 

IN COLOMBIA. B. E. Jaramillo 1,2 , J. Olivero 1,2 , 

K. Caballero 2 and E. Stashenko 3 . 1 Agrochemical 

Research Group, Chemical Program, Faculty of 

Sciences, University of Cartagena, Cartagena, 

Bolivar, Colombia, 2 Enviromental and 

Computational Chemistry Group (GQAC). Faculty 

of Pharmaceutical Sciences, University of Cartagena, 

Cartagena, Bolivar, Colombia and 3 National Center 

of Research for the Agro-industrialization of 

Aromatic Plant Species and Tropical Medicines- 

CENIVAM, Industrial University of Santander, 

Bucaramanga, Santander, Colombia. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Persistent Organic Compounds (POPs) 

Chairperson(s): Senthilkumar Pk, The University of Iowa, Iowa City, 

IA, and David Szabo, University of North Carolina at Chapel Hill, 

Morrisville, NC. 




HEPATIC GENE EXPRESSION PROFILING 

IN PERFLUOROHEXANE SULFONATE- 

EXPOSED WILD-TYPE AND PPARα-NULL 

MICE. M. B. Rosen 1 , J. R. Schmid 2 , K. P. Das 3 , 

H. Ren 4 , B. D. Abbott 3 and C. Lau 3 . 1 Integrated 

Systems Biology, U.S. EPA, Research Triangle 

Park, NC, 2 Biostatistics and Bioinformatics, U.S. 

EPA, Research Triangle Park, NC, 3 Toxicology 

Assessment, U.S. EPA, Research Triangle Park, NC 

and 4 Genomics Research Core, U.S. EPA, Research 



EFFECTS OF BIOREMEDIATION ON 

TOXICITY AND GENOTOXICITY OF 

PAH-CONTAMINATED SOIL USING 

GENETIC ENGINEERED CELL LINES. J. 

Hu, J. Nakamura and M. D. Aitken. Department of 

Environmental Sciences & Engineering, Gillings 

School of Global Public Health, University of North 

Carolina at Chapel Hill, Chapel Hill, NC. 


PERFLUOROPHOSPHONIC 

ACID ACTIVATES PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR- 

ALPHA BUT NOT CONSTITUTIVE 

ANDROSTANE RECEPTOR IN THE MURINE 

LIVER. K. P. Das 1 , M. B. Rosen 2 , C. R. Wood 1 , B. 

Abbott 1 and C. Lau 1 . 1 Toxicity Assessment Division, 

ORD, NHEERL, U.S. EPA, Research Triangle 

Park, NC and 2 Integrated System Toxicity Division/ 

NHEERL/ORD, U.S. EPA, Research Triangle Park, 

NC. 

314 






Platform Sessions



Abstract # 


ACTIVATION OF MOUSE AND HUMAN 

PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-ALPHA (PPAR) BY 

PERFLUOROALKYL ACIDS (PFAAS) OF 5, 

7, 8, 11, AND 12 CARBON CHAIN LENGTHS 

IN COS-1 CELLS. C. J. Wolf, C. Lau and B. D. 

Abbott. Toxicity Assessment Division, U.S. EPA, 

ORD, NHEERL, Research Triangle Park, NC. 


DDA, A BIOMARKER FOR 

ENVIRONMENTAL DDT EXPOSURE. Z. 

Chen 1 , H. H. Vega 1 , S. M. Patrick 2 , M. S. Bornman 2 

and R. I. Krieger 1 . 1 Personal Chemical Exposure 

Program, Department of Entomology, Environmental 

Toxicology Graduate Program, University of 

California Riverside, Riverside, CA and 2 Department 

of Urology, University of Pretoria, Steve Biko 

Academic Hospital, South Africa. 


STRUCTURE-ACTIVITY RELATIONSHIP 

FOR INDUCTION OF CYTOCHROMES P450 

BY NON-DIOXINLIKE POLYCHLORINATED 

BIPHENYLS IN CULTURED RAT 

HEPATOCYTES. M. Gährs, R. Roos and D. 

Schrenk. Food Chemistry and Toxicology, University 

of Kaiserslautern, Kaiserslautern, Germany. 


STRUCTURAL AND FUNCTIONAL INJURY 

INDUCED BY FLUORINATED ORGANIC 

COMPOUNDS IN PREFRONTAL CORTEX 

OF MALE RAT. A. Lafuente 1 , A. Caride 1 , N. 

Pereiro 1 , V. Franco 1 , R. Moyano 2 and A. Anadón 3 . 

1 

Laboratory of Toxicology, Faculty of Sciences, 

Universidad de Vigo, Orense, Spain, 2 Department 

of Pharmacology, Toxicology, Legal Medicine 

and Forensic Sciences, Universidad de Córdoba, 

Cordoba, Spain and 3 Department of Toxicology 

and Pharmacology, Faculty of Veterinary Medicine, 

Universidad Complutense, Madrid, Spain. 


GENDER SPECIFIC DIFFERENCES IN 

LEVELS OF PERSISTENT ORGANIC 

POLLUTANTS IN AN ELDERLY 

POPULATION IN SWEDEN – PROSPECTIVE 

INVESTIGATION OF THE VASCULATURE 

IN UPPSALA SENIORS (PIVUS). S. 

Salihovic 1 , L. Mattioli 1 , G. Lindström 1 , P. Lind 2 , L. 

Lind 3 and B. van Bavel 1 . 1 School of Science and 

Technology, Örebro University, MTM Research 

Centre, Örebro, Sweden, 2 Department of Medical 

Sciences, University Hospital, Occupational and 

Environmental Medicine, Uppsala, Sweden and 

3 

Department of Medical Sciences, University 

Hospital, Acute and Internal Medicine, Uppsala, 

Sweden. 

Abstract # 


POLYCHLORINATED BIPHENYL 153 

WORSENS DIET-INDUCED OBESITY AND 

NON-ALCOHOLIC FATTY LIVER DISEASE 

IN C57/BL6 MICE. M. Cave 1,2 , B. Gregory 1 , R. 

McCAllister 1 , K. Falkner 1 , D. Conklin 1 , D. Young 1 , 

C. McClain 1,2 and A. Bhatnagar 1 . 1 Department of 

Medicine/GI, University of Louisville, Louisville, 

KY and 2 Robley Rex Veterans Administration 

Medical Center, Louisville, KY. 


TETRABROMOBISPHENOL A, BUT NOT 

BISPHENOL A, IS A POTENT MODULATOR 

OF THE TYPE 1 RYANODINE RECEPTOR. 

R. Zhang and I. N. Pessah. Department of Molecular 

Biosciences, School of Veterinary Medicine, 



HUMAN ORGAN ANION TRANSPORTING 

POLYPEPTIDES (OATPS) 1B1, 1B3 AND 2B1 

TRANSPORT PERFLUOROCARBOXYLIC 

ACIDS. B. Hagenbuch 1 , M. Boissier 1 , Y. M. 

Weaver 1 , D. J. Ehresman 2 , S. Chang 2 and J. L. 

Butenhoff 2 . 1 Pharmacology, The University of Kansas 

Medical Center, Kansas City, KS and 2 Medical 

Department, 3M Center, St. Paul, MN. 


METABOLOMIC ANALYSIS OF SERUM 

AFTER TREATMENT WITH THE 

EMERGING POP FLAME RETARDANT 

HEXABROMOCYCLODODECANE (HBCD): 

COMMERCIAL MIXTURE, ALPHA AND 

GAMMA STEREOISOMERS ELICIT 

DIFFERENTIAL EFFECTS IN INFANTILE 

MICE. D. T. Szabo 1,2 , W. Pathmasiri 3 , J. J. 

Diliberto 2 , S. Sumner 3 and L. S. Birnbaum 4 . 

1 

University of North Carolina, Chapel Hill, NC, 2 U.S. 

EPA, Research Triangle Park, NC, 3 RTI International, 

Research Triangle Park, NC and 4 NCI/NIEHS, 



INTERACTION BETWEEN DIETARY 

SELENIUM LEVELS AND PCB126 

EXPOSURE ON PON1 GENE EXPRESSION 

AND ACTIVITY IN RATS. H. Shen 1 , B. Wang 1 , 

I. Lai 1 , L. W. Robertson 1,2 and G. Ludewig 1,2 . 

1 

Interdisciplinary Graduate Program in Human 

Toxicology, University of Iowa, Iowa City, IA and 

2 

Occupational and Environmental Health, University 

of Iowa, Iowa City, IA. 


PCB77 DECHLORINATION MIXTURES 

MODULATE PROINFLAMMATORY 

EVENTS IN VASCULAR ENDOTHELIAL 

CELLS. K. Eske, C. Barton, A. Palumbo, S. Han, 

Z. Majkova, E. Zahran, L. Bachas, D. Bhattacharyya, 

M. Toborek and B. Hennig. Superfund Research 

Program, University of Kentucky, Lexington, KY. 

Wednesday 







315



Wednesday 



TELOMERE DYSFUNCTION AND 

TELOMERASE REACTIVATION IN HUMAN 

SKIN KERATINOCYTES: A POSSIBLE NEW 

MECHANISM OF PCB CARCINOGENESIS. 

P. Senthilkumar, A. Klingelhutz, L. Robertson and 

G. Ludewig. Human Toxicology, The University of 

Iowa, Iowa City, IA. 


GLOBAL ASSESSMENT OF 

POLYBROMINATED DIPHENYL 

ETHERS IN SPERM WHALE (PHYSETER 

MACROCEPHALUS) SKIN. L. Savery 1,2,3 , S. 

Eagle 4 , H. M. Stapleton 4 , I. Kerr 5 , W. Thompson 2,3 

and J. P. Wise, Sr. 1,2,3 . 1 Wise Laboratory of 





Applied Medical Sciences, University of Southern 

Maine, Portland, ME, 4 Nicholas School of the 

Environment, Duke University, Durham, NC and 

5 

Ocean Alliance, Lincoln, MA. 


UNDERSTANDING THE TOXICITY OF 

BROMKAL 70-5DE, A PBDE FLAME 

RETARDANT MIXTURE, USING A YEAST 

MODEL. B. Gaytan, C. Monroy, A. Loguinov 

and C. Vulpe. University of California at Berkeley, 

Berkeley, CA. 


THE GENDER DIFFERENCE IN 

SENSITIVITY TO ACUTE TOXICITY OF 

TCDD IS REVERSED IN MICE COMPARED 

WITH RATS. R. Pohjanvirta 1 , H. Miettinen 2 , 

S. Sankari 3 and J. Lindén 1,4 . 1 Department of Food 

Hygiene and Environmental Health, University 

of Helsinki, University of Helsinki, Finland, 

2 

Department of Environmental Health, National 

Institute for Health and Welfare, Kuopio, Finland, 

3 

Central Laboratory of the Department of Equine 

and Small Animal Medicine, University of Helsinki, 

Helsinki, Finland and 4 Department of Veterinary 

Biosciences, University of Helsinki, Helsinki, 

Finland. Sponsor: M. Viluksela. 


REVERSE CAUSATION OF DIOXIN 

DOSE-RESPONSE TRENDS FOR RISK OF 

DIABETES MELLITUS TYPE 2 AMONG 

OPERATION RANCH HAND VIETNAM 

VETERANS. B. D. Kerger 1 , P. K. Scott 2 , M. 

Pavuk 3 , M. Gough 4 and D. J. Paustenbach 5 . 1 Health 

Science Resource Integration, Tallahassee, FL, 

2 

ChemRisk, Pittsburgh, PA, 3 Centers for Disease 

Control and Prevention, Atlanta, GA, 4 Private 

Consultant, Berkeley, CA and 5 ChemRisk, San 

Francisco, CA. 


UNUSUALLY HIGH LEVELS OF 

BISPHENOL-A IN CASH RECEIPTS. R. C. 

Achuthan 1 , S. Babu 1 , S. N. Uppu 3 , K. Smith 1 , N. 

L. Parinandi 2 and R. M. Uppu 1 . 1 Environmental 

Toxicology, Southern University, Baton Rouge, LA, 

2 

DHLRI, The Ohio State University Medical Center, 

Columbus, OH and 3 Prairieville Middle, Prairieville, 

LA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Pharmacokinetics and Disposition 

Chairperson(s): Michele Bouchard, University de Montréal, Québec, 

Canada. 




PHARMACOKINETICS, TISSUE 

DISTRIBUTION, EXCRETION BALANCE, 

AND METABOLITE PROFILING 

FOLLOWING A SINGLE INTRAVENOUS 

OR ORAL DOSE OF [ 14 C]-FORODESINE IN 

RATS. D. Draganov 1 , D. Sved 1 , L. Harman 2 and B. 

S. Levine 3 . 1 Metabolism, WIL Research Laboratories, 

LLC, Ashland, OH, 2 BioCryst Pharmaceuticals, 

Inc., Durham, NC and 3 Levine & Associates, LLC, 

Chicago, IL. 


PHARMACOKINETICS, EXCRETION 

BALANCE, AND METABOLITE PROFILING 

FOLLOWING A SINGLE INTRAVENOUS 

OR ORAL DOSE OF [ 14 C]-FORODESINE IN 

CYNOMOLGUS MONKEYS. B. S. Levine 1 , D. 

Sved 2 , L. Harman 3 and D. Draganov 2 . 1 Levine & 

Associates, LLC, Chicago, IL, 2 Metabolism, WIL 

Research Laboratories, LLC, Ashland, OH and 

3 

BioCryst Pharmaceuticals, Inc., Durham, NC. 


INHALATION KINETICS OF 1, 

1-DIFLUOROETHANE IN HUMANS. L. 

Ernstgård 1 , W. Dekant 2 , S. Juran 1 , B. Lind 1 , 

B. Sjögren 1 and G. Johanson 1 . 1 Institute of 

Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden and 2 University of Wuerzburg, 

Wuerzburg, Germany. 


TOXICOKINETICS OF FOLPET 

BIOMARKERS IN ORALLY AND 

DERMALLY EXPOSED VOLUNTEERS. 

A. Berthet 1,2 , M. Bouchard 1 and B. Danuser 2 . 

1 

Department Environmental & Occupational Health, 

University of Montréal, Montréal, QC, Canada 

and 2 Institute for Work and Health, Lausanne, 

Switzerland. 


TISSUE DISTRIBUTION AND EXCRETION 

OF SR13668 IN RATS. J. M. Gow 1 , K. 

O’Loughlin 1 , A. Ta 1 , L. Jong 1 , I. M. Kapetanovic 2 

and C. E. Green 1 . 1 Biosciences Division, SRI 

International, Menlo Park, CA and 2 National Cancer 



PHARMACOKINETICS OF A PYRETHROID 

INSECTICIDE MIXTURE IN THE RAT. D. 

G. Ross 1 , J. M. Starr 2 , E. J. Scollon 3 , K. M. Crofton 1 , 

M. J. Wolansky 4 , M. F. Hughes 1 and M. J. DeVito 5 . 

1 

ORD/NHEERL, U.S. EPA, Research Triangle Park, 

NC, 2 ORD/NERL, U.S. EPA, Research Triangle 

Park, NC, 3 OCSPP/HED, U.S. EPA, Alexandria, VA, 

4 

University of Buenos Aires, Buenos Aires, Argentina 

and 5 NTP, NIEHS, Research Triangle Park, NC. 

316 






Platform Sessions



Abstract # 


EVALUATING PHARMACOKINETICS AND 

BIOAVAILABILITY OF LEVOFLOXACIN 

IN RATS. A. Banerjee 1 , K. Kabirov 1 , T. Martín- 

Jiménez 2 and A. Lyubimov 1 . 1 Toxicology Research 

Laboratory, University of Illinois at Chicago, 

Chicago, IL and 2 College of Veterinary Medicine, 

University of Tennessee, Knoxville, TN. 


ROLE OF INTESTINAL P450 AND 

P-GLYCOPROTEIN IN MODULATING THE 

BIOAVAILABILITY OF ORAL LOVASTATIN. 

Y. Zhu. Environmental Health Sciences, Wadsworth 

Center, New York State Department of Health, and 


York at Albany, Albany, NY. Sponsor: X. Ding. 


PARAQUAT DISPOSITION: A POTENTIAL 

ROLE FOR P-GLYCOPROTEIN 

TRANSPORT. S. Lacher, F. Cardozo-Pelaez and E. 

L. Woodahl. University of Montana, Missoula, MT. 


THE IMPORTANCE OF EFFLUX 

TRANSPORTERS IN CNS EXPOSURE TO 

AVERMECTIN INSECTICIDES. A. M. Dalzell 1 , 

F. M. Williams 2 , P. Mistry 3 , J. Wright 3 and C. D. 

Brown 1 . 1 Cell & Molecular Biosciences, University 

of Newcastle, Newcastle-Upon-Tyne, United 

Kingdom, 2 Medical Toxicology Centre, University of 

Newcastle, Newcastle-Upon-Tyne, United Kingdom 

and 3 Syngenta, Bracknell, United Kingdom. Sponsor: 

R. Peffer. 


SENSITIVE AND SPECIFIC FLUORESCENT 

PROBES FOR FUNCTIONAL ANALYSIS 

OF ALL THREE MAJOR TYPES OF 

MAMMALIAN ABC TRANSPORTERS. W. 

F. Patton, I. V. Lebedeva, P. Pande, D. Shen and D. 

Gatica. R&D, Enzo Life Sciences, Farmingdale, NY. 

Sponsor: J. Davis. 


OAT2 REPRESENTS AN INITIAL STEP 

IN THE RENAL TUBULAR SECRETION 

OF GUANINE-CONTAINING ANTIVIRAL 

DRUGS. Y. Cheng and R. Pelis. DMPK-DDI, 

Novartis Institutes for BioMedical Research, East 

Hanover, NJ. 


COMPARISON OF TRANSPORTER 

EXPRESSION IN BRAIN, EYE, TESTIS, AND 

PLACENTA. F. Selwyn, J. Liu and C. Klaassen. 

Pharmacology and Toxicology, University of Kansas 



DIFFERENTIAL HEPATIC AND INTESTINAL 

PHASE-II BIOTRANSFORMATION 

ENZYME/TRANSPORTER EXPRESSION 

AND SERUM BISPHENOL A (BPA) LEVELS 

IN MOUSE MODELS OF OBESITY AND 

DIABETES. O. DiPrete 1 , V. R. More 1 , J. 

Xu 1 , D. Doerge 2 and A. Slitt 1 . 1 Biomedical and 

Pharmaceutical Sciences, University of Rhode 

Island, Kingston, RI and 2 Division of Biochemical 


Research, U.S. FDA, Jefferson, AR. 

Abstract # 


TOXICOKINETICS OF 

PERFLUOROOCTANOIC ACID (PFOA) AND 

PERFLUOROOCTANE SULFONATE (PFOS) 

AFTER A SINGLE INTRAVENOUS OR 

GAVAGE ADMINISTRATION TO HARLAN 

SPRAGUE-DAWLEY RATS. S. Hong 1 , V. 

Robinson 2 , S. Gibbs 1 , S. W. Graves 1 , B. Burback 1 , M. 

Eifrid 1 and C. Smith 2 . 1 Battelle Memorial, Columbus, 

OH and 2 NIEHS, NIH, Research Triangle Park, NC. 


TOXICOKINETICS OF 

PERFLUOROHEXANOIC ACID (PFHXA) 

AND PERFLUOROHEXANE-1-SULPHONIC 

ACID POTASSIUM SALT (PFHSKSLT) 

AFTER A SINGLE INTRAVENOUS OR 

GAVAGE ADMINISTRATION TO HARLAN 

SPRAGUE-DAWLEY RATS. S. Gibbs 1 , V. 

Robinson 2 , S. Hong 1 , S. W. Graves 1 , B. Burback 1 , 

C. Granville 1 , M. Eifrid 1 and C. Smith 2 . 1 Battelle 

Memorial, Columbus, OH and 2 NIEHS, NIH, 



ABSORPTION AND EXCRETION OF 14 C- 

PERFLUOROOCTANOIC ACID (PFOA) 

IN BEEF CATTLE. J. Huwe 1 , S. Lupton 1 , D. J. 

Smith 1 , K. Dearfield 2 and J. J. Johnston 3 . 1 USDA, 

ARS, Biosciences Research Laboratory, Fargo, ND, 

2 

USDA, FSIS, Office of Public Health Science, 

Washington, D.C. and 3 USDA, FSIS, Office of 

Public Health Science, Fort Collins, CO. 


SPECIES-SPECIFIC FACTORS WHEN 

PREDICTING SYSTEMIC CLEARANCE OF 

ENB-0040 IN RABBITS VIA AN ALLOMETIC 

SCALING APPROACH. C. Jomphe 1 , I. Lemire 2 , 

P. Leonard 2 , M. Reimer 1 and M. Beliveau 1 . 1 RAS, 

Pharsight Corporation, Montréal, QC, Canada and 

2 

Enobia Pharmacology Montréal, QC, Canada. 


METABOLISM AND DISPOSITION OF 

2-METHOXY-4-NITROANILINE IN MALE 

AND FEMALE SPRAGUE-DAWLEY RATS 

AND B6C3F1 MICE. S. Waidyanatha 1 , Q. 

Zhan 2 , I. Surh 1 , S. Warren 2 , P. Patel 2 , S. Black 2 , J. 

Burgess 2 and J. Mathews 2 . 1 National Institute of 


Park, NC and 2 RTI International, Research Triangle 

Park, NC. 


METABOLISM AND DISPOSITION OF 

N-BUTYLPARABEN FOLLOWING ORAL 

AND DERMAL ADMINISTRATION. J. 

Mathews 1 , S. Black 1 , C. Blystone 2 , S. Brown 1 , P. 

Patel 1 , A. Etheridge 1 and S. Waidyanatha 2 . 1 RTI 

International, Research Triangle Park, NC and 

2 




DIMETHYLETHANOLAMINE INCREASED 

SERUM CHOLINE, BUT DID NOT ALTER 

[14C]-CHOLINE TISSUE DISTRIBUTION 

IN WISTAR HAN RATS. J. M. Sanders 2 , C. J. 

Wegerski 1 , M. Doyle-Eisele 1 and J. D. McDonald 1 . 

1 

LRRI, Albuquerque, NM and 2 NTP/NIEHS, 

Reserach Triangle Park, NC. 

Wednesday 







317



Wednesday 



TOXICOKINETICS OF CAPTAN 

BIOMARKERS IN ORALLY AND 

DERMALLY EXPOSED VOLUNTEERS. M. 

Bouchard 1 , A. Berthet 1,2 and D. Vernez 2 . 1 Department 

Environmental & Occupational Health, University 

of Montréal, Montréal, QC, Canada and 2 Institute for 

Work and Health, Lausanne, Switzerland. 


IMPACT OF NON-LINEAR 

PHARMACOKINETICS AND METABOLISM 

OF CHLORPYRIFOS ON BIOLOGICAL 

RESPONSE IN THE RAT. M. Bartels 1 , M. 

S. Marty 1 , J. A. Hotchkiss 1 and D. R. Juberg 2 . 

1 

Toxicology, Dow Chemical, Midland, MI and 

2 

Toxicology, Dow AgroSciences, Indianapolis, IN. 


COMPARISON OF THE EFFECT OF ASSAY 

CONDITIONS ON INTERPRETATION 

OF TIME-DEPENDENT INHIBITION OF 

CYTOCHROME P450 ENZYMES USING 

SINGLE POINT AND IC50 SHIFT ASSAYS. 

K. Fox 2 , R. Pearson 2 , P. Butler 2 , C. Dilworth 2 and K. 

Tsaioun 1,2 . 1 Apredica, Watertown, MA and 2 Cyprotex, 

Macclesfield, United Kingdom. 


REACTIVITY OF BRO3- EXPLAINS POOR 

APPARENT ABSORPTION OF LOW ORAL 

DOSES F344 RATS. R. J. Bull 1 , N. Kolisetty 2 , 

Z. Guo 3 , J. W. Fisher 4 , J. A. Cotruvo 5 and B. S. 

Cummings 2 . 1 Washington State University, Richland, 

WA, 2 University of Georgia, Athens, GA, 3 Center for 

Water Technology Public Utility Board Singapore, 

Singapore, 4 U.S. FDA, Jefferson, AR ad 5 Joseph 

Cotruvo & Associates LLC, Washington, D.C. 


GENETIC VARIATION IN ISOGENIC 

STRAINS OF LABORATORY MICE ALTERS 

DISPOSITION IN KIDNEYS AND LIVERS 

AFTER ACUTE EXPOSURE TO [14C] 

BENZENE. R. Kuester 1 , G. A. Knudsen 1 , M. 

L. Cunningham 2 and G. Sipes 1 . 1 Department of 

Pharmacology, University of Arizona, Tucson, AZ 

and 2 NTP NIEHS, Montréal, QC, Canada. 


PYRIDAZINE REDUCES 

TRICHLOROACETIC ACID (TCA) 

BIOAVAILABILITY BY ENHANCING ITS 

URINARY ELIMINATION. J. Bruckner, S. Lee, 

C. A. White, S. Muralidhara and R. Govindaarajan. 

PBS, University of Georgia, Athens, GA. 


DETERMINATION OF TACROLIMUS IN 

RAT WHOLE BLOOD USING DRIED BLOOD 

SPOT ANALYSES BY LC-MS/MS. M. Kim 1 , G. 

Ray 1 , Y. Liu 1 , R. Losson 2 and G. Bricker 2 . 1 KCAS, 

Shawnee, KS and 2 Xenometrics, Stilwell, KS. 

Sponsor: D. Dandekar. 


A SENSITIVE LC-MS/MS ASSAY FOR 

DETERMINATION OF BENAZEPRIL AND 

BENAZEPRILAT IN DOG PLASMA. C. 

Chung, M. Luna, Y. Liu, G. Ray and D. Dadgar. 

KCAS, Shawnee, KS. Sponsor: D. Dandekar. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment: Models and Approaches for 

Inhaled Agents 

Chairperson(s): Annie Jarabek, U.S. EPA, Research Triangle Park, NC, 

and Richard Corley, Pacific Northwest National Laboratory, Richland, 

WA. 




EVALUATION OF ADVERSE EFFECTS 

ON HUMAN LUNG FUNCTION CAUSED 

BY OZONE. R. L. Prueitt 1 and J. E. Goodman 2 . 

1 

Gradient, Seattle, WA and 2 Gradient, Cambridge, 

MA. 


MODELING NF-κB REDOX SENSITIVITY: 

APPLICATIONS TO OZONE-INDUCED 

LUNG INFLAMMATION. D. J. Miller and P. 

D. White. U.S. EPA, Washington, D.C. Sponsor: S. 

Vulimiri. 


COMBINED CFD/PBPK MODELS FOR 

DETERMINING SITE-SPECIFIC UPTAKE 

AND TISSUE CONCENTRATIONS OF 

REACTIVE GASES IN THE RESPIRATORY 

TRACT OF RATS AND HUMANS. R. A. 

Corley 1 , S. Kabilan 1 , J. E. Carson 1 , R. Jacob 1 , 

K. R. Minard 1 , R. W. Glenny 2 , S. Pipavath 2 , M. 

Fanucchi 3 and D. R. Einstein 1 . 1 Pacific Northwest 

National Laboratory, Richland, WA, 2 University of 

Washington, Seattle, WA and 3 University of Alabama 

at Birmingham, Birmingham, AL. 


MODELING VAPOR UPTAKE AND TISSUE 

DISPOSITION IN HUMAN LUNGS. M. Singal 1 , 

B. Asgharian 2 , O. T. Price 2 , J. S. Schroeter 3 and 

J. S. Kimbell 4 . 1 Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ, 2 Health Effects 

& Medical Response, Applied Research Associates, 

Raleigh, NC, 3 Division of Computational Biology, 

The Hamner Institutes for Health Sciences, 

Research Triangle Park, NC and 4 Department of 

Otolaryngology/Head and Neck Surgery, University 

of North Carolina at Chapel Hill, Chapel Hill, NC. 


DOSIMETRY OF SOLUBLE, REACTIVE 

VAPORS IN THE UPPER RESPIRATORY 

TRACT OF THE SPRAGUE-DAWLEY 

RAT USING A COMPUTATIONAL FLUID 

DYNAMICS MODEL. J. Schroeter 1 , J. S. 

Kimbell 2 , B. Asgharian 3 and M. Singal 4 . 1 The Hamner 


Park, NC, 2 Otolaryngology/Head and Neck Surgery, 


Hill, NC, 3 Applied Research Associates, Inc., 

Raleigh, NC and 4 Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ. 

318 






Platform Sessions



Abstract # 


MODELS FOR EVALUATION OF 

THERAPEUTIC INTERVENTION OF 

INTERNALLY DEPOSITED AMERICIUM. R. 

A. Guilmette 1 , W. M. Weber 1 , M. Doyle-Eisele 1 , G. 

Miller 2 , L. Bertelli 2 and J. D. McDonald 1 . 1 Lovelace 

Respiratory Research Institute, Albuquerque, NM 

and 2 Los Alamos National Laboratories, Los Alamos, 

NM. 


MODELING FIBER INHALABILITY AND 

DEPOSITION IN THE HUMAN AND RAT 

RESPIRATORY TRACT. B. Asgharian 1 , O. T. 

Price 1 , S. H. Gavett 2 and A. M. Jarabek 2 . 1 Health 

Effects & Medical Response, Applied Research 

Associates, Raleigh, NC and 2 U.S. EPA, Research 



TRANSLATION OF INHALED FIBER 

DOSE ACROSS SPECIES AND DIFFERENT 

EXPERIMENTAL DESIGNS: FIBER 

EQUIVALENT DIAMETER. O. Price 1 , B. 

Asgharian 1 , S. H. Gavett 2 and A. M. Jarabek 2 . 

1 

Applied Research Associates, Inc., Raleigh, NC and 

2 



DEVELOPMENT OF A PHYSIOLOGICALLY 


MODEL FOR THE DISPOSITION 

OF PROPYL SERIES COMPOUNDS 

(PROPYL ACETATE, PROPANOL, 

PROPIONALDEHYDE, AND PROPIONIC 

ACID) IN RATS. L. M. Sweeney 1,2 and T. S. Poet 3 . 

1 

Naval Medical Research Unit-Dayton, Wright- 

Patterson Air Force Base, Wright-Patterson Air 

Force Base, OH, 2 Toxicology Excellence for Risk 

Assessment, Cincinnati, OH and 3 Battelle Pacific 

Northwest National Laboratory, Richand, WA. 


USING MARGINS OF EXPOSURE AS 

A SEGREGATION TOOL FOR RISK 

ASSESSMENT OF TOBACCO SMOKE 

TOXICANTS. S. Fiebelkorn, F. H. Cunningham 

and C. Meredith. Group R&D, British American 

Tobacco, Southampton, United Kingdom. 


USE OF CONTROL BANDING AND 

SENSORY IRRITATION (RD 50 

) DATA TO 

ASSESS OCCUPATIONAL EXPOSURE 

VALUES FOR N-PROPYL, N-BUTYL, AND 

N-PENTYL PROPIONATE. S. M. Krieger 1 , D. R. 

Geter 1 , T. J. Cawley 1 , M. Osterloh-Quiroz 2 and J. A. 

Hotchkiss 1 . 1 The Dow Chemical Company, Midland, 

MI and 2 Dow Europe GmbH, Horgen, Switzerland. 


ASSESSING NON-CANCER HEALTH RISK 

FROM INHALED PCBS. G. M. Lehmann 1 and J. 

Schaum 2 . 1 ORD, U.S. EPA, Research Triangle Park, 

NC and 2 ORD, U.S. EPA, Washington, D.C. 

Abstract # 


STRUCTURE-ACTIVITY MODELS FOR 

CHEMICAL INHALATION HEALTH 

GUIDANCE VALUES. C. J. Collar 1 , T. Miller 2 , 

R. M. Garrett 2 and E. Demchuk 1 . 1 Division of 

Toxicology and Environmental Medicine, ATSDR/ 

CDC, Atlanta, GA and 2 Department of Defense, 

Washington, D.C. Sponsor: B. Fowler. 


THORACIC DAMPING AND THE 

RELATIONSHIP BETWEEN PENH OF THE 

THORACIC AIR-FLOW (I T 

) AND TIDAL 

MIDEXPIRATORY FLOW (EF 50 

). D. G. Frazer, 

J. S. Reynolds, W. T. Goldsmith, W. G. McKinney, 

M. C. Jackson and A. A. Afshari. HELD, CDC / 

NIOSH, Morgantown, WV. Sponsor: A. Hubbs. 


FRONT-LINE CELLS IN LUNG DISEASE: 

SUB-CELLULAR LOCALIZATION 

OF PROTEINS WHOSE STATES ARE 

DEPENDENT ON THAT OF CDKN2A. G. 

Acquaah-Mensah. Massachusetts College of 

Pharmacy & Health Sciences, Worcester, MA. 


HOW MUCH FORMALDEHYDE EXISTS IN 

EXHALED BREATH? J. E. Whalan, D. DeVoney 

and S. V. Vulimiri. U.S. EPA, Washington, D.C. 


DNA DAMAGE AND OXIDATIVE STRESS 

IN RATS INTRATRACHEALLY EXPOSED 

TO LOW-LEVEL COMBINED COBALT 

AND CHROMIUM. N. Yoshioka 1 , K. Hosoda 1 , 

H. Nakashima 2 , T. Michikawa 1 , M. Nakano 1 and K. 

Omae 1 . 1 Department of Preventive Medicine and 

Public Health, Keio University School of Medicine, 

Tokyo, Japan and 2 Department of Preventive 

Medicine and Public Health, National Defense 

Medical College, Tokorozawa, Saitama, Japan. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Mechanistic Assessment of Chemical Mixtures 

Chairperson(s): Rory B. Conolly, U.S. EPA, Research Triangle Park, NC. 




MODELING MIXTURES OF 

ENVIRONMENTAL ESTROGENS 

DETECTED IN U.S. SURFACE WATERS 

WITH AN IN VITRO ESTROGEN MEDIATED 

TRANSCRIPTIONAL ACTIVATION ASSAY 

(T47D-KBLUC). D. S. Bermudez 1,2 , L. Gray 2 

and V. S. Wilson 2 . 1 Molecular Biomedical Sciences, 

North Carolina State University, Raleigh, NC 

and 2 Reproductive Toxicology Branch, U.S. EPA, 


Wednesday 







319



Wednesday 



IN VITRO EXPOSURE AND EVALUATION 

OF MILITARY FUELS AND BIOFUELS. K. L. 

Mumy 1 , T. L. Doyle 1 , M. R. Okolica 1 , R. P. Adkins 1 

and G. T. Eldridge 2 . 1 Naval Medical Research Unit - 

Dayton, Wright-Patterson AFB, OH and 2 Naval Air 

Warfare Center Aircraft Division, Patuxent River, 

MD. 


DOSE-RESPONSE EVALUATION OF NON- 

ADDITIVE HEPATIC EFFECTS OF PCB153 

AND TCDD IN MICE. A. K. Kopec 1,2 , M. L. 

D’Souza 1,2 , B. D. Mets 1 , L. D. Burgoon 1,2 , J. R. 

Harkema 2,3 , C. Tashiro 4 , D. Potter 4 , B. Sharratt 4 , S. 

E. Reese 5 , K. J. Archer 5 and T. R. Zacharewski 1,2 . 

1 

Biochemistry & Molecular Biology, Michigan State 



MI, 3 Pathobiology & Diagnostic Investigations, 


4 

Wellington Laboratories, Inc., Guelph, ON, 

Canada and 5 Biostatistics, Virginia Commonwealth 



DETERMINING A ROBUST D-OPTIMAL 

DESIGN FOR TESTING FOR DEPARTURE 

FROM ADDITIVITY IN A MIXTURE OF 

FOUR PFAAS. C. Carr 1 , C. Gennings 1 , B. D. 

Abbott 2 , J. E. Schmid 2 , W. Wan 1 , L. Burgoon 2 , 

C. J. Wolf 2 and C. Lau 2 . 1 Biostatistics, Virginia 

Commonwealth University, Richmond, VA and 

2 



PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC (PBPK) 

MODELING OF TWO BINARY 

MIXTURES: METABOLIC ACTIVATION 

OF CARBON TETRACHLORIDE BY 

TRICHLOROETHYLENE AND METABOLIC 

INHIBITION OF CHLOROFORM BY 

TRICHLOROETHYLENE. M. V. Evans 1 , H. M. 

Yang 2 , K. A. Yokley 3 , A. McDonald 1 , Y. M. Sey 1 , C. 

R. Eklund 1 and J. Simmons 1 . 1 NHEERL/ORD, U.S. 

EPA, Research Triangle Park, NC, 2 NCEA/ORD, 

U.S. EPA, Washington, D.C. and 3 Mathematics and 

Statistics, Elon University, Elon, NC. 


INTEGRATED MULTI-DISCIPLINARY 

ASSESSMENT OF ENVIRONMENTALLY 

REALISTIC COMPLEX MIXTURES OF 

DRINKING WATER DISINFECTION 

BY-PRODUCTS (DBPS) (THE 4LAB STUDY). 

J. Simmons 1 , M. G. Narotsky 1 , L. K. Teuschler 2 , 

J. G. Pressman 3 , E. S. Hunter 1 , G. E. Rice 2 , G. R. 

Klinefelter 1 , J. M. Goldman 1 , T. F. Speth 3 , L. F. 

Strader 1 , R. J. Miltner 3 , S. Parvez 2 , A. McDonald 1 , 

D. S. Best 1 , C. A. Dingus 4 and S. D. Richardson 5 . 

1 

NHEERL/ORD, U.S. EPA, Research Triangle 

Park, NC, 2 NCEAORD, U.S. EPA, Cincinnati, OH, 

3 

NRMRL/ORD, U.S. EPA, Cincinnati, OH, 4 Battelle, 

Columbus, OH and 5 NERL/ORD, U.S. EPA, Athens, 

GA. 


A FOUR-STEP APPROACH FOR 

EVALUATION OF DOSE-ADDITIVITY. R. 

C. Hertzberg 1 , Y. Pan 2 , R. Li 2 , L. T. Haber 3 , R. 

Lyles 2 , V. C. Moser 4 , D. W. Herr 4 and J. Simmons 4 . 

1 

Biomathematics Consulting, Atlanta, GA, 

2 

Department of Statistics, Emory University, Atlanta, 

GA, 3 Toxicology Excellence for Risk Assessment, 

Atlanta, GA and 4 NHEERL, U.S. EPA, Research 



TOXICITY OF TUNGSTEN AND COBALT 

MIXTURES IN EMBRYONIC ZEBRAFISH. 

J. L. Freeman, J. M. Schultheis, D. R. Robbins and 

S. M. Peterson. Health Sciences, Purdue University, 



SIMULTANEOUS EXTRACTION AND 

DETECTION OF BISPHENOL A AND 

GENISTEIN. J. Coughlin 1,2,3 and B. Buckley 1,2,3 . 

1 

Toxicology, Rutgers University, Piscataway, NJ, 

2 

JGPT, Rutgers University, Piscataway, NJ and 

3 

Environmental and Occupational Health Sciences 

Institute, Rutgers University, Piscataway, NJ. 


REACTIVITY OF SELECTED 

OSTEOLATHYROGENS WITH A MODEL 

COFACTOR FOR LYSYL OXIDASE. H. 

Bensinger 1 , N. Genco 1 , R. G. Bergosh 2 and D. A. 

Dawson 1 . 1 Biology/Toxicology, Ashland University, 

Ashland, OH and 2 Chemistry, Geology, and Physics, 

Ashland University, Ashland, OH. Sponsor: D. Fort. 


THE SYNERGISTIC EFFECT OF SODIUM 

CHLORITE AND BROMOCHLOROACETIC 

ACID ON BROMATE-INDUCED RENAL 

CELL DEATH. X. Zhang 1 , R. J. Bull 2 , J. 

A. Cotruvo 3 , J. Fisher 4 and B. S. Cummings 1 . 

1 

Pharmaceutical and Biomedical Sciences, University 

of Georgia, Athens, GA, 2 MoBull Consulting, 

Richland, WA, 3 Joseph Cotruvo & Associates, 

LLC, Washington, D.C. and 4 National Center for 

Toxicological Research, U.S. FDA, Jefferson, AR. 


CELL SIGNAL TRANSDUCTION TO 

PREDICT MIXTURE INTERACTIONS. J. 

Boyd, X. Gao, H. Williams, C. Kinzer and J. Vrana. 

Bennett Department of Chemistry, West Virginia 



PIFITHRIN-α INCREASES IGF- 

1R INHIBITOR MEDIATED HEPG2 

HEPATOCARCINOMA DEATH. X. Gao, H. 

Williams, C. Kinzer, J. Vrana and J. Boyd. Bennett 

Department of Chemistry, West Virginia University, 



PBPK MODELING OF THE AGGREGATE 

AND CUMULATIVE EXPOSURES 

OF RATS TO TOLUENE, N-HEXANE, 

CYCLOHEXANE, AND ISOOCTANE. N. 

Kaveh, M. Gagné, G. Charest-Tardif, R. Tardif and 

K. Krishnan. Université de Montréal, Montréal, QC, 

Canada. 

320 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Mechanisms of Aspiration Injury and Airway 

Disease 

Chairperson(s): Deepak Bhalla, Wayne State University, Detroit, MI. 




NAIL MANGANESE AS A BIOMARKER OF 

WELDING FUME EXPOSURE. J. M. Antonini, 

J. R. Roberts and K. Sriram. NIOSH, Morgantown, 

WV. 


PERIPHERAL BLOOD GENE EXPRESSION 

PROFILING REVEALS SILICA-INDUCED 

PULMONARY TOXICITY. R. Sellamuthu, C. 

Umbright, J. Roberts, R. Chapman, S. Young, D. 

Richardson, D. Leonard, W. McKinney, B. Chen, 

D. Frazer, S. Li, M. Kashon and P. Joseph. National 

Institute for Occupational Safety and Health 

(NIOSH), Morgantown, WV. 


BIOACTIVATION OF THE 

NASAL TOXICANT 2, 

6-DICHLOROBENZONITRILE: AN 

ASSESSMENT OF METABOLIC ACTIVITY 

IN HUMAN NASAL MUCOSA AND 

IDENTIFICATION OF BIOMARKERS OF 

EXPOSURE AND POTENTIAL TOXICITY. 

F. Xie 1,2 , X. Zhou 1 , J. D’Agostino 1 , D. Spink 1 and 

X. Ding 1 . 1 Wadsworth Center, New York State 

Department of Health, Albany, NY and 2 School 




SYSTEMIC UPTAKE OF 14 C 2, 

3-BUTANEDIONE ADMINISTERED 

BY INTRATRACHEAL INSTILLATION 

IN MALE SPRAGUE-DAWLEY RATS 

AND OROPHARYNGEAL ASPIRATION 

IN MALE B6C3F1 MICE. T. Fennell 1 , D. 

Morgan 2 , S. Watson 1 and S. Waidyanatha 2 . 1 RTI 

International, Research Triangle Park, NC and 

2 

National Toxicology Program, National Institute of 


Park, NC. 


RESVERATROL, AN AHR LIGAND, 

ALLEVIATES BACTERIAL ENTEROTOXIN- 

INDUCED ACUTE LUNG INJURY VIA 

UPREGULATION OF MIRNA 155 AND 

SUBSEQUENT INCREASE IN MYELOID- 

DERIVED SUPPRESSOR CELLS. S. A. 

Rieder, P. Nagarkatti and M. Nagarkatti. Pathology 

Microbiology and Immunology, University of South 


Abstract # 


MOLECULAR PATHWAYS OF PULMONARY 

INFLAMMATION FOLLOWING 

ASPIRATION AND INHALATION OF 

STAINLESS STEEL WELDING FUME IN 

MICE. P. C. Zeidler-Erdely, A. Erdely, M. Kashon, 

S. Li and J. Antonini. HELD, NIOSH, Morgantown, 

WV. 


EFFECTS OF PARTICULATE AIR 

POLLUTION DURING BEIJING OLYMPIC 

GAMES IN A MOUSE MODEL. K. Tzan 1 , 

X. Xu 1 , S. Jiang 1 , J. Aronovsky 1 , A. Wang 2 , S. 

Rajagopalan 2,3 and Q. Sun 1,2,3 . 1 Public Health, The 

Ohio State University, Columbus, OH, 2 Davis 

Heart and Lung Research Institute, The Ohio State 

University, Columbus, OH and 3 Cardiology, The 

Ohio State University, Columbus, OH. 


OVER-EXPRESSION OF THE NF-κB 

MEMBER RELB DAMPENS THE 

PRO-INFLAMMATORY EFFECTS OF LONG- 

TERM CIGARETTE SMOKE EXPOSURE. 

D. McMillan 1,3 , T. H. Thatcher 3,4 , S. Maggirwar 2 , 

P. J. Sime 1,3,4 and R. P. Phipps 1,2,3 . 1 Environmental 

Medicine, University of Rochester, Rochester, 

NY, 2 Microbiology and Immunology, University 

of Rochester, Rochester, NY, 3 Lung Biology and 

Disease, University of Rochester, Rochester, NY and 

4 

Pulmonary and Critical Care Medicine, University 

of Rochester, Rochester, NY. 


ADJUVANT EFFECT OF 1Ç3-β-GLUCAN 

(ZYMOSAN) EXPOSURE IN A MOUSE 

OVALBUMIN ALLERGY MODEL. S. Young, 

M. Wolfarth, J. R. Roberts, M. L. Kashon and J. M. 

Antonini. NIOSH, Morgantown, WV. 


ROLE OF SURFACTANT PROTEIN-D 

(SP-D) IN REGULATING MACROPHAGE 

PHENOTYPE, INFLAMMATION, AND 

LUNG FUNCTION IN ELDERLY MICE 

FOLLOWING OZONE (O3) INHALATION. 

A. M. Groves 1 , J. D. Laskin 2 , A. J. Gow 1 and D. L. 

Laskin 1 . 1 Rutgers University, Piscataway, NJ and 

2 



GLUTATHIONE DEPLETION POTENTIATES 

CIGARETTE SMOKE INDUCED AIRWAY 

INFLAMMATION. B. J. Day 1,2,3 , E. Min 1 and 

N. S. Gould 1,2 . 1 Medicine, National Jewish Health, 

Denver, CO. 2 Pharmaceutical Sciences, University 

of Colorado AMC, Aurora, CO and 3 Medicine, 

University of Colorado AMC, Aurora, CO. 


THE GLUTATHIONE SYNTHESIS GENE 

GCLM MODULATES PULMONARY 

INFLAMMATION FOLLOWING 

INTRANASAL INSTILLATION OF DIESEL 

EXHAUST PARTICULATE. C. Weldy 1 , C. 

C. White 1 , D. P. Cox 1 , H. Wilkerson 1 , S. Gill 2 , 

W. Parks 2 and T. J. Kavanagh 1 . 1 Environmental 

and Occupational Health Sciences, University 

of Washington, Seattle, WA and 2 Pulmonary and 

Critical Care Medicine, University of Washington, 

Seattle, WA. 

Wednesday 







321



Wednesday 



AIRBORNE ORGANIC PARTICULATE 

MATTER AS A LUNG INFLAMMATION 

INDUCER: ROLE OF PHOSPHOLIPASE 

A2. S. R. Kotha 1 , M. G. Piper 1 , B. P. Caristophe 1 , 

N. Patric 1 , R. M. Uppu 2 , M. B. Clay 1 and N. L. 

Parinandi 1 . 1 Division of Pulmonary, Allergy, 

Critical Care, and Sleep Medicine, The Ohio State 

University College of Medicine, Columbus, OH and 

2 

Department of Environmental Toxicology, Southern 

University and A&M College, Baton Rouge, LA. 


THE ROLE OF TRANSFORMING GROWTH 

FACTOR BETA 1 (TGF-β1) IN TOBACCO- 

SMOKE-INDUCED LUNG INJURIES. L. L. 

Hoang and K. E. Pinkerton. Center for Health and 

the Environment, University of California Davis, 

Davis, CA. 


RESPIRATORY AND SYSTEMIC 

RESPONSES TO URBAN SUMMER 

AND WINTER SUB-MICRON FINE AND 

ULTRAFINE PARTICULATE MATTER. L. 

E. Plummer 1 , C. M. Carosino 1 , K. J. Bein 2 , A. S. 

Wexler 2 and K. E. Pinkerton 1 . 1 Center for Health and 

the Environment, University of California, Davis, 

CA and 2 Civil and Environmental Engineering, 

University of California, Davis, CA. 


PARTICLE UPTAKE OF GASEOUS AIR 

TOXICS MODIFIES OBSERVED TOXICITY 

OF PM. S. M. Ebersviller 1 , K. Lichtveld 1 , J. Zavala 1 , 

Y. Lin 1 , K. G. Sexton 1 , I. Jaspers 1,2 and H. Jeffries 1 . 

1 

Environment Sciences and Engineering, University 

of North Carolina at Chapel Hill, Chapel Hill, NC 

and 2 CEMALB, University of North Carolina at 



CONTRIBUTIONS OF TRPV1 AND TRPM8 

TO LUNG INJURY BY COAL FLY ASH. C. 

A. Reilly, C. E. Deering-Rice, M. E. Johansen, J. K. 

Roberts, E. G. Romero, J. M. Veranth and G. S. Yost. 

Pharmacology and Toxicology, University of Utah, 

Salt Lake City, UT. 


ACTIVATION OF HUMAN TRPA1 BY 

DIESEL EXHAUST PARTICLES (DEP): 

ASSOCIATION WITH LUNG INJURY. C. 

Deering-Rice, E. G. Romero, J. M. Veranth, G. S. 

Yost and C. A. Reilly. Pharmacology/Toxicology, 



MECHANISMS OF CHLORINE 

HYPERSENSITIVITY IN ASTHMA. S. 

Balakrishna 1 , B. F. Bessac 1 , W. Song 2 , A. I. 

Caceres 1 , T. Nicola 3 , S. F. Doran 2 , A. Yadav 2 , 

N. Ambalavanan 3 , S. Matalon 2 and S. E. Jordt 1 . 

1 

Pharmacology, Yale School of Medicine, New 

Haven, CT, 2 Anesthesiology, University of Alabama 

at Birmingham, Birmingham, AL and 3 Pediatrics, 

University of Alabama at Birmingham, Birmingham, 

AL. 


BLEOMYCIN-INDUCED LUNG 

ENDOTHELIAL CYTOSKELETAL 

REARRANGEMENT IS REGULATED BY 

THIOL-REDOX. R. B. Patel 1 , L. Sauers 1 , R. M. 

Uppu 2 and N. L. Parinandi 1 . 1 Division of Pulmonary, 

Allergy, Critical Care, and Sleep Medicine, The Ohio 

State University College of Medicine, Columbus, 

OH and 2 Department of Environmental Toxicology, 

Southern University and A&M College, Baton 

Rouge, LA. 


HMGB1 IN HYPEROXIA-COMPROMISED 

HOST ABILITY TO CLEAR PSEUDOMONAS 

AERUGINOSA PNEUMONIA. V. S. Patel 1 , 

R. Sitapara 1 , B. Phan 1 , A. Gore 1 , R. Malla 1 and 

L. L. Mantell 1,2 . 1 Department of Pharmaceutical 

Sciences, St. John’s University, Jamaica, NY and 

2 

The Feinstein Institute for Medical Research, North 

Shore-LIJ Health Science, Manhasset, NY. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Toxicology of the Gulf Oil Spill 

Chairperson(s): John Wise, University of Southern Maine, Portland, ME. 




A WHOLE BODY INHALATION EXPOSURE 

SYSTEM FOR THE OIL DISPERSANT 

COREXIT 9500 WITH PULMONARY 

FUNCTION RESULTS FROM AN INITIAL 

SET OF EXPOSURES WITH RATS. W. T. 

Goldsmith, W. G. McKinney, M. C. Jackson, J. S. 

Reynolds, J. Cumpston and D. G. Frazer. HELD, 

CDC/NIOSH, Morgantown, WV. Sponsor: A. Hubbs. 


GENE AND PROTEIN EXPRESSION 

BIOMARKERS IN FUNGICIDE EXPOSED 

ZEBRAFISH. D. C. Bencic 1 , R. Wang 1 , A. D. 

Biales 1 , R. W. Flick 1 , D. L. Villeneuve 2 , G. T. Ankley 2 

and D. L. Lattier 1 . 1 U.S. EPA/ORD/NERL/EERD, 

Cincinnati, OH and 2 U.S. EPA/ORD/NHEERL/ 

Medical, Duluth, MN. Sponsor: H. Choudhury. 


GENES FROM BONE MARROW OF 

BENZENE TREATED MICE, COUPLED 

WITH STRUCTURAL ANALYSIS OF 

BENZENE AND SIMILAR CHEMICALS IN 

OIL SPILLS, JOINTLY PREDICT ACUTE 

MYELOID LEUKEMIA AND POSSIBLE 

MECHANISM. D. Mitic Potkrajac 1 , G. Apic 1 , 

F. Bonner 1 and R. B. Russell 2 . 1 Cambridge Cell 

Networks Ltd., Cambridge, United Kingdom 

and 2 Cell Networks, University of Heidelberg, 

Heidelberg, Germany. Sponsor: P. Hewitt. 

322 






Platform Sessions



Abstract # 


CHEMICAL DISPERSANTS USED IN THE 

GULF OF MEXICO ARE CYTOTOXIC 

AND GENOTOXIC TO HUMAN SKIN 

FIBROBLASTS. J. Wise 1,2 , S. Wise 1,2,3 , H. Xie 1,2,3 

and J. P. Wise 1,2,3 . 1 Wise Laboratory of Environmental 






Portland, ME. 


DEVELOPING A WHALE CELL LINE AT 

SEA TO EVALUATE THE CYTOTOXICITY 

AND GENOTOXICITY OF CHEMICAL 

DISPERSANTS USED IN THE GULF OF 

MEXICO OIL CRISIS. C. F. Wise 1,2,4 , M. 

Braun 1,2,4 , J. P. Wise 1,2,4 , S. S. Wise 1,2,3 , I. Kerr 2,4 , 

H. Xie 1,2,3 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 






Maine, Portland, ME and 4 Ocean Alliance, Lincoln, 

MA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Endocrine Toxicology 

Chairperson(s): Tammy Stoker, U.S. EPA, Research Triangle Park, NC. 




BONE HOMEOSTASIS IS NOT ALTERED 

IN MCHR1-DEFICIENT MICE. B. Gemzik 1 , 

J. A. Tamasi 2 , J. J. Devenny 2 , B. J. Murphy 2 , W. N. 

Washburn 3 and B. D. Car 1 . 1 Discovery Toxicology, 

Bristol-Myers Squibb Company, Princeton, NJ, 

2 

Discovery Biology, Bristol-Myers Squibb Company, 

Princeton, NJ and 3 Discovery Chemistry, Bristol- 

Myers Squibb Company, Princeton, NJ. 


A NOVEL SENSITIVE AND SELECTIVE 

REAL-TIME CELLULAR ASSAY FOR 

DETECTION OF ENDOCRINE DISRUPTORS 

USING NATIVE ENDOCRINE SIGNALING 

PATHWAYS. C. Jin 1 , Y. Abassi 1 , X. Xu 1 , X. 

Wang 1 , W. Zhang 2 and S. Gabos 2 . 1 Acea Biosciences, 

San Diego, CA and 2 Alberta Health and Wellness, 

Edmonton, AB, Canada. Sponsor: M. Lo. 


THE IMPACT OF EPIDERMAL GROWTH 

FACTOR RECEPTOR INHIBITION ON 

ENERGY HOMEOSTASIS. M. Biggs 1 , D. 

Threadgill 2 , T. Ghashghaei 3 and T. Lee 4 . 1 Toxicology, 

University of North Carolina at Chapel Hill, 

Chapel Hill, NC, 2 Genetics, North Carolina State 

University, Raleigh, NC, 3 Department of Molecular 

and Biomedical Sciences, North Carolina State 

University, Raleigh, NC and 4 Genetics, University of 


Abstract # 


SCIENTIFICALLY RELEVANT 

INFORMATION TO EVALUATE THE 

ENDOCRINE DISRUPTING POTENTIAL 

OF ISOPHORONE. N. M. Berdasco and D. R. 

Geter. Toxicology and Environmental Research and 

Consulting, The Dow Chemical Company, Midland, 

MI. 


EXENATIDE AND SITAGLIPTIN: THEIR 

ROLE IN AUTOPHAGOSOME REGULATED 

TOXICITY IN PANCREATITIS. R. Rouse, L. 

Zhang and D. A. Volpe. U.S. FDA, Silver Spring, 

MD. 


IMPROVING THE IN VIVO PREDICTIVE 

VALUE OF THE ER-CALUX 

BIOASSAY BY COMBINING IN VITRO 

ESTROGENICITY RESULTS WITH KINETIC 

CHARACTERISTICS OF ESTROGENIC 

COMPOUNDS. W. Brand 1 , A. Punt 1,2 , A. J. Murk 2 , 

M. Schriks 1 , A. P. van Wezel 1 and M. B. Heringa 1 . 

1 

KWR Watercycle Research Institute, Nieuwegein, 

Netherlands and 2 Division of Toxicology, 

Wageningen University, Wageningen, Netherlands. 


PCB-153 AND BDE-47 INCREASE 

THYROXINE (T ) CATABOLISM IN RAT 

4 

AND HUMAN HEPATOCYTES. V. M. 

Richardson 1,2 and M. J. DeVito 3 . 1 ORD/NHEERL/ 

ISTD, U.S. EPA, Research Triangle Park, NC, 

2 

Curriculum in Toxicology, University of North 

Carolina at Chapel Hill, Chapel Hill, NC and 

3 

Toxicology Branch, NIEHS/NTP, Research Triangle 

Park, NC. 


TRICLOSAN DECREASES RAT 

THYROXINE: MODE-OF-ACTION, 

DEVELOPMENTAL SUSCEPTIBILITY AND 

HUMAN RELEVANCE. K. B. Paul 1,2 , J. M. 

Hedge 2 , S. O. Simmons 2 , M. J. DeVito 3,1 and K. M. 

Crofton 2,1 . 1 Toxicology, University of North Carolina 

at Chapel Hill, Chapel Hill, NC, 2 Integrated Systems 

Toxicology Division, NHEERL, ORD, U.S. EPA, 

Research Triangle Park, NC and 3 NTP, NIEHS, 



EVALUATION OF SUBSTANCES 

ROUTINELY TAKEN IN EVERYDAY LIFE 

IN THE H295R STEROIDOGENESIS ASSAY. 

H. Tinwell, S. Colombel and R. Bars. Research 

Toxicology, Bayer SAS, Sophia Antipolis Cedex, 

France. 


BISPHENOL A DISRUPTS STEROIDOGENIC 

PATHWAYS AND ADRENAL AND SEX 

HORMONE SECRETION IN THE HUMAN 

ADRENOCORTICAL H295R CELL LINE. A. 

Oskarsson 1 ,. Ohlsson 1 , C. Jansson 2 and E. Ullerås 1 . 

1 

Department of Biomedical Sciences and Veterinary 

Public Health, Swedish University of Agricultural 

Sciences, Uppsala, Sweden and 2 Department 

of Aquatic Sciences and Assessment, Swedish 

University of Agricultural Sciences, Uppsala, 

Sweden. 

Wednesday 







323



Wednesday 



METABOLITE PATTERNS TO 

DIFFERENTIATE DIRECT FROM INDIRECT 

HYPOTHYROID EFFECTS. V. Strauss 1 , E. 

Fabian 1 , M. Herold 2 , H. Kamp 1 , M. Kapp 1 , G. 

Krennrich 1 , R. Looser 2 , W. Mellert 1 , A. Prokoudine 2 , 

T. Walk 2 , J. Wiemer 2 and B. van Ravenzwaay 1 . 

1 

BASF SE, Ludwigshafen, Germany and 

2 

Metanomics, Berlin, Germany. Sponsor: R. Parod. 


TCDD, PCB126, AND PCB153 AFFECT 

HYPOTHALAMIC GNRH AND KISS-1 

SIGNALING IN VITRO, BUT NOT IN VIVO. 

K. Solak, F. Wijnolts, M. van den Berg and M. van 

Duursen. Toxicology, IRAS, Utrecht University, 



TCDD INDUCES BIOMARKERS 

FOR ENDOMETRIOSIS IN HUMAN 

ENDOMETRIUM CARCINOMA CELL LINE. 

K. van Ede, S. Stelloo, M. van den Berg and M. van 

Duursen. Toxicology, IRAS, Utrecht University, 



SODIUM PHENOBARBITAL: ASSESSMENT 

OF PUBERTAL DEVELOPMENT AND 

THYROID FUNCTION IN A COMBINED 

MALE AND FEMALE PUBERTAL ASSAY. 

M. Blanck, H. Vincent, E. Debruyne, A. Veillon, 

E. Balme, C. Pallen and C. Langrand-Lerche. 

Experimental Toxicology, Bayer SAS, Sophia 

Antipolis, France. Sponsor: E. Debruyne. 


ACTIVITY OF LARGE-MOUTH BASS 

ESTROGEN RECEPTORS IN RESPONSE 

TO MODEL COMPOUNDS. R. E. Weil 1 , D. 

S. Barber 2 and N. D. Denslow 2 . 1 Pharmacology, 

University of Florida, Gainsville, FL and 

2 

Physiological Sciences, University of Florida, 



IMPACT OF OSRI ON ANIMAL USE AND 

SCREENING BURDEN FOR TIER I EDSP 

COMPLIANCE. S. C. Gehen 1 and W. R. Jones 2 . 

1 

Dow AgroSciences, LLC, Indianapolis, IN and 

2 

CropLife America, Washington, D.C. 


ORAL EXPOSURE TO BISPHENOL A 

IMPACTS ELECTROCARDIOGRAPHIC 

PARAMETERS IN CD-1 MICE. C. B. Lo, T. 

B. McCutchan, E. L. Kendig and S. M. Belcher. 

Pharmacology, University of Cincinnati, Cincinnati, 

OH. 


INTEGRATING HUMAN AND 

TOXICOLOGICAL EVIDENCE TO 

UNDERSTAND PCB EFFECTS ON THE 

DEVELOPING BRAIN. F. Parham 1 , A. Wise 2 , D. 

A. Axelrad 3 , K. Z. Guyton 3 , C. J. Portier 4 , L. Zeise 5 , 

R. T. Zoeller 6 and T. J. Woodruff 2 . 1 National Institute 

for Environmental Health Science, Research Triangle 

Park, NC, 2 University of California, San Francisco, 

CA, 3 U.S. EPA, Washington, D.C., 4 Centers for 

Disease Control and Prevention, Atlanta, GA, 

5 

California EPA, Oakland, CA and 6 University of 

Massachusetts, Amherst, MA. 


GENISTEIN NEGATES THE INHIBITORY 

EFFECTS OF LETROZOLE ON 

AROMATASE RELATED TO MALIGNANT, 

BUT NOT HEALTHY BREAST TISSUE. M. 

van Duursen 1 , E. de Morree 1 , S. Nijmeijer 1 , P. de 

Jong 2 and M. van den Berg 1 . 1 Institute for Risk 


Netherlands and 2 Department of Internal Medicine, 

St. Antonius Hospital, Nieuwegein, Netherlands. 


EFFECTS OF REDUCED-PHYTOESTROGEN 

DIETS ON DEVELOPMENT OF CD1 AND 

C57BL/6N MICE. E. L. Kendig, S. M. Christie, 

D. R. Buesing, C. K. Cookman, R. B. Gear, C. B. 

Lo and S. M. Belcher. Pharmacology, University of 



DEVELOPMENTAL TOXICITY OF 

O-METHYLATED METABOLITES OF 

BISPHENOL A. K. C. Pangallo, E. Kirichenko, 

K. Cooper and L. A. White. Biochemistry and 

Microbiology, Rutgers University, New Brunswick, 

NJ. 


SERINE PROTEASE INHIBITOR, AEBSF, 

STRONGLY IMPAIRS EXPRESSION OF 

PROINFLAMMATORY IFNγ AND RELATED 

BIOMOLECULES FROM SPLENOCYTES 

FROM ESTROGEN-TREATED C57BL/6 

MICE. E. Karpuzoglu 1 , R. M. Gogal 1 and A. 

Ahmed 2 . 1 Department of Anatomy and Radiology, 

University of Georgia, Athens, GA and 2 Department 

of Biomedical Sciences and Pathobiology, Virginia 

Maryland Regional College of Veterinary Medicine, 

Blacksburg, VA. 


LOW-DOSE BPA ALTERS CA CYCLING AND 

PROMOTES ARRHYTHMOGENESIS IN THE 

FEMALE HEART. S. M. Belcher, S. Yan, Y. Chen, 

M. Dong and H. Wang. Pharmacology, University of 



ARSENITE INHIBITS 3T3-L1 

ADIPOGENESIS AND SUPPRESSES 

INDUCTION OF NUCLEAR RECEPTORS 

DURING THE EARLIEST STAGES OF 

DIFFERENTIATION. F. J. Zandbergen 1 , V. 

Chatikavanij 1 , C. D. Kozul-Horvath 2 and J. W. 

Hamilton 1 . 1 Bay Paul Center, Marine Biological 

Laboratory, Woods Hole, MA and 2 Department of 

Immunology, Dartmouth Medical School, Lebanon, 

NH. 


SCREENING, CLASSIFICATION, AND 

MECHANISM OF ACTION OF ENDOCRINE 

DISRUPTING CHEMICALS. X. Wang, G. Du, 

O. Shen, H. Sun, L. Xu, H. Chen, Y. Xia, A. Gu and 

S. Wang. Nanjing Medical University, Institute of 

Toxicology, Nanjing Jiangsu, China. 

324 






Platform Sessions



Abstract # 


EFFECTS OF CHOLESTEROL-ALTERING 

PHARMACEUTICALS ON CHOLESTEROL 

METABOLISM, STEROIDOGENESIS, AND 

GENE EXPRESSION IN THE FATHEAD 

MINNOW (PIMEPHALES PROMELAS). S. Y. 

Skolness 1,2 , J. Cavallin 2 , E. Durhan 2 , K. Jensen 2 , M. 

Kahl 2 , C. LaLone 2 , E. Makynen 2 , D. Villeneuve 2 , L. 

Wehmas 2 and G. Ankley 2 . 1 University of Minnesota, 

Duluth, MN and 2 U.S. EPA Mid-Continent Ecology 

Division, Duluth, MN. 


RETINOIC ACID MODULATES AHR- 

MEDIATED EFFECTS OF TCDD IN 

OSTEOBLASTIC CELLS. M. Herlin 1 , R. 

Heimeier 1 , M. Korkalainen 2 , M. Viluksela 2 and H. 

Håkansson 1 . 1 Institute of Environmental Medicine, 


2 

National Institute for Health and Welfare, Kuopio, 

Finland. 


DETERMINING STRUCTURAL 

DETERMINANTS OF PHTHALATE 

ANTIANDROGENIC POTENCY IN VITRO 

USING RAT AND MOUSE LEYDIG TUMOR 

CELLS. R. A. Clewell, K. Edwards, J. Campbell, 

H. Clewell and M. Andersen. The Hamner Institutes, 



ISOLATION AND CHARACTERIZATION 

OF CHEMOPREVENTATIVE ANALYTES 

FROM AN ACETONE EXTRACT OF KOLA 

ACUMINATA. J. Wynder 1,2 and W. G. Gray 1,2 . 

1 

Chemistry, Southern University A&M College, 

Baton Rouge, LA and 2 Environmental Toxicology, 

Southern University Baton Rouge, Baton Rouge, LA. 


EFFECT OF NOREPINEPHRINE, 

ENDOGENOUS DOPAMINE, AND 

EXOGENOUS DOPAMINE ON PROLACTIN 

RELEASE IN AN OVARIECTOMIZED RAT 

MODEL. D. A. Brott 1 , P. Campbell 1 , P. Bentley 1 , 

H. Andersson 2 , J. Stewart 3 , R. Huby 3 and L. Kinter 1 . 

1 

Global Safety Assessment, R&D, AstraZeneca 

Pharmaceuticals, Wilmington, DE, 2 Global Safety 

Assessment, R&D, AstraZeneca Pharmaceuticals, 

Södertälje, Sweden and 3 Global Safety Assessment, 

R&D, AstraZeneca Pharmaceuticals, Alderley Park, 



IDENTIFICATION OF ENDOCRINE 

DISRUPTORS USING AN ORGANOTYPIC 

VAGINAL TISSUE MODEL. S. Ayehunie, 

K. LaRosa, T. Landry, J. E. Sheasgreen and M. 

Klausner. MatTek Corp, Ashland, MA. Sponsor: P. 

Hayden. 


EVALUATION OF SUBCHRONIC TOXICITY 

AND ESTROGENIC ACTIVITY OF BLACK 

COHOSH IN FEMALE WEANLING B6C4F1 

MICE EXPOSED BY GAVAGE. M. Mercado- 

Feliciano 1 , M. D. Stout 1 , C. A. Granville 2 , M. 

Hejtmancik 2 , R. Newbold 1 , M. K. Vallant 1 and P. M. 

Foster 1 . 1 National Toxicology Program, NIEHS, 

Research Triangle Park, NC and 2 Battelle Memorial 

Institute, Columbus, OH. 

Abstract # 


IMPLEMENTATION OF TIER I 

MAMMALIAN ASSAYS FOR THE U.S. EPA 

ENDOCRINE DISRUPTOR SCREENING 

PROGRAM (EDSP). S. Papineni 1 , A. Tobia 2 and 

M. S. Marty 3 . 1 Dow AgroSciences, Indianapolis, IN, 

2 

Nufarm Americas, Inc., Cary, NC and 3 The Dow 

Chemical Company, Midland, MI. 


EFFECTS OF FASTING ON ENDOGENOUS 

PTH LEVELS IN CYNOMOLGUS 

MONKEYS. C. Ruh 1 , N. Doyle 1 , P. Bednarek 2 and 

S. Y. Smith 1 . 1 Charles River Laboratories, Senneville, 

QC, Canada and 2 Cytochroma Inc., Markham, ON, 

Canada. 


EFFECTS OF ACUTE AND CHRONIC 

ALCOHOL EXPOSURE ON CELL 

SIGNALING IN BETA-ENDORPHIN (βEP) 

NEURONS OF THE HYPOTHALAMUS. 

L. Louis and S. Dipak. Rutgers University, New 

Brunswick, NJ. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Aquatic and Ecotoxicology 

Chairperson(s): Louis Trombetta, St Johns University, Jamaica, NY, and 

John Christopher, CH2M/Hill, Elk Grove, CA. 




MIXTURES OF ANTI-ANDROGENS 

AT ENVIRONMENTALLY RELEVANT 

CONCENTRATIONS DISPLAY SIGNIFICANT 

ADVERSE EFFECTS ON HORMONES 

AND GENE EXPRESSION COMPARED TO 

SINGLE EXPOSURES AND THE CONTROL. 

J. P. Crago 1 and R. Klaper 2 . 1 Biological Sciences, 

University of Wisconsin Milwaukee, Milwaukee, 

WI and 2 School of Freshwater Sciences, University 

of Wisconsin Milwaukee, Milwaukee, WI. Sponsor: 

R. Hutz. 


COMPARATIVE EVALUATION OF 

THE EFFECTS OF POLYBROMINATED 

DIPHENYLETHER (DE-71) AND ETHYLENE- 

BIS-TETRABROMOPHTHALIMDE (EBTBP) 

ON THYROID HORMONE-MEDIATED 

ANURAN METAMORPHOSIS. D. Fort 1 , 

R. Rogers 1 , P. Guiney 2 and J. Weeks 2 . 1 Fort 

Environmental Labs, Stillwater, OK and 2 SC Johnson 

& Sons, Racine, WI. 

Wednesday 







325



Wednesday 



OECD VALIDATION STUDY ON THE 

TRANSFERABILITY, INTRA- AND INTER- 

LABORATORY REPRODUCIBILITY OF 

THE ZEBRAFISH EMBRYO TOXICITY 

TEST. F. Busquet 1 , S. Belanger 2 , T. Braunbeck 3 , G. 

Carr 2 , M. Halder 1 , A. Kleensang 1 , A. Lillicrap 4 , S. 

Walter-Rohde 5 and P. Amcoff 6 . 1 JRC IHCP ECVAM, 

European Commission, Ispra, Italy, 2 Procter & 

Gamble, Cincinnati, OH, 3 University of Heidelberg, 

Heidelberg, Germany, 4 NIVA, Oslo, Norway, 5 UBA, 

Dessau-Rosslau, Germany and 6 Environment, Health 

and Safety Division, OECD, Paris, France. Sponsor: 

M. Embry. 


HISTOPATHOLOGICAL AND ENZYME 

CHANGES IN CLARIAS GARIEPINUS 

(BURCHELL 1822) EXPOSED TO NITRITE 

AT DIFFERENT WATER TEMPERATURES. 

F. Ajani 1 , B. O. Emikpe 2 and O. K. Adeyemo 3 . 

1 

Animal Science & Fisheries Management, Bowen 

University, lwo, Iwo, Osun, Nigeria, 2 Department of 

Veterinary Pathology, University of lbadan, lbadan, 

Nigeria and 3 Department of Veterinary Public Health 

and Preventive Medicine, University of lbadan, 

lbadan, Nigeria. 


CHEMICAL ACTIVATION OF THE 

NUCLEAR RECEPTOR HR96 IN DAPHNIA 

PULEX BY ENVIRONMENTAL CHEMICALS. 

E. Karimullina 1,3 , Y. Li 1 and W. S. Baldwin 1,2 . 

1 

Environmental Toxicology Program, Clemson 

University, Clemson, SC, 2 Biological Sciences, 

Clemson University, Clemson, SC and 3 Institute 

of Plant & Animal Ecology, Russian Academy of 

Sciences, Ural Branch, Yekaterinburg, Russian 

Federation. 


SIMULTANEOUS QUANTITATION OF 

TESTOSTERONE AND ESTRADIOL 

IN HUMAN CELL LINE (H295R) 

BY LIQUID CHROMATOGRAPHY- 

POSITIVE ATMOSPHERIC PRESSURE 

PHOTOIONIZATION TANDEM MASS 

SPECTROMETRY. F. Zhang, D. L. Rick, L. H. 

Lynn, A. W. Perala, D. R. Geter and M. J. Bartels. 

The Dow Chemical Company, Midland, MI. 


EFFECTS OF PHARMACEUTICALS USED 

FOR BREAST CANCER TREATMENT 

ON REPRODUCTION AND AROMATASE 

ACTIVITY IN A MARINE FISH. L. J. Mills 1 , 

R. Gobell 1 , G. Zaroogian 1 , M. Simoneau 1 , D. Borsay 

Horowitz 1 , M. Hotchkiss 2 , N. Tinfo 2 and S. Laws 2 . 

1 

NHEERL, Atlantic Ecology Division, U.S. EPA, 

Narragansett, RI and 2 NHEERL, Toxicity Assessment 

Division, U.S. EPA, Research Triangle Park, NC. 


THE APPLICATION OF 

THERMOLUMINESCENCE IN 

ECOTOXICOLOGY. G. Repetto 1 , J. L. Zurita 2 , 

M. Roncel 3 and J. Ortega 3 . 1 Biología Molecular e Ing. 

Bioquímica, University Pablo de Olavide, Sevilla, 

Spain, 2 Fundación Progreso y Salud, Sevilla, Spain 

and 3 Instituto de Bioquímica Vegetal y Fotosíntesis. 

University of Sevilla-CSIC, Sevilla, Spain. Sponsor: 

M. Lanaspa. 


TISSUE DISTRIBUTION OF MERCURY IN 

ALASKA SCULPIN SPECIES. S. Bhojwani, 

C. Lieske and T. O’Hara. University of Alaska 

Fairbanks, Fairbanks, AK. 


PROTEOMIC ANALYSIS OF A MODEL 

FISH SPECIES EXPOSED TO INDIVIDUAL 

PESTICIDES AND A BINARY MIXTURE. 

A. D. Biales, D. C. Bencic, K. Blocksom, D. L. 

Lattier, R. Flick and L. Jim. ORD NERL, U.S. EPA, 

Cincinnati, OH. Sponsor: H. Choudhury. 


TRIBUTYLTIN (TBT), AN ENDOCRINE 

DISRUPTOR IN ZEBRAFISH. C. L. McGinnis 

and J. F. Crivello. Physiology and Neurobiology, 



THE EFFECTS OF COPPER PYRITHIONE 

ON DEVELOPING ZEBRAFISH EMBRYOS. 

K. M. Almond and L. D. Trombetta. Pharmaceutical 



TISSUE SPECIFIC EXPRESSION OF 

ORGANIC ANION TRANSPORTING 

POLYPEPTIDES IN NATIVE FISH SPECIES. 

K. Steiner 1 , K. Shigehiro 2 , A. Meyer 2 and D. R. 

Dietrich 1 . 1 Human & Environmental Toxicology, 


2 

Zoology and Evolutionary Biology, University of 

Konstanz, Konstanz, BW, Germany. 


INTERACTIVE EFFECTS OF BENZO(α) 

PYRENE, BENZALKONIUM CHLORIDE, 

AND SEWAGE EFFLUENT ON MEDAKA 

EMBRYOS. A. McElroy and J. Gondek. School 

of Marine and Atmospheric Sciences, Stony Brook 

University, Stony Brook, NY. Sponsor: R. Di Giulio. 


THE GULF OIL CRISIS: IMPACT ON 

WHALES. S. S. Wise 1,2,3 , I. Kerr 2,4 , J. P. Wise 1,2,4 , C. 

F. Wise 1,2,4 , J. Wise 1,2,4 , C. Gianios 1,2,4 , M. Braun 1,2,4 , 

B. Wallace 4 , I. Glass 4 , R. Walker 4 , C. LaCerte 1,2,4 , 

J. McKay 1,2,4 , T. Li Chen 1,2,4 , J. Martino 1,2,4 , G. 

Chapman 1,2,4 , R. Duffy 1,2,4 , R. Leighton 1,2,4 , K. 

Joyce 1,2,4 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 






Maine, Portland, ME and 4 Ocean Alliance, Lincoln, 

MA. 


IMPOSEX IN PLICOPURPURA PANSA 

(MOLLUSCA:NEOGASTROPODA) AS 

A POTENTIAL MARINE POLLUTION 

BIOINDICATOR IN NAYARIT AND 

SINALOA, MEXICO. D. Domínguez 1 , A. 

Patron 2,1 , L. Robledo 1 , J. Velazquez 1 and B. 

Quintanilla 3,1 . 1 Laboratorio de Toxicologia, 

Universidad Autónoma de Nayarit, Tepic, Nayarit, 

Mexico, 2 Fisiologia, Universidad Autonoma de 

Mexico, DF, Mexico and 3 Toxicologia, Cinvestav, 

DF, Mexico. 

326 






Platform Sessions



Abstract # 


IN VITRO METABOLISM OF DIAZEPAM 

IN CHANNEL CATFISH (ICTALURUS 

PUNCTATUS). C. Overturf and D. Huggett. 

University of North Texas, Denton, TX. 


QUEEN CONCH (STROMBUS GIGAS) 

REPRODUCTIVE DYSFUNCTION IN 

NEARSHORE AREAS OF THE FLORIDA 

KEYS – A POSSIBLE LINK TO CU AND ZN. 

D. Spade 1 , A. Feswick 1 , R. A. Glazer 2 , D. S. Barber 1 

and N. D. Denslow 1 . 1 Center for Environmental 

and Human Toxicology, University of Florida, 

Gainesville, FL and 2 Fish and Wildlife Research 

Institute, Florida Fish and Wildlife Conservation 

Commission, Marathon, FL. 


COAL MINING INDUCES OXIDATIVE 

STRESS, DNA DAMAGE, AND 

ALTERATIONS IN RED BLOOD CELL 

MORPHOLOGY IN WILD MICE. A. Guerrero- 

Castilla 1 , J. Olivero-Verbel 1 , M. Cabarcas-Montalvo 1 , 

H. Corrales-Aldana 1 , M. Guerra-Hernandez 1 , L. 

Carranza-Lopez 1 and M. Moreno-Contreras 2 . 

1 

Environmental and Computational Chemistry 

Group, University of Cartagena, Cartagena, 

Colombia and 2 Popular University of Cesar, 

Valledupar, Colombia. 


LEAD POISONING FROM INGESTED 

AMMUNITION IS PRECLUDING 

RECOVERY OF THE ENDANGERED 

CALIFORNIA CONDOR. M. Finkelstein 1 , 

D. Doak 2 , J. Grantham 4 , D. George 3 and D. R. 

Smith 1 . 1 University of California, Santa Cruz, CA, 

2 

University of Wyoming, Laramie, WY, 3 NPS, 

Pinnacles National Monument, CA and 4 U.S. Fish 

and Wildlife Service, Ventura, CA. 


OCCURRENCE OF SSRI’S IN PUGET 

SOUND STREAMS AND EFFECTS ON FISH: 

AN INTEGRATED FIELD AND LAB STUDY. 

I. Schultz 1 , E. Walters 2 , M. Sroufe 3 and J. Nagler 4 . 

1 

Battelle PND, Sequim, WA, 2 Battelle PND, Sequim, 

WA, 3 Battelle PND, Sequim, WA and 4 Biological 

Sciences, University of Idaho, Moscow, ID. 


DROSOPHILA AS A MODEL TO 

DISSECT THE SIGNALING PATHWAY 

MEDIATING THE TOXICITY OF FUNGAL 

VOLATILE ORGANIC COMPOUNDS IN 

DOPAMINERGIC NEURONS. A. A. Inamdar 

and J. W. Bennett. Rutgers University, New 

Brunswick, NJ. Sponsor: J. Richardson. 


COMPARATIVE RESPONSES TO 

DIPHENHYDRAMINE IN TWO FISH 

MODELS. J. Berninger, B. W. Brooks and B. Du. 

Baylor University, Waco, TX. 

Abstract # 


BEHAVIORAL, REPRODUCTIVE, 

AND GENOMIC RESPONSES TO 

NEUROPHARMACEUTICALS AT 

SUBCLINICAL CONCENTRATIONS 

FOUND IN THE ENVIRONMENT: FISH AS 

INDICATORS OF POTENTIAL HUMAN 

CONSEQUENCES OF LOW-DOSE 

EXPOSURES. R. Klaper. School of Freshwater 


Milwaukee, WI. Sponsor: R. Hutz. 


TOXICOLOGICAL MECHANISMS OF 

AZASPIRACID: AN EMERGING ALGAL 

TOXIN IN U.S. WATERS. M. Twiner 1 , P. Hess 2 , 

R. El-Ladki 1 , S. Butler 1 and G. Doucette 3 . 1 Natural 

Sciences, University of Michigan, Dearborm, MI, 

2 

Département Environnement, Microbiologie & 

Phycotoxines, IFREMER, Nantes, France and 

3 

Marine Biotoxins Program, NOAA/National Ocean 

Service, Charleston, SC. 


SEASONAL DYNAMICS OF COLORED 

DISSOLVED ORGANIC MATTER IN THE 

LENA, MACKENZIE, AND YENESEI 

RIVERS. K. E. Goodman 2 , S. A. Walker 1 and R. 

W. Amon 1 . 1 Marine Science, Texas A&M University, 

Galveston, TX and 2 Natural Sciences, Albany State 

University, Albany, GA. Sponsor: L. Wrensford. 


EFFECTS OF PCB CONTAMINATION ON 

ACTIVITIES OF OXIDATIVE STRESS 

ENZYMES IN S. ATROMACULATUS LIVERS. 

K. Shortt 1 , D. Sparks 2 , D. Millsap 2 and J. B. Watkins 1 . 

1 

Indiana University, Bloomington, IN and 2 U.S. Fish 

and Wildlife, Bloomington, IN. 


THE TOXIC EFFECTS OF CHROMIUM 

COMPOUNDS IN NORTH ATLANTIC 

RIGHT WHALE, AND SPERM WHALE 

CELLS. T. Li Chen 1,2,3 , J. Martino 1,2,3 , S. S. Wise 1,2,3 , 

C. LaCerte 1,2,3 , F. Shaffiey 1,2 , H. Xie 1,2,3 , A. L. 

Holmes 1,2,3 , K. McPhearson 1,2 , I. Kerr 4 , R. Payne 4 , 

S. D. Kraus 5 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 






Maine, Portland, ME, 4 Ocean Alliance, Lincoln, MA 

and 5 Edgerton Research Laboratory, New England 

Aquarium, Boston, MA. 


TOXICITY AND BIOACCUMULATION 

OF MERCURY (II) CHLORIDE IN TWO 

GENERA OF EARTHWORMS. A. C. Nichols 

and D. A. Steffy. Physical and Earth Sciences, 

Jacksonville State University, Jacksonville, AL. 

Wednesday 







327



Wednesday 



COMPARISON OF CHROMIUM TOXICITY 

ON HUMAN, STELLER SEA LION, SPERM 

WHALE, AND NORTHERN RIGHT WHALE 

SKIN CELLS. C. LaCerte 1,2,3 , T. Li Chen 1,2,3 , A. 

Holmes 1,2,3 , S. Wise 1,2,3 , S. Kraus 4 , F. Gulland 5 and 

J. P. Wise 1,2,3 . 1 Wise Laboratory of Environmental 






Portland, ME, 4 Edgerton Research Laboratory, New 

England Aquarium, Boston, MA and 5 The Marine 

Mammal Center, Sausalito, CA. 


CYTOTOXIC AND MUTAGENIC EFFECTS 

OF THE HAIR DYE REACTIVE RED 

51 AND ITS DEGRADATION USING 

PHOTOELECTROCATALYSIS. T. B. Zanoni 1 , 

D. P. Oliveira 1 , L. E. Fraga 2 , M. B. Zanoni 2 and N. R. 

Pissuti 1 . 1 Universidade de São Paulo, Ribeirão Preto, 

Brazil and 2 Quimica Analítica, UNESP, Araraquara, 

São Paulo, Brazil. 


COMPARISON BETWEEN THE 

EFFICIENCY OF TREATMENTS BY 

PHOTOELECTROCATALYSIS AND 

CONVENTIONAL CHLORINATION UNDER 

AQUATIC TOXICITY ENDPOINT. E. A. 

Ferraz 1 , T. M. Lizier 2 , M. B. Zanoni 2 and D. P. 

Oliveira 1 . 1 Faculdade de Ciências Farmacêuticas 

de Ribeirão Preto - Universidade de São Paulo, 

Ribeirão Preto, São Paulo, Brazil and 2 Universidade 

Estadual Paulista Júlio de Mesquita Filho - UNESP, 

Araraquara, São Paulo, Brazil. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Food Safety and Nutrition 

Chairperson(s): William Tolleson, U.S. FDA, Jefferson, AR, and Edmond 

Creppy, University of Bordeaux, Bordeaux, France. 




MULTIPLE ANALYSES OF MEAT 

CONTENTS IN CANNED DOG FOOD AND 

VEGAN BONE TREATS. M. Hsieh 2 , C. Chou 1 , P. 

Shih 1 and H. Hsieh 2 . 1 Veterinary Medicine, National 

Chung-Hsing University, Taichung, Taiwan and 

2 

Graduate Institute of Microbiology and Public 

Health, National Chung Hsing University, Taichung, 

Taiwan. 


ELUCIDATING THE MECHANISM OF 

VITAMIN A UPTAKE IN TUMOR-PRONE, 

VITAMIN A-SENSITIVE TISSUES. C. E. 

Schulte 1,2 and M. J. Rowling 1 . 1 Food Science and 

Human Nutrition, Iowa State University, Ames, 

IA and 2 Interdepartmental Graduate Program in 

Toxicology, Iowa State University, Ames, IA. 

Sponsor: S. Hendrich. 


VITAMIN D STATUS MAY BE 

COMPROMISED BY THE CONSUMPTION 

OF FOODS RICH IN PCBS AND DIOXINS: 

RESULTS FROM A POPULATION WITH A 

WIDE RANGE OF SEAFOOD INTAKE—THE 

NORWEGIAN FISH AND GAME STUDY. M. 

A. Haugen, B. Birgisdottir, A. Brantsæter, H. K. 

Knutsen, H. E. Kvalem, J. Alexander and H. M. 

Meltzer. Department of Food Safety and Nutrition, 

Norwegian Institute of Public Health, Oslo, Norway. 

Sponsor: M. Løvik. 


ULTRAVIOLET LIGHT (254 NM) 

INACTIVATION OF FOODBORNE 

PATHOGENS ON FOODS AND STAINLESS 

STEEL SURFACES. D. M. Barton 1 , P. Landrio 1 , 

D. E. Fulford 1 , W. J. Mackay 1 , J. E. Sites 2 , M. 

Musgrove 2 and C. H. Sommers 2 . 1 Biology & Health 

Services, Edinboro University of Pennsylvania, 

Edinboro, PA and 2 Food Safety Intervention 

Technologies Research Unit, U.S. Department of 

Agriculture, Wyndmoor, PA. 


CHARACTERIZATION OF SHIGA- 

LIKE PROTEIN TOXINS I AND II FROM 

ESCHERICHIA COLI O157:H7. K. Nguyen 1 , W. 

H. Tolleson 1 , A. Mugengana 2 and W. B. Melchior 1 . 

1 



2 

Department of Chemistry, Philander Smith College, 



ADULTERATION OF COMMERCIAL 

FRUIT JUICES DETECTED BY HPAEC- 

CD. M. Wilson 1 and W. R. LaCourse 2 . 1 Toxicology, 

University of Maryland Baltimore, Baltimore, MD 

and 2 Chemistry and Biochemistry, University of 

Maryland Baltimore County, Baltimore, MD. 


EVALUATION OF ARISTOLOCHIC 

ACID DERIVATES IN MILK BY LIQUID 

CHORMATOGRAPHY TANEM MASS 

SPECTROMETRY. C. Juan 1,2 , A. Rittieni 1 , A. 

Juan-Garcia 3 , G. Font 2 and J. Mañes 2 . 1 Scienza 

degli Alimenti, Università di Napoli “Federico II”, 

Portici, Italy, 2 Medicina Preventiva i Salut Publica, 

Ciencies de l’ Alimentació, Toxicologia I Medicina 

Legal, Valencia University, Burjassot, Valencia, 

Spain and 3 Basic Medical Science, Purdue University 

Cytometry Laboratories, West Lafayette, IN. 


RETAINED BACTERICIDAL ACTIVITY 

OF DIPHENYLIODONIUM CHLORIDE 

IMPREGNATED IN ALGINATE BEADS 

FOLLOWING EXPOSURE TO STOMACH- 

SIMULATING PH CONDITIONS. S. V. Epps 1 , 

N. A. Krueger 2 , T. D. Phillips 1 , R. B. Harvey 2 , 

J. Taylor 1 , R. C. Anderson 2 and D. J. Nisbet 2 . 

1 

Veterinary Integrative Biosciences/Toxicology, 

Texas A&M University, College Station, TX and 

2 

USDA/ARS, Southern Plains Agricultural Research 

Center, College Station, TX. 

328 






Platform Sessions



Abstract # 


ACUTE AND SUB-CHRONIC TOXICITY 

OF USNIC ACID IN MICE AND RATS. J. E. 

Seng 1 , A. Babb 1 , A. Ali 1 , S. M. Lewis 2 , H. Badgley 1 , 

G. Olson 1 and J. E. Leakey 2 . 1 Toxicologic Pathology 

Associates, Jefferson, AR and 2 Office of Scientific 

Coordination, National Center for Toxicological 

Research, Jefferson, AR. 


NOVEL FEEDING BIOASSAY 

FOR CHARACTERIZATION OF 

DEOXYNIVALENOL-INDUCED FEED 

REFUSAL IN THE MOUSE. B. Flannery 1,2 and 

J. Pestka 1,3 . 1 Food Science and Human Nutrition, 


2 

Center for Integrative Toxicology, Michigan State 

University, East Lansing, MI and 3 Microbiology and 


Lansing, MI. 


COMPARISON OF THE DOSE-RESPONSES 

OF 7- AND 28-DAY CO-EXPOSURES TO 

MELAMINE AND CYANURIC ACID IN 

F344 RATS. G. Gamboa da Costa 1 , C. C. Jacob 1 , 

L. VonTungeln 1 , G. Olson 4 , D. G. Hattan 3 , R. 

Reimschuessel 2 and F. A. Beland 1 . 1 U.S. FDA 

National Center for Toxicological Research, 

Jefferson, AR, 2 U.S. FDA Center for Veterinary 

Medicine, Laurel, MD, 3 U.S. FDA Center for Food 

Safety and Applied Nutrition, College Park, MD and 

4 

Toxicologic Pathology Associates, Jefferson, AR. 


A 90-DAY DIETARY TOXICITY STUDY 

OF R, R-MONATIN SALT, A NATURAL 

HIGH POTENCY SWEETENER, IN RATS. 

J. Hlywka 1 , W. A. Brathwaite 1 , A. I. Nikiforov 2 , 

M. L. Rihner 2 and A. K. Eapen 3 . 1 Cargill Inc., 

Wayzata, MN, 2 Toxicology Regulatory Services, 

Charlottesville, VA and 3 WIL Research Laboratories 

LLC, Ashland, OH. 


EVALUATION OF THE HYPERSENSITIVITY 

POTENTIAL OF ALTERNATIVE BUTTER 

FLAVORINGS: ARE THEY SAFE 

SUBSTITUTES FOR DIACETYL? S. Anderson, 

J. Franko, E. Lukomska and B. J. Meade. NIOSH, 



BEAUVERICIN-INDUCED OXIDATIVE 

STRESS IN CHO-K1 CELLS IS PREVENTED 

BY VITAMINS AND FLAVONOIDS. G. 

Font 1 , L. Haro 1 , J. Mañes 1 , A. Anadón 2 and M. J. 

Ruiz 1 . 1 Laboratorio de Toxicología, Universidad de 

Valencia, Burjassot, Valencia, Spain and 2 Department 

of Toxicology and Pharmacology, Faculty of 

Veterinary Medicine, Universidad Complutense, 

Madrid, Spain. 


SIMULTANEOUS DETERMINATION OF 

TYPE B TRICHOTHECENE MYCOTOXINS 

AND THEIR DERIVATIVES IN WHEAT 

BY LC/MS/MS. T. Kadota 1 , M. Kimura 2 , S. 

Hirano 1 , O. Tajima 1 , T. Nakajima 3 , Y. Kamata 4 

and Y. Sugita-Konishi 4 . 1 Kirin Holdings Co., Ltd., 

Kanagawa, Japan, 2 RIKEN ASI, Saitama, Japan, 

3 

National Agricultural Research Center for Kyushu- 

Okinawa Region, Kumamoto, Japan and 4 Division. 

Microbiology, NIHS Japan, Tokyo, Japan. 

Abstract # 


EFFECTS OF FUMONISINS IN ETHANOL 

PRODUCTION. E. Bilsten and G. Munkvold. 

Plant Pathology, Iowa State University, Ames, IA. 


COMBINATIVE TOXICITY OF MYCOTOXIN 

MIXTURES IN ANIMALS AND HUMAN 

CELLS. G. Qian, L. Tang and J. Wang. 

Environmental Health Science, University of 

Georgia, Athens, GA. 


MYCOTOXINS MULTI-CONTAMINATION 

OF PRESCHOOL AGE CHILDREN IN 

BENIN: PRELIMINARY STUDY IN THE ZOU 

REGION. E. E. Creppy 1 , J. Tabe-Dumond 1,2 , S. 

Moukha 1,2 and B. Sangare-Tigori 1,3 . 1 Toxicology, 

University Bordeaux 2, Bordeaux, France, 

2 

Toxicology, University Bordeaux 2, Bordeaux, 

Gironde, France and 3 Toxicology Department, 

University of Abidjan, Abidjan, CÙte d’Ivoire. 


PYRROCIDINE A TOXICITY IN MICE. S. 

Hooser 1 , C. R. Wilson 1 , G. N. Burcham 1 , W. M. 

Haschek-Hock 2 and D. T. Wicklow 3 . 1 Animal 

Disease Diagnostic Laboratory, Purdue University, 

West Lafayette, IN, 2 Department of Pathobiology, 

University of Illinois, Urbana, IL and 3 Bacterial 

Foodborne Pathogens and Mycology Research Unit, 

USDA ARS, Peoria, IL. 


FOOD ANTIOXIDANTS HAVING NO, 

OR WELL-SPECIFIED, LEVELS OF 

ESTROGENIC ACTIVITY (EA). C. Z. Yang 1 

and G. Bittner 1,2,3 . 1 CertiChem, Inc., Ausin, TX, 

2 

PlastiPure, Austin, TX and 3 University of Texas, 

Austin, TX. Sponsor: R. Tice. 


TOXICITY OF RIBBON WORM 

CEPHALOTHRIX SPECIES ON THE 

SURFACE OF THE SHELL OF CULTURED 

OYSTERS IN HIROSHIMA BAY, 

HIROSHIMA PREFECTURE, JAPAN. M. 

Asakawa. Graduate Schoool of Biosphere Science, 

Hiroshima University, Higashi-Hiroshima, Japan. 


DIFFERENTIAL HEAT STABILITY OF 

RACTOPAMINE IN LIQUID AND PROTEIN 

MATRICES. C. Chou 1 , P. Lan 1 , M. Hsieh 2 and W. 

Chang 3 . 1 Veterinary Medicine, National Chung-Hsing 

University, Taichung, Taiwan, 2 Graduate Institute of 

Microbiology and Public Health, National Chung- 

Hsing University, Taichung, Taiwan and 3 Animal 

Disease Diagnostic Center, National Chung-Hsing 

University, Taichung, Taiwan. 


STABILIZING EFFECTS 

OF PH, GALACTOSE, AND 

EXOPOLYSACCHARIDES ON THERMAL 

INACTIVATION OF RICIN IN FOODS. W. 

H. Tolleson 1 , O. A. Triplett 1 and L. S. Jackson 2 . 

1 



2 

National Center for Food Safety and Technology, 

Summit-Argo, IL. 

Wednesday 







329



Wednesday 



A KINETIC STUDY OF THERMAL 

INACTIVATION OF THE BIOTERRORISM 

AGENT RICIN IN FOODS FOR INFANTS 

AND SMALL CHILDREN. O. A. Triplett 1 , 

W. H. Tolleson 1 and L. S. Jackson 2 . 1 Division of 

Biochemical Toxicology, National Center for 

Toxicological Research, Jefferson, AR and 2 National 

Center for Food Safety and Technology, Summit- 

Argo, IL. 


OCTOPUS AS A FOOD PRODUCT: A 

SIGNIFICANT SOURCE OF ESSENTIAL 

ELEMENTS (CU AND CR) AND HUMAN 

EXPOSURE TO TOXIC ELEMENTS (PB). 

L. Saldivar 1 , T. Rodríguez-S 1 , M. Castilla-M 1 , M. 

A. Zezzi-A 2 and F. Barbosa-J 3 . 1 Chemistry Faculty, 

Universidad Nacional Autónoma de México, 

Universitaria, D.F., Mexico, 2 Chemistry Institute, 

State University of Campinas, Campinas, Sao Paulo, 

Brazil and 3 Faculty of Pharmaceutical Sciences, 

University of Sao Paulo, Ribeirao Preto, Sao Paulo, 

Brazil. Sponsor: D. Acosta. 


DETERMINATION OF TOXIN 

CONTAMINATION IN DIETARY 

SUPPLEMENTS MARKETED IN GERMANY. 

A. H. Heussner 1 , J. Fastner 2,1 and D. R. Dietrich 1 . 

1 

Human & Environmental Toxicology, University of 

Konstanz, Konstanz, Germany and 2 Section II 3.3 - 

Drinking-Water Resources and Treatment, Federal 

Environmental Agency, Berlin, Germany. 


SPIRULINA: TRANSITION FROM 

POOR MAN’S FOOD TO A DIETARY 

SUPPLEMENT. J. C. Griffiths, G. I. Giancaspro 

and N. Sarma. Documentary Standards, U.S. 

Pharmacopeia, Rockville, MD. 


FIFTY YEARS OF CHANGE: FATE AND 

FORTUNE OF SELENIUM AND MERCURY. 

J. C. Griffiths 1 , S. A. Jordan 2 and T. L. Cecil 1 . 1 United 

States Pharmacopeia, Rockville, MD and 2 Health 

Canada, Ottawa, ON, Canada. 


RISK ASSESSMENT OF CHICORY ROOT 

EXTRACT AS A FOOD INGREDIENT. R. 

A. Matulka and G. A. Burdock. Burdock Group, 

Orlando, FL. 


USP COMPENDIAL MONOGRAPHS FOR 

DIETARY SUPPLEMENTS: HELPING TO 

ENSURE PRODUCT QUALITY—BLACK 

COHOSH AS A CASE STUDY. N. D. Sarma 1 , 

G. I. Giancaspro 1 , M. Sharaf 1 , J. C. Griffiths 1 , 

S. A. Jordan 2 and R. J. Marles 2 . 1 United States 

Pharmacopeia, Rockville, MD and 2 Health Canada, 

Ottawa, ON, Canada. 


SAFETY ASSESSMENT OF FOOD 

INGREDIENTS ORIGINATING FROM 

GENETICALLY MODIFIED BACTERIA. L. 

Dolan and G. A. Burdock. Burdock Group, Orlando, 

FL. 


APPROACH FOR DETERMINING IF 

DATA ON HETEROLOGOUS STRAINS OF 

SIMILAR SPECIES WOULD SUPPORT 

THE SAFETY OF A PARTICULAR STRAIN 

WHERE DATA ARE LACKING. S. Choi, K. 

Howse and A. Roberts. Cantox Health Sciences 

International, Mississauga, ON, Canada. Sponsor: L. 

Haighton. 


COMPOSITION OF MULTIPLE LOTS OF 

EVENING PRIMROSE OIL COMPARED 

WITH CORN OIL. T. Cristy 1 , S. Graves 1 , V. 

G. Robinson 2 and C. Smith 2 . 1 Battelle Memorial 

Institute, Columbus, OH and 2 National Institute of 


Park, NC. 


MINERAL CONTENT OF COMMONLY 

INGESTED BEVERAGES AND BOREHOLE 

WATER IN NNEWI, NIGERIA. O. Orisakwe 1 , 

H. Enuh 2 , N. Ekwo 2 , V. Obidile 2 and A. Ibekie 2 . 

1 

University of Port Harcourt, Rivers State, Nigeria, 

Port Harcourt, Nigeria and 2 Nnamdi Azikiwe 

University, Nnewi, Nigeria. 


1:00 PM to 2:00 PM 

Room 140A 

Exhibitor Hosted Session: Electric Cell-Substrate Impedance 

Sensing: A Label Free, Non-Invasive Method of Cell 

Measurement 

Presented by: Applied BioPhysics, Inc. 

An overview of the use of impedance (both simple and complex) to 

detect cell morphological changes. Emphasis will be placed on the use of 

difference AC frequencies to distinguish cell parameters. Various ECIS 

applications will be discussed including proliferation, cell invasion, automated 

cell migration, barrier function, toxicology and signal transduction. 


1:15 PM to 2:15 PM 

Room 201 

Meet the Director: Center for Scientific Review Director 

Chairperson(s): Cheryl Lyn Walker, University of Texas M.D. 

Anderson Cancer Center, Smithville, TX. 

Lecturer: Sy Garte, Center for Scientific Review, Bethesda, MD. 

The Center for Scientific Review (CSR) is the portal for NIH 

grant applications and their review for Scientific merit. The recent 

history of the peer review process for toxicology and environmental 

health sciences grant applications will be discussed, including the 

experience of the pilot Special Emphasis Panel (SEP) on Systemic 

Injury from Environmental Exposure (SIEE). Analysis of data, 

and lessons learned from this pilot will be presented. Alternative 

approaches, geared toward ensuring the optimum quality and 

fairness of review for toxicology grants will be described, and 

preliminary results from recent review cycles will be shared. 

The presentation will include an interactive segment, whereby audience 

members will be encouraged to share their experiences with the peer 

review process, and contribute ideas for improvement. 

330 






Platform Sessions



Abstract # 


1:30 PM to 4:15 PM 

Room 147 

Symposium Session: Autophagy in Toxicology: Essential 

Process, Adaptive Process, and Disease Process 

Chairperson(s): Walter Klimecki, Universtiy of Arizona, Tucson, AZ, and 

Joel Meyer, Duke University, Durham, NC. 

Sponsor: 


Endorsed by: 




Autophagy is a cellular process by which organelles, cytoplasm, and specific 

proteins are delivered to the lysosome where they are degraded. Autophagy 

has been described for at least four decades, but the scope and the importance 

of this programmed cellular response have only recently come into 

focus, heralded by an exponential increase in autophagy publications. One 

clear message that is emerging from these early studies of autophagy is 

its relevance to the field of toxicology. Diverse xenobiotics are capable of 

perturbing autophagy, with effects ranging from autophagy induction to 

complete inhibition. The functional consequences of these perturbations are 

complex: in some instances autophagy induction is cytoprotective, however 

in some instances its induction is a cell death pathway. The significance of 

autophagy to toxicology is underscored by its fundamental role in biology. 

It is an ancient process. Many autophagy pathway members were initially 

characterized in Saccharomyces cerevisiae, where autophagy can be induced 

by nutrient deprivation. In Drosophila melanogaster autophagy plays a 

critical role in embryonic development, responding to steroid signaling 

pathways by executing programmed cell death. In species from Caenorhabditis 

elegans to Homo sapiens autophagy plays a key role in mitochondrial 

dynamics and in clearing damaged mitochondria. In the immune system 

autophagy is critical to antigen presentation, the development of regulatory 

and effector functions, and the acquisition of tolerance. Thus, autophagy 

plays an evolutionarily conserved role in multiple biological processes. The 

ability of environmental stress and xenobiotics such as inorganic arsenic 

to modulate autophagy points to the need for an appreciation of this longknown, 

but poorly understood, pathway in toxicology. 

#2444 1:30 OVERVIEW. W. Klimecki. University of Arizona, 

Tucson, AZ. 

#2445 1:45 AUTOPHAGY IN DEVELOPMENT: A 

LIFE OR DEATH DECISION. E. Baehrecke. 

Department of Cancer Biology, University of 

Massachusetts Medical School, Worcester, MA. 

Sponsor: W. Klimecki. 

#2446 2:15 AUTOPHAGY IN IMMUNITY AND 

INFLAMMATION. V. Deretic. Department. of 

Molecular Genetics and Microbiology, University 

of New Mexico, Albuquerque, NM. Sponsor: W. 

Klimecki. 

#2447 2:45 ARSENIC, AUTOPHAGY, AND 

IMMUNOTOXICITY. W. Klimecki, R. M. 

Douglas, F. Zhao and A. M. Bolt. Department 



#2448 3:15 THE ROLES OF MITOCHONDRIAL FUSION, 

FISSION, AND AUTOPHAGY IN REMOVING 

DAMAGED MITOCHONDRIAL DNA. J. 

Meyer. Duke University, Durham, NC. 

Abstract # 

#2449 3:45 MITOPHAGY AS A MECHANISM OF 

MITOCHONDRIAL TURNOVER AND 

QUALITY CONTROL. J. J. Lemasters. 

Pharmaceutical & Biomedical Sciences and 

Biochemistry & Molecular Biology, Medical 



1:30 PM to 4:15 PM 

Room 150 




Symposium Session: Human Pluripotent Stem Cells and 

Neural Progenitors As Models of Gene-Environment 

Interactions in Neurological Disease 

Chairperson(s): Aaron Bowman, Vanderbilt University, Nashville, TN, 

and Pamela J. Lein, University of California Davis, Davis, CA. 

Sponsor: 


Endorsed by: 



A complex relationship of environmental and genetic risk factors underlies 

many neurodevelopmental and neurodegenerative diseases, yet identification 

of causative factors has been severely hampered by the lack of rigorous 

experimental models that incorporate the combinatorial influence of diverse 

toxicants and the inherent genetic variation in human susceptibility and 

exposure. This complexity and the likelihood that the balance of genetic 

and environmental influences varies tremendously between individuals also 

complicate epidemiological studies aimed at identifying environmental risk 

factors for specific neurological diseases. The increasing availability and 

characterization of human neuroprogenitor cells has accelerated the development 

of models for high- throughput screening for chemicals with potential 

adverse effects on the developing human nervous system. The more recent 

development of induced pluripotent stem cell (iPSC) technology now 

permits the establishment of differentiated in vitro cultures of patientspecific 

neurons to assess susceptibility to neurotoxicants. The advantage of 

this approach is that environmental risk may be evaluated without a priori 

knowledge of an individual’s genetic risk factors. A number of technical and 

theoretical hurdles need to be overcome before the full potential of these 

approaches can be realized. Thus it is important to highlight the newest 

research by experts in this burgeoning field to frame the possibilities of 

iPSC technology and human neural progenitors for the study of genetic and 

environmental risk factors that influence the susceptibility to and progression 

of neurological diseases. In conclusion, the potential human iPSC 

approaches offer for translational toxicology and assessment of human risk 

factors will be discussed. 

#2450 1:30 HUMAN PLURIPOTENT STEM CELLS AND 

NEURAL PROGENITORS AS MODELS OF 

GENE-ENVIRONMENT INTERACTIONS IN 

NEUROLOGICAL DISEASE. A. B. Bowman 1 

and P. J. Lein 2 . 1 Neurology, Vanderbilt University, 

Nashville, TN and 2 Molecular Biosciences, 


Medicine, Davis, CA. 

1:30 INTRODUCTION. Aaron Bowman 

#2451 1:35 APPLICATIONS OF HUMAN STEM CELL 

TECHNOLOGY TO NEUROTOXICOLOGY. 

P. J. Lein. VM: Molecular Biosciences, University of 


Wednesday 







331



Wednesday 


#2452 2:07 USING NEURAL PROGENITOR CELLS 

IN HIGH-THROUGHPUT SCREENS FOR 

DEVELOPMENTAL NEUROTOXICANTS: 

TRIUMPHS AND TRAGEDIES. T. J. Shafer, M. 

Culbreth, J. M. Breier and W. R. Mundy. Integrated 

Systems Toxicology, U.S. EPA, Research Triangle 

Park, NC. 

#2453 2:39 TRENDS OF THE IPSC TECHNOLOGY 

FOR BIOMEDICAL RESEARCH AND CELL 

THERAPY: POTENTIAL OF PROTEIN- 

INDUCED IPSCS. K. Kim. McLean Hospital/ 

Harvard Medical School, Belmont, MA. Sponsor: A. 

Bowman. 

#2454 3:11 IN VITRO MODELS OF ANGELMAN 

AND PRADER-WILLI SYNDROME VIA 

INDUCED PLURIPOTENT STEM CELL 

TECHNOLOGY. M. Lalande. Genetics and 

Developmental Biology, University of Connecticut 

Health Center, Farmington, CT. 

#2455 3:43 PATIENT-DERIVED STEM CELLS AS 

A TRANSLATIONAL MODEL FOR 

NEUROTOXICOLOGICAL RISK. A. B. 

Bowman. Neurology, Vanderbilt University, 



1:30 PM to 4:15 PM 

Room 145 



Symposium Session: The Use of Epidemiological Data and 

PBPK Modeling in a Risk Assessment: Manganese As a Case 

Study 

Chairperson(s): Harvey J. Clewell, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, and Daniel Krewski, University of 

Ottawa, Ottawa, Ontario, Canada. 

Sponsor: 


Endorsed by: 




Manganese (Mn) is an essential element that is neurotoxic at high exposures. 

In recent years there has been increasing use of PBPK modeling in quantitative 

risk assessments to support animal-to-human extrapolation when human 

risk estimates are based on animal studies. However, any risk assessment 

for the neurological effects of Mn would likely be based on epidemiological 

data from occupational exposures to inhaled Mn in dust. Nevertheless, the 

risk assessment for manganese (Mn) provides an opportunity to apply PBPK 

modeling in a different aspect of quantitative risk assessment: replacing 

default uncertainty factors with chemical-specific adjustment factors. The 

critical issues in a Mn risk assessment based on occupational epidemiology 

data are the nature and extent of the uncertainty factors that should be 

applied to account for uncertainties regarding interindividual variability, 

susceptible sub-populations, duration of exposure, and different forms 

of Mn. We will describe the epidemiological evidence for the neurotoxic 

effects of Mn and explore the use of PBPK models for Mn in adult and 

perinatal animals and humans to predict the effect of key sources of uncertainty 

on the target tissue Mn dose, elucidate the dose-dependent mode of 

action for the neurological effects of Mn, and quantify the impact of human 

variability, life-stage, and other uncertainties on risks estimated from occupational 

epidemiology studies. 

#2456 1:30 THE USE OF EPIDEMIOLOGICAL 

DATA AND PBPK MODELING IN A RISK 

ASSESSMENT: MANGANESE AS A CASE 

STUDY. H. J. Clewell 1 , M. Andersen 1 , V. Tait 2 , 

H. Roels 3 and W. Boyes 4 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, 

NC, 2 University of Ottawa, Ottawa, ON, Canada, 

3 

Université Catholique de Louvain, Brussels, 

Belgium and 4 U.S. EPA, Research Triangle Park, NC. 

1:30 INTRODUCTION. Harvey Clewell 

#2457 1:35 COLLECTION OF CHEMICAL- 

SPECIFIC TOXICOLOGICAL AND 

PHARMACOKINETIC DATA TO IMPROVE 

RISK ASSESSMENTS BASED ON 

EPIDEMIOLOGY: EXAMPLE OF MN. W. K. 

Boyes. U.S. EPA, Research Triangle Park, NC. 

#2458 2:07 BIOMARKERS OF EXPOSURE TO 

MANGANESE AND PROSPECTIVE 

STUDIES OF ITS NEUROTOXIC EFFECTS 

IN OCCUPATIONAL COHORTS. H. A. 

Roels. Louvain Centre of Toxicology and Applied 

Pharmacology, Université catholique de Louvain, 

Brussels, Belgium. Sponsor: H. Clewell. 

#2459 2:39 THE USE OF PBPK MODELS FOR MONKEY 

AND HUMAN TO INVESTIGATE THE DOSE- 

RESPONSE FOR THE NEUROLOGICAL 

EFFECTS OF MN. H. J. Clewell 1 , J. D. 

Schroeter 1 , M. Yoon 1 , A. Nong 1 , M. D. Taylor 2 and 

M. E. Andersen 1 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 Afton 

Chemical, Richmond, VA. 

#2460 3:11 APPLICATION OF PBPK MODELING TO 

EVALUATE SAFE EXPOSURES TO A TOXIC 

BUT ESSENTIAL METAL. M. E. Andersen. 

Computational Biology, The Hamner Institutes for 


#2461 3:43 HAZARD ASSESSMENT FOR THE 

ESSENTIAL ELEMENT MANGANESE 

BASED ON TOXICOLOGICAL, 

EPIDEMIOLOGICAL, AND MECHANISTIC 

DATA: SUSCEPTIBLE SUB-POPULATIONS 

AND INTER-INDIVIDUAL VARIABILITY. 

V. Tait 1,2 , F. Salehi 2 , M. Croteau 2 , N. Karyakina 1,2 , 

N. Shilnikova 2 , A. Ngom 2 and D. Krewski 2,1 . 1 Risk 

Sciences International Inc., Ottawa, ON, Canada 

and 2 University of Ottawa, Ottawa, ON, Canada. 

Sponsor: M. Andersen. 

332 






Platform Sessions



Abstract # 


1:30 PM to 4:15 PM 

Room 144 


Workshop Session: Advancing Predictive Ecotoxicology 

Testing and Environmental Risk Assessment in the 21st 

Century 

Chairperson(s): Michelle Embry, ILSI Health and Environmental 

Sciences Institute, Washington, D.C., and David Volz, University of South 


Sponsor: 


Endorsed by: 

Hispanic Organization for Toxicologists Special Interest Group 


Following the publication of the National Research Council (NRC) Report 

on Toxicity Testing in the 21st Century: A Vision and a Strategy increased 

attention has been given to the development and use of new technologies 

and methods for toxicity testing. It is hoped that these new approaches will 

aid in the design of a routine testing strategy that will provide data that are 

applicable to the broadest possible range of chemicals, endpoints, and lifestages, 

while also providing greater detail concerning mode of action and 

dose/concentration-response, and reducing the overall costs, animal use, and 

time spent on testing. This Tox21 vision has impacted testing approaches 

for not only human health, but also ecological risk assessment. Therefore it 

is important to address these current initiatives aimed at advancing regulatory 

ecotoxity testing strategies. Novel approaches that could be integrated 

into an intelligent, tiered ecotoxicity testing strategy are under development. 

Additionally, concepts for utilizing chemical mode of action and/or adverse 

outcome pathways as a basis for developing 21st century test methods and 

associated predictive tools, initially developed as part of a SETAC Pellston 

workshop, have been expanded on several fronts. Advances in the application 

of QSAR and modeling approaches, cell-based assays, and ‘omics 

methodologies as well as recent OECD efforts to develop a fish testing 

framework will be highlighted. Our focus will be to discuss approaches 

to coordinate the development of new human health and environmental 

toxicity testing strategies, share key lessons and advances and create effective 

partnerships between human health and ecotoxicology communities. 

#2462 1:30 ADVANCING PREDICTIVE 

ECOTOXICOLOGY TESTING AND 

ENVIRONMENTAL RISK ASSESSMENT IN 

THE 21 ST CENTURY. M. Embry 1 and D. Volz 2 . 

1 

ILSI HESI, Washington, D.C. and 2 University of 

South Carolina, Columbia, SC. 

1:30 INTRODUCTION. Michelle Embry 

#2463 1:35 ADVERSE OUTCOME PATHWAYS AND 

SYSTEMS BIOLOGY AS CONCEPTUAL 

APPROACHES TO SUPPORT 

DEVELOPMENT OF 21 ST CENTURY TEST 

METHODS AND EXTRAPOLATION TOOLS. 

D. L. Villeneuve 1 , M. R. Embry 2 and D. C. Volz 3 . 

1 

U.S. EPA Mid-Continent Ecology Division, Duluth, 

MN, 2 ILSI Health and Environmental Sciences 

Institute, Washington, D.C. and 3 Department of 

Environmental Health Sciences, University of South 


#2464 2:07 ADVANCES AND OUTLOOKS FOR QSARS 

IN ECOTOXICOLOGY. S. A. Villalobos 1 , S. E. 

Belanger 2 and P. Ranslow 3 . 1 Nalco, Naperville, IL, 

2 

Procter & Gamble, Cincinnati, OH and 3 Consortium 

for Environmental Risk Management, Hallowell, 

ME. 

Abstract # 

#2465 2:39 FISH EMBRYO AND CELL LINE ASSAYS 

AS POTENTIAL ALTERNATIVES FOR 

FISH TOXICITY TESTS. K. Schirmer 1 , K. 

Tanneberger 1 , M. Knöbel 1,3 , N. Kramer 2 , J. Hermens 2 , 

S. Scholz 3 , N. Bols 4 , L. Lee 5 and C. Hafner 6 . 1 Eawag, 

Swiss Federal Institute of Aquatic Science and 

Technology, Dübendorf, Switzerland, 2 Institute of 

Risk Assessment Sciences, University of Utrecht, 

Utrecht, Netherlands, 3 UFZ, Helholtz Centre 

for Environmental Research, Leipzig, Germany, 

4 

University of Waterloo, Waterloo, ON, Canada, 

5 

Wilfrid Laurier University, Waterloo, ON, Canada 

and 6 Hydrotox GmbH, Freiburg, Germany. Sponsor: 

M. Embry. 

#2466 3:11 CRITICAL EVALUATION OF ANIMAL 

ALTERNATIVE TESTS FOR THE 

IDENTIFICATION OF ENDOCRINE ACTIVE 

SUBSTANCES. F. Busquet 1 , S. Belanger 2 , R. 

Davi 3 , B. Demeneix 4 , J. Denny 5 , M. Embry 6 , M. 

Léonard 7 , M. McMaster 8 , L. Ortego 9 , P. Renner 10 , D. 

Villeneuve 5 and S. Scholz 10 . 1 JRC, IHCP, ECVAM, 

European Commission, Ispra, Italy, 2 Procter & 

Gamble, Cincinnati, OH, 3 ExxonMobil, Annandale, 

NJ, 4 Muséum National d’Histoire Naturelle, CNRS, 

Paris, France, 5 U.S. EPA, Duluth, MN, 6 ILSI HESI, 

Washington, D.C., 7 L’Oréal Recherche Avancée, 

Aulnay sous Bois, France, 8 Environment Canada, 

Burlington, ON, Canada, 9 Bayer CropScience, 

Research Triangle Park, NC and 10 UFZ, Leipzig, 

Germany. 

#2467 3:43 THE OECD FISH TESTING FRAMEWORK 

PROJECT. L. Touart 1 , G. Ankley 2 , M. Embry 3 , 

A. Gourmelon 4 , T. Iguchi 5 , G. Maack 6 , P. 

Matthiessen 7 , J. Wheeler 8 and C. Willett 9 . 1 OCSPP/ 

Office of Science Coordination and Policy, U.S. 

EPA, Washington, D.C., 2 Office of Research and 

Development, NHEERL, Mid-Continent Ecology 

Division, U.S. EPA, Duluth, MN, 3 ILSI Health and 

Environmental Sciences Institute, Washington, 

D.C., 4 Organisation for Economic Cooperation and 

Development (OECD), Paris, France, 5 National 

Institute for Basic Biology (NIBB), Okazaki, Japan, 

6 

Umweltbundesamt (UBA), Dessau, Germany, 

7 

Consultant, Ulverston, United Kingdom, 8 Syngenta, 

Bracknell, United Kingdom and 9 PETA, Norfolk, 

VA. 


1:30 PM to 4:15 PM 

Room 204 

Workshop Session: De-Risking the Potential for 

Cardiovascular Toxicity of Type-2 Diabetic Drugs: Preclinical 

and Clinical Strategies 

Chairperson(s): Alan Bass, Merck & Co., Kenilworth, NJ, and Peter 

Hoffmann, Novartis, East Hanover, NJ. 

Sponsor: 


Endorsed by: 


Discovery of effective therapies for the treatment of Type 2 Diabetes (T2D) 

remains an important and critical unmet medical need for society. As with 

the development of most new pharmaceuticals, the risk of failure of a 

compound to achieve marketing authorization remains high. As a result, 

the pharmaceutical industry has placed a strong commitment in implementing 

strategies that de-risk the chance of failure when a compound is 

selected for development. This commitment is reflected in the increasing 

Wednesday 







333




complexity of safety evaluations and dedication of resources as a compound 

advances through development. Ultimately, the experiences gained over 

the course of this time informs whether the de-risking strategy pursued 

has been effective. As shown in the area of development of T2D drugs, the 

knowledgebase upon which decisions are made is limited because scientists 

do not fully understand the relationship of different therapeutics for 

T2D to unwanted cardiovascular toxicities. However, standard models of 

cardiovascular toxicity have been established and provide some reassurance 

of a compound’s safety. In those cases, though, where there is evidence 

of a relationship, investigators still cannot say how well their preclinical 

models and early clinical phase monitoring predict the observed outcome 

when a therapy is given over a life-time. Against this backdrop a debate of 

best practices in cardiovascular safety testing will ensue based on a current 

understanding of the state of science in the areas of safety pharmacology, 

toxicology-pathology, and clinical pharmacology. Ultimately, our panel of 

experts will advocate for integration of information emerging from each of 

these scientific disciplines that will lead to de-risking the potential adverse 

cardiovascular outcomes of T2D drugs. 


1:30 PM to 4:15 PM 

Room 206 

Workshop Session: Meeting the Challenges of Respiratory 

Toxicology Testing—In Search of Best Practices 

Chairperson(s): James Wagner, Michigan State University, East Lansing, 

MI, and Flemming Cassee, RIVM, Netherlands, Bilthoven, Netherlands. 

Sponsor: 


Endorsed by: 




Wednesday 

#2468 1:30 DE-RISKING THE POTENTIAL FOR 

CARDIOVASCULAR TOXICITY OF TYPE 

2 DIABETIC DRUGS: PRECLINICAL AND 

CLINICAL STRATEGIES. A. S. Bass 1 and P. 

K. Hoffmann 2 . 1 Global Safety Assessment, Merck 

& Co., Kenilworth, NJ and 2 Preclinical Safety, 

Novartis, East Hanover, NJ. 

1:30 INTRODUCTION. Alan Bass 

#2469 1:35 ADVERSE CARDIOVASCULAR RISK 

ASSOCIATED WITH THERAPEUTICS FOR 

TYPE 2 DIABETES: CHALLENGES TO 

IDENTIFYING ACCURATE, PREDICTIVE 

PRECLINICAL MODELS OF TOXICITY. A. 

S. Bass. Global Safety Assessment, Merck & Co., 

Kenilworth, NJ. 

#2470 2:07 MODELING CARDIOVASCULAR TOXICITY 

OF THERAPIES FOR TYPE 2 DIABETES IN 

VITRO. P. Hoffmann. Novartis, East Hanover, NJ. 

Sponsor: P. Bentley. 

#2471 2:39 CARDIOVASCULAR TOXICITY OF TYPE 2 

DIABETES DRUGS, PRECLINICAL IN VIVO 

MODELS AND SPECIALIZED PROTOCOLS 

FOR IDENTIFYING CARDIOVASCULAR 

RISK. P. C. Levesque. Discovery Toxicology, 

Bristol-Myers Squibb, Pennington, NJ. Sponsor: A. 

Bass. 

#2472 3:11 PRECLINICAL MODELING OF 

CARDIOVASCULAR RISK FOR TYPE 2 

DIABETES DRUGS: A PATHOLOGIST’S 

PERSPECTIVE. B. R. Berridge. Safety 

Assessment, GlaxoSmithKline, Research Triangle 

Park, NC. Sponsor: A. Bass. 

#2473 3:43 CLINICAL MODELING OF 

CARDIOVASCULAR TOXICITY OF TYPE 

2 DIABETES DRUGS: REGULATORY 

EXPECTATIONS AND EXPERIENCE. D. E. 

Gutstein. Clinical Research, Merck & Co., Rahway, 

NJ. Sponsor: A. Bass. 

Inhalation exposure to airborne materials in the home, workplace, and 

outdoors can produce adverse responses in the airways of both healthy and 

compromised individuals. Creating comparable exposure/response scenarios 

in laboratory animals presents significant challenges for the respiratory 

toxicologist, and over the last decade a number of new approaches have 

been adopted that complement or replace older practices. However many of 

these new advances are neither widespread nor widely accepted. Indeed the 

choices of airway exposure, and types and methods of data collection can 

provide the researcher with an array of disparate results, thereby creating 

a challenge for meaningful risk assessment. We will examine the value of 

popular and perhaps controversial methodological approaches to evaluate 

toxic airway responses. Beginning with a critical survey of exposure techniques, 

presentations will expand into the limitations of animal models, the 

predictive value of acute responses for chronic and functional responses, 

the special challenges with testing nanomaterials, and the evolution on in 

vitro approaches. Together the presentations are intended to foster scientific 

discussions and debate that may unify our thinking on the best practices for 

respiratory toxicology testing, and in the long term provide research tools to 

improve human health. 

#2474 1:30 MEETING THE CHALLENGES OF 

RESPIRATORY TOXICOLOGY TESTING -IN 

SEARCH OF BEST PRACTICES. J. Wagner 1 

and F. Cassee 2 . 1 Michigan State University, East 

Lansing, MI and 2 RIVM, Bilthoven, Netherlands. 

1:30 INTRODUCTION. James G. Wagner 

#2475 1:38 DOSING THE RESPIRATORY TRACT. G. 

Oberdörster. Environmental Medicine, University of 


#2476 2:05 CAN ANIMAL INHALATION AND 

INTRATRACHEAL INSTILLATION (IT) 

STUDIES BE MADE TO SIMULATE HUMAN 

EXPOSURE SCENARIOS? G. E. Hatch. 

National Health and Environmental Effects Research 

Laboratory, U.S. EPA, Research Triangle Park, NC. 

#2477 2:31 SAMPLING THE AIRWAY: IMPROVING 

THE PREDICTIVE AND TOXICOLOGICAL 

VALUE OF BRONCHOALVEOLAR LAVAGE. 

U. P. Kodavanti. EPHD/NHEERL/ORD, U.S. EPA, 


#2478 2:57 SCREENING FOR TOXIC AIRWAY 

RESPONSES: THE COMPARATIVE 

TOXICOLOGICAL VALUE OF PULMONARY 

FUNCTION TESTING APPROACHES. J. 

Wagner. Michigan State University, East Lansing, 

MI. 

334 






Platform Sessions



Abstract # 

#2479 3:23 SPECIAL CONSIDERATIONS FOR THE 

DELIVERY OF NANOMATERIALS TO THE 

RESPIRATORY TRACT: IMPLICATIONS 

FOR INTERPRETATION OF RESULTS. A. 

Elder. Environmental Medicine, University of 


#2480 3:49 SCREENING FOR TOXIC AIRWAY 

RESPONSES: THE TRANSLATIONAL 

VALUE OF IN VITRO APPROACHES. R. 

Devlin. U.S. EPA, Research Triangle Park, NC. 


1:30 PM to 4:15 PM 

Room 202A 

Workshop Session: Polishing Today’s Job Candidate in a 

Tough Economy 

Chairperson(s): Aimen Farraj, U.S. EPA, Research Triangle Park, NC, 

and Barbara Kaplan, Michigan State University, East Lansing, MI. 

Sponsor: 


An overall stubbornly high unemployment rate coupled with industry 

downsizing and institutional program cuts has fostered a tepid job market 

for toxicologists. Fewer jobs mean greater competition for limited openings. 

Thus the onus is on job candidates to make sure that they are putting their 

best foot forward during the job-seeking process. To that end, job candidates 

must not only polish their research credentials, but also their job-seeking 

skills. Therefore, our panel of experts from divergent fields will discuss the 

importance of having a well-rounded portfolio. Candidates will come to 

understand the value of a good publication record, acquiring experience and 

skills outside of the laboratory, and the necessity for sound communication 

skills. It has become increasingly important that job seekers be aware of the 

job application process including writing a resume/CV and interviewing. 

Our panel will provide some insight and share some insider information 

relative to the hiring practices of human resource departments. Additionally, 

there will be a discussion of the common unflattering mistakes and, or 

pitfalls that candidates can sometimes make and ways to avoid them. 

#2481 1:30 POLISHING TODAY’S JOB CANDIDATE 

IN A TOUGH ECONOMY. A. K. Farraj. 

Environmental Public Health Division, NHEERL, 


#2482 1:35 PUBLICATION IS THE FOUNDATION OF A 

COMPETITIVE JOB APPLICATION. G. B. 

Corcoran. Pharmaceutical Sciences, Wayne State 

University, Detroit, MI. 

#2483 2:01 STAND OUT AMONGST YOUR PEERS: 

WAYS TO DISTINGUISH YOURSELF 

BEYOND PUBLICATION RECORD. I. 

Jaspers. University of North Carolina at Chapel Hill, 

Chapel Hill, NC. 

#2484 2:27 COMMUNICATION SKILLS: AN ESSENTIAL 

ELEMENT TO YOUR PORTFOLIO. D. L. 

Costa. Office of Research & Development, U.S. 


#2485 2:53 WHAT IS THE EMPLOYER LOOKING 

FOR? INSIGHT FROM A JOB PLACEMENT 

PROFESSIONAL. T. Leyden. The Leyden Group, 

Greenwood Village, CO. Sponsor: A. Farraj. 

#2486 3:19 AN INSIDER PERSPECTIVE: HIRING 

PROCESSES WITHIN THE BIOTECH/ 

PHARMACEUTICAL INDUSTRY. R. Ragsdale. 

HR, Genentech & Roche, South San Francisco, CA. 

Sponsor: A. Farraj. 

Abstract # 



1:30 PM to 4:15 PM 

Room 143 

Platform Session: Airborne Particulates and Health Effects 

Chairperson(s): Jake McDonald, Lovelace Respiratory Research 

Institute, Albuquerque, NM, and Gabriele Grunig, New York University, 

Tuxedo, NY. 

#2487 1:30 TISSUE CONCENTRATIONS AND 

IMMUNOLOGICAL EFFECTS IN C3H/HEJ 

MICE, FOLLOWING AN INHALATION 

EXPOSURE TO TWO PARTICLES SIZE OF 

BE AND BEAL. A. Adam-Poupart 1 , C. Muller 1 , 

F. Salehi 2 , B. Mazer 2 , G. Chevalier 3 , Y. Cloutier 3 , G. 

Truchon 4 , J. Lambert 5 and J. Zayed 1 . 1 Department 

of Environmental and Occupational Health, Faculty 

of Medicine, University of Montréal, Montréal, QC, 

Canada, 2 Meakins-Christie Laboratories, McGill 

University, Montréal, QC, Canada, 3 Department 

of Biological Sciences, University of Québec 

in Montréal, Montréal, QC, Canada, 4 Institut de 

Recherche Robert-Sauvé en Santé et en Sécurité du 

Travail, Montréal, QC, Canada and 5 Department 

of Social and Preventive Medicine, Faculty of 

Medicine, University of Montréal, Montréal, QC, 

Canada. 

#2488 1:49 CIGARETTE SMOKE EXTRACT 

ENHANCED AMBIENT ULTRAFINE 

PARTICLE-INDUCED OXIDATIVE STRESS 

IN ENDOTHELIAL CELLS. Y. Mo 1 , R. 

Wan 1 , S. Chien 2 , D. J. Tollerud 1 and Q. Zhang 1 . 

1 



2 

Surgery, University of Louisville, Louisville, KY. 

#2489 2:08 COMPARATIVE TOXICITY OF BIODIESEL 

EXHAUST AND PETROLEUM DIESEL 

EXHAUST PARTICULATE MATTER USING 

WKY RAT ALVEOLAR MACHROPHAGES. 

L. Bhavaraju 2 , J. Shannahan 2 , A. Williams 3 , R. 

McCormick 3 , J. McGee 1 , U. Kodavanti 1 and M. 

Madden 1 . 1 ORD, NHEERL, EPHD, U.S. EPA, 

Chapel Hill, NC, 2 Curriculum in Toxicology, 


Hill, NC and 3 Fuels Performance Group, National 

Renewable Energy Labs, Golden, CO. 

#2490 2:27 GSTP1 POLYMORPHISM DETERMINES 

SUSCEPTIBILITY TO ACUTELY 

DECREASED PROTEASOME ACTIVITY 

FOLLOWING HUMAN INHALATION OF 

FRESH AEROSOLS. H. M. Kipen 1 , S. Gandhi 1 , 

D. Rich 2 , P. Ohman 2 , R. Laumbach 1 , Z. Fan 1 , L. 

Chen 3 , J. Zhang 2 and K. Madura 3 . 1 Department of 

Environmental & Occupational Medicine, UMDNJ- 


NJ, 2 UMDNJ-School of Public Health, Piscataway, 

NJ and 3 Department of Biochemistry, UMDNJ- 


NJ. 

Wednesday 







335



Wednesday 


#2491 2:45 EXPOSURE DURING ALLERGIC 

SENSITIZATION TO URBAN SUMMER 

AND WINTER SAN JOAQUIN VALLEY 

COMBINED FINE/ULTRAFINE 

CONCENTRATED AMBIENT PARTICLES 

IN A MOUSE MODEL OF ALLERGIC 

AIRWAY INFLAMMATION. C. Carosino 1,2 , L. 

E. Plummer 1,2 , M. J. Kleeman 3 and K. E. Pinkerton 2 . 

1 


California Davis, Davis, CA, 2 Center For Health 

and the Environment, University of California 

Davis, Davis, CA and 3 Civil and Environmental 

Engineering, University of California Davis, Davis, 

CA. 

#2492 3:03 SECONDHAND TOBACCO SMOKE, 

ANTIOXIDANT ENZYMES, AND AIRWAY 

DEVELOPMENT IN MALE AND FEMALE 

MICE. L. S. Van Winkle, J. Chan, P. Edwards, V. 

Rosauro, K. Sutherland and A. Buckpitt. University 

of California Davis, Davis, CA. 

#2493 3:21 ATMOSPHERIC AEROSOLS FORMED 

FROM BIOGENIC AND ANTHROPOGENIC 

PRECURSOR REACTIONS AND COAL 

COMBUSTION EMISSIONS SHOW MILD 

VASCULAR TOXICITY COMPARED WITH 

MOTOR VEHICLE EXHAUST. J. McDonald 1 , 

M. Doyle-Eisele 1 , A. Lund 1 , M. Campen 3 , E. 

Knipping 2 and A. Rohr 2 . 1 Lovelace, Albuqueruque, 

NM, 2 Electric Power Research Institute, Palo Alto, 

CA and 3 University of New Mexico, Albuquerque, 

NM. 

#2494 3:39 UNIQUE ASSOCIATIONS OF PM2.5 – 

INDUCED CHANGES IN HEART RATE 

VARIABILITY IN SPONTANEOUSLY 

HYPERTENSIVE RATS WITH WIND 

DIRECTION AND SPECIFIC SOURCES 

IN STEUBENVILLE, OH. J. G. Wagner 1 , A. 

Kamal 2 , M. Morishita 2 , B. Mukherjee 2 , G. J. Keeler 2 , 

J. R. Harkema 1 and A. C. Rohr 3 . 1 Michigan State 

University, East Lansing, MI, 2 University Michigan, 

Ann Arbor, MI and 3 Electrical Power Research 

Institute, Palo Alto, CA. 

#2495 3:57 INHALATION OF ULTRAFINE 

PARTICULATE MATTER INDUCES 

INFLAMMATORY GENE EXPRESSION IN 

STRIATUM THROUGH NRF-2 AND NF-κB 

PATHWAYS IN RATS EXPOSED IN MEXICO 

CITY. R. Guerra-Garcia 1 , E. Vera-Aguilar 2 , G. 

Gookin 3 , M. Uribe-Ramirez 1 , A. Campbell 4 , J. 

Camacho 2 , M. Kleinman 3 and A. De Vizcaya-Ruiz 1 . 

1 

Department of Toxicology, Cinvestav, Mexico City, 

Mexico, 2 Department Pharmacology, Cinvestav, 

Mexico City, Mexico, 3 Division of Occupational and 

Environmental Medicine, Department of Medicine, 

University of Irvine, Irvine, CA and 4 Department of 

Pharmacological Sciences, Western University of 

Health Sciences, Pomona, CA. 


1:30 PM to 4:15 PM 

Room 202B 

Platform Session: Nrf2 and Antioxidant Response Networks 

Chairperson(s): Curtis Klaassen, University of Kansas Medical Center, 

Kansas City, KS, and Joshua P. Gray, U.S. Coast Guard Academy, New 

London, CT. 

#2496 1:30 NRF2 IN TOXICOLOGY: FROM 

MONOFUNCTIONAL INDUCERS TO THE 

NEXT GENERATION OF THERAPY. C. D. 

Klaassen. Pharmacology, University Kansas Medical 


#2497 1:51 TRANSCRIPTIONAL REGULATION OF THE 

HUMAN FERRITIN GENE THROUGH AN 

ANTI-OXIDANT RESPONSIVE ELEMENT 

BY CORE HISTONE MODIFICATIONS. B. 

Huang, K. Iwasaki and Y. Tsuji. Environmental 


University, Raleigh, NC. Sponsor: J. Ninomiya-Tsuji. 

#2498 2:12 ACTIVATION OF NRF2 BY INTRINSIC AND 

EXTRINSIC LIGANDS. A. Chia, R. Megherbi, 

I. Copple, N. R. Kitteringham, L. E. Randle, C. 

E. Goldring and K. Park. Molecular & Clinical 

Pharmacology, University of Liverpool, Liverpool, 

Merseyside, United Kingdom. Sponsor: D. Mendrick. 

#2499 2:33 KEAP1-KNOCKDOWN AND HEPATOCYTE- 

SPECIFIC SIRT1 DELETION CONFER 

RESISTANCE TO FASTING-INDUCED 

DOWN-REGULATION OF NRF2-TARGET 

GENE EXPRESSION. S. Kulkarni 1 , J. Xu 1 , 

W. Wei 1 , X. Li 2 , M. Yamamoto 3 and A. Slitt 1 . 

1 

Biomedical and Pharmaceutical Sciences, University 

of Rhode Island, Kingston, RI, 2 National Institute 

of Environmental Health Sciences, National 

Institutes of Health, Research Triangle Park, NC 

and 3 Department of Medical Biochemistry, Tohoku 

University Graduate School of Medicine, Sendai, 

Japan. 

#2500 2:54 A BIOCHEMICAL AND PROTEOMIC 

ANALYSIS OF THE EFFECT OF NRF2 GENE 

DELETION ON ACUTE ACETAMINOPHEN- 

INDUCED HEPATOTOXICITY. C. E. Goldring, 

L. E. Randle, R. L. Sison, N. R. Kitteringham, D. 

Denk, R. E. Jenkins, J. Walsh, B. Lane, A. Kipar 

and K. Park. Molecular & Clinical Pharmacology, 

University of Liverpool, Liverpool, Merseyside, 

United Kingdom. Sponsor: D. Mendrick. 

#2501 3:15 PROFILING ENVIRONMENTAL 

CHEMICALS IN THE ANTIOXIDANT 

RESPONSE ELEMENT PATHWAY USING 

QUANTITATIVE HIGH-THROUGHPUT 

SCREENING (QHTS). S. J. Shukla 1 , R. Huang 1 , 

S. O. Simmons 2 , R. R. Tice 3 , K. L. Witt 3 and M. Xia 1 . 

1 

NIH Chemical Genomics Center, Rockville, MD, 

2 

U.S. EPA, Research Triangle Park, NC and 3 National 

Toxicology Program, Research Triangle Park, NC. 

#2502 3:35 NUCLEAR FACTOR E2-RELATED FACTOR 

1 IS INVOLVED IN ARSENIC-INDUCED 

ANTIOXIDANT RESPONSE IN HUMAN 

KERATINOCYTES. R. Zhao 1 , Y. Hou 1 , P. 

Xue 1 , C. G. Woods 1 , J. Fu 1 , M. P. Waalkes 2 , M. 

E. Andersen 1 and J. Pi 1 . 1 The Hamner Institutes, 

Reaserach Triangle Park, NC and 2 NTP, NIEHS, 

NIH, Research Triangle Park, NC. 

336 






Platform Sessions



Abstract # 

#2503 3:55 BENEFICIAL ROLE OF NRF2 IN 

REGULATING NADPH GENERATION 

AND CONSUMPTION. K. C. Wu, J. Y. Cui and 

C. D. Klaassen. Pharmacology, Toxicology, and 




2:30 PM to 3:30 PM 

Room 201 

Meet the Director: U.S. FDA Director 

Chairperson(s): Michael P. Holsapple, International Life Sciences 


Lecturer: Jesse Goodman, U.S. FDA, Silver Spring, MD. 

U.S. FDA has defined regulatory science as the science of developing 

new tools, standards and approaches to assess the safety, efficacy, quality 

and performance of U.S. FDA-regulated products (see Advancing Regulatory 

Science for Public Health, 2010, accessible at: www.fda.gov/ 

scienceresearch/specialtopics/regulatoryscience/ucm228202.htm). 

No area of science is more important to our ability to predict a product’s 

safety, or assess the potential significance of chemical substances 

in products, than toxicology. Well performed toxicology studies have 

undoubtedly protected consumers from many unsafe products and from 

contaminants that pose true threats to health. Yet most of the toxicology 

tools in use for regulatory assessment have as of yet been essentially 

unchanged by the molecular and cellular revolutions of the last 40 years. 

A wealth of innovation based on application of genomic, proteomic, 

metabolic, cell based and modeling tools is being applied, largely in 

the research community, to assessing the effects of novel and existing 

compounds. These tools, if and as they are validated for their predictive 

capabilities, offer the potential to revolutionize toxicology and its 

use in safety assessments, dramatically improving our ability to detect, 

understand and manage potential risks. Improvements should occur both 

in sensitivity and in specificity—the goal should be to detect true risks, 

but to not reject products that are safe due to false positive signals that 

may not be predictive of target effects in humans (or, for that matter, 

in other parts of the ecosystem). In addition, there are compelling 

reasons to limit animal testing where other methods may either replace 

or improve prediction. In recognition of this potential, U.S. FDA has 

made “Transforming Toxicology” one of its broad strategic priorities 

in its Advancing Regulatory Science Initiative. U.S. FDA is including 

support for new approaches to toxicology in its joint NIH/FDA regulatory 

science grants, as well as in efforts in both its product centers and 

at the National Center for Toxicological Research. Enhancing toxicology 

studies for nanoparticles would receive enhanced support at U.S. FDA, 

and through collaborative studies, under the President’s 2011 budget 

proposal currently before Congress, which includes the first dedicated 

budget support line for regulatory science at U.S. FDA. The Office of 

the Chief Scientist recently formed a new U.S. FDA-wide Chemical 

and Environmental Science Council (CESC) to serve as a focus for 

more proactively managing the growing U.S. FDA portfolio of crosscutting 

chemical and toxicology issues, and to enhance scientific and 

policy communication, collaboration and training across U.S. FDA and 

with external partners. U.S. FDA has been increasingly engaged with 

colleagues in diverse agencies such as NIEHS (including through the 

NTP), U.S. EPA (including through the Tox-21 initiative and multiple 

specific issues), CDC and CPSC, among others. Such collaboration has, 

for example, been critical in the scientific response to potential health 

threats from the Gulf Oil Spill. Through these and other efforts, U.S. 

FDA has raised the profile of toxicology within the Agency and signaled 

its support for collaboration to advance the science needed to inform the 

best possible decisions. 

Abstract # 


3:45 PM to 4:45 PM 

Room 201 

Meet the Director: U.S. EPA Director 

Chairperson(s): Michael P. Holsapple, International Life Sciences 


Lecturer: Paul Anastas, U.S. EPA, Washington, D.C. (invited). 

Paul Anastas, Ph.D. is the Assistant Administrator for EPA’s Office 

of Research and Development (ORD) and the Science Advisor to 

the Agency. Known widely as the “Father of Green Chemistry” for 

his groundbreaking research on the design, manufacture, and use of 

minimally-toxic, environmentally-friendly chemicals, Dr. Anastas has an 

extensive record of leadership in government, academia, and the private 

sector. 

Dr. Anastas will participate in the Annual Meeting as guest lecturer in 

the Meeting the Director series of lectures, as well as serve as a panelist 

in a Workshop session entitled “Safer Products for a Sustainable World: 

Linking Chemical Design and Toxicology”, which will take place on 

Tuesday, March 8 from 9:00 AM to 11:45 AM. 


4:30 PM to 5:50 PM 

Room 144 

Roundtable Session: Assessment of Nanoparticle Exposure in 

Occupational Settings and in Inhalation Toxicology Studies: 

Is There a Best Dosemetric to Use? 

Chairperson(s): Günter Oberdörster, University of Rochester, Rochester, 

NY, and David Warheit, DuPont Haskell Global Centers, Newark, DE. 

Sponsor: 


Endorsed by: 




Nanotechnology involves the design and manipulation of materials at the 

nanoscale size range. The capacity for assessing hazards or quantifying 

exposures to engineered nanomaterials for workers or consumers is limited, 

and may require new or different methodologies to provide information 

for effective risk assessment and risk management. Exposure assessments 

are important components for determining health risks. However, currently 

used methodologies are inadequate for quantifying nanoparticulate exposures, 

because most of the occupational exposure data is represented in the 

gravimetric form of mass/volume of sampled air. Our goal is to address this 

controversial issue with a focus on practicability of measurements under 

workplace conditions. Therefore it is important to discuss the proposed 

change in dose metrics for inhalation toxicity studies with engineered aerosolized 

amorphous silica nanoparticles. Accordingly, rats were exposed to 

freshly generated nanoparticles at two different particle size ranges. The 

particle aerosols were characterized by particle numbers using SMPS technology. 

Our panel of experts will address the merits of using surface area 

metrics based on measurements of particle numbers and material-specific 

density for quantifying particle exposures and their use for risk assessment. 

Our panel will present real-time instrumentation for measuring airborne 

particle surface area and morphology of nanoparticle agglomerates—two of 

the important metrics for toxicity evaluation. In addition, recent exposure 

assessments in manufacturing facilities involving silicon nanoparticles and 

carbon nanotubes will be presented. It is also important to note the effect of 

agglomerate structure size on the bioactivity of nanoparticles and present 

current methods used to disperse nanoparticles for in vitro and in vivo 

testing which we will address. Finally, we will discuss methods to convert in 

vivo lung burdens to appropriate in vitro test concentrations of nanoparticles 

for hazard screening. 

Wednesday 







337



Wednesday 


#2504 4:30 ASSESSMENT OF NANOPARTICLE 

EXPOSURE IN OCCUPATIONAL SETTINGS 

AND IN INHALATION TOXICOLOGY 

STUDIES: IS THERE A BEST DOSEMETRIC 

TO USE? D. B. Warheit 1 and G. Oberdorster 2 . 

1 

DuPont Haskell Global Centers, Wilmington, DE 

and 2 University of Rochester, Rochester, NY. 

4:30 INTRODUCTION. David B. Warheit 

4:40 A CHANGE IN DOSE METRICS FOR 

INHALATION TOXICITY STUDIES WITH 

ENGINEERED NANOPARTICLES. David B. 

Warheit 

4:50 THE MERITS OF USING SURFACE AREA 

METRICS BASED ON MEASUREMENTS 

OF PARTICLE NUMBERS AND MATERIAL- 

SPECIFIC DENSITY FOR QUANTIFYING 

PARTICLE EXPOSURES. Günter Oberdӧrster 

5:00 REAL-TIME INSTRUMENTATION FOR 

MEASURING AIRBORNE PARTICLE 

SURFACE AREA AND MORPHOLOGY OF 

NANOPARTICLE AGGLOMERATES. David 

Y. Pui 

5:10 THE EFFECT OF AGGLOMERATE 

STRUCTURE SIZE ON THE BIOACTIVITY 

OF NANOPARTICLES. Vincent Castranova 



4:30 PM to 5:50 PM 

Room 143 



Informational Session: Progress of the Tox21 Consortium in 

High-Throughput Bioactivity Profiling of Chemicals 

Chairperson(s): Robert Kavlock, U.S. EPA, Research Triangle Park, NC, 

and Chris Austin, National Human Genome Research Institute, Bethesda, 

MD. 

Sponsor: 


Endorsed by: 




In 2008, the National Institute of Environmental Health Sciences/National 

Toxicology Program, the NIH Chemical Genomics Center, and the U.S. 

EPA’s National Center for Computational Toxicology entered into a Memorandum 

of Understanding to collaborate on the research, development, 

validation, and translation of new and innovative test methods to characterize 

key steps in toxicity pathways. The U.S. FDA joined this consortium 

in 2010. A central component is the exploration of high-throughput 

screening, as well as high-throughput whole genome analytical methods, 

to evaluate mechanisms of toxicity. The goals of the Tox21 Community are 

to investigate the use of these new tools, along with existing chemical and 

biological information, to prioritize substances for further in-Department 

toxicological evaluation, identify mechanisms of action for further investigation, 

and develop predictive models for in vivo biological response. 

Success is expected to result in test methods for toxicity testing that are 

more mechanistically based and economically efficient; as a consequence, 

a reduction or replacement of animals in regulatory testing is anticipated to 

occur in parallel with an increased ability to evaluate the large numbers of 

chemicals that currently lack adequate toxicological evaluation. In the past 

year, Tox21 has completed assembly of a library of ~10, 000 chemicals and 

338 

began screening the library against molecular targets and pathways at the 

rate of one assay per week. Our panel of experts will inform the scientific 

community of progress in meeting the Tox21 goals, by focusing on the strategies 

for chemical and assay selection, workflows for data management and 

analysis, and understanding the human significance of results. The Tox21 

effort represents the largest and most comprehensive evaluation of interaction 

of environmental chemicals with toxicity pathways and is helping to 

pave the way for the use of high-throughput screening tools in hazard identification, 

chemical prioritization, and risk assessment. 

#2505 4:30 PROGRESS OF THE TOX21 CONSORTIUM 

IN HIGH-THROUGHPUT BIOACTIVITY 

PROFILING OF CHEMICALS. R. Kavlock 1 and 

C. Austin 2 . 1 U.S. EPA, Research Triangle Park, NC 

and 2 NIH Chemical Genomics Center, Gaithersburg, 

MD. 

4:30 INTRODUCTION. Chris Austin 

4:35 THE STRATEGY FOR DESIGN OF THE 

10,000 CHEMICAL LIBRARY AND 

CHEMOINFORMATIC 

CHARACTERIZATION. Ann Richard 

4:53 THE STRATEGY FOR ASSAY SELECTION 

AND ASSAY QUEUE. Kristine Witt 

5:11 INFORMATIC APPROACHES TO ANALYSIS 

OF 10K CHEMICAL LIBRARY. Ruili Huang 

5:29 USING HUMAN DATA TO UNDERSTAND 

AND INTERPRET TOX21 SCREENING 

RESULTS. David Jacobson-Kram 

5:47 CLOSING REMARKS. Robert Kavlock 


4:30 PM to 5:50 PM 

Room 145 

Informational Session: Toxicological Considerations of 

Pharmacotherapy during Pregnancy 

Chairperson(s): Susan Laffan, GlaxoSmithKline, King of Prussia, PA, and 

Ofelia Olivero, National Cancer Institute, Bethesda, MD. 

Sponsor: 


Endorsed by: 



Pharmacotherapy of pregnant women is challenging and requires considerations 

for the mother and the fetus. Almost every pregnant woman is 

exposed to some type of medication during pregnancy. Many pregnant 

women refuse medically important agents or conversely, are prescribed 

drugs deemed safe despite evidence of possible teratogenicity and/or genotoxicity. 

An overview of the proposed new pregnancy labeling categories 

based on reproductive toxicology and present results of pharmacokinetic 

studies in pregnant women funded by the U.S. FDA Office of Women’s 

Health will be provided. It is therefore important to offer a medical perspective 

on the challenges involved in treating pregnant and lactating women as 

a population and as individuals. This process, known as theranostics, will 

be useful and allow U.S. to tailor medical treatments for individual patients. 

Because of this process we can focus on maternal pharmacotherapy and 

role of the placenta in modulation and transfer of agents to the conceptus. 

In addition, we will be able to examine a range of in vitro assessments for 

studying the human placenta and animal models as well as investigating 

maternal and fetal advantages of novel nanomedicines. To fully assess the 

issue of phamacotherapy, it is important to discuss the unique challenges of 

supporting clinical trials in pregnant women while developing a novel medicine 

for preterm labor. Finally, research on the transplacental carcinogenicity 






Platform Sessions



Abstract # 

of nucleoside analogs and implications on the therapeutic use for HIV will 

be discussed. 

#2506 4:30 TOXICOLOGICAL CONSIDERATIONS 

OF PHARMACOTHERAPY DURING 

PREGNANCY. S. Laffan 1 , M. Miller 3 , C. 

Buhimschi 4 , R. Miller 5 , D. Stanislaus 1 and O. 

Olivero 2 . 1 Safety Assessment, GlaxoSmithKline, 

King of Prussia, PA, 2 Laboratory of Cancer Biology 

and Genetics, National Cancer Institute, Bethesda, 

MD, 3 National Center for Toxicology Research, U.S. 

FDA, Washington, D.C., 4 Obstetrics & Gynecology, 

Yale University, New Haven, CT and 5 Obstetrics 

and Gynecology, University of Rochester School of 

Medicine and Dentistry, Rochester, NY. 

4:30 UPDATE ON FDA’S PROPOSED 

PREGNANCY LABELING AND PK OF 

PHARMACEUTICALS IN PREGNANCY. 

Margaret Miller 

4:44 CHALLENGES IN CHOOSING THE RIGHT 

DRUG FOR PREGNANT OR LACTATING 

WOMEN. Catalin Buhimschi 

4:58 PLACENTAL TRANSPORT OF DRUGS – 

IMPLICATIONS FOR FETAL EXPOSURE. 

Richard Miller 

5:12 DEVELOPMENT OF NOVEL MEDICINE 

FOR PRE-TERM LABOR: CHALLENGES 

IN SUPPORTING CLINICAL TRIALS IN 

PREGNANT WOMEN. Dinesh Stanislaus 

5:26 TRANSPLACENTAL CARCINOGENESIS OF 

THE ANTI-RETROVIRAL DRUG AZT. Ofelia 

Olivero 


Abstract # 

Notes 


4:30 PM to 6:30 PM 

Renaissance Ballroom West A and B 

Special Interest Group Meeting/Reception: Women in 


Wednesday Evening, March 9 

5:00 PM to 6:30 PM 

TBD 

Wednesday Evening 

Regional Chapter Reception: Michigan (Happy Hour/Social 

Gathering) 

Wednesday 

Wednesday Evening, March 9 

6:00 PM to 7:30 PM 

See room listings below. 

Specialty Section Meeting/Reception: Biological 

Modeling (Room 149), Drug Discovery Toxicology (Room 

103), Ethical, Legal, and Social Issues (Room 156), 

Immunotoxicology (Salon H), Inhalation and Respiratory 

(Room 102), Mechanisms (Salon I), Mixtures (Room 140A), 

Reproductive and Developmental Toxicology (Salon G) 







339



Thursday 


Thursday Morning, March 10 

6:30 AM to 7:50 AM 

Room 147 

Thursday Morning 

Issue Session: What It Means to Be Global 

Chairperson(s): Ruth Roberts, AstraZeneca, Macclesfield, 

United Kingdom, and William Slikker, Jr., U.S. FDA, Jefferson, AR. 

As defined by some, globalization describes the process by which 

regional economies, societies, and cultures have become integrated 

through a global network of communication, transportation, and trade. 

For many, the advent of the Internet has made the production of knowledge 

a global enterprise, with unlimited possibilities for communication, 

collaboration, and data sharing across international boundaries. 

In April 2009, SOT and the Global Strategy Task Force finalized and 

commenced implementation of an SOT Global Strategy highlighting four 

parts of the SOT Strategic Plan 2008–2011 for global efforts: 

• Become a global forum for novel discoveries 

• Strengthen global partnerships 

• Increase reliance of global decision makers on science 

• Strengthen and deepen member engagement to address global needs 

As part of this workstream, this special issues session will present the 

perspectives of four different constituent stakeholders who will address 

two key questions: 

• What does global mean? 

• What are the pros and cons of globalization? 

Featuring an open discussion, this session will be of interest to a broad 

range of participants who both wish to hear where the global agenda in 

toxicology stands today and those who wish to influence the outcome of 

the discussions. 

• Globalization: An Industrial Perspective, Robert Wallis, Pfizer 

Global Drug Safety Research and Development, New London, CT 

• Globalization: An Academic Perspective, Jin Ren Shanghai Institute 

of Materia Medica Pudong, Shanghai 

• Globalization: A Regulatory Perspective, Jan Wilhelm van der 

Laan, National Institute for Public Health and the Environment, 

Bilthoven, The Netherlands 

• Globalization: A CRO Perspective, Peter J. Sausen, Covance 

Laboratories, Inc., Madison, WI 


6:30 AM to 7:50 AM 

Room 143 



Informational Session: Beyond Science and Decisions: From 

Problem Formulation to Dose-Response 

Chairperson(s): Roberta Grant, Texas Commission on Environmental 

Quality, Austin, TX, and Michael Dourson, Toxicology Excellence for Risk 

Assessment, Cincinnati, OH. 

Sponsor: 


Endorsed by: 


In follow up to reports released in 2007 and 2008 by the National 

Academies of Science (NAS), specifically their report Science and Decisions: 

Advancing Risk Assessment, we will focus our discussion on the 

approaches for moving the science of dose-response assessment forward. 

We will present findings and discuss progress from the first and second 

of three workshops organized with a multi-stakeholder approach to share 

information, ideas, and techniques in support of developing practical 

problem-driven risk assessment guidance. The first of these workshops 

was held in Austin, Texas in March 2010. This workshop highlighted 

relevant work in issue identification and assessment methods, followed by 

brainstorming on purpose-focused methods as well as selection of 20 case 

proposals. The second workshop took place in October 2010 in Crystal 

City, Virginia, in tandem with the Federal and State Risk Assessment and 

Toxicology Conference. A third workshop is scheduled to take place in 

March or April 2011. At this meeting, the case proposal presentations 

will be evaluated by a yet-to-be identified science panel selected from the 

second and third workshops. The panel of experts will build consensus on 

purpose-specific dose-response methods. One of the primary goals of these 

workshops is to develop practical guidance for the use of risk assessment 

techniques applicable to specific issue identification (e.g., prioritization, 

screening and full assessment) and use by risk managers at a variety of 

levels (e.g., states, regional managers, people in a variety of agencies, and 

in the private sector). Specific case proposals will be used as examples to 

identify useful dose-response techniques. 

#2507 6:30 BEYOND SCIENCE AND DECISIONS: 

FROM PROBLEM FORMULATION TO 

DOSE-RESPONSE. M. L. Dourson 1 and R. L. 

Grant 2 . 1 Toxicology Excellence for Risk Assessment, 

Cincinnati, OH and 2 Toxicology Division, Texas 

Commission on Environmental Quality, Austin, TX. 

6:30 INTRODUCTION. 

6:35 PROBLEM FORMULATION AND RISK 

ASSESSMENT NEEDS. Bette Meek 

6:50 NAS (2008) FINDINGS AND CURRENT EPA 

RISK ASSESSMENT FORUM EFFORTS N 

ON EXTENSIONS OF THIS WORK. Edward 

Ohanian 

7:05 ETHYL BENZENE: A CASE STUDY USING 

MODE OF ACTION (MOA) FRAMEWORK 

ASSESSMENT FOR UNDERSTANDING 

HUMAN RELEVANCE OF CANCER 

RESPONSE. James Bus 

7:20 ESTIMATING RISK ABOVE THE EFFECTS 

SCREENING LEVEL: A CASE STUDY USING 

CATEGORICAL REGRESSION. Elena Craft 

340 






Platform Sessions



Abstract # 

7:35 INCORPORATING BIOLOGY INTO THE 

DOSE RESPONSE ASSESSMENT OF 

NUCLEAR RECEPTORS AGONISTS. Melvin 

Andersen 


6:30 AM to 7:50 AM 

Room 145 



Education-Career Development Session: Bringing Toxicology 

to the Decision-Makers Table: Opportunities for Science 

Policy Positions in Washington, D.C. 

Chairperson(s): Nancy Beck, U.S. Office of Management and Budget, 

Washington, D.C., and Minerva Mercado-Feliciano, National Institute of 

Environmental Health Sciences, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 

Hispanic Organization for Toxicologists Special Interest Group 


If toxicologists are truly going to improve and protect public and environmental 

health, not only do we need to continually be advancing the science, 

but we also need to bring our expertise and knowledge to the policy makers 

attention. We will need more toxicologists who can translate the information 

generated in the laboratory to the policy and regulatory arenas. With 

the 2011 SOT Annual Meeting being held in Washington, D.C., we are 

provided with a perfect opportunity to hear from local scientists who have 

successfully transitioned out of the academic laboratory focused on discovering 

mechanisms of action into working in policy and regulatory settings 

that impact public and environmental health. We will highlight the various 

types of positions and opportunities that exist in and around our nation’s 

capital. Come and learn about what skills and training are most useful to 

transition from the laboratory to a toxicology policy-maker and regulatory 

scientist. Our panel of experts include scientists currently doing science 

policy and regulatory work for a variety of organizations, representing the 

federal government, private sector, and non-governmental organizations 

(NGO). Before the interactive roundtable discussion begins, a brief overview 

summary of the career paths taken, the types of work these scientists 

are engaged in, and options available for SOT scientists seeking a change 

will be highlighted. 

#2508 6:30 Bringing Toxicology to the Decision-Makers 

Table: Opportunities for Science Policy and 

Regulatory Science Positions in Washington, 

D.C., N. Beck 1 and M. Mercado-Feliciano 2 . 1 Office 

of Management and Budget, Washington, D.C. and 

2 


6:30 Introduction. Nancy Beck and Minerva Mercado- 

Feliciano 

6:36 A Non-Government Organization Perspective, 

Jennifer McPartland 

6:44 Opportunities for Research and Training in a 

Federal Regulatory Agency, Peter Goering 

6:52 A Law Firm and Congressional Perspective, Pat 

Donnelly 

7:00 An Industry Perspective, Tim Pastoor 

7:08 Panel Discussion/Q&A. 

Abstract # 


8:00 AM to 9:00 AM 

Ballroom C 

Keynote Plenary Lecture: U.S. EPA Vision 

Lecturer: Lisa Jackson (invited), U.S. EPA, 


Administrator Lisa P. Jackson, head of the U.S. EPA, 

the federal agency responsible for protecting the health 

and environment for all Americans. As Administrator 

of the U.S. EPA, she and a staff of more than 17,000 

professionals are working across the nation to usher in a green economy, 

address health threats from toxins and pollution, and renew public trust 

in U.S. EPA’s work. 

Ms. Jackson has pledged to focus on core issues of protecting air and 

water quality, preventing exposure to toxic contamination in our communities, 

and reducing greenhouse gases. She has promised that all of U.S. 

EPA’s efforts will follow the best science, adhere to the rule of law, and 

be implemented with unparalleled transparency. 

Ms. Jackson has made it a priority to focus on vulnerable groups 

including children, the elderly, and low-income communities that 

are particularly susceptible to environmental and health threats. In 

addressing these and other issues, she has promised all stakeholders a 

place at the decision-making table. 

Before becoming U.S. EPA’s Administrator, Jackson served as Chief of 

Staff to New Jersey Governor Jon S. Corzine and Commissioner of the 

state’s Department of Environmental Protection (DEP). Prior to joining 

DEP, she worked for 16 years as an employee of the U.S. EPA. 

Ms. Jackson is a summa cum laude graduate of Tulane University and 

earned a master’s degree in chemical engineering from Princeton University. 

She was born in Pennsylvania and grew up a proud resident of New 

Orleans, Louisiana. Ms. Jackson now resides in Washington, D.C. 


8:30 AM to 12:00 NOON 

East Salon 

Poster Session: Alternatives to Mammalian Models 

Chairperson(s): Mary Jane Cunningham, Nanomics Biosciences Inc., 

Cary, NC. 

Displayed: 8:30 AM–12:00 NOON 



PREVALIDATION OF LIVER SLICES AS 

A MODEL FOR THE EARLY ONSET OF 

LIVER FIBROSIS TO TEST ANTI-FIBROTIC 

DRUGS. I. M. Westra 1 , G. M. Groothuis 1 and 

P. Olinga 2 . 1 Pharmacokinetics, Toxicology, and 

Targeting, University of Groningen, Groningen, 

Netherlands and 2 Pharmaceutical Technology and 

Biopharmacy, University of Groningen, Groningen, 

Netherlands. Sponsor: A. Vickers. 

Thursday 







341



Thursday 



NEURONAL NETWORKS COUPLED TO 

MEA FOR IN VITRO NEUROTOXICITY 

TESTING: RESULTS FROM A RING TRIAL. 

B. Scelfo 1 , A. Novellino 2 , A. Price 1 , T. Palosaari 1 , T. 

Sobanski 3 , G. Gross 4 , T. J. Shafer 7 , A. F. Johnstone 7 , 

A. Gramowski 5 , O. Schroeder 6 , F. Benfenati 8 , M. 

Chiappalone 8 , S. Martinoia 8 , B. Tedesco 8 and M. 

Whelan 1 . 1 IHCP, JRC, Ispra, Italy, 2 ETT S.r.l., 

Genova, Italy, 3 ECHA, Helsinki, Finland, 4 University 

of North Texas, Denton, TX, 5 University of Rostock, 

Rostock, Germany, 6 NeuroProof GmbH, Rostock, 

Germany, 7 U.S. EPA, Research Triangle Park, NC 

and 8 Italian Institute of Technology, Genova, Italy. 


IDENTIFICATION OF HUMAN 

HEPATOTOXICANTS BY HIGH-CONTENT 

IMAGING IN MICROPATTERNED HUMAN 

HEPATOCYTE COCULTURES. R. A. Kemper 1 

and S. Khetani 2 . 1 Integrative Toxicology, Boehringer 

Ingelheim Pharmaceuticals, Ridgefield, CT and 

2 

Research and Development, Hepregen Corporation, 

Medford, MA. 


DEVELOPMENT OF AN INTEGRATIVE 

APPROACH FOR THE PREDICTION OF 

SYSTEMIC TOXICITY: COMBINATION OF 

CELL TOXICITY, PHARMACOLOGICAL, 

AND PHYSICAL CHEMICAL PROPERTIES. 

R. R. Note 1 , H. Noçairi 1 , M. Thomas 1 , L. Bourouf 1 , 

J. M. McKim 2 , G. Ouédraogo 1 and J. Meunier 1 . 

1 

L’Oréal, Aulnay Sous Bois, France and 2 Ceetox, 

Kalamazoo, MI. Sponsor: H. Toutain. 


EVALUATION OF SENSCEETOX® AN 

INTEGRATIVE MODEL FOR IDENTIFYING 

CHEMICAL SENSITIZERS. A. Del Bufalo 1 , 

R. Note 1 , S. Teissier 1 , C. Gomes 1 , C. Piroird 1 , J. 

Ovigne 1 , J. M. McKim 2 and J. Meunier 1 . 1 L’Oréal, 

Aulnay sous Bois, France and 2 Ceetox, Kalamazoo, 

MI. Sponsor: H. Toutain. 


DETERMINING THE EFFECTS OF 

GLUTATHIONE ON DEVELOPMENTAL 

METHYLMERCURY EXPOSURE. R. H. 

Klingler and M. J. Carvan. GLWI, University of 

Wisconsin Milwaukee, Milwaukee, WI. 


DEVELOPMENT OF AN INTEGRATIVE 

APPROACH FOR THE PREDICTION OF 

SYSTEMIC TOXICITY: COMBINATION OF 

CELL TOXICITY AND METABOLISM DATA. 

M. Thomas, R. R. Note, J. Eilstein, D. Duché, G. 

Ouédraogo and J. Meunier. L’Oreal, Aulnay Sous 

Bois, France. Sponsor: H. Toutain. 


LIVER-SPECIFIC FUNCTIONS AND 

EPIGENETIC STATUS OF HEPARG UNDER 

VARIOUS CULTURE CONDITIONS. N. 

Kramer, C. Klotz, J. van den Brink and B. Blaauboer. 

Institute for Risk Assessment Sciences, Utrecht 

University, Utrecht, Netherlands. 


DEVELOPMENT OF A CAENORHABDITIS 

ELEGANS MOVEMENT ASSAY FOR 

ASSESSING NEUROTOXICITY. J. H. 

Freedman, D. W. Snyder, W. A. Boyd and G. E. 

Kissling. NIEHS, Durham, NC. 


DEVELOPMENT OF AN IN VITRO 

DEVELOPMENTAL NEUROTOXICITY 

(DNT) SCREENING ASSAY USING THE 

HUMAN NT2/D1 CELL LINE. M. A. Taylor 1,2 , 

L. Kan 1 and M. S. Marty 1 . 1 The Dow Chemical 

Company, Midland, MI and 2 Ashland Chemical 

Company, Dublin, OH. 


A NOVEL IN VITRO MODEL OF HUMAN 

INTRAEPITHELIAL NEOPLASIA. L. Allen- 

Hoffmann, E. Gill, M. Pickart, L. Shapiro, N. Peters, 

C. Rasmussen, C. Krueger and M. Hoffmann. 

University of Wisconsin Madison, Madison, WI. 


DIFFERENTIAL EFFECT OF 

CHLOROPYRIFOS ON EPIGENETIC 

MARKERS IN PROLIFERATING AND 

DIFFERENTIATING HUMAN NEURAL 

STEM CELL. H. Kim, X. Yu, S. Hong, J. Park and 

E. M. Faustman. DEOHS, University of Washignton, 

Seattle, WA. 


IN VITRO ALGIMATRIX 3D CELL 

CULTURE SYSTEM, AN ALTERNATIVE TO 

MAMMALIAN MODELS FOR NON-SMALL 

CELL LUNG CANCER. M. Sachdeva 1 , A. R. 

Patel 1 , M. Chougule 1 and A. Sams 2 . 1 Pharmacy, 

Florida A&M University, Tallahassee, FL and 

2 

Invitrogen Corporation, Carlsbad, CA. 


MICROPATTERNED PRIMARY 

HEPATOCYTE CO-CULTURES FOR DRUG 

METABOLISM AND TOXICITY STUDIES. 

S. Khetani, A. Moore, S. Krzyzewski, J. Gaffney, C. 

Kanchagar, J. Shi and J. McGeehan. Research and 

Development, Hepregen, Medford, MA. Sponsor: 

D. Keller. 


ASSESSING CHRONIC TOXICITY OF 

FIALURIDINE IN A MICROPATTERNED 

HEPATOCYTE CO-CULTURE MODEL. S. 

Krzyzewski 1 , S. Khetani 1 and S. Barros 2 . 1 Research 

and Development, Hepregen, Medford, MA and 

2 

Alnylam Pharmaceuticals, Cambridge, MA. 


TRANSCRIPTIONAL INDUCTION OF 

ALDO-KETO REDUCTASES (AKRS) BY 

BENZO[A]PYRENE IN JURKAT CELL LINE. 

B. S. Barrón-Vivanco 1,3 , E. González-Barbosa 3 , I. M. 

Medina-Díaz 3 , A. E. Rojas-García 3 , S. Rothenberg 1 , 

G. Elizondo 2 and A. Albores 1 . 1 Toxicology, 

Cinvestav-Ipn, México, Mexico, 2 Cell Biology, 

Cinvestav-Ipn, México, Mexico and 3 Laboratorio 

de Contaminación y Toxicología Ambiental, 

Universidad Autónoma de Nayarit, Tepic, Nayarit, 

Mexico. 

342 






Platform Sessions



Abstract # 


DATACHIP/METACHIP 2.0: AN IMPROVED 

CHIP PLATFORM FOR 3D CELL-BASED 

TOXICOLOGY ASSAYS. M. Lee 1 , J. Ryan 1 , 

S. Brooks 1 , J. Gray 1 , D. Lee 2 , S. Jeong 2 , J. Yang 2 , 

B. Ku 2 , Y. Will 3 and S. Nadanaciva 3 . 1 Solidus 

Biosciences, Inc., San Francisco, CA, 2 Central R & 

D Institute, Samsung Electro-mechanics Co., Suwon, 

Republic of Korea and 3 Compound Safety Prediction, 



HIGH-THROUGHPUT GENE 

TRANSFECTION ON A THREE- 

DIMENSIONAL (3-D) CELL MICROARRAY 

PLATFORM FOR METABOLISM-INDUCED 

TOXICOLOGY SCREENING. S. Kwon 1 , J. 

Gray 2 , B. Ku 3 , J. Ryan 2 , D. Clark 4 , J. Dordick 1 and 

M. Lee 2 . 1 Department of Chemical and Biological 

Engineering, Rensselaer Polytechnic Institute, Troy, 

NY, 2 Solidus Biosciences, Inc., San Francisco, 

CA, 3 Central R & D Institute, Samsung Electro- 

Mechanics Co., Suwon, Republic of Korea and 

4 

Department of Chemical Engineering, University of 

California Berkeley, Berkeley, CA. 


CELL TOXICITY AND INTERLEUKIN (IL) 

8 PRODUCTION: UNIQUE RELATIONSHIP 

WITH ALLERGENICITY. I. Kimber 1 , C. 

F. Portsmouth 1 , R. Pendlington 2 , G. Maxwell 2 

and R. J. Dearman 1 . 1 University of Manchester, 

Manchester, United Kingdom and 2 Unilever Safety 

& Environmental Assurance Centre, Bedford, United 

Kingdom. 


SCREENING DRUG-INDUCED 

MITOCHONDRIAL TOXICITY USING A 

HIGH-THROUGHPUT DUAL-PARAMETER 

CELL BASED ASSAY. J. Hynes 2 , C. Carey 2 , S. 

Kirwan 2 , R. Swiss 1 and Y. Will 1 . 1 Compound Safety 


Groton, CT and 2 Luxcel Biosciences, Cork, Ireland. 


USING MULTIPLE ASSAYS TO ASSESS 

DRUG-INDUCED MITOCHONDRIAL 

TOXICITY IN EARLY TOXICOLOGY 

TESTING. R. Swiss, P. Rana and Y. Will. 

Compound Safety Prediction, Pfizer Global Research 

& Development, Groton, CT. 


JC-1 MITOCHONDRIAL MEMBRANE 

POTENTIAL MEASUREMENTS OF 

H9C2 CELLS GROWN IN GLUCOSE 

AND GALACTOSE CONTAINING 

MEDIA DOES NOT PROVIDE 

ADDITIONAL PREDICTIVITY TOWARDS 

MITOCHONDRIAL TOXICITY 

ASSESSMENT. P. Rana, Y. Will and S. 

Nadanaciva. Compound Safety Prediction, Pfizer 

Global Research & Development, Groton, CT. 


TREATMENT OF FATTY ACIDS INCREASES 

THE SUSCEPTIBILITY OF CELLS TO 

TOXIC COMPOUND INDUCED INJURY. 

Y. Luo, P. Rana and Y. Will. Compound Safety 


Groton, CT. 

Abstract # 


ER-STRESS AS A CONTRIBUTOR TO 

HEPATOTOXICITY: DEVELOPMENT OF 

A SCREENING PARADIGM. T. Schroeter, L. 

Qui, M. Pletcher and Y. Will. Compound Safety 


Groton, CT. 


HIGH-CONTENT IMAGING ASSAY 

FOR DETECTING ACCUMULATION 

OF COMPOUNDS IN LYSOSOMES. S. 

Nadanaciva 1 , S. Lu 2 and Y. Will 1 . 1 Compound Safety 


Groton, CT and 2 DSRD, Pfizer Global Research & 

Development, La Jolla, CA. 


CUTANEOUS WOUND HEALING IN THE 

EPIDERM-FT FULL-THICKNESS IN 

VITRO HUMAN SKIN MODEL. P. J. Hayden, 

A. Armento, C. Cooney, G. Stolper, M. Li, H. 

Kandarova and M. Klausner. MatTek Corporation, 

Ashland, MA. 


EVALUATION OF EPISKIN AND EPIDERM 

SKIN IRRITATION METHODS FOR 

TESTING SILICON-BASED MATERIALS. M. 

L. Jovanovic, J. Arthurton and P. Jean. Dow Corning, 

Auburn, MI. 


COMPARISON OF FCM AND ELISA IN 

THE EVALUATION OF THE OF SKIN 

SENSITIZATION BY NON-RADIOACTIVE 

MURINE LOCAL LYMPH NODE ASSAY 

USING BROMODEOXYURIDINE. Y. Yum 1 , 

Y. Lee 1 , K. Jung 2 , K. Lim 2 , J. Park 1 , H. Park 1 , J. 

Kim 1 , J. Yang 1 , S. Sohn 1 , J. Chung 3 and S. Han 1 . 

1 

Toxioclogical Evaluation and Research Department, 

National Institute of Drug and Food Safety 

Evaluation, Seoul, Republic of Korea, 2 Amorepacific 

Corporation R&D Center, Yougin-si, Republic of 

Korea and 3 College of Pharmacy, Seoul National 



ADAPTATION OF THE RAT HEPATOCYTES 

LONG-TERM CULTURE FOR HIGH- 

CONTENT IMAGING TO PREDICT 

CHRONIC LIVER TOXICITY IN VITRO. G. 

Davide, C. Zehnacker, P. Couttet, S. Chibout, O. 

Grenet, M. Uteng, F. Pognan, M. Dong and A. Wolf. 

Translational Sciences/Investigative Toxicology, 

Novartis Institute for Biomedical Research (NIBR), 



AN IN SILICO APPROACH FOR 

COMPUTING OCCUPATIONAL EXPOSURE 

LIMITS OF ORGANIC SOLVENTS. M. 

Debia and K. Krishnan. Département de Santé 

Environnementale et Santé au Travail, Université de 

Montréal, Montréal, QC, Canada. 


PREDICTION OF HEPATOTOXICITY IN 

ZEBRAFISH. C. Callol, C. Quevedo and A. 

Letamendia. Biobide S.L., San Sebastian, Spain. 

Sponsor: S. Tripathi. 

Thursday 







343



Thursday 



PREDICTION OF DRUG-INDUCED LIVER 

INJURY WITH HIGH SENSITIVITY AND 

SPECIFICITY WITH HIGH-CONTENT 

CELL-BASED IMAGING. R. N. Ghosh, S. 

J. Hong, B. A. Samson, K. Corkan, M. Pietila, 

C. Vasudevan and J. R. Haskins. Thermo Fisher 

Scientific, Pittsburgh, PA. 


GENE EXPRESSION PROFILING OF AN 

IN VITRO HUMAN SKIN MODEL AFTER 

PSORALEN PLUS ULTRAVIOLET LIGHT- 

INDUCED PHOTOTOXICITY. L. F. Pratt 1 , G. 

L. DeGeorge 1 and M. Cunningham 2 . 1 MB Research 

Laboratories, Spinnerstown, PA and 2 Nanomics 

Biosciences, Inc., Cary, NC. 


OXIDATIVE STRESS AND HYPOXIA AS 

FACTORS IN PHOTOTOXIC DAMAGE 

TO A RECONSTITUTED HUMAN SKIN 

MODEL: GENE EXPRESSION PROFILING 

EVIDENCE. M. Cunningham 2 , L. F. Pratt 1 and 

G. L. DeGeorge 1 . 1 MB Research Laboratories, 

Spinnerstown, PA and 2 Nanomics Biosciences, Inc., 

Cary, NC. 


8:30 AM to 12:00 NOON 

East Salon 

Poster Session: Alternatives to Animal Models in Toxicology 

Chairperson(s): Robert Landsiedel, BASF SE, Ludwigshafen am Rhein, 

Germany. 


Author Attended: 10:15 AM–12:00 NOON 


A NEW IN VITRO MODEL FOR 

IDENTIFYING LIVER SPECIFIC TOXICITY 

(LST). J. M. McKim, B. Wallace, P. C. Wilga, C. 

Toole, H. Wagner, A. Swanson and K. Rutherford. 

CeeTox, Inc., Kalamazoo, MI. 


DEVELOPING AN IN VITRO MODEL TO 

DETERMINE KIDNEY SPECIFIC TOXICITY 

(KST). J. F. Pregenzer 1 , K. Leach 2 , B. Feng 3 , B. 

Wallace 1 , D. Keller 1 , J. Willoughby 1 and J. M. 

McKim 1 . 1 CeeTox, Inc., Kalamazoo, MI, 2 Compound 

Safety Prediction, Pfizer Global Research and 

Development, Groton, CT and 3 Pharmacokinetics 

and Drug Metabolism, Pfizer Global Research and 



IN VITRO ASSESSMENT OF EYE 

TOLERANCE USING THE SKINETHIC HCE 

TEST METHOD APPLIED TO INGREDIENTS 

USED IN COSMETICS. M. H. Grandidier, N. 

Alépée, S. Blond, J. Eilstein, D. Duché, J. Cotovio 

and J. R. Meunier. L’Oréal, Aulnay sous Bois, 

France. Sponsor: H. Toutain. 


USING FUNDULUS HETEROCLITUS TO 

STUDY BENZO(A)PYRENE EFFECTS 

ON THE HYPOTHALAMUS-PITUITARY- 

GONAD (HPG) AXIS. F. T. Booc 1 , C. Thornton 1 , 

D. MacLatchy 2 , A. Lister 2 and K. L. Willett 1 . 

1 

Pharmacology, University of Mississippi, University, 

MS and 2 Biology, Wilfrid Laurier University, 

Waterloo, ON, Canada. 


PORCINE ADRENAL CORTEX 

MICROSOMES AS IN VITRO ALTERNATIVE 

ASSAY FOR SCREENING ON SEX 

STEROIDOGENESIS TOXICITY. M. Roelofs 1,2 , 

M. van den Berg 1 , A. H. Piersma 2,1 and M. B. van 

Duursen 1 . 1 Endocrine Toxicology, Institute for Risk 


Netherlands and 2 National Institute for Public Health 

and the Environment, Bilthoven, Netherlands. 


EARLY DISRUPTION OF ANGIOGENESIS- 

RELATED GENES BY METHYL 

TERT-BUTYL ETHER (MTBE) LEADS TO 

VASCULAR SPECIFIC LESIONS IN THE 

ZEBRAFISH (DANIO RERIO). J. A. Bonventre, 

L. A. White and K. R. Cooper. Joint Graduate 

Program in Toxicology, Rutgers University/UMDNJ, 



EFFECT OF TRIAZINES ON 

TESTOSTERONE BIOSYNTHESIS IN BLTK1 

MURINE LEYDIG TUMOR CELLS. A. L. 

Forgacs 1 , Q. Ding 1 , I. T. Huhtaniemi 2 , N. A. Rahman 2 

and T. R. Zacharewski 1 . 1 Michigan State University, 

East Lansing, MI and 2 University of Turku, Turku, 

Finland. 


IMPROVEMENTS AND LIMITATIONS OF 

THE BOVINE CORNEAL OPACITY AND 

PERMEABILITY TEST (BCOP, OECD TEST 

GUIDELINE 437) IN ROUTINE TESTING 

FOR SEVERE OCULAR IRRITANTS. H. 

Raabe 3 , A. Schrage 1 , R. Curren 3 , K. Norman 3 , S. 

N. Kolle 2 , M. Rey-Moreno 2 , B. van Ravenzwaay 2 

and R. Landsiedel 2 . 1 Product Safety, BASF SE, 

Ludwigshafen, Germany, 2 Experimental Toxicology 

and Ecology, BASF SE, Ludwigshafen, Germany and 

3 

Institute for In Vitro Sciences, Inc., Gaithersburg, 

MD. 


ECVAM PREVALIDATION STUDY ON 

SKIN SENSITISATION ALTERNATIVES: 

UPDATE ON PROGRESS. A. Angers-Loustau 1 , 

D. Basketter 2 , P. Aeby 3 , S. Aiba 4 , N. Alépée 8 , T. 

Ashikaga 5 , T. Cole 1 , A. Compagnoni 1 , G. Gerberick 6 , 

S. Hoffmann 7 , J. Ovigne 8 , J. Richmond 9 , H. 

Sakaguchi 10 and S. Casati 1 . 1 European Commission 

(Joint Research Centre), Ispra, Italy, 2 DABMEB 

Consultancy Ltd., Sharnbrook, Bedfordshire, United 

Kingdom, 3 Colipa, Skin Tolerance Task Force, 

Brussels, Belgium, 4 Tohoku University Graduate 

School of Medicine, Sendai, Japan, 5 Shiseido 

Quality Assessment Center, Yokohama, Japan, 

6 

Procter & Gamble, Cincinnati, OH, 7 Seh Consulting 

& Services, Koln, Germany, 8 L’Oréal Research, 

Aulnay-sous-Bois, France, 9 Home Office, Dundee, 

United Kingdom and 10 Kao Corporation Safety 

Science Research Laboratories, Tochigi, Japan. 

344 






Platform Sessions



Abstract # 


LEYDIG CELLS RESPONSES TO 

STIMULATION WITH LUTEINIZING 

HORMONE IN CULTURES FROM RATS OF 

DIFFERENT AGE. P. Balbuena, J. L. Campbell, 

R. Clewell and H. J. Clewell. The Hamner Institutes 

of Health Sciences, Research Triangle Park, NC. 


AN ORGANOTYPIC MICROLIVER 

PLATFORM FOR HIGH-THROUGHPUT 

DRUG TESTING. S. Messner 1 , B. Machi 1 , 

S. Hammad 2 , J. M. Kelm 1 , J. G. Hengstler 2 and 

W. Moritz 1 . 1 InSphero AG, Zürich, Switzerland 

and 2 IfADo Dortmund, Technical University of 

Dortmund, Dortmund, Germany. Sponsor: C. Corton. 


QUANTIFICATION OF UVA-INDUCED 

REACTIVE OXYGEN SPECIES IN PRIMARY 

HUMAN KERATINOCYTES TREATED 

WITH ANTIOXIDANTS. K. Norman, H. 

Inglis and G. Mun. Institute for In Vitro Sciences, 

Gaithersburg, MD. Sponsor: E. Dahl. 


IN VITRO ASSESSMENT OF SKIN 

IRRITATION POTENTIAL OF SURFACTANT 

BASED FORMULATIONS USING 3-D 

SKIN RECONSTRUCTED TISSUES AND 

CYTOKINE EXPRESSION ANALYSIS. L. 

Gandolfi 1 , N. Tierney 1 , D. Johnson 1 , R. Walters 1 , 

M. Fevola 1 , E. Gunn 1 , K. Martin 1 , A. Kong 2 , A. 

Hilberer 2 , N. Barnes 2 , N. Wilt 2 , J. R. Nash 2 , H. 

Inglis 2 , H. Raabe 2 and G. Costin 2 . 1 Johnson & 

Johnson, Skillman, NJ and 2 Institute for In Vitro 

Sciences, Inc., Gaithersburg, MD. 


USE OF EPIDERM FULL THICKNESS (EFT) 

SKIN CULTURES AS AN IN VITRO MODEL 

FOR WOUND HEALING. P. Hayden2, M. 

Sachdeva 1 , P. P. Shah 1 , U. S. Desai 1 , R. Patlolla 1 and 

M. Klausner 2 . 1 Pharmacy, Florida A&M University, 

Tallahassee, FL and 2 MatTek Corporation, Ashland, 

MA. 


IN VITRO BILIARY CLEARANCE OF 

PERFLUOROOCTANOATE IN SANDWICH- 

CULTURED HEPATOCYTES FROM RATS. 

D. Nabb, R. Mingoia and X. Han. DuPont Haskell 

Global Centers for Health & Environmental 

Sciences, Newark, DE. 


IDENTIFICATION OF NOVEL 

BIOMARKERS OF FORMALDEHYDE 

TOXICITY IN HUMANS USING 

FUNCTIONAL TOXICOGENOMICS IN 

YEAST. M. North 1 , C. Romero 1,2 , A. Loguinov 1 , M. 

T. Smith 2 , L. Zhang 2 and C. D. Vulpe 1 . 1 Department 

of Nutritional Science & Toxicology, The University 

of California Berkeley, Berkeley, CA and 2 Division 

of Environmental Health Sciences, School of Public 

Health, The University of California Berkeley, 

Berkeley, CA. 

Abstract # 


VALIDATION RESULTS AND METHODS 

FOR IMPROVING IN VITRO TIER 1 

ENDOCRINE DISRUPTION SCREENING 

ASSAYS. C. Toole, D. P. Blakeman, N. Nichols, 

M. Clark, H. Wagner, B. Wallace and J. M. McKim. 

CeeTox, Inc., Kalamazoo, MI. 


A NOVEL STRATEGY FOR IN VITRO 

ASSAY PLATFORM TO PREDICT SKIN 

SENSITIZING POTENTIAL OF BROAD 

RAW MATERIALS. M. Miyazawa 1 , Y. Nukada 1 , 

K. Saito 1 , H. Sakaguchi 1 , N. Nishiyama 1 and F. 

Gerberick 2 . 1 Kao Corporation, Tochigi, Japan and 

2 

Procter & Gamble Company, Cincinnati, OH. 


GENE EXPRESSION ANALYSIS OF 

PRECISION-CUT HUMAN LIVER SLICES 

INDICATE STABLE EXPRESSION OF 

HEPATOXICITY RELATED GENES. M. 

G. Elferink 2 , P. Olinga 1 , E. M. van Leeuwen 3 , 

S. Bauerschmidt 3 , J. Polman 3 , W. G. Schoonen 4 , 

S. H. Heisterkamp 5,6 and G. M. Groothuis 2 . 

1 

Pharmaceutical Technology and Biopharmacy, 

Groningen Research Institute for Pharmacy, 

Groningen, Netherlands, 2 Pharmacokinetics, 

Toxicology and Targeting, Groningen Research 

Institute for Pharmacy, Groningen, Netherlands, 

3 

Molecular Design and Informatics, MSD, Oss, 

Netherlands, 4 Toxicology &Drug Disposition, 

MSD, Oss, Netherlands, 5 Biostatistics and Research 

Decision Sciences, MSD, OSS, Netherlands and 

6 

Bioinformatics Centre, University of Groningen, 

Groningen, Netherlands. Sponsor: A. Vickers. 


MEDIA SERUM LEVELS AND IN VITRO 

HEPATIC ABSORPTION OF LINDANE. E. 

L. Croom and R. A. Pegram. Office of Research and 

Development, National Health and Environmental 

Effects Research Laboratory, U.S. EPA, Research 



AN IN VITRO MODEL FOR THE STUDY OF 

BACTERIAL COLONIZATION OF HUMAN 

EXTRAPLACENTAL MEMBRANES: 

ROLE OF ANTIMICROBIAL PEPTIDES. E. 

Boldenow 1 , S. Jones 1 , C. Xi 1 , R. Lieberman 2 and 

R. Loch-Caruso 1 . 1 Environmental Health Sciences, 

University of Michigan, Ann Arbor, MI and 

2 

Obstetrics and Gynecology, University of Michigan, 

Ann Arbor, MI. 


EVALUATION OF AN ORAL CARE 

PRODUCT SAFETY SCREENING PROGRAM 

UTILIZING THE IN VITRO SKINETHIC 

HUMAN GINGIVAL EPITHELIUM (RHG) 

AND ORAL BUCCAL (RHO) MODELS. 

L. Wurzburger 1 , P. Kazmi 1 , T. Re 1 , A. Alonso 2 , 

B. Bertino 2 , N. Barnes 3 , A. de Brugerolle de 

Fraissinette 2 , A. Hilberer 3 , H. Raabe 3 , N. Wilt 3 and 

V. Srinivasan 1 . 1 L’Oreal USA Products, Clark, NJ, 

2 

SkinEthic Laboratories, Nice, France and 3 Institute 

for In Vitro Sciences, Inc., Gaithersburg, MD. 

Thursday 







345



Thursday 



TRANSLATIONAL RESPONSE TO 

ARSENITE LEADS TO P-BODY AND PAB1P- 

CONTAINING GRANULE ASSEMBLY 

IN THE YEAST SACCHAROMYCES 

CEREVISIAE. V. Stribinskis, M. W. Gordon, J. 

P. Moore, S. R. Ellis and K. S. Ramos. Biochemistry 

and Molecular Biology, University of Louisville, 



VALIDATION OF IN VITRO DIGESTION 

MODELS FOR POLYCYCLIC AROMATIC 

HYDROCARBON BIOACCESSIBILITY 

FROM SOIL USING THE IN VIVO SWINE 

MODEL. K. James 1 , R. E. Peters 1 , B. Laird 1 , 

W. Ma 2 , M. Wickstrom 3 , G. Stephenson 2 and 

S. D. Siciliano 4 . 1 Soil Science, University of 

Saskatchewan, Saskatoon, SK, Canada, 2 Stantec 

Consulting Inc., Guelph, ON, Canada, 3 Toxicology 

Centre, University of Saskatchewan, Saskatoon, 

SK, Canada and 4 Toxicology Group, University of 

Saskatchewan, Saskatoon, SK, Canada. Sponsor: L. 

Weber. 


IN VITRO EVALUATION OF AIRWAY 

TOXICITY USING THE EPIAIRWAY 

ORGANOTYPIC IN VITRO HUMAN AIRWAY 

MODEL. G. R. Jackson, J. Bolmarcich, H. 

Kandarova, S. Letasiova, M. Klausner and P. J. 

Hayden. MatTek Corp., Ashland, MA. 


DEVELOPMENT OF THE REPLACEMENT 

OCULAR BATTERY-ROBATT-TIERED 

TESTING STRATEGY OF ALTERNATIVE 

TOXICOLOGY TESTS TO REPLACE 

THE NEED FOR RABBIT EYE TESTS. D. 

Cerven, G. DeGeorge and M. Piehl. MB Research 

Laboratories, Spinnerstown, PA. 


THE EYES HAVE IT: CALF VERSUS ADULT 

EYES IN THE BOVINE CORNEAL OPACITY 

AND PERMEABILITY (BCOP) ASSAY. D. A. 

Donahue 2 , D. Cerven 1 , G. DeGeorge 1 and J. Avalos 2 . 

1 

MB Research Laboratories, Spinnerstown, PA and 

2 

Kao Brands Company, Cincinnati, OH. 


APPLICATION OF AVAILABLE 

ALTERNATIVE METHODS TO PREDICT 

SKIN SENSITIZATION OF PRESERVATIVES. 

S. Martinozzi Teissier, C. Piroird, S. Ringeissen, 

J. Eilstein, D. Duché, J. Ovigne and J. Meunier. 

L’Oréal, Aulnay sous Bois, France. Sponsor: H. 

Toutain. 


IL-18 SECRETION AS A MARKER 

FOR IDENTIFICATION OF CONTACT 

SENSITIZERS IN THE EPIDERM IN VITRO 

HUMAN SKIN MODEL. W. Deng, J. Oldach, A. 

Armento, S. Ayehunie, H. Kandarova, S. Letasiova, 

M. Klausner and P. J. Hayden. MatTek Corporation, 

Ashland, MA. 


INCREASED ARSENIC BIOACCESSIBILITY 

DUE TO MICROBIAL ACTIVITY DOES NOT 

AFFECT ARSENIC BIOAVAILABILITY. B. 

Laird 1 , T. Van De Wiele 2 , M. Dodd 4 , S. Casteel 3 

and S. D. Siciliano 1 . 1 University of Saskatchewan, 

Saskatoon, Saskatchwean, Canada, 2 Ghent 

University, Ghent, Belgium, 3 University of Missouri 

Columbia, Columbia, MO and 4 Royal Roads 

University, Victoria, BC, Canada. Sponsor: L. Weber. 


AN INTEGRATED APPROACH TO THE 

RISK ASSESSMENT OF DRUG PRODUCTS. 

M. Derzi 1 and R. Naven 2 . 1 DSRD, Pfizer, Cambridge, 

MA and 2 CSPG, Pfizer, Groton, CT. Sponsor: Y. Will. 


PARP-1 ACTIVITY IS INVOLVED IN 

THE SOLAR UV-INDUCED CUTANEOUS 

INFLAMMATORY RESPONSE IN THE 

EPIDERM-FT IN VITRO HUMAN SKIN 

MODEL. H. Kandarova, A. Armento, J. Oldach, C. 

Cooney, G. Stolper, M. Klausner and P. J. Hayden. 

MatTek Corporation, Ashland, MA. 


TIMECOURSE OF HEALING AFTER 

UV-INDUCED DAMAGE IN THE EPIDERM- 

FT IN VITRO HUMAN SKIN MODEL. G. 

Stolper, C. Cooney, A. Armento, J. Oldach, S. 

Letasiova, M. Klausner and P. J. Hayden. MatTek 

Corporation, Ashland, MA. 


8:30 AM to 12:00 NOON 

East Salon 

Poster Session: Disease Prevention 

Chairperson(s): Richard LoPachin, Montefiore Medical Center, Bronx, 

NY, and Bruce Fowler, ATSDR/CDC, Atlanta, GA. 




A FULLERENE DECREASED 

ORGANOPHOSPHATE-INDUCED TOXICITY 

IN MICE. M. Ehrich 1 , K. Fuhrman 1 , J. Hinckley 1 , 

B. S. Jortner 1 , S. Werre 1 , R. Van Tassell 2 , Z. Zhao 3 

and C. R. Kepley 3 . 1 Virginia-Maryland Regional 

College of Veterinary Medicine, Virginia Tech, 

Blacksburg, VA, 2 Luna Innovations, Blacksburg, VA 

and 3 Luna NanoWorks, Danville, VA. 


PROLINE RICH POLYPEPTIDES MITIGATE 

THE EFFECTS OF WHOLE-BODY 

IRRADIATION IN MICE. K. D. Thrall 1 , M. 

Franch 2 , J. E. Morris 1 and R. E. Weller 1 . 1 Battelle, 

Pacific Northwest Division, Richland, WA and 

2 



PROTECTIVE ROLE OF DEFEROXAMINE 

ON BEHAVIORAL EFFECTS IN 

TRANSGENIC (TG-2576) MICE EXPOSED 

TO A HIGH ALUMINUM DOSE. M. Gómez, J. 

L. Domingo, T. Garcia, D. Ribes and M. Colomina. 

Toxicology and Environmental Health, Universitat 

Rovira i Virgili, Reus, Spain. 

346 






Platform Sessions



Abstract # 


ARE THE NEUROTOXIC EFFECTS OF 

MANGANESE DUE TO BLOCKAGE OF 

POST-SYNAPTIC DOPAMINE RECEPTORS. 

M. Nelson, T. Adams, D. Beaubrun, M. A. Carroll 

and E. J. Catapane. Biology, Medgar Evers College, 

Brooklyn, NY. 


THE ABILITY OF PAS, ACETYLSALICYLIC 

ACID, AND CALCIUM EDTA TO PROTECT 

AGAINST THE TOXIC EFFECTS OF 

MANGANESE ON MITOCHONDRIAL 

RESPIRATION AND MEMBRANE 

POTENTIAL IN THE GILL OF 

CRASSOSTREA VIRGINICA. C. Saddler, L. 

Duncanson, J. Joseph, S. Crawford, E. J. Catapane 

and M. A. Carroll. Biology, Medgar Evers College, 

Brooklyn, NY. 


INTERNATIONAL WORKSHOP ON 

ALTERNATIVE METHODS TO REDUCE, 

REFINE, AND REPLACE THE USE OF 

ANIMALS IN VACCINE POTENCY AND 

SAFETY TESTING. J. Kulpa-Eddy 1 , R. 

McFarland 2 , R. Isbrucker 3 , M. Halder 4 , H. Kojima 5 , 

B. Jones 6 , N. Johnson 6 , D. Allen 6 , E. Lipscomb 6 , 

S. Morefield 6 , W. Casey 7 and W. Stokes 7 . 1 USDA, 

Riverdale, MD, 2 U.S. FDA, Rockville, MD, 3 Health 

Canada, Ottawa, ON, Canada, 4 ECVAM, Ispra, 

Italy, 5 JaCVAM, Tokyo, Japan, 6 ILS, Inc., Research 

Triangle Park, NC and 7 NICEATM, NIEHS, 



ENERGY BALANCE IN MICE CONSUMING 

A HIGH FAT DIET AND WHEY PROTEIN. 

H. G. Shertzer 1 , S. E. Woods 1 , M. Krishan 1 , M. 

Genter 1 and K. J. Pearson 2 . 1 Environmental Health, 

University of Cincinnati Medical Center, Cincinnati, 

OH and 2 Graduate Center for Nutritional Sciences, 

University of Kentucky, Lexington, KY. 


A COMPARATIVE STUDY OF 

NICOTINAMIDE AND TAURINE FOR ANTI- 

DIABETIC AND ANTIOXIDANT ACTIONS IN 

STREPTOZOTOCIN-INDUCED DIABETES 

IN RATS. K. G. Pandya and C. A. Lau-Cam. St. 

John’s University, Jamaica, NY. 


COMPARISON OF THE EFFECTS 

OF NICOTINAMIDE AND TAURINE 

IN THE BRAIN AND SPINAL CORD 

AGAINST OXIDATIVE STRESS BY 

STREPTOZOTOCIN-INDUCED DIABETES 

IN RATS. S. N. Patel and C. A. Lau-Cam. St. 

John’s University, Jamaica, NY. 


PROTECTIVE EFFICACY OF A 

COMBINATION OF HUPERZINE A 

STEREOISOMERS AGAINST SOMAN 

EXPOSURE IN GUINEA PIGS. Y. Wang 1 , Y. 

Wei 1 , S. Oguntayo 1 , N. Jensen 2 and M. P. Nambiar 1,3 . 

1 

Closed Head Injury, Walter Reed Army Institute 

of Research, Silver Spring, MD, 2 Collaborative 

Research Facility, U.S. Army Medical Research 

Institute of Chemical Defense, Edgewood, MD 

and 3 Department of Medicine, Uniformed Services 

University of the Health Sciences, Bethesda, MD. 

Abstract # 


ENHANCED NRF2 ACTIVATION 

ATTENUATES FASTING-INDUCED FATTY 

LIVER. J. Xu 1 , J. Moscovitz 1 , M. Yamamoto 2 and A. 

L. Slitt 1 . 1 Biomedical and Pharmaceutical Sciences, 

University of Rhode Island, Kingston, RI and 

2 

Medical Biochemistry, Tohoku University Graduate 

School of Medicine, Sendai, Japan. 


PROTECTION OF RETINAL VESSELS 

FROM HYPEROXIC INJURY BY 

β-NAPHTHOFLAVONE (BNF) IN NEWBORN 

RATS. X. Couroucli, Y. W. Liang, L. Wang, W. 

Jiang and B. Moorthy. Pediatrics, Baylor College of 

Medicine, Houston, TX. 


HYPOXIA-ISCHEMIA TRIGGERS BAX 

PHOSPHORYLATION, TRANSLOCATION, 

AND RESULTANT CELL DEATH 

PHENOTYPE. S. Krishnan 1 , M. Gill 2 and R. 

Perez-Polo 1 . 1 Biochemistry and Molecular Biology, 

University of Texas Medical Branch, Galveston, TX 

and 2 Northwestern University, Chicago, IL. Sponsor: 

J. Ward. 


ESTIMATING THE GLOBAL PUBLIC 

HEALTH IMPLICATIONS OF ELECTRICITY 

AND COAL CONSUMPTION. J. M. Gohlke 1,4 , 

R. Thomas 4 , A. Woodward 3 , D. Campbell-Lendrum 2 , 

A. Pruss-Ustun 2 , S. Hales 2 and C. J. Portier 4 . 

1 


Alabama at Birmingham, Birmingham, AL, 2 Public 

Health and Environment, World Health Organization, 

Geneva, Switzerland, 3 Population Health, 

University of Auckland, Auckland, New Zealand 

and 4 Laboratory of Molecular Toxicology, NIEHS, 



SELENIUM FROM OCEAN FISH PREVENTS 

METHYLMERCURY TOXICITY. L. Raymond 

and N. Ralston. Energy & Environmental Research 

Center, University of North Dakota, Grand Forks, 

ND. 


IS CHELATION THE MECHANISM 

OF ACTION OF P-AMINOSALICYLIC 

ACID (PAS) IN THE TREATMENT OF 

MANGANISM? V. Petion, J. Rios, J. Mayne, J. 

Hilaire, D. Nicholson, D. Skeete, K. Ruddock, M. A. 

Carroll and E. J. Catapane. Biology, Medgar Evers 

College, Brooklyn, NY. 



TOXICITY: THERAPEUTIC EFFECT OF 

PARA-AMINO SALICYLIC ACID IN A RAT 

MODEL. A. Epur 1,2 , J. Xu 1,2 , W. Zheng 1 and 

U. Dydak 1,2 . 1 School of Health Sciences, Purdue 

University, West Lafayette, IN and 2 Department of 

Radiology and Imaging Sciences, Indiana University 


Thursday 







347



Thursday 



DIABETES-INDUCED CARDIAC 

INFLAMMATION AND PATHOLOGICAL 

CHANGES WERE PREVENTED BY WHOLE- 

BODY LOW-DOSE IRRADIATION. C. 

Zhang 2,1 , X. Li 2,1 and L. Cai 1,2 . 1 Department of 

Pediatrics, University of Louiville, Louisville, 

KY and 2 Chinese-American Research Institute for 

Diabetic Complications, Wenzhou, Jilin, China. 


8:30 AM to 12:00 NOON 

East Salon 

Poster Session: Developmental Neurotoxicity: General 

Chairperson(s): Phillip Bushnell, U.S. EPA, Research Triangle Park, NC, 

and Dongren Yang, University of California Davis, Davis, CA. 


Author Attended: 10:15 AM–12:00 NOON 


SEROTONIN, OXIDATIVE STRESS, AND 

DOPAMINE PATHWAYS: THE TARGETS 

FOR AUTISM TREATMENT. A. L. Palazzolo 1,2 

and E. Demchuk 1 . 1 Division of Toxicology & 

Environmental Medicine, ATSDR/CDC, Atlanta, 

GA and 2 Biomedical Engineering, Rensselaer 

Polytechnic Institute, Troy, NY. Sponsor: B. Fowler. 


UNRAVELING THE EFFECTS OF 

DEVELOPMENT ON THE OLFACTORY 

SYSTEM IN A BRDU-INDUCED 

DEVELOPMENTAL DISORDER MODEL 

RAT. M. Kuwagata 1,2 , T. Ogawa 2,3 , T. Nagata 1 

and S. Shioda 2 . 1 Toxicology, Hatano Research 

Institute, FDSC, Hadano, Japan, 2 Anatomy I, Showa 

University School of Medicine, Shinagawa, Tokyo, 

Japan and 3 Anti-Aging, Medicine Funded Research 

Labs, Showa University School of Medicine, 

Shinagawa, Tokyo, Japan. 


PHENCYCLIDINE-INDUCED APOPTOSIS 

AND CHANGES IN GENE EXPRESSION IN 

POSTNATAL RAT PUPS. N. V. Sadovova 1 , F. 

Liu 2 , X. Zhang 2 , L. Shi 3 , L. Guo 3 , F. Quan 4 , Z. Wen 4 , 

C. Wang 2 , T. A. Patterson 5 , J. P. Hanig 2 , M. G. Paule 2 

and W. Slikker 2 . 1 Toxicologic Pathology Associates, 

Jefferson, AR, 2 Division of Neurotoxicology, 

NCTR/U.S. FDA, Jefferson, AR, 3 Division of 

System Toxicology, NCTR/U.S. FDA, Jefferson, AR, 

4 

Z-Tech, ICF International Company, Jefferson, AR 

and 5 CDER /U.S. FDA, Silver Spring, MD. 


GENE EXPRESSION IN KETAMINE- 

EXPOSED RAT BRAIN. C. Wang 1 , Q. Shi 2 , 

L. Guo 3 , T. A. Patterson 1 , S. Dial 2 , Q. Li 4 , N. 

Sadovova 5 , X. Zhang 1 and J. P. Hanig 6 . 1 Division of 


Research /U.S. FDA, Jefferson, AR, 2 Division 

of Systems Toxicology, National Center for 

Toxicological Research /U.S. FDA, Jefferson, 

AR, 3 Division of Biomedical Toxicology, National 

Center for Toxicological Research /U.S. FDA, 

Jefferson, AR, 4 Microarray Core Facility, UTSW 

Medical Center, Dallas, TX, 5 Toxicologic Pathology 

Associates, Jefferson, AR and 6 Center for Drug 

Evaluation and Research /U.S. FDA, Silver Spring, 

MD. 


MIDAZOLAM-INDUCED CHANGES IN 

GENE EXPRESSION IN POSTNATAL RAT 

PUP BRAIN. F. Liu 1 , S. W. Rainosek 2 , J. Zhang 3 , 

L. Guo 4 , L. Shi 5 , N. Sadovova 6 , M. G. Paule 1 and 

W. Slikker 1 . 1 Division of Neurotoxicology, National 

Center for Toxicological Research, Jefferson, AR, 

2 

UAMS College of Medicine, Little Rock, AR, 

3 

Z-Tech, an ICF International Company at NCTR, 

Jefferson, AR, 4 Division of Biomedical Toxicology, 

NCTR /U.S. FDA, Jefferson, AR, 5 Division of 

System Toxicology, NCTR /U.S. FDA, Jefferson, AR 

and 6 Toxicologic Pathology Associates, Jefferson, 

AR. 


DIFFERENT APOPTOTIC RESPONSE 

IN MOUSE BRAIN AFTER NEONATAL 

EXPOSURE TO DIFFERENT FLAME 

RETARDANTS. H. Viberg. Department. 

Environmental Toxicology, Uppsala University, 



SEX SPECIFIC EFFECTS ON NEUROGLIAL 

DEVELOPMENT FOLLOWING 

DEVELOPMENTAL EXPOSURE TO PCBs: 

IMPLICATIONS FOR ADHD RISK IN 

MALES. R. F. Seegal 1,2 , K. Andrews 1 , S. Sanchez- 

Morrissey 1 , K. O. Brosch 1 and V. M. Miller 1,2 . 

1 

Wadsworth Center, New York State Department of 

Health, Albany, NY and 2 School of Public Health, 

University at Albany, Albany, NY. 


PRE-PULSE INHIBITION AND THE 

STARTLE RESPONSE IN GENETICALLY 

DIFFERENT PCB-TREATED MICE. C. P. 

Curran, B. Hays, E. Altenhofen, R. Floyd and A. 

Mynhier. Biological Sciences, Northern Kentucky 

University, Highland Heights, KY. 


GENETIC DIFFERENCES IN ADULT STRESS 

RESPONSE FOLLOWING GESTATIONAL 

AND LACTATIONAL EXPOSURE TO 

POLYCHLORINATED BIPHENYLS IN MICE. 

E. Altenhofen, B. Hays, C. Kamau-Cheggeh, A. 

Ashworth, J. Phillips and C. P. Curran. Biological 

Sciences, Northern Kentucky University, Highland 

Heights, KY. 

348 






Platform Sessions



Abstract # 


GENETIC DIFFERENCES IN PORSOLT 

FORCED SWIM BEHAVIOR AND PEAK 

CORTICOSTERONE LEVELS IN PCB AND 

CORN OIL-TREATED MICE. C. Kamau- 

Cheggeh, R. Floyd, E. Altenhofen, B. Hays and C. 

P. Curran. Biological Sciences, Northern Kentucky 

University, Highland Heights, KY. 


DEVELOPMENTAL EXPOSURE TO PBDE 

209 ALTERS ADULT SUSCEPTIBILITY TO 

PARAOXON AND NICOTINE: GENDER 

AND NEUROBEHAVIOURAL ANALYSIS. S. 

Buratovic, A. Fredriksson, H. Viberg and P. Eriksson. 

Department of Environmental Toxicology, Uppsala 

University, Uppsala, Sweden. 


CO-EXPOSURE TO RADIATION AND 

ENVIRONMENTAL TOXICANTS (PBDE 

99 AND MEHG) DURING A DEFINED 

CRITICAL PHASE OF NEONATAL BRAIN 

DEVELOPMENT ENHANCES COGNITIVE 

DEFECTS IN ADULT MICE. P. Eriksson 1 , 

B. Stenerlöw 2 , A. Fredriksson 1 and S. Sundell- 

Bergman 3 . 1 Department of Environmental 

Toxicology, Uppsala University, Uppsala, Sweden, 

2 

Division of Biomedical Radiation Sciences, 

Rudbeck Laboratory, Uppsala University, Uppsala, 

Sweden and 3 Department of Soil and Environment, 

Swedish University of Agricultural Sciences, 



PERINATAL EXPOSURE OF MICE TO 

DIOXIN INDUCES DEPRESSION-LIKE 

BEHAVIOR IN A LOW-DOSE SPECIFIC 

MANNER. A. Haijima, Y. Zhang, T. Endo, 

M. Kakeyama and C. Tohyama. Laboratory of 

Environmental Health Sciences, Center for Disease 

Biology and Integrative Medicine, Graduate School 

of Medicine, University of Tokyo, Tokyo, Japan. 


ASSESSING LATER-LIFE BEHAVIORAL 

PHENOTYPES IN RESPONSE TO 

PRENATAL EXPOSURE TO BENZOPYRENE. 

M. M. McCallister 1 , M. Maguire 2 , A. Ramesh 3 and D. 

B. Hood 4 . 1 Neuroscience and Pharmacology, Meharry 

Medical College, Nashville, TN, 2 Neuroscience and 

Pharmacology, Meharry Medical College, Nashville, 

TN, 3 Biochemistry and Cancer Biology, Meharry 

Medical College, Nashville, TN and 4 Neuroscience 

and Pharmacology, Meharry Medical College, 



DEVELOPMENTAL IODIDE DEFICIENCY: 

REDUCTIONS IN THYROID HORMONES 

AND IMPAIRED HIPPOCAMPAL 

TRANSMISSION. M. Gilbert 1 , J. Hedge 1 , R. 

Zoeller 2 , K. Kannan 3 , K. Crofton 1 , L. Valentin- 

Blasini 4 , B. Blount 4 and J. Fisher 5 . 1 U.S. EPA, 

Research Triangle Park, NC, 2 University of 

Massachusetts, Amherst, MA, 3 New York 

Department Health, Albany, NY, 4 CDC, Atlanta, GA 

and 5 U.S. FDA, Little Rock, AR. 

Abstract # 


IMPAIRED PERFORMANCE ON AN 

OPERANT LEARNING TASK DURING 

LIFETIME EXPOSURE TO ACRYLAMIDE 

IN FISCHER 344 RATS. M. G. Paule 1 , 

C. S. Roegge 1 and J. D. Garey 2 . 1 Division of 


Research U.S. FDA, Jefferson, AR and 2 SRC, Inc., 

Arlington, VA. 


BIOFUELS HEALTH RESEARCH AT THE 

EPA: INITIAL STUDIES WITH INHALED 

ETHANOL IN RATS. P. J. Bushnell 1 , T. E. 

Beasley 1 , W. K. Boyes 1 , H. El-Masri 1 , P. A. Evansky 1 , 

J. Ford 1 , M. E. Gilbert 1 , D. W. Herr 1 , W. R. LeFew 1 , 

S. A. Martin 1 , K. L. McDaniel 1 , E. D. McLanahan 2 , 

V. C. Moser 1 , D. K. MacMillan 1 and W. M. Oshiro 1 . 

1 

NHEERL, U.S. EPA, Research Triangle Park, NC 

and 2 NCEA, U.S. EPA, Research Triangle Park, NC. 


ACETAMINOPHEN METABOLITES 

MAY MODULATE HIPPOCAMPAL 

SENSITIVITY TO SEROTONIN AND SOCIAL 

INTERACTION BEHAVIOR THROUGH CB1 

RECEPTORS. G. G. Gould 1 , L. Nguyen 2 , T. F. 

Burke 2 , J. G. Hensler 2 , K. Treat 1 , L. C. Daws 1 and 

T. Gu 3 . 1 Physiology, University of Texas Health 

Science Center at San Antonio, San Antonio, TX, 

2 

Pharmacology, University of Texas Health Science 

Center at San Antonio, San Antonio, TX and 

3 

Restorative Dentistry, University of Texas Health 

Science Center at San Antonio, San Antonio, TX. 


PERSISTENT CNS EFFECTS OF 

POSTNATAL EXPOSURE TO 

CONCENTRATED AMBIENT PARTICLES. 

J. L. Allen, J. N. Finkelstein, C. J. Johnston, G. 

Oberdörster and D. A. Cory-Slechta. Environmental 

Medicine & Pediatrics, University of Rochester 

Medical Center, Rochester, NY. 


LIFE SPAN ALCOHOL EXPOSURE 

MONITORED BY FDG BRAIN PET 

IMAGING. MORE INFORMATION FROM 

FEWER ANIMALS. D. De Groot 1 , M. Boogaard 1 , 

R. Nederlof 1 , M. Berk 1 , E. Uitvlugt 2 , L. vd Horst 1 , 

M. Otto 1 , A. Wolterbeek 1 and E. De Vries 2 . 1 TNO 

Quality of Life, Zeist, Netherlands and 2 Groningen 

University Medical Center, Groningen, Netherlands. 

Sponsor: R. Woutersen. 


APPLICATION OF LONG-TERM 

AUTOMATED MONITORING OF HOME- 

CAGE BEHAVIOUR IN DEVELOPMENTAL 

NEUROTOXICITY STUDIES. N. Onishchenko, 

S. Spulber and S. Ceccatelli. Department of 

Neuroscience, Karolinska Institutet, Stockholm, 

Sweden. 

Thursday 







349



Thursday 



AUTOMATED VIDEO IMAGE ANALYSIS 

FOR ACTIVITY MONITORING IN 

AN EXTENDED ONE GENERATION 


LEAD ACETATE. D. J. Esdaile 1 , R. Kubaszky 1 , T. 

Hanley 2 , D. Minnema 2 and R. Lewis 3 . 1 Lab Research 

Ltd., Veszprem, Hungary, 2 Syngenta Crop Protection 

LLC, Greensboro, NC and 3 Syngenta, Jealotts Hill, 

Bracknell, United Kingdom. 


PERIPHERAL NEUROPATHY IN 

AN EXTENDED ONE GENERATION 


LEAD ACETATE. J. Wright 1 , P. Maslej 2 , R. 

Kubaszky 2 , D. J. Esdaile 2 , T. Hanley 3 , D. Minnema 3 

and R. Lewis 1 . 1 Syngenta, Jealotts Hill, Bracknell, 

United Kingdom, 2 Lab Research Ltd., Veszprem, 

Hungary and 3 Syngenta Crop Protection LLC, 



EVALUATION OF THE EFFECT OF 

DONEPEZIL AND CLONIDINE ON 

LEARNING MEMORY AND STARTLE 

RESPONSE IN WISTAR RATS USING ANY- 

MAZE VIDEO TRACKING SYSTEM AND 

STARTLE MONITOR SYSTEM. M. V. Patel, 

S. M. Paneliya and K. Z. Patani. Toxicology, Jai 

Research Foundation, Valvada, Gujarat, India. 

Sponsor: P. Deshmukh. 


IN VIVO LONGITUDINAL MAGNETIC 

RESONANCE SPECTROSCOPY OF THE 

DEVELOPING RAT BRAIN. S. Liachenko and J. 

Ramu. Neurotoxicology, NCTR/U.S. FDA, Jefferson, 

AR. Sponsor: M. Paule. 


EFFECT OF LOW-GLUCOSE OR HIGH- 

INSULIN CONDITION ON RAT PRIMARY 

PERIPHERAL NEURON. T. Kawataki, T. 

Yamamoto, H. Takatani, M. Wasaki and E. Kume. 

Safety Research Laboratory, Mitsubishi Tanabe 

Pharmacology Corporation, Saitama, Japan. Sponsor: 

J. Sugimoto. 


SYNAPTOGENESIS IN PRIMARY 

HIPPOCAMPAL NEURONS IS MODULATED 

BY ETHANOL-TREATED ASTROCYTES. 

P. J. Roque 1 , L. G. Costa 1 , G. Giordano 1 and M. 

Guizzetti 2 . 1 DEOHS, University of Washington, 

Seattle, WA and 2 Department of Psychiatry, 

University of Illinois at Chicago and Jesse Brown VA 

Medical Center, Chicago, IL. 


CHRONIC EXPOSURE REDUCES ACUTE 

DOMIC ACID TOXICITY IN VITRO: ROLE 

OF GLUTATHIONE. G. Giordano 1 , T. J. 

Kavanagh 1 , E. M. Faustman 1 and L. G. Costa 1,2 . 

1 


Health Sciences, University of Washington, 


Pharmacology and Forensic Science, University of 



METHYLMERCURY AND NON-DIOXIN 

LIKE POLYCHLORINATED BIPHENYLS 

INTERFERE WITH NEURONAL 

DIFFERENTIATION OF CORTICAL 

NEURAL STEM CELLS. W. Ibrahim 1 , R. 

Tofighi 1 , P. Rebellato 2 , R. Bose 1 , P. Andersson 3 , 

P. Uhlen 2 and S. Ceccatelli 1 . 1 Department of 

Neuroscience, Karolinska Institutet, Stockholm, 

Sweden, 2 Department of Medical Biochemistry 

and Biophysics, Karolinska Institutet, Stockholm, 

Sweden and 3 Department of Chemistry, Umeå 

Universitet, Umeå, Sweden. 


NON-DIOXIN-LIKE POLYCHLORINATED 

BIPHENYLS (PCBS) ENHANCE DENDRITIC 

GROWTH IN CULTURED HIPPOCAMPAL 

NEURONS VIA RYANODINE RECEPTOR 

(RYR)-DEPENDENT ACTIVATION OF 

CALCIUM-DEPENDENT SIGNALING 

PATHWAYS. D. D. Bose 1 , D. Yang 1 , G. Wayman 2 , 

A. Lesiak 2 , D. Bruun 1 , I. N. Pessah 1 and P. J. Lein 1 . 

1 

Veterinary Molecular Biosciences, University of 

California Davis, Davis, CA and 2 Veterinary and 

Comparative Anatomy, Washington State University, 

Pullman, WA. 


ENANTIOSELECTIVE EFFECTS OF 

PCB136 ON DENDRITIC GROWTH ARE 

RYANODINE RECEPTOR-DEPENDENT. D. 

Yang 1 , I. Kania-Korwel 2 , D. Bose 1 , A. Ghogha 1 , I. 

Pessah 1 , H. Lehmler 2 and P. Lein 1 . 1 VM: Molecular 

Biosciences, University of California Davis, Davis, 

CA and 2 Occupational & Environmental Health, 

University of Iowa, Iowa City, IA. 


POLYCHLORINATED BIPHENYLS (PCBS) 

ALTER GLUTAMATE RELEASE FROM 

PRESYNAPTIC NERVE TERMINALS 

ISOLATED FROM THE RAT HIPPOCAMPUS 

INDEPENDENT OF ARYL HYDROCARBON 

RECEPTOR (AHR) MEDIATED GENE 

TRANSCRIPTION. N. Newman and F. Schanne. 

Pharmaceutical Sciences, St. John’s University, 

Queens, NY. 


NEUROBEHAVIORAL AND 

TRANSCRIPTIONAL CONSEQUENCES OF 

ESTROGEN RELATED RECEPTOR GAMMA 

ACTIVATION BY LOW-DOSE BISPHENOL 

A EXPOSURE DURING NEUROGENESIS. 

K. S. Saili, M. M. Corvi, J. Przybyla, J. K. LaDu, 

K. A. Anderson and R. L. Tanguay. Department 

of Environmental & Molecular Toxicology, 

Environmental Health Sciences Center, Oregon State 


350 






Platform Sessions



Abstract # 


EFFECTS OF RADIO FREQUENCY 

RADIATION EXPOSURE FROM MOBILE 

PHONES ON BRAIN MICROVESSEL 

ENDOTHELIAL CELLS, A MODEL OF 

BLOOD BRAIN BARRIER: AN IN VITRO 

STUDY. E. Cuevas 1 , S. M. Lantz 1 , W. J. Trickler 1 , 

B. R. Robinson 1 , G. D. Newport 1 , P. C. Howard 2 , N. 

J. Walker 3 , M. Wyde 3 , A. Desta 4 , M. G. Paule 1 and 

S. F. Ali 1 . 1 Neurochemistry Laboratory, Division 

of Neurotoxicology, NCTR/U.S. FDA, Jefferson, 

AR, 2 Office of Scientific Coordination, NCTR/U.S. 

FDA, Jefferson, AR, 3 National Toxicology Program, 

NIEHS, Research Triangle Park, NC and 4 ODE, 

CDRH/U.S. FDA, Silver Spring, MD. 


REARING CONDITIONS DIFFERENTIALLY 

AFFECT THE LOCOMOTOR BEHAVIOR 

OF LARVAL ZEBRAFISH, BUT NOT THEIR 

RESPONSE TO VALPROATE-INDUCED 

DEVELOPMENTAL NEUROTOXICITY. D. 

Zellner 1 , B. Padnos 2 , D. L. Hunter 2 , R. C. MacPhail 3 

and S. Padilla 2 . 1 Meredith College, Raleigh, NC, 

2 

ISTD, U.S. EPA, Research Triangle Park, NC and 

3 

TAD, U.S. EPA, Research Triangle Park, NC. 


ASSESSMENT OF CHEMICAL EFFECTS 

ON NEURITE OUTGROWTH, NEURONAL 

POLARIZATION, AND SYNAPTOGENESIS 

IN RAT CORTICAL NEURONS USING HIGH 

CONTENT IMAGE ANALYSIS. B. L. Robinette, 

J. A. Harrill and W. R. Mundy. Integrated Systems 

Toxicology Division, NHEERL, U.S. EPA, Research 



8:30 AM to 12:00 NOON 

East Salon 

Poster Session: Cancinogenesis II 

Chairperson(s): Sakina Eltom, Meharry Medical College, Nashville, TN. 




INITIATING EFFECTS OF 

METHYLEUGENOL IN RAT LIVER. M. 

J. Iatropoulos, A. M. Jeffrey, J. Duan and G. M. 

Williams. Department of Pathology, New York 

Medical College, Valhalla, NY. 


LIVER TOXICITY FOLLOWING KAVA 

KAVA ADMINISTRATION IN F344 RATS 

AND B6C3F1 MICE. M. Behl 1 , R. S. Chhabra 1 , 

A. Nyska 2 , L. Fomby 3 , B. R. Sparrow 3 , M. R. 

Hejmancik 3 and P. C. Chan 1 . 1 NTP, NIH, Research 

Triangle Park, NC, 2 Timrat and Sackler School of 

Medicine, Tel Aviv University, Timrat, Israel and 

3 

Battelle, Columbus, OH. 

Abstract # 


USING DNA-BASED MEASUREMENT 

OF ONCOMUTATION TO UNDERSTAND 

CARCINOGEN MODE OF ACTION. Y. 

Wang, F. Meng, P. B. McKinzie, M. B. Myers and 

B. L. Parsons. Division of Genetic and Molecular 


Research/U.S. FDA, Jefferson, AR. 


ANALYSIS OF PEROXISOME 

PROLIFERATOR-ACTIVATED 

RECEPTOR GAMMA (PPARγ) 

AGONIST TROGLITAZONE-INDUCED 

TRANSCRIPTIONAL CHANGES IN MOUSE 

ENDOTHELIAL CELLS. S. Kakiuchi-Kiyota 1 , 

L. L. Arnold 1 , P. Koza-Taylor 2 , S. Suzuki 3 and S. M. 

Cohen 1 . 1 Pathology and Microbiology, University 

of Nebraska Medical Center, Omaha, NE, 2 Pfizer 

Drug Safety and Development, Groton, CT and 

3 

Department of Experimental Pathology and Tumor 

Biology, Nagoya City University Graduate School of 

Medical Sciences, Nagoya, Aichi, Japan. 


RALOXIFENE IS CYTOTOXIC TOWARD 

VARIOUS ESTROGEN RECEPTOR 

NEGATIVE CELL LINES. S. Taurin, B. 

D. Yadav, K. B. Tran and R. J. Rosengren. 

Pharmacology & Toxicology, Univeristy of Otago, 

Dunedin, New Zealand. 


CYTOTOXIC POTENTIAL OF A NOVEL 

CURCUMIN ANALOG RL-71 IN IN VITRO 

AND IN VIVO MODELS OF ESTROGEN 

RECEPTOR NEGATIVE BREAST CANCER. 

B. D. Yadav 1 , S. Taurin 1 , L. Larsen 2 and R. J. 

Rosengren 1 . 1 Pharmacology & Toxicology, 

Univeristy of Otago, Dunedin, New Zealand and 

2 

Plant and Food Research Limited, Dunedin, Otago, 

New Zealand. 


RAP80 PLAYS A CRITICAL ROLE IN 

MAINTAINING GENOMIC STABILITY. 

Z. Yin and A. M. Jetten. LRB, NIEHS, Research 



ACTIN AND VIMENTIN PROTEINS WITH 

N-TERMINAL DELETION DETECTED IN 

TUMOR BEARING RAT LIVERS INDUCED 

BY INTRAPORTAL-VEIN INJECTION OF 

HA-RAS TRANSFECTED RAT LIVER CELLS. 

Y. Nakamura 1 , A. Kominami 1 , Y. Tsujimoto 1 , E. 

Park 1 , K. Sato 1 , C. Chang 2 , B. L. Upham 2 and J. E. 

Trosko 2 . 1 Food Sciences and Nutritional Health, 

Kyoto Prefectural University, Kyoto, Japan and 

2 

National Food Safety and Toxicology Center, 


Thursday 







351





SULFORAPHANE INDUCES 

GLUTATHIONE-S-TRANSFERASE 

ACTIVITY AND DECREASES AFLATOXIN 

B1-DNA ADDUCTS IN SPRAGUE-DAWLEY 

RATS. J. L. Fiala 1,2 , N. Wiriyachan 3,4 , P. A. Egner 5 , 

J. D. Groopman 5 , R. G. Croy 1,2 , P. Navasumrit 3 , M. 

Ruchirawat 3,4 and J. M. Essigmann 3,4 . 1 Biological 

Engineering, Massachusetts Institute of Technology, 

Cambridge, MA, 2 Chemistry, Massachusetts Institute 

of Technology, Cambridge, MA, 3 Laboratory of 

Environmental Toxicology, Chulabhorn Research 

Institute, Bangkok, Thailand, 4 Faculty of Science, 

Mahidol University, Bangkok, Thailand and 

5 




DOSE RESPONSE CHARACTERIZATION 

OF DIETARY PHENOBARBITAL-INDUCED 

GENE EXPRESSION, ENZYME INDUCTION, 

AND CELL PROLIFERATION IN THE 

LIVERS OF MALE AND FEMALE MICE. 

B. Gollapudi 1 , H. Kan 1 , A. Wood 1 , J. Murray 1 , S. 

Hester 2 , A. Goetz 3 , R. Currie 4 and D. Geter 1 . 1 The 

Dow Chemical Company, Midland, MI, 2 U.S. 

EPA, Research Triangle Park, NC, 3 Syngenta Crop 

Protection, Inc., Greensboro, NC and 4 Syngenta Ltd., 

Bracknell, Berkshire, United Kingdom. 


OXIDATIVE DNA DAMAGE AND 

DNA BINDING INDUCED BY 2, 2-BIS 

(BROMOMETHYL)-1, 3-PROANEDIOL IN 

HUMAN BLADDER CELLS: POSSIBLE 

DUAL MECHANISMS IMPLICATED IN ITS 

CARCINOGENICITY. W. Kong, R. K. Kuester, 

A. Gallegos and I. Sipes. Pharmacology, University 



TRICHLOROETHYLENE- AND 

TETRACHLOROETHYLENE-INDUCED 

RENAL CARCINOGENESIS: INSIGHTS 

FROM HUMAN, ANIMAL BIOASSAY, AND 

MECHANISTIC STUDIES. M. R. Gwinn, K. Z. 

Guyton, J. Jinot, C. S. Scott, K. A. Hogan and W. A. 

Chiu. U.S. EPA, Washington, D.C. 


COMPARISON OF AFLATOXIN-DNA 

ADDUCT LEVELS IN MALE AND FEMALE 

INFANT B6C3F1 MICE. L. L. Woo 1 , P. A. Egner 2 , 

C. Belanger 1 , R. Wattanawaraporn 1 , L. Trudel 1 , 

G. N. Wogan 1,3 , J. D. Groopman 2 , R. G. Croy 1,3 

and J. M. Essigmann 1,3 . 1 Biological Engineering, 

Massachusetts Institute of Technology, Cambridge, 

MA, 2 Environmental Health Sciences, Johns Hopkins 

Bloomberg School of Public Health, Baltimore, 

MD and 3 Chemistry, Massachusetts Institute of 

Technology, Cambridge, MA. 


NO LUNG TOXICITY FROM STYRENE IN 

CYP2F2 KNOCKOUT MICE. G. Cruzan 1 , J. S. 

Bus 2 , X. Ding 3 , J. A. Hotchkiss 2 , J. R. Harkema 4 and 

R. Gingell 5 . 1 ToxWorks, Bridgeton, NJ, 2 Toxicology 

and Environmental Research and Consulting, Dow 

Chemical Company, Midland, MI, 3 New York State 

Department of Health, Wadsworth Center for Labs. 

and Research, State University of New York at 

Albany, Albany, NY, 4 Pathobiology and Diagnostic 

Investigation, Michigan State University, East 

Lansing, MI and 5 Environmental and Product Health, 

Shell Oil Company, Houston, TX. 


COVALENT BINDING OF 14 C 

2-METHOXY-4-NITROANILINE IN MALE 

SPRAGUE-DAWLEY RATS. R. Snyder 1 , S. 

Waidyanatha 2 , I. Surh 2 , T. Banks 1 , P. Patel 1 , S. Black 1 

and T. Fennell 1 . 1 RTI International, Research Triangle 

Park, NC and 2 National Toxicology Program, 




DIFFERENTIAL MODULATION OF 

CANCER-RELATED MOLECULAR 

NETWORKS IN HUMAN AND RAT 

URINARY BLADDER CELLS EXPOSED TO 

TRIVALENT ARSENICALS. K. Bailey 1 , K. 

Wallace 2 , S. Thai 2 , D. C. Wolf 2 , S. W. Edwards 2 and R. 

C. Fry 1 . 1 Environmental Sciences and Engineering, 


Hill, NC and 2 U.S. EPA, Research Triangle Park, NC. 


THE EFFECTS OF ORAL TREATMENT 

WITH TRANSFLUTHRIN ON THE 

BLADDER EPITHELIUM OF RATS 

AND MICE AND ITS METABOLITE, 

TETRAFLUOROBENZOIC ACID ON 

UROTHELIAL CELLS IN VITRO. S. M. 

Cohen 1 , L. Arnold 1 , S. Lautraite 2 , L. Sheets 2 , S. 

Wason 2 , B. Stahl 2 , D. Eigenberg 3 , K. L. Pennington 1 , 

S. Kakiuchi-Kiyota 1 and M. Yokohira 1 . 1 University 

of Nebraska Medical Center, Omaha, NE, 2 Bayer 

AG, Bayer CropScience, Monheim, Germany and 

3 

Xenometrics, Stilwell, KS. 


NEUROBEHAVIORAL ALTERATIONS IN 

CARG-BOX BINDING FACTOR-A KNOCK- 

OUT MICE. J. T. Barrett 1,2 , J. R. Richardson 2 , 

X. Zhang 3 , M. Fang 2 , K. R. Reuhl 2,4 and H. Zarbl 2 . 

1 

GSBS, UMDNJ, Piscataway, NJ, 2 EOHSI, RWJMS, 

UMDNJ, Piscataway, NJ, 3 University of Washington, 

Seattle, WA and 4 Rutgers, Piscataway, NJ. 


INFLUENCE OF BENZO(A)PYRENE (BAP) 

BIOTRANSFORMATION ON BAP-INDUCED 

CYTOTOXICITY IN HT-29 HUMAN COLON 

CANCER CELLS. J. N. Myers and A. Ramesh. 

Biochemistry & Cancer Biology, Meharry Medical 


Thursday 

352 






Platform Sessions



Abstract # 


EFFECTS OF SUBCHRONIC SODIUM 

ARSENITE ON MALIGNANT 

TRANSFORMATION MARKERS IN MCF-7 

CELLS. A. D. Rios-Perez 1 , R. Ruiz-Ramos 1 , L. T. 

Lopez-Carrillo 2 and M. E. Cebrian 1 . 1 Toxicology, 

CINVESTAV, Mexico City, DF, Mexico and 2 CISP, 

INSP, Cuernavaca, Morelos, Mexico. 


DOES HELICOBACTER PYLORI 

PARTICIPATE IN T HELPER-1 MEDIATED 

IMMUNE ACTIVATION IN COLORECTAL 

CANCER PATIENTS? B. A. Engin 1 , A. Karakaya 1 

and A. Engin 2 . 1 Department of Toxicology, Gazi 

University, Faculty of Pharmacy, Ankara, Turkey and 

2 

Department of General Surgery, Gazi University, 

Faculty of Medicine, Ankara, Turkey. 


TOXICOGENOMIC PROFILING OF 

FORMALDEHYDE-EXPOSED NORMAL 

AND TRANSFORMED HUMAN ORAL 

KERATINOCYTES. R. Ceder 1 , M. Merne 1 , J. 

Nilsson 1 , C. Staab 2 , J. Höög 2 , C. M. Thompson 3 

and R. C. Grafström 1,4 . 1 Institute of Environmental 

Medicine, Karolinska Institutet, Stockholm, 

Sweden, 2 Department of Medical Biochemistry 

and Biophysics, Karolinska Institutet, Stockholm, 

Sweden, 3 ToxStrategies, Inc., Katy, TX and 4 Medical 

Biotechnology, VTT Technical Research Centre of 

Finland, Turku, Finland. 


A GENOME-WIDE CELL SIGNALING RNA- 

INTERFERENCE SCREEN TO IDENTIFY 

NOVEL REGULATORS OF THE DNA 

DAMAGE RESPONSE. B. van de Water 1 , J. 

Carreras 1 , L. von Stechow 1 , R. Sidappa 1 , A. Pines 2 , J. 

Olsen 3 , H. Vrieling 2 , L. Mullenders 2 and E. Danen 1 . 

1 

Division of Toxicology, Leiden University, Leiden, 

Netherlands, 2 Department of Toxicogenetics, Leiden 

University Medical Center, Leiden, Netherlands 

and 3 Panum Institute, University of Copenhagen, 

Copenhagen, Denmark. 


GLUCOSE ENHANCES MENADIONE 

MEDIATED HYDROGEN PEROXIDE 

FORMATION IN BETA CELLS. M. A. Palo 1 , 

T. L. Womack 1 , E. Heart 2 and J. P. Gray 1,2 . 1 Science 

Chemistry, United States Coast Guard Academy, 

New London, CT and 2 Biocurrents Research Center, 

Marine Biological Laboratory, Woods Hole, MA. 


THE DURATION OF THE EVALUATION 

PERIOD OF THE POSITIVE CONTROL 

GROUP FOR RASH2 SHORT-TERM 

CARCINOGRNICITY STUDIES. S. A. Shah, 

M. A. Paranjpe and E. A. Zahalka. Mammalian 

Toxicology, BioReliance Corporation, Rockville, 

MD. 


CYTOTOXICITY OF ARSENICALS ON 

HUMAN BRONCHIAL EPITHELIAL CELLS 

IN VITRO. L. Arnold, S. Kakiuchi-Kiyota, K. L. 

Pennington and S. M. Cohen. University of Nebraska 

Medical Center, Omaha, NE. 

Abstract # 


FORMATION OF TAMOXIFEN (TAM)-DNA 

ADDUCTS IN MONKEYS AND HUMANS. 

E. Hernandez Ramon 1 , K. John 1 , R. A. Woodward 2 

and M. C. Poirier 1 . 1 NCI/NIH, Bethesda, MD and 

2 

NICHD/NIH, Poolesville, MD. 


INVOLVEMENT OF CONSTITUTIVE 

ANDROSTANE RECEPTOR (CAR) IN THE 

PROCESS OF LIVER HYPERTROPHY AND 

HEPATOCARCINOGENESIS-INDUCED 

BY CYP2B-INDUCING NON-GENOTOXIC 

HEPATOCARCINOGENS IN MICE (2). K. 

Inoue 1 , M. Yoshida 1 , Y. Sakamoto 1 , M. Takahashi 1 , Y. 

Taketa 1 , S. Hayashi 1 , S. Ozawa 2 and A. Nishikawa 1 . 

1 

Division of Pathology, National Institute of Health 

Sciences, Tokyo, Japan and 2 School of Pharmacy, 

Iwate Medical University, Iwate, Japan. 


DNA DAMAGE MODULATION IN XPA(-/-) 

P53(+/-) AND WILD TYPE C57BL/6 MICE 

FED BENZO[A]PYRENE WITHOUT OR 

WITH CHLOROPHYLLIN (CHL) FOR 

28 DAYS. K. John 1 , M. I. Churchwell 2 , F. A. 

Beland 2 , M. M. Pratt 3 , G. McMullen 1 and M. C. 

Poirier 1 . 1 Center for Cancer Research, National 

Cancer Institute, NIH, Bethesda, MD, 2 Division 

of Biochemical Toxicology, National Center for 

Toxicological Research, U.S. FDA, Jefferson, AR 

and 3 National Center for Environmental Assessment, 

Office of Research and Development, U.S. EPA, 



EXPOSURE TO URBAN PARTICULATE 

MATTER INDUCES A DECREASE 

IN E-CADHERIN EXPRESSION IN 

MULTICELLULAR TUMOR SPHEROIDS. 

F. M. Bernal-Herrera 1 , C. M. García-Cuéllar 2 , R. 

Morales-Barcenas 2 , Y. Sánchez-Pérez 2 and Y. I. 

Chirino 1 . 1 Unidad de Biomedicina, Universidad 

Nacional Autonoma de Mexico, Edo. Mex, Mexico 

and 2 Subdirección de Investigación Básica, Instituto 

Nacional de Cancerologia, Mexico, Mexico. 

Sponsor: H. Glauert. 


STUDIES ON METABOLISM OF 1, 

4-DIOXANE. W. Eck 1 , J. Fishbein 2 , B. Ginevan 2 , 

N. Koissi 2 and N. Shah 2 . 1 Directorate of Toxicology, 

U.S. Army Public Health Command, Aberdeen 

Proving Ground, MD and 2 Department of Chemistry 

and Biochemistry, University of Maryland Baltimore 

County, Linthicum, MD. 


THE IN VIVO ROLE OF ADIPOCYTE- 

SPECIFIC PPARγ IN ENVIRONMENTAL 

RISK FACTOR-MEDIATED BREAST 

TUMOURIGENESIS. G. Skelhorne-Gross 1 , N. 

Peterson 1 , R. Rubino 1 , S. SenGupta 1 and C. Nicol 1,2 . 

1 

Pathology and Molecular Medicine, Queen’s 

University, Kingston, ON, Canada and 2 Division of 

Cancer Biology and Genetics, Queen’s University, 

Kingston, ON, Canada. 

Thursday 







353



Thursday 



9:00 AM to 11:45 AM 

Room 143 


Symposium Session: Developmental Exposure to 

Environmental Toxicants: From Persistent Toxicities to 

Diseases 

Chairperson(s): Michele La Merrill, Mount Sinai School of Medicine, 

New York, NY, and Thomas Simones, University of Montana, Missoula, 

MT. 

Sponsor: 


Endorsed by: 




Ontogenesis involves extensive stem cell expansion and differentiation 

to create the physical architecture of tissues. This process is mediated by 

the coordination of multiple developmental pathways that involve a large 

number of key molecular regulators. Deregulation of these pathways may 

lead to chronic diseases, such as obesity, diabetes, cancer, and cardiovascular 

disease, which altogether are responsible for the majority of deaths in 

the United States. Recent experimental evidence suggest that if a developing 

organism is subjected to certain stressors, including exposure to various 

environmental toxicants, during the highly susceptible window of ontogenesis, 

the physical architecture and molecular milieu may be persistently 

altered, leading to dysfunction and disease in the adults. Correlations have 

been established between developmental exposure to certain environmental 

toxicants and adult diseases. Novel molecular and cellular approaches 

are being utilized to elucidate the mechanisms by which environmental 

toxicants disrupt developmental pathways and cause adult diseases. We 

will demonstrate both the breadth and the Department of the most cutting 

edge research in the toxicities and molecular mechanisms that support this 

emerging paradigm. Persistent and novel toxicities resulting from developmental 

exposures to environmental toxicants of human relevance, including 

halogenated hydrocarbons, metals, and phenols, will be presented in this 

symposium. In summary, our attention will be devoted to focusing on how 

these exposures during development give rise to long-term adverse effects or 

disease outcomes in endocrine, immune, nervous, metabolic, and reproductive 

systems. 

#2662 9:00 DEVELOPMENTAL EXPOSURE TO 

ENVIRONMENTAL TOXICANTS: FROM 

PERSISTENT TOXICITIES TO DISEASES. 

M. La Merrill 1 , T. Simones 2 , B. Hannas 3 , J. Larocca 4 , 

S. Li 5 , B. Winans 6 , K. M. Streifel 7 , E. Tokar 8 and E. 

Kendig 9 . 1 Mount Sinai School of Medicine, New 

York, 2 University of Montana, Missoula, MT, 

3 

U.S. EPA, Research Triangle Park, NC, 4 Brown 

University, Providence, RI, 5 University of Georgia, 

Athens, GA, 6 University of Rochester, Rochester, 

NY, 7 Colorado State University, Fort Collins, Co., 

8 

National Toxicology Program, Research Triangle 

Park, NC and 9 University of Cincinnati, Cincinnati, 

OH. 

9:00 INTRODUCTION. Michele A. La Merrill 

#2663 9:08 INVESTIGATION OF THE MECHANISM 

FOR PHTHALATE-INDUCED 

TOXICITY DURING MALE SEXUAL 

DIFFERENTIATION IN THE RAT. B. Hannas, 

J. Furr, C. Lambright, V. S. Wilson and L. Gray. 

Reproductive Toxicology Branch, U.S. EPA, 


#2664 9:33 ROLE OF NEUROINFLAMMATION IN 

DEVELOPMENTAL VULNERABILITY 

TO MANGANESE. K. Streifel, J. Moreno 

and R. Tjalkens. Toxicology Program, Center for 

Environmental Medicine, Environmental and 

Radiological Health Sciences, Colorado State 

University, Fort Collins, CO. 

#2665 9:58 THE ROLE OF STEM CELLS IN 

ARSENIC-INDUCED TRANSPLACENTAL 

CARCINOGENESIS. E. J. Tokar and M. P. 

Waalkes. NTP, NIEHS, NIH, Research Triangle Park, 

NC. 

#2666 10:23 ACTIVATION OF THE ARYL 

HYDROCARBON RECEPTOR 

REPROGRAMS THE DEVELOPING 

IMMUNE SYSTEM. B. Winans, S. R. Marr and B. 

Lawrence. Department of Environmental Medicine, 

University of Rochester Medical Center, Rochester, 

NY. 

#2667 10:48 THE EFFECTS OF ORAL BISPHENOL A 

EXPOSURE IN THE DEVELOPING CD1 

AND C57BL/6 MOUSE. E. Kendig, S. Christie, 

C. Cookman, C. Lo, D. Buesing, T. McCutchan, 

J. Cooper and S. Belcher. Pharmacology and Cell 

Biophysics, University of Cincinnati, Cincinnati, 

OH. 

#2668 11:13 A BBDR-HPT AXIS MODEL FOR THE 

LACTATING RAT AND NURSING PUP: 

EVALUATION OF IODIDE DEFICIENCY. 

S. Li 1 and J. W. Fisher 2 . 1 Biostatistics, Medical 

College of Georgia, Augusta, GA and 2 Food & Drug 

Administration, Jefferson, AR. 



9:00 AM to 11:45 AM 

Room 150 

Symposium Session: Vascular Injury: A Figment of Your 

Inflammation? 

Chairperson(s): Holly Smith, Eli Lilly and Company, Greenfield, IN, and 

Michael Lawton, Pfizer, Groton, CT. 

Sponsor: 


Endorsed by: 


Because drug-induced vascular injury (Division ) is a process rather than a 

single disease entity, diagnosing and predicting it is like chasing an apparition—there 

are many sightings but the descriptions are often different. The 

preclinical finding of vascular injury was initially described in rats and dogs, 

but has also been observed in mice and non-human primates in recent years. 

While vasculitis in humans appears to be immune-related, the triggers that 

induce blood vessels to become damaged and inflamed in animals have not 

been determined. In addition, it is difficult to distinguish the primary event 

from secondary inflammation that accompanies the induced damage. In 

animals, the injury can be observed within hours of drug exposure, whereas 

in humans it may not appear for weeks or months. With the disparity of 

observations between preclinical species and humans, it is unclear whether 

drugs that cause vascular injury or immune-mediated vasculitis in animals 

do so in humans, and whether a finding of preclinical Division predicts the 

risk of vascular injury in humans. As pharmaceutical companies expand 

their drug discovery efforts into new chemical spaces, higher incidences of 

preclinical Division are being observed in a broader variety of organs, which 

continue to impede drug development. If Division in animals represents a 

real hazard to humans, it is paramount for the pharmaceutical industry to 

354 






Platform Sessions



Abstract # 

develop means for early detection and monitoring of vascular injury. An 

overview of the current understanding of the pathobiology of vascular injury 

will be provided and the challenges in diagnosing and predicting Division 

with new advances in biomarker strategies will be discussed. In an exploration 

of the impact of Division on drug development, investigative models 

and case studies will be shared using examples of small and large moleculeinduced 

vascular injury in animals. 

#2669 9:00 VASCULAR INJURY: A FIGMENT OF YOUR 

INFLAMMATION? H. W. Smith 1 and M. P. 

Lawton 2 . 1 Eli Lilly and Company, Indianapolis, IN 

and 2 Pfizer, Groton, CT. 

9:00 INTRODUCTION. Holly Smith 

#2670 9:05 THE PATHOBIOLOGY OF VASCULAR 

INJURY. J. R. Turk. Amgen, Thousand Oaks, CA. 

Sponsor: M. Lawton. 

#2671 9:37 THE IMPACT OF VASCULAR INJURY ON 

DRUG DEVELOPMENT. W. Kerns. Accellient 

Partners LLC, Harvard, MA. 

#2672 10:09 PROGRESS IN IDENTIFYING 

BIOMARKERS OF VASCULAR INJURY. B. 

E. Enerson. Drug Safety Research and Development, 

Pfizer, Groton, CT. Sponsor: M. Lawton. 

#2673 10:41 IMMUNE-MEDIATED VASCULAR INJURY 

IN NON-HUMAN PRIMATES. J. L. Bussiere 1 

and C. Johnson 2 . 1 Toxicology, Amgen, Inc., 

Thousand Oaks, CA and 2 Pathology, Amgen, Inc., 

Thousand Oaks, CA. 

#2674 11:13 IMAGING AS A TRANSLATIONAL TOOL 

FOR ASSESSING CLINICAL RELEVANCE 

OF DRUG-INDUCED VASCULAR INJURY. A. 

Lerman. Mayo Clinic, Rochester, MN. Sponsor: H. 

Smith. 


9:00 AM to 11:45 AM 

Room 151 

Workshop Session: Are We There Yet? Attrition in the 

Pharmaceutical Industry and Impactful Strategies for 

Reducing Failure 

Chairperson(s): Cynthia Afshari, Amgen, Inc., Thousand Oaks, CA, and 

James Stevens, Lilly Research Laboratories, Indianapolis, IN. 

Sponsor: 


Abstract # 

platforms, genomics, and protein/biochemical analyses. Gaps or areas for 

future research support will be highlighted as appropriate. 

#2675 9:00 ARE WE THERE YET? – ATTRITION IN 

THE PHARMACEUTICAL INDUSTRY AND 

IMPACTFUL STRATEGIES FOR REDUCING 

FAILURE. J. Stevens 6 , C. Afshari 5 , B. Car 1 , I. 

Cotgreave 2 , K. Kolaja 3 and B. Pennie 4 . 1 Bristol- 

Myers Squibb, Lawrenceville, NJ, 2 Astra-Zeneca, 

Uppsala, Sweden, 3 Roche, Nutley, NJ, 4 Pfizer, 

Groton, CT, 5 Amgen Inc., Thousand Oaks, CA and 

6 

Lilly, Indianapolis, IN. 

9:00 INTRODUCTION. James Stevens 

#2676 9:05 THE INTEGRATION OF MULTI- 

DISCIPLINARY APPROACHES WITH 

DISCOVERY TOXICOLOGY IN 

OPTIMIZING DRUG CANDIDATES. B. 

D. Car. Pharmaceutical Candidate Optimization, 

Bristol-Myers Squibb, Princton, NJ. 

#2677 9:32 POTENTIAL USES OF STEM CELL 

TECHNOLOGY IN EARLY PIPELINE 

SAFETY SCREENING. I. Cotgreave. Global 

Safety Assessment, Molecular Toxicology, 

AstraZeneca, Södertälje, Sweden. Sponsor: C. 

Afshari. 

#2678 9:59 EFFECTIVE AND EMERGING PLATFORMS 

FOR PREDICTIVE TOXICOLOGY. K. L. 

Kolaja. Nonclinical Safety, Hoffmann-LaRoche, 

Nutley, NJ. 

#2679 10:26 MULTI-PARAMETRIC APPROACHES TO 

THE PROBABILISTIC ASSESSMENT OF 

TOXICITY ACROSS CHEMICAL SERIES IN 

DRUG DISCOVERY. W. D. Pennie. Compound 

Safety Prediction, Pfizer Inc., Groton, CT. Sponsor: 

C. Afshari. 

#2680 10:53 SAFETY RELATED DELAYS AND 

ATTRITION RATES GUIDE PREDICTIVE 

AND DISCOVERY TOXICOLOGY 

STRATEGIES. C. Afshari. Comparative Biology 

and Safety Sciences, Discovery Toxicology, Amgen 

Inc., Thousand Oaks, CA. 

#2681 11:19 INTEGRATION OF IN VITRO AND IN SILICO 

APPROACHES INTO AN ATTRITION- 

DRIVEN EARLY SAFETY ASSESSMENT 

STRATEGY. J. L. Stevens. Toxicology, Lilly 

Research Laboratory, Indianapolis, IN. 

Endorsed by: 


There have been many reports over the years that indicate a significant 

amount of attrition of candidate molecules in the pharmaceutical industry is 

due to safety related failures. In the recent years new approaches have been 

deployed to shift safety related attrition earlier in the pipeline. The impact 

of these new strategies will not be fully realized until they are in place for 

a number of years. In the meantime, there is no way to objectively assess to 

what extent and in what manner we are improving as an industry and what 

further changes and areas of research are needed. Therefore it is important to 

begin dialogue that aims to provide a forum to discuss contemporary views 

of the rate and causes of current safety related pharmaceutical attrition. An 

analysis of the strategies that appear to be most useful (or least useful) to 

drive this attrition earlier, i.e. fail fast will be included. Varying perspectives 

will be provided on the primary reasons for safety related attrition within 

companies and the current strategies deployed to address the problem. 

Special focus will be given to the early stage portfolio work through the 

first in human trials. The strategies that will be discussed will include the 

integration of in vitro and in vivo models with technologies such as imaging 


9:00 AM to 11:45 AM 

Room 201 

Workshop Session: Autoimmunity Versus Systemic 

Hypersensitivity: Commonalities Useful for Immunotoxicity 

Testing 

Chairperson(s): Raymond Pieters, Utrecht University, Utrecht, 

Netherlands, and Dori Germolec, National Toxicology Program, Research 


Sponsor: 


Chemical-induced systemic hypersensitivity and autoimmunity are immunotoxicological 

phenomena that concern chemicals ranging from drugs to 

environmental pollutants. These phenomena are difficult to predict, in part 

due to lack of knowledge of underlying mechanisms, although neoantigenspecific 

immune responses co-stimulated by signals from the innate immune 

Thursday 







355



Thursday 


system combined with complex genetic susceptibilities are considered 

crucial. In case of systemic hypersensitivity to drugs, i.e. drug allergy, 

immune responses to non-self drug-modified antigens may be intermingled 

with responses to self-antigens. Immune responses against self-antigens are 

hallmark of autoimmune diseases; however, a low level of self-reactivity 

is present in healthy individuals and is considered important for immunological 

homeostasis. The distinction between allergic and autoimmune 

responses induced by chemicals may be a very fine line, reflecting the 

relative antigenicity of the novel- and self-proteins involved. Importantly, 

development of allergic or autoimmune clinical phenomena, including 

nature and type, may depend on individual susceptibilities (i.e. genetic 

polymorphisms), or coinciding environmental triggers (e.g. microbial 

interactions). The complex etiology and lack of mechanistic knowledge is a 

challenge for risk assessment as at present no single model is available that 

may predict chemical-induced autoimmunity and systemic allergy. Hazard 

and risk assessment of these phenomena will likely require a more holistic 

translational approach. Exploring the similarities and differences between 

chemical-induced autoimmunity and systemic allergy is an important step 

to establish a methodological framework to identify chemicals with the 

potential to induce these immune system toxicities. Therefore we will focus 

on the complex relationship between chemical-induced autoimmunity and 

systemic allergy and the identification of methods, mechanistic commonalities 

and strategies that would be useful for risk assessment. 

#2682 9:00 AUTOIMMUNITY VERSUS SYSTEMIC 

HYPERSENSITIVITY: COMMONALITIES 

USEFUL FOR IMMUNOTOXICITY 

TESTING. R. Pieters 1 and D. Germolec 2 . 1 IRAS, 

Utrecht University, Utrecht, Netherlands and 

2 

Toxicology Branch, National Toxicology Program, 


9:00 INTRODUCTION. Raymond Pieters 

#2683 9:05 AUTOIMMUNITY AND AUTOIMMUNE 

DISEASE. N. Rose. Johns Hopkins University, 

Baltimore, MD. Sponsor: R. Pieters. 

#2684 9:37 AUTOIMMUNITY VS. ALLERGY: A 

CRITICAL NEED IN SAFETY TESTING. R. 

R. Dietert. Microbiology and Immunology, Cornell 

University, Ithaca, NY. 

#2685 10:09 MECHANISMS UNDERLYING 

HEXACHLOROBENZENE-INDUCED 

IMMUNOTOXICITY: COMPARISON WITH 

IDIOSYNCRATIC DRUG REACTIONS. J. 

Ezendam 1 and R. Pieters 2 . 1 National Institute for 

Public Health and the Environment, Bilthoven, 

Netherlands and 2 Institute for Risk Assessment 

Sciences, Utrecht, Netherlands. 

#2686 10:41 AUTOIMMUNITY IN IDIOSYNCRATIC 

DRUG REACTIONS. J. Uetrecht. University of 


#2687 11:13 TRICHLOROETHYLENE-INDUCED 

AUTOIMMUNITY; DEPENDENCE 

ON METABOLISM AND GENETIC 

SUSCEPTIBILITY. K. Gilbert 1,2 . 1 Microbiology 

and Immunology, Arkansas Children’s Hospital 

Research Institute, Little Rock, AR and 2 University 

of Arkansas for Medical Sciences, Little Rock, AR. 


9:00 AM to 11:45 AM 

Room 145 



Workshop Session: PBPK Model Use in Risk Assessment: 

Why Being Published Is Not Enough 

Chairperson(s): Paul Schlosser, U.S. EPA, Research Triangle Park, NC, 

and Eva McLanahan, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 



While publication of a physiologically-based pharmacokinetic (PBPK) 

model in a peer-review journal is a mark of good science, evaluation of 

published models and the supporting computer code can identify issues 

or shortcomings that can be barriers to their use in risk assessment. The 

quality of human health risk assessments must be sustained, including use 

of appropriate PBPK models and other quantitative tools for dose-response 

evaluation and interspecies extrapolation. A published model can be modified 

to address assessment-specific issues, and having clear criteria can 

reduce the number of review and revision iterations and hence the time 

needed to bring a model to application. As probabilistic (population) PBPK 

models are being implemented, parameter choices to fully characterize 

population variability become critical. Thus a thorough but efficient process 

for the review and implementation of PBPK models is necessary. While 

a typical process and set of criteria were created specifically for PBPK 

models, the principles may be applied to other types of computational 

models (e.g., dose-response) as they are developed. We have convened a 

panel of experts in biologically-based modeling and relevant quantitative 

methods to not only describe and discuss model evaluation and criteria, but 

also issues and choices that arise in model application and assuring reasonable 

certainty, as well as computational tools now available for improving 

model quality. Addressing issues identified during the review and application 

of PBPK models for human health risk assessments provides an 

opportunity to improve the science of PBPK modeling as a whole. Attendees 

will obtain knowledge to improve their models for use in risk assessment, 

evaluate when and how a model can be applied with a fair degree of 

certainty, and better understand the constraints and requirements that may 

otherwise limit use of a PBPK model. Finally, we will conclude with a panel 

discussion and dialogue on the criteria, processes, methods, and choices that 

can best assure the use of quality PBPK models in future risk assessments. 

#2688 9:00 PBPK MODEL USE IN RISK ASSESSMENT: 

WHY BEING PUBLISHED IS NOT ENOUGH. 

E. D. McLanahan. ORD/NCEA, U.S. EPA, Research 


9:00 INTRODUCTION. Eva McLanahan 

#2689 9:05 A PROCESS FOR THE EVALUATION AND 

IMPLEMENTATION OF PBPK MODELS IN 

HUMAN HEALTH RISK ASSESSMENTS. H. 

A. El-Masri. NHEERL, U.S. EPA, Research Triangle 

Park, NC. 

#2690 9:37 APPLICATION-SPECIFIC 

CONSIDERATIONS IN EVALUATION 

OF PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC (PBPK) MODELS. L. 

M. Sweeney. TERA, Cincinnati, OH. 

356 






Platform Sessions



Abstract # 

#2691 10:09 CHARACTERIZATION OF POPULATION 

DISTRIBUTIONS IN PBPK MODEL 

PARAMETERS. H. J. Clewell. The Hamner 


Park, NC. 

#2692 10:41 ALTERNATE APPROACHES AND ISSUES IN 

INTEGRATING PHARMACOKINETIC WITH 

BENCHMARK-DOSE (BMD) MODELING. P. 

M. Schlosser. NCEA, U.S. EPA, Washington, D.C. 

#2693 11:13 EXPLICIT PHARMACOKINETIC 

MODELING: TOOLS FOR 

DOCUMENTATION, VERIFICATION, AND 

PORTABILITY. J. F. Wambaugh 1 , R. Tornero- 

Velez 2 , E. McLanahan 3 , Y. Tan 2 , W. Setzer 1 and 

I. Shah 1 . 1 National Center for Computational 

Toxicology, U.S. EPA, Research Triangle Park, NC, 

2 

National Exposure Research Laboratory, U.S. EPA, 

Research Triangle Park, NC and 3 National Center 

for Environmental Assessment, U.S. EPA, Research 



9:00 AM to 11:45 AM 

Room 144 


Workshop Session: Role of Biomarkers in Assessing Tobacco 

Harm Reduction: A Toxicological Perspective 

Chairperson(s): Charles Timchalk, Pacific Northwest National 

Laboratory, Richland, WA, and Richard Corley, Pacific Northwest 


Sponsor: 


Abstract # 

#2694 9:00 ROLE OF BIOMARKERS IN ASSESSING 

TOBACCO HARM REDUCTION: A 

TOXICOLOGICAL PERSPECTIVE. C. 

Timchalk and R. Corley. Pacific Northwest National 


9:00 INTRODUCTION. Richard Corley 

#2695 9:05 LEGISLATIVE AND REGULATORY 

OVERVIEW. M. Zeller. Pinney Associates, 

Bethesda, MD. Sponsor: C. Timchalk. 

#2696 9:37 ASSOCIATION BETWEEN THE DESIGN, 

CONTENTS, EMISSIONS, USE AND 

BIOMARKERS OF EXPOSURE FROM 

TOBACCO PRODUCTS. D. L. Ashley. Center 

for Tobacco Products, U.S. FDA, Rockville, MD. 

Sponsor: C. Timchalk. 

#2697 10:09 TOBACCO CARCINOGEN AND 

TOXICANT BIOMARKERS: POTENTIAL 

APPLICATIONS IN TOBACCO HARM 

REDUCTION AND REGULATION. S. S. Hecht, 

J. Yuan and D. K. Hatsukami. Masonic Cancer 

Center, University of Minnesota, Minneapolis, MN. 

Sponsor: C. Timchalk. 

#2698 10:41 MODE OF ACTION: ASSESSMENT OF 

CANCER RISK AND IDENTIFICATION OF 

KEY DATA NEEDS. A. R. Boobis. Centre for 

Pharmacology & Therapeutics, Imperial College 

London, London, United Kingdom. 

#2699 11:13 QUANTITATIVE RISK ASSESSMENT: 

A COMPUTATIONAL DOSIMETRY 

FRAMEWORK FOR TOBACCO HARM 

REDUCTION. C. Timchalk, J. G. Teeguarden and 

R. A. Corley. Battelle Pacific Northwest Division, 

Richland, WA. 

Endorsed by: 



In 2009, the Family Smoking Prevention and Tobacco Act was passed by 

Congress, signed into law, and the U.S. FDA was tasked with regulating 

tobacco. The U.S. FDA’s stated goals are to use the best available science to 

guide the development and implementation of effective public health strategies 

to reduce the burden of illness and death caused by tobacco products. 

A potential component of this effort is the implementation of a risk/harm 

reduction strategy, in which the removal or reduction of harmful ingredients 

within tobacco products is one possible approach. In this regard, a joint 

World Health Organization (WHO) and International Agency for Cancer 

Research (IARC) working group proposed a strategy for lowering toxicant 

yields in tobacco products based on animal and human toxicity data for 

individual constituents. This risk based approach requires the prioritization 

of main stream smoke (MSS) constituents according to their individual 

risk of developing cancer. In this context, we will explore current and new 

strategies that have the potential to identify priority constituents for reduction. 

This will include strategies that utilized conventional approaches 

to MSS risk assessment which calculate risks according to exposure and 

hazard. A potential alternative approach for evaluation of MSS constituents 

exploits a strategy developed by the International Program on Chemical 

Safety (IPCS) to improve individual chemical risk assessment utilizes a 

weight-of-evidence approach within a mode-of-action (MOA) framework. 

Finally, a Quantitative Risk Assessment (QRA) strategy will be considered 

which combines advanced computational and experimental lung dosimetry, 

smoking patterns and behavior data, human variability, and available 

toxicity/cancer potency factors to develop compound-specific comparative 

estimates of risk for MSS constituents. The primary focus will be placed on 

both the strengths and weaknesses of the various approaches in the context 

of a MSS harm reduction strategy. 

Thursday 







357

Photos courtesy of San Francisco Convention & Visitors Bureau. 

March 11–15, 2012 

51 st 


and ToxExpo 

San Francisco 

California 

Deadline for Proposals for SOT 2012 

Annual Meeting Sessions: April 30, 2011 

WHY SUBMIT A PROPOSAL? 

1. To present new developments in toxicology. 

2. To provide attendees an opportunity to learn 

about state-of-the-art technology and how it 

applies to toxicological research. 

3. To provide attendees an opportunity to learn 

about the emerging fields and how they apply to 

toxicology. 

SESSION TYPES 

Continuing Education—Emphasis on quality 

presentations of generally accepted, established 

knowledge in toxicology 

Note: CE Courses will be held on Sunday. 

Symposia—Cutting-edge science; new areas, 


Workshops—State-of-the-art knowledge in 

toxicology 

Roundtables—Controversial subjects 

2012 Thematic Approach 

The Scientific Program Committee will continue 

the thematic approach for the 2012 Annual 

Meeting. Additional details regarding the themes 

will be available on the SOT Web site. 

Please note that while we are actively soliciting 

proposals for the themes, all proposal submissions 

will be reviewed for their timeliness and relevance 

to the field of toxicology. 

Historical Highlights—Review of a historical 

body of science that has impacted toxicology 

Informational Sessions—Scientific planning or 

membership development 

Education-Career Development Sessions— 

Sessions that provide the tools and resources to 

toxicologists that will enhance their professional 

and scientific development 

Submit your proposal on-line at www.toxicology.org 



Author Index (Continued) 

A 

Aarden, L............................................ 1150 

Abassi, Y............................................. 2344 

Abbott, B D.......... 1609, 2237, 2240, 2306 

Abbott, B............................................ 2239 

Abbott, K.............................................. 429 

Abbott, L C....................................... 1629* 

Abdel Rasoul, G................................. 1328 

Abdelhameed, M................................ 1924 

AbdelRahman, E A............................... 527 

Abdel-Rahman, S Z............................ 1360 

Abdo, N................................................ 981 

Abe, Y......... 1494, 2080, 2083, 2084, 2085 

Abert, S................................................. 514 

Abler, L L.................................. 1624, 1626 

Abo, T................................................. 1001 

Abou-Donia, M B............................. 1334* 

Abou-Hadeed, A A.............................. 1374 

Abraham, W M................................. 2219* 

Abramas, R......................................... 1165 

Abrams, R......................................... 1161* 

Abramson, S....................................... 2164 

Abston, E............................................ 256* 

AbuElhija, M.......................................... 63 

Abuladze, N.......................................... 203 

Achuthan, R C.................................. 2256* 

Ackerman, S L.................................... 842* 

Ackley, D............................................ 1425 

Acosta-Saavedra, L C........ 403, 686, 1386, 

1387 

Acquaah-Mensah, G......................... 2300* 

Acton, P J............................................ 184* 

Ada, A O................................. 1361*, 1362 

Ada, T G................................... 1361, 1362 

Adachi, H.............................................. 321 

Adai, A.................................................. 876 

Adamcakova-Dodd, A............ 1474, 1496* 

Adamo, M............................................. 619 

Adam-Poupart, A.............................. 2487* 

Adams, J G......................................... 2153 

Adams, J............................................... 657 

Adams, R.......................... 215, 1595, 1936 

Adams, T............................................ 2579 

Adams, V H...................................... 1383* 

Addae, C........................................... 1358* 

Addis, M................................... 2020, 2037 

Adebesin, D.......................................... 346 

Adeyemi, O......................................... 2230 

Adeyemo, O K.................................... 2381 

Adjei, S............................................... 1267 

Adkins, R P......................................... 2304 

Adriaens, E........................................... 996 

Adzu, B............................................... 2206 

Aeby, P.......................................... 88, 2551 

Afantitis, A............................................ 494 

Afeseh Ngwa, H............................... 2134* 

Afshari, A A........................................ 2299 

Afshari, A............................................ 563* 

Afshari, C....................... 244, 2675, 2680* 

Agaba, A G......................................... 2206 

Agarwal, C.......................................... 1756 

Agarwal, R................................ 1756, 2040 

Agbor, L N.......................................... 554* 

Agnew, J............................................... 773 

Aguayo, R A....................................... 1128 

Aguilar, D C....................................... 200* 

Aguilar-Alonso, P................................. 270 

Aguilar-Madrid, G.............................. 1972 

Aguirre, S............................................. 804 

Agusa, T............................................ 1979* 

Ahlberg Helgee, E.............. 153, 480, 729* 

Ahlström, H........................................ 1201 

Ahmad, T.............................................. 461 

Ahmed, A............................................ 2364 

Ahmed, S............................................ 371* 

Ahn, K................................................ 1762 

Ahn, S M.............................................. 516 

Ahn, T....................................... 1911, 1916 

Ahn, Y................................................. 1826 

Ahrenhoerster, L............................... 1126* 

Ahuja, M............................................. 527* 

Aiba, S................................................ 2551 

Aidoo, A.............................................. 1548 

Ainslie, G............................................ 247* 

Aisaki, K............................................. 1596 

Aitken, M D........................................ 2238 

Aizawa, Y............................................. 663 

Ajani, F............................................. 2381* 

Ajay, A K.............................................. 765 

Ajay, D.................................................1113 

Ajjimaporn, A........................... 764*, 1996 

Ajuh, P.................................................. 970 

Akay, C................................................. 324 

Akhtar, M.......................................... 1350* 

Akhter, H............................................ 1293 

Akindele, J.......................................... 2230 

Akkari, K............................................ 1526 

Akkerman, M...................................... 2034 

Alamneh, Y......................................... 2024 

AlBakheet, S......................................... 569 

Albee, L D.......................................... 1929 

Albertini, R........................................... 281 

Albin, R L............................................. 943 

Albores, A................................. 1372, 2524 

Albores-Garcia, D................... 1386*, 1387 

Albrecht, R M..................................... 2165 

Albuquerque, E X..................... 2034, 2035 

Alcendor, D J...................................... 1065 

Aldana-Madrid, M L......................... 2119* 

Al-Dieri, A............................................ 251 

Al-Dissi, A N........................................ 186 

Aldossari, A........................................ 1186 

Al-Doush, I......................................... 1208 

Aleksandrowicz, D............................. 1922 

Aleksunes, L M................ 740, 1058, 1079, 

1088, 2104 

Aleksunes, L............................. 171, 1047* 

Alencar, M M..................................... 1484 

Alenius, H............................................... 55 

Aleo, M D................................. 1741, 1746 

Aleo, M................................................. 528 

Alépée, N........ 645, 646, 1554, 2545, 2551 

Alexander, A N................................... 1931 

Alexander, D......................................... 745 

Alexander, J...................... 611, 1636, 2412 

Alexeeff, G V...................................... 472* 

Alfaro-Moreno, E............................. 2066* 

Alford, P W......................................... 1898 

Algaier, J W...................................... 1578* 

Alger, K................................................ 555 

Ali, A................................................... 2418 

Ali, R.................................................. 320* 

Ali, S F......... 506, 846*, 1456, 1464, 1614, 

1761, 2627 

Ali, S..................................................... 849 

Alipour, M.......................................... 1269 

Alkelch, A M...................................... 1374 

Allagadda, V............................. 113, 2168* 

Allemand, F........................................ 1541 

Allemang, A................................ 339, 1481 

Allen, A................................................. 577 

Allen, D................ 1016, 1017, 1521, 2581 

Allen, J L.......................................... 2612* 

Allen, J...................................... 1214, 2190 

Allen, K...............................................1119 

Allen, P................................. 323, 325, 776 

Allen-Hoffmann, L................... 647, 2519* 

Allgeier, S H....................................... 1624 

Allio, T.............................................. 1540* 

Al-Mazroua, H A................................ 196* 

Almond, K M.................................... 2389* 

Almond, R............................................ 95* 

Almudena, V....................................... 2186 

Alonso, A............................................ 2564 

Alpar, S............................................... 1361 

Alpers, C N......................................... 1938 

Alqallaf, A........................................... 1770 

Al-Rasheed, N M.................................. 196 

Alrowaily, N F.......................... 1388, 1389 

Alsagabi, M........................................ 1770 

The numerals following the author’s names refer to the abstract numbers. 


Al-Saigh, S........................................... 371 

Al-Saleh, I......................................... 1208* 

Alsberg, T........................................... 1839 

Alshabbaheen, A................................. 1208 

ALShammari, B M............................. 569* 

Alt, L A................................................. 268 

Altamirano-Lozano, M................. 285, 286 

Altenhofen, E................ 2601, 2602*, 2603 

Alter, S P............................................. 182* 

Altera, K............................................. 1432 

Alton, K B............................................ 745 

Aluru, N.................................. 1642*, 1776 

Amann, M............................................. 803 

Amara, I.............................................. 309* 

Ambalavanan, N................................. 2335 

Amcoff, P............................................ 2380 

Ameller, T........................................... 1926 

Ament, Z............................................. 875* 

Amin, S G............................................. 699 

Amir, A................................................. 891 

Ammenhauser, A D............................. 1578 

Amon, R W......................................... 2403 

Amores, A........................................... 1775 

Amoscato, A............................. 1179, 1285 

Amouzougan, E A............................. 1855* 

An, J.................................................... 2064 

Anadón, A....................... 1352, 2243, 2423 

Anadon, A......................................... 2108* 

Anagnostopoulos, A.............................. 133 

Ananthakrishnan, G.............................. 760 

Anantharam, V.......... 173, 845, 2130, 2134 

Anastas, P........................................... 909* 

Ancha, M............................................ 2046 

Andersen, M E............... 9*, 366, 701, 706, 

715, 940, 1719*, 1735, 2001, 2141, 2459, 

2460*, 2502 

Andersen, M............ 117, 941, 1823, 2370, 

2456 

Anderson, D.................... 2145, 2146, 2150 

Anderson, K A............................ 699, 2626 

Anderson, O S............................ 100, 102* 

Anderson, P E..................................... 2042 

Anderson, R C.................................... 2417 

Anderson, S E................................. 86, 667 

Anderson, S...................................... 2422* 

Andersson, B............................ 680*, 2052 

Andersson, H............................ 959*, 2372 

Andersson, P....................................... 2622 

Anderton, M J..................................... 792* 

Ando, C............................................... 1446 

Ando, Y............................................... 1184 

Andras, I............................................... 260 

Andrews, K......................................... 2600 

Andrews, L........................................... 486 

Andrus, A K........................................ 1324 

Aneskievich, B J........................... 384, 395 

Anestis, D............................................. 738 

Ang, C................................................... 291 

Anger, K............................................. 2106 

Anger, W K............................. 1218, 1329* 

Angers-Loustau, A...................... 81, 2551* 

Angrish, M M....................................1115* 

Ankley, G T.................................. 19, 2339 

Ankley, G.................. 18*, 730, 2368, 2467 

Annand, R......................... 935, 1889, 1903 

Ansari, G A........................................... 551 

Ansari, G............................................. 1286 

Anson, B..........................215*, 1163, 1164 

Anthérieu, S........................................ 1579 

Antignac, E......................................... 1559 

Antolino Lobo, I............................... 1834* 

Antonini, J M......... 185, 563, 1759, 2317*, 

2325 

Antonini, J.......................................... 2322 

Anwar-Mohamed, A......................... 1975* 

Anzai, T.............................................. 963* 

Aoki, M......................................... 425, 436 

Aoyama, H........................................ 1062* 

Apana, S M......................................... 1661 

Api, A.................. 90, 91, 491*, 1034, 1560 

Apic, G............................................... 2340 

Apostoli, A J....................................... 957* 

Applegate, D R........................... 534, 1606 

Applegate, D....................................... 1311 

Apte, M............................................... 1214 

Aquirre, S............................................. 204 

Aracava, Y................................ 2034, 2035 

Arai, R.................................................. 521 

Arakawa, S......................................... 1101 

Araki, M............................................. 1062 

Archer, K J.......................................... 2305 

Archibong, A E................................. 1065* 

Ares, I................................................. 2108 

Arevaro, M........................................... 315 

Arezzo, J........................................... 1806* 

Argento Martell, L................................ 791 

Arias-Salvatierra, D............................ 1387 

Armel, S E............................................ 610 

Armento, A.......... 343, 1003*, 2534, 2571, 

2574, 2575 

Arndt, D A............................................ 60* 

Arnold, L L................................. 232, 2633 

Arnold, L................................ 2646, 2655* 

Arnold, M E........................................ 1230 

Arnold, M........................................... 1760 

Aronovsky, J....................................... 2323 

Aronstam, R S.......................... 1485, 2177 

Arora, M........................................... 1237* 

Arp, E W............................................... 237 

Arreola-Mendoza, L................. 757*, 1972 

Arrington, J E............................. 650, 651* 

Arsenescu, R................................. 218, 364 

Arsenescu, V............................... 218*, 364 

Arslan, O................................... 2052, 2060 

Arteel, G E.......................................... 2002 

Arteel, G............................................... 460 

Arthurton, J......................................... 2535 

Arts, J...................................................... 84 

Arvidson, K........................ 155*, 492, 495 

Asakawa, M............................ 1571, 2430* 

Aschner, M.......... 1207, 1330, 2121, 2123, 

2124, 2128, 2131, 2135, 2205 

Asgharian, B....... 2289, 2290, 2292*, 2293 

Ashikaga, T......................................... 2551 

Ashley, D L....................................... 2696* 

Ashworth, A........................................ 2602 

Aslamkhan, A G.................................. 1966 

Atanasov, I............................................ 203 

Atchison, W D............... 1344, 1345, 1384, 

1385, 1395, 1397, 1400, 1401 

Atta-Safoh, S........................................ 315 

Attene-Ramos, M S............................ 493* 

Atterson, P R....................................... 1914 

Atwal, S.............................................. 1897 

Au, T C............................................... 1460 

Aubrecht, J.................................. 876, 1425 

Auerbach, S S............... 1096, 1593*, 1822 

Auerbach, S.......................................... 876 

Austin, C P.................................... 482, 493 

Austin, C..................................... 981, 2505 

Authier, S.............. 562*, 1919, 1920, 1921 

Autio, R.............................................. 2052 

Autrup, H............................................ 2070 

Auttachoat, W................. 80, 98, 653, 655* 

Avalos, J.................................... 1551, 2569 

Avens, H............................................. 1263 

Avery, R.............................................. 1924 

Avila, A............................................. 1808* 

Avila, D................................. 1085*, 2124* 

Avlasevich, S........................................ 333 

Awad-allah, M R................................. 1374 

Awori, M................................. 1911, 1916* 

Axelrad, D A....................................... 2360 

Ayala, N........................................ 659, 670 

Aydin, A.............................................. 324* 

Ayehunie, S.......................... 87, 652, 1049, 

2373*, 2571 

Ayllon-Vergara, J C............................ 1972 

Aylward, L L........................... 1424*, 1940 

Aylward, L............................................ 920 

Author Index 


359


Author Index 


Ayotte, P.............................................. 1694 

Ayukawa, Y......................................... 1046 

Azeke, J................................................ 893 

Aztatzi-Aguilar, O G.................. 593, 2172 

Azzaoui, K............................................ 853 

Azzopardi, D......................................... 990 

B 

B’Hymer, C...................................... 1428* 

Baba, F.................................................. 521 

Babb, A............................................... 2418 

Babcock, A S...................................... 416* 

Babcock, G F........................................ 656 

Babiarz, J............1159, 1161, 1163*, 1164, 

1165 

Babich, M A.................. 1243, 1244*, 1569 

Babich, M........................................... 1214 

Babin, M C......................................... 2031 

Babiuk, R P........................................... 133 

Babu, S............................................... 2256 

Bachas, L............................................ 2250 

Bachman, A................................. 234*, 486 

Bacigalupo, C M................................. 1942 

Backos, D S...................................... 1280* 

Badding, M A...................................... 382* 

Baden, D G................................. 808, 2219 

Badger, T............................................ 1302 

Badgley, H.......................................... 2418 

Badireddy, A R.................................... 1176 

Badtke, L.......................................... 1209* 

Bae, H................................................... 769 

Bae, O......................................... 294, 1884 

Baehrecke, E..................................... 2445* 

Baer, C................................................ 2099 

Baeuerle, P A........................................ 803 

Bagchi, A............................................ 1966 

Bagchi, D............................................ 1893 

Bagchi, M........................................... 1893 

Baghdadi, K.......................................... 812 

Bagley, B D...................................... 1317* 

Bahinski, A........................................... 762 

Bahl, A................................................ 1966 

Baier-Anderson, C.............................. 497* 

Bailey, D............................................... 781 

Bailey, J............................................ 1886* 

Bailey, K..................... 2020, 2039*, 2645* 

Bailey, L A...................... 1935, 1944, 1949 

Bailey, L............................................ 1948* 

Bailey, W J........................................ 1966* 

Bain, L................................................ 1621 

Baines, C............................................... 451 

Bainy, A.............................................. 1840 

Baker, A A......................................... 1857* 

Baker, A H.......................................... 352* 

Baker, B.............................................. 1214 

Baker, G.............................................. 1463 

Baker, P E........................................... 169* 

Baker, T K........................................... 1902 

Baksi, S................................................. 738 

Bakulski, K......................................... 943* 

Balakrishna, S................................... 2335* 

Balbuena, P....................................... 2552* 

Balciuniene, J..................................... 1770 

Baldrick, P.......................................... 806* 

Baldwin, J........................................... 1754 

Baldwin, W S............ 348, 553, 1861, 2382 

Balenstein, M...................................... 1430 

Ball, G L....................... 1531, 1532*, 1536 

Ball, J G........................................ 461, 741 

Ballard, D W....................................... 1443 

Ballatori, N........................................... 312 

Ballesta, J P............................................. 39 

Ballinger, C......................................... 1293 

Balme, E............................................. 2356 

Bammler, T K..................................... 1326 

Bandaogo, Z......................................... 346 

Bandele, O........................................ 1577* 

Bandiera, S............................... 1818, 1820 

Banerjee, A............................. 1885, 2263* 

Banerjee, N....................................... 2231* 

Banerjee, R....................................... 2202* 

Bangsberg, D R................................... 2206 

Bankoti, J............................................ 1131 

Banks, C............................................. 1330 

Banks, T.............................................. 2644 

Banno, H............................................... 269 

Bannon, D I.................... 725, 1383, 1604* 

Banton, M............................................. 564 

Bao, W...................................... 725*, 1604 

Baras, B.............................................. 1027 

Barba-Escobedo, P A........................ 1881* 

Barber, D S............ 161, 754, 1482*, 2357, 

2395 

Barber, D............................................ 2053 

Barbier, O C........................................ 2172 

Barbosa-J, F........................................ 2434 

Barchowsky, A............................ 121, 1968 

Barenys, M............................................. 71 

Barger, M............................................ 2081 

Bar-Ilan, O.............................. 1461*, 1483 

Barile, F A................................. 1019, 1021 

Baris, T................................................. 961 

Barjesteh van Waalwijk 

van Doorn-Khosrovani, S..................... 616 

Barker, D.............................................. 392 

Barlow, N J....................................... 1322* 

Barnes, J............................................... 792 

Barnes, N.................................. 2555, 2564 

Barnett, J B........................................... 665 

Baron, D............................................... 670 

Barone, L............................................ 1441 

Barone, S.............................................. 417 

Barrass, N............................................. 792 

Barrera-Hernandez, A......................... 2201 

Barrett, J T........................................ 2647* 

Barrier, M............................................. 982 

Barron, M............................................. 826 

Barrón-Vivanco, B S.............. 1372, 2524* 

Barrón-Vivanco, B.............................. 2116 

Barros, S............................................. 2523 

Barrow, P C......................................... 1623 

Bars, R.......................................... 69, 2351 

Barski, O A........................................... 262 

Bartel, J................................... 1197, 2184* 

Bartels, M J................ 703, 704, 705, 1324, 

2100, 2105, 2107, 2383 

Bartels, M......................................... 2279* 

Bartholomew, P M............................ 1156* 

Bartnikas, T.......................................... 511 

Barton, C............................................. 2250 

Barton, D M...................................... 2413* 

Barton, H A......................................... 938* 

Baruwati, B......................................... 1757 

Barve, A S............................................. 392 

Barve, S...................... 391, 392, 690, 1085 

Basavarajappa, M S.................. 1036, 1038 

Basavarajappa, M............................. 1037* 

Basketter, D........................................ 2551 

Baskin, I I........................................... 1336 

Bass, A S............................... 2468*, 2469* 

Bassiri, A............................................... 662 

Basta, N T........................................... 1938 

Basu, H S.............................................. 782 

Basu, N................................................. 292 

Bates, H K............................................ 298 

Bateson, T F.................... 330, 1945, 1946* 

Bathula, C........................................... 1994 

Batog, A.............................................. 1230 

Battelli, L A................... 56, 58, 575*, 1557 

Bauch, C................................. 1002*, 1009 

Baucom, C C........................................ 377 

Baudet, S..................................... 559*, 576 

Bauer, S M............................................ 673 

Bauerschmidt, S.................................. 2561 

Baumeister, J........................................ 809 

Bayir, H.............................................. 1285 

Baynes, R E.......................................... 710 

Baynes, R............................................ 642* 

Bazar, M A.......................................... 1544 

Beach, S L......................................... 1753* 

Beam, A.............................................. 716* 



Beard, K................................................ 812 

Bearden, E............................................ 934 

Beardslee, R A.................................... 122* 

Beasley, T E................................ 707, 2610 

Beattie, P............................................... 908 

Beaubrun, D........................................ 2579 

Beaudry, C.......................................... 1226 

Beaver, L............................................... 396 

Bechara, E J........................................ 1296 

Becher, G............................................ 1636 

Beck, B D................................. 1950, 1952 

Beck, N................................. 1527*, 2508* 

Beck, T W..................................... 558, 561 

Becker, K................................................ 75 

Bedja, D.............................. 206, 214, 1514 

Bednarek, P......................................... 2376 

Beebe, L E.......................................... 1922 

Beedanagari, S.................................... 1837 

Beer, C................................................ 2070 

Beeson, C C.......................................... 751 

Beeson, G C.......................................... 751 

Beger, R D................................ 140, 1678* 

Beger, R.............................................. 1434 

Beggs, K M....................................... 1658* 

Beggs, K............................................... 878 

Behl, M............................................. 2631* 

Behrsing, H P...................................... 973* 

Behrsing, T....................................... 1533* 

Beier, E E............................................ 293* 

Beier, J.................................................. 460 

Bein, K J............................................. 2331 

Beischlag, T V...................................... 372 

Bejugam, N......................................... 2050 

Beland, F A............. 379, 1304, 2420, 2658 

Belanger, C......................................... 2642 

Belanger, S E...................................... 2464 

Belanger, S................................ 2380, 2466 

Belaz, K A................................. 1335, 1676 

Belcher, S M................. 2359, 2362, 2365* 

Belcher, S............................................ 2667 

Beliveau, M........................................ 2274 

Bell, M P............................................. 1324 

Bello, S M....................................... 4, 133* 

Bellot, M....................................... 441, 442 

Belmonte, F........................................ 206* 

Belot, N............................................... 1314 

Bemis, J C............................................. 11* 

Bemis, J.............................................. 1416 

Benbrook, D M................................... 1885 

Bench, G............................................. 1308 

Bencic, D C............................ 2339*, 2387 

Benfenati, F........................................ 2510 

Bengtsson, J........................................ 1845 

Benigni, R............................................. 483 

Benipal, B............................................. 752 

Benitez-Trinidad, A...................2115, 2116 

Benkovic, S A......................................... 59 

Bennett, J W....................................... 2399 

Bensinger, H............................. 504, 2312* 

Benson, E M......................................... 543 

Benson, J M.............................. 808, 1134* 

Benson, W.......................................... 826* 

Bentley, P.................................... 742, 2372 

Benz, C............................................... 1888 

Berdasco, N M.................................. 2346* 

Berg, J M............................................ 2175 

Berg, J..................................... 2068, 2166* 

Bergamaschi, M M............................. 802* 

Berger-Ritchie, J........................... 659, 670 

Berges, A............................................... 187 

Bergosh, R G...................................... 2312 

Berhanu, W M.................................... 734* 

Berk, M............................................... 2613 

Berman, R........................................... 1771 

Bermúdez de León, M...............2115, 2116 

Bermudez, D S........................ 1023, 2303* 

Bermudez, D....................................... 1022 

Bermudez, E............................. 601, 1951* 

Bernal-Herrera, F M......................... 2659* 

Bernard-Flores, M A........................... 1400 

Berninger, J....................................... 2400* 

Bernstein, A I...................................... 181* 

Bernstein, D I...................................... 1367 

Bernstein, D M................................... 600* 

Berridge, B R.................................... 2472* 

Berridge, M S..................................... 1661 

Berry, C C........................................... 2076 

Bertelli, L............................................ 2291 

Berthet, A...................... 1240, 2260*, 2278 

Bertino, B........................................... 2564 

BéruBé, K........................................... 1069 

Besas, J............................................... 1298 

Besenhofer, L M................................. 758* 

Bessac, B F......................................... 2335 

Bessems, J......................................... 1522* 

Best, D S................................... 1032, 2308 

Betts, C J............................................. 211* 

Beuger, V.............................................. 522 

Beushausen, S..................................... 1438 

Bevilacqua, V H............................... 2017* 

Beyer, A.............................................. 1599 

Beyer, L A............................... 1950, 1952* 

Beyer, R P........................................... 1326 

Beyer, R.............................................. 1465 

Bhalla, D K........................................... 592 

Bhalla, D............................................. 1190 

Bhalli, J A................................. 320, 1406* 

Bhalli, J............................................... 1412 

Bhat, V S................................. 1531*, 1536 

Bhatia, S....................................... 419, 491 

Bhatnagar, A........................ 190, 259, 262, 

1170, 2245 

Bhattacharyya, D................................ 2250 

Bhattacharyya, M H............................ 277* 

Bhattacharyya, S....................... 1434, 1678 

Bhattarai, T........................................... 115 

Bhaumick, D......................................... 329 

Bhavaraju, L..................................... 2489* 

Bhobho, T E.......................................... 771 

Bhojwani, S...................................... 2386* 

Bhoopalan, V...................................... 592* 

Bhopale, K K........................................ 551 

Bialecki, R A......................................... 399 

Bialecki, R............................................ 742 

Biales, A D.............................. 2339, 2387* 

Bickerton, S J........................................ 211 

Bienfait, B............................................. 141 

Bietto, F M.......................................... 1059 

Bigas, E............................................... 1221 

Bigelow, D J............................. 1283, 1284 

Bigelow, D.......................................... 1287 

Biggemann, L..................................... 2024 

Biggs, M........................................... 2345* 

Bihaqi, S W....................................... 2187* 

Bijlani, K H.............................1191*, 1192 

Bijwaard, K......................................... 1369 

Bilgen, S............................................. 1361 

Bility, M T............................................ 357 

Bill, M A............................................. 1784 

Billack, B............................................ 2023 

Billington, R....................... 223, 858, 2107 

Bilsten, E.......................................... 2425* 

Binienda, Z......................................... 506* 

Bird, M G.............................................. 243 

Birgisdottir, B..................................... 2412 

Biris, A................................................ 2077 

Birkholz, D A...................................... 1201 

Birnbaum, L S............................. 709, 2248 

Birnbaum, L........................................ 1252 

Biswal, S........................................... 1790* 

Biswas, P............................................ 2051 

Bitan, G............................................... 1779 

Bittles, V............................................. 2098 

Bittner, G.................................. 624*, 2429 

Blaauboer, B J....................... 13, 991, 1877 

Blaauboer, B..................... 496, 1015, 2516 

Blachere, F M......................................... 86 

Black, A T............. 637, 1749*, 1750, 1751 

Black, C............................................ 1910* 

Black, K.............................................. 779* 




Black, S........................... 2275, 2276, 2644 

Blackburn, K......................................... 719 

Blackwell, D......................................... 555 

Blaich, G............................................... 796 

Blain, P G............................................. 114 

Blair, I A............................................. 1831 

Blair, I................................................. 1681 

Blair, L F............................................. 1754 

Blair, L.................................................. 583 

Blake, C L......................................... 1247* 

Blake, J C............................................ 2227 

Blakely, J L......................................... 1300 

Blakeman, D P.................................... 2559 

Blanck, M......................................... 2356* 

Blatz, V............................................... 1005 

Blazanin, N................................... 222, 357 

Blocksom, K....................................... 2387 

Blömeke, B........................... 88, 639, 1863 

Blomme, E A...................................... 1592 

Blomme, E................................ 1853, 1900 

Blond, S.............................................. 2545 

Blount, B C........................................... 702 

Blount, B................................... 1424, 2608 

Blum, J L...................... 1067, 1069*, 2057 

Blystone, C......................................... 2276 

Bobadilla, N.......................................... 765 

Boberg, J R........................................... 199 

Bodes, E.............................................. 1430 

Bodnar, W................................... 946, 1687 

Bodone Sipos, E................................. 260* 

Bodreddigari, S..................................... 349 

Boecker, J D....................................... 2022 

Boehme, K.......................................... 1410 

Boekelheide, K................... 65, 1043, 2191 

Boere, J F.............................................. 605 

Boermans, H J.................................... 682* 

Boess, F.............................. 426, 441*, 442 

Boetticher, M...................................... 1635 

Bogdan, A........................................... 1319 

Bogen, K T............................... 632*, 1316 

Boggs, A............................................. 1447 

Bohn, A................................................. 550 

Bohnenberger, S................................. 326* 

Boissier, M.......................................... 2247 

Boitano, A E.......................................... 360 

Boitano, S................................. 1477, 1990 

Boitier, E............................................... 876 

Boldenow, E..................................... 2563* 

Boley, S E........................................... 1932 

Bolger, M.................................... 882, 2153 

Bolmarcich, J...................................... 2567 

Bolon, B.............................................. 1761 

Bols, N................................................ 2465 

Bolstad, H............................................. 498 

Bolt, A M................................ 1988*, 2447 

Bolton, J L............................................ 227 

Bolton, S............................................... 541 

Bonati, L....................................... 347, 368 

Bonato, V.................................... 150, 1587 

Bonifas, J.......................................... 1863* 

Bonn, M B.................................. 109, 1508 

Bonner, F............................................ 2340 

Bonner, J C..................... 1195, 2176, 2178 

Bontempi, E.......................................... 629 

Bonventre, J A.................................. 2548* 

Boobis, A R....................................... 2698* 

Booc, F T.......................................... 2546* 

Boogaard, M....................................... 2613 

Boogaard, P J........................................ 486 

Boon, L............................................... 1139 

Boorman, G.................................. 247, 447 

Borazjani, A.............................. 2086, 2098 

Bordeerat, N K.................................. 1687* 

Borgerding, M F................................. 1241 

Borgert, C J............................................... 8 

Borgert, C............................................. 476 

Borland, M G.............. 354, 355, 358, 1780 

Bornman, M S.................................... 2241 

Borsay Horowitz, D............................ 2384 

Bort, A................................................. 760* 

Bortner, C D....................................... 1070 

Bory, C.......................................... 559, 576 

Bose, D D......................................... 2623* 

Bose, D............................................... 2624 

Bose, R............................................... 2622 

Bossart, G............................................. 657 

Bosslet, K............................................. 803 

Botta, D................................... 1193*, 1465 

Botteron, C........................................... 648 

Bouchard, G.................................. 635, 636 

Bouchard, M................. 1240, 2260, 2278* 

Boucheix, O.......................................... 559 

Boudreau, M D......................... 245, 2067* 

Bourcy, K S........................................ 208* 

Bourcy, K.............................................. 207 

Bourke, C H...................................... 1639* 

Bourouf, L.......................................... 2512 

Bousquet, R W...................................... 578 

Bover, W............................................... 243 

Boverhof, D R.................................... 906* 

Bowens, C M...................................... 1755 

Bowes, J.................................... 1897, 1915 

Bowlin, G L.......................................... 653 

Bowman, A B........................... 2121, 2132, 

2450*, 2455* 

Bowman, C J........................................ 618 

Boyd, J.................... 400, 401, 2314*, 2315 

Boyd, R................................................. 801 

Boyd, S................................................. 654 

Boyd, W A.............................. 1744*, 2517 

Boyd, W................................................ 159 

Boyer, S..................... 153, 154*, 156, 479, 

480, 729, 1915 

Boyes, W K......... 707, 2078*, 2457*, 2610 

Boyes, W............................................ 2456 

Boyle, T................................................ 516 

Boyle-Holmes, Y................................ 1929 

Boyles, R.............................................. 470 

Boysen, G................................. 1262, 1843 

Bozorgnia, S......................................... 277 

Bracken, W M..................................... 796* 

Bracken, W......................................... 1524 

Bracker, A........................................... 1568 

Bradfield, C A................................... 1705* 

Bradfield, C.......................................... 393 

Bradford, B................................... 247, 447 

Bradham, K D..................................... 2009 

Bradman, A....................... 625, 1222, 1237 

Braendli-Baiocco, A........................... 1423 

Braley-Mullen, H................................ 1508 

Brambila, E......................................... 270* 

Bramble, L.......................................... 1463 

Branam, A......................................... 1624* 

Brand, W........................................... 2348* 

Brandeis, R......................................... 2013 

Branham, W S..................................... 1594 

Branham, W........................................ 1097 

Brantsaeter, A.................................... 1636* 

Brantsæter, A...................................... 2412 

Brathwaite, W A................................. 2421 

Braue, E H.......................................... 2022 

Braue, E................................................ 893 

Brauers, K........................................... 1586 

Braun, A...................................... 960, 1766 

Braun, J................................................. 238 

Braun, M......................... 304*, 2342, 2392 

Braunbeck, T...................................... 2380 

Braydich-Stolle, L K......................... 2182* 

Breen, M........... 730*, 730*, 1215*, 1215* 

Brees, D.............................................. 1438 

Breier, J M.......................................... 2452 

Bremer, S............................................ 1017 

Brennan, R J..................................... 1739* 

Bricker, G........................................... 2284 

Bridges, C........................................... 761* 

Briffaux, J................................... 560*, 648 

Brigham, M D..................................... 1898 

Brigo, A..................................... 152*, 1814 

Brill, S....................................... 1458, 1469 

Brimijoin, S........................................ 1549 



Britt, J K........................................... 1947* 

Brittebo, E............................................. 959 

Brix, A................................................... 235 

Broberg, K.......................................... 1985 

Brochu, P............................................ 597* 

Brocker, C......................................... 1276* 

Brocksmith, D....................................... 635 

Broderick, M....................................... 1075 

Brodeur, J...................................... 597, 598 

Brodsky, B.......................................... 2205 

Broeders, J........................................ 1015* 

Broka, D............................................. 2008 

Bronstein, J............................. 1774, 1779* 

Brooks, A M...................................... 1931* 

Brooks, B W................... 964, 1873*, 2400 

Brooks, J D................................... 633, 634 

Brooks, J............................................... 642 

Brooks, S............................................ 2525 

Brorby, G............................................ 1265 

Brosch, K O........................................ 2600 

Brott, D A.......................................... 2372* 

Brott, D....................................... 742, 1602 

Brouwer, K L...................................... 1081 

Brouwer, K......................................... 1080 

Brown, A M........................................ 1166 

Brown, A............................................... 459 

Brown, B G......................................... 1241 

Brown, C D......................................... 2266 

Brown, C............................................. 346* 

Brown, D A........................................... 193 

Brown, E T......................................... 338* 

Brown, J M................................. 193, 1186 

Brown, J S.......................................... 2156 

Brown, J...................................... 461*, 741 

Brown, L........................... 635*, 636, 1431 

Brown, M R........................................ 1897 

Brown, P................................. 1519*, 1520 

Brown, R B........................................... 744 

Brown, R D............................................. 98 

Brown, R P........................ 1*, 754*, 1312, 

1313, 1434 

Brown, R............................. 492, 781, 1767 

Brown, S..................................... 339, 2276 

Browne, R........................................... 1330 

Brownfield, M S................................... 755 

Bruce, C.............................................. 1563 

Bruce, E D.......................................... 1607 

Bruce, S W............................................ 315 

Bruckner, J V...................................... 1817 

Bruckner, J........................................ 2283* 

Bruening-Wright, A.......................... 1166* 

Brughera, M............................ 1045, 1576* 

Brundage, K.......................................... 665 

Brunnemann, K D................................. 972 

Brunner, T............................................. 671 

Bruno, M E....................................... 2159* 

Brunshidle, T...................................... 1550 

Brustio, R...................................... 61, 1600 

Bruun, D A........................................ 1444* 

Bruun, D................................... 1330, 2623 

Bryan, I............................................... 1620 

Bryant, T............................................... 520 

Bryce, S...................................... 333*, 339 

Brzak, K A.......................................... 1324 

Bu, W.................................................... 542 

Buabeid, M A........................................ 527 

Bubier, J A............................................ 133 

Bucek, A..................................... 256, 1514 

Bucio, L.....................................1112, 1301 

Buck, B................................................. 670 

Buck, R C..................................... 586, 587 

Buck, W R................................ 1592, 1900 

Buckley, B.......................................... 2311 

Buckley, L A....................................... 777* 

Buckpitt, A R........................................ 580 

Buckpitt, A............. 887, 888*, 1679, 1832, 

1849*, 2492 

Budinsky, R A....................................... 859 

Budinsky, R.................... 367, 1365*, 1366 

Buesen, R...................................... 75, 1008 

Buesing, D R...................................... 2362 

Buesing, D.......................................... 2667 

Bugarski, A D..................................... 1462 

Bugel, S M.......................................... 976* 

Buhimschi, C...................................... 2506 

Bui Nguyen, T M.............................. 2099* 

Bui, A.................................................. 1627 

Bui, P H............................................ 1837* 

Bull, R J.......................... 774, 2281*, 2313 

Bullard, K........................................... 1321 

Bunin, D............................................. 1106 

Bunker, K L............................................ 59 

Buntz, J G........................................... 189* 

Buonocoro, C...................................... 1269 

Buono-Dalton, C................................... 430 

Buratovic, S...................................... 2604* 

Burback, B................................ 2271, 2272 

Burch, P.............................................. 1746 

Burcham, G N..................................... 2428 

Burcham, P C...................................... 567* 

Burdock, G A............................ 2438, 2440 

Burek, C J............................................. 739 

Burgess, J L........................................ 1990 

Burgess, J............................................ 2275 

Burgess, L C....................................... 771* 

Burgoon, L D...................................... 2305 

Burgoon, L.......... 419*, 1354, 1734*, 2306 

Burkart, D L.......................................... 133 

Burke, T F........................................... 2611 

Burke, T................................................ 931 

Burkhalter, B.................. 1261, 1542, 1693 

Bürki-Thurnherr, T......... 680, 2052, 2060* 

Burkman, R T..................................... 1765 

Burks, T.............................................. 2072 

Burlak, T............................................. 1938 

Burleson, F G.................................... 1146* 

Burleson, G R..................................... 1146 

Burlingame, A....................................... 817 

Burnett, D M......................................... 237 

Burnham, K.......................................... 129 

Burnham, M P..................................... 1915 

Burns-Naas, L............................... 623, 804 

Burnum, K E....................................... 1488 

Burpee, B.............................................. 254 

Bury, D............................................... 1524 

Bus, J S............................................... 2643 

Bus, J.................................................... 49* 

Busch, S.............................................. 1436 

Buse, E................................................ 1566 

Bushkofsky, J R................................ 1120* 

Bushnell, P J............................. 707, 2610* 

Busquet, F............................. 2380*, 2466* 

Bussiere, J L........................... 881*, 2673* 

Bussières, M......................................... 524 

Busta, E............................... 158, 492, 495* 

Butala, J................................................ 234 

Butenhoff, J L..................................... 2247 

Butenhoff, J.......................................... 706 

Butler, P.............................................. 2280 

Butler, S.................................. 2225*, 2402 

Butt, M.................................................. 801 

Butterfield, D...................................... 1460 

Butz, N.................................................. 962 

Byarugaba, D...................................... 2206 

C 

C Gard, J M........................................ 1682 

Caballero, K........................................ 2236 

Cabarcas-Montalvo, M.............. 132, 149*, 

2396 

Cabré, M............................................. 1331 

Caccese, R.......................................... 1430 

Caceres, A I......................................... 2335 

Cadet, J................................................. 486 

Cahill, S.............................................. 807* 

Cai, L............ 210, 756, 1294*, 1664, 2593 

Cai, P.............. 423*, 434, 536, 1502, 1503 

Cajero, M............................................ 1696 

Calabro, A R..................................... 1021* 

Calafat, A............................................ 1943 

Author Index 


361


Author Index 


Calderon-Aranda, E S........ 403, 686, 1386, 

1387 

Caldwell, J.......................................... 1273 

Callard, I P.......................................... 2092 

Callol, C.................................. 1743, 2539* 

Camacho, J......................................... 2495 

Camacho, L................................. 617, 747* 

Camarillo, J M.......................... 1976, 1997 

Camenisch, T D........................ 2000, 2008 

Cameron, H L....................................... 228 

Cammack, J........................................ 1767 

Cammett, A......................................... 1364 

Campbell, A.............................. 1376, 2495 

Campbell, J L.............................. 707, 2552 

Campbell, J........ 1266, 1823, 1824, 1846*, 

2370 

Campbell, P........................................ 2372 

Campbell, S C................................... 1695* 

Campbell-Lendrum, D........................ 2589 

Campen, M....................... 189, 1696, 2493 

Campion, C........................................... 349 

Campion, S N......................................... 65 

Campion, S......................................... 1088 

Campleman, S..................................... 1937 

Cancela, L M...................................... 2147 

Canerdy, T D....................................... 1893 

Canet, M J................................... 413, 1108 

Cannon, C......................................... 1049* 

Cannon, K E..................................... 1726* 

Cantonwine, D...................................... 292 

Cantor, G H..........................................1119 

Cantor, J O.................................1191, 1192 

Cantore, M.......................................... 1276 

Cantu-Soto, E..................................... 1984 

Cao, C J.............................................. 1544 

Cao, J................................................ 1064* 

Cao, L............................. 1040, 1617, 1973 

Cao, X............................................... 1405* 

Capacio, B A....................................... 2015 

Capaldi, R........................................... 1896 

Capello, C F........................................ 1639 

Cappellini, D......................................... 298 

Cappon, G D......................................... 15* 

Cappon, G........................................... 623* 

Car, B D.................................. 2343, 2676* 

Car, B.......................................... 876, 2675 

Carathers, M R...................................... 989 

Carathers, M........................................... 83 

Carballo, M A......................... 2112*, 2232 

Carbery, I d......................................... 535* 

Card, J W............................................ 1323 

Cardellach, F....................... 612, 613, 614* 

Cardon, M........................................... 1022 

Cardoso, A F............................... 525*, 547 

Cardozo-Pelaez, F............................... 2265 

Carey, C.............................................. 2528 

Caride, A............................................. 2243 

Carioto, M............................................. 797 

Caristophe, B P................................... 2329 

Carl, K.................................................. 342 

Carlisle, J.................................... 498, 1533 

Carll, A P..................................... 570, 607* 

Carlson, E A.................... 474, 1959, 1961* 

Carlson, K R........................... 1244, 1569* 

Carlson, P.......................................... 1745* 

Carlson-Lynch, H................................. 489 

Carlsson, L.......................... 153*, 154, 480 

Carmichael, P........................................ 117 

Carmody, M W................................. 1641* 

Carnahan, J........................................... 244 

Carne, A................................................ 966 

Carney, E.......................................... 2192* 

Carosino, C M.................................... 2331 

Carosino, C....................................... 2491* 

Carpenter, E E................................... 1809* 

Carr, C.............................................. 2306* 

Carr, G J.............................................. 1595 

Carr, G................................................ 2380 

Carr, R L........................................... 1325* 

Carranza-Lopez, L.............................. 2396 

Carrasquer, C........................................ 488 

Carraway, M......................................... 191 

Carreras, J........................................... 2652 

Carrizales-Yánez, L............................ 1255 

Carrizales-Yáñez, L............................ 1373 

Carro, S............................................... 1687 

Carro, T............................................. 1637* 

Carroll, B A......................................... 1893 

Carroll, M A........... 346, 2125, 2579, 2580, 

2591 

Carson, J E.......................................... 2288 

Carter, C A.......................................... 513* 

Cartwright, I..................................... 1978* 

Carvan III, M J................................... 1051 

Carvan, M J........................... 1588, 1774*, 

1778*, 2514 

Casado, F L......................................... 1158 

Casado-Pena, F L.............................. 1157* 

Casanova, N A.................................. 2232* 

Casati, B....................................... 61, 1600 

Casati, S...................................... 81*, 2551 

Cascio, J A.......................................... 1508 

Casella, G............................................. 476 

Casey, W....................... 1016, 1017*, 2581 

Casillas, R P......... 1749, 1750, 1751, 2026, 

2030 

Casinghino, S...................................... 1141 

Casper, D.............................................. 161 

Cassee, F R......................................... 605* 

Cassee, F............................................. 2474 

Cassis, L................................................ 218 

Casteel, S W....................................... 1938 

Casteel, S............................................ 2572 

Castellano, V...................................... 2108 

Castilla-M, M..................................... 2434 

Castranova, V............ 53, 56, 58, 194, 575, 

1178, 1180, 1181, 1182, 1183, 1185, 1188, 

1454, 1459, 1471, 1492, 1800*, 2072, 

2081 

Castrén, E........................................... 1391 

Castro, D............................................. 231* 

Castro, G D....................................... 1059* 

Castro, J A........................................... 1059 

Castro, L............................................. 1070 

Castro-Coronel, Y............................... 394* 

Catapane, E J......... 346, 2125, 2579, 2580, 

2591 

Catlin, N............................................... 65* 

Cattley, R T......................................... 1968 

Cavagnaro, J......................................... 881 

Cavalieri, E........................................... 880 

Cavallin, J........................................... 2368 

Cavarec, L........................................... 1541 

Cave, M.......................1110*, 1111, 2245* 

Cawley, T J......................................... 2296 

Cearfoss, J......................................... 1099* 

Cebrián, M E.................................... 1983* 

Cebrian, M E...................................... 2649 

Ceccatelli, S.................... 1391, 2614, 2622 

Cecil, T L............................................ 2437 

Ceder, R.................................... 135, 2651* 

Ceger, P..................................... 1016, 1017 

Celius, T................................................ 361 

Centeno, J A.......................................... 573 

Cerignoli, F....................................... 1894* 

Cerreta, J M.....................1191, 1192, 1653 

Certa, U............................................... 1163 

Cerven, D R.................................... 83, 989 

Cerven, D................................ 2568*, 2569 

Cezar, G G.............................................. 72 

Cha, J.................................................... 628 

Chadalapaka, G........................... 955*, 956 

Chadwick, K D................................... 1765 

Chagas, M............................................. 802 

Chakraborty, S.................................. 2123* 

Chalencon, E......................................... 559 

Chalifour, L............................... 2188, 2189 

Chambers, E....................................... 391* 

Chambers, H W.................................. 2014 

Chambers, H................... 1371, 2049, 2113 

Chambers, J E..................................... 2014 

Chambers, J.................... 1371, 2049, 2113 



Chambers, M C..................................... 128 

Chan, H............................................... 1394 

Chan, J................................................ 2492 

Chan, K................................................. 799 

Chan, M K.......................................... 1673 

Chan, M P......................................... 1567* 

Chan, M................................................ 334 

Chan, P C............................................ 2631 

Chand, R............................................... 552 

Chanda, S.................................... 542, 2020 

Chandler, J K...................................... 2025 

Chandler, K J............................ 982*, 1619 

Chandra, J............................................. 948 

Chandrasena, R P.................................. 227 

Chaney, J................................................. 85 

Chang, C................................... 1369, 2637 

Chang, D....................................... 721, 723 

Chang, J............................................ 1446* 

Chang, M............................................ 1204 

Chang, S............................................. 2247 

Chang, T K........................................... 377 

Chang, W.................................... 359, 2431 

Chang, X............................................. 719* 

Chang, Y................................. 2026, 2030* 

Channell, M........................................ 1696 

Chanvorachote, P................................ 1668 

Chao, M............................................ 1408* 

Chapin, R E.......................................... 623 

Chapline, C......................................... 2007 

Chapman, G D...................................... 160 

Chapman, G........................................ 2392 

Chapman, K.............................. 1563, 1564 

Chapman, R S..................................... 1759 

Chapman, R........................................ 2318 

Chappie, D J......................................... 863 

Charbonneau, M................................... 599 

Charest-Tardif, G...................... 1226, 2316 

Chari, R................................................. 931 

Charlier, H A....................................... 1855 

Charlot, D........................................... 1894 

Charzynska, A..................................... 1144 

Chassy, B............................................ 1525 

Chatikavanij, V................................... 2366 

Chatterjee, S....................................... 685* 

Chaudhuri, S....................................... 459* 

Chavan, H......................................... 1277* 

Cheeseman, M A................................. 1767 

Cheesman, E......................................... 812 

Cheikh-Rouhou, M........................... 1836* 

Chekhun, V........................................... 104 

Chellman, G J......................................... 15 

Chen, B T........ 53, 58, 185, 194, 563, 1759 

Chen, B..................................... 1471, 2318 

Chen, C............ 250, 300, 307, 542*, 1273, 

1393*, 1665, 2114, 2195* 

Chen, F............................................... 1459 

Chen, H........................ 331, 337, 479, 490, 

1918, 2367 

Chen, J...................................... 1302, 1617 

Chen, K............................... 299, 300, 1665 

Chen, L................ 76, 118, 260, 581, 1235, 

1259, 1495, 1680*, 2118, 2490 

Chen, M............ 138, 427, 435*, 934, 1053 

Chen, Q....................................... 200, 1279 

Chen, R............................................... 1939 

Chen, S............... 118, 227, 385*, 386, 876 

Chen, T B............................................ 1459 

Chen, T......... 126*, 365*, 375, 1429, 2077 

Chen, V H........................................... 809* 

Chen, W.................. 675, 677*, 1393, 2114 

Chen, X................................... 1501*, 1850 

Chen, Y...................... 74*, 299, 300*, 307, 

689, 742*, 1014, 1171*, 1289, 1369, 1393, 

1415*, 1665, 1850, 1998, 2365 

Chen, Z......................... 1680, 2118, 2241* 

Cheng, B............................................... 679 

Cheng, L............................................... 265 

Cheng, Q..............................................1113 

Cheng, S........................................... 1347* 

Cheng, Y........................................... 2268* 

Chequer, F D..................................... 1418* 

Cherrington, N J......................... 413, 1108 

Cherrington, N.................................... 1077 

Chesher, C.......................................... 1923 

Chesler, S............................................ 572* 

Chesne, C.................................... 935, 1903 

Chevalier, G........................................ 2487 

Chevalier, H J....................................... 289 

Chevrier, J........................................... 1237 

Chhabra, R S............................. 323*, 2631 

Chi, L.................................................. 2117 

Chia, A.............................................. 2498* 

Chiao, E...........................1163, 1164, 1165 

Chiappalone, M.................................. 2510 

Chibout, S........................ 430, 1092, 1107, 

1436, 2537 

Chien, S...................................... 609, 2488 

Chilcott, R P............................. 2021, 2022 

Child, M.................................................. 87 

Child, T......................................... 211, 792 

Chilloux, A.......................................... 1663 

Chini, N.............................................. 1432 

Chiou, J................................................... 39 

Chipinda, I............................................ 86* 

Chipman, J K...................................... 2021 

Chirila, M........................................... 1180 

Chirino, Y I......................................... 2659 

Chism, J................................................ 662 

Chiu, W A........................................... 2641 

Chmielewski, G.................................. 618* 

Cho, A K............................................. 1305 

Cho, K......................................... 590, 1480 

Cho, M.......................................... 240, 383 

Cho, S................................................. 1315 

Chodakowski, K................................. 1469 

Choi, B............................ 769, 1212, 1478* 

Choi, C........................................ 845, 2212 

Choi, E.................................................. 364 

Choi, H............................370, 1118, 1449* 

Choi, J.............164*, 249*, 260, 977, 1118, 

1343, 1467, 2063, 2064, 2207, 2208, 2209, 

2210, 2212*, 2213, 2214, 2215, 2216, 

2224 

Choi, K....... 707, 1823*, 1824, 1846, 2096 

Choi, S S............................................. 137* 

Choi, S.............................................. 2441* 

Choi, Y.....................................1117, 1118* 

Cholanians, A B.................................. 1306 

Chon, T................................................. 977 

Chopinaud, M....................................... 560 

Chou, C................................... 2410, 2431* 

Chou, S............................................. 1530* 

Chougule, M....................................... 2521 

Chouinard, L......................................... 512 

Chow, E................................................ 396 

Chowdhury, P..................................... 786* 

Chowdhury, S....................................... 745 

Chrisler, W B........................................ 404 

Christensen, C M.................................. 276 

Christensen, K...................................... 316 

Christian, B J........................................ 546 

Christie, S M....................................... 2362 

Christie, S........................................... 2667 

Chu, F................................................... 817 

Chu, H................................................... 415 

Chuang, S............................................. 788 

Chui, R W............................................. 184 

Chung, C........................................... 2285* 

Chung, J.................... 294, 975, 1884, 2536 

Chung, Y.............. 977*, 1467, 2207, 2209, 

2211, 2212, 2213*, 2216, 2217, 2218 

Churchwell, M I.................................. 2658 

Chusuei, C C....................................... 2177 

Chyan, V............................................. 1677 

Cicalese, R.......................................... 1231 

Cicciu, N............................................... 519 

Cicerchi, C.......................................... 1086 

Cichocki, J............................................ 580 

Cidlowski, J.......................................... 151 

Ciloy, J M............................................. 157 

Cimino Reale, G........................... 61, 1600 

Cinelli, S........................................... 1231* 




Claessen, S.......................................... 1585 

Clapper, M L......................................... 359 

Clark, A J............................................ 2107 

Clark, C R............................................. 237 

Clark, D.............................................. 2526 

Clark, E................................................. 719 

Clark, G.............................................. 1017 

Clark, J.................................................. 685 

Clark, M...................................... 148, 2559 

Clark, N.............................................. 1144 

Clark, O E........................................... 2027 

Clarke, E........................................... 1172* 

Clarke, J B.......................................... 1922 

Clarke, J C............................................ 797 

Clarke, J...................................... 788, 1892 

Clarke, K............................................... 772 

Clarkson, E D......................... 2018, 2022* 

Clavijo, D............................................1112 

Clay, M B............................................ 2329 

Clay, P............................................... 1314* 

Cleall, P.................................... 1160, 1438 

Clemens, C L.......................................111* 

Clemens, J............................................. 639 

Clément, C............................................ 648 

Clerc, R G............................................. 387 

Clewell, H J......................................... 13*, 

701, 706, 707, 715, 940, 941, 1735*, 1953, 

2141, 2456*, 2459*, 2552, 2691* 

Clewell, H........................ 496, 1823, 1824, 

1846, 2370 

Clewell, R A...................................... 2370* 

Clewell, R............... 117, 1824, 1846, 2552 

Cline, P V............................................ 1264 

Clothier, K A......................................... 710 

Cloutier, Y................................. 1455, 2487 

Cnubben, N H............................1150, 1151 

Co, A L.................................................. 169 

Coady, K............................................. 2094 

Coash, J E........................................... 1929 

Coates, N............................................ 1473 

Coats, S................................................. 803 

Cobban, T......................................... 1222* 

Cobbett, P........................................... 2055 

Coccini, T................................... 61, 1470* 

Cochran, R C.................................... 1251* 

Cocker, D R.......................................... 606 

Cohen Hubal, E A..................... 1813, 2156 

Cohen, J D................................ 402, 1159* 

Cohen, L............................................... 891 

Cohen, M D........................................ 1259 

Cohen, M.......................... 891, 1235, 2013 

Cohen, S M........... 232, 2633, 2646*, 2655 

Cohle, C.............................................. 1645 

Colacino, J........................................ 1216* 

Colagiovanni, D B.............................. 798* 

Colangelo, J L....................................... 437 

Colatsky, T J......................................... 145 

Colatsky, T................................ 1426, 1452 

Cole, S H................................ 1141*, 1497 

Cole, T B............... 169, 1270, 1326*, 1692 

Cole, T................................................ 2551 

Coll, O.......................................... 613, 614 

Collar, C J......................................... 2298* 

Colleoni, F............................................ 965 

Collette, W............................................ 204 

Collinge, M......................................... 1141 

Collins, B J......................................... 2227 

Collins, D............................................ 1438 

Collins, J L.......................................... 1755 

Collins, L............................................ 1687 

Collotta, A..................................... 61, 1600 

Colombel, S........................................ 2351 

Colombo, P............................. 1045*, 1576 

Colomina, M....................................... 2578 

Colomina, T...................................... 1331* 

Colón-Rodriguez, A.......................... 1397* 

Colucci, M.......................................... 1663 

Coluccio, D............................... 1161, 1437 

Compagnoni, A................................... 2551 

Compton, D R................................... 1723* 

Conboy, C M...................................... 1770 

Conklin, D J................................ 190, 1170 

Conklin, D.......................................... 2245 

Connors, K A...................................... 964* 

Conolly, R B............................................. 9 

Conolly, R............................................. 730 

Contrera, J F....................................... 487* 

Coogan, T............................................. 622 

Cook, A....................................... 400, 401* 

Cook, D..................................... 1915, 2229 

Cooke, M P........................................... 360 

Cookinham, J L................................... 1578 

Cookman, C K.................................... 2362 

Cookman, C........................................ 2667 

Cool, D R............................................ 2089 

Coombes, H............................ 1371, 2113* 

Coombs, D............................................ 577 

Cooney, C....................... 2534, 2574, 2575 

Cooney, P............................................ 2148 

Cooper, D M......................................... 511 

Cooper, J............................................. 2667 

Cooper, K R........................ 873, 976, 2548 

Cooper, K............................................ 2363 

Cooper, R L............................... 1032, 1042 

Cooper, R............................................ 1031 

Cooper, S D........................................ 2227 

Copeland, C B.................................... 1511 

Copeland, T.......................................... 502 

Copple, B L..........................................1119 

Copple, I............................................. 2498 

Corcoran, G B................................... 2482* 

Cordova-Lozano, F............................. 2076 

Corkan, K........................................... 2540 

Corke, S................................................ 990 

Corley, R A........... 699, 1450, 2288*, 2699 

Corley, R................................... 1284, 2694 

Cormier, S A....................................... 1491 

Corney, S.............................................. 963 

Cornwall, C..............................1143, 1147* 

Coronado, G D.....................................2111 

Coronado, M............................. 256, 1514* 

Corrales, E............................................ 612 

Corrales-Aldana, H............................. 2396 

Correia, L.............................................. 555 

Corsini, E.................................... 965, 966* 

Corson, N............................................ 2051 

Corton, C................................ 1095, 1311* 

Corton, J............................................... 367 

Corvi, M M............................. 1071*, 2626 

Cory-Slechta, D A................ 1205*, 1699*, 

2151, 2190, 2612 

Cory-Slechta, D.................................... 293 

Coslo, D M........................................... 375 

Costa, D L................. 570, 607, 608, 2484* 

Costa, L G.......... 1270*, 1326, 1332, 2620, 

2621 

Costa, M N.......................................... 1717 

Costa, M................................... 813*, 816* 

Costello, B...........................................1110 

Costin, G............................................. 2555 

Cote, I................................................... 489 

Cotgreave, I.................. 1905, 2675, 2677* 

Cotovio, J.......................... 645, 1554, 2545 

Cotruvo, J A.............................. 2281, 2313 

Cotruvo, J............................................. 774 

Cotton, P............................................... 792 

Coughlin, J........................................ 2311* 

Coulombe, R A................................... 1234 

Coulson, M......................................... 1098 

Coulthard, T........................................ 1322 

Couroucli, X..................................... 2587* 

Coussement, W..................................... 622 

Couttet, P............................................ 2537 

Covert, D............................................ 1535 

Covey, J................................................ 799 

Cowan, J............................................. 1060 

Cox, C................................................. 1754 

Cox, D P............................................. 2328 

Cox, D................................................. 1465 

Cozart, C R......................................... 2067 



Cracknell, S.......................................... 577 

Crago, J P.......................................... 2378* 

Craig, G.............................................. 2164 

Craig, Z R..................... 1035*, 1036, 1038 

Craig, Z............................................... 1037 

Crameri, F............................................. 784 

Crane, A L......................................... 2103* 

Crawford, R B...................................... 373 

Crawford, R................................ 654, 1137 

Crawford, S......................................... 2580 

Crawford-Brown, D.............................. 485 

Creppy, E E....................................... 2427* 

Creton, S............................................. 1564 

Crippa, J................................................ 802 

Criste, R................................................ 803 

Cristy, T............................................ 2442* 

Crivello, J F........................................ 2388 

Crochemore, C.................................... 1290 

Crofton, K M.................... 702, 2262, 2350 

Crofton, K........................................... 2608 

Crooks, I............................................... 969 

Croom, E L....................................... 2562* 

Crosby, J............................................... 216 

Crosby, M................................. 339*, 1481 

Cross, D M............................................ 618 

Cross, K P....................... 484, 1812, 1816* 

Cross, K................................................ 136 

Croteau, M.......................................... 2461 

Crouse, L C......................................... 1544 

Crow, A..................................... 1371, 2113 

Crow, J A.......................................... 2098* 

Crowell, S R....................................... 699* 

Croy, R G.................................. 2638, 2642 

Crum, C M.......................................... 2036 

Cruz, E.................................................. 430 

Cruzan, G.......................................... 2643* 

Csanaky, I L.......................................... 548 

Cuellar, C............................................ 1347 

Cuevas, A K........................................ 2058 

Cuevas, A............................................ 581* 

Cuevas, E M....................................... 1614 

Cuevas, E.......................................... 2627* 

Cui, J Y............................................... 2503 

Cui, X................................................... 535 

Cui, Y J............................................. 1643* 

Cui, Z.................................................... 987 

Culbreth, M E..................................... 867* 

Culbreth, M......................................... 2452 

Cumberbatch, M............................. 94*, 95 

Cummings, B S................. 774, 2281, 2313 

Cumpston, A................................. 194, 563 

Cumpston, J L..................................... 1459 

Cumpston, J...................... 563, 1471, 2338 

Cunningham, A R................................. 488 

Cunningham, C................................... 2195 

Cunningham, F H................... 1565*, 2295 

Cunningham, M L....................... 732, 2282 

Cunningham, M...................... 2541, 2542* 

Cunny, H C......................................... 1593 

Curran, C P....... 1866*, 2601*, 2602, 2603 

Curren, R............................................ 2550 

Currie, R A.................................... 874, 875 

Currie, R............................................. 2639 

Currier, J........................................... 1986* 

Curriero, F............................................ 931 

Custer, L.............................................. 1412 

Cyphert, J M....................................... 602* 

Czakai, K............................................ 107* 

Czarnecki, L................. 1379, 1380*, 1381, 

1382, 2133 

Czasch, S.............................................. 743 

Czerny, C............................................ 1648 

Czuprynski, C J.........................1138, 1168 

D 

D’Agostino, J...................................... 1848 

D’Agostino, J...................................... 2319 

D’Amico, L....................................... 1740* 

d’Argembeau-Thornton, L.................... 466 

D’Costa, G J....................................... 2179 

D’Orazio, J........................................... 115 

D’Souza, M L..................................... 2305 

D’Souza, S E........................ 190, 259, 262 

da Rocha, M S...................................... 525 

Dachir, S................................... 891, 2013* 

Dadgar, D............................................ 2285 

Dadson, O A...................................... 2117* 

Dahl, E.................................................. 339 

Dahms, J K......................................... 1318 

Dai, R................................................ 1890* 

Dail, M.................................... 1371*, 2113 

Dailey, L............................................... 901 

Dalsenter, P R..................................... 1611 

Dalton, C H......................................... 2022 

Dalvie, D............................................. 1821 

Dalzell, A M...................................... 2266* 

Damian, P......................................... 1529* 

Damiens, M............................................ 92 

Damiri, B.................................. 553*, 1861 

Dammanahalli, K................................ 1830 

Damodaran, T V................................. 1334 

Damoiseaux, R..................................... 369 

Dan, D....................................... 1041, 1048 

Dan, M.................................... 1460, 2065* 

Danen, E............................................. 2652 

Daneshian, M...................................... 870* 

Dang, Z............................................. 1537* 

Daniel, C............................................. 1239 

Daniels, K K....................................... 1028 

Daniels, K............................................. 117 

Danilenko, D......................................... 776 

Danks, A............................................. 1563 

Danuser, B.......................................... 2260 

Danzeisen, R......................................... 473 

Dao, K................................................. 1332 

Dary, C C.............................................. 723 

Dary, C........................................ 721, 1239 

Das, K P.............. 1609, 1625, 2237, 2239* 

Das, S.......................... 206, 214, 735, 939* 

Dasari, S............................................. 128* 

Dasenbrock, C...................................... 960 

Dasgupta, R.......................................... 678 

Dasmahapatra, A K....................... 968, 992 

Daston, G P......................................... 1595 

Davi, R................................................ 2466 

David, M............................................... 536 

David, R................................................ 234 

Davide, G.......................................... 2537* 

Davies, C.............................................. 497 

Davis, A P............................................. 130 

Davis, B.............................................. 1533 

Davis, F............................................... 1258 

Davis, J................................................. 325 

Davis, L K......................................... 1042* 

Davis, M............................................. 1740 

Davis, R.................................... 1770, 1923 

Davis, S................................................. 698 

Davis, T A........................................... 2010 

Davis, T.............................................. 1535 

Davis, W P.......................................... 1922 

Davisson, V........................................ 1608 

Daws, L C........................................... 2611 

Dawson, D A............. 503*, 504, 505, 2312 

Dawson, S........................................... 1908 

Day, B J.......................... 258, 1756, 2327* 

Day, K................................................. 1533 

Day, R M............................................ 2010 

de Bock, L............................................. 616 

De Bock, M........................................ 1656 

de Brugerolle de Fraissinette, A.......... 2564 

De Brugerolle de Fraissinette, A.......... 645, 

646 

de Camargo, J V........ 242*, 525, 531, 547, 

2110 

De Castro, C......................................... 688 

De Franchi, E...................................... 1020 

de Gastyne, J D..................................... 181 

De Geest, B......................................... 1656 

De Groot, D............................ 1640, 2613* 

de Heer, R C......................................... 780 

de Jong, E..................................... 71*, 991 

Author Index 


363


Author Index 


de Jong, P............................................ 2361 

De Jonghe, S......................................... 622 

de Kok, T............................................ 1585 

de la Peña, E......................................... 327 

De La Rosa, A................................... 1489* 

de Lange, J.......................................... 1017 

de Morree, E....................................... 2361 

de Oliveira, M C........................... 525, 547 

de Peyster, A..................................... 1876* 

De Raaf, M........................................... 195 

De Schaepdrijver, L.............................. 622 

de Souza, A O..................................... 1667 

De Vizcaya-Ruiz, A......... 593, 1972, 2172, 

2495 

De Vooght, V........................................ 681 

De Vries, E.......................................... 2613 

De Vuyst, E......................................... 1656 

DeAbrew, K........................................ 1135 

Deal, F.............................................. 1016* 

Dean, C J............................................ 1932 

Dean, C................................................. 779 

Dean, D A............................................. 382 

Deans, R............................................. 1160 

Dearfield, K........................................ 2273 

Dearman, R J......... 90, 91, 93*, 94, 95, 96, 

2527 

Debelie, F............................................. 315 

Debia, M........................................... 2538* 

Debruyne, E........................................ 2356 

Deckert, R R....................................... 2022 

Decristofaro, M................................... 1603 

Decrock, E.......................................... 1656 

Dederick, E........................................... 470 

Deering-Rice, C E.............................. 2333 

Deering-Rice, C................................ 2334* 

DeGeorge, G L.......... 83*, 989, 2541, 2542 

DeGeorge, G............................. 2568, 2569 

Degn, L L.................................... 707, 2078 

DeGroat, J........................................... 1696 

DeGroot, D......................................... 1105 

DeHate, R B...................................... 1236* 

Dekant, W........................... 107, 739, 2259 

Del Bufalo, A.................................... 2513* 

Del Pino, J.......................................... 1352 

Del Razo, L M........................... 757, 1972, 

1980, 2201* 

Del Razo, L......................... 394, 947, 1982 

del Val, G................................................ 95 

Delaney, B.......................................... 1525 

Delclos, K............................................. 617 

Delcroix, M......................................... 2062 

Delker, D A........................................... 774 

Dell, L................................................. 1936 

Dellinger, B................................ 188, 1491 

DeLorme, M P.................... 585, 586, 587* 

DeLuca, J.................................. 343*, 1003 

DeMar, J C........................................ 2018* 

Demchuk, E........... 140, 142, 1811*, 2298, 

2594 

Demeester, J........................................ 1656 

Demeneix, B....................................... 2466 

Dene, H................................................. 133 

Deng, W............................................ 2571* 

Deng, X............................... 679*, 696, 697 

Deng, Y............................................... 2228 

Denise, O.............................................. 539 

Denison, M S................................ 347, 368 

Denison, M......................................... 1105 

Denk, D............................................... 2500 

Dennis, W E........................................ 1604 

Denny, J.............................................. 2466 

Denslow, N D................... 19*, 2357, 2395 

DeOliveira, G H...................... 1335, 1676* 

Der, K....................................... 1040, 1617 

Derakhchan, K...................................... 184 

Derbyshire, N....................................... 211 

Dere, E.............................................. 1584* 

Deretic, V.......................................... 2446* 

Derk, R....................................1181*, 1182 

Derreza-Greeven, C............................ 1233 

Dertinger, S............. 315, 333, 1412*, 1416 

Derzi, M............................................ 2573* 

Desai, S N............................................. 766 

Desai, U S........................................... 2556 

Desai, V G.......................................... 1594 

DeSantis, A S.......................... 2032*, 2033 

Deschl, U............................................ 1018 

Descotes, J............................................ 661 

DeSesso, J M...................................... 810* 

Deshpande, S...................................... 2017 

DeSilver, D....................................... 1587* 

DeSimone, M C.................................. 550* 

Desino, K.............................................. 507 

DeSmet, K D...................................... 549* 

Desroches, R....................................... 2125 

Desta, A............................................... 2627 

Detrisac, C J.................................. 794, 795 

DeVeaux, L......................................... 1869 

Devenny, J J........................................ 2343 

DeVillier, D......................................... 1340 

Devine, C K........................................ 2178 

DeVito, M J.................... 2262, 2349, 2350 

Devito, M J........................................... 709 

Devlin, R................................. 1215, 2480* 

DeVoney, D..................... 1945, 1946, 2301 

Devorak, J L....................................... 2022 

Dewailly, ............................................ 1694 

DeWitt, J................................... 205, 1620* 

DeWoskin, R S................................... 737* 

Dey, J K.................................... 109*, 1508 

Deyo, J.................................................. 234 

Dhakal, K............................................ 1109 

Dhanasekaran, M.................................. 527 

Di Giulio, R T..................................... 1760 

Di Giulio, R........................................ 318* 

Di Lenarda, E...................................... 1107 

Di Marco, P....................................... 1878* 

Di, Z.............................................. 409, 431 

Diabo, C.................................. 1645*, 1932 

Dial, S....................................... 1097, 2597 

Diao, H............................................... 1025 

Díaz Gómez, M I................................ 1059 

Diaz Otero, J M................................ 1345* 

Diaz, D................................................ 856* 

Díaz-Barriga, F......................... 1255, 1373 

Diaz-Bech, P......................................... 284 

Diaz-Fuentes, P..................................... 284 

Diaz-Llera, S....................................... 2206 

Diaz-Sanchez, D................................... 901 

DiCicco-Bloom, E.............................. 1390 

Diehl, L M.......................................... 1922 

Diener, L............................................. 2060 

Diener, P............................................. 2169 

Diener, R M........................................ 1034 

Dierolf, D............................................ 1863 

Dietert, R R....................................... 2684* 

Dietrich, D R........... 165, 166, 760, 1213*, 

1233, 2390, 2435 

Dietrich, D............................................ 476 

Dietz, B M............................................ 227 

Dietz, Y............................................... 1410 

DiFiore, D............................................. 497 

Digiovanni, J......................................... 958 

Diliberto, J J........................................ 2248 

Dillman, J F......................... 543, 544, 641, 

1753, 2036 

Dillon, D............................................... 969 

Dilworth, C......................................... 2280 

DiNatale, B......................................... 363* 

Dinesdurage, H......................... 1312, 1313 

Ding, H......................................... 273, 918 

Ding, L.............................................. 1981* 

Ding, Q................................... 1039*, 2549 

Ding, W.................................... 320, 1548* 

Ding, X.............. 230, 538, 582, 884, 885*, 

1487, 1848, 1860, 2073, 2319, 2643 

Dingemans, M M................................ 496* 

Dingess, K.......................................... 2193 

Dingle, R............................................... 364 

Dingus, C A........................................ 2308 



Dinu, C Z................................................ 59 

Dion, C............................................... 1455 

Dionnet, F........................................... 1555 

Dipak, S.............................................. 2377 

DiPrete, O......................................... 2270* 

Dishaw, L............................................ 869* 

Distel, M............................................. 1364 

Ditewig, A......................................... 1853* 

Diwan, B A........................................... 233 

Diwan, S B........................................ 1220* 

Dix, D J................... 715, 1619, 1813, 2156 

Dix, D........................... 714, 716, 717, 727 

Dixit, R................................................. 803 

Dixon, D............................................. 1070 

Doak, D............................................... 2397 

Dobrovolsky, V N............ 879, 1405, 1406, 

1411* 

Doctor, B P............................... 2024, 2029 

Doctor, B............................................ 2041 

Dodd, C A............................... 1357, 2127* 

Dodd, D E............. 601, 1951, 1953, 1954* 

Dodd, M.............................................. 2572 

Dodd-Butera, T................................. 1075* 

Dodge, D G............................. 1268*, 1935 

Doerge, D R.......................... 68, 708, 1548 

Doerge, D............................................ 2270 

Doherty-Lyons, S P............................. 666* 

Doitsch, E........................................... 1207 

Dolan, L............................................ 2440* 

Dolinoy, D C.............. 100, 102, 943, 1216, 

1720* 

Dolinoy, D.......................................... 1616 

Dombkowski, A A................................. 859 

Domingo, J L............... 1221, 1245, 1246*, 

1331, 2578 

Domingues, A....................................... 547 

Domínguez, D................................... 2393* 

Dominguez, M...................................1112* 

Domino, S E....................................... 2186 

Domoradzki, J................................... 1644* 

Donahue, C......................................... 1156 

Donahue, D A......................... 1551, 2569* 

Donepudi, A C.................................. 1078* 

Dong, M................. 249, 430, 1107*, 1436, 

2224*, 2365, 2537 

Dong, W...................................... 78*, 1777 

Donley, E L............................................. 72 

Donna, F..................................... 629, 1238 

Donner, E............................................ 2162 

Donninger, R........................................ 806 

Donohue, J........................................ 1538* 

Donovan, C......................................... 1142 

Doolittle, C J....................................... 1091 

Doolittle, J.......................................... 1535 

Doorn, J A........................................... 1336 

Dopp, E............................................... 1162 

Doran, S F........................................... 2335 

Dorchies, O......................................... 1439 

Dordick, J........................................... 2526 

Dorko, K............................................... 615 

Dorman, D C...................... 573, 701, 2141 

Dorta, D J.......................................... 1667* 

dos Santos, G...................................... 1172 

Doshi, U................................................ 381 

Doshna, C......................................... 1746* 

Dott, W............................................. 1589* 

Doucette, G............................... 2226, 2402 

Douglas, R M............................ 1988, 2447 

Dourson, M L....................... 1796*, 2507* 

Dowling, N F...................................... 1204 

Downie, D........................................... 1310 

Downs, M........................................... 1696 

Downs, T.................................. 341*, 1481 

Doxzon, B F........................................ 2022 

Doyle, N............................................. 2376 

Doyle, T L........................................... 2304 

Doyle-Eisele, M......... 539, 540*, 552, 594, 

1683, 1690, 1822, 2043, 2044, 2050, 2277, 

2291, 2493 

Dragan, Y........................ 1430, 1441, 1602 

Draganov, D............................ 2257*, 2258 

Dragomir, A................................ 457*, 458 

Draper, K............................................ 1913 

Dreher, K...................... 1473*, 1493, 2167 

Dreyfus, M A.................................... 1243* 

Drobná, Z........................ 1980, 1981, 1986 

Drobna, Z........................ 947, 1982*, 1987 

Drummond, D..................................... 1888 

Druwe, I............................................ 2000* 

Du, B................................................... 2400 

Du, G.................................................. 2367 

Du, Y................................................... 2138 

Duan, J........................................ 972, 2630 

Duarte, F V......................................... 1087 

Dubray, C............................................ 1438 

Duché, D........................ 1006, 1554, 2515, 

2545, 2570 

Duensing, T........................................ 1910 

Dufault, R......................................... 2120* 

Duffel, M W........................................ 1820 

Duffel, M............................................ 1830 

Duffy, P A......................................... 1098* 

Duffy, R.................................... 303*, 2392 

Dugas, T R................................ 1320, 1491 

Dugas, T................................................ 183 

Duggan, A S...................................... 1526* 

Duggineni, D...................................... 1170 

Duguay, F......................................... 1920* 

DuMond, J W........................................111 

Dumont, J......................................... 1579* 

Duncan, M.......................................... 1754 

Duncanson, L...................................... 2580 

Dunlevy, J R....................................... 1995 

Dunn, M.................................. 1161, 1437* 

Dunn, R T........................................... 876* 

Dunnick, J K....................................... 1593 

Dunnick, J............................................. 235 

Dupuis, C.............................................. 559 

Durhan, E............................................ 2368 

Duval, S................................................ 520 

Duvall, M.............................................. 518 

Dvorak-Ewell, M.................................. 791 

Dwyer, J L............................................. 70* 

Dwyer-Nield, L D................................. 407 

Dybdal, N............................................. 881 

Dydak, U......................... 2139, 2140, 2592 

Dykens, J.............................................. 987 

E 

Eaddy, A C........................................ 1300* 

Eaddy, S................................................ 440 

Eagle, S............................................... 2252 

Eapen, A K.......................................... 2421 

Earnest, D J....................................... 1704* 

Eastmond, D A........................ 1273, 1934* 

Eaton, D L........................................... 924* 

Eaton, D.............................................. 1465 

Eaton, J................................................. 207 

Ebeling, S............................................. 328 

Ebersviller, S M................................ 2332* 

Ebersviller, S........................................ 565 

Ebert, E S.......................................... 1572* 

Eble, J E.............................................. 2195 

Echeverria, D........................................ 610 

Eck, W S............................................. 1544 

Eck, W.............................................. 2660* 

Eckhert, C D......................................... 408 

Eddy, S M......................................... 1741* 

Edebert, I.......................................... 1905* 

Edwards, J........................................... 267* 

Edwards, K......................................... 2370 

Edwards, P C...................................... 1196 

Edwards, P........................ 887, 1849, 2492 

Edwards, S W..................................... 2645 

Edwards, S........................................ 1736* 

Edwards, T.......................................... 1644 

Efremenko, A........................................ 496 

Efterfield, D........................................ 1431 

Egara, Y.............................................. 1305 

Egner, P A................................. 2638, 2642 

Ehresman, D J..................................... 2247 




Ehrich, M.................................. 993, 2576* 

Eichinger, L........................................ 1550 

Eickel, D................................................. 75 

Eidemiller, B....................................... 1875 

Eifrid, M................................... 2271, 2272 

Eigenberg, D....................................... 2646 

Eilstein, J............ 1006*, 2515, 2545, 2570 

Einstein, D R...................................... 2288 

Eisenbrandt, D L....................... 952, 2100* 

Eiserich, J P........................................ 1105 

Eken, A................................................. 324 

Eklund, C R............................ 1581*, 2307 

Eklund, C.............................................. 711 

Eklund, M............................................. 480 

Ekwo, N.............................................. 2443 

El ALi, Z................................................. 92 

El Gendy, M........................................ 405* 

El Majidi, N...................................... 1226* 

Elcombe, C R................ 1041, 1048*, 1613 

Elcombe, C................................... 223, 367 

Elder, A................................... 2051, 2479* 

Eldridge, G T...................................... 2304 

Eldridge, S R...................................... 1785 

Elfarra, A A........................................... 755 

El-Fawal, H A........................... 1388, 1389 

Elferink, M G.................................... 2561* 

Elgui de Oliveira, D............................ 2110 

Eliacin, K............................................ 1140 

Elizondo, G................................. 388, 2524 

El-Kadi, A O............................. 1841, 1975 

El-kadi, A.............................................. 309 

El-Kadi, A............................................. 405 

El-Ladki, R............................. 2226*, 2402 

Ellefson, M E...................................... 1242 

Elliott, G S............................................ 778 

Ellis, D.............................................. 1764* 

Ellis, G................................................ 1009 

Ellis, S R............................................. 2565 

Ellis-Hutchings, R.............................. 2192 

Ellison, C A................... 2097, 2106*, 2117 

El-Masri, H A.................................... 2689* 

El-Masri, H......................... 707, 718, 2610 

Elraghy, O......................................... 1861* 

Else, A................................................... 996 

Eltom, S E............................................. 248 

Eltze, T................................................ 1002 

Elvati, P.............................................. 2161 

Ema, M..................................... 1044, 2082 

Embry, M R........................................ 2463 

Embry, M...................... 2462*, 2466, 2467 

Emde, B.............................................. 743* 

Emerick, G L.......................... 1335*, 1676 

Emikpe, B O....................................... 2381 

Emmen, H................................... 195, 1014 

Emond, C............................................ 709* 

Emter, R.............................................. 1009 

Enayetallah, A..................................... 147* 

Encarnacao, P C.................................. 384* 

End, P.................................................. 1107 

Enderle, T............................................. 316 

Endo, N............................................... 1062 

Endo, T............................................... 2606 

Endoh, D............................................. 1684 

Endoh, S................................... 1177, 2082 

Endres, C J............................................ 164 

Enelow, R........................................... 1989 

Enerson, B E..................................... 2672* 

Engelke, K.......................................... 799* 

Engin, A.............................................. 2650 

Engin, B A........................................ 2650* 

Engle, S K........................................... 202* 

Engle, V................................................ 826 

Englert, N A........................................ 103* 

English, C......................................... 1715* 

English, J C......................................... 1532 

Engström, K........................................ 1985 

Ennulat, D........................................... 1438 

Enright, B P.......................................... 790 

Enriquez, C..........................................1112 

Entezarizaher, T................................ 1272* 

Enuh, H............................................... 2443 

Eom, H.................. 977, 1467, 2063*, 2064 

Eppig, J T.............................................. 133 

Epps, S V.......................................... 2417* 

Epstein, T............................................ 1654 

Epur, A.............................................. 2592* 

Erdal, S............................................... 1258 

Erdei, E............................................... 1696 

Erdely, A......................... 185*, 1492, 2322 

Erdem, O............................................... 324 

Erdmann, D......................................... 2154 

Ergle, D............................................... 1288 

Erickson, J.......................................... 1485 

Ericson Jogsten, I................................ 1221 

Erikson, K M...................................... 2121 

Erikson, K........................................... 2148 

Eriksson, P.............................. 2604, 2605* 

Erives, G V......................................... 1306 

Erlanger-Rosengarten, A..................... 2205 

Ernstgård, L............................ 1217, 2259* 

Erratico, C......................................... 1818* 

Escudero, C....................................... 1997* 

Esdaile, D J........... 664, 1030, 2615*, 2616 

Eske, K............................................. 2250* 

Eskenazi, B.......................... 337, 625, 709, 

1222, 1237 

Espada, S.............................................. 495 

Esparza, D C......................................... 808 

Espinosa-Fematt, J.............................. 1206 

Espinoza-Aguirre, J.............................. 285 

Essigmann, J M........................ 2638, 2642 

Estep, C A........................................... 2181 

Estevan, C............................................. 979 

Estévez, J............................................ 2101 

Etheridge, A........................................ 2276 

Etheridge, M D............................. 544, 641 

Ethridge, S E....................................... 1523 

Euling, S Y.......................................... 1945 

Eum, S.................................................. 260 

Evans, A.............................................. 1685 

Evans, J E........................................... 1196 

Evans, J G........................................... 1098 

Evans, M V............................. 1581, 2307* 

Evansky, P A............................... 707, 2610 

Everds, N E........................................... 778 

Everds, N.............................................. 779 

Everett, D............................................ 1563 

Everley, P A........................................ 2036 

Evilia, C.............................................. 1869 

Ewart, L............................ 148, 201*, 1912 

Eyre, R................. 1050, 1060, 1061, 1143, 

1144, 1147, 1445 

Ezendam, J.............................. 1011, 2685* 

F 

Fabbri, M............................................ 1470 

Fabian, E........ 224, 640, 724, 1002, 1004*, 

1005, 1440, 1562, 2353 

Fadeel, B.............54, 135, 680, 1179, 1180, 

1189, 2052*, 2072 

Fadrowski, J................................ 767, 768* 

Fagnoni, M............................................. 61 

Failli, P................................................ 1276 

Fair, P A................................................ 658 

Fair, P.................................................. 657* 

Fairweather, D............................ 256, 1514 

Fajt, V................................................... 533 

Falcon-Rodriguez, C I................ 285*, 286 

Falkner, K C......................................... 460 

Falkner, K......................1110, 1111*, 2245 

Falvo, R.............................................. 1140 

Fan, R................................................... 679 

Fan, T.................................................. 1991 

Fan, X............................. 542, 1286*, 1510 

Fan, Z.................................................. 2490 

Fang, J............................. 379, 1097, 1304* 

Fang, M........................... 184, 1708*, 2647 

Fang, X............................................... 942* 

Fang, Z.............................................. 2220* 

Fanucchi, M.............................. 1293, 2288 

Faqi, A S....................... 1630*, 1645, 1646 



Farahat, F M......... 1218, 1329, 2106, 2117 

Farin, F M........................................... 1326 

Farland, W H............................ 830*, 883* 

Farmer, P............................................... 486 

Farnsworth, N R................................... 227 

Faroon, O.............................................. 860 

Farooqui, M Y................................... 1835* 

Farraj, A K................ 570, 607, 608, 2481* 

Farrar, D G................................ 1048, 1613 

Fastner, J............................................. 2435 

Fattinger, C........................................... 316 

Faust, J.................................................. 472 

Faustman, E M..........................925*, 2111, 

2520, 2621 

Fautz, R............................................... 1001 

Fay, M J.............................................. 268* 

Fazio, J................................................ 1312 

Fears, R L........................................... 1938 

Fechter, L D........................................ 160* 

Fedorov, Y............................................ 398 

Fedyk, E R.......................................... 660* 

Fegert, I....................................... 224, 2095 

Fehling, K........................................... 502* 

Feil, M E............................................. 2199 

Feinleib, M......................................... 1939 

Feist, S W........................................... 1071 

Feld, M H.......................................... 2092* 

Feldman, R......................................... 2205 

Feldstein, A E........................................ 759 

Feltis, B N........................................... 2179 

Feng, B............................................... 2544 

Feng, L.................................................. 954 

Feng, W H............................................... 54 

Feng, W........................................ 207, 208 

Feng, Y.................................................. 481 

Fennell, T R........................................ 2227 

Fennell, T................................ 2320*, 2644 

Fenske, R.......................................... 1218* 

Fenton, S E............................... 1089, 1622 

Ferguson, M.......................................... 995 

Ferguson, S........................................... 715 

Ferguson, T........................................... 738 

Fernandes, R....................................... 1437 

Fernandez, J A.................................... 2161 

Fernandez, J........................................ 1654 

Fernando, H........................................ 551* 

Fernando, R A..................................... 2227 

Fernando, T................................1122, 1124 

Ferraz, E A........................................ 2409* 

Ferreira, D W...................................... 444* 

Ferslew, B C..................................... 1081* 

Ferslew, K........................................... 1819 

Feswick, A.......................................... 2395 

Fevola, M............................................ 2555 

Fiala, J L........................................... 2638* 

Fidler, T P........................................... 1851 

Fiebelkorn, S........................... 1565, 2295* 

Fiechter, D A....................................... 1834 

Fiedler, R............................................ 1412 

Fielden, M..................................... 244, 876 

Fields, P E............................................. 694 

Fiene, S................................................. 215 

Fier, I D................................................. 440 

Fierke, C A............................................ 163 

Figueroa, D E.................................... 2068* 

Fikree, H............................................. 1323 

Filer, D L............................................... 276 

Filgo, A J........................................... 1089* 

Filipov, N M............................. 1357, 2127 

Finkelstein, J N......................... 2190, 2612 

Finkelstein, M................................... 2397* 

Finkelstein, Y.................................... 1207* 

Fischer, A.......................................... 1013* 

Fischer, H.................................... 855, 1232 

Fischer, K............................................ 2158 

Fishbein, J........................................... 2660 

Fisher, A A.......................................... 1433 

Fisher, C D.......................................... 1108 

Fisher, J W........ 160, 702, 774, 2281, 2668 

Fisher, J........... 708*, 712, 731, 2313, 2608 

Fishman, S N...................................... 1324 

Fisk, L................................................... 936 

Fitsanakis, V A.............. 1073, 1356, 1871* 

Fitzgerald, L............................ 1261, 1693* 

Fitzgerald, R......................................... 267 

Fitzpatrick, S C................................. 1309* 

Flake, G P............................................. 245 

Flannery, B....................................... 2419* 

Flaws, J A....................... 1033, 1035, 1036, 

1038, 1219 

Flaws, J............................................... 1037 

Fleming, E J........................................ 2042 

Fleming, M D....................................... 511 

Fleming-Weis, S............................... 1922* 

Fletcher, B L..................................... 2227* 

Fleurance, R.......................................... 661 

Flick, R W........................................... 2339 

Flick, R............................................... 2387 

Flint, N.................................................. 387 

Flor, S................................................. 335* 

Florence, R L............................ 1460, 2065 

Flores-Molina, M.................... 1970, 1971* 

Flower, L............................................... 489 

Flowers, L........................................... 1955 

Floyd, R.................................... 2601, 2603 

Fluharty, K.................................... 97, 1367 

Flynn, T................................................ 995 

Foertsch, L.......................................... 1009 

Fohey, J............................................... 1924 

Fokkens, P H......................................... 605 

Foldbjerg, R...................................... 2070* 

Foley, C M............................................ 558 

Foley, J D............................................ 1320 

Foley, J F............................................ 1096 

Fomby, L............................................. 2631 

Font, G.......................... 1608, 2416, 2423* 

Forbes, P D......................................... 1785 

Ford, B................................................ 1444 

Ford, J......................................... 707, 2610 

Ford, S M.................................. 763, 1874* 

Fordahl, S C...................................... 2148* 

Foreman, J E....................................... 359* 

Forgacs, A L.................... 917, 1584, 2549* 

Forster, R................................ 1926, 1927* 

Forsythe, W S..................................... 1466 

Fort, D............................................... 2379* 

Fort, M.................................................. 778 

Fortin, M C........................... 1768*, 2104* 

Fortner, J............................................... 804 

Fortoul, T I.......... 284*, 285, 286, 287, 288 

Fortuny, C............................................. 612 

Foss-Smith, G....................................... 990 

Foster, A L........................................... 1938 

Foster, A................................................ 429 

Foster, E................................................ 96* 

Foster, J................................................. 792 

Foster, M L......................................... 573* 

Foster, P M.......................................... 2374 

Foster, P.............................................. 1022 

Foster, W G..................... 228*, 1026, 1072 

Foth, H W............................................. 983 

Fourches, D........................................... 139 

Fournier, S........................ 562, 1919, 1920 

Fowler, A............................................ 1572 

Fowler, B A................................. 140, 1204 

Fowler, B.............................................. 860 

Fowler, D A......................................... 731* 

Fowler, P............................................... 969 

Fowles, J............................................... 564 

Fox, D A............................................ 1698* 

Fox, J J.................................................. 164 

Fox, K............................................... 2280* 

Fox, M A............................................. 931* 

Fox, S M......................... 1344, 1384, 1401 

Foxenberg, R J.................................... 2097 

Frady, S....................................... 871, 1760 

Fraga, L E........................................... 2408 

Fraij, B................................................ 1515 

Fraites, M J....................................... 1032* 

Frame, S R............................................ 587 

Author Index 


365


Author Index 


Francesconi, K A................................ 1974 

Franch, M........................................... 2577 

Franchi, C S........................ 242, 531, 2110 

Francis, M............................................. 455 

Franco, V............................................ 2243 

Franklin, C C...................................... 1280 

Franklin, C.......................................... 1508 

Franklin, S J...................................... 1730* 

Franko, J L.......................................... 667* 

Franko, J............................................. 2422 

Franks, D G........................ 368, 410, 1776 

Franzosa, J A............................... 897, 898* 

Fraser, A.............................................. 1917 

Frasier, C R........................................... 193 

Frawley, R P.......................................... 98* 

Frazer, D G....... 58, 185, 563, 2299*, 2338 

Frazer, D........................... 194, 1471, 2318 

Frazier, K............................................ 1899 

Frederick, B A............................... 946, 950 

Frederick, D M................................... 422* 

Fredriksson, A........................... 2604, 2605 

Fredriksson, L............................. 409*, 431 

Freedman, J H............ 274, 389, 986, 1378, 

1744, 2517* 

Freedman, J........................................... 159 

Freeman, A........................................ 1312* 

Freeman, J J........................................ 237* 

Freeman, J L........ 1747, 2090, 2142, 2144, 

2310* 

French, J E............................................ 732 

French, J............................................... 235 

French, K............................................ 1899 

Freudenrich, T M.................................. 867 

Freund, Y.............................................. 542 

Frick, A................................................. 962 

Friderichs-Gromoll, S................. 622, 1566 

Friedrichs, B......................................... 187 

Friend, S....................................... 563, 575 

Frisancho, A.......................................... 256 

Fritz, C A.............................................. 437 

Fritz, J M............................................ 407* 

Fritz, K S........................ 1084, 1280, 1282 

Fry, R C.................................... 1601, 2645 

Fry, R.................................. 310, 947, 1987 

Fu, J.......................................... 2001, 2502 

Fu, X................................................. 2137* 

Fu, Z......................................... 449*, 1643 

Fuchs, T C............................................. 743 

Fuentes-Reyes, M............................. 2116* 

Fuhrken, P........................................... 1173 

Fuhrman, K......................................... 2576 

Fuhrman, L E...................................... 274* 

Fuhrmann, S......................................... 803 

Fujihara, J........................................... 1979 

Fujii, S................................................ 1044 

Fujimura, M.................... 1494, 2084, 2085 

Fujisaki, T............................................. 621 

Fujita, K............................................ 1177* 

Fujiwara, R......................................... 386* 

Fujiwara, Y................................... 269, 770 

Fukami, T.................................... 428, 2079 

Fukui, H.............................................. 1177 

Fukushima, S...................................... 1547 

Fukushima, T........................................ 662 

Fukuzaki, K........................................ 1145 

Fulford, D E........................................ 2413 

Fullerton, A M.................................. 1093* 

Fulton, R............................................... 783 

Fulton, S............................................... 160 

Funabashi, H................................. 321, 425 

Funk, J A............................................. 750* 

Funk, J................................................ 1423 

Funk, K A............................................ 1454 

Furlong, C E........... 169, 1270, 1326, 1692 

Furnari, M A....................................... 537* 

Furniss, M J.......................................... 973 

Furr, J.............................. 1022, 1023, 2663 

Furtado, M.................... 2020*, 2037, 2039 

Furukawa, F.......................................... 508 

Furukawa, T.......................................... 649 

Fuscoe, J C...................... 1369, 1415, 1594 

Fussell, K C........................................ 1292 

Futscher, B W........................... 815*, 1976 

G 

Gabilondo, L....................................... 2170 

Gabos, S...................................... 997, 2344 

Gabriels, J............................................. 439 

Gabrielson, K...................... 206, 214, 1514 

Gabrielsson, S....................................... 680 

Gaca, M D............................................ 990 

Gadhia, S R....................................... 1019* 

Gadson, M.......................................... 697* 

Gaffney, J............................................ 2522 

Gagné, M............................................ 2316 

Gagnon, F........................................... 1226 

Gährs, M........................................... 2242* 

Gaido, K W......................................... 2191 

Gaikwad, N W...................................... 880 

Gairola, C......................................... 1190* 

Gairola, G............................................. 115 

Gaj, S.................................................. 1585 

Galbiati, V.................................. 965*, 966 

Galbraith, D........................................ 1210 

Galbreath, E.......................................... 881 

Galdanes, K.................................. 579, 591 

Gallagher, J........................................... 310 

Galland, F............................................. 444 

Gallegos, A......................................... 2640 

Gallegos-Arreola, M........................... 1206 

Galli, C L............................ 965, 966, 1877 

Gallicchio, L....................................... 1219 

Gallichio, V S..................................... 1136 

Galligan, J J........................................ 1282 

Galligan, J......................................... 1084* 

Gallitz, I................................................ 187 

Gallucci, R............................................ 643 

Galluppi, J............................................. 788 

Galluzzo, D....................................... 1342* 

Gálvez-Peralta, M....................... 313*, 314 

Galvin, K............................................ 1218 

Gamboa da Costa, G.................. 747, 1434, 

2420* 

Gamer, A O............................................. 82 

Gan, H................................................. 1224 

Gandhi, S............................................ 2490 

Gandolfi, A........... 1976, 1977, 1983, 1997 

Gandolfi, J A....................................... 1677 

Gandolfi, L........................................ 2555* 

Ganey, P E....... 433, 443, 878, 1093, 1652, 

1658 

Gangwal, S....................... 714, 727, 2156* 

Gao, B................................................... 184 

Gao, J.................................................. 1482 

Gao, S................................................... 219 

Gao, X.......... 400, 401, 1070*, 1193, 1465, 

2314, 2315* 

Garate-Morales, J L............................ 2076 

Garcia, L............................................... 787 

Garcia, T............................................. 2578 

Garcia-Arenas, G................................ 1206 

García-Cuéllar, C M........................... 2659 

Garciafigueroa, Y................................ 1968 

García-Lopez, J G............................... 2201 

Garcia-Reyero, N.................................... 19 

Garcia-Vargas, G G............................. 1980 

Garcia-Vargas, G........................ 947, 1982 

Gardea-Torresdey, J............................ 1489 

Gardner, C R............................... 455, 456* 

Gardner, C.......................................... 1710 

Gardner, D.......................................... 2229 

Gardner, R M.................................... 1985* 

Garey, J D........................................... 2609 

Garg, R.............................................. 1524* 

Gargas, M L........................................ 736* 

Garibaldi, P........................................... 325 

Garley, M K...................................... 1883* 

Garley, M............................................ 1882 

Garner, C D......................................... 1224 

Garner, C............................................ 1909 

Garnyuk, V......................................... 2047 

Garrabou, G........................ 612, 613*, 614 



Garrett, B J.......................................... 1259 

Garrett, B.......................................... 1235* 

Garrett, C M...................................... 2059* 

Garrett, R M.............................. 1811, 2298 

Garrett, S H.. 764, 772*, 1973, 1994, 1995, 

1996 

Garrett, S............................................. 818* 

Garrison, B R...................................... 1169 

Garside, H J...................................... 1897* 

Garside, H........................................... 1909 

Garssen, J................................................ 89 

Garthoff, L H........................................ 516 

Gasiewicz, T A...........................1157, 1158 

Gaspar, A C......................................... 1024 

Gasper, C................................ 1040*, 1617 

Gasteiger, J........................................... 141 

Gatica, D............................................. 2267 

Gato, W E........................................... 380* 

Gaudreau, ........................................... 1694 

Gauggel, S.............................. 1213, 1233* 

Gaurdiola, J..........................................1111 

Gautier, J........................................... 1439* 

Gavaghan, C....................................... 1915 

Gavett, S H............. 601*, 602, 2292, 2293 

Gavett, S............................................... 603 

Gavin, C.............................................. 2126 

Gavin, T................................................ 161 

Gavina, J M........................................ 481* 

Gaylor, D............................................ 1542 

Gaytan, B.......................................... 2253* 

Ge, P..................................................... 203 

Ge, Y................................................... 2159 

Gear, R B............................................ 2362 

Gearhart, C A........................................ 160 

Gearhart, J M...................................... 2042 

Gearhart, J................................. 2014, 2049 

Geckle, L S......................................... 933* 

Gehen, S C........................................ 2358* 

Gelein, R................................... 2051, 2190 

Gelineau van Waes, J.......................... 1448 

Gemzik, B............................. 1722*, 2343* 

Genco, N................................... 504*, 2312 

Genell, C............................................... 662 

Geng, W.................................... 1161, 1437 

Gennings, C........................................ 2306 

Genter, M.............. 538, 1761*, 1879, 2582 

Gentner, N J.......................................... 186 

Geoly, F................................................ 555 

Georas, S N........................................... 673 

George, A............................................ 1771 

George, D............................................ 2397 

George, G N........................................ 1633 

Georgieva, I I............................ 1357, 2127 

Georgieva, N I.................................... 1262 

Gerberick, F.................. 85, 90, 1009, 2560 

Gerberick, G....................................... 2551 

Gerebtzoff, G........................................ 152 

Gerecke, D R....... 1749, 1750, 1751, 2026, 

2028, 2030, 2031, 2032, 2033 

Gerevini, M......................................... 1877 

Gerges, N............................................ 1908 

Gerhardy, C........................................... 560 

Gerken, D K........................................ 2234 

Gerlach, S............................................. 967 

Gerlovina, I........................................... 134 

Germolec, D R.............................. 98, 1367 

Germolec, D............................. 1519, 2682 

Geronilla, K.......................................... 351 

Gerstenfeld, L C................................... 352 

Gerstner, B.......................................... 2126 

Gertrud, S........................................... 1468 

Gervais, F............................................. 661 

Gervais, J............................................ 1921 

Geter, D R....................... 2296, 2346, 2383 

Geter, D.................................... 223*, 2639 

Gez, R......................................... 891, 2013 

Ghandehari, H..................................... 2173 

Ghare, S................................................ 392 

Ghashghaei, T..................................... 2345 

Ghio, A.................................................. 603 

Ghogha, A................................. 1327, 2624 

Ghoneim, M H.................................. 1374* 

Ghosh, R N....................................... 2540* 

Giancaspro, G I......................... 2436, 2439 

Gianios, C........................................... 2392 

Gibbs, S.................................. 2271, 2272* 

Gibson, C J......................................... 171* 

Giclas, P................................................ 800 

Giddings, A......................................... 1412 

Giebel, N............................................... 615 

Giebultowicz, J..................................... 396 

Gieré, R................................................. 328 

Giffen, P S............................................ 999 

Gift, J S................................................. 473 

Gigliotti, A.................................. 540, 1683 

Gilbert, J..................................... 935, 1889 

Gilbert, K.......................................... 2687* 

Gilbert, M E................................ 702, 2610 

Gilbert, M......................................... 2608* 

Gilbert, S G......................................... 922* 

Gilbert, S................................. 1880*, 2120 

Gill, E................................................. 2519 

Gill, H....................................... 1889, 1903 

Gill, M................................................ 2588 

Gill, S E.............................................. 1193 

Gill, S.................................................. 2328 

Gillespie, M E......................................... 4* 

Ginevan, B.......................................... 2660 

Gingell, R........................................... 2643 

Ginjupalli, G....................................... 348* 

Ginsberg, G L................................... 1568* 

Ginsberg, G......................................... 1962 

Giordano, G........ 1270, 1332, 2620, 2621* 

Girish, C............................................. 1250 

Giron, M I............................................. 388 

Girón-Pérez, I..................................... 2116 

Girtsman, T A....................................... 57* 

Giusti, A.............................................. 1576 

Glab, J................................................. 148* 

Glahn, F.............................................. 983* 

Glaser, K B........................................... 688 

Glass, I................................................ 2392 

Glass, J................................................ 1517 

Glavich, G............................................. 550 

Glaze, E.............................................. 1740 

Glazer, R A......................................... 2395 

Glazier, G............................................ 520* 

Gleason, C.......................................... 1412 

Glenn, B S.......................................... 1945 

Glenny, R W....................................... 2288 

Glick, A B..................................... 222, 357 

Glick, A............................................. 1783* 

Glista, E E..................... 1195, 2176*, 2178 

Glover, K P....................................... 2162* 

Glover, M C........................................ 209* 

Glover, M.............................................. 183 

Gminski, R............................................ 328 

Goad, J T............................................. 1893 

Gobejishvili, L.............................. 391, 392 

Gobell, R............................................. 2384 

Goda, Y............................................... 1100 

Godschalk, R W.................................... 616 

Goebel, C................................................ 88 

Goedken, M.......................................... 740 

Goel, S.............................................. 1262* 

Goergens, A.......................................... 499 

Goering, P L........................ 744, 754, 1434 

Goetz, A.............................................. 2639 

Goetz, G.............................................. 1588 

Gogal, R M............. 295, 296*, 1628, 2364 

Gohlke, J M................ 1567, 1963*, 2589* 

Golbraikh, A....................................... 159* 

Golden, R.............................................. 476 

Goldenberg, E....................................... 328 

Goldman, J M........................... 1042, 2308 

Goldman, S......................................... 1199 

Goldring, C E.................. 446, 2498, 2500* 

Goldsmith, R..................... 721*, 723, 1239 

Goldsmith, W T...................... 2299, 2338* 

Goldstone, J V.................................. 1859* 

Goldstone, J........................................ 1840 

Golembiewski, B................................ 1568 




Gollapudi, B B.............................. 223, 952 

Gollapudi, B................... 858, 2192, 2639* 

Golub, M............................................. 1771 

Gomes, A P......................................... 1087 

Gomes, C............................................ 2513 

Gomes, J............................................. 2091 

Gomes, M E...................................... 1223* 

Gomez Quiroz, L.......................1112, 1301 

Gómez, M......................................... 2578* 

Gomez, S.............................................. 143 

Gomez-Rubio, P............................... 1984* 

Gómez-Ruiz, C..................................... 593 

Gonçalves, M............................ 1335, 1676 

Goncharov, N.......................... 1543, 2047* 

Gondek, J............................................ 2391 

Gong, Y................................................. 249 

Gonsebatt, M E........................... 462, 1373 

Gonsebatt-Bonaparte, M....................... 286 

Gonzales, A................................... 528, 530 

Gonzales, F J...................................... 1890 

Gonzalez, C...................................... 1456* 

Gonzalez, F J........ 354, 355, 357, 358, 359 

Gonzalez, L......................................... 2062 

González-Arias, C.............................. 2116 

González-Barbosa, E.......................... 2524 

Gonzalez-Vergara, E........................... 2076 

Gonzalez-Villalva, A............................. 284 

González-Weller, D............................ 1228 

Goodale, B C.................................... 1638* 

Goode, G............................................. 248* 

Gooderham, N J.................................... 874 

Goodman, J E................ 1268, 1545, 1935, 

1944*, 2286 

Goodman, J I........................................ 429 

Goodman, K E.................................. 2403* 

Goodman, R.......................................... 692 

Goodrich, J......................................... 292* 

Goodway, R.......................................... 577 

Goodwin, J M................................... 1498* 

Gookin, G R........................................ 606* 

Gookin, G........................... 584, 596, 2495 

Goossens, D.......................................... 670 

Goravanahally, M............................. 1557* 

Gorbunov, N V.................................. 1169* 

Gordon, C........................................... 568* 

Gordon, M K........ 2030, 2031, 2032, 2033 

Gordon, M W...................................... 2565 

Gordon, R K....................................... 2018 

Gordon, R................................. 2031, 2130 

Gordon, T................ 6, 571, 579, 591, 2194 

Gore, A...................................... 261*, 2337 

Goretzki, L.......................................... 1896 

Gorman, P........................................... 1141 

Gorski, J................................................ 978 

Gosens, I............................................... 605 

Gosink, M..................................... 125, 150 

Goss, J A............................................. 1898 

Gosse, J A............................................. 254 

Goswami, M......................................... 115 

Goth, S................................................ 1130 

Gothi, A..................................... 1552, 1574 

Göttel, M............................................... 224 

Gotti, A............................................... 1582 

Goudreau, J L..................................... 1400 

Gough, B............................................... 506 

Gough, M............................................ 2255 

Gould, G G..................... 964, 1881, 2611* 

Gould, N S................................ 258*, 2327 

Gourmelon, A..................................... 2467 

Govindaarajan, R................................ 2283 

Gow, A J.................................... 2038, 2326 

Gow, A.................... 257, 637, 1709, 1713* 

Gow, J M.......................................... 2261* 

Gower, J................................................ 662 

Goyal, V.......................... 1552, 1574, 1933 

Gracia-Mora, I...................................... 593 

Grafström, R C......................... 135*, 2651 

Graham, J S....... 543, 544, 641, 892*, 893, 

2021, 2022 

Graham, J............................................ 953* 

Graham, M.............................. 1897, 1909* 

Graham, U M............................ 1460, 2065 

Grajeda-Cota, P.................................. 2119 

Gramowski, A..................................... 2510 

Grandidier, M H....................... 645, 2545* 

Grandjean, P....................................... 1391 

Grant, K................................................ 497 

Grant, R L................................. 1523, 2507 

Grantham, J......................................... 2397 

Granum, B............................................ 611 

Granville, C A......................... 2234*, 2374 

Granville, C........................................ 2272 

Grassian, V H........................... 1474, 1496 

Gratacos, E........................................... 613 

Gratz, K................................................ 647 

Graves, S W.............................. 2271, 2272 

Graves, S............................................. 2442 

Gray, J P.............................................. 2653 

Gray, J....................................... 2525, 2526 

Gray, Jr, E........................................... 1022 

Gray, L E............................................... 20* 

Gray, L............................ 1023, 2303, 2663 

Gray, W G................................... 131, 2371 

Gray, W............................................... 1068 

Graziano, J H...................................... 833* 

Green, A L........................................... 105* 

Green, B.................................... 1097, 2229 

Green, C E................................ 1106, 2261 

Green, G............................................... 164 

Green, L................................................ 798 

Green, M D......................................... 1925 

Green, S................................................ 792 

Greenberger, J S.................................. 1655 

Greene, N............................ 147, 936, 1815 

Greene, P............................................ 929* 

Greene, R.............................................. 826 

Greene, S............................................ 811* 

Greenhaw, J........................................ 1678 

Gregg, J............................................... 1770 

Gregory, B.................................1110, 2245 

Grenet, O............................................ 2537 

Grenwis, J........................................... 1930 

Gretzula, C.......................................... 1966 

Grey, B................................................ 1625 

Gribaldo, L.......................................... 1470 

Griffin, J L............................................ 875 

Griffin, K............................................ 1645 

Griffin, S............................................. 1267 

Griffith, L............................................ 1311 

Griffith, R W......................................... 710 

Griffith, W C........................................2111 

Griffiths, J C............... 2436*, 2437*, 2439 

Griggs, M.............................................. 789 

Grignard, E......................................... 1017 

Grimes, J..................................... 447, 1824 

Grimes, S D........................ 782*, 783, 917 

Grimm, D A........................................ 1558 

Gritsenko, M A................................... 1283 

Grobéty, B............................................. 328 

Groetters, S......................................... 1004 

Grollman, A........................................ 250* 

Groom, A............................................ 2071 

Groopman, J D.......... 46*, 831, 2638, 2642 

Grooten, L............................................. 622 

Groothuis, G M......................... 2509, 2561 

Groothuis, G............................. 1014, 1766 

Grosberg, A....................................... 1898* 

Grosdidier, E......................................... 661 

Gross, C L........................................... 2027 

Gross, E A......................... 601, 1953, 1954 

Gross, G.............................................. 2510 

Gross, R................................................ 803 

Gross, S A......................................... 1210* 

Grotendorst, G R................................ 1754 

Grotendorst, G.................................... 2019 

Gröters, S.................................... 224, 2095 

Grote-Wessels, S............................... 1232* 

Grothaus, J............................................ 719 

Groves, A M...................................... 2326* 

Gruber, U................................................ 73 



Gruene, M............................................. 739 

Grulke, E A............................... 1460, 2065 

Grunig, G............................................ 571* 

Gu, A................................................... 2367 

Gu, H.................................................. 2138 

Gu, J.................................. 230, 538*, 2073 

Gu, M........................................ 1756, 2040 

Gu, T................................................... 2611 

Gu, X...................... 397, 445*, 1081, 1088 

Guallar, E.................................... 767, 1974 

Guan, D............................................... 1359 

Guan, X................................................. 947 

Guarisco, J........................................ 2025* 

Guazzetti, S........................................... 629 

Guengerich, F P.................................... 128 

Guerra, M T.............................. 531, 1024* 

Guerra-Garcia, R.............................. 2495* 

Guerra-Hernandez, M......................... 2396 

Guerrero-Castilla, A.......................... 2396* 

Guerrette, Z........................................2111* 

Guerriero, F................................ 468, 996* 

Guest, R................................................ 996 

Guffroy, M................................ 1438, 1439 

Guguen-Guillouzo, C......................... 1579 

Guha, M............................................ 1430* 

Guidry, P............................................. 2045 

Guilarte, T R......................................... 164 

Guillette, L J....................................... 1447 

Guillouzo, A........................................ 1579 

Guilmette, R A........................ 2050, 2291* 

Guiney, P............................................. 2379 

Guinn, D............................................. 505* 

Guizzetti, M........................................ 2620 

Gul, H............................................... 1691* 

Gulhan, M........................................... 1361 

Gulland, F........................................... 2407 

Gunawan, R.............................. 720*, 1943 

Gunderson, A...................................... 1783 

Gunderson, M P.................................. 1447 

Gunier, R............................................ 625* 

Gunn, E............................................... 2555 

Gunter, K............................................ 2126 

Gunter, T E....................................... 2126* 

Gunther, W.......................................... 1412 

Guo, B................................................. 2175 

Guo, C J.............................................. 2038 

Guo, C................................................. 257* 

Guo, G L....................................1104, 1119 

Guo, J................................................ 1315* 

Guo, L........ 215, 438*, 934, 1097*, 1165*, 

1407, 2596, 2597, 2598 

Guo, N................................................ 1185 

Guo, S................................................. 1364 

Guo, T L.................................................. 98 

Guo, T................................................. 1196 

Guo, X.............................. 206, 214, 1407* 

Guo, Y J............................................ 1850* 

Guo, Y................................................. 1643 

Guo, Z......................................... 217, 2281 

Gupta, R C........................................ 1893* 

Gupta, R K................................ 1033, 1036 

Gurevich, I........................................ 1167* 

Gurnani, M........................................... 430 

Gury, T................................................ 1439 

Gut, C P................................................ 736 

Guth, K............................................... 640* 

Gutiérrez, J......................................... 1228 

Gutierrez-Ruiz, C......................1112, 1301 

Gutman, H.................................. 891, 2013 

Gutstein, D E.................................... 2473* 

Guyton, K Z...................... 330, 2360, 2641 

Gwinn, M R.......... 330, 1867, 1868, 2641* 

Gwinn, P O......................................... 1960 

Gwinn, W M....................................... 578* 

H 

Ha, H........... 1825, 1826, 1827, 1844, 2221 

Haag, V............................................... 1927 

Haas, D............................................... 1364 

Haber, L T................................. 473*, 2309 

Haberzettl, P..................... 190, 262, 1170* 

Hablas, A............................................. 1216 

Hack, C............................................. 2042* 

Hacke, K............................................... 238 

Hackett, D........................................... 2075 

Haddad, R......................................... 2188* 

Haddad, S........................................... 1836 

Hadi, M............................................. 1014* 

Hafner, C............................................ 2465 

Hagenbuch, B................................... 2247* 

Haggard, D E........................................ 276 

Haggerty, H............................... 1502, 1503 

Haghverdian, B A............................... 584* 

Haghverdian, B..................................... 606 

Hagiwara, A........................................ 1547 

Hahn, M E......................... 368, 410, 896*, 

1642, 1776* 

Hahn, M.............................................. 1774 

Hahn, R A....................... 2031, 2032, 2033 

Haighton, L A................................... 1323* 

Haijima, A......................................... 2606* 

Haiker, M.............................................. 387 

Hailey, J................................................ 781 

Haines, D.......................................... 2045* 

Hajela, R K......................................... 1397 

Hakansson, H...................................... 1877 

Håkansson, H...................................... 2369 

Hakulinen, P......................................... 672 

Haladi, S............................................... 682 

Halder, M.................................. 2380, 2581 

Hale, G................................................ 1152 

Hales, S............................................... 2589 

Hall, C A................................... 2021, 2022 

Hall, C................................................... 326 

Hall, D G............................................ 1443 

Hall, D................................................ 1364 

Hall, J.......................................... 389*, 549 

Hall, M L.............................................. 688 

Hall, S J.................................... 1043, 2191 

Hallak, J................................................ 802 

Halle, T................................................. 520 

Hallmark, N........................................ 1041 

Halmes, N........................................... 1947 

Halpern, W............................................ 776 

Halubai, S........................................... 2186 

Hamade, A K............................ 1472, 1948 

Hamade, A........................................ 1949* 

Hamblen, J M..................................... 1960 

Hamers, R J........................................ 1483 

Hamers, R........................................... 1461 

Hamilla, S........................................... 1312 

Hamilton, G A....................................... 762 

Hamilton, J W........................... 1989, 2366 

Hamilton, P V..................................... 1128 

Hamilton, R C....................................... 543 

Hamilton, T......................................... 1748 

Hammad, S......................................... 2553 

Hammerschlag, M R............................. 666 

Hammond, B G..................... 1728*, 1733* 

Hammond, D................................ 303, 304 

Hammond, S A...................................... 803 

Hammond, T G................................. 1915* 

Hammond, T......................................... 201 

Hamon, J............................................... 853 

Hamre III, J........................................... 973 

Han, E.................. 684, 2207, 2209*, 2211, 

2214, 2217, 2218 

Han, J.................................................... 975 

Han, S.......... 212, 592, 1016, 1190, 2180*, 

2250, 2536 

Han, T..................................... 1369*, 1594 

Han, W...................................... 954, 1659* 

Han, X..................................... 1580*, 2557 

Hanan, E............................................... 799 

Hanazato, M................... 621, 1225, 1573* 

Hance, M............................................ 1915 

Hancer, F............................................ 1361 

Hanig, J P.................................. 2596, 2597 

Hankey, P A.......................................... 456 

Hankinson, O.............................. 369, 1837 

Hanks, C....................................... 635, 636 

Author Index 


367


Author Index 


Hanley, T................. 664, 1030, 2615, 2616 

Hanna, N............................................. 1058 

Hannas, B..................... 1022, 2662, 2663* 

Hannon, H......................................... 1395* 

Hannon, P R........................................ 1035 

Hansen, R........................................... 1770 

Happo, M.............................................. 671 

Harbison, R D................. 1199, 1236, 1247 

Harbison, S C............................ 1199, 1247 

Harbo, S............................................ 1248* 

Harbourt, D....................................... 1517* 

Hardas, S S......................................... 1460 

Hardej, D........................ 302, 1865*, 2087 

Hardisson, A....................................... 1228 

Hardwick, R N.................................. 1108* 

Hardy, C................................................ 577 

Hardy, D............................................. 1438 

Hargitai, J............................................ 664* 

Hargreaves, A........................................ 201 

Harigae, M.......................................... 1062 

Harkema, J R....... 670, 1463*, 2305, 2494, 

2643 

Harleman, J........................................... 201 

Harley, K............................................. 1237 

Harman, J.............................................. 62* 

Harman, L................................. 2257, 2258 

Harmon, M....................................... 1696* 

Haro, L................................................ 2423 

Haron, M H......................................... 968* 

Harper, S............................................. 2009 

Harpur, E.................................. 1438, 1439 

Harrill, A H............................... 440*, 1735 

Harrill, A....................................... 549, 940 

Harrill, J A.......................... 31*, 867, 2629 

Harrill, J.............................................. 1095 

Harris, A J......................................... 2152* 

Harris, C C.......................................... 926* 

Harris, C............................................. 1616 

Harris, M A......................................... 1597 

Harris, M................... 916, 921, 1261, 1693 

Harris, R K.......................................... 1578 

Harris, R................................. 2043, 2044* 

Harris, S A............................................ 50* 

Harrison, B........................................... 193 

Harrison, T.......................................... 1106 

Harrod, K.............................................. 539 

Hartley, D P........................................ 852* 

Hartman, J H..................................... 1843* 

Hartman, N R...................................... 2074 

Hartman, N......................................... 1426 

Hartwig, A........................................... 1469 

Haruyama, E..................................... 1046* 

Harvey, R B........................................ 2417 

Harvey, R............................................ 1681 

Harvey, W A...................................... 1091* 

Harvison, P J......................................... 422 

Haschek-Hock, W M.......................... 2428 

Hasegawa, G..................................... 1370* 

Hasegawa, M.................................... 1618* 

Hasegawa, R....................................... 1044 

Hasegawa, T......................................... 770 

Haseman, J.......................................... 1521 

Hashiguchi, T........................................ 266 

Haskell, K........................................... 1500 

Haskett, S.......................................... 1142* 

Haskins, J R........................................ 2540 

Haskins, K A..................................... 1452* 

Haskins, K.......................................... 1426 

Hassall, D............................................. 577 

Hassan, S A......................................... 1629 

Hasselgren, C.............................. 154, 479* 

Hassoun, E................................ 251*, 1099 

Hastings, K L.................................... 1925* 

Haswell, L E......................................... 990 

Hatayama, T.......................................... 687 

Hatch, G E........................................ 2476* 

Hatlelid, K.......................................... 1214 

Hatsukami, D K.................................. 2697 

Hattan, C M...................................... 1682* 

Hattan, D G......................................... 2420 

Hattori, H.............................................. 649 

Haug, L S............................................ 1636 

Haugen, M A..................................... 2412* 

Haugen, M.................................. 611, 1636 

Haugh, C............................... 728, 733, 937 

Haupt, T............................................ 1819* 

Hawkins, B........................................... 350 

Haws, L......... 916*, 921, 1261, 1542, 1693 

Hay, E B................................................ 313 

Hayakawa, K...................................... 1105 

Hayakawa, T......................................... 246 

Hayashi, D............................................ 963 

Hayashi, H.................. 683, 689, 693, 1403 

Hayashi, K................................ 663, 1001* 

Hayashi, S......................... 325, 1090, 2657 

Hayashi, T........................................... 1001 

Hayden, P J................ 343, 466, 652, 1003, 

1750, 2534*, 2567, 2571, 2574, 2575 

Hayden, P.......................................... 2556* 

Hayes, E P............................................... 6* 

Hayes, M D............................................. 93 

Haykal-Coates, N................. 570, 607, 608 

Hays, B........................... 2601, 2602, 2603 

Hays, S M........................................... 1940 

Hays, S.......... 712, 920*, 1266, 1424, 1941 

Haywood, M M.................................. 1915 

Hazari, M S......................... 570, 607, 608* 

Hazen, M.............................................. 327 

He, K................................................. 1662* 

He, L..................................................... 313 

He, X................................................... 411* 

He, Y......................................... 954*, 1659 

He, Z................................................... 1614 

Head, A............................................... 1152 

Head, J.............................................. 1132* 

Heart, E............................................... 2653 

Hébert, C D........................... 273, 917, 918 

Hebert, C D......................... 782, 783, 1593 

Hebert, T R........................................... 209 

Hebert, V Y....................... 183*, 209, 1491 

Hebert, V............................................ 1320 

Hebestreit, M........................................ 998 

Hecht, S S............................... 834*, 2697* 

Heck, D E................ 458, 637, 1292, 1749, 

1750, 1751, 1752, 1838, 2028 

Heck, D................................................. 108 

Hedge, J M.......................................... 2350 

Hedge, J.............................................. 2608 

Hedley, K............................................ 1160 

Heflich, R H.. 320, 1405, 1406, 1411, 1548 

Heflich, R........................................... 1412 

Hegde, V L.......................................... 674* 

Hegde, V............................................... 676 

Heger, N............................................ 2191* 

Heggland, S J........................................ 276 

Heideman, W............. 197, 198, 213, 1461, 

1483, 1647 

Heier, A............................................... 1430 

Heilbrun, L P....................................... 620* 

Heilman, J............................................. 255 

Heimeier, R......................................... 2369 

Heindel, N D................... 1751, 2028, 2032 

Heisterkamp, S H................................ 2561 

Hejmancik, M R................................. 2631 

Hejtmancik, M.......................... 2234, 2374 

Helfant, L............................................ 1622 

Helm, W.............................................. 1991 

Helmer, M................................... 165, 166* 

Hemachandra, L P............................... 227* 

Hemkens, M......................................... 204 

Hemmer, M........................................... 826 

Hempel, K........................................... 971* 

Henderson, R G.................................. 298* 

Hendricks, C....................................... 1893 

Hendriks, B......................................... 1888 

Hendy, O............................................. 1328 

Hengstler, J G..................................... 2553 

Henio-Adeky, S.................................. 1696 

Hennen, J...................................... 88*, 639 

Hennig, B.............. 212*, 1495, 2180, 2250 



Henry, L...............................................1110 

Henry, N............................................... 658 

Henry, P................................................ 567 

Henry, S H.............................. 1534*, 2153 

Henry, S P............................................. 216 

Henry, S................................................ 800 

Hensler, J G........................................ 2611 

Hensley, J B........................................ 2191 

Henwood, A........................................ 1412 

Heo, J.................................................... 589 

Heppenheimer, A.............................. 1012* 

Herbert, K........................................... 1589 

Herbin-Davis, K................................... 232 

Herd, H............................................... 2173 

Heredia Ortiz, R................................ 1240* 

Heringa, M B...................................... 2348 

Heringa, M.......................................... 483* 

Herlin, M.......................................... 2369* 

Herman, J K...................................... 1924* 

Herman, R........................................... 1525 

Hermansky, S J................................... 882* 

Hermens, J................................ 1015, 2465 

Hermsen, S............................................. 71 

Hernandez Ramon, E........................ 2656* 

Hernandez Resendiz, I...................... 1301* 

Hernandez, A S............................. 613, 614 

Hernandez, A........................................ 346 

Hernandez, R U.................................. 1983 

Hernandez, R.................... 184, 421*, 1083 

Hernandez, T R................................... 1002 

Hernández-Avila, M............................. 292 

Hernández-Cadena, L......................... 1373 

Hernández-Castellanos, E................... 1972 

Hernandez-Gonzalez, S...................... 1203 

Hernández-Ochoa, I............................ 1038 

Hernandez-Ojeda, S.............................. 285 

Herndon, J M.................................... 1306* 

Herndon, J........................................... 1829 

Herold, M............... 724, 1440, 1562, 2353 

Herouet-Guicheney, C........................ 1556 

Herpers, B................................... 409, 431* 

Herr, D W............... 707, 1355, 2309, 2610 

Herrera-Moreno, F.............................. 2116 

Herrgen, K.......................................... 739* 

Herring, K........................................... 2098 

Herrmann, J...................................... 1907* 

Hertzberg, R C...................... 1795*, 2309* 

Hertz-PIcciotto, I................................ 1770 

Hess, M................................................. 726 

Hess, P................................................ 2402 

Hester, S D.............................. 1095*, 1311 

Hester, S.............................................. 2639 

Hesterberg, T W.................................. 1472 

Heussner, A H................................... 2435* 

Hewitt, K.............................................. 990 

Hewitt, P G......................................... 1410 

Hewitt, P..................................... 743, 1590 

Heyen, J................................................ 204 

Heyer, N J............................................. 610 

Heyward, S......................................... 1864 

Hickey, C A......................................... 591* 

Hickey, C.............................................. 579 

Higaki, T............................................... 974 

Higashisaka, K................ 1494, 2084, 2085 

Higuchi, S............................................. 428 

Hilaire, J............................................. 2591 

Hilberer, A...................... 1551, 2555, 2564 

Hilderbrand, S C................................. 1186 

Hileman, S............................................ 692 

Hill, A E.............................................. 1641 

Hill, B..................................................1111 

Hill, R................................................. 1563 

Hill, T.................................................. 631* 

Hillamo, R............................................ 672 

Hillebold, D........................................ 1526 

Hillebrecht, A.................................... 1814* 

Hiltke, T R........................................ 1867* 

Hilton, H................................... 1502, 1503 

Himmelstein, M W........................... 1591* 

Himmelstein, M.................................... 486 

Hinckley, J.......................................... 2576 

Hinderliter, P M.......... 704, 705*, 851, 866 

Hines, E P............................... 1089, 1697* 

Hines, R N................................ 615*, 1088 

Hines, S A............................................. 863 

Hinkley, G K..................................... 2053* 

Hinrichsen, S...................................... 1162 

Hinson, J A............................................ 459 

Hinton, D E......................................... 1777 

Hirabayashi, Y.......................... 123, 1154* 

Hiraga, T............................................. 1684 

Hirai, T.................................... 2080, 2083* 

Hiraku, Y............................................ 1487 

Hirano, S............................................. 2424 

Hirata-Koizumi, M........................... 1044* 

Hirayama, A.......................................... 521 

Hirkaler, G................................ 1161, 1437 

Hirogaki, C........................................... 321 

Hirose, A................................... 1044, 1194 

Hirose, R............................................. 1305 

Hirsch, C........................................... 2158* 

Hirschi, K........................................... 837* 

Hirvonen, M................................. 671, 672 

Hitchcock, J........................................ 522* 

Hitoshi, K......................................... 1184* 

Hixon, M L......................................... 1055 

Hixon, M............................................. 1612 

Hlywka, J.......................................... 2421* 

Ho, C................................................. 2211* 

Ho, R........................................... 940, 1735 

Ho, S H............................................. 2175* 

Ho, S................................................... 1377 

Ho, T................................. 299, 1393, 1998 

Hoagland, E.......................................... 995 

Hoang, L L........................................ 2330* 

Hobbs, C A.................................. 323, 325* 

Hoberman, A M........................ 1034, 1785 

Hoberman, A....................................... 1318 

Hocevar, B A..................................... 1082* 

Hodge, M.............................................. 351 

Hodges, M.................................... 635, 636 

Hodgson, E......................................... 2096 

Hoenerhoff, M J.......................... 245, 1089 

Hoet, P H.................................. 2062, 2163 

Hoet, P.................................................. 681 

Hoetker, D J.......................................... 190 

Hoffman, A............................................. 33 

Hoffman, C......................... 571, 666, 1069 

Hoffman, E......................................... 1238 

Hoffmann, D............................... 744*, 765 

Hoffmann, M...................................... 2519 

Hoffmann, P K.................................... 2468 

Hoffmann, P...................................... 2470* 

Hoffmann, S........................................ 2551 

Hoflack, J.................................... 387*, 442 

Hofmann, H........................................ 2158 

Hofseth, L........................................... 1133 

Hofsteen, P J....................................... 197* 

Hogan, C........................................... 2130* 

Hogan, K A......................................... 2641 

Hoidal, J.............................................. 1287 

Hojo, H............................................... 1062 

Hojo, R............................................. 1490* 

Hojyo, M............................................... 322 

Holaskova, I................................ 665*, 692 

Holcomb, N........................................ 115* 

Holian, A........................1178, 1454, 1711* 

Holladay, J............................................ 296 

Holladay, S D.................... 295, 296, 1628* 

Hollady, J.............................................. 295 

Holland, N.......................................... 1237 

Holle, E................................................. 553 

Hollingshead, B D................................ 372 

Holly, M................................................ 714 

Holmes, A L...................... 278*, 279, 2405 

Holmes, A........................................... 2407 

Holmes, E............................................. 45* 

Holmes, S........................................... 1689 

Holmuhamedov, E.............................. 1649 

Holstege, D......................................... 2088 




Holt, H K............................................ 2132 

Holz, J................................................... 809 

Holzman, S A........................................ 347 

Homiski, C.......................................... 1500 

Honarvar, N.................................... 82, 224 

Hong, G............................................ 1621* 

Hong, H L............................................. 245 

Hong, H................................................ 140 

Hong, S J............................................ 2540 

Hong, S......................... 2271*, 2272, 2520 

Hong, Y S......................................... 1256* 

Hood, D B................................. 2203, 2607 

Höög, J........................................ 135, 2651 

Hooper, A.............................................. 125 

Hoopes, M............................................ 982 

Hooser, S................................ 2223, 2428* 

Hooth, M J............................................ 915 

Hooven, L A.............................. 396*, 1702 

Hope, E F.......................................... 1319* 

Horacio, O.......................................... 1833 

Horie, H.............................................. 425* 

Horie, M............................................. 1177 

Horio, F............................................... 1062 

Horton, L...................................... 579, 591 

Horwitz, V.................................. 891, 2013 

Hosoda, K........................................... 2302 

Hosokawa, M........................................ 663 

Hossain, M M............................. 170*, 171 

Hotchkiss, J A.............. 2100, 2105*, 2279, 

2296, 2643 

Hotchkiss, M....................................... 2384 

Hou, Y....................................... 2001, 2502 

Houck, K A......................................... 2156 

Houck, K..................... 141, 716, 717, 1760 

Houde, M.............................................. 657 

Houghton, J....................................... 1105* 

Houseman, E....................................... 2191 

Howard, P C............................. 1464, 2627 

Howard, P........................................... 2174 

Howe, K................................................ 987 

Howell, B A.............................. 940*, 1735 

Howell, B J......................................... 1966 

Howell, B.............................................. 941 

Howse, K............................................ 2441 

Hoyer, P B........................................... 1054 

Hristozov, D.................................. 155, 495 

Hsieh, E J............................................ 1692 

Hsieh, H.............................................. 2410 

Hsieh, M................................. 2410*, 2431 

Hsin, H................................................ 1901 

Hu, C................................................. 1899* 

Hu, H............................................ 292, 943 

Hu, J...................... 448*, 582, 1648, 2238* 

Hu, W.............................. 204*, 1153, 1906 

Hu, X........................................ 1193, 1465 

Hu, Y................................................. 1782* 

Huang, B........................................... 2497* 

Huang, C.................. 299, 307, 1393, 1665, 

1998*, 2114 

Huang, H................................... 2125, 2187 

Huang, K........................................... 2125* 

Huang, M........................ 945, 1831*, 2028 

Huang, P........................................... 1102* 

Huang, R..................... 482, 493, 981, 2501 

Huang, W.................................. 517, 1427* 

Huang, Y................................. 1485, 2177* 

Huang, Z..................................... 176, 1364 

Huard, L................................................ 788 

Hubbard, A............................................ 134 

Hubbs, A F...................... 56, 59, 575, 1557 

Hubbs, A........................... 58*, 1185, 1454 

Huber, L................................................ 202 

Huby, R............................................... 2372 

Huderson, A C.................................. 1670* 

Hudson, A......................................... 1497* 

Hugens, E............................................. 310 

Huggett, D.......................................... 2394 

Hughes, M F........................... 2009*, 2262 

Huh, D...................................... 762, 1901* 

Huhtaniemi, I T......................... 1039, 2549 

Huiyan, P............................................ 1494 

Hulderman, T............................ 185, 1492* 

Hulse, E J............................................ 1447 

Hulsey, T............................................... 657 

Hung, D......... 299*, 300, 307, 1393, 1665, 

2114 

Hunter, A............................................... 652 

Hunter, D L......................... 871, 872, 2628 

Hunter, E S......................................... 2308 

Hunter, K............................................ 1253 

Hunter, L J.......................................... 1084 

Hunter, R.............................................. 517 

Hunter, S............................................... 982 

Hurst, C............................................. 1892* 

Hurtt, M E............................................. 623 

Hussain, L............................................. 207 

Hussain, S M....... 1453, 1464, 1761, 2059, 

2181 

Hussain, S......................... 846, 1764, 2182 

Hussainzada, N....................... 1330*, 2099 

Hutchinson, A..................................... 2125 

Hutchinson, L....................................... 254 

Hutchinson, R W.......................... 1, 1767* 

Hutchison, J........................................ 1479 

Hutz, R J................................... 1051, 1588 

Huwe, J............................................. 2273* 

Huynh, M............................................ 1417 

Hwang, G.................................... 306*, 308 

Hwang, Y............. 2207, 2208, 2210, 2211, 

2212, 2213, 2214*, 2215 

Hynes, D....................................... 532, 805 

Hynes, J............................................ 2528* 

I 

Iaiza, P.................................................. 316 

Iatropoulos, M J................................ 2630* 

Ibekie, A.............................................. 2443 

Ibrahim, W........................................ 2622* 

Ichihara, G......................... 175, 176, 177*, 

1446, 1487 

Ichihara, S............................ 175, 176, 177, 

1446, 1487* 

Igarashi, K.......................................... 1596 

Igarashi, Y........................................... 124* 

Igor, K................................................... 946 

Igor, P.................................................... 950 

Igoshi, Y...................................... 64, 2200* 

Iguchi, T.............................................. 2467 

Ihlaseh, S M................................ 525, 547* 

Iida, S.................................................. 1547 

Ikemi, N............................................ 1632* 

Ikeuchi, R............................................. 663 

Il’Giovine, Z......................................... 504 

Im, J................................ 684, 2209, 2218* 

Imai, T...................................... 246*, 1044 

Imaida, K.............................................. 232 

Imaizumi, S......................................... 1837 

Imamura, Y........................................... 266 

Imbert, S............................................... 464 

Imran, S................................................ 716 

Imsilp, K............................................. 1828 

Inamdar, A A..................................... 2399* 

Inawaka, K............................................ 974 

Inayat-Hussain, S H.......................... 1673* 

Ingber, D E................................. 762, 1901 

Ingerman, L........................................ 1530 

Ingermanson, R................................... 1894 

Inglis, H.................................... 2554, 2555 

Inman, A O.......... 1176, 2072, 2154, 2155* 

Inoue, K.......................... 627, 1090, 2657* 

Inoue, T........................... 123*, 1154, 1403 

Inturi, S..................................... 1756, 2040 

Irikura, D.......................................... 1211* 

Irons, R D........................................... 1210 

Irons, T D............................................ 872* 

Irving, R M......................................... 755* 

Irwin, R D........................................... 1096 

Isariyodom, S...................................... 1828 

Isbrucker, R........................................ 2581 

Iscan, M.................................. 1361, 1362* 

Ishida, K............................................. 1922 



Ishihara, Y........................................... 1370 

Ishola, I............................................. 2230* 

Ismail, A.............................................. 1328 

Ito, M.................................................... 521 

Ito, S......................................... 649*, 1684 

Itoh, N......... 1494, 2080, 2083, 2084, 2085 

Ivan, R.......................................... 946, 950 

Ivanov, I.............................................. 2069 

Ivy, J H.............................................. 1810* 

Iwahashi, H......................................... 1177 

Iwamoto, N......................................... 1305 

Iwasaki, K........................................... 2497 

Iwata, H.......................... 353*, 1684, 1979 

Izumi, H................................................ 638 

J 

Jaar, B G............................................... 773 

Jaar, B........................................... 767, 768 

Jabbour, R........................................... 2017 

Jacewicz, M...................... 935, 1889, 1903 

Jacinto, E Y........................................... 422 

Jack, J................................. 728, 733, 937* 

Jackson, A R....................................... 676* 

Jackson, B........................................... 2007 

Jackson, D A....................................... 1605 

Jackson, D................................. 1330, 2099 

Jackson, G R..................................... 2567* 

Jackson, L S.............................. 2432, 2433 

Jackson, M C............................ 2299, 2338 

Jackson-Humbles, D........................... 1463 

Jacob, C C........................................... 2420 

Jacob, C.............................................. 1434 

Jacob, R.............................................. 2288 

Jacobs, A....................... 1518*, 1519, 1520 

Jacobs, J M..................... 1283, 1284, 1450 

Jacobs, J................................................ 129 

Jacobs, S............................................... 809 

Jacobsen, M C...................................... 211 

Jacobson Kram, D................................ 876 

Jacobson, P B........................................ 688 

Jaeckh, C................................. 1004, 1005* 

Jaeschke, H......... 448, 450*, 451, 452, 453 

Jain, A K................................. 1756, 2040* 

Jakubowski, E M................................ 2011 

Jakubowski, J A.................................... 777 

Jalava, P........................................ 671, 672 

Jallal, B................................................. 803 

James, K........................................... 2566* 

James, L P............................................. 459 

James, O P............................................ 178 

James, R C.......................................... 1947 

James, S A..................................... 946, 950 

Jamieson, J........................................ 1821* 

Jan, B.................................................... 696 

Jan, Y.................................................. 458* 

Jana, S........................... 1552, 1574*, 1933 

Jang, K................................................ 762* 

Jang, W......................................... 294, 975 

Jannuzzi Madureira, D...................... 1599* 

Janovitz, E B....................................... 1451 

Jansson, C........................................... 2352 

Janus, E R........................................... 927* 

Janus, E................................................. 931 

Jarabek, A M........... 485*, 601, 2292, 2293 

Jarabek, A............................................. 486 

Jaramillo, B E................................... 2236* 

Jaramillo, R........................................... 539 

Jardim, M J......................................... 901* 

Jarema, K A............................ 1337, 1338* 

Jarnagin, K............................................ 542 

Jarrett, T................................................ 295 

Jaskot, R............................................. 1473 

Jaspers, I............... 565, 1601, 2332, 2483* 

Javdan, M........................................... 1272 

Jaworska, J.............................................. 85 

Jayadev, S........................................... 1364 

Jayanna, P K..................................... 2046* 

Jayaram, B.......................................... 1578 

Jayasinghe, B S................................. 1634* 

Jean, P................................................. 2535 

Jean, Y.................................................. 746 

Jeannot, E............................................. 447 

Jedynska, A D..................................... 1413 

Jeevaragen, A................................ 303, 304 

Jefcoate, C R....................1120, 1138, 1168 

Jeffay, S................................................ 982 

Jefferson, W............................ 2197*, 2198 

Jeffrey, A M.............................. 972*, 2630 

Jeffries, H.................................... 565, 2332 

Jeffy, B................................................ 1602 

Jelakovic, B.......................................... 250 

Jeng, A................................................ 1291 

Jenkins, R E........................................ 2500 

Jennings, P............................................ 739 

Jenny, M J......................... 410, 1642, 1776 

Jensen, K............................................. 2368 

Jensen, N............................................. 2585 

Jensen, T J........................................... 1976 

Jeong, H........................... 684, 1826, 1827, 

2207, 2208, 2209, 2210*, 2211, 2212, 

2213, 2214, 2215, 2216, 2217*, 2217*, 

2218, 2221 

Jeong, S............................... 101, 746, 2525 

Jeong, T............... 684, 1825*, 1826, 1827, 

1844, 2221 

Jeoung, S....................................1117, 1118 

Jessen, B................ 204, 785, 1153*, 1650, 

1891, 1906 

Jessica, S............................................... 950 

Jester, J................................................ 1481 

Jetten, A M.......................................... 2636 

Jetten, M........................................... 1585* 

Jeurink, P V............................................. 89 

Jewell, W T......................................... 1679 

Jewell, W.............................................. 888 

Jez, J M............................................. 1729* 

Ji, J...................................................... 1762 

Ji, Q C................................................. 1230 

Ji, Z..................................................... 337* 

Jia, W.................................................. 2148 

Jia, Z................................................. 1303* 

Jiang, J.................................... 1512, 1655* 

Jiang, Q............................................... 205* 

Jiang, S............................................... 2323 

Jiang, W.................. 110, 1856, 2137, 2587 

Jiang, Y........................... 1561, 2139, 2140 

Jianmongkol, S................................... 1336 

Jim, L.................................................. 2387 

Jiménez Vélez, B D...................... 668, 669 

Jimenez-Badillo, S E.......................... 1456 

Jiménez-Mendoza, E........................ 1255* 

Jin, C................................................. 2344* 

Jin, G................................................. 1129* 

Jin, H................................................... 1287 

Jing, H M............................................ 2136 

Jinno, H................................................. 412 

Jinot, J....................................... 1946, 2641 

Jo, E M................................................ 1256 

Jo, W..................................................... 817 

Joachim, K............................................ 671 

Joaquin, V......................................... 1092* 

Jobes, M L............................................ 537 

Johannessen, L N.................................. 253 

Johansen, M E.................................... 2333 

Johanson, G.......... 713*, 1217, 1575, 2259 

Johansson, E......................................... 313 

Johansson, L....................................... 1201 

John, K............................ 116, 2656, 2658* 

John, W................................................. 716 

John-Baptiste, A.................. 528, 530, 1427 

Johns, D O.......................................... 330* 

Johnson, B P............................. 393*, 1705 

Johnson, C.......................................... 2673 

Johnson, D E......................................... 229 

Johnson, D R...................................... 291* 

Johnson, D.................................. 497, 2555 

Johnson, F O..................................... 1401* 

Johnson, G T................. 1199*, 1236, 1247 

Johnson, J....................... 723, 1239, 1402* 

Johnson, K J........................................ 2191 

Johnson, K........................ 67*, 1066, 1196 

Author Index 


369


Author Index 


Johnson, M B.................................... 1073* 

Johnson, M S.................... 736, 1420, 1544 

Johnson, N................................ 1521, 2581 

Johnson, R J........................................ 1086 

Johnson, R L....................................... 1770 

Johnson, V J................................ 97*, 1367 

Johnson, W D..................... 516, 794, 795* 

Johnson, W........................................... 207 

Johnston, C J........................... 2190*, 2612 

Johnston, C................................... 647, 654 

Johnston, J J........................................ 2273 

Johnston, J.......................................... 1526 

Johnstone, A F.................................... 2510 

Johnstone, A M................................. 1354* 

Jokiniemi, J................................... 671, 672 

Jolly, C M........................................... 1674 

Jolly, P E............................................. 1674 

Jomphe, C......................................... 2274* 

Jones, B A........................................... 1241 

Jones, B..................................... 1521, 2581 

Jones, D P........................................... 1349 

Jones, D................................................ 44* 

Jones, H................................................ 938 

Jones, K.............................................. 2017 

Jones, M Y.......................................... 2077 

Jones, R................................................. 351 

Jones, S............................................... 2563 

Jones, T R..................................... 100, 102 

Jones, W R.......................................... 2358 

Jones, Y............................................... 2174 

Jong, L................................................ 2261 

Jonyas, A M........................................ 1964 

Joo, H.................. 1823, 1824*, 1846, 2096 

Jordan, H............................................... 781 

Jordan, S A................................ 2437, 2439 

Jordan, S............................................... 826 

Jordan, W H........................................ 1443 

Jordt, S E............................................ 2335 

Jordt, S.................................................. 574 

Jörnvall, H............................................ 135 

Jortner, B S......................................... 2576 

Joseph, J.............................................. 2580 

Joseph, L B....................................... 1751* 

Joseph, P............................................. 2318 

Joshee, L............................................... 761 

Joshi, P.......................................... 650, 651 

Joshi-Barve, S............. 391, 392, 690, 1085 

Josse, R............................................... 1579 

Jovanovic, M L................................. 2535* 

Jowsey, P A......................................... 114* 

Joyce, K.................................... 282*, 2392 

Juan, C.................................... 1608, 2416* 

Juan-Garcia, A........................ 1608*, 2416 

Juberg, D R............. 47*, 1324, 2105, 2279 

Judson, R S......................................... 1619 

Judson, R............. 714, 716, 717, 727, 728, 

912*, 1813* 

Jules, G E.......................................... 2203* 

Julien, E................................................ 158 

Jung, D...................................... 318, 2007* 

Jung, H.................................................. 975 

Jung, K.............................. 589, 975*, 2536 

Juran, S A.......................................... 1575* 

Juran, S............................................... 2259 

Jureziz, A............................................ 1654 

Jursa, T................................................ 1238 

Jutooru, I D......................................... 956* 

Jutooru, I............................................... 955 

K 

Kabalka, G.......................................... 1661 

Kabilan, S........................................... 2288 

Kabirov, K K.................................... 1885* 

Kabirov, K.......................................... 2263 

Kabobel, O.......................................... 2121 

Kadambi, V J........................................ 660 

Kadar, T.................................... 891*, 2013 

Kadereit, S............................................ 868 

Kadiiska, M B....................... 1435*, 1512* 

Kadiiska, M.......................................... 685 

Kadota, T.......................................... 2424* 

Kagan, V E.................25*, 54, 1180, 1189, 

1285, 1462, 1655, 1669, 2072 

Kagan, V............................................. 1179 

Kahl, M............................................... 2368 

Kahl, R................................................ 1877 

Kai, K................................................. 1101 

Kai, T.......................................... 425, 436* 

Kaido, T................................................ 663 

Kaiser, J............................................ 1958* 

Kaji, T................................................... 412 

Kajikawa, M........................................... 99 

Kakeyama, M..................................... 2606 

Kakiuchi-Kiyota, S........ 232, 2633*, 2646, 

2655 

Kakuni, M................................... 510*, 532 

Kale, V M........................................... 1300 

Kale, V................................................ 748* 

Kallman, M J........................ 1724*, 1805* 

Kallman, M......................................... 1804 

Kalmes, M.................................... 88, 639* 

Kalmes, R........................................... 1265 

Kaltenhaeuser, J................................ 73, 75 

Kaluzhny, Y........................ 343, 466, 1003 

Kalyanaraman, B................................ 2130 

Kamada, H........... 1494, 2080, 2083, 2084, 

2085 

Kamal, A............................................. 2494 

Kamata, Y................................. 1211, 2424 

Kamath, A............................................. 776 

Kamau-Cheggeh, C................ 2602, 2603* 

Kamel, A............................................. 1031 

Kamendulis, L M................................ 1082 

Kameoka, S..............................1159, 1164* 

Kamerling, S......................................... 528 

Kaminski, N E...................678, 1135, 1137 

Kaminski, N.......... 226, 345, 654, 675, 677 

Kamniski, N E...................................... 373 

Kamp, H G.............................. 1440, 1562* 

Kamp, H........................... 724, 1008, 2353 

Kamperschroer, C............1142, 1148, 1149 

Kamrin, M.......................................... 1875 

Kamura, K.......................................... 1046 

Kan, H L............................................... 952 

Kan, H..................................... 1459*, 2639 

Kan, L H............................................... 223 

Kan, L................................................. 2518 

Kan, R K................................... 1755, 2025 

Kanchagar, C...................................... 2522 

Kandarova, H......... 466, 1003, 2534, 2567, 

2571, 2574* 

Kanderova, H........................................ 644 

Kang, C..................................... 1762, 1763 

Kang, F............................................... 2005 

Kang, H....................................... 101, 746* 

Kang, J Y............................................ 2005 

Kang, J.......................................... 101, 746 

Kang, M.............. 1825, 1826*, 1827, 1844 

Kang, S....................................... 294, 1884 

Kang, Y......................................... 207, 208 

Kania-Korwel, I...................... 1820*, 2624 

Kannan, K........................................... 2608 

Kannemeier, C.................................... 1173 

Kanno, J.................................. 1154, 1596* 

Kansy, M........... 33*, 152, 852, 855*, 1814 

Kanthasamy, A G.............. 173, 2130, 2134 

Kanthasamy, A................. 173, 845*, 845*, 

2130, 2134 

Kanungo, J........................................ 1614* 

Kapetanovic, I M......... 782, 783, 794, 795, 

1106, 1885, 2261 

Kaphalia, B S........................................ 551 

Kaplan, B F........................................... 678 

Kaplan, B...................... 345, 654, 675, 677 

Kaplan, C.............................................. 555 

Kapp, M.................. 724, 1440, 1562, 2353 

Kappeler, C J.................................... 1054* 

Kappeler, K....................................... 1279* 

Kapralov, A A........................................ 54* 

Kapralova, V....................................... 1179 

Kaput, J............................................... 1097 



Karacaoglan, V......................... 1361, 1362 

Karadzovska, D.................................. 634* 

Karakaya, A........................................ 2650 

Karakitsios, S.............................. 865, 1582 

Karchner, S I..................... 368*, 410, 1776 

Karetsky, V........................................... 343 

Karim, A............................................. 2225 

Karimullina, E.................................. 2382* 

Karin, N J........................ 129, 1450, 1457* 

Karman, B........................................... 1037 

Karmaus, P.................................. 675*, 677 

Karpuzoglu, E................................... 2364* 

Karrow, N A.......................................... 682 

Karyakina, N....................................... 2461 

Kashon, M L......... 58, 59, 185, 1557, 2325 

Kashon, M................................ 2318, 2322 

Kaspareit, J......................................... 1566 

Kass, M D........................................... 1381 

Kassel, K M.........................................1119 

Katagiri, H............................................ 663 

Katavolos, P.......................................... 507 

Kathman, S J........................... 1224*, 1241 

Kato, A.................................................. 175 

Katoh, M..................................... 687, 1184 

Katoh, Y................................................ 510 

Katre, A............................................... 1293 

Katwa, P............................................ 1186* 

Kavanagh, T J................. 1193, 2328, 2621 

Kavanagh, T........................................ 1465 

Kaveh, N........................................... 2316* 

Kavlock, R J............................. 1619, 2156 

Kavlock, R........................ 714, 717, 2505* 

Kawabata, T T.................1141, 1148, 1149, 

1497, 1500 

Kawabata, T.............................. 1142, 1498 

Kawabe, M........................................... 508 

Kawada, T............................................. 691 

Kawaguchi, H..................................... 638* 

Kawai, R............................................... 649 

Kawamura, S........................................ 974 

Kawamura, Y...................................... 1403 

Kawashima, K.................................... 1632 

Kawataki, T...................................... 2619* 

Kazmi, P..................................... 467, 2564 

Ke, S..................................................... 945 

Kearney, K R.................................... 1914* 

Kedderis, G............................... 1421, 1422 

Keebaugh, A J..................................... 596* 

Keebaugh, A................................. 584, 606 

Keeler, G J.......................................... 2494 

Keenan, J.......................................... 1263* 

Keenan, R E...................................... 1960* 

Keene, A M....................................... 2074* 

Kegelman, T A...................................... 585 

Keil, D E............................................... 670 

Keil, D.................................................. 659 

Keiser, M............................................ 854* 

Kelkar, H.............................................. 947 

Keller, D....................... 978*, 1094*, 2544 

Kelley, M A....................................... 1491* 

Kelley, N............................................. 2020 

Kelley, T............................................... 315 

Kelly, D P............................................ 586* 

Kelly, K A................................. 178*, 1348 

Kelly, K M.......................................... 1209 

Kelly, K................................................. 747 

Kelly, P................................................. 872 

Kelm, J M........................................... 2553 

Kelman, B J...................................... 1546* 

Kemp, D............................................. 781* 

Kemper, R A..................................... 2511* 

Kempinas, W G.................................. 1024 

Kendig, E L............................. 2359, 2362* 

Kendig, E................................ 2662, 2667* 

Kendrick-Parker, C....................1163, 1164 

Kenfield, J........................................... 1060 

Kennedy, D................................... 791, 801 

Kenneke, J............................................ 721 

Kennet, S.............................................. 946 

Kensler, T W................. 831*, 1786, 1789* 

Kent, M L........................................... 1071 

Kenyon, A........................................... 1759 

Kenyon, E M...................................... 711* 

Keough, E........................................... 1966 

Kepley, C R........................................ 2576 

Keravec, V................................ 1290, 1555 

Kerdine-Römer, S................................. 92* 

Kerger, B D....................................... 2255* 

Kerger, B..................................... 502, 1947 

Kern, C............................................. 2149* 

Kern, P.................................................... 85 

Kern, R J............................................. 2048 

Kerns, W........................................... 2671* 

Kerr, I........ 1870*, 2252, 2342, 2392, 2405 

Kerr, R........................................ 295*, 296 

Kerry, P J............................................ 1098 

Kerwien, S............................................ 983 

Kerzee, J........................................... 1879* 

Keselica, M......................................... 1603 

Keshava, C........................................ 1955* 

Keshava, N......................................... 1220 

Keve, S................................................. 801 

Khalifa, M............................................. 569 

Khan, I A....................................... 968, 992 

Khan, M.................... 112, 390, 1286, 1510 

Khan, Q M............................................ 320 

Khan, S................................................. 91* 

Khanal, T.................................. 2213, 2221 

Khang, D........................................... 2061* 

Khetani, S...........1094, 1311, 2511, 2522*, 

2523 

Khlebnikova, N................................... 1543 

Khoh-Reiter, S.................................... 785* 

Kholmukhamedov, A........................ 1648* 

Khozoie, C.......................... 354, 357, 358* 

Kiang, J G........................................... 1169 

Kido, T.................................................. 663 

Kienast, M F....................................... 1611 

Kijima, K.............................................. 321 

Kikura-Hanajiri, R.............................. 1100 

Kilford, J............................................... 969 

Killilea, D W......................................... 297 

Kim, B G............................................ 1256 

Kim, C S..................................... 516, 1938 

Kim, C................................ 589, 590, 1480 

Kim, D S............................................. 1256 

Kim, D............ 628*, 635, 769, 1293, 1478 

Kim, E......................................... 353, 1684 

Kim, H................. 108*, 1826, 1827, 2211, 

2214, 2221*, 2520* 

Kim, J H...................................... 169, 1692 

Kim, J........ 486, 1212, 1449, 1474*, 1488, 

1496, 2215*, 2217, 2536 

Kim, K.......................... 294, 1884*, 2453* 

Kim, M........................... 197, 198*, 2284* 

Kim, N.......................................... 768, 773 

Kim, S............ 654, 917, 977, 1197, 1597*, 

1660*, 1884, 2054, 2061, 2184 

Kim, T................................................... 765 

Kim, Y M............................................ 1256 

Kim, Y................................................ 1763 

Kimani, P W..................................... 1056* 

Kimbell, J S.............................. 2289, 2290 

Kimber, I.................. 90, 91, 93, 94, 95, 96, 

902*, 903*, 2527* 

Kimoto, T............................................ 1412 

Kimura, J.............................................. 425 

Kimura, M.......................................... 2424 

Kimura, T...................................... 412, 436 

Kimzey, M J........................................ 1281 

Kindt, E............................................... 1427 

King, A R............................................ 1641 

King, B................................................. 130 

King, R S............................................ 1862 

Kinkaid, A............................................. 876 

Kinsky, O.......................................... 1281* 

Kinter, L B.......................................... 1602 

Kinter, L............................ 742, 1430, 2372 

Kinzer, C......................... 400*, 2314, 2315 

Kipar, A............................................... 2500 




Kipen, H M....................................... 2490* 

Kirby, P............................................... 1420 

Kirchner, J............................................ 778 

Kirchner, S.......................................... 316* 

Kirichenko, E...................................... 2363 

Kirk, S A............................................. 1152 

Kirkpatrick, D............................. 564, 1644 

Kirman, C R.............................. 477, 1940* 

Kirman, C................................... 920, 1424 

Kirsch-Volders, M.............................. 2062 

Kirwan, S............................................ 2528 

Kisby, G E.......................................... 1333 

Kisin, E...............1179, 1180*, 1189, 1462, 

2072, 2160 

Kiss, L................................................. 1966 

Kissel, H............................................... 522 

Kissling, G E.......... 482, 1089, 1367, 2517 

Kitahashi, T.......................................... 246 

Kitajima, S.......................................... 1596 

Kitazawa, T......................................... 1684 

Kitchel, D......................................... 1425* 

Kitoh, J................................................. 176 

Kitteringham, N R.................... 2498, 2500 

Klaassen, C D.............................. 449, 548, 

694, 740, 1104, 1114, 1643, 1706*, 1788*, 

1850, 2496*, 2503 

Klaassen, C......................................... 2269 

Klangkaew, N..................................... 1828 

Klaper, R................. 60, 1051, 2378, 2401* 

Klaunig, J.............................................. 367 

Klausner, M................. 87, 343, 466*, 652, 

1003, 1049, 2373, 2534, 2556, 2567, 2571, 

2574, 2575 

Kleeman, M J...................................... 2491 

Kleensang, A....................................... 2380 

Klei, L R........................................... 1968* 

Klein, D................................................ 624 

Klein, M............................................ 1727* 

Klein, T E......................................... 1737* 

Kleinbeck, S....................................... 1575 

Kleinedler, J J................................... 1320* 

Kleinjans, J C.......................................... 79 

Kleinjans, J............................... 1585, 1586 

Kleinman, M T............................. 593, 606 

Kleinman, M....................... 584, 596, 2495 

Kleinow, K.......................................... 1627 

Kleinsorge, E...................................... 2112 

Kleinstreuer, N C............... 72*, 836, 840*, 

1619 

Kleinstreuer, N...................................... 982 

Klim, A M......................................... 2055* 

Klimecki, W T.......................... 1984, 1988 

Klimecki, W.......................... 2444*, 2447* 

Klimentidis, Y C................................. 1984 

Klinefelter, G R.................................. 2308 

Klingelhutz, A..................................... 2251 

Klingler, R H.................................... 2514* 

Klingler, R.......................................... 1778 

Klocke, C R........................................ 1855 

Klossner, A N...................................... 1770 

Klotz, C............................................... 2516 

Kluetzman, K........................................ 582 

Klug, M................................................. 315 

Kluwe, W............................................ 1603 

Knaak, J B........................ 723, 2097, 2106 

Knadle, S A......................................... 498* 

Knadler, M............................................ 777 

Knafla, A L....................................... 1266* 

Knapp, D............................................. 1437 

Knapp, G W........................................ 1583 

Knapton, A.......................................... 2074 

Knebel, J............................................... 960 

Knickelbein, K E.................................. 121 

Knippels, L M......................................... 89 

Knipping, E................................. 594, 2493 

Knöbel, M........................................... 2465 

Knoell, D L........................................... 314 

Knowlton, M......................................... 133 

Knuckles, T L................................... 1471* 

Knudsen, G A............................ 732*, 2282 

Knudsen, N H................................... 1862* 

Knudsen, T B...................... 72, 836*, 1619 

Knudsen, T............................ 717, 728, 982 

Knutsen, H K............................ 1636, 2412 

Ko, G.......... 1340, 1825, 1826, 1827, 1844 

Ko, M.......................................... 528*, 530 

Kob, M................................................ 1645 

Kobayashi, M............................. 691, 1062 

Kobayashi, N...................................... 2082 

Kobayashi, T....................................... 1487 

Kobayashi, Y...................................... 2079 

Kobos, E............................................. 1127 

Kodavanti, P R.................................... 1583 

Kodavanti, P S.................................. 1298* 

Kodavanti, U P....... 568, 602, 604*, 2477* 

Kodavanti, U............................... 603, 2489 

Koeper, L............................................ 1013 

Koeppel, F.......................................... 1919 

Koerner, M............................................ 450 

Koester, A........................................... 1882 

Kohistani, N.......................................... 241 

Kohno, Y............................................. 2200 

Koissi, N............................................. 2660 

Koivisto, E L......................................... 634 

Koivisto, E............................................ 642 

Kojima, H............. 322*, 1016, 1017, 2581 

Kolaja, K L....................................... 2678* 

Kolaja, K.........215, 316, 1159, 1161, 1163, 

1164, 1165, 2675 

Kolhoff, S............................................. 666 

Kolisetty, N............................... 774*, 2281 

Kolle, S N......................... 82*, 1002, 2550 

Kolle, S................... 644, 971, 1007*, 1008 

Komano, T.......................................... 1001 

Komatsu, L......................................... 994* 

Komatsu, S........................................... 649 

Kombarova, M.................................. 1543* 

Kominami, A....................................... 2637 

Komiya, K.......................................... 1547 

Komiyama, A C.................................... 754 

Komiyama, A...................................... 1312 

Komiyama, M......................................... 64 

Könczöl, M......................................... 328* 

Kondraganti, S R.................................. 110 

Konemann, M..................................... 1893 

Kong, A............................................... 2555 

Kong, M.............. 1825, 1826, 1827*, 1844 

Kong, Q.............................................. 1561 

Kong, W............................................ 2640* 

Konhilas, J.......................................... 1054 

Kooter, I M....................................... 1413* 

Kopec, A K..................... 917, 1597, 2305* 

Kopelovich, L............................... 794, 795 

Koplovitz*, I..................................... 2016* 

Kopylev, L............................................ 475 

Kopytek, S............................................ 790 

Korashy, H M........................... 196, 1841* 

Korbas, M........................................... 1633 

Koren, G............................................... 810 

Korkalainen, M................................... 2369 

Kormendy, Z......................................... 254 

Korobkova, E A.................................. 319* 

Korte, C S......................................... 1057* 

Korte, S H......................... 514, 780, 1566* 

Kortenkamp, A...................................... 21* 

Korzus, G............................................ 1896 

Kosaka, T.............................................. 663 

Kosmider, B........................................ 415* 

Kostadinova, R M............................... 426* 

Kostrubsky, S.................................... 1321* 

Kostyniak, P J..................................... 1771 

Kosyk, O....................... 247, 447, 944, 981 

Kotagiri, A.......................................... 1779 

Kotha, S R.............................. 1299, 2329* 

Kotler, M L......................................... 1227 

Koturbash, I................................ 944, 950* 

Kou, V................................................ 1130 

Koufaris, C......................................... 874* 

Kough, J L........................................ 1731* 

Koujitani, T........................................... 321 



Kourteva, G.............................. 1502, 1503 

Kovalova, N........................................ 654* 

Kowalkowski, K............................... 1900* 

Koza-Taylor, P.................................... 2633 

Kozul-Horvath, C D........................... 2366 

Kozul-Horvath, C............................. 1989* 

Kracko, D A........................................ 1754 

Kracko, D......................................... 2043* 

Kraemer, D........................................... 533 

Kramer, J W........................................ 1166 

Kramer, N............................... 2465, 2516* 

Krantz, D E........................................... 168 

Krantz, Q T........................................... 607 

Krantz, Q.............................................. 568 

Kraus, S D.......................................... 2405 

Kraus, S.............................................. 2407 

Krause, M W....................................... 1546 

Krawiec, D................................ 888, 1832* 

Krcmarik, K........................................ 1395 

Kreatsoulas, C..................................... 1966 

Kreklau, E........................................... 1902 

Kremer, J J.......................................... 558* 

Krennrich, G........... 724, 1440, 1562, 2353 

Krenrich, G......................................... 1007 

Krewski, D.......................................... 2461 

Krieger, R I..................... 1680, 2118, 2241 

Krieger, S M................. 2100, 2105, 2296* 

Krishan, M.......................................... 2582 

Krishnamoorthy, A...................... 744, 765* 

Krishnamurthy, P................................ 1277 

Krishnan, K........ 500*, 501, 597, 598, 722, 

2316, 2538 

Krishnan, S....................................... 2588* 

Kroehle, J P....................................... 1930* 

Kroll, K J................................................ 19 

Krone, P H.......................................... 1633 

Krsmanovic, L............................ 315, 1412 

Krueger, C.......................................... 2519 

Krueger, N A....................................... 2417 

Krueger, W.................................. 395, 1167 

Krug, H F............ 2060, 2157*, 2158, 2169 

Krug, H....................................... 680, 2052 

Kruhlak, N L....................................... 136* 

Krul, C A............................................. 1413 

Krul, C.................................................. 341 

Krystek, P............................................. 605 

Krzyzewski, S............... 1094, 2522, 2523* 

Ku, B......................................... 2525, 2526 

Ku, T C............................................... 2018 

Kubaszky, R.......... 664, 1030*, 2615, 2616 

Kubota, A.......................................... 1840* 

Kubota, H........................................... 1490 

Kubota, R............................................ 1194 

Kuehl, P J.............................................. 808 

Kuehl, P.............................................. 552* 

Kuenekke, B....................................... 1423 

Kuester, R K............................... 732, 2640 

Kuester, R......................................... 2282* 

Kuhlman, C L................................... 1433* 

Kuhls, M C......................................... 1966 

Kuhn, E............................................... 2056 

Kuhn, M.............................................. 1587 

Kuiper, H A....................................... 1732* 

Kuk, R................................................. 999* 

Kulbicki, K........................................... 931 

Kulkarni, G....................................... 2034* 

Kulkarni, P........................................ 1313* 

Kulkarni, S R...................................... 1862 

Kulkarni, S................................ 414, 2499* 

Kullman, S W............................. 78, 1777* 

Kullman, S.......................................... 1774 

Kulpa-Eddy, J................................... 2581* 

Kulthong, K........................................ 2079 

Kumagai, K....................................... 1101* 

Kumagai, N................. 683*, 687, 689, 693 

Kumagai, S......................................... 1828 

Kumagai, Y................................. 412, 1305 

Kumar, R.................... 735, 939, 940, 1735 

Kumar, S............................................... 666 

Kume, E.............................................. 2619 

Kumpf, S W........................................ 1149 

Kunak, S C.......................................... 1361 

Kunak, S H......................................... 1362 

Kung, T S............................................ 873* 

Kunisue, T............................................ 702 

Kunito, T............................................. 1979 

Kunzmann, A...................................... 2052 

Kuper, F.......................................... 84, 630 

Kurata, Y............................................. 1403 

Kurdyukov, I....................................... 2047 

Kurkowsky, B....................................... 998 

Kurokawa, H....................................... 1787 

Kurt, B................................................ 1361 

Kurtovich, E......................................... 337 

Kurtz, C L............................................. 940 

Kurunthachalam, K..................... 702, 2186 

Kuryshev, Y A..................................... 1166 

Kurzatkowksi, D M.......................... 1351* 

Küsters, S............................................ 1439 

Kusunoki, Y........................................ 1154 

Kutanzi, K........................................... 944* 

Kuwagata, M.......................... 2185, 2595* 

Kuzmin, A........................................... 1645 

Kuzmitcheva, G.................................. 2048 

Kuzuya, K........................................... 1446 

Kvalem, H E..................... 611, 1636, 2412 

Kwakye, G........................................ 2121* 

Kwekel, J C...................................... 1594* 

Kwekel, J............................................ 1369 

Kwon, H............................................. 1476 

Kwon, M............................................. 1763 

Kwon, S.................................... 589, 2526* 

L 

La Du, J K........................................... 1638 

La Merrill, M.................................... 2662* 

Laarakkers, C M................................... 463 

Labahn, S.............................................. 670 

Labarre, D........................................... 1919 

Labarussiat, A....................................... 464 

Labenski, M L..................................... 1433 

Labrecque, M P................................... 372* 

LaCerte, C............. 282, 2392, 2405, 2407* 

Lacey, C J........................................... 2028 

Lachau-Durand, S................................. 622 

Lacher, S........................................... 2265* 

LaCourse, W R................................... 2415 

Lacy, T................................................ 1835 

LaDu, J K.................................. 1071, 2626 

Laffan, S B............................................ 999 

Laffan, S................................... 662, 2506* 

LaFiandra, E....................................... 1544 

Lafleur, M A......................................... 421 

Lafleur, M......................................... 1083* 

Lafuente, A....................................... 2243* 

Lahesmaa, R....................................... 2052 

Lahoti, T S.......................................... 362* 

Lai, I..............................1103, 1109*, 2249 

Lai, L W.............................................. 1274 

Lai, Y.................................................... 938 

Lainee, P P.......................................... 1909 

Lainée, P............................................. 1912 

Lainee, P............................................... 201 

Laiosa, M............................................ 1126 

Laird, B................................... 2566, 2572* 

Lai-Zhang, J........................................ 1592 

Lakatos, P........................................... 1126 

Lalande, M........................................ 2454* 

Lalayeva, N................... 1060*, 1061, 1146 

Lalko, J F.............................. 90*, 91, 905* 

LaLone, C........................................... 2368 

Lam, T T............................................. 546* 

Lamb, C M.......................................... 570* 

Lamb, C................................................ 607 

Lamb, J C............................................ 2094 

Lamberg, H........................................... 672 

Lambert, C.......................................... 1579 

Lambert, J........................................... 2487 

Lambert, T.......................................... 1438 

Lambright, C........................... 1022*, 2663 

Lamm, S H........................................ 1939* 

Author Index 


371


Author Index 


Lammens, L.......................................... 622 

Lamond, A............................................ 970 

Lan, P.................................................. 2431 

Lan, Y................................................... 518 

Lanaspa, M A.................................... 1086* 

Landauer, M R.................................. 2010* 

Landes, C.............................................. 442 

Landolph, J R...................................... 236* 

Landrio, P........................................... 2413 

Landry, T......................... 652*, 1049, 2373 

Landsiedel, R................. 82, 640, 644, 971, 

1002, 1004, 1005, 1007, 1008, 1009, 1020, 

1458, 1468, 1469, 1798*, 2550 

Lane, B............................................... 2500 

Lane, J................................................... 797 

Lane, R................................................. 882 

Lange, C C.......................................... 1242 

Langenbach, R.................................... 1195 

Langrand-Lerche, C............................ 2356 

Lanham, K.......................................... 213* 

Lanphear, C...................................... 1646* 

Lantz, D................................................ 283 

Lantz, R.............................................. 1990 

Lantz, S M................................ 1464, 2627 

Lapin, C A........................................... 1472 

LaPres, J J................................... 127*, 373 

Lara-Montoya, S........................2115, 2116 

LaRocca, J........................................ 1612* 

Larocca, J............................................ 2662 

LaRosa, K................................. 1049, 2373 

Larsen, L............................................. 2635 

Larsen, M L.............................1120, 1168* 

Larsen, M............................................ 1138 

Larson, H............................................ 229* 

Larson, J L........................................ 1995* 

Larson, J........................................... 1051* 

LaSalle, J.......................................... 1771* 

Lash, L H............................................ 752* 

Laskin, A............................................. 2171 

Laskin, D L.......... 455, 456, 457, 458, 637, 

895, 1292, 1749, 1750, 1751, 1752, 1838, 

2028, 2326 

Laskin, D.............................. 1709*, 1710* 

Laskin, J D........... 108, 455, 456, 457, 458, 

637, 895*, 1292, 1399, 1749, 1750*, 1751, 

1752, 1838, 2028, 2033, 2326 

Laskin, J.............................................. 1710 

Laskowski, M..................................... 2162 

Latchoumycandane, C........................ 759* 

Latendresse, J R.................................. 617* 

Lattier, D L............................... 2339, 2387 

Lau, A..................................... 377*, 1278* 

Lau, C........ 1609, 1625, 2237, 2239, 2240, 

2306 

Lau, E C.............................................. 1348 

Lau, S S....... 402, 753, 1274*, 1281, 1306, 

1433, 1672, 1682, 1829, 2003 

Lau-Cam, C A................. 1271, 2583, 2584 

Lau-Cam, C........................................ 2023 

Lauder, B.............................................. 567 

Laukens, D............................................ 698 

Laumbach, R....................................... 2490 

Laurent, S........................................... 1926 

Laurenzana, E M........................ 365, 378* 

Lauterbach, J H................................. 1558* 

Lautraite, S......................................... 2646 

Lavado, R........................................... 2102 

Lavallée, S.......................................... 1140 

Lavin Williams, A................................. 810 

Lavoie, E............................................... 497 

Law, B F............................................. 1557 

Lawal, H O........................................... 168 

Lawanprasert, S T............................. 1842* 

Lawler, C.......................................... 1773* 

Lawlor, T E................................. 331, 1918 

Lawlor, T.............................................. 334 

Lawrence, B.....................1129, 1132, 2666 

Lawrence, D A............................ 698, 1442 

Lawrence, J W.................... 184, 421, 1083 

Lawrence, Q....................................... 1578 

Lawrence, R........................................ 1748 

Laws, S............................................... 2384 

Lawton, K A.......................................... 438 

Lawton, M P....................................... 2669 

Lawton, M.......................................... 838* 

Layko, D K......................................... 1951 

Laynes, L A....................................... 1307* 

Layton, A............................................ 1553 

Le, M.................................................... 615 

Le, R................................................... 1308 

Leach, K L.......................................... 970* 

Leach, K..................................... 150, 2544 

Leach, M............................................... 881 

Leakey, J E.......................................... 2418 

Leander, K R....................................... 1966 

Lear, A M.............................................. 160 

Learn, D B........................................ 1785* 

Learn, D................................................ 796 

Leavens, T L............................... 710*, 711 

LeBaron, M J.................... 223, 952*, 2192 

Lebedeva, I V..................................... 2267 

Lebofsky, M.......................................... 451 

Leborgne, C........................................ 1541 

Lebrun, S.............................................. 187 

Leclaire, J................................. 1006, 1554 

Ledbetter, A D............................... 568, 604 

Ledbetter, A................................ 707, 1473 

Ledet, R.............................................. 131* 

Ledney, G........................................... 1169 

Lee, A.................................................... 561 

Lee, B..............590, 768, 773, 1117*, 1118 

Lee, C................................. 354, 355, 1480 

Lee, D U........................................... 1891* 

Lee, D........ 785, 1825, 1826, 1827, 1844*, 

2525 

Lee, E G.............................................. 643* 

Lee, E.................................................. 2131 

Lee, G....................................... 1467, 2009 

Lee, J........ 308*, 353, 1170, 1212*, 1212*, 

1762, 1762, 1763*, 1763*, 1864 

Lee, K.............589, 590*, 684, 1117, 1118, 

1212, 1480, 2217 

Lee, L.................................................. 2465 

Lee, M................. 843*, 1998, 2525*, 2526 

Lee, N................................................... 803 

Lee, S............249, 975, 1118, 1660, 2054*, 

2061, 2283 

Lee, T.......................................... 769, 2345 

Lee, W................................................ 241* 

Lee, Y.................................................. 2536 

LeFew, W R................................ 707, 2610 

LeFew, W............................................ 718* 

Lege, P.................................................. 559 

Legrand, J..................... 661*, 1926*, 1927 

Legris, S.............................................. 1140 

Lehman, M R...................................... 1754 

Lehman-McKeeman, L D................... 1451 

Lehman-McKeeman, L......................... 548 

Lehmann, G M.................................. 2297* 

Lehmann, I.......................................... 1599 

Lehmler, H...................... 1820, 1830, 2624 

Lehoux, S.................................. 1970, 1971 

LeHuray, A........................................ 1957* 

Leibold, E........................................... 1440 

Leighton, R................................. 304, 2392 

Leighton, V....................................... 1152* 

Lein, P J......................... 1329, 2106, 2450, 

2451*, 2623 

Lein, P................... 1327, 1330, 1444, 2624 

Leist, M............................... 868*, 870, 980 

Lelièvre, D.......................................... 645* 

Lemaire, M............................. 1970*, 1971 

Lemarié, C A............................. 1970, 1971 

Lemasters, J J........... 448, 451, 1648, 1649, 

1651, 2449* 

Lemire, I............................................. 2274 

Lemke, E............................................... 558 

Lentz, C................................................ 325 

Lenz, B............................................... 1423 

Leonard, D.................................. 563, 2318 



Léonard, J........................................... 1439 

Léonard, M......................................... 2466 

Leonard, P........................................... 2274 

Leonard, S........................................... 1180 

Leon-Chavez, B A................................ 270 

Léreaux, G.......................................... 1006 

Lerman, A......................................... 2674* 

Lesage, E........................ 779, 1911*, 1916 

LeSauteur, L........................................ 1140 

Leseman, D L....................................... 605 

Lesiak, A............................................. 2623 

Lesinski, G B...................................... 1784 

Letamendia, A........................... 1743, 2539 

Letasiova, S.................... 2567, 2571, 2575 

Letizia, C.............................................. 491 

Leuschner, J.......................................... 809 

Leverette, R...................................... 1409* 

Levesque, P C................................... 2471* 

Levi, F............................................... 1707* 

Levin, E D.......................................... 1378 

Levine, B S............................. 2257, 2258* 

Levine, J............................................. 1535 

Levine, M........................................... 1525 

Levitt, P............................................ 1772* 

LeVora, J............................................... 179 

Levy, J I................................................ 864 

Lewandowski, T................................. 417* 

Lewis, A S......................................... 1937* 

Lewis, B.............................................. 1645 

Lewis, E M................................. 618, 1034 

Lewis, J A........................................... 1605 

Lewis, J........................... 1330, 1696, 2099 

Lewis, R J......................................... 1956* 

Lewis, R.......... 243, 664, 1030, 2615, 2616 

Lewis, S M.......................................... 2418 

Lewis, S S........................................... 2090 

Lewis, S............................................ 1747* 

Leybaert, L.......................................... 1656 

Leyden, T.......................................... 2485* 

Li Chen, T..................... 2392, 2405*, 2407 

Li, A A....................................... 862*, 1348 

Li, A P................................................... 381 

Li, A.................................................... 564* 

Li, B.................................................... 756* 

Li, C.................................................... 1740 

Li, D.................................................... 2121 

Li, F.................................................... 1850 

Li, G J............................................... 2136* 

Li, G.........................337, 1102, 1119, 2220 

Li, H...................................................... 313 

Li, J............... 434, 536, 1502*, 1503, 1506 

Li, L........................ 213, 582*, 1848, 1860 

Li, M..............................1103*, 1109, 2534 

Li, N.................................................... 1086 

Li, Q.......................................... 691*, 2597 

Li, R.......................................... 1999, 2309 

Li, S............. 185, 702*, 1779, 2318, 2322, 

2662, 2668* 

Li, T...................................................... 588 

Li, W............... 219, 882, 993*, 1487, 1664 

Li, X......... 39, 225*, 414, 997, 1224, 1306, 

2139, 2140, 2499, 2593 

Li, Y........................ 348, 1303, 1444, 2382 

Li, Z.......................................... 126, 1429* 

Liachenko, S........................... 1928, 2618* 

Liang, M............................................... 803 

Liang, S............................................... 2006 

Liang, Y W.......................................... 2587 

Liao, C................................................ 2186 

Libalova, H........................................... 119 

Liberati, T........................................... 988* 

Liberda, E N..................................... 2058* 

Liberda, E............................................. 581 

Liberman, S A....................................... 100 

Lichtenstein, S.................................... 2020 

Lichtveld, K.............................. 565*, 2332 

Lieberman, A P..................................... 943 

Lieberman, R...................................... 2563 

Liebler, D C.......................................... 128 

Lien, Y H............................................ 1274 

Lieske, C................................. 1249*, 2386 

Lietz, M.............................................. 187* 

Ligon, J............................................... 1525 

Liguori, M J........................................ 1592 

Liguori, M........................................... 1853 

Lillicrap, A.......................................... 2380 

Lim, D................................................. 2064 

Lim, H................................................. 1904 

Lim, K....................... 294, 975, 1884, 2536 

Limaye, P B........................................ 548* 

Lin, C.................................................... 518 

Lin, G.................................................... 109 

Lin, H................................................ 1441* 

Lin, J B............................................. 1453* 

Lin, J K................................................. 236 

Lin, Y S................................................. 169 

Lin, Y................ 66, 70, 1657*, 1886, 2332 

Lin, Z.................................... 1357*, 1671* 

Lind, B................................................ 2259 

Lind, L................ 1200, 1201, 1202*, 2244 

Lind, M P...................... 1200, 1201*, 1202 

Lind, P................................................ 2244 

Lindén, J............................................. 2254 

Linder, S............................................. 2174 

Lindley, J............................................ 1893 

Lindner, G........................................... 1526 

Lindsey, C............................................. 751 

Lindstrom, A....................................... 1625 

Lindström, G....................................... 2244 

Ling, Y.................................................. 799 

Lingle, W.............................................. 278 

Linthicum, A......................................... 642 

Lioy, P J................................................ 108 

Lipari, J................................................. 507 

Lippmann, M................................ 579, 591 

Lipscomb, E.............................. 1521, 2581 

Lipscomb, J C................................. 2, 1220 

Lisa, H M.......................................... 2087* 

Lison, D F........................................... 850* 

Lison, D.............................................. 2062 

Lisowski, A......................................... 1900 

Lister, A.............................................. 2546 

Liston, A L.................................. 185, 1492 

Lithgow, G J......................................... 297 

Littke, M H................................. 129, 1475 

Little, L C............................................. 535 

Little, S................................................. 144 

Liu, A.................................................. 1890 

Liu, B.................................................... 574 

Liu, C.................................................... 793 

Liu, F........ 121*, 434*, 1661, 2596, 2598* 

Liu, G.................................................. 1230 

Liu, H........................................ 1224, 2001 

Liu, J Z................................................ 2136 

Liu, J.......................... 301, 626*, 635, 636, 

759, 1122*, 1123, 1643, 2004, 2005, 

2006*, 2269 

Liu, L P............................................... 2136 

Liu, L............................................ 204, 517 

Liu, M................................................... 314 

Liu, Q................................................ 1588* 

Liu, R................................................ 1293* 

Liu, S.............................. 230, 2073*, 2151 

Liu, T.................................................. 1488 

Liu, X.................................................... 163 

Liu, Y......................... 393, 455*, 456, 458, 

961*, 995*, 1275, 1680, 1705, 1710, 2284, 

2285 

Liu, Z.................................................... 934 

Lizárraga, D........................................ 1586 

Lizarraga, L E................................... 1829* 

Lizier, T M................................ 1418, 2409 

Llamas Vidales, J................................ 534* 

Lleberia, X.......................................... 1221 

Lloyd, A................................................ 730 

Lo, C B................................... 2359*, 2362 

Lo, C................................................... 2667 

Lobach, A............................................ 509* 

Loboa, E G.......................................... 1758 

Loccisano, A E.......................... 706*, 1768 




Loch-Caruso, R........................ 1052, 1056, 

1057, 2563 

Lock, E A.......................................... 1685* 

Lock, E................................................. 981 

Lockey, J E......................................... 1267 

Lockridge, O....................................... 1692 

Löfstedt, L.......................................... 1905 

Loftis, J............................................... 1620 

Loguinov, A.............................. 2253, 2558 

Lohmayer, R....................................... 1162 

Lollies, A............................................. 1130 

Lommen, A......................................... 1585 

Lomnicki, S........................................ 1491 

Lomteva, I........................................... 1543 

Long, C M.......................................... 1472 

Long, L..................................... 2139, 2140 

Long, T............................................... 1215 

Long, Z............................................. 2140* 

Longo, M............................................ 1045 

Longwell, B........................................ 275* 

Lookingland, K J................................ 1400 

Loomis, D............................... 1980*, 1982 

Loomis, M............................................ 779 

Looser, R................ 724, 1440, 1562, 2353 

LoPachin, R M.................................... 161* 

Loper, J............................................... 1572 

Lopez Nigro, M M.............................. 2232 

Lopez, M............................................... 613 

Lopez, R A.......................................... 789* 

Lopez, R............................................. 1630 

Lopez, T.................................... 1680, 2118 

Lopez-Bayghen, E................................ 394 

López-Campos, C............................... 1372 

Lopez-Carrillo, L T............................. 2649 

Lopez-Carrillo, L................................ 1983 

Lopez-Gonzalez, M l.......................... 1833 

López-Moya, A................................... 1372 

Lopez-Valdez, N......................... 285, 286* 

Lopez-Zepeda, L S............................. 288* 

Lord-Garcia, J L................................. 1274 

Lorget, F............................................. 791* 

Losa, S M.......................................... 1063* 

Losson, R............................................ 2284 

Louis, K M................................ 1483, 2165 

Louis, K.............................................. 1461 

Louis, L............................................. 2377* 

Louise-May, S....................................... 150 

Louisse, J............................................ 991* 

Lourenço, A S..................................... 1611 

Lourens, N............................................ 195 

Lovaglio, J.......................................... 1248 

Love, P................................................ 1924 

Loveless, S E................................ 586, 587 

Loveless, S............................................ 470 

Løvik, M....................................... 253, 611 

Low, Y................................................ 139* 

Lowe, K................................................ 862 

Lowe-Krentz, L J................................ 1451 

Lowit, A................................................ 48* 

Lowndes, H E..................................... 1375 

Lowney, Y W.................................... 1265* 

Lowry, D T.............................................. 59 

Lowry, D............................................. 1180 

Lowther, D.......................................... 1553 

Lu, B................................................... 125* 

Lu, C................................................... 1053 

Lu, D................................................. 1681* 

Lu, H......................................1114*, 1137* 

Lu, J.......................................... 433*, 1939 

Lu, K............................. 1683, 1690*, 1691 

Lu, S....................................... 1650*, 2533 

Lu, T......................... 299, 300, 307*, 1393 

Lu, Y...........301, 1187, 1188, 2004*, 2005, 

2006 

Lu, Z................................................... 1077 

Luanpitpong, S..............1187, 1188, 1668* 

Lucas, S N............................................ 189 

Lucchini, R............................... 629*, 1238 

Lucero, J............................................... 583 

Luch, A............................................. 73, 75 

Lucker, P............................................. 1888 

Ludewig, G.. 335, 1103, 1209, 1854, 2249, 

2251 

Ludwig, I S......................................... 1834 

Ludwig, S............................................. 69* 

Luebke, R W....................................... 1511 

Luebke-Wheeler, J.............................. 1173 

Luft, J.................................................... 556 

Lukomska, E....................... 665, 667, 2422 

Lulla, A............................................. 2023* 

Lumley, L A........................................ 2012 

Lumley, L........................ 2020, 2037, 2039 

Lummus, Z L...................................... 1367 

Lumpkin, C......................................... 1302 

Lumpkin, H L..................................... 2022 

Luna, A L.................................... 403, 686* 

Luna, M L........................................... 1488 

Luna, M.............................................. 2285 

Lund, A K........................................... 583* 

Lund, A............................................... 2493 

Lung Chi, C........................................ 2058 

Luo, D................................................. 1185 

Luo, L................................................. 437* 

Luo, Y............................................... 2531* 

Lupton, S............................................ 2273 

Luque, B............................................. 1387 

Luster, M I.......................................... 1367 

Lutterbuese, P....................................... 803 

Luu, H D............................................. 1315 

Luu, K................................................. 1910 

Luyendyk, J P....................................1119* 

Luyts, K............................................ 2163* 

Lydon, H L.......................................... 2022 

Lydon, H........................................... 2021* 

Lye, C................................................. 2071 

Lyke, D F.......................................... 1355* 

Lyles, R............................................... 2309 

Lyman, M E........................................ 2015 

Lynch, A.............................................. 1412 

Lynch, C............................................. 305* 

Lynch, K............................................. 1438 

Lynes, M A.......................................... 1442 

Lynes, M............................................... 698 

Lynn, L H............................................ 2383 

Lynn, S.................................................. 373 

Lyon, J L........................................... 2194* 

Lyons, M A......................................... 1810 

Lyubimov, A V.................................... 1885 

Lyubimov, A....................................... 2263 

M 

Ma, H................................ 112*, 984, 2220 

Ma, J K............................................... 2081 

Ma, J Y.............................................. 2081* 

Ma, J....................... 215, 844*, 1040, 1617 

Ma, L.................................................. 2136 

Ma, Q.................................................... 411 

Ma, W................................................. 2566 

Ma, X........................................ 1850, 1999 

Ma’ayan, A....................................... 1738* 

Maack, G............................................ 2467 

MacCormack, A.................................. 1166 

MacCoss, M J..................................... 1692 

MacDonald, T C............................... 1633* 

MacGregor, J A................................... 1964 

MacGregor, J............................ 1412, 1416 

Machemer, T......................................... 800 

Machen, M.......................................... 1356 

Machesky, N J.................................... 1593 

Machi, B............................................. 2553 

Machlachlan, T..................................... 881 

MacIntosh, D...................................... 1214 

MacIver, B.......................................... 2007 

Mack, C.............................................. 1354 

Mackay, K........................................... 797* 

Mackay, W J....................................... 2413 

MacKenzie, S A.................................. 585* 

MacKinnon, M..................................... 596 

MacLatchy, D..................................... 2546 

MacMillan, D K.................................. 2610 

Macon, M B...................................... 1622* 



MacPhail, R C....... 871, 872, 1298, 1337*, 

1338, 1460, 1583, 2628 

Macphee, C H..................................... 1669 

MacPherson, L M............................... 356* 

Madanayake, T W............................... 1851 

Maddalena, R...................................... 1214 

Madden, M C...................................... 825* 

Madden, M......................................... 2489 

Madejczyk, M S.................................. 312* 

Madhukar, B V......................... 1074, 2055 

Madl, A K......................................... 1196* 

Madren-Whalley, J S.......................... 2017 

Madura, K........................................... 2490 

Maeda, A............................................. 1655 

Maeda, M.................... 683, 687, 689*, 693 

Maeder-Althaus, X............................. 2060 

Magaña-Aguirre, J J........................... 1372 

Magby, J P........................................ 1341* 

Magee, T............................................. 1425 

Maggirwar, S...................................... 2324 

Maghni, K........................................... 1455 

Magilnick, N....................................... 203* 

Magness, S.......................................... 1645 

Maguire, M M.................................... 2203 

Maguire, M......................................... 2607 

Magun, B E............................................. 34 

Magun, B.............................................. 35* 

Mahadevan, B................................... 1765* 

Mahagaokar, S...................................... 237 

Mahapatra, C...................................... 1392 

Maher, J M................................ 413, 1592* 

Maher, J................................................ 507 

Mahle, D............................................. 167* 

Mahler, B J......................................... 1229 

Mahne, S............................................. 188* 

Ma-Hock, L........ 1458*, 1468, 1469, 1798 

Mai, D................................................... 236 

Maier, C................................................ 662 

Mair, D C............................................ 1242 

Majkova, Z......................................... 2250 

Makhaeva, G F......................... 861*, 1336 

Mäki-Paakkanen, J............................... 672 

Makori, N............. 1050, 1060, 1061, 1146 

Makris, S L....................................... 1945* 

Makynen, E......................................... 2368 

Malarkey, D E............................. 245, 1096 

Malay, E................................................ 254 

Malek, A............................................. 2169 

Malfatti, M A.................................... 2056* 

Malik, N.................................... 488*, 1252 

Malkinson, A M.................................... 407 

Malla, R.................................... 263*, 2337 

Mallavarapu, S.................................... 2177 

Mally, A................................................ 107 

Malony, D........................................... 1696 

Malshet, V.......................................... 1518 

Mamczarz, J...................................... 2035* 

Mammoto, A....................................... 1901 

Manautou, J E............ 397*, 444, 445, 740, 

1081, 1088 

Mañes, J.................................... 2416, 2423 

Mangas, I............................................ 2101 

Mangipudy, R S.................................. 1230 

Maniratanachote, R........................... 2079* 

Manjanatha, M G.......................... 68, 1548 

Manjanatha, M.................................... 1405 

Mann, J F...................................... 782, 783 

Mann, K K........................ 352, 1970, 1971 

Mans, D.................................... 1426, 1452 

Mantell, L L................................ 22*, 2337 

Mantell, L..................................... 23*, 263 

Mantovani, A.................................... 1712* 

Manzo, L....................................... 61, 1470 

Mapes, J.............................................. 1439 

Marable, B R...................................... 1336 

Marafante, E................................. 61, 1600 

Marano, K M.......................... 1224, 1241* 

Marcek, J...................................... 793, 804 

March, T H........................................... 808 

March, T............................................. 1754 

Marchand, L S.................................. 1509* 

Marchetti, F.......................................... 337 

Marcos, R........................................... 1418 

Marcum, R........................................ 1513* 

Marget-Müller, S.................................. 316 

Margie, P............................................... 657 

Margosches, E.................................... 1520 

Mari, M............................................... 1246 

Mariano, G.......................................... 1198 

Mariano, R.......................................... 1340 

Marinovich, M.............................. 965, 966 

Marion, T.......................................... 1080* 

Markham, D A.................................... 2100 

Marles, R J.......................................... 2439 

Maronpot, R.......................................... 325 

Marr, S R............................................ 2666 

Marrero-Rosado, B........................... 1385* 

Marroquin, L............................. 204, 1906* 

Marroquin-Cardona, A.............. 1674, 2228 

Marrot, L..................................... 464, 1554 

Marsden, E C.................................... 1623* 

Marsh, K............................................. 1524 

Marshak, D......................................... 1763 

Marshall, H......................................... 1909 

Marsillach Lopez, J.......................... 1692* 

Martel, D............................................... 520 

Martens, J........................................... 2062 

Martin, C............................................. 1766 

Martin, D P......................................... 173* 

Martin, D.............................................. 845 

Martin, E............................................... 486 

Martin, J T.......................................... 1447 

Martin, K............................................ 2555 

Martin, M T.............................. 717*, 1813 

Martin, M...................... 495, 714, 727, 728 

Martin, S A................................ 707*, 2610 

Martin, S................................... 1156, 1689 

Martinez, J M...................................... 863* 

Martínez, M A........................... 1352, 2108 

Martinez, M C...................................... 388 

Martinez, M F....................................... 242 

Martínez, M........................................ 2108 

Martinez-Ceballos, E.......................... 1358 

Martinez-Cuevas, P P......................... 1456 

Martínez-Larrañaga, M R....... 1352*, 2108 

Martinez-Murillo, F............................ 1369 

Martinez-Salinas, R............................ 1206 

Martinis, B............................................ 802 

Martín-Jiménez, T.............................. 2263 

Martino, J........................ 279*, 2392, 2405 

Martino-Andrade, A J....................... 1611* 

Martinoia, S........................................ 2510 

Martinozzi Teissier, S....................... 2570* 

Martinozzi-Teissier, S......................... 1010 

Marty, M A............................................ 498 

Marty, M S......... 1324*, 2094, 2279, 2375, 

2518 

Maryoung, L A.................................. 2102* 

Marziaz, M......................................... 2045 

Masereeuw, R....................................... 463 

Masiuk, K E........................................ 222* 

Maslej, P................................... 1030, 2616 

Mason, M D........................................ 2164 

Mason, M.............................................. 304 

Mason, R J............................................ 415 

Mason, R P................................... 265, 685 

Mason, R............................................. 1512 

Massa, C B........................................ 2038* 

Massari, J.......................................... 1296* 

Masters, B S........................................ 1295 

Masters, J H........................................ 1991 

Mastovich, J............................................ 59 

Mastrandrea, N J................................. 1682 

Mastrandrea, N................................... 402* 

Masumura, K.......................... 1403, 1404* 

Masunov, A E........................................ 734 

Masutomi, N......................................... 438 

Matalon, S........................................... 2335 

Matanoski, G........................................ 773 

Matheson, J M.................................... 1868 

Author Index 


373


Author Index 


Matheson, J................... 1214*, 1518, 1519 

Matheson, R........................................ 1883 

Mathesono, J..................................... 1520* 

Mathew, A........................................... 1160 

Mathews, J.............................. 2275, 2276* 

Mathews, S......................................... 690* 

Mathur, S.................................. 2052, 2060 

Matikainen, S.......................................... 55 

Matis, S............................................... 1915 

Matis-Mitchell, S.................................. 156 

Matsebatlela, T M............................... 1136 

Matson, C........................................... 1760 

Matsumoto, A..................................... 1171 

Matsumoto, H..................................... 1598 

Matsumoto, I................................. 321, 425 

Matsumura, F...................................... 1130 

Matsuno, Y............................ 64, 621, 2200 

Matsuyama, T............................. 649, 1101 

Matt, F.................................................. 870 

Mattalloni, M S................................... 2147 

Mattes, W............................................ 1734 

Matthews, B D.................................... 1901 

Matthews, E J........................... 484*, 1816 

Matthews, J........................... 356, 361, 371 

Matthiessen, P..................................... 2467 

Mattie, D R......................... 160, 702, 1866 

Mattingly, C........................................ 130* 

Mattioli, L........................................... 2244 

Mattison, D........................................... 495 

Mattsson, A....................................... 1610* 

Mattuck, R L....................................... 1952 

Mattuck, R........................................ 1545* 

Matulka, R A..................................... 2438* 

Maurer, J............................................... 231 

Maurer, L.......................................... 1654* 

Mauthe, R............................................. 486 

Maxwell, G......................................... 2527 

May, J................................................... 517 

May, R D...................................... 273, 918 

Mayeno, A N............................. 1809, 1810 

Mayer, A M........................................... 688 

Mayer, G D................................. 113, 2168 

Mayfield, D B..................................... 1944 

Mayne, J............................................. 2591 

Mazer, B............................................. 2487 

Mazur, C............................................... 721 

McCaffrey, K............................ 1063, 1064 

McCahan, S........................................ 1066 

McCain, P........................................... 1526 

McCall, R............................................. 528 

McCallister, M M............................. 2607* 

McCAllister, R.................................... 2245 

McCandless, E.............................. 528, 530 

McCarthy, A.......................................... 155 

McCarthy, B....................................... 1258 

McCarthy, J......................................... 1214 

McCartney, A E................................ 1128* 

McCauley, L A............................ 626, 1333 

McClain, C................ 391, 392, 690, 1085, 

1110, 1111, 2245 

McClain, S............................................ 893 

McClure, P................................ 489*, 1955 

McCluskey, J D.................................. 1199 

McConnachie, L A.............................. 1193 

McConnachie, L............................... 1465* 

McConnell, K J..................................... 150 

McCorkel, M M................................ 1477* 

McCormick, D L......................... 794*, 795 

McCormick, R.................................... 2489 

McCoy, M C......................................... 771 

McCracken, J...................................... 1170 

McCrohan, C R..................................... 297 

McCulloch, S D............................ 120, 122 

McCullough, S S.................................. 459 

McCutchan, T B................................. 2359 

McCutchan, T..................................... 2667 

McDaniel, K L................ 1339, 1355, 2610 

McDaniel, L P......................................... 68 

McDaniel, P L..................................... 1548 

McDearmon, E L................................ 1705 

McDearmon, E..................................... 393 

McDermott, J E.................................. 1717 

McDiarmid, M.................................... 281* 

McDonald, A............................. 2307, 2308 

McDonald, J D......... 540, 583, 1754, 1822, 

2277, 2291 

McDonald, J.............. 539, 552, 594, 1683, 

1690, 2043, 2044, 2493* 

McDonnell, E V.................................. 2191 

McDonough, J H.......... 2015*, 2016, 2025 

McDonough, P M............................... 1894 

McDougall, R..................................... 2106 

McDowell, E........................................... 67 

McDunn, J.......................................... 1106 

McElroy, A........................................ 2391* 

McElwee, M K................................... 986* 

McEwen, G D................................... 1234* 

McFarland, R...................................... 2581 

McGann, J P........ 1379, 1380, 1381, 1382, 

2133 

McGarrigle, B P........................ 2097, 2103 

McGee, J............................. 310, 603, 2489 

McGeehan, J....................................... 2522 

McGill, M R....................................... 453* 

McGinnis, C L.................................. 2388* 

McGinnis, C......................................... 316 

McGinty, D................................. 491, 1560 

McGovern, D...................................... 2164 

McGrath, P.......................................... 1742 

McGregor, D....................................... 289* 

McGuigan, C F................................... 997* 

McGuinty, A............................. 1425, 1438 

McGuire, J M.................................... 2011* 

McInally, K........................................... 811 

McIntosh, B................................ 393, 1705 

McIntosh, L J...................................... 1348 

McIntosh, L.......................................... 862 

Mcintyre, A R.........................1143*, 1144, 

1147, 1445 

McIntyre, B........................................... 790 

McIntyre, G................................ 789, 1630 

McIntyre, T M...................................... 759 

McKarns, S C............................. 109, 1508 

McKay, J............................................. 2392 

McKee, L............................................ 1054 

McKeon, M............................... 331, 1918* 

McKim, J M......... 978, 2512, 2513, 2543*, 

2544, 2559 

McKim, K L......................................... 239 

McKinney, W G........................ 2299, 2338 

McKinney, W.................. 53, 58, 194, 2318 

McKinzie, P B.................. 239, 879*, 2632 

McLanahan, E D.......................... 702, 707, 

2610, 2688* 

McLanahan, E..................................... 2693 

McLaren, M C...................................... 758 

McLellan, C J............... 1531, 1532, 1536* 

McLoughlin, C E.................. 80, 653*, 655 

McMahon, T....................................... 1519 

McMartin, K E...................................... 758 

McMaster, M...................................... 2466 

McMillan, D..................................... 2324* 

McMillian, M................................... 1904* 

McMullen, G...................................... 2658 

McNutt, P.................................... 77*, 1748 

McPhail, B T......................................... 140 

McPhearson, K................................... 2405 

Meacher, D................................... 596, 606 

Meade, B J.................................. 667, 2422 

Means, J C............................................ 380 

Medeiros, M K.................................. 1977* 

Medeiros, M M................................... 1976 

Medeirous, M K.................................. 1677 

Medina, I M........................................ 388* 

Medina-Díaz, I M............................... 2524 

Medina-Díaz, M........................2115, 2116 

Meehan, L............................................. 472 

Meek, B.......................................... 2*, 914 

Meek, E C......................................... 2014* 

Meek, E........................... 1371, 2049, 2113 



Meeks, B D........................................... 352 

Megherbi, R........................................ 2498 

Mehta, R D........................................... 329 

Mehta, V........................... 197, 1624, 1626 

Mei, H................................................. 1852 

Mei, M.................................................. 214 

Mei, N......................................... 68*, 1407 

Meidenbauer, J.................................... 1742 

Meier, W............................................. 1924 

Mein, J............................ 935, 1889, 1903* 

Meistrich, M......................................... 63* 

Mekenyan, O........................................ 464 

Melagraki, G......................................... 494 

Melchior, W B.................................... 2414 

Meldrum, B................................... 295, 296 

Melgar-Paniagua, E M........................ 1972 

Mellert, W............. 724, 1440*, 1562, 2353 

Mellon, I............................................... 115 

Mellor, H.............................................. 792 

Melnyk, S............................................. 447 

Meloon, M.......................................... 1078 

Meltzer, H M.............................. 611, 2412 

Meltzer, H........................................... 1636 

Méndez Torres, L B.............................. 669 

Mendez, L B....................................... 595* 

Méndez, L B......................................... 668 

Mendez, L M........................................ 606 

Mendez, L..................................... 584, 596 

Mendez, W.......................................... 1538 

Mendez-Rojas, M A............................ 2076 

Mendrick, D L.................................... 1678 

Meng, F........................... 239, 1953*, 2632 

Mennecozzi, M........................... 420*, 937 

Mensa, X............................................... 146 

Mercado-Feliciano, M............ 2374*, 2508 

Mercer, K.......................................... 1302* 

Mercer, P............................................. 2051 

Mercer, R R.......................... 56*, 58, 2081 

Mercer, R............................................ 1183 

Merchant, J A...................................... 1209 

Merchant-Borna, K................. 1205, 2151* 

Mercola, M......................................... 1894 

Meredith, C............... 969, 990, 1565, 2295 

Merfort, I.............................................. 328 

Merker, M............................................. 289 

Merli, D.................................................. 61 

Merne, M............................................ 2651 

Merrell, M D....................................... 413* 

Merrick, B A..................................... 1096* 

Merrill, J........................................... 1553* 

Mersch-Sundermann, V........................ 328 

Mertens-Talcott, S U.......................... 2233 

Mesa, D................................................. 973 

Mesens, N......................................... 1895* 

Mesngon, M............................................ 77 

Messier, E............................................. 415 

Messina, J........................................... 1526 

Messner, S........................................ 2553* 

Metea, M R......................................... 1914 

Mets, B D...................................1115, 2305 

Mettil, W................................. 2145*, 2146 

Metushi, I G........................................ 424* 

Meulenbelt, J...................................... 1834 

Meunier, J R........... 645, 646, 1554*, 2545 

Meunier, J................ 464, 469, 1006, 1010, 

2512, 2513, 2515, 2570 

Meyer, A............................................. 2390 

Meyer, F.................................................. 75 

Meyer, J............................................ 2448* 

Meyer, K................................. 1040, 1617* 

Meyer, L.............................................. 1525 

Meyerholtz, K..................................... 2223 

Meyers, A............................................ 1260 

Meza-Montenegro, M M.................... 1984 

Miao, J................................................ 2006 

Miao, L....................................... 756, 1294 

Micciche, A F...................................... 2199 

Michaelson, J S..................................... 797 

Michaelson, J...................................... 1599 

Michaelsson, K......................... 1200, 1201 

Michaud, R......................................... 1926 

Michel, J............................................. 827* 

Michikawa, T...................................... 2302 

Michimae, Y......................................... 321 

Mickens, J A....................................... 1064 

Mickle, B M.......................................... 643 

Miettinen, H........................................ 2254 

Migliaccio, C T................................. 1127* 

Migliaccio, C...................................... 1711 

Mikaelian, I............................... 1161, 1437 

Mikaelian, R..................................... 1919* 

Mikhailov, D......................................... 853 

Mikheev, V B.......................... 1466*, 1475 

Mikkleson, A....................................... 2173 

Milano, J................................... 1441, 1602 

Milano, S.................................... 559, 576* 

Milatovic, D............................ 1330, 2128* 

Milburn, M V.............................. 438, 745* 

Milchak, L.......................................... 1516 

Milcova, A............................................ 119 

Miles, C O.......................................... 2225 

Milhorn, D........................................ 1748* 

Millan, A............................................. 2170 

Millar, M............................................. 1041 

Miller, A L......................................... 2027* 

Miller, B.............................................. 2174 

Miller, C S............................................ 620 

Miller, C.............................................. 1419 

Miller, D B.................................. 178, 1348 

Miller, D J............................... 1273, 2287* 

Miller, D............................. 350, 398, 2012 

Miller, G P.......................................... 1843 

Miller, G W......................... 181, 182, 841* 

Miller, G............................................. 2291 

Miller, J A................................... 180, 399* 

Miller, J............................................... 1479 

Miller, M G............................... 2088, 2119 

Miller, M R........................................... 605 

Miller, M............................................. 2506 

Miller, P G................................ 109, 1508* 

Miller, R A.......................................... 1954 

Miller, R.............................................. 2506 

Miller, S R.......................................... 1219 

Miller, T.................................... 1811, 2298 

Miller, V M......................................... 2600 

Mills, E M............................................. 958 

Mills, L J........................................... 2384* 

Millsap, D........................................... 2404 

Miltner, R J......................................... 2308 

Mimouni, C........................................... 661 

Min, E......................................... 258, 2327 

Minai Tehrani, A......................... 240*, 383 

Minarchick, V C......................... 192*, 194 

Minard, K R.......... 851, 1466, 1475*, 2288 

Minatovicz, B C.................................. 1611 

Minden, A............................................. 537 

Ming, M...................................... 954, 1659 

Mingoia, R.......................................... 2557 

Minh, T B........................................... 1979 

Mink, P................................................. 862 

Minnema, D............ 664, 1030, 2615, 2616 

Minocha, S........................................ 1486* 

Minowa, Y.................................... 139, 436 

Miranda, C.......................................... 1378 

Miró, .................................................... 612 

Miro, O......................................... 613, 614 

Mirowsky, J E..................................... 579* 

Mirsalis, J C...................................... 1432* 

Mishin, V...................... 1292, 1399, 1838* 

Mishra, A.......................1181, 1182, 1183* 

Mishra, R............................................ 1574 

Miskin, R.............................................. 449 

Misra, H P........................................... 1303 

Misra, M................................... 513, 1288* 

Misra, S............................................... 311* 

Mistry, M............................................ 812* 

Mistry, P.................................... 1589, 2266 

Mitchell, A.......................................... 561* 

Mitchell, D........................................ 1923* 

Mitchell, J B....................................... 1275 




Mitchell, K A.................. 1091, 1128, 1855 

Mitchell, N J..................................... 1674* 

Mitchell, V L..................................... 1938* 

Mitchelmore, C L............................... 828* 

Mitic Potkrajac, D............................ 2340* 

Mitjans, M.................................... 965, 966 

Mitkus, R J.......................................... 726* 

Mitra, M S.............................................. 5* 

Mitsutani, M....................................... 1062 

Mittelstaedt, R A....................... 1405, 1548 

Miura, N............................................. 271* 

Miura, T............................................ 1305* 

Miura, Y................................................ 689 

Miyahara, N.......................................... 687 

Miyajima-Tabata, A............................ 1100 

Miyakawa, H...................................... 1512 

Miyake, M............................................ 438 

Miyanaga, N....................................... 1969 

Miyaso, H............................................. 64* 

Miyawaki, I........................................... 425 

Miyazawa, M.......................... 1000, 2560* 

Miyoshi, N............................................ 638 

Mizuno, K........................................... 2082 

Mizutamari, M.................................... 1046 

Mlochowski, J..................................... 2023 

Mo, Y........................................ 609, 2488* 

Moberly, A H................ 1379, 1380, 2133* 

Mocarelli, P.......................................... 709 

Mockus, S............................................. 130 

Moeller, B C..................................... 1683* 

Moeller, B........................................... 1690 

Moeller, T......................................... 1864* 

Moffet, M............................................ 2037 

Moffett, D............................................. 731 

Moffett, M.......................................... 2020 

Moggs, J............................................... 446 

Moghe, A............................................ 392* 

Mohamed-Ahmed-Ali, L.................... 2170 

Mohammadi Bardbori, A.................... 1839 

Mohammmadi-Bardbori, A................. 1852 

Mohr, S............................................... 784* 

Moilanen, L H............... 1317, 1318*, 1319 

Mokashi, V P....................... 160, 290, 656, 

1383, 1570 

Moland, C L........................................ 1594 

Molinaro, A........................................... 688 

Momot, D........................................... 116* 

Mondal, M S....................................... 439* 

Monks, T J............... 402, 753, 1274, 1281, 

1306, 1433, 1672, 1682, 1829, 2003 

Monnot, A D................. 1377*, 2137, 2138 

Monroy, C........................................... 2253 

Monteil, C............................... 1290*, 1555 

Monteiro-Riviere, N A..............1174, 1175, 

1176, 1758, 2072, 2154*, 2155 

Montes-Grajales, D............................... 149 

Montiel-Dávalos, A............................. 2066 

Montoya, L......................................... 1851 

Montoya, M........................................ 1901 

Montoya-Durango, D E...................... 406* 

Moody, A............................................ 1438 

Moody, C J.......................................... 1663 

Moon, B.............................. 562, 576, 1920 

Moon, S J.............................................. 617 

Moon, Y.............. 34, 36*, 252*, 370, 1449 

Moore, A B......................................... 1070 

Moore, A............................................. 2522 

Moore, D................................... 1502, 1503 

Moore, J L........................................... 989* 

Moore, J P........................................... 2565 

Moore, M M..................... 332, 1407, 1415 

Moore, R J.......................................... 1488 

Moore, R W............................ 1624, 1626* 

Moore, S A.......................................... 577* 

Moore, T..................................... 951, 2109 

Moores, M............................................ 211 

Moorthy, B.............. 110, 230, 1856*, 2587 

Moos, P J.......................................... 2173* 

Mootsikapun, P................................... 1364 

Moraes, C............................................. 207 

Morais, R N........................................ 1611 

Morales, J........................................... 355* 

Morales-Barcenas, R.......................... 2659 

Morawiec, L........................................ 1436 

Mordasky Markell, L................ 222, 1780* 

Morden, M.......................................... 1266 

More, V R............................... 1077*, 2270 

Morefield, S........................................ 2581 

Moreira, E G........................................2111 

Morelle, D........................................... 1027 

Morén, C............................................. 612* 

Moren, C....................................... 613, 614 

Moreno, J............................................ 2664 

Moreno-Contreras, M......................... 2396 

Moretto, A......................................... 1877* 

Morgan, D L......................................... 578 

Morgan, D........................................... 2320 

Morgan, S J......................................... 1592 

Morgenthal, K....................................... 289 

Mori, C........... 64, 621*, 1225, 1573, 2200 

Morikawa, T......................................... 627 

Morimoto, T........................................ 974* 

Morimoto, Y....................................... 1177 

Morin, D......... 887, 888, 1679, 1832, 1849 

Morin, J................................... 1290, 1555* 

Morishita, M....................................... 2494 

Morishita, Y.................. 1494, 2084*, 2085 

Morita, M.............................................. 510 

Moritz, W............................................ 2553 

Mörk, A................................................. 713 

Morlacci, L........................................... 497 

Morris, G............................................ 1535 

Morris, J B........................ 574, 580*, 889* 

Morris, J E.......................................... 2577 

Morrow, J.................................... 788, 1922 

Morry, D W....................................... 1967* 

Mortensen, H...................................... 819* 

Moscovitz, J...................1113, 1116*, 2586 

Moser, J................................................ 572 

Moser, V C.......... 1339*, 1355, 2309, 2610 

Mossman, B.......................................... 27* 

Mostert, V........................................... 499* 

Motohashi, H...................................... 1787 

Motokado, T......................................... 638 

Motsinger-Reif, A............................... 822* 

Moudgal, C J...................................... 1965 

Moukha, S........................................... 2427 

Moulin, P............................................ 1603 

Moura, M............................................ 1484 

Mousa, S A................................ 1388, 1389 

Moussa, E A........................................ 1629 

Moutos, C........................................... 1302 

Moyano, R.......................................... 2243 

Moyer, B J........................................ 1055* 

Mu, X................................................ 1561* 

Mudalige, T........................................ 2174 

Mueller, L..................................... 441, 442 

Mueller, S O........................... 1410*, 1590 

Mueller, W.......................................... 1232 

Muenyi, C S...................................... 1991* 

Mugengana, A..................................... 2414 

Muhammed, M................................... 2072 

Muir, D................................................. 657 

Mukherjee, B...................................... 2494 

Mulgrew, K........................................... 803 

Mulla, M A.................... 1552, 1574, 1933* 

Mullenders, L...................................... 2652 

Muller, C............................................. 2487 

Muller, J................................................ 316 

Müller, L............................................... 387 

Muller, U W........................................ 1443 

Mulligan Tuttle, A M........................ 1026* 

Mumper, R J....................................... 1486 

Mumtaz, M M................................... 1793* 

Mumtaz, M................................. 712*, 860 

Mumy, K L........................................ 2304* 

Mun, G.................................... 1551*, 2554 

Mun, M................................................. 229 

Mundy, W R............ 867, 2078, 2452, 2629 

Mundy, W............................................. 28* 

Muñiz Ortiz, J..................................... 1978 

Muñiz Rivera-Cambas, A..................... 287 



Muniz, J............................................ 1333* 

Munkvold, G....................................... 2425 

Muñoz-Soto, B................................. 1372* 

Muntner, P............................................ 767 

Murai, A.............................................. 1062 

Muralidhara, S.................. 774, 1817, 2283 

Muramatsu, K....................................... 649 

Muramatsu, M.................................... 1404 

Muravnick, K........................................ 804 

Murayama, A...................................... 2185 

Muresan, S............................................ 479 

Murk, A J............................................ 2348 

Murli, H.............................. 331, 334, 1918 

Murphy, B J........................................ 2343 

Murphy, C G......................................... 130 

Murphy, D J.............................................. 3 

Murphy, L................................. 951*, 1095 

Murphy, M.......................................... 1248 

Murphy, S......................................... 1635* 

Murr, A S............................................ 1042 

Murray, A R....................1180, 1189, 1462, 

2072*, 2160 

Murray, A............................................ 1179 

Murray, I A.................................... 360, 362 

Murray, J R........................................... 771 

Murray, J.......................... 223, 1412, 1896, 

2192, 2639 

Muse, W.............................................. 2012 

Musgrove, M...................................... 2413 

Muskhelishvili, L.................................. 617 

Musson, D............................................. 801 

Mustafa, A........................................... 1628 

Mustarelli, P............................................ 61 

Muster, W........................................... 1814 

Mutanguha, E M................................. 1342 

Mutch, E............................................. 2071 

Muthas, D........................................... 156* 

Muthumalage, T...................... 1253*, 1254 

Muthusamy, V..................................... 2179 

Mutyam, S.......................................... 2050 

Muzzio, M.................................... 794, 795 

Myatt, G............................................ 1812* 

Myers, D............................................. 1027 

Myers, J N.............................. 1670, 2648* 

Myers, M B..................... 239*, 1953, 2632 

Myers, P A.......................................... 1938 

Myhre, A............................................. 2162 

Mylavarapu, V B.............................. 1264* 

Mylchreest, E.................................... 1028* 

Mynhier, A.......................................... 2601 

N 

N’Guyen, A........................................... 661 

N’jai, A U.......................................... 1138* 

N’Jai, A U........................................... 1168 

Na, C................................................... 2224 

Na, D................................................... 2224 

Nabb, D............................................. 2557* 

Nabeshi, H........... 1494, 2080, 2083, 2084, 

2085 

Nacci, D E.......................................... 1776 

Naciff, J M........................................ 1595* 

Nadadur, S S......................................... 10* 

Nadai, M............................................. 1184 

Nadal, M....................... 1221*, 1245, 1246 

Nadanaciva, S........ 970, 1650, 2525, 2530, 

2533* 

Nadeev, A............................................ 2047 

Nagano, K.......... 1494, 1547*, 2080, 2083, 

2084, 2085 

Naganuma, A...................... 306, 308, 1969 

Nagaosa, R.......................................... 2082 

Nagarkatti, M... 674, 676, 949, 1133, 1507, 

1666, 2321 

Nagarkatti, P S...................................... 674 

Nagarkatti, P.......... 676, 949*, 1133, 1507, 

1666, 2321 

Nagase, H............................................. 770 

Nagata, R............... 638, 1046, 1050, 1060, 

1061, 1145 

Nagata, T............................................ 2595 

Nagatomo, K....................................... 1145 

Nagatsuka, S............................... 532*, 805 

Nagle, R.............................................. 1682 

Nagler, J.............................................. 2398 

Nagy, L E.............................................. 759 

Nahar, M S.......................................... 100* 

Nahar, M........................... 102, 1216, 1616 

Naik, V................................................ 594* 

Nakajima, M................................. 428, 510 

Nakajima, T................................ 515, 2424 

Nakamura, J........................................ 2238 

Nakamura, M............................ 1016, 1017 

Nakamura, S......................................... 177 

Nakamura, T............................. 1062, 1145 

Nakamura, Y..................................... 2637* 

Nakanishi, J.............................. 1177, 2082 

Nakano, M.......................................... 2302 

Nakao, S............................................... 606 

Nakaoka, H..................... 621, 1225*, 1573 

Nakashima, H..................................... 2302 

Nakashima, M..................................... 805* 

Nakatsu, N............................................ 124 

Nakgawa, T........................................... 423 

Nambiar, M P................. 894*, 2024, 2029, 

2041, 2585 

Namork, E............................................. 611 

Napierska, D H................................. 2062* 

Napierska, D....................................... 2066 

Naquet, P.............................................. 444 

Naravaneni, R..................................... 329* 

Narayanan, P......................................... 778 

Narotsky, M G.......................... 1032, 2308 

Narotsky, M........................................ 1042 

Narvaez, J......................................... 2172* 

Nascimento, M G.................................. 525 

Nash, J R............................................. 2555 

Nash, M............................................ 1388* 

Nasr, J................................................. 1689 

Nass, R........................................ 179, 1396 

Natsch, A........................................... 1009* 

Nau, H..................................................... 75 

Naufal, Z S.......................................... 1224 

Naughton, B A.......................... 534, 1606* 

Nauth, T B.......................................... 1770 

Navas-Acien, A......................... 767, 1974* 

Navasumrit, P..................................... 2638 

Naven, R T............................................ 936 

Naven, R............................................. 2573 

Navid, A.............................................. 1308 

Naya, M............................................ 2082* 

Nazo, N............................................... 1757 

Ndeto, R N........................................ 1515* 

Neaga, A........................................... 1929* 

Neal, A P................................. 1344*, 1345 

Neal, B.............................................. 2094* 

Nealley, E W....................................... 2027 

Nebert, D W........................ 313, 314, 824* 

Nederlof, R............................... 1640, 2613 

Needleman, H....................................... 626 

Nees, M................................................. 135 

Neff, R.................................................. 931 

Negga, R........................................... 1356* 

Neigh, A................................................ 849 

Nekrasova, T......................................... 537 

Nel, A E............................................ 1716* 

Nelson, C.................................... 774, 2009 

Nelson, M......................................... 2579* 

Nemery, B......................... 681, 2062, 2163 

Nesbit, D............................................... 197 

Nesnow, S................................. 951, 2109* 

New, L......................................... 534, 1606 

Newbold, R......................................... 2374 

Newland, C......................................... 1886 

Newland, M C.................................... 1402 

Newman, N C..................................... 1761 

Newman, N....................................... 2625* 

Newport, G D................. 1464, 1661, 2627 

Newsome, J......................................... 1663 

Nez, T................................................. 1696 

Ng, H H.............................................. 1106 

Ng, H.................................................. 1432 

Author Index 


375


Author Index 


Ng, W................................................ 1499* 

Ngalame, N N................................... 2199* 

Ngom, A.............................................. 2461 

Nguyen, B........................................... 2091 

Nguyen, H......................................... 1847* 

Nguyen, K......................................... 2414* 

Nguyen, L................................... 804, 2611 

Nguyen, O............................................. 849 

Nguyen, P................................. 961, 1275* 

Niaz, M S............................................ 1065 

Nicholas, Z......................................... 2125 

Nichols, A C...................................... 2406* 

Nichols, G............................................. 662 

Nichols, H............................................. 982 

Nichols, N........................................... 2559 

Nicholson, D............................. 1765, 2591 

Nicklaus, R............................... 1161, 1437 

Nicol, C....................................... 957, 2661 

Nicola, T............................................. 2335 

Nicolàs, M............................................ 612 

Nicolas, M.................................... 613, 614 

Nicolaysen, P H.................................. 1557 

Nicolette, J.......................................... 1412 

Niculescu, M....................................... 1987 

Nie, L H.............................................. 1686 

Niedzwiecki, A................................... 2222 

Niehoff, M........................ 556, 557*, 1232 

Nielsen, U........................................... 1888 

Niesor, E J............................................. 387 

Niggemann, B..................... 556*, 557, 622 

Nijmeijer, S......................................... 2361 

Nikiema, P A..................................... 1688* 

Nikiforov, A I...................................... 2421 

Nikkilä, O........................................... 1391 

Niknam, Y......................................... 1327* 

Nikula, K.............................................. 811 

Nilsen, A M......................................... 253* 

Nilsson, J............................................ 2651 

Nimmannit, U..................................... 1668 

Ning, B............................................... 1097 

Ninomiya, S.......................................... 532 

Nioi, P................................................... 876 

Nirogi, R....................... 1552*, 1574, 1933 

Nisbet, D J.......................................... 2417 

Nishikawa, A.......... 627, 1044, 1090, 1403, 

2657 

Nishimaki, F....................................... 1547 

Nishimura, T..................................... 1194* 

Nishimura, Y............... 683, 687, 689, 693* 

Nishiyama, N............................ 1000, 2560 

Nishizawa, T....................................... 1547 

Niwattisaiwong, N.............................. 1842 

Niyikiza, C.......................................... 1888 

Niyogi, S............................................... 311 

Njan, A A.......................................... 2206* 

Noble, D G.......................................... 928* 

Noçairi, H........................................... 2512 

Noel, A.............................................. 1455* 

Noguchi, T.......................................... 1547 

Noguera-Julian, A................................. 612 

Noh, J........................................ 294*, 1884 

Nohmi, T................................. 1403*, 1404 

Nohynek, G......................................... 1559 

Noiles, W.......................................... 2189* 

Nomaru, K............................................ 353 

Nomura, T............................................. 521 

Nong, A........... 481, 700*, 701, 2141, 2459 

Noratto, G D..................................... 2233* 

Noratto, G........................................... 2231 

Norman, K.......... 1009, 1551, 2550, 2554* 

North, M................................... 134, 2558* 

Nostrand, T A........................................ 116 

Notch, E G............................................ 113 

Note, R R........................ 464, 2512*, 2515 

Note, R........................................ 469, 2513 

Nothem, M A...................................... 1652 

Novak, P............................................. 1677 

Novellino, A.............................. 1020, 2510 

Novilla, M........................................... 1050 

Nowak, P............................................ 1566 

Nowinski, S M.................................... 958* 

Ntamack, A........................................... 736 

Nukada, Y................................. 1000, 2560 

Numano, T............................................ 508 

Nunez, J................................................ 545 

Nuño, N...............................................1112 

Nur, N M............................................. 2018 

Nurkiewicz, T R................. 192, 194, 1471 

Nuwaysir, E...............................1164, 1173 

Nuywasir, E........................................ 1163 

Nygaard, U C........................................ 611 

Nykyforchyn, C.................................. 1746 

Nyland, J F.......................................... 2196 

Nyska, A..................................... 602, 2631 

O 

O’Brien, P J.......................................... 30* 

O’Brien, T J.............................. 273*, 918* 

O’Callaghan, J P............................... 1348* 

O’Connell, T............................... 447, 1824 

O’Donnell, J C.................................... 2015 

O’Donnell, J....................................... 2012 

O’Donnell, L....................................... 1148 

O’Donnell, M W................................... 516 

O’Donovan, M.................................... 1098 

O’Hara, T.................................. 1249, 2386 

O’Keefe, S J........................................ 2179 

O’Loughlin, K.................................... 2261 

O’Neal, C............................................ 1068 

O’Neill, C..................................... 791, 801 

O’Reilly, P.......................................... 2091 

O’Shaughnessy, P T.................. 1474, 1496 

O’Shea, S............................................ 981* 

Obama, T............................................ 1194 

Obeng, A M.......................................... 446 

Oberdörster, G......................... 2051, 2190, 

2475*, 2612 

Oberdorster, G.................................... 2504 

Oberley, T D......................................... 877 

Oberli, A................................................. 88 

Obernberger, I....................................... 671 

Oberst, M D.......................................... 803 

Obert, L................................................. 125 

Oberto, G............................................ 1231 

Oberyszyn, T.................................... 1784* 

Obhan, S............................................. 1388 

Obidile, V........................................... 2443 

Ocampo-Gomez, G................. 1203, 1206* 

Ochiai, S....................................... 64, 2200 

Ochs, S.....................................1122, 1123* 

Odegaard, M........................... 1473, 1493* 

Odermatt, A......................................... 1436 

Odin, M................................................. 536 

Odinecs, A............................................. 775 

Odio, C............................................... 347* 

Ogami, A............................................. 1177 

Ogawa, K............................................ 1044 

Ogawa, T................................ 2185*, 2595 

Oguntayo, S.................... 2029, 2041, 2585 

Ogura, T.......................... 1494, 2084, 2085 

Oh, S............................................682, 1118 

Ohlsson, ............................................. 2352 

Ohman, P............................................ 2490 

Ohno, Y................................. 124, 139, 436 

Ohta, H................................................. 663 

Ohtani, K.............................................. 515 

Oikawa, S........................................... 1446 

Oishi, H................................................. 321 

Okada, N................................................. 99 

Okle, O....................................... 165*, 166 

Okolica, M R.............................. 736, 2304 

Olaharski, A J........................................ 784 

Olaharski, A.......................... 441, 442, 876 

Oldach, J......................... 2571, 2574, 2575 

Oldenburg, S....................................... 849* 

Olejnik, N............................................. 994 

Oleksiak, M F..................................... 1776 

Oleksiak, M........................................ 1675 

Olenyuk, B Z...................................... 1433 

Olgun, N S........................................ 1076* 

Olin, S................................................... 882 



Olinga, P......................... 1766, 2509, 2561 

Olivas-Calderon, E............................. 1206 

Oliveira, D P........... 336, 1418, 2408, 2409 

Oliveira, D............................................ 802 

Oliveira, G R...................................... 336* 

Oliveira, R V............................. 1335, 1676 

Oliver, M.............................................. 281 

Olivera, D S...................................... 1755* 

Olivero, J............................................ 2236 

Olivero, O A.......................................... 116 

Olivero, O........................................... 2506 

Olivero-Verbel, J............... 132*, 149, 2396 

Olivier, A............................................ 1109 

Olivier, B............................................ 2201 

Olivier, K J......................................... 1888 

Oller, A R.............................................. 298 

Olomu, I N........................................ 1074* 

Olsen, A................................................ 267 

Olsen, G W....................................... 1242* 

Olsen, J............................................... 2652 

Olson, G.................................... 2418, 2420 

Olson, J R............ 1218, 1328, 1329, 1330, 

2097, 2103, 2106, 2117 

Olson, M J............................................ 468 

Olson, M............................................... 996 

Omae, K.............................................. 2302 

Omiecinski, C J.................. 365, 378, 1847 

Omiecinski, C........................... 375*, 1858 

Omri, A............................................... 1269 

Omura, S............................................. 1487 

Onaivi, E S............................................ 964 

Onda, H................................................. 133 

Oneda, S................................. 1060, 1061* 

Ong, C................................................... 774 

Onishchenko, N................................ 2614* 

Onken, S............................................. 1009 

Ono, A....................... 124, 436, 1016, 1044 

Onthank, D........................................... 812 

Onyenwe, W......................................... 229 

Onyon, L............................................. 1310 

Ooshima, K......................................... 1001 

Ooshima, Y................................. 638, 1046 

Oota, T................................................ 1632 

Opdenakker, G...................................... 681 

Opdyke, C........................................... 930* 

Ophir, A.............................................. 1207 

Oprea, T I.............................................. 479 

Opresko, P L......................................... 121 

Orak, D............................................... 467* 

Orisakwe, O...................................... 2443* 

Orlando, E F........................................... 19 

Orlicky, D........................................... 1171 

Ornelas, J M........................................ 1983 

Orogo, A M........................................... 136 

Orr, A W.............................................. 1320 

Orr, G.......................................... 851, 2171 

Orren, D................................................ 115 

Ortega, A............................................... 394 

Ortega, J.............................................. 2385 

Ortega-Zuñiga, C.................................. 132 

Ortego, L............................................. 2466 

Ortiz, P A.................................. 290*, 1570 

Ortiz-Martínez, M G........................... 668* 

Oruganti, M........................................ 1277 

Oshima, R............................................. 231 

Oshiro, W M............................... 707, 2610 

Osimitz, T G....................................... 913* 

Osinski, M A......................................... 558 

Oskarsson, A........................... 1610, 2352* 

Osorio-Sanchez, J............................... 1517 

Osorio-Yáñez, C............................... 1972* 

Osterburg, A R.................................... 656* 

Osterhout, C A.................................... 1569 

Osterloh-Quiroz, M............................ 2296 

Ostrosky, P.................................2115, 2116 

Ota, M................................................... 974 

Otani, J.................................................. 502 

Otsubo, Y............................................ 1145 

Otsuki, T..................... 683, 687*, 689, 693 

Ott, V L............................................. 1173* 

Ottenhoff, L D.................................... 688* 

Ottinger, M................................. 172, 1637 

Otto, M..................................... 1640, 2613 

Ouedraogo, G..................................... 1554 

Ouédraogo, G........................... 2512, 2515 

Oury, T.................................................. 24* 

Overmann, G J.................................... 1595 

Overturf, C........................................ 2394* 

Ovigne, J M........................................ 1554 

Ovigne, J............. 1010*, 2513, 2551, 2570 

Owens, M J......................................... 1639 

Ozawa, S................................... 1090, 2657 

Özkaynak, H......................................... 310 

P 

Pacheco, B.......................................... 1696 

Pachel, C............................................. 1002 

Pacotto, V M....................................... 531* 

Pacurari, M....................................... 1185* 

Padden, B.............................................. 507 

Padgett, E.............................................. 195 

Padgett, W.......................................... 2109 

Padilla, S................. 871*, 872, 1760, 2628 

Padilla-Banks, E..................... 2197, 2198* 

Padilla-Carlin, D J................................ 602 

Padmanabhan, V............................... 2186* 

Padnos, B.................................... 871, 2628 

Paepke, O............................................ 1252 

Page, K E............................................ 297* 

Paine, M................................................ 549 

Pak, I................................................... 1966 

Pak, T.................................................. 2020 

Palacio, F............................................ 2170 

Palacios-Hernandez, T D.................. 2076* 

Palate, B.............................................. 1927 

Palazzolo, A L................................... 2594* 

Palkar, P S........................................... 354* 

Pallardy, M............................................. 92 

Pallen, C............................................. 2356 

Palmeira, C M................................... 1087* 

Palmer, H.................................. 1563, 1923 

Palmer, R F........................................... 620 

Palmer, R K........................................ 254* 

Palo, M A.......................................... 2653* 

Palomäki, J........................................... 55* 

Palosaari, T......................................... 2510 

Palumbo, A......................................... 2250 

Palyulin, V A............................... 861, 1336 

Pamies, D.............................................. 979 

Pan, H....................................... 2084, 2085 

Pan, W.................................................. 778 

Pan, Y.................................................. 2309 

Panchal, J L....................................... 1124* 

Panda, S.............................................. 1295 

Pande, P.............................................. 2267 

Pandey, S........................ 1552, 1574, 1933 

Pandini, A............................................. 368 

Pandiri, A R........................................ 245* 

Pandya, K G...................................... 2583* 

Paneliya, S M...................................... 2617 

Pang, Y................................................ 1549 

Pangallo, K C.................................... 2363* 

Panter, K............................................. 2229 

Papineni, S........................................ 2375* 

Papoutsi, M......................................... 1603 

Paranjpe, M A..........................1113*, 2654 

Paranjpe, M..................................315, 1116 

Parbatani, A......................................... 1260 

Parchment, R E..................................... 973 

Parham, F.......................................... 2360* 

Parikh, M C...................................... 1271* 

Parinandi, N L.......................... 1299, 2256, 

2329, 2336 

Park, B............... 2207*, 2210, 2211, 2213, 

2214, 2217 

Park, D.............................................. 1742* 

Park, E................................................ 2637 

Park, H............................ 1762, 1763, 2536 

Park, J D............................................. 1256 

Park, J.769*, 975, 1478, 1762, 1763, 1888, 

2218, 2520, 2536 




Park, K.............................. 446, 2498, 2500 

Park, M................................................. 260 

Park, P................................................... 765 

Park, S S............................................. 1326 

Park, S......................252, 370*, 383*, 1118 

Park, Y H.......................................... 1257* 

Park, Y................ 101, 249, 746, 975, 2224 

Parker, C M........................................... 237 

Parker, K K......................................... 1898 

Parkinson, C U............................ 290, 1570 

Parks, B................................................. 962 

Parks, W C.......................................... 1193 

Parks, W.............................................. 2328 

Parman, T.......................................... 1106* 

Parrish, M E........................................ 2011 

Parrott, W............................................ 1525 

Parsons, B L...................... 239, 1953, 2632 

Parsons, G N....................................... 2178 

Parsons, P J........................................... 773 

Parsons, P.............................................. 768 

Partridge, C R................................... 1267* 

Parvez, S............................................. 2308 

Passage, J K........................................ 1324 

Passage, J............................................ 2192 

Pastorello, T........................................ 1484 

Pastori, F............................................. 1231 

Patani, K Z.......................................... 2617 

Patel, A R............................................ 2521 

Patel, H J............................................. 1076 

Patel, M L........................................... 936* 

Patel, M V......................................... 2617* 

Patel, M............................................... 1297 

Patel, N................................................. 688 

Patel, P.................... 430, 2275, 2276, 2644 

Patel, R B................................ 1299, 2336* 

Patel, R D.............................................. 374 

Patel, S N.......................................... 2584* 

Patel, V S.......................................... 2337* 

Pathi, S........................................ 220*, 955 

Pathmasiri, W........................... 2202, 2248 

Patierno, S R................................. 273, 918 

Patisaul, H B....................................... 1063 

Patisaul, H........................................... 1064 

Patlolla, A......................................... 2075* 

Patlolla, R........................................... 2556 

Pato, A M.......................................... 1346* 

Patric, N.............................................. 2329 

Patrick, S M........................................ 2241 

Patron, A............................................. 2393 

Patrone, L.......................................... 1230* 

Patterson, T A........................... 2596, 2597 

Patton, A............................................... 798 

Patton, W F....................................... 2267* 

Paul, G.................................................. 577 

Paul, K B.......................................... 2350* 

Paul, R.............................................. 1250* 

Paule, M G........... 1464, 1614, 1661, 2596, 

2598, 2609*, 2627 

Pauli, G F.............................................. 227 

Paulose, T......................................... 1038* 

Paulson, H L......................................... 943 

Pauluhn, J............................... 904*, 1799* 

Paustenbach, D J................................. 2255 

Paustenbach, D......................... 1210, 1263 

Pavkov, K L...................................... 1029* 

Pavuk, M............................................. 2255 

Payne, R.............................................. 2405 

Paysinger, E.......................................... 791 

Pazos, P............................................... 1017 

Pearce, M G...................... 879, 1406, 1548 

Pearce, M............................................ 1411 

Pearson, C C....................................... 1578 

Pearson, C I................................ 534, 1606 

Pearson, K J........................................ 2582 

Pearson, R........................................... 2280 

Pechacek, N............................ 1516, 1550* 

Pechenevskii, Y.................................. 2047 

Peden-Adams, M M.................... 658, 659* 

Peden-Adams, M.................................. 670 

Pedersen, J A............................. 1483, 2165 

Pedersen, J.......................................... 1461 

Peet, M M......................................... 1932* 

Peffer, R C............................................ 375 

Pegram, R A................................ 711, 2562 

Pehl-DeSilva, A T................................. 236 

Pei, W................................................. 1166 

Peijnenburg, A A................................... 695 

Peijnenburg, A.................................... 1585 

Pelallo-Martínez, N A............... 1255, 1373 

Pelis, R................................................ 2268 

Pelletier, J............................................. 254 

Pellis, L............................................... 1585 

Pelsue, S............................................... 278 

Peltier, R............................................... 579 

Pence, L.................................... 1434, 1678 

Pendlington, R.................................... 2527 

Peng, Q....................................... 528, 530* 

Penn, A................................................ 1627 

Pennie, B............................................. 2675 

Pennie, W D...................................... 2679* 

Penning, T M...................................... 1831 

Penning, T........................................... 1681 

Pennings, J L........................................... 79 

Pennings, J.......................................... 1011 

Pennington, K L................ 232, 2646, 2655 

Penninks, A H..........................1150, 1151* 

Penninks, A........................................... 630 

Penno, C........................................... 1436* 

Penton, H.............................................. 619 

Perala, A W............................... 1324, 2383 

Peralta, J R.......................................... 1489 

Perati, P R............................................. 217 

Perdew, G H.......... 360, 362, 363, 372, 374 

Pereira, E R............................... 2034, 2035 

Pereira, F C........................................... 506 

Pereiro, N............................................ 2243 

Perelló, G............................................ 1221 

Peretz, J................................... 1033*, 1038 

Perez, A............................................... 2164 

Perez-Polo, R...................................... 2588 

Perez-Tilve, D....................................... 760 

Perkins, E J........................... 19, 725, 1604 

Perkins, M W.................................... 2041* 

Perkins, M........................................... 2029 

Permenter, M.................................... 1605* 

Perron-Lepage, M................................. 648 

Perry, C..................................... 1080, 1542 

Perry, M J.............................................. 864 

Persaud, R................................. 486, 1559* 

Person, R............................................. 272* 

Peschar, M.......................................... 195* 

Pessah, I N......... 1769*, 1770, 1771, 2246, 

2623 

Pessah, I.......................... 1130, 1327, 2624 

Pestka, J J...................................... 34*, 38* 

Pestka, J.................................... 1662, 2419 

Peterlin-Masic, L.................................. 154 

Peters, A M......................................... 398* 

Peters, D......................... 1426, 1452, 2074 

Peters, J M............ 354, 355, 357, 358, 359 

Peters, N............................................. 2519 

Peters, R E................................ 526*, 2566 

Petersen, D R.................. 1084, 1280, 1282 

Petersen, E.......................................... 1938 

Peterson, L A....................................... 1417 

Peterson, M....................................... 1935* 

Peterson, N................................. 957, 2661 

Peterson, R E........... 197, 198, 1461, 1483, 

1624, 1626, 1647 

Peterson, R............................................ 213 

Peterson, S M........ 1747, 2090, 2144, 2310 

Peterson, S........................................ 2142* 

Peterson, T S....................................... 1071 

Peterson, Y K........................................ 751 

Petion, V........................................... 2591* 

Petito Boyce, C................................... 1268 

Petrick, J S........................................ 1525* 

Petrikovics, I........ 1260, 1689, 2045, 2046, 

2048* 

Petritis, B O........................................ 1488 



Petro, A............................................. 1378* 

Peyret, T.............................................. 722* 

Pfaff, T................................................ 1232 

Pfau, J C........................ 1509, 1513, 1869* 

Pfister, J.............................................. 2229 

Pfister, T.............................................. 1423 

Pfluger, P T........................................... 760 

Pfuhler, S.......................... 339, 341, 1481* 

Phadnis, A S...................................... 1135* 

Phalen, R F........................................... 595 

Pham, N.................................... 888, 1679* 

Phan, B............................................... 2337 

Philbert, M A............ 162, 163, 1654, 2161 

Philip, R.............................................. 1369 

Phillip, O S....................................... 1068* 

Phillips, G J........................................ 990* 

Phillips, J............................................ 2602 

Phillips, P M................... 1337, 1338, 1339 

Phillips, R D....................................... 1041 

Phillips, T D........ 1523*, 1674, 2228, 2417 

Phipps, R P......................................... 2324 

Phonethepswath, S.................... 1412, 1416 

Pi, J................................... 366, 2001, 2502 

Piccirillo, V......................................... 243* 

Piché, M S........................................ 1140* 

Pickart, M........................................... 2519 

Pickering, I J....................................... 1633 

Pickersgill, N........................................ 560 

Pickett, M A...................................... 1447* 

Picut, C................................................. 564 

Piehl, M.............................................. 2568 

Pierre, B.............................................. 598* 

Pierre, Z.............................................. 2041 

Piersma, A H................... 71, 79, 991, 2547 

Pieters, R................. 89, 1139, 2682*, 2685 

Pieterse, B........................................... 1213 

Pietila, M............................................ 2540 

Pietka-Ottlik, M.................................. 2023 

Pietrantonio, P.................................... 1476 

Pietrosimone, K.................................. 698* 

Pietruska, J.......................................... 1612 

Pietrzak, D.......................................... 1899 

Pike, J............................................... 1066* 

Pike, S................................................... 677 

Pil, H................................................. 2216* 

Pillco, A.............................................. 327* 

Pin, S..................................................... 206 

Pine, M................................... 1340*, 1476 

Pines, A............................................... 2652 

Pinkerton, K E....... 541, 1196, 2330, 2331, 

2491 

Pinnavaia, T.......................................... 654 

Pino, M............................................... 2023 

Piñol, R............................................... 2170 

Pinto-Martin, J...................................... 626 

Pipavath, S.......................................... 2288 

Piper, M G.......................................... 2329 

Pique, C.............................................. 1623 

Piroird, C........................ 1010, 2513, 2570 

Pirow, R.................................................. 75 

Pissuti, N R......................................... 2408 

Pitt, B R.............................................. 1285 

Piva, T J.............................................. 2179 

Pizzurro, D........................................ 1332* 

Plahovinsak, J L.................. 543, 544, 641* 

Planchart, A....................................... 1631* 

Planer-Friedrich, B............................. 1162 

Platt, V.................................................. 446 

Platz, S.......................................... 441, 442 

Plavicki, J S...................................... 1647* 

Pletcher, J M....................................... 1922 

Pletcher, M T.................... 150, 1498, 1587 

Pletcher, M........................ 147, 1671, 2532 

Plonka, W........................................... 157* 

Plummer, L E.......................... 2331*, 2491 

Plummer, S M......................... 1041*, 1048 

Plunkett, L M.................................... 1964* 

Plusquellec, C..................................... 1541 

Pluta, L J............................................... 366 

Po, I P............................................... 2033* 

Poapolathep, A.................................. 1828* 

Poapolathep, S.................................... 1828 

Pöch, G................................. 503, 504, 505 

Podhorniak, L..................................... 1031 

Podraza, D.......................................... 1936 

Podzamczer, D.................................... 1364 

Poeltl, D................................................ 980 

Poet, T S........... 703*, 704, 705, 866, 2294 

Pognan, F................. 430, 439, 1092, 1107, 

1436, 1603, 2537 

Pogribna, M V.................................... 2067 

Pogribny, I.................. 104, 245, 944, 946* 

Pohjanvirta, R................................... 2254* 

Pointon, A......................................... 1908* 

Poirier, M C....................... 116, 961, 1275, 

2656, 2658 

Polack, E............................................... 788 

Polina, S................................................ 206 

Politano, V T........................... 1034*, 1560 

Polk, W W.......................................... 985* 

Pollard, J W...................................... 1714* 

Pollock, M C............................. 1268, 1937 

Polman, J............................................ 2561 

Pomeroy-Black, M........................... 1872* 

Pomper, M G........................................ 164 

Pompon, D.......................................... 1859 

Pongrakhananon, V................1187*, 1188, 

1668 

Ponzi, C............................................ 1921* 

Pope, C............................................... 1850 

Popichak, K A....................................... 180 

Popovic, M............................................. 7* 

Popp, J A............................................. 1879 

Porcel de Peralta, M........................... 2112 

Porter, D W............. 53, 56, 58, 575, 1454* 

Porter, D.............................478, 1178, 1185 

Porter, V.............................................. 1127 

Portier, C J...................... 1567, 2360, 2589 

Portier, C............................................... 719 

Portier, R............................................... 108 

Portsmouth, C F............................ 94, 2527 

Posner, M............................................ 2093 

Postlethwait, E M................................. 26* 

Postlethwait, E.................................... 1293 

Postlethwait, J H............................... 1775* 

Postlethwait, J..................................... 1774 

Postma, D S........................................ 1363 

Poth, A H........................ 326, 1012, 1528* 

Pothakos, K....................................... 2150* 

Pottackal, J.......... 1380, 1381*, 1382, 2133 

Pottenger, L H............................. 332*, 486 

Potter, C............................................ 1160* 

Potter, D.............................................. 2305 

Potter, P M................................ 2086, 2098 

Poulin, D............................................... 811 

Poulsen, K L............................... 443, 878* 

Pounds, J G.............. 851, 922, 1283, 1284, 

1450, 1488 

Pounds, J................................... 1287, 2171 

Powell, A............................................. 1431 

Powell, C.............................................. 786 

Powell, H............................................ 1098 

Powell, W H......................................... 347 

Powers, C M......................................... 869 

Powers, K W....................................... 1482 

Powers, K........................................... 2053 

Powis, M L......................................... 361* 

Powrie, R H...................................... 1613* 

Poy, N................................................... 793 

Prabhudesai, S.................................... 1779 

Prajapati, M.................................. 323, 325 

Prasad, R............................................. 2159 

Prasad, S........................................... 2091* 

Pratt, L F................................. 2541*, 2542 

Pratt, M M.......................................... 2658 

Pratt, N.......................................1143, 1147 

Pravasi, S D........................................ 766* 

Préfontaine, A..................................... 524* 

Prefontaine, G G................................... 372 

Pregenzer, J F................................... 2544* 

Author Index 


377


Author Index 


Prell, R................................................ 776* 

Pressman, J G..................................... 2308 

Preston, J............................................... 486 

Preterre, D................................. 1290, 1555 

Price, A............................................... 2510 

Price, J A............................................. 1457 

Price, J H............................................ 1894 

Price, M................................................ 419 

Price, O T.................................. 2289, 2292 

Price, O............................................. 2293* 

Price, P S............... 705, 866*, 1580, 1794* 

Price, S...................................... 1430, 1877 

Priem, S................................................ 809 

Priestly, B........................................... 1878 

Pringle, R B........................................ 2014 

Pringle, R.......................................... 2049* 

Prins, P A............................................ 217* 

Pritchard, J............................................ 954 

Pritsos, C................................. 1253, 1254* 

Pritsos, K............................................ 1253 

Pritt, M L.......................................... 1443* 

Proctor, D.......................... 914*, 916, 921* 

Profumo, A.............................................. 61 

Prohaska, D................................. 789, 1630 

Prokai, L............................................... 172 

Prokofieva, D...................................... 2047 

Prokoudine, A......... 724, 1440, 1562, 2353 

Pronk, T.............................................. 1011 

Proper, S............................................. 670* 

Proscura, E.......................................... 2205 

Prosser, K N.......................................... 964 

Prous Blancafort, J................................ 146 

Prozialeck, W C.................................... 268 

Prueitt, R L....................................... 2286* 

Prues, S L.............................................. 160 

Pruett, S................................ 679, 696, 697 

Prummer, M.......................................... 316 

Prunier, B.............................................. 469 

Pruss-Ustun, A.................................... 2589 

Przybyla, J.......................................... 2626 

Pu, D................................................... 465* 

Pu, Y..................................................... 250 

Pucaj, K............................................ 1269* 

Puchalski, J........................................... 650 

Puga, A................................................ 814* 

Pujol, J................................................ 1541 

Pulci, R............................................... 1576 

Pullen, N............................................... 522 

Punt, A................................................ 2348 

Puppala, D.................................. 147, 150* 

Pushkar, Y........................................... 1377 

Pushkin, A............................................. 203 

Putnam, E A........................................ 1509 

Putt, D A............................................... 752 

Puzas, E................................................ 293 

Pyatt, D................................... 1424, 1941* 

Q 

Qamar, S............................................... 488 

Qi, Y...................................................... 791 

Qian, G................. 984, 1688, 2204, 2426* 

Qian, W........................... 1283, 1284, 1488 

Qian, Y...................................... 1031, 1185 

Qin, C..................................................... 12 

Qin, Q................................................... 304 

Qiu, J..................................................... 798 

Qiu, Y.................................................. 2148 

Qu, Q.................................................. 2058 

Qu, W.................................................. 265* 

Qu, Y..................................................... 184 

Quaak, M.......................................... 1363* 

Quadt-Humme, S.................................. 187 

Quan, F............................................... 2596 

Quarck, R.................................. 2062, 2066 

Quartarone, E.......................................... 61 

Quayson, A........................................... 468 

Queiroz, R............................................. 802 

Quesenberry, R D............................... 1457 

Quevedo, C............................. 1743*, 2539 

Qui, L.................................................. 2532 

Quinney, J........................................... 1041 

Quinones, J......................................... 1347 

Quinones, O.......................................... 774 

Quintanilla, B..................................... 2393 

Quintanilla-Vega, B....... 1255, 1373, 2115, 

2116 

Quintans, L N..................................... 1059 

R 

Raabe, H............. 1551, 2550*, 2555, 2564 

Rabbah, A........................................... 1208 

Raber, A.............................................. 1160 

Rabieh, S........................................... 1162* 

Rabinowitz, J...................................... 144* 

Rabolli, V.................................... 850, 2062 

Rachman, N.......................................... 882 

Radabaugh, T R................................ 2003* 

Radchenko, E V.................................... 861 

Radford, M......................................... 1063 

Radi, Z A................................................. 14 

Radilov, A................................. 1543, 2047 

Raegan, W J........................................ 1425 

Raffaele, K C...................................... 1945 

Rafter, I............................................... 1905 

Rager, J E.......................................... 1601* 

Rager, J................................................. 947 

Raghavamenon, A C........................... 1307 

Raghavan, N......................................... 876 

Raghavan, S.................................. 735, 939 

Ragsdale, R....................................... 2486* 

Rahavendran, R.................................... 517 

Rahman, N A............................ 1039, 2549 

Railer, R F........................................... 2022 

Rainosek, S W.................................... 2598 

Rajab, N F........................................... 1673 

Rajagopalan, S.................................... 2323 

Rajaraman, G........................................ 377 

Rakwal, R........................................... 2185 

Ralston, N V..................................... 1398* 

Ralston, N........................................... 2590 

Ramachandran, A................................ 451* 

Ramaiah, S.......................................... 1441 

Raman, G.............................................. 188 

Raman, L.......................................... 2031* 

Raman, P............................................. 345* 

Ramesh, A.............. 217, 1065, 1670, 2203, 

2607, 2648 

Ramirez Gonzalez, V............................ 744 

Ramirez, F M.................................... 1672* 

Ramirez, G J......................................... 595 

Ramirez, V P....................................... 395* 

Ramirez, V............................................ 765 

Ramirez-Lee, A................................... 1456 

Ramoju, S........................................... 2091 

Ramone, S........................................... 1696 

Ramos da Silva, S............................. 2110* 

Ramos, E................................... 1352, 2108 

Ramos, K S................................. 406, 2565 

Ramshesh, V K..................................... 448 

Ramu, J............................................... 2618 

Rana, P................ 1910, 2529, 2530*, 2531 

Rand, M D........................................ 1392* 

Randle, L E............................... 2498, 2500 

Randle, L.............................................. 446 

Randle, M............................................. 988 

Rando, R............................................. 1419 

Ranjan, R.......................................... 1556* 

Rankin, G O.......................................... 738 

Rannug, A..................... 1839, 1845, 1852* 

Rannug, U..................... 1839*, 1845, 1852 

Ranslow, P.......................................... 2464 

Rantamäki, T...................................... 1391 

Rao, C V............................................... 783 

Rao, R............................................... 1666* 

Raoof, A................................................ 622 

Rappaport, S......................................... 337 

Rasmussen, C........................... 647*, 2519 

Rasmussen, T P................................... 1167 

Raso, A.................................................. 567 

Rasoulpour, R J........................... 858, 2192 

Rasoulpour, R............................... 12*, 223 

Rastogi, A........................................... 1378 



Ratcliffe, R H...................................... 2018 

Rath, M............................................... 2222 

Rathmacher, J A.................................. 1451 

Rathman, J F......................................... 469 

Rattel, B................................................ 803 

Rauk, I.................................................. 253 

Ravanat, J L.......................................... 289 

Ravis, W............................................. 1886 

Ravone, M.......................................... 1163 

Ray, G....................................... 2284, 2285 

Ray, M.................................................. 712 

Ray, S D................................................ 766 

Ray, S.................................................. 1875 

Raymond, L J...................................... 1398 

Raymond, L...................................... 2590* 

Re, T A.................................................. 467 

Re, T......................................... 1559, 2564 

Reagan, W J........................................ 555* 

Reagen, W K....................................... 1242 

Rebellato, P......................................... 2622 

Reboulet, J E......................................... 160 

Recht, J............................................... 1214 

Recio, L.................. 323, 325, 1421*, 1422 

Recio-Vega, R......................... 1203*, 1206 

Redden, J............................................ 1553 

Reddy, G................................... 736, 1420* 

Reddy, S T.......................................... 1837 

Redelman, D....................................... 1253 

Redfern, W S.................................... 1912* 

Reed, K L.................................... 566, 2162 

Reed, R................................................. 801 

Reese, D H.............................................. 74 

Reese, S E........................................... 2305 

Reid, F M............................ 543, 544*, 641 

Reid, K R.................................. 1545, 1937 

Reif, D M............................................ 1619 

Reif, D........................................ 714*, 727 

Reif, J.................................................... 657 

Reilly, C A.............................. 2333*, 2334 

Reilly, L M.......................................... 2017 

Reimer, M........................................... 2274 

Reimers, B.......................................... 1340 

Reimschuessel, R................................ 2420 

Reinhold, P E...................................... 1442 

Reisfeld, B................................ 1809, 1810 

Reising, A............................................. 430 

Reisinger, K................................ 341, 1005 

Reitzel, A M........................................ 1776 

Remacha, M............................................ 39 

Rembovskiy, V................................... 2047 

Remillard, C A.................................... 168* 

Ren, H................................................. 2237 

Ren, S................................................... 803 

Ren, X........................................... 817, 953 

Render, J............................................... 804 

Renner, P............................................. 2466 

Renzi, P................................................. 599 

Reo, N V............................................... 167 

Repetto, G......................................... 2385* 

Resnick, B............................................. 931 

Retterer, S........................................... 2056 

Rettie, A E............................................. 169 

Reuhl, K R................................ 1375, 2647 

Reuhl, K.............................................. 1399 

Reus, A.................................................. 341 

Reuter, H J............................................ 967 

Reuter, H............................................. 1009 

Reverte, I............................................ 1331 

Rey Moreno, M C............................... 2095 

Reyes, J L............................................. 757 

Rey-Moreno, M.................................. 2550 

Reynolds, J S...................... 97, 2299, 2338 

Reynolds, J............................... 811, 1888* 

Reynolds, M................................. 275, 305 

Reynolds, S H......................................... 59 

Rezk, P...................................... 2029, 2041 

Reznik, S E......................................... 1076 

Rhee, M................................................ 977 

Rho, O................................................... 958 

Rhodes, M........................................... 662* 

Rhomberg, L R............ 1721*, 1944, 1948, 

1949 

Rhone, J.............................. 543*, 544, 641 

Rhoney, S.............................................. 310 

Ribes, D.............................................. 2578 

Rice, C D.................................. 416, 1136* 

Rice, C........................................ 657, 2143 

Rice, G E............................................ 2308 

Rice, J M........................................... 1442* 

Rice, J S.............................................. 2017 

Rice, R H.............................................. 631 

Rich, C................................................ 1442 

Rich, D................................................ 2490 

Richard, A................................... 141, 158* 

Richard, V................................... 430, 1092 

Richards, J H...................................... 1298 

Richards, J.......................... 603, 798, 1473 

Richardson, D..................................... 2318 

Richardson, J R............ 105, 170, 171, 873, 

1341, 1399, 1857, 2104, 2647 

Richardson, P........................................ 811 

Richardson, R J......... 162*, 163, 861, 1336 

Richardson, S D.................................. 2308 

Richardson, V M............................... 2349* 

Richards-Smith, B................................ 133 

Richburg, J H.......................... 66, 70, 1657 

Richburg, J.............................................. 62 

Richert, H........................................... 514* 

Richman, L........................................... 803 

Richmond, J........................................ 2551 

Richt, J A.............................................. 845 

Richter, E D........................................ 1207 

Richter, R J......................................... 1692 

Rick, D L.............. 2100, 2105, 2107, 2383 

Rider, C V................................... 16, 1792* 

Riebeling, C.......................................... 75* 

Rieder, S A........................................ 2321* 

Rieswijk, L........................................ 1586* 

Rietjens, I M......................................... 991 

Rietmann, R.......................................... 316 

Rieux, E................................................ 559 

Riggenbach, J A.................................. 1784 

Rigler, P.............................................. 1905 

Rigler, R.............................................. 1905 

Rihner, M L......................................... 2421 

Riley, R T.......................................... 1448* 

Rimsky, R........................................... 1322 

Ringeissen, S.................... 464*, 469, 2570 

Rios, J................................................. 2591 

Rios-Perez, A D................................ 2649* 

Ripp, S L............................................... 618 

Rise, M L............................................ 1588 

Ritter, D................................................ 960 

Ritter, L............................................... 1539 

Rittieni, A............................................ 2416 

Rivera, E............................................... 668 

Rivera-Del Valle, N............................ 948* 

Riviere, J E.............. 633*, 634, 710, 1174, 

1176, 2072, 2154, 2155 

Rivina, Y............................................. 340* 

Roach, J................................................ 440 

Robbins, C A....................................... 1546 

Robbins, D R...................................... 2310 

Robbins, S........................................... 1939 

Roberg, K.............................................. 135 

Robert, D.............................................. 184 

Robert, K J.......................................... 1813 

Roberts, A........................................... 2441 

Roberts, D J................................ 331, 1918 

Roberts, D........................................... 1412 

Roberts, J E......................................... 2078 

Roberts, J K........................................ 2333 

Roberts, J R........ 1759*, 2181, 2317, 2325 

Roberts, J.................................... 776, 2318 

Roberts, K C....................................... 1570 

Roberts, R............................................. 792 

Roberts, S C.......................................... 869 

Roberts, S................................. 1915, 2053 

Robertson, B............................. 2020, 2037 

Robertson, D G................................... 523* 




Robertson, D....................................... 1451 

Robertson, L W................................... 2249 

Robertson, L..........1103, 1109, 1854, 2251 

Robin, M............................................. 1579 

Robinette, B L................................... 2629* 

Robinson, B L..................................... 1464 

Robinson, B R.................................... 2627 

Robinson, C T....................................... 656 

Robinson, E.............................. 1388, 1389 

Robinson, G........................................ 1377 

Robinson, J F.......................................... 79 

Robinson, J......................................... 1608 

Robinson, K.............................. 619*, 1390 

Robinson, S............ 211, 812, 1563, 1564*, 

1912 

Robinson, V G.................................... 2442 

Robinson, V.............................. 2271, 2272 

Robledo, L.......................................... 2393 

Robledo, M L........................................ 388 

Robledo-Marenco, L..................2115, 2116 

Rockwell, C E..................................... 694* 

Rockwood, G A.................................. 2046 

Roda, E......................................... 61, 1470 

Rodgers, K L....................................... 2027 

Rodriguez, A M.................................. 1755 

Rodriguez, P......................................... 268 

Rodríguez, R I.................................... 669* 

Rodriguez-Kessler, G T.................... 1387* 

Rodriguez-Lara, V.............................. 287* 

Rodríguez-Olibarría, G....................... 2119 

Rodríguez-S, T.................................... 2434 

Roede, J R........................................... 1280 

Roede, J............................................ 1349* 

Roegge, C S........................................ 2609 

Roelofs, M........................................ 2547* 

Roels, H A......................................... 2458* 

Roels, H.............................................. 2456 

Roesslein, M....................................... 2158 

Rogan, E............................................... 880 

Rogers, A.............................................. 983 

Rogers, E N...................................... 2235* 

Rogers, J L.......................................... 1810 

Rogers, L K....................................... 2193* 

Rogers, R A........................................... 600 

Rogers, R............................................ 2379 

Rogiers, V........................................... 1656 

Roh, J................................................ 2064* 

Rohlman, D S........................... 1218, 1329 

Rohlman, D....................................... 1328* 

Rohr, A C............................................ 2494 

Rohr, A.............................. 594, 1646, 2493 

Rojanasakul, Y................1181, 1182, 1183, 

1187, 1188*, 1668 

Rojas, A E............................................. 388 

Rojas, E....................................2115*, 2116 

Rojas-García, A E............................... 2524 

Rolf, M................................................. 156 

Rollins, D E........................................ 1695 

Rolo, A P............................................. 1087 

Roman, L............................................ 1295 

Romano, T............................................ 657 

Romer, E............................................. 1124 

Romero, A C......................................... 979 

Romero, C........................................... 2558 

Romero, D M.................................... 1227* 

Romero, E G............................. 2333, 2334 

Romero-Toledo, I............................... 1372 

Romoser, A A.................................... 2183* 

Romoser, A......................................... 2068 

Roncaglioni, A...................................... 483 

Roncal-Jimenez, C A.......................... 1086 

Roncel, M........................................... 2385 

Rondelli, C M................................... 1360* 

Ronis, M J........................................... 1302 

Rönn, M.................................. 1200*, 1201 

Roomi, M.......................................... 2222* 

Roomi, N W........................................ 2222 

Rooney, A A...................................... 1701* 

Rooney, A........................................... 1697 

Roos, R............................................... 2242 

Roosmarijn, V..................................... 1656 

Roque, P J......................................... 2620* 

Roquet, M............................................. 646 

Rorije, E................................................ 496 

Rosas-Hernandez, H........................... 1456 

Rosauro, V.......................................... 2492 

Roscoe, D........................................... 1369 

Rose, C............................................... 780* 

Rose, N............................................. 2683* 

Rose, S.................................................. 788 

Rose, T................................................ 1936 

Rosen, M B............................. 2237*, 2239 

Rosenblum, L K.................... 1067*, 2057* 

Rosencrance, A B................................ 1604 

Rosenfeld, C S.................................... 1078 

Rosengren, R J.......................... 2634, 2635 

Rosenstein, M C................................... 130 

Rosenthal, G J....................................... 798 

Rosenzweig, B.................................... 1426 

Roskos, L.............................................. 803 

Ross, D G.......................................... 2262* 

Ross, D..................................... 1663, 1673 

Ross, I................................................. 516* 

Ross, J H............................................. 1251 

Ross, J................................................... 223 

Ross, M K..................... 1325, 2086*, 2098 

Ross, M............................................... 636* 

Ross, S.................................................. 117 

Rossenu, S............................................ 809 

Rossetti, F............................... 2020, 2037* 

Rossi, A................................................. 522 

Rossi, E M.............................................. 55 

Rossi, F............................................... 1919 

Roszell, L E.......................................... 927 

Roter, A H................................... 534, 1606 

Roth, A........................ 387, 426, 441, 442* 

Roth, R A......... 433, 443, 878, 1093, 1652, 

1658 

Rothenberg, S..................................... 2524 

Rothen-Rutishauser, B.......................... 328 

Rothman, N......................................... 823* 

Rothwell, C C................................... 2036* 

Rotroff, D M......................................... 715 

Rountree, M R.................................... 1619 

Rouquié, D.............................................. 69 

Rouse, M........................................... 1507* 

Rouse, R................................. 2074, 2347* 

Rousset, F........................................... 1010 

Rovira, C............................................. 899* 

Rovira, J.............................................. 1246 

Rovira, N.............................................. 612 

Rowe, C................................................ 446 

Rowland, A M................................... 1851* 

Rowland, D......................................... 1444 

Rowlands, J..................... 859*, 1365, 1366 

Rowley, D............................................. 688 

Rowley, N........................................... 1463 

Rowling, M J...................................... 2411 

Rowsey, P J........................................... 568 

Roy, R............................................... 1516* 

Roy, S................................................. 334* 

Royland, J E............................ 1298, 1583* 

Rozek, L S.......................... 100, 943, 1216 

Rubenstein, N....................................... 400 

Rubino, R.................................... 957, 2661 

Rubinstein, T........................... 1380, 1381, 

1382*, 2133 

Rubio, C............................................ 1228* 

Rubio, M............................................... 388 

Rubitski, E............................................ 32* 

Ruchirawat, M.................................... 2638 

Ruddle, N H........................................ 1508 

Ruddock, K......................................... 2591 

Rudraiah, S....................................... 1088* 

Ruegg, C L............................................ 787 

Ruff, A L............................................. 1753 

Ruh, C............................................... 2376* 

Ruiz, M J............................................ 2423 

Ruiz, M............................................... 1608 

Ruiz, P........................................ 712, 860* 



Ruiz-Aracama, A................................ 1585 

Ruiz-Ramos, R................................... 2649 

Rumbeiha, W K.................................. 545* 

Rundhaug, J E....................................... 958 

Rushmore, T H..................................... 422 

Russ, K A.................................. 163, 2161* 

Russel, F G........................................... 463 

Russell, R B........................................ 2340 

Rusyn, I................ 41*, 139, 143, 247, 447, 

494, 820*, 944, 981 

Rutherford, K...................................... 2543 

Ruusunen, J........................................... 672 

Ruxrungtham, K................................. 1364 

Ryals, J A.............................................. 438 

Ryan, C M............................................. 408 

Ryan, C................................................. 85* 

Ryan, J...................................... 2525, 2526 

Ryan, K............................................. 1297* 

Ryan, P C............................................ 803* 

Ryan, P H............................................ 1267 

Ryde, I T............................................... 869 

Ryu, H................................................. 1763 

Ryu, Y................................................... 975 

S 

Saathoff, J G..................................... 1176* 

Saavedra, L........................................... 420 

Sabbioni, G......................................... 1419 

Sabnekar, P............................... 2029, 2041 

Sabolsky, E M....................................... 192 

Sacaan, A.................................... 517, 1427 

Sacco, M............................................. 1470 

Sace, D.................................................. 528 

Sace, F.................................................. 530 

Sachdeva, K.......................................... 507 

Sachdeva, M........................... 2521*, 2556 

Saddler, C......................................... 2580* 

Sadeu, J............................................. 1072* 

Sadovova, N V.................................. 2596* 

Sadovova, N............................. 2597, 2598 

Sadrieh, N............................................. 137 

Safe, S H............................................... 956 

Safe, S................. 220, 221, 225, 226, 900* 

Saffarini, C........................................ 1043* 

Safruk, A M........................................ 1942 

Sagelsdorf, P......................................... 289 

Sager, T M........................................ 1178* 

Saghir, S A........................................ 2107* 

Sahar, R...................................... 891, 2013 

Sahu, M............................................... 2051 

Saili, K S........................................... 2626* 

Saito, F.............................................. 1598* 

Saito, K................................... 1000*, 2560 

Saito, M.............................................. 1211 

Saito, T................................................ 2185 

Sakaguchi, H......... 1000, 1001, 2551, 2560 

Sakai, N.............................................. 1062 

Sakai, S................................................. 566 

Sakamoto, Y............................ 1090*, 2657 

Sakamuru, S.......................................... 493 

Sakasai, K........................................... 1062 

Salazar, J G......................................... 1331 

Salazar, K D...................................... 1511* 

Salazar, K.............................................. 596 

Salazar-Garcia, S................................ 1456 

Saldivar, L......................................... 2434* 

Salehi, F.................................... 2461, 2487 

Salem, H............................................... 572 

Salewsky, T..........1143, 1144*, 1147, 1445 

Salicru, E.............................................. 465 

Salihovic, S................... 1200, 1202, 2244* 

Salinas, K.............................................. 489 

Salisbury, J............................................ 278 

Salisbury, R....................................... 1125* 

Salisbury, T......................................... 351* 

Sall, D................................................... 202 

Salmen-Muniz, R........................ 185, 1492 

Salminen, W F.............................. 432, 454 

Salminen, W............................. 1678, 2174 

Saltzman, L......................................... 1214 

Salva, J................................................ 1356 

Samadfam, R...................................... 512* 

Samberg, M E................................... 1758* 

Sambuco, C P..................................... 1785 

Sampath, S............................................ 430 

Sample, A............................................ 2164 

Sampson, U K....................................... 217 

Sams, A............................................... 2521 

Samson, B A....................................... 2540 

Samson, B............................................. 398 

Sanabria, M......................................... 1024 

Sanada, H............................................ 1403 

Sanbuissho, A..................... 649, 777, 1101 

Sanchez Soria, P............................... 2008* 

Sánchez, B N........................................ 292 

Sanchez, E I.......................................... 757 

Sanchez, S......................................... 1686* 

Sanchez-Guerra, M A......................... 1972 

Sánchez-Guerra, M................. 1255, 1373* 

Sanchez-Lozada, L G......................... 1086 

Sanchez-Morrissey, S......................... 2600 

Sánchez-Pérez, Y................................ 2659 

Sanchez-Salas, J L.............................. 2076 

Sánchez-Santed, F.............................. 1331 

Sanchez-Soria, P................................. 2000 

Sanders, A........................................... 310* 

Sanders, J M........................... 1822, 2277* 

Sanders, K M...................................... 2078 

Sanders, M.......................................... 1437 

Sanders, N........................................... 1656 

Sandrof, M A...................................... 2191 

Sandy, M S........................ 498, 1962, 1967 

Sangare-Tigori, B............................... 2427 

Sankaran, G............................ 1680, 2118* 

Sankari, S............................................ 2254 

Sansbury, B..........................................1111 

Sant, K E........................................... 1616* 

Santamaria, A...................................... 1198 

Santana, R B....................................... 1484 

Santanam, N......................................... 351 

Santillo, M.......................................... 1577 

Santostefano, M J............................... 778* 

Saraceni-Richards, C A......................... 130 

Sarangi, A........................................... 1486 

Sarazan, R........................................... 1930 

Sareen, P............................................... 315 

Sarfaraz, S........................................... 104* 

Sargent, E............................................ 476* 

Sargent, L M......................................... 59* 

Sargent, L............................................ 1180 

Sarigiannis, D A............. 61*, 865*, 1582*, 

1600* 

Sarimveis, H......................................... 494 

Sarkissian, L....................................... 1323 

Sarlo, K....................................... 719, 1481 

Sarma, A............................................. 763* 

Sarma, N D....................................... 2439* 

Sarma, N............................................. 2436 

Sartor, M A........................................... 943 

Sasaki, J C.............................................. 11 

Sasaki, J.............................................. 1904 

Satarug, S.............................................. 764 

Sathiakumar, N................................... 829* 

Sato, A................................................. 1062 

Sato, D................................................ 2007 

Sato, H.................................................. 438 

Sato, K........................................ 963, 2637 

Satoh, M..................................... 269*, 770 

Satoh, T................................................. 963 

Sauers, L............................................. 2336 

Saunders, J...................... 1981, 1986, 1987 

Saunthararajah, Y.................................. 799 

Savery, L........................................... 2252* 

Savolainen, K......................................... 55 

Savtchenko, A..................................... 1894 

Sawa, C............................................... 2185 

Sawaryn, C M....................................... 618 

Sax, S N.............................................. 1268 

Sayal, A................................................. 324 

Sayers, B C................... 1195*, 2176, 2178 

Author Index 


379


Author Index 


Sayes, C M............. 533, 2068, 2069, 2166, 

2175, 2183 

Sayes, C.................................. 1476, 1802* 

Sayre, P............................................... 1797 

Scabilloni, J F......................................... 56 

Scally, A.............................................. 1909 

Scarino, A........................................... 599* 

Scase, K................................................ 195 

Scelfo, B........................................... 2510* 

Schad, K............................................... 441 

Schaefer, G........................................... 776 

Schaefer-Korting, M............................. 640 

Schaeublin, N M............................... 2181* 

Schafer, R................................... 665, 692* 

Schanne, F.......................................... 2625 

Schäper, M.......................................... 1575 

Schatz, A R......................................... 1865 

Schatz, J.................................... 1197, 2184 

Schaum, J............................................ 2297 

Schechtman, L.................................... 1309 

Scheckel, K G..................................... 2009 

Schecter, A........................................ 1252* 

Scheffler, B E........................................ 942 

Scheiber, J........................................... 857* 

Schell, J............................................... 1572 

Schepky, A G...................................... 967* 

Schepky, A.......................................... 1009 

Scherhag, A................................... 946, 950 

Schettgen, T............................................ 88 

Scheumann, J........................................ 430 

Scheynius, A............................... 680, 2052 

Schibler, U........................................ 1703* 

Schick, J S.......................................... 1784 

Schiestl, R H................................. 238, 340 

Schiffrin, E L...................................... 1970 

Schildknecht, S........................... 868, 980* 

Schirmer, K............................. 1599, 2465* 

Schisler, M R........................................ 952 

Schladweiler, M C................ 568, 602, 604 

Schladweiler, M.................................... 603 

Schlager, J J.............................. 1464, 2031 

Schlappal, A E.................................... 172* 

Schlatter, J R......................................... 972 

Schlenk, D.................................. 17*, 2102 

Schlezinger, J J..................................... 352 

Schlosser, P M.................................. 2692* 

Schmahai, T.......................................... 804 

Schmal, O............................................. 739 

Schmid, J E......................................... 2306 

Schmid, J R......................................... 2237 

Schmid, T E.......................................... 337 

Schmidt, R H...................................... 2002 

Schmidt, R.......................................... 460* 

Schmitt, C S........................................ 1590 

Schmitt, T........................................... 1678 

Schmuczerova, J................................... 119 

Schnackenberg, L K............................ 1678 

Schnackenberg, L............................... 1434 

Schneider, A.......................................... 803 

Schneider, B................................ 163, 1432 

Schneider, J................... 2145, 2146*, 2150 

Schneider, M......................................... 957 

Schneider, P A................................... 1148* 

Schneider, S........................................ 2095 

Schnellmann, R G........................ 749, 750, 

751, 1300 

Schnellmann, R..................................... 748 

Schoeny, R........................ 486, 919*, 1940 

Scholand, M........................................ 1287 

Scholz, S................................... 2465, 2466 

Schondelmeyer, R S................... 109, 1508 

Schook, A C........................................ 1705 

Schook, A.............................................. 393 

Schoonen, W G................................... 2561 

Schopfer, L M..................................... 1692 

Schrage, A................... 82, 644*, 971, 2550 

Schrand, A M...................................... 2059 

Schrand, A........................................... 1453 

Schray, R................................... 2145, 2150 

Schreiner, C A....................................... 237 

Schrenk, D................................ 367*, 2242 

Schriks, M........................................... 2348 

Schroeder, O....................................... 2510 

Schroeter, J D................... 701, 2141, 2459 

Schroeter, J S...................................... 2289 

Schroeter, J....................................... 2290* 

Schroeter, T....................................... 2532* 

Schroth, G............................................. 947 

Schuck, F............................................ 1004 

Schuetz, C............................................. 738 

Schuh, R............................................... 172 

Schuhmacher, M....................... 1245, 1246 

Schuler, D............................................. 289 

Schulte, C E...................................... 2411* 

Schulte, N........................................... 1902 

Schulte, P A......................................... 911* 

Schultheis, J M................................... 2310 

Schultz, B........................................... 1215 

Schultz, I........................................... 2398* 

Schultz, T W......................... 503, 504, 505 

Schulz, M.................................. 971, 1469* 

Schulz, S M........................................ 2018 

Schulz, V J........................................ 1139* 

Schussheim, Y.................................... 2205 

Schwald, M......................................... 1436 

Schwartz, B S............................. 773, 835* 

Schwartz, B........................................... 768 

Schwartz, J.............................. 1648, 1649* 

Schwarzman, M.................................. 910* 

Schwegler-Berry, D........... 563, 575, 1180, 

1462, 1759 

Scinicariello, F.................................. 1204* 

Sciullo, E............................................ 1533 

Sciuto, A M......................................... 1755 

Sciuto, A............................................. 2041 

Scognamiglio, J........................ 491, 1560* 

Scollon, E J......................................... 2262 

Scott, C S............................................ 2641 

Scott, J A............................................... 199 

Scott, K............................................... 969* 

Scott, P K............................................ 2255 

Scott, P................................................ 2038 

Scott, T.................................................. 115 

Scott, W.................................... 517*, 1427 

Scuito, A M......................................... 2029 

Seagrave, J.............................. 1754, 2019* 

Seales, P.............................................. 2009 

Seaman, C................................... 468*, 996 

Searfoss, G H........................................ 876 

Sebag, I..................................... 2188, 2189 

Sebastian, M M..................................... 14* 

Secor, J D.......................................... 1299* 

Sedykh, A...................................... 139, 143 

Seegal, R F........................................ 2600* 

Seeka, P.............................................. 1842 

Seeley, M................................ 1545, 1950* 

Seeman, J.............................................. 546 

Segal, L............................................. 1027* 

Seidler, F J............................................ 869 

Seifeldin, I.......................................... 1216 

Seiler, A E....................................... 73*, 75 

Seilkop, S.............................................. 298 

Seki, T........................................... 321, 425 

Sekita, K............................................. 1154 

Seko, Y.................................................. 770 

Selcer, B................................................ 295 

Selgrade, M......................................... 470* 

Selin, H............................................... 1310 

Sellamuthu, R................................... 2318* 

Sellars, T............................................. 1438 

Selleck, S B...................................... 1770* 

Sellers, E N................................. 109, 1508 

Selman, F B........................................ 2105 

Selvakumar, S....................................... 765 

Selwyn, F.......................................... 2269* 

Senal, I.................................................. 184 

Seng, J E........................................... 2418* 

Seng, W L................................. 1740, 1742 

SenGupta, S................................ 957, 2661 

Senn, J................................................... 797 



Sens, D A................. 764, 772, 1973, 1994, 

1995, 1996* 

Sens, M.......... 764, 772, 1973, 1994, 1995, 

1996 

Senthilkumar, P................................. 2251* 

Seo, J................................. 746, 2216, 2218 

Seok, S.................................................. 975 

Sepulveda, M S................................... 1747 

Sepúlveda, M S............................. 19, 2090 

Serex, T L..................................... 586, 587 

Serex, T................................................. 470 

Serke, B L......................................... 2051* 

Serov, A............................................... 1905 

Seshachellam, V................................. 1196 

Seto, H................................................ 1225 

Settivari, R................................ 179*, 1396 

Setzer, R...................................... 716, 1813 

Setzer, W............................................. 2693 

Sewald, K............................................. 960 

Sexton, H.................................... 542, 1378 

Sexton, K G...................... 565, 1601, 2332 

Sexton, K............................................ 1069 

Sey, Y M............................................. 2307 

Shaddock, J G.......... 320, 879, 1405, 1411, 

1548 

Shadley, J D.......................................... 615 

Shafer, T J............. 867, 1354, 2452*, 2510 

Shaffiey, F........................................... 2405 

Shah, I....................... 728*, 733, 937, 2693 

Shah, M M............................................ 592 

Shah, N............................................... 2660 

Shah, P P............................................. 2556 

Shah, R............................. 151*, 159, 2096 

Shah, S A.......................................... 2654* 

Shahane, S............................................ 493 

Shaiba, L A............................... 1388, 1389 

Shaikh, O............................................ 735* 

Shaligram, S S.................................. 1376* 

Shan, W.............................................. 877* 

Shaner, B E........................................... 750 

Shang, J............................................... 1978 

Shang, P.............................................. 1224 

Shangari, N..................... 430*, 1092, 1766 

Shankar, G N.................................... 2050* 

Shankaran, H........................................ 404 

Shannahan, J H..................................... 602 

Shannahan, J............................. 603*, 2489 

Shao, J................................................... 695 

Shao, Y.............................................. 1394* 

Shapira, E........................................... 2205 

Shapiro, A........................................... 1538 

Shapiro, L........................................... 2519 

Sharaf, M............................................ 2439 

Sharapova, T....................................... 1592 

Sharma, A......................................... 1504* 

Sharma, B............................................. 682 

Sharma, P............................................ 2053 

Sharma, S.............................................. 329 

Sharpe, M R.......................................... 453 

Sharpe, M........................................... 1160 

Sharratt, B........................................... 2305 

Shaw, J R............................................ 2007 

Shaw, P J............................................... 452 

Shea, C.................................................. 954 

Shearn, C T............................... 1084, 1282 

Sheasgreen, J E................................... 2373 

Sheasgreen, J........................................ 652 

Sheets, L............................................. 2646 

Shehata, T..................................... 303, 304 

Sheik Mohideen, S...................... 176*, 177 

Sheila, M............................................. 1041 

Shelley, R L........................................ 773* 

Shelton, S D.................................. 68, 1405 

Shen, A.............................. 393, 529*, 1705 

Shen, C L............................................ 2204 

Shen, D............................................... 2267 

Shen, H............................................. 2249* 

Shen, L................................................ 800* 

Shen, O............................................... 2367 

Shen, S.............................................. 1860* 

Shen, X................................................. 626 

Shen, Z.......................................... 517, 804 

Shepard, K.............. 323, 325, 1421, 1422* 

Shepherd, D M...........................1131, 1134 

Shepherd, K R...................................... 182 

Sheridan, R P...................................... 1966 

Sherlock, J............................................ 876 

Sherman, K........................................... 396 

Sherratt, P............................................. 790 

Shertzer, H G.......................... 1761, 2582* 

Sherwood, C L.................................. 1990* 

Sheu, T.................................................. 293 

Shi, J.............. 301, 301, 315*, 1179, 1412, 

2004, 2004, 2005*, 2006, 2052, 2522 

Shi, L...................... 126, 1097, 2596, 2598 

Shi, Q......................... 138, 427, 432*, 934, 

2174, 2597 

Shi, Y.................................................. 1999 

Shibato, J............................................ 2185 

Shigehiro, K........................................ 2390 

Shih, P................................................. 2410 

Shih, T M............................................ 2025 

Shih, T...................................... 2012, 2016 

Shilnikova, N...................................... 2461 

Shimada, H......................................... 266* 

Shimada, T.................................... 532, 805 

Shimamura, Y..................................... 521* 

Shimek, J M...................................... 1258* 

Shimizu, K.......................................... 1194 

Shimoda, M.......................................... 621 

Shimojo, N.......................................... 2200 

Shimonaka, M..................................... 1370 

Shin, H........................................ 101*, 746 

Shin, J......................................... 256, 1212 

Shines, C J............................................ 578 

Shinkai, Y................................. 412*, 1305 

Shioda, S................................... 2185, 2595 

Shirai, T.............................................. 1598 

Shirley, D L......................................... 2196 

Shivachar, A.......................................... 344 

Shmurak, V......................................... 2047 

Shoaf, C.............................................. 1220 

Shockley, K R........................... 482*, 1593 

Shoenfelt, J......................................... 1960 

Shoichet, B........................................... 854 

Shoieb, A............................................. 1438 

Shortt, K........................................... 2404* 

Shou, L.................................................. 493 

Shpyleva, S........................................... 104 

Shray, R.............................................. 2146 

Shuey, C.............................................. 1696 

Shukla, S J........................................ 2501* 

Shurin, G V......................................... 1189 

Shurin, M R........................................ 1189 

Shutsky, T........................................... 1412 

Shvedova, A A........54, 1180, 1189, 1462*, 

2072, 2160 

Shvedova, A........................................ 1179 

Siciliano, S D.................... 526, 2566, 2572 

Sidappa, R........................................... 2652 

Sidaway, J E........................................ 1908 

Siddiqui, M A........................................ 190 

Sidoryk-Wegrzynowicz, M............... 2131* 

Siebert, M........................................... 1840 

Siegel, D............................................. 1663 

Siegel, L.............................................. 932* 

Siegel, P D.................................... 86, 1557 

Siegrist, K J............................................ 59 

Siegrist, K........................................... 1180 

Sieli, P T............................................. 1078 

Siemann, L G...................................... 1578 

Sienkiewicz, M................................... 2091 

Sierra-Santoyo, A.............................. 1833* 

Siew, L E............................................. 1673 

Sifre, M I............................................ 1070 

Sigal, E............................................. 1942* 

Siitonen, P H....................................... 2067 

Silbergeld, E K........ 403, 686, 1386, 1387, 

1974, 2196 

Silbergeld, E......................................... 767 




Siler, S Q..................................... 940, 1735 

Silinski, M A....................................... 2227 

Silkworth, J B....... 474, 1959*, 1960, 1961 

Sills, R C..................................... 245, 1096 

Silmon, A............................................ 2071 

Silva, E................................................... 21 

Silva, R F............................................ 1024 

Silveira-Gramont, M I........................ 2119 

Simcox, N........................................... 1568 

Sime, P J............................................. 2324 

Simeonova, P P........................... 185, 1492 

Simion, F A......................................... 1551 

Simion, T............................................ 1001 

Simmonds, M A.................................. 276* 

Simmons, C........................................ 1936 

Simmons, D........................................ 1103 

Simmons, J.............. 8*, 1581, 1792, 2307, 

2308*, 2309 

Simmons, S O........................... 2350, 2501 

Simmons, S......................................... 1757 

Simões, A M....................................... 1087 

Simon, D....................................... 768, 773 

Simon, M............................................ 893* 

Simon, N............................................... 647 

Simoneau, M....................................... 2384 

Simones, T.............................. 1131*, 2662 

Simoniello, M..................................... 2112 

Simons, J B......................................... 1755 

Simpson, T.......................................... 1430 

Sims, P................................................ 650* 

Sina, J................................................... 876 

Sinclair, G................................... 179, 1396 

Singal, M................................ 2289*, 2290 

Singer, M............................................ 1904 

Singer, N............................................. 2026 

Singer, R M......................................... 174* 

Singer, T....... 152, 215, 387, 426, 441, 442, 

784, 1159, 1161, 1163, 1164, 1165, 1437, 

1814 

Singh, A V........................................... 1619 

Singh, A.............................. 728, 982, 1790 

Singh, B.............................................. 1133 

Singh, K P................................1157, 1158* 

Singh, K................................................ 106 

Singh, N P................................. 949, 1133* 

Singh, S............................................... 1171 

Singh, U...................................... 949, 1133 

Singhal, R................................... 443*, 878 

Singleton, S T..................................... 2117 

Sinha, S............................................... 1779 

Sinko, P J.................................. 1751, 2028 

Sioutas, C.............................................. 596 

Sipes, G............................................... 2282 

Sipes, I G.............................................. 732 

Sipes, I...................................... 1054, 2640 

Sipes, N S......................................... 1619* 

Sipes, N................................................. 982 

Sisco, M................................................ 571 

Sison, R L........................................... 2500 

Sitapara, R A....................................... 264* 

Sitapara, R.......................................... 2337 

Sites, J E............................................. 2413 

Sithu, S D............................ 190, 259*, 262 

Sjögren, B........................................... 2259 

Ska, B................................................. 1226 

Skare, J............................................... 486* 

Skeete, D............................................. 2591 

Skelhorne-Gross, G.......................... 2661* 

Skelly, B............................................. 1236 

Skoglund, R........................................ 1516 

Skolness, S Y.................................... 2368* 

Skuba, E.................................... 1092, 1603 

Slaven, J.............................................. 1367 

Slawik, B................................................ 75 

Slieker, R.......................................... 1640* 

Slikker, W............. 1464, 1661, 2596, 2598 

Slitt, A L.............. 1078, 1079*, 1862, 2586 

Slitt, A...........414, 1077, 1113, 1116, 2270, 

2499 

Sloan, R C............................................. 193 

Sloter, E D.......................................... 1029 

Slotkin, T A........................................... 869 

Sly, J..................................................... 315 

Smart, R................................................ 954 

Smathers, R L......................... 1084, 1282* 

Smeester, L............................... 947*, 1601 

Smit, J........................................... 89, 1139 

Smith, A M.............................................. 72 

Smith, A................................................ 577 

Smith, C L............................................. 133 

Smith, C S........................................... 1578 

Smith, C.......................... 2271, 2272, 2442 

Smith, D J........................................... 2273 

Smith, D R............... 625, 629, 1222, 1237, 

1238*, 2149, 2397 

Smith, E.............................................. 1821 

Smith, H W....................................... 2669* 

Smith, J N........................... 703, 704*, 705 

Smith, K H................................ 2018, 2022 

Smith, K J........................................... 360* 

Smith, K.............................................. 2256 

Smith, L C........................................... 1482 

Smith, L W...................................... 90, 491 

Smith, L................................................ 151 

Smith, M A.......................................... 749* 

Smith, M J...................... 80*, 98, 653, 655 

Smith, M T.......................................... 2558 

Smith, M V......................................... 1744 

Smith, M....................................... 159, 817 

Smith, N................................................ 947 

Smith, P A......................................... 2069* 

Smith, P F............................................. 660 

Smith, R D.......................................... 1488 

Smith, S S........................................... 1447 

Smith, S Y.......................... 512, 619, 1911, 

1916, 2376 

Smith, T J.............................................. 864 

Smith, W J.......................................... 2027 

Smulders, S......................................... 681* 

Smurthwaite, C................................... 738* 

Smyth, M.............................................. 43* 

Snapp, H M......................................... 1230 

Snawder, J E....................................... 1428 

Snel, C.................................................. 630 

Snow, S J............................................ 191* 

Snyder, D W....................................... 2517 

Snyder, R J........................................ 2167* 

Snyder, R...................... 1473, 2202, 2644* 

Snyder, S............................................... 774 

Sobanski, T......................................... 2510 

Soderlund, D M...................... 1343*, 1353 

Soelberg, J............................................ 699 

Soga, T.................................................. 521 

Sogorb, M A........................................ 979* 

Soh, M.............................................. 1994* 

Sohn, S................................................ 2536 

Sokolov, V B......................................... 861 

Sokolowska, M................................. 1725* 

Sokolowski, K B............................... 1390* 

Sokolowski, S....................................... 529 

Solaimani, P........................................ 369* 

Solak, K............................................ 2354* 

Soldin, O........................................... 2135* 

Soleimani, M........................................ 313 

Soliman, A.......................................... 1216 

Sollome, J J......................................... 2000 

Soltani, K.............................................. 954 

Soman, K............................................ 1286 

Somers, G............................................. 577 

Somerville, S M.................................. 2018 

Somji, S....... 764, 772, 1973*, 1994, 1995, 

1996 

Sommer, E............................................ 497 

Sommer, R J....................................... 1641 

Sommers, C H.................................... 2413 

Somps, C............................................. 793* 

Somuncu, I............................................ 324 

Son, S............................................ 101, 746 

Son, Y................................................... 975 

Sonawane, B....................................... 1934 



Sonders, P........................................... 1412 

Song, C............................... 589, 590, 1480 

Song, D............................................... 1654 

Song, J................ 589*, 1420, 2029*, 2041 

Song, K............................. 977, 1762, 1763 

Song, W.............................................. 2335 

Sontag, R L........................................... 404 

Soojhawon, I....................................... 2024 

Sooresh, A......................................... 1476* 

Sophie, S............................................. 1509 

Sordo, M....................................2115, 2116 

Soriano, M.......................................... 2026 

Sorrentino, J.......................................... 946 

Sorribas, V........................................ 2170* 

Sosa-Holt, C....................................... 1346 

Soshilov, A A........................................ 368 

Soukup, D............................................. 670 

Souza, V.....................................1112, 1301 

Soydas, E............................................ 1362 

Soykut, B.............................................. 324 

Spade, D........................................... 2395* 

Spaet, R............................................... 1603 

Sparkenbaugh, E M................ 1395, 1652* 

Sparks, D............................................ 2404 

Sparrow, B R...................................... 2631 

Sparrow, S................................. 577, 1563* 

Sparvero, L J..................................... 1285* 

Sparvero, L......................................... 1179 

Spassova, M A.......................... 475, 1273* 

Spearow, J........................................... 1533 

Spector, J.............................................. 768 

Speiran, K L...................................... 2196* 

Speirs, I C................................. 1654, 2161 

Speth, T F........................................... 2308 

Spieker, J.............................................. 967 

Spielmann, H.......................................... 75 

Spinardi-Barbisan, A T......................... 547 

Spindle, R W............................... 539*, 540 

Spink, B C............................................ 103 

Spink, D C............................................ 103 

Spink, D.............................................. 2319 

Spitsbergen, J M................................. 1588 

Spjuth, O..................................... 154, 480* 

Sprando, R L......................................... 994 

Spratt, M............................................... 87* 

Springer, S............................................ 315 

Springthorpe, B................................... 1915 

Spruijt, B M.......................................... 780 

Spulber, S................................ 1391*, 2614 

Squibb, K.............................................. 281 

Sram, R J.............................................. 119 

Sreevalsan, S............................... 226*, 955 

Srinivasan, V.................... 467, 1559, 2564 

Sriram, K............................................ 2317 

Sriram, R........................................... 1928* 

Srivastava, S....................... 190*, 259, 262 

Srivatsan, V...................................... 1817* 

Sriwichai, P....................................... 2071* 

Sroufe, M............................................ 2398 

St. Claire III, R L................................ 1080 

St. Peter, E.......................................... 1932 

Staab, C A............................................. 135 

Staab, C............................................... 2651 

Staab, J.................................................. 143 

Stahl, B............................................... 2646 

Staley, J L............................................ 2107 

Stämpfli, M......................................... 1026 

Stamyr, K.......................................... 1217* 

Stanislaus, D J...................................... 999 

Stanislaus, D....................................... 2506 

Stanko, J P................................ 1089, 1622 

Stankowski Jr., L F............................... 334 

Stankowski, L F........................ 331*, 1918 

Stankowski, L..................................... 1412 

Stanley, K A........................................ 1071 

Stannard, D......................................... 1027 

Stanton, B A........................................ 2007 

Stapleton, H M............................ 869, 2252 

Stapleton, M K.................................. 1868* 

Stapleton, P G..................................... 194* 

Star, A........................................... 54, 1189 

Starkey Lewis, P J.............................. 446* 

Starling, J J........................................... 777 

Starr, J M............................................ 2262 

Starr, T B............................................. 474* 

Starr, T................................................ 1964 

Stashenko, E....................................... 2236 

Staska, L............................................. 1248 

Staskal, D............................................ 1693 

Staskal-Wikoff, D................... 1261, 1366* 

States, J................. 1991, 2002, 2199, 2235 

States, V A.......................................... 1991 

Stauber, A............................................ 1902 

Stauffer, A............................................. 387 

Stebounova, L V................................. 1496 

Stedman, D B...................................... 1741 

Steemans, M....................................... 1895 

Steen, D...................................... 935, 1903 

Steenbergen, C.............................. 206, 214 

Stefan, K............................................. 1317 

Stefaniak, A B..................................... 1759 

Steffen, Y.............................................. 187 

Steffy, D A.......................................... 2406 

Stegelmeier, B.................................... 2229 

Stegeman, J J...................................... 1859 

Stegeman, J......................................... 1840 

Steiner, K.......................................... 2390* 

Steiner, S............................................. 1654 

Stelloo, S............................................. 2355 

Stemmer, K........................... 165, 166, 760 

Stenerlöw, B....................................... 2605 

Stephan-Gueldner, M........................ 1423* 

Stephani, R A...................................... 1076 

Stephenson, G..................................... 2566 

Sternberg, J................................... 557, 622 

Steuerwald, A J..................................... 773 

Steuerwald, A........................................ 768 

Stevens, G........................................... 1821 

Stevens, J L............................. 1902, 2681* 

Stevens, J.......................................... 2675* 

Stevens, R C....................................... 1692 

Stevenson, R S.................................... 2022 

Stewart, B E............................ 1882*, 1883 

Stewart, B......................................... 1308* 

Stewart, C W......................................... 237 

Stewart, H E.......................................... 600 

Stewart, J J........................................ 1431* 

Stewart, J.................................. 1441, 2372 

Stewart, S........................ 1426, 1452, 2074 

Stickland, K........................................ 788* 

Stickney, J................................... 489, 1955 

Stiegler, N............................................. 870 

Stierum, R........................................... 1585 

Stimmer, L.......................................... 1439 

Stinchcombe, S................................. 2095* 

Stitzinger, M....................................... 1014 

Stockelman, M G........ 290, 573, 656, 1383 

Stockton, P S....................................... 1096 

Stoker, T E.............................. 1031*, 1042 

Stokes, W............. 418*, 1016, 1017, 1518, 

1519, 1520, 1521*, 1553, 2581 

Stølevik, S B....................................... 611* 

Stolle, K................................................ 187 

Stolper, G...................... 2534, 2574, 2575* 

Stone, H F........................................... 787* 

Stone, M............................................. 2020 

Stone, S................................................. 185 

Stonerook, M........................................ 562 

Stong, D.............................................. 1430 

Storer, R D.......................................... 1879 

Storfer, S............................................. 1364 

Stout, A................................................. 798 

Stout, B............................................... 1910 

Stout, K A............................................. 181 

Stout, M D................................ 915*, 2374 

Stoyanovsky, D A............................... 1655 

Strach, W............................................ 1834 

Strader, L F......................................... 2308 

Strader, L............................................ 1031 

Author Index 


381


Author Index 


Strauss, V......... 82, 724, 1440, 1458, 1468, 

1562, 2095, 2353* 

Street, S M.......................................... 1108 

Streicker, M.......................................... 323 

Streifel, K M....................................... 2662 

Streifel, K......................................... 2664* 

Streitmatter, S..................................... 2139 

Stribinskis, V.................................... 2565* 

Strickland, J.......................................... 465 

Strom, J................................................. 200 

Strom, S C............................................ 615 

Strother, D E....................................... 477* 

Struble, C A........................................ 1588 

Stryker, S.................................... 523, 1451 

Strynar, M J........................................ 1622 

Strynar, M........................................... 1625 

Stubbs, J E............................................ 160 

Stueckle, T A..................................... 1182* 

Stueckle, T.................................1181, 1187 

Stump, C S.......................................... 1281 

Sturgeon, J L........................................... 59 

Styblo, M............... 947, 1980, 1981, 1982, 

1986, 1987 

Su, C....... 299, 300, 307, 1393, 1665, 1998 

Su, S.................................................. 1858* 

Su, Z..................................................... 126 

Suarez, J K.......................................... 1771 

Suarez, S C......................................... 120* 

Subramaniam, R P................................ 475 

Subramanian, K.................... 176, 735, 939 

Subramanian, R P............................... 1946 

Suda, M....................................... 515, 1490 

Sudowe, R............................................. 670 

Sugaya, C.............................................. 663 

Sugimoto, M......................................... 521 

Sugimoto, N........................................ 1194 

Sugita-Konishi, Y........... 1211, 1828, 2424 

Suguro, M............................................. 508 

Suh, H........................................1117, 1118 

Suh, K................................................... 762 

Sukamoto, T...................... 638, 1046, 1145 

Sukhija, H R............................1191, 1192* 

Sulentic, C E....................................... 1122 

Sulentic, C.............1121, 1123, 1124, 1125 

Sullivan, K...................... 470, 1527, 2129* 

Sullivan, N J....................................... 1784 

Sullivan, T.................................. 797, 1892 

Sultana, R........................................... 1460 

Summers, C........................................ 429* 

Sumner, S J......................................... 2202 

Sumner, S............................................ 2248 

Sun, B................................................. 117* 

Sun, G................................................. 2001 

Sun, H................................................. 2367 

Sun, J........................................ 1434, 1678 

Sun, Q................................................. 2323 

Sun, R................................................... 457 

Sun, X................................................... 798 

Sun, Y....................................... 265, 1993* 

Sun, Z................................................. 1102 

Sundell-Bergman, S............................ 2605 

Sung, J...................................... 1762, 1763 

Sunohara, A........................................... 521 

Sunouchi, M..................................... 1100* 

Suntres, Z............................................ 1269 

Suppiramaniam, V................................ 527 

Sura, R................................................ 2192 

Surh, I............................. 235*, 2275, 2644 

Sussan, T................................................... 5 

Suter, L.......................................... 441, 442 

Suter-Dick, L................................ 387, 426 

Sutherland, D S................................... 2070 

Sutherland, K.............................. 887, 2492 

Sutter, C H........................ 349*, 474, 1961 

Sutter, T R................................... 474, 1961 

Sutter, T................................................ 349 

Suva, L................................................ 1302 

Suzen, S.............................................. 1361 

Suzuki, O.............................................. 962 

Suzuki, S M........................................ 1692 

Suzuki, S........................... 232, 2200, 2633 

Suzuki, T................................... 1184, 1787 

Suzuki, Y............................................ 175* 

Sved, D..................................... 2257, 2258 

Svoboda, K K..................................... 2032 

Swanson, A......................................... 2543 

Swanson, B......................................... 1173 

Swanson, H......................................... 364* 

Swanson, M S....................................... 237 

Swartz, C.......................... 325, 1421, 1422 

Sweder, K........................................... 1412 

Sweeney, L M............... 736, 2294*, 2690* 

Sweeney, T D........................................ 775 

Swenberg, J A.......................... 1683, 1687, 

1690, 1691 

Swenberg, J........................................... 486 

Swenson, L J....................................... 1546 

Swift, B............................................... 1081 

Swiss, R.............. 1650, 1671, 2528, 2529* 

Swita, B N.......................................... 1466 

Switalla, S........................................... 960* 

Switzer, R C........................................ 1348 

Symington, S B................................... 1342 

Sysa Shah, P......................................... 214 

Szabo, D T........................................ 2248* 

T 

Ta, A.................................................... 2261 

Ta, T.................................................... 1771 

Tabb, D L.............................................. 128 

Tabe-Dumond, J................................. 2427 

Tabolt, G............................................... 662 

Tachiki, H............................................. 805 

Tachovsky, A....................................... 1542 

Tacou, R B............................................ 644 

Tafrova, J.............................................. 893 

Taguchi, K.......................................... 1787 

Taha, M................................................. 453 

Tahara, M............................................ 1194 

Tait, V..................................... 2456, 2461* 

Taiyeb, A M........................................ 533* 

Tajima, O............................................ 2424 

Takahashi, J S..................................... 1705 

Takahashi, J.......................................... 393 

Takahashi, K L.................................... 1062 

Takahashi, M.................. 627*, 1090, 2657 

Takahashi, T...................................... 1969* 

Takahashi, Y............................. 638, 1145* 

Takamune, M............................ 1403, 1404 

Takatani, H......................................... 2619 

Takeshita, H........................................ 1979 

Taketa, Y................................... 1090, 2657 

Takeuchi, Y........................................... 663 

Takeyoshi, M...................................... 1598 

Tal, T L....................................... 897*, 898 

Tal, T..................................................... 896 

Talcott, S M........................................ 2231 

Tam, K J................................................ 372 

Tamasi, J A.......................................... 2343 

Tan, C................................................... 723 

Tan, J................................................... 1343 

Tan, M............................................... 2002* 

Tan, W......................................... 696*, 697 

Tan, Y.......... 210*, 721, 1239*, 1294, 2693 

Tan, Z.................................................. 1850 

Tanabe, S............................................ 1979 

Tanaka, I............................................. 1177 

Tanaka, T............................................ 1404 

Tanaka-Kagawa, T................................ 412 

Taneva, E S....................................... 1653* 

Tang, H................................................. 143 

Tang, L.................. 984*, 1688, 2204, 2426 

Tang, S...................................... 113*, 2168 

Tang, Y.................................................. 812 

Tanguay, R L............ 897, 898, 1071, 1638, 

2626 

Tanguay, R.......................................... 1479 

Tanimoto, A................................ 638, 1046 

Tanneberger, K.................................... 2465 

Tannenbaum, L............................. 295, 296 

Tanos, R...................................... 360, 374* 



Tantisira, M H..................................... 1842 

Tao, J....................................................... 83 

Tao, S................................................ 1289* 

Tapanainen, M............................ 671, 672* 

Tappenden, D M......................... 127, 373* 

Tardif, R.................. 599, 1226, 1455, 2316 

Tartaro, K R...................................... 1149* 

Taschwer, M....................................... 1924 

Tashiro, C........................................... 2305 

Tashiro, T.............................................. 663 

Tateno, C............................................... 510 

Tateno-Mukaidani, C............................ 532 

Tatum-Gibbs, K R............................ 1625* 

Tatum-Gibbs, K.................................. 1622 

Taurin, S................................. 2634*, 2635 

Tavcar, R........................................... 1913* 

Taylor, A J..................... 1195, 2176, 2178* 

Taylor, A............................................... 577 

Taylor, J.............................................. 2417 

Taylor, K H........................................... 573 

Taylor, M A....................................... 2518* 

Taylor, M D............................ 2141*, 2459 

Taylor, M.............................................. 701 

Taylor, S................................................ 244 

Taylor, T N............................................ 182 

Tchao, R................................................ 422 

Tchounwou, P B................ 338, 1223, 1887 

Teaf, C.............................................. 1535* 

Teague, S V......................................... 1196 

Tedesco, B.......................................... 2510 

Teeguarden, J G............. 851*, 1457, 1475, 

1717*, 1943*, 2699 

Teeguarden, J.............................. 720, 2171 

Teissier, S.................................. 1554, 2513 

Tell, L A................................................ 710 

Tellew, J E............................................. 360 

Tellez-Plaza, M..................................... 767 

Téllez-Rojo, M M................................. 292 

Teng, Y.................................................. 670 

Tennant, A........................................... 1757 

Tenneson, K........................................ 519* 

Teodoro, J S........................................ 1087 

Teppen, B.............................................. 654 

Teramoto, S......................................... 1062 

Teranishi, M........................................ 1101 

Teraoka, H........................................ 1684* 

Terasaki, N............................................ 99* 

Terpstra, A........................................... 1646 

Terrell, A........................................... 1417* 

Terry, C............................. 223, 858*, 2107 

Terry, J................................................ 1489 

Terse, P................................................. 799 

Tesh, V L......................................... 34, 37* 

Tessema, T.......................................... 1260 

Tetz, L M.......................................... 1052* 

Teuschler, L K..................................... 2308 

Tewari-Singh, N..................... 1756*, 2040 

Tewfik, A............................................ 1770 

Tewksbury, E W.................................... 601 

Tezak, Z.............................................. 1369 

Thach, T D............................................ 787 

Thackaberry, E A................................ 790* 

Thai, S................................................. 2645 

Thakali, S............................................ 1952 

Thakkar, N............................................ 108 

Thakur, A K........................................ 490* 

Thakur, A.................................... 331, 1918 

Tham, K Y............................................ 402 

Thatcher, G R....................................... 227 

Thatcher, T H...................................... 2324 

The Federal Interagency, M................ 471* 

Thelander, G....................................... 1217 

Theunissen, P T.................................... 79* 

Thévenod, F.......................................... 241 

Thiagrarjan, G..................................... 2173 

Thiede, M................................. 1156, 1500 

Thiffeault, C.............................. 1142, 1412 

Thomas, D J.............. 232, 233, 1981, 2009 

Thomas, D M........................................ 592 

Thomas, F K....................................... 2227 

Thomas, H T......................................... 211 

Thomas, J.............................................. 952 

Thomas, K.......................................... 1068 

Thomas, L........................................... 1199 

Thomas, M.............................. 2512, 2515* 

Thomas, R S........ 51*, 127, 366, 373, 715, 

859, 1135, 1591, 1606 

Thomas, R.............. 134*, 821*, 962, 1567, 

1593, 2589 

Thomas, S................................... 935*, 983 

Thomas, T A....................................... 1244 

Thomas, T........................................... 1214 

Thomassen, L.............................. 850, 2062 

Thompson, B.......................................2111 

Thompson, C M.............. 1336, 1597, 2651 

Thompson, C.................... 916, 921, 1542* 

Thompson, D E................................. 1260* 

Thompson, D............................ 1050, 1689 

Thompson, J......................................... 345 

Thompson, K L................................... 1452 

Thompson, K.................................... 1426* 

Thompson, L C................................... 193* 

Thompson, M..................................... 1262 

Thompson, W..................................... 2252 

Thomsen, C......................................... 1636 

Thomson, S A..................................... 2011 

Thorne, P S............................... 1474, 1496 

Thornton, C................................. 942, 2546 

Thorsrud, B............................... 1040, 1617 

Thrall, B D.............. 851, 1457, 1475, 1488 

Thrall, B.............................................. 129* 

Thrall, K D.............................. 1248, 2577* 

Threadgill, D............................... 550, 2345 

Thuilliez, C......................................... 648* 

Thummel, K E...................................... 169 

Thuot, R.............................................. 1226 

Thurman, D................................. 742, 1602 

Tian, H.............................................. 1467* 

Tian, Y.................................... 945*, 2097* 

Tice, R R................... 482, 493, 1096, 2501 

Tice, R.................................................. 981 

Tichenor, S............................................ 788 

Tidwell, R............................................. 549 

Tie, Y................................ 140*, 142, 1811 

Tiernan, C......................................... 1400* 

Tierney, N........................................... 2555 

Tiesma, S.............................................. 559 

Tiesman, J P........................................ 1595 

Tiffany, S G........................................ 1695 

Tilton, S C............................... 1450*, 1638 

Tilton, S................................................ 897 

Timchalk, C.......... 703, 704, 2694*, 2699* 

Timme-Laragy, A R.................. 410*, 1776 

Timothy, L............................................ 342 

Tinfo, N.............................................. 2384 

Tinoco-Mendez, M............................... 593 

TInwell, H......................................... 2351* 

Tinwell, H............................................... 69 

Tipney, H............................................ 1084 

Tipper, J................................................ 539 

Tipple, T E.......................................... 2193 

Tjalkens, R B................................ 180, 399 

Tjalkens, R................................ 2129, 2664 

Tkach, A........................ 1189*, 1462, 2072 

Toal, B................................................ 1568 

Tober, K L........................................... 1784 

Tobia, A............................................... 2375 

Tobin, G.............................................. 2074 

Toborek, M........................ 212, 260, 1495, 

2180, 2250 

Tochigi, S.................................. 2080, 2083 

Todaka, E................ 621, 1225, 1573, 2200 

Todd, A C.............................................. 773 

Todd, A................................................. 768 

Todd, K L.................................. 1063, 1064 

Todor, I................................................. 104 

Todorov, M........................................... 464 

Tofighi, R............................................ 2622 

Tohyama, C......................................... 2606 

Tokar, E J.................................. 233, 2665* 




Tokar, E.......................... 272, 1155*, 1992, 

1993, 2662 

Tokumoto, M...................................... 770* 

Tolando, R.......................................... 1864 

Tolic, A............................................... 2171 

Tollerud, D J............................... 609, 2488 

Tolleson, W H............... 2414, 2432*, 2433 

Tolson, C B......................................... 142* 

Tomar, R S.......................................... 1967 

Tomazela, D........................................ 1692 

Tomczuk, M.......................................... 133 

Tomita, M............................................. 521 

Tomoo, T............................................. 1092 

Ton, T T................................................ 245 

Tong, W...................... 138, 427, 435, 934* 

Tonkin, E............................................ 775* 

Toole, C.................................. 2543, 2559* 

Topczewski, J..................................... 1778 

Topham, C.......................................... 317* 

Topinka, J........................................... 119* 

Torchalski, B......................................... 241 

Tornero-Velez, R........ 52*, 721, 723, 1239, 

2693 

Tornier, C.................................... 645, 646* 

Torous, D.......................................... 1416* 

Torres, J A........................................... 344* 

Torres-Aviles, N A...................... 403*, 686 

Torres-Sanchez, L............................... 1983 

Torti, V................................ 204, 793, 804* 

Toselli, P............................................... 219 

Tosti, L.................................................... 81 

Touart, L........................................... 2467* 

Townson, D........................................... 811 

Toy, J................................................... 1518 

Toyoda, Y.............................................. 428 

Toyoda-Hokaiwado, N.............. 1403, 1404 

Trager, R............................................... 751 

Trainer, M......................................... 1539* 

Tran, D.................................................. 778 

Tran, K B............................................ 2634 

Tran, L.............................................. 1803* 

Trang, P K........................................... 1979 

Trappe, S............................................. 1005 

Trask, J.................................................. 962 

Trask, O................................................ 29* 

Traum, T J........................................... 1517 

Treadway, J............................. 1197*, 2184 

Treas, J................................................ 106* 

Treat, K............................................... 2611 

Treinen, K A......................................... 790 

Tremblay, P....................................... 1694* 

Trempus, C........................................... 954 

Treumann, S.............................. 1458, 1798 

Trickler, W J........................... 1464*, 2627 

Trimble, A........................................... 2093 

Triplett, O A............................ 2432, 2433* 

Tritscher, A............................................ 882 

Trombetta, L D............... 1350, 1351, 2389 

Troncy, E........................... 562, 1919, 1921 

Tropsha, A............ 139, 143, 159, 465, 494, 

1486 

Trosko, J E.......................................... 2637 

Trouba, K.............................................. 790 

Trout, B R........................................... 180* 

Troxell, T.............................................. 882 

Truax, J............................................... 1521 

Truchon, G................................ 1455, 2487 

Trudel, L J........................................... 1408 

Trudel, L............................................. 2642 

Trump, S............................................. 1599 

Truong, L.......................................... 1479* 

Tsai, F C.............................................. 1967 

Tsaioun, K............... 935, 1889, 1903, 2280 

Tsaiprailis, G....................................... 1281 

Tsaneva, M........................................... 420 

Tsang, V............................................ 1987* 

Tschöp, M H......................................... 760 

Tseng, M T................................ 1460, 2065 

Tseng, Y............................................ 2114* 

Tsibul’skaya, E................................... 1543 

Tsuboi, I.............................................. 1154 

Tsuji, J S........................................... 1316* 

Tsuji, Y................................................ 2497 

Tsujimoto, Y....................................... 2637 

Tsukui, T............................................... 428 

Tsu-Ming, C................................ 725, 1604 

Tsumura, A.......................................... 1196 

Tsuneyama, K....................................... 428 

Tsunoda, M......................................... 663* 

Tsunoda, S........... 1494, 2080, 2083, 2084, 

2085 

Tsuruda, L..................................... 791, 801 

Tsusaki, H.............1060, 1061, 1143, 1144, 

1146, 1147, 1445 

Tsutsumi, H................................... 508, 521 

Tsutsumi, Y.......... 1494, 2080, 2083, 2084, 

2085 

Tukey, R H.................................... 385, 386 

Tumer, N......................................... 34, 39* 

Tuomela, S.......................................... 2052 

Tupper, E.............................................. 254 

Turcan, R.............................................. 807 

Turcot, A............................................. 1226 

Turk, J R........................................... 2670* 

Turkel, D J......... 1379*, 1380, 1381, 1382, 

2133 

Turner, J.............................................. 1354 

Turney, T W........................................ 2179 

Turteltaub, K......... 1308, 2043, 2044, 2056 

Tveria, L............................................... 891 

Tverya, L............................................ 2013 

Twaddle, N C........................................ 708 

Twamley, M........................................ 1427 

Twiner, M..................... 2225, 2226, 2402* 

Tymiak, A........................................... 1230 

Tyner, K M.................................. 994, 2074 

Tyurin, V A....................................... 1669* 

Tyurin, V............................................. 1179 

Tyurina, Y Y........................................ 1669 

Tyurina, Y......................................... 1179* 

Tzan, K............................................. 2323* 

U 

Uchida, K............................................ 1177 

Udasin, R G...................................... 1292* 

Uehara, T.................... 139, 247, 447*, 944 

Uematsu, Y......................................... 321* 

Ueng, T................................................. 588 

Uetrecht, J P...................... 424, 1501, 1506 

Uetrecht, J.................. 434, 509, 536, 1499, 

1502, 1503*, 1504, 1505, 2686* 

Uetrecth, J............................................. 423 

Uheida, A............................................ 2072 

Uhlen, P.............................................. 2622 

Uhlik, M............................................... 202 

Uhlirova, K........................................... 119 

Uitvlugt, E.......................................... 2613 

Uji, M....................................... 2080, 2083 

Ukai, N............................................... 1684 

Ullerås, E.................................. 1610, 2352 

Ulrich, E............................................... 721 

Ulrichts, H............................................ 809 

Umbright, C........................................ 2318 

Umemura, T........................................ 1403 

Unice, K.............................................. 1263 

Unrine, J M............................... 1460, 2065 

Unterreiner, D....................................... 636 

Upham, B L........................................ 2637 

Uppu, R M........... 1299, 1307, 2256, 2329, 

2336 

Uppu, S N........................................... 2256 

Upton, P.................................... 1687, 1691 

Urakawa, C......................................... 1062 

Urano, K..................................... 508*, 521 

Urban, J D............................... 1261*, 1365 

Urban, J............................................... 1693 

Urban, L A.......................................... 853* 

Urban, P.............................................. 1859 

Uribe-Ramirez, M............. 593, 2172, 2495 

Ursic, B M.......................................... 2018 

Urushidani, T........................ 124, 139, 436 



Usenko, C Y...................................... 1607* 

Uski, O................................................ 671* 

Uteng, M..................................... 430, 2537 

Utsunomiya, S...................................... 638 

V 

v. Landenberg, F....................... 743, 1590* 

Vahter, M............................................ 1985 

Vaidya, V S................................... 744, 765 

Vaillancourt, R R................................ 2000 

Vajdos, J.............................................. 1156 

Valberg, P A............................ 1472*, 1935 

Valcke, M.................................... 500, 501* 

Valdés-Arzate, A................................. 593* 

Valdovinos, C..................................... 462* 

Valencia, A............................................ 146 

Valentin, J................ 148, 201, 1897, 1909, 

1912, 1915 

Valentin-Blasini, L...................... 702, 2608 

Valentine, J......................................... 1230 

Valentine, Z......................................... 1342 

Valentovic, M............................. 461, 741* 

Valenzuela-Quintanar, A I................... 2119 

Valerio, L G...................... 137, 146*, 1812 

Valiyaveettil, M................................ 2024* 

Vallanat, B............................................ 604 

Vallant, M K................... 1593, 2234, 2374 

Vallenti, T W......................................... 964 

Vallero, R O........................................ 1771 

van Bavel, B......... 1200, 1202, 1221, 2244 

Van Beneden, R J................................ 1745 

Van Bilsen, J H....................................... 89 

van de Sandt, J J................................... 991 

van de Water, B............................ 409, 431, 

1586, 2652* 

Van De Wiele, T.................................. 2572 

van Delft, J H........................................ 611 

van Delft, J................................ 1585, 1586 

van den Berg, J................................... 1222 

van den Berg, M............ 1139, 1834, 2354, 

2355, 2361, 2547 

van den Brink, J.................................. 2516 

van der Burg, B................................... 1213 

van der Harst, J E.................................. 780 

van der Veen, J.................................. 1011* 

van Duursen, M B............................... 2547 

van Duursen, M............. 1139, 1834, 2354, 

2355, 2361* 

van Ede, K........................................ 2355* 

van Esch, B C....................................... 89* 

Van Goethem, F.................................. 1895 

Van Gompel, J.................................... 1895 

van Leeuwen, E M.............................. 2561 

van Loveren, H....................611, 695, 1011 

Van Metre, P C.................................... 1229 

van Mierlo, G J........................1150*, 1151 

van Mierlo, G........................................ 630 

van Ravenzwaay, B....... 82, 224, 640, 644, 

724*, 971, 1002, 1004, 1005, 1007, 1008*, 

1020, 1440, 1458, 1468, 1469, 1562, 1798, 

2095, 2353, 2550 

Van Rozendaal, B................................. 195 

van Schayck, C P................................ 1363 

van Schooten, F J........................ 616, 1363 

Van Shura, K E................................... 2015 

van Someren, E................................... 1585 

van Swelm, R P.................................. 463* 

Van Tassell, R..................................... 2576 

van Thriel, C....................................... 1575 

van Triel, J............................................ 84* 

Van Tuyl, A........................................... 791 

van Velsen, F....................................... 622* 

van Vugt, M A..................................... 1413 

van Wezel, A P.................................... 2348 

Van Wijk, H...................................... 1917* 

Van Winkle, L S............... 580, 884*, 887*, 

1196, 2492* 

Van Winkle, L.......... 582, 888, 1635, 1832, 

1849 

Van Wjingaarden, E............................ 1205 

Van Zomeren-Dohm, A....................... 1216 

Vandebriel, R...................................... 1011 

Vanden Heuvel, J.................................. 345 

VanderZanden, M................................. 647 

VandeVoort, C..................................... 1635 

Vandjelovic, N.................................... 1303 

VanDuyn, N.............................. 179, 1396* 

Vanhaecke, T...................................... 1656 

Vanhees, K.......................................... 616* 

Vanlandingham, M............................... 708 

Vanoirbeek, J........................................ 681 

Vant Hof, W........................................ 1160 

Vanwelkenhuysen, I.............................. 622 

Vardy, A................................................ 223 

Varela, A T.......................................... 1087 

Vargas, H M.................................. 184, 778 

Vargesson, N....................................... 839* 

Varma, R............................................. 1757 

Varner, K J............................................ 188 

Vasa, S.................................................. 151 

Vasanthakumari, V.............................. 221* 

Vasiliou, V...................... 1171, 1276, 1879 

Vassallo, J D..................................... 1451* 

Vassallo, J............................................. 523 

Vasudevan, C...................................... 2540 

Vaughan, J M.................................... 1259* 

Vaughan, J........................................... 1235 

Vazquez-Martin, C................................ 970 

vd Horst, L................................ 1640, 2613 

Vedamurthy, R.......................... 1552, 1574 

Vedar, M............................................. 1237 

Veenstra, S.......................................... 1027 

Vega, H H........................................... 2241 

Vega, H..................................... 1680, 2118 

Veggi, A B........................................... 1484 

Veillon, A............................................ 2356 

Vekich, S............................................... 517 

Velasco-Rodriguez, V......................... 1203 

Velazquez, J........................................ 2393 

Veldman, G M...................................... 796 

Velez, E............................................... 678* 

Velten, M............................................ 2193 

Venkatakrishnan, P........................... 1295* 

Vera-Aguilar, E................................... 2495 

Veranth, J M.............................. 2333, 2334 

Verbeek, R P....................................... 1413 

Verda, D.............................................. 1010 

Verhoef, A............................................... 71 

Vernez, D............................................ 2278 

Veronesi, B....................................... 1757* 

Verwei, M............................................. 991 

Vetrano, A........................................... 1058 

Vette, A............................................... 1215 

Veverka, K................................ 1911, 1916 

Vezina, C M.............................. 1624, 1626 

Vézina, M............................. 519, 520, 524 

Viau, C................................................ 1226 

Viberg, H................................ 2599*, 2604 

Vickers, A................................. 1766, 1907 

Vidal, V............................................. 1384* 

Viereck, M.............................................. 67 

Viet, P H............................................. 1979 

Vieyra-Lobato, M R.............................. 270 

Vigoren, E M.......................................2111 

Vij, P................................................... 302* 

Vijay, V....................................... 427*, 435 

Vikholm, K......................................... 1610 

Vikrant, V............................................. 934 

Vilanova, E............................... 979, 2101* 

Vilavert, L......................................... 1245* 

Villa, S................................................ 1231 

Villa-Bellosta, R................................. 2170 

Villalobos, S A.................................. 2464* 

Villanueva, L R................................... 1622 

Villeneuve, D L................. 19, 2339, 2463* 

Villeneuve, D.................... 730, 2368, 2466 

Viluksela, M....................................... 2369 

Vincent, H........................................... 2356 

Vincent, L........................................... 1541 

Vinken, M......................................... 1656* 

Violi, A................................................ 2161 

Author Index 


383


Author Index 


Virgolini, M...................................... 2147* 

Visan, A................................................... 75 

Vissinga, C............................................ 778 

Vitsky, A............................................. 1427 

Vladykovskaya, E N................... 190, 262* 

Vlasseros, F.............................. 1911, 1916 

Voelkner, W.......................................... 326 

Vogel, C............................................ 1130* 

Vogel, S............................................. 1020* 

Vögelin, D............................................ 316 

Vohr, H...................................... 1013, 1412 

Voitenko, N......................................... 2047 

Volarath, P................................... 141*, 714 

Volger, O L......................................... 695* 

Volland, J................................................ 75 

Vollrath, A........................................... 1705 

Volpe, D A........................................... 2347 

Volz, D C.................................. 1634, 2463 

Volz, D................................................ 2462 

von Mandach, U................................. 2169 

von Stechow, L................................... 2652 

von Stein, R T................................... 1353* 

Vonderfecht, S...................................... 244 

vonKienlin, M..................................... 1423 

VonTungeln, L.................................... 2420 

Vorrink, S U........................................ 1496 

Vose, J................................................... 880 

Voss, K A.......................................... 2153* 

Vrabel, M.............................................. 497 

Vrana, J............................. 400, 2314, 2315 

Vrieling, H................................ 1586, 2652 

Vuillemenot, B.................................... 801* 

Vulimiri, S V......... 1273, 1934, 1946, 2301 

Vulpe, C D.......................................... 2558 

Vulpe, C............................ 134, 817*, 2253 

Vuong, D............................................. 1432 

Vyskocil, A.......................................... 1226 

W 

W.M. Kwong, R.................................... 311 

Waalkes, M P.................... 266, 2502, 2665 

Waalkes, M.............. 233*, 265, 272, 1155, 

1987, 1992, 1993 

Wachsmuth, L..................................... 1322 

Wacksman, M..................................... 1572 

Wada, H.............................................. 1618 

Wada, T................................................. 376 

Wade, M.............................................. 1533 

Wagena, E J........................................ 1363 

Wages, P........................................... 2093* 

Wagner, G C......................................... 537 

Wagner, H......................... 978, 2543, 2559 

Wagner, J G...................................... 2494* 

Wagner, J.................... 1463, 2474*, 2478* 

Wagner, S M............................. 2197, 2198 

Wagner, S.............................................. 998 

Wagner, T............................................ 1340 

Wagoner, M P................................... 1602* 

Waidyanatha, S.............. 337, 2275*, 2276, 

2320, 2644 

Waikar, S............................................... 744 

Waissmann, W.................................. 1484* 

Walderhaug, M O................................. 726 

Waldmann, C...................................... 2060 

Wales, M E......................................... 2048 

Walgren, J........................................... 1902 

Walinchus, L................... 2145, 2146, 2150 

Walisser, J A........................................ 1705 

Walisser, J............................................. 393 

Walk, T................... 724, 1440, 1562, 2353 

Walker, L A........................................... 968 

Walker, M K............................... 199*, 554 

Walker, N J............. 245, 848*, 2067, 2627 

Walker, N.............................................. 719 

Walker, P......................... 935, 1889*, 1903 

Walker, R............................................ 2392 

Walker, S A......................................... 2403 

Walker, V............................................ 1687 

Wall, H G.............................................. 601 

Wallace, A D..................................... 2096* 

Wallace, B........................ 978, 2392, 2543, 

2544, 2559 

Wallace, K................................ 2159, 2645 

Wallace, W.................................... 303, 304 

Walmsley, R.............................. 317, 1414* 

Walsh, J............................................... 2500 

Walsh, M T........................................... 554 

Walter, M.............................................. 289 

Walter-Rohde, S.................................. 2380 

Walters, D M....................................... 1186 

Walters, E............................................ 2398 

Walters, R........................................... 2555 

Walton, J............................................. 1516 

Waltz, M J......................................... 2160* 

Waltz, M............................................. 2072 

Wambaugh, J F............... 715, 733*, 2693* 

Wambaugh, J................................ 728, 937 

Wan, L................................................... 893 

Wan, R...................................... 609*, 2488 

Wan, W............................................... 2306 

Wan, Y................................................ 1185 

Wanda, B.............................................. 950 

Wang, A......................... 714, 1049, 1760*, 

2156, 2323 

Wang, B.......................... 313, 1854*, 2249 

Wang, C................ 776, 1661, 2596, 2597* 

Wang, F............................................. 2204* 

Wang, G.......................... 390, 808*, 1510* 

Wang, H...................... 3*, 164, 1485, 2365 

Wang, J D............................... 2026*, 2030 

Wang, J...... 76*, 112, 390*, 528, 530, 984, 

1286, 1303, 1510, 1688, 1896, 2204, 2426 

Wang, K W......................................... 1443 

Wang, K.................................... 1209, 1854 

Wang, L.56, 110*, 541*, 1181, 1182, 1183, 

1187, 1188, 1668, 1856, 2587 

Wang, M............................................... 549 

Wang, N Y........................................ 1965* 

Wang, R........... 68, 515*, 700, 1359, 1490, 

2339 

Wang, S........................... 1053, 1120, 2367 

Wang, T........................... 430, 1092, 1603* 

Wang, W................ 97, 1036*, 1037, 1173, 

1457, 1475, 2056 

Wang, X............. 350*, 1053, 1815*, 2344, 

2367* 

Wang, Y........... 162, 163*, 239, 360, 1292, 

1752*, 1953, 2585*, 2632* 

Wang, Z.................................... 314*, 1082 

Waraich, N K...................................... 2027 

Ward, A B........................................... 1325 

Ward, C............................................. 1198* 

Ward, R............................................... 1520 

Ward, T............................................... 1127 

Wareing, B............................................ 644 

Warheit, D B................ 566*, 847*, 1801*, 

2162, 2504* 

Warheit, D......................................... 1797* 

Warisnoicharoen, W........................... 1842 

Warner, M............................................. 709 

Warren, S............................................ 2275 

Warren, T.............1143, 1144, 1147, 1445* 

Wasaki, M........................................... 2619 

Washburn, L L...................................... 133 

Washburn, W N.................................. 2343 

Wason, S C......................................... 864* 

Wason, S............................................. 2646 

Watanabe, F........................................ 2077 

Watanabe, K H........................................ 19 

Watanabe, K.......................................... 730 

Watari, T............................................... 246 

Waters, K M............. 129, 404, 1283, 1284, 

1450, 1457, 1638, 1717 

Waters, K.............................................. 897 

Watkins, A M.................................... 1609* 

Watkins, J B........................................ 2404 

Watkins, P B....................... 440, 940, 1735 

Watkins, P............................................. 549 

Watkins, R W.............................. 782, 783* 

Watoson, R.......................................... 1061 



Watson, D E................................ 202, 1443 

Watson, R E...................................... 1050* 

Watson, S.................................... 812, 2320 

Watson, W........................................... 255* 

Wattanawaraporn, R........................... 2642 

Wayman, G......................................... 2623 

Weaver, V........................... 767*, 768, 773 

Weaver, Y M....................................... 2247 

Webb-Robertson, B....... 129, 1283, 1284*, 

1287, 1450, 1488 

Weber, D........................................... 2143* 

Weber, G J.................... 1747, 2090*, 2142 

Weber, K............................................... 289 

Weber, L P........................................... 186* 

Weber, O..................................... 430, 1107 

Weber, T J........................................... 404* 

Weber, W M............................ 1754*, 2291 

Weber, W.................................. 2019, 2050 

Weddle, D............................................. 507 

Weeks, J.............................................. 2379 

Wegener, A J....................................... 2025 

Wegerski, C J...................................... 2277 

Wegerski, C...................................... 1822* 

Wegrzyn, J.......................................... 1321 

Wegrzynowicz, M................... 2121, 2132* 

Wehmas, L.......................................... 2368 

Wei, B................................................... 238 

Wei, K H............................................. 2136 

Wei, K................................................. 1894 

Wei, W............................ 414*, 1466, 2499 

Wei, X................................................. 2138 

Wei, Y................... 582, 1852, 1999*, 2585 

Weig, B C......................................... 1375* 

Weihe, P.............................................. 1391 

Weil, R E........................................... 2357* 

Weinbauer, G........................ 556, 557, 622 

Weinhold, R S..................................... 1567 

Weinhouse, C........................................ 100 

Weinman, S A....................................... 451 

Weinman, S........................................... 447 

Weinstein, E J....................................... 535 

Weir-Hauptman, A M.............................. 72 

Weis, C................................................ 2174 

Weisel, C P............................................ 108 

Weisenburger, D D............................... 880 

Weisensee, D...................................... 998* 

Weiser, T...................... 152, 215, 316, 387, 

426, 441, 442, 784, 1159, 1163, 1164, 

1165, 1814 

Weiss, B.............................................. 923* 

Weisskopf, M G.................................. 1686 

Weissmann, D................................... 1541* 

Welbers, A........................................... 1232 

Welch, K........................................... 2229* 

Weldon, R H......................................... 337 

Weldy, C S.......................................... 1193 

Weldy, C........................................... 2328* 

Weller, P.................................... 1412, 1416 

Weller, R E.......................................... 2577 

Wels, B................................................ 1103 

Welsh, C................................................ 731 

Wen, X...................................... 740*, 1047 

Wen, Z................................................ 2596 

Wenck, H.............................................. 967 

Weng, C.................................................. 63 

Weng, Z.................................... 515, 1359* 

Wennerberg, L...................................... 940 

Werder, R.............................................. 316 

Werre, S.............................................. 2576 

Wessling, F......................................... 2158 

West, L................................................ 2039 

West, P R................................................ 72 

Westbrook, A M.................................. 238* 

Weston, D........................................... 2151 

Westra, I M....................................... 2509* 

Wetmore, B A..................................... 715* 

Wexler, A S......................................... 2331 

Wexler, P............. 419, 1310*, 1875*, 1880 

Whalan, J E....................................... 2301* 

Whalan, J.................................. 1220, 1946 

Whalley, C E..................................... 2012* 

Wheeler, C............................................ 280 

Wheeler, J S.......................................... 731 

Wheeler, J........................................... 2467 

Wheeling, C........................................ 2039 

Whelan, M.................................. 420, 2510 

White Jr, K L.......................................... 98 

White, C A................................ 1817, 2283 

White, C C................................ 1193, 2328 

White, C W............................... 1756, 2040 

White, C.............................................. 1465 

White, G............................................. 1548 

White, K L.............................. 80, 653, 655 

White, K N............................................ 297 

White, L A................. 873, 976, 2363, 2548 

White, P D...................... 475*, 1273, 2287 

White, S S................................. 1089, 1622 

Whitebread, S....................................... 853 

Whitelegge, J P..................................... 408 

Whiting, P........................................... 1310 

Whitten, K A............................. 1755, 2015 

Whittingham, A..................................... 996 

Whritenour, J...................... 7, 1497, 1500* 

Wible, R................................................ 349 

Wick, P................ 2052, 2060, 2158, 2169* 

Wickham, T J...................................... 1888 

Wickliffe, J K...................................... 1360 

Wicklow, D T...................................... 2428 

Wickramasinghe, N S........................... 262 

Wickstrom, M............................. 526, 2566 

Wiecinski, P N.................................. 2165* 

Wiegers, T C......................................... 130 

Wiemann, C........................................ 224* 

Wiemann, M....................................... 1458 

Wiemer, J................ 724, 1440, 1562, 2353 

Wiench, B........................................... 1002 

Wiench, K..................... 1468*, 1469, 1798 

Wierenga, L........................................ 2039 

Wiese, J................................................. 983 

Wiesenfeld, P...................................... 1577 

Wiesner, M R...................................... 1176 

Wijeyesakere, S J...................... 162, 1336* 

Wijnolts, F.......................................... 2354 

Wilbois, W.......................................... 1232 

Wild, C P..................................... 42*, 832* 

Wild, J R............................................. 2048 

Wildt, S J............................................ 511* 

Wilga, P C........................................... 2543 

Wiliams, G M....................................... 972 

Wilke, A................................ 1804*, 1807* 

Wilkerson, H....................................... 2328 

Wilkerson, J........................................ 1193 

Wilkins, D G....................................... 1695 

Will, Y.......... 147, 1650, 1671, 1910, 2525, 

2528, 2529, 2530, 2531, 2532, 2533 

Willard, P A......................................... 1557 

Willard, P........................................ 58, 575 

Willet, C.............................................. 1527 

Willett, C............................................ 2467 

Willett, K L................................. 942, 2546 

Willhite, C C....................................... 1536 

Williams, A K....................................... 319 

Williams, A......................................... 2489 

Williams, C A................................... 1936* 

Williams, C D............................. 450, 452* 

Williams, C J............................ 2197, 2198 

Williams, C M...................................... 314 

Williams, C........................................... 453 

Williams, D E....................................... 699 

Williams, D J...................................... 1569 

Williams, E S.................................... 1229* 

Williams, F M................... 114, 2071, 2266 

Williams, G M.......................... 1018, 2630 

Williams, G T..................................... 1673 

Williams, G........................................... 486 

Williams, H............... 400, 401, 2314, 2315 

Williams, J G.................................... 1018* 

Williams, J H...................................... 1688 

Williams, J L......................................... 359 

Williams, L R............................ 736, 1544* 




Williams, L....................................... 1675* 

Williams, M A..................................... 673* 

Williams, N......................................... 2171 

Williams, P L........................................ 984 

Williams, R................... 1215, 1438, 1615* 

Williams, S................................... 295, 296 

Willis, D N.......................................... 574* 

Willoughby, J...................................... 2544 

Wills, L P............................................ 751* 

Wills, L................................................. 318 

Wills, R............................................... 2113 

Willson, G A............................... 601, 1951 

Willy, J A.......................................... 1902* 

Wilson, A............................................ 727* 

Wilson, C L......................................... 1224 

Wilson, C R........................................ 2428 

Wilson, C.......................................... 2223* 

Wilson, D.................................. 1322, 1517 

Wilson, H.............................................. 955 

Wilson, M J....................................... 1419* 

Wilson, M......................................... 2415* 

Wilson, N............................................ 1572 

Wilson, V S............. 16*, 1023, 2303, 2663 

Wilson, V............................................ 1022 

Wilt, N............................ 1551, 2555, 2564 

Wiltshire, T......................................... 962* 

Wimmer, J........................................... 1233 

Winans, B............................... 2662, 2666* 

Wincent, E.............................. 1839, 1845* 

Wind, M........................... 418, 1518, 1519, 

1520, 1553 

Winder, B S......................................... 2088 

Wingard, C J............................... 193, 1186 

Wingfield, M...................................... 1233 

Winitthana, T...................................... 1842 

Winnik, W........................................... 2159 

Winsett, D W........................ 570, 607, 608 

Winters, J.............................................. 323 

Wiriyachan, N..................................... 2638 

Wirth, J R............................................ 658* 

Wirth, M............................................... 745 

Wise Jr., J P......................................... 280* 

Wise Sr., J P.......................................... 280 

Wise, A................................................ 2360 

Wise, C F................................ 2342*, 2392 

Wise, J P.............. 278, 279, 282, 303, 304, 

1870, 2164, 2341, 2342, 2342, 2392, 2392, 

2405, 2407 

Wise, J............................ 303, 2341*, 2392 

Wise, K............................................... 1957 

Wise, S S............................ 278, 279, 2342, 

2392*, 2405 

Wise, S...................................... 2341, 2407 

Wise, Sr., J P....................................... 2252 

Wisler, J.............................................. 244* 

Witriol, A M........................................ 1755 

Witt, K L............................. 323, 493, 2501 

Wittern, K............................................. 967 

Witzmann, F A........................................ 10 

Wiwatratana, D................................... 1344 

Wnek, S M.............................. 1677, 1976* 

Wogan, G N.............................. 1408, 2642 

Wohlleben, W........................... 1458, 1798 

Wohlman, I M................................... 2028* 

Wolansky, M J................ 1227, 1346, 2262 

Wolf, A............................. 430, 1092, 1107, 

1436, 1603, 1766*, 2537 

Wolf, C J................................. 2240*, 2306 

Wolf, D C................................ 1718*, 2645 

Wolf, D................................................. 367 

Wolf, M................................................. 158 

Wolfarth, M G............................. 53*, 1454 

Wolfarth, M.....................1178, 1185, 2325 

Wolfinger, R D............................ 725, 1604 

Wolterbeek, A........................... 630*, 2613 

Wolthoorn, J...............................1150, 1151 

Womack, T L...................................... 2653 

Wong, B A............. 290, 1570*, 1953, 1954 

Wong, J............................................... 118* 

Wong, S................................................ 775 

Wong, V A............................................ 601 

Woo, L L........................................... 2642* 

Wood, A...................................... 223, 2639 

Wood, C R................................ 1609, 2239 

Wood, J............................................. 1438* 

Woodahl, E L...................................... 2265 

Woodin, B........................................... 1840 

Woodruff, R S..................................... 2077 

Woodruff, T J...................................... 2360 

Woods, C G..................... 366*, 2001, 2502 

Woods, J S.......................................... 610* 

Woods, R............................................ 1771 

Woods, S E......................................... 2582 

Woodward, A...................................... 2589 

Woodward, R A................................... 2656 

Worden, M.......................................... 1463 

Workman, H C................ 536*, 1502, 1503 

Worley, R R.......................................... 731 

Wormser, U............................. 1207, 2205* 

Worth, A................................................ 483 

Wourms, M J..................................... 1121* 

Wouters, D.......................................... 1150 

Woutersen, R A..................................... 991 

Wrench, N............................... 1022, 1023* 

Wright, D.............................................1115 

Wright, F............................................... 981 

Wright, J M......................................... 1810 

Wright, J........ 874, 875, 1030, 1589, 2266, 

2616* 

Wright, P F........................................ 2179* 

Wright, R............................................ 1238 

Wrobel, J............................................... 260 

Wruck, C J.......................................... 1002 

Wu, A.......................................... 542, 1427 

Wu, C...................................... 1485*, 2177 

Wu, D.................................................. 1130 

Wu, F.................................................. 2153 

Wu, H.................................. 299, 300, 1665 

Wu, J..................................................... 118 

Wu, K C............................................ 2503* 

Wu, M................................................. 992* 

Wu, N........................................ 1178, 1454 

Wu, P........................................ 1460, 2065 

Wu, Q.......... 301*, 379*, 2004, 2005, 2006 

Wu, T.......................................... 413, 1997 

Wu, X................................................ 1830* 

Wu, Y.................................................. 1234 

Wu, Z.................................................. 1459 

Wurzburger, L................................... 2564* 

Wyde, M E.......................................... 2234 

Wyde, M............................................. 2627 

Wynder, J.......................................... 2371* 

Wynne, R............................................ 1302 

Wyrobek, A J........................................ 337 

X 

Xanthi, C............................................. 1856 

Xi, C................................................... 2563 

Xia, M......................... 482, 493, 981, 2501 

Xia, Q..................................................... 67 

Xia, X............................1174*, 1176, 2154 

Xia, Y................................ 76, 1053*, 2367 

Xiang, Z................................................ 558 

Xiangrong, L....................................... 2231 

Xiao, R.............................................. 1627* 

Xiao, S................................................ 1025 

Xiao, Y Q............................................ 1929 

Xie, F................................ 538, 582, 2319* 

Xie, G................................................. 2148 

Xie, H............ 279, 303, 304, 2164*, 2341, 

2342, 2405 

Xie, J................................................... 1224 

Xie, R.................................................. 1672 

Xie, W................................................. 376* 

Xie, Y................................................ 2171* 

Xing, C................................................. 337 

Xiong, J Q................................. 1067, 2057 

Xu, B..................................................... 200 

Xu, F................................................... 1904 

Xu, H.................................................. 1561 



Xu, J............. 133, 414, 1079, 1862, 2139*, 

2140, 2270, 2499, 2586*, 2592 

Xu, L......................................... 2074, 2367 

Xu, P................................................... 1199 

Xu, X................................ 987, 2323, 2344 

Xu, Y... 206, 214*, 331, 342*, 1918, 1992* 

Xue, P..................................... 2001*, 2502 

Xue, S......................... 183, 209, 984, 2204 

Y 

Yacovino, L....................................... 1058* 

Yadav, A.............................................. 2335 

Yadav, B D.............................. 2634, 2635* 

Yafawi, R...................................... 528, 530 

Yagi, M................................................. 649 

Yahata, Y............................................. 1211 

Yakabe, Y............................................ 1598 

Yalcin, M............................................ 1389 

Yamada, H............................ 124, 139, 436 

Yamada, K E....................................... 408* 

Yamada, M................................ 1403, 1404 

Yamada, T............................. 321, 425, 436 

Yamada, Y............................................. 175 

Yamaguchi, T........................................ 175 

Yamamoto, C........................................ 412 

Yamamoto, M.................412, 1113, 1787*, 

2499, 2586 

Yamamoto, S........................................ 687 

Yamamoto, T...................................... 2619 

Yamashita, K................. 1494, 2084, 2085* 

Yamazaki, K....................................... 1547 

Yamazaki, M......................................... 438 

Yamazaki, S.......................................... 804 

Yamazoe, Y........................................... 532 

Yan, C....................................... 626, 1663* 

Yan, J............................ 1429, 2004, 2077* 

Yan, S.................................................. 2365 

Yan, Y................................................. 1775 

Yan, Z............................................... 2089* 

Yanagiba, Y................................. 515, 1490 

Yanamala, N........................................... 54 

Yang, C Z.................................. 624, 2429* 

Yang, C...................... 155, 158, 469*, 492, 

495, 1016 

Yang, D................................... 2623, 2624* 

Yang, F...................................... 478*, 2136 

Yang, G................................................. 377 

Yang, H M.......................................... 2307 

Yang, H................... 370, 589, 1449, 1480* 

Yang, J................. 684*, 987*, 1294, 1890, 

2209, 2218, 2525, 2536 

Yang, L.................... 127, 880*, 2039, 2220 

Yang, Q............................................... 381* 

Yang, S........................ 1399*, 1461, 1483* 

Yang, T................................................ 1166 

Yang, W...................................... 230, 2073 

Yang, X.................. 432, 454*, 1561, 1678, 

1847, 2174 

Yang, Y........ 299, 300, 479, 589, 876, 940, 

941*, 1592, 1665*, 1735, 1853, 1900 

Yaniger, S.............................................. 624 

Yano, T................................................ 1969 

Yanochko, G....................................... 1821 

Yanova, N............................................. 104 

Yao, P.................................... 66*, 70, 1657 

Yao, Y............................... 207, 230*, 2073 

Yaqoob, N........................................... 1685 

Yarborough, K M.................................. 366 

Yassine, H N....................................... 1281 

Yasuda, M............................................. 508 

Yasui, K............................................ 1571* 

Yasui, Y............................................... 1404 

Yasutake, A........................................... 266 

Ye, L.................................................... 492* 

Ye, X................................................. 1025* 

Yeager, R.................................... 507*, 518 

Yeatts, J................................................. 642 

Yedjou, C G.................... 338, 1223, 1887* 

Yellowhair, M..................................... 283* 

Yen, C............... 299, 300, 307, 1393, 1998 

Yeow, A............................................... 2009 

Yesupriya, A........................................ 1204 

Yi, J..................................................... 1471 

Yin, Z................................................ 2636* 

Ying, X............................................... 1322 

Yli-Pirilä, P........................................... 672 

Yokel, R A............................... 1460*, 2065 

Yokley, K A......................................... 2307 

Yokohira, M.............................. 232*, 2646 

Yokoi, T............................ 428*, 510, 2079 

Yong, K Y........................................... 1274 

Yoo, S................... 1825, 1826, 1827, 1844 

Yoon, H............................................... 1016 

Yoon, M.................. 701*, 941, 2141, 2459 

Yoshida, M........................ 627, 1090, 2657 

Yoshida, T............. 902, 907*, 2080*, 2083 

Yoshida, Y........................................... 1177 

Yoshikawa, T....... 1494, 2080, 2083, 2084, 

2085 

Yoshikawa, Y........................................ 428 

Yoshioka, N...................................... 2302* 

Yoshioka, Y..... 1494*, 2080, 2083, 2084, 2 

085 

Yost, G S............... 886*, 1848, 2333, 2334 

You, C H............................................. 1256 

Young, D............................................. 2245 

Young, J................................................ 969 

Young, M.......................................... 1368* 

Young, S H........... 1189, 1462, 1492, 2072 

Young, S.......... 337, 659, 670, 1459, 1759, 

2318, 2325* 

Younis, H S......................................... 216* 

Yourick, D...................... 2020, 2037, 2039 

Yourick, J J......................................... 890* 

Yu, H......................................... 588*, 1561 

Yu, I........................................ 1762*, 1763 

Yu, J C.................................... 1689*, 2046 

Yu, L............................... 995, 1070, 1291* 

Yu, S D................................................ 1256 

Yu, S..................................................... 628 

Yu, X..........................................2111, 2520 

Yu, Y................................................... 2128 

Yu,......................................................... 553 

Yuan, J.................................... 1364*, 2697 

Yuan, Y..................................... 1344, 1397 

Yucesoy, B.................................. 97, 1367* 

Yudate, H T........................................... 436 

Yum, Y.............................................. 2536* 

Yun, H..................................... 2054, 2208* 

Yurdagul, A......................................... 1320 

Yuspa, S H........................................ 1781* 

Z 

Zablotsky, J........................................... 931 

Zacharewski, T R............917*, 1039, 1115, 

1584, 1597, 2305, 2549 

Zacur, H.............................................. 1219 

Zadworny, M...................................... 1465 

Zaffo, B J................................ 1388, 1389* 

Zahalka, E A....................................... 2654 

Zahran, E............................................ 2250 

Zaikova, T........................................... 1479 

Zaja-Milatovic, S................................ 2128 

Zakeri, Z............................................. 1272 

Zakharov, A D..................................... 1885 

Zaldívar Comenges, J........................... 733 

Zalups, R K........................................... 761 

Zamurovic, N...................................... 1436 

Zandbergen, F J................................ 2366* 

Zandstra, P.......................................... 1888 

Zangar, R.......................................... 1287* 

Zanoncelli, S....................................... 1045 

Zanoni, M B............ 336, 1418, 2408, 2409 

Zanoni, T B....................................... 2408* 

Zarbl, H......... 40*, 953, 1702*, 1708, 2647 

Zaroogian, G....................................... 2384 

Zavala, J.............................................. 2332 

Zavecz, J H........................................... 209 

Zawia, N H......................................... 2187 

Zawia, N........................................... 1700* 

Zayed, J............................................... 2487 

Zefirov, N S.......................................... 861 

Author Index 


385


Author Index 


Zehnacker, C....................................... 2537 

Zehr, R D............................................ 1622 

Zeidler-Erdely, P C............ 185, 563, 1492, 

2322* 

Zeiger, E....................................... 332, 486 

Zeise, L................. 472, 1962*, 1967, 2360 

Zelikoff, J T......................... 22, 666, 1067, 

1069, 2057 

Zeller, M........................................... 2695* 

Zellner, D.......................................... 2628* 

Zenick, H............................................ 908* 

Zezzi-A, M A...................................... 2434 

Zgoda-Pols, J R.................................... 745 

Zhai, Y.................................................. 376 

Zhan, L................................................ 207* 

Zhan, Q............................................... 2275 

Zhang, B................................... 260, 1495* 

Zhang, C........................... 384, 395, 2593* 

Zhang, D D................. 1278, 1786*, 1791* 

Zhang, F.......................... 486, 753*, 2383* 

Zhang, H........................................... 1488* 

Zhang, J......... 213, 934, 1085, 1279, 1452, 

1549*, 2142, 2144*, 2490, 2598 

Zhang, K............................................... 772 

Zhang, L W....................................... 1175* 

Zhang, L............... 76, 143, 176, 337, 494*, 

817, 947, 1831, 2074, 2347, 2558 

Zhang, M.................................... 138*, 934 

Zhang, Q.......... 117, 609, 744, 754, 1434*, 

1463, 2001, 2488 

Zhang, R........................................... 2246* 

Zhang, T.............................................. 2136 

Zhang, W............................................ 2344 

Zhang, X Y......................................... 2136 

Zhang, X...................... 723*, 1239, 1283*, 

1284, 1359, 1450, 1505*, 1651*, 1661*, 

2313*, 2596, 2597, 2647 

Zhang, Y J......................................... 1104* 

Zhang, Y................ 449, 548, 2137, 2174*, 

2220, 2606 

Zhao, B............................. 954, 1105, 2078 

Zhao, C Y............................................ 2136 

Zhao, D............................................... 518* 

Zhao, F.............................. 413, 1025, 2447 

Zhao, G................................................. 465 

Zhao, P................................................ 1359 

Zhao, R............................................. 2502* 

Zhao, Y................................... 219*, 1664* 

Zhao, Z............................................... 2576 

Zheng, G........................................... 2122* 

Zheng, J...................................... 236, 1860 

Zheng, R............................................. 637* 

Zheng, W........... 1377, 1896*, 2122, 2136, 

2137, 2138*, 2139, 2140, 2144, 2592 

Zheng, X................................. 1677*, 1976 

Zheng, Y............................................. 1359 

Zhong, H............................................. 2002 

Zhong, Q............................................... 752 

Zhong, W.............................................. 877 

Zhongxian, G........................................ 774 

Zhou, A............................................... 1234 

Zhou, B................................................. 945 

Zhou, G............................................... 1856 

Zhou, H........................... 145*, 1662, 1850 

Zhou, J.............................. 219, 1525, 1561 

Zhou, S................................................. 179 

Zhou, T................................................. 332 

Zhou, X........... 538, 582, 764, 1848*, 2319 

Zhou, Z......................................... 210, 945 

Zhu, B................................. 354, 357*, 358 

Zhu, H............... 139, 143*, 465, 494, 1303 

Zhu, J.................................................... 700 

Zhu, K................................................... 439 

Zhu, P.................................................. 1053 

Zhu, X............................................... 1506* 

Zhu, Y............................................... 2264* 

Ziemek, D............................................. 147 

Zihlmann, C.......................................... 441 

Zimmer, B............................................. 868 

Zimmerman, N........................... 629, 1238 

Zimmerman, R P................................. 1303 

Zimmermann, C.................................... 244 

Zisch, A............................................... 2169 

Zitomer, N C....................................... 1448 

Ziv-Gal, A......................................... 1219* 

Zmarowski, A....................................... 195 

Zoeller, R T................................. 702, 2360 

Zoeller, R............................................ 2608 

Zoffmann, S.......................................... 316 

Zokowski, K J..................................... 1922 

Zong, Q......................................... 528, 530 

Zoni, S.................................................. 629 

Zottola, M........................................... 2046 

Zsabo, M............................................. 1269 

Zuardi, A............................................... 802 

Zucker, R M........................................ 2078 

Zuehlke, U............................................ 557 

Zuno, F G................................ 2088*, 2119 

Zurita, J L........................................... 2385 

Zuscik, M.............................................. 293 

Zverina, E A.......................................... 163 

Zychowski, K................................... 2228* 





Abstract Key Word Index (Continued) 

The numerals following each key word refer to 

the relevant abstract number(s). 

[18F]FDG microPET imaging and 

animal 3Rs...................................... 2613 

1, 1, 1-Trichloroethane................... 1817 

1, 2-dichloroethane........................... 330 

1, 3-Butadiene................................. 1687 

1, 3-dibromopropane........................ 684 

1, 3-dinitrobenzene............ 69, 162, 163, 

1654 

1, 4-Dioxane................................... 2660 

15dPGJ2-G....................................... 345 

1Ç3-b-Glucan................................. 2325 

1H-NMR Metabonomics.................. 739 

2, 3 Butanedione............................. 2320 

2, 3, 7, 8-TCDD...................... 353, 1626 

2, 3, 7, 8-tetrachlorodibenzop-dioxin........................................... 

2606 

2, 3, 7, 8-tetrachlorodibenzop-dioxin 

(TCDD)........... 199, 859, 1093, 

2254 

2, 3, 7, 8-tetrachloro-dibenzop-dioxin 

(TCDD)............................ 1124 

2, 4-D........................................ 49, 2094 

2, 5-dimethylfuran.......................... 1261 

2, 5-hexanedione................................. 65 

2008 Beijing Olympic Games........ 2323 

21st Century Toxicity Testing......... 1539 

2-aminoanthracene........................... 380 

2-hydroxyethoxyacetic acid............ 2660 

2-methoxy-4-nitroaniline...... 2275, 2644 

2R vs 3R......................................... 1522 

3, 5-Dichloroaniline.......................... 738 

3, 5-dimethylaminophenol.............. 1408 

3, 5-Dimethylaniline....................... 1408 

3D cell culture.................................. 987 

3D culture systems......................... 1766 

3D in vitro culture........................... 2521 

3-D liver tissue............................... 1606 

3-D reconstructed tissues................ 2555 

3’IgHRR......................1122, 1123, 1124 

3-Methylindole............................... 1848 

3Rs................................ 858, 1563, 1564 

3Rs committment............................ 1554 

3T3 NRU.......................................... 464 

4-aminobiphenyl............................... 118 

4EBP1............................................. 1682 

4-hydroxynonenal................. 1280, 1282 

8-hydroxydeoxyguanosine............. 2204 

8-oxo-G..................................... 120, 122 

ABC transporter.............. 171, 413, 2267 

ABC Transporters........................... 1078 

ABCB6........................................... 1277 

abuse............................................... 1727 

Abuse Liability............................... 1724 

Abuse Liability Assessment.......... 1723, 

1726 

Abuse Potential..................... 1723, 1725 

acai juice......................................... 2415 

Accreditation.................................. 1878 

Acetaldehyde.................................. 2288 

acetaminophen......... 393, 444, 445, 446, 

447, 448, 449, 450, 451, 452, 453, 454, 

455, 456, 457, 458, 459, 460, 461, 463, 

940, 941, 1269, 1585, 1710, 1735, 1881, 

2074, 2500 

acetylation......................................... 817 

acetylcholinesterase............. 2012, 2014, 

2102, 2116 

aCGH.............................................. 1369 

acoustic startle................................ 2601 

acrolein.......... 190, 259, 567, 574, 1085, 

1280 

acrylamide.................. 68, 246, 737, 882 

acrylic ester polymers..................... 1468 

ACSA protocol..................... 1030, 2616 

Acteoside........................................ 2214 

Actin............................................... 2225 

Activity........................................... 1864 

activity inhibition............................ 1863 

acute exposure.................................. 500 

Acute inhalation..... 473, 585, 586, 2105, 

2567 

acute inhalation exposure............... 1575 

acute kidney injury......... 742, 750, 1425 

Acute Lung Injury.......................... 2321 

acute toxicity...... 564, 1564, 1577, 2254 

acyl glucuronide............................. 1904 

adaptive............................................. 660 

ADC.................................................. 125 

adducts............................................ 2658 

adenosine A2A receptor.................... 132 

Adenosine deaminase............... 162, 163 

ADHD............................................. 2600 

Adhesion molecules.............. 1972, 2062 

adipocyte......................................... 2366 

adipogenesis..................................... 352 

adipose............................................ 1968 

adjuvant.......................................... 1027 

adjuvants........................................... 726 

ADME........................ 2261, 2273, 2676 

ADME/TK...................................... 1522 

adolescent....................................... 1328 

Adriamycin..................................... 2222 

adult stem cells............................... 1758 

adverse chemical reaction................. 821 

adverse drug reactions.... 853, 857, 2686 

adverse effect.................................. 1721 

Adverse Events................................. 729 

adverse outcome pathway................. 964 

adverse perinatal outcome................ 613 

AEGL.............................................. 2298 

AEOL 10150................................... 1756 

aerosol............................................... 584 

Aerosol delivery............................... 240 

aerosol generation............................. 577 

aerosol generator.............................. 563 

Aflatoxin............ 984, 1096, 1534, 1674, 

1688, 2228, 2638, 2642 

aflatoxin B1.................................... 1828 

aflatoxin B2.................................... 1828 

Aflatoxin-albumin adduct............... 1688 

aflatoxins........................................ 1018 

African Dust............................. 668, 669 

Age-related susceptibility..... 1298, 1324 

aggregate exposure........................... 865 

aggregation....................................... 843 

Aging.................................... 1154, 1339 

agriculture....................................... 1730 

Ah Receptor............ 362, 374, 945, 1855 

AHR......... 127, 248, 355, 363, 371, 373, 

416, 474, 1114, 1126, 1130, 1132, 1219, 

1507, 1638, 1854 

AHR antagonism.............................. 362 

AhR ligand...................................... 1136 

AhR Ligands............................. 309, 361 

AhR nuclear translocator 

(ARNT)........................................... 1704 

AhR, Cyp1b1, Microarray.............. 1138 

AHR2.............................................. 1776 

AHRR............................................. 1776 

AIPT................................................. 569 

Air pollutant.................................... 1937 

air pollution........... 189, 583, 607, 1601, 

2286, 2332, 2480, 2490, 2612 

air pollution exposure model.......... 1215 

Air pollution metals........................ 2494 

airborne particulate matter................ 573 

Airborne PCBs................................ 2297 

Aircraft........................................... 1247 

aircraft lubricant............................... 169 

airway..................................... 887, 1635 

Airway Epithelium........................... 998 

airway hyper-responsiveness.......... 2478 

Airway pathology....................... 84, 575 

airway resistance............................ 2299 

AKR................................................ 2524 

Akt KD............................................. 240 

AKT/COX-2................................... 1659 

ALAD............................................. 1204 

albumin................................... 589, 2320 

alcohol........................ 1059, 1271, 2377 

Alcohol Cirrhosis............................ 1077 

Alcoholic cardiomyopathy............... 210 

alcoholic liver disease............. 551, 1282 

aldehyde dehydrogenase....... 1171, 1276 

aldehyde dehydrogenase 5................ 798 

ALDH2........................................... 1359 

aldosterone........................................ 387 

Algimetrics..................................... 2521 

alginate........................................... 2417 

Alheimer’s disease............................ 841 

alkylphenols...................................... 144 

allergen............................................... 94 

Allergic Asthma................................ 673 

allergic inflammation...................... 2491 

allergy............ 93, 530, 965, 1463, 2325, 

2422, 2684 

Allometry........................................ 2274 

allyl alcohol...................................... 564 

Aloe vera.......................................... 245 

alpha MUPA mice............................. 449 

alpha synuclein............................... 1347 

ALT............................... 439, 1101, 1603 

ALT1................................................. 439 

ALT2................................................. 439 

Alternative.......................................... 82 

Alternative Animal Model..... 971, 1007, 

1008 

alternative eye irritation test..... 466, 975 

alternative method(s)................. 71, 644, 

965, 975, 1002, 1006, 1518, 1519, 1520, 

2568, 2581 

alternative model........ 1321, 2517, 2518 

alternative models........................... 1774 

alternative test methods........... 418, 967, 

2510 

Alternative testing strategy............... 724 

alternative to in vivo testing............ 1013 

alternatives.................. 1309, 2462, 2564 

alternatives methods....................... 1554 

alternatives to animals......... 1898, 1901, 

2465 

Aluminium........................................ 297 

Aluminium sulfate.......................... 1044 

aluminum................................ 726, 2578 

aluminum citrate............................... 758 

Alveolar epithelial cells.................. 2171 

alveolar macrophage......................... 407 

alveolar ventilation rate.................... 598 

alveolo-capillary barrier................. 2163 

Alzheimer’s.................................... 1700 

Alzheimer’s Disease........ 172, 527, 843, 

943, 2187 

ambient particles............................... 581 

ambient particulate matter.............. 2331 

Ambulatory perfusion....................... 560 

Ames Assay.................................... 1814 

Ames test.................... 1370, 2077, 2304 

aminonitriles................................... 1835 

amiodarone............................... 433, 569 

amioidarone.................................... 1653 

Amitraz........................................... 1352 

Amodiaquine............................ 423, 434 

amorphous nanosilica........... 2062, 2080 

amorphous silica............................. 1457 

Amorphousilica................................ 129 

amphibole......................................... 600 

amphiboles...................................... 1936 

AMPK................................... 1159, 2215 

amylin............................................... 734 

anakinra.............................................. 27 

analysis........................................... 1986 

Analytical Methods........................ 2157 

Analytical techniques..................... 1558 

Anaphylactoid................................... 786 

ancestry........................................... 1984 

Androgen.................................. 19, 1024 

anesthesia.......................................... 520 

aneuploidy........................................ 337 

aneurysm........................................... 217 

Angelman and Prader-Willi............ 2454 

Angiogenesis..... 839, 1388, 1389, 1743, 

2548 

Angiotensin II................................... 210 

aniline............................. 112, 390, 1286 

animal alternative model................ 2380 

animal alternative tests......... 2463, 2466 

animal model................... 187, 510, 536, 

1754, 1755 

Animal models..... 7, 80, 509, 522, 1435, 

1504, 2291 

Animal models of human 

disease............................................. 1149 

antagonism........................................ 360 

antagonist........................................ 2219 

Anthocyanin............... 2212, 2215, 2216 

anti-Allergic.................................... 2218 

anti-androgen.................................. 2663 

antibody............................................ 803 

Anticancer Activity......................... 1303 

anticancer agent................................ 249 

Anticancer agents................. 1596, 1663 

anticonvulsants............................... 2025 

antidepressant......................... 319, 1639 

antidepressant therapy.................... 1363 

anti-drug antibodies........................ 2673 

Anti-fibrotic drugs.......................... 2509 

antigenotoxicity.............................. 2232 

Antimicrobial Peptides................... 2563 

Antimony, Metal............................... 773 

antineoplastic.................................... 221 

antioxidant.............. 24, 175, 1136, 2554 

antioxidant response..... 593, 1786, 2502 

Antioxidant response element........ 2501 

Antioxidants................... 329, 637, 2023 

Antisense.......................................... 800 

antisense oligonucleotide.................. 216 

anti-tumor immunity......................... 689 

antiviral drugs................................. 2268 

Antral follicles................................ 1037 

anxiety.............................................. 802 

Anxiogenic....................................... 545 

APC.................................................. 359 

apical ectoplasmic specialization....... 64 

Apocynin and derivatives............... 1307 

Apoptosis........... 70, 108, 228, 248, 299, 

300, 409, 450, 691, 948, 1026, 1187, 

1191, 1653, 1655, 1658, 1659, 1660, 

1661, 1664, 1666, 1673, 1751, 1887, 

1910, 2054, 2089, 2596, 2599, 2634 

Apoptosis/cell survival....................... 92 

Apoptosis; ROS................................ 307 

aquaporin........................................ 2007 

aquatic toxicology.......................... 2378 

arbutin................................... 1826, 2221 

Arctic.............................................. 2403 

ARE................................................ 2497 

Arginase.......................................... 2132 

aristolochic acid...................... 250, 2416 

Aromatase....................................... 2361 

Aromatic Amine Drugs................... 1499 

Aromatic amines............................. 1579 

Arrhythmia............. 184, 607, 608, 1919 

arsenic.............................. 115, 301, 394, 

817, 833, 1278, 1621, 1641, 1745, 1938, 

1939, 1940, 1942, 1968, 1969, 1970, 

1971, 1972, 1974, 1975, 1976, 1977, 

1979, 1980, 1981, 1982, 1983, 1986, 

1987, 1988, 1989, 1991, 1992, 1993, 

1997, 1999, 2000, 2001, 2003, 2006, 

2007, 2008, 2009, 2199, 2447, 2502, 

2645, 2649, 2665 

Arsenic biotransformation.............. 1985 

Arsenic exposure.................. 1937, 2002 

arsenic methylation............... 1978, 1984 

Arsenic methyltransferase................ 232 

Arsenic toxicity.............................. 1277 

arsenic trioxide....................... 338, 1887 

arsenicals.......................................... 815 

Key Word Index 


387






Arsenite.... 232, 1279, 1973, 1994, 1995, 

1996, 2366, 2565 

Artemia franciscana........................ 2236 

Arthritis................................. 1511, 1893 

Artificial Turf.................................. 1568 

Aryl hydrocarbon receptor...... 103, 218, 

349, 351, 353, 356, 360, 364, 368, 372, 

405, 1121, 1122, 1127, 1134, 1139, 

1158, 1631, 1642, 1897, 2369 

aryl hydrocarbon receptor (AHR)... 347, 

1129, 1157, 1704, 2666 

aryl hydrocarbon receptor 

interacting protein........................... 1366 

Aryl hydrocarbon receptor 

nuclear translocator................ 372, 1365 

Aryl hydrocarbon receptor 

repressor........................................... 353 

AS3MT polymorphism................... 1980 

AS3MT/M287T polymorphism...... 1981 

Asbestos..... 24, 601, 602, 683, 687, 689, 

693, 1247, 1509, 1511, 1935, 1936 

asphalt fumes.................................... 237 

assessments....................................... 619 

asthma...................... 599, 606, 681, 886, 

1372, 2335 

Asthma model................................... 904 

asthmatic inflammation.................... 253 

astrocyte.......................................... 1350 

astrocytes............ 163, 2129, 2620, 2664 

Astroglial cells.................................. 344 

ATCA.............................................. 1689 

atherosclerosis..... 190, 209, 1202, 1712, 

1970, 1971, 2086, 2113, 2180 

Athersclerosis................................... 183 

atmosphere.............................. 594, 2493 

Atopic Dermatitis........................... 2207 

ATP................................................. 1520 

ATP depletion................................. 1671 

ATP Synathase.................................. 373 

ATP-binding cassette transporters.... 535 

ATP-competitive............................... 401 

Atrazine... 665, 1031, 1032, 1042, 1071, 

1357, 1747, 2090, 2093 

Atresia............................................. 1033 

attention.......................................... 1618 

attrition................................. 2675, 2680 

Aurora............................................... 792 

Australasia...................................... 1878 

autism.......... 610, 620, 992, 1769, 1770, 

1771, 1772, 1773, 2611 

Autism Spectrum Disorder............. 2594 

Autohpagy...................................... 2446 

autoimmune................ 1515, 2683, 2686 

autoimmune disease..... 949, 1514, 1628, 

2196, 2687 

Autoimmunity.... 287, 1508, 1509, 1510, 

2682, 2683, 2684 

Automated........................................ 153 

automated micronuclei scoring......... 339 

autophagy........ 1278, 1655, 1749, 1988, 

2031, 2347, 2444, 2445, 2447, 2448 

avian............................. 205, 1018, 1620 

Azo dye........................................... 1418 

azo dyes.......................................... 2409 

AZT.................................................. 116 

B cell activation.............................. 1125 

B cells............................................. 1513 

B lymphocytes................................ 1666 

B(a)P................................................. 217 

B[a]P metabolome.......................... 1681 

B[a]P-7, 8-dione............................. 1831 

bacteria........................... 548, 844, 2441 

bacterial metabolism....................... 1827 

BAG1................................................ 166 

baicalin........................................... 1825 

Balb 3T3 NRU test......................... 1012 

BaP................................ 814, 1599, 2203 

Barium............................................ 1228 

base excision repair.......................... 112 

Basic Red 51................................... 2408 

Bax.................................................. 2588 

bayesian............................................ 478 

Bayesian Network............................ 716 

BBB & BCB................................... 1478 

BBDR-HPT axis model.................. 2668 

b-catenin........................................... 985 

B-cells............................................. 1121 

Bcl-xL............................................... 200 

BCOP.................................... 2550, 2569 

BCRP.............................................. 1047 

Beauvericin..................................... 2423 

Behavior.... 588, 872, 1329, 1337, 1338, 

1340, 1490, 2143, 2150 

Behavioral....................................... 1724 

behavioral development.................. 2628 

behavioral effects.............................. 871 

Behavioral toxicity............... 1886, 2609 

Behaviour....................................... 2614 

Belief Theory.................................... 729 

Benazepril....................................... 2285 

benchmark dose analysis................ 2692 

benzene.......... 337, 731, 732, 824, 1210, 

1255, 1263, 1373, 1941, 2282 

Benzo(a)pyrene.... 699, 942, 1065, 1670, 

1695, 2546, 2607, 2648 

Berberine.............................. 1117, 1850 

beryllium............................... 1529, 2487 

beta cell........................................... 2653 

beta-amyloid................................... 2138 

beverage,......................................... 2443 

BFRs............................................... 2200 

Bibliometry..................................... 1484 

Bile acid........................ 437, 1104, 1643 

bile acids................................. 548, 1080 

Biliary Excretion............................ 2557 

Bilirubin............................................ 386 

bilobalide.......................................... 377 

bioaccessibility... 298, 1942, 2566, 2572 

bioactivation............................. 73, 2220 

bioanalysis...................................... 1230 

bioanalytical................................... 1926 

Bioassay.......................................... 1419 

Bioavailability........... 1178, 1265, 1938, 

2009, 2263, 2566 

biocompatability........ 1312, 1313, 1314, 

1550 

Biodegradable....................................... 1 

biodegradation.............................. 25, 54 

biodiesel...................... 1413, 1462, 2489 

Biodiesel exhaust.............................. 606 

biodistribution............. 1460, 2065, 2084 

BioEpisteme..................................... 137 

Biofuel.................................... 707, 1547 

bioinformatics.......... 128, 130, 133, 151, 

859, 1336 

Bioinformatics tools............................. 4 

biokinetic model............................. 1316 

biokinetics....................................... 2170 

biological barrier............................ 1763 

Biological Descriptors...................... 488 

biological modeling......... 481, 703, 704, 

705, 735, 940, 1735, 2287 

Biological models............................. 702 

biological monitoring......................... 50 

Biological Pathway Networks........ 1598 

biological pathways.................. 143, 532 

biological toxins................... 2043, 2044 

biological warfare........................... 2042 

Biologically Based Dose 

Response........................................... 702 

Biologically effective dose............... 865 

biologically-based models.............. 2688 

Biologics........................................... 809 

Biomarker............................................... 

164, 185, 202, 436, 438, 440, 744, 745, 

880, 934, 1066, 1101, 1185, 1237, 1238, 

1288, 1426, 1427, 1438, 1440, 1442, 

1443, 1444, 1446, 1448, 1451, 1492, 

1494, 1506, 1680, 1682, 1685, 1693, 

1695, 2241, 2317, 2669, 2696 

Biomarker and Biomonitoring........ 1239 

Biomarker discovery.... 135, 1281, 1433 

Biomarker Genes............................ 1677 

biomarkers.............................................. 

51, 281, 310, 453, 521, 737, 833, 838, 

888, 947, 1110, 1204, 1240, 1241, 1258, 

1264, 1283, 1284, 1330, 1425, 1428, 

1432, 1434, 1435, 1676, 1678, 1683, 

1684, 1692, 1785, 2043, 2044, 2111, 

2117, 2148, 2232, 2260, 2278, 2672 

biomass........................................... 1535 

Biometrics......................................... 635 

Biomonitoring............ 1424, 1449, 1942, 

1943, 1974 

Biomonitoring Equivalent.............. 1940 

biopesticides................................... 1731 

Biopharmaceuticals..... 809, 1150, 1151, 

1922 

bioremediation................................ 2238 

biosafety......................................... 1517 

Biosensor........................................ 1260 

Biosignature.................................... 1442 

Biosimilars........................................ 806 

Biosolids Microconstituents........... 1264 

Biospectrum...................................... 156 

biotechnology................................. 1525 

bioterrorism............... 2414 , 2432, 2433 

biotherapeutics........................ 881, 2673 

Biotransformation...... 1418, 1818, 1819, 

1825, 1826, 1827, 1833, 2102 

birds.......................................... 295, 296 

birth defects...................................... 810 

bi-specific......................................... 776 

Bisphenol A..................... 100, 102, 708, 

720, 959, 1025, 1033, 1064, 1078, 1252, 

1315, 1612, 1720, 1943, 2186, 2246, 

2256, 2352, 2363, 2365, 2626, 2667 

Bisphenol AF.................................. 1660 

Bisphenol-A.......................... 1063, 2270 

Bizzy................................................. 131 

black cohosh................................... 2374 

Bladder................................. 1677, 2645 

bladder cancer................................. 1997 

bleomycin......................................... 540 

Blood.............................................. 2318 

blood brain barrier.......................... 2627 

Blood Cadmium................................ 767 

blood lead............................... 628, 1538 

Blood mercury................................ 1256 

Blood pressure........ 202, 557, 568, 1930 

blood-brain barrier.................. 993, 2266 

blood-brain barrier (BBB).............. 1495 

Blood-brain-barrier......................... 1464 

blue-green algae.................... 2435, 2436 

BMAA...................................... 165, 166 

Body Temperature.......................... 1925 

body weight...................................... 518 

bone.............................. 291, 1302, 2274 

bone formation................................ 2343 

bone lead......................................... 1686 

Bone marrow.......................... 101, 1168 

bone marrow toxicity.... 785, 1153, 1906 

Bone marrow, Spleen, thymus, 

blood............................................... 1138 

Boolean Networks............................ 937 

Botanical dietary supplements.......... 227 

botanical extracts.............................. 995 

bottlenose dolphin............................ 657 

Botulinum........................................... 77 

botulinum toxin type A..................... 787 

Bovine Corneal Opacity and 

Permeability Assay......................... 1551 

bowhead whale................................. 279 

BP oil spill...................................... 2342 

BPA....................................... 2311, 2359 

BPDE.............................................. 2235 

B-Raf................................................ 244 

brain........................................ 174, 2495 

brain metastases................................ 260 

BrdU................. 1154, 1518, 2536, 2595 

breast cancer...... 21, 111, 229, 248, 351, 

953, 957, 1983, 2661 

breast cancer risk............................ 1203 

Breast carcinogenesis....................... 230 

Breast milk........................................ 386 

Brevenal............................................ 808 

bromate................................... 774, 2281 

Brominated flame retardants.......... 1268 

bromodichloromethane............. 685, 711 

bromopropane........................... 176, 177 

bronchial epithelial cells................. 2655 

Bronchoalveolar lavage.......... 573, 2477 

Brown Norway rats......................... 2685 

BSEP............................................... 2543 

BTEX.............................................. 1261 

butadiene......................................... 1843 

butylparaben................................... 2276 

Butyrylcholinesterase..................... 1335 

C(60) fullerene................................ 1177 

C. elegans........ 274, 389, 984, 986, 994, 

1073, 1356, 1744, 1872, 2123, 2517 

C/EBPb........................................... 1117 

C2C12............................................. 1295 

Caco-2 cells.......................... 1015, 1021 

cadmium.......... 265, 266, 267, 268, 269, 

270, 271, 272, 274, 275, 276, 277, 313, 

389, 412, 764, 769, 770, 771, 772, 1155, 

1973, 1992, 1994, 1995, 1996 

Cadmium oxide nanoparticles....... 1067, 

2057 

Cadmium transport........................... 241 

cADPR.............................................. 408 

Caenorhabditis elegans.................... 297 

Caffeine.......................................... 1659 

Calcium............. 1477, 1890, 2376, 2623 

Calcium Channel.................. 1342, 1344 

Calcium channels............................ 1395 

calcium homeostasis....................... 1485 

Calcium-independent 

phospholipase A2............................ 1300 

California.......................................... 910 

Caloric Restriction.......................... 1862 

Calpain............................................ 1341 

Calpain 10......................................... 749 

cAMP................................................ 402 

Campylobacter................................ 2417 

Canary Islands................................ 1228 

cancer............... 115, 318, 354, 358, 477, 

760, 764, 782, 783, 804, 896, 900, 1069, 

1712, 1714, 1740, 1743, 1790, 1964, 

1967, 1973, 1994, 1995, 2251 

Cancer biomarker............................. 877 

Cancer mode of action..... 224, 914, 952, 

1934, 2632 

Cancer Potency............................... 1956 

cancer potency estimate.................... 498 

Cancer Prevention.......................... 2411 

cancer progression............................ 228 

cancer risk assessment...................... 486 

Cancer Stem Cells............................ 231 

candidate loci.................................... 822 

Canine Hepatocytes........................ 1853 

cannabidiol....................................... 802 

Cannabinoid.................... 674, 964, 1325 

Cannabinoid Receptor...................... 344 

Cannabinoids................... 226, 675, 676, 

678, 1666 

canned dog food............................. 2410 

Capsaicin.............................. 2210, 2333 

capsule administration...................... 514 

Captan............................................. 2278 

captopril.......................................... 2010 

CAR................................................ 2657 

Carbaryl................................ 1338, 1339 

Carbon disulfide............................. 1220 

carbon monoxide.................... 614, 1075 

carbon nanomaterials...................... 1174 

carbon nanoparticles....................... 1190 

Carbon Nanotube........1182, 1184, 1186, 

1803 






carbon nanotubes.................................... 

54, 55, 61, 848, 1178, 1181, 1187, 1188, 

1195, 1196, 1797, 1800, 2178 

carbon tetrachloride.......................... 247 

carbonyl stress................................ 1296 

carbonylation.................................. 1297 

Carboxyhemoglobin....................... 1217 

carboxylesterases........ 1857, 2086, 2098 

carcinogenesis.......... 106, 219, 233, 242, 

508, 525, 876, 926, 1188, 1404, 1780, 

1782, 2645, 2647, 2698 

Carcinogenesis screening................... 12 

carcinogenicity.... 484, 777, 1403, 1528, 

1816, 1946, 2654 

carcinoma......................................... 244 

Cardiac.................................... 188, 1371 

Cardiac cell death............................. 210 

Cardiac channels..................... 215, 1166 

cardiac gene expression.................... 604 

cardiac hypertrophy........................ 1437 

cardiac injury.................................. 1907 

cardiac ischemia............................... 193 

cardiac lesions................................ 2015 

cardiac myoblasts............................. 973 

Cardiac Neuronal Agent................... 812 

cardiac output................................... 598 

Cardiac Safety.................................. 215 

Cardiac toxicity............ 204, 1589, 1915 

Cardiac troponin I............................. 211 

cardiolipin....................................... 1285 

Cardiomyocytes.................... 1163, 1164 

cardiorespiratory................... 1290, 2494 

Cardiotoxicity...... 150, 205, 1161, 1164, 

1432, 1888, 1898, 1908, 2472 

Cardiotoxicity Mechanisms.............. 147 

Cardiotrophin-1................................ 196 

cardiovascular.................. 189, 218, 558, 

561, 583, 1241, 1696, 2188, 2189, 2468, 

2469, 2471, 2473, 2667 

cardiovascular complications......... 2593 

cardiovascular disease..... 185, 187, 554, 

1492, 2199, 2203 

Cardiovascular diseases.................. 1459 

cardiovascular drug safety.... 2672, 2674 

Cardiovascular Function................... 184 

cardiovascular safety....... 145, 146, 147, 

2670 

cardiovascular system..................... 1637 

Cardiovascular Toxicity.............. 3, 2470 

Cardiovascular Toxicology...... 183, 201, 

208, 211 

career.............................................. 2482 

Career Development....................... 2508 

Career planning.............................. 2485 

Carotid intima-media thickness...... 1972 

Cash receipts................................... 2256 

catalase........................................... 2147 

Catalytic bioscavenger.................... 2024 

catecholamines............................... 2015 

categorical regression....................... 473 

cattle............................................... 2273 

Causal reasoning............................... 147 

caveolae.......................................... 1750 

caveolin........................................... 1749 

CB1 receptor................................... 1881 

CB2................................................... 344 

CCNG2............................................. 371 

CCO.................................................. 207 

CD-1 Mice........................................ 507 

CD24 Neg....................................... 1406 

CD25................................................. 288 

CD4................................................. 2687 

CD4+ T lymphocyte......................... 547 

CD40L............................................ 1137 

CD90............................................... 1082 

C-DIM.............................................. 225 

cdr-1.................................................. 274 

CEES.............................................. 2040 

Celiac.............................................. 1515 

cell based imaging.............................. 29 

cell culture...................................... 1870 

Cell cycle................................ 390, 1154 

cell cycle status................................. 339 

cell death............. 450, 1656, 2313, 2533 

cell differentiation............................. 837 

cell proliferation......... 1004, 1851, 1852 

Cell signaling........................ 1990, 2377 

cell toxicity........................... 2512, 2515 

cell uptake................... 1175, 1758, 2053 

cell viability............................ 985, 2529 

Cell-based Toxicity Assay.............. 2651 

cellular aging.................................. 1654 

Cellular microarray............... 2525, 2526 

Cement plants................................. 1246 

Centella Asiatica..................... 527, 1842 

central nervous system........... 835, 2345 

centrosome amplification................. 278 

CeO2 Nanoparticles........................ 1473 

cerebrospinal fluid................ 1924, 2138 

ceria...................................... 1460, 2065 

cerium oxide........................... 605, 1489 

cerium oxide nanoparticle.............. 2081 

CFD-PBPK..................................... 2288 

c-FLIP............................................. 1657 

CFU-GM......................................... 1172 

Chamomile..................................... 1559 

Characterization.............................. 1578 

chemical.................................. 930, 2464 

Chemical and Biological Weapons... 927 

chemical burns.................................. 893 

chemical carcinogenesis......... 957, 2661 

Chemical composition...................... 672 

chemical dispersants..... 828, 1577, 2342 

Chemical Genetics............................ 231 

chemical mixture............................ 1810 

Chemical mixtures..... 8, 417, 633, 1581, 

2309, 2314 

Chemical Prioritization..................... 714 

chemical reactivity.......................... 2312 

Chemical respiratory allergy.... 902, 906 

chemical safety................................. 497 

Chemical Sensitizers.......................... 92 

chemical toxicity.............................. 981 

chemical versus non-chemical 

stressors.......................................... 1796 

Chemical warfare.................. 2029, 2041 

chemical warfare materiel................ 928 

Chemical warfare nerve agents...... 2024 

chemical weapons............................. 931 

chemical-induced immunotoxicity... 652 

chemokine......................................... 674 

chemokines..................................... 1781 

chemopreventative.......................... 2371 

Chemoprevention.... 227, 405, 782, 783, 

1404, 1702, 1708, 1885, 2638 

Chemoprevention/ 

Chemotherapy................................. 2261 

Chemopreventive............................ 2231 

Chemotherapeutics............................. 62 

chemotherapy................................... 900 

Chemotypes.................................... 1559 

Chemweapons................................... 932 

CHHSL........................................... 1533 

chicory root extract......................... 2438 

children.......... 610, 612, 625, 629, 1243, 

1538, 1569, 1941 

children’s health risk......................... 498 

Chimeric mouse................................ 532 

China............................................... 1224 

ChIP-Seq........................................... 358 

chip-x enrichment analysis............. 1738 

chirality................................... 721, 1820 

Chlamydia pneumoniae.................... 666 

chlorination..................................... 2409 

Chlorine.......................................... 2038 

Chlorine hypersensitivity................ 2335 

Chlorine Vapor.................................. 543 

chlorophyllin................................... 2658 

chloroprene..................................... 1591 

chloropropanols.............................. 1967 

chlorotriazine herbicides................ 2549 

chlorpromazine............................... 1015 

Chlorpyrifos............. 342, 862, 866, 993, 

1324, 1325, 1326, 1327, 1331, 2089, 

2096, 2103, 2105, 2106, 2279, 2520 

Chlorpyrifos oxon........................... 1327 

CHO, TK6 Cells............................... 320 

CHO-K1 cells................................. 2423 

cholesterol....................................... 1116 

cholesterol synthesis......................... 374 

choline............................................ 2277 

Cholinesterase....................... 2106, 2279 

cholinesterase inhibition....... 1324, 2048 

Chorioallantoic Membrane 

Vascular Assay (CAMVA).............. 1551 

Choroid Plexus.................... 1377, 2122, 

2136, 2137 

chromate........................................... 757 

chromatin.......................................... 109 

Chromatin Immunoprecipitation...... 615 

chromium......... 121, 273, 279, 280, 303, 

754, 814, 2405 

Chromosome aberrations.................. 334 

Chromosome damage..................... 2164 

chromosome instability.................... 278 

Chronic obstructive pulmonary 

disease..................................... 960, 2330 

chronic organophosphate 

toxicity............................................ 1207 

Chronic toxicity.............................. 1182 

chronic toxicology............................ 519 

chronotherapeutics.......................... 1707 

chronotoxicity......................... 393, 1705 

chrysotile.......................................... 600 

Cigarette......................................... 1026 

cigarette smoke........ 415, 513, 574, 666, 

960, 998, 1069, 1072, 1190, 1254, 1288, 

2288, 2324, 2327, 2492 

Cigarette Smoke Condensate............ 985 

Cigarette Smoke Exposure............. 2194 

Cigarette Smoke Extract................. 2488 

Cigarettes.............................. 1219, 1224 

cilostazol........................................... 533 

cinacalcet.......................................... 779 

Cinnabar............................... 2004, 2005 

circadian................................... 271, 396 

circadian clock.................................. 393 

Circadian oscillators....................... 1703 

Circadian Rhythm........ 446, 1104, 1436, 

1702, 1705 

cis-2-butene-1, 4-dial...................... 1417 

Cisplatin........... 62, 104, 740, 741, 1586, 

1668, 1991 

Clara cell........................................... 887 

cleanup............................................ 1533 

Clearance........................................ 1763 

cleft palate.............................. 810, 1632 

climate change................................ 2589 

Clinical................................. 1288, 1725 

Clinical Pharmacology................... 2473 

cluster analysis................................ 1526 

CMML............................................ 1210 

Cnestis ferruginea........................... 2230 

CNS........................................ 775, 1924 

CNV................................................ 1770 

coagulation..................................... 1119 

coal miners...................................... 1212 

Coarse particles................................ 579 

cobalt................................................ 305 

co-culture model............................. 2163 

co-cultures...................................... 2066 

CODP exacerbation........................ 1289 

cognition......................................... 1205 

cognitive ability................................ 628 

cognitive decline............................. 2609 

cognitive function............................. 835 

collaboration..................................... 418 

collagen-sandwich culture.............. 2537 

colon............................. 302, 1670, 2648 

Colon Cancer.......................... 359, 1171 

Colon tumors.................................... 245 

colorectal cancer............................. 2650 

combination of non-animal skin 

sensitization data............................ 2570 

combination therapy......................... 785 

Combustion Particles.............. 188, 1627 

Comet............................................... 315 

Comet assay............................. 320, 321, 

322, 323, 329, 336, 341, 343, 972, 1003, 

1548, 2077, 2162 

communication....................... 933, 2484 

Communities..................................... 932 

community based participatory 

research........................................... 1249 

community health................... 931, 1696 

comparative toxicity....................... 1744 

Complement..................................... 800 

complex disease................................ 821 

complex I........................................ 1297 

complex mixtures..................... 119, 327 

compound conservation.................... 577 

compound optimization.................... 855 

compound safety screening............ 1902 

compound selectivity...................... 1815 

Computational Assessment............... 152 

computational fluid dynamics........ 2290 

Computational modeling...... 9, 836, 840 

Computational models........................ 33 

computational toxicology.......... 60, 143, 

146, 152, 484, 489, 492, 712, 714, 715, 

730, 908, 912, 913, 1619, 1809, 1814, 

1816 

COMT............................................. 1831 

Concanavalin A............................... 1093 

concentrated ambient particles...... 2491, 

2612 

Condor............................................ 2397 

Confounding variables, fasting 

effects................................................ 523 

Connexin........................................... 771 

connexin channels.......................... 1656 

Constitutive Androstane 

Receptor........... 224, 365, 375, 377, 378, 

952, 1090 

Consumer Product.......................... 1545 

contact allergen................................... 87 

Contact allergy.................................... 84 

Contact Hypersensitivity.................... 87 

contact sensitization........ 98, 1011, 2571 

contaminated soils.......................... 2009 

contaminated surfaces...................... 863 

Contamination........................ 807, 1932 

Continuing education...................... 1878 

Continuous infusion........................ 1917 

Continuous intravenous infusion.... 1566 

Contraception................................. 1765 

control contamination..................... 1932 

controlled substance....................... 1727 

Convulsion...................................... 1805 

convulsions....... 1804, 1806, 1807, 1808 

COPD................................... 1287, 2324 

COPD - mechanism.......................... 541 

Copepode........................................ 1571 

copper.... 1103, 1376, 1377, 1378, 1453, 

2122 

Copper Nanoparticles.................... 1464, 

1474, 1486 

Copper Pyrithione........................... 2389 

copper-doped titanium dioxide....... 2051 

Copy Number Variation.................. 1368 

coral.................................................. 828 

Cord blood BDNF.......................... 1391 

Corexit................................................ 74 

COREXIT 9500.............................. 2338 

Coronary........................................... 194 

Cortical Neuronal Function........... 2588, 

2607 

Cosmetic Directive - REACH.......... 645 

Cosmetics....................................... 1527 

Countermeasures............................ 2050 



389






Covalent Binding.................... 755, 2644 

Cox10............................................... 207 

COX-2............................................ 1195 

CP31398................................... 794, 795 

cPLA2 and cytokine IL-8............... 2329 

Cramer............................................ 2573 

C-reactive protein........................... 2000 

creatine........................................... 1928 

crisis and emergency risk 

communication................................. 933 

critical effect......................... 1715, 1716 

Crohn’s disease............................... 1134 

cross species differences....... 1584, 1591 

cross-contamination........................ 1932 

Crumb Rubber................................ 1568 

CrVI.................................................. 919 

Cry1C............................................. 1556 

cryopreserved hepatocytes.............. 2522 

Crystalline Silica.................. 2082, 2318 

CSE................................................. 1289 

Cu Homeostasis.............................. 2137 

Culex............................................... 1436 

cumulative.............................. 472, 1794 

Cumulative Exposure........... 1580, 1582 

cumulative risk assessment.... 864, 1580, 

1792, 1793, 1795 

cumulative toxicity............................. 20 

Curcumin...................... 392, 2233, 2235 

curcumin analogs............................ 2635 

cutaneous metabolism........................ 86 

CW agent........................................ 2021 

Cyanide............. 1217, 1260, 1835, 2045 

Cyanide antagonism....................... 2046 

Cyanide biomarker......................... 1689 

Cyanuric Acid......................... 747, 2420 

Cyclodextrin................................... 1552 

Cyclodextrins.................................... 790 

cyclosarin........................................ 2012 

Cyclosporine A................................. 739 

cynomolgus..................................... 1923 

Cynomolgus monkey....... 514, 518, 546, 

556, 622, 780, 1046, 1145, 1146, 1232, 

1566 

Cynomolgus monkeys............ 557, 1061 

Cyp................................................. 1675 

CYP enzymes................................. 2280 

CYP induction................................ 2242 

CYP isoform................................... 1846 

CYP P450......................................... 141 

CYP17............................................ 2547 

CYP1A............................................ 1897 

CYP1A1...... 199, 309, 364, 1839, 1845, 

1852, 1975 

Cyp1b1........................................... 1120 

CYP2A5................................. 538, 1848 

Cyp2b............................................... 553 

CYP2B6.......................................... 2103 

CYP2B6 polymorphisms................ 1364 

CYP2E1.......................... 321, 515, 1843 

Cyp2f2................ 582, 1848, 1860, 2643 

CYP2F2-knockout.......................... 2643 

CYP2S1................................ 1837, 1854 

CYP3A4........................................... 422 

CYP450................................ 2110, 2234 

CYP450 polymorphisms................ 2111 

CYPs............................................... 1362 

cysteine............................................. 411 

Cytochrome b gene......................... 1374 

cytochrome c oxidase..................... 2045 

Cytochrome P450............ 230, 369, 396, 

639, 886, 1100, 1392, 1818, 1820, 1833, 

1837, 1838, 1840, 1842, 1844, 1859, 

1909, 2079, 2097, 2103, 2220 

Cytochrome P450 1A1................... 1841 

Cytochrome P450 1A1 

(CYP1A1)......................................... 405 

Cytochrome P450 2D6..................... 142 

Cytochrome P450 2S1.................... 1851 

Cytochrome P450 3A4..................... 140 

cytochrome P450 reductase............ 1292 

Cytochrome P4501A2.................... 1856 

cytochrome P450s................ 1850, 1861 

cytochromes P450.......................... 1168 

cytokeratin 18................................. 1110 

cytokine..... 38, 631, 665, 693, 696, 697, 

988, 1056 

cytokine analysis............................ 2555 

cytokine lung.................................... 571 

Cytokine release............................... 258 

Cytokine Stimulation and SHS....... 1253 

cytokines...... 22, 643, 1065, 1140, 2054, 

2160, 2325 

cytokinesis block method................. 326 

Cytoprotection................................ 2498 

Cytoskeletal Alterations.................. 2336 

Cytotoxic T lymphocyte................... 677 

Cytotoxic T Lymphocytes (CTL)..... 683 

Cytotoxicity....................... 30, 301, 304, 

379, 578, 770, 884, 969, 990, 997, 1176, 

1321, 1415, 1480, 2063, 2174, 2179, 

2646, 2648, 2655 

DACT............................................. 1357 

daily inhalation rates......................... 597 

danger signals................................. 1505 

danio rerio...................................... 1638 

Daphnia magna....................... 348, 2382 

DART.................................... 1040, 1617 

Data Analysis.................................. 1871 

Data analysis, pathway analysis........... 4 

data integration................................... 85 

data mining............................... 148, 158 

data sharing....................................... 495 

database.................................... 133, 158 

database design................................. 155 

database development..................... 1540 

database overview.......................... 1540 

DataChip/MetaChip........................ 2525 

DBS (dried blood spot)......... 1230, 1231 

DDT............................ 1208, 1833, 2241 

deca-brominated diphenyl ether......... 64 

Decabromodiphenyl ethane............ 1268 

decision analysis............................... 485 

Decision Support.............................. 480 

Decision Tree............................ 470, 482 

decision tree algorithm..................... 469 

decitabine.......................................... 799 

Decontamination............................. 2021 

deer mice.......................................... 551 

deferoxamine.................................. 2578 

DEHP.............................. 496, 617, 1824 

Delayed neurotoxicity.................... 1381 

Delayed-type hypersensitivity........... 80, 

1145 

Delta-9-tetrahydrocannabinol........... 677 

dendrimers...................................... 2173 

Dendrite Growth............................. 2624 

dendritic cell............................. 94, 1130 

dendritic cells....... 652, 675, 1129, 1131, 

1175, 2527 

dental.............................................. 1317 

dental material................................ 1318 

deoxynivalenol............. 516, 1662, 2419 

Depleted Uranium.................... 281, 283 

depression-like behavior................. 2606 

depurinating estrogen DNA 

adducts.............................................. 880 

derivatives....................................... 2424 

Dermal...................................... 635, 890 

dermal absorption........................... 1251 

Dermal Irritation....................... 467, 989 

dermal penetration............................ 640 

Dermatitis......................................... 643 

dermatotoxicity............................... 2028 

DES................................................. 2192 

detecting unexpected protein 

modifications.................................... 128 

developing brain............................. 2598 

Development.... 1609, 1629, 1635, 1647, 

1698, 2150, 2197, 2198, 2389 

development exposure.................... 1989 

Developmental........... 1029, 1325, 1615, 

1644, 2618 

Developmental & Reproductive 

toxicity.... 1034, 1073, 1560, 2095, 2192 

developmental and reproductive 

toxicity.................................. 1027, 2662 

developmental database.................... 495 

developmental exposure........ 873, 1641, 

2189 

Developmental Immunotoxicity....... 662 

Developmental 

immunotoxicology.......................... 2666 

Developmental neurotoxicity.... 31, 867, 

869, 871, 1332, 1352, 1391, 2601, 2602, 

2603, 2604, 2605, 2614, 2622, 2628, 

2629 

Developmental 

Neurotoxicology......... 2450, 2452, 2590 

Developmental Origins of Adult Disease 

1697, 1701, 2188, 2194, 2662 

Developmental Teratology............. 1623 

developmental toxicity.......... 71, 73, 76, 

836, 838, 840, 898, 991, 1044, 1075, 

1619, 1630, 2370, 2626 

Developmental Toxicology........ 72, 105, 

158, 1614, 1621, 1637 

Developmental, Energy 

Metabolism/Disregulation.............. 2248 

Dextran-40...................................... 1160 

DFP................................................... 167 

DHA................................................ 2193 

Di (n-butyl) phthalate..................... 2191 

di(2-ethylhexyl) phthalate.............. 1846 

diabetes............................ 145, 149, 267, 

609, 752, 1077, 1079, 1294, 1980, 2001, 

2255, 2270, 2347, 2471, 2583 

diabetes mellitus............................. 2472 

Diabetes stress................................ 2584 

diabetic inflammation..................... 2593 

diabetic nephropathy........................ 756 

diagnostic........................................ 2314 

diazepam......................................... 2394 

Dibenzo(def, p)chrysene................... 699 

Dibenzofuran.................................. 1087 

dibutylphthalate.............................. 1041 

Dichloroacetate................................. 251 

Dichloro-diphenyldichloroethylene............................... 

403 

Dichlorvos...................................... 2099 

diclofenac......................................... 766 

Dicyclohexylamine........................... 642 

diesel......................................... 568, 570 

diesel exhaust........... 565, 605, 606, 607, 

608, 1472 

diesel exhaust particle(s)......... 604, 609, 

901,1234, 2334 

Diesel Exhaust Particulate.............. 2328 

dietary exposure...................... 611, 1526 

Dietary intake................................. 2412 

Dietary Phytochemicals.................... 110 

dietary risk...................................... 1796 

dietary supplement(s)........... 2418, 2435 

Diethylenetriamine trinitrate.......... 1420 

diethylnitrosamine............................ 321 

Diethylstilbestrol............................ 2188 

differentially expressed genes........ 2598 

differentiation......................... 222, 2366 

digestibility......................................... 96 

Diisocyanates.................................. 1367 

DIKI...................................... 1430, 1602 

DILI........................ 431, 536, 970, 1895 

Dioxanone....................................... 2660 

dioxin....................... 349, 350, 356, 474, 

654, 976, 1121, 1125, 1126, 1158, 1628, 

1959, 1961, 2255, 2354, 2355 

dioxin-like compound........... 1365, 1366 

Dioxins........................................... 1265 

Dioxins and furans.................. 361, 1246 

dipentyl phthalate........................... 2663 

Diphenhydramine........................... 2400 

diphenylditelluride............................ 302 

diphenyliodoinum chloride............. 2417 

Discovery........................................ 2676 

disease model.................................... 187 

Disease Prevention............................. 40 

disease risk...................................... 1702 

disease risk factor........................... 1198 

disease-environment interactions... 1774 

diseases............................................. 528 

dispersants.............................. 825, 2341 

Dispersibility.................................. 1480 

Disposition......... 732, 1080, 2043, 2044, 

2275, 2276 

distribution.................. 1194, 2174, 2277 

dithiocarbamates............................. 1347 

diuron dose-response........................ 525 

Division.......................................... 2671 

DMAE............................................ 2277 

DMEL............................................. 1516 

DMSO............................................. 1422 

DNA Adduct................. 486, 1690, 2642 

DNA adducts........................ 1683, 1691 

DNA binding................ 319, 2640, 2644 

DNA damage................................... 117, 

122, 265, 323, 325, 329, 338, 342, 1373, 

1548, 2027, 2071, 2640, 2652 

DNA double strand breaks.............. 2164 

DNA interaction................................ 481 

DNA methylation..... 102, 815, 942, 943, 

944, 946, 950, 1616, 1720, 1987 

DNA microarray............................. 1605 

DNA Repair............. 114, 117, 283, 954, 

1976, 2636 

DNA repair capacity....................... 1360 

DNA sequence................................ 2441 

DNA strand breaks......................... 1303 

DNA Synthesis................................. 122 

DNEL................................................ 499 

DNT................................................ 2595 

Docking............................................ 149 

Dog................. 211, 520, 560, 619, 2285 

Dogs.................................................. 528 

DOHaD........................................... 2185 

Domoic acid.................................... 2621 

dopamine..... 168, 346, 506, 1378, 1394, 

2149, 2399, 2579 

Dopamine neuron........................... 1400 

dopamine transporter.............. 868, 1347 

dopaminergic.................................... 872 

dopaminergic neurons....................... 980 

dopaminergic toxicity..................... 1357 

Dopaminergics................................ 2372 

Dose Addition................................. 2306 

dose reconstruction......................... 1810 

Dose response...................... 1960, 2161, 

2507, 2639 

dose response modeling.......... 478, 1978 

Dose-Dependent Transitions.......... 1719 

Dose-Limiting Toxicity.................. 1524 

Dose-Response........ 332, 473, 475, 477, 

733, 917, 1248, 1273, 2255, 2420 

dosimetry..... 595, 850, 851, 1475, 2118, 

2699 

dosimetry of nanomaterials.............. 846 

doubly labeled water................. 597, 598 

Doxorubicin................... 104, 204, 1855, 

1884, 1888 

Draize............................................. 2568 

Draize Alternative............................. 466 

dried blood spot.......... 1232, 1926, 2284 

Dried Blood Spot (DBS).................. 517 

drinking water.... 997, 1221, 1531, 1532, 

1536, 1542, 1951, 1952, 2443 

Drinking water limit................... 6, 1536 

Drosophila............................ 1978, 2445 

drug........................................... 435, 443 

drug abuse liability......................... 1722 

drug abuse potential........................ 1722 

Drug cardiotoxicity............... 1165, 1894 

drug delivery............................. 350, 653 






drug development...... 1148, 1804, 1807, 

1808, 1896 

drug discovery...................... 2519, 2678 

Drug Disposition............................ 1915 

drug dose-response relationship..... 1575 

Drug hypersensitivity reactions............ 7 

Drug impurities........................... 6, 1812 

Drug induced liver injuries (DILI)... 940 

drug induced liver injury.................. 438 

Drug induced liver injury (DILI)..... 409, 

425, 427, 446, 878, 2511 

drug interaction............................... 1844 

Drug metabolism.................... 534, 1097 

Drug metabolizing enzymes............ 615, 

1855 

drug metabolizing enzymes, 

transporters..................................... 2266 

Drug of abuse................................. 1834 

drug processing genes....................... 449 

Drug Products................................. 2573 

Drug residues.................................... 710 

drug screening...................... 1898, 2677 

drug transporters......... 1058, 1108, 1915 

drug-drug interaction...................... 2280 

Drug-drug Interactions..................... 381 

drug-induced hepatotoxicity..... 431, 463 

drug-induced liver injury......... 138, 423, 

428, 435, 934 

Drug-induced Phospholipidosis........ 137 

drug-induced vascular injury......... 2669, 

2670, 2672, 2674 

Drug-related adverse events..... 549, 854 

Drywall........................................... 1214 

Duodenum........................................ 269 

duox.................................................. 631 

dyslipidemia................................... 1115 

dysrhythmia.................................... 2114 

E2F/Rb/HDAC1/2............................ 406 

E7 oncoprotein.................................. 406 

EAAT1/GLAST................................ 394 

early age............................................ 701 

Early Safety...................................... 784 

Early safety profiling................ 479, 855 

Earthworms..................................... 2406 

ECa233........................................... 1842 

E-cadherin....................................... 2659 

ECC1 cell line................................. 2355 

ECG.............. 195, 562, 570, 1919, 2359 

economic adulteration.................... 2415 

economy......................................... 2481 

Ecotoxicity.................... 327, 1482, 2465 

ecotoxicology........ 16, 826, 2397, 2462, 

2463, 2464, 2467 

EDSP.................................... 2358, 2559 

education.................... 1866, 1870, 1872, 

1875, 1880 

Education and Career 

Development..................................... 419 

Education and Outreach....... 1865, 1869 

EEG...................................... 1355, 1806 

EFT-300.......................................... 2556 

EGCG............................................... 212 

EGFR................................................ 776 

Egypt..................................... 1216, 1218 

eicosanoids..................................... 1837 

elastase............................................ 1652 

Elastomer........................................ 1550 

Electrocardiographic......................... 558 

electrophile..................................... 1787 

Electrophoresis............................... 1374 

Electroretinogram............................. 520 

electroretinography........................... 793 

elimination...................................... 1460 

Embryo implantation...................... 1025 

Embryo toxicity.............................. 2391 

embryogenesis................................ 1634 

embryonic development.......... 410, 839, 

1616, 2445 

embryonic stem cell.......................... 979 

embryonic stem cell differentiation.... 76 

embryonic stem cell test....... 73, 75, 991 

Embryonic stem cells....... 77, 837, 1019 

embryotoxicity........................ 979, 1045 

emerging science.............................. 883 

Employment................................... 1879 

EMS................................................ 1405 

EMT.................................................. 953 

encapsulation.................................. 1358 

endocannabinoid............................. 2611 

endocannabinoids........................... 2086 

Endocrine................ 18, 246, 2094, 2559 

endocrine active agent...................... 623 

endocrine active substances............ 2466 

endocrine disrupter................. 692, 1537 

Endocrine disrupters....................... 2373 

endocrine disrupting (ED) 

activity............................................ 2367 

endocrine disruption........ 67, 494, 1066, 

2202, 2346, 2348, 2351, 2358 

endocrine disruptor...... 624, 2092, 2186, 

2349, 2352, 2375, 2383, 2388, 2602, 

2603, 2667 

Endocrine disruptor screening........ 2375 

endocrine disruptors...... 531, 730, 1016, 

1017, 1047, 2344, 2362, 2429 

endocrine mode of action................. 622 

Endocrine Disrupting Chemicals.... 2091 

endocrine-disrupting chemicals 

(EDCs)............................................ 2367 

endogenous AHR ligand....... 1839, 1845 

Endometriosis................................. 2355 

endoplasmic reticulum (ER) 

stress............................................... 1998 

Endoplasmic Reticulum Stress........ 252, 

2030 

Endorphins...................................... 2377 

endothelial...................... 189, 262, 1493 

endothelial cell.............. 212, 2180, 2633 

Endothelial cell function................. 2066 

Endothelial Cells............ 191, 455, 2250 

endothelial dysfunction............ 186, 581 

Endothelial function......................... 554 

endothelial progenitor cell.............. 2058 

endothelial progenitor cells............ 1170 

endothelin-1.................................... 1076 

Endothelium..................................... 959 

Endotoxins........................................ 668 

energetic.......................................... 1544 

energy............................................. 1535 

energy metabolism.......................... 2315 

energy policy.................................. 2589 

engine emission.............................. 1413 

engine emissions............................. 1555 

engineering..................................... 1730 

Entomopathogenic nematodes........ 1250 

ENU................................................ 1406 

environmental................................. 2394 

environmental cardiology............... 1170 

Environmental Contaminants......... 1579 

environmental effects..................... 1489 

environmental epigenetics................ 102 

environmental exposure.................. 1970 

environmental health.............. 883, 1873 

Environmental monitoring.............. 1246 

Environmental oxidants...................... 23 

Environmental pollutants................ 1567 

Environmental predictors............... 1567 

Environmental Statistics................... 714 

environmental tobacco smoke......... 186, 

1253, 1254 

environmental toxicants.................... 819 

environmental toxicology............... 1257 

enzyme inhibition........................... 2098 

Enzyme replacement therapy........... 791 

Enzymes......................................... 2381 

eosinophil peroxidase......................... 54 

EPA................................................. 2559 

EPA standard................................... 1223 

epidemiological study....................... 292 

Epidemiology........ 47, 48, 49, 50, 1198, 

1207, 1258, 1946, 1956 

EPIDERM............................. 2535, 2560 

Epidermal Growth Factor 

Receptor.......................................... 2345 

epidermal model............................... 322 

epigenetic.............. 106, 813, 1771, 2520 

epigenetic changes............................ 108 

epigenetic regulation.............. 949, 2666 

epigenetic toxicity............................ 123 

Epigenetics...... 5, 12, 42, 100, 103, 105, 

109, 110, 814, 817, 883, 946, 947, 950, 

1167, 1621, 1700, 2071, 2187 

Epigenomics............................. 12, 1720 

epilepsy................................. 2020, 2037 

EpiOcular.......................................... 644 

Episkin............................................ 2535 

Epithelial Lung Cells........................ 983 

epoxide........................................... 1843 

eQTL................................................... 41 

equine flesh..................................... 1211 

ER binding affinity........................... 494 

ER stress....... 37, 262, 1083, 2224, 2532 

ErbB2................................................ 206 

ErbB3................................................ 776 

Erionite........................................... 1267 

ERK.......................................... 276, 404 

ERK1/2 mediated inflammation..... 2329 

ER-negative.................................... 2634 

ER-negative breast cancer.............. 2635 

ER-negative xenograft.................... 2635 

ER-stress; MAPK............................. 307 

Erythrophagocytosis......................... 294 

ESL................................................. 1523 

Essential oils................................... 2236 

essentiality...................................... 2459 

esterases.......................................... 2047 

Estrogen......... 19, 172, 624, 1023, 1043, 

1064, 1272, 2344, 2364, 2365 

Estrogen carcinogenesis................... 227 

estrogen mediated........................... 2303 

estrogen receptor........... 144, 372, 1016, 

1017, 1708 

estrogen receptor activation............ 2357 

estrogen receptor beta..................... 2365 

Estrogenic Activity................. 860, 2429 

Estrogens...................................... 17, 21 

estrus cycle..................................... 1042 

ETBE...................................... 515, 1531 

ethanol......... 679, 707, 968, 1082, 1301, 

1302, 2147, 2620 

ethinylestradiol................................. 113 

EthoVision XT.................................. 780 

Ethyl Glurcuronide......................... 1819 

Ethyl tert-butyl ether (ETBE)......... 1490 

ethylene bisdithiocarbamate........... 2087 

ethylene glycol poisoning................. 758 

Ethylenediamine dinitrate............... 1420 

europe............................................. 1877 

Everyday compounds..................... 2351 

Evidence Combination..................... 729 

evolution......................................... 1729 

ex vivo............................................... 823 

EXCELERITE................................ 2228 

Excipients............................... 507, 1928 

Excitatory amino acid..................... 1571 

excretion......................................... 1194 

Exercise............................................ 537 

Exhaled breath................................ 2301 

Exhaled Breath Condensate pH...... 1212 

Exosomes.......................................... 680 

experimental autoimmune 

encephalomyelitis........................... 1507 

Experimental Design...................... 2306 

export................................................ 312 

Exposome............................... 42, 44, 46 

Exposomics......................................... 43 

exposure....... 51, 824, 1181, 1224, 1243, 

1244, 1259, 1794 

exposure assessment.................. 50, 700, 

731, 1239, 1251, 1258, 1262, 1545, 

2118, 2504 

exposure at schools........................... 498 

exposure model............................... 1266 

exposure risk................................... 1264 

exposure science................................. 52 

exposure-based testing.................... 1522 

expression profiling........................ 1410 

Extended one generation study........ 664, 

1030, 2615, 2616 

Extractable and Leachable.............. 1315 

extractable/leachable...................... 1323 

Extrapolation...................... 2, 938, 2476 

eye..................................................... 793 

eye irritant....................................... 1521 

eye irritation.................. 996, 1553, 2545 

F1...................................................... 663 

F1-extended one generation 

study............................................... 1560 

Factor XI........................................... 216 

FAS................................................. 2215 

FAS Facial anomalies in rats.......... 1640 

FasL................................................ 1657 

Fasting.................................. 2499, 2586 

fathead minnow.............................. 2368 

fatty acids........................................ 2531 

fau................................................... 1673 

FceRI.............................................. 2218 

FDA guidelines............................... 1723 

Fe-depleted....................................... 769 

Feed Refusal................................... 2419 

Feed restriction............................... 1574 

female............................................. 1024 

female puberty................................ 1042 

female reproduction........................ 1061 

Females/Gender Differences............ 583 

Fenvalerate..................................... 1070 

Ferritin.................................. 2003, 2497 

ferroportin......................................... 312 

Fertility....................... 1040, 1050, 1923 

fetal....................................... 1022, 1635 

fetal basis of adult disease.... 1043, 2191 

Fetal Growth................................... 1645 

fetal growth restriction................... 2085 

fetal liver......................................... 2185 

Fetal programming............................. 15 

fetal testis........................................ 1611 

fetal toxicity.................................... 2095 

FFPE tissue..................................... 1590 

Fiber depositin in the lung.............. 2292 

fiber equivalent diameter................ 2293 

Fiber inhalability.................. 2292, 2293 

fiber pleura toxicology..................... 600 

fiber separation............................... 2293 

Fibrinogen......................................... 765 

Fibroblast.......................................... 303 

Fibroblast Cells............................... 2341 

Fibrogenic Mediators...................... 1183 

fibrosis................ 602, 1082, 1119, 2178 

FICZ..................................... 1132, 1845 

FICZ, 6-formylindolo[3, 2-b] 

carbazole............................... 1839, 1852 

Fipronil........................................... 1355 

Fire causalities................................ 1217 

Fire Sleeve...................................... 1247 

First-Pass Elimination.................... 1817 

fish.................... 1537, 2384, 2391, 2465 

Fish advisory.................................. 1572 

fish and amphibians........................ 2466 

fish consumption.................. 1256, 1572 

fish consumption advisory.............. 1249 

Fish model...................................... 1777 

Fish Testing..................................... 2467 

Fisher 344 rat.................................... 245 

Fishing survey................................ 1572 

flame retardant...................... 2253, 2640 

Flame Retardants.................... 869, 2379 

flavonoids......................................... 616 



391






flow cytometry................. 331, 339, 650, 

651, 748, 1143, 1144, 1412, 1431, 1445, 

1608, 1910 

flow-through diffusion cell............... 634 

Fluojade B...................................... 2037 

fluorescent zebrafish....................... 1614 

Fluoride........................................... 2201 

fluoxetine........................................ 2398 

FMO3............................................. 1088 

Focal adhesion kinase..................... 1387 

Follicle........................ 1033, 1035, 1036 

folliculogenesis............................... 1072 

Folpet.............................................. 2260 

Food.................... 882, 1252, 2120, 2416 

food additive........................... 325, 2630 

food additives................................... 155 

food allergy............... 89, 96, 1139, 2080 

Food animals.................................... 710 

Food contaminant............................. 627 

food defense.......................... 2432, 2433 

food deprivation.............................. 2185 

food ingredient................................ 2438 

Food Ingredients............................. 2440 

Food Nutrition................................ 2429 

food safety....... 1525, 1688, 2415, 2427, 

2434 

foodborne pathogens...................... 2413 

Formaldehyde............ 1683, 1690, 1719, 

1944, 1945, 1946, 1947, 1948, 1949, 

2301, 2558, 2651 

formaldehyde dehydrogenase........... 798 

Formulation.......................... 2050, 2442 

FOXA1............................................. 371 

FOXI1............................................. 1602 

foxq1............................................... 1631 

Fractional Exhaled Nitric Oxide..... 1212 

Fragrance........................................ 1034 

free fatty acids................................ 1301 

free radicals.................. 685, 1296, 1512 

frontal cortex.................................. 2146 

fructose........................................... 1086 

Fry..................................................... 953 

FSH................................................. 2398 

FT-ICR-MS..................................... 1291 

Fuel................................................. 2304 

fullerene................................ 1194, 2576 

fullerenes........................................ 2161 

fumonisin........................................ 1448 

Fumonisins..................................... 2425 

function........................................... 1729 

functional assay.............................. 1142 

functional measurements................ 1912 

Functional observational battery.... 1549 

Functional Toxicogenomics............ 2558 

functionalization................... 2076, 2165 

Fundulus....................... 318, 1776, 2546 

Fundulus heteroclitus..................... 2007 

Fungi............................................... 2399 

furan........................................ 972, 1417 

future................................................. 922 

FXR................................................ 1104 

GABA............................................. 2140 

GADD45a............................... 317, 1414 

GAL4/UAS-enhancer trap.............. 1467 

Galantamine.................................... 2034 

galectin-3.......................................... 457 

gallstones........................................ 1113 

Gamma Imaging............................... 552 

Gap junction................................... 2637 

gas dosimetry.................................. 2290 

gaseous anesthetic.......................... 1661 

gasoline emissions.......................... 2610 

Gastrointestinal..................... 1427, 2165 

Gastrointestinal Toxicity........... 542, 792 

GC/MS............................................ 1695 

gemfibrozil..................................... 1890 

Gender difference........................... 2254 

gene drug disease relationships...... 1737 

gene environment interaction........ 1773, 

1985 

gene expression....................... 119, 124, 

126, 131, 196, 255, 380, 381, 591, 813, 

820, 993, 1096, 1157, 1177, 1383, 1415, 

1457, 1470, 1503, 1594, 1598, 1639, 

1853, 2059, 2091, 2110, 2145, 2183, 

2239, 2371, 2524, 2597 

gene expression profile................... 1590 

Gene expression profiling...... 135, 2052, 

2318 

gene expression, gene regulation...... 413 

gene network.................................... 131 

gene networks................................. 2322 

gene profiling.................................. 1011 

gene regulation........ 365, 369, 376, 378, 

1135, 1429, 1847, 1851, 2534 

Gene Signaling............................... 2092 

gene signature................................. 1587 

gene silencing................................. 1153 

gene therapy...................................... 382 

Gene transfection............................ 2526 

gene-environment............................. 292 

Generic drug..................................... 805 

Genes and Environment................. 1769 

genetic............................................... 842 

Genetic analysis................................ 962 

Genetic differences............................. 63 

genetic polymorphism.................... 1979 

genetic polymorphisms................... 1270 

genetic regulation............................. 374 

genetic susceptibility.............. 550, 1392 

Genetic Toxicity............................... 273 

Genetic toxicology........................ 11, 32 

Genetic Variability............................ 142 

Genetically Modified Bacteria....... 2440 

Genetics.......................................... 1367 

geniposide....................................... 1827 

genistein...................... 2010, 2311, 2361 

genome duplication........................ 1775 

Genomic........................................... 876 

genomic marker.............................. 1561 

genomics............. 442, 1601, 1717, 2090 

genotoxic........................................ 1950 

Genotoxic impurities........................ 152 

Genotoxicity.............. 59, 116, 119, 238, 

279, 280, 281, 282, 283, 317, 322, 324, 

327, 328, 330, 331, 332, 333, 340, 343, 

918, 997, 1003, 1005, 1180, 1359, 1403, 

1405, 1410, 1412, 1414, 1415, 1419, 

1420, 1422, 1469, 1918, 2027, 2075, 

2115, 2238, 2575 

genotoxicity and genomics............. 2652 

genotoxin........................................ 1429 

Genotyping..................................... 1369 

gentoxicity........................................ 318 

germ cells........................................ 1657 

Gestation......................................... 1031 

gestation/lactation................... 706, 2104 

Gestational Exposure...................... 1032 

Gestational Membranes.................. 2563 

GHS classification............................ 645 

GILZ................................................. 200 

Gini Coefficient.............................. 1815 

ginseng.............................................. 968 

Glia........................................... 178, 180 

Global Chemicals Management..... 1310 

Global Chemicals Policy................ 1310 

Global Health.......................... 831, 2589 

glucocorticoid........................... 200, 886 

Glucosamine................................... 1893 

Glutamate......... 1401, 1513, 2025, 2625 

glutamate cysteine ligase................ 1280 

glutamate transporter........................ 394 

glutamine transporter...................... 2131 

Glutathione.............................. 258, 259, 

425, 752, 1106, 1193, 1308, 1421, 1778, 

1835, 2328, 2514, 2621 

Glutathione conjugates................... 2319 

Glutathione S-Transferases............... 388 

glutathione-depletion...................... 2327 

glutathione-s-transferase................. 1447 

glycation end products...................... 391 

glyceraldehyde-3-phosphate 

dehydrogenase................................ 1305 

Glycogen......................................... 1620 

glycolytic rate................................. 2528 

Glycosylation.................................. 1084 

Glyphosate...................................... 2108 

Glyphosate herbicides.......... 1073, 1356 

Glyphosate-surfactant herbicides... 2114 

GMO foods..................................... 1732 

GnRH.............................................. 2354 

gold nanoparticles...... 1051, 1479, 2059, 

2074, 2174 

Göttingen minipig................... 559, 1623 

GPER.............................................. 1634 

G-protein coupled receptor 

(GPCR)........................................... 2343 

gpt assay......................................... 1405 

gpt delta transgenic rat.................... 1403 

Graduate education......................... 1876 

Grant............................................... 1768 

green chemistry............... 497, 908, 909, 

910, 911, 912, 913 

green engineering............................. 909 

Green Tea Polyphenols................... 2204 

GreenScreen HC............................. 1414 

Growth............................................ 1067 

growth faltering................................ 832 

GSH.................................................. 753 

GSNO reductase............................... 798 

GST................................................. 1982 

GST polymorphisms....................... 2112 

GSTs............................................... 1362 

GT-094.............................................. 220 

guideline........................................... 471 

Guideline Studies............................ 2107 

guidelines.............................. 1256, 2467 

Guinea Pig............................ 2034, 2035 

Gulf of Mexico......................... 825, 826 

Gum Guggul................................... 2234 

GWAS................................................. 43 

gynecological.................................. 2374 

H295R................................... 2351, 2547 

H2A histone.................................... 2205 

H9C2, glucose, galactose................. 973 

H9c2s.............................................. 1908 

Haber’s Rule..................................... 572 

haematology................................... 2230 

hair.................................................. 1238 

hairless guinea pig.......................... 2013 

Halfnium Oxide.............................. 1477 

Haloacetates.................................... 1099 

Halogenated aromatic 

hydrocarbons.................................... 924 

Haloperidol..................................... 1615 

Hands-on............................... 1867, 1868 

Hanford Miniature Swine................. 636 

haplotype........................................ 1360 

harm reduction................................ 2694 

harmonization........................... 418, 495 

hazard assessment............................. 497 

hazard categorization...................... 1519 

Hazard characterization.................. 1945 

hazard classification....................... 1521 

hazard identification................. 903, 907 

HCS................................................ 1889 

HCV.................................................. 447 

HDAC............................................... 690 

HDAC inhibitors.............................. 948 

HDAC6........................................... 1279 

HDO................................................. 556 

health................ 922, 923, 924, 925, 926 

health and safety............................. 1517 

health effects................................... 1223 

health guidance value..................... 1811 

health guidance values.................... 2298 

Health Monitoring Data.................. 1199 

health risk assessment............. 597, 2292 

hearing loss....................................... 160 

heart.... 203, 213, 442, 1647, 2008, 2359 

Heart failure...................... 196, 208, 214 

Heart rate.................... 1166, 1487, 1645 

Heart Rate Variability....................... 596 

Heart Regeneration................... 197, 198 

heart slices...................................... 1907 

Heat Shock Protein................. 395, 1750 

heat stability.................................... 2431 

Heatox............................................... 882 

heavy metal....................................... 295 

Heavy metals........................ 1223, 1605 

hedgehog signaling pathway.......... 1631 

helicobacter pylori.......................... 2650 

Hematologic toxicity........................ 509 

Hematological Effects.................... 1473 

hematopoietic progenitor cells....... 1168 

hematopoietic stem cell........ 1153, 1158 

Hematopoietic stem cells...... 1157, 1500 

hematotoxicity............ 1557, 1949, 2340 

heme oxygenase-1.......................... 2216 

hemochromatosis.............................. 511 

Hemodynamics................................. 559 

Hemoglobin.................................... 2320 

Hemorrhagic shock/ 

Resuscitation................................... 1648 

hemostasis....................................... 2047 

hemostatic system................... 433, 2022 

HepaRG................ 420, 935, 1903, 2516 

HepaRG cells.................................. 1579 

Heparin............................................. 440 

Hepatic and renal toxicity............... 2222 

Hepatic cells................................... 1097 

Hepatic fibrosis............................... 2212 

hepatic gene expression.................. 1584 

hepatic steatosis.............................. 1117 

Hepatic stellate cells....................... 2212 

hepatic toxicity..................... 2522, 2523 

Hepatic transporters.......................... 534 

Hepatitis C........................................ 690 

Hepatocarcinogenesis..................... 2657 

hepatocellular carcinoma...... 1096, 1674 

Hepatocyte.................... 429, 1098, 1173 

hepatocytes.......... 311, 366, 1822, 1864, 

2349, 2537, 2557 

Hepatoprotective effect................... 2224 

Hepatotoxicants................................ 532 

hepatotoxicity.................. 139, 397, 420, 

421, 424, 427, 428, 432, 434, 443, 444, 

445, 448, 451, 454, 459, 805, 941, 995, 

1089, 1119, 1173, 1269, 1577, 1590, 

1678, 1705, 1710, 1735, 1834, 1899, 

1905, 2418, 2539, 2540 

hepatotoxins...................................... 426 

hepatoxicity.................................... 2561 

hepcidin............................................ 511 

HepG2........................... 422, 1162, 1841 

HepG2 cells.......................... 1667, 2531 

Heptachlor.......................................... 98 

Heptototoxicity....................... 437, 1966 

herbal.............................................. 2631 

herbal supplement................. 2374, 2439 

herbicide diuron................................ 547 

Hexabromocyclododecane............. 1252 

hexachlorobenzene............... 1358, 2685 

hexahydro-1, 3, 5-trinitro-1, 

3, 5-triazine....................................... 736 

Hexavalent chromium..... 278, 915, 916, 

917, 918, 920, 921, 2407 

hexavalent chromium (CrVI)......... 1597 

HGF................................................ 1112 

HIF-1.............................................. 1652 

high content.................................... 2540 

High Content Analysis...................... 420 

high content cell-based imaging........ 28, 

31, 2511 

High Content Image Analysis.......... 398, 

2629 

high content imaging.................... 29, 32 

High Content Screening.......... 33, 1895, 

1966 

High Content Screening Assay....... 1903 






High Definition Oscillometry........... 561 

high fat diet........................... 2002, 2213 

High Performance Metabolic 

Profiling.......................................... 1257 

High Throughput................... 316, 1813, 

1894, 2553 

high throughput screening........ 333, 369 

High throughput toxicity testing......... 13 

high-content screening assay.......... 1889 

high-throughput................................ 982 

High-throughput assay.................... 2121 

High-throughput Screening........... 1760, 

2505 

hippocampus..... 1375, 1390, 2145, 2146 

hiring............................................... 2486 

Histiotrophic nutrition.................... 1616 

histone acetyltransferase................... 107 

histone H2AX................................... 878 

histone modification..... 815, 1019, 2497 

Histone Modifications.............. 946, 950 

histopathology.................... 58, 560, 648 

historical......................................... 2437 

Historical Control Data................... 1028 

history............. 923, 924, 925, 926, 1880 

history of safe use........................... 1728 

HIV gp120........................................ 677 

HIV HLA........................................ 1364 

HIV infection.................................... 612 

HIV therapy.................................... 1275 

HIV-antiretrovirals............................ 613 

HLA-specific.................................. 1498 

HMGB1.......................... 263, 264, 2337 

HMGCoA reductase......................... 789 

HMG-CoA Reductase Inhibitor...... 1630 

HNE.................................................. 262 

HNSCC............................................. 363 

HO-1............................................... 2127 

Homologous Recombination............ 114 

Homology modeling......................... 368 

Host defense................................... 1474 

Host resistance................................ 1129 

Hot flashes...................................... 1219 

house dust....................................... 1229 

Housekeeping Gene Expression..... 1753 

Hovenia dulcis extract.................... 2224 

HPA axis............................... 1699, 2151 

HPLC/MS/MS................................ 1689 

HPLC-MS/MS................................ 1428 

HR96............................................... 2382 

Hras................................................... 357 

hRPTC............................................ 2544 

HSP70............................................... 166 

Hsp70 and liver............................... 2199 

HSP90............................... 214, 793, 804 

HTS................................................... 340 

human........ 474, 981, 1847, 1959, 1961, 

2259 

Human biotransformation............... 2097 

human bladder epithelial................ 1977 

Human blood plasma...................... 2244 

human bronchoalveolar 

H358 cells....................................... 1681 

human embryonic stem cells.......... 1167 

human epidermal keratinocytes...... 1176 

human exposure level....................... 435 

Human Growth Hormone............... 1156 

human health risk assessment........ 1229, 

1266 

human health risks.......................... 1245 

Human Hepatocytes...... 381, 1094, 2096 

human keratinocyte cell line.......... 1011, 

2059 

human kinetic adjustment factor..... 500, 

501 

human liver slices........................... 2561 

human lung cells............................. 1831 

human lymphocytes.......................... 326 

human metabolism................ 1823, 1824 

human neural progenitor cells.......... 870 

Human Peripheral Blood 

Lymphocytes..................................... 334 

human placenta............................... 2169 

human plasma................................. 2195 

human primary hepatocytes.............. 859 

Human Relevance........................... 1933 

human renal proximal tubule cells... 762 

human skin equivalents.................. 1012 

human stem cell.............................. 2455 

human stem cell-derived 

cardiomyocyte................................ 1165 

human THP-1 macrophages........... 2053 

human variability.............................. 821 

humanized mAb.............................. 1929 

humoral immunity............................ 678 

Huntington’s disease............. 2121, 2132 

huperzine A..................................... 2585 

HUVECs......................................... 1999 

hydrocarbons.................................. 2316 

hydrofluorocarbon.......................... 2259 

hydrogen peroxide.......................... 1532 

Hydrogen Sulfide............................ 1214 

hydroquinone.................................. 1673 

hydroxyl radicals............................ 1292 

hydroxylated fullerene 

nanoparticles................................... 1176 

hydroxylated PBDEs...................... 1607 

Hypercholesterolemia..................... 1113 

hypercholesterolemic...................... 1112 

hyperoxia.... 261, 264, 1856, 2193, 2587 

hypersensitivity.......... 83, 470, 620, 667, 

989, 1497, 1498, 2422 

Hypertension................... 199, 554, 2008 

Hyperthyroidism............................. 2353 

hypertrophy....................................... 207 

Hypotension...................................... 778 

hypothalamic peptide...................... 2343 

hypothalamic-pituitary-thyroid......... 702 

Hypothalamus....................... 1063, 2354 

Hypothesis Generation..................... 480 

Hypothyroidism.............................. 2353 

hypoxia........................................... 1652 

IATA................................................ 1539 

ICAM-1............................................ 259 

ICH S6............................................ 1912 

ICH S9............................................ 1912 

ID gene............................................. 445 

idiosyncratic drug reactions..... 424, 509, 

1499, 1501, 1504 

Idiosyncratic Hepatotoxicity........... 936, 

1014, 1658 

Idiosyncratic Liver Toxicity............. 510 

IE-Cpr-Null..................................... 2264 

IFN-gamma....................................... 694 

IgE................................ 530, 2080, 2207 

IgE antibody..................................... 903 

IgE+ B lymphocytes......................... 530 

IGF-1........................................ 351, 407 

IGF-1R.................................... 788, 2315 

IL-1 Beta............................... 1040, 1617 

IL-12................................................. 796 

IL-18............................................... 2571 

IL-1b................................................... 57 

IL-2................................................... 345 

IL-23................................................. 796 

IL-33............................................... 1514 

IL-6........................................... 441, 442 

IL-7................................................. 1502 

ILSI................................................. 1525 

image................................................ 448 

Image analysis................................ 2615 

Imaging................................... 429, 2618 

immune cells......................... 1141, 1891 

Immune function.............................. 658 

immune monitoring for latent 

viruses............................................. 1148 

Immune regulation.................... 680, 949 

immune response............................ 2042 

immune responses.............................. 23 

immune suppression............... 678, 1013 

immune system............................... 1189 

immune tolerance........................... 1502 

immune-competent cells................. 2052 

Immune-mediated toxicity.............. 2686 

immune-modulating....................... 2083 

Immunodeficient mice.................... 1512 

immunodevelopment........................ 630 

immunogenicity.................... 1150, 1151 

Immunoglobulin regulation............ 1124 

Immunohistochemistry..................... 881 

immunolocalization.......................... 575 

immunological mechanisms............. 902 

immunology.................. 657, 1126, 2446 

immunomodulation................. 698, 1169 

Immunomodulator............................ 692 

Immunomodulatory compounds..... 1140 

immunopathology........................... 1709 

Immunophenotyping................ 528, 529, 

650, 651 

immunosuppression........... 80, 652, 659, 

667, 675, 676, 1133, 1189 

immunotoxic..................................... 695 

immunotoxicity........................ 185, 649, 

650, 654, 659, 661, 663, 667, 670, 679, 

682, 691, 1125, 1131, 1133, 1140, 1145, 

1146, 1628, 1988, 1989 

Immunotoxicity testing..................... 664 

immunotoxicology........... 287, 571, 653, 

655, 673, 1143, 1147, 1148, 1152, 1504, 

2422, 2682, 2685 

impedance....................................... 2344 

Implant.................................................. 1 

Imposex................................ 1068, 2393 

improved catheter dosing............... 1913 

in ovo.............................................. 1684 

in silico....... 157, 469, 1559, 2679, 2681 

in silico analysis............................... 132 

in silico model.......................... 137, 464 

in silico prediction.................... 496, 855 

In situ perfusion.............................. 1377 

in utero............................................ 1612 

in utero exposure.......... 616, 1055, 1069 

in vitro...... 640, 803, 850, 939, 969, 978, 

982, 990, 1002, 1020, 1023, 1354, 1539, 

1553, 1650, 1671, 1821, 1888, 1908, 

1966, 2070, 2167, 2303, 2454, 2463, 

2516, 2543, 2544, 2550, 2554, 2629, 

2678, 2679 

in vitro-in vivo extrapolation............. 13, 

715, 1975 

in vitro airway model...................... 1003 

in vitro alternative........................... 2373 

in vitro Alternative Method...... 87, 1010 

in vitro Alternatives...... 998, 1528, 2032 

in vitro Animal Alternative 

Method.................................. 1049, 1555 

in vitro assay......................... 1000, 2540 

in vitro assays..................................... 28 

in vitro biliary clearance................. 1081 

in vitro cornea model........... 2031, 2032, 

2033 

in vitro cytotoxicity.... 1021, 1234, 2226 

in vitro developmental 

neurotoxicity testing....................... 2518 

in vitro drug testing............... 1165, 1899 

in vitro evaluation platform............ 2158 

in vitro Gastrointestinal Model....... 2572 

in vitro human skin model................ 647 

in vitro Human Skin Models......... 2541, 

2542 

in vitro-in vivo correlation...... 856, 2348 

in vitro-in vivo extrapolation............ 733 

in vitro method comparison.............. 565 

in vitro Methodology........................ 905 

in vitro methods.................................. 14 

in vitro methylation........................ 1981 

in vitro Micronucleus................ 32, 2162 

in vitro micronucleus assay.............. 343 

in vitro model............. 1009, 1902, 2370, 

2513, 2519 

In vitro model for inhalation............ 983, 

2567 

in vitro model for vapor 

exposure.......................................... 2304 

in vitro models........................ 430, 1766 

in vitro neurotoxicity.......................... 31 

in vitro prediction..................... 317, 935 

in vitro screening........... 717, 996, 1897, 

2564, 2680 

in vitro skin..................................... 2574 

in vitro skin irritation.............. 467, 2555 

in vitro skin model...... 2534, 2571, 2575 

in vitro skin sensitization test... 85, 2560 

in vitro test...................................... 1010 

in vitro testing..... 739, 1905, 2470, 2480 

in vitro toxicity assays......... 1094, 1889, 

1903 

in vitro Toxicology................. 534, 1606 

in vivo..... 1045, 1470, 1562, 2234, 2261 

in vivo alternative............................. 341 

in vivo comet/micronucleus 

combination.................................... 1481 

in vivo gene mutation...................... 2632 

in vivo imaging............................... 2674 

in vivo micronucleus....................... 1416 

in vivo model.................................. 1018 

in vivo mutation...................... 879, 1416 

inbred mouse strain........................... 822 

Indirubin........................................... 416 

Indium particles................................ 578 

individualized prevention strategies... 46 

indoles............................................. 1507 

indoor.............................................. 1244 

indoor air pollutant biomonitoring... 977 

Indoor Air Quality...... 1214, 1215, 1573 

Indoor dust...................................... 1268 

indoor mold...................................... 174 

Induced Pluripotent Stem Cell......... 215, 

1173, 2453 

induced pluripotent stem cells....... 1167, 

2451 

inducible nitric oxide synthase......... 684 

Infants............................................. 1060 

inflammasome.............. 27, 35, 55, 1711 

Inflammation....... 55, 61, 217, 218, 238, 

254, 314, 416, 452, 539, 599, 643, 668, 

669, 756, 901, 1091, 1105, 1128, 1134, 

1294, 1462, 1709, 1780, 1782, 1784, 

1785, 1997, 2028, 2127, 2181, 2190, 

2205, 2323, 2331, 2446 

inflammatory bowel disease..... 36, 1133 

inflammatory bowel diseases........... 364 

Inflammatory cytokines.................. 1570 

inflammatory response..................... 573 

inflammatory responses...................... 25 

influenza......................................... 1132 

Informatics........................................ 419 

infusion models.............................. 1931 

Ingenuity Pathway Analyses............... 26 

Inhalation......... 290, 540, 563, 564, 589, 

594, 599, 601, 605, 1152, 1196, 1458, 

1546, 1570, 1755, 1762, 1882, 1954, 

2012, 2475, 2476, 2493 

Inhalation dose.................................. 572 

Inhalation elicitation threshold......... 904 

Inhalation exposure..... 588, 1471, 2029, 

2610 

inhalation exposures....................... 2338 

Inhalation nanotoxicology.............. 1466 

Inhalation Risk Assessment.............. 587 

Inhalation Safety Assessment.......... 585, 

587 

Inhalation study.............................. 1459 

inhalation toxicity....... 1547, 2057, 2567 

Inhalation toxicology........... 53, 58, 585, 

586, 587, 1468 

Inhaled.................................. 1883, 2058 

inhibition......................................... 1844 

initiation/promotion................ 237, 2630 

Injection.......................................... 1902 



393






innate immune system.................... 2196 

Innate Immunity............. 256, 673, 1990 

inorganic arsenic........... 550, 1998, 2655 

insecticide....................................... 1343 

Insecticides........................... 1227, 1353 

Inspector Toxicology...................... 1865 

Instillation....................................... 1458 

Insulin............................................... 811 

insulin release................................... 267 

insulin signaling.............................. 2001 

Insuline Resistance......................... 2201 

Intake.............................................. 1228 

Integrated Testing Strategy............... 858 

integration....................................... 1918 

integrative......................................... 939 

integrative approach... 2512, 2513, 2515 

interleukin 17...................................... 93 

interleukin 8.................................... 2527 

interleukin-1....................................... 35 

international harmonization............ 2157 

International Treaties...................... 1310 

Interspecies extrapolation................. 920 

intervention..................................... 2582 

Interview preparation...................... 2485 

intestinal bacteria............................ 2221 

intestinal metabolism...................... 1825 

Intestinal P450................................ 2264 

Intracellular trafficking..................... 382 

intracerebroventricular..................... 801 

Intramuscular injection..................... 648 

intranasal instillation...................... 1761 

Intratracheal instillation.......... 590, 2331 

intravenous....................................... 617 

Intravenous infusion....................... 1931 

Intraventricular conduction 

delay............................................... 2114 

Intravitreous administration............ 1927 

intravitreous injection....................... 546 

investigational toxicology.............. 1592 

iodine.............................................. 2608 

ion cyclotron resonance mass 

spectrometry....................................... 44 

Ionic Liquids................................... 1578 

Ionizing radiation.............. 63, 879, 2605 

IPS cell cardiomyocytes................. 1161 

iPSCs.............................................. 2454 

IQ...................................................... 626 

IRIS................................................. 1958 

Iron Homeostasis.............................. 603 

iron metabolism................................ 511 

Iron Oxide....................................... 2166 

Iron transport.......................... 269, 1651 

Iron Uptake..................................... 1649 

Irritation................................ 1947, 2535 

ischemia reperfusion....................... 1651 

Ischemic Reperfusion Injury.......... 1274 

islet................................................. 2653 

ISO Standard 10993....................... 1550 

Isodecyl benzoate........................... 1029 

Isomalathion................................... 1336 

Isophorone...................................... 2346 

isoproterenol................................... 1907 

Itch...................................................... 70 

IVOS............................................... 1050 

Jacketed external telemetry.............. 559 

JAK2................................................. 403 

JET jacketed external telemetry....... 557 

JMJD1A............................................ 816 

JNK................................................... 299 

job................................................... 2482 

Job Market Survey.......................... 1879 

jobs....................................... 2481, 2486 

JP-8 jet fuel....................................... 160 

juvenile..................................... 619, 630 

Juvenile dog...................................... 779 

Juvenile testing................................. 195 

Juvenile Toxicity................ 15, 618, 622, 

623, 662 

K–12........................... 1866, 1867, 1868 

K–12 education............................... 1869 

Kainate.................................... 399, 1297 

Kava extract...................................... 454 

Keap1.............................411, 1116, 1787 

keratinocyte.............................. 631, 892 

keratinocyte metabolism..................... 88 

keratinocytes........................... 349, 1753 

Kernicterus....................................... 386 

ketamine............................... 1614, 2597 

key event......................................... 1721 

kidney...... 744, 747, 752, 754, 757, 760, 

761, 764, 765, 767, 768, 769, 772, 774, 

1434, 1594, 2282, 2313, 2544 

kidney biomarkers.......................... 1439 

Kidney Injury........................ 1300, 1648 

kidney injury molecule 1.................. 759 

kidney toxicity................................ 1439 

KIM-1............................................. 1602 

kinase enrichment analysis............. 1738 

kinase inhibitors.............................. 1172 

kinase therapeutics............................ 401 

Kinases................................... 150, 1906 

Kinetics......................... 709, 1232, 2610 

Kisspeptin....................................... 1063 

KIT.................................................. 1054 

Knockdown-mice............................. 553 

Knockout mice.................................. 230 

knockout mouse................................ 885 

knowledge base................ 155, 427, 934 

Knowledgebase................................. 728 

KRAS............................................... 239 

K-ras....................................... 879, 2632 

Kupffer cells........................... 430, 1092 

L1 Retrotransposon.......................... 406 

L6 myoblasts.................................. 1890 

Label............................................... 2410 

lactate dehydrogenase..................... 1447 

Lactating rat and pup...................... 2668 

Lactation......................................... 1031 

lactoferrin........................................... 95 

LAMP-2.......................................... 1452 

Langerhans cell................................... 94 

Langerhans cells................................. 95 

laser scanning cytometry................ 1899 

LC/MS/MS..................................... 2424 

LC/MS-MS..................................... 2383 

LC50............................................... 2236 

LC-ESI-MS..................................... 1669 

LC-MS/MS....... 2195, 2284, 2285, 2416 

LD50............................................... 2577 

Lead................................. 294, 295, 296, 

686, 835, 1204, 1205, 1533, 1698, 1699, 

1841, 2138, 2142, 2143, 2145, 2146, 

2150, 2187, 2397 

Lead (Pb).......... 1697, 1701, 2144, 2151 

Lead Exposure........................ 943, 2147 

lead, pb............................................. 626 

Learning.......................................... 1875 

Learning and Memory.......... 1646, 2617 

Lectin.............................................. 2223 

Leflunomide........................... 432, 1610 

left ventricular pressure.................. 1930 

Leiomyoma..................................... 1070 

let-7g................................................. 383 

Lethargic......................................... 1385 

Letrozole......................................... 2361 

leukemia........... 1941, 1944, 1949, 2340 

Leukemia Therapy.......................... 1887 

Leukotrienes................................... 1192 

levomethorphan.............................. 1100 

Leydig cells.................................... 2552 

Libby Amphibole.... 601, 602, 603, 1511 

life span low dose alcohol 

exposure................................ 1640, 2613 

Lifecycle......................................... 1594 

ligand-induced activation............... 1634 

Ligand-Protein complex................... 149 

lindane............................................ 2562 

LINE................................................... 99 

lipid................................................. 1115 

Lipid peroxidation.......................... 2423 

Lipid Trafficking............................ 1282 

lipidomics....................... 551, 875, 1426 

lipids............................................... 2531 

lipoatrophy...................................... 1156 

Lipopolysaccharide................... 170, 516 

Lipopolysaccharide (LPS)....... 171, 688, 

1450 

lipopolysaccharides........................ 1169 

Liposomal-NAC............................. 1269 

Lipoxygenase.................................. 1192 

liver.......................... 140, 142, 270, 365, 

375, 392, 426, 430, 440, 452, 455, 456, 

461, 462, 1004, 1083, 1098, 1099, 1102, 

1103, 1109, 1112, 1115, 1311, 1502, 

1503, 1603, 1641, 1643, 1788, 1853, 

2002, 2079, 2109, 2237, 2245, 2282, 

2404, 2496, 2516, 2532, 2553, 2631 

liver cancer..................................... 2642 

Liver Cancer..................................... 945 

liver carcinogenesis.......... 223, 874, 875 

Liver Disease.................................. 1958 

Liver fibrosis.................................. 2509 

Liver function................................. 1909 

liver hypertrophy.................. 1090, 2657 

Liver injury.................. 434, 1084, 1093, 

1101, 1648 

Liver Regeneration......................... 1091 

Liver Slices............................. 421, 1830 

Liver Toxicity... 1088, 1106, 2074, 2543 

Liver tumor....................................... 224 

Livestock waste................................ 229 

LLNA............. 82, 83, 91, 907, 963, 989, 

1518, 1519, 1520, 2536 

LNTE.............................................. 1676 

Local lymph node............................. 468 

Local Lymph Node Assay.................. 82 

local lymph node assay (LLNA)........ 81 

Local Tolerance.............................. 1922 

Locomotion..................................... 1742 

Locomotor activity......................... 2615 

long term effect............................... 1334 

long-term........................................ 1913 

Long-term estrogen exposure........... 103 

long-term peak exposure................ 1226 

Lovastatin....................................... 2264 

Low Dose................................ 404, 1697 

low dose linearity........................... 1962 

Low dose radiation......................... 2593 

low-dose linearity............................. 475 

loxapine................................ 1882, 1883 

LPS........................................... 443, 686 

Luminex xMAP................................ 743 

Lumping........................................... 718 

Lunar Dust................................ 303, 304 

lung.................. 268, 272, 289, 539, 617, 

884, 885, 1179, 1188, 1191, 1195, 1463, 

1752, 1759, 2082, 2300, 2333, 2334, 

2489, 2492 

Lung cancer.......... 249, 286, 1185, 2521 

lung cancer cell migration................ 383 

lung cell.......................................... 1181 

lung cells......................................... 1601 

Lung development.......................... 2193 

lung diseases................................... 2477 

lung dosimetry................................ 2289 

Lung epithelial cells......................... 300 

Lung Fibrosis....... 53, 1293, 1294, 1454, 

2081, 2160 

lung function........................... 541, 1762 

Lung function measurement........... 2326 

Lung inflammation.... 1193, 1474, 2051, 

2328, 2487 

lung injury.................. 24, 56, 567, 2038 

lung metabolism............................. 1849 

lung modeling................................. 2299 

Lung slice......................................... 988 

lung toxicity.................................... 1901 

Luteinizing hormone...................... 2552 

lymph node....................................... 288 

Lymphoblastoid.............................. 2447 

Lymphocryptovirus......................... 1149 

lymphocyte....................... 337, 656, 665 

lymphocytes.................................... 2226 

lyophilization.................................... 893 

Lysosome........................................ 1650 

lysosomes....................................... 2533 

lysyl oxidase..................................... 219 

MABEL............................................ 803 

Macrophage........... 258, 578, 682, 1127, 

1128, 1272, 1711, 2161 

macrophage activation...................... 456 

macrophages...... 457, 1136, 1709, 1710, 

1712, 1713, 1714 

macrophages activation.................... 878 

maghemite...................................... 2170 

magnetic nanoparticle..................... 1475 

magnetic tracking............................. 514 

Magnetite.......................................... 328 

Mainstream cigarette smoke............. 983 

MALDI Imaging Mass 

Spectrometry................................... 1285 

male infertility................................ 1053 

Male Reproductive............................. 62 

malignant mesothelioma..................... 27 

Mammary Cancer............................. 231 

Mammary Gland................... 1612, 1622 

mancozeb.............................. 1356, 2087 

maneb...... 625, 1222, 1349, 1350, 1351, 

2087 

manganese....... 173, 312, 625, 629, 701, 

845, 1102, 1222, 1237, 1238, 2122, 

2123, 2124, 2125, 2128, 2131, 2132, 

2135, 2136, 2139, 2140, 2141, 2148, 

2149, 2317, 2456, 2457, 2458, 2459, 

2460, 2461, 2579, 2580, 2591, 2592, 

2664 

Manganese Exposure...................... 2137 

manganese nanoparticles................ 2182 

manganese neurotoxicity..... 2129, 2130, 

2133 

Manganese transport....................... 2121 

Manganism....... 2125, 2579, 2580, 2591 

mannan............................................. 253 

mannan binding lectin...................... 253 

manufactured engineered 

nanomaterials.................................... 846 

manufactured gas plants................. 1236 

Manuscript...................................... 1768 

MAP kinase.................................... 2036 

MAPK..................... 118, 244, 402, 1393 

Mapping............................................ 857 

margin of exposure............... 1565, 2295 

Marin County CA............................. 229 

Marine mammal................................ 658 

Marine Mammals............................ 2407 

marine pollution.................... 1870, 2252 

marine product................................ 2219 

marker for developmental 

retardation....................................... 1640 

Markov Chain Monte Carlo 

(MCMC)........................................... 722 

mars dust........................................... 304 

MASOT.......................................... 1865 

Mass Spectrometry...... 408, 1257, 1578, 

1682, 2011, 2017 

mass transfer..................................... 632 

mast cell............................................ 254 

mast cells........................................ 1500 

Maternal.......................................... 1615 

maternal dietary intake................... 1636 

Maternal-fetal toxicity.................... 1075 

Mathematical Modeling........ 1240, 2069 

matrix metalloproteinase.................. 132 

matrix metalloproteinase-9............. 2208 

matrix metalloproteinases............... 2081 

MCF-7 cells.................................... 2371 

MCTT HCE model........................... 975 

MDMA................................. 1306, 1829 

Mdr1a............................................... 535 

MDSCs............................................. 676 






MEC................................................. 929 

mechanism of action................. 130, 966 

Mechanisms.................................. 5, 421 

Mechanisms of action........... 2225, 2402 

mechlorethamine............................ 2023 

Medaka..................... 78, 968, 992, 1777 

Medical Device........ 1, 978, 1314, 1317, 

1318, 1319, 1321, 1323, 1767 

medical devices.......... 1312, 1313, 1316 

medicinal herbs............................... 1118 

Medium chain chlorinated 

paraffins.......................................... 1613 

medium-term bioassay...................... 242 

Megakaryocytes................................ 284 

megalin........................................... 1746 

MEHP........................................... 66, 70 

Melamine...................... 747, 1434, 2420 

Melamine mixture............................ 746 

membrane potential........................ 2530 

membrane transporter....................... 203 

menadione....................................... 2653 

menstrual cycle............................... 1061 

menthol................................... 574, 1409 

mercapturic acids............................ 1428 

mercuric chloride............................ 1629 

mercury.................... 292, 301, 309, 610, 

761, 986, 1249, 1299, 1398, 1633, 2005, 

2196, 2386, 2406 

Mercury-selenium interactions....... 2590 

Mesalamine..................................... 1303 

Mesenchymal stem cells.......... 78, 1156, 

1169 

Mesoporous silica nanoparticles..... 2054 

Mesothelial Cells............................ 1509 

Mesothelioma......................... 683, 1935 

Met receptor.................................... 1772 

metabolic capability........................ 1053 

metabolic flux................................. 1308 

Metabolic interactions.................... 1836 

metabolic profile............................... 167 

metabolic syndrome...... 175, 1086, 1446 

metabolism.... 426, 708, 884, 889, 1006, 

1100, 1105, 1306, 1822, 1828, 1834, 

1838, 1860, 1968, 1979, 2104, 2221, 

2275, 2276, 2279, 2394, 2515 

Metabolism and disposition........... 2257, 

2258 

Metabolism-induced toxicology..... 2526 

Metabolite profiling........................ 2353 

metabolites...................................... 2011 

Metabolome.................................... 1440 

metabolomic profiling...................... 521 

metabolomics....... 44, 72, 438, 523, 724, 

735, 745, 1562, 1678, 1694, 1850, 2109 

Metabolomics, Biomarker, Amino 

Acid, NMR, Mixture...................... 2248 

metabonomic...................................... 45 

metabonomics................................... 523 

metagenomics..................................... 45 

metal........................... 2067, 2069, 2072 

Metal Genes.................................... 2168 

Metal nanoparticles........................ 1370 

Metal oxide nanoparticles...... 680, 1485, 

2052 

Metallothionein........ 265, 272, 389, 412, 

698, 1378, 1447, 1996 

Metallothionein-3..................... 771, 818 

Metals.............................. 208, 282, 285, 

291, 296, 297, 310, 669, 915, 923, 947, 

1019, 1384, 1401, 2176, 2302, 2396, 

2406, 2434, 2437 

Metals and Minerals......................... 670 

Metalworking................................... 642 

Metamorphosis............................... 2379 

metastasis................................ 228, 1714 

Methacholine.................................. 1921 

Methamidophos.............................. 1335 

Methanol......................................... 1691 

method............................................ 2475 

Method validation......... 644, 1231, 2356 

methods................................... 575, 2479 

methods and models....................... 2474 

Methomyl....................................... 1337 

Methotrexate..................................... 805 

methoxychlor.............. 1035, 1037, 1038 

methyl hexanol............................... 1546 

methyl paraben............................... 1823 

methyl tertiary butyl ether.............. 1951 

Methylarsonous Acid........................ 233 

methylation............................. 101, 1858 

methyldithiocarbamate..................... 696 

methylglyoxal................................. 1296 

methylisothiocyanate........................ 696 

methyllycaconitine......................... 2229 

Methylmercury.............. 306, 308, 1385, 

1386, 1387, 1390, 1391, 1392, 1393, 

1394, 1395, 1397, 1399, 1400, 1402, 

1694, 1778, 2514 

Methylmercury; pancreatic 

b-cells............................................... 307 

methylselenocysteine...................... 1708 

MFTA................................................ 861 

mice................................ 233, 799, 1490 

Micellar formulation....................... 2046 

Micro Electrode Array.................... 2510 

Microarray....... 126, 145, 395, 679, 725, 

1604, 1638, 2096, 2203, 2339, 2395 

Microarray Analysis............. 2541, 2542 

Microarray gene expression........... 2402 

Microarrays....................................... 986 

Microbial.......................................... 471 

microbiome......................................... 45 

microbubbles.................................. 1092 

microcirculation................................ 192 

microcosm...................................... 1482 

Microcystin..................................... 2436 

microcystins.......................... 2390, 2435 

microelectrode array....................... 1020 

microfluidic system.......................... 762 

Microglia.................................. 170, 688 

Microglia activation........................ 2129 

Microglial Activation.............. 171, 2130 

microglial cells............................... 1713 

microgravity..................................... 280 

Microminipig.................................... 638 

micronuclei....................................... 333 

Micronucleus.......................... 315, 1421 

micronucleus in vitro........................ 326 

Micronucleus test.............................. 316 

Micronucleus/Comet assay............... 342 

Micropatterned co-culture.............. 1094 

microPET........................................ 1661 

Micropillar...................................... 2525 

microRNA........ 383, 896, 897, 898, 900, 

901, 945, 1441, 1503, 1586 

micro-RNA....................................... 151 

microRNA-27a............................... 2233 

microRNAs............................. 268, 1999 

microscopy......................................... 29 

microsomal epoxide hydrolase...... 1847, 

1858 

microsomal metabolism.................. 1846 

microsome........................................ 169 

microtechnology................... 2522, 2523 

Microtox........................... 503, 504, 505 

Microtox assay................................ 1313 

Microtubules..................................... 382 

microvascular......................... 581, 1471 

midazolam...................................... 2598 

Migration........................................ 2061 

mineral............................................ 2443 

Mineral Fibers................................ 1267 

Minimal Risk Level........................ 1530 

minipig.......... 630, 636, 786, 1248, 1921 

minipigs........................ 529, 1150, 1151 

miR-34a.......................................... 1429 

miRNA....... 874, 899, 1163, 1585, 1642, 

2231 

miRNA155..................................... 2321 

miRNAs.......................................... 1643 

mitchondrial dynamics................... 2448 

Mitochodrial..................................... 373 

Mitochondria................... 184, 429, 432, 

441, 451, 453, 493, 614, 750, 958, 961, 

1087, 1304, 1608, 1653, 2045, 2125, 

2528, 2529, 2530, 2580 

mitochondria toxicity...................... 1905 

mitochondria-apoptosis.................... 613 

Mitochondrial biogenesis................. 748 

mitochondrial differences............... 2126 

mitochondrial DNA........................ 2448 

mitochondrial Dysfunction..... 209, 1086 

Mitochondrial Electrogenic 

Calcium Uniporter.......................... 1649 

mitochondrial function............206, 1111 

mitochondrial membrane 

potential.......................................... 1654 

mitochondrial oxidative stress........ 1651 

Mitochondrial Permeability 

Transition.............................. 1649, 2449 

Mitochondrial toxicity..... 612, 751, 936, 

1896 

mitogen-activated protein 

kinase (MAPK)..................... 1057, 2036 

Mitogen-activated protein 

kinases............................................ 1998 

mitophagy....................................... 2449 

mitosis............................. 107, 357, 1095 

mitotic spindle.................................. 335 

Mixture....... 18, 2262, 2305, 2307, 2313 

Mixture Analysis Methods............. 2309 

mixture modeling............................ 2303 

mixture toxicology.............................. 21 

mixtures......... 16, 17, 65, 476, 503, 504, 

505, 718, 1227, 1262, 1580, 1582, 1792, 

1795, 2092, 2250, 2302, 2308, 2310, 

2316, 2332, 2387, 2426 

Mixtures, Metals............................... 773 

Mll translocations............................. 616 

MMA(III)....................................... 1677 

MMP-9................................. 2210, 2214 

MMP9/13........................................ 2649 

MMPs..................................... 609, 2363 

Mn toxicity..................................... 2126 

MOA............................................... 1095 

mode................................................. 367 

mode of action........... 69, 223, 485, 858, 

919, 921, 1565, 1736, 1948, 1955, 2095, 

2507, 2639, 2698 

model.............................................. 1538 

model confidence............................ 2690 

Modeling.... 136, 725, 1736, 1810, 2291, 

2689 

modeling pathway response............. 400 

Mode-of-Action...................... 916, 2350 

molecular docking............................ 140 

Molecular dosimetry....................... 1690 

molecular dynamic simulation......... 734 

molecular mechanisms................... 1774 

Molecular modeling.................. 144, 162 

Molecular network................................ 9 

molecular pathways analysis.......... 1600 

molecular toxicology, 

mechanism(s) of toxicity................ 1592 

Molinate.......................................... 2088 

monkey......... 524, 661, 788, 1849, 1913 

Mono-2-Ethylhexyl Phthalate........ 1052 

monoamine....................................... 177 

Monoclonal antibody...... 797, 809, 1922 

monocytes / macrophages............... 1971 

Monomethylarsonous acid.............. 1976 

montmorillonite.............................. 2228 

Morpholino..................................... 1741 

Morris Maze................................... 1646 

Morris water maze................ 2035, 2617 

Mortality......................................... 1567 

Motilin.............................................. 786 

Motor deficit................................... 1402 

Motorcycle exhaust.......................... 588 

mouse............. 133, 289, 590, 595, 1439, 

1625, 2419 

Mouse Laboratory Diet................... 2362 

mouse liver..................................... 1095 

Mouse Model.................. 542, 681, 1496 

mouse models................................. 1497 

MPTP................................................ 980 

MRI....................................... 1423, 2139 

MRL and RfD................................. 1811 

Mrp......................................... 414, 1079 

MRP2................................................ 740 

Mrp4....................................... 397, 1081 

MRS.................. 1928, 2140, 2592, 2618 

MTBE......................... 1950, 1952, 2548 

mtDNA........................................... 2449 

mTOR............................................... 695 

MUC5AC....................................... 2211 

mucociliary clearance....................... 552 

muconic acid................................... 1255 

mucosal immunotoxicity.................... 36 

multicellular tumor spheroids......... 2659 

Multicontamination........................ 2427 

multidrug resistance........................ 2267 

multifunctional proteins.................... 400 

multigenerational............................ 1747 

multiple sclerosis............................ 1508 

Multiple-Path Particle 

Dosimetry....................................... 2156 

Multiroute......................................... 711 

MULTITEST.................................... 490 

Multiwall Carbon Nanotubes......... 1183 

multi-walled carbon nanotube........ 1186 

multi-walled carbon nanotubes.... 53, 58, 

59, 193, 194 

municipal solid waste..................... 1245 

munitions.................................. 928, 932 

muscarinic receptor........................ 1485 

mutagen.............................................. 99 

Mutagenesis................ 1404, 1417, 1419 

mutagenic....................................... 1950 

mutagenic carcinogen..................... 1934 

mutagenicity............ 68, 918, 919, 1370, 

1407, 1413, 1418, 1812, 2641 

mutation................ 239, 331, 1411, 1412 

mutation assay.................................. 325 

MWCNT......................... 57, 1798, 1799 

MXR............................................... 2391 

mycotoxin......................... 38, 984, 2426 

mycotoxins.................... 682, 832, 2153, 

2425, 2427 

myeloid derived suppressor cell....... 674 

Myeloperoxidase............................ 1105 

Myelosuppression........................... 1172 

myocarditis............................. 256, 1514 

myopathy........................................ 1451 

myotoxicity....................................... 789 

N, N-diethylnitrosamine................... 247 

N1E-115 Cells................................ 1345 

Na-arsenite...................................... 1990 

NAC.................................................. 753 

N-acetylcysteine............................. 1109 

NAD+-sensing enzymes................. 1703 

NADPH.......................................... 2503 

NADPH oxidase................... 1302, 2130 

NADPH oxidase system................. 1307 

NAFLD................................. 1108, 2213 

nano particle................................... 1487 

Nano particles................................. 2169 

nano-aerosol generation.................. 1466 

nanocomposite material.................. 1798 

Nanomaterial....... 653, 851, 1480, 1488, 

1717, 2082, 2083, 2085, 2156 

nanomaterial characterization.1174, 1760 

Nanomaterials.......... 10, 25, 1177, 1319, 

1469, 1711, 1797, 2159, 2173 

Nanoparticle.... 129, 192, 655, 719, 849, 

1453, 1470, 1716, 2058, 2072, 2170 

nanoparticle aerosol generation...... 1455 

nanoparticle exposure..................... 2504 

Nanoparticle hazard studies.... 847, 1454 



395






nanoparticle size............................. 2067 

Nanoparticle toxicity.... 847, 1472, 1801 

nanoparticles.................... 56, 994, 1180, 

1183, 1185, 1189, 1191, 1197, 1233, 

1459, 1463, 1478, 1483, 1489, 1493, 

1757, 1799, 2051, 2055, 2062, 2076, 

2078, 2162, 2164, 2171, 2172, 2176, 

2184, 2479 

nano-particles................................. 1466 

nanosilica........................................ 2084 

nanosilver................... 1476, 1482, 1757 

nano-silver........................................ 994 

nano-specific controls..................... 2158 

Nanotechnology................................ 848 

Nanotoxicity.... 1455, 1486, 1488, 1757, 

2073, 2171, 2172, 2182 

nanotoxicity testing........................ 2158 

Nanotoxicology................... 60, 61, 846, 

849, 850, 1186, 1456, 1465, 1468, 1479, 

1481, 1484, 1487, 1492, 1494, 1600, 

1759, 1760, 1764, 1802, 1803, 1901, 

2056, 2060, 2068, 2069, 2070, 2157, 

2160, 2166, 2167, 2181, 2183 

Nanotubes....................................... 1192 

Naphthalene............. 240, 243, 580, 582, 

887, 888, 1236, 1421, 1422, 1679, 1832, 

1849, 1953, 1954, 1955, 1956, 1957 

NAPQI.............................................. 458 

nasal.................................................. 580 

nasal carcinogenesis....................... 1953 

Nasal toxicity.......................... 513, 1954 

NASH............................................. 1108 

NAT1.............................................. 1863 

Natriuretic peptides.......................... 202 

natural killer cells........................... 1142 

natural product................................ 2428 

Natural Products........... 479, 2220, 2222 

natural sweetener............................ 2421 

nausea............................................... 148 

NCBC............................................... 285 

NCL2................................................ 801 

nd-SPME........................................ 1015 

nebulizer........................................... 584 

Neonatal................................ 2588, 2599 

neonatal/prepubertal exposure.......... 618 

Neonate rats...................................... 746 

Neoplastic transformation.............. 1182 

neopterin......................................... 2650 

nephropathy...................................... 250 

Nephrotoxicity......... 549, 738, 740, 743, 

755, 763, 766, 1438, 1587, 1746, 2005 

Nephrotoxicity, Metals..................... 773 

nerve agent........ 2015, 2016, 2025, 2585 

nervous system............................... 1020 

Network............................................ 127 

network analysis............................. 1738 

neural development........................ 1340 

Neural Differentiation......................... 79 

Neural Stem Cell........ 1390, 2520, 2622 

neurite outgrowth.............................. 870 

Neurobehavior........................ 862, 2647 

neurobehavioral changes..... 1379, 1380, 

2401 

neurobehavioral toxicity......... 174, 2626 

neurobehavioral toxicology.............. 897 

Neurodegeneration.................. 164, 179, 

182, 842, 844, 845, 1396, 1397, 1401, 

2128, 2455 

Neurodegenerative diseases.... 172, 1331 

Neurodevelopment............... 1772, 2144 

neurodevelopmental......................... 620 

neurodevelopmental toxicity........... 868, 

2360 

Neuroendocrine.............................. 1064 

neurogenesis..... 1375, 1388, 1389, 2401 

Neuroimaging................................. 2592 

Neuroinflammation................... 178, 180 

neuron............................................. 1354 

neuronal.......................................... 1358 

neuronal cell culture............. 2510, 2619 

Neuronal cells................................. 1333 

neuronal damage............................. 2037 

neuronal differentiation........ 2518, 2622 

Neuronal Injury.............................. 2619 

Neuronal migration............... 1386, 1387 

Neuropathy Target Esterase.............. 979 

neurophysiology........ 1354, 1379, 1380, 

1382, 2133 

Neuroprogenitor cell......................... 867 

neuroprotectants............................. 2014 

neuroprotection............. 161, 2049, 2585 

Neurotoxic Metals................ 1381, 2134 

neurotoxicity............ 173, 176, 178, 527, 

626, 629, 1220, 1226, 1227, 1306, 1330, 

1334, 1339, 1346, 1351, 1376, 1388, 

1389, 1393, 1397, 1398, 1399, 1443, 

1444, 1464, 1805, 1829, 2018, 2055, 

2101, 2108, 2141, 2142, 2148, 2182, 

2243, 2458, 2461, 2576, 2608, 2611, 

2612, 2627, 2664 

neurotoxicity, pesticides................. 1207 

Neurotoxicology.............. 77, 175, 1328, 

1329, 1353, 1355, 1384, 2149, 2450, 

2451, 2455 

neurotoxin....................................... 2039 

neutrophil.......................................... 433 

neutrophils........................................ 681 

nevirapine....................................... 1505 

new chemicals database...................... 81 

New Food borne diseases............... 1211 

Next Generation Sequencing.... 126, 151 

NF-B................................................. 264 

Nf-kappa B............................... 263, 431 

NFkappaB............................... 409, 1130 

NF-kappaB....................................... 257 

NF-kB................................... 2287, 2324 

NF-kB/Rel........................................ 399 

NGF.................................................. 462 

NHANES.................... 1241, 1261, 1693 

NHP.................................................. 561 

nickel....... 236, 275, 299, 305, 813, 816, 

1316, 1604 

Nicotinamide.................................. 2584 

Nicotine............................................ 111 

nitrated proteins.............................. 1286 

nitric oxide.................... 261, 1713, 2061 

Nitric Oxide Synthase..................... 1295 

nitrite............................................... 2381 

Nitrogen Mustard............................ 2026 

nitrosative stress............................... 637 

nitrotyrosine.................................... 1287 

nitroxide.......................................... 1407 

NK cell.............................................. 693 

NLRP3................................................ 57 

N-methyl-d-aspartate...................... 2596 

N-methyl-D-aspartate (NMDA) receptor 

2597 

NMR................................................. 167 

NNK................................................. 219 

No Effect Level.............................. 1947 

NO2 Engine emissions................... 1290 

NOAEL........................................... 1524 

noise.................................................. 160 

non alcoholic fatty liver disease..... 2582 

Non Human Primate............... 539, 1920 

non human primates......................... 562 

non small cell lung cancer.............. 1361 

Non-additive effects....................... 2305 

non-cancer risk assessment............. 1962 

Non-cancer toxicity........................ 1945 

non-chemical stressor..................... 1794 

non-chemical stressors......... 1792, 1793, 

1795 

nonclinical safety assessment........... 662 

Nonclinical Toxicology.................. 1925 

Nonclinical vehicles......................... 790 

non-coding RNA............................... 899 

Non-genotoxic.......................... 874, 875 

non-genotoxic hepatocarcinogen.... 1090 

nonheme iron enzymes..................... 816 

non-Hodgkin lymphoma................... 880 

Nonhuman Primate......................... 1645 

non-human primate................. 555, 1146 

Non-Human Primates..................... 1754 

nonlinear......................................... 1960 

non-mammalian model species........ 977 

Non-small cell lung cancer............... 407 

nonthermal food irradiation............ 2413 

Non-Traditional Vehicle................... 781 

noradrenergic.................................... 177 

norepinephrine transporter (NET) ligand 

812 

normalization.................................... 725 

noval formulation............................. 787 

NRF1.............................................. 2502 

NRF2....... 179, 411, 412, 413, 414, 415, 

593, 694, 1009, 1113, 1114, 1116, 1278, 

1396, 1787, 1788, 1789, 1790, 2496, 

2499, 2503, 2586 

Nrf2-Keap1.................... 92, 1786, 1791, 

2498, 2500 

NRTI................................. 183, 209, 961 

NSAID, tolfenamic acid................... 955 

NTE................................................ 1335 

N-terminal valine adducts............... 1687 

NTP Tox21........................................ 493 

nuclear receptor....... 225, 348, 354, 376, 

2382 

nuclear receptors............. 378, 952, 1857 

nucleoside reverse transcriptase 

inhibitors......................................... 1275 

nucleotide excision repair........ 113, 115, 

116 

Oatp.............................. 548, 2247, 2390 

obesity.......... 685, 760, 988, 1120, 1200, 

1201, 1450, 1698, 1862, 2270, 2345 

obesogens....................................... 1201 

occupational.................................... 2458 

occupational asthma................. 97, 1367 

occupational exposure......... 1180, 1220, 

1267, 2139, 2156 

Occupational exposure limit................. 6 

occupational health........................... 911 

occupational safety......................... 2504 

occupational standard..................... 1529 

occurrence....................................... 1221 

Ocean.............................................. 2403 

ochratoxin............................... 763, 1534 

ochratoxin A.............................. 107, 320 

Octopus........................................... 2434 

ocular................................ 524, 546, 890 

Ocular injury................................... 1748 

ocular irritation........... 1001, 2550, 2569 

ocular safety.......................... 1521, 1553 

ocular toxicity................................... 804 

Ocular Toxicology.......................... 2568 

OECD..................................... 646, 2569 

oecd validation study...................... 2380 

oedema............................................ 1160 

OEL............................ 1803, 2296, 2538 

Office Environment........................ 1225 

off-target effects................................ 853 

off-target pharmacology................... 854 

OH-PCB136................................... 1830 

OH-PCBs.......................................... 621 

oil dispersants................................. 2338 

Oil Spill........... 825, 826, 827, 828, 830, 

1263, 1963, 2341, 2392 

oil spills.......................................... 2340 

Olfactory bulb................................. 2595 

olfactory dysfunction...................... 2134 

Olfactory Sensory Neurons............ 1382 

Olfactory toxicity......... 538, 1379, 1380, 

1382, 2133, 2319 

Olfactory translocation..................... 290 

Oligonucleotide................................ 800 

Omeprazole....................................... 361 

Omic biomarkers........ 1106, 1440, 1441 

omics........................... 1585, 1597, 1715 

‘omics............................................. 1734 

-omics technologies............................ 42 

oncogenes......................................... 236 

oncological drugs............................ 1576 

Oncology................................ 792, 1427 

Ontogenesis.................................... 2662 

Ontogeny.......................................... 615 

Ontology................................. 728, 2693 

oocyte maturation........................... 1072 

oocyte meiotic maturation................ 533 

oocyte morphology........................... 533 

Oocytes........................................... 1342 

OP antagonism................................ 2048 

OP Hydrolyses................................ 2048 

OP pesticides.................................. 1333 

Operant behavior.................. 1402, 1886 

ophthalmology.................................. 519 

opioid drugs...................................... 775 

OPs exposure.................................. 1692 

Optimum design of experiments...... 478 

Oral................................................... 273 

oral toxicity............................. 787, 1547 

Ordnance Environmental 

Program.......................................... 1544 

organ toxicity.................................. 1671 

organic anion transport..................... 763 

organic anion transporters.............. 2268 

Organic UV Filters......................... 2179 

organophosphate........ 1326, 1676, 2049, 

2120 

Organophosphate Insecticide.......... 1327 

Organophosphates..... 1444, 2018, 2098, 

2102, 2113 

organophosphorous pesticides....... 1330, 

2097 

organophosphorus........................... 2101 

organophosphorus compound......... 2576 

Organophosphorus compounds........ 861 

Organophosphorus pesticide........... 2117 

Organophosphorus pesticides......... 1332 

organoselenium............................... 2023 

organotin................................. 695, 2393 

Organotypic.................................... 2553 

organotypic model............................ 466 

oryza sativa japonica...................... 2205 

Oscillations....................................... 404 

osmotic stress.................................. 1276 

osteoarthritis..................................... 512 

osteoblast.......................................... 276 

osteoblast differentiation................ 2217 

osteoblastogenesis............................ 352 

Osteoblasts...................................... 2369 

Osteolathyrism........................ 627, 2312 

osteoporosis.............................. 277, 293 

outdoor smog chamber..................... 565 

Outreach............................... 1867, 1868 

Ovarian failure................................ 1065 

Ovarian follicle depletion............... 1026 

ovarian steroidogenesis.................. 1051 

Ovarian toxicology......................... 1036 

ovariectomized rat.......................... 2372 

ovary........................... 1035, 1054, 1055 

oxalate crystals................................. 758 

Oxaxolidione.................................... 987 

oxidant.................................... 698, 2175 

oxidant stress.................................. 1290 

oxidative damage............................ 1102 

Oxidative Damage............................ 111 

Oxidative DNA adducts.................. 1856 

oxidative DNA damage.................. 1548 

oxidative environmental pollutants.... 22 

Oxidative Injury.................... 1274, 1300 

oxidative lipidomics............. 1179, 1669 

oxidative phosphorylation.... 1304, 2126 






oxidative stress........ 161, 206, 324, 338, 

410, 460, 461, 462, 697, 741, 757, 948, 

1059, 1099, 1270, 1271, 1276, 1277, 

1283, 1284, 1291, 1298, 1301, 1308, 

1333, 1376, 1435, 1461, 1462, 1465, 

1491, 1510, 1665, 1672, 1716, 1764, 

1786, 1788, 1789, 2040, 2063, 2068, 

2124, 2128, 2166, 2216, 2488, 2490, 

2496, 2498, 2501, 2503, 2583, 2621 

Oxidative stress and 

inflammation......................... 1057, 2495 

oxidative stress enzymes................ 2404 

oxidized phospholipids..................... 759 

oxime.......................... 2014, 2016, 2049 

oxycodone......................................... 775 

oxygen consumption............. 2528, 2529 

Oyster............................................. 2430 

ozone.... 26, 592, 604, 1244, 1293, 2286, 

2287, 2326 

P bodies........................................... 2565 

p16.......................................... 104, 2300 

p21WAF1........................................ 1791 

p27kip1........................................... 1070 

p27kip-cyclin D1.............................. 402 

p38 mitogen activated protein 

kinase.............................................. 2064 

P450........................................ 885, 1864 

p53...................... 117, 1977, 2235, 2315 

p53 haploinsufficient mice............... 235 

p53 mutation................................... 1953 

p53 stabilizer............................ 794, 795 

p62 autophage................................. 1791 

Pafuramidine..................................... 549 

PAH........................................ 355, 1213 

PAH-contaminated soil................... 2238 

PAHs................. 1074, 1373, 2396, 2524 

pain................................................... 512 

PAK6................................................ 537 

palmitate......................................... 1664 

pancreas............................................ 380 

pancreatic cancer.................... 225, 1663 

pancreatitis...................................... 2347 

Paraoxon............................... 2113, 2604 

Paraoxonase................ 1270, 1326, 2249 

Paraoxonase 1................................. 2024 

Paraquat..................... 1295, 1348, 1349, 

1665, 2265 

Parkinson disease.................... 179, 1396 

Parkinsonism.................................... 545 

parkinsons disease............................ 980 

Parkinson’s disease.......... 168, 181, 182, 

841, 843, 1348, 1394, 1779, 2123, 2124, 

2134 

PARP..................................... 1672, 2574 

Particle.................................. 2333, 2491 

particle characterization........ 1233, 1801 

particles......................... 566, 1235, 1259 

particokinetic model....................... 1457 

Particulate Matter........................... 2659 

particulate matter..... 591, 593, 671, 672, 

1213, 1215, 1233, 1570, 2495 

Particulate Matter (PM2.5)............ 1170, 

2323 

Particulate Matters.......................... 1291 

partition coefficient......................... 1809 

Pathological lesions........................ 1933 

Pathology.................................. 201, 536 

Pathway analysis...................... 125, 716 

Pathway and network analysis........ 1739 

pathways........................................... 130 

Pax5................................................ 1123 

Pb............................................ 293, 1700 

Pb toxicity......................................... 293 

PBDE.................................... 1667, 2253 

PBDE 209....................................... 2604 

PBPK............... 700, 707, 709, 721, 736, 

889, 941, 2456, 2689, 2691, 2693 

PBPK and Biological modeling...... 2307 

PBPK model.... 706, 708, 710, 711, 713, 

718, 719, 737, 1239, 2690 

PBPK Modeling........... 2, 699, 712, 720, 

731, 1581, 2141, 2294, 2316, 2460 

PBPK models........................ 2457, 2688 

PBPK/PD.................................. 723, 866 

PC/PS Hemodialyzers.................... 1315 

PC12 cells........... 869, 1344, 1345, 1383 

PCB......... 1203, 1960, 2250, 2623, 2624 

PCB 126................................ 1103, 1109 

PCB126........................................... 1854 

PCB136........................................... 1830 

PCB3 metabolites............................. 335 

PCBs.......... 621, 860, 1637, 2245, 2249, 

2251, 2404, 2412, 2601, 2602, 2603 

PCLis.............................................. 1004 

PCR-RFLP...................................... 1374 

PDE4 Inhibitor.................................. 542 

PDTC/Cu complex........................... 300 

penetration........................................ 632 

Penh................................................ 2299 

peppermint oil................................. 1107 

Peptide Adducts.............................. 1679 

peptide aggregation.......................... 734 

peptide reactivity.............. 90, 905, 2545 

Percellome...................................... 1596 

perfluorinated compounds.... 1221, 1636 

Perfluorinated Phosphonic Acid..... 1625 

Perfluoroalkyl acid......................... 2240 

perfluorochemicals................. 657, 2240 

Perfluorooctane sulfonate............... 2243 

Perfluorooctanoate.......................... 2557 

perfluorophosphonic acid............... 2239 

Perinatal.............................................. 15 

Perinatal Exposure................ 1078, 2606 

perinatal hypothyroidism................ 1618 

Peripheral Neuropathy.................... 2616 

Permeability transition.................... 1087 

peroxidation.................................... 2385 

peroxisome proliferator-activated 

receptor gamma...................... 957, 2661 

Persistant Organic Chemicals, 

POP, Flame Retardant..................... 2248 

persistent organic pollutants 

(POPs)....... 212, 1200, 1202, 1593, 2244 

Personal Care Products................... 1551 

personality........................................ 628 

pesticide............... 181, 692, 1038, 1222, 

1329, 1350, 1351, 1549, 1680, 1964, 

2118, 2339, 2517 

Pesticide exposure.......................... 1218 

Pesticide Mixtures.......................... 1346 

Pesticides......... 105, 168, 242, 388, 531, 

703, 704, 705, 864, 1202, 1250, 1328, 

1779, 2110, 2111, 2112, 2115, 2116, 

2120, 2244, 2387 

PET Imaging Agent.......................... 812 

petroleum.......................................... 108 

petroleum diesel.............................. 2489 

PFAA.............................................. 2247 

PFAAs............................................... 706 

PFBA.............................................. 1242 

PFHXA........................................... 2272 

PFHxS................................... 2237, 2272 

PFOA....... 205, 1089, 1242, 1609, 1620, 

1622, 2271 

PFOA/PFOS................................... 2273 

PFOS..................... 658, 659, 1242, 2271 

P-glycoprotein........................ 241, 2267 

P-glycoprotein/ABCB1.................. 2265 

pH effects........................................ 2155 

pha.................................................. 1206 

Phagocytic activation........................ 251 

Phagocytosis........................... 263, 1272 

Phamacokinetics............................. 2263 

Pharmaceutical... 894, 2368, 2677, 2680 

pharmaceutical agents.................... 2681 

Pharmaceutical Ecotoxicology....... 2400 

pharmaceutical treatment................ 2594 

Pharmaceuticals................... 1563, 1608, 

1836, 2384 

pharmacogenomics......................... 1737 

Pharmacokinetic............. 517, 856, 1809 

pharmacokinetic and 

pharmacodynamic modeling............ 864 

pharmacokinetic model.................. 2692 

pharmacokinetics......... 48, 51, 726, 732, 

808, 920, 1266, 2056, 2100, 2257, 2258, 

2262, 2274, 2281 

pharmacological promiscuity........... 853 

Pharmacological similarity............... 156 

Pharmacology....................... 1886, 2512 

phase I............................................. 1706 

phase II........................................... 1706 

Phase II biotransformation............. 1824 

Phencyclidine................................. 2596 

Phenethyl Alcohol.......................... 1034 

phenobarbital........................ 2356, 2639 

phenotype............................... 363, 1718 

Phosphatases..................................... 226 

phosphatidylserine.......................... 1669 

Phosphatidylserine exposure............ 294 

Phosphodiesterase............................. 391 

Phospholipidosis............ 136, 436, 1426, 

1452 

Phospholipids................................. 2195 

phosphorylated kinase.................... 2159 

Photocarcinogenesis....................... 1785 

photocarcinogenicity........................ 796 

Photo-clastogenicity......................... 334 

photoelectrocatalysis............ 2408, 2409 

photosynthesis................................ 2385 

Phototosensitization........................ 2542 

Phototoxicity.......... 157, 464, 638, 1012, 

2078, 2541 

phthalate...... 67, 234, 1022, 1036, 1066, 

1216, 1243, 1569, 2202, 2370 

phthalates............. 20, 1039, 1055, 1201, 

1611, 2378 

Phthalimide and phthalic acid........ 2260 

phycotoxins................. 2225, 2226, 2402 

Physical chemical............................. 852 

physicochemical characterization 

of particles........................................ 847 

physiochemical property...... 1650, 2177 

physiologically based kinetic 

modeling........................................... 991 

physiologically based 

pharmacokinetic modeling...... 865, 938, 

1582 

Phytoestrogen....................... 2197, 2198 

phytoestrogens............ 1053, 1062, 2362 

phytopolyphenols............................. 161 

Pig-a.............................. 315, 1406, 1416 

PIK3CA............................................ 239 

Pill................................................... 1765 

piperine........................................... 2208 

PK................................................... 1929 

PKC................................................ 2208 

placenta................................. 1058, 1074 

plant toxin....................................... 2229 

Plastics.............................................. 624 

Platelet............................................ 1884 

Platelets............................................. 778 

Platycodon Grandiflorum.... 2207, 2209, 

2211, 2213, 2217 

PLD................................................. 1299 

pleura.................................... 2176, 2178 

Pleural pressure................................ 576 

Plicopurpura pansa......................... 2393 

PLLA.............................................. 1322 

Pluripotent Stem Cells.......... 1163, 1164 

PM Exposure.................................. 2332 

PM health effects............................ 2494 

pmk-1.............................................. 2064 

PML.................................................. 660 

PMSF.............................................. 2101 

Pneumotachometer, Correlation 

analysis............................................. 576 

POCIS............................................. 2398 

point of zero charge........................ 2177 

Pol Eta.............................................. 120 

Policy.............................................. 1527 

pollutant.......................................... 1085 

pollution................................ 1543, 2396 

pollution burden................................ 472 

polybrominated diphenyl ether...... 1771, 

2599 

Polybrominated diphenyl ethers.... 1818, 

2605 

polybrominated diphenyl ethers 

(PBDEs)................................ 1607, 2252 

Polychlorinated biphenyls..... 260, 1820, 

2242 

polychlorinated biphenyls 

(PCBs )... 1203, 1495, 2360, 2600, 2625 

polychloroprene.............................. 1557 

Polycyclic Aromatic Hydrocarbon... 526 

polycyclic aromatic 

hydrocarbons........................ 1229, 2566 

polycyclic aromatic hydrocarbons, 

Benzo(a)pyrene............................... 1138 

Polyethylene Glycol......................... 781 

poly-l-lactic acid............................. 1322 

polymorphism............. 1361, 1362, 1778 

polymorphisms..................... 1255, 1372 

polyphenols............................. 995, 2231 

Polysorbate 80...................... 1911, 1916 

polystyrene nanosphere.................... 719 

PON 1............................................. 1371 

PON1.............................................. 1209 

POP................................................. 2241 

POPs..................................... 2200, 2305 

population diversity.......................... 820 

population variability....... 501, 713, 819, 

1984 

port catheter system........................ 1566 

Positive Control.............................. 2654 

postmenopausal women.................... 277 

postnatal.......................................... 2663 

postnatal body weight..................... 1025 

Postnatal Development................... 2190 

post-translational modifications....... 214 

potassium bromate.......................... 1273 

potentiation....................................... 766 

PPAR.... 234, 354, 358, 716, 1120, 1609 

PPAR agonist.................................. 1437 

PPAR alpha........................... 2237, 2240 

PPAR beta......................................... 357 

PPARa............................................... 366 

PPARa............................................... 379 

PPAR-alpha.......................... 1089, 2239 

PPARb/d................................... 355, 359 

PPARg...................................... 345, 352 

PPD................................................. 1863 

Pralidoxime..................................... 2018 

prasugrel........................................... 777 

pre and postnatal exposure............. 1636 

Precision-Cut Liver Slices............. 1014, 

1900, 2509 

Precision-cut lung slices................... 960 

precision-cut tissue slices............... 1766 

Preclinical..................................... 3, 806 

preclinical safety..................... 518, 1917 

preclinical studies........................... 1927 

Preclinical Toxicology............ 507, 1141 

Prediabetes...................................... 2201 

prediction........................................ 1410 

Prediction Model.................... 717, 1598 

Prediction Tools.............................. 1814 

Predictive in vitro model................ 2537 

predictive methods.................... 148, 902 

predictive modeling........................ 1587 

Predictive models............................. 852 

Predictive toxicology.............. 123, 2679 

Pregnancy........ 1067, 1625, 1985, 2186, 

2197, 2506 

pregnane X receptor......................... 377 

pregnane X receptor (PXR)............ 1840 

prenatal cigarette smoke................. 2194 

prenatal exposure.......... 611, 1208, 2607 

Prenatal stress....................... 1639, 1699 



397






preservatives................................... 2570 

pressure sensors.............................. 1930 

preterm birth..... 1052, 1057, 1076, 2563 

Prevalidation................................... 2551 

Preventive Medicine....................... 1225 

Primary B Cells.............................. 1137 

Primary cell cultures....................... 1332 

Primary dendritic cells...................... 967 

primary hepatocyte culture... 1656, 2511 

primary hepatocytes.............. 1861, 2523 

Primate.................................. 1914, 1924 

primates.............................................. 26 

Primrose.......................................... 2442 

prion.................................. 841, 844, 845 

prion disease..................................... 173 

problem formulation....................... 2507 

Procoagulant activation.................. 1884 

Product Design............................... 2696 

product development...................... 2564 

Profenofos....................................... 2117 

professional development............... 2484 

Program development..................... 1876 

prohapten...................................... 86, 88 

Prohormone convertase.................. 2089 

proinflammatory............................. 1748 

proinflammatory mediators.............. 260 

Prolactin.......................................... 2372 

proliferation.............................. 639, 951 

promoter........................................... 397 

Pro-oxidant actions......................... 1307 

propanol.......................................... 2294 

propentofylline................................. 506 

propiconazole......................... 951, 2109 

propyl acetate.................................. 2294 

propyl paraben................................ 1823 

Prostate........................................... 1624 

Prostate cancer...................... 1043, 2091 

prostate development...................... 1626 

proteasome...................................... 2490 

Protein................... 127, 842, 1730, 2453 

protein adducts...................... 1262, 1433 

protein aerosol.................................. 589 

Protein binding............................... 2348 

protein corona................................. 1488 

protein denaturation........................ 1733 

protein hydrolysates............................ 89 

Protein Kinase.................................... 34 

protein kinase C.............................. 2131 

Protein Ligand Binding.................... 408 

Protein Microarray.......................... 1442 

protein safety.... 1728, 1731, 1732, 1733 

Protein-protein interaction 

network............................................. 134 

proteins........................................... 1729 

proteolytic enzymes............................ 96 

proteome......................................... 2136 

Proteomics....................... 129, 213, 970, 

1084, 1283, 1286, 1446, 1450, 1745, 

2017, 2159, 2223, 2387 

proteomics...................................... 1284 

Pseudoallergic & anaphylactoid 

reactions................................................ 7 

pseudoallergy.................................. 1500 

Pseudoestrogens............................. 2256 

Pseudomonas aeruginosa................ 2337 

Psidium guajava.............................. 2218 

PTEN................................................ 954 

PTH................................................. 2376 

pubertal assay................................. 2356 

public health..................... 23, 830, 2153 

publication...................................... 2482 

pulmonary...... 566, 594, 811, 895, 2167, 

2190 

pulmonary disease and toxicology... 590 

pulmonary exposure......................... 192 

pulmonary fibrisos............................ 540 

Pulmonary Function............. 1199, 1800 

pulmonary health............................ 2057 

pulmonary inflammation. 186, 541, 603, 

1458, 2327 

pulmonary injury............................ 1190 

pulmonary injury biomarkers......... 2477 

Pulmonary Toxicity... 1178, 1473, 1496, 

1798 

Purinergic Signaling....................... 1477 

PXR.................................................. 385 

Pyrethroid........... 723, 1341, 2104, 2119 

pyrethroid pesticide........................ 1476 

pyrethroid pesticides.... 873, 1340, 1342, 

2093 

pyrethroids....... 1343, 1344, 1345, 1857, 

2262 

Pyridazine....................................... 2283 

Pyriproxyfen..................................... 348 

Pyrosequencing................................. 101 

pyrrocidine...................................... 2428 

Q-dots................................... 1197, 2184 

qHTS......................................... 493, 981 

qHTS data......................................... 482 

qPCR............................................... 1368 

QSAR...... 136, 139, 146, 157, 159, 465, 

468, 483, 487, 492, 494, 496, 499, 721, 

723, 861, 1812, 2464, 2538 

QSAR modeling..................... 484, 1816 

QSAR/QSPR.................................... 633 

qsars.................................................. 849 

QT prolongation............................... 195 

Quality assurance............................ 2439 

quantitation..................................... 1926 

Quantitative behavioural 

assessment........................................ 780 

quantitative high throughput 

screening......................................... 2501 

Quantitative Structure Activity 

Relationship.................................... 1811 

Quantitative structure-activity 

relationships QSAR................ 722, 2298 

quantitative trait loci......................... 823 

Quantum dot................................... 1193 

quantum dot nanoparticles............. 1175, 

2154, 2155 

Quantum Dots............ 1197, 1465, 2168, 

2183, 2184 

quinolone........................................ 1076 

quinone........................................... 1292 

Quinones......................................... 1433 

QWBA (quantitative whole body 

authoradiography)........................... 2257 

R, R-monatin.................................. 2421 

R2C................................................... 999 

rabbit minipig................................. 1927 

Rabbits............................................ 1630 

Ractopamine................................... 2431 

Rad23................................................ 306 

radiation.............. 324, 1248, 2010, 2577 

radio frequency radiation................ 2627 

Radionuclide Decorporation........... 2291 

rainbow trout.................................. 1588 

Raman............................................. 1260 

raoxifene......................................... 2634 

RAP80............................................ 2636 

Ras................................ 951, 1781, 2637 

ras oncogene................................... 1783 

rasH2................................................. 508 

rasH2 mouse..................................... 521 

RasH2 Transgenic Mice................. 2654 

rat..................... 246, 512, 555, 738, 774, 

1423, 2281 

rat and fetal alcohol syndrome....... 2613 

rat hepatocytes...................... 1107, 2242 

Rat Model....................................... 1819 

Rat primary Hepatocytes................ 1595 

rat spleen........................................... 547 

Rat Testicular cell line...................... 999 

rat urinary bladder............................ 525 

Rat, Rabbit........................................ 648 

rats.......................................... 649, 1611 

RD50............................................... 2296 

RDX.................................................. 736 

REACH................... 298, 470, 499, 1516 

reaction chemistry.......................... 1558 

reactive intermediate........................ 319 

reactive metabolite.......................... 1832 

Reactive Metabolites............... 154, 424, 

425, 888 

Reactive Orange 16.......................... 336 

reactive oxygen............................... 1859 

Reactive Oxygen Species........ 191, 579, 

591, 1000, 1052, 1273, 1491, 1655, 

1838, 2175 

reactive oxygen species (ROS)....... 2560 

read-across........................................ 298 

Realgar.................................. 2004, 2006 

ReCell............................................... 892 

receptor-mediated............................. 475 

receptors......... 346, 350, 367, 384, 1892 

reconstituted model.......................... 975 

reconstructed human skin................. 341 

recruiting......................................... 2486 

Red algae........................................ 1571 

red blood cells................................. 1411 

Redistribution ® Technology.............. 398 

Redox.................................... 1299, 1349 

Redox state....................................... 877 

reduced intrauterine growth.............. 614 

Reendothelialization....................... 1320 

reference concentrations................... 502 

Reference database............................... 4 

reference dose....................... 1542, 1940 

Reference Ranges............................. 636 

Regeneration..................................... 765 

regulation.................... 1727, 2376, 2695 

regulation/policy............................... 996 

Regulatory...................................... 2508 

regulatory acceptance..................... 1309 

Regulatory Developmental 

toxicity............................................ 1623 

regulatory evolution........................ 1775 

Regulatory Requirements............... 2375 

regulatory T cells.......... 689, 1131, 1139 

Regulatory Toxicology........ 1527, 1563, 

1793 

Renal............................................... 1438 

renal absorption.............................. 2283 

renal biomarkers............................... 754 

renal drug transporter....................... 762 

renal failure..................................... 1561 

renal fibrosis..................................... 759 

Renal Injury...................................... 748 

Renal Proximal Tubule Cells.... 749, 751 

renal toxicity..................................... 745 

Renal Toxicology............................ 1274 

Repeat Dose Studies....................... 1524 

Repin................................................. 545 

reporter assays................................ 2532 

reproducibility................................ 1562 

reproduction..... 1024, 1038, 1074, 2384, 

2395, 2546 

Reproduction and Development.... 1060, 

2202 

Reproductive..... 1029, 1030, 1050, 1059 

reproductive organ.......................... 1046 

Reproductive outcome.................... 1208 

Reproductive Performance............. 1028 

Reproductive Toxiciology.............. 1147 

reproductive toxicity................... 16, 717 

reproductive toxicology............ 67, 1051 

reprogramming............................... 2453 

reprotoxicity................................... 1231 

resazurin......................................... 1904 

research and job-seeking skills....... 2483 

research experience 

for undergraduates.......................... 1873 

residues........................................... 2119 

resorufin.......................................... 1904 

Respiratory...... 1196, 1914, 1920, 1921, 

2476 

respiratory allergen........................... 907 

Respiratory allergy..................... 84, 903 

respiratory effects............................. 611 

Respiratory epithelium......... 2329, 2480 

respiratory sensitization........ 90, 97, 905 

Respiratory thoracic impedance....... 576 

respiratory toxicity..... 1555, 2029, 2041, 

2474, 2478 

respiratory tract.... 595, 889, 2290, 2475, 

2478, 2479 

Respiratory, lung............................. 2474 

Restenosis....................................... 1320 

Resume preparation........................ 2485 

resveratrol........... 741, 1670, 2227, 2321 

Retailers.......................................... 2115 

retinoic acid................ 1506, 2088, 2369 

retinol.................................................. 74 

Retinopathy of prematurity............. 2587 

retrotransposons.................................. 99 

r-H2AX............................................. 118 

Rhabdomyosarcoma and 

canine cancers................................... 955 

rhinitis................................................. 97 

Rhinovirus...................................... 1289 

Ribbon worm.................................. 2430 

Ribosomal RNA Cleavage.............. 1662 

Ribosome...................................... 34, 38 

Ribosome inactivating protein............ 39 

ribosome-inactivating protein......... 2414 

Ribosome-inactivating stress............ 370 

Ribosomes.......................................... 39 

ribotoxic stress.................. 35, 36, 37, 39 

ricin................... 2017, 2223, 2432, 2433 

right whale...................................... 2405 

Rip1.................................................. 308 

risk..................... 367, 1263, 1535, 1936, 

2694, 2699 

Risk and Safety Assessment........... 2630 

Risk Assessment.................. 2, 8, 11, 13, 

47, 48, 49, 52, 154, 332, 471, 476, 480, 

483, 485, 489, 500, 501, 502, 586, 701, 

703, 704, 705, 712, 720, 830, 848, 851, 

862, 904, 916, 921, 925, 931, 1251, 

1346, 1424, 1529, 1530, 1531, 1532, 

1534, 1536, 1537, 1543, 1545, 1554, 

1568, 1569, 1576, 1581, 1701, 1715, 

1717, 1728, 1732, 1733, 1767, 1797, 

1799, 1805, 1813, 1877, 1933, 1934, 

1937, 1939, 1955, 1963, 1964, 1965, 

2106, 2286, 2289, 2296, 2307, 2308, 

2309, 2438, 2456, 2457, 2459, 2460, 

2462, 2538, 2573, 2682, 2688, 2689, 

2690, 2691, 2692 

Risk Assessment Methods.............. 1938 

Risk Characterization..................... 1680 

risk communication.......................... 933 

risk exposure................................... 2431 

risk management................... 1517, 2153 

risk versus benefits......................... 1796 

rituximab........................................... 661 

Rivers.............................................. 2403 

RNAi....................................... 522, 1861 

rodent chow diet............................. 1062 

Rodent Study.................................. 1909 

rodents.................................... 519, 2614 

ROS.... 220, 415, 753, 1668, 2003, 2070 

rotenone.......................................... 1900 

RT-PCR arrays................................ 1583 

RUNX2........................................... 2217 

rural population.............................. 1209 

Ryanodine....................................... 2623 

Ryanodine receptor............... 2246, 2624 

S-(1, 2-Dichlorovinyl)-L-cysteine 

sulfoxide........................................... 755 

S100A4/7........................................ 2649 

S1P.................................................. 1892 

safer alternatives............... 911, 912, 913 

Safety............. 10, 558, 811, 1765, 2428, 

2437, 2439 

Safety Assessment... 651, 742, 782, 783, 

790, 808, 1060, 1317, 1318, 1319, 1323, 

1541, 1561, 1892, 1896, 1911, 1916, 

1925, 2440, 2441 






safety assessment: non-phamaceutical............................................ 

1560 

safety biomarker............................... 124 

safety evaluation............. 467, 491, 1552 

Safety Pharmacology........... 3, 201, 852, 

1724, 2468, 2469, 2471 

Safety testing............................ 11, 2684 

Salmonella mutagenicity assay......... 336 

Salmonella/microsome 

mutagenicity assay.......................... 1409 

sandwich-cultured hepatocytes....... 1081 

SAR................................................ 1965 

Sarcocysis. fayeri............................ 1211 

sarin...................................... 1334, 2035 

SAS................................................... 490 

SBDP-145....................................... 1443 

school.............................................. 1546 

Science and Decisions.................... 1962 

science outreach.............................. 1866 

Science Policy...................... 1484, 2508 

Scopolamine............... 1646, 2016, 2041 

Screening..................... 867, 1523, 1910, 

2452, 2675 

screening assays.............................. 2367 

screening levels................................ 863 

Sculpin............................................ 2386 

SDF-1b........................................... 1664 

Seafood........................................... 1974 

seafood safety................................. 1963 

Secondhand Smoke.............. 1253, 1254 

secondhand tobacco smoke.............. 834 

segmental duplication..................... 1770 

Seizure.................................... 399, 1742 

seizures... 1804, 1806, 1807, 1808, 2020 

Selection......................................... 1675 

Selenium....................... 311, 1398, 2249 

Semicarbazide................................... 627 

senescence...................................... 1764 

senna................................................. 235 

sennosides......................................... 235 

sensitive populations........................ 472 

sepiapterin reductase...................... 1399 

Serine hydrolases............................ 1336 

serine protease inhibitor................. 2364 

serotonin......................... 346, 964, 1881 

serotonin transporter gene.............. 1363 

SERT............................................... 1829 

Sertoli cell........................................... 66 

serum.................................... 1023, 2562 

sex................................................... 2492 

sex differences................................ 2600 

sexual development........................ 1071 

sexual differentiation.......................... 20 

sexual dimorphism.................... 266, 396 

sexual maturity............................... 1923 

SHE cell transformation................. 1528 

SHetA2........................................... 1885 

Shiga toxins.............................. 37, 2414 

Shipping.......................................... 1431 

short time exposure......................... 1001 

Short-term health effects.................. 829 

Sick Building Syndrome................. 1573 

Sick-building Syndrome................. 1225 

signal transduction.......... 400, 937, 2314 

Signaling Pathways................ 328, 1891 

Signature........................................... 876 

SILAC............................................... 970 

silica...................................... 2083, 2173 

silica nanoparticles............... 2053, 2085 

siloxanes........................................... 700 

Silver..................................... 1759, 2181 

Silver nanoparticle................ 1762, 1763 

Silver Nanoparticles............ 1456, 1467, 

1758, 1761, 2063, 2064, 2067, 2071, 

2075, 2079 

Similarity Ensemble Approach......... 854 

single cell toxicity........................... 1234 

single nucleotide polymorphism.... 1365, 

1366, 1371 

single walled carbon nanotubes.......... 59 

siRNA,.............................................. 553 

Sirt 1................................................. 414 

Sirt1................................................ 2499 

Size................................................. 2065 

skeletal muscle................................ 1451 

skeletal muscle toxicity.................. 1589 

skills................................................ 2481 

skin............ 83, 508, 543, 544, 632, 637, 

641, 642, 1006, 1750, 1751, 1780, 1781, 

1782, 1993, 2026, 2030, 2072, 2554 

skin absorption.................................. 634 

skin carcinogenesis.......... 222, 237, 958, 

1783, 1784 

skin cells........................................... 639 

Skin corrosion................................... 646 

skin inflammation................. 1783, 2574 

Skin injury............................ 1756, 2013 

Skin irritation.............. 91, 469, 645, 646 

skin model...................................... 1005 

skin penetration.......... 1107, 2154, 2155 

skin permeability.............................. 633 

skin rash...................... 1364, 1501, 1505 

skin sensitization... 86, 90, 91, 465, 967, 

974, 978, 1000, 1002, 1009, 1010, 2513, 

2527, 2536, 2551 

skin sensitization assay....................... 88 

skin substitute................................... 892 

skin toxicity.............................. 965, 966 

skin tumorigenesis............................ 954 

small Maf proteins.......................... 2127 

small scale inhalation studies........... 577 

Smoke............................................... 592 

smoke inhalation............................... 567 

Smokeless Tobacco......................... 1558 

smoking.......................................... 1287 

smoking cessation........................... 1363 

Smooth muscle of trachea.............. 1456 

S-nitrosylation.................................. 257 

social anxiety disorder...................... 802 

Social Media..................................... 419 

society............................................. 1880 

SOD.................................................. 165 

sodium.............................................. 203 

Sodium channel...................... 170, 1341 

sodium channels................... 1343, 1353 

soft electrophiles............... 503, 504, 505 

Soil.......................................... 526, 1265 

Soil Dust........................................... 670 

Soil Ingestion.................................. 2572 

solute carrier transporter (SLC)...... 1597 

Solutol............................................... 781 

solvent neurotoxicity...................... 1575 

soman.......................... 2020, 2034, 2039 

Sp proteins........................................ 956 

Sp Transcription factors............ 226, 955 

SP1.................................................. 1858 

species differences.......................... 2100 

Specificity Protein............................ 384 

Specificity protein transcription 

factors............................................... 956 

Specificity proteins........................... 220 

spectroscopy................................... 2312 

sperm count.................................... 2230 

sperm whale.................................... 2405 

sperm whales.................................. 2252 

Spermatogenesis................................. 63 

sphinganine 1-phosphate................ 1448 

Sphingolipids.................................... 241 

Spirulina......................................... 2436 

spleen................................................ 112 

spleen lymphocytes........................ 1411 

splenocytes..................................... 2364 

Splenotoxity...................................... 390 

Splice Variants.................................. 375 

Sprague-Dawley Rat....................... 1028 

Sprague-Dawley rats.............. 531, 2075 

SPRAYERS.................................... 2116 

Spring Valley.................................... 928 

ST depression................................... 570 

Stability........................................... 1431 

stable isotope dilution tandem 

mass spectrometry.......................... 1681 

startle response............................... 2617 

STAT1alpha...................................... 403 

STAT3....................................... 441, 956 

static diffusion cell............................ 634 

statin................................................. 789 

statistical association...................... 2594 

Statistics.................................... 134, 727 

status epilepticus............................. 2039 

steatogenic hepatotoxicity.............. 1118 

steatohepatitis................................. 1114 

Steatosis................................ 1958, 2586 

Stem cell...... 74, 894, 1155, 1171, 1992, 

1993, 2450 

Stem Cell-derived 

Cardiomyocytes.............................. 1894 

Stem cells......... 14, 68, 72, 79, 890, 891, 

895, 982, 1159, 1166, 2451, 2452, 2665, 

2677 

Stent................................................ 1320 

stereology....................................... 1348 

Steroid hormones............................ 1436 

steroid pathway................................. 999 

Steroidogenesis.......... 1037, 1039, 1041, 

1048, 2352, 2368, 2383, 2547, 2549 

Steroids........................................... 2135 

stochastic gene expression................ 123 

Store-operated calcium channels.... 1672 

S-transalkylation............................. 1305 

StrataTest.......................................... 647 

stress............................. 165, 1205, 2151 

Stress Response.................................. 34 

stress response mutant.................... 1467 

stress test........................................... 608 

striatum............................................. 506 

Strombus gigas (conch).................. 1068 

Structural Alerts................................ 154 

Structure........................................... 857 

Structure activity relationships......... 468 

Structure Activity Relationships 

(SAR)...................... 141, 488, 860, 1595 

structure bioactivity relationship.... 1800 

structure-activity............................. 1967 

structure-activity relationships... 75, 936 

Styrene............. 1199, 1226, 1359, 1530, 

1860, 2643 

subcellular localization................... 2300 

subchronic toxicity......................... 2421 

subchronic toxicology.................... 1918 

Subcutaneous.................................... 618 

subretinal.......................................... 524 

substrate-competitive........................ 401 

Substructure Identification............... 153 

suicidality....................................... 1541 

sulfolane......................................... 1542 

sulforaphane........................... 460, 2638 

Sulfotransferase.............................. 1862 

Sulfur donors.................................. 2046 

Sulfur Mustard................. 114, 544, 641, 

1748, 1749, 1752, 1753, 1754, 1755, 

1756, 2013, 2019, 2026, 2027, 2028, 

2030, 2036, 2040 

Sulfuryl Fluoride............................ 2100 

SULT1A1........................................ 1368 

Sunitinib......................................... 1159 

Superantigen................................... 1512 

Superfund............................... 323, 1675 

Surface cleanup................................ 863 

surfactant protein-D.......................... 257 

surfactants....................................... 1526 

Surgery.............................................. 270 

surgical glove.................................. 1557 

Surrogate......................................... 1965 

survival........................................... 1361 

susceptibility......... 271, 819, 1337, 1338 

susceptibility biomarkers................ 2112 

susceptible populations................... 2461 

Suspension Cells............................... 316 

sustainable........................ 908, 909, 910 

SW-480........................................... 2233 

SWCNT.......................................... 1179 

Swedish snus.................................. 1198 

Swine................................................ 526 

synaptic plasticity........................... 2625 

synaptogenesis................................ 2620 

synchrotron..................................... 1633 

Synergy........................................... 2306 

Synoviocytes..................................... 362 

Synthetic Tandem Repeat 

Promoter screening......................... 1703 

System biology................................. 481 

Systemic Dose................................ 2107 

systemic toxicity................... 1312, 1549 

Systems biology........... 9, 135, 366, 937, 

1721, 1734, 1736, 1737, 1739 

Systems Toxicology.............. 1593, 1739 

T cell......................................... 687, 694 

T cell independent antibody 

response............................................ 649 

T cell subsets...................................... 93 

Tacrolimus...................................... 2284 

Tai Chi............................................ 2204 

TAM-DNA adducts......................... 2656 

Tamoxifen............................... 428, 2656 

TARC.............................................. 2209 

Target Safety............................. 125, 522 

Taurine........................ 1271, 2583, 2584 

TCCD............................................. 1704 

TCDD........................ 78, 197, 198, 213, 

654, 709, 1091, 1122, 1123, 1128, 1135, 

1137, 1584, 1588, 1624, 1647, 1684, 

1777 

TCP................................................. 1692 

TD50................................................. 487 

TDAR....................................... 660, 664 

teeth................................................ 1237 

Telemetry.............. 562, 568, 1919, 1920 

tellurium tetrachloride...................... 302 

Telomere........................................... 121 

Telomeres....................................... 2251 

temperature..................................... 2381 

Tempol.............................................. 961 

TEQ...................................... 1959, 1961 

teratogen............................... 1610, 2506 

teratogenesis................................... 1045 

teratogenicity...................................... 75 

Teratology....................................... 1617 

terpenes........................................... 2154 

testes........................... 1022, 1041, 1048 

testicular toxicity................................ 69 

testis...................... 64, 1441, 2084, 2191 

Testosterone................ 1032, 1039, 2088 

Testosterone proprionate................. 2189 

tetrabromobisphenol A.......... 1056, 2246 

Tetrachloroethylene........................ 2641 

tetrahydrouridine.............................. 799 

tetrazolate....................................... 1544 

Tetrodotoxin................................... 2430 

Text Mining...................................... 728 

Tg2576 mice................................... 1331 

TGFbeta............................................ 222 

TGF-beta........................................... 687 

Th17................................................ 1506 

Th17 cells....................................... 1501 

Thalidomide...................................... 839 

Therapeutic Antibody..................... 1891 

therapy............................................ 1790 

Thermodynamics-Based Partition 

Index............................................... 1815 

Thermoluminescence...................... 2385 

Thiabendazole................................. 1821 

thiazolidinedione.............................. 422 

Thioarsenates.................................. 1162 

Thiols-Redox.................................. 2336 

thioredoxin.................................. 95, 877 

thioredoxin reductase.............. 458, 1663 

THP-1............................................... 966 

THPI............................................... 2278 

Threshold.......................................... 477 



399






Thrombocytopenia............................ 778 

Thrombopoietin................................ 284 

thrombosis........................................ 190 

Thryoid Hormone........................... 2360 

thyroid................................... 2608, 2668 

Thyroid disruption.......................... 2350 

Thyroid Gland................................ 1423 

thyroid hormone................... 1618, 2349 

Thyroid hormones.......................... 2135 

tiered approach............................... 1001 

Time-Course..................................... 194 

time-dependent............................... 1718 

time-dependent inhibition............... 2280 

TIMP-2............................................... 66 

TiO2...................................... 2073, 2078 

TiPARP................................... 356, 1599 

Tissue Cross Reactivity.................... 881 

Tissue distribution.......................... 2386 

Tissue Dosimetry............................ 1719 

Tissue exposure................................ 856 

tissue:air partition coefficient 

(Pta).................................................. 722 

Tissue-Selective Carcinogens........... 488 

titanium dioxide...................... 655, 1483 

Titanium dioxide nanoparticles..... 1455, 

1461, 1471, 2066, 2077 

Titanium dioxide particles.............. 1801 

titanium nanoparticle...................... 2180 

titanium nanoparticles.................... 1454 

Titanium Nanostructure.................. 2061 

titanium particulates......................... 566 

TLR4................................................. 697 

TNIP1............................................... 384 

Tobacco...................... 1372, 2694, 2695, 

2698, 2699 

tobacco carcinogens........................ 2697 

Tobacco products............................ 2696 

Tobacco smoke.... 969, 990, 1409, 1565, 

2295, 2330 

tobacco toxicant biomarkers............ 834, 

2697 

TOC................................................ 1523 

Toll Like Receptors.......................... 686 

toll-like receptor 4.......................... 1495 

Toluene................................. 1298, 1583 

topiramate......................................... 810 

Torcetrapib................................ 387, 556 

Tottering......................................... 1385 

ToxCast..................... 141, 143, 715, 727 

toxic effects..................................... 2392 

Toxic Load........................................ 572 

toxic tort.......................................... 2152 

Toxicant Exposure............................ 749 

Toxicant susceptibility.................... 1395 

Toxicants......................................... 2295 

Toxicity.............................................. 10, 

18, 266, 275, 305, 515, 582, 746, 797, 

820, 930, 1250, 1453, 1668, 1740, 1821, 

1826, 1882, 1883, 1900, 2004, 2006, 

2076, 2206, 2407, 2408, 2426, 2631 

Toxicity Biomarkers in Mouse 

Lung.................................................. 671 

toxicity mechanisms........ 569, 735, 939, 

2060, 2590 

Toxicity path..................................... 134 

toxicity pathway........... 822, 1813, 2505 

Toxicity pathways................... 962, 1583 

Toxicity prediction...................... 33, 935 

toxicity screening.............................. 973 

Toxicity study................................. 1574 

Toxicity Testing in the 

21st century.................................... 2505 

toxicogenomic................................ 1541 

toxicogenomics.................... 19, 41, 124, 

138, 139, 436, 823, 824, 906, 917, 1586, 

1589, 1593, 1603, 2073, 2152, 2401, 

2651, 2652, 2681 

Toxicogenomics and mode 

of action.......................................... 1596 

Toxicogenomics, Hepatotoxicity, 

Liver..................................... 1592, 1606 

Toxicokinetic................ 517, 2108, 2259 

Toxicokinetics.... 807, 1230, 1240, 2105, 

2107, 2265, 2271, 2272, 2693 

toxicological screening................... 2519 

Toxicology........... 5, 8, 47, 56, 592, 788, 

1576, 2676 

Toxicology 21................................. 1309 

Toxicology education..................... 1874 

toxicology history............................. 922 

Toxicology Jobs.............................. 1879 

toxicology screening........................... 14 

Toxicology training........................ 1876 

Toxicophores.................................... 153 

toxicoproteomics............ 128, 513, 2500 

toxin................................................ 2219 

ToxInsight......................................... 398 

TPP1................................................. 801 

trace metals..................................... 2395 

Traditional medicine....................... 2206 

training............................................ 1877 

Transcript ‘Omics............................. 489 

transcript profiling............................ 868 

transcription factor.................. 410, 1969 

transcriptional alterations............... 2633 

transcriptional regulation................ 2647 

transcriptome................ 387, 1599, 1627 

transcriptomics.................. 60, 79, 1591, 

1600, 1718 

Transcriptomics /gene 

expressing............................. 1595, 2378 

transepithelial electrical 

resistance........................................ 1021 

Transfluthrin................................... 2646 

transformation......................... 236, 1155 

Transforming growth factor beta... 1293, 

2330 

transgenic animal model................... 204 

transgenic mice............................... 2578 

transglutaminase............................. 1515 

transition metal oxide 

nanoparticles................................... 2177 

translational imaging...................... 1322 

translational inhibition.................... 2565 

Translational Toxicology................ 1014 

translocation................................... 2163 

transplacental carcinogenesis......... 2665 

transplacental exposure........ 2169, 2506 

transport........................ 761, 1478, 2247 

transport kinetics.............................. 311 

Transporters....... 938, 1047, 1077, 1079, 

1706, 2269 

triaryl phosphate............................... 169 

triazoles............................................... 71 

tributyltin................................ 663, 2388 

Tributyltin (TBT)............................ 1068 

Trichloroacetate................................ 251 

Trichloroacetic acid........................ 2283 

Trichloroethene............................... 1510 

trichloroethylene.......... 550, 1685, 1836, 

2641, 2687 

Trichloroethylene,........................... 1817 

trichothecene................................... 2424 

Triclosan......................... 254, 379, 2350 

trimethyltin..................................... 1375 

Triple Uptake Inhibitors................. 1430 

trivalent chromium........................... 915 

trivalent methylated metabolites..... 1986 

Troglitazone.................. 510, 1080, 2633 

trophoblast...................................... 1056 

troponin............................................. 555 

troponin I.............................. 1161, 1437 

TRP channel................................... 2335 

TRPA1............................................ 2334 

TSCA................................................ 417 

TSPO/PBR........................................ 164 

TTC......................................... 487, 1767 

tubulin............................................... 335 

tularemia......................................... 2042 

Tumor Analysis................................. 490 

tumor necrosis factor..... 109, 238, 1508, 

1658 

tumor progression............................. 777 

tumor transcriptome........................ 1707 

tumorigenesis.......................... 234, 2636 

Tungstate.......................................... 656 

tungsten............... 291, 1383, 1604, 2310 

Tungsten alloy.................................. 290 

turkey................................................ 972 

Tutorial........................................... 1875 

two-electron reduction.................... 1305 

Two-generation reproductive 

toxicity............................................ 1044 

Type 2 diabetes.......... 1281, 2468, 2469, 

2470, 2473, 2582 

Tyrosine hydroxylase...................... 1400 

ubiquitination.................................... 306 

ubiquitin-conjugating enzyme.......... 770 

UC-II............................................... 1893 

Uganda............................................ 2206 

UGT.................................................. 385 

Ultrafine Particles......... 191, 1491, 2488 

ultrafine particulates......................... 596 

ultrasound imaging......................... 1092 

ultraviolet light............................... 1784 

Umbilical cord........................ 621, 2200 

Uncertainty Factor............................ 866 

uncertainty factors............................ 713 

uncoupling proteins.......................... 958 

Undergraduate Education.... 1871, 1873, 

1874 

Undergraduate research.................. 1872 

Unexploded Ordnance...................... 927 

Unfolded Protein Response............ 1083 

uptake................................... 2165, 2562 

Uptake kinetics....................... 313, 2390 

uranium................................... 282, 1696 

urban particulate matter.................... 571 

Urethane........................................... 286 

Urinary............................................ 1679 

urinary biomarkers.................. 742, 1694 

Urinary bladder....................... 232, 2646 

Urinary Cadmium..................... 767, 768 

urinary fibrinogen............................. 744 

urinary protein biomarker................. 743 

Urine biomarkers.............................. 463 

urothelial carcinomas........................ 250 

UROtsa........................................... 1162 

Usnic acid....................................... 2418 

UV.................................................... 113 

uv inactivation................................ 2413 

UVA.................................................. 638 

UVB................................................ 2033 

vaccine potency.............................. 2581 

vaccine safety................................. 2581 

vaccine safety assessment............... 1027 

vaginal irritation testing........ 1049, 1314 

vaginal tissue model............. 1049, 2373 

validation..................... 529, 1016, 1017, 

2152, 2545 

Valproic acid..................................... 992 

Vanadium.......... 284, 285, 286, 287, 288 

vanadium pentoxide.......................... 289 

Vanin-1............................................. 444 

vapor intrusion................................ 1236 

vapor uptake modeling................... 2289 

variability........................................ 2691 

vascular........................................... 1493 

vascular development....... 836, 837, 840 

vascular injury........................ 838, 2671 

Vascular permeability....................... 959 

Vascular reactivity............................ 193 

vascular toxicity.............................. 2670 

Vasculitis....................... 797, 2669, 2673 

VCD................................................ 1054 

vector control.................................. 1476 

vegan bone treat.............................. 2410 

vegetable......................................... 2119 

VEGFR1......................................... 2587 

vehicle-effect.................................... 963 

vehicles............................................. 963 

Ventilator-associated pneumonia.... 2337 

vesicant........................................... 1751 

Vesicant injury.............. 894, 2031, 2033 

vesicants............................... 1752, 2032 

Vibrio vulnificus............................... 688 

Vimentin......................................... 2637 

Vinculin.......................................... 1386 

viral infection.................................... 256 

Viral load monitoring..................... 1149 

virtual liver....................................... 733 

Virtual Tissues................................ 1619 

Vitamin A........................................ 2411 

Vitamin D....................................... 2412 

Vitamin K....................................... 1613 

Vitamin-status................................... 310 

vitellogenin................................. 17, 976 

VMAT2..................................... 181, 182 

VOC...................................... 1424, 1693 

VOCs.................................... 1573, 1952 

volatile organic compounds..... 502, 596, 

977, 1245, 2399 

VX.............................. 1543, 2011, 2022 

warfare organophosphates.............. 2047 

water column.................................... 827 

watercress....................................... 2232 

weapons............................................ 930 

weathering........................................ 827 

Weight of Evidence...... 727, 1944, 1948 

welding............................................. 563 

welding fume........................ 2317, 2322 

Werner syndrome protein................. 121 

WGA............................................... 1369 

whale cells............................ 2342, 2392 

Wistar Rats................. 1552, 1574, 1951 

WKY rats........................................ 1062 

Wnt................................................. 1624 

Wnt signaling.................................. 1626 

Wnt/b-Catenin................................ 1741 

Wnt/beta catenin pathway................ 249 

Wood combustion..................... 671, 672 

wood furnace.................................. 1213 

wood smoke.................................... 1127 

Workers........................................... 1218 

Wound................................... 2021, 2022 

wound healing...... 893, 895, 2534, 2556 

wound repair................................... 2575 

Writing............................................ 1768 

WTC..................................... 1235, 1259 

xCT Transporter.............................. 1513 

xenobiotic metabolism............ 647, 1707 

xenobiotics........................................ 376 

Xenoestrogens.................................. 110 

Xenopus.......................................... 2379 

Xenopus laevis.................................. 347 

Xpa(-/-)p53(+/-) mice..................... 2658 

XPC...................................... 1360, 1991 

X-radiation.......................................... 65 

x-ray fluorescence (xrf).................. 1686 

yeast........................................ 340, 2558 

yeast deletion library...................... 2253 

Y-family DNA Polymerases............. 120 

Yil006w............................................ 308 

Yucatan Minipig............................... 635 

Zebrafish.......................... 197, 198, 871, 

873, 896, 897, 898, 942, 976, 1071, 

1461, 1479, 1483, 1588, 1629, 1633, 

1642, 1740, 1741, 1742, 1743, 1744, 

1745, 1746, 1747, 1779, 1840, 1859, 

2090, 2093, 2142, 2143, 2144, 2168, 

2310, 2339, 2363, 2388, 2389, 2514, 

2539, 2548, 2628 

Zebrafish embryo toxicity... 1607, 1610, 

1627, 2380 

zebrafish larvae....................... 872, 1895 

Zidovudine...................................... 1304 

Zinc................................................... 314 

zinc deficiency.................................. 756 

zinc finger nuclease.......................... 535 






Zinc nanoparticles................ 1496, 2060 

Zinc Oxide Nanoparticles............... 2179 

ZIP transporters........................ 313, 314 

ziram................................................. 691 

zygacine.......................................... 2229 



401


2010–2011 Council 

Michael P. Holsapple 

Jon C. Cook 

William Slikker, Jr. 

President 

2010–2011 

Vice President 

2010–2011 

Vice President-Elect 

2010–2011 

LeadershIP 

• 50 th Year Anniversary SOT Task Force, 

Council Contact 

• Board of Publications, Member 

• Council Subcommittees: 

FDA/NCTR Liaison Group, Chair 

• NICHD Liaison Group, Member 

• Endowment Fund Board, Ex-Officio 

Member 

• Finance Committee, Member 

• Global Strategy Task Force, 

Co-Contact 

• IUTOX Councilor, Member, Council 

Contact 

T: 202.659.3306 ext. 151 F: 202.659.3617 

mholsapple@ilsi.org 

• Board of Publications, ad hoc 

Member, Council Contact 


• FDA/NCTR Liaison Group, Member 

• NIEHS Liaison Group, Member 


• Global Strategy Task Force, Council 

Contact 

• IUTOX Councilor, Member 

• Nominating Group for Honorary 

Members, Member 

• Scientific Program Committee, 

Member, Chair 

T: 860.715.2693 F: 860.715.9890 

jon.c.cook@pfizer.com 

• Awards Committee, Council Contact 


NIOSH Liaison Group, Member 

• Social Networking, Member 


• Scientific Program Committee, 

Member, Co-Chair 

T: 870.543.7517 F: 870.543.7576 

william.slikker@fda.hhs.gov 

Lawrence R. Curtis 

John B. Morris 

Peter L. Goering 

Treasurer 

2009–2011 

Treasurer-Elect 

2010–2011 

Secretary 

2010–2012 


EPA Liaison Group, Member 

NIOSH Liaison Group, Chair 

• Non-SOT Meeting, Component, 

Regional Chapter, and Global Funding, 

Co-Chair 

• SOT Affiliates and Sponsors, Member 


Member 

• Exhibitor Liaison Working Group, 


• Finance Committee, Chair, Council 

Contact 


EPA Liaison Group, Member 



Co-Chair 



Member 


• Scientific Liaison Task Force, Council 

Contact 

• Communications Committee, 



CDC Liaison Group, Chair 

• NIOSH Liaison Group, Member 



Member 

• Newsletter Editor 

• Regional Chapters, Council Contact 

T: 541.737.1764 F: 541.737.3178 

larry.curtis@oregonstate.edu 

T: 860.486.3590 F: 860.486.5792 

john.morris@uconn.edu 

T: 301.796.0253 F: 301.796.9826 

peter.goering@fda.hhs.gov 



2010–2011 Council (Continued) 

Cheryl Lyn Walker 

Matthew S. Bogdanffy 

Susan J. Borghoff 

Past President 

2010–2011 

Councilor 

2009–2011 

Councilor 

2009–2011 

• Audit Committee, Council Contact 


NIEHS Liaison Group, Chair 

• NICHD Liaison Group, Member 

• Endowment Fund Board, Member, 



• Nominating Committee, Council 

Contact 

• Nominating Group for Honorary 

Members, Member, Council Contact 

T: 512.237.9525 F: 512.237.2475 

chwalker@mdanderson.org 


CDC Liaison Group, Member 

EPA Liaison Group, Chair 

Social Networking, Member 


• Disease Prevention Task Force, 


• Education Committee, Council 

Contact 

• Specialty Sections, Council Contact 

T: 203.798.5339 F: 203.798.5797 

matthew.bogdanffy@boehringeringelheim.com 

• Committee on Diversity Initiatives, 



CDC Liaison Group, Member 

NICHD Liaison Group, Chair 



Member 

• Social Networking, Chair 

• SOT Affiliates and Sponsors, Chair 

• Data Task Force, Council Contact 

• Membership Committee, Council 

Contact 

• Special Interest Groups, Council 

Contact 

T: 919.281.1110 ext. 717 F: 919.281.1118 

sborghoff@ils-inc.com 

LeadershIP 

Donald A. Fox 

Michael P. Waalkes 

Shawn Douglas Lamb 

Councilor 

2010–2012 

Councilor 

2010–2012 

Executive Director 

• Career Research and Development 

Committee, Council Contact 

• Council Subcommittee: 

• NIEHS Liaison Group, Member 

• Research Funding Committee, 


• Student Advisory Council, Council 

Contact: 

• Regional Chapter/Special Interest 

Group Graduate Committee 

• Specialty Section Graduate Committee 

• CCT Conferences Committee, Council 

Contact 

• CE Committee, Council Contact 


FDA/NCTR Liaison Group, Member 



Member 

• Postdoctoral Assembly, Council 

Contact 

• Professional Needs Assessment Task 

Force, Council Contact 

• Audit Committee, Staff Liaison 


Member 

• Finance Committee, Staff Liaison 

• Global Strategy Task Force, Staff 

Liaison 

• IUTOX Councilors, Staff Liaison 

• Nominating Committee, Staff Liaison 

T: 713.743.1964 F: 713.743.2053 

dafox@uh.edu 

T: 919.541.2328 F: 919.541.3970 

mwaalkes@nc.rr.com 

T: 703.438.3115 F: 703.438.3113 

shawnl@toxicology.org 


403


Elected and Appointed Committees 

LeadershIP 

Elected Committees 

Awards Committee 

Harold Zenick, Chair (2010–2011), Member (2009–2011) 

Robert E. Chapin, Member (2010–2012) 

Lori A. Dostal, Member (2009–2011) 

Jay I. Goodman, Member (2009–2011) 

Douglas A. Keller, Member (2009–2011) 

Serrine S. Lau, Member (2010–2012) 

Ruth A. Roberts, Member (2010–2012) 

William Slikker, Jr.* 

Matthew J. Price** 

Membership Committee 

Thomas M. Monticello, Chair (2009–2011), 

Member (2008–2011) 

Darol E. Dodd, Member (2008–2011) 

Terry Gordon, Member (2009–2012) 

Abigail C. Jacobs, Member (2010–2013) 

Robert L. Tanguay, Member (2009–2012) 

Alice R. Villalobos, Member (2010–2013) 

James R. Roede, Postdoctoral Representative (2010–2011) 

Ofek Bar-Ilan, Student Representative (2009–2012) 

Susan J. Borghoff* 


Nominating Committee 

Kenneth S. Ramos*, Chair (2010–2011), Member (2010–2011) 

Deborah A. Cory-Slechta, Member (2010–2012) 

Vicki L. Dellarco, Member (2010–2012) 

Tammy R. Dugas, Member (2009–2011) 

Julie E. Goodman, Member (2009–2011) 

Michael F. Hughes, Member (2010–2012) 

Kimberley Anne Treinen, Member (2010–2012) 

Kendall B. Wallace, Member (2009–2011) 

Cheryl Lyn Walker* 

Shawn Douglas Lamb ** 

Appointed Committees 

50 th Year Anniversary SOT Task Force (FAST) 

Martin A. Philbert, Chair (2010–2012), Member (2006–2012) 

Meryl H. Karol, Co-Chair, Member (2006–2012) 

Linda S. Birnbaum, Member (2006–2012) 

James S. Bus, ad hoc (2008–2012) 

Gary P. Carlson, Member (2006–2012) 

Jack H. Dean, Member (2007–2012) 

Dennis J. Devlin, Member (2007–2012) 

John Doull, Member (2006–2012) 

David L. Eaton, Member (2006–2012) 

William C. Hays, Member (2006–2012) 

Ernest Hodgson, Member (2006–2011) 

Lisa A. Opanashuk, Member (2007–2012) 

Dennis James Paustenbach, Member (2007–2012) 

Robert A. Scala, Member (2006–2012) 

Ronald B. Tjalkens, Member (2007–2012) 

Michael P. Holsapple* 

Clarissa Russell Wilson** 

Audit Committee 

George P. Daston, Chair (2010–2011), Member (2008–2011) 

Jeffrey M. Charles, Member (2007–2012) 

David L. Eaton, Member (2010–2013) 

Cheryl Lyn Walker* 

Shawn Douglas Lamb** 

Board of Publications 

Hartmut Jaeschke, Chair (2009–2011), Member (2007–2011) 

Janice E. Chambers, Member (2010–2014) 

Michael P. Holsapple, Member (2009–2011) 

Serrine S. Lau, Member (2009–2013) 

Lois D. Lehman–McKeeman, ToxSci Editor, Auditor (2003–2011) 

Ivan Rusyn, Member (2008–2012) 

Jon C. Cook*, ad hoc (2010–2011) 

Marcia Lawson** 


Hisham K. Hamadeh, Chair (2010–2011), Member (2008–2011) 

Carmen Booker, Member (2010–2011) 

Marila Cordeiro-Stone, Member (2009–2012) 

Aimen K. Farraj, Member (2010–2013) 

Barbara L. F. Kaplan, Member (2010–2013) 

Richard Davis Storer, Member (2009–2012) 

Courtney E. W. Sulentic, Member (2010–2013) 

Vasilis Vasiliou, Member (2009–2012) 

Donna D. Zhang, Member (2008–2011) 

Chidozie Joshua Amuzie, Postdoctoral 

Representative (2010–2011) 

Xiaochu Zhang, Student Representative (2010–2011) 

Donald A. Fox* 



Adrian Nanez, Chair (2009–2011), Member (2008–2011) 

Yolanda Banks Anderson, Member (2009–2012) 

Nathan J. Cherrington, Member (2009–2012) 

Julio Cesar Davila, Member (2008–2011) 

Erin P. Hines, Member (2010–2013) 

Elaine Valerie Knight, Member (2010–2013) 

José E. Manautou, ad hoc (2009–2011) 

W. David McGuinn, Member (2008–2011) 

Jennifer L. Rayner, Member (2009–2012) 

Leslie Recio, Member (2010–2013) 

Enrique Fuentes-Mattei, Postdoctoral 

Representative (2010–2011) 

Chad Broker, Student Representative (2010–2011) 


Betty Eidemiller** 

* Council Contact 

** Staff Liaison 

TBD=To be determined 



Elected and Appointed Committees (Continued) 

Communications Committee 

Drew A. Badger, Chair (2010–2011), Member (2008–2011) 

George M. Gray, Member (2010–2012) 

Paul C. Howard, Member (2009–2012) 

Daland R. Juberg, Member (2008–2011) 

José E. Manautou, Member (2010–2012) 

Laine Peyton Myers, Member (2008–2011) 

Jennifer Orme-Zavaleta, Member (2010–2013) 

Timothy P. Pastoor, Member (2010–2013) 

Katie Sprugel, Member (2008–2011) 

Prasad Krishnan, Postdoctoral Representative (2010–2011) 

Heather Bolstad, Student Representative (2009–2011) 

Peter L. Goering* 

Martha Lindauer** 

Communications Subcommittee: Animals in Research 

Working Group 

Laine Peyton Myers, Chair (2010–2011), Member (2010–2011) 

Denise E. Fillman-Holliday, Member (2009–2011) 

Steve G. Gilbert, Member (2009–2011) 

Betina J. Lew, Member (2010–2011) 

Timothy P. Reilly, Member (2009–2011) 


Communications Subcommittee: 

Congressional Task Force 

George B. Corcoran, Chair (2009–2011), Member (2009–2011) 

George M. Gray, Member (2009–2011) 

Carol J.M. Henry, Member (2010–2011) 


Erik R. Janus, Member (2010–2011) 

Daland R. Juberg, Member (2009–2011) 

Timothy LaBranche, Member (2010–2011) 

Mark W. Lafranconi, Member (2010–2011) 

James C. Lamb, IV, Member (2010–2011) 

Martin Stephens, Member (2010–2011) 


Communications Subcommittee: 

Editorial Board 

Katie Sprugel, Chair (2010–2011), Member (2010–2011) 

Drew A. Badger, Member (2010–2011) 

James S. Bus, Member (2010–2011) 

Paul Anthony Duffy, Member (2009–2011) 

Paul C. Howard, Member (2010–2011) 

Lois D. Lehman–McKeeman, Member (2009–2011) 

Jennifer Gibson Schnellmann, Member (2009–2011) 

Judith T. Zelikoff, Member (2009–2011) 

Heather Bolstad, Student Representative (2010–2011) 


Contemporary Concepts in Toxicology (CCT) 

Conferences Committee 

Deborah A. Cory-Slechta, Chair (2009–2011), 

Member (2008–2012) 

James S. Bus, Member (2010–2013) 

Chris Corton, Member (2010–2013) 

Dale Hattis, Member (2008–2011) 

James P. Luyendyk, Member (2008–2011) 

Timothy Richard Zacharewski, Member (2009–2012) 

Michael P. Waalkes* 


Continuing Education Committee 

Christopher A. Reilly, Chair (2010–2011), Member (2008–2011) 

Hadi Falahatpisheh, Member (2008–2011) 

Kathleen Gabrielson, Member (2009–2012) 

Hanan N. Ghantous, Member (2010–2013) 

Debra L. Laskin, Member (2009–2012) 

James Patrick O’Callaghan, Member (2010–2013) 

J. Craig Rowlands, Member (2010–2013) 

Stephen H. Safe, Member (2009–2012) 

Yanan Tian, Member (2008–2011) 

Mayurranjan Mitra, Postdoctoral Representative (2010–2011) 

Colleen McLoughlin, Student Representative (2010–2011) 


David Rosse** 

Council Subcommittee for Non-SOT Meeting, Component, 

Regional Chapter, and Global Funding 

Lawrence R. Curtis, Co-Chair (2010–2011), Member (2009–2011) 

John B. Morris, Co-Chair (2010–2011), Member (2010–2011) 

Susan J. Borghoff, Member (2009–2011) 

Peter L. Goering, Member (2009–2011) 

Michael P. Waalkes, Member (2010–2012) 


Council Subcommittee on Social Networking 

Susan J. Borghoff, Chair (2009–2011), Member (2009–2011) 

Matthew S. Bogdanffy, Member (2009–2011) 

William Slikker, Jr., Member (2010–2011) 


Council Subcommittee on SOT Affiliates and Sponsors 



Lawrence R. Curtis, Member (2010–2011) 

John B. Morris, Member (2010–2011) 


Data Task Force 

Ronald N. Hines, Member (2009–2011) 

Martin A. Philbert, Member (2009–2011) 


Debbie O’Keefe** 



Thomas W. Kensler, Chair (2010–2011), Member (2009–2012) 

Matthew J. Campen, Member (2008–2011) 

Erica L. Dahl, Member (2009–2012) 

Bruce A. Fowler, Member (2010–2013) 

James Patrick Mastin, Member (2008–2011) 

Donna L. Mendrick, Member (2010–2013) 

Matthew S. Bogdanffy* 


LeadershIP 


405



LeadershIP 


Aaron Barchowsky, Chair (2009–2011), Member (2007–2011) 

Lorrene A. Buckley, Member (2009–2012) 

Dori R. Germolec, Member (2008–2011) 

Robin C. Guy, Member (2009–2012) 

Thomas A. Lewandowski, Member (2010–2013) 

Jean C. Pfau, Member (2010–2013) 

Stephen B. Pruett, Member (2008–2011) 

Sidhartha D. Ray, ad hoc (2010–2011) 

Xianai Wu, Postdoctoral Representative (2010–2011) 

Arunkumar Asaithambi, Student Representative (2010–2011) 

Matthew S. Bogdanffy* 


Education Subcommittee: K–12 Task Force 

Maureen R. Gwinn, Chair (2009–2011), Member (2009–2011) 

Aaron Barchowsky, Education Committee Chair (2009–2011) 

Pedro L. Del Valle, Member (2010–2011) 

Suzanne Compton Fitzpatrick, Member (2009–2011) 

Thomas J. Flynn, Member (2010–2011) 

Kathleen Gabrielson, Member (2009–2011) 

Joanna M. Matheson, Member (2009–2011) 

Dori R. Germolec, Education Committee Liaison (2009–2011) 


Education Subcommittee: ToxLearn Work Group 

Phil Wexler, Chair (2004–2011), Member (2004–2011) 

John H. Duffus, Member (2004–2011) 

Tammy R. Dugas, Member (2006–2011) 

Sue M. Ford, Member (2006–2011) 

Jane Huggins, Member (2006–2011) 

Michael A. Kamrin, Member (2004–2011) 

Paul Wright, Member (2004–2011) 

Lorrene A. Buckley, Education Committee Liaison (2010–2012) 

Sidhartha D. Ray, Education Committee Liaison (2007–2011) 


Education Subcommittee: Undergraduate Education 

Aaron Barchowsky, Chair (2009–2011), Member (2009–2011) 

Teresa G. Dodd-Butera, Member (2009–2011) 

Sue M. Ford, Member (2009–2011) 

Wesley G.N. Gray, Member (2009–2011) 

Sara Hegglund, Member (2009–2011) 

Mindy F. Reynolds, Member (2009–2011) 

Jean C. Pfau, Education Committee Liaison (2011–2013) 


Endowment Fund Board 

Norbert E. Kaminski, Member (2007–2011) 

Martin A. Philbert, Member (2010–2013) 

Kenneth S. Ramos, Member (2009–2011) 

Jacqueline H. Smith, Member (2008–2011) 

Robert G. Tardiff, Member (2009–2013) 

Cheryl Lyn Walker*, Member (2010–2012) 

James S. Woods, Member (2009–2012) 

Lawrence R. Curtis, Ex-Officio Member (2009–2011) 

Michael P. Holsapple, Ex-Officio Member (2010–2011) 

Shawn Douglas Lamb, Ex-Officio Member (2006–2011) 

John B. Morris, Ex-Officio Member (2010–2013) 


Exhibitor Liaison Working Group 

Cyndi Bono, HT (ASCP), Member (2009–2012) 

Valerie Cole, Member (2009–2011) 

Steve Hachtman, Member (2009–2012) 

Lawrence R. Curtis* 

Liz Kasabian ** 

Finance Committee 

Lawrence R. Curtis*, Chair (2009–2011), Member (2008–2011) 

Gail Darlene Chapman, Member (2008–2011) 

Jon C. Cook, Member (2010–2012) 

John DiGiovanni, Member (2009–2012) 


Craig Marcus, Member (2010–2013) 



Government Liaison Groups 

CDC/ATSDR 

Peter L. Goering, Chair (2010–2011), Member (2010–2011) 


Susan J. Borghoff, Member (2010–2011) 

Bruce A. Fowler, Agency Contact (2010–2011) 


EPA 

Matthew S. Bogdanffy, Chair (2010–2011), 

Member (2010–2011) 

Lawrence R. Curtis, Member (2010–2011) 


Harold Zenick, Agency Contact (2010–2011) 


FDA/NCTR 

Michael P. Holsapple, Chair (2010–2011), 

Member (2010–2011) 


Michael P. Waalkes, Member (2010–2011) 

Ron N. Hines, Ex Officio Member (2010–2011) 

James A. Popp, Ex Officio Member (2010–2011) 

Margaret Ann Miller, Agency Contact (2010–2011) 


NICHD 



Cheryl Lyn Walker, Member (2010–2011) 


NIEHS 

Cheryl Lyn Walker, Chair (2010–2011), Member (2010–2011) 


Donald A. Fox, Member (2010–2011) 

John M. Balbus, Agency Contact (2010–2011) 


NIOSH 

Lawrence R. Curtis, Chair (2010–2011), Member (2010–2011) 

Peter L. Goering, Member (2010–2011) 


Martin A. Philbert, Ex-Officio Member (2010–2011) 


* Council Contact 

** Staff Liaison 

TBD=To be determined 




Global Strategy Task Force 

Ruth A. Roberts, Chair (2009–2012), Member (2010–2012) 

S. Satheesh Anand, Association of Scientists 

of Indian Origin (2009–2012) 

Laura Andrews, Women in Toxicology (2009–2012) 

Silvia B.M. Barros, Member (2009–2012) 

Kok Wah Hew, Member (2009–2012) 

Ji–Eun Lee, Korean Toxicologists Association 

in America (2009–2012) 

Anthony M. Ndifor, Toxicologists of African Origin (2009–2012) 

Betzabet Quintanilla–Vega, Hispanic Organization of Toxicologists 

(2009–2012) 

Denise Robinson Gravatt, Member (2009–2012) 

Tao Wang, American Association of Chinese in Toxicology (2010–2012) 

Jon C. Cook* 

Michael P. Holsapple* 


Historian 

Peter L. Goering* 


Nominating Group for Honorary Members 

Kenneth S. Ramos, Chair (2010–2011), Member (2010–2011) 


Cheryl Lyn Walker*, Member (2010–2011) 


Postdoctoral Assembly (PDA) Executive Board 

Sarah Campion, Chair (2010–2011), Member (2009–2011) 

Michele La Merrill, Vice-Chair (2010–2012) 

Vijay M. Kale, Secretary (2010–2011) 

Marie Chantale Fortin, Treasurer (2010–2011) 

Anne Elizabeth Loccisano, Councilor (2010–2011) 



Professional Needs Assessment Task Force 

Mary Beth Genter, Chair (2010–2011), Member (2009–2012) 

Gary P. Carlson, Member (2010–2013) 

Barbara D. Davis, Member (2009–2011) 

James C. Lamb, IV, Member (2008–2011) 

James A. Popp, Member (2009–2012) 

Mari S. Stavanja, Member (2010–2013) 



Job Market Survey Subcommittee 

J. Kevin Kerzee, Chair † (2010–2011), Member (2010–2012) 

Mary Beth Genter † , Member (2010–2012) 

James A. Popp † , Member (2010–2012) 

Richard Davis Storer ‡ , Member (2010–2012) 

Vasilis Vasiliou‡, Member (2010–2012) 

Betty Eidemiller, Data Task Force Liaison 


†Representatives from the Professional Needs Assessment 

Task Force 

‡Representatives from the Career Resource and Development 

Committee 


Nancy I. Kerkvliet, Chair (2010–2011), Member (2009–2012) 

Michael Aschner, Member (2010–2013) 

Jonathan A. Doorn, Member (2009–2012) 

Joel G. Pounds, Member (2008–2011) 

Alvaro Puga, Member (2008–2011) 

Hollie I. Swanson, Member (2010–2013) 



Scientific Liaison Task Force 

David G. Kaufman, Chair (2010–2011), Member (2009–2012) 

John M. DeSesso, Member (2010–2011) 

Kenneth L. Hastings, Member (2010–2013) 

Thomas B. Knudsen, Member (2008–2011) 

Qiang Ma, Member (2010–2013) 

Dennis J. Naas, Member (2010–2012) 

Jeffrey I. Everitt, ad hoc (2008–2011) 

John B. Morris* 


Scientific Program Committee 

Jon C. Cook*, Chair (2010–2011), Member (2009–2011) 

William Slikker, Jr., Co–Chair (2010–2011), 

Member (2010–2011) 

Cynthia A. Afshari, Member (2008–2011) 

Leigh Ann Burns Naas, Member (2009–2012) 

Myrtle A. Davis, Member (2008–2011) 

Paul M.D. Foster, Member (2009–2012) 

Annie M. Jarabek, Member (2009–2012) 

Abby A. Li, Member (2010–2014) 

Charlene A. McQueen, Member (2007–2011) 

Terrence J. Monks, Member (2008–2011) 

Richard S. Pollenz, Member (2008–2011) 

James L. Stevens, Member (2010–2014) 

David B. Warheit, Member (2009–2012) 

Peter K. Working, Member (2010–2014) 

Nichelle Sankey** 

LeadershIP 


407



LeadershIP 

Student Advisory Council (SAC) 

Ofek Bar-Ilan, President (2010–2011), Member (2009–2011) 

Jessica R. Placido, President–Elect (2010–2011), 

Member (2010–2011) 

Thomas Simones, Secretary/Treasurer (2010–2011), Member (2010–2011) 

James Michael Berg, Member (2010–2011) 

Michael G. Borland, Member (2010–2011) 


David Rosse** 

Student Advisory Council (SAC): Regional Chapter/Special 

Interest Group Graduate Committee 

Ofek Bar-Ilan, Chair (2010–2011), Member (2010–2011) 

Jessica R. Placido, Chair-Elect (2010–2011), Member (2010–2011) 

James Michael Berg, Secretary (2010–2011), Gulf Coast (2010–2011) 

Erin M. G. Allen, Central States (2010–2011) 

Kevin Michael Beggs, Michigan (2010–2011) 

Heather M. Bolstad, Northern California (2010–2011) 

Josephine A. Bonventre, Mid-Atlantic (2010–2011) 

Marie M. Bourgeois, Southeastern (2010–2011) 

Chad Nicholas Brocker, Mountain West (2010–2011) 

Tammy Elmergreen, Midwest (2010–2011) 

Jennifer Leigh Head, Women in Toxicology (2010–2011) 

Afeseh Ngwa Hilary, Toxicologists of African Origin (2010–2011) 

Jim Kleinedler, South Central (2010–2011) 

Senthilkumar Perumal Kuppusamy, Association of Scientists 

of Indian Origin (2010–2011) 

Narae Lee, Korean Toxicologists Association in America (2010–2011) 

Colleen Elizabeth McLoughlin, National Capital (2010–2011) 

Arpit Mehta, Allegheny-Erie (2010–2011) 

Katie Beth Paul, North Carolina (2010–2011) 

Richard L. Salisbury, Jr., Ohio Valley (2010–2011) 

Sarah Y. Skolness, Northland (2010–2011) 

Parrisa S. Solaimani, Southern California (2010–2011) 

Jose A. Torres, Hispanic Organization of Toxicologists (2010–2011) 

Chad S. Weldy, Pacific Northwest (2010–2011) 

Li Xu, American Association of Chinese in Toxicology (2010–2011) 


David Rosse** 

Student Advisory Council (SAC): Specialty Section Graduate 

Committee 

Thomas Simones, Chair (2010–2011), 

Regulatory and Safety Evaluation (2010–2011) 

Michael G. Borland, Secretary (2010–2011), Carcinogenesis (2010–2011) 

Arunkumar Asaithambi, Drug Discovery Toxicology (2010–2011) 

Christopher M. Carosino, Biological Modeling (2010–2011) 

Fanny L. Casado-Pena, Biotechnology (2010–2011) 

Andrea S. DeSantis, In Vitro and Alternative Methods (2010–2011) 

Jill Anne Franzosa, Molecular Biology (2010–2011) 

Nicholas Heger, Reproductive and Developmental 

Toxicology (2010–2011) 

Christina A. Hickey, Inhalation and Respiratory (2010–2011) 

Sarah E. Lacher, Ethical, Legal, and Social Issues (2010–2011) 

Eric N. Liberda, Nanotoxicology (2010–2011) 

Lydia Marie Louis, Occupational and Public Health (2010–2011) 

Jingtao Lu, Comparative and Veterinary (2010–2011) 

Jason P. Magby, Neurotoxicology (2010–2011) 

Ashley P. Pettit, Cardiovascular Toxicology (2010–2011) 

Ronald B. Pringle, Mixtures (2010–2011) 

Gayatri Sankaran, Dermal Toxicology (2010–2011) 

David Taylor Szabo, Risk Assessment (2010–2011) 

Jeffrey D. Vassallo, Mechanisms (2010–2011) 

Lu Wang, Toxicologic and Exploratory Pathology (2010–2011) 

Sandra S. Wise, Metals (2010–2011) 

Xiaochu Zhang, Immunotoxicology (2010–2011) 


David Rosse** 

SOT Liaison Representatives 

American Association for the Advancement 

of Science (AAAS) Representative 

Charlene A. McQueen 

Association for Assessment and Accreditation of Laboratory 

Animal Care (AAALAC) Board of Trustees Representative 

Loren Koller 

International Union of Toxicology (IUTOX) Councilors 


Jay I. Goodman, Member (2010–2013) 

Michael P. Holsapple*, Member (2010–2013) 


Cheryl Lyn Walker, Member (2010–2013) 




Regional Chapter—Officers 

Allegheny-Erie (86*) 

Kelly A. Brant, President 

Sachin S. Devi, President-Elect 

Aaron Barchowsky, Vice President 

Robin E. Gandley, Secretary 

William James Mackay, Treasurer 

Nicolas A. Stewart, Past President 

James P. Fabisiak, Councilor 

Jim Scabilloni, Councilor 

Mark Weisberg, Councilor 

Fujun Liu, Postdoctoral Representative 

Arpit Mehta, Student Representative 

Central States (87*) 

Jonathan A. Doorn, President 

Lora L. Arnold, President-Elect 

Hans-Joachim Lehmler, Secretary/Treasurer 

Anumantha G. Kanthasamy, Past President 

James P. Luyendyk, Councilor 

Susan C. McKarns, Councilor 

Shashi K. Ramaiah, Councilor 

Xianai Wu, Postdoctoral Representative 

Erin M. G. Allen, Student Representative 

Gulf Coast (111*) 

Bhagavatula Moorthy, President 

Erica D. Bruce, Vice President 

Christie M. Sayes, Secretary 

Alice R. Villalobos, Treasurer 

Shawn B. Bratton, Past President 

R. Timothy Miller, Councilor 

Laura M. Plunkett, Councilor 

Gensheng Wang, Postdoctoral Representative 

James Michael Berg, Student Representative 

Lake Ontario (21*) 

TBA 

Michigan (175*) 

Joanne Caroline English, President 

Bjorn A. Thorsrud, President-Elect 

Robert G. Ellis-Hutchings, Secretary/Treasurer 

Alan P. Brown, Past President 

Nancy Anne M. Berdasco, Councilor 

Alice Hudder, Councilor 

Roseann L. Vorce, Councilor 

Rohit Singhal, Postdoctoral Representative 

Kevin Michael Beggs, Student Representative 

Mid-Atlantic (503*) 

Kenneth R. Reuhl, President 

Raymond G. York, Vice President 

Janet C. Gould, Vice President-Elect 

Gloria B. Post, Secretary 

Lauren M. Tarantino Hutchison, Treasurer 

Anthony R. Schatz, Past President 

Lin Mantell, Councilor 

John Michael Mitchell, Councilor 

Karl A. Traul, Councilor 

TBA, Postdoctoral Representative 

Josephine A. Bonventre, Senior Student Representative 

Nicole S. Olgun, Junior Student Representative 

Midwest (222*) 

Matthew D. Schroeder, President 

Christina R. Wilson, President-Elect 

Thomas A. Mably, Secretary 

Molly S. Weiler, Treasurer 

Walter C. Prozialeck, Past President 

Michael L. Biehl, Councilor 

Gregory L. Erexson, Councilor 

Susan M. Henwood, Councilor 

Lise I. Loberg, Councilor 


Tammy Elmergreen, Student Representative 

Mountain West (115*) 

Matthew D. Reed, President 

Donna D. Zhang, Vice President 

Cynthia Ju, Vice President-Elect 

Kevin Welch, Secretary/Treasurer 

Philip J. Moos, Past President 

Jean C. Pfau, Councilor 

Mingyi W. Trimble, Councilor 

Robert Kuester, Postdoctoral Representative 

Gabriel A. Knudsen, Senior Student Representative 

Chad Nicholas Brocker, Student Representative 

National Capital Area (255*) 

Pamela L. Chamberlain, President 

Laurie E. Roszell, Vice President 

Erik R. Janus, Secretary 

Thomas J. Flynn, Treasurer 

Jennifer W. Sekowski, Past President 

Robert J. Mitkus, Councilor 

Syril D. Pettit, Councilor 

Rosemary A. Schuh, Councilor 

Matthew John Smith, Postdoctoral Representative 

Colleen Elizabeth McLoughlin, Student Representative 

North Carolina (374*) 

Melanie Louise Foster, President 

Darol E. Dodd, Vice President 

Michael F. Hughes, Vice President-Elect 

Brenda Faiola, Secretary/Treasurer 

David J. Thomas, Past President 

Christal C. Bowman, Councilor 

Jamie C. Dewitt, Councilor 

Brante P. Sampey, Postdoctoral Representative 

Katie Beth Paul, Student Representative 

Northeast (290*) 

Laura Andrews, President 

Paul Nugent, Vice President 

Nicole W. Hurst, Secretary/Treasurer 

Graeme B.J. Smith, Past President 

Felicity April Grzemski, Councilor 

Laura M. Plunkett, Councilor 

Vishal S. Vaidya, Councilor 


TBA, Senior Student Representative 

TBA, Junior Student Representative 

LeadershIP 

* Membership totals as printed in the 

most recent Membership Directory 


409


Regional Chapter—Officers (Continued) 

LeadershIP 

Northern California (361*) 

Tao Wang, President 

Karen L. Steinmetz, Vice President 

Jeffrey S. Tepper, Vice President-Elect 

Veronique Valerie Lauriault, Secretary 

Karen Riveles, Treasurer 

Stephen M. DiZio, Past President 

Mark R. Fielden, Councilor 

Amy H. Kim, Councilor 

Matthew North, Postdoctoral Representative 

Heather M. Bolstad, Student Representative 

Northland (96*) 

Timothy M. O’Brien, President 

Nathan R. Pechacek, President-Elect 

Catherine F. Jacobson, Secretary/Treasurer 

John W. Nichols, Past President 

Kelly P. Coleman, Councilor 

Helen M. Goeden, Councilor 

John R. MacDonald, Councilor 


Sarah Y. Skolness, Student Representative 

Ohio Valley (186*) 

Mary Beth Genter, President 

Courtney E.W. Sulentic, President-Elect 

Lynette K. Rogers, Vice President 

Jason C. Lambert, Secretary 

Jeffrey D. Moehlenkamp, Treasurer 

Amy L. Roe, Past President 

Janelle S. Crossgrove, Councilor 

Bernard K. Gadagbui, Councilor 

Scott C. Wesselkamper, Councilor 

Raja S. Settivari, Postdoctoral Representative 

Richard L. Salisbury, Student Representative 

Pacific Northwest (160*) 

Rafael A. Ponce, President 

Stacey Lynn Harper, Vice President 

David L. Stone, Vice President-Elect 

Linda L. Carlock, Secretary/Treasurer 

Cecile M. Krejsa, Past President 

Susan C. Tilton, Councilor 

Kristen A. Mitchell, Councilor 

Tamara Tal, Postdoctoral Representative 

Chad S. Weldy, Student Representative 

South Central (93*) 

Heather E. Kleiner, President 

Tucker A. Patterson, Vice President 

Barbara L. Parsons, Vice President-Elect 

Kartik Shankar, Secretary 

Yunfeng Zhao, Treasurer 

Russell L. Carr, Past President 

Guangping Chen, Councilor 


Jim Kleinedler, Student Representative 

Southeastern (108*) 

Brian S. Cummings, President 

Charlene A. McQueen, Vice President-Elect 

Carol S. Wood, Secretary/Treasurer 

Essam E. Enan, Past President 

Gary W. Miller, Councilor 

Rick G. Schnellmann, Councilor 

Jeffrey William Fisher, Councilor 

James R. Roede, Postdoctoral Representative 

Marie M. Bourgeois, Student Representative 

Southern California (373*) 

Robert T. Dunn, President 

Anthony M. Ndifor, Vice President 

Andrew M. Seacat, Vice President-Elect 

Thomas A. Zanardi, Secretary 

Tina Leakakos, Treasurer 

Michelle J. Horner, Past President 

A. Jacob Jabbour, Councilor 

Aida I. Sacaan, Councilor 

Gregory J. Stevens, Councilor 

David J. Castro, Postdoctoral Representative 

Parrisa S. Solaimani, Student Representative 

Regional Chapter Governance Group 

Anthony R. Schatz, Chair 

Tao Wang, Vice Chair 

Laura Andrews, Member 

Anumantha G. Kanthasamy, Member 

Jennifer W. Sekowski, Member 

Peter L. Goering, Council Contact 

John Bae, Staff Liaison 





Specialty Section—Officers 

Biological Modeling (134*) 

Robert S. DeWoskin, President 

James V. Bruckner, Vice President 

Hisham A. El-Masri, Vice President-Elect 

Jerry L. Campbell, Secretary/Treasurer 

Richard A. Corley, Past President 

Michael J. Bartels, Councilor 

Jeffry Schroeter, Councilor 

Susan Ritger-Crowell, Postdoctoral Representative 

Christopher M. Carosino, Student Representative 

Biotechnology (109*) 

Barbara J. Mounho, President 

Janet B. Clarke, Vice President 

Hanan N. Ghantous, Vice President-Elect 

Theresa Reynolds, Secretary/Treasurer 

Leigh Ann Burns Naas, Councilor 

Timothy K. MacLachlan, Councilor 

Andrea B. Weir, Councilor 

Holly Mortensen, Postdoctoral Representative 

Fanny L. Casado-Pena, Student Representative 

Carcinogenesis (255*) 

Vernon E. Walker, President 

David E. Williams, Vice President 

Helmut Zarbl, Vice President-Elect 

Ivan Rusyn, Secretary/Treasurer 

Charlene A. McQueen, Past President 

Nancy G. Doerrer, Councilor 

Heather E. Kleiner, Councilor 


Michael G. Borland, Student Representative 

Cardiovascular Toxicology (55*) 

Timothy Nurkiewicz, President 

Matthew J. Campen, Vice President 

Kevin L. Dreher, Vice President-Elect 

Srikanth S. Nadadur, Secretary 

Hong Wang, Treasurer 

Daniel J. Conklin, Councilor 

W. David McGuinn, Councilor 

Dennis J. Murphy, Councilor 

Mayurranjan S. Mitra, Postdoctoral Representative 

Ashley P. Pettit, Student Representative 

Comparative and Veterinary (103*) 

Kathleen Gabrielson, President 

Ann F. Hubbs, Vice President 

Louise C. Abbott, Vice President-Elect 

Ramesh Chandra Gupta, Secretary/Treasurer 

Mike J. Murphy, Past President 

Ronald E. Baynes, Councilor 

Uford A. Madden, Councilor 

Sachin Bhusari, Postdoctoral Representative 

Jingtao Lu, Student Representative 

Dermal Toxicology (146*) 

William Gerald Reifenrath, President 

Jeffrey J. Yourick, President-Elect 

Carol L. Sabourin, Vice President 

Adrienne T. Black, Secretary/Treasurer 

George DeGeorge, Past President 

Cynthia A. Ryan, Senior Councilor 

Linda C. Mutter, Councilor 

Lauren Mordasky Markell, Postdoctoral Representative 

Gayatri Sankaran, Student Representative 

Drug Discovery Toxicology (370*) 

Cynthia A. Afshari, President 

Craig E. Thomas, Vice President 

John A. Wisler, Vice President-Elect 

Melissa C. Rhodes, Secretary/Treasurer 

John W. Davis, Past President 

Michael A. Breider, Councilor 

Daniel C. Kemp, Councilor 

Kimberly A. Henderson, Postdoctoral Representative 

Arunkumar Asaithambi, Student Representative 

Ethical, Legal, and Social Issues (77*) 

Phil Wexler, President 

John P. Norman, Vice President 

Sol M. Bobst, Vice President-Elect 

Cindy M. Hoorn, Secretary/Treasurer 

Melinda J. Pomeroy-Black, Past President 

Don W. Korte, Councilor 

Robert C. MacPhail, Councilor 

Daniel J. Hochman, Postdoctoral Representative 

Sarah E. Lacher, Student Representative 

Food Safety (162*) 

Ray A. Matulka, President 

Kenneth A. Voss, Vice President 

James C. Griffiths, Vice President-Elect 

Timothy D. Phillips, Secretary/Treasurer 

Jia Sheng Wang, Past President 

Stephen A. Ruckman, Councilor 


TBA, Student Representative 

Immunotoxicology (393*) 

Leigh Ann Burns Naas, President 

Rodney R. Dietert, Vice President 

Gregory S. Ladics, Vice President-Elect 

Jacintha M. Shenton, Secretary/Treasurer 

Jean F. Regal, Past President 

Wendy J. Komocsar, Councilor 

Kazuichi Nakamura, Councilor 

Jennifer Lynne Franko, Postdoctoral Representative 

Xiaochu Zhang, Student Representative 

In Vitro and Alternative Methods (246*) 

Sue M. Ford, President 

Vincent A. Murphy, Vice President 

Sharon A. Meyer, Vice President-Elect 

Diane Hardej, Secretary/Treasurer 

David G. Allen, Past President 

Kylee E. Eblin, Councilor 

Greg Falls, Councilor 

Vijay M. Kale, Postdoctoral Representative 

Andrea S. DeSantis, Student Representative 



LeadershIP 


411


Specialty Section—Officers (Continued) 

LeadershIP 

Inhalation and Respiratory (274*) 

Vincent Castranova, President 

James G. Wagner, Vice President 

Michael T. Kleinman, Vice President-Elect 

Dale W. Porter, Secretary/Treasurer 

JeanClare Seagrave, Past President 

Flemming R. Cassee, Councilor 

Amy K. Madl, Councilor 

Jacob D. McDonald, Councilor 

Laura S. Van Winkle, Councilor 

Mehdi Saeed Hazari, Postdoctoral Representative 

Christina A. Hickey, Student Representative 

Mechanisms (345*) 

José E. Manautou, President 

Joan B. Tarloff, Vice President 

Michael D. Aleo, Vice President-Elect 

Patricia E. Ganey, Secretary/Treasurer 

Dennis R. Petersen, Past President 

Peter J. Harvison, Councilor 

Vasilis Vasiliou, Councilor 

Yinglin Liu, Postdoctoral Representative 

Jeffrey D. Vassallo, Student Representative 

Medical Device (60*) 

Lori H. Moilanen, President 

Richard W. Hutchinson, Vice President 

Ron Brown, Vice President-Elect 

Edward E. Reverdy, Secretary/Treasurer 

Jon N. Cammack, Councilor 

Robert T. Przygoda, Councilor 



Metals (177*) 

Aaron Barchowsky, President 

J. Christopher States, Vice President 

Michael F. Hughes, Vice President-Elect 

John Pierce Wise, Secretary/Treasurer 

Wei Zheng, Past President 

William E. Achanzar, Councilor 

John J. LaPres, Councilor 

Brooke E. Tvermoes, Postdoctoral Representative 

Sandra S. Wise, Student Representative 

Mixtures (79*) 

Kannan Krishnan, President 

Michael L. Dourson, Vice President 

Kendall B. Wallace, Vice President-Elect 

David R. Mattie, Secretary/Treasurer 

Jane Ellen Simmons, Past President 

Bruce A. Fowler, Councilor 

Paul S. Price, Councilor 

Cynthia V. Rider, Postdoctoral Representative 

Ronald B. Pringle, Student Representative 

Molecular Biology (168*) 

Christopher A. Reilly, President 

Russell S. Thomas, Vice President 

Chris Corton, Vice President-Elect 

Kristine L. Willett, Secretary/Treasurer 

Michael J. Carvan, Past President 

Nancy D. Denslow, Senior Councilor 

J. Craig Rowlands, Junior Councilor 

Karma C. Fussell, Student Councilor 

Cassandra Rice, Postdoctoral Representative 

Jill Anne Franzosa, Student Representative 

Nanotoxicology (287*) 

David B. Warheit, President 

Justin G. Teeguarden, Vice President 

Joyce S. Tsuji, Vice President-Elect 

Stephen M. Roberts, Secretary/Treasurer 

Annette B. Santamaria, Past President 

Christie M. Sayes, Councilor 

Nigel J. Walker, Councilor 

Yongbin Zhang, Postdoctoral Representative 

Eric N. Liberda, Student Representative 

Neurotoxicology (341*) 

Stephen M. Lasley, President 

Pamela J. Lein, President-Elect 

Gary W. Miller, Vice President 

Timothy Joseph Shafer, Secretary/Treasurer 

Susan L. Schantz, Past President 

Vanessa A. Fitsanakis, Councilor 

Sue Marty, Councilor 


Jason P. Magby, Student Representative 

Occupational and Public Health (203*) 

Allison L. Stock, President 

Michael Christopher Madden, Vice President 

Michael E. Ottlinger, Vice President-Elect 

Jenny R. Roberts, Secretary/Treasurer 

Eileen P. Hayes, Past President 

Anne H. Chappelle, Councilor 

William E. Luttrell, Councilor 

Jorge Gerardo Muñiz Ortiz, Postdoctoral Representative 

Lydia Marie Louis, Student Representative 

Ocular Toxicology (71*) 

Mark Vezina, President 

JoAnn C. L. Schuh, President-Elect 

Brian J. Christian, Vice President 

Marina T. Seme Nelson, Secretary/Treasurer 

Margaret E. Collins, Past President 

Timothy K. MacLachlan, Councilor 

Vasilis Vasiliou, Councilor 



Regulatory and Safety Evaluation (738*) 

Brian G. Short, President 

Timothy P. Pastoor, Vice President 

Paul Brown, Vice President-Elect 

Cynthia A. Afshari, Secretary/Treasurer 

James C. Lamb, IV, Past President 

Nancy B. Beck, Councilor 

Lorrene A. Buckley, Councilor 







Specialty Section—Officers (Continued) 

Reproductive and Developmental Toxicology (347*) 

Alan Hoberman, President 

Edward W. Carney, Vice President 

Barry S. McIntyre, Vice President-Elect 

Warren G. Foster, Secretary/Treasurer 

Mark E. Hurtt, Past President 

Winnie Jeng, Councilor 

Kamin Johnson, Councilor 

Robert M. Parker, Councilor 

Yvonne Dao Hoang, Postdoctoral Representative 

Nicholas Heger, Student Representative 

Risk Assessment (634*) 

Elaine M. Faustman, President 

Robinan Gentry, Vice President 

John C. Lipscomb, Vice President-Elect 

Calvin C. Willhite, Secretary/Treasurer 

Edward V. Ohanian, Past President 

Rory B. Conolly, Councilor 

Joanne Caroline English, Councilor 

Anne Elizabeth Loccisano, Postdoctoral Representative 

David Taylor Szabo, Student Representative 

Toxicologic and Exploratory Pathology (162*) 

Glenn H. Cantor, President 

Douglas C. Wolf, Vice President 

Norman J. Barlow, Vice President-Elect 

Tomas F. Magee, Secretary/Treasurer 

Charles W. Qualls, Past President 

Brian J. Day, Councilor 

Zaher A. Radi, Councilor 

Chidozie Joshua Amuzie, Postdoctoral Representative 

Lu Wang, Student Representative 

Specialty Section Governance Group 

Cynthia A. Afshari, Member 

Leigh Ann Burns Naas, Member 

Elaine M. Faustman, Member 

José E. Manautou, Member 

Brian G. Short, Member 

Matthew S. Bogdanffy, Council Contact 

Kim von Brook, Staff Liaison 

Stem Cells (NEW) 

Michael P. Waalkes, President 

Robert E. Chapin, Vice President 

Thomas A. Gasiewicz, Vice President-Elect 

Erik J. Tokar, Interim Officer 

Don A. Delker, Councilor 

Rebecca C. Fry, Councilor 

R. Clark Lantz, Councilor 

Amy M. Skinner, Postdoctoral Representative 

LeadershIP 




413


Special Interest Group—Officers 

LeadershIP 

American Association of Chinese in Toxicology (187*) 

Jia Sheng Wang, President 

Diana J. Auyeung-Kim, President-Elect 

John C. Zhuang, Secretary 

Xueyan (Peter) Mu, Treasurer 

Y. James Kang, Past President 

Tao Wang, Councilor 

Yi Yang, Councilor 

Jiaqin (Jack) Yao, Councilor 

Yu Janet Zang, Postdoctoral Representative 

Li Xu, Student Representative 

Association of Scientists of Indian Origin (131*) 

Binu K. Philip, President 

Vinayak Srinivasan, Vice President 

Saryu Goel, Vice President-Elect 

Sachin S. Devi, Secretary/Treasurer 

Sanjay Chanda, Past President 

Beby Jayaram, Councilor 

Anumantha G. Kanthasamy, Councilor 

Vikrant Vijay, Councilor 

Prasad Krishnan, Postdoctoral Representative 

Senthilkumar Perumal Kuppusamy, Student Representative 

Hispanic Organization of Toxicologists (74*) 

Pedro L. Del Valle, President 

Ofelia A. Olivero, Vice President 

Minerva Mercado Feliciano, Secretary 

Sergio A. Villalobos, Treasurer 

Braulio D. Jimenez-Velez, Past President 

Javier Avalos, Councilor 

Ranulfo Lemus Olalde, Councilor 

Betina J. Lew, Councilor 

Enrique Fuentes-Mattei, Postdoctoral Representative 

Jose A. Torres, Student Representative 

Korean Toxicologists Association in America (44*) 

Woon-Gye Chung, President 

Sang-Tae Kim, Vice President 

James H. Kim, Secretary/Treasurer 

Ji-Eun Lee, Past President 

Jin Ho Chung, Councilor 


Narae Lee, Student Representative 

Toxicologists of African Origin (79*) 

Claude McGowan, President 

Irene M. Abraham, Vice President 

Kristini Miles, Secretary/Treasurer 

Marquea D. King, Past President 

Elena K. Braithwaite, Councilor 

Eunice Musvasva, Councilor 


Hilary Afeseh Ngwa, Student Representative 

Women in Toxicology (467*) 

Suzanne C. Fitzpatrick, President 

Brinda Mahadevan, President-Elect 

Kristina D. Chadwick, Vice President 

Deborah E. Keil, Secretary/Treasurer 

Laura Andrews, Past President 

Leigh Ann Burns Naas, Councilor 

Tao Wang, Councilor 

Louisa A. Hooven, Postdoctoral Representative 

Jennifer Leigh Head, Student Representative 

Special Interest Group Collaboration Group 

Diana J. Auyeung-Kim, Co-Chair 

Pedro L. Del Valle, Co-Chair 

Irene M. Abraham, Member 

Kristina D. Chadwick, Member 

Woon-Gye Chung, Member 

Sang-Tae Kim, Member 

Brinda Mahadevan, Member 

Claude McGowan, Member 

Ofelia A. Olivero, Member 

Binu K. Philip, Member 

Vinayak Srinivasan, Member 

Tao Wang, Member 

Susan J. Borghoff, Council Contact 

Kim von Brook, Staff Liaison 





Endowment Fund Donor Contribution Form 

SOT Endowment Family of Funds 

The individual Funds that make up the SOT Endowment Fund are briefly described below. All are, or intend to become, Permanently Restricted Net Asset 

Funds, with their assets invested so their Funds will be continued in perpetuity with proceeds used for the purpose(s) identified by their original donor or 

those who provided leadership for creating each specific Fund. 

General Purpose Funds 

• Educational Activities—Proceeds from this Fund support a margin of 

excellence in SOT Educational Activities. 

• International Activities—Proceeds from this Fund will be used to 

promote the involvement of the SOT in international activities such as those 

of the International Union of Toxicology. 

*Help exhaust the SOT Council Approved $750,000 50 th Anniversary Match. Your contributions can have twice the IMPACT. In 2011, matches will focus 

on the four SOT General Purpose Funds and funds that support the General Purpose Fund. 

• Mary Amdur Student Award—Inhalation and Respiratory SS 

• Young Soo Choi Student Scholarship Award—Korean Toxicologists 

Association in America SIG 

• Laxman S. Desai ASIO Student Award—Association of Scientists of 

Indian Origin SIG 

• Diversity Initiatives—Committee on Diversity Initiatives 

• John Doull Student Award—Risk Assessment SS 

• Founders Fund—Founders Fund recipient selected by Awards Committee 

• Angelo Furgiuele Young Investigator Technology Award— 

Reproductive and Developmental Toxicology SS 

• Perry J. Gehring Biological Modeling Student Award—Biological 

Modeling SS 

• Perry J. Gehring Diversity Student Travel Award—Committee on 

Diversity Initiatives 

• Perry J. Gehring Risk Assessment Student Award—Risk 

Assessment SS 

• Harry W. Hays Memorial—SOT Education and/or Priority Needs Fund* 

• Health and Environmental Science Institute Immunotoxicology 

Young Investigator Student Award—Immunotoxicology SS 

• Vera W. Hudson and Elizabeth K. Weisburger Scholarship—Women 

in Toxicology SIG 

• Frank C. Lu Food Safety Student Award—Food Safety SS 

• Jean Lu Student Scholarship Award—American Association of Chinese 

in Toxicology SIG 

Individual Recognition 

(Cumulative Contributions) 

• Benefactor—Cumulative contributions of 

$10,000 or more. 

• Paracelsus Circle Lifetime Member— 

Cumulative contribution of $5,000 or more. 

Alternatively, a contribution of $500 and 

statement of intent to contribute $5,000 

within 10 years. 


Recognition Levels 

Individual Recognition 

(Based on July–June Fiscal Year Giving) 

• Paracelsus Circle—$500 or more 

• Gold—$250–$499 or more 

• Silver—$100–$249 or more 

• Bronze—$40–$99 in a given year 

415 

Corporate/Institutional Recognition 

(Based on July–June Fiscal Year Giving) 

• Diamond—Over $10,000 

• Platinum—$5,000–$9,999 

• Gold—$2,500–$4,999 

• Silver—$1,000–$2,499 

Donors who give $40 or more will be identified by name in the SOT Endowment Fund Annual Report and other Fund literature unless they wish to remain 

anonymous. In the case of couples who are both members of the SOT, the Recognition Level is based on the contribution of each individual. Thus, a $500 

joint contribution from a couple who are both members of the SOT is recognized at the Gold Level and a $1,000 joint contribution is recognized at the 

Paracelsus Circle Level. 

501(c)3 Charitable Organization 

• SOT Priorities—Proceeds from this Fund support the highest priority needs 

of the Society as determined by the SOT Council. 

• Student Travel—Proceeds from this Fund will be used to support 

student travel. 

Specific Purpose Funds 

These Funds match the interests of the donors with the future financial needs of SOT, its Specialty Sections (SS), Special Interest Groups (SIG), and 

Regional Chapters (RC). 

• Roger O. McClellan Student Award—Comparative and Veterinary SS 

and Toxicologic and Exploratory Pathology SS 

• Harihara Mehendale ASIO Student Award—Association of Scientists of 


• Metals Specialty Section Student Research Award—Metals SS 

• Molecular Biology Student Award—Molecular Biology SS 

• Pacific Northwest Toxicology Development—Pacific Northwest RC 

• Emil A. Pfitzer Drug Discovery Student Award—Drug Discovery 

Toxicology SS 

• Gabriel L. Plaa Education Award—Mechanisms SS 

• Regulatory and Safety Evaluation Student Award—Regulatory and 

Safety Evaluation SS 

• Renal Toxicology Fellowship Award—Mechanisms SS 

• Robert J. Rubin Student Travel Award—Mechanisms SS and Risk 

Assessment SS 

• Dharm V. Singh ASIO Student Award—Association of Scientists of 


• Dharm V. Singh Carcinogenesis Award—Carcinogenesis SS 

• Carl C. Smith Student Mechanisms Award—Mechanisms SS 

• Ronald G. Thurman Student Travel Award—Mechanisms SS 

• Toxicologists of African Origin Endowment—Toxicologists of African 

Origin SIG 

The SOT Endowment Fund is part of the Society of Toxicology, a charitable, non-profit, 501(c)3 organization under the Internal Revenue Code. 

The SOT Tax Identification Number is 52-605-7050. Contributions to the SOT Endowment Fund typically will be considered tax-deductible contributions. 

The Society of Toxicology will provide written acknowledgement of all contributions made to the SOT Endowment Fund.

Contribution Information 

I wish to be identified by name as an 

Endowment Fund Donor by Recognition 

Level, as shown on the following page, 

in the SOT Endowment Fund Annual Report. 

Name for acknowledgement: 

I do not want to be publicly identified 

as a Donor; I wish to remain anonymous. 

I intend to contribute $5,000 or more within 

ten years in order to be recognized as a 

Paracelsus Circle Lifetime Member. 

(For budget purpose only—not legally enforceable.) 

My employer will match my contribution. 

(Please enclose your employer’s Matching Gift Form) 

Employer 

Please contact me concerning the following: 

To assist in arranging a Corporate Gift/Stock 

or other assets. 

Naming the SOT Endowment Fund in my 

Will or Trust. 

Purchasing a Charitable Gift Annuity. 

Establishing a new Fund. 

Contributing securities, property, etc. 

Other 

I am giving my gift ($500 minimum): 

In memory of 

In honor of 

Mail or Fax to: 

Society of Toxicology Endowment Fund 

1821 Michael Faraday Drive, Suite 300 

Reston, VA 20191 

Fax: 703.438.3113 

Donor Contribution Form 

The SOT Endowment Fund is a family of Funds created to match the interests of Donors 

with the future financial needs of the SOT, its Specialty Sections, Special Interest Groups, 

and Regional Chapters. The individual Funds and Recognition Levels are briefly described 

on the following page. 

Donor Information 

Name 

Affiliation 

Address 

City 

Country 

Telephone 

E-Mail 

State/Region 


Fax 


Education $ 

International Activities $ 

SOT Priorities $ 

Student Travel $ 

Specific Purpose Funds 

(Listed on the following previous page) 

Payment 

Enclosed is a check for $ ________________ 

Zip 

$ 

$ 

$ 

$ 

$ 

$ 

TOTAL $ 

AMEX Discover Diners MasterCard Visa 

Credit Card # 

Name on Card 

Signature 

Date 

Exp Date 

Check # __________ 

Individuals who are interested in making a donation to create a specific purpose Fund 

or individuals from a Specialty Section or other formal/informal group who are interested 

in providing leadership for creating a specific purpose Fund are encouraged to contact 

Clarissa Wilson at SOT Headquarters by telephone: 703.438.3115 or 

e-mail: clarissa@toxicology.org. 

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _


Endowment Fund (Continued) 

2009–2010 Contributions by Fund 

The SOT Endowment Fund Board, on behalf of the entire membership of the Society of Toxicology, gratefully acknowledges 

the generosity of the many donors who made contributions to the SOT Endowment Fund. 

2009–2010 Honor Roll of Contributors 

Mary and Joseph F. Borzelleca 

Young Soo Choi 

Laxman S. Desai 

Barbara Gehring and Family 

LIFETIME CONTRIBUTION BENEFACTORS 

Cumulative contributions of $10,000 or more 

Joe and Teri LeBeau 

Frank C. Lu and Family 

Roger O. and Kathleen M. 

McClellan 

Harihara M. and 

Rekha Mehendale 

Mark R. Montgomery 

Dennis James Paustenbach 

James A. and Gloria Jean Popp 

K.S. Rao 

Dharm V. Singh 

Elizabeth K. Weisburger 

John and Vera Doull 

Jerry B. Hook 

Curtis and Cherry Klaassen 

Paracelsus CIRCLE LIFETIME MEMBERS 

Cumulative contributions of $5,000 to $9,999 

Frank and Sally Kotsonis 

Kannan Krishnan 

Jacqueline H. Smith 

Thomas R. Sutter 

Robert G. Tardiff 

James S. Woods 

Daniel and Patricia Acosta 

Linda S. and David Birnbaum 

Kim Boekelheide and Janet Austin 

Matthew S. and Renee Bogdanffy 

Brad Bolon 

Balbir S. Brar 

Dennis J. and Leigh Ann Burns Naas 

Steven D. and Elaine S. Cohen 

Jon C. and Judith R. Cook 

George B. and Anna Karen Corcoran 

David L. Eaton 

Paul W. and Grace Ferguson 

Bruce A. Fowler 

Angelo and Christine Furgiuele 

Michael A. Gallo 

Donald E. and Elly Gardner 

Paracelsus CIRCLE LIFETIME MEMBERS 

An initial contribution of $500 or more and a commitment to make cumulative 

contributions of $5,000 or more within a ten year period. 


Bernard D. Goldstein & Russellyn Carruth 

Jay I. Goodman 

William C. Hays 

Bob & Diane Higginbotham 

Ronald N. Hines and D. Gail McCarver 

Charles H. Hobbs 

Michael and Mona Holsapple 

Rudolph E. and Susan Jaeger 

James E. and Lisa Klaunig 

Elaine Valerie Knight 

Herman F. Kraybill 

Gary L. Lage 


Lois D. Lehman-McKeeman 

Gary and Patti Miller 

Nancy A. Monteiro-Riviere 


Robert E. and Ursula Osterberg 

Martin A. Philbert 

Betty C. Pyne 

Kenneth S. Ramos 

Donald J. Reed 

Charles F. Reinhardt 

Rick G. Schnellmann 

I. Glenn Sipes 

William and Cristine Slikker 

Robert J. Staab 

Cheryl Lyn Walker 

Kendall B. and Gail A. Wallace 

John E. Whalan 

Clarissa and Tim Wilson 

Reference 


417



2009–2010 Contributions Honor Roll of Contributors 

by Fund 

M.L. Ament 

Susan J. Borghoff 

Blair U. Bradford 

Jules Brodeur 

Robert E. Chapin 

Lung-Chi Chen 

Mary E. Davis 

Michael L. Dourson 

Marion F. Ehrich 

Nancy A. Gillett 

William R. Hewitt 

Dr. and Mrs. Elton R. Homan 

Thomas W. Kensler 

Mark J. Reasor 


Lena M. King 

Robert E. Larson 

Jose E. Manautou 

Paracelsus CIRCLE 

$500 or more in 2009–2010 

Ronald P. Mason 

Jay Murray 

Richard Nass 

Edward V. Ohanian 

Brian G. Priestly 

K.S. Rao 

Mark J. Reasor 

Karl K. Rozman 

Ivan Rusyn 

Robert A. Scala 

Neill H. Stacey 

Yoshiyuki Takei 

Melba B. Thurman 

Harold E. Williamson 

Ronald K. Wolff 

Lauren A. Woods 

Wei and Wendy Zheng 

Zhi Zhong 

John and Terri Ament 

Rob and Susan Ament 

Jack and Shelley Arthur 

Barry and Dorothy Bays 

Supratim Choudhuri 

James G. Conway 

Robert E. Dudley 

Michael J. Graziano 

Daher Ibrahim Aibo 

David R. Johnson 

Jie Liu and Yaping Liu 

GOLD ENDOWMENT 

$250–$499 in 2009–2010 

Seth Worley and Kathleen 

McDonough 

Claude McGowan 

Anonymous Donor 

Jennifer L. Rayner 

Ninfa I. Redmond 

Denise Robinson Gravatt 

Stephen H. Safe 

Gary L. Sprague 

J. Christopher States 

Robert J. Szot 

Hide Tsukamoto 

John Pierce Wise, Sr. 

SILVER ENDOWMENT 

$100–$249 in 2009–2010 

Reference 

Joan Abbott 

Cynthia A. Afshari 

Yves Alarie 

Melvin E. Andersen 

Ned Ballatori 

Aaron Barchowsky 

Norman J. and Valerie G. Barlow 

R. David Bauer 

Barbara D. Beck 

Janet M. Benson 

Arthur A. Bickford 

Diann L. Blanset 

Anonymous Donors 

Vernon L. Carter 

George M. Cherian 

Gaston A. Chevalier 

Henry D. Connor 

Edmond E. Creppy 


Thomas D. Darby 

Michael and Bonnie Dazenski 

Robert H. DeWit 

Betty Eidemiller 

Robert and Rosemary A. Fallar 

Anna and John Field 

Gregory L. Finch 

Donald A. Fox 

James C. Garbutt 

Olivia and Kris Gardner 

Zoltan Gregus 

Mark E. Hahn 

Melanie Harder 

Eric B. Harstad 

Dylan P. Hartley 

Danuta J. Herzyk 

M. M. Hess 

Robert and Rose Hester 

Alan M. Hood 

Conrad J. Housand 

Michael F. Hughes 

Moritake Iijima 

Henry M. Kissman 

Ning Li 

Troy and Kimberly Lindemann 

Hong Lu 

Koren K. Mann 

Michael and Sally Mann 

Lin Mantell 

Jo Ann Miller 

Karen and Victor Nakano 

Richard W. Pfeifer 

Gary Pfitzer 

Pierre Raymond 

Caroline J. Riley 

Larry W. Robertson 

Tetsuo Satoh 

Imogene Sevin 

Jim Spratt 

Katie Sprugel 

Mari S. Stavanja 

Aron Farrel Stein 

Weiyi Su 

Barry H. Thomas 

John A. Thomas 

Erik J. Tokar 

Harold Veal 


James G. Wagner 

Yu-Jui Yvonne Wan 

Hedley and Barbara 

Weeks 

Daniel Wierda 

Morris S. Zedeck 




2009–2010 Contributions Honor Roll of Contributors 

by Fund 

Jane and Fred Berghaus 

Alan P. Brown 

Mary Campbell 

Xingguo Cheng 

Guoli Dai 

Wen-Xing Ding 


Barbara F. Hales 

Alice and Rita Kulig 

Steven C. Lewis 

Michael I. Luster 

Qiang Ma 

BRONZE ENDOWMENT 

$40–$99 in 2009–2010 

Lawrence F. Mancini 

Ana Navas-Acien 

Sidney D. Nelson 

Ann and Marty Paul 

Gary O. Rankin 

Claus Peter Siegers 

Dale & Lynn Sparrow 

Joan B. Tarloff 

Monica A. Valentovic 

Youcai Zhang 

Institutional Contributors 

Gradient 

GOLD 

$2,500–$4,999 

Boehringer Ingelheim 

SILVER 

$1,000–$2,499 

Cantox Health Sciences Inc. 

Amgen Foundation on behalf of 

Katherine H. Sprugel and Cynthia A. Afshari 

Genentech on behalf of Dylan Hartley and Eric Harstad 

EMPLOYERS MATCHING EMPLOYEE 

Pfizer Foundation on behalf of 

Leigh Ann Burn-Naas, Frank Kotsonis, Gregory Finch, Denise 

Robinson-Gravatt, and Robert Chapin 




Barbara D. Beck 

Matthew and Renee Bogdanffy 


Paul W. and Grace Ferguson 

Michael A. Gallo 

Daher Ibrahim Aibo 



Bruce A. Fowler 

Ronald N. Hines and 

D. Gail McCarver 


EDUCATION FUND 

Elaine V. Knight 


Lin Mantell 

Sharon A. Meyer 



INTERNATIONAL ACTIVITIES FUND 



Robert J. Staab 

SOT 50 th Anniversary Match 

John A. Thomas 

Harold Veal 



Jacqueline H. Smith 



Reference 


419




Joan Abbott 

Marge Aguis 


M.L. Ament 




Linda and David Birnbaum 

Diann L. Blanset 

Kim Boekelheide and Janet Austin 




Robert E. Chapin 






SOT PRIORITY NEEDS FUND 

Micaela G. Foley 


Bernard Goldstein and Russellyn Carruth 

Jay I. Goodman 



M. M. Hess 



Jerry B. Hook 






Seth Worley and Kathleen McDonough 

Jo Ann Miller 

Nancy A. Monteiro-Riviere 


Martha D. Nelson 


Richard W. Pfeifer 

Martin A. Philbert 







Jacqueline H. Smith Dale and Lynn Sparrow 

Gary L. Sprague 



Hedley and Barbara Weeks 


Morris S. Zedeck 


Susan Borghoff 

STUDENT TRAVEL FUND 


Donald A. Fox 



Special Purpose Funds 

Funds that did not receive contributions are listed in the front of this report. 

Reference 

Melvin E. Andersen 

Janet Benson 

Lung-Chi Chen 

MARY AMDUR STUDENT AWARD FUND 


Gregory L. Finch 


Rudolph John Jaeger 



Weiyi Su 


John E. Whalan 

YOUNG SOO CHOI STUDENT SCHOLARSHIP AWARD FUND 

Young S. Choi Roger O. and Kathleen M. McClellan SOT 50 th Anniversary Match 

Daniel and Patricia Acosta 

Susan Borghoff 


Betty J. Eidemiller 


DIVERSITY INITIATIVES FUND 

Jennifer L. Rayner 



Mari S. Stavanja 

Jay Murray 

FOUNDERS FUND 






Conrad J. Housand 

PERRY J. GEHRING BIOLOGICAL MODELING STUDENT AWARD FUND 


Betty J. Eidemiller 


PERRY J. GEHRING DIVERSITY STUDENT TRAVEL AWARD FUND 

Jay Murray 



Jay Murray 

PERRY J. GEHRING RISK ASSESSMENT STUDENT AWARD FUND 

Edward V. Ohanian 


Jon Seymour 

George B. Corcoran 


Eastman Charitable Foundation 

HARRY W. HAYS MEMORIAL FUND 

William C. Hays 



HEALTH AND ENVIRONMENTAL SCIENCE INSTITUTE IMMUNOTOXICOLOGY YOUNG INVESTIGATOR 

STUDENT AWARD FUND 

Dennis J. and Leigh Ann Burns Nass 

Michael and Mona Holsapple 

Michael I. Luster 


Daniel Wierda 




Roger O. and Kathleen M. McClellan 

VERA W. HUDSON AND ELIZABETH K. WEISBURGER SCHOLARSHIP FUND 

Imogene Sevin 


Elizabeth K. Weisburger 


Norman J. and Valerie G. 

Barlow 

Arthur A. Bickford 

Brad Bolon 

Vernon L. Carter 

JEAN Lu STUDENT SCHOLARSHIP AWARD FUND 


ROGER O. McCLELLAN STUDENT AWARD FUND 


Nancy A. Gillett 



Roger O. and 

Kathleen M. McClellan 



Reference 

HARIHARA MEHENDALE ASSOCIATION OF SCIENTISTS OF INDIAN ORIGIN STUDENT AWARD FUND 



Harihara M. and Rekha Mehendale 



421




Aaron Barchowsky 



METALS SPECIALTY SECTION STUDENT RESEARCH AWARD FUND 

Michael F. Hughes 

Koren K. Mann 


Richard Nass 

J. Christopher States 


Erik J. Tokar 

John Pierce Wise, Sr. 

Wei and Wendy Zheng 

Mark E. Hahn 


MOLECULAR BIOLOGY STUDENT AWARD FUND 



Qiang Ma 

PACIFIC NORTHWEST TOXICOLOGY DEVELOPMENT FUND 

Katie Sprugel 

GABRIEL L. PLAA EDUCATION AWARD FUND 

Reference 

Yves Alarie 

Daniel L. Azarnoff 

Ned Ballatori 

Jules Brodeur 


Chuan Chen 

Xingguo Cheng 

George M. Cherian 




George B. and Anna Karen 

Corcoran 

Guoli Dai 


Wen-Xing Ding 

John D. Doherty 

John Doull 

Cindy Afshari 



Robert E. Dudley 




Zoltan Gregus 

Barbara F. Hales 

Eric B. Harstad 

Dylan P. Hartley 

William R. Hewitt 


Alan M. Hood 

Jerry B. Hook 

Moritake Iijima 


Lena M. King 



Frank and Sally Kotsonis 

Kannan Krishnan 

Gary L. Lage 


Beth Levant 

Steven C. Lewis 

Ning Li 

Troy and Kimberly Lindemann 

Jie Liu and Yaping Liu 

Hong Lu 

Roger O. and Kathleen M. 

McClellan 

Brian G. Priestly 

Kenneth S. Ramos 

K.S. Rao 



Larry W. Robertson 

Karl K. Rozman 

EMIL A. PFITZER DRUG DISCOVERY STUDENT AWARD FUND 

Lois D. Lehman-McKeeman Robert and Ursula Osterberg 

Jay Murray 

Doug Young Ryu 

Stephen H. Safe 

Tetsuo Satoh 

Larry P. Sheets 

Claus-Peter Seigers 

Jim Spratt 

Neill H. Stacey 

Aron Stein 


Barry H. Thomas 

Kendall B. Wallace 

Yu-Jui Yvonne Wan 

John B. Watkins 

Daniel Wierda 

Harold E. Williamson 

Lauren A. Woods 

Youcai Zhang 

Gary Pfitzer 


REGULATORY AND SAFETY EVALUATION STUDENT AWARD FUND 

Robert and Ursula Osterberg 






Mary E. Davis 

Gary and Patti Miller 

Gary Rankin and Monica Valentovic 

RENAL TOXICOLOGY FELLOWSHIP AWARD FUND 

Rick G. Schnellmann 


Joan B. Tarloff 


ROBERT J. RUBIN STUDENT TRAVEL AWARD FUND 

Thomas W. Kensler Mark J. Reasor SOT 50 th Anniversary Match 

Alan P. Brown 


George B. Corcoran 

Mark E Hahn 


CARL C. SMITH MECHANISMS STUDENT AWARD FUND 



Jay Murray 

Sidney D. Nelson 





Blair U. Bradford 

Mary Campbell 

Henry D. Connor 


J. C. Garbutt 

RONALD G. THURMAN STUDENT TRAVEL AWARD FUND 


Ronald P. Mason 


Ivan Rusyn 


Yoshiyuki Takei 


Hide Tsukamoto 

Zhi Zhong 

Edmond E. Creppy 

TOXICOLOGISTS OF AFRICAN ORIGIN 

Michael L. Dourson 

Our thanks and deep appreciation 

to all the members and friends of the Society who 

have contributed to our previous goal of reaching 

$1 million in donations by the 50th Anniversary year. 

Reference 

The number of named funds has grown to 30 at the time of this printing. 

Students are the main beneficiaries of the awards from the various Funds. 

Help exhaust the SOT Council Approved $750,000 50th Anniversary Match. 

Your contribution can have twice the IMPACT 


423




Recognition of Others 

Reference 

IN honor OF 

YOUNG SOO CHOI 


BOB AND DIANE HIGGINBOTHAM 


JOHN DOULL 

Jerry B. Hook 

FRANK C. LU 


KOREN MANN 


ROGER O. MCCLELLAN 


ELIZABETH K. WEISBURGER 



IN Memory OF 

MARY AMDUR 

Rudolph John Jaeger 

ANASUYA 

Desai S. Laxman 

CHARLES C. CAPEN 


MILDRED CHRISTIAN 

Robert and Ursula Osterberg 

HERBERT CORNISH 


HAROLD C. HODGE 


VERA W. HUDSON 



FRANCIS “FRANK” J. MECLER 

Joan Abbott 

Marge Aguis 

Beverly P. Ament 


M.L. Ament 










Micaela G. Foley 


M. M. Hess 




Seth Worley and Kathleen McDonough 

Rose P. Mecler 

Jo Ann Miller 


Martha D. Nelson 


Adler Pollock & Sheehan P.C. 


Dale and Lynn Sparrow 

Harold Veal 

Hedley and Barbara Weeks 

GABRIEL L. PLAA 





Lena M. King 





Caron Reed 


CARON REED 


RONALD G. THURMAN 

Mary Campbell 



JANET LANE EAton 


SHELDON D. MURPHY 


HARRY W. HAYS 



EMIL A. PFITZER 

Gary Pfitzer 



SOT Affiliates 

Abbott Laboratories 

Abbott Park, Illinois 

Charles River 

Wilmington, Massachusetts 

ISIS Services, LLC 

San Carlos, California 

Absorption Systems 

Exton, Pennsylvania 

Alcon Research Ltd. 

Fort Worth, Texas 

American Chemistry Council 

Arlington, Virginia 

American Petroleum Institute 


Ani Lytics, Inc. 

Gaithersburg, Maryland 

AstraZeneca R&D 

Södertälje, Sweden 

BASi Evansville 

Mount Vernon, Indiana 

Battelle 

Columbus, Ohio 

Bayer HealthCare Pharmaceuticals 

Montville, New Jersey 

Biogen Idec, Inc. 

Cambridge, Massachusetts 

Boehringer Ingelheim 

Pharmaceuticals, Inc. 

Ridgefield, Connecticut 

Bristol-Myers Squibb Company 

Princeton, New Jersey 

CANTOX 

Mississauga, Ontario, Canada 

Celgene Corporation 

Summit, New Jersey 

Celsis In Vitro Technologies 

Baltimore, Maryland 

Chevron Corporation 

Richmond, California 


Piscataway, New Jersey 

Covance Laboratories Inc. 

Madison, Wisconsin 

Daiichi Sankyo Company Limited 

Shizuoka, Japan 

The Dial Corporation, 

A Henkel Company 

Scottsdale, Arizona 

Dow Chemical Company 

Midland, Michigan 

Dow Corning Corporation 

Midland, Michigan 

The Dupont Haskell Global Centers for 

Health and Environmental Sciences 

Newark, Delaware 

Eli Lilly and Company 

Indianapolis, Indiana 

ExxonMobil Biomedical Sciences, Inc. 

Annandale, New Jersey 

Genentech, Inc. 

South San Francisco, California 

GlaxoSmithKline 

King of Prussia, Pennsylvania 

The Hamner Institutes 

for Health Sciences 

Research Triangle Park, North Carolina 

Hoffmann-La Roche, Inc. 

Nutley, New Jersey 

Honeywell International, Inc. 

Morristown, New Jersey 

J&J Pharma R&D Companies 

(Centocor, J&JPRD, Tibotec) 

Raritan, New Jersey 

Metabolon, Inc. 

Research Triangle Park, North Carolina 

Millennium: 

The Takeda Oncology Company 

Cambridge, Massachusetts 

MPI Research 

Mattawan, Michigan 

Novartis Pharmaceuticals Corporation 

East Hanover, New Jersey 

Pfizer, Inc. 

Groton, Connecticut 

Procter & Gamble Company 

Cincinnati, Ohio 

RTC Research Toxicology Centre S.P.A. 

Pomezia, Italy 

sanofi-aventis 

Bridgewater, New Jersey 

Seguani, Ltd. 

Ledbury, Herefordshire, United Kingdom 

Suburban Surgical Company, Inc. 

Wheeling, Illinois 

Syngenta 

Greensboro, North Carolina 

Toxicology Excellence for 

Risk Assessment (TERA) 

Cincinnati, Ohio 

WIL Research Laboratories, LLC. 

Ashland, Ohio 

Reference 

If your organization is interested in participating in the SOT Affiliate program, 

please contact marcia@toxicology.org 


425

“We celebrate the Society of Toxicology 

to the study, practice and application of 

toxicology science for the protection 

of public health.” 

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. 

Director, National Institute of Environmental Health Sciences 

and National Toxicology Program 

National Institute of 

Environmental Health Sciences 

www.niehs.nih.gov 

SOT Exhibit 1414 

Read live updates from the 

SOT 50th Anniversary 

Meeting www.niehs.nih.gov/liveatsot 

Get your FREE poster – 

Benchmarks in Toxicology 

Meet the Director 

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. 

Wednesday, March 9, 2011 

9:30 -10:30 a.m. 

Room 201 


National Toxicology Program 

www.ntp.niehs.nih.gov 


Environmental Health Perspectives 

www.ehponline.org 


Experience the new digital journal 

www.ehponline.org/godigital 

NIEHS-SOTProgramAd-7x9.5.indd 1 

1/3/11 12:37 PM 



Notes 


427


Notes 



Notes 


429


Notes 



Headquarters Staff 

Society of Toxicology Headquarters 

1821 Michael Faraday Drive, Suite 300, Reston, Virgina 20190 

Tel: 703.438.3115 • Fax: 703.438.3113 • E-mail: sothq@toxicology.org • Web site: www.toxicology.org 

Staff Contact Extension E-mail Activity 

Shawn Douglas Lamb 1444 shawnl@toxicology.org Executive Director 

Clarissa Russell Wilson 1455 clarissa@toxicology.org Deputy Executive Director 

Rosibel Alvarenga 1432 rosibel@toxicology.org Membership Services 

John Bae 1660 johnb@toxicology.org Career Resource and Development, Membership 

Services, Regional Chapters 

Donna Breskin 1440 donna@toxicology.org Administration 

Chris Cerniglia 1445 chris@toxicology.org Publications/World Wide Web 

Krystle Correll 1436 krystle@toxicology.org Administration 

Jim Dailey 1428 jimd@toxicology.org Endowment, Registration 

Betty Eidemiller 1430 bettye@toxicology.org Committee on Diversity Initiatives, Data Task Force, 

Education Committee, Postdoctoral Assembly, 


Veronica Fisher 1450 vfisher@toxicology.org Financials 

Laura Helm 1403 laura@toxicology.org Exhibits, Meetings 

Becca Isakower 1447 becca@toxicology.org Administration 

Ed Jennings 1453 ed@toxicology.org Financials 

Liz Kasabian 1454 liz@toxicology.org Exhibits 

Colleen Kelley-Vaquerano 1426 colleen@toxicology.org Publications/World Wide Web 

Maureen Kettering 1443 maureen@toxicology.org Exhibits, Meetings 

Marcia Lawson 1446 marcia@toxicology.org Board of Publications, Communiqué, Council 

Subcommittee for Non-SOT Meeting, Component, 

Regional Chapter, and Global Funding, Professional 

Needs Assessment Task Force, Scientific Liaison Task 

Force 

Martha Lindauer 1640 martha@toxicology.org Communications, Congressional Relations, Media 

Renee Maisel 1423 renee@toxicology.org Exhibits, Meetings 

Tonia Masson 1433 tonia@toxicology.org Administration 

Tim McKinney 1439 tim@toxicology.org Financials 

Tierre Miller 1451 tierre@toxicology.org Administration 

Debbie O’Keefe 1441 debbie@toxicology.org Data Task Force, Publications/World Wide Web 

Christy Ours 1602 christy@toxicology.org Administration 

Sue Pitsch 1442 sue@toxicology.org Administration 

Heidi Prange 1424 heidi@toxicology.org Meetings 

Matthew Price 1429 matthew@toxicology.org Awards Committee, Membership Services, Social Media 

Kelly Roberts 1601 kelly@toxicology.org Membership Services 

David Rossé 1438 davidr@toxicology.org Continuing Education Committee, Graduate 

Committees, Student Advisory Council 

Nichelle Sankey 1431 nichelle@toxicology.org Scientific Program Committee 

Christopher Tucker 1603 christopher@toxicology.org Publications/World Wide Web 

Elisa Turner 1461 elisa@toxicology.org Publications/World Wide Web 

Jennifer Ventura 1400 sot_admin@toxicology.org Administration 

Kim von Brook 1600 kimberly@toxicology.org Membership Services, Special Interest Groups, 

Specialty Sections 

Devin Yates 1434 devin@toxicology.org Publications/World Wide Web 

Reference 


431

Annual 

Meeting 

Sponsorship 

Opportunities 

Sponsorship Opportunities Are 

Still Available and Help To: 

• Show your company’s 

commitment to advancing 

toxicology 

• Gain valuable exposure to 7,000 

attendees 

• Keep meeting registration 

fees affordable to scientists, 

students, and all attendees, 

thereby bringing more 

participants together at this 

important event 

• reduce your bottom line— 

contributions are tax deductible 

under 501(c)3 provisions 

Sponsorship Gives You: 

• recognition in all Annual 

Meeting publications and 

promotional materials, 

ToxExpo Directory, the Sot 

Web site, in post-meeting 

newsletters, and colorful 

signage and banners at the 

meeting 

• the right to host an Exhibitor/ 

Sponsor Hosted Session at the 


• Invitations to the President’s 

Reception 

• And much more! 

The Diamond Level Sponsors 

($10,000 or more) can be found 

on the back cover. 

For more information contact 

Sot Headquarters and ask for 

Liz Kasabian at 703.438.3115 or 

e-mail liz@toxicology.org. 


appreciates the generous contributions 

of the 50th Annual Meeting Sponsors 

Abbott Laboratories 

Allergan Inc 

Ani Lytics, Inc 

AstraZeneca 

Pharmaceuticals LP 

BioReliance® Corporation 

BASF Corporation 

Bayer HealthCare 

Pharmaceuticals 

Bioculture (Mauritius) Ltd 

Chevron Corporation 

Daiichi Sankyo Co., Ltd. 

DuPont Haskell Global Centers 

for Health and Environmental 

Sciences 

Eastman Charitable Foundation 

Biosafety Research Center, 

Foods, Drugs and Pesticides 

Data Sciences International 

(DSI) 

Environmental Mutagen Society 

ExxonMobil 

Kubtec X-Ray 

Research Institute for Fragrance 

Materials, Inc. 

Platinum 

($5,000–$9,999) 

Gold 

($2,500–$4,999) 

Silver 

($1,000–$2,499) 

(as of January 10, 2011) 

Burroughs Wellcome Fund 

Covance 

Definiens, Inc. 

NCTR/FDA 

sanofi-aventis 

Eli Lilly and Company 

Elsevier 

Gradient Corporation 

The Hamner Institutes 

for Health Sciences 

HistroTox Labs, Inc. 

NSF International 

ToxServices LLC 

WIL Research Laboratories, LLC 

SafeBridge 

Consultants, Inc. 

Safety Pharmacology Society 

Society of Toxicologic Pathology 

Teratology Society 

Toxicology Excellence for 

Risk Assessment (TERA)

QUICK REFERENCE 

Visit www.mwata.com 

for more information and 

complete Metro map.


appreciates the generous contributions 

of the 50th Annual Meeting Sponsors 

Diamond 

($10,000 or more) 

Amgen Inc. 

Battelle 

Charles River 

MPI Research 

50 th 

American Chemistry Council 

Boehringer Ingelheim Pharmaceuticals, Inc. 

Bristol-Myers Squibb Company 

Centers for Disease Control and Prevention 

Grant No. 1H13EH000680-01 


Hoffmann-La Roche Inc 


J&J Pharma R&D Companies 

(Centocor, J&JPRD, Tibotec) 

National Institute of Environmental 

Health Sciences (NIEHS) 

National Toxicology Program (NTP) 

Pfizer Global Research & Development 

SOT Endowment Fund 

Anniversary Annual Meeting and ToxExpo TM 

Society of Toxicology 

1821 Michael Faraday Drive, Suite 300 • Reston, VA 20190 

T: 703.438.3115 • F: 703.438.3113 • E-mail: sothq@toxicology.org 


(as of January 10, 2011) 

National Toxicology Program (NTP) 

Cert no. XXX-XXX-XXX X 

We are proud to print this publication entirely on Forest Stewardship Council 

certified paper. FSC certification ensures that the paper in this publication 

contains fiber from well-managed and responsibly harvested forests that meet 

strict environmental and socioeconomic standards.

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?